<SEC-DOCUMENT>0001628280-22-006547.txt : 20220317
<SEC-HEADER>0001628280-22-006547.hdr.sgml : 20220317
<ACCEPTANCE-DATETIME>20220317161442
ACCESSION NUMBER:		0001628280-22-006547
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220317
DATE AS OF CHANGE:		20220317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		22748688

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>xfor-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:97cd003e-9c40-40fd-8096-f110f9c5294b,g:4b68d2f2-b861-47a0-89c8-6e5f887cc91d,d:71bd745117f84268bb875bce92ea6db3--><html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xfor="http://www.x4pharma.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMS0xLTEtMS0yMDk0MA_e1a96f6c-b105-4af2-a47c-0d188566f10c">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMi0xLTEtMS0yMDk0MA_351beaa2-2baf-4cdd-a29b-5524dce3fb13">False</ix:nonNumeric><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfNC0xLTEtMS0yMDk0MA_b227d98c-872d-43a2-a34a-6c6938d69cee">2021</ix:nonNumeric><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfNS0xLTEtMS0yMDk0MA_eb0346f1-13cd-45b4-bf26-490f39cfa39a">FY</ix:nonNumeric><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfNy0xLTEtMS0yMDk0MA_27e4cc91-53ad-4c95-aeb8-c832a7c47c7f">Delaware</ix:nonNumeric><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfOS0xLTEtMS0yMDk0MA_7904e6a5-890f-4109-a5d7-8070be49f95b">61 North Beacon Street</ix:nonNumeric><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMTAtMS0xLTEtMjA5NDA_4b0737b9-6325-42ca-a1ed-3c188491520c">4th Floor</ix:nonNumeric><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMTEtMS0xLTEtMjA5NDA_bae15610-582b-44d7-be1f-e9a1ca8693c1">Massachusetts</ix:nonNumeric><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMTItMS0xLTEtMjA5NDA_2614ee0a-d4cf-4a10-8247-b77f4290fe1b">Boston</ix:nonNumeric><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMTMtMS0xLTEtMjA5NDA_ea7399ef-7d82-46b3-81db-6a33266dca43">02134</ix:nonNumeric><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMTQtMS0xLTEtMzI5MDg_5640202b-406a-46d2-a705-63865014a927">10-K</ix:nonNumeric><ix:nonFraction unitRef="reporting_unit" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTEvZnJhZzozZTJlNDYyODAwNjc0ZDNjYmZkZmIxOWY4M2JiOTNkMi90ZXh0cmVnaW9uOjNlMmU0NjI4MDA2NzRkM2NiZmRmYjE5ZjgzYmI5M2QyXzIy_c5f1c124-34cb-48e0-964c-7358b6da33b4">1</ix:nonFraction><ix:nonNumeric contextRef="i45311149808649259f5690565adeef41_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzEyNDI_d21e8b58-0c5c-4b61-b8a2-5336b084744c">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica45cd390e2849f4b2b75e21159c3a2f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i124b0568b1914873ac60885d7abe74b5_I20220314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib7fea33dfd0f43f88c85204776483478_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedee6e787d804eec9aef3377417aa32d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i572b67d5b62c4080a9192cbe762029fb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8462e5cfa36e4e91b441a3ad10cfb348_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ecf8ce3e9b74e56acb8ff0af3fb7c60_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b86b7cc383415ab9c2160568c774c4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i176b3693f32c4dc59cff0f728a8aa927_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9399ce4d3f59464796fe4fa19123abea_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13bac80900904f72b4b9131b22a45f6a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia15232c68ac3485b97f216f1936f809b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib34264e2c11b4c15b0b5b0a7b86698e8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c7918b22f9243ddaf0f3d3d10ab77d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd5d9882306b44ada5d3504a50879658_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4db0920d51934739ab1e898d8dd9ec84_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e6ba7741627488daf0ea92b674d371a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ea504a912184f6781687f27b056d117_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a487a492bc94ba59c6f135aa8c86c42_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i373cd781460447af8b7b7a8138e80603_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac2e90cc41804bbb8dbab70f418649b8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cef3e8a10ac450289a7a934bddd328c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf1406e0d5074a2d82a899bd3bb3214a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820d81ce3a29475a8c344011da28e038_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed4bb840e6c490cb44e0c1b2416b76b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id095d9ce2828470d851a6cbfc3424820_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11e0524bed0045f9a3d87f7528ddd21a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i764dfda255314eb5b4c9af8e6f5029a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a7b73207d14b36af0c17c6d6540372_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i153dbfb5749f4329b178c4b7931cafdc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d20d773aefb40a2ab1e4fd2d6abeacc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38b2bc6981e4baeac34e666d1e848eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4851434b4d774d8bab2622f9881c9440_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f79127b745453d84e4c71a65761e38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if884965b97674d2897920860dc9dd9de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64ff3d38d9274c5cb80f3c6ad6dc0169_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50217e3e4bd4418faec03cc4d6e2b168_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8eb923c43342b496d1759d3a72b849_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54176cdc44bb45e8811df78b7fe967ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dacdd07b5414e26a65fa9a53ef63e97_D20190313-20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xfor:ArsanisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-13</xbrli:startDate><xbrli:endDate>2019-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib146624f4ddd4ad1ad0d121c7a5b8e07_I20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xfor:ArsanisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if607c1606fbc49f59e2bf4de1d5b33a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:CambridgeMAOperatingLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38b2d39313774d1fa99f7f76bc2c53de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:CambridgeMAOperatingLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i420c5ba492444c13b294e4e2a546f0a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c4ebf0462b4732860b5713ee5382d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica794810f5b2410aa3cb05ea67f5c7f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce2db152304447e9853c0b52d13069e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d8948ba512458fa854441df3e3e3bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4963d68c5d634e58ab61d1a2cddf748b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e897132b145489baf3f95f1211bbfe1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id55dcfd048fd4851ae346aa2bda82ea8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c76fdda3bb7478080cca4e3d51fa3d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a725b19ab442bbb8edee0d639f20dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc17360a88043f9b6abb29bb3af7296_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77964c20016f452c85f7147fb9ecc320_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33f057257bb48b2afd09c10a0ad9385_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icda50709fc3f40a7ab505de422bb1006_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>xfor:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i9784cfb07e534c2e87bde589e4247ab1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GenzymeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3dd65af95a4a2aba2fdcc47b856359_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GenzymeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i225e901df8314c699611cba3ac017ff1_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88010e5c3d6844f290c1e8ba4fb22318_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ceee2c8aded43179b9372ebcdc986a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad92d608e2c943b5a764b11f90964ae8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f97f5094be74d7ba79c0c8d4e004d44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ce81a516a94a338811f3c4a44d3f09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8606b5dae8b041ddbf2eda066e840243_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1954fbe47872474aa699d20fef1a95c1_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:BidmcAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i380c26c2cda946c08040104fb3a0b055_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:BidmcAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8829b46536ce4ec9827623894b9f4010_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:BidmcAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62733706ba0e4d2db3cb0b4113c64983_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:BidmcAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id39cf2b1c7eb411c8bf1eb3d7c157ca3_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:DFCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:DFCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf4a376dcdfb4942aaeaac1e7d14026a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xfor:MTSAustriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07dd80c3754e46e787921f0939875ae9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac899978347d423a8c974cde8043327f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie326aa2ac0af4123b2815995684d76f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c580853b2d45d38376f5d122ceae9e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ac70d6741a4930924fed60eceb574a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd109dd37804ba9bfecda161164e492_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:AbbiskoAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce09a35448e44b7923a92354c5363c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:AbbiskoAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f0240e57043459f99d9c4df35fbe4a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad1d2efd6bc94ac6831e430b69a1aaae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0c66368b5a4481390647875c1cd56b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41915bc16d8a42a0b9187f4f75b87df1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29e21fcd99849af88c7d951ec6f37ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52444c1398e14dcba086b4397b35d5a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe6cb9ee46884d369d83ce82d8bf1038_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i280356e3a07941a2bcd0573cdc71bda1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8b2e9b7ab3a498986022689b55633be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6aa3b74a39643e7b24682ca039984a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42028c40df934c66818f46c7b7a459d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92061fb2c1cd4c7cbb46ced4db254c28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b315bcebad4db0a5801ae168cf944a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12294001c3724c64a759185c687b58e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7406aa31e3374111bed602d9d3287a73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84c45f7f16b4da88327ddbf122756a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb0a1ce7184c4d82850f7e0ca90dd59a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if504bda89d6b40c4857f885c3a5dd5be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e4745ffaea4f638a14e69eb5e2e780_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee282cd049d2469f96e0d412a363884a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife90678c9c334675bb4fb9c5a64484fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad13cbd0ab104e089c980b940e3d7116_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79fc5b3e5da4f21bc81f95a0112b9b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc702a2739324d80b4ef222aca509be2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie38293cc2bff405a9e1e6bc59761a28b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06df3f074d7447b6806efcb5f9c98d10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddc7cf15c96346e19207edcffa291f0c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e2a6d6e83924b2daa8ee08212fd793d_D20181001-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6605f338210c4eb6af0923abf8445fec_I20201221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesFirstAmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia221aaf88dc34cd18ee78f500786ae65_I20201221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:DiscretionaryBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesFirstAmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i441b3dd525cf4ccba63a00aba76d1e05_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesAmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf2b97d940c42ffbf9fc1761bc75923_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesAmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cd6cf3938894c7ebded737f6ab8df03_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesAmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03e6b6f8a9c740948d0f053e9e9b88c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58af1e2574894b2ea2b9227befb6de70_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i044152b2a50d4484a5e19b0c3e40e9a3_D20230701-20230701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e9fe3e1ad55446c8ece9e5d397f6127_D20240701-20240701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i815e2b3d5b21461cb22c4cf956eab5d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8783c36c8464089a5c02a0e660c689e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a84700b1c1468b831735d87f46a242_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie11078f4d8a0419ea19c205259a627ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21716a46c2a345a29fc88ac84ad6249e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f823743b9a246098193cea2dbb84829_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70dd855dda9a41448556d07389f6ef62_D20191111-20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-11</xbrli:startDate><xbrli:endDate>2019-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="iec7ca8d65d8941a693c86e1d5e2e006d_I20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96305963db034551a189b94796a2792a_D20190313-20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-13</xbrli:startDate><xbrli:endDate>2019-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i649b92ccef0a45d48c9c43fe57d79944_I20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie206b7a7c0f04cad9646717d502a7f9d_D20190313-20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-13</xbrli:startDate><xbrli:endDate>2019-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib03c7b0ffaa94e54a5fcb3da8d3bffcd_D20190313-20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-13</xbrli:startDate><xbrli:endDate>2019-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb04900d7d94d69b89541fbd440e0f4_I20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30884f0e4d634f7b8bc5bacaa38c8f3e_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:NewViennaLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief7e7ceedd0a4127b22dedc2456e45ed_I20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:NewViennaLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dfd25fd846b472ba0ec52e244589a8e_D20210201-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:NewViennaLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af38d4d2ff7443faf6ac2b41a13a62e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:CambridgeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f4a3cbd5679460ab78ce920e0af42b2_I20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1ee4ca82b14441a5df67868c7c2fee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f4b97ac998545cd8301f39db19e7d4d_D20190416-20190416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-16</xbrli:startDate><xbrli:endDate>2019-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a1dd2dc5c7e49e4a433ec1811b9e03c_D20191129-20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-29</xbrli:startDate><xbrli:endDate>2019-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f1955aa1b534854878550a58ccbf898_I20190416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30903cfad3dd426ab86057983e126f26_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5faaf777d178421b83561c0fd16627c8_D20191126-20191126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-26</xbrli:startDate><xbrli:endDate>2019-11-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie12ba0825f69455cbb72564897ee2268_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i997f64043d3c48f79904457d31ed425b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358bda413e094c3b8732326b0da80424_I20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4dbd5cea64e45acb7901cd8377332fd_I20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc0e7e2a65446eaaa63bbb1c1af5689_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberNineTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i445218cd5fbd4b9cb04297a8f4e11d1d_I20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b714c637a6647028b196f7cbd99f053_I20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2348e83e324b7b82456649b542f965_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eea12429adf41968b80ecfea410785d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33bf01c5e0304c2189fa034c75eb5241_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5e02cabb20347e4812e2c13fe49c590_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberNineteenTwoThousandEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09e8bb1f0686446a9a8a7b9564378965_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarchThirteenTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22fa089c31854eeeaeeac178d4940454_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnAprilSixteenTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c23f7b906f436f93692639aef06e09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddf524fe86fd469f8009f330de097712_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd64677f69e44d5ba2d48dae0391b34_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice9673b6146f4de3b3a39b86599af702_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic04f75350f324bb38f14095eadb12430_D20190412-20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-12</xbrli:startDate><xbrli:endDate>2019-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc57ac90fb9b4a139e8cb4ea7c012b1c_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d3611fd3c8401fb735dc5668ae2bdd_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f7afe3aab394972900909f3eb5f8d6e_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c32e3e005c345c99931e9ec6e8fd87d_I20191126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie95bdf26dc21489e97c2cbbf4958cf38_I20191126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2e5e675d68a4f6fb4aacb2424a63a15_I20191126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0367f472bfd0499fb8ee3740bd659aef_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xfor:SalesAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9356b89607b64810becde53ca7553153_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xfor:SalesAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id058b9443dcc41a5ab90c45eaf52eb0f_D20210318-20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e2c3583b72c4f10ba6fe68a4c9b2efc_D20150801-20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GenzymeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-01</xbrli:startDate><xbrli:endDate>2015-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaea2c14fe1c4ed986fa022e040501e2_D20150801-20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-01</xbrli:startDate><xbrli:endDate>2015-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090e4c427ee048bc8e9fcdb0974c1506_D20210318-20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic20f813c6ba64ecd9f76496c37a6e54f_D20210318-20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66be0cd2cf4d4a42b63843821d7cd60e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba06b4b4e67a4951be1cc5d6e6014f25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb68bbb183674891a54f752fa22ab0ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dca859173e44d0ab9e6a946325f25cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xfor:IncentiveStockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45311149808649259f5690565adeef41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xfor:NonStatutoryOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cdc5828b647427eac8834bfe5c3918d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xfor:NonStatutoryOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ce1b0b961a4ecf8f39191f8d76e3f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:A2015EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9744171d8b784611a88ca1bbe96d8305_I20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb5c3f88dc04b4394011f548ecf9639_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cda38b2da094f1989f1b4c220bb9a44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic32c961b47444fdbb27d84656b34b323_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41788cc835c403ebdb1e9b363ffce18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">xfor:EmployeeStockPurchasePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib547fe50b2a14b3280afdd293833e80c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">xfor:EmployeeStockPurchasePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bc5c13e743746e4a019f4cf7a0c9b49_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">xfor:EmployeeStockPurchasePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id65e88b8d02845c0a717fe27c8e5d78e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c91a1db75564f1a9f51565f80cc6989_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd6c8456214d407ab97760fec4594b56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b422ab3eb7e4a40aa972b2f8fff304f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia31a8d360da2400681748e55aab5c168_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if04d43b561c5475e947351e2ef934ba6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48c01b2e36084c58b99dee21b846e65d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0418b0f1a84b1485cef1e8244c3bbe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if641bd9c2d33474caad13fd26380c7bd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i097aafa6f7b841a1a0aa11212d0ac628_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f7ea03d3dc4a2db15e7efdf72553a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f34441bf9943299037a918d5a88ca2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5afd505d65084ae68ba1922355482038_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19aaafe0d3d04513a526d073e5d54606_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e74a770feb4868bd1ab0a23e223cd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4203c993d0e41018d52d1c410bc3e56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i610800df2fc44c33b927d13481ffc06a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icea0d3791b8d40149f121f9b367a9acd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c50656da4cf4784852c501bf1c61d57_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78bed59ffcf84935afe7d39665a6ed77_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac33b1c38294eb99c02be51a19dfc6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib495f27eee5643c1aa40007ea1e395be_D20190416-20190416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-16</xbrli:startDate><xbrli:endDate>2019-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i834346b84a2147ecbd3cf27e5b2b7a1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia358f6661177462caadde0fb55c0679c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f118f44cef4d8da8cb50ea3570142e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i574f61ac83b744e4bac8486593ef48b8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ebe6af4f44d4c56a5d0c7916e1a7f3e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce6e198f34e4961a5cb7083bbca2927_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b7de7a2f0e407ba0289ebb81300e0e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7ed78f3d9464a2eb083a1251fd15435_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9372c9ab8f97446b99dcb15a6e0b1733_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c8d1f64e434ebbac09001eadf96f1d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc0f8bba43d64d859d8549ce3f940062_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2a4f9e0d29b44b3a8c743db5ab19895_D20220114-20220114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xfor:AspireCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-14</xbrli:startDate><xbrli:endDate>2022-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d9b7bf5f3ef40dbb4d96393c1905d90_D20220114-20220114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xfor:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-14</xbrli:startDate><xbrli:endDate>2022-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie34513bfd4ce4c4298a4866e8aa61aad_D20201014-20201014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-14</xbrli:startDate><xbrli:endDate>2020-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a4a6cada334ffd9ee919af14b029f6_I20220114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief44e634dee347efb955cc9c643e8ca1_D20220114-20220114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-14</xbrli:startDate><xbrli:endDate>2022-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5720729ba9eb468d8f2396ce7f061f2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e984764b25842acb5cf371ed696787e_I20220314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9413c149a6a46d882b610a2ff34f1ff_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4e1b15e8914a5da92a4b13a532378d_I20220209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c992b94297b4f968244daa96427847c_D20220209-20220209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75e45f429fc6401584184ad501a62f94_D20220303-20220303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-03</xbrli:startDate><xbrli:endDate>2022-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i520c1054445641ac8c06d14b69d2bea3_I20220303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f62b2544f6c4e2398c83ef365be248c_I20220303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4b699affe54fdf8181d6649b333e5f_I20220114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie187101e5927453095022efb8232686c_I20220209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:Q12022PIPEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-09</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i71bd745117f84268bb875bce92ea6db3_7"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"><div><span><br/></span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.465%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6NDZjMGJhZWRkN2E5NDc0Y2EzZWM3Y2RjOTcxNGYwMjQvdGFibGVyYW5nZTo0NmMwYmFlZGQ3YTk0NzRjYTNlYzdjZGM5NzE0ZjAyNF8wLTAtMS0xLTMyNjUzL3RleHRyZWdpb246MzhiNDk1YzNkZGJiNDU1ODkxYTE2ODUzODI1MDZiNWRfNDk0NzgwMjMyNTAzOQ_5640202b-406a-46d2-a705-63865014a927">10-K</ix:nonNumeric></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"></td><td style="width:2.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6NGNmZWI3NDE1ZjQwNDRmYTg4NDA2Y2QwMWZiYzM3ODUvdGFibGVyYW5nZTo0Y2ZlYjc0MTVmNDA0NGZhODg0MDZjZDAxZmJjMzc4NV8wLTAtMS0xLTIwOTQw_4d441a8c-a7a3-4eaf-9cde-65c8bcbd6d67">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18yOTk_e563dbad-76c2-4597-813c-51fb466db35e"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18yOTk_baa31d10-b28e-4919-a307-f8be78572e01">December 31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"></td><td style="width:2.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6NzcyMGU4Yjk4YjMxNDk2Y2EyNjJmMmM5ODAwOGIxMGEvdGFibGVyYW5nZTo3NzIwZThiOThiMzE0OTZjYTI2MmYyYzk4MDA4YjEwYV8wLTAtMS0xLTMyOTA0_3c05c02c-6200-4e24-985f-5a63d1e3fc95">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from    to </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNzA_42c6e4de-6935-4bbb-a7d0-5fd212f20605">001-38295</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_________________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y180Nzk_48912097-4e31-4cd7-a582-8cb823e4a653">X4 PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">________________________________________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.689%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8wLTAtMS0xLTIwOTQwL3RleHRyZWdpb246NWVkYWMzODFlMGE3NDRhNDg1YjFlZDU4NzVjNTZmYTNfNQ_27e4cc91-53ad-4c95-aeb8-c832a7c47c7f">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%">(State or other jurisdiction of</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8wLTEtMS0xLTIwOTQwL3RleHRyZWdpb246MjI0ZWQ1YWQ1ODI3NGM3N2I4Y2NiNzRiZDJlYzFiMGFfMTA5OTUxMTYyNzgyMA_197a1343-c7ca-4c09-837c-29eda66fe1c6">27-3181608</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%">(I.R.S. Employer</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8yLTAtMS0xLTIwOTQwL3RleHRyZWdpb246MWU1OWM2ZWNiN2M2NDk0M2FhNDBmZjdjZGE3OWZiNTlfNQ_7904e6a5-890f-4109-a5d7-8070be49f95b">61 North Beacon Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8yLTAtMS0xLTIwOTQwL3RleHRyZWdpb246MWU1OWM2ZWNiN2M2NDk0M2FhNDBmZjdjZGE3OWZiNTlfOQ_4b0737b9-6325-42ca-a1ed-3c188491520c">4th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8yLTAtMS0xLTIwOTQwL3RleHRyZWdpb246MWU1OWM2ZWNiN2M2NDk0M2FhNDBmZjdjZGE3OWZiNTlfMTI_2614ee0a-d4cf-4a10-8247-b77f4290fe1b">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8yLTAtMS0xLTIwOTQwL3RleHRyZWdpb246MWU1OWM2ZWNiN2M2NDk0M2FhNDBmZjdjZGE3OWZiNTlfMTY_bae15610-582b-44d7-be1f-e9a1ca8693c1">Massachusetts</ix:nonNumeric></span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8yLTEtMS0xLTIwOTQwL3RleHRyZWdpb246NDgxNTJlZjI1NGNiNGZjYTg3YzRiYTA4NGQ2M2E1MzlfNQ_ea7399ef-7d82-46b3-81db-6a33266dca43">02134</ix:nonNumeric></span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y182NDU_c025ee48-3306-4909-ab84-baf46428696f">857</ix:nonNumeric>) <ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y182NDk_4f888a77-3272-4ca4-a6e4-86223831abef">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:31.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6OGI1OGYxNDEyNTMxNGYyYThmOTJmMzY1YzJkNjI5Y2IvdGFibGVyYW5nZTo4YjU4ZjE0MTI1MzE0ZjJhOGY5MmYzNjVjMmQ2MjljYl8xLTAtMS0xLTIwOTQw_910a5344-73b5-4dad-8e60-b78e077e460c">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6OGI1OGYxNDEyNTMxNGYyYThmOTJmMzY1YzJkNjI5Y2IvdGFibGVyYW5nZTo4YjU4ZjE0MTI1MzE0ZjJhOGY5MmYzNjVjMmQ2MjljYl8xLTItMS0xLTIwOTQw_ed7810a8-e42c-465e-ba30-13d95df13068">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6OGI1OGYxNDEyNTMxNGYyYThmOTJmMzY1YzJkNjI5Y2IvdGFibGVyYW5nZTo4YjU4ZjE0MTI1MzE0ZjJhOGY5MmYzNjVjMmQ2MjljYl8xLTQtMS0xLTIwOTQw_00ce34d6-37a5-4f4c-8c7d-a082a4e34c3a">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  &#160;Yes&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjc4_84d7b1b6-ea88-4aec-b7d7-42c062043c4b">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjcx_d9706a96-a287-40a3-a4cd-fb5c16a7df39">No</ix:nonNumeric>&#160; &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days <ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjcy_88a175d7-c41e-42b6-8c19-4d9f5e0a8f77">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (of this chapter) during the preceding 12 months (of for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjcz_e361f7d2-5bc1-4751-9e18-ff6d7ac8d8bc">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.118%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Large Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MzQ2ZTQyMGEzOTk3NGFiNGIyYTZiZGMyNDRjMzk0MzkvdGFibGVyYW5nZTozNDZlNDIwYTM5OTc0YWI0YjJhNmJkYzI0NGMzOTQzOV8xLTAtMS0xLTIwOTQw_18246dbd-8dfd-49db-a48b-b7d00db4c0b8">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MzQ2ZTQyMGEzOTk3NGFiNGIyYTZiZGMyNDRjMzk0MzkvdGFibGVyYW5nZTozNDZlNDIwYTM5OTc0YWI0YjJhNmJkYzI0NGMzOTQzOV8xLTQtMS0xLTIwOTQw_96b056e1-c441-4d7b-a28b-542fe6a643b8">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MzQ2ZTQyMGEzOTk3NGFiNGIyYTZiZGMyNDRjMzk0MzkvdGFibGVyYW5nZTozNDZlNDIwYTM5OTc0YWI0YjJhNmJkYzI0NGMzOTQzOV8yLTQtMS0xLTIwOTQw_f224d76e-d77b-4b8b-8902-d097acac4556">&#9746;</ix:nonNumeric></span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18yNDEy_17343d9f-c998-4d15-925b-8798729ecadf">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on an attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  Yes&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjc1_14246325-df15-4343-8171-bb4538c604c8">&#9744;</ix:nonNumeric>&#160;&#160;&#160;No&#160; &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjc2_d5a4df9c-50e9-4997-9ac9-77729ec38f4e">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">On June 30, 2021, the aggregate market value of the Registrant&#8217;s voting common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="ica45cd390e2849f4b2b75e21159c3a2f_I20210630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zMDMy_4b9fc1c1-c569-4f55-bf67-531249d541f9">158</ix:nonFraction> million based upon the closing sale price on the Nasdaq Capital Market reported on June 30, 2021.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.103%"><tr><td style="width:1.0%"></td><td style="width:31.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MTFkYjJkOWE3OWViNDY5NmJlNDI0N2ZiZGQ5ZjEyNGYvdGFibGVyYW5nZToxMWRiMmQ5YTc5ZWI0Njk2YmU0MjQ3ZmJkZDlmMTI0Zl8wLTEtMS0xLTMyMDIz_9caf83f2-5223-4fe3-9472-2a3f82126f67">PricewaterhouseCoopers LLP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MTFkYjJkOWE3OWViNDY5NmJlNDI0N2ZiZGQ5ZjEyNGYvdGFibGVyYW5nZToxMWRiMmQ5YTc5ZWI0Njk2YmU0MjQ3ZmJkZDlmMTI0Zl8wLTItMS0xLTMyMDI5_f982cfad-a132-4624-843e-56be904acfc0">Boston, Massachusetts, US</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Firm ID</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MTFkYjJkOWE3OWViNDY5NmJlNDI0N2ZiZGQ5ZjEyNGYvdGFibGVyYW5nZToxMWRiMmQ5YTc5ZWI0Njk2YmU0MjQ3ZmJkZDlmMTI0Zl8wLTMtMS0xLTMyMDI1_99c85bef-de89-4e66-9321-040bebbe8ae0">238</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of March&#160;14, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i124b0568b1914873ac60885d7abe74b5_I20220314" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zMTQ2_b78b2617-1263-4b17-a764-7438e5478966">30,809,376</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.001 par value per share outstanding. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"><div><span><br/></span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjc3_c0454bc9-aa2f-48cb-a2df-4ad49742fcbd" escape="true">Portions of the registrant&#8217;s definitive proxy statement, the (&#8220;2022 Proxy Statement&#8221;) for its&#160;2022&#160;Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant's fiscal year ended&#160;December&#160;31, 2021,&#160;are incorporated by reference into Part III of this Annual Report on Form 10-K.</ix:nonNumeric> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_22">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_25">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_25">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_28">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_28">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_28">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_31">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_31">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_31">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_34">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_34">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_34">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_37">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_37">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_37">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_40">Item 4</a>.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_40">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_40">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_43">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_46">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_46">MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_46">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_49">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_49">[RESERVED]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_49">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_52">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_52">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_52">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_79">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_79">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_79">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_82">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_82">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_82">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_85">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_85">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_85">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_88">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_88">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_88">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_91">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_91">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_91">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_620">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_94">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_97">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_97">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_97">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_100">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_100">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_100">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_103">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_103">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_103">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_106">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_106">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_106">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_109">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_109">PRINCIPAL ACCOUNT</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_109">ANT</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_109"> FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_109">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_112">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_115">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_115">EXHIBIT</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_115"> AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_115">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_118">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_118">94</a></span></div></td></tr></table></div><div id="i71bd745117f84268bb875bce92ea6db3_19"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that relate to future events or to our future operations or financial performance.&#160;These statements may be identified by such forward-looking terminology as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this report, regarding, among other things:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing, progress and reporting of results of our current trials of mavorixafor, including our global Phase 3 clinical trial in patients with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;), syndrome, our Phase 1b clinical trial in combination with ibrutinib in patients with Waldenstr&#246;m&#8217;s </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">macroglobulinemia (&#8220;Waldenstr&#246;m&#8217;s&#8221;), and our Phase 1b clinical trial as monotherapy in patients with severe congenital Neutropenia (&#8220;SCN&#8221;) and chronic neutropenia disorders;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, timing, design, progress, and results of our current and future preclinical studies and clinical trials of X4P-002&#160;and&#160;X4P-003&#160;or any of our other product candidates or our research and development programs that we pursue; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of the ongoing COVID-19 pandemic on our business, operations, strategy, goals and anticipated timelines; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the diversion of healthcare resources away from the conduct of clinical trials as a result of the ongoing COVID-19 pandemic and its variants, including the diversion of hospitals serving as our clinical trial sites and of hospital staff or independent physicians supporting the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential benefits, including clinical utility, that may be derived from any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of and our ability to obtain and maintain regulatory approval of our existing product candidates or any product candidates that we may develop in the future, and any related restrictions, limitations, or warnings in the label of any approved product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to research, develop, manufacture and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of our regulatory filings for our product candidates, along with regulatory developments in the United States and other foreign countries;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the size and growth potential of the markets for our product candidates, if approved, and the rate and degree of market acceptance of our product candidates, including reimbursement that may be received from payors; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the benefits of U.S. Food and Drug Administration and European Commission designations, including, without limitation, Fast Track, Orphan Drug and Breakthrough Therapy;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract and retain qualified employees and key personnel;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitive position and the development of and projections relating to our competitors or our industry;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding our ability to obtain and maintain intellectual property protection;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our estimates and expectations regarding future operations, financial position, revenues, costs, expenses, uses of cash, capital requirements or our need for additional financing;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to in-license, acquire, develop and commercialize additional product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of laws and regulations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to identify additional product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to raise additional capital; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our strategies, prospects, plans, expectations or objectives.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should refer to the section titled &#8220;Risk Factors&#8221; in this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, references in this Annual Report to &#8220;X4&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to X4 Pharmaceuticals, Inc. and its subsidiaries.  </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i71bd745117f84268bb875bce92ea6db3_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ITEM 1. &#160;&#160;&#160;&#160;BUSINESS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are late-stage clinical biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, with an initial focus on the treatment of people with immune system dysfunction. Our lead product candidate, mavorixafor, is a first-in-class, small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Due to mavorixafor&#8217;s demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (&#8220;WBCs&#8221;), we believe that mavorixafor has the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies (&#8220;PIDs&#8221;) and certain types of cancer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently studying the safety and efficacy of mavorixafor in a global Phase 3 clinical trial for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. We are also conducting a Phase 1b clinical trial of mavorixafor in people with chronic neutropenia, and a Phase 1b clinical trial of mavorixafor in combination with the Bruton tyrosine kinase inhibitor (&#8220;BTKi&#8221;) ibrutinib in people with Waldenstr&#246;m&#8217;s macroglobulinemia (&#8220;Waldenstr&#246;m&#8217;s&#8221;), a rare B-cell lymphoproliferative disorder, and confirmed mutations to both the CXCR4 and MYD88 genes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed enrollment in our global Phase 3 clinical trial of mavorixafor for the treatment of in WHIM syndrome, which we refer to as the &#8220;4WHIM trial&#8221;, in the third quarter of 2021, with 31 patients enrolled. We currently expect to report top-line data from the trial in the fourth quarter of 2022. The U.S. Food and Drug Administration (&#8220;FDA&#8221;) has granted certain special designations to mavorixafor, including Breakthrough Therapy Designation for the treatment of adults with WHIM syndrome, Fast Track Designation for adults with WHIM syndrome, and Rare Pediatric Designation for the treatment of people aged 12 to 18 with WHIM syndrome, which could result in accelerated review by the FDA. We have begun building our commercial team in anticipation of a possible New Drug Application (&#8220;NDA&#8221;) submission to the FDA in the second half of 2023, with the goal of obtaining approval for mavorixafor for the treatment of people in the United States, aged 12 and older, with WHIM syndrome should the final Phase 3 data support the filing of an NDA. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The incidence and prevalence of WHIM syndrome are not well established. Over the past several years, we have conducted multiple market research studies, querying both physicians and insurance databases, that have indicated that the prevalence of WHIM syndrome worldwide is significantly higher than previous registries have suggested. These studies have suggested that there may be as many as 3,700 WHIM patients in the United States based on certain WHIM-like phenotypes. In addition, in December 2021, we announced that our clinical and laboratory research had resulted in the identification of a new missense mutation (&#8220;D84H&#8221;) that shows gain-of-function signaling and WHIM disease phenotype. We believe that the frequency of the D84H mutation, as derived from broad population genomic databases, further supports our current WHIM prevalence estimate of 1,000 to 3,500 or more patients in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following announcements of positive preliminary data from both of the ongoing Phase 1b clinical trials of mavorixafor during 2021, we have continued patient enrollment. Additional data are expected from the Phase 1b clinical trial in chronic neutropenia by the third quarter of 2022 and from the Phase 1b clinical trial in Waldenstr&#246;m&#8217;s in the second half of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Our Strategy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to discover, develop, and commercialize novel therapeutics that address diseases resulting from dysfunction of the immune system by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Completing our ongoing global Phase 3 clinical trial to enable the approval of mavorixafor for the treatment of patients with WHIM syndrome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To date, we have reported positive data from our Phase 2 clinical trial with long-term extension of mavorixafor in patients with WHIM syndrome, achieving clinical proof-of-concept, observing long-term and clinically meaningful increases in neutrophil and lymphocyte counts, decreased frequency of infections, reductions in the number of wart lesions, and a favorable tolerability profile. We are conducting a global Phase 3 pivotal clinical trial, which we refer to as the 4WHIM trial, and completed enrollment in this trial in the third quarter of 2021.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Driving community awareness of WHIM syndrome and building patient registries</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are building our efforts to increase awareness of underserved serious rare diseases, including WHIM syndrome, among patients, physicians, and their support systems. In addition to sponsored market research and outreach, we have partnered with key patient foundations and registries, including the Jeffrey Modell Foundation, University of Washington, Immune Deficiency Foundation, and Hopitaux Universitaires Est Parisien (Trousseau La Roche-Guyon). In addition, we have deployed a field force of Medical Science Liaisons (&#8220;MSLs&#8221;) and Patient Diagnostic Liaisons (&#8220;PDLs&#8221;) in the United States to further drive education and awareness of WHIM syndrome and to assist in identifying WHIM patients. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advancing mavorixafor in additional indications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To maximize the potential of mavorixafor, we have initiated two Phase 1b proof-of-concept clinical trials in two additional indications:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Chronic neutropenia: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Phase 1b</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial investigating the safety and efficacy of mavorixafor in patients with chronic idiopathic neutropenia is ongoing; preliminary results to date from the trial have been positive, with all patients reporting increases in WBCs, and absolute neutrophil, lymphocyte, and monocyte counts (&#8220;ANC,&#8221; &#8220;ALC,&#8221; and &#8220;AMC&#8221;).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Waldenstr&#246;m&#8217;s macroglobulinemia:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a Phase 1b dose-ranging trial investigating the safety and efficacy of mavorixafor in combination with ibrutinib in patients with confirmed MYD88 and CXCR4 mutations is ongoing; preliminary results have been positive, with meaningful decreases in immunoglobulin M (&#8220;IgM&#8221;) levels, increases in hemoglobin, and a 100% overall response rate (&#8220;ORR&#8221;) seen in patients as of the data cut-off date of October 12, 2021.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advancing earlier-stage product candidates and leveraging insights into CXCR4 biology to further expand our pipeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have advanced X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, into pre-IND studies. We beleive this lead-optimization program could potentially enable us to pursue broader opportunities in CXCR4-dependent disorders and primary immunodeficiencies. Our second development program is X4P-002, a CXCR4 antagonist designed to cross the blood-brain barrier and provide appropriate therapeutic exposures to potentially treat brain cancers in combination therapy, which is being evaluted in IND-elabling studies. We may potentially expand the program to cover other CNS and non-CNS diseases where CXCR4 inhibitors may provide therapeutic benefit. In addition, we are also leveraging our insights into CXCR4 biology and our research capabilities to identify other targets and develop additional product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Independently commercializing our product candidates in certain indications and geographies where we believe we can maximize value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Given the potential of our product candidates to treat a wide variety of diseases, we believe that it will be important to maintain our leadership role with respect to our development and commercialization efforts. We plan to independently develop therapeutic candidates in additional indications where we believe there are high unmet medical needs, including other rare diseases, and markets in that we believe we could successfully market and commercialize, if approved. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pursuing additional strategic collaborations for mavorixafor in immuno-oncology indications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Currently, we have an ongoing strategic collaboration under which we have licensed mavorixafor rights in China to Abbisko, a privately held immuno-oncology research and development company. Additionally, we intend to pursue strategic collaborations for future development and potential commercialization of mavorixafor in certain immuno-oncology indications in other global regions in order to maximize stockholder value of the program and our asset, while maintaining our focus on developing mavorixafor for the treatment of rare diseases. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div><img src="xfor-20211231_g1.jpg" alt="xfor-20211231_g1.jpg" style="height:270px;margin-bottom:5pt;vertical-align:text-bottom;width:696px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">X4 Pharmaceuticals, Data on File  1. Phase 2 open label trial extension (OLE) trial for WHIM ongoing  2. Company market research. Qessential m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:107%">arket research, 2019 and IPM. ai artificial intelligence study, 2020   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">3. Estimate using Andersen et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:107%">J Intern Med. 2016 Jun:279(6):566-75   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:107%">WM Epidemiology Analysis Nemetz Group. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Our Focus on CXCR4</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CXCR4, or C-X-C chemokine receptor type 4, is a G-coupled protein receptor, or GCPR, and its sole ligand is the chemokine CXCL12. Chemokines are signaling proteins that guide the migration of immune cells within the body by binding to receptors on the surface of target cells. When CXCR4 is stimulated by CXCL12, it plays a key role in regulating the expansion, maturation, and trafficking of white blood cells, or leukocytes, and maintaining healthy immune system function. (see Figure 1).</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Figure 1: The CXCL12/CXCR4 Pathway: Regulators of Healthy Immune System Function</span></div><div><img src="xfor-20211231_g2.jpg" alt="xfor-20211231_g2.jpg" style="height:416px;margin-bottom:5pt;vertical-align:text-bottom;width:696px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dysregulation of white blood cells contributes to a broad range of serious conditions with unmet medical needs. This dysregulation can be caused by several factors:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the case of PIDs, such as WHIM syndrome and certain neutropenia conditions, overstimulation or overactivation of the CXCR4 pathway can be caused by mutations in the CXCR4 receptor, called &#8220;gain of function&#8221; mutations, that immobilize WBCs in the bone marrow where they are produced. This can dramatically impact their ability to move into the blood and circulate throughout the body to maintain a healthy immune system.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In certain lymphomas, such as Waldenstr&#246;m&#8217;s, CXCR4 pathway dysfunction can cause cancerous B cells to remain in the bone marrow, shielding them from effective cancer therapeutics and impacting the ability to maintain a healthy immune system.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the inhibition of the CXCL12/CXCR4 signaling pathway has the potential to improve immune cell maturation and trafficking and create therapeutic benefit across a wide variety of diseases, whether caused by CXCR4 mutation or not. In previous clinical and research studies, CXCR4 antagonism has been proven to: increase the maturation and mobilization of WBCs in all those dosed, including healthy volunteers, increase circulating neutrophils, lymphocytes, and monocytes, reduce bacterial and viral infections, and reduce lymphoma burden in combination with approved oncology therapeutics.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further supporting this hypothesis, inhibition of the CXCR4 receptor has been validated by the FDA-approved product plerixafor for injection (marketed as Mozobil&#174;). Plerixafor is a CXCR4 antagonist that has been shown to induce white blood cell mobilization and is used as an injectable therapy for short-term treatment in preparation for stem-cell transplants. In a published investigator-sponsored pilot study of WHIM patients, twice-daily injections of low-dose plerixafor demonstrated increased WBC counts and reduced infections and wart lesions. Plerixafor is not approved for the treatment of WHIM syndrome nor are we aware of any plans to develop and commercialize it as a treatment for patients with WHIM syndrome or any other immunodeficiencies.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Our Development of Mavorixafor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate is mavorixafor, a first-in-class, oral, selective small molecule CXCR4 antagonist that inhibits receptor binding by CXCL12, the cognate ligand of CXCR4. Mavorixafor is designed to correct the abnormal signaling caused by the dysfunction of the receptor/ligand interaction and enable mobilization and trafficking of immune cells, increasing levels of circulating WBCs, including neutrophils, to improve immune system function.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, more than 200 patients in clinical trials have been dosed with mavorixafor, which has demonstrated a favorable tolerability profile. In these trials, we have observed drug exposure in patients, a 23-hour half-life, and the bioavailability of mavorixafor to support once-daily oral dosing, which we believe would provide convenient dosing and better patient compliance for chronic or life-long use, if approved. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we presented summary data supporting what we believe to be a broader potential for mavorixafor than previously understood:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ongoing studies across a wide variety of diseases, including WHIM syndrome, chronic idiopathic neutropenia Waldenstr&#246;m&#8217;s, and clear cell renal cell carcinoma (&#8220;ccRCC&#8221;), show that oral administration of mavorixafor increases blood neutrophils, lymphocytes, and monocytes durability over months. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mavorixafor efficacy has been observed with short-term and long-term treatment both alone and in combination with other therapies, including axitinib, ibrutinib, and granulocyte-colony stimulating factor (&#8220;G-CSF&#8221;).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We believe that these results suggest that mavorixafor, through its mechanism of CXCR4 antagonism, has the potential to reduce the prevalence and/or severity of a broader array of immunodeficiencies than previously recognized, regardless of the presence or absence of CXCR4 mutations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for mavorixafor utilizes well established small molecule chemistry, creating the potential for a commercial product that can be supported by specialty pharmacy distribution.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Mavorixafor in WHIM Syndrome</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PIDs are a group of more than 450 rare, chronic disorders in which flaws in the immune system cause increased susceptibility to infections and, in some cases, increased risk of cancers. WHIM syndrome is a rare PID that results from &#8220;gain of function&#8221; mutations in the single gene that encodes for the CXCR4 receptor. In healthy individuals, the CXCR4 receptor is typically internalized into the cell after CXCL12 binds to it, enabling the receptor to be appropriately &#8220;recycled&#8221; and the signaling to be diminished. In WHIM patients, however, a mutation truncates the intracellular portion of the CXCR4 receptor, which prevents the post-binding internalization (&#8220;normal recycling&#8221;) of the receptor. As a result, the CXCR4 receptor is maintained on the surface of the cell and is exposed to the ligand, which creates a perpetual &#8220;on&#8221; signal and retention of WBCs in the bone marrow where they are produced, leading to the chronic peripheral neutropenia, lymphopenia and monocytopenia that are the clinical hallmarks of WHIM syndrome. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to life-long cytopenias, WHIM patients can clinically present with additional manifestations of the disease, such as warts related to infection with the Human Papilloma Virus (&#8220;HPV&#8221;). Based on publications from the French Severe Congenital Neutropenia Registry and the broader literature, it is estimated that between 30% and 40% of WHIM patients develop HPV-associated cancers as they age. Patients may also demonstrate low immunoglobulin, or IG, levels, also known as hypogammaglobulinemia and pathology assessments of bone marrow samples (aspirates) of patients with WHIM syndrome show a hyper-dense population of pre-apoptotic immune cells in the bone marrow, a condition known as myelokathexis. These conditions reduce the body&#8217;s ability to achieve a healthy immune response. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a diagnosis of WHIM syndrome, all four classic characteristics of warts, hypogammaglobulinemia, infections, and myelokathexis do not need to be present, which can complicate the diagnosis of these patients. Genetic testing is used to definitively diagnose WHIM syndrome by confirming the presence of a mutation in the CXCR4 receptor where only one mutated gene needs to be affected to cause the disorder. The diagnosis of WHIM syndrome may occur at any age: about one-half of reported patients are diagnosed as children, primarily before of at the age of 18 years, with the other half diagnosed as adults, mostly between 18 and 40 years of age.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The incidence and prevalence of WHIM syndrome are not well established. We believe that this is due to the relatively recent understanding of the genetics underlying WHIM syndrome, lack of universal or accessible genetic testing, and limited medical education and awareness of the disease, which is in part driven by the lack of available disease-modifying treatments. Based on a preliminary independent market research study that we sponsored in the U.S. conducted by a third-party research firm, we believe that the prevalence of WHIM syndrome worldwide is significantly higher than previous registries suggest. The study solicited </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">input from community-based physicians of different specialties, including physicians focused on non-malignant hematology, immunology, dermatology, pulmonology, and infectious diseases, who are known to manage and/or treat patients with WHIM syndrome. The 212 physicians across these specialties identified to participate in this study reported more than 1,700 patients in the United States with genetically confirmed or highly probable WHIM syndrome. In addition, we have also completed a study using artificial intelligence, interrogating a database of approximately 300 million American lives that included up to 10 years of insurance claims on diagnoses, drug treatments, procedures, and treatment pathways. This study suggests that there may be as many as 3,700 WHIM patients in the United States based on the WHIM-like phenotypes described.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced that our clinical and laboratory research has resulted in a broader understanding of the spectrum of WHIM syndrome, both phenotypically and genotypically. The first CXCR4 mutation determined to cause WHIM syndrome was identified in 2003. Since then, several CXCR4 mutations have been identified as &#8220;gain of function&#8221; mutations causing WHIM syndrome. Our research has subsequently identified a new missense mutation, called D84H, that is relatively frequent in the general population. The D84H mutation is the first mutation to be identified outside of the C-terminus of the CXCR4 receptor showing gain-of-function signaling and WHIM disease phenotype. We believe that the frequency of the D84H mutation, as derived from broad population genomic databases, further supports our current WHIM prevalence estimate of 1,000 to 3,500 or more patients in the United States. Our research into additional WHIM-causing genetic mutations and expanded understanding of the clinical phenotype is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">Clinical Development of Mavorixafor in WHIM Syndrome</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to treating WHIM syndrome involves blocking abnormal CXCR4 signaling using our CXCR4 antagonist candidate, mavorixafor. Mavorixafor has been shown to bind to the mutated CXCR4 receptor in a manner that blocks the receptor from being stimulated by CXCL12 regardless of the presence of the ligand, enabling WBCs to properly mature and release into the bloodstream, restoring normal immune cell numbers and function.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we initiated a Phase 2 clinical trial of mavorixafor for the treatment of patients with WHIM syndrome. This trial was an open-label, dose-escalation trial in eight WHIM patients conducted at two sites in the United States and Australia pursuant to an Investigational New Drug (&#8220;IND&#8221;) application that we submitted to the FDA in June 2016. The primary objective of the Phase 2 clinical trial was to determine the safety and tolerability of mavorixafor and to determine the dose of mavorixafor for exploration in a Phase 3 pivotal clinical trial. The secondary objective of the Phase 2 trial was to evaluate the potential efficacy of mavorixafor in patients with WHIM syndrome by measuring biomarkers, specifically absolute neutrophil and lymphocyte counts, over 24-hour dosing cycles. The frequency of infections, antibiotic use, hospitalizations, severity of warts lesions, and vaccine titer levels, among other metrics, were also examined. To be included in the trial, patients must have had a confirmed genetic diagnosis of WHIM syndrome, be at least 18 years of age and have a neutrophil count equal to or less than 400/&#181;L or a lymphocyte count equal to or less than 650/&#181;L. Patients who had been infected with the human immunodeficiency virus (&#8220;HIV&#8221;) were excluded from the trial, as were patients with recent exposure to plerixafor.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the trial, patients received escalating doses of mavorixafor starting at 50 mg once daily to up to 400 mg once daily. Patients received starting doses higher than 50 mg once daily as the trial progressed based on the safety and biomarker response data of earlier patients enrolled in the trial. Patients were dose-escalated from their starting dose based on an in-hospital 24-hour measurement of ANC and ALC above or below the pre-defined target thresholds of 600/&#181;L and 1,000/&#181;L, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the dose-titration portion of the Phase 2 clinical trial in March 2018 and, based on the reported results, the Data Review Committee recommended the Phase 3 dose of 400 mg administered once daily. The choice of time above threshold for absolute neutrophil count (&#8220;TAT-ANC&#8221;), defined as the number of hours during which the absolute neutrophil count is raised above a 500 cells per microliter threshold, was selected as the primary endpoint of the Phase 3 clinical trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results from the dose-titration portion of the trial were as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mavorixafor was not associated with any treatment-related serious adverse events and was observed to be well tolerated in daily doses of up to 400 mg for durations of up to 400 days. Treatment-related adverse events reported were dry mouth (n=2), nausea (n=4), dry eye (n=1), nasal dryness (n=2), dyspepsia (n=1), conjunctivitis (n=1) and rash (n=1). All adverse events were Grade 1 (mild). </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ANCs were increased in total numbers (cells/&#181;L) as well as duration of increase (hours) over the course of the intra-day assessment. The increase in ANC vs. pre-dosing levels was observed in all evaluable patients in the trial (n=7). In five of seven patients (71%), ANCs were consistently elevated above the pre-defined target threshold of 600/&#181;L at peak as well as throughout the 24-hour assessment period. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Similarly, ALCs were increased in total numbers (cells/&#181;L) as well as duration of increase with the treatment of mavorixafor. The increase in ALCs were observed in all evaluable patients (n=7) with six of seven patients (86%) exceeding the pre-defined target threshold of 1,000/&#181;L for ALCs (the lower limit of normal) throughout the 24-hour assessment period. (These thresholds of 600/&#181;L for ANCs and 1,000/&#181;L for ALCs correspond to the National Cancer Institute&#8217;s adverse event grading system, which considers ANCs below 500/&#181;L to be severe or life threatening and ALCs of 1,000/&#181;L within the range of healthy individuals.)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients experienced improved infection rates, as reported by patients and the trial investigators. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant and visible reductions in wart lesions were also reported in a patient with a history of untreatable severe wart lesions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following completion of the dose-titration portion of the Phase 2 clinical trial, patients were allowed to continue on study drug in a Phase 2 open-label extension trial. In June 2020, we announced the following positive data from the open-label extension portion of the Phase 2 clinical trial:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sustained, dose-dependent increases in WBCs, ANC, and ALC were achieved; higher doses of mavorixafor were shown to increase the TAT-ANC at least 4.5-fold versus the TAT-ANC at lower doses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">These long-term hematological improvements correlated with fewer infections and reduced numbers of cutaneous warts.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">A decreased yearly infection rate from 4.63 [95%CI 3.3,6.3] events in the 12 months prior to the trial, to 2.27 [95%CI 1.4, 3.5] events when treated with mavorixafor at higher doses once daily; notably, deeper reductions in yearly infection rates correlated with increased time on treatment.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The patients with cutaneous warts on hands and/or feet at baseline achieved an average 75% reduction in the number of warts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mavorixafor was well-tolerated for the extended duration of up to more than two years without any attributable serious adverse effects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced the following additional data from the Phase 2 open-label extension trial of mavorixafor in WHIM patients:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mavorixafor continued to show durable increases in neutrophils, lymphocytes, and monocytes, sustained improvements in infections and warts, and has been well tolerated (median treatment duration = 148.4 weeks).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreases in mean annualized infection rates correlated well with TAT-ANC.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Standardized patient interviews revealed that long-term treatment with mavorixafor was well tolerated and continued to demonstrate beneficial treatment effects, including decreased frequency, severity, and duration of infections and fewer hospital/doctor visits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we initiated 4WHIM, a pivotal, global, randomized, double-blind, placebo-controlled, multicenter Phase 3 clinical trial designed to evaluate the efficacy and safety of mavorixafor in genetically confirmed WHIM patients. Originally designed to enroll 18-28 patients, the trial achieved full enrollment in September 2021, with 31 patients who are aged 12 and older receiving either 200-400 mg mavorixafor or placebo orally once daily for 52 weeks; all patients then become eligible to receive treatment with mavorixafor in an open-label trial extension. The primary endpoint of the 4WHIM trial is a clinically relevant reduction of duration of severe neutropenia as measured by the increase in TAT-ANC (500 cells per microliter) in peripheral blood. Secondary endpoints include time above threshold-absolute lymphocyte count (TAT-ALC) of &#8805; 1000 cells/&#956;L over a 24-hour period, a composite clinical efficacy endpoint for mavorixafor based on total infection score and total wart change score, total wart change score for mavorixafor based on central blinded, independent review of 3 target skin regions, total infection score for mavorixafor based on number and severity of infections adjudicated by a blinded, independent adjudication committee; and a number of quality-of-life measurements and other exploratory endpoints.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has granted several special designations for mavorixafor in the WHIM indication that could result in accelerated review, should the clinical results of the 4WHIM study support an NDA filing. The FDA has granted Breakthrough Therapy Designation for mavorixafor for the treatment of adults with WHIM. The FDA has also granted Fast Track Designation for mavorixafor for adults with WHIM and Rare Pediatric Designation for mavorixafor for the treatment of WHIM patients aged 12 to 18.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect to report top-line data from the 4WHIM trial in the fourth quarter of 2022 and are targeting submission to the FDA of an NDA in the second half of 2023 with the goal of obtaining approval for mavorixafor for the treatment of people in the United States, aged 12 and older, with WHIM syndrome should the final Phase 3 data support the filing of an NDA. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">Limited Current Treatment Landscape for WHIM Syndrome</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there are no approved targeted therapies for the treatment of WHIM syndrome and care is limited to the treatment of the syndrome&#8217;s different symptoms. The care of WHIM patients is mainly focused on the prevention and management of infections. None of these treatments, however, has been clinically proven to be effective for treating WHIM syndrome nor do any address the underlying cause of this multi-faceted disease, the genetic defect of the CXCR4 receptor. Current symptoms and their limitations are as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Warts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The presence of warts in WHIM syndrome is driven by an underlying HPV infection. Standard treatments, such as topical therapies (for example, imiquimod and salicylic acid), cryotherapy and laser therapy, as well as more aggressive approaches, such as cauterization or surgical removal, have been ineffective in providing durable treatment of warts associated with chronic HPV infections. As WHIM patients generally have limited response to vaccines, the HPV vaccine appears to have limited effectiveness. The number, size and severity of visible warts in WHIM patients can have a significant negative impact on the patient&#8217;s quality of life and result in social anxiety issues. Left untreated, chronic HPV-infections are also known to increase the risk of cancer. Patients with WHIM syndrome are reported to have more frequent occurrences of difficult to treat HPV-associated cancers, such as head and neck and anogenital cancers.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Hypogammaglobulinemia: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intravenous or subcutaneous immunoglobulin (&#8220;IG&#8221;) administration, referred to as IVIG or SCIG, respectively, can be administered to patients with low IG levels. In WHIM patients, the administration of IG therapies raises IG levels, but has shown no impact on circulating leukocytes and limited or no impact on immune responses. IG treatment of patients with WHIM syndrome is based on empirical and anecdotal evidence, and there are no clinical data demonstrating the efficacy of IG treatment for WHIM syndrome. IG treatment also does not treat or protect against HPV-associated symptoms and diseases, such as warts and certain cancers. Furthermore, IG administration is costly and time consuming.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Infections: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bacterial infections are managed with antibiotics. Acute infections usually resolve, although we are aware of reports from clinicians citing death due to pneumonia or sepsis in young WHIM patients. Importantly, even with antibiotic use, infections recur more frequently and persist longer in patients with WHIM syndrome. Further, the toll of multiple, chronic infections in WHIM patients has been known to lead to devastating irreversible pathologies such as hearing loss due to chronic ear infections and bronchiectasis, or damaged lung airways. Patients are sometimes given granulocyte-colony stimulating factor, or G-CSF, to increase neutrophil counts, but G-CSF has demonstrated little, if any, impact on lymphopenia or the incidence of infections in WHIM patients. In a small registry of eight WHIM patients in France, three of the four patients who received G-CSF continued to have persistent, repeated infections. Side effects of G-CSF have been reported to include disabling bone pain, which can be more severe in certain age groups. Additional, less common, treatment-limiting complications of chronic G-CSF administration include myelofibrosis and leukemia. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Myelokathexis: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G-CSF is sometimes used to treat the myelokathexis characteristic of WHIM syndrome to try to increase the number of neutrophils outside of the bone marrow, but G-CSF has no effect on lymphocytes and other types of white blood cells. Side effects of G-CSF can include mild to severe bone pain, myelofibrosis, and leukemia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the costs of managing the chronic impact of WHIM syndrome are unknown, the per-patient cost of treating PIDs that are similar to WHIM syndrome, based on drug costs alone, exceeds $100,000 per year in the United States for therapies such as antibiotics, IVIG, SCIG and/or G-CSF, despite the limited effectiveness of these treatments. Beyond these estimated direct costs, other costs associated with direct and indirect management of the disease, such as repeated immunization, physician visits, or hospitalizations, have not been quantified but are likely to be significant. We believe that there is a significant need for a treatment targeting the underlying excessive signaling caused by mutations to the CXCR4 receptor, which is the established cause of WHIM syndrome.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Mavorixafor for the treatment of Chronic Neutropenia (&#8220;CN&#8221;)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to its demonstrated ability to broadly and durably elevate WBCs including neutrophils, we believe that mavorixafor may be useful in the treatment of patients with severe congenital neutropenia, or SCN, and other chronic neutropenia disorders. Chronic neutropenia is defined as periods lasting more than three (3) months persistently or intermittently where there are abnormally low levels of neutrophils circulating in the blood, and may be congenital, idiopathic, or cyclic. Like WHIM syndrome, chronic neutropenia disorders, including SCN, are rare blood conditions similarly characterized by increased risks of infections and cancer due to abnormally low levels of neutrophils in the body. In all cases, the CXCL12/CXCR4 pathway is the key regulator of neutrophil release from the bone marrow.Additionally, some sub-types of CN have mechanisms that overlap with signaling of the CXCL12/CXCR4 pathway. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently completed an electronic medical records study to better understand the risk of serious or severe infection in people with CN in the United States, analyzing the medical records of 44 healthcare organizations treating approximately 66 million patients. The analysis examined patients who had experienced at least two Serious Infections Events (&#8220;SIEs&#8221;) following a documentation of chronic neutropenia in each calendar year compared with those who did not have neutropenia. SIEs are defined as infections requiring hospitalization or intravenous antibiotics or that result in disability or death. The results of this analysis indicated that the incidence rate of SIEs per 100,000 person days was increased for all levels of chronic neutropenia: it was two times greater for patients with any chronic neutropenia (ANC less than 1,500 cells per microliter) and four times greater for patients with severe congenital neutropenia (ANC less than 500 cells per microliter). The risk of serious infection increased with the worsening of neutropenia. Approximately 25% of patients with chronic neutropenia had at least 2 SIEs in the latest calendar year examined, which was 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this analysis, an initial extrapolation from the approximate 66 million patient sample to the total U.S. population would yield 20,000 patients with CN, with a prevalence of ~7 in 100,000.  X4 plans to continue to refine this estimate based on additional analyses, as prevalence estimates vary in rare disease.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G-CSF is the current standard of care for CN and is used to stimulate the bone marrow to produce neutrophils. Side effects of G-CSF include disabling bone pain, which can be more severe in certain age groups. Additional, less common, treatment-limiting complications of chronic G-CSF administration include myelofibrosis and leukemia. In CN cases that are unresponsive to G-CSF, or if leukemia has developed, bone marrow transplants have been made with varying degrees of success. Bone marrow transplantation is often applied to severe neutropenia from bone marrow failure. Bone marrow transplants bring additional risks into the management of the disorders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">Clinical Development of Mavorixafor in Chronic Neutropenia</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a proof-of-concept, Phase 1b clinical trial designed to assess the safety and tolerability of daily, oral mavorixafor in participants with SCN and other chronic neutropenia disorders. In addition, the trial is evaluating the neutrophil response in these patient populations as an independent agent or in combination with G-CSF. The trial is now enrolling patients with moderate and severe congenital neutropenia to assess the safety and tolerability of one dose of mavorixafor and to measure the effect of this one dose on patient neutrophil counts in the peripheral blood. Originally designed to enroll up to 45 patients in total and treated for 14 days, we have reduced the enrollment goal in the trial to include up to 25 patients across a variety of neutropenia conditions; and reduced the treatment duration from 14 days to 1 day. Our data shows one day of treatment is sufficient to assess bone marrow reserve and response to mavorixafor, and  we believe approximately 25 study participants will be sufficient to complete the enrollment goals of the trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced initial results from the ongoing mavorixafor Phase 1b clinical trial in patients with CN. Four adult patients with chronic idiopathic neutropenia taking stable, daily injections of G-CSF had their WBCs, ANC, ALC, and AMC measured over 6 hours the day before and on the following day after administration of the first dose of mavorixafor. The results from the trial showed a clear and consistent elevation of WBCs, ANC, ALC, and AMC in all 4 patients, which was seen after 1 hour and sustained over 6 hours. We expect to announce additional data from this ongoing Phase 1b clinical trial by the third quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Mavorixafor in Waldenstr&#246;m's macroglobulinemia</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that mavorixafor may be used to treat certain blood cancers, including Waldenstr&#246;m&#8217;s. Waldenstr&#246;m&#8217;s is a rare form of non-Hodgkin&#8217;s lymphoma and B-cell lymphoproliferative disorder most often caused by mutations in a gene for MYD88. Approximately 30-40% of all Waldenstr&#246;m&#8217;s patients have been shown to have second mutation, a somatic WHIM-like activating mutation in the CXCR4 gene in the cancer cells that define this rare form of lymphoma. Mutational status influences both clinical presentation and prognosis as well as provides potential implications for therapeutic options. Patients with the CXCR4 mutations have higher serum immunoglobulin M (&#8220;IgM&#8221;) levels and greater incidence of symptomatic hyperviscosity. These patients also have a worse prognosis and weaker responses to treatment with Bruton tyrosine kinase (BTK) inhibitors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Waldenstr&#246;m&#8217;s, somatic mutations of CXCR4 have been found to be associated with activating and pro-survival signaling of tumor cells, as well as the possible acquisition of resistance to several drugs, including anti-CD20 monoclonal antibodies, and BTK inhibitors, such as ibrutinib, the current standard of care. For example, Waldenstr&#246;m&#8217;s patients with a CXCR4 mutation who have been treated with ibrutinib have generally not responded as well to treatment as compared to patients without a CXCR4 mutation. Seminal work from Dr. Steven P. Treon M.D., Ph.D., of Harvard Medical School and colleagues, have demonstrated that patients with the double mutation (MYD88/CXCR4-WHIM) have a lower rate of Very Good Partial Response, or VGPR, and Minor Response (&#8220;MR&#8221;) as well as longer time to MR (31% vs. 7% VGPR, 94% vs. 71% for MR and 1 month to MR in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">single-mutation vs. 7.3 months in the double-mutation population). This is true in treatment-na&#239;ve patients with similar worse outcomes in the double-mutation population shown by both Drs. Treon and Buske in previously treated patients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Clinical Development of Mavorixafor in Waldenstr&#246;m's Macroglobulinemia</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we initiated a Phase 1b clinical trial of mavorixafor, in combination with ibrutinib, in patients with Waldenstr&#246;m&#8217;s and confirmed MYD88 and CXCR4 genetic mutations. The ongoing Phase 1b, open-label, multicenter, single-arm clinical trial examines intra-patient dose escalation, safety, pharmacokinetics, and pharmacodynamics of mavorixafor in combination with ibrutinib in 12 to 18 patients aged 18 years or older. In the trial, all three cohorts (Cohorts A, B and C) are dosed with oral, once-daily doses of ibrutinib 420mg. In Cohorts A and B, patients are initiated on a dose of oral, once-daily 200 mg mavorixafor (low dose) and are escalated to 400mg mavorixafor (mid-dose) after 28 days if tolerated and no dose-limiting toxicities are observed in at least five of six participants. Patients in Cohort C are initiated a does of oral, once daily 400mg mavorixafor. Participants are escalated to 600mg mavorixafor (high dose) after 400 mg mavorixafor is deemed tolerable. All patients are followed in the trial for adverse events and change from baseline in serum IgM and hemoglobin, pharmacokinetics, and pharmacodynamic markers, including peripheral WBCs and clinical response. Clinical responses are also determined over time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced clinical results from the ongoing Phase 1b dose-ranging clinical trial:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of the data cutoff of October 12, 2021, 16 patients were enrolled, with 14 being evaluable, all evaluated at low- (200 mg) and mid-level (400mg) dosing of mavorixafor. The median duration of treatment at that time was 272.5 days (range 33-435 days) and 12 patients remained on study. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For all patients on study at that time, including both frontline and refractory, the median level of serum IgM reduced from 47.2 g/L (n=14) at baseline to 7.73 g/L (n=3) after 12 months of treatment. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In 10 patients evaluable for response, the ORR was 100% (ORR defined as a greater than 25% but less than 50% reduction in serum IgM), with four achieving a Major Response (greater than 50% reduction in serum IgM), including one Very Good Partial Response of greater than 90% reduction in serum IgM. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The median level of hemoglobin approached normal, increasing by approximately 38 g/L from baseline (n=14) to month 12 (n=3). </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Overall, the combination of mavorixafor and ibrutinib was tolerated with a manageable safety profile at the low- and mid-level dosing of mavorixafor. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial has successfully enrolled patients to assess the safety of the 600mg dose; no dose limiting toxicities occurred and all patients in the trial at the 400mg dose are now eligible to be dose-escalated to the 600mg dose of mavorixafor. We anticipate reporting additional data from this trial during the second half of 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This trial is being conducted as part of a collaboration with The Leukemia &amp; Lymphoma Society (&#8220;LLS&#8221;) to accelerate the development of mavorixafor for the treatment of Waldenstr&#246;m&#8217;s. Mavorixafor was selected for LLS&#8217;s Therapy Acceleration Program&#174;, a strategic initiative where LLS builds business alliances and collaborations with biotechnology companies and academic researchers to speed the development of new therapies for blood cancers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Mavorixafor in Immuno-Oncology Indications </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In solid tumors, the tumor micro-environment (&#8220;TME&#8221;) consists of the tumor cells and cancer associated fibroblasts (&#8220;CAFs&#8221;), each of which overproduce growth factors and chemokines to support immune-suppression and malignant cell proliferation and growth. Evidence suggests that the pro-tumor signals between tumor cells and CAFs occur, in part, through chemokine signaling, including through the over-production of CXCL12. The CXCL12/CXCR4 pathway has been shown to be overstimulated in more than 20 solid and blood-derived tumor types. Excessive stimulation of CXCR4 due to high concentrations of CXCL12 influences the trafficking of immune cells, including myeloid-derived suppressor cells, or MDSCs, CD4+ regulatory T cells (&#8220;Tregs&#8221;), CD8+ T cells (&#8220;killer T cells&#8221;), and mature dendritic cells. We believe that blocking CXCR4 overstimulation can lead to improved immune cell trafficking and increase the absolute number of CD8+ T-cells, thereby also increasing the ratio of CD8+ T-cells to Tregs in the TME, turning the TME from an immunosuppressive environment to an immunostimulatory one.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously, we have completed three clinical trials in solid tumors (two in clear cell renal cell carcinoma, one in melanoma) to explore the impact of mavorixafor on relevant tumor biomarkers and clinical responses. In all studies, combination of mavorixafor with standard of care proved to be well-tolerated and showed favorable impact on key immune-response biomarkers (e.g. increased proliferation of CD8+ T-cells and CD8+ T-cells to Treg ratios in the TME) and improvement in clinical metrics (response rates) vs. historical controls of single-agent standard of care. On-going trials in triple-negative breast cancer are being undertaken by Abbisko, our strategic partner for development and commercialization in greater China. Future development and potential commercialization of mavorixafor in potential immuno-oncology indications in markets outside of greater China will be pursued only as part of additional potential strategic collaboration(s).</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Earlier-Stage Candidates and Research Efforts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also advancing two early stage candidates: X4P-003, a second-generation CXCR4 antagonist designed to have</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enhanced properties relative to mavorixafor, potentially enabling broader opportunities in CXCR4-dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist with a unique distribution profile for potential use in CXCR4-dependent diseases in the periphery, but also with the ability to cross the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers and other diseases where exposure in brain is essential. We anticipate that we will file an IND application for X4P-002 in the second half of 2022.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Other firms also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical, biotechnology, and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors with us, particularly through collaborative arrangements with large and established companies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize therapeutics that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain marketing approvals for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected because in some cases insurers or other third-party payors, including government programs, seek to encourage the use of generic products. This may have the effect of making branded products less attractive to buyers from a cost perspective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of other companies that are developing CXCR4 inhibitors that are in a similar stage of development as mavorixafor, including BioLineRx (motixafortide), Noxxon (NOXA12), Upsher-Smith, Polyphor (Balixafortide) and Glycomimetics (GMI1359). To our knowledge, there do not appear to be any competitors with programs in development for WHIM syndrome or CN. With respect to chronic neutropenia, filgrastim injections (human granulocyte colony-stimulating factor (&#8220;G-CSF&#8221;)) and two biosimilars (Zarxio and Nivestym) are FDA-approved to reduce the incidence and duration of after-effects of severe neutropenia (e.g.&#8218; fever&#8218; infections&#8218; oropharyngeal ulcers) in symptomatic patients with congenital neutropenia&#8218; cyclic neutropenia&#8218; or idiopathic neutropenia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Waldenstr&#246;m&#8217;s, there are several treatment approaches currently being developed, including targeted therapies and immunotherapies (as monotherapies and combination therapies), chemotherapy, stem cell transplantation, and cancer vaccines.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To our knowledge, only mavorixafor is targeting the CXCR4 pathway. The Bristol Meyers Squibb anti CXCR4 antibody was discontinued from development. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, manufacturing facilities for the production of clinical or commercial quantities of mavorixafor or any of our other product candidates. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates and any products that we may develop.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a master services agreement (&#8220;the Aptuit Agreement&#8221;) in place with Aptuit (Oxford) Ltd (&#8220;Aptuit&#8221;), pursuant to which Aptuit develops and manufactures the active pharmaceutical ingredient, or API, for mavorixafor. We use this mavorixafor drug substance in our Phase 3 clinical trial for the treatment of WHIM and in our other clinical trials. Aptuit is our sole supplier for mavorixafor drug substance and is currently manufacturing mavorixafor drug substance at a commercially relevant scale to support our ongoing and anticipated future clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The term of the Aptuit Agreement expires on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 19, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">unless terminated by us and/or Aptuit as follows: (i) by mutual agreement of the parties; (ii) by us, if there is a material breach by the other party that remains uncured; (iii) by us, in the event of insolvency or bankruptcy of Aptuit; or (iv) by either party, upon 30 days&#8217; written notice.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have a master services agreement in place with Mayne Pharma Inc. (&#8220;Mayne Pharma&#8221;), which is our sole manufacturer  for the final capsule drug product formulation of mavorixafor for use in our clinical trials. The term of the master services agreement expires on September 10, 2023, and may be terminated by (1) us upon 30 days-notice to Mayne Pharma or (2) by either party following a material breach by the other party that remains uncured for 30 days.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain the supplies of our active pharmaceutical ingredient (&#8220;API&#8221;) and drug products from Aptuit and Mayne Pharma pursuant to typical industry standard clinical supply agreements. We believe that both API and drug product manufacturers have the capability and capacity to manufacture currently projected clinical trial supply and commercial volumes of mavorixafor and we are engaged in active discussions with both parties to plan anticipated commercial manufacturing arrangements. We obtain the supplies of our product candidates from these manufacturers under master services contracts and specific work orders. However, we do not have long-term supply arrangements in place. We do not currently have arrangements in place for redundant supply or a second source for API. If any of our current manufacturers becomes unavailable to us for any reason, we believe that there are a number of potential replacements, although we might incur some delay in identifying and qualifying such replacements. </span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Genzyme</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we entered into a license agreement with Genzyme, or the Genzyme Agreement, pursuant to which we were granted an exclusive license to certain patent applications and other intellectual property owned or controlled by Genzyme related to the CXCR4 receptor to develop and commercialize products containing licensed compounds (including but not limited to mavorixafor) for all therapeutic, prophylactic and diagnostic uses with the exception of autologous and allogenic human stem cell therapy. Genzyme has retained the exclusive right to use the intellectual property licensed to us in specific indications related to</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genzyme&#8217;s product Mozobil&#174; and allogenic/autologous hematopoietic stem cell transplantation treatments. Genzyme has also</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retained the non-exclusive right to conduct preclinical research involving compounds in any field, including any fields licensed to</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us, but has not retained rights to conduct any clinical development or commercialization of those compounds identified in the</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement in any of the fields licensed to us. We are primarily responsible for the preparation, filing, prosecution and</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintenance of all patent applications and patents covering the intellectual property licensed to us under the agreement at our sole</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are obligated to use commercially reasonable efforts to develop and commercialize licensed products for use in the field in the United States and at least one other major market country. We have the right to grant sublicenses of the licensed rights that cover mavorixafor to third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we wish to grant a sublicense to any licensed product other than mavorixafor, we are obligated to first offer the sublicense to Genzyme. If Genzyme expresses written interest for the sublicense, then we will negotiate exclusively with Genzyme for a certain stated period to obtain a license to such rights, after which Genzyme shall have no further rights with respect to such licensed product and we will be free to negotiate a sublicense with respect to such licensed product with any third party.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to pay Genzyme milestone payments in the aggregate amount of up to $25 million, contingent upon our achievement of certain late-stage regulatory and sales milestones with respect to licensed products, and tiered royalties based on net sales of licensed products that we commercialize under the Genzyme agreement. Our obligation to pay royalties for each licensed product expires on a country-by-country basis on the latest of (i) the expiration of licensed patent rights that cover that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licensed product in that country, (ii) the expiration of regulatory exclusivity in that country and (iii) ten years after the first commercial sale of such licensed product in that country. Royalty rates are subject to reduction under the agreement in specified circumstances, including in any country if we are required to obtain a license from any third party to the extent our patent rights might infringe the third party&#8217;s patent rights, if a licensed product is not covered by a valid claim in that country or if sales of generic products reach certain thresholds in that country. Sublicenses that we enter into under the Genzyme agreement, including our license agreement with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbisko </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligate us to pay Genzyme a percentage of certain upfront, maintenance fees, milestone payments and royalty payments paid to us by the sublicensee. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Genzyme Agreement will continue until the later of the expiration of the last to expire valid claim of the patents licensed under the agreement that cover any licensed product, the expiration of regulatory exclusivity applicable to any licensed product and 10 years from the date of first commercial sale of any licensed product. Either we or Genzyme may terminate the Genzyme Agreement in the event of the bankruptcy or uncured material breach by the other party. Genzyme may terminate the Genzyme Agreement if we or our affiliates initiate a patent challenge of the patents licensed under the agreement. We may terminate the Genzyme Agreement immediately upon notice to Genzyme if we reasonably believe that the development or commercialization of a licensed compound or product under the Genzyme agreement would result in a material safety issue for patients.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Georgetown University</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we entered into a license agreement with the Georgetown University, or Georgetown, pursuant to which we obtained an exclusive, worldwide license to practice certain methods, and to make, have made, use, sell, offer for sale and import products, covered by licensed patent rights&#160;co-owned&#160;by Georgetown. The rights licensed to us are for all therapeutic, prophylactic and diagnostic uses in all disease indications in humans and animals. We have the right to grant sublicenses of the licensed rights to third parties to the extent consistent with the terms of the Georgetown agreement.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Georgetown agreement we paid a&#160;one-time&#160;only, upfront fee of $50 thousand, and we may be required to pay milestone payments of up to an aggregate of $800 thousand related to commercial sales of a licensed product. We are responsible for all patent prosecution costs incurred with respect to the licensed patents. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize licensed product, to make licensed product reasonably available to the public, to obtain government approvals for licensed product and to market licensed product in quantities sufficient to meet the market demand.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Georgetown agreement will continue until the expiration of the last valid claim within the patent rights covering the licensed products. Georgetown may terminate the Georgetown agreement or convert our license to non-exclusive in the event (i)&#160;we fail to pay any amount and fail to cure such failure within 30 days after receipt of notice, (ii)&#160;we default in our obligation to obtain and maintain insurance and fail to remedy such breach within 45 days after receipt of notice, (iii)&#160;we declare insolvency or bankruptcy or (iv) we materially default in the performance of any material obligations under the Georgetown agreement which is not cured within a certain period from the date of written notice of such default. We may terminate the Georgetown agreement at any time upon at least 60 days&#8217; written notice.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Beth Israel Deaconess Medical Center</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we entered into a license agreement with Beth Israel Deaconess Medical Center, or BIDMC, pursuant to which we obtained an exclusive, worldwide license to make, have made, use, sell, offer for sale and import of licensed products and certain processes covered by licensed patent rights&#160;co-owned&#160;by BIDMC and a nonexclusive royalty-free right to use certain information pertaining to any invention claimed in the licensed patents that is owned by BIDMC to develop, make, have made, use, have used, sell, have sold and commercialize such licensed products and processes. The rights licensed to us are for all fields of use. We have the right to grant sublicenses of the licensed rights to third parties to the extent consistent with the terms of the BIDMC agreement.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the BIDMC agreement we paid a&#160;one-time&#160;only, upfront fee of $20 thousand and we are responsible for all future patent prosecution costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the BIDMC agreement will continue until the expiration of the last valid claim within the patent rights covering the licensed product. BIDMC may terminate the agreement in the event (i)&#160;we fail to pay any amount and fail to cure such failure within 15 days after receipt of notice, (ii) the insurance coverage that we are obligated to maintain under the agreement is terminated and we fail to obtain replacement insurance within a certain period of time following notice to BIDMC, or (iii)&#160;we declare insolvency or bankruptcy. In addition, if we are in material breach of any material provisions of the BIDMC agreement and fail to remedy such breach within 60 days after receipt of notice, BIDMC may terminate the BIDMC agreement or terminate any licenses granted under the BIDMC agreement with respect to the country or countries in which such material breach has occurred. We may terminate the BIDMC agreement at any time upon at least 90 days&#8217; written notice.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Dana Farber Cancer Institute </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, we entered into a license agreement with Dana Farber Cancer Institute (&#8220;DFCI&#8221;) pursuant to which we obtained a non-exclusive, worldwide license to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">use, make, have made, develop, market, import, distribute, sell and have sold</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> licensed products and certain processes covered by licensed patent rights&#160;owned&#160;by DFCI. The rights licensed to us are for the therapeutic use of our CXCR4 antagonists for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Waldenstr&#246;m</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8217;s in combination with BTK inhibitors, including ibrutinib. We have the right to grant sublicenses of the licensed rights to third parties to the extent consistent with the terms of the DFCI agreement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the DFCI agreement we paid a&#160;one-time, upfront fee of $25 thousand and we are responsible for the reimbursement of certain future patent prosecution cost and the payment of an annual maintenance fee. We are obligated to pay DFCI milestone payments in the aggregate amount of up to approximately $32 million, contingent upon our achievement of certain regulatory and sales milestones with respect to licensed products, and a flat royalty based on net sales of licensed products that we commercialize under the DFCI agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The term of the DFCI agreement will continue until the expiration of the last valid claim within the patent rights covering the licensed product. DFCI may terminate the DFCI agreement in the event (i)&#160;we fail to pay any amount and fail to cure such failure within 30 days after receipt of notice, (ii) we cease to carry on our business with respect to the licensed products or process, (iii) the insurance coverage that we are obligated to maintain under the DCFI agreement is terminated and we fail to obtain replacement insurance within a certain period of time following notice to DFCI, (iv) we </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">fail to comply with certain diligence obligations and cure any such default within 60 days after receipt of written notice, (v) we have granted a sublicense without notifying DFCI or on terms inconsistent with the terms required of sublicenses under the DCFI agreement, (vi) an officer of our company, an affiliate or sublicensee is convicted of a felony relating to the manufacture, use, sale or importation of a licensed product, (vii) we or any of our affiliates, sublicensees or sublicensees&#8217; affiliates </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">initiate a patent challenge of the patents licensed under the DFCI agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or assists others in doing so </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or (viii)&#160;we declare insolvency or bankruptcy. In addition, if we are in material breach of any material obligations under the DFCI agreement and fail to remedy such breach within 90 days after receipt of notice, DFCI may terminate the DFCI agreement or terminate any licenses granted under the agreement. We may terminate the DFCI agreement at any time upon at least 90 days&#8217; written notice.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Abbisko Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we entered into a license agreement with Abbisko. Under the terms of the agreement, we granted Abbisko the exclusive right to develop, manufacture and commercialize mavorixafor in mainland China, Taiwan, Hong Kong and Macau. The agreement provides Abbisko with the exclusive rights in this territory to develop and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. Pancreatic cancer, ovarian cancer and triple negative breast cancer will be explored initially. We retain the full rest-of-world rights to develop and commercialize mavorixafor outside of Greater China for all indications and the ability to utilize data generated pursuant to the Abbisko collaboration for rest-of-world development. In addition, Abbisko has the right of first refusal if we determine to pursue additional products in the Abbisko Territory, as defined in the agreement. We entered into a separate agreement in April 2020 whereby we will provide Abbisko with a clinical supply and, if the product is commercialized in the territory licensed by Abbisko, we intend to enter into a commercial supply of the licensed compound.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement with Abbisko, upon the closing of a qualified financing of Abbisko, as defined in the agreement, which occurred in March 2020, Abbisko made a one-time, non-refundable, non-creditable financial milestone payment of $3 million to us. We are also eligible to receive potential development, regulatory and commercial milestone payments of up to $208&#160;million, which will vary based on the ultimate sales, if any, of the approved licensed products. Upon commercialization of mavorixafor in the Abbisko Territory, we are eligible to receive a tiered royalty, with a percentage range in the low double-digits, on net sales of approved licensed products. Abbisko is obligated to use commercially reasonable efforts to develop and commercialize mavorixafor in the Abbisko Territory. Abbisko has responsibility for all activities and costs associated with the further development, manufacture and commercialization of mavorixafor in the Abbisko Territory.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our product candidates depends in large part on our ability to obtain and maintain intellectual property protection for our product candidates, including mavorixafor, and our preclinical compounds and core technologies. Our policy is to seek to protect our intellectual property position by, among other methods, filing U.S. and foreign patent applications related to the technology, inventions and improvements that are important to the development and implementation of our business strategy. We also rely on trade secrets,&#160;know-how&#160;and continuing technological innovation to develop and maintain our proprietary position.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file patent applications directed to our product candidates, preclinical compounds and related technologies to establish intellectual property positions on these compounds and their uses in disease. As of December 31, 2021, we owned or exclusively licensed</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued U.S. patents,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 pending U.S. non-provisional patent applications, seven pending U.S. provisional patent application, and approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177 PCT and foreign patents and patent applications in the following foreign jurisdictions: Belgium, Brazil, Canada, China, European Patent Office, France, Germany, Great Britain, Hong Kong, India, Ireland, Italy, Israel, Japan, Lichtenstein, Mexico, Netherlands, New Zealand, Singapore, South Africa, Spain, Sweden and Switzerland.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, our&#160;in-licensed&#160;intellectual property portfolio for mavorixafor included</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">four issued U.S. patents and one pending U.S. patent application directed to compositions of matter for mavorixafor, which are expected to expire in December 2022 excluding possible patent term extensions of up to an additional five years. The intellectual property portfolio for mavorixafor also included one issued U.S. patent with claims directed to a crystalline salt form of mavorixafor, one issued U.S. patent directed to pharmaceutical compositions of mavorixafor in unit dosage form, and four issued U.S. patents directed to methods of making mavorixafor and key intermediates. We also had four issued U.S. patents directed to compositions and methods of making chemical compounds related to the X4P-001 program. Approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corresponding PCT and foreign patents and patent applications directed to compositions of matter and related chemical compounds as well as methods of making and methods of use were issued or pending. All of the above patents and patent applications were exclusively licensed to us pursuant to the terms of the Genzyme agreement.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have filed our own patent applications with respect to the mavorixafor and&#160;X4P-002&#160;product candidates. Some of these patent applications are co-owned with Genzyme, BIDMC or Georgetown, with their rights exclusively licensed to us. As of December 31, 2021, our independently generated intellectual property portfolio included four granted U.S. patents, nine pending U.S. non-provisional patent applications, seven pending U.S. provisional patent application, and approximately 57 pending PCT and foreign patent applications related to our mavorixafor clinical programs in cancer and primary immunodeficiencies. In addition, we have two granted U.S. patents, four pending U.S.&#160;non-provisional&#160;patent applications, two granted U.S. patents, and approximately 35 pending PCT and foreign patent applications related to our preclinical compounds and&#160;X4P-002&#160;in glioblastoma. Patents issuing from these applications, if any, are expected to expire between 2036 and 2042.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a&#160;non-provisional&#160;patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, (the &#8220;USPTO&#8221;), in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a U.S. patent that covers a drug or biological product may also be eligible for patent term extension when approval from the FDA is granted, provided statutory and regulatory requirements are met. In the future, if our product candidates receive approval from the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical trials for each drug and other factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent term extension or other favorable adjustment to the term of any of our patents.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates, including mavorixafor, and our preclinical compounds, and our core technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, patent applications that we may file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may receive in the future may be challenged, invalidated or circumvented. For example, prior to March&#160;16, 2013, in the United States, patent applications were subject to a &#8220;first to invent&#8221; rule of law. Applications filed after March&#160;16, 2013 (except for certain applications claiming the benefit of earlier-filed applications) are subject to a &#8220;first to file&#8221; rule of law.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discoveries reported in the scientific literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We cannot be certain that any existing or future application will be subject to the &#8220;first to file&#8221; or &#8220;first to invent&#8221; rule of law, that we were the first to make the inventions claimed in our existing patents or pending patent applications subject to the prior laws, or that we were the first to file for patent protection of such inventions subject to the new laws. If third parties prepare and file patent applications in the United States that also claim technology we have claimed in our patents or patent applications, we may have to participate in interference proceedings in the USPTO to determine priority of invention, which could result in substantial costs to us, even if the eventual outcome is favorable to us. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we rely upon unpatented trade secrets,&#160;know-how,&#160;and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses requiring invention assignment, to grant us ownership of technologies that are developed under those agreements.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA Approval Process</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDCA, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as imposition of clinical holds, refusal by the FDA to approve pending NDAs, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, civil penalties and criminal prosecution.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical product development in the United States typically involves preclinical or other nonclinical laboratory and animal tests and the submission to the FDA of an IND, which must become effective before clinical testing may commence. For commercial approval, the sponsor must submit adequate tests by all methods reasonably applicable to show that the drug is safe for use under the conditions prescribed, recommended or suggested in the proposed labeling. The sponsor must also submit substantial evidence, generally consisting of adequate, well-controlled clinical trials to establish that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended or suggested in the proposed labeling. In certain cases, the FDA may determine that a drug is effective based on one clinical study plus confirmatory evidence. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the nonclinical tests must comply with federal requirements, including the FDA&#8217;s good laboratory practices regulations and the U.S. Department of Agriculture&#8217;s, or USDA&#8217;s, regulations implementing the Animal Welfare Act. The results of nonclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term nonclinical tests, such as animal studies of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A&#160;30-day&#160;waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has not imposed a clinical hold on the IND or otherwise commented or questioned the IND within this&#160;30-day&#160;period, the clinical trial proposed in the IND may begin.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations, (ii)&#160;in compliance with GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors, and (iii)&#160;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial either is not being conducted in accordance with the FDA requirements or presents an unacceptable risk to the clinical trial patients. The trial protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board, or IRB, at each site where a trial will be conducted for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or may impose other conditions.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In general, in Phase 1, the initial introduction of the drug into healthy human volunteers or, in some cases, patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses and, if possible, early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. The FDA may, however, determine that a drug is effective based on one clinical trial plus confirmatory evidence. In some cases, the FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval to gather additional information on the drug&#8217;s effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the United States. The NDA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee, subject to certain exceptions and waivers, such as for orphan-designated drugs.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an&#160;in-depth&#160;review. Under the performance goals established pursuant to the Prescription Drug User Fee Act the FDA aims to complete review of 90% of standard&#160;(non-priority)&#160;NDAs within 10 months filing and within six months for priority NDAs. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee, which is typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with current GMP is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for health care professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hatch-Waxman Act</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book Listing</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#8217;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be bioequivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of,&#160;pre-clinical&#160;or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are considered to be therapeutically equivalent to the listed drug, are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug in accordance with state law.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book. Specifically, the applicant must certify that: (i)&#160;the required patent information has not been filed; (ii)&#160;the listed patent has expired; (iii)&#160;the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv)&#160;the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement, certifying that its proposed ANDA labeling does not contain (or carves out) any language regarding the patented&#160;method-of-use,&#160;rather than certify to a listed&#160;method-of-use&#160;patent.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA application also will not be approved until any applicable&#160;non-patent&#160;exclusivity listed in the Orange Book for the referenced product has expired.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusivity</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon NDA approval of a new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity during which time the FDA cannot receive any ANDA or 505(b)(2) application seeking approval of a drug that references a version of the NCE drug. Certain changes to a drug, such as the addition of a new indication to the package insert, are associated with a three-year period of exclusivity during which the FDA cannot approve an ANDA or 505(b)(2) application that includes the change.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ANDA or 505(b)(2) application may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification and thus no ANDA or 505(b)(2) application may be filed before the expiration of the exclusivity period.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Five-year and three-year exclusivities do not preclude FDA approval of a 505(b)(1) application for a duplicate version of the drug during the period of exclusivity, provided that the 505(b)(1) applicant conducts or obtains a right of reference to all of the preclinical studies and adequate and well controlled clinical trials necessary to demonstrate safety and effectiveness.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Extension</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of the drug&#8217;s testing phase&#8212;the time between IND submission and NDA submission&#8212;and all of the review phase&#8212;the time between NDA submission and approval up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Promotion</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse Event Reporting and GMP Compliance</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as Phase 4 testing, require a REMS special communications regarding the safety of the drug or heightened surveillance to monitor the effects of an approved product, or may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to GMP after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with GMP. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with GMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing or if previously unrecognized problems are subsequently discovered.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Exclusivity and Pediatric Use</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Best Pharmaceuticals for Children Act, or BPCA, provides NDA holders a&#160;six-month&#160;period of exclusivity attached to any other exclusivity listed with FDA&#8212;patent or&#160;non-patent&#8212;for&#160;a drug if certain conditions are met. Conditions for pediatric exclusivity include a determination by the FDA that information relating to the use of a new drug in the pediatric population may produce health benefits in that population; a written request by the FDA for pediatric studies; and agreement by the applicant to perform the requested studies and the submission to the FDA, completion of the studies in accordance with the written request, and the acceptance by the FDA of the reports of the requested studies within the statutory timeframe. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective, unless the sponsor has received a deferral or waiver from the FDA. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted. The sponsor or the FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data need to be collected before the pediatric studies begin. </span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drugs</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition&#8212;generally a disease or condition that affects fewer than 200,000 individuals in the United States (or affects more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales of such drug in the United States). Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. If the FDA designates an orphan drug based on a finding of clinical superiority, the FDA must provide a written notification to the sponsor that states the basis for orphan designation, including &#8220;any plausible hypothesis&#8221; relied upon by the FDA. The FDA must also publish a summary of its clinical superiority findings upon granting orphan drug exclusivity based on clinical superiority.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Breakthrough Designation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A product can be designated as a breakthrough therapy by FDA if it is intended to treat a serious or life-threatening condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A sponsor may request that a product candidate be designated as a breakthrough therapy concurrently with the submission of an IND or any time before an end-of-Phase-2 meeting, and the FDA must determine if the product candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s request. If so designated, the FDA shall act to expedite the development and review of the product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s marketing application, including by meeting with the sponsor throughout the product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s development, providing timely advice to the sponsor to ensure that the development program to gather pre-clinical and clinical data is as efficient as practicable, involving senior managers and experienced review staff in a cross-disciplinary review, assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor, and taking steps to ensure that the design of the clinical trials is as efficient as practicable.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Europe/Rest of World Government Regulation</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are and will be subject, either directly or through our distribution partners, to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products, if approved.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in&#160;non-U.S.&#160;countries prior to the commencement of clinical trials or marketing of the product in those countries.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, medicinal products are subject to extensive&#160;pre-&#160;and post-marketing regulation by regulatory authorities at both the European Union and national levels. Additional rules also apply at the national level to the manufacture, import, export, storage, distribution and sale of controlled substances. In many E.U. member states, the regulatory authority responsible for medicinal products is also responsible for controlled substances. Responsibility is, however, split in some member states. Generally, any company manufacturing or distributing a medicinal product containing a controlled substance in the European Union will need to hold a controlled substances license from the competent national authority and will be subject to specific record-keeping and security obligations. Separate import or export certificates are required for each shipment into or out of the member state.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials and Marketing Approval</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries outside of the United States have a process that requires the submission of a clinical trial application much like an IND prior to the commencement of human clinical trials. In all cases, the clinical trials must be conducted in accordance with the International Conference on Harmonization, or ICH, guidelines on GCP and other applicable regulatory requirements.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain regulatory approval to place a drug on the market in the European Union, we must submit a marketing authorization application. This application is similar to the NDA in the United States, with the exception of, among other things, country-specific document requirements. All application procedures require an application in the common technical document, or CTD, format, which includes the submission of detailed information about the manufacturing and quality of the product, and&#160;non-clinical&#160;and clinical trial information. Drugs can be authorized in the European Union by using (i)&#160;the centralized authorization procedure, (ii)&#160;the mutual recognition procedure, (iii)&#160;the decentralized procedure or (iv)&#160;national authorization procedures.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission created the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are valid throughout the European Union and, by extension (after national implementing decisions) in Iceland, Liechtenstein and Norway, which, together with the E.U. member states, comprise the European Economic Area, or EEA. Applicants file marketing authorization applications with the EMA, where they are reviewed by a relevant scientific committee, in most cases the Committee for Medicinal Products for Human Use, or CHMP. The EMA forwards CHMP opinions to the European Commission, which uses them as the basis for deciding whether to grant a marketing authorization. This procedure results in a single marketing authorization granted by the European Commission that is valid across the European Union, as well as in Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human drugs that are: (i)&#160;derived from biotechnology processes, such as genetic engineering, (ii)&#160;contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii)&#160;officially designated &#8220;orphan drugs&#8221; (drugs used for rare human diseases) and (iv)&#160;advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines. The centralized procedure may at the voluntary request of the applicant also be used for human drugs which do not fall within the above-mentioned categories if the CHMP agrees that (a)&#160;the human drug contains a new active substance not yet approved on November&#160;20, 2005; (b) it constitutes a significant therapeutic, scientific or technical innovation or (c)&#160;authorization under the centralized procedure is in the interests of patients at the E.U. level.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of a marketing authorization application by the EMA is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP), with adoption of the actual marketing authorization by the European Commission thereafter. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest from the point of view of therapeutic innovation, defined by three cumulative criteria: the seriousness of the disease to be treated, the absence of an appropriate alternative therapeutic approach, and anticipation of exceptional high therapeutic benefit. In this circumstance, the EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those medicinal products for which the centralized procedure is not available, the applicant must submit marketing authorization applications to the national medicines regulators through one of three procedures: (i) the mutual recognition procedure (which must be used if the product has already been authorized in at least one other E.U. member state, and in which the E.U. member states are required to grant an authorization recognizing the existing authorization in the other E.U. member state, unless they identify a serious risk to public health), (ii) the decentralized procedure (in which applications are submitted simultaneously in two or more E.U. member states) or (iii)&#160;national authorization procedures (which results in a marketing authorization in a single E.U. member state).</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mutual Recognition Procedure</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mutual recognition procedure, or MRP, for the approval of human drugs is an alternative approach to facilitate individual national marketing authorizations within the European Union. Basically, the MRP may be applied for all human drugs for which the centralized procedure is not obligatory. The MRP is applicable to the majority of conventional medicinal products and must be used if the product has already been authorized in one or more member states.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The characteristic of the MRP is that the procedure builds on an already&#8211;existing marketing authorization in a member state of the European Union that is used as a reference in order to obtain marketing authorizations in other E.U. member states. In the MRP, a marketing authorization for a drug already exists in one or more member states of the European Union and subsequently marketing authorization applications are made in other E.U. member states by referring to the initial marketing authorization. The member state in which the marketing authorization was first granted will then act as the reference member state. The member states where the marketing authorization is subsequently applied for act as concerned member states. The concerned member states are required to grant an authorization recognizing the existing authorization in the reference member state, unless they identify a serious risk to public health.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MRP is based on the principle of the mutual recognition by E.U. member states of their respective national marketing authorizations. Based on a marketing authorization in the reference member state, the applicant may apply for marketing authorizations in other member states. In such case, the reference member state shall update its existing assessment report about the drug in 90 days. After the assessment is completed, copies of the report are sent to all member states, together with the approved summary of product characteristics, labeling and package leaflet. The concerned member states then have 90 days to recognize the decision of the reference member state and the summary of product characteristics, labeling and package leaflet. National marketing authorizations shall be granted within 30 days after acknowledgement of the agreement.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any E.U. member state refuses to recognize the marketing authorization by the reference member state, on the grounds of potential serious risk to public health, the issue will be referred to a coordination group. Within a timeframe of 60 days, member states shall, within the coordination group, make all efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific committee for arbitration. The opinion of this EMA Committee is then forwarded to the European Commission for the start of the decision making process. As in the centralized procedure, this process entails consulting various European Commission Directorates General and the Standing Committee on Human Medicinal Products.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Exclusivity</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, marketing authorization applications for generic medicinal products do not need to include the results of&#160;pre-clinical&#160;and clinical trials, but instead can refer to the data included in the marketing authorization of a reference product for which regulatory data exclusivity has expired. If a marketing authorization is granted for a medicinal product containing a new active substance, that product benefits from eight years of data exclusivity, during which generic marketing authorization applications referring to the data of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such generic products may not be placed on the market. The&#160;two-year&#160;period may be extended to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Medicinal Products</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA&#8217;s Committee for Orphan Medicinal Products, or COMP, may recommend orphan medicinal product designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the European Union. Additionally, this designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the product in the European Union would be sufficient </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to justify the necessary investment in developing the medicinal product. The COMP may only recommend orphan medicinal product designation when the product in question offers a significant clinical benefit over existing approved products for the relevant indication. Following a positive opinion by the COMP, the European Commission adopts a decision granting orphan status. The COMP will reassess orphan status in parallel with EMA review of a marketing authorization application and orphan status may be withdrawn at that stage if it no longer fulfills the orphan criteria (for instance because in the meantime a new product was approved for the indication and no convincing data are available to demonstrate a significant benefit over that product). Orphan medicinal product designation entitles a party to financial incentives such as a reduction of fees or fee waivers and 10 years of market exclusivity is granted following marketing authorization. During this period, the competent authorities may not accept or approve any similar medicinal product, unless it offers a significant clinical benefit. This period may be reduced to six years if the orphan medicinal product designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Development</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, companies developing a new medicinal product must agree to a Pediatric Investigation Plan, or PIP, with the EMA and must conduct pediatric clinical trials in accordance with that PIP unless a waiver applies, for example, because the relevant disease or condition occurs only in adults. The marketing authorization application for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the PIP are eligible for a&#160;six-month&#160;extension of the protection under a supplementary protection certificate (if the product covered by it qualifies for one at the time of approval). This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Coverage, Pricing and Reimbursement</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of pharmaceutical products in the United States will depend, in part, on the extent to which the costs of the products will be covered by third-party payers, such as government health programs, and commercial insurance and managed health care organizations. These third-party payers are increasingly challenging the prices charged for medical products and services. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval. In the United States, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third party payors in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the&#160;FDA-approved&#160;drugs for a particular indication. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the containment of health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, utilization management and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If these third-party payers do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries and included a major expansion of the prescription drug benefit under Medicare Part D. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Part D is available through both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from&#160;non-governmental&#160;payers.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the ACA, was enacted with the goal of expanding coverage for the uninsured while at the same time containing overall health care costs. With regard to pharmaceutical products, among other things, the ACA expanded and increased industry rebates for drugs covered under Medicaid programs and made changes to the coverage requirements under the Medicare D program. There have been challenges to certain aspects of the ACA. For example, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling,  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 28, 2021, President Biden issued an executive order to initiate a special enrollment for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several Presidential executive orders, Congressional hearings and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. It is unclear whether these or similar policy initiatives will be implemented in the future. Further, Congress is considering additional health reform measures.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Further, it is possible </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that additional governmental action is taken in response to the COVID-19 pandemic.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, some E.U. jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. Such differences in national pricing regimes may create price differentials between E.U. member states. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States. In the European Union, the downward pressure on healthcare costs in general, particularly prescription medicines, has become intense. As a result, barriers to entry of new products are becoming increasingly high and patients are unlikely to use a drug product that is not reimbursed by their government.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future operations may subject us to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our research and proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. The laws that may affect our ability to operate include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal transparency laws, including the federal Physician Payments Sunshine Act, that require drug manufacturers to disclose payments and other transfers of value provided to physicians, (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners) and teach&#160;&#160;&#160;&#160;ing hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain requirements on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, and their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign and state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state and local laws governing the disclosure of payments to health care professionals, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state laws that require the reporting of information related to drug pricing, state and local laws requiring the registration of pharmaceutical sales representatives and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Human Capital Policies and Procedures</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83 full-time employees. Of these employees, 52 were engaged in research and development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 31 were engaged in general and administrative functions. All of our employees are located in the United States or Vienna, Austria. We have no collective bargaining agreements with our employees and have not experienced any work stoppages. We consider our relationship with our employees to be good.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human capital is critical to our success. Our overarching human capital resource strategy is to recruit, hire, incentivize and retain employees consistent with our stage of operations and strategic objectives. We believe we offer our employees compensation that is competitive and consistent with the markets in which we operate, namely the Greater Boston and the &#160;&#160;&#160;&#160;Vienna, Austria metropolitan areas. We supplement base cash employee compensation with awards of stock options and/or restricted stock units under our equity incentive plans. We review employee performance annually and our Compensation Committee approves associated merit increases and annual incentive bonus payments during the first quarter of the year annually. When needed, we augment our employee base with outside consultants who specialize in various fields.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware in 2010 under the name Arsanis Inc. Following the Merger with X4 Therapeutics Inc. (formerly X4 Pharmaceuticals Inc.) on March 13, 2019, we changed our name to X4 Pharmaceuticals, Inc. Our principal executive offices are located at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134 and our telephone number is (857) 529-8300.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a website at http://www.x4pharma.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy statements, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge on our website as soon as reasonably practicable after electronically filing such reports with the SEC. Such reports and other information may be accessed through the SEC's website at www.sec.gov. Information contained in our website is not part of this or any other report that we file with or furnish to the SEC. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. &#160;&#160;&#160;&#160;RISK FACTORS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our securities involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Annual Report, including our audited consolidated financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects, or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. We cannot assure you that any of the events discussed below will not occur. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Selected Risks Associated with Our Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business faces significant risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. You should carefully review and consider the full discussion of our risk factors in the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report. Some of the more significant risks include the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:13.8pt">We have incurred significant losses and have not generated revenue from product sales since our inception. We expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We will require substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate any product development programs or commercialization efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Raising additional capital may cause dilution to our investors, restrict our operations or require us to relinquish rights to our technologies or product candidates. Future debt obligations may expose us to risks that could adversely affect our business, operating results and financial condition and may result in further dilution to our stockholders.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We depend almost entirely on the success of our lead product candidate, mavorixafor, which we are developing initially for the treatment of WHIM syndrome, for the treatment of SCN and chronic neutropenia disorders, for the treatment of Waldenstr&#246;m&#8217;s, and contingent on a potential strategic partner, for the treatment of ccRCC. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, mavorixafor or any other product candidate.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We expect to develop mavorixafor, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">The regulatory review and approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, including mavorixafor, our business will be substantially harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We depend on license agreements with Genzyme, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Georgetown University to permit us to use patents and patent applications. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">The results of clinical trials may not support our product candidate claims.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We may fail to enroll a sufficient number of patients in our clinical trials in a timely manner, which could delay or prevent clinical trials of our product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">If the commercial opportunity in WHIM syndrome, CN or Waldenstr&#246;m&#8217;s is smaller than we anticipate, our potential future revenue from mavorixafor for the treatment of any of the diseases may be adversely affected and our business may suffer.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of our product candidates, or our entry into licensing, collaboration or similar arrangements, could be delayed or prevented.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">A breakthrough therapy designation or Fast Track designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and neither of these designations increases the likelihood that our product candidates will receive marketing approval.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Even if we are able to commercialize mavorixafor or any other product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We have minimal experience manufacturing our product candidates on a large clinical or commercial scale and have no manufacturing facility. We are currently dependent on a single third party manufacturer for the manufacture of mavorixafor, the active pharmaceutical ingredient, or API, and a single manufacturer of mavorixafor finished drug product capsules. If we experience problems with these third parties, the manufacturing of mavorixafor could be delayed, which could harm our results of operations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We rely on third-party CROs to conduct our preclinical studies and clinical trials. If these CROs do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Disruptions in our supply chain could delay the commercial launch of our product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We may depend on such collaborations for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We may engage in future acquisitions or in-licenses of technology that could disrupt our business, cause dilution to our stockholders and harm our financial condition and operating results.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">If we are unable to protect our intellectual property rights, our competitive position could be harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">The global coronavirus pandemic is adversely affecting, and is expected to continue to adversely affect, our business, including our clinical trials and preclinical studies. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Our future success depends on our ability to retain executives and to attract, retain and motivate key personnel in a competitive environment for skilled biotechnology personnel.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Our stock price is expected to continue to be volatile.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We are an &#8220;emerging growth company,&#8221; and a &#8220;smaller reporting company&#8221; and as a result of the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception. We expect to continue to incur losses for the foreseeable future and we may never achieve or maintain profitability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical biopharmaceutical company with a limited operating history.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. Our net losses were $88.7 million, $62.1 million and $52.8 million for the years ended December 31, 2021, 2020 and 2019 respectively, and we had an accumulated deficit of $282.9 million as of December 31, 2021. We have funded our operations to date primarily with proceeds from sales of common stock, warrants and prefunded warrants for the purchase of our preferred stock and our common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for at least the next few years as we conduct additional clinical trials for our product candidates; continue to discover and develop additional product candidates; acquire or in-license other product candidates and technologies; maintain, expand and protect our intellectual property portfolio; hire additional clinical, scientific and commercial personnel; establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval; seek regulatory approvals for any product candidates that successfully complete clinical trials; establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval; and add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts.We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. For example, we experienced delays in clinical trial site activation and slower patient enrollment in some of our clinical trials as a result of the COVID-19 pandemic, which have delayed our expectations regarding our ability to report data from those trials, and we may encounter additional delays, disruptions and other direct and indirect negative effects of the ongoing COVID-19 pandemic on our clinical trials. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. The net losses we incur may fluctuate significantly from quarter to quarter and year to year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate profits from operations and thereafter to remain profitable depends heavily on:</span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, number, progress, duration, endpoints, cost, results and timing of clinical trials and nonclinical studies of our current or potential future product candidates, including in particular the scope, progress, duration, endpoints, cost, results and timing for completion of our Phase 3 trial of mavorixafor for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;) syndrome, our Phase 1b clinical trial of mavorixafor for the treatment of Severe Congenital Neutropenia (&#8220;SCN&#8221;) and other chronic neutropenia disorders, and our Phase 1b clinical trial of mavorixafor for the treatment of Waldenstr&#246;m&#8217;s macroglobulinemia (&#8220;Waldenstr&#246;m&#8217;s&#8221;);</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise sufficient funds to support the development and potential commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes and timing of regulatory reviews, approvals or other actions;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of any other business, product or technology that we acquire or in which we invest;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture any approved products on commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish a sales and marketing organization or suitable third-party alternatives for any approved product; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of product candidates and programs that we pursue.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current plans, we do not expect to generate significant revenue from product sales unless and until we (or a potential future licensee or collaborator) obtain marketing approval for, and commercialize, one or more of our current or potential future product candidates. Neither we nor a licensee may ever succeed in obtaining marketing approval for, or commercializing, our product candidates and, even if we do, we may never generate revenues that are significant enough to generate profits from operations. Even if we do generate profits from operations, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to generate profits from operations and remain profitable would decrease our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or continue our operations. A decline in our value could also cause you to lose all or part of your investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may alter or delay our plans. Assuming that we complete the development of and obtain marketing approval for any of our product candidates, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate any product development programs or commercialization efforts.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed a large amount of cash since inception. We expect our research and development expenses to increase in future periods as we continue to advance the clinical development of our product candidates and prepare for the launch and commercialization of any product candidates for which we receive regulatory approval, including potentially building our own commercial organization to address the United States and certain other markets. In addition, if we obtain marketing approval for any of our product candidates that are not then subject to licensing, collaboration or similar arrangements with third parties, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. Furthermore, we expect to incur additional costs associated with operating as a public company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have cash and cash equivalents of $81.8 million. We have a covenant under our Hercules Loan Agreement that requires that we maintain a minimum level of cash, as defined, beginning on September 1, 2022. Based on our current cash flow projections and with no additional funding, we believe we may not be able to maintain the minimum cash required to satisfy this covenant. In such event, Hercules could require the repayment of all outstanding debt. We expect to seek additional funding to sustain our future operations, and to satisfy certain covenants under our debt facility with Hercules, which may include raising funds through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. While we have successfully raised capital in the past, our ability to raise capital in future periods is not assured. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will require substantial additional funding to carry out our business plans, including the clinical development of mavorixafor. Further, even if and when we believe we have sufficient capital for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. We cannot be certain that additional funding will be available on acceptable terms, or at all. The ongoing COVID-19 pandemic has already resulted in a significant disruption of global financial markets. If the disruption continues or future variants of COVID-19 emerge globally, we could experience an inability to access additional capital when and if needed. If we are unable to raise additional capital when needed or in sufficient amounts or on terms acceptable to us, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts of one or more of our product candidates or one or more of our other research and development initiatives. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also could be required to:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek new or additional collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">relinquish or license on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates, particularly our Phase 3 trial of mavorixafor for the treatment of WHIM syndrome, our Phase 1b clinical trial of mavorixafor for the treatment of SCN and chronic neutropenia disorders, and our Phase 1b clinical trial of mavorixafor for the treatment of Waldenstr&#246;m&#8217;s;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the clinical development plans that we establish for these product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number and characteristics of product candidates and programs that we develop or may in-license;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to obtain marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights covering our product candidates, including any such patent claims and intellectual property rights that we have licensed from Genzyme pursuant to the terms of our license agreement with Genzyme or from other third parties;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost and timing of completion of commercial-scale outsourced manufacturing activities with respect to our product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the success of any other business, product or technology that we acquire or in which we invest;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our need and ability to hire additional management and scientific and medical personnel;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs to operate as a public company, including the need to implement additional financial and reporting systems and other internal systems and infrastructure for our business;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">market acceptance of our product candidates, to the extent any are approved for commercial sale; </span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the effect of competing technological and market developments; and,</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">business interruptions resulting from pandemics and public health emergencies, including those related to the ongoing COVID-19 pandemic, geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not raise additional capital in sufficient amounts, or on terms acceptable to us, we may be prevented from pursuing discovery, development and commercialization efforts, which will harm our business, operating results and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our investors, restrict our operations or require us to relinquish rights to our technologies or product candidates. Future debt obligations may expose us to risks that could adversely affect our business, operating results and financial condition and may result in further dilution to our stockholders.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. The ongoing COVID-19 pandemic has already resulted in a significant disruption of global financial markets. If the disruption persists or if future variants of COVID-19 emerge globally, we could experience an inability to access additional capital. Other than our common stock purchase agreement with Lincoln Park Capital Fund LLC (&#8220;Lincoln Park&#8221;), pursuant to which Lincoln Park is obligated, subject to certain limitations, to purchase up to $50.0 million in the aggregate of shares of our common stock, we do not have any committed external sources of funds and may seek to raise additional capital at any time. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or other distributions, acquiring or licensing intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business and may result in liens being placed on our assets and intellectual property. For example, our debt facility with Hercules contains a minimum cash financial covenant that we project we would be in violation of in the third quarter of 2022 based on our current cash flow projections, assuming we do not raise additional funding. If we default on such indebtedness, with Hercules or a future lender we could lose such assets and intellectual property.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through licensing, collaboration or similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financings or through licensing, collaboration or similar arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not generated revenues from any product sales since inception and may never become profitable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated revenues from any product sales. Our ability to generate revenue and become profitable depends upon our ability to successfully obtain marketing approval and commercialize our product candidates, including mavorixafor, X4P-002, X4P-003 or other product candidates that we may develop, in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for these product candidates, we are unable to predict the extent of any future losses and do not know when any of these product candidates will generate revenue for us, if at all. Our ability to generate revenue from mavorixafor or any of our current or future product candidates also depends on a number of additional factors, including our ability to:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully complete development activities, including all necessary nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">complete and submit New Drug Applications to the FDA and obtain regulatory approval for indications for which there is a commercial market;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">complete and submit marketing applications to, and obtain regulatory approval from, foreign regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">set and obtain a commercially viable price for our products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtain commercial quantities of our products at acceptable cost levels;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">develop a commercial organization capable of sales, marketing and distribution for the products we intend to sell ourselves in the markets in which we have retained commercialization rights;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">find suitable collaborators to help us market, sell and distribute our approved products in other markets; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtain coverage and adequate reimbursement from third-party, including government, payors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because of the numerous risks and uncertainties associated with product development, including the possibility that our product candidates may not advance through development or demonstrate safety and efficacy for their intended uses, the FDA or any other regulatory agency may require additional clinical trials or nonclinical studies. We are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability, and such expense could increase beyond our expectations if the FDA or any other regulatory agency requires such additional clinical trials or nonclinical studies as part of the application and approval process or post-approval process if we are successful at achieving regulatory approval. Even if we are able to successfully complete the development and regulatory reviews described above, we anticipate incurring significant costs associated with commercializing these products, if they are approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to generate revenues from the sale of our product candidates, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our discovery and preclinical development efforts, expand our business or continue our operations and may require us to raise additional capital that may dilute your ownership interest. A decline in our value could also cause you to lose all or part of your investment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Development of Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend almost entirely on the success of our lead product candidate, mavorixafor, which we are developing initially for the treatment of WHIM syndrome, for the treatment of SCN and chronic neutropenia disorders, for the treatment of Waldenstr&#246;m&#8217;s, and with a potential strategic partner, for the treatment of ccRCC. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, mavorixafor or any other product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends almost entirely on the successful clinical development, regulatory approval and commercialization of mavorixafor. We currently have no products for sale and may never be able to develop marketable drug products. We are conducting a global Phase 3 pivotal clinical trial of our lead product candidate, mavorixafor and may be required to complete additional nonclinical studies and clinical trials before we can seek regulatory approval. We are also conducting a Phase 1b clinical trials of mavorixafor for the treatment of SCN and chronic neutropenia disorders and for Waldenstr&#246;m&#8217;s. While we have investigated mavorixafor for the treatment of ccRCC, we do not intend to develop mavorixafor for this indication on our own. Our other programs, including X4P-002 and X4P-003, are still in the preclinical development stage. The clinical trials of our product candidates are, and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review and regulation by government authorities in the United States and in other countries where we intend to test and, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must successfully meet a number of critical developmental milestones, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developing dosages that will be well-tolerated, safe and effective;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">completing the development and scale-up to permit manufacture of our product candidates in commercial quantities and at acceptable costs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">demonstrating through pivotal clinical trials that each product candidate is safe and effective in patients for the intended indication;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time necessary to achieve these developmental milestones for any individual product candidate is long and uncertain, and we may not successfully complete these milestones for mavorixafor or any other product candidates that we may develop. We have not yet completed development of any product candidate. We also may not be able to finalize the design or formulation for our other programs, X4P-002 and X4P-003, a next generation molecule for the treatment of rare diseases linked to defects in CXCR4 trafficking.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to test and develop our product candidates and may explore possible design or formulation changes to address safety, efficacy, manufacturing efficiency and performance issues to the extent any arise. We may not be able to complete development of any product candidates that demonstrate safety and efficacy and that will have a commercially reasonable treatment and storage period. If we are unable to complete development of mavorixafor or any other product candidates that we may develop, we will not be able to commercialize and earn revenue from them.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to develop mavorixafor, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop mavorixafor, and may develop future product candidates, in combination with one or more currently approved cancer therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also evaluate mavorixafor or any other future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market and sell mavorixafor or any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the drugs that we choose to evaluate in combination with mavorixafor or any product candidate we develop, we may be unable to obtain approval of or market mavorixafor or any product candidate we develop.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory review and approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, including mavorixafor, our business will be substantially harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of drugs in development in the United States, only a small percentage receive FDA regulatory approval and are commercialized in the United States. We are not permitted to market mavorixafor or any other product candidate in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries or jurisdictions, such as the marketing authorization application, or MAA, in the European Union from the European Medicines Agency (&#8220;EMA&#8221;). Prior to submitting an NDA to the FDA for approval of mavorixafor for the treatment of WHIM syndrome, we will need to successfully complete our current Phase 3 pivotal clinical trial of mavorixafor in patients with WHIM syndrome, and we may be required by the FDA to conduct additional clinical trials and/or nonclinical studies to support potential approval. Successfully completing clinical trials and obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process, and the FDA, or a comparable foreign regulatory authority, may delay, limit or deny approval of mavorixafor for the treatment of WHIM syndrome or other indications for many reasons, including, among others:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disagreement with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disagreement with the sufficiency of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to demonstrate the safety and efficacy of mavorixafor or any other product candidate for its proposed indications;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to demonstrate that any clinical and other benefits of mavorixafor or any other product candidate outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a negative interpretation of the data from our nonclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">deficiencies in the manufacturing or control processes or failure of third-party manufacturing facilities with which we contract for clinical and commercial supplies to comply with current Good Manufacturing Practice requirements, or cGMPs;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">insufficient data collected from clinical trials of mavorixafor or changes in the approval requirements that render its nonclinical and clinical data insufficient to support the filing of an NDA or to obtain regulatory approval; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in clinical practice in or approved products available for the treatment of the target patient population that could have an impact on the indications that we are pursuing for mavorixafor or our other product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or a comparable foreign regulatory authority may also require more information, including additional nonclinical or clinical data to support approval, which may delay or prevent approval of our commercialization plans, or cause us to abandon the development program. Even if we obtain regulatory approval, our product candidates may be approved for fewer or more limited indications than we request, such approval may be contingent on the performance of costly post-marketing clinical trials, or we may not be allowed to include the labeling claims necessary or desirable for the successful commercialization of such product candidate. For instance, it is possible that mavorixafor could be approved for an indication but fail to be used for treating patients in that indication due to the availability of other available treatments or then-accepted clinical practice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and Dana-Farber Cancer Institute to permit us to use patents and patent applications. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and Dana-Farber Cancer Institute under which we were granted rights to patents and patent applications that are important to our business. We rely on these license agreements in order to be able to use various proprietary technologies that are material to our business, including certain patents and patent applications that cover our product candidates, including mavorixafor. Our rights to use these patents and patent applications and employ the inventions claimed in these licensed patents are subject to the continuation of and our compliance with the terms of our license agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreement with Genzyme imposes upon us various diligence, payment and other obligations, including the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our obligation to pay Genzyme milestone payments in the aggregate amount of up to $25.0 million, contingent upon our achievement of certain late-stage regulatory and sales milestones with respect to licensed products.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our obligation to pay Genzyme tiered royalties based on net sales of licensed products that we commercialize under the agreement.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our obligation to pay Genzyme a certain percentage of cash payments received by us or our affiliates in consideration for the grant of a sublicense under the license granted to us by Genzyme.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with any of our obligations under the Genzyme license agreement, or we are subject to a bankruptcy, Genzyme may have the right to terminate the license agreement, in which event we would not be able to market any product candidates covered by the license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to July 2014, we did not control the prosecution, maintenance, or filing of the patents and patent applications that are licensed to us under the Genzyme license agreement, or the enforcement of these patents and patent applications against infringement by third parties. Thus, these patents and patent applications were not drafted by us or our attorneys, and we did not control or have any input into the prosecution of these patents and patent applications prior to our execution of the Genzyme license agreement in July 2014. Under the terms of the license agreement with Genzyme, since July 2014, we have controlled the right to control the prosecution, maintenance, and filing of the patents and patent applications that are licensed to us, and the enforcement of these patents and patent applications against infringement by third parties. However, we cannot be certain that the same level of attention was given to the drafting and prosecution of these patents and patent applications as we may have used if we had control over the drafting and prosecution of such patents and patent applications. We also cannot be certain that drafting or prosecution of the patents and patent applications licensed to us has been conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our license agreement with Beth Israel Deaconess Medical Center, we paid an upfront, one-time fee for the rights granted by the license agreement. This license agreement imposes upon us various obligations, including the requirement to provide Beth Israel Deaconess Medical Center with progress reports at regular intervals and to maintain specified levels of insurance. Beth Israel Deaconess Medical Center may terminate the agreement for our non-payment, insolvency or default of material obligations. We have the right to terminate the agreement for any reason upon 90 days&#8217; advance written notice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreement with Georgetown imposes upon us various diligence, payment and other obligations, including our obligations to pay Georgetown milestone payments in the aggregate amount of up to $0.8 million, contingent upon our achievement of certain sales milestones with respect to licensed products, to deliver reports upon certain events and at regular intervals and to maintain customary levels of insurance. Georgetown may terminate the agreement for our non-payment, insolvency, failure to maintain insurance or default of material obligations. We have the right to terminate the agreement for any reason upon 60 days advance written notice.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreement with the Dana-Farber Cancer Institute (&#8220;DFCI&#8221;) imposes upon us various diligence, payment and other obligations, including our obligations to pay DFCI milestone payments in the aggregate amount of up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $32.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contingent upon our achievement of certain regulatory and sales milestones with respect to licensed products, to deliver reports at regular intervals and to maintain certain minimum levels of insurance.  DFCI may terminate the agreement if (i) we cease to carry on our business with respect to the licensed products, (ii) we default on diligence, insurance, payment or any other material obligations, (iii) one of our officers or that of a sublicensee is convicted of a felony relating to the manufacture, use, sale or importation of one or more licensed product, (iv) we become insolvent, (v) we grant a sublicense without notifying DFCI or on terms inconsistent with the terms required of sublicenses under the agreement or (vi) we bring a patent challenge against the licensed products. We have the right to terminate the agreement for any reason upon 90 days advance written notice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise under any of our license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and/or Dana-Farber Cancer Institute regarding the intellectual property that is subject to such license agreement, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope of rights granted under the applicable license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether and the extent to which our technology and processes infringe on intellectual property that is not subject to the applicable license agreement;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our diligence obligations with respect to the use of the licensed technology under the applicable license agreement to develop and commercialize products and technologies, including the level of effort and specific activities that will satisfy those diligence obligations; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us and our collaborators.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain any of our license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, certain of the above risks and uncertainties may be amplified as a result of the impact of the ongoing COVID-19 notwithstanding the commencement of vaccination efforts. The extent to which COVID-19 may impact our license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and/or Dana-Farber Cancer Institute, or any other third-party partner, will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19, including virus variants, and the actions to contain COVID-19, treat its impact or develop herd immunity, among others. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of clinical trials may not support our product candidate claims.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our clinical trials are completed as planned, we cannot be certain that their results will support the proposed product candidates, that the FDA or foreign government authorities will agree with our conclusions regarding such results, or that the FDA or foreign governmental authorities will not require additional clinical trials. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful and the results of later clinical trials often do not replicate the results of prior clinical trials and preclinical testing. The clinical trial results may fail to demonstrate that our product candidates are safe for humans and effective for the intended indications. This failure could cause us to abandon a product candidate and may delay development of other product candidates. Any delay in, or termination of, our clinical trials will delay or prevent the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submission of our marketing applications (NDA and/or MAA) and, ultimately, our ability to obtain approval and commercialize our product candidates and generate product revenues. Information about certain clinical trials, including results (positive or negative) will be made public according to each country&#8217;s clinical trial register policies. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in our clinical trials may lead to a delay in the submission of our marketing approval application and jeopardize our ability to potentially receive approvals and generate revenues from the sale of our products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in our current or future clinical trials, including our Phase 3 trial of mavorixafor for the treatment of WHIM syndrome, our Phase 1b clinical trial of mavorixafor for the treatment of SCN and chronic neutropenia disorders, and our Phase 1b clinical trial of mavorixafor for the treatment of Waldenstr&#246;m&#8217;s. As a result of the ongoing COVID-19 pandemic, we have experienced delays in clinical trial site activation and slower patient enrollment in our clinical trials of mavorixafor for the treatment of WHIM syndrome, Waldenstr&#246;m&#8217;s and SCN and chronic neutropenia disorders. In addition, currently there is a conflict involving Russia and Ukraine, and our Phase 3 trial of mavorixafor for the treatment of WHIM syndrome includes a trial site located in Russia, where three of the patients enrolled are located. We might have to close this site in light of the conflict. While we do not currently believe our clinical trial timelines are significantly impacted, we cannot be certain what the overall impact of this conflict will be on our ability to conduct and complete clinical trials on schedule. Clinical trials may be delayed, suspended or terminated for a variety of reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">direct and indirect effects of the ongoing COVID-19 pandemic on various aspects and stages of the clinical development process, including the potential impact to expected site activation, enrollment and participation in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the diversion of healthcare resources away from the conduct of clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic, or unforeseen events such as the armed conflict between Russia and Ukraine;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we are able to execute;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inability, delay or failure in identifying and maintaining a sufficient number of trial sites, many of which may already be engaged in competing clinical trial programs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in recruiting and enrolling suitable subjects to participate in a trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in having subjects complete a trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in reaching agreement on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in obtaining institutional review board (&#8220;IRB&#8221;) approval to conduct a clinical trial at each site;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays resulting from negative or equivocal findings of the Data Safety Monitoring Board (&#8220;DSMB&#8221;) if any;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">ambiguous or negative results;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">decision by the FDA, a comparable foreign regulatory authority, or recommendation by a DSMB to suspend or terminate clinical trials at any time for safety issues or for any other reason;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inadequate drug product for use in nonclinical studies or clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">lack of adequate funding to continue the product development program; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in governmental regulations or requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to enroll a sufficient number of patients in our clinical trials in a timely manner, which could delay or prevent clinical trials of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the rate at which we can recruit and enroll patients in testing our product candidates, and we have made certain assumptions about the rate at which we can enroll patients in our clinical trials. The timing of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing mavorixafor and any other current or future product candidates that we may develop as well as completion of required follow-up periods. For example, as a result of the ongoing COVID-19 pandemic, we have experienced, and expect to continue to experience, enrollment at a slower pace at certain of our clinical trial sites than initially expected. In addition, certain of our clinical trial sites have suspended enrollment due to facility closures, quarantine, travel restrictions and other governmental restrictions. As a result, our original expectations regarding the timing of results from our clinical trials of mavorixafor for the treatment of WHIM syndrome, SCN and chronic neutropenia disorders and Waldenstr&#246;m&#8217;s were delayed, which we expect will have a material adverse impact on our clinical trial plans and timelines.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot identify patients to participate in our clinical trials, whether due to COVID-19 or otherwise, or if patients are unwilling to participate in our clinical trials for any reason, including if patients choose to enroll in competitive clinical trials for similar patient populations, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of mavorixafor and any other current or future product candidates that we may develop may be delayed. These delays could result in increased costs, delays in advancing our current or future product candidates, including mavorixafor, X4P-002 or X4P-003, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial, to complete our clinical trials in a timely manner. In particular, we are currently evaluating mavorixafor for the treatment of WHIM syndrome, SCN and chronic neutropenia disorders and Waldenstr&#246;m&#8217;s, rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the duration of clinical trials, is also affected by many factors, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays or difficulties in clinical site activation, including difficulties in training clinical site investigators and clinical site staff; </span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">diversion or prioritization of healthcare resources away from the conduct of our clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, particularly for clinical trials that require in-patient monitoring following administration of the product candidate;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19, being forced to quarantine, or being unable to visit clinical trial locations;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the size and nature of the patient population (particularly with respect to orphan drugs which, by definition, are intended for a relatively small patient population);</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the eligibility criteria for the clinical trial in question;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the design of the clinical trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability to obtain and maintain patient consents;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the risk that enrolled subjects will drop out before completion (including due to unforeseen events such as the armed conflict between Russia and Ukraine);</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drug that may be approved or for which clinical trials are initiated for the indications that we are investigating;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our CROs and our trial sites&#8217; efforts to facilitate timely screening and enrollment in clinical trials and</span></div><div style="padding-left:85.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while we will have agreements governing their activities, we have limited control over their actual performance;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">patient referral practices of physicians; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to monitor patients adequately during and after treatment, which may be affected by COVID-19. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may be forced to delay, limit or terminate ongoing or planned clinical trials of our product candidates, which would delay our ability to obtain approvals and generate product revenues from any of these product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the commercial opportunity in WHIM syndrome, SCN and chronic neutropenia disorders or Waldenstr&#246;m&#8217;s is smaller than we anticipate, our potential future revenue from mavorixafor for the treatment of any of the diseases may be adversely affected and our business may suffer.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the size of the commercial opportunities in any of our target indications is smaller than we anticipate, we may not be able to achieve profitability and growth. We are developing mavorixafor initially as a treatment for patients with WHIM syndrome and also as a treatment for other rare diseases, including primary immunodeficiencies such as SCN and chronic neutropenia disorders and cancer such as Waldenstr&#246;m&#8217;s. WHIM syndrome, SCN and chronic neutropenia disorders and Waldenstr&#246;m&#8217;s each have a limited patient population.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we are aware of only a few small available patient registries for WHIM syndrome, and we rely on various estimates and assumptions to estimate the addressable WHIM syndrome population. Based on a broad online survey of physicians to validate current prevalence estimates and additional research using artificial intelligence, which interrogated a database of more than 300 million anonymized patient records that spanned 10 years of insurance claims, we estimate there are up to 3,700 diagnosed and undiagnosed WHIM patients in the United States, many of whom were previously undiagnosed. If the commercial opportunity in WHIM syndrome is smaller than we anticipate, whether because our estimates of the addressable patient population prove to be incorrect or for other reasons, our potential future revenue from mavorixafor may be adversely affected and our business may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is critical to our ability to grow and become profitable that we successfully identify patients with WHIM syndrome, CN and Waldenstr&#246;m&#8217;s. Our projections of the number of people who have WHIM syndrome (or its other potential primary immunodeficiencies), CN or Waldenstr&#246;m&#8217;s are based on a variety of sources, including third-party estimates and analyses in the scientific literature, and may prove to be incorrect. Further, new information may emerge that changes our estimate of the prevalence of these diseases or the number of patient candidates for each disease. The effort to identify patients for treatment is at an early stage, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the addressable patient population for our indications may be limited or may not be amenable to treatment with mavorixafor, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of our product candidates, or our entry into licensing, collaboration or similar arrangements, could be delayed or prevented.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">diversion or prioritization of healthcare resources away from the conduct of clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic or unforeseen events such as the armed conflict between Russia and Ukraine;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate (including due to unforeseen events such as the armed conflict between Russia and Ukraine);</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulators, institutional review boards or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may experience delays in reaching, or we may fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks or undesirable side effects;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulators, institutional review boards or independent ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, institutional review boards or independent ethics committees to suspend or terminate the clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in testing or marketing approvals. We have experienced delays in clinical trial site activation and slower patient enrollment in our Phase 3 clinical trial of mavorixafor in patients with WHIM syndrome and our Phase 1b clinical trial of mavorixafor in patients with Waldenstr&#246;m&#8217;s and SCN and chronic neutropenia disorders as a result of the ongoing COVID-19 pandemic. Significant preclinical study or clinical trial delays, including as a result of COVID-19, also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, if they are approved, or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, unforeseen global events such as the armed conflict between Russia and Ukraine could adversely affect the conduct of our clinical trials and harm our business and results of operations. In late February 2022, Russian military forces launched significant military action against Ukraine. Around the same time, the United States, the United Kingdom, the European Union, and several other nations announced a broad array of new or expanded sanctions, export controls, and other measures against Russia and others supporting Russia&#8217;s economy or military efforts. This armed conflict between Russia and Ukraine, including any resulting sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries, have created global security concerns that could result in a regional conflict and otherwise have a lasting impact on regional and global economies, any or all of which could disrupt our supply chain and adversely affect our ability to conduct ongoing and future clinical trials of our product candidates, including our Phase 3 trial of mavorixafor for the treatment of WHIM syndrome, which currently includes a trial site in Russia, where three of the patients enrolled are located. We might have to close this site in light of the conflict. While we do not currently believe our clinical trial timelines are significantly impacted, we cannot be certain what the overall impact of this conflict will be on our ability to conduct clinical trials and our business in general.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Preliminary or top-line data may include, for example, data regarding a small percentage of the patients enrolled in a clinical trial, and such preliminary data should not be viewed as an indication, belief or guarantee that other patients enrolled in such clinical trial will achieve similar results or that the preliminary results from such patients will be maintained. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Marketing and Commercialization of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakthrough therapy designation or Fast Track designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and neither of these designations increases the likelihood that our product candidates will receive marketing approval.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained both breakthrough therapy and Fast Track designations for mavorixafor for the treatment of adult patients with WHIM and we may pursue those designations for other product candidates as well. A breakthrough therapy is defined as a product that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. A breakthrough therapy designation affords the possibility of rolling review, enabling the FDA to review portions of our marketing application before submission of a complete application, and possibly, priority review. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a drug or biologic candidate is intended for the treatment of a serious or life-threatening condition or disease and the drug demonstrates the potential to address unmet medical needs for the condition, the sponsor may apply for Fast Track designation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy and Fast Track designation are within the discretion of the FDA. Accordingly, even if we believe that our product candidates meet the criteria for designation as a breakthrough therapy or Fast Track designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of either or both of a breakthrough therapy designation or Fast Track designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies or for Fast Track designation, the FDA may later decide that the products no longer meet the conditions for qualification.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is possible that we may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates, which could limit the potential profitability of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for the treatment or prevention of rare diseases or conditions with relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the (&#8220;Orphan Drug Act&#8221;), the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is defined as a patient population of fewer than 200,000 individuals in the United States. We received orphan drug designation from the FDA for mavorixafor for the treatment of WHIM syndrome in October 2018, and from the EMA in July 2019. If a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication during that time period with some exceptions. A similar provision in the European Union allows 10 years of exclusivity in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that marketing exclusivity is no longer justified. Orphan drug exclusivity may be lost in both the United States and Europe under certain situations, such as the inability of the holder of the orphan drug designation to produce sufficient quantities of the drug to meet the needs of patients with the rare disease or condition or for certain other reasons.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales and marketing capabilities to market and sell our product candidates, we may be unable to generate any revenue.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are ultimately successful in obtaining regulatory approval of mavorixafor for the treatment of WHIM syndrome or another indication, in order to market and sell mavorixafor and our other product candidates in development, we currently intend to build and develop our own sales, marketing and distribution operations. Although our management team has previous experience with such efforts, there can be no assurance that we will be successful in building these operations. If we are unable to establish adequate sales, marketing and distribution capabilities, we may not be able to generate product revenue and may not become profitable. We will also be competing with many companies that currently have extensive and well-funded sales and marketing operations. If any of our product candidates are approved, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among hospitals, physicians, patients and healthcare payors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not gain market acceptance among hospitals, physicians, health care payors, patients and the medical community. Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the efficacy and safety of such product candidates as demonstrated in clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the clinical indications for which the product candidate is approved;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acceptance by major operators of hospitals, physicians and patients of the product candidate as a safe and effective treatment, particularly the ability of mavorixafor and our other product candidates to establish themselves as a new standard of care in the treatment paradigm for the indications that we are pursuing;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the potential and perceived advantages of our product candidates over alternative treatments as compared to the relative costs of the product candidates and alternative treatments;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the prevalence and severity of any side effects with respect to our product candidates, including mavorixafor;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to offer any approved products for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing of market introduction of our products as well as competitive products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our pricing, and the availability of coverage and adequate reimbursement by third party payors and government authorities;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">relative convenience and ease of administration; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the effectiveness of our sales and marketing efforts and those of our potential future collaborators.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be delays in getting our product candidates, if approved, on hospital or insurance formularies or limitations on coverages that may be available in the early stages of commercialization for newly approved drugs. If any of our product candidates are approved but fail to achieve market acceptance among hospitals, physicians, patients or health care payors, we will not be able to generate significant revenues, which would have a material adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by any of our product candidates that we may develop or acquire could cause us or the FDA or other regulatory authorities to interrupt, delay or halt our clinical trials and could result in more restrictive labels or the delay or denial of marketing approval by the FDA or other regulatory authorities of such product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. In addition, any drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar drugs) after such approval, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may withdraw or limit their approval of such product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be required to change the way such product candidates are distributed or administered, conduct additional clinical trials or change the labeling of the product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require a Risk Evaluation and Mitigation Strategy plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be subject to regulatory investigations and government enforcement actions;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may decide to remove such product candidates from the marketplace after they are approved;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our reputation may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties and any approved products will be subject to extensive post-approval regulatory requirements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval for a product candidate, it would be subject to extensive ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The safety profile and efficacy of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, these regulatory authorities may require labeling changes or the FDA may require establishment of a Risk Evaluation Mitigation Strategy (&#8220;REMS&#8221;), or similar strategy, impose significant restrictions on a product&#8217;s indicated uses or marketing, impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Progress reports are required at quarterly intervals, every six months and at annual intervals depending upon the country, and more frequently if serious adverse events occur.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers of drugs and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with cGMPs and other applicable regulatory requirements, the FDA may, among other things:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">issue warning letters;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">request modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refuse to approve pending applications or supplements to applications filed by us;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and generate revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">restrictions on the labeling, marketing, distribution or use of a product;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">requirements to conduct post-approval clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">warning or untitled letters;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">withdrawal of the products from the market;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">recall of products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refusal to permit the import or export of our products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">product seizure; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell some of our product candidates if and when they are approved.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are risks involved both with establishing our own sales and marketing capabilities and with entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future products; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenue to us may be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of cancer, such as ccRCC. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, mavorixafor, is in clinical development for the treatment of WHIM syndrome, chronic neutropenia and Waldenstr&#246;m&#8217;s, respectively. We are aware of other companies that are developing CXCR4 inhibitors that are in a similar stage of development as mavorixafor, including BioLineRx, Noxxon, Upsher-Smith, Polyphor and Glycomimetics. To our knowledge, there do not appear to be any competitors with programs in development for WHIM syndrome or chronic neutropenia disorders. With respect to chronic neutropenia, filgrastim injections (human granulocyte colony-stimulating factor (G-CSF)) and two biosimilars (Zarxio and Nivestym ) are FDA-approved to reduce the incidence and duration of afteraffects of severe neutropenia (e.g.&#8218; fever&#8218; infections&#8218; oropharyngeal ulcers) in symptomatic patients with congenital neutropenia&#8218; cyclic neutropenia&#8218; or idiopathic neutropenia</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In Waldenstr&#246;m&#8217;s, there are several treatment approaches currently being developed, including targeted therapies and immunotherapies (as monotherapies and combination therapies), chemotherapy, stem cell transplantation, and cancer vaccines. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic products. This may make it difficult for us to achieve our business strategy of using our product candidates in combination with existing therapies or replacing existing therapies with our product candidates.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may develop products that are more effective, have a better safety profile, are more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products sooner than we may obtain approval for our product candidates, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties may compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. If regulatory approval is obtained, sales of any future product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable foreign regulatory authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for any future product candidates in the European Union from the European Commission following the opinion of the European Medicines Agency, if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a product candidate is approved, the FDA or the European Commission, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of any future product candidates in certain countries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we seek approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we seek approval of our product candidates outside of the United States, we expect that we will be subject to additional risks in commercialization including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">different regulatory requirements for approval of therapies in foreign countries;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reduced protection for intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">foreign reimbursement, pricing and insurance regimes;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters and public health epidemics, such as the ongoing COVID-19 pandemic.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in and outside of Europe with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their own products in foreign countries to be very challenging.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize mavorixafor or any other product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws and regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted and, in some markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize mavorixafor or any other product candidate successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. and E.U. healthcare industries and elsewhere is cost containment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will be available for mavorixafor or any other product that we commercialize and, if coverage and reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for mavorixafor may be particularly difficult because of the higher prices typically associated with drugs directed at smaller populations of patients. In addition, third-party payors are likely to impose strict requirements for reimbursement of a higher priced drug, and any launch of a competitive product is likely to create downward pressure on the price initially charged. If reimbursement is not available or is available only to a limited degree, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the applicable regulatory authority. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacturing, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. In the European Union, reference pricing systems and other measures may lead to cost containment and reduced prices. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to develop product candidates and commercialize products and our overall financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk with respect to commercial sales of any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reduced resources of our management to pursue our business strategy;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">decreased demand for any products that we may develop;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">significant costs to defend any related litigation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">increased insurance costs; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability to commercialize any products that we may develop.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain clinical trial insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we continue clinical trials or begin commercialization of any products. Insurance coverage is increasingly expensive. We may not be able to obtain or maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to significant penalties, including administrative, civil and criminal penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any drugs on the market, we are, and once we begin commercializing our product candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in the jurisdictions in which we conduct our business. Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, as well as market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid; a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal false claims laws impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; in addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal physician payment transparency requirements, sometimes referred to as the &#8220;Sunshine Act&#8221; under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the &#8220;ACA&#8221;), require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), information related to payments and other transfers of value to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals and the ownership and investment interests of physicians and their immediate family members in such manufacturers;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, and their subcontractors that use, disclose, or otherwise process individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, drug pricing or marketing expenditures;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">state and local laws that require the registration of pharmaceutical sales representatives; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">state and foreign laws also govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict post-approval activities and affect our ability to sell profitably any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Medicare covers certain drug purchases by the elderly and eligible disabled people and introduced a reimbursement methodology based on average sales prices for physician-administered drugs. In addition, Medicare may limit the number of drugs that will be covered in any therapeutic class. Ongoing cost reduction initiatives and future laws could decrease the coverage and price that we will receive for any approved products. While Medicare beneficiaries are limited to most elderly and certain disabled individual, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our product candidates are the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">extension of manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expansion of eligibility criteria for Medicaid programs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expansion of the entities eligible for discounts under the Public Health Service Act&#8217;s pharmaceutical pricing program;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">new requirements to report to CMS financial arrangements with physicians, as defined by such law, and teaching hospitals;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a new requirement to annually report to FDA drug samples that manufacturers and distributors provide to physicians; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been challenges to certain aspects of the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Presidential executive orders, Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. It is unclear whether these or similar policy initiatives will be implemented in the future. Further, Congress is considering additional health reform measures.  At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot predict what healthcare reform initiatives may be adopted in the future. However, we expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we will receive for any approved product. These new laws may result in additional reductions in Medicare and other healthcare funding. Any reduction in payments from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our product candidates may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements. Further, it is possible that additional governmental action will be taken in response to the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect its business, results of operations and financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and other anti-corruption laws that apply in countries where we do business and may do business in the future. The FCPA and these other laws generally prohibit us, our officers and employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA violations, and may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which its international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the U.S. government and authorities in the European Union or the United Kingdom, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which we collectively refer to as Trade Control Laws.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control Laws by U.S. or other authorities could also have an adverse impact on our reputation, business, results of operations and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have minimal experience manufacturing our product candidates on a large clinical or commercial scale and have no manufacturing facility. We are currently dependent on a single third party manufacturer for the manufacture of mavorixafor, the active pharmaceutical ingredient (&#8220;API&#8221;), and a single manufacturer of mavorixafor finished drug product capsules. If we experience problems with these third parties, the manufacturing of mavorixafor could be delayed, which could harm our results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate facilities for the manufacture of mavorixafor or any other product candidate. We currently have no plans to build our own clinical or commercial scale manufacturing capabilities. We currently work exclusively with one manufacturer for the production of mavorixafor, the API, and a single manufacturer of mavorixafor finished drug product capsules. We cannot guarantee that these third parties will continue to perform their contractual duties in a timely and satisfactory manner as a result of the ongoing COVID-19 pandemic, which could negatively impact our supply chain activities and our clinical supply. While we believe we have adequate supply into 2022, this projection may be proven incorrect. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our projected needs for clinical supplies to support our activities through regulatory approval and commercial manufacturing, the manufacturer with whom we currently work will need to increase its frequency and/or scale of production or we will need to find additional or alternative manufacturers. We have not yet secured alternate suppliers in the event the current manufacturer we utilize is unable to meet demand, or if otherwise we experience any problems with them. If such problems arise and we are unable to arrange for alternative third-party manufacturing sources, we are unable to find an alternative third party capable of reproducing the existing manufacturing method or we are unable to do so on commercially reasonable terms or in a timely manner, we may not be able to complete development of our product candidates, or market or distribute them.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured our product candidates ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility of breach of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing agreement by the third party because of factors beyond our control (including a failure to synthesize and manufacture our product candidates or any products that we may eventually commercialize in accordance with our specifications), and the possibility of termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP and similar foreign standards. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and some state agencies, and are subject to periodic unannounced inspections for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA or other regulatory authority approval before being implemented. FDA requirements also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, the manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain cGMP compliance. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates or products if they are approved in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of products, injunction, or imposing civil and criminal penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current manufacturer and any future manufacturers may not be able to manufacture our product candidates at a cost or in quantities or in a timely manner necessary to make commercially successful products. If we successfully commercialize any of our product candidates, we may be required to establish large-scale commercial manufacturing capabilities. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical study and commercial manufacturing capacity. We have no experience manufacturing pharmaceutical products on a commercial scale and some of these manufacturers will need to increase their scale of production to meet our projected needs for commercial manufacturing, the satisfaction of which may not be met on a timely basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party CROs to conduct our preclinical studies and clinical trials. If these CROs do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third-party contract research organizations, or CROs, and clinical data management organizations to monitor and manage data for our ongoing preclinical and clinical programs. Although we control only certain aspects of their activities, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We also rely on third parties to conduct our preclinical studies in accordance with Good Laboratory Practice, or GLP, requirements and the Laboratory Animal Welfare Act of 1966 requirements. We, our CROs and our clinical trial sites are required to comply with regulations and current Good Clinical Practices, or GCP, and comparable foreign requirements to ensure that the health, safety and rights of patients are protected in clinical trials, and that data integrity is assured. Regulatory authorities ensure compliance with GCP requirements through periodic inspections of trial sponsors and trial sites. If we, any of our CROs or our clinical trial sites fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials or a specific site may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If CROs do not successfully carry out their contractual obligations or meet expected timelines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs may also fail to meet expected timelines as a result of circumstances beyond their control, including the ongoing COVID-19 pandemic. As a result of the ongoing COVID-19 pandemic, we have experienced delays in clinical trial site activation and slower patient enrollment in our clinical trials of mavorixafor in patients with WHIM, Waldenstr&#246;m&#8217;s and CN, which could delay our ability to obtain regulatory approval for or successfully commercialize our product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions in our supply chain could delay the commercial launch of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any significant disruption in our supplier relationships could harm our business. We currently rely on a single source supplier of mavorixafor, as well a single supplier for the finished product capsules for mavorixafor. If either of these single source suppliers suffers a major natural or man-made disaster at its manufacturing facility, we would not be able to manufacture mavorixafor on a commercial scale until a qualified alternative supplier is identified. Although alternative sources of supply exist, the number of third party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers. Any significant delay in the supply of a product candidate or its key materials for an ongoing clinical study could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If we or our manufacturers are unable to purchase these key materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed, which would impair our ability to generate revenues from the sale of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the ongoing COVID-19 pandemic continues to persist for an extended period of time an impacts essential distribution systems such as FedEx and postal delivery, or if the armed conflict involving Russia and Ukraine, including any resulting sanctions, continues or escalates, we could experience disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our products, which would adversely impact our ability to deliver products to clinical trial sites or to generate sales of and revenues from our approved products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, to provide accurate information to the FDA or comparable foreign regulatory authorities, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee or third party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and, particularly in light of the work-from-home policies we have implemented in response to the ongoing COVID-19 pandemic and applicable stay-at-home orders or similar restrictions, the precautions we take to detect and prevent this activity, such as employee training, may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have established, and may seek to selectively establish in the future, collaborations, and, if we are unable to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may depend on such collaborations for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, and may selectively seek in the future, third-party collaborators for the development and commercialization of our product candidates. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our product candidates pose many risks to us, including that:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or products if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to one or more product candidates or products may not commit sufficient resources to the marketing and distribution of such drugs;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or products or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may lose certain valuable rights under circumstances identified in our collaborations if we undergo a change of control;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. In addition, if a future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in future acquisitions or in-licenses of technology that could disrupt our business, cause dilution to our stockholders and harm our financial condition and operating results.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we currently have no specific plans to acquire any other businesses or in-license any additional products or technology, we may, in the future, make acquisitions or licenses of, or investments in, companies, products or technologies that we believe are a strategic or commercial fit with our current product candidates and business or otherwise offer opportunities for us. In connection with these acquisitions or investments, we may:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue stock that would dilute our stockholders&#8217; percentage of ownership;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expend cash;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur debt and assume liabilities; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur amortization expenses related to intangible assets or incur large and immediate write-offs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may be unable to find suitable acquisition or license candidates and we may not be able to complete acquisitions or licenses on favorable terms, if at all. If we do complete an acquisition or license, we cannot assure you that it will ultimately strengthen our competitive position or that it will not be viewed negatively by customers, financial markets or investors. Further, the Merger poses, and future acquisitions or licenses could also pose, numerous additional risks to our operations, including:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">problems integrating the purchased or licensed business, products or technologies;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases to our expenses</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to have discovered undisclosed liabilities of the acquired or licensed asset or company;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management&#8217;s attention from their day-to-day responsibilities;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">harm to our operating results or financial condition;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> entrance into markets in which we have limited or no prior experience; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential loss of key employees, particularly those of the acquired entity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to complete one or more acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition without a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent laws and rulings by U.S. courts make it difficult to predict how patents will be issued or enforced in our industry.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may have a significant impact on our ability to protect our technology and enforce our intellectual property rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been numerous recent changes to the patent laws and to the rules of the United States Patent and Trademark Office, or USPTO, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act, or AIA, which was signed into law in 2011, includes a transition from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, and changes the way issued patents are challenged. Certain changes, such as the institution of inter partes review proceedings, that allow third parties to challenge newly issued patents, came into effect on September 16, 2012. The burden of proof required for challenging a patent in these proceedings is lower than in district court litigation, and patents in the biologics and pharmaceuticals industry have been successfully challenged using these new post-grant challenges. In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in specified circumstances or weakening the rights of patent owners in specified situations. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, these substantive changes to patent law associated with the AIA may further weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future, all of which could harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the patent positions of companies engaged in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Two cases involving diagnostic method claims and &#8220;gene patents&#8221; have recently been decided by the Supreme Court. On March 20, 2012, the Supreme Court issued a decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc., or Prometheus, a case involving patent claims directed to measuring a metabolic product in a patient to optimize a drug dosage amount for the patient. According to the Supreme Court, the addition of well-understood, routine or conventional activity such as &#8220;administering&#8221; or &#8220;determining&#8221; steps was not enough to transform an otherwise patent ineligible natural phenomenon into patent eligible subject matter. On July 3, 2012, the USPTO issued guidance indicating that process claims directed to a law of nature, a natural phenomenon or an abstract idea that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the claim amounts to significantly more than the natural principle itself should be rejected as directed to non-statutory subject matter. On June 13, 2013, the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., or Myriad, a case involving patent claims held by Myriad Genetics, Inc. relating to the breast cancer susceptibility genes BRCA1 and BRCA2. Myriad held that isolated segments of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patent eligible subject matter, but that complementary DNA, which is an artificial construct that may be created from RNA transcripts of genes, may be patent eligible.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that our efforts to seek patent protection for our technology and products will not be negatively impacted by the changes described above, future rulings in district court cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact the Supreme Court&#8217;s decisions may have on the ability of life science companies to obtain or enforce patents relating to their products and technologies in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, although the Supreme Court has held in Myriad that isolated segments of naturally occurring DNA are not patent-eligible subject matter, certain third parties could allege that activities that we may undertake infringe other gene-related patent claims, and we may deem it necessary to defend ourselves against these claims by asserting non-infringement and/or invalidity positions, or pay to obtain a license to these claims. In any of the foregoing or in other situations involving third-party intellectual property rights, if we are unsuccessful in defending against claims of patent infringement, we could be forced to pay damages or be subjected to an injunction that would prevent us from utilizing the patented subject matter. Such outcomes could harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property rights, our competitive position could be harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our ability to protect our proprietary technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary technology and products. Where we have the right to do so under our license agreements, we seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and products that are important to our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patents, including those patent rights licensed to us by third parties, are highly uncertain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The steps we have taken to police and protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside the United States. The rights already granted under any of our currently issued patents and those that may be granted under future issued patents may not provide us with the proprietary protection or competitive advantages that we are seeking. If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to patent rights, we do not know whether any of the pending patent applications for any of our product candidates will result in the issuance of patents that protect our technology or products, or which will effectively prevent others from commercializing competitive technologies and products. Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Further, the examination process may require us or our licensors to narrow the claims, which may limit the scope of patent protection that may be obtained. Although our license agreement with Genzyme includes a number of issued patents that are exclusively licensed to us, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or have licensed from third parties may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such patents, or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and products. Protecting against the unauthorized use of our patented technology, trademarks and other intellectual property rights is expensive, difficult and may, in some cases, not be possible. In some cases, it may be difficult or impossible to detect third party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be required to incur significant expenses to obtain our intellectual property rights, and we cannot ensure that we will obtain meaningful patent protection for our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, it is also possible that we will fail to identify patentable aspects of further inventions made in the course of our development and commercialization activities before they are publicly disclosed, making it too late to obtain patent protection on them. Further, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shortly after such candidates are commercialized. We expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents. This includes in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of a patent that covers an approved product where the permission for the commercial marketing or use of the product is the first permitted commercial marketing or use, and as long as the remaining term of the patent does not exceed 14 years. However, the applicable authorities, including the FDA in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and these foreign laws may also be subject to change. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2013, the United States transitioned to a &#8220;first to file&#8221; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art prior to the issuance of a patent by the USPTO and may become involved in post-grant review or derivation proceedings for applications filed on or after March 16, 2013, interference proceedings for applications filed before March 16, 2013, ex parte reexamination, or inter partes review challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position with respect to third parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO, and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the possibility of litigation relating to infringement claims asserted against it, we may become a party to other patent litigation and other proceedings, including inter partes review proceedings, post-grant review proceedings, derivation proceedings declared by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future technologies or product candidates or products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">litigation or other proceedings could impair our ability to compete in the marketplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our intellectual property, including patents that may issue to or be licensed by us. As a result, we may be required to file claims in an effort to stop third-party infringement or unauthorized use. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. This can be prohibitively expensive, particularly for a company of our size, and time-consuming, and even if we are successful, any award of monetary damages or other remedy we may receive may not be commercially valuable. In addition, in an infringement proceeding, a court may decide that our asserted intellectual property is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our intellectual property does not cover its technology. An adverse determination in any litigation or defense proceedings could put our intellectual property at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the breadth or strength of our patent or other intellectual property rights is compromised or threatened, it could allow third parties to commercialize our technology or products or result in our inability to commercialize our technology and products without infringing third-party intellectual property rights. Further, third parties may be dissuaded from collaborating with us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings brought by the USPTO or its foreign counterparts may be necessary to determine the priority of inventions with respect to our patent applications, and we may also become involved in other proceedings, such as re-examination proceedings, before the USPTO or its foreign counterparts. Due to the substantial competition in the pharmaceutical space, the number of such proceedings may increase. This could delay the prosecution of our pending patent applications or impact the validity and enforceability of any future patents that we may obtain. In addition, any such litigation, submission or proceeding may be resolved adversely to us and, even if successful, may result in substantial costs and distraction to our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Moreover, intellectual property law relating to the fields in which we operate is still evolving and, consequently, patent and other intellectual property positions in our industry are subject to change and are often uncertain. We may not prevail in any of these suits or other efforts to protect our technology, and the damages or other remedies awarded, if any, may not be commercially valuable. During the course of this type of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to several license agreements and may need to obtain additional licenses from others to advance our research and development activities or allow the commercialization of our current product candidates and any that we may identify and pursue in the future. Our currently license agreements impose, and we expect that future license agreements will impose, various development, diligence, commercialization, and other obligations on us. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">From time to time, we may need to rely on licenses to proprietary technologies, which may be difficult or expensive to obtain or we may lose certain licenses which may be difficult to replace.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain licenses to patents and other proprietary rights held by third parties to develop, manufacture and market our product candidates. If we are unable to timely obtain these licenses on commercially reasonable terms and maintain these licenses, our ability to commercially market our product candidates may be inhibited or prevented, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates, and to use our proprietary technologies without infringing the proprietary rights of third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference and various post grant proceedings before the USPTO, non-U.S. opposition proceedings, and German nullity proceedings. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of any such infringement claims, or to avoid potential claims, we may choose or be compelled to seek intellectual property licenses from third parties. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us likely would be nonexclusive, which would mean that our competitors also could obtain licenses to the same intellectual property. Ultimately, we could be prevented from commercializing a product candidate or technology or be forced to cease some aspect of our business operations if, as a result of actual or threatened infringement claims, we are unable to enter into licenses of the relevant intellectual property on acceptable terms. Further, if we attempt to modify a product candidate or technology or to develop alternative methods or products in response to infringement claims or to avoid potential claims, we could incur substantial costs, encounter delays in product introductions or interruptions in sales. Ultimately, such efforts could be unsuccessful.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock and negatively impact our ability to raise additional funds. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our trade secrets are difficult to protect and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technologies and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality, non-competition, non-solicitation, and invention assignment agreements with our employees and consultants that obligate them to assign to us any inventions developed in the course of their work for us. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. As a result, we may be forced to bring claims against third parties, or defend claims that they bring against us, to determine ownership of what we regard as our intellectual property. Monitoring unauthorized disclosure is difficult and we do not know whether the procedures that we have followed to prevent such disclosure are or will be adequate. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States may be less willing or unwilling to protect trade secrets. If any of the technology or information that we protect as trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor, our competitive position would be harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees, including members of our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. All such individuals, including each member of our senior management, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. In general, we have sought patent protection of our intellectual property in the following jurisdictions: US, Canada, China, Japan </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and in countries within Europe via the European Patent Office. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The global COVID-19 pandemic is adversely affecting, and is expected to continue to adversely affect, our business, including our clinical trials and preclinical studies. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by public health crises such as pandemics or similar outbreaks in regions where we have concentrations of clinical trial sites or other business operations, which could cause significant disruption in the operations of third party manufacturers and CROs upon whom we rely. The ongoing COVID-19 pandemic initially resulted in a variety of restrictions in order to reduce the spread of the disease, including state and local orders across the United States and other countries worldwide, which, among other things, have directed individuals to stay at their places of residence, directed businesses and governmental agencies to limit non-essential operations at physical locations, prohibited certain non-essential gatherings, and ordered restrictions on travel. While many such restrictions have been lifted and vaccination efforts are ongoing, governmental restrictions may be re-imposed in light of rising incidence of COVID-19 cases and the discovery of variants of the virus.While we expect vaccinated employees to return to our Boston headquarters in early 2022, we also anticipate that work-from-home arrangements will persist to some degree. The effects of our work-from-home policies, as well as any government restrictions on in-office work that may be implemented or re-implemented in the future, may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions the speed of vaccination efforts, the efficacy of vaccines against current and future, including occupancy limits and social distancing requirements, variants of the SARS-CoV-2 virus and other limitations on our ability to conduct our business in the ordinary course. In addition, because of the challenging immune profile of both immunodeficient patients and cancer patients, COVID-19 may impact our clinical trial patients more significantly than clinical trials with patients who are not immunocompromised. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarantines, stay-at-home and similar government orders related to COVID-19, if instituted in new jurisdictions or re-imposed in jurisdictions where they were previously lifted,</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may adversely impact our business operations and the business operations of our CROs conducting our clinical trials and our third-party manufacturing facilities in the United States and other countries. Although vaccination efforts are on-going, many businesses continue to operate remotely, with limited personnel or with other impacts as a result of the ongoing pandemic. We cannot guarantee that these third parties will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic, which could negatively impact our supply chain activities and our clinical supply. Early in the pandemic, we experienced challenges in providing trial drugs to patients enrolled in our clinical trials, and where necessary and practical have implemented direct-to-patient shipments from clinical sites. If the COVID-19 pandemic persists or if future variants of COVID-19 emerge globally and impacts the distribution system on which we rely or essential distribution systems such as FedEx and postal delivery, we could experience disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our product candidates, which would adversely impact our ability to carry out our clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the ongoing COVID-19 pandemic, we are experiencing disruptions that could severely impact our business, clinical trials and preclinical studies, including:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling patients in our clinical trials, including travel restrictions on patients and constraints on the capacity of our clinical trial sites;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site activation, including difficulties in training clinical site investigators and clinical site staff;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion or prioritization of healthcare resources away from the conduct of clinical trials and towards the COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, particularly for clinical trials that require in-patient monitoring following administration of the product candidate;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or disruptions in the availability of clinical site staff, who, as healthcare providers, may have heightened exposure to COVID-19 or whose services may be diverted to the care of COVID-19 patients or to vaccination efforts, would adversely impact our clinical trial operations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of our key clinical trial activities, such as clinical assessments at pre-specified time points during the trial and clinical trial site data monitoring, due to limitations on travel imposed or recommended by governmental entities, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced ability to engage with the medical and investor communities due to the cancellation of conferences scheduled throughout the year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors arising from the ongoing COVID-19 pandemic could worsen in countries that are already experiencing high levels of COVID-19, could continue to spread to additional countries, or could, particularly as new variants of the virus are discovered, return to countries where the pandemic has been partially contained, whether through vaccination, herd immunity or otherwise, each of which could continue to adversely impact our ability to conduct clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results. These and other factors may also arise from future pandemics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of COVID-19, including the spread of new variants of the SARS-CoV-2 virus, which has caused a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by, and the duration of, COVID-19 is difficult to assess or predict, a widespread and sustained pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a sustained or deepened recession or market correction resulting from the spread of COVID-19 and the impacts of an enduring pandemic could materially affect our business and the value of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to evolve. The extent to which the ongoing COVID-19 pandemic will continue to impact our business, our clinical development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions, social distancing requirements, business closures in the United States and other countries, and the timing of the roll-out of coronavirus vaccines and the efficacy of those vaccines against current and future variants of the coronavirus and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain executives and to attract, retain and motivate key personnel in a competitive environment for skilled biotechnology personnel.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. We are highly dependent upon members of our current management team, including Paula Ragan, Ph.D., our Chief Executive Officer, the loss of whose services may adversely impact the achievement of our objectives. Although we have an employment agreement with Dr. Ragan, this agreement is at-will and does not prevent her from terminating her employment with us at any time by providing the requisite advance notice. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to retain our management team and other key employees, and to attract and retain qualified personnel in the future. The loss of the services of certain members of our senior management or key employees could prevent or delay the implementation and completion of our strategic objectives, or divert management&#8217;s attention to seeking qualified replacements. The competition for qualified personnel in the pharmaceutical field is intense and we cannot guarantee that we will be able to retain our current personnel or attract and retain new qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had 83 full-time employees. As our development and commercialization plans and strategies develop, or as a result of any future acquisitions, we will need additional managerial, operational, development, sales, marketing, financial and other resources. Our management, personnel and systems currently in place will not be adequate to support this future growth. Future growth would impose significant added responsibilities on our employees, including:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our clinical trials effectively;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, recruiting, maintaining, motivating and integrating additional employees;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our internal development efforts effectively while complying with our contractual obligations to licensors, contractors and other third parties;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our managerial, development, operational and finance systems; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanding our facilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative, research and development, and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing the company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render our technologies and products obsolete or uncompetitive.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render certain of our products obsolete or uncompetitive. This is particularly true in the development of therapeutics for oncology indications where new products and combinations of products are rapidly being developed that change the treatment paradigm for patients. There is no assurance that our product candidates will be the best, have the best safety profile, be the first to market, or be the most economical to make or use. The introduction of competitive therapies as alternatives to our product candidates could dramatically reduce the value of those development projects or chances of successfully commercializing those product candidates, which could have a material adverse effect on our long-term financial success.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will compete with companies in the United States and internationally, including major pharmaceutical and chemical companies, specialized CROs, research and development firms, universities and other research institutions. Many of our competitors have greater financial resources and selling and marketing capabilities, greater experience in clinical testing and human clinical trials of pharmaceutical products and greater experience in obtaining FDA and other regulatory approvals than we do. In addition, some of our competitors may have lower development and manufacturing costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cyber security incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could harm our ability to operate our business effectively and adversely affect our business and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we, our contract research organizations and other third parties on which we rely collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems. These applications and data encompass a wide variety of business-critical information including research and development information and business and financial information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy. Because of the work-from-home policies we implemented due to COVID-19, information that is normally protected, including company confidential information, may be less secure. Additionally, despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, breaches, unauthorized access, interruptions due to employee error or malfeasance or other disruptions, or damage from natural disasters, terrorism, war and telecommunication and electrical failures. &#160;&#160;&#160;&#160;In addition, due to the COVID-19 pandemic, we have enabled substantially all of our employees to work remotely, which may make us more vulnerable to cyberattacks. Any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. We have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, government enforcement actions and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct research, development and commercialization activities, process and prepare company financial information, manage various general and administrative aspects of our business and damage our reputation, in addition to possibly requiring substantial expenditures of resources to remedy, any of which could adversely affect our business. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our research, development and commercialization efforts could be delayed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics (including but not limited to the COVID-19 pandemic) and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on a single third-party manufacturer to provide the active pharmaceutical ingredient for mavorixafor and a single third-party manufacturer to provide fill and finish services for the final drug product formulation of mavorixafor for use in clinical trials. Our ability to obtain clinical supplies of product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss, or NOL, carryforwards could expire unused and be unavailable to offset future tax liabilities because of their limited duration or because of restrictions under U.S. tax law. As of December 31, 2021, we had U.S. federal and state NOLs of $315.0 million and $308.2 million, respectively. Our NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Act, as modified by the CARES Act, our federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal NOLs, particularly for tax years beginning after December 31, 2020, may be limited. It is uncertain if and to what extent various states will conform to the Tax Act and the CARES Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code of 1986, as amended, or Section 382, contains rules that limit the ability of a company that undergoes an ownership change to utilize its net operating losses, or NOLs, and tax credits existing as of the date of such ownership change. Under the rules, such an ownership change is generally any change in ownership of more than 50% of a company&#8217;s stock within a rolling three-year period. The rules generally operate by focusing on changes in ownership among stockholders considered by the rules as owning, directly or indirectly, 5% or more of the stock of a company and any change in ownership arising from new issuances of stock by the company. We have experienced multiple ownership changes since our inception and are conducting a study to assess whether an ownership change has occurred and whether these ownership changes will limit the future use of our NOL carryforwards. Future ownership changes as defined by Section 382 may further limit the amount of NOL carryforwards that could be utilized annually to offset future taxable income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our term loan contains restrictions that limit our flexibility in operating our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a loan and security agreement, as most recently amended in February 2022, with Hercules, secured by a lien on substantially all of our assets, including intellectual property. This loan contains various covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sell, transfer, lease or dispose of certain assets;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur indebtedness;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">encumber or permit liens on certain assets;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain investments;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain restricted payments, including paying dividends on, or repurchasing or making distributions with respect to, our common stock; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into certain transactions with affiliates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The covenants also include a requirement that, from and after an initial test date of September 1, 2022 we maintain cash in an aggregate amount greater than or equal to the greater of (i) $30.0 million, or (ii) six multiplied by a metric based on prior months&#8217; cash expenditures; provided, however, that from and after our achievement of certain financing milestones through June 30, 2022, we must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount of $30.0 million. Following the achievement of certain operational performance milestones, the required level shall be reduced to the greater of $20.0 million, or, if we had not met the financing milestones noted above, three multiplied by the current cash expenditures metric; and provided further, that subject to the achievement of additional operational milestones, this covenant will be extinguished. Based on our current cash and cash equivalents and our current operating plan, we believe that if we fail to raise additional capital by June 30, 2022, we would be in violation of the minimum cash described above in the third quarter of 2022. A breach of any of the covenants under the loan and security agreement could result in a default under the loan. Upon the occurrence of an event of default under the loan, the lenders could elect to declare all amounts outstanding, if any, to be immediately due and payable and terminate all commitments to extend further credit. If there are any amounts outstanding that we are unable to repay, the lenders could proceed against the collateral granted to them to secure such indebtedness.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is expected to continue to be volatile.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock could continue to be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or the ability of our collaborators to develop product candidates and conduct clinical trials that demonstrate such product candidates are safe and effective;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or the ability of our collaborators to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any our product candidates to demonstrate safety and efficacy, receive regulatory approval and achieve commercial success;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license, manufacturing and supply agreements;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us or our licensors to prosecute, maintain or enforce our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any inability to obtain adequate supply of product candidates or the inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse decisions by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new or competing products by our competitors;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial and development projections that we may provide to the public;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain intellectual property protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including intellectual property or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us of material developments in our business, financial condition and/or operations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if securities or industry analysts do not publish research or reports about us, or if they issue an adverse or misleading opinions regarding our business and stock;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market or macroeconomic conditions;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to our markets generally, including with respect to other products and potential products in such markets;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry, political and market conditions, including, but not limited to the ongoing impact of the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companies trading in the stock market in general, and Nasdaq in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic, may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our business, financial condition, results of operations and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company,&#8221; and a &#8220;smaller reporting company&#8221; and as a result of the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;), and may remain an emerging growth company until December 31, 2022. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reduced disclosure obligations regarding executive compensation; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors may find our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even following the termination of our status as an emerging growth company, we will be able to take advantage of the reduced disclosure requirements applicable to smaller reporting companies (as that term is defined in Rule 12b-2 of the Exchange Act) and, in particular, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are no longer eligible to use exemptions from various reporting requirements, we may be unable to realize our anticipated cost savings from these exemptions, which could have a material adverse impact on our operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced, in part, on the research and reports that industry or financial analysts publish about us or our business. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current expectation is that we will retain our future earnings to fund the development and growth of our business. In addition, the terms of our debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future. We are prohibited from declaring or paying any cash dividends under our existing loan and security agreement with Hercules Capital, Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the effect that sales, particularly sales by our directors, executive officers, and significant stockholders, may have on the prevailing market price of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have filed registration statements on Form S-8 registering the issuance of shares of common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. Shares registered under these registration statements are available for sale in the public market subject to vesting arrangements and exercise of options, as well as Rule 144 in the case of our affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002 and the rules and regulations of The Nasdaq Global Market. Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting in this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal control over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting beginning with this Annual Report. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. When we cease to be an emerging growth company and we no longer qualify as a non-accelerated filer, we will be required to incur substantial additional professional fees and internal costs to expand our accounting and finance functions in order to include such attestation report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our consolidated financial statements. Our internal control over financial reporting will not prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. If we identify one or more material weaknesses in our internal controls, investors could lose confidence in the reliability of our consolidated financial statements, the market price of our stock could decline and we could be subject to sanctions or investigations by The Nasdaq Global Market, the SEC or other regulatory authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in securities class action litigation or shareholder derivative litigation that could divert management&#8217;s attention and harm our business and insurance coverage may not be sufficient to cover all costs and damages.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action or shareholder derivative litigation has often followed certain significant business transactions, such as the sale of a business division or announcement of a merger. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. We may become involved in this type of litigation in the future, including litigation, if any, that may result in connection with the Merger. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation often is expensive and diverts management&#8217;s attention and resources, which could adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and by-laws may discourage, delay or prevent a merger, acquisition or other change in control of our Company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">allow the authorized number of our directors to be changed only by resolution of the board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">limit the manner in which stockholders can remove directors from the board;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to the board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">limit who may call stockholder meetings;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">authorize the board of directors to issue preferred stock without stockholder approval, which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the board of directors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or by-laws.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with the Company for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between the Company and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the Company or our directors, officers, employees or stockholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on the Company&#8217;s behalf, any action asserting a breach of fiduciary duty owed by our directors, officers, other employees or stockholders to the Company or our stockholders, any action asserting a claim against the Company arising pursuant to the Delaware General Corporation Law or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware, or any action asserting a claim arising pursuant to our certificate of incorporation or by-laws or governed by the internal affairs doctrine. This provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or our directors, officers, employees or stockholders, which may discourage such lawsuits against the Company and our directors, officers, employees or stockholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, if a court were to find this provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. &#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. &#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease approximately 28,000 square feet of office space at 61 North Beacon Street, 4th Floor, Boston, Massachusetts, which serves as our corporate headquarters. The lease expires on November 30, 2026. The base monthly payment on the lease is approximately $86 thousand as of December 31, 2021, subject to specified annual increases of approximately 3% during the term of the lease and not including operating expenses, certain utilities, taxes and insurance for which we are responsible. We have the right to sublease the premises, subject to landlord consent and we have the right to renew the lease for an additional five years at the then-prevailing effective market rental rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease approximately 1,200 square meters of laboratory and office space in Vienna, Austria under a lease that will expire in March 2028, with a monthly payment of approximately $25 thousand.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. &#160;&#160;&#160;&#160;LEGAL PROCEEDINGS </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i71bd745117f84268bb875bce92ea6db3_46"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. &#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock commenced trading on the Nasdaq Global Market under the symbol &#8220;ASNS&#8221; on November 16, 2017. Prior to that date, there was no public trading market for our common stock. On March 13, 2019, we completed a business combination in accordance with the terms of the Merger Agreement, by and among us, X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and the Merger Sub, pursuant to which, among other matters, Merger Sub merged with and into X4 Therapeutics, Inc., with X4 Therapeutics, Inc. continuing as our wholly-owned subsidiary and the surviving corporation of the merger. Following the Merger, on March 13, 2019, we effected a 1-for-6 reverse stock split of our common stock and changed our name to &#8220;X4 Pharmaceuticals, Inc.&#8221; On March 13 2019, following the completion of the Merger, our common stock began trading on the Nasdaq Global Market under the symbol &#8220;XFOR&#8221;. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Our Common Stock</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, there were 77 holders of record of our common stock. one of which is Cede &amp; Co., a nominee for Depository Trust Company (&#8220;DTC&#8221;). All of the shares of common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC, and are considered to be held of record by Cede &amp; Co. as one stockholder.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as previously reported by us on our Current Reports on Form 8-K or Quarterly Reports on Form 10-Q, we did not sell any securities during the period covered by this Annual Report that were not registered under the Securities Act.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. &#160;&#160;&#160;&#160;[RESERVED]</span></div><div style="margin-top:18pt"><span><br/></span></div><div style="margin-top:18pt"><span><br/></span></div><div style="margin-top:18pt"><span><br/></span></div><div style="margin-top:18pt"><span><br/></span></div><div style="margin-top:18pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">   &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and the other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report, our actual results could differ materially from the results described in or implied by these forward-looking statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">For the discussion of the financial condition and results of operations for the year ended December 31, 2020 compared to the year ended December 31, 2019, refer to &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; to our Annual Report on Form 10-K filed with the SEC on March 19, 2021. </span></div><div id="i71bd745117f84268bb875bce92ea6db3_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, with an initial focus on people with immune system dysfunction. Our lead product candidate, mavorixafor, is a first-in-class, small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Due to mavorixafor&#8217;s demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells, we believe that mavorixafor has the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies (&#8220;PIDs&#8221;) and certain types of cancer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently studying the safety and efficacy of mavorixafor in a global Phase 3 clinical trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;) syndrome, a rare, inherited PID, caused by genetic mutations in the CXCR4 receptor gene. We are also conducting a Phase 1b clinical trial of mavorixafor in people with a range of chronic neutropenia disorders, both with and without CXCR4 mutations, and a Phase 1b clinical trial of mavorixafor in combination with the Bruton tyrosine kinase inhibitor (&#8220;BTKi&#8221;) ibrutinib in people with Waldenstr&#246;m&#8217;s macroglobulinemia (&#8220;Waldenstr&#246;m&#8217;s&#8221;), a rare B-cell lymphoproliferative disorder, and confirmed mutations to both the CXCR4 and MYD88 genes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed enrollment our global Phase 3 clinical trial of mavorixafor, which we refer to as the 4WHIM trial, in the third quarter of 2021, with 31 patients enrolled and currently expect to report top-line data from the trial in the fourth quarter of 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration (&#8220;FDA&#8221;) has granted certain special designations to mavorixafor, including Breakthrough Therapy Designation for the treatment of adults with WHIM syndrome, Fast Track Designation for adults with WHIM syndrome, and Rare Pediatric Designation for the treatment of people aged 12 to 18 with WHIM syndrome, which could result in accelerated review and approval by the agency. We have begun building our commercial team in anticipation of a possible New Drug Application (&#8220;NDA&#8221;) submission to the FDA in the second half of 2023, with the goal of obtaining approval for mavorixafor for the treatment of people in the United States, aged 12 and older with WHIM syndrome, should the final Phase 3 data support the filing of an NDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following announcements of positive preliminary data from both of the ongoing Phase 1b clinical trials of mavorixafor during 2021, we are continuing patient enrollment in the trials. Additional data are expected from the Phase 1b clinical trial in chronic neutropenia by the third quarter of 2022 and from the Phase 1b clinical trial in Waldenstr&#246;m&#8217;s in the second half of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to mavorixafor, we are advancing earlier-stage product candidates to further expand our pipeline. We have advanced a lead optimization program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X4P-003, a second-generation CXCR4 antagonist is designed to have an enhanced properties relative to mavorixafor, potentially enabling broader opportunities in CXCR4 disorders and primary immunodeficiencies. A second program is in lead optimization: X4P-002, a CXCR4 antagonist designed to cross the blood-brain barrier and provide appropriate therapeutic exposures to potentially treat brain cancers in combination therapy. We are also continuing to leverage our insights into CXCR4 biology and our research capabilities to identify other targets and develop additional product candidates. We anticipate that we will file an Investigational New Drug application with the FDA to begin clinical development of X4P-002 in the second half of 2022.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated revenue from product sales and do not expect to generate significant revenue from the sale of our products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div style="margin-top:18pt"><img src="xfor-20211231_g1.jpg" alt="xfor-20211231_g1.jpg" style="height:270px;margin-bottom:5pt;vertical-align:text-bottom;width:696px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">X4 Pharmaceuticals, Data on File  1. Phase 2 open label trial extension (OLE) trial for WHIM ongoing  2. Company market research. Qessential market research, 2019 and IPM. ai artificial intelligence study, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:107%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">3. Estimate using Andersen et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:107%">J Intern Med. 2016 Jun:279(6):566-75   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:107%">WM Epidemiology Analysis Nemetz Group. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Business Update </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the continued COVID-19 pandemic, we have implemented business continuity measures designed to address and mitigate the impact of the COVID-19 pandemic on our employees, our business, including our clinical trials, supply chains and third-party providers. We continue to closely monitor the COVID-19 pandemic as we evolve our business continuity plans and response strategy. While we are currently operating under a &#8220;hybrid&#8221; model in which in-person attendance in the office is optional, we expect all employees who have been vaccinated back to the office in early 2022. While we are experiencing limited financial impacts at this time, given overall disruptions to the global economy, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the COVID-19 pandemic and continued uncertainty related to its abatement or the possible discovery of new variants of the SARS-CoV-2 virus, our business, financial condition, results of operations and growth prospects could be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to clinical development, we continue to implement risk-based approaches in accordance with FDA and European Medicines Agency (&#8220;EMA&#8221;) COVID-19 guidance, which includes virtual and remote patient visits and monitoring where possible, while prioritizing patient safety, maintaining trial continuity and preserving data integrity. We have experienced, and expect to continue to experience, a disruption or delay in our ability to initiate trial sites and/or enroll and assess patients in several of our clinical programs as a result of the ongoing COVID-19 pandemic, notwithstanding vaccination efforts. While not currently impacted, there could be an impact on our ability to supply study drug, report trial results, or interact with regulators, ethics committees or other important agencies due to limitations in regulatory authority employee resources or otherwise. In addition, we rely on contract research organizations (&#8220;CROs&#8221;) or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the ongoing COVID-19 pandemic. If the COVID-19 pandemic continues and persists, we could experience further disruptions to our clinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply Chain</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work closely with our third-party manufacturers, distributors and other partners to manage our supply chain activities and mitigate potential disruptions to our clinical supply as a result of the ongoing COVID-19 pandemic. We have business continuity plans in place and have manufacturing plans that will meet our global supply demands going forward. To best support our patients, we continue to work with our vendors to provide the option for direct-to-patient drug shipments from clinical sites. If the ongoing COVID-19 pandemic impacts essential distribution systems we could experience disruptions to our supply chain and operations, which could adversely impact our ability to carry out our clinical trials.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Activities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we could experience delays in the timing of review and/or our interactions with the FDA or the European Commission (&#8220;EC&#8221;) due to, for example, inability to conduct planned physical inspections related to regulatory approval, or the diversion of efforts of the FDA or EC and attention to approval of other therapeutics or other activities related to COVID-19, which could delay approval decisions with respect to the preparation and submission to the FDA of a new drug application (&#8220;NDA&#8221;), or the preparation and submission to the EC of a Marketing Authorization Application (&#8220;MAA&#8221;), and otherwise delay or limit our ability to make planned regulatory submissions or obtain new product approvals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Impact</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic continues to evolve and has already resulted in a significant disruption of global financial markets. If the disruption continues or future variants of COVID-19 emerge globally we could experience an inability to access additional capital, which could in the future negatively affect our operations.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2021 and 2020&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:61.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, we recorded $3.0 million in revenue related to our license agreement with Abbisko Therapeutics Co., Ltd., or Abbisko, due to the achievement of a financial milestone in March 2020. There was no similar revenue recorded in the year ended December 31, 2021. Pursuant to our license agreement with Abbisko, we are eligible to receive potential development and regulatory milestone payments, which vary based on the number of indications developed, and potential commercial milestone payments based on annual net sales of mavorixafor-based licensed products. The transaction price related to these development and regulatory milestones has been allocated to the delivery to Abbisko of the license to develop and commercialize mavorixafor, was satisfied at the inception of the arrangement in July 2019 and has been fully constrained. With respect to the remaining development and regulatory milestones, we will re-evaluate the constraint on the transaction price associated with these milestones in each reporting period and as uncertain events are resolved or other changes in circumstances </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates, including employee salaries and related expenses, expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with third parties, such as consultants and contract research organizations (&#8220;CROs&#8221;); the cost of manufacturing drug products for use in our preclinical studies and clinical trials, including under agreements with third parties, such as consultants and contract manufacturing organizations (&#8220;CMOs&#8221;); facilities, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance; costs related to compliance with regulatory requirements; and payments made under third-party licensing agreements. We expense research and development costs as incurred. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.540%"><tr><td style="width:1.0%"></td><td style="width:59.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct research and development expenses by product candidate:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mavorixafor (X4P-001)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X4P-002</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X4P-003</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $50.6 million for the year ended December 31, 2021 (&#8220;2021&#8221;), as compared to $41.9 million for the year ended December&#160;31, 2020 (&#8220;2020&#8221;), reflecting an increase of $8.7 million. The increase in research and development expenses in 2021 as compared to 2020 was primarily due to higher clinical trial expenses and third-party manufacturing costs related to mavorixafor to support our three ongoing clinical trials and increased consulting and professional services expenses related to these clinical trials. Research and development expenses also increased in 2021 due to an increase in unallocated expenses, primarily due to an increase in head count within our manufacturing, regulatory and clinical operations functions, resulting in higher compensation expenses, including stock-based compensation. In addition, unallocated research and development expense increased due to additional facility costs associated with our leased facilities, which are allocated to research and development departments based on respective head-count.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses, particularly&#160;for&#160;our mavorixafor programs,&#160;will&#160;increase over the next several years as we continue to conduct our WHIM4 trial and our Phase 1b clinical trials of mavorixafor in CN and Waldenstr&#246;m&#8217;s. Research and development expenses related to our X4P-002&#160;and X4P-003 programs were not significant in 2021 relative to our overall research and development expenses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs, as well as professional fees for legal, patent, consulting, investor and public relations, accounting, and audit services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $24.7 million in 2021, as compared to $21.0 million in 2020, reflecting an increase of $3.7 million. The increase in general and administrative expenses in 2021 as compared to 2020 was primarily due to an increase in stock-based compensation costs, higher recruiting costs and an increase in facility costs. Our head-count in general and administrative functions was relatively consistent with the prior period. We expect general and administrative expenses will grow in the future as we continue to build out our selling, general and administrative functions.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Impairment </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested quantitatively for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. During the fourth quarter of 2021, our market capitalization, measured as the price of our common stock multiplied by shares of common stock outstanding, dropped below the value of our net assets, including goodwill. As we have one reporting unit, we determine its fair value based on the market approach, taking into consideration the market value of the company as a whole and any control premium that might be realized upon the sale of the reporting unit. As a result of the sustained decline in the market price of our common stock, the fair value of our single reporting unit, measured based on our market capitalization as of December 31, 2021, was lower than its carrying value and we concluded that goodwill was impaired. Accordingly, we recorded an impairment charge of $9.8 million to reduce the carrying amount of goodwill to $17.4 million as of December 31, 2021. Should the market value of our common stock continue to decline, additional impairment charges may be recorded in future periods. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.545%"><tr><td style="width:1.0%"></td><td style="width:60.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December  31,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.75pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.75pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of preferred stock warrant and derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in other expense, net, of $1.5 million for the year ended December 31, 2021 as compared to 2020 was primarily due to higher interest expense due to a higher average outstanding borrowings associated with our loan facility with Hercules Capital Inc. (&#8220;Hercules&#8221;) and a decline in interest income earned on our money market investments.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, we recorded an immaterial income tax provision related to our Austrian subsidiary. For the year ended December 31, 2020, we recorded an income tax provision of $0.1 million related to local withholdings associated with a milestone payment received from a customer in a foreign jurisdiction. We do not expect to record a significant income tax benefit or expense for several years as we have significant net operating loss carryforwards that are fully reserved until such time as we begin to generate meaningful taxable income in our U.S. jurisdiction. We expect this will occur when and if we are able to commercialize our drug products in the future.  </span></div><div><span><br/></span></div><div id="i71bd745117f84268bb875bce92ea6db3_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have funded our operations primarily with proceeds from sales of common stock, warrants and prefunded</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants for the purchase of our preferred stock and our common stock, sales of preferred stock, proceeds from the issuance of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible debt and borrowings under loan and security agreements. We have entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Agreement (&#8220;ATM Sales Agreement&#8221;), with B. Riley Securities, Inc., Cantor Fitzgerald &amp; Co., and Stifel, Nicolaus &amp; Company, Incorporated (collectively the &#8220;Sales Agents&#8221;), pursuant to which we may offer and sell, at our sole discretion through one or more of the Sales Agents, shares of our common stock having an aggregate offering price of up to $50.0 million. To date, we have sold approximately $15.0 million of our common stock, prior to issuance costs, under the ATM Sales Agreement.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we entered into a common stock purchase agreement, the (&#8220;Aspire Agreement&#8221;) with Aspire Capital LLC (&#8220;Aspire Capital&#8221;), pursuant to which Aspire Capital committed to purchase, at our request from time to time over a 36-month period, shares of our common stock having an aggregate offering price of up to $50.0 million, subject to certain limitations. In January 2022, we terminated the Aspire Agreement and entered into an agreement, (the&#8220;LPC Agreement&#8221;) on similar terms with Lincoln Park Capital Fund LLC (&#8220;Lincoln Park&#8221;), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pursuant to which we have the right to sell to Lincoln Park shares of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock, having an aggregate value of up to $50.0 million, subject to certain limitations and conditions , at our request during a 36-month period. The shares of common stock that we may sell under the LPC Agreement are capped at 5.6&#160;million, which amount may be adjusted under certain conditions as defined in the LPC Agreement. In January 2022, we raised $3.0 million from the sale of shares of our common stock through the LPC Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we entered into a securities purchase agreement with several institutional and accredited investors (&#8220;Investors&#8221;) pursuant to which we issued and sold shares of common stock and, in lieu of common stock, pre-funded warrants to purchase shares of common stock for gross proceeds of $53.0 million, before offering expenses. We subsequently registered for resale the common stock and the issuance of the shares of common stock underlying the pre-funded warrants held by the Investors. In November 2021, we raised approximately $10.0 million through the sale of pre-funded warrants to an investor. We subsequently registered for resale the shares of common stock issuable upon exercise of the pre-funded warrants held by this investor.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding prefunded warrants are currently exercisable for a nominal amount subject to a cap on the applicable investor&#8217;s beneficial ownership interest in our common stock of 9.99%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have borrowed $32.5&#160;million through our loan facility with Hercules. Under this facility we may borrow an additional $17.5 million in term loans through December 2022 at the lender&#8217;s sole discretion. Principal payments under the loan facility with Hercules commence in February 2023, and the Hercules agreement matures in July 2024. The Hercules loan agreement contains a minimum cash covenant as described below. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any products and we do not expect to generate revenue from sales of any products for several years, if at all. As of December 31, 2021, our cash and cash equivalents were $81.8 million and our restricted cash balance was $1.3 million. We expect that our research and development and general and administrative expenses will continue to increase as we focus on completing the necessary development, obtaining regulatory approval and preparing for potential commercialization of our product candidates. Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2022. We have a covenant under our loan facility with Hercules that requires that we maintain a minimum level of cash, as defined, beginning on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 1, 2022. If we are in violation of this covenant, Hercules could require the repayment of all outstanding debt. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These conditions and events raise substantial doubt about our ability to continue as a going concern for the one-year period following the issuance of our consolidated financial statements for the year ended December 31, 2021. To finance our operations, we will need to raise additional capital, which cannot be assured. Unless and until we reach profitability in the future, we will require additional capital to fund our operations, which could be raised through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or commercialization efforts, which would adversely affect our business prospects, or we may be unable to continue operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities for each of the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.540%"><tr><td style="width:1.0%"></td><td style="width:66.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.555%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88,696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,063)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,905)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58,818)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,384)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,702&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, net cash used in operating activities was $70.9 million, primarily resulting from our net losses of $88.7 million, adjusted for noncash expenses of $19.3 million and changes in our operating assets and liabilities of $1.5 million. Noncash expenses primarily includes a goodwill impairment of $9.8 million and stock-based compensation expense of $6.2 million. The change in operating assets and liabilities was primarily due to an increase in prepaid expenses due to the timing of payments related to our CROs and a reduction in lease liabilities due to monthly rent payments made during 2021; partially offset by an increase in accounts payable due to an increase in our operating expenses. Cash used in operating activities was higher for the year ended December 31, 2021 as compared to the prior year primarily due to higher net losses in the current year. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, cash used in investing activities of $0.6 million, primarily related to furniture and laboratory equipment purchases related to leased facility in Vienna, Austria. During the year ended December 31, 2020, cash used in investing activities of $1.4 million, primarily related to furniture and laboratory equipment purchases related to our Boston lease, and our research and development center in Vienna, Austria. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;During the year ended December 31, 2021, net cash provided by financing activities was $74.2 million, consisting primarily of net proceeds from two private placements of our equity securities, which included prefunded warrants, and the sale of shares of our common stock through our ATM Sales Agreement. During the year ended December 31, 2020, net cash provided by financing activities was $12.4 million, consisting primarily of proceeds from our loan facility with Hercules, as amended.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan and Security Agreement with Hercules Capital, Inc. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a loan facility with Hercules, which was subsequently amended in December 2018, June 2019, March 2020, December 2020, and February 2022 (as amended, the &#8220;Hercules Loan Agreement&#8221;). As of December 31, 2021, we have borrowed an aggregate of  $32.5&#160;million under the Hercules Loan Agreement, which provides for aggregate maximum borrowings of $50.0 million, including  $32.5&#160;million of current borrowings, and additional term loans available through December 31, 2022, of up to $17.5 million in the discretion of Hercules&#8217; investment committee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Hercules Loan Agreement bear interest at a variable rate equal to the greater of (i)&#160;&#160;8.75% or (ii)&#160;&#160;8.75% plus&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;prime rate minus 6.0%. In an event of default and until such event is no longer continuing, the interest rate applicable to borrowings under the agreement would be increased by 4.0%. As of December 31, 2021, the interest rate applicable to borrowings was 8.75% and we were not in default on the Hercules Loan Agreement. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings are repayable in monthly interest-only payments through January 1, 2023, and in equal monthly payments of principal and accrued interest from February&#160;1, 2023 until the maturity date of the loan, which is July&#160;1, 2024. At our option, we may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 1.0% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the principal amount outstanding as of the date of repayment, in each case depending on when such repayment is made. In addition, aggregate end-of-term charges of $2.9 million are payable in the amounts of $0.8 million, which was paid on January 1, 2022, and $1.3&#160;million and $0.8&#160;million on July 1, 2023 and July 1, 2024, respectively, which dates are accelerated upon the prepayment of the Hercules Loan Agreement at our election or upon an event of default. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Hercules Loan Agreement are collateralized by substantially all of our personal property and other assets except for our intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property). Our obligations under the agreement are subject to acceleration upon occurrence of specified events of default, including payment default, insolvency and a material adverse change in our business, operations or financial or other conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Hercules Loan Agreement, we have agreed to affirmative and negative covenants. The covenants also include a requirement that, from and after a defined initial test date of September 1, 2022 that we maintain cash in an aggregate amount equal to the greater of $30.0 million or six multiplied by a metric based on prior months&#8217; cash expenditures; provided, however, that from and after our achievement of certain financing milestones through June 30, 2022, we must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount of $30.0 million. Following the achievement of certain performance milestones, the required cash shall be reduced to the greater of $20.0 million, or, if we had not met the financing milestones noted above, three multiplied by the current cash expenditures metric; and provided further, that subject to the achievement of additional operational milestones, this covenant will be extinguished. A breach of any of the covenants under the Hercules Loan Agreement could result in a default under the loan. Upon the occurrence of an event of default under the loan facility with Hercules, the lender could elect to declare all amounts outstanding, if any, to be immediately due and payable and terminate all commitments to extend further credit. If there are any amounts outstanding that we are unable to repay, the lenders could proceed against the collateral granted to them to secure such indebtedness.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Lease Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have long-term lease obligations for office and laboratory space. Non-cancellable lease obligations are $1.6 million in 2022, $1.6 million in 2023, $1.4 million in 2024, and $3.1&#160;million thereafter. </span></div><div><span><br/></span></div><div id="i71bd745117f84268bb875bce92ea6db3_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash and cash equivalents will allow us to fund operations into the fourth quarter of 2022. As noted above, in order to satisfy a minimum cash covenant in our Hercules Loan Agreement, we will be required to raise additional capital, which may be through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. During 2022 and beyond, assuming no changes to our current operational expectations, we expect our expenses to continue to increase in connection with our ongoing activities, particularly as we advance the current and anticipated clinical trials of our product candidates in development. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our funding requirements. Our short term and long term funding requirements will depend on and could increase significantly as a result of many factors, including:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates, particularly our Phase 3 pivotal clinical trial of mavorixafor for the treatment of patients with WHIM syndrome, our Phase 1b clinical trial of mavorixafor in CN and our Phase 1b clinical trial of mavorixafor in Waldenstr&#246;m&#8217;s;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued global impact of the ongoing COVID-19 pandemic and its effect on our ongoing clinical trials, our supply chain and the financial markets in general;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain marketing approval for our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights covering our product candidates, including any such patent claims and intellectual property rights that we have licensed from Genzyme pursuant to the terms of our license agreement with Genzyme;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of completion of commercial-scale outsourced manufacturing activities with respect to our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of any other business, product or technology that we acquire or in which we invest;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need and ability to hire additional management and scientific and medical personnel;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs to continue to operate as a public company, including the need to implement additional financial and reporting systems and other internal systems and infrastructure for our business;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our product candidates, to the extent any are approved for commercial sale; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. We have effective universal shelf registration statements on Form S-3 registering the sale</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our common stock, warrants to purchase our common stock and other securities on terms that we may determine; due to our current public float and applicable SEC rules and regulations, our ability to raise capital pursuant to these shelf registration statements may be limited. We have an ATM Sales Agreement with the Sales Agents, pursuant to which we have offered to sell and continue to offer to sell, at our sole discretion through one or more of the Sales Agents, shares of our common stock having an aggregate offering price of up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$50.0 million, of which we have sold $15.0 million to date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We have entered into a common stock purchase agreement with Lincoln Park Capital, pursuant to which Lincoln Park Capital has committed to purchase, at our request from time to time over a 36-month period, shares of our common stock having an aggregate offering price of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> $50.0 million, of which $3.0 million have been sold to date, subject to certain limitations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through future equity offerings or debt financings, the ownership interest of our stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or eliminate our product development efforts or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_70"></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note&#160;2 to our consolidated financial statements included elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160; As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to them at that time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our significant vendors, we confirm the accuracy of these estimates with the service providers and make</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors in connection with preclinical development activities;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CROs and investigative sites in connection with preclinical studies and clinical trials; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CMOs in connection with the production of preclinical and clinical trial materials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base the expense recorded related to external research and development on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;We measure all stock-based awards granted to employees, directors and consultants based on the grant-date fair value of the award and recognized compensation expense, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. The stock-based awards that we have issued to date include a service-based vesting condition and the expense for these awards is recognized using the straight-line method. We have also issued stock-based awards with performance-based vesting conditions that vest in part upon our achievement of operational milestones and over time thereafter for the subsequent two years as the employee continues to provide services. We assess the probability of achievement of these operational milestones and recognize stock-based compensation for these awards using the accelerated attribution model based on the fair value of the awards as of the date of grant and our best estimate of the date each operational milestone will be achieved. We update our estimates related to the probability and timing of achievement of the operational milestones each period until the award either vests or is forfeited</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option grants is estimated on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and an expected dividend yield. Prior to the closing of the Merger and the listing of our common stock on the Nasdaq Capital Market, our board of directors historically determined, as of the date of each option grant and with input from our management, the assistance of a third-party valuation specialist the estimated fair value of our common stock on the date of grant based on a number of objectives and subjective factors. Since&#160;the Merger and the listing of our common stock on the Nasdaq Capital Market, we have relied on the market price of our common stock to determine the fair value on the date of grant. As our common stock does not have a sufficient history of trading, we estimate our volatility based on the historical volatility of publicly traded peer companies. We estimate the expected term of our stock awards by utilizing the &#8220;simplified&#8221; method, which calculates the expected term based on weighted average midpoint of the award&#8217;s vesting and expiration dates. We determine the risk-free interest rate by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. We estimate that no dividends will be paid as we do not expect to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions underlying these valuations represent the best estimates of our management, which involve inherent uncertainties and the application of our judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, the resulting share-based compensation expense could be materially different.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are generated primarily through research, development and commercialization agreements.  The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses, or options to obtain licenses, to our intellectual property, and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; milestone payments; payments for clinical product supply, and royalties on future product sales. To date, our license agreement with Abbisko represents our only revenue-generating agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We analyze our arrangements to assess whether such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, or ASC 808, we allocate the contract consideration between such joint operating activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customers, or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606. Our policy is to recognize amounts allocated to joint operating activities as a reduction in research and development expense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, we recognize revenue when our customers obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligation(s) in the contract and determine whether these are distinct; (3) determine the transaction price; (4) allocate the transaction price to the performance obligation(s) in the contract; and (5) recognize revenue when (or as) we satisfy our performance obligation(s). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested quantitatively for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that we operate in a single operating segment and have a single reporting unit. To perform its quantitative test, we compare the fair value of our single reporting unit to the carrying value of its net assets, including goodwill. We use our market capitalization (common shares outstanding multiplied by the price per share of our common stock) to measure the fair value of the reporting unit. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, we measure the impairment loss as the excess of the carrying value over the fair value of the reporting unit. See Note 4 for more information on our goodwill impairment test as of December 31, 2021. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). The JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to &#8220;opt out&#8221; of this provision and, as a result, we will comply with new or revised accounting standards when they are required to be adopted by public companies that are not EGCs.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. &#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller reporting company, we are not required to provide disclosure for this Item. </span></div><div id="i71bd745117f84268bb875bce92ea6db3_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. &#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements contain a Report of Independent Registered Public Accounting Firm PricewaterhouseCoopers LLP, Boston, Massachusetts, US (Firm ID 238)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An index of those financial statements is found in Item 15 of Part IV of this Annual Report.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_85"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. &#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports we file and submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, who serve as our principal executive officer and principal financial officer, respectively, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. Based on such evaluation, our Chief Executive Officer and Chief  Financial Officer have  concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the company. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company&#8217;s principal executive and principal financial officers and effected by the company&#8217;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting,  as defined in the Exchange Act Rule 13a-15(f). Management conducted an assessment of our internal control over financial reporting based on the framework established in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Based on the assessment, management concluded that, as of December 31, 2021, our internal control over financial reporting was effective.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting due to an exemption established by the JOBS Act for &#8220;emerging growth companies&#8221;.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no significant change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. &#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i71bd745117f84268bb875bce92ea6db3_620"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. &#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i71bd745117f84268bb875bce92ea6db3_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. &#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the information set forth in the sections titled &#8220;Proposal 1- Election of Directors,&#8221; &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; and &#8220;Executive Officers&#8221; in our 2022 Proxy Statement.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.    &#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this Item is incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation&#8221; in our 2022 Proxy Statement. </span></div><div id="i71bd745117f84268bb875bce92ea6db3_103"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.    &#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the information set forth in the section titled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our 2022 Proxy Statement.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_106"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.    &#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the information set forth in the section titled &#8220;Transactions with Related Persons and Indemnification&#8221; and &#8220;Information regarding the Board of Directors and Corporate Governance&#8221; in our 2022 Proxy Statement.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.    &#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the information set forth in the section titled &#8220;Principal Accountant Fees and Services&#8221; contained in our 2022 Proxy Statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i71bd745117f84268bb875bce92ea6db3_115"></div><div style="-sec-extract:summary;margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. &#160;&#160;&#160;&#160;EXHIBIT AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are included on pages F-1 through F-36 attached hereto and are filed as part of this Annual Report.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.655%"><tr><td style="width:1.0%"></td><td style="width:34.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Page</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_127">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_127">F-2</a></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">PricewaterhouseCoopers LLP</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Boston, MA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;(Firm ID 238)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_130">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_130">F-3</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_133">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_133">F-4</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_136">Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Equity (Deficit)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-5</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_139">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_139">F-</a>6</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i71bd745117f84268bb875bce92ea6db3_142">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_142">F-</a>7</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) Financial Statement Schedules:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) Exhibits.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Se File/ Ref No.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312518334447/d663229dex21.htm">Agreement and Plan of Merger, dated November 26, 2018, by and among the Company, Artemis AC Corp. and X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">11/27/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312518354676/d675880dex21.htm">First Amendment to Agreement and Plan of Merger, dated December 20, 2018, by and among the Company, Artemis AC Corp. and X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">12/20/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519069279/d721507dex21.htm">Second Amendment to Agreement and Plan of Merger, dated March 8, 2019, by and among the Company, Artemis AC Corp. and X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/8/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020009266/ex31amendedcharter.htm">Restated Certificate of Incorporation, as amended, as of June 10, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">6/11/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517348213/d495338dex32.htm">Amended and Restated By-laws of the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">11/20/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex41.htm">Form of Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex42.htm">Form of Warrant to Purchase Common Stock of the Company (formerly Series A Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.)) issued to Silicon Valley Bank and Life Science Loans, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex43.htm">Form of Warrant to Purchase Common Stock of the Company (formerly Series A Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.)) issued to Maxim Partners LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex44.htm">Form of Warrant to Purchase Common Stock of the Company (formerly Series B Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.)).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex45.htm">Form of Warrant to Purchase Common Stock of the Company (formerly Series B Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.)) issued to Hercules Capital, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex46.htm">Warrant Modification Agreement, dated as of December&#160;11, 2018, with Hercules Capital, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519106621/d734812dex41.htm">Form of Prefunded Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/12/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519106621/d734812dex42.htm">Form of Class A Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/12/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519302716/d838637dex41.htm">Form of Prefunded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/29/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519302716/d838637dex42.htm">Form of Class B Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">11/29/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828021005139/securitiespurchaseagreement.htm">Securities Purchase Agreement, dated March 18, 2021, by and among X4 Pharmaceuticals, Inc. and the persons party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828021005139/regrights.htm">Registration Rights Agreement, dated March 18, 2021, by and among X4 Pharmaceuticals, Inc. and the persons party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828021005139/formofprefundedwarrant.htm">Form of March 2021 Prefunded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828021022069/ex101securitiespurchaseagr.htm">Securities Purchase Agreement, dated November 5, 2021, by and among X4 Pharmaceuticals, Inc. and the persons party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">11/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828021022069/ex102registrationrightsagr.htm">Registration Rights Agreement, dated November 5, 2021, by and among X4 Pharmaceuticals, Inc. and the persons party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">11/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828021022069/ex41formofprefundedwarrant.htm">Form of November 2021 Prefunded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">11/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312520213051/d85689dex12.htm">Controlled Equity Offering</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:83%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:83%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312520213051/d85689dex12.htm">SM </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312520213051/d85689dex12.htm">Sales Agreement, dated as of August 7, 2020, by and between X4 Pharmaceuticals, Inc. and B. Riley Securities, Inc., Cantor Fitzgerald &amp; Co. and Stifel, Nicolaus &amp; Company, Incorporated.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">S-3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8/7/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828021005202/descriptionofcommonstock.htm">Description of Registered Securities </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/19/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828022004915/ex41formofpre-fundedwarrant.htm">Form of March 2022 Prefunded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/3/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828022004915/ex101securitiespurchaseagr.htm">Securities Purchase Agreement, dated March 3, 2022, by and among X4 Pharmaceuticals, Inc. and the persons party thereto. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/3/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828022004915/ex102registrationrightsagr.htm">Registration Rights Agreement, dated March 3, 2022, by and among X4 Pharmaceuticals, Inc. and the persons party thereto. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/3/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.1@</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex1011.htm">2015 Employee, Director and Consultant Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.2@</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519095792/d711669dex1012.htm">Form of Stock Option Agreement under the 2015 Employee, Director and Consultant Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">4/2/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.3@</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519176532/d765457dex106.htm">Form of Restricted Stock Unit Agreement under the 2015 Employee, Director and Consultant Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/17/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.4@</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020009216/xfor_06102020xamendedandre.htm">Amended and Restated 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/10/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">333-239082</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.5@</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517315505/d427310dex108.htm">Form of Incentive Stock Option Agreement under the 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.6@</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517315505/d427310dex109.htm">Form of Nonstatutory Stock Option Agreement under the 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.7@</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312518334447/d663229dex106.htm">Form of Restricted Stock Agreement under the 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/27/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.8@</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519176532/d765457dex105.htm">Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.9@</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020009216/x4-2017planxformofperforma.htm">Form of Performance-Based Restricted Stock Unit </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/10/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">333-239082</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.10@</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517315505/d427310dex1010.htm">2017 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.11@</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519176532/d765457dex101.htm">X4 Pharmaceuticals,&#160;Inc. 2019 Inducement Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/17/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.12@</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519176532/d765457dex102.htm">Form&#160;of Stock Option Agreement under the 2019 Inducement Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/17/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.13@</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519176532/d765457dex103.htm">Form&#160;of Restricted Stock Agreement under the 2019 Inducement Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/17/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.14@</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519176532/d765457dex104.htm">Form&#160;of Restricted Stock Unit Agreement under the 2019 Inducement Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/17/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.15@</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517333514/d427310dex1036.htm">Form of Indemnification Agreement (for directors and executive officers</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517333514/d427310dex1036.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/06/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.16@</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex102.htm">Director Compensation Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.17@</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex103.htm">Amended and Restated Executive Employment Agreement, dated as of March&#160;13, 2019, by and between the Company and Paula Ragan, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.18@</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828020006998/ex101.htm">Amendment to Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, dated February 13, 2020 by and between the Company and Paula Ragan, Ph.D. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.19*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex1019.htm">Second Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Adam S. Mostafa. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex1020.htm">Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Derek Meisner</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex1021.htm">Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Art Taveres</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.22*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex1022.htm">Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Diego Cadavid</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex1023.htm">Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Mary DiBiase</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.24@</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020015792/bridgerconsultingagree.htm">Consulting Agreement, dated September 17, 2020, by and between the Company and Gary Bridger</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/05/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.25#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519145463/d944716dex105.htm">License Agreement, dated as of July&#160;10, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, LLC) and Genzyme Corp., a Sanofi company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.26#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519145463/d944716dex106.htm">Amendment No.&#160;1 to License Agreement, dated as of October&#160;23, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Genzyme Corporation, a Sanofi company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.27#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519145463/d944716dex107.htm">License Agreement, dated as of December&#160;13, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Georgetown University.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7#</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.28#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519145463/d944716dex108.htm">Exclusive License Agreement, dated as of December&#160;23, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Beth Israel Deaconess Medical Center.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8#</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828021005202/dfci.htm">License Agreement, dated as of November 13, 2020, by and between X4 Pharmaceuticals Inc. and the Dana Farber Cancer Institute. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/19/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex109.htm">Loan and Security Agreement, dated as of October&#160;19, 2018, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Hercules Capital, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex1010.htm">Amendment No.&#160;1 to Loan and Security Agreement, dated as of December&#160;11, 2018, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Hercules Capital, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519185089/d636978dex101.htm">Amended and Restated Loan and Security Agreement, dated as of June&#160;27, 2019, by and among X4&#160;Pharmaceuticals, Inc., X4&#160; Therapeutics, Inc., Hercules Capital, Inc. and Hercules Capital Funding Trust&#160;2019-1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/28/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020003723/amendmentno1toloanands.htm">Amendment No. 1 to Loan and Security Agreement, dated March 13, 2020, by and between X4 Pharmaceuticals, Inc. and Hercules Capital, Inc.  </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/17/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312520326132/d56889dex101.htm">Amendment No. 2 to Amended and Restated Loan and Security Agreement, dated as of December 21, 2020, by and among X4 Pharmaceuticals, Inc., each of its Qualified Subsidiaries (including X4 Therapeutics, Inc.), the Lender, and Hercules Capital, Inc., as Agent</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/23/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828022002106/ex101amendment3toloanandse.htm">Amendment No. 3 to Amended and Restated Loan and Security Agreement, dated as of December 21, 2020, by and among X4 Pharmaceuticals, Inc., each of its Qualified Subsidiaries (including X4 Therapeutics, Inc.), the Lender, and Hercules Capital, Inc., as Agent</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/09/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex10111.htm">Lease, dated as of January&#160;20, 2017, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Brickman 955 Massachusetts LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020003484/ex1032leasedatedasofno.htm">Lease, dated as of November 11, 2019, by and between X4 Pharmaceuticals Inc. and Beacon North Village, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/12/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519103832/d733375dex101.htm">Settlement Agreement, dated as of March 8, 2019, by and among X4 Pharmaceuticals, Inc. (formerly Arsanis, Inc.), Artemis AC Corp., X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.), Arsanis Biosciences GmbH and &#214;sterreichische Forschungsf&#246;rderungsgesellschaft GmbH.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/11/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020003484/ex35masterservicesagre.htm">Master Services Agreement, dated September 10, 2015, by and between X4 Pharmaceuticals Inc. and Mayne Pharma Inc. (formerly known as Metrics, Inc.).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/12/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020003484/ex1036amendment1tomast.htm">Amendment No. 1 to Master Services Agreement, dated August 25, 2017, by and between X4 Pharmaceuticals Inc. and Mayne Pharma Inc. (formerly known as Metrics, Inc.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/12/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020003484/ex1037amendment2tomast.htm">Amendment No. 2 to Master Services Agreement, dated February 28, 2020, by and between X4 Pharmaceuticals Inc. and Mayne Pharma Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/12/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020003484/ex1038masterservicesag.htm">Master Services Agreement, dated February 19, 2016, by and between X4 Pharmaceuticals Inc. and Aptuit (Oxford) Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/12/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828020003484/ex1039amendment1tomast.htm">Amendment No. 1 to Master Services Agreement, dated February 19, 2016, by and between X4 Pharmaceuticals Inc. and Aptuit (Oxford) Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/12/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000162828021005202/aptuitamendment2.htm">Amendment No. 2 to Master Services Agreement, dated February 19, 2021, by and between X4 Pharmaceuticals Inc. and Aptuit (Oxford) Limited.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">10.48</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/19/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex_211xlistofsubsidiaries2.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex-231pricewaterhousecoope.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex-311q42021.htm">Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex-312q42021.htm">Certification of the Chief Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex-321q42021.htm">Certification of the Chief Executive Officer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex-321q42021.htm"> and Chief Financial Officer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex-321q42021.htm">, as required by Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">SXRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Cover Page Interactive Data File (formatted as Inline XBRL)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30pt">Filed herewith</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished and not filed herewith</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed &#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">@&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan</span></div><div id="i71bd745117f84268bb875bce92ea6db3_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. &#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: March&#160;17, 2022</span></div></td><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Paula Ragan</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Paula Ragan, Ph D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Date</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Paula Ragan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Paula Ragan, Ph.D.</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Executive Officer)</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Adam S. Mostafa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer and Treasurer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adam S. Mostafa</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Michael S. Wyzga</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Michael S. Wyzga</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ William Aliski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">William E. Aliski</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Gary J. Bridger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gary J. Bridger, Ph.D.</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Francoise De Craecker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;17, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Francoise De Craecker</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Alison Lawton</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alison F. Lawton</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ David McGirr</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">David McGirr</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Murray W. Stewart</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;17, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Murray W. Stewart, M.D.</span></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.515%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:95%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_127">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_127">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_130">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_130">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_133">Consolidated Statements of Operations</a> and Comprehensive Loss</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_133">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_136">Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Equity (Deficit)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_136">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_139">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_139">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration:none" href="#i71bd745117f84268bb875bce92ea6db3_142">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">F-7</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of X4 Pharmaceuticals, Inc.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of X4 Pharmaceuticals, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock, redeemable common stock and stockholders&#8217; equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2021, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has certain conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.120%"><tr><td style="width:1.0%"></td><td style="width:6.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ PricewaterhouseCoopers LLP</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boston, Massachusetts</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2016.</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"><tr><td style="width:1.0%"></td><td style="width:72.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzMtMS0xLTEtMjA5NDA_4841dc6f-838b-4805-85a9-ea428a2587ab">81,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzMtMy0xLTEtMjA5NDA_a0287f36-6bce-41ef-9dd3-eeb15e811b73">78,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development incentive receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="xfor:ResearchAndDevelopmentIncentiveReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzQtMS0xLTEtMjA5NDA_0cecbac6-571c-4bf6-9c20-747e34773655">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="xfor:ResearchAndDevelopmentIncentiveReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzQtMy0xLTEtMjA5NDA_9a18ae40-5d79-4dca-a984-5fabe87c585d">917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzUtMS0xLTEtMjA5NDA_9ce6bded-587a-46b0-8d71-dc4c65381f39">5,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzUtMy0xLTEtMjA5NDA_cc1190e5-c9c0-4dd9-ab17-f552a7f711a3">3,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzYtMS0xLTEtMjA5NDA_35d2764d-a4e8-4f8b-bea0-b1653d581e64">87,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzYtMy0xLTEtMjA5NDA_f1780210-e950-4352-b102-5b59d19f2134">83,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzctMS0xLTEtMjA5NDA_07354f83-931c-4b48-b0e3-731f091ababb">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzctMy0xLTEtMjA5NDA_2b98a0be-1e2e-4b4e-85fe-457ee822e6c1">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzgtMS0xLTEtMjA5NDA_e6d708e3-ad1a-439c-8184-d6f4d33b5857">17,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzgtMy0xLTEtMjA5NDA_3873fd7d-524c-40f2-a83a-c80b58582e82">27,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzktMS0xLTEtMjA5NDA_c03a58f9-f021-4538-a920-ddf50f9d09a4">8,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzktMy0xLTEtMjA5NDA_5abad821-81d1-4f48-9c80-2f380cb7b475">7,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzEwLTEtMS0xLTIwOTQw_421c8eb2-853c-463e-b56c-a0b2fbb99601">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzEwLTMtMS0xLTIwOTQw_21253a7a-b724-45eb-85c9-b222a791e1d3">3,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzExLTEtMS0xLTIwOTQw_6977bd6c-74a4-44a4-9826-35838025f201">117,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzExLTMtMS0xLTIwOTQw_250a0ab4-37fb-48d9-857c-70eb78b5c06c">122,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE0LTEtMS0xLTIwOTQw_aa10247e-b21e-4bf8-bc41-e7d26e6b43f2">4,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE0LTMtMS0xLTIwOTQw_5778456c-6927-404f-8b1a-c6e35ea4c360">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE1LTEtMS0xLTIwOTQw_effbafdc-fb47-4f42-b1df-702b3e36b7a0">7,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE1LTMtMS0xLTIwOTQw_11584f53-d5c0-4eee-a140-78c97676f829">8,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE2LTEtMS0xLTIwOTQw_d02de8eb-c7cb-43d0-85b8-c52b207034aa">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE2LTMtMS0xLTIwOTQw_efee1350-26b6-44b8-993b-bbc40c3bb599">786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE3LTEtMS0xLTIyOTA2_9461fd5f-329e-4d0f-ba88-9f70cb211b39">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE3LTMtMS0xLTIyOTE3_bd3432ef-dc7d-4132-96b5-462bd0d9614a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE3LTEtMS0xLTIwOTQw_7f3f412c-5e19-46f8-835e-b093fb03eb4a">14,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE3LTMtMS0xLTIwOTQw_d3abe624-cc10-4436-8732-fb2773cca0b0">11,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including accretion, net of discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="xfor:LongTermDebtNonCurrentIncludingAccrection" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE4LTEtMS0xLTIwOTQw_adf0cb05-a824-4c30-84a8-e8a5f505d839">33,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="xfor:LongTermDebtNonCurrentIncludingAccrection" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE4LTMtMS0xLTIwOTQw_bcada0e7-8c17-413f-8966-a22dcdb89f89">33,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE5LTEtMS0xLTIwOTQw_b2db3ab9-7780-4858-9239-eb5d3ee8d5f4">4,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE5LTMtMS0xLTIwOTQw_9831c511-4d54-4ec5-8ae1-1dc66e48a1a8">4,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIwLTEtMS0xLTIwOTQw_41b495ad-b6ed-408e-b368-8296d0e6549c">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIwLTMtMS0xLTIwOTQw_ee642691-4741-481a-8256-8d844aecce7a">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIxLTEtMS0xLTIwOTQw_40f271dc-4857-4b46-9f33-f14b410c3048">52,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIxLTMtMS0xLTIwOTQw_8951dadf-0af6-41f3-9b9a-ab5ea3571dab">50,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIyLTEtMS0xLTIwOTQw_45905920-cc0f-482b-a1d8-3bd9b1fac91b"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIyLTMtMS0xLTIwOTQw_63ea7083-259f-443c-ab69-842515dd1be4"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTg_353be018-cfe3-4607-b99d-0908e6ca1a52"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTg_8f584324-c4ee-449a-97d1-b48a21641c38">0.001</ix:nonFraction></ix:nonFraction> par value. <ix:nonFraction unitRef="shares" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMzI_9da05b84-b52c-4c0b-b26d-33501d3f440d"><ix:nonFraction unitRef="shares" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMzI_e18a517f-1fed-4594-a06d-f812edbda00a">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December 31, 2021 and December 31, 2020, respectively; <ix:nonFraction unitRef="shares" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTIx_8a493780-a82f-49be-9e6f-98f1df151f38"><ix:nonFraction unitRef="shares" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTIx_a1b11bf1-1296-498e-aecd-3024972e65a7">28,127,657</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTA5OTUxMTYyODAxNg_3f2e4547-57a4-422d-9455-cc7df03e7945"><ix:nonFraction unitRef="shares" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTA5OTUxMTYyODAxNg_60e9ad08-000e-40db-a75b-f79f206008e2">16,305,731</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTEtMS0xLTIwOTQw_d4fb8fb7-851e-4bbc-af66-d14d95cf8788">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTMtMS0xLTIwOTQw_a3457f01-5137-43da-8795-45c80c2c0d0d">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI1LTEtMS0xLTIwOTQw_de3a429c-0921-4726-918a-93319120d463">347,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI1LTMtMS0xLTIwOTQw_378fde8b-711c-482d-beb6-25478a056f22">267,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI2LTEtMS0xLTIwOTQw_9729950e-cbae-4be9-b51f-3a1b622f1420">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI2LTMtMS0xLTIwOTQw_22b46b0a-8910-4bb6-83fc-e4bfeaccfa0a">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI3LTEtMS0xLTIwOTQw_22a66740-e097-4e40-8819-d47b232958d3">282,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI3LTMtMS0xLTIwOTQw_902ec729-f4e1-40d3-bbb2-9d0b21a237a1">194,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI4LTEtMS0xLTIwOTQw_3ce4dbd7-9bd2-4bd7-a2e0-4aa5199ecd67">64,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI4LTMtMS0xLTIwOTQw_cdced4eb-fa09-4e06-912a-97a5825d4aa1">72,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI5LTEtMS0xLTIwOTQw_2b762dc4-70c3-48b6-9aa3-096b686b634a">117,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI5LTMtMS0xLTIwOTQw_5317bd7b-777d-4943-8218-602e26f7cd2a">122,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The accompanying notes are an integral part of these consolidated financial statements</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:62.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzItMS0xLTEtMjA5NDA_64c37d92-4972-4a27-abe3-1954a14bba5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzItMy0xLTEtMjA5NDA_72fb5fe5-5976-4074-9a1e-a1a32d73ac1f">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzItNS0xLTEtMjA5NDA_38bfbc44-a968-478f-ae5f-58e9273979cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzQtMS0xLTEtMjA5NDA_1169d4be-31b2-46c2-9b5a-e4a9c73174cb">50,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzQtMy0xLTEtMjA5NDA_2f2999bf-f5ea-4680-804f-ad0c4900adb1">41,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzQtNS0xLTEtMjA5NDA_92aa94aa-045a-4c2a-9bea-801280d657c4">30,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzUtMS0xLTEtMjA5NDA_f5579993-d235-4d0b-ad9b-116002568b82">24,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzUtMy0xLTEtMjA5NDA_f473bcc9-a219-44f5-87ae-f7c632742d31">20,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzUtNS0xLTEtMjA5NDA_1dfcdb13-a89b-4f89-9e6f-93b82e4ea6d0">17,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtMS0xLTEtMjQ2ODQ_a33cd8f7-3034-4a58-b67a-3348b73c0088">9,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtMy0xLTEtMjQ2OTM_67240a0e-2907-40f8-83ec-585e2e51c5a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtNS0xLTEtMjQ3MDA_05e1841b-f985-4be2-9dda-8aa5bc73cdf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on transfer of nonfinancial assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtMS0xLTEtMjA5NDA_734d722c-e56c-47e2-9dbd-28deda23f54b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtMy0xLTEtMjA5NDA_e21d9815-b8e5-45c6-8427-e5d72eb6c929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtNS0xLTEtMjA5NDA_5476a137-99a3-416a-889d-8770d719dd8a">3,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzctMS0xLTEtMjA5NDA_57295849-8c88-4e94-bc14-a4f41ca469d4">85,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzctMy0xLTEtMjA5NDA_9f76a6e7-de19-48b8-a100-0dd98e6f8307">62,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzctNS0xLTEtMjA5NDA_8713251f-18e3-44bd-8d93-52e6a9978e7a">51,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzgtMS0xLTEtMjA5NDA_a5b3b8a3-1dce-4804-a767-51c7b41f44b9">85,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzgtMy0xLTEtMjA5NDA_5ba321a7-746f-4e8f-bc04-2c122ad608f4">59,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzgtNS0xLTEtMjA5NDA_946ade17-6b7c-42e0-b942-f86e11f37de0">51,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEwLTEtMS0xLTIwOTQw_d631cbef-5ab1-4438-b311-c2dac11e9005">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEwLTMtMS0xLTIwOTQw_004516b5-be89-451b-a180-ce07c5404119">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEwLTUtMS0xLTIwOTQw_8b7df6fc-a58a-44f8-bdcf-09bd52366ee7">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzExLTEtMS0xLTIwOTQw_890aa1da-7e58-4fca-a874-ff89a586d12e">3,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzExLTMtMS0xLTIwOTQw_482491d5-6c14-4871-a0d3-470c242a2d64">2,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzExLTUtMS0xLTIwOTQw_59a11b8a-f64d-4d93-90ce-231a56a789fb">2,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of preferred stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEyLTEtMS0xLTIwOTQw_ae551835-4bc6-4c85-b250-827abf3da085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEyLTMtMS0xLTIwOTQw_949bf2bf-09a3-47b5-9341-922da6f84bfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEyLTUtMS0xLTIwOTQw_270a89c1-5d0e-439c-8585-e67565ac8508">288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEzLTEtMS0xLTIwOTQw_6968aa11-e228-4eb1-ab33-d1a94fca9322">366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEzLTMtMS0xLTIwOTQw_1eb011f2-b23b-46a0-b76b-6951f3cf2c02">437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEzLTUtMS0xLTIwOTQw_8e8e2be5-aa35-427c-bcfd-7e035262cec4">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE0LTEtMS0xLTIwOTQw_8c6fb076-01f4-4c17-b722-83727e0a95b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE0LTMtMS0xLTIwOTQw_e8cfa013-5595-45dc-bb07-ff3274708222">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE0LTUtMS0xLTIwOTQw_1943cb61-b80d-4e20-9b82-0f02f4f6e808">566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE1LTEtMS0xLTIwOTQw_b98a3021-8ddd-4131-a0d5-9eaf0d6d18b6">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE1LTMtMS0xLTIwOTQw_2b671815-602f-43ce-93e5-da547ec661fd">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE1LTUtMS0xLTIwOTQw_13c492ed-0f50-40ad-a5ce-9e5db2679164">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE2LTEtMS0xLTIwOTQw_43fa6532-1df7-4b50-9f45-01feade2df02">3,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE2LTMtMS0xLTIwOTQw_66717fe3-cacd-4650-a5a3-a4226cf878a5">2,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE2LTUtMS0xLTIwOTQw_1a50974a-4a09-4024-83d6-271b8e7758e7">1,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE3LTEtMS0xLTIwOTQw_7834e1ee-8d17-49cf-80d0-d4e6776fcf4e">88,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE3LTMtMS0xLTIwOTQw_81e70eab-d483-4273-b5f4-4ca2f8299c78">61,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE3LTUtMS0xLTIwOTQw_d3d2f98d-57e0-44d4-b9e6-bc1d4f1fac33">52,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE4LTEtMS0xLTIwOTQw_7506a8f9-ea8f-498a-bc06-59a40cd45861">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE4LTMtMS0xLTIwOTQw_e0cc0092-954c-4e92-9ac2-8040f7a07b41">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE4LTUtMS0xLTIwOTQw_79d196b5-20f0-4579-8b50-e4fd28386ced">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE5LTEtMS0xLTIwOTQw_7022ec17-9143-4e18-9ebd-a6be1db9605f">88,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE5LTMtMS0xLTIwOTQw_f0defb84-800c-4d18-a679-570d41f7bcfb">62,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE5LTUtMS0xLTIwOTQw_3e8b9df4-1a4f-4af6-8146-eb29bcac1e28">52,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruing dividends on Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIwLTEtMS0xLTIwOTQw_91061fa7-6579-457b-ba9e-a3ddf0ca6147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIwLTMtMS0xLTIwOTQw_cec9f4c6-e60b-44d3-a208-a7acda79aca0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:TemporaryEquityDividendsAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIwLTUtMS0xLTIwOTQw_e19251f8-0a3d-44f3-a61b-b50fb48100b1">592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend on Class B Warrant price reset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIxLTEtMS0xLTIyMTA4_826d96b3-00e3-449b-bf2f-131ecfaf410e">13,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIxLTMtMS0xLTIyMTA4_c416d35e-c8d0-4a90-a0cc-626fffe28791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIxLTUtMS0xLTIyMTA4_85097665-9454-40ff-9eed-bfbb00961c0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIyLTEtMS0xLTIwOTQw_4a916e5c-0e58-4db7-ad27-72ddd14a6882">102,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIyLTMtMS0xLTIwOTQw_7921055e-95d9-42d8-8e5e-8135e10c5dcd">62,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIyLTUtMS0xLTIwOTQw_03dcdc84-e44f-4ef2-be83-72f9e954ca23">53,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIzLTEtMS0xLTIwOTQw_95efe689-2c28-4f71-9bb2-b46f9dc468f2">3.99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIzLTMtMS0xLTIwOTQw_ff0e219e-d888-4d62-820d-520551baef81">3.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIzLTUtMS0xLTIwOTQw_a26d1ca7-3f54-44e8-aeb6-a11f323a46ed">4.63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI0LTEtMS0xLTIwOTQw_c8911434-14fa-4c0f-996b-0d4b4cd5be97">25,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI0LTMtMS0xLTIwOTQw_20459814-9c8f-45a7-a5cf-a9b81ec7be86">20,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI0LTUtMS0xLTIwOTQw_7065e09e-e841-48c1-8b2e-f33383f155ea">11,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI2LTEtMS0xLTIwOTQw_5a21fb3b-0476-44f1-bef8-7ef52005622a">88,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI2LTMtMS0xLTIwOTQw_10d7559f-1cde-4004-ad3b-05cff5352937">62,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI2LTUtMS0xLTIwOTQw_8edcdbf5-cb87-4461-b23c-9c6d385c69f4">52,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI3LTEtMS0xLTIwOTQw_32c186a4-2d16-4b3f-8621-397a3d1893c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI3LTMtMS0xLTIwOTQw_ea083ede-ccba-42dc-b720-1a87568a286e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI3LTUtMS0xLTIwOTQw_4609de80-6b04-49f9-8577-25fdceb2da90">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI4LTEtMS0xLTIwOTQw_0c41decd-2397-4513-82c8-34503cbf580d">88,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI4LTMtMS0xLTIwOTQw_5befb7db-6697-4b48-b911-c48cb45161d2">62,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI4LTUtMS0xLTIwOTQw_3fa83e8f-909d-46fe-bc23-6564d726f3bc">52,926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The accompanying notes are an integral part of these consolidated financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_136"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.348%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.348%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.493%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Series Seed, A and B</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Convertible Preferred</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Redeemable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Deficit) Equity</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i572b67d5b62c4080a9192cbe762029fb_I20181231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMS0xLTEtMjA5NDA_df67ba12-0a32-4ab4-b54c-3f4b0569bb39">40,079,567</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i572b67d5b62c4080a9192cbe762029fb_I20181231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMy0xLTEtMjA5NDA_308c72a4-7da1-4381-9a96-fc910e87edf4">64,675</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8462e5cfa36e4e91b441a3ad10cfb348_I20181231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtNS0xLTEtMjA5NDA_05461faf-2252-40af-90ae-87b951869ec1">107,371</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8462e5cfa36e4e91b441a3ad10cfb348_I20181231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtNy0xLTEtMjA5NDA_89c64764-0b0c-4da5-a574-7f41b9c69dce">734</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ecf8ce3e9b74e56acb8ff0af3fb7c60_I20181231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMTAtMS0xLTIwOTQw_5319f095-b7dc-4813-8cde-df72e0968938">351,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecf8ce3e9b74e56acb8ff0af3fb7c60_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMTItMS0xLTIwOTQw_1e0e63dc-848c-4451-bf1a-258e2b2eca41">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b86b7cc383415ab9c2160568c774c4_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMTQtMS0xLTIwOTQw_79fa2ba7-7949-4232-847c-3c70cb7e2547">2,151</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176b3693f32c4dc59cff0f728a8aa927_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMTYtMS0xLTIwOTQw_c1bb9023-3875-4ca3-ac02-2bd28234d79a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9399ce4d3f59464796fe4fa19123abea_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMTgtMS0xLTIwOTQw_0423767c-b699-43a0-8f47-b6f41f51fc7c">79,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMjAtMS0xLTIwOTQw_d6ec5b03-dc29-425a-9adf-3b2fcff11e4a">77,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of redeemable common stock into common stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia15232c68ac3485b97f216f1936f809b_D20190101-20191231" decimals="INF" sign="-" name="xfor:ConversionOfRedeemableCommonStockToCommonStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzktNS0xLTEtMjA5NDA_9719fe8c-8d59-4efb-9d64-fc5ad1d00f46">107,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia15232c68ac3485b97f216f1936f809b_D20190101-20191231" decimals="-3" sign="-" name="xfor:ConversionOfRedeemableCommonStockToCommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzktNy0xLTEtMjA5NDA_655fe9da-8360-41b8-9a2d-277badbecbaf">734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231" decimals="INF" name="xfor:ConversionOfRedeemableCommonStockToCommonStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzktMTAtMS0xLTIwOTQw_baefd410-cad9-4879-a779-66d4c22d1854">107,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231" decimals="-3" name="xfor:ConversionOfRedeemableCommonStockToCommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzktMTQtMS0xLTIwOTQw_4017de09-e628-4434-b460-bf3f5ca929d3">734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:ConversionOfRedeemableCommonStockToCommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzktMjAtMS0xLTIwOTQw_bce6f307-10cd-48d9-866e-80ad0a3bec6d">734</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of convertible preferred shares into common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib34264e2c11b4c15b0b5b0a7b86698e8_D20190101-20191231" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTEtMS0xLTIwOTQw_a2ee6bd2-6701-4ce9-bdcc-2ab294a41961">40,079,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib34264e2c11b4c15b0b5b0a7b86698e8_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTMtMS0xLTIwOTQw_239bfb41-75dd-4d52-b4be-cff9dcf16dfd">64,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTEwLTEtMS0yMDk0MA_03f7e8d7-a474-43e4-b159-9cca166fbf45">3,808,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTEyLTEtMS0yMDk0MA_256a6696-f736-4a67-8be9-2a39941c53da">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTE0LTEtMS0yMDk0MA_300a1be3-3e09-4eae-9bcf-194508b5b1b2">64,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTIwLTEtMS0yMDk0MA_6b2b61e9-96d2-43ee-8671-f70636dd012b">64,675</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange of common stock in connection with Merger</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzExLTEwLTEtMS0yMDk0MA_bd20eb06-0878-414e-97d0-e2e969a18b9d">2,440,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzExLTEyLTEtMS0yMDk0MA_d41a090c-ed74-4a7a-bcd4-e0a91f23585b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzExLTE0LTEtMS0yMDk0MA_cea25c7b-52c4-4cf9-923e-5013c55a4d5a">45,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzExLTIwLTEtMS0yMDk0MA_5c7153f7-5c09-432e-bcad-c468ac24e3e5">45,541</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of replacement equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEyLTE0LTEtMS0yMDk0MA_7ab7c097-75b3-4606-8691-20f6400956e3">817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEyLTIwLTEtMS0yMDk0MA_d911f495-a38a-4a85-b0cc-035f7ebbde60">817</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification of warrant liability to permanent equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231" decimals="-3" name="xfor:AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEzLTE0LTEtMS0yMDk0MA_e52788cc-e353-4ac2-b348-50b9ac2931ef">5,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEzLTIwLTEtMS0yMDk0MA_4b8fef13-3db5-4292-9ad1-38c29a993a82">5,235</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i9c7918b22f9243ddaf0f3d3d10ab77d4_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246Yzg2NWNjZjZlMjc5NDYyOGJhNTk2ZGVmNjBmNjkxZjBfMTEx_fd3cb8cd-ca15-4929-bb6e-f03dbd342fff">11.4</ix:nonFraction> million </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231" decimals="INF" name="xfor:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE0LTEwLTEtMS0yMDk0MA_ba9ebeb3-63f9-497e-8729-f1ffaf81b12b">9,336,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231" decimals="-3" name="xfor:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE0LTEyLTEtMS0yMDk0MA_ec5d274d-a655-4f69-ba0c-bbaeeef6ea25">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231" decimals="-3" name="xfor:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE0LTE0LTEtMS0yMDk0MA_2619920c-8971-4ef6-9d73-9f7a17acbc92">139,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE0LTIwLTEtMS0yMDk0MA_a4738aa3-6357-459b-8499-94d90779b54f">139,388</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE1LTEwLTEtMS0yMDk0MA_258c2e9d-a9af-4b5d-a1bf-c3501139dd6b">50,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE1LTEyLTEtMS0yMDk0MA_d752c4cf-64bd-45ed-9d7a-6353e5a4dfba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE1LTE0LTEtMS0yMDk0MA_b12a3d66-cf0a-4527-a259-d4f912978517">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE1LTIwLTEtMS0yMDk0MA_d31df909-bccd-4d61-b82c-4026ef8f9275">345</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231" decimals="INF" name="xfor:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE2LTEwLTEtMS0yMDk0MA_4cb32bd7-fc1e-438b-9c97-2f6b61fb9ff4">33,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231" decimals="-3" name="xfor:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE2LTE0LTEtMS0yMDk0MA_98dc2893-2e53-4070-8888-b184b938c66c">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE2LTIwLTEtMS0yMDk0MA_fa3ffbdc-e97f-4704-bcb2-70fddacc6f02">447</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE3LTE0LTEtMS0yMDk0MA_6d135327-1965-4855-8111-0aac63770d80">2,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE3LTIwLTEtMS0yMDk0MA_1299424c-92eb-4bc8-a431-a331e8ef0c11">2,050</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd5d9882306b44ada5d3504a50879658_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE4LTE2LTEtMS0yMDk0MA_665cff66-e1f8-407f-bb40-a86818402cc4">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE4LTIwLTEtMS0yMDk0MA_dfd27cf4-2482-42ca-bb8c-75f255312f90">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4db0920d51934739ab1e898d8dd9ec84_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE5LTE4LTEtMS0yMDk0MA_36b922ba-f3eb-4db9-8f1c-8fc3b62e034d">52,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE5LTIwLTEtMS0yMDk0MA_1551cd39-d5a8-43d1-b5a4-b60f77e01ab4">52,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e6ba7741627488daf0ea92b674d371a_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTEtMS0xLTIwOTQw_e5a12d66-e13e-45f3-ae0d-ad4055dc98fe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6ba7741627488daf0ea92b674d371a_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTMtMS0xLTIwOTQw_de7c974d-685c-42d6-9425-7ea8a34b2178">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ea504a912184f6781687f27b056d117_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTUtMS0xLTIwOTQw_ecc93510-dc6c-411d-827d-d0aab1b4a1d0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ea504a912184f6781687f27b056d117_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTctMS0xLTIwOTQw_54ca94ce-8c3a-4594-835f-e40ba1190bdc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a487a492bc94ba59c6f135aa8c86c42_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTEwLTEtMS0yMDk0MA_1d90293a-9ddc-4eb8-b0d3-8e639a0c4a2d">16,128,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a487a492bc94ba59c6f135aa8c86c42_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTEyLTEtMS0yMDk0MA_ec9f9fa0-985b-4320-b79b-2f580e3f82ce">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i373cd781460447af8b7b7a8138e80603_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTE0LTEtMS0yMDk0MA_e8874ebe-407e-45ae-89ca-6aadaca7f8a8">261,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac2e90cc41804bbb8dbab70f418649b8_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTE2LTEtMS0yMDk0MA_4db4b12e-0c72-469b-9340-5c07098feb1b">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cef3e8a10ac450289a7a934bddd328c_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTE4LTEtMS0yMDk0MA_095ce1d6-10a2-4dfa-9d9d-bdf6af4e0bac">132,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTIwLTEtMS0yMDk0MA_d19f4f35-019c-4064-b35c-f2f78b7b0889">129,220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c7918b22f9243ddaf0f3d3d10ab77d4_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTEwLTEtMS0yMDk0MA_e94b5780-2970-4052-b696-889f3d2ab5d4">17,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7918b22f9243ddaf0f3d3d10ab77d4_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTEyLTEtMS0yMDk0MA_261f65f3-c4f7-4c4f-b423-9cb6054e25c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1406e0d5074a2d82a899bd3bb3214a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTE0LTEtMS0yMDk0MA_58c418bc-bcd0-4449-8069-ca183e5538ab">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTIwLTEtMS0yMDk0MA_343a9642-c7f1-44b3-a2e5-d06b5ce64861">127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1406e0d5074a2d82a899bd3bb3214a_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIyLTE0LTEtMS0yMDk0MA_1b7c9e0e-6ea1-4a61-97e3-570031dc65b0">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIyLTIwLTEtMS0yMDk0MA_ff5bdf88-5143-47c6-9cc9-d1648abc4464">5,428</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTEwLTEtMS0yMDk0MA_225c869e-6332-495b-9e3d-a769c19eaa50">26,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1406e0d5074a2d82a899bd3bb3214a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTE0LTEtMS0yMDk0MA_777530c5-7fb1-4d0b-bce1-011aa56a58dc">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTIwLTEtMS0yMDk0MA_d4f0c51c-648c-4712-ad61-be1906e11413">169</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTEwLTEtMS0yMDk0MA_d9bee1e9-ed8a-4bde-9d4a-c44e298a2736">132,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf1406e0d5074a2d82a899bd3bb3214a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTE0LTEtMS0yMDk0MA_72f4fa8d-2be5-4095-abdf-3b0da60f4991">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTIwLTEtMS0yMDk0MA_6e6deda1-292a-4b4e-8205-d547ee408525">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i820d81ce3a29475a8c344011da28e038_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI1LTE4LTEtMS0yMDk0MA_ec15160f-630f-4859-9b56-8e76f6518289">62,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI1LTIwLTEtMS0yMDk0MA_7edc0120-694a-4758-83c1-acb1b6faf143">62,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i5ed4bb840e6c490cb44e0c1b2416b76b_I20201231" xsi:nil="true" name="us-gaap:TemporaryEquitySharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTEtMS0xLTIwOTQw_8c2f8121-9dc9-4e46-967d-7f0857403f18"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5ed4bb840e6c490cb44e0c1b2416b76b_I20201231" xsi:nil="true" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTMtMS0xLTIwOTQw_46c9a19b-7da7-4c40-8caf-eeffd456b42b"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="id095d9ce2828470d851a6cbfc3424820_I20201231" xsi:nil="true" name="us-gaap:TemporaryEquitySharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTUtMS0xLTIwOTQw_3d8ff65c-68f7-4519-ae82-d719dd63e801"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id095d9ce2828470d851a6cbfc3424820_I20201231" xsi:nil="true" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTctMS0xLTIwOTQw_ea19e808-494f-4f55-aa53-cc5796d1bd13"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11e0524bed0045f9a3d87f7528ddd21a_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTEwLTEtMS0yMDk0MA_18d0fcd4-7304-4395-992c-2899eb50d48d">16,305,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e0524bed0045f9a3d87f7528ddd21a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTEyLTEtMS0yMDk0MA_e667e3d7-09bd-4199-b3e3-4061e5960026">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764dfda255314eb5b4c9af8e6f5029a7_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTE0LTEtMS0yMDk0MA_b814f9a4-aade-49d9-b8aa-ce5dfbbaa2b3">267,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9a7b73207d14b36af0c17c6d6540372_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTE2LTEtMS0yMDk0MA_7bfea6ca-254d-4f95-bef1-e71249c10a87">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153dbfb5749f4329b178c4b7931cafdc_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTE4LTEtMS0yMDk0MA_497fbb18-ef15-4315-aaf7-e7cf164062e8">194,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTIwLTEtMS0yMDk0MA_1ca44b47-f5de-4a34-8c31-60d7382bb766">72,799</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, redeemable common stock and pre-funded warrants for the purchase of common stock, net of issuance costs of $4.4  million </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d20d773aefb40a2ab1e4fd2d6abeacc_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTUtMS0xLTIxNDIw_fe35c42f-afcf-41aa-9ded-8fdab671fbdb">229,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d20d773aefb40a2ab1e4fd2d6abeacc_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTctMS0xLTIxNDIw_e00ad86a-02a7-4391-9eee-f9b7d22a77f0">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTEwLTEtMS0yMTQyMA_1d96cdcf-37ac-4165-8671-78a0c484205e">9,435,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTEyLTEtMS0yMTQyMA_b20c2c8a-d2bd-440e-856a-86b958123da5">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38b2bc6981e4baeac34e666d1e848eb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTE0LTEtMS0yMTQyMA_52d8794d-a24d-4b89-b8ec-287753881f88">73,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTIwLTEtMS0yMTQyMA_cf6a4d88-c653-4c99-964d-48e730b82279">73,868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTEwLTEtMS0yMTQyOQ_b25d2674-3db9-4f76-9e32-fea28ce13010">45,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38b2bc6981e4baeac34e666d1e848eb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTE0LTEtMS0yMTQyOQ_0001a728-ad5b-4d9d-be17-4fc2c4077987">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTIwLTEtMS0yMTQyOQ_0cdfb6f0-2cc7-4b13-a324-f673bb39f7c7">219</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTEwLTEtMS0yMTQyOQ_ced4932f-696a-4c7e-ae2e-d8de25ab05f0">5,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38b2bc6981e4baeac34e666d1e848eb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTE0LTEtMS0yMTQyOQ_9c14345b-cae8-4797-b852-eaec62516f8d">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTIwLTEtMS0yMTQyOQ_4e1384e3-71a0-4ba0-860d-b7bbcf7a0d4a">40</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of pre-funded warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231" decimals="INF" name="xfor:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI1LTEwLTEtMS0yMTQyOQ_72a42782-1c41-455e-8c35-9fae75fa58b2">2,129,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231" decimals="-3" name="xfor:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI1LTEyLTEtMS0yMTQyOQ_b7134618-61b3-4fbb-83c1-40f05a72f4c5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI1LTIwLTEtMS0yMTQyOQ_6bb5f06c-b2d9-4941-88a8-100baf709389">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTEwLTEtMS0yMTQyOQ_9004e88b-ef28-4d75-a7d2-2b9c4d85088f">204,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTIwLTEtMS0yMTQyOQ_475eace6-240a-4a8e-9042-262e851f2441">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase and retirement of redeemable common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI3LTUtMS0xLTIxNDI5_67cf086b-fcd9-48ce-a2b3-69e029d8ddb5">229,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d20d773aefb40a2ab1e4fd2d6abeacc_D20210101-20211231" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI3LTctMS0xLTIxNDI5_dd193a7b-2c80-4180-8cc8-7e7d63ba3877">1,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI3LTIwLTEtMS0yMTQyOQ_003bb8f4-255d-44be-9845-1d2697789670">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38b2bc6981e4baeac34e666d1e848eb_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI4LTE0LTEtMS0yMTQyOQ_d0eed81d-1dbe-4eb9-80df-b3daae931eec">6,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI4LTIwLTEtMS0yMTQyOQ_1c2cd843-f296-406c-98b7-d8ca911086e8">6,180</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4851434b4d774d8bab2622f9881c9440_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI5LTE4LTEtMS0yMTQyOQ_32e27d24-f54a-4481-9194-0d519bfdbe22">88,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI5LTIwLTEtMS0yMTQyOQ_697e3f89-7008-480a-a0bb-36756809e004">88,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i58f79127b745453d84e4c71a65761e38_I20211231" xsi:nil="true" name="us-gaap:TemporaryEquitySharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI5LTEtMS0xLTI4NDI2_fc146611-4291-4e40-be62-8caf0b8245b4"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i58f79127b745453d84e4c71a65761e38_I20211231" xsi:nil="true" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI5LTMtMS0xLTI4NDI2_b021e53f-a894-4eca-992d-cdb75a90ba14"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if884965b97674d2897920860dc9dd9de_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTUtMS0xLTIxNDI5_60a0d684-acf0-46a9-add6-e28b16cfdff4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if884965b97674d2897920860dc9dd9de_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTctMS0xLTIxNDI5_d6306a62-4f7a-4266-ab7a-1fba0799d536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64ff3d38d9274c5cb80f3c6ad6dc0169_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTEwLTEtMS0yMTQyOQ_b1fb7c95-dddc-4769-bd82-2960fe2ed1c5">28,127,657</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64ff3d38d9274c5cb80f3c6ad6dc0169_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTEyLTEtMS0yMTQyOQ_5f9f5fb0-103c-4cda-8f66-3d5c24723ff0">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50217e3e4bd4418faec03cc4d6e2b168_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTE0LTEtMS0yMTQyOQ_0206898a-5f3f-4412-9237-91f4f44ff233">347,374</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b8eb923c43342b496d1759d3a72b849_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTE2LTEtMS0yMTQyOQ_e2d00d7f-c352-48b6-a329-b3dffdc252bc">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54176cdc44bb45e8811df78b7fe967ae_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTE4LTEtMS0yMTQyOQ_c8378bff-615c-478d-8f9e-dd322bb448ba">282,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTIwLTEtMS0yMTQyOQ_6bdc80b3-9942-4163-bd55-f55592f380e0">64,412</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="63" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">The accompanying notes are an integral part of these consolidated financial statements</span></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMtMS0xLTEtMjA5NDA_fddff930-c91f-4e0b-bc50-98666c1919ba">88,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMtMy0xLTEtMjA5NDA_a818a1b8-adf7-4ea4-9bb3-91e21ed2c435">62,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMtNS0xLTEtMjA5NDA_63772221-89ec-4d89-a418-8bfcdf775f11">52,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzUtMS0xLTEtMjA5NDA_5188c55f-7b88-411d-878b-9441ef941b33">6,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzUtMy0xLTEtMjA5NDA_b45000f4-937c-44f3-b3c5-74facb9ca60e">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzUtNS0xLTEtMjA5NDA_cffcaf3f-39b2-4cf9-9660-e70db80ec272">2,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzYtMS0xLTEtMjA5NDA_f70ffcf0-1643-4593-aeee-011ec21d4bed">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzYtMy0xLTEtMjA5NDA_f656bb85-85de-4a90-a4a6-c095a37cf56e">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzYtNS0xLTEtMjA5NDA_92be13e6-acb9-4902-8e6e-1f628c882b8a">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctMS0xLTEtMjQ5MDk_c4596918-bca9-4b28-ad21-90ee6fc90049">9,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctMy0xLTEtMjQ5MTY_93c7caf7-5ebb-4c80-ba4a-2690922d5d0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctNS0xLTEtMjQ5MjM_46ce44e8-70ec-44f1-bca2-140cc2d09aa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on transfer of non-financial assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctMS0xLTEtMjA5NDA_786f0bcb-edb7-4582-91af-855016db2ee7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctMy0xLTEtMjA5NDA_24d51a8e-076f-48c9-993d-d6161e181bc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctNS0xLTEtMjA5NDA_04536759-2bcd-42df-99c6-c09d48f1a111">3,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:NonCashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzgtMS0xLTEtMjA5NDA_1d715745-a315-4bdc-bf14-4127dee544d1">1,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzgtMy0xLTEtMjA5NDA_9dd43480-9ace-4b9a-b6a1-0c4d9ad7a536">879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzgtNS0xLTEtMjA5NDA_efb127a5-1345-44c3-bca5-026ecdcf682d">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accretion of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzktMS0xLTEtMjA5NDA_f6adfe8f-ac42-48b0-ba2e-b6306e9394c7">756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzktMy0xLTEtMjA5NDA_1e445b8b-6e89-4c1d-b393-7014fb7d681a">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzktNS0xLTEtMjA5NDA_43b1cb2d-ab9e-4e4b-b891-d96bed1a44fe">695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEwLTEtMS0xLTIwOTQw_d9a2c005-24d3-4cf8-99e0-184c06de4709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEwLTMtMS0xLTIwOTQw_2c002828-c225-42b1-b6d3-f67c8d1b43a5">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEwLTUtMS0xLTIwOTQw_c1d10148-6512-475a-bd39-2ddfc94b4675">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of preferred stock warrant and derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzExLTEtMS0xLTIwOTQw_7dadd906-4752-4d32-bdb9-df38f0d01635">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzExLTMtMS0xLTIwOTQw_eb7e2e1e-033a-4e8d-94ff-8327285fe9cf">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzExLTUtMS0xLTIwOTQw_16084cb0-24f5-4206-8787-2d2c551d2b11">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEyLTEtMS0xLTIwOTQw_2f059066-3724-4d59-b345-fdfbc9960948">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEyLTMtMS0xLTIwOTQw_e8be4d51-0f27-4cf1-ae23-1adbd9509161">413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEyLTUtMS0xLTIwOTQw_0056c27b-da13-48d1-a6df-88022ab16d34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets and research and development incentive receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE0LTEtMS0xLTIwOTQw_0ad8764d-e406-4227-8f01-25407afe0cf0">1,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE0LTMtMS0xLTIwOTQw_081b2d6e-c13a-4f38-8e2c-3a5fa9a913d3">1,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE0LTUtMS0xLTIwOTQw_de512b99-1443-471c-ac8e-2b184140e6dd">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE1LTEtMS0xLTIwOTQw_1081c65b-ff02-411f-b84a-ae4ea6e40f10">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE1LTMtMS0xLTIwOTQw_03267c97-6787-4110-8df4-9779e3aae56c">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE1LTUtMS0xLTIwOTQw_8d7de448-5798-4385-8b2c-6424a23676ab">2,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE2LTEtMS0xLTIwOTQw_4a44ba75-00be-469c-907d-5845b849f240">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE2LTMtMS0xLTIwOTQw_8358003a-85e4-40f5-9e5d-8a23135f2e1a">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE2LTUtMS0xLTIwOTQw_b0adebba-981f-4291-9466-36dec4c8cf32">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="xfor:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE3LTEtMS0xLTIwOTQw_0f44895d-d4ba-4844-8692-a542a1f1de2a">698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="xfor:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE3LTMtMS0xLTIwOTQw_6001753b-565d-4db0-bac6-0dbd1d2c1dc7">1,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="xfor:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE3LTUtMS0xLTIwOTQw_cf608bcd-6e92-4b80-a4be-abde36a79b77">753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset, net of non-cash portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE4LTEtMS0xLTIwOTQw_4a4e37c0-2116-4450-b516-5a7fe4a81b2f">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE4LTMtMS0xLTIwOTQw_bee56822-561b-46ed-9314-562109133f1e">3,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE4LTUtMS0xLTIwOTQw_79107f82-7033-47ca-aa21-4add4651f4d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE5LTEtMS0xLTIwOTQw_f804a9f0-eee0-4d9c-ae06-c4301bc7fef9">70,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE5LTMtMS0xLTIwOTQw_918b77ff-b371-4e62-9c9f-8bba1eb86c90">58,818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE5LTUtMS0xLTIwOTQw_8342940f-c974-4953-98de-7d461fc1ae9a">48,055</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash acquired in connection with the Merger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIxLTEtMS0xLTIwOTQw_70f40c67-2e2d-43fe-a638-9ad1b6f279c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIxLTMtMS0xLTIwOTQw_79bdb56d-73b8-4210-8e4c-f95cec29cc42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIxLTUtMS0xLTIwOTQw_b04ccbab-1796-4d10-bd91-a3b57b3b93d0">26,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from transfer of non-financial assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIyLTEtMS0xLTIwOTQw_202f1d80-14aa-41ed-be71-eff83c368397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIyLTMtMS0xLTIwOTQw_ca2fa08d-6224-4400-9e08-418c216f82b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIyLTUtMS0xLTIwOTQw_f4ec505c-911e-4636-b140-0124a73b04cc">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property, equipment and intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIzLTEtMS0xLTIwOTQw_555bd57c-10ab-4b6f-ab01-b3b844ee3307">615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIzLTMtMS0xLTIwOTQw_8dadd94d-4713-435a-b1d4-8f27f8abd200">1,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIzLTUtMS0xLTIwOTQw_16cb1138-851b-4110-b972-9ffb3eea8a4b">174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI0LTEtMS0xLTIwOTQw_0b6d1609-d64d-4266-b804-15ac4ff42af3">615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI0LTMtMS0xLTIwOTQw_4bffefc9-e711-4ad4-a707-3cd9c4d72eb6">1,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI0LTUtMS0xLTIwOTQw_ea453984-4b93-442f-b837-4c4894390c21">27,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options, warrants and pre-funded warrants an issuance of shares of common stock under employee stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:ProceedsFromExerciseOfStockOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI2LTEtMS0xLTIwOTQw_860329a0-a3e8-4884-ab47-c8e9e109d316">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:ProceedsFromExerciseOfStockOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI2LTMtMS0xLTIwOTQw_3924602b-c5a8-42e4-b50c-334b6a3a488f">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:ProceedsFromExerciseOfStockOptionsAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI2LTUtMS0xLTIwOTQw_f86fa0ae-c537-4fea-a733-3121ba7bb739">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee taxes paid related to net share settlement of vested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI3LTEtMS0xLTIwOTQw_85df5fd7-810b-473d-8354-bfecd0478721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI3LTMtMS0xLTIwOTQw_a5e6b9a1-145a-4274-8f1f-a20a3804cb21">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI3LTUtMS0xLTIwOTQw_0362abfd-abb1-41ff-9a78-510c3166c9cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from borrowings under loan and security agreements, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI4LTEtMS0xLTIwOTQw_bd54a16a-d572-4113-8b5b-594d37fba590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI4LTMtMS0xLTIwOTQw_52f695df-16e7-4c70-9c8d-5621dad1a926">12,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI4LTUtMS0xLTIwOTQw_16d8e259-bf4d-4d09-8e15-eba3159fcc6f">9,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of borrowings under loan and security agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTEtMS0xLTIwOTQw_2d2392f3-3dc6-4f23-ab8f-c9cb9b55ac5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTMtMS0xLTIwOTQw_6061f7c3-77da-49aa-a7cc-9fdba9dbb0a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTUtMS0xLTIwOTQw_6bd4f808-dd6b-43eb-9009-9d45c6b27ed1">9,368</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of shares of common stock, redeemable common stock, warrants and pre-funded warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMyLTEtMS0xLTIwOTQw_0e86a8a2-81cc-49fc-ab69-2481977753c2">75,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMyLTMtMS0xLTIwOTQw_d3b74589-e79b-4b73-bcaf-f2681b69fdb3">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMyLTUtMS0xLTIwOTQw_66a05378-ca3d-485c-b7cc-e7458e2faedf">139,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement and retirement of redeemable common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTEtMS0xLTIxNjg5_3b4e54ec-1e71-415a-ad24-4bec3f2702aa">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTMtMS0xLTIxNjg5_11d32fab-dc97-4c8b-9a44-d78049b6d931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTUtMS0xLTIxNjg5_8a88a74e-2a1a-4973-8098-e40df8feb184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMzLTEtMS0xLTIwOTQw_3c6f7cdd-4b1d-4b3c-904d-df9c0af41f6a">74,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMzLTMtMS0xLTIwOTQw_93d84f4e-4745-4ecc-beb0-c8ac8e30b778">12,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMzLTUtMS0xLTIwOTQw_f386cfe8-b181-438c-80b5-a52e1cb031b2">140,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM0LTEtMS0xLTIwOTQw_75ede47d-b54b-4ed4-a208-48280ada82d4">319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM0LTMtMS0xLTIwOTQw_0b64f5e2-abf0-46a2-82b3-814e6bdf18d9">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM0LTUtMS0xLTIwOTQw_9de4c16d-9a06-451b-83e0-001aca24d785">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM1LTEtMS0xLTIwOTQw_6d58520e-d5d6-485f-a075-1931d3999220">2,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM1LTMtMS0xLTIwOTQw_ca4cfc67-b885-4cc5-b83f-aea837397838">47,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM1LTUtMS0xLTIwOTQw_0c869328-b136-450b-869c-9e6c4855a39a">119,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM2LTEtMS0xLTIwOTQw_2cabfdf5-0938-4b29-81a6-3e968ee1aaca">80,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM2LTMtMS0xLTIwOTQw_fe93ae28-ee78-424c-ae20-d1ed906d8c40">128,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM2LTUtMS0xLTIwOTQw_be03a281-68d4-47bf-8f4a-94e26ba3fc65">8,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM3LTEtMS0xLTIwOTQw_4e0a8e42-f26a-4a5d-aec6-e6cd42b5f9ef">83,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM3LTMtMS0xLTIwOTQw_c57e9e4a-f548-4a6c-bc02-a346ac84ebe9">80,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM3LTUtMS0xLTIwOTQw_f1ad6674-ca51-4cd8-91cc-2f67629e0c3a">128,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQwLTEtMS0xLTIwOTQw_3eb3a79c-9b6d-4453-a1f5-950cd88b6466">2,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQwLTMtMS0xLTIwOTQw_3821f426-dc98-488a-b1dd-0ced9f6df4ce">2,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:97%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQwLTUtMS0xLTIwOTQw_a88d5908-6475-4687-81a1-8cc63e21fb96">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of property, equipment and right-of-use assets included in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTEtMS0xLTIwOTQw_bc883f7b-b93c-4386-b6f9-0b9b4faa8d07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTMtMS0xLTIwOTQw_afb03b58-066d-49f2-a2ea-3cc24f13eee1">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTUtMS0xLTIwOTQw_6d523f97-e662-4aaf-8ff8-94ad02ccaae3">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of right-of-use assets financed by lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTEtMS0xLTIxNzIy_11f1ccc4-808d-4e18-8fb4-8e63e1d3c917">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTMtMS0xLTIxNzIy_40c575cc-143e-4caf-8a99-27e2ed829440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTUtMS0xLTIxNzIy_14cf9156-9cbc-4619-899f-baff59db47ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs not yet paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:StockAndWarrantIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQzLTEtMS0xLTIwOTQw_6257aa5d-264c-42d1-98e3-ec1a8f9ca9a7">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:StockAndWarrantIssuanceCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQzLTMtMS0xLTIwOTQw_8edf76a7-9099-48dd-bf79-b8a533399c9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:StockAndWarrantIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQzLTUtMS0xLTIwOTQw_62146c3d-d022-4e32-9922-b9c45673ddaa">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of convertible preferred stock into common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:ConversionOfConvertiblePreferredStockToCommonStockValues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ0LTEtMS0xLTIwOTQw_d0b98bf8-a15b-461b-8dbc-a57e69ad0124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:ConversionOfConvertiblePreferredStockToCommonStockValues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ0LTMtMS0xLTIwOTQw_2a1ed8a8-3f3c-4367-a4b1-6165e40f938c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:ConversionOfConvertiblePreferredStockToCommonStockValues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ0LTUtMS0xLTIwOTQw_6c63333d-c0fa-4d1c-9c98-12eb26e3a3e8">64,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of redeemable common stock into common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:ConversionOfRedeemableCommonStockToCommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ1LTEtMS0xLTIwOTQw_3b9f332a-3725-4249-9f60-59e457835193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:ConversionOfRedeemableCommonStockToCommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ1LTMtMS0xLTIwOTQw_c7b0c84c-ce2f-4969-a1fa-01f3ad2674dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:ConversionOfRedeemableCommonStockToCommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ1LTUtMS0xLTIwOTQw_78d16797-0abc-4881-b691-be26dbe5b3e6">734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of convertible preferred stock warrants into common stock warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ2LTEtMS0xLTIwOTQw_77757ef6-5e4a-4249-96f0-871dccccf547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ2LTMtMS0xLTIwOTQw_def483b6-fb05-47d1-8aca-2daed652b896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ2LTUtMS0xLTIwOTQw_a3a9e350-bbc5-4699-8f8b-0f636c091e0a">5,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of net assets acquired in the Merger in exchange for common shares, excluding cash acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:FairValueOfNetAssetsAcquiredInReverseMerger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ3LTEtMS0xLTIwOTQw_5869c871-f57c-4c8c-844f-7c5c4342cda5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:FairValueOfNetAssetsAcquiredInReverseMerger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ3LTMtMS0xLTIwOTQw_f103033a-0f35-4da8-8968-561859e034e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:FairValueOfNetAssetsAcquiredInReverseMerger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ3LTUtMS0xLTIwOTQw_ab1d4050-2803-49cf-838e-9d6b6c2bd3aa">19,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div id="i71bd745117f84268bb875bce92ea6db3_142"></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzEwMzMy_882d0ff2-a729-49d7-9e53-977f551ec75a" continuedAt="i9235624a292e4b648e7d3493ffa733f0" escape="true">NATURE OF THE BUSINESS AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i9235624a292e4b648e7d3493ffa733f0" continuedAt="i244dae00373e47709424685e47446643"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X4 Pharmaceuticals, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a late-stage clinical biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases. The Company&#8217;s lead product candidate, mavorixafor, is a potential first-in-class, once-daily, oral inhibitor of CXCR4 and is currently in a Phase 3 clinical trial for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. The Company is also conducting a 14-day, proof-of-concept Phase 1b clinical trial of mavorixafor in patients with chronic neutropenia disorders, and a Phase 1b clinical trial of mavorixafor in combination with ibrutinib in Waldenstr&#246;m&#8217;s macroglobulinemia. The Company is headquartered in Boston, Massachusetts and has an additional facility in Vienna, Austria. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern Assessment&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-15,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2014-15&#8221;), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. As of December 31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzE0NzY_815909d9-328f-4281-aed9-18ae1a892460">81.8</ix:nonFraction> million of cash and cash equivalents and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzE1Mzg_ee7682f5-4996-4f49-96d6-4f3db6e4d771">282.9</ix:nonFraction> million. As further discussed in Note 2, the Company has a covenant under its Amended and Restated Loan Agreement  (the &#8220;Hercules Loan Agreement&#8221;) with Hercules Capital Inc. (&#8220;Hercules&#8221;), which will require that the Company maintain a minimum level of cash, as defined, beginning on </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 1, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is in violation of this covenant, Hercules could require the repayment of all outstanding debt. Based on its current cash expenditure forecast and considering this covenant, the Company expects that its existing cash and cash equivalents will fund its operations into the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fourth quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company believes that, in the aggregate, these conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Nevertheless, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In order to fund its operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> beyond 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company will need to raise additional funds, which could be through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If the Company is unable to obtain future funding when needed, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or pre-commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. There is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The impact of the ongoing COVID-19 pandemic continues to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Impacts to the Company&#8217;s business have included temporary closures or postponements of activation of its clinical trial sites or facilities, disruptions or restrictions on its employees&#8217; ability to travel, disruptions to or delays in ongoing clinical trials, including patient enrollment at a slower pace than initially projected and the diversion of healthcare resources away from the conduct of the Company&#8217;s clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as the Company&#8217;s clinical trial sites and hospital staff supporting the conduct of the Company&#8217;s clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Arsanis&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;26, 2018, Arsanis, Inc., a publicly held Delaware corporation (&#8220;Arsanis&#8221;), Artemis AC Corp., a Delaware corporation and a wholly-owned subsidiary of Arsanis (&#8220;Merger Sub&#8221;), and X4 Therapeutics, Inc. (&#8220;X4&#8221;) entered into an Agreement and Plan of Merger, as amended on December&#160;20, 2018 and March&#160;8, 2019 (the &#8220;Merger Agreement&#8221;), pursuant to which the Merger Sub merged with and into X4, with X4 surviving the merger as a wholly-owned subsidiary of Arsanis. The transactions described in the foregoing sentence may be referred to in these consolidated financial statements as &#8220;the Merger.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as a reverse merger in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Under this method of accounting, X4 was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i)&#160;the Company&#8217;s stockholders own a substantial majority of the voting rights in the combined organization, (ii)&#160;the Company designated a majority of the members of the initial board of directors of the combined organization and (iii)&#160;the Company&#8217;s senior management hold all key positions in the senior management of the combined organization. Accordingly, for accounting purposes, the business combination was treated as the equivalent of X4 issuing stock to acquire the net assets of Arsanis. As a result, as of the closing date of the Merger, the net assets of Arsanis were recorded at their acquisition-date fair values in the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i244dae00373e47709424685e47446643"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements of the Company and the reported operating results prior to the business combination are those of the Company. In addition, transaction costs incurred by the Company in connection with the business combination have been expensed as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;13, 2019, Arsanis, X4 and Merger Sub completed the Merger pursuant to the terms of the Merger Agreement. Pursuant to the terms of the Merger Agreement, each outstanding share of X4&#8217;s common stock and preferred stock was exchanged for <ix:nonFraction unitRef="number" contextRef="i1dacdd07b5414e26a65fa9a53ef63e97_D20190313-20190313" decimals="INF" name="xfor:BusinessCombinationShareExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzgxODY_6512ab49-6cb6-4b51-a1c7-dbe8fe7671be">0.5702</ix:nonFraction> shares of Arsanis&#8217; common stock (the &#8220;Exchange Ratio&#8221;). In addition, all outstanding options exercisable for common stock and warrants exercisable for convertible preferred stock of X4 became options and warrants exercisable for the same number of shares of common stock of Arsanis multiplied by the Exchange Ratio. In connection with the Merger, X4 changed its name to X4 Therapeutics, Inc. Following the closing of the Merger, X4 Therapeutics, Inc. became a wholly-owned subsidiary of the Company, which changed its name to X4 Pharmaceuticals, Inc. As used herein, the words &#8220;the Company&#8221; refers to, for periods following the Merger, X4 Pharmaceuticals, Inc. (formerly Arsanis, Inc.), together with is direct and indirect subsidiaries, and for periods prior to the Merger, X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.), and its direct and indirect subsidiaries, as applicable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the Merger, stockholders of X4 owned approximately <ix:nonFraction unitRef="number" contextRef="ib146624f4ddd4ad1ad0d121c7a5b8e07_I20190313" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzkxNTM_49d6903d-cd41-492e-b512-01764197ba64">64</ix:nonFraction>% of the combined organization&#8217;s outstanding common stock. On March&#160;14, 2019, the combined organization&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;XFOR.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;13, 2019, immediately following the closing of the Merger, the Company effected a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1-for-6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Unless otherwise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">noted, all references to common stock share and per share amounts have also been adjusted to reflect the exchange ratio of <ix:nonFraction unitRef="number" contextRef="i1dacdd07b5414e26a65fa9a53ef63e97_D20190313-20190313" decimals="INF" name="xfor:BusinessCombinationShareExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzk5ODU_c96c7a39-c7fe-416d-a469-172da1697f69">0.5702</ix:nonFraction>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH (&#8220;X4 Austria&#8221;), which is incorporated in Vienna, Austria, and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div id="i71bd745117f84268bb875bce92ea6db3_148"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDkw_79721b5c-223c-4d82-ab8a-9e567cb4e6e2" continuedAt="i632d1d9150f24a668bde5e7d92b4fee4" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i632d1d9150f24a668bde5e7d92b4fee4" continuedAt="i66f1a695de2e42698ff87880173ed9d2"><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc4_38afc8f5-47c5-4df2-949a-d13a76e7c347" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and the constraint of variable consideration from contracts with customers. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The COVID-19 pandemic has impacted and is expected to continue to impact the clinical development timelines for certain of the Company's clinical programs. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s consolidated financial statements.</span></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDcw_2227df33-07c0-4cc0-82ea-a43d5353eaca" continuedAt="id89beed829844116888e77fc7df32bd4" escape="true">Foreign Currency and Currency Translation&#8212; </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id89beed829844116888e77fc7df32bd4">The functional currency of the Company&#8217;s foreign subsidiary, X4 Austria, is the U.S. dollar but X4 Austria maintains its books and records in Euro. Monetary assets and liabilities are translated at current exchange rates as of the balance sheet date, non-monetary assets such as property and equipment and equity accounts are translated at historic rates and income and expenses are translated at the average exchanges rates for the period. Adjustments resulting from the translation of the consolidated financial statements of the Company&#8217;s foreign operations into U.S. dollars are included in the determination of net loss and are recorded in other expense, net.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i66f1a695de2e42698ff87880173ed9d2" continuedAt="i1a74c35a2773446e8a05000b0700f8fc"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDY3_28cc0137-58a6-4ca4-a115-13cb9cf512b0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Significant Suppliers&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and research and development incentive receivables. The Company generally maintains cash balances in various operating accounts at financial institutions that management believes to be of high credit quality in amounts that may exceed federally insured limits. The Company has not experienced losses related to its cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of active pharmaceutical ingredients and formulated drugs.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDcz_da0d82b4-f5a0-429a-b2a5-fca350e35898" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December&#160;31, 2021 and 2020.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg2_7df0113b-0b9f-4ae3-b8e5-c11ab6d6cd9e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"><tr><td style="width:1.0%"></td><td style="width:68.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:97%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Letter of credit security: Cambridge lease</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if607c1606fbc49f59e2bf4de1d5b33a6_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzEtMS0xLTEtMjA5NDA_03d10196-306f-4859-a66c-d121c117b7a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b2d39313774d1fa99f7f76bc2c53de_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzEtMy0xLTEtMjA5NDA_e89f421e-ed31-4f7c-8088-a44f6f1d591e">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Letter of credit security: Waltham lease </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i420c5ba492444c13b294e4e2a546f0a6_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzItMS0xLTEtMjA5NDA_7e908f8c-b57d-4d34-8a49-76fb3b188873">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c4ebf0462b4732860b5713ee5382d7_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzItMy0xLTEtMjA5NDA_08a8deeb-4d23-4e4b-b940-f1ac4484ce5e">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Letter of credit security: Vienna Austria lease</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica794810f5b2410aa3cb05ea67f5c7f5_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzMtMS0xLTEtMjA5NDA_c9549536-2c10-4ae6-bb60-c71729070323">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce2db152304447e9853c0b52d13069e_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzMtMy0xLTEtMjA5NDA_b8f942fc-f37c-46f6-9b7d-91caf8f085f4">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Boston lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d8948ba512458fa854441df3e3e3bd_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzQtMS0xLTEtMjA5NDA_a9d3c969-0282-4dcc-ba5f-9627876d7b74">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4963d68c5d634e58ab61d1a2cddf748b_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzQtMy0xLTEtMjA5NDA_32504454-fc53-46f3-9641-904e04c161f0">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzYtMS0xLTEtMjA5NDA_032a0a8e-00c1-4721-be46-b9282a69dbb8">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzYtMy0xLTEtMjA5NDA_e3d71efe-00b6-443e-a134-62f169e3fb51">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzctMS0xLTEtMjA5NDA_d3959ead-f218-4849-a61b-c749976e9049">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzctMy0xLTEtMjA5NDA_e5a8a330-d2fa-4cb1-9432-c9bbd21d3fa7">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e897132b145489baf3f95f1211bbfe1_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzgtMS0xLTEtMjA5NDA_1e59d8d0-675c-4ea5-9861-5e17a1cd0dcf">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55dcfd048fd4851ae346aa2bda82ea8_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzgtMy0xLTEtMjA5NDA_209fe493-ff02-40e3-b9c7-c5c282f479a0">1,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s lease agreement for its facilities in Massachusetts and Austria, the Company maintains letters of credit, which are secured by restricted cash, for the benefit of the landlord. In accordance with the Company&#8217;s Loan and Security Agreement with Hercules, as most recently amended on February 9, 2022 and as further described in Note 7, effective as of the earlier of (a) certain specified events impacting the Company&#8217;s Phase III trial of mavorixafor for the treatment of WHIM syndrome and (b) September 1, 2022, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest as further described in Note 7.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="xfor:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDcx_f36d8cc0-4ef8-4dbf-a4f2-7225d5a0e802" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets to the sum to the total of amounts shown in the Company&#8217;s consolidated statements of cash flows as of December&#160;31, 2021, 2020, 2019 and 2018:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:46.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzEtMS0xLTEtMjA5NDA_deec8f4c-0e5c-4652-9872-a663c3a7ca24">81,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzEtMy0xLTEtMjA5NDA_429901b6-7441-4cf7-bc76-1b0b6ff9aa6a">78,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzEtNS0xLTEtMjA5NDA_af8ae244-e74d-4ce5-b777-5de38f0147fb">126,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzEtNy0xLTEtMjA5NDA_0fe71895-6195-487a-ba55-5c54ba1124de">8,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current (included within prepaid expenses and other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzItMS0xLTEtMjA5NDA_d3959ead-f218-4849-a61b-c749976e9049">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzItMy0xLTEtMjA5NDA_861d4e9d-595a-46ae-ba5d-23f7dffcc254">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzItNS0xLTEtMjA5NDA_cb15feab-9104-4ea7-a252-ab03abaf3ca0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzItNy0xLTEtMjA5NDA_bc90582b-1940-406e-9c54-0e69d96c652b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current (included within other assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e897132b145489baf3f95f1211bbfe1_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzMtMS0xLTEtMjA5NDA_1e59d8d0-675c-4ea5-9861-5e17a1cd0dcf">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzMtMy0xLTEtMjA5NDA_825d2574-6ae0-4156-993b-11fca39b830e">1,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzMtNS0xLTEtMjA5NDA_31c2b347-7776-47b7-b22c-23c718f05bae">1,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzMtNy0xLTEtMjA5NDA_1ad8d7dc-71aa-4788-be31-8eb2fd32cd34">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzQtMS0xLTEtMjA5NDA_2a0d3cc7-0817-477f-aef3-b089bbaae976">83,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzQtMy0xLTEtMjA5NDA_75a9c2a1-0eda-4b32-98eb-021fdec81841">80,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzQtNS0xLTEtMjA5NDA_3902cb70-a890-4a73-877d-c9830089cb41">128,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzQtNy0xLTEtMjA5NDA_f0fd0f5a-bbaf-4121-8010-9585488f7e85">8,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDY0_0483ef62-6cd1-4de6-92f0-0fae4c1ccfb6" continuedAt="i4551f655db1e4ac29c7883cf27b65e13" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="xfor:PropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg1_2398ec26-ad68-4520-9406-45c1f1a7789a" continuedAt="i0be14d2955aa4b08b6e49027b7f97107" escape="true">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:</ix:nonNumeric></span></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i1a74c35a2773446e8a05000b0700f8fc" continuedAt="i59bd8193d14e429eb14269d31de64046"><ix:continuation id="i4551f655db1e4ac29c7883cf27b65e13"><div><ix:continuation id="i0be14d2955aa4b08b6e49027b7f97107"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c76fdda3bb7478080cca4e3d51fa3d7_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzEtMS0xLTEtMjA5NDAvdGV4dHJlZ2lvbjpjZWVlOGRkODJiMGE0Yjk0OWE1NGNkMjJkNDM2YzAyMl80_060e9437-9a3a-4110-8173-cb9a8898401c">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i98a725b19ab442bbb8edee0d639f20dd_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzEtMS0xLTEtMjA5NDAvdGV4dHJlZ2lvbjpjZWVlOGRkODJiMGE0Yjk0OWE1NGNkMjJkNDM2YzAyMl8xMA_18233494-7457-4168-a48a-a4b7e9b45f78">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cc17360a88043f9b6abb29bb3af7296_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzItMS0xLTEtMjA5NDA_65c8ad6c-b434-43b3-8602-ea5c6348eeb7">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i77964c20016f452c85f7147fb9ecc320_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzMtMS0xLTEtMjA5NDAvdGV4dHJlZ2lvbjo4YzViNGJlZmE5MjQ0ZTdkYTc5NTI4ZTQ4NWQ0YjRlOF80_dab89219-15fa-4640-a2d9-633b537913f0">3</ix:nonNumeric> to <ix:nonNumeric contextRef="ic33f057257bb48b2afd09c10a0ad9385_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzMtMS0xLTEtMjA5NDAvdGV4dHJlZ2lvbjo4YzViNGJlZmE5MjQ0ZTdkYTc5NTI4ZTQ4NWQ0YjRlOF8xMA_c9d2bb8f-1a6b-4d5e-9836-45861bfdf0dc">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or <ix:nonNumeric contextRef="icda50709fc3f40a7ab505de422bb1006_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzQtMS0xLTEtMjA5NDAvdGV4dHJlZ2lvbjo0NDk2YTgxOTU5MWQ0MTQ4YjM4NzMzYWExMjdiMWQyY18yOQ_251e63c7-36fa-411b-9b7d-59b39e702340">10 years</ix:nonNumeric></span></div></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.</span></div></ix:continuation><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="xfor:RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg3_b471481a-4109-4550-99a1-c6ddaac89512" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right-of-Use Assets and Leases&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;), Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 842&#8221;). Under ASC 842, at the inception of an arrangement, the Company determines whether the arrangement contains a lease based on the unique facts and circumstances present. Leases with a non-cancellable term greater than one year are recognized on the balance sheet as right-of-use assets with associated current and non-current lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Options to renew a lease are not included in the Company&#8217;s initial lease term assessment unless there is reasonable certainty that the Company will renew the lease. If a lease is cancellable without penalty, the Company excludes from the lease term periods following the cancellation notice period unless it is reasonably certain that the Company will not cancel the lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use operating asset may be required for items such as incentives received or accrued rent. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates it incurs to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company has referenced the effective rate of its Hercules borrowings, as adjusted for differences terms, to determine calculate its incremental borrowing rate for each of its operating leases. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 842, components of a lease are split into lease components and non-lease components. A policy election is available pursuant to which an entity may elect to not separate lease and non-lease components. Rather, each lease component and the related non-lease components are accounted for together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components as a combined lease component for its office and laboratory building leases.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc5_33aa04e9-8339-44ed-abdd-5da68200f2b0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value. To date, the Company has not recorded any material impairment losses on long-lived assets.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg4_2ea8ac87-834b-4ba8-8dad-bf32bd479f0b" continuedAt="i283fb9acf9cf40baabb3dfd95b6d2322" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i59bd8193d14e429eb14269d31de64046" continuedAt="i3167e89583d94635a5c526b28445d306"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i283fb9acf9cf40baabb3dfd95b6d2322" continuedAt="i5ab83a0ed58e4ef8a6cf54d16a351bd4">Goodwill is tested quantitatively for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action, a significant decline in the price of the Company&#8217;s common stock, or unanticipated competition. </ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ab83a0ed58e4ef8a6cf54d16a351bd4">The Company has determined that it operates in a single operating segment and has a single reporting unit. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. See Note 4 for more information on the Company&#8217;s goodwill impairment test as of December 31, 2021.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="xfor:IntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDgw_0279c8a4-5b4d-43c3-8eb9-2d6ba0bd3bfe" continuedAt="ie9b8a7b9bc3244958a6abd0a7ebc133c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the Merger, the Company acquired certain in-process research and development (&#8220;IPR&amp;D&#8221;) assets, which were classified as indefinite-lived intangible assets. Acquired IPR&amp;D represents the fair value assigned to research and development assets that the Company acquires and have not been completed at the acquisition date. The fair value of IPR&amp;D acquired in a business combination is recorded on the Company&#8217;s consolidated balance sheets at the acquisition-date fair value and is determined by estimating the costs to develop the technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the projected net cash flows to present value. IPR&amp;D is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned or transferred to a third party.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected discounted cash flow models used to estimate the Company&#8217;s IPR&amp;D reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Probability of successfully completing clinical trials and obtaining regulatory approval;</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market size, market growth projections, and market share;</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Estimates of future cash flows from potential milestone payments and royalties related to out-licensed product sales; and</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A discount rate reflecting the Company's weighted average cost of capital and specific risk inherent in the underlying assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie9b8a7b9bc3244958a6abd0a7ebc133c">During the year ended December 31, 2019, the Company entered into an out-licensing arrangement with a third party that transferred the rights to develop and commercialize one of the programs underlying an IPR&amp;D intangible asset. In addition, the Company entered into amended out-licensing option agreements with a third party who had previously entered into an option agreement with Arsanis to license the rights to develop and commercialize two other programs underlying the IPR&amp;D intangible assets. Following the amendment to these option agreements, the options were exercised by the third party and the in-process research and development programs were out-licensed to the third party. As of December 31, 2019, all programs underlying IPR&amp;D intangible assets acquired in the Merger were transferred to these third parties. As a result of the transfer of the IPR&amp;D projects to third parties, the Company derecognized the IPR&amp;D intangibles asset through a charge to &#8220;loss on transfer of nonfinancial assets&#8221; during 2019. (See Note 15)</ix:continuation> </span></div><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDY1_32c73d10-c361-4143-bea9-62159c1a7184" continuedAt="ie9bf70ffa25148dba2e70488472e4e90" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i3167e89583d94635a5c526b28445d306" continuedAt="ief0a01900ed84593a0f5593d7e306552"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie9bf70ffa25148dba2e70488472e4e90">Prior to the Merger, the Company&#8217;s preferred stock warrant liability and preferred stock repurchase liability were carried at fair value, determined according to Level&#160;3 inputs in the fair value hierarchy described above. The embedded derivative liability related to the redemption features of the Company&#8217;s debt with Hercules as described further below is carried at fair value and is a Level 3 measurement. The Company&#8217;s cash equivalents, consisting of money market funds invested in U.S. Treasury securities, are carried at fair value, determined based on Level 1 and Level&#160;2 inputs in the fair value hierarchy described above. The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company&#8217;s outstanding loan and security agreement with Hercules approximates its fair value at December&#160;31, 2021 because the debt bears interest at a variable market rate and the Company&#8217;s credit risk has not materially changed since the inception of the agreement.</ix:continuation> </span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc0_262c37c6-89b7-4a59-9095-b381e242cb5e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDgx_d8b13678-a8d1-4b2a-81a9-08ebb8725750" continuedAt="ibc7006a3f1a74664831e1a9b251215e2" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2018, the Company adopted ASC Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;), as amended, using the modified retrospective transition method. The modified retrospective method requires that the cumulative effect of initially applying ASC 606 be recognized as an adjustment to the opening balance of retained earnings or accumulated deficit of the annual period that includes the date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of initial application. The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had no</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements that were in the scope of ASC 606 on January&#160;1, 2018 and thus there was no impact to the consolidated financial statements as a result of the adoption. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaboration arrangements and leases. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are generated primarily through research, development and commercialization agreements. The terms of these agreements may contain multiple promised goods and services, which may include (i) licenses, or options to obtain licenses, to the Company&#8217;s technology, and (ii) in certain cases, services in connection with the manufacturing of preclinical and clinical materials. Payments to the Company under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; milestone payments; payments for clinical and commercial product supply, and royalties on future product sales. To date, the Company&#8217;s license agreement with Abbisko Therapeutics Co., Ltd. (&#8220;Abbisko&#8221;) represents its only revenue-generating agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and are therefore within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are deemed to be within the scope of ASC 808, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of ASC 606. The Company&#8217;s policy is generally to recognize amounts received from collaborators in connection with joint operating activities that are within the scope of ASC 808 as a reduction in research and development expense. To date, there have been no transactions within the scope of ASC 808.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company determines it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligation(s) in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligation(s) in the contract; and (5) recognize revenue when (or as) the Company satisfies its performance obligation(s). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and; allocating the transaction price to each performance obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ief0a01900ed84593a0f5593d7e306552" continuedAt="i969f420b67a4427d8070666133d33eea"><ix:continuation id="ibc7006a3f1a74664831e1a9b251215e2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: </span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and </span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time based on the use of an output or input method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes non-refundable payments for contingent milestones, including preclinical research and development, clinical development and regulatory, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most-likely-amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of the achievement of contingent milestones and the likelihood of a significant reversal of such milestone revenue, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect licensing revenue in the period of adjustment. This quarterly assessment may result in the recognition of revenue related to a contingent milestone payment before the milestone event has been achieved.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i969f420b67a4427d8070666133d33eea" continuedAt="ib2f8d2b9ce884e24a5d50dba9251f641"><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="xfor:ResearchAndDevelopmentProgramsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDgy_09c74b36-50c6-4d32-8e38-e2d50536d2d6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Programs&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds under the research and development incentive program from the Austrian government are recognized as other income in an amount equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. Incentive income recognized upon incurring qualifying expenses in advance of receipt of proceeds from research and development incentives is recorded in the consolidated balance sheet as research and development incentive receivable.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDgz_4134a6de-7480-42ea-80fd-2d9701e1d0a8" continuedAt="ic01599dbf97049458a527ff80e7c8a0f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with internal research and development and external research and development services, including drug development and preclinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers.</span></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic01599dbf97049458a527ff80e7c8a0f">Nonrefundable advance payments for services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the related services have been performed, or when it is no longer expected that the goods will be delivered or the services rendered.</ix:continuation> </span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDY2_9a133d9f-e82c-4f36-a314-afe3d0fa768e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg5_fddeae18-ea57-4210-9c96-b6d22faf7a15" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs consist of payments made to secure commitments under certain debt financing arrangements. These amounts are recognized as interest expense over the period of the financing arrangement using the effective interest method. If the financing arrangement is canceled or forfeited, or if the utility of the arrangement to the Company is otherwise compromised, these costs are recognized as interest expense immediately. The Company&#8217;s consolidated financial statements present debt issuance costs related to a recognized debt liability as a direct reduction from the carrying amount of that debt liability.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg0_5f8a1218-7c46-479a-b3fc-188fa57bd5de" continuedAt="i919b4b259d7e499a9fc0bdb96349fc17" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures all stock-based awards granted to employees, nonemployees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has also issued stock-based awards with performance-based vesting conditions that vest in part upon the Company&#8217;s achievement of operational milestones and over time thereafter for the subsequent two years as the employee continues to provide services. The Company assesses the probability of achievement of these operational milestones and recognizes stock-based compensation for these awards using the accelerated attribution model based on the fair value of the awards as of the date of grant and its best estimate of the date each operational milestone will be achieved. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for only the portion of awards that are expected to vest. In developing a forfeiture rate estimate, the Company has considered its historical experience to estimate pre-vesting forfeitures for service-based awards. The impact of a forfeiture rate adjustment is recognized in full in the period of adjustment, and if the actual forfeiture rate is materially different from the Company&#8217;s estimate, the Company may be required to record adjustments to stock-based compensation expense in future periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Prior to March&#160;13, 2019, the Company was a private company and lacked company-specific historical and implied volatility information for its common stock. Therefore, the Company estimates its expected common stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ib2f8d2b9ce884e24a5d50dba9251f641" continuedAt="i9f3cffb411b642af9e1a31b6e36b7a56"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i919b4b259d7e499a9fc0bdb96349fc17">the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc1_53c911ba-35b9-408f-a5b5-012759ab5cd4" continuedAt="ic0ebd382c7d246ad8c31f0b4c29cf8ef" escape="true">Derivative Liabilities: Hercules Loan Redemption Feature&#8212; </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0ebd382c7d246ad8c31f0b4c29cf8ef">The Company&#8217;s loan agreement with Hercules (see Note&#160;7) contains a redemption feature that, upon an event of default, provides Hercules the option to accelerate and demand repayment of the debt, including a prepayment premium, or, at its election, charge additional contingent interest fees on any overdue interest or principal payments. The redemption feature meets the definition of a derivative instrument as the repayment of the debt contains a substantial premium, resulting in the redemption feature not being clearly and closely related to its host instrument. Accordingly, the Company classifies this derivative as a liability within other liabilities (non-current) on its consolidated balance sheets. The derivative liability was initially recorded at fair value on the date of the Hercules Loan Agreement and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of this derivative liability, which is included in other liabilities, are recognized as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss. Changes in the fair value of this derivative liability will continue to be recognized until all amounts outstanding under the Hercules Loan Agreement are repaid or until the Hercules Loan Agreement is terminated.</ix:continuation> </span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc2_21a0a9c1-2e7f-4a54-aa9f-272861e66c06" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021 and 2020, all foreign currency remeasurement gains and losses were included in net loss as the Company has deemed the functional currency of its foreign subsidiary to be the U.S. Dollar. Comprehensive loss includes net loss as well as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">translation adjustments of</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzM0NDc2_e1b32c87-f8e6-4a2f-9762-ddf6afb4e316">119</ix:nonFraction> thousand for the year ended December 31, 2019. </span></div><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc3_5e799dfb-c372-4d17-a206-0dde7c14099d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDcy_309e7ab1-234d-482b-aebd-023155537dd7" continuedAt="i13e731fbf0424c4c81f0122b258a1104" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to the Merger with Arsanis on March 13, 2019, the Company followed the two-class method when computing net loss per share as the Company had issued shares that met the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. In addition, during the year ended December 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of subsequent sales of common stock. Such adjustment is accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#8217;s common stock and the estimated remaining life of the outstanding Class B Warrants. </span></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i9f3cffb411b642af9e1a31b6e36b7a56" continuedAt="ic44f67a0b516456199974ddc81948211"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i13e731fbf0424c4c81f0122b258a1104">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Basic shares outstanding includes the weighted average effect of the Company&#8217;s outstanding prefunded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive shares of common stock. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of convertible preferred stock or common stock are considered potential dilutive shares of common stock.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDY5_67cfab32-2d6b-4cc5-a9d6-1fb5038dc12d" continuedAt="i453ea96fe030486b90545a36001a317a" escape="true">Recently Issued Accounting Pronouncements</ix:nonNumeric></span></div></ix:continuation><div><ix:continuation id="ic44f67a0b516456199974ddc81948211" continuedAt="iff50ff903f3b4d7eab54a4f6b903bd7a"><ix:continuation id="i453ea96fe030486b90545a36001a317a" continuedAt="i6f88eb4b43004dd89619772e425c03b2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In accordance with ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Derivative and Hedging (Topic 815), and Leases (Topic 842)- Effective Dates, </span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff50ff903f3b4d7eab54a4f6b903bd7a"><ix:continuation id="i6f88eb4b43004dd89619772e425c03b2">as the Company meets the definition of a &#8220;smaller reporting company&#8221;, the Company has elected to defer the adoption of ASU 2016-13 until January 1, 2023. The Company expects that the adoption of ASU 2016-13 may accelerate the timing and could increase the level of credit loss expense in the consolidated statement of operations and will likely require an increased level of disclosure in the notes to the consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i71bd745117f84268bb875bce92ea6db3_154"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzE0OTUy_f54652a4-473e-4e81-9d1d-248e5fcdbe82" continuedAt="icf3332ae3e2b494a8568758c864cb229" escape="true">LICENSE, COLLABORATION AND FUNDING ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="icf3332ae3e2b494a8568758c864cb229" continuedAt="ibcdcd9c5d2dd4c74913124f48bacf5d0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genzyme Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2014, the Company entered into a license agreement with Genzyme  (the &#8220;Genzyme Agreement&#8221;) pursuant to which the Company was granted an exclusive license to certain patents and intellectual property owned or controlled by Genzyme related to the CXCR4 receptor to develop and commercialize products containing licensed compounds (including but not limited to mavorixafor) for all therapeutic, prophylactic and diagnostic uses, with the exception of autologous and allogenic human stem cell therapy. Under the terms of the Genzyme Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize licensed products for use in the field in the United States and at least one other major market country. The Company has the right to grant sublicenses of the licensed rights that cover mavorixafor to third parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Genzyme Agreement, the Company is obligated to pay Genzyme milestone payments in the aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="i9784cfb07e534c2e87bde589e4247ab1_D20210101-20211231" decimals="-5" name="xfor:MilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzEwNTI_fc59ccc1-e825-40eb-8833-ca83d063cef3">25.0</ix:nonFraction> million, contingent upon the achievement by the Company of certain clinical-stage regulatory and sales milestones with respect to licensed products. The Company is also obligated to pay Genzyme tiered royalties based on net sales of licensed products that the Company commercializes under the agreement. The obligation to pay royalties for each licensed product expires on a country-by-country basis on the latest of (i)&#160;the expiration of&#160;licensed patent rights that cover that licensed product in that country, (ii)&#160;the expiration of regulatory exclusivity in that country and (iii)&#160;ten years after the first commercial sale of such licensed product in that country. Royalty rates are subject to reduction under the agreement in specified circumstances, including in any country if the Company is required to obtain a license from any third party to the extent the Company&#8217;s patent rights might infringe the third party&#8217;s patent rights, if a licensed product is not covered by a valid claim in that country or if sales of generic products reach certain thresholds in that country. If the Company enters into a sublicense under the Genzyme Agreement, the Company will be obligated to pay Genzyme a percentage of certain upfront fees, maintenance fees, milestone payments and royalty payments paid to the Company by the sublicensee. Under the Genzyme Agreement, the Company will itself manufacture and supply, or enter into manufacturing or supply agreements with Genzyme or third parties to manufacture and supply, clinical and commercial supplies of licensed compounds and each licensed product. The Company is also responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Genzyme Agreement will remain in effect until the expiration of the royalty term in all countries for all licensed products.&#160;The Genzyme Agreement may be terminated by either party with at least 90 days&#8217; notice in the event of material breach by the other party that remains uncured for 90 days, by either party for insolvency or bankruptcy of the other party, immediately by Genzyme if the Company challenges the licensed patents, or immediately by the Company if a material safety issue arises. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ibcdcd9c5d2dd4c74913124f48bacf5d0" continuedAt="iaea6ef94496241cbad3dddbb0aebd7fa"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:PaymentOnObligationUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzMzMjY_786fbb90-c277-4635-830f-57fd5d5e831c">0.9</ix:nonFraction>&#160;million of payment obligations to Genzyme. For the years ended December 31, 2021 and 2019, the Company did <ix:nonFraction unitRef="usd" contextRef="iad3dd65af95a4a2aba2fdcc47b856359_D20190101-20191231" decimals="INF" name="xfor:PaymentOnObligationUnderLicenseAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzM0MjY_39633822-ae17-4b08-8c72-8a7f973c3fed"><ix:nonFraction unitRef="usd" contextRef="i9784cfb07e534c2e87bde589e4247ab1_D20210101-20211231" decimals="INF" name="xfor:PaymentOnObligationUnderLicenseAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzM0MjY_41c7f22b-c59c-47b0-b551-f63bd6c8df07">no</ix:nonFraction></ix:nonFraction>t incur any payment obligations to Genzyme under the Genzyme Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Georgetown Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company entered into a license agreement (the &#8220;Georgetown Agreement&#8221;) with Georgetown University (&#8220;Georgetown&#8221;) pursuant to which the Company obtained an exclusive, worldwide license to make, have made, use, sell, offer for sale and import of products covered by patent rights co-owned by Georgetown. The rights licensed to the Company are for all therapeutic, prophylactic and diagnostic uses in all disease indications in humans and animals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Georgetown Agreement, the Company paid a one-time, upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i225e901df8314c699611cba3ac017ff1_D20161201-20161231" decimals="-3" name="xfor:OneTimeUpfrontPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzQwODE_b4d9613d-bc2d-4806-83be-c085f5608145">50</ix:nonFraction> thousand and the Company may be required to make milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i225e901df8314c699611cba3ac017ff1_D20161201-20161231" decimals="-3" name="xfor:MilestonePaymentsPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzQxNjg_a912035e-1b63-417f-aa9e-162492eea938">800</ix:nonFraction> thousand related to commercial sales of a product. The Company recorded the upfront payment as research and development expense in the consolidated statement of operations and comprehensive loss because the acquired technology represented in-process research and development and had no alternative future use. Under the Georgetown Agreement, the Company is solely responsible for all development and commercialization activities and costs in its respective territories. The Company is also responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights. The term of the Georgetown Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event (i)&#160;the Company fails to pay any amount and fails to cure such failure within 30 days after receipt of notice, (ii)&#160;the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within 45 days after receipt of notice, or (iii)&#160;the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown Agreement at any time upon at least <ix:nonNumeric contextRef="i225e901df8314c699611cba3ac017ff1_D20161201-20161231" name="xfor:MilestoneContractTerminationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzUzNDg_9c2bdce8-41e2-43b7-9e9c-13cf176a13df">60</ix:nonNumeric> days&#8217; written notice.  During the years ended December&#160;31, 2021, 2020 and 2019, the Company did <ix:nonFraction unitRef="usd" contextRef="i88010e5c3d6844f290c1e8ba4fb22318_D20190101-20191231" decimals="INF" name="xfor:PaymentOnObligationUnderLicenseAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU0MzY_9712e907-c4db-48ee-9f9a-a03c95973ea9"><ix:nonFraction unitRef="usd" contextRef="i0ceee2c8aded43179b9372ebcdc986a8_D20210101-20211231" decimals="INF" name="xfor:PaymentOnObligationUnderLicenseAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU0MzY_ddf1da52-3692-457b-bd6a-4348d26ef73a"><ix:nonFraction unitRef="usd" contextRef="iad92d608e2c943b5a764b11f90964ae8_D20200101-20201231" decimals="INF" name="xfor:PaymentOnObligationUnderLicenseAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU0MzY_fd5bf045-0f8e-4d6e-9e72-826528e9092f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t incur any payment obligations to Georgetown under the Georgetown Agreement and <ix:nonFraction unitRef="usd" contextRef="i9f97f5094be74d7ba79c0c8d4e004d44_I20211231" decimals="INF" name="xfor:MilestonePaymentObligation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU1MTk_4813a8cc-d490-464d-847c-3925f07bbd31"><ix:nonFraction unitRef="usd" contextRef="if1ce81a516a94a338811f3c4a44d3f09_I20201231" decimals="INF" name="xfor:MilestonePaymentObligation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU1MTk_8fb23a5a-de0b-4a43-bd65-f723ae3d9b2d"><ix:nonFraction unitRef="usd" contextRef="i8606b5dae8b041ddbf2eda066e840243_I20191231" decimals="INF" name="xfor:MilestonePaymentObligation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU1MTk_b2d04d22-bb36-4bd8-b660-d4ab7e0a858b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> milestone payments were made or due under the Georgetown Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beth Israel Deaconess Medical Center Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company entered into a license agreement (the &#8220;BIDMC Agreement&#8221;) with Beth Israel Deaconess Medical Center (&#8220;BIDMC&#8221;), pursuant to which the Company obtained an exclusive, worldwide license to make, have made, use, sell, offer for sale and import products covered by patent rights co-owned by BIDMC. The rights licensed to the Company are for all fields of use. Under the terms of the BIDMC Agreement, the Company paid a one-time, upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i1954fbe47872474aa699d20fef1a95c1_D20161201-20161231" decimals="-3" name="xfor:OneTimeUpfrontPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzYxMDQ_e859041c-4f97-4b32-96a4-7501a9e0cc00">20</ix:nonFraction> thousand and the Company is responsible for all future patent prosecution costs. The Company recorded the upfront payment as research and development expense in the consolidated statement of operations because the acquired technology represented in-process research and development and had no alternative future use. The term of the BIDMC Agreement will continue until the expiration of the last valid claim within the patent rights covering the licensed products. BIDMC may terminate the agreement in the event (i)&#160;the Company fails to pay any amount and fails to cure such failure within 15 days after receipt of notice, (ii)&#160;the Company is in material breach of any material provision of the BIDMC Agreement and fails to remedy such breach within 60 days after receipt of notice, or (iii)&#160;the Company declares insolvency or bankruptcy. The Company may terminate the BIDMC Agreement at any time upon at least 90 days&#8217; written notice.  The Company did <ix:nonFraction unitRef="usd" contextRef="i380c26c2cda946c08040104fb3a0b055_D20200101-20201231" decimals="INF" name="xfor:PaymentOnObligationUnderLicenseAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzcwNTE_4e20afcb-e3b3-4286-983d-c8ec5d416355"><ix:nonFraction unitRef="usd" contextRef="i8829b46536ce4ec9827623894b9f4010_D20210101-20211231" decimals="INF" name="xfor:PaymentOnObligationUnderLicenseAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzcwNTE_e843c3d1-6265-4f66-b39c-49c471e6aeb7"><ix:nonFraction unitRef="usd" contextRef="i62733706ba0e4d2db3cb0b4113c64983_D20190101-20191231" decimals="INF" name="xfor:PaymentOnObligationUnderLicenseAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzcwNTE_e8816431-d415-4fe1-9ffb-5d327eee43e7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t incur any payment obligations under the BIDMC Agreement during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dana Farber Cancer Institute Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a license agreement (the &#8220;DFCI Agreement&#8221;) with the Dana Farber Cancer Institute (&#8220;DFCI&#8221;) pursuant to which the Company obtained a non-exclusive, royalty-bearing license to use, make, have made, develop, market, import, distribute, sell and have sold products covered by patent rights owned by DFCI. Under the terms of the DFCI Agreement, the Company paid a one-time, upfront fee of $<ix:nonFraction unitRef="usd" contextRef="id39cf2b1c7eb411c8bf1eb3d7c157ca3_D20201101-20201130" decimals="-3" name="xfor:OneTimeUpfrontPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc2MjM_fcbb5497-43d4-46d0-a4e9-65dad121afd9">25</ix:nonFraction> thousand and approximately $<ix:nonFraction unitRef="usd" contextRef="id39cf2b1c7eb411c8bf1eb3d7c157ca3_D20201101-20201130" decimals="-3" name="xfor:CollaborativeAgreementExpenseReimbursement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc2NDQ_1621f971-9637-43aa-91f8-b6dfdf6c0035">35</ix:nonFraction>&#160;thousand for reimbursement of DFCI&#8217;s past patent expenses relating to the patent rights. The Company will pay <ix:nonFraction unitRef="number" contextRef="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231" decimals="2" name="xfor:CollaborativeArrangementObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc3NDg_bc182657-53cc-4f6e-85b5-d4b30190425c">25</ix:nonFraction>% of DFCI&#8217;s ongoing patent prosecution expenses and an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231" decimals="-3" name="xfor:CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc4Mzg_b9f1c18a-0f76-4d07-920c-3f308a50a4d5">10</ix:nonFraction>&#160;thousand in each of the first three years, $<ix:nonFraction unitRef="usd" contextRef="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231" decimals="-3" name="xfor:CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc4NzU_ecea90b2-e557-470c-9686-22d6c62b9f2c">40</ix:nonFraction>&#160;thousand in each of the subsequent three years and $<ix:nonFraction unitRef="usd" contextRef="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231" decimals="-3" name="xfor:CollaborativeAgreementFutureExpectedAnnualFeesThereafter" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc5MjA_54f7a853-ac5b-4978-91fe-363394d0b3d1">50</ix:nonFraction>&#160;thousand every year after that until commercialization. The Company may be required to make milestone payments of up to an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231" decimals="-3" name="xfor:PaymentOnObligationUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzgwNjQ_c79ce50e-bf04-4460-99b1-99a7f700cd57">32.0</ix:nonFraction> million related to development, regulatory and commercial sales events. No such milestone payments have been incurred to date. The Company recorded the upfront payment as research and development expense in the consolidated statement of operations and comprehensive loss because the acquired technology represented in-process research and development and had no alternative future use. The term of the DCFI Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. DFCI may terminate the agreement if certain events occur. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="iaea6ef94496241cbad3dddbb0aebd7fa" continuedAt="i6cfbdee9b9074e129afddd24012cbf86"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Incentive Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's wholly-owned subsidiary X4 Austria participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses incurred by X4 Austria. Under the program, the reimbursement rate for qualifying research and development expenses incurred by the Company through X4 Austria is <ix:nonFraction unitRef="number" contextRef="ibf4a376dcdfb4942aaeaac1e7d14026a_D20210101-20211231" decimals="INF" name="xfor:ReimbursementRateForResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzkwNzc_b241f78c-ad6e-41a0-bb99-42e0e3b995da">14</ix:nonFraction>% for the current year. X4 Austria also participated in a COVID-19 incentive program, which provides reimbursement for qualified capital spending during a defined time period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes incentive income from Austrian research and development incentives when qualifying expenses have been incurred, there is reasonable assurance that the payment will be received, and the consideration can be reliably measured. Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each reporting date, management estimates the reimbursable incentive income available to the Company based on available information at the time.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the years ended December&#160;31, 2021 and 2020, the amounts due under these programs were $<ix:nonFraction unitRef="usd" contextRef="i07dd80c3754e46e787921f0939875ae9_I20211231" decimals="-5" name="xfor:GrantAndIncentiveReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzI3NDg3NzkwODQ1MDg_f69e5e94-7b33-409f-9f23-2ce6ea829a54">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iac899978347d423a8c974cde8043327f_I20201231" decimals="-5" name="xfor:GrantAndIncentiveReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzMyOTg1MzQ4OTkzMzA_2e7d7684-16f9-44ec-a3e0-4735dd2730c3">0.9</ix:nonFraction> million, respectively, which is included in research and development incentive receivable on the consolidated balance sheet. During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ie326aa2ac0af4123b2815995684d76f6_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzI3NDg3NzkwODQ1MTU_6c3be5e5-7a71-4885-8980-436546ce025f">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i16c580853b2d45d38376f5d122ceae9e_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzEwOTk1MTE2NDM4NjI_5336c4c8-4357-4f04-8f93-5fa0158dd03b">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if1ac70d6741a4930924fed60eceb574a_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzEwOTk1MTE2NDM4NjU_5a51e459-0b82-44d2-902b-5e05da97f9f2">0.4</ix:nonFraction> million, respectively, of income related to the program on the consolidated statement of operations and comprehensive loss within &#8220;other income&#8221;.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Abbisko Agreement </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into a license agreement with Abbisko (the &#8220;Abbisko Agreement&#8221;). Under the terms of the Abbisko Agreement, the Company granted Abbisko the exclusive right to develop, manufacture and commercialize mavorixafor in mainland China, Taiwan, Hong Kong and Macau, the (&#8220;Abbisko Territory&#8221;). The agreement provides Abbisko with the exclusive rights in the Abbisko Territory to develop and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in multiple oncology indications. The Company retains the full rest-of-world rights to develop and commercialize mavorixafor outside of Greater China for all indications and the ability to utilize data generated pursuant to the Abbisko collaboration for rest-of-world development. Assuming mavorixafor is developed by Abbisko in six indications, the Company would be entitled to milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="iccd109dd37804ba9bfecda161164e492_I20211231" decimals="-5" name="xfor:PotentialMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzExMTMx_265cbc3f-f92a-4bca-8d14-b87653e00cba">208.0</ix:nonFraction>&#160;million, which will vary based on the ultimate sales, if any, of the approved licensed products. In addition, upon commercialization of mavorixafor in the Abbisko Territory, the Company is eligible to receive a tiered royalty, with a percentage range in the low double-digits, on net sales of approved licensed products. Abbisko is obligated to use commercially reasonable efforts to develop and commercialize mavorixafor in the Abbisko Territory. Abbisko has responsibility for all activities and costs associated with the further development, manufacture and commercialization of mavorixafor in the Abbisko Territory.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of a qualified financing (as such term is defined in the Abbisko Agreement), Abbisko was required to pay the Company a one-time, non-refundable, non-creditable financial milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i3ce09a35448e44b7923a92354c5363c2_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzExOTYw_a6779858-91b7-4dbe-8131-6586fbcaa007">3.0</ix:nonFraction> million. Abbisko achieved such qualified financing in March 2020 and, as a result, the Company was eligible to receive the milestone payment, which was received by the Company in April 2020. The Company is also eligible to receive potential development and regulatory milestone payments, which vary based on the number of indications developed, and potential commercial milestone payments based on annual net sales of mavorixafor-based licensed products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into the Abbisko Agreement, the Company evaluated the Abbisko Agreement under ASC 606 and determined the Abbisko Agreement contained a single performance obligation related to the exclusive license to develop and commercialize mavorixafor and the transfer of know-how that was satisfied at the inception of the arrangement. The transaction price related to the transfer of the license and know-how was fully constrained and the Company ascribed no transaction price to the development, regulatory and commercial milestones under the &#8220;most-likely amount&#8221; method. The Company concluded that any consideration related to the initial transfer of the license and know-how will be recognized when it is probable that Abbisko will achieve the related financial milestone and other operational milestones. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Abbisko and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur. As a result of Abbisko&#8217;s achievement of the qualified financing, the Company reversed the constraint related to this milestone and recognized $<ix:nonFraction unitRef="usd" contextRef="i3ce09a35448e44b7923a92354c5363c2_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzEwOTk1MTE2NDI4MzU_a6779858-91b7-4dbe-8131-6586fbcaa007">3.0</ix:nonFraction> million of license revenue during the year ended December 31, 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i6cfbdee9b9074e129afddd24012cbf86"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the future sale of clinical and commercial supply are optional goods that will be subject to the customer's future purchasing decisions and do not represent performance obligations in the Abbisko Agreement. The Company concluded that the amount to be charged for the clinical supply will be reflective of market value and, therefore, the Abbisko Agreement does not provide a discount on such supply that would be accounted for as material right at the outset of the contract. In arriving at these conclusions, the Company considered the complexity of the manufacturing process for the licensed compound and the potential ability for Abbisko to obtain the compound directly from other manufactures in the future. The Company expects that it will recognize revenue at a point in time when such clinical supply (and commercial supply, if applicable) is delivered to Abbisko in the future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the transaction price, including its estimated variable consideration for milestones included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div></ix:continuation><div id="i71bd745117f84268bb875bce92ea6db3_157"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzQ5NDc4MDIzMzc3NDU_1e18d19a-1372-4d86-b69e-ad2a57ebe7ad" continuedAt="i4e2c66e7022945f2a2fa83a69fc3377d" escape="true">FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i4e2c66e7022945f2a2fa83a69fc3377d" continuedAt="i6171ad2b9787488091c5a442fe906ea7"><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzQxMjg_b750b653-8a0f-405d-85ef-1798e4afe419" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0240e57043459f99d9c4df35fbe4a4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzMtMS0xLTEtMjA5NDA_d8e0449c-b939-499c-bb09-61ad981a8470">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1d2efd6bc94ac6831e430b69a1aaae_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzMtMy0xLTEtMjA5NDA_89661581-5d0d-4c65-8ca8-4f7e77992b09">27,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c66368b5a4481390647875c1cd56b3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzMtNS0xLTEtMjA5NDA_a97109d0-2b10-4cc9-be23-5f2b9fb7cbe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41915bc16d8a42a0b9187f4f75b87df1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzMtNy0xLTEtMjA5NDA_6196ca80-e2f7-4dc7-8244-2e7bd4ca6a1e">47,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0240e57043459f99d9c4df35fbe4a4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzQtMS0xLTEtMjA5NDA_e3cc5517-d62c-467f-82c0-2fe7787ad997">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1d2efd6bc94ac6831e430b69a1aaae_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzQtMy0xLTEtMjA5NDA_4580c453-2f5e-4634-8c92-1ebde7a30924">27,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c66368b5a4481390647875c1cd56b3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzQtNS0xLTEtMjA5NDA_b96eb2a9-739f-47da-8a27-c3b2a4bfa996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41915bc16d8a42a0b9187f4f75b87df1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzQtNy0xLTEtMjA5NDA_36ab0494-89e2-4bc1-ad0f-5d9971f4bd17">47,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0240e57043459f99d9c4df35fbe4a4_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzYtMS0xLTEtMjA5NDA_08202086-2fe5-4485-be51-6008dced5b7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1d2efd6bc94ac6831e430b69a1aaae_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzYtMy0xLTEtMjA5NDA_fb8014e7-42e5-4513-a9b4-55c95c67e04e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c66368b5a4481390647875c1cd56b3_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzYtNS0xLTEtMjA5NDA_f1e70f05-92fe-4833-93c5-b01e88ff748d">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41915bc16d8a42a0b9187f4f75b87df1_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzYtNy0xLTEtMjA5NDA_1c20acf7-ec7c-4e1f-bb2e-8b684563501d">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0240e57043459f99d9c4df35fbe4a4_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzctMS0xLTEtMjA5NDA_9cb3d801-dd1c-44ed-9cde-9949827669b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1d2efd6bc94ac6831e430b69a1aaae_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzctMy0xLTEtMjA5NDA_9f331b77-d608-4e76-8d75-61388d7f03d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c66368b5a4481390647875c1cd56b3_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzctNS0xLTEtMjA5NDA_d095593f-6ea1-4bfb-ba13-b38608fb56e2">821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41915bc16d8a42a0b9187f4f75b87df1_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzctNy0xLTEtMjA5NDA_b4597964-b569-42ce-b6c6-1a12d7ef94e4">821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2020 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29e21fcd99849af88c7d951ec6f37ba_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzMtMS0xLTEtMjA5NDA_fd465a07-ca8c-4ce4-a4ab-43e1d84644cb">16,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52444c1398e14dcba086b4397b35d5a2_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzMtMy0xLTEtMjA5NDA_5e11dda6-e0db-4d74-b04d-2e1661354f61">28,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe6cb9ee46884d369d83ce82d8bf1038_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzMtNS0xLTEtMjA5NDA_0b8b15f9-df7f-4141-a74c-ac2f37a1980c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280356e3a07941a2bcd0573cdc71bda1_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzMtNy0xLTEtMjA5NDA_4ea26e70-a891-4fc7-8538-751704b3c685">44,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29e21fcd99849af88c7d951ec6f37ba_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzQtMS0xLTEtMjA5NDA_c3378028-7eff-44f6-82a8-f723d6b9fad5">16,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52444c1398e14dcba086b4397b35d5a2_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzQtMy0xLTEtMjA5NDA_80eafca5-4968-4591-ad29-25b552b09970">28,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe6cb9ee46884d369d83ce82d8bf1038_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzQtNS0xLTEtMjA5NDA_698dcde6-a7d3-4f13-b02e-81e326e23809">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280356e3a07941a2bcd0573cdc71bda1_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzQtNy0xLTEtMjA5NDA_820815f5-0c19-4d80-bff9-e3c4867c9683">44,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b2e9b7ab3a498986022689b55633be_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzYtMS0xLTEtMjA5NDA_ac5fca5f-05ac-44fb-8c46-5fd0ea8b4391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6aa3b74a39643e7b24682ca039984a8_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzYtMy0xLTEtMjA5NDA_8227dd92-eb0e-4662-ae08-455aad133b61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42028c40df934c66818f46c7b7a459d1_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzYtNS0xLTEtMjA5NDA_f09f45a6-cd9f-4a21-a3ee-3e3e8d25db12">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92061fb2c1cd4c7cbb46ced4db254c28_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzYtNy0xLTEtMjA5NDA_1d1f84b6-a35a-4649-b3e4-ffbc448eb6a9">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29e21fcd99849af88c7d951ec6f37ba_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzctMS0xLTEtMjA5NDA_8300ccb7-098c-4363-ace3-923ec17d1071">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52444c1398e14dcba086b4397b35d5a2_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzctMy0xLTEtMjA5NDA_37486488-4c5c-4535-bd98-450a37c64604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe6cb9ee46884d369d83ce82d8bf1038_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzctNS0xLTEtMjA5NDA_50f19b1e-dbfc-43b8-8e66-072335827c38">455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280356e3a07941a2bcd0573cdc71bda1_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzctNy0xLTEtMjA5NDA_b012635c-1b60-43fc-89f4-a6bcf1f665f6">455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents consisted of money market funds invested in U.S. Treasury securities. The money market funds were valued based on reported market pricing for the identical asset or by using inputs observable in active markets for similar securities, which represents a Level&#160;2 measurement in the fair value hierarchy.</span></div><div style="margin-top:10pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzQxMjk_680099db-71ad-44c1-96ae-94ecbe72551a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s warrant liability and derivative liability, for which fair values are determined using Level&#160;3 inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"><tr><td style="width:1.0%"></td><td style="width:76.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Embedded Derivative Liability</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b315bcebad4db0a5801ae168cf944a_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTowMmMxNGQ5ZjA5ODY0NTYyYmYwN2RhMDhlZmIxNDA1Yi90YWJsZXJhbmdlOjAyYzE0ZDlmMDk4NjQ1NjJiZjA3ZGEwOGVmYjE0MDViXzQtMy0xLTEtMjA5NDA_82a521d0-6466-400f-9a03-e13b6a34cac1">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12294001c3724c64a759185c687b58e4_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTowMmMxNGQ5ZjA5ODY0NTYyYmYwN2RhMDhlZmIxNDA1Yi90YWJsZXJhbmdlOjAyYzE0ZDlmMDk4NjQ1NjJiZjA3ZGEwOGVmYjE0MDViXzUtMy0xLTEtMjA5NDA_4a517bb8-0a0d-4fd4-8388-96150f3f0399">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7406aa31e3374111bed602d9d3287a73_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTowMmMxNGQ5ZjA5ODY0NTYyYmYwN2RhMDhlZmIxNDA1Yi90YWJsZXJhbmdlOjAyYzE0ZDlmMDk4NjQ1NjJiZjA3ZGEwOGVmYjE0MDViXzYtMy0xLTEtMjA5NDA_dc9a4773-2d0a-4882-9753-2e0af3137902">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia84c45f7f16b4da88327ddbf122756a5_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTowMmMxNGQ5ZjA5ODY0NTYyYmYwN2RhMDhlZmIxNDA1Yi90YWJsZXJhbmdlOjAyYzE0ZDlmMDk4NjQ1NjJiZjA3ZGEwOGVmYjE0MDViXzctMy0xLTEtMjE5NDA_18356007-e856-4fe4-9584-266432213a8b">366</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb0a1ce7184c4d82850f7e0ca90dd59a_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTowMmMxNGQ5ZjA5ODY0NTYyYmYwN2RhMDhlZmIxNDA1Yi90YWJsZXJhbmdlOjAyYzE0ZDlmMDk4NjQ1NjJiZjA3ZGEwOGVmYjE0MDViXzgtMy0xLTEtMjE5NDA_91a9acab-f5ee-4a72-84e7-0586cd5917b2">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><ix:continuation id="i6171ad2b9787488091c5a442fe906ea7"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Embedded Derivative Liability&#8212;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative liability recognized in connection with the Company&#8217;s loan agreement with Hercules (see Note&#160;7), which is associated with additional fees due to Hercules upon events of default, was determined based on significant inputs not observable in the market, which represents a Level&#160;3 measurement within the fair value hierarchy. The fair value of this embedded derivative liability, which is reported within other non-current liabilities on the consolidated balance sheets, is estimated by the Company at each reporting date based, in part, on the results of third-party valuations, which were prepared based on a discounted cash flow model that considered the timing and probability of occurrence of a redemption upon an event of default, the potential amount of prepayment fees or contingent interest upon an event of default and the Company&#8217;s risk-adjusted discount rate of 14%. As of December&#160;31, 2021 and December&#160;31, 2020, the fair value of this derivative liability was $<ix:nonFraction unitRef="usd" contextRef="ic0c66368b5a4481390647875c1cd56b3_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzQxMDE_f1e70f05-92fe-4833-93c5-b01e88ff748d">821</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i42028c40df934c66818f46c7b7a459d1_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzQxMDg_f09f45a6-cd9f-4a21-a3ee-3e3e8d25db12">455</ix:nonFraction> thousand, respectively.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested quantitatively for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. During the fourth quarter of 2021, the Company&#8217;s market capitalization, measured as the price of the Company&#8217;s common stock multiplied by common shares outstanding, was below the value of the Company&#8217;s net assets, including goodwill. As a result of the sustained decline in the market price of the Company&#8217;s common stock, the fair value of the Company&#8217;s single reporting unit, determined based on Company&#8217;s market capitalization on December 31, 2021, was lower than its carrying value and the Company concluded that goodwill was impaired. Accordingly, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzEwOTk1MTE2Mzk2NTM_2d6ec310-bf7c-4c02-917c-22d88444a931">9.8</ix:nonFraction> million to reduce the carrying amount of goodwill to $<ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzEwOTk1MTE2NDA1NjI_383680f8-0c49-4530-9419-ed03f8f9b20f">17.4</ix:nonFraction>&#160;million as of December 31, 2021. Should the market value of the Company&#8217;s common stock continue to decline, additional impairment charges may be recorded in the future. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzEwOTk1MTE2NDAzNjc_eb282c08-c3c8-4750-9754-91f2c0b1715c" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward of the Company&#8217;s goodwill and accumulated impairment losses.  </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"><tr><td style="width:1.0%"></td><td style="width:80.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, gross amount, at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzEtMi0xLTEtMzAzNzU_59ba0a50-14f9-433d-ada6-66594768c9bb">27,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment loss, at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzItMi0xLTEtMzAzODA_92a73d24-b457-45e5-922d-d672bd8e1236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzQtNi0xLTEtMjkxOTY_b54002c4-2a0c-43bb-9500-a2f6508c1efa">27,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzUtNi0xLTEtMjkxOTY_68106217-2ddc-447c-806d-262e623460fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzYtNi0xLTEtMjkxOTY_efabfb5b-9b00-4e3d-9d34-8a3d6ea80187">9,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzctNi0xLTEtMjkxOTY_126289a9-54c2-4a56-9daa-8bb64aba7126">17,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90ZXh0cmVnaW9uOmJmZjcwNTk0NGY4NTQ3ZjZhZTcxNDAyNTMyYTgxNDU4XzI2NA_9dcb5b45-99be-44d4-a1d2-e101a698085e" continuedAt="i5e8abd94041a46aa80d81c4958a7fd5d" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i5e8abd94041a46aa80d81c4958a7fd5d" continuedAt="i297490914c5c4b289ec794acd4cd4afa"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90ZXh0cmVnaW9uOmJmZjcwNTk0NGY4NTQ3ZjZhZTcxNDAyNTMyYTgxNDU4XzI2Mw_d1473b4e-5a63-4b5b-9413-303fcb385867" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.896%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if504bda89d6b40c4857f885c3a5dd5be_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzEtMS0xLTEtMjA5NDA_9bc6edc9-e3a6-4df4-8fb4-e4f36d87034d">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e4745ffaea4f638a14e69eb5e2e780_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzEtMy0xLTEtMjA5NDA_47db4429-3915-4700-bad4-65f6863c050b">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee282cd049d2469f96e0d412a363884a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzItMS0xLTEtMjA5NDA_46b58041-1061-4b10-a16d-0a145e9592a4">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife90678c9c334675bb4fb9c5a64484fc_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzItMy0xLTEtMjA5NDA_c7a84bab-5a77-4e78-86f6-c0cc7fe8a516">910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad13cbd0ab104e089c980b940e3d7116_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzMtMS0xLTEtMjA5NDA_c3bc71f5-c908-4f65-9825-b0be7cf31ed1">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79fc5b3e5da4f21bc81f95a0112b9b9_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzMtMy0xLTEtMjA5NDA_cddfff24-88f8-4761-b524-ae0bae093021">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc702a2739324d80b4ef222aca509be2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzQtMS0xLTEtMjA5NDA_13a5d065-4fee-4ced-943f-ffb48292338a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38293cc2bff405a9e1e6bc59761a28b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzQtMy0xLTEtMjA5NDA_a684f624-2c31-417f-a71a-3c7ed7283521">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06df3f074d7447b6806efcb5f9c98d10_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzUtMS0xLTEtMjA5NDA_51c9b0fc-782b-4354-be0e-7f7d4a38f502">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc7cf15c96346e19207edcffa291f0c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzUtMy0xLTEtMjA5NDA_581c4b17-0ae4-46a9-b3fd-bdf9ce0267be">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzYtMS0xLTEtMjA5NDA_e43e16ec-cfac-4804-84e3-2dc010f61478">2,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzYtMy0xLTEtMjA5NDA_ced03ebf-4715-402e-af49-be705a44329f">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzctMS0xLTEtMjA5NDA_5ca6c871-24e3-4e80-934f-0eee84d49890">724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzctMy0xLTEtMjA5NDA_71072401-aaeb-4158-98a4-ac3108f95c92">274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzgtMS0xLTEtMjA5NDA_cbbf7999-7d24-43ef-bbac-edf721186d11">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzgtMy0xLTEtMjA5NDA_58be4b24-464a-4bea-bd4e-1624ec290110">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i297490914c5c4b289ec794acd4cd4afa">Depreciation and amortization expense related to property and equipment was approximately $<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90ZXh0cmVnaW9uOmJmZjcwNTk0NGY4NTQ3ZjZhZTcxNDAyNTMyYTgxNDU4XzE3OQ_12750ced-9a54-44a5-97c1-1b1446a8af4e">499</ix:nonFraction> thousand, $<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90ZXh0cmVnaW9uOmJmZjcwNTk0NGY4NTQ3ZjZhZTcxNDAyNTMyYTgxNDU4XzE4Mw_c61c0936-15f3-44d8-96b5-b663d6141eca">351</ix:nonFraction> thousand, and $<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90ZXh0cmVnaW9uOmJmZjcwNTk0NGY4NTQ3ZjZhZTcxNDAyNTMyYTgxNDU4XzE5MQ_24c57391-80fd-4c37-a4d7-f6653943422a">103</ix:nonFraction>&#160;thousand for the years ended December 31, 2021, 2020 and 2019, respectively.</ix:continuation> </span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i71bd745117f84268bb875bce92ea6db3_163"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="xfor:AccruedExpensesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90ZXh0cmVnaW9uOjcyODY4ZGM5MjU4NTRiOTZiMWRkNWM5ZDkwOGM1MDJmXzY5_8d9de8d4-ad6b-4af3-80a2-9f916a3e4a08" continuedAt="ifbf91889a82b41088671b40f28549d07" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="ifbf91889a82b41088671b40f28549d07"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90ZXh0cmVnaW9uOjcyODY4ZGM5MjU4NTRiOTZiMWRkNWM5ZDkwOGM1MDJmXzcw_f8a9f141-7a45-434e-bb05-9deb083506bb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzEtMS0xLTEtMjA5NDA_999fd609-33ca-4880-932d-2956e81b1683">5,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzEtMy0xLTEtMjA5NDA_a0e08511-789e-4c58-8335-f6e7bead7098">3,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="xfor:AccruedExternalResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzItMS0xLTEtMjA5NDA_e415eea4-42f9-47e1-b338-88cabdd42b46">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="xfor:AccruedExternalResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzItMy0xLTEtMjA5NDA_31537070-6c1e-4eac-a891-6f92e230e282">3,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzMtMS0xLTEtMjA5NDA_177ec833-825d-4c12-b26d-847da1f4da89">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzMtMy0xLTEtMjA5NDA_15b7d11b-b49a-42b1-bf57-ef257da7736e">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzQtMS0xLTEtMjA5NDA_f3a98ae8-79ab-4aa1-8f4c-ef21cc7262c4">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzQtMy0xLTEtMjA5NDA_8db89237-04d3-42d2-86d2-21f862b57486">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzUtMS0xLTEtMjA5NDA_6d83eaa5-4885-408d-9238-081daac35ebd">7,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzUtMy0xLTEtMjA5NDA_afa0a44e-a0af-4d1e-b5cc-b031370c6d6d">8,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="i71bd745117f84268bb875bce92ea6db3_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzkzNjA_261cd5be-cc87-4577-9a48-ffdbc4aa05bc" continuedAt="i749587476044456c88c0d6320473ec13" escape="true">LONG-TERM DEBT</ix:nonNumeric></span></div><ix:continuation id="i749587476044456c88c0d6320473ec13" continuedAt="i648a2ae3b93e4469af662de3512d27d0"><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzkzNjE_e596ee13-0375-4e13-873b-d213f30d1dbd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzEtMS0xLTEtMjA5NDA_c213fbd0-0d35-401b-acc4-50e4ba2c3bdb">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzEtMy0xLTEtMjA5NDA_0007bfc6-a1a6-450e-9a12-de82575a3766">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt premium, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzItMS0xLTEtMjA5NDA_1d9ccc8f-d117-4440-9ed7-47943d3f53be">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzItMy0xLTEtMjA5NDA_4f0d568d-7eaa-4802-bdb8-e186e849c5f3">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative accrual of end of term payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" sign="-" name="xfor:AccretionOnLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzMtMS0xLTEtMjA5NDA_2391077b-43aa-4ad2-9be5-92d38d54f795">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" sign="-" name="xfor:AccretionOnLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzMtMy0xLTEtMjA5NDA_b15a4ad2-73f9-4f58-be72-b793ca0bdec5">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="xfor:LongTermDebtIncludingAccretion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzQtMS0xLTEtMjA5NDA_50762749-50d4-42c5-bdae-21bedfd18adc">33,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="xfor:LongTermDebtIncludingAccretion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzQtMy0xLTEtMjA5NDA_ca25c375-f4ab-42dc-84ee-d4b50d95f3f5">33,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzUtMS0xLTEtMjIwNDE_887f25d6-214d-4dab-aecd-afa0379ba15b">795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzUtMy0xLTEtMjIwNTk_0495613f-3b4a-4f0d-9ffb-2f90eb658b22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzYtMS0xLTEtMjIwNDE_e9b5f40c-e713-43f4-8314-5538b75abb01">33,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzYtMy0xLTEtMjIwNTk_09e15300-2830-4cca-b6ce-ab01341fdb43">33,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hercules Loan Agreements-&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into the Hercules Loan Agreement, as amended in June 2019, December 2019, March 2020, December 2020, and February 2022, with Hercules, under which the Company has borrowed an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i0e2a6d6e83924b2daa8ee08212fd793d_D20181001-20210331" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NTE2Nzk_8ff4a9db-0feb-48c5-ba11-b393139c0922">32.5</ix:nonFraction>&#160;million of term loans to date. The Hercules Loan Agreement provides for maximum borrowings of up to $<ix:nonFraction unitRef="usd" contextRef="i6605f338210c4eb6af0923abf8445fec_I20201221" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2Mzk3MzM_53691066-140a-4195-bc8c-85627242e547">50.0</ix:nonFraction> million, which include, subject to Hercules investment committee&#8217;s sole discretion, a right of the Company to request that Hercules make additional term loan advances in an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="ia221aaf88dc34cd18ee78f500786ae65_I20201221" decimals="-3" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDAxOTM_81ef8c44-8456-4af1-9262-7581b3235ff6">17.5</ix:nonFraction> million through December 31, 2022. Borrowings under the Hercules Loan Agreement accrue interest at a variable rate equal to the greater of (i)&#160;<ix:nonFraction unitRef="number" contextRef="i441b3dd525cf4ccba63a00aba76d1e05_D20190601-20190630" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2MzkzNDU_0204841f-e472-4931-a479-2078cf7c3c25">8.75</ix:nonFraction>%, or (ii)&#160;<ix:nonFraction unitRef="number" contextRef="iedf2b97d940c42ffbf9fc1761bc75923_D20190601-20190630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2MzkzNTc_b1fcf7bc-7281-4eb3-a72f-b95e588a9d66">8.75</ix:nonFraction>% plus&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;prime rate minus <ix:nonFraction unitRef="number" contextRef="i4cd6cf3938894c7ebded737f6ab8df03_D20190601-20190630" decimals="2" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2Mzk0MDc_4a4d92e0-50d6-4220-a9b2-657741eac762">6.0</ix:nonFraction>%.&#160;&#160;In an event of default, and until such event is no longer continuing, the interest rate applicable to borrowings under the Amended and Restated Loan Agreement would be increased by <ix:nonFraction unitRef="number" contextRef="i441b3dd525cf4ccba63a00aba76d1e05_D20190601-20190630" decimals="2" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2Mzk2NDk_d2ba2ba8-105a-410e-9df3-18e90011f9e1">4.0</ix:nonFraction>%.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i648a2ae3b93e4469af662de3512d27d0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Hercules Loan Agreement are repayable in monthly interest-only payments through January 1, 2023, and in equal monthly payments of principal and accrued interest from February 1, 2023 until the maturity date of the loan, which is July 1, 2024. The Company may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium of up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i03e6b6f8a9c740948d0f053e9e9b88c3_I20211231" decimals="INF" name="xfor:DebtInstrumentPrePaymentPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzI3NDg3NzkwOTM0MjY_b5b1cfe6-2b46-44bb-b020-2cf7c64d1d04">1.0</ix:nonFraction>% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the principal amount outstanding as of the date of repayment.&#160;In addition, the Hercules Loan Agreement provides for payments of $<ix:nonFraction unitRef="usd" contextRef="i58af1e2574894b2ea2b9227befb6de70_D20220101-20220101" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDA4ODk_41538761-77f4-4ddd-9821-b75f3a89a37c">0.8</ix:nonFraction> million, which was settled on January 1, 2022, $<ix:nonFraction unitRef="usd" contextRef="i044152b2a50d4484a5e19b0c3e40e9a3_D20230701-20230701" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDA4OTQ_4bf0b420-3fbe-4efd-b578-72c1a8d1061c">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1e9fe3e1ad55446c8ece9e5d397f6127_D20240701-20240701" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDA5MDI_23e5a9e3-9149-474d-906f-a7e47c7074f3">0.8</ix:nonFraction>&#160;million payable on July 1, 2023 and July 1, 2024, respectively, which payments are accelerated upon the prepayment of the borrowings upon the Company&#8217;s election on upon default of the loan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the Company&#8217;s personal property and other assets except for their intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Hercules Loan Agreement, effective as of the earlier of (a) certain specified events impacting the Company&#8217;s Phase 3 trial of mavorixafor for the treatment of WHIM and (b) September 1, 2022, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount greater than or equal to the greater of $<ix:nonFraction unitRef="usd" contextRef="i815e2b3d5b21461cb22c4cf956eab5d1_I20211231" decimals="-3" name="xfor:LineOfCreditCovenantMinimumCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDM0NjA_b2c75f00-635f-4a8b-9ec1-f10288bd60df">30.0</ix:nonFraction> million or six multiplied by a metric based on prior months&#8217; cash expenditures; provided, however, that from and after the Company&#8217;s achievement of certain financing milestones through June 30, 2022, the Company must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i815e2b3d5b21461cb22c4cf956eab5d1_I20211231" decimals="-3" name="xfor:LineOfCreditCovenantMinimumCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NTI0NDM_b2c75f00-635f-4a8b-9ec1-f10288bd60df">30.0</ix:nonFraction> million. Following the achievement of certain operational performance milestones, the required level shall be reduced to the greater of $<ix:nonFraction unitRef="usd" contextRef="ie8783c36c8464089a5c02a0e660c689e_I20211231" decimals="-3" name="xfor:LineOfCreditCovenantMinimumCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDM2OTk_99cc5c5f-c655-4e70-bd74-61c09b738fa7">20.0</ix:nonFraction> million, or, if the Company had not met the financing milestones noted above, three multiplied by the current cash expenditures metric; and provided further, that subject to the achievement of additional operational milestones, this covenant will be extinguished. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hercules Loan Agreement restricts the Company&#8217;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized interest expense under the Hercules Loan Agreement as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the years ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a84700b1c1468b831735d87f46a242_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzItMS0xLTEtMjIzNTE_867f551d-a0d3-4064-ac5e-527514b3f5d2">3,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11078f4d8a0419ea19c205259a627ba_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzItMy0xLTEtMjIzNTE_993c58b1-5a1d-4391-b1b6-469aeb9b5199">2,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21716a46c2a345a29fc88ac84ad6249e_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzItNS0xLTEtMjIzNTE_9e42fed2-06d9-4356-8ddd-0862fbd48a40">1,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a84700b1c1468b831735d87f46a242_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzMtMS0xLTEtMjIzNTE_54f4967e-ce0d-4682-95e2-98e3baecc968">756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11078f4d8a0419ea19c205259a627ba_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzMtMy0xLTEtMjIzNTE_e8869c39-191c-40be-bba0-93db97fd50c4">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21716a46c2a345a29fc88ac84ad6249e_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzMtNS0xLTEtMjIzNTE_e9cbfa57-cbf0-4ffb-a232-43e7fec932a3">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual effective interest rate on the Hercules Loan Agreement as of December&#160;31, 2021 is <ix:nonFraction unitRef="number" contextRef="i03e6b6f8a9c740948d0f053e9e9b88c3_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzkxMjM_0ac3c7bc-e0c0-449e-976b-8749f4fab583">10.7</ix:nonFraction>%. There were <ix:nonFraction unitRef="usd" contextRef="i7f823743b9a246098193cea2dbb84829_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzkxNDM_a06edf4b-ff78-4932-9bf5-a20c0a91ab0a">no</ix:nonFraction> principal payments due or paid under the Hercules Loan Agreement during the year ended December&#160;31, 2021.</span></div><div style="margin-top:18pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzkzNjI_b5b4570b-4e9e-40ac-9c40-619d8a91674d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, future principal payments and accrued end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"></td><td style="width:76.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.026%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTo4ZGY3NGZlNDdhNzQ0MGFjODQwODZlNGM1NDQwMzY1Zi90YWJsZXJhbmdlOjhkZjc0ZmU0N2E3NDQwYWM4NDA4NmU0YzU0NDAzNjVmXzEtMS0xLTEtMjA5NDA_794261e6-8ec9-48c0-8888-305f9334e7b7">795</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTo4ZGY3NGZlNDdhNzQ0MGFjODQwODZlNGM1NDQwMzY1Zi90YWJsZXJhbmdlOjhkZjc0ZmU0N2E3NDQwYWM4NDA4NmU0YzU0NDAzNjVmXzItMS0xLTEtMjA5NDA_1eabb795-b0f9-4cb7-825f-567d75306d5b">21,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTo4ZGY3NGZlNDdhNzQ0MGFjODQwODZlNGM1NDQwMzY1Zi90YWJsZXJhbmdlOjhkZjc0ZmU0N2E3NDQwYWM4NDA4NmU0YzU0NDAzNjVmXzMtMS0xLTEtMjA5NDA_bc2514e7-4d76-41be-8959-81385364a411">11,391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including end-of-term payments</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTo4ZGY3NGZlNDdhNzQ0MGFjODQwODZlNGM1NDQwMzY1Zi90YWJsZXJhbmdlOjhkZjc0ZmU0N2E3NDQwYWM4NDA4NmU0YzU0NDAzNjVmXzUtMS0xLTEtMjA5NDA_594a3ebd-5e40-48c8-9a27-8878c5c5fa13">33,657</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:18pt"><span><br/></span></div><div style="margin-top:18pt"><span><br/></span></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_169"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzY1MTc_cc37db75-7569-4691-82ea-47693575f256" continuedAt="i5da1b0d473d846f6a263c8cb7fb98a0a" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i5da1b0d473d846f6a263c8cb7fb98a0a" continuedAt="i8bc2790fc3b2436596c575b91e2a8cbb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements for its facilities in Boston, Massachusetts, which is the Company&#8217;s principal executive offices; Vienna, Austria, which is the Company&#8217;s research and development center; and Waltham, Massachusetts, which the Company has sublet to a third party. The Company previously had a lease agreement for a facility in Cambridge, Massachusetts, which served as its prior corporate headquarters. There are no restrictions or financial covenants associated with any of the lease agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Boston Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i70dd855dda9a41448556d07389f6ef62_D20191111-20191111" decimals="0" name="xfor:CurrentOfficeSpaceUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzQ5NDc4MDIzNTU4NTc_36e6d722-b394-4ec1-9b87-8eb01e9b95e1">28,000</ix:nonFraction> square feet of office space in Boston, Massachusetts (&#8220;Boston Lease&#8221;), which leased was entered into in November 2019 and serves as the Company&#8217;s headquarters. Base rental payments are approximately $<ix:nonFraction unitRef="usd" contextRef="i70dd855dda9a41448556d07389f6ef62_D20191111-20191111" decimals="-3" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzQ5NDc4MDIzNTU4NTg_65f2f88c-2cd5-4c97-a639-7c29091bc3c5">1.0</ix:nonFraction> million annually, plus certain operating expenses.  The term of the Boston Lease will continue until November 2026, unless earlier terminated. The Company has the right to sublease the premises, subject to landlord consent and also has the right to renew the Boston Lease for an additional <ix:nonNumeric contextRef="iec7ca8d65d8941a693c86e1d5e2e006d_I20191111" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzQ5NDc4MDIzNTU4NTk_152146b9-7455-4ae2-be39-1449185f8e43">five years</ix:nonNumeric> at the then prevailing effective market rental rate. The Company is required to maintain a security deposit in the form of a letter of credit for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the benefit of the landlord.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Boston lease, the Company participated in the construction of the office space and incurred construction costs to prepare the office space for its use, which have been partially reimbursed by the landlord. The Company concluded that these construction costs generate and enhance the landlord&#8217;s assets, and, as such, unreimbursed construction costs incurred to prepare the office space for its use have been classified a part of the right-of-use asset. The commencement date for the Boston Lease was September 1, 2020 upon substantial completion of the landlord's asset. On the commencement date, the Company recognized a lease liability of $4.6&#160;million reflecting the future rent payments for the term of the Boston Lease discounted at the Company&#8217;s collateralized borrowing rate, and a right-of-use asset of $8.0&#160;million measured as the lease liability plus rent payments made and unreimbursed construction costs incurred prior to the commencement date. The Company began recognizing rent expense &#160;&#160;&#160;&#160;following the commencement date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Waltham Lease&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i96305963db034551a189b94796a2792a_D20190313-20190313" decimals="-3" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzIxODU_e611d172-452c-425d-8001-cd55fc3ceeef">6,000</ix:nonFraction> square feet of office space in Waltham, Massachusetts (&#8220;Waltham Lease&#8221;). The Waltham Lease, as amended, commenced on January 1, 2019, and expires approximately <ix:nonNumeric contextRef="i649b92ccef0a45d48c9c43fe57d79944_I20190313" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzIzMzU_a5c5ec97-557c-4c9c-b20d-268643f23924">5</ix:nonNumeric> years from the commencement date. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="i96305963db034551a189b94796a2792a_D20190313-20190313" decimals="-3" name="xfor:AggregateBaseRent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzIzOTc_1c8ddee7-37a7-4c4c-8c15-0f9ba480bdfb">263</ix:nonFraction>&#160;thousand annually. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#8217; right-of-use assets or lease liabilities. The Company is subleasing the space to a third party for the duration of the lease. The right-of-use asset is being amortized to rent expense over the <ix:nonNumeric contextRef="ie206b7a7c0f04cad9646717d502a7f9d_D20190313-20190313" name="xfor:OperatingLeaseRightOfUseAssetAmortizationTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzI4MDI_85e6819d-6933-487f-826d-fefc07e7f000">5</ix:nonNumeric> year term of the lease.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vienna Austria Leases&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has an operating lease, as amended, for approximately <ix:nonFraction unitRef="sqft" contextRef="ib03c7b0ffaa94e54a5fcb3da8d3bffcd_D20190313-20190313" decimals="-2" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzI5MTg_228dbe01-c1a4-4ab6-8c0a-c6471892f024">400</ix:nonFraction> square meters of laboratory and office space in Vienna, Austria, which commenced on March 1, 2019, as amended, for a term of <ix:nonNumeric contextRef="ibdb04900d7d94d69b89541fbd440e0f4_I20190313" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzMwNDg_f6c64689-fae7-426c-986a-22802c1408c6">2</ix:nonNumeric> years terminating in April 2021. The annual base rent for the previous lease was approximately $<ix:nonFraction unitRef="usd" contextRef="ib03c7b0ffaa94e54a5fcb3da8d3bffcd_D20190313-20190313" decimals="-3" name="xfor:AggregateBaseRent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzMxMzE_e0de4d08-2024-4209-9dc6-b83b7227ee4c">154</ix:nonFraction>&#160;thousand. In September 2020, the Company entered into a new operating lease for approximately <ix:nonFraction unitRef="sqft" contextRef="i30884f0e4d634f7b8bc5bacaa38c8f3e_D20200901-20200901" decimals="-2" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzM0NDE_663d1477-f839-4b2f-9abb-5bae40d25917">1,200</ix:nonFraction> square meters of laboratory and office space in Vienna, Austria (&#8220;Vienna Lease&#8221;), which commenced in February 2021 following construction of laboratory and office space for a term of <ix:nonNumeric contextRef="ief7e7ceedd0a4127b22dedc2456e45ed_I20200901" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzM1NzM_27d1f1b4-769d-4768-b4e0-1f3e1a5b7fb4">7</ix:nonNumeric> years. The Company contributed $709 thousand to building improvements, which are classified as part of the right-of-use asset. The Company recorded a right-of-use asset and associated lease liabilities upon the commencement of the Vienna Lease in the first quarter of 2021. The annual base rent for the Vienna Lease, following a <ix:nonNumeric contextRef="i5dfd25fd846b472ba0ec52e244589a8e_D20210201-20210731" name="xfor:LesseeOperatingLeaseRentFreePeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzM3Njg_3e1d7690-af18-443c-be46-1e4aa4055dd6">6</ix:nonNumeric>-month rent free period, will be approximately $<ix:nonFraction unitRef="usd" contextRef="i30884f0e4d634f7b8bc5bacaa38c8f3e_D20200901-20200901" decimals="-3" name="xfor:AggregateBaseRent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzM4MTc_5cf039aa-0b24-42f8-9543-82fb68407879">300</ix:nonFraction> thousand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cambridge Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In August 2017, the Company entered into a non-cancellable operating lease agreement for office space of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately <ix:nonFraction unitRef="sqft" contextRef="i7af38d4d2ff7443faf6ac2b41a13a62e_D20210101-20211231" decimals="-3" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzQ5NDc4MDIzNTU4NzM_a625449c-f45b-4be1-b5bf-11d47f5666cc">13,000</ix:nonFraction> square feet in Cambridge, Massachusetts (&#8220;Cambridge Lease&#8221;), which had an original expiration date of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 31, 2022. Base rent was approximately $<ix:nonFraction unitRef="usd" contextRef="i7af38d4d2ff7443faf6ac2b41a13a62e_D20210101-20211231" decimals="-3" name="xfor:AggregateBaseRent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzQ5NDc4MDIzNTU4ODE_84652321-65f7-4e5a-9413-75530bbb49b6">832</ix:nonFraction>&#160;thousand annually and the monthly rent expense was recognized on a straight-line basis over the term of the lease as the Company amortizes the associated operating lease right-of-use asset. The Company reached an agreement with the landlord on July 17, 2020 to terminate the lease effective September 30, 2020 in exchange for a fee. The Company accounted for the lease modification prospectively from the date of the termination through the new lease termination date of September 30, 2020, at which time the right-of-use asset and associated lease liabilities were retired from the consolidated balance sheet. The Company was required to maintain a letter of credit of $264&#160;thousand, secured by restricted cash, for the benefit of the landlord through December 31, 2020.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i8bc2790fc3b2436596c575b91e2a8cbb"><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzY1MTg_b5d05669-3916-40d6-a99a-a1a6122479e2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three years ended December&#160;31, 2021, 2020, and 2019 were as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:40.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzItMi0xLTEtMjA5NDA_df811954-249d-471c-b0da-0204c4fb8ca2">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzItNC0xLTEtMjA5NDA_3290b3f1-76bb-441e-a8b6-1c9fc40683f1">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzItNi0xLTEtMjY2MDY_e49edd92-91ef-4a1b-a63e-ca2bf55fca01">827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzMtMi0xLTEtMjA5NDA_d7a13d3a-ab8e-414b-a571-b31af66766bc">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzMtNC0xLTEtMjA5NDA_a4068e34-6c95-461d-8e5d-0ccfee5b7532">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzMtNi0xLTEtMjY2MjU_9c10ff56-38cc-4218-825b-03d9fd382276">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzQtMi0xLTEtMjA5NDA_9cf5c70a-b530-401f-94ce-c7c8c97bade4">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzQtNC0xLTEtMjA5NDA_3c894205-de91-48f6-a844-7f751bdb1e31">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzQtNi0xLTEtMjY2MzI_0cd89f93-47bf-4975-80e0-a186eb9f27f1">949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzctMi0xLTEtMjA5NDA_a76f78af-384f-4a92-b6e7-dacd35448ac6">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzctNC0xLTEtMjA5NDA_c38e92d1-6fd8-4f08-b652-f2e0edb0f0d4">3,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzctNi0xLTEtMjY2Mzk_ed3a49a7-dccf-4fac-a68c-6cb137c6e050">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Leased assets obtained in exchange for new operating lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:97%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzgtMi0xLTEtMjA5NDA_aca0ffbf-42c9-4a8b-be0a-52c2810514eb">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzgtNC0xLTEtMjA5NDA_f5ed7876-ef0d-4bff-9214-6a8409752ebe">5,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzgtNi0xLTEtMjY2NDY_74735c6d-ddf1-4b49-88fd-4f4ca2361dff">484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzktMi0xLTEtMjA5NDA_8f46ec62-7f11-4249-a14c-5b1241564d85">5.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzktNC0xLTEtMjA5NDA_888e780a-5637-4ab5-ae25-0bd014534e21">5.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzktNi0xLTEtMjY2NTM_0f9d9568-75f0-46db-9016-c5899d5eb401">3.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzEwLTItMS0xLTIwOTQw_148293db-d11f-4b16-9542-c2af17930089">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzEwLTQtMS0xLTIwOTQw_b8bff499-ece9-4379-b96a-7b1e04d670cf">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzEwLTYtMS0xLTI2NjYw_e76acbee-377e-4854-b0a3-7cf91cfa0dd7">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzExLTItMS0xLTIwOTQw_c959da6a-af4b-4fcd-af4a-4eff2f912fda">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzExLTQtMS0xLTIwOTQw_0d4ff793-4099-468c-b2da-ea604938fb95">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzExLTYtMS0xLTI2NjY3_7e282d5c-2122-48b5-92a7-63db425fd3bb">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzY1MTQ_515786ed-2bdc-4b07-b5f0-f150f606ecb8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities due under lease agreements that have commenced as of December&#160;31, 2021 are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"><tr><td style="width:1.0%"></td><td style="width:78.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzEtMS0xLTEtMjA5NDA_9b20420e-6fed-46cf-9a85-50d1f97c9e54">1,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzItMS0xLTEtMjA5NDA_836f8d70-4229-44ea-9b5a-f3ad979442d2">1,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzMtMS0xLTEtMjA5NDA_d88c0eec-024f-4fba-808c-4d70c10700c9">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzQtMS0xLTEtMjA5NDA_54847360-329b-48dd-906e-0bfe9dcf4ab2">1,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzUtMS0xLTEtMjA5NDA_79a1de07-34de-4b41-beee-ffdd579c9b35">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzYtMS0xLTEtMjA5NDA_daca3dca-8c1b-4a82-b4e9-73280e66f487">7,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzctMS0xLTEtMjA5NDA_e64b7c92-160e-44e6-b477-817b14a88dfc">1,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzgtMS0xLTEtMjA5NDA_cb673c2c-6b2f-487a-8c9b-82a1e375870d">5,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div id="i71bd745117f84268bb875bce92ea6db3_172"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzIvZnJhZzpiOGQ4NGM4MzU3Yzk0ZmIxYjViMTgyNmZmODFjMjU1YS90ZXh0cmVnaW9uOmI4ZDg0YzgzNTdjOTRmYjFiNWIxODI2ZmY4MWMyNTVhXzMwNzE_59183d0d-6681-466d-9ddb-56a2eaa2d816" continuedAt="i8304ff135d8740adb34ece3bcbcdbdf0" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i8304ff135d8740adb34ece3bcbcdbdf0" continuedAt="i9acadb6e3d4b4f7fa94b69e37415a1c6"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with clinical research organizations (&#8220;CROs&#8221;) pursuant to which the Company and the CROs are conducting clinical trials of mavorixafor&#160;for the treatment of WHIM syndrome, Waldenstr&#246;m&#8217;s and CN. The Company may terminate these agreements by providing notice pursuant to the contractual provisions of such agreements and would incur early termination fees. The Company also has agreements with contract manufacturing organizations (&#8220;CMOs&#8221;) for the production of mavorixafor for use in clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 3 for a summary of the Company&#8217;s license agreements, which commit the Company to contingent milestone and royalty fees based on future operational events. In March 2021, the Company terminated its license agreement with Adimab LLC and has no further obligations on the agreement. &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i9acadb6e3d4b4f7fa94b69e37415a1c6"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31, 2021 or December&#160;31, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div></ix:continuation><div style="margin-top:18pt"><span><br/></span></div><div id="i71bd745117f84268bb875bce92ea6db3_175"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzQ5NDc4MDIzMzYxMDI_4e8f10b1-9a35-42ab-8142-7d19eb7c3b7d" continuedAt="i59a83a9e340942cb925a6f99536d590e" escape="true">PREFERRED AND COMMON STOCK WARRANTS</ix:nonNumeric></span></div><ix:continuation id="i59a83a9e340942cb925a6f99536d590e" continuedAt="i9217451fb9594402a413497d9b5e21e0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, the Company issued warrants for the purchase of its preferred stock and had classified these preferred stock warrants as a liability on its consolidated balance sheet as the warrants were deemed to be freestanding financial instruments that may have required the Company to transfer assets upon exercise. The liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and was subsequently remeasured to fair value as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss. Upon the closing of the Merger, pursuant to the Merger Agreement, all of the outstanding X4 preferred stock was converted to common stock and the X4 preferred stock warrants converted to warrants for the purchase of common stock. The Company assessed the features of the warrants and determined that they qualified for classification as permanent equity upon the closing of the Merger. Accordingly, the Company remeasured the warrants to fair value upon the closing of the Merger, which was $<ix:nonFraction unitRef="usd" contextRef="i8f4a3cbd5679460ab78ce920e0af42b2_I20190313" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzExNTE_1a0cc4ea-6a05-48bc-ae4a-a36b4aa5cc36">5.2</ix:nonFraction>&#160;million at March&#160;13, 2019, with $<ix:nonFraction unitRef="usd" contextRef="i8b1ee4ca82b14441a5df67868c7c2fee_I20210331" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzExNzg_3111a7db-668d-4d45-a4fd-020882980af1">288</ix:nonFraction>&#160;thousand of expense recorded during the three months ended March&#160;31, 2019. Upon the closing of the Merger, the warrant liability was reclassified to additional paid-in capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its issuance of common stock in public offerings that closed on April 16, 2019 and November 29, 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="i8f4b97ac998545cd8301f39db19e7d4d_D20190416-20190416" decimals="INF" name="xfor:ClassOfWarrantOrRightIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzE0ODk_663070fc-b0a0-494c-9a53-1bdc624c60a2">3,900,000</ix:nonFraction> Class A warrants, which are exercisable for shares of the Company's common stock, and <ix:nonFraction unitRef="shares" contextRef="i5a1dd2dc5c7e49e4a433ec1811b9e03c_D20191129-20191129" decimals="INF" name="xfor:ClassOfWarrantOrRightIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzE1Nzg_994aa8d8-e8b9-4b94-9756-3310d1acd091">5,416,667</ix:nonFraction> Class B warrants, which are exercisable for shares of the Company's common stock or prefunded warrants to purchase shares of the Company's common stock. The Class A warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9f1955aa1b534854878550a58ccbf898_I20190416" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzE3ODE_053dfafe-e329-4d6b-bae7-3df867a7b366">13.20</ix:nonFraction> per warrant, expire on April 15, 2024 and were immediately exercisable upon issuance. The Class B warrants were immediately exercisable upon issuance, had an initial exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i30903cfad3dd426ab86057983e126f26_I20191129" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzE5NTc_3e89c92b-0fb4-43cd-ac6e-abd0e1d3b7fa">15.00</ix:nonFraction> per share and expire on a date that is the earlier of (a) the date that is <ix:nonNumeric contextRef="i5faaf777d178421b83561c0fd16627c8_D20191126-20191126" name="xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzIxMDM_6966d187-5ef8-4e12-94a1-c5e33879845f">30</ix:nonNumeric> calendar days from the date on which the Company issues a press release announcing top-line data from its Phase 3 clinical trial of mavorixafor for the treatment of patients with WHIM syndrome (or, if such date is not a business day, the next business day) and (b) November 28, 2024. The Class B warrants have a contingent price adjustment feature pursuant to which the exercise price of the Class B warrants is adjusted to the lowest weighted average offering price at which the Company sells its common stock or certain securities convertible into or exercisable for the Company&#8217;s common stock in one or more subsequent offerings, if the weighted average offering price for such offering is below $<ix:nonFraction unitRef="usdPerShare" contextRef="i30903cfad3dd426ab86057983e126f26_I20191129" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODgwMzA_3e89c92b-0fb4-43cd-ac6e-abd0e1d3b7fa">15.00</ix:nonFraction>. As a result of the sales of the Company&#8217;s stock at below $<ix:nonFraction unitRef="usdPerShare" contextRef="i30903cfad3dd426ab86057983e126f26_I20191129" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzE2NDkyNjc0NDgxODk_3e89c92b-0fb4-43cd-ac6e-abd0e1d3b7fa">15.00</ix:nonFraction> during the year ended December 31, 2021, the exercise price of the Class B Warrants was ultimately adjusted to $<ix:nonFraction unitRef="usdPerShare" contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2MzUwMzk_db32f683-b169-4131-82e0-5d5c8badd82f">3.65</ix:nonFraction>. On March 23, 2021, the Company completed a private placement sale of its common stock priced at $8.70 and in the fourth quarter of 2021, the Company sold shares of its common stock at various price points, the lowest of which was $<ix:nonFraction unitRef="usdPerShare" contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg3OTc_fac2fc83-c8a3-48ec-8eb8-277aec0b64df">3.65</ix:nonFraction>. Accordingly, the exercise price of the Class B warrants was ultimately adjusted to $<ix:nonFraction unitRef="usdPerShare" contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg3OTg_3b94a08a-18bf-4200-9aab-6de31f67eaad">3.65</ix:nonFraction> as of December 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, in connection with the sale of its common stock in a private placement, the Company issued pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie12ba0825f69455cbb72564897ee2268_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4MDY_cf396b2e-378a-40cf-8601-d75884205ed1">50,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i997f64043d3c48f79904457d31ed425b_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4MTU_26302f55-00ce-41f5-9a55-3dd1c75ae92d">8.70</ix:nonFraction> per share of common stock (or $<ix:nonFraction unitRef="usdPerShare" contextRef="i358bda413e094c3b8732326b0da80424_I20210323" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4MzM_46834671-68c5-4726-8b58-dda58e7fa4c6">8.69</ix:nonFraction> per pre-funded warrant). The price per pre-funded warrant represents the price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i997f64043d3c48f79904457d31ed425b_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4MjQ_26302f55-00ce-41f5-9a55-3dd1c75ae92d">8.70</ix:nonFraction> per share sold in the private placement, minus the $<ix:nonFraction unitRef="usdPerShare" contextRef="ib4dbd5cea64e45acb7901cd8377332fd_I20210323" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4NDQ_4107738c-4107-4343-80c8-4d90323904ee">0.01</ix:nonFraction> per share exercise price of each such pre-funded warrant. The pre-funded warrants are exercisable, subject to certain beneficial ownership restrictions, at any time after their original issuance and will not expire. </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i9217451fb9594402a413497d9b5e21e0"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company entered into a securities purchase agreement pursuant to which it agreed to issue and sell to an investor, in a private placement, pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="iffc0e7e2a65446eaaa63bbb1c1af5689_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4NTg_c4c737a7-4a7a-4a8c-8abe-a91cd7c5de97">2,008,032</ix:nonFraction> shares of the Company&#8217;s common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i445218cd5fbd4b9cb04297a8f4e11d1d_I20211109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4NjY_7e2f45db-09da-422f-9a3b-659087cfaed0">4.97</ix:nonFraction> per pre-funded warrant (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">representing the price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iffc0e7e2a65446eaaa63bbb1c1af5689_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4ODM_fc07253f-75ab-4e15-8eea-bc248bec20d7">4.98</ix:nonFraction> per share in the private placement, minus the $<ix:nonFraction unitRef="usdPerShare" contextRef="i4b714c637a6647028b196f7cbd99f053_I20211109" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4NzU_be201be2-234b-402d-91d5-d767faa29a6d">0.01</ix:nonFraction> per share exercise price of each such pre-funded warrant)</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The pre-funded warrants are exercisable at any time after their original issuance and will not expire.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="xfor:ScheduleOfOutstandingWarrantsTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMzNjE_80003a11-8f03-43f4-b9ab-9dff0cbbc5c9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of outstanding warrants for the period ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Number of warrants</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term (Years)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable as of  December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzUtMS0xLTEtMjA5NDA_d8b91f98-956e-44ba-8f28-d5ed3ace036c">13,354,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="2" name="xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzUtMy0xLTEtMjA5NDA_b28b884a-e75f-454e-af1e-cc0f742e02bd">13.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" name="xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzUtNS0xLTEtMjA5NDA_b09cf4c4-ae6a-4fef-adc9-963903381e55">3.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="xfor:ClassOfWarrantOrRightIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzYtMS0xLTEtMjA5NDA_61fdb862-e5e8-4269-8799-89b275d6cadf">2,058,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="xfor:ClassOfWarrantOrRightExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzUtMS0xLTEtMjM5Njk_7e840ed9-c900-4b85-8e09-3f4b9098579d">2,130,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="xfor:ClassOfWarrantOrRightExpired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzYtMS0xLTEtMjM5OTM_4050bda9-b5c2-4aa0-b70f-6a8f93a3b5c3">25,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzctMS0xLTEtMjA5NDA_0c3e0594-8d20-42b4-820a-0aa39e4359f6">13,257,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="2" name="xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzctMy0xLTEtMjA5NDA_57bcc236-1e3e-4aff-be9d-b9781c266871">7.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzctNS0xLTEtMjA5NDA_9b69d004-5471-47e6-b3c1-aacf8a887d17">2.7</ix:nonNumeric></span></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company&#8217;s outstanding warrants to purchase shares of common stock consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.735%"><tr><td style="width:1.0%"></td><td style="width:33.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.425%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Issuable</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 25, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a2348e83e324b7b82456649b542f965_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEtMi0xLTEtMjA5NDA_ebf8f055-4f51-4980-9110-0dcd6aea39f1">5,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a2348e83e324b7b82456649b542f965_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEtNC0xLTEtMjA5NDA_e78fd035-478c-4c27-b959-75e73e2432cc">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 24, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 28, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1eea12429adf41968b80ecfea410785d_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzItMi0xLTEtMjA5NDA_d30aabaf-51b6-4761-a6b5-5e9f44d210c5">115,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1eea12429adf41968b80ecfea410785d_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzItNC0xLTEtMjA5NDA_da635238-9f5a-4e1c-b996-eef955c5ec2a">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 28, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 12, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33bf01c5e0304c2189fa034c75eb5241_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzQtMi0xLTEtMjA5NDA_9c07dee9-201a-4ab0-9333-0d1a197061f6">20,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33bf01c5e0304c2189fa034c75eb5241_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzQtNC0xLTEtMjA5NDA_71816b89-b723-4d30-94be-9947894398a8">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 12, 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 19, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5e02cabb20347e4812e2c13fe49c590_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzUtMi0xLTEtMjA5NDA_a92501bb-a21d-49f7-b061-325c33857491">20,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id5e02cabb20347e4812e2c13fe49c590_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzUtNC0xLTEtMjA5NDA_5090f534-023f-401b-83af-8beeab3671d0">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 19, 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 13, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09e8bb1f0686446a9a8a7b9564378965_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzYtMi0xLTEtMjA5NDA_ac76abcb-3cd4-4d4d-92a4-46c9354fbf00">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i09e8bb1f0686446a9a8a7b9564378965_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzYtNC0xLTEtMjA5NDA_a2caf6da-db49-4c47-b949-b7795c48f4f5">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 12, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 16, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22fa089c31854eeeaeeac178d4940454_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzctMi0xLTEtMjA5NDA_8b084ca4-5621-428d-9a5c-a1f7db92ee2a">3,866,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22fa089c31854eeeaeeac178d4940454_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzctNC0xLTEtMjA5NDA_c8bae902-c812-48dd-b952-fff18c820407">13.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzktMi0xLTEtMjA5NDA_59b4a8c7-9879-4115-a9c3-ee0762feedc7">5,416,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzktNC0xLTEtMjA5NDA_db32f683-b169-4131-82e0-5d5c8badd82f">3.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 28, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69c23f7b906f436f93692639aef06e09_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEwLTItMS0xLTIwOTQw_74ebe51c-daa9-43b6-971d-820d3506c611">1,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69c23f7b906f436f93692639aef06e09_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEwLTQtMS0xLTIwOTQw_9da3b7c5-12c1-4c0d-ab2a-a831338f0bdb">12.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 23, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie12ba0825f69455cbb72564897ee2268_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzExLTItMS0xLTIzMzMw_388d4a58-7729-4059-a959-c6d25530326a">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i997f64043d3c48f79904457d31ed425b_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzExLTQtMS0xLTIzMzQ0_6bc97754-1a33-465b-8791-ef8e7609625c">8.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 9, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffc0e7e2a65446eaaa63bbb1c1af5689_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEyLTItMS0xLTIzMzM3_cc8166a2-ee0a-49ff-9179-f490753806ca">2,008,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iffc0e7e2a65446eaaa63bbb1c1af5689_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEyLTQtMS0xLTIzMzUx_45716721-3436-4069-a2c4-82db56a2f122">4.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzExLTItMS0xLTIwOTQw_590ddb40-ce2a-4c07-8446-34a913663c5a">13,257,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) In November 2019, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="iddf524fe86fd469f8009f330de097712_I20191129" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyMTU_a56bd920-133b-40e8-8611-3f28f12ca214">11.999</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="i0bd64677f69e44d5ba2d48dae0391b34_I20191129" decimals="-5" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyNDU_6eeeb928-01e0-476e-95f4-461a60572897">21.0</ix:nonFraction> million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i0bd64677f69e44d5ba2d48dae0391b34_I20191129" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODk4MjE_bc8adfa9-f067-4f5a-b336-f1e1a734ea9c">0.001</ix:nonFraction> per pre-funded warrant. </span></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) In March 2021, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="i358bda413e094c3b8732326b0da80424_I20210323" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzI3NDg3NzkwNzM0MzY_46834671-68c5-4726-8b58-dda58e7fa4c6">8.69</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="ib4dbd5cea64e45acb7901cd8377332fd_I20210323" decimals="-3" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzI3NDg3NzkwNzM1Mzk_1160c256-6874-4c39-b5f9-c075cdd53ae2">435</ix:nonFraction> thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="ib4dbd5cea64e45acb7901cd8377332fd_I20210323" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODk4MjY_4107738c-4107-4343-80c8-4d90323904ee">0.01</ix:nonFraction> per pre-funded warrant.</span></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) In November 2021, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="i445218cd5fbd4b9cb04297a8f4e11d1d_I20211109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODk4NDE_7e2f45db-09da-422f-9a3b-659087cfaed0">4.97</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="ice9673b6146f4de3b3a39b86599af702_I20211130" decimals="-3" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODc0NTA_625099b9-b4a8-4a6b-a259-ba63b7c67aa7">10.0</ix:nonFraction> million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i4b714c637a6647028b196f7cbd99f053_I20211109" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODk4NDY_be201be2-234b-402d-91d5-d767faa29a6d">0.01</ix:nonFraction> per pre-funded warrant.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div id="i71bd745117f84268bb875bce92ea6db3_178"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzcyNDI_eb03b82b-90cc-4dd2-8ed0-92b69ed20506" continuedAt="i0b4e7ca73bba4e0abccf4b1e68ba515a" escape="true">COMMON STOCK, REDEEMABLE COMMON STOCK AND PREFERRED STOCK</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i0b4e7ca73bba4e0abccf4b1e68ba515a" continuedAt="ie84e3f81350943d8b883c51e89e30117"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s Certificate of Incorporation, as amended and restated, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzQ2Mw_4235cdd0-099b-4a64-9873-1e6ca1021ec7">125,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzUwNg_431e6f99-17e4-4cb3-980c-aa5b8629f7aa"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzUwNg_4e215f32-0a8c-4fe2-9f60-3609b24e1bfa">0.001</ix:nonFraction></ix:nonFraction> par value common stock. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. <ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="us-gaap:DividendsCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4Xzk2Mg_dd2a421a-fe4d-4959-b799-02a4c9ccbe79">No</ix:nonFraction> cash dividends </span></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ie84e3f81350943d8b883c51e89e30117" continuedAt="ic8e7cbe79ccb4ad5a4e101d276d72f46"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been declared or paid to date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;12, 2019, the Company sold <ix:nonFraction unitRef="shares" contextRef="ic04f75350f324bb38f14095eadb12430_D20190412-20190412" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEyNDc_07f44a8a-1316-4b4e-b1fe-b724024b80a5">5,670,000</ix:nonFraction> shares of common stock and, in lieu of common stock, prefunded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ibc57ac90fb9b4a139e8cb4ea7c012b1c_I20190412" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEzMzQ_6bbe01e8-66a3-45e9-bb5a-8a67214f01d6">2,130,000</ix:nonFraction> shares of common stock, and accompanying Class&#160;A warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ic5d3611fd3c8401fb735dc5668ae2bdd_I20190412" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE0MDc_cec05837-4c72-4333-9c6e-a39f250154ce">3,900,000</ix:nonFraction> shares of its common stock. The common stock was issued at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f7afe3aab394972900909f3eb5f8d6e_I20190412" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE0OTQ_978709dc-54d0-4876-8571-fb425e421eb0">11.00</ix:nonFraction> per share and accompanying Class&#160;A warrant and the prefunded warrants were issued at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc57ac90fb9b4a139e8cb4ea7c012b1c_I20190412" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE1OTM_4f8ab273-d735-4e2d-9ac9-289956368958">10.999</ix:nonFraction> per prefunded warrant and accompanying Class&#160;A warrant. The Class&#160;A warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic5d3611fd3c8401fb735dc5668ae2bdd_I20190412" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE2OTk_f6b95a7b-a9e2-4728-bb80-58d389d42018">13.20</ix:nonFraction>, will expire <ix:nonNumeric contextRef="ic04f75350f324bb38f14095eadb12430_D20190412-20190412" name="xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE3MTU_12b4a340-944f-4fa8-b966-20d9d3c00954">5</ix:nonNumeric> years from the date of issuance, and are immediately exercisable with certain restrictions. The gross proceeds from the offering, which closed on April 16, 2019, were $<ix:nonFraction unitRef="usd" contextRef="ic04f75350f324bb38f14095eadb12430_D20190412-20190412" decimals="-5" name="xfor:ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE4Nzk_3762b6a5-f924-4dc2-89e7-95ca667fccc1">85.8</ix:nonFraction> million before deducting underwriting discounts and offering expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 26, 2019, the Company sold <ix:nonFraction unitRef="shares" contextRef="i5faaf777d178421b83561c0fd16627c8_D20191126-20191126" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzIxNzk_20278519-23ed-4569-b2d7-9a3f423712f3">3,666,667</ix:nonFraction> shares of common stock and, in lieu of common stock, prefunded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i8c32e3e005c345c99931e9ec6e8fd87d_I20191126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzIyNjY_fc897d08-4970-4006-a5ed-ad5ed062d0da">1,750,000</ix:nonFraction> shares of common stock, and accompanying Class&#160;B warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ie95bdf26dc21489e97c2cbbf4958cf38_I20191126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzIzMzk_17fcef91-639e-415d-be2e-b493dec8ce4a">5,416,667</ix:nonFraction> shares of its common stock or prefunded warrants to purchase shares of common stock. The common stock was issued at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic2e5e675d68a4f6fb4aacb2424a63a15_I20191126" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzI0ODM_c207cd6f-0efa-464e-aa7c-61e8d6111964">12.00</ix:nonFraction> per share and accompanying Class&#160;B warrant and the prefunded warrants were issued at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8c32e3e005c345c99931e9ec6e8fd87d_I20191126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzI1ODI_42c99f77-9721-43c2-93cd-9478791371ef">11.999</ix:nonFraction> per prefunded warrant and accompanying Class&#160;B warrant. The Class B warrants have an exercise price of  $<ix:nonFraction unitRef="usdPerShare" contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE2NDkyNjc0NTA3Mzk_741c2478-783a-4af5-a636-44636952d69a">3.65</ix:nonFraction> per warrant, as adjusted based on a down-round contingent price adjustment feature; expire on a date that is the earlier of (a) the date that is <ix:nonNumeric contextRef="i5faaf777d178421b83561c0fd16627c8_D20191126-20191126" name="xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzI4MzA_76bad7ae-5b4b-4375-afb2-85a9e7bf5e3d">30</ix:nonNumeric> calendar days from the date on which the Company issues a press release announcing top-line data from its Phase 3 clinical trial of mavorixafor for the treatment of patients with WHIM syndrome (or, if such date is not a business day, the next business day) and (b) November 28, 2024; and were immediately exercisable upon issuance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald &amp; Co., and Stifel, Nicolaus &amp; Company, Incorporated (collectively the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell, at the Company&#8217;s sole discretion through one or more of the Sales Agents, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i0367f472bfd0499fb8ee3740bd659aef_D20200807-20200807" decimals="-5" name="xfor:SaleOfStockNumberOfSharesAuthorizedInTransactionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzM3NjA_287567b0-1de4-4faa-ba5f-18621eb02ae3">50.0</ix:nonFraction>&#160;million. To date, the Company has sold approximately $<ix:nonFraction unitRef="usd" contextRef="i9356b89607b64810becde53ca7553153_I20211231" decimals="-5" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE2NDkyNjc0NTE4MzQ_540c8bf4-548c-491d-bbdd-d151ab41f1ab">14.3</ix:nonFraction> million, net of offering costs, of common stock under the ATM Sales Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2021, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with several institutional and accredited investors (the &#8220;Investors&#8221;) pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the &#8220;Private Placement&#8221;) an aggregate of <ix:nonFraction unitRef="shares" contextRef="id058b9443dcc41a5ab90c45eaf52eb0f_D20210318-20210318" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1MjA_d68c3ff9-71da-483a-83a1-551cf97f0c28">6,271,836</ix:nonFraction> shares of common stock and, to certain Investors, in lieu of common stock, pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie12ba0825f69455cbb72564897ee2268_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1MzA_cf396b2e-378a-40cf-8601-d75884205ed1">50,000</ix:nonFraction> shares of common stock at a price of $8.70 per share of common stock (or $<ix:nonFraction unitRef="usdPerShare" contextRef="i358bda413e094c3b8732326b0da80424_I20210323" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1NDQ_46834671-68c5-4726-8b58-dda58e7fa4c6">8.69</ix:nonFraction> per pre-funded warrant). The Private Placement closed on March 23, 2021 and the Company received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="id058b9443dcc41a5ab90c45eaf52eb0f_D20210318-20210318" decimals="-5" name="xfor:ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1NjI_15921d50-e410-464e-b4e1-23a36c7159c6">55.0</ix:nonFraction> million, before deducting offering expenses payable by the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the common stock offerings, the Company evaluated the Class A, Class B and prefunded warrants for liability or equity classification in accordance with the provisions of ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and determined that equity treatment was appropriate because neither the Class A, Class B or prefunded warrants meet the definition of a liability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2020, the Company entered into a common stock purchase agreement (the &#8220;Aspire Purchase Agreement&#8221;) with Aspire Capital Fund, LLC, (&#8220;Aspire Capital&#8221;), which provided that, upon the terms and subject to the conditions and limitations set forth in the Aspire Purchase Agreement, Aspire Capital was committed to purchase up to an aggregate of $50.0 million of shares of the Company&#8217;s common stock at the Company&#8217;s request from time to time during the 36-month term of the Purchase Agreement. Concurrently with entry into the Aspire Purchase Agreement, the Company also entered into a registration rights agreement with Aspire Capital (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company filed with the SEC a prospectus supplement to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-242372), registering the issuance and sale of common stock that the Company may offer to Aspire Capital from time to time under the Aspire Purchase Agreement. No shares of common stock were sold pursuant to the Aspire Purchase Agreement. As further discussed in Note 16, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in January 2022 the Company elected to terminate the Aspire Purchase Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Common Stock&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the July 2014 license agreement with Genzyme (see Note&#160;3), in August 2015, the Company issued to Genzyme for no additional consideration <ix:nonFraction unitRef="shares" contextRef="i7e2c3583b72c4f10ba6fe68a4c9b2efc_D20150801-20150831" decimals="INF" name="xfor:StockIssuedDuringPeriodSharesLicenseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzYxNDA_90e006f5-ed45-4674-9389-33ccd41fb5dc">107,371</ix:nonFraction> shares of common stock, which had an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="idaea2c14fe1c4ed986fa022e040501e2_D20150801-20150831" decimals="-3" name="xfor:StockIssuedDuringPeriodValueLicenseAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzYyMDQ_f6473887-07c7-4068-bf3a-308ca899f3c4">734</ix:nonFraction> on the date of issuance. Genzyme had the right to require the Company to repurchase all, but not less than all, of these shares of common stock at any time during the term of the license agreement for a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7e2c3583b72c4f10ba6fe68a4c9b2efc_D20150801-20150831" decimals="INF" name="xfor:CommonStockRepurchasePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzY0MTk_bafc024e-cca9-4d42-ba8e-cd6735f39137">0.001</ix:nonFraction> per share. Because of this redemption feature, the shares of common stock issued to Genzyme were classified outside of stockholders&#8217; deficit on the consolidated balance sheets. As a result of the Merger, these shares were exchanged for common stock.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8e7cbe79ccb4ad5a4e101d276d72f46" continuedAt="ia44b3574dcbb400eab4fc130f52fbc48">On March 18, 2021, the Company entered into an Option Agreement, as amended (the &#8220;Option Agreement&#8221;) with Abingworth Bioventures 8 LP (&#8220;Abingworth Bioventures 8&#8221;), which was one of the Investors party to the Securities Purchase Agreement. Pursuant to the Option Agreement, if the Company and a syndicate, of which Abingworth Bioventures 8 was a part, did not execute a definitive co-development agreement, as defined in the Option Agreement, by August 2, 2021, Abingworth Bioventures 8 could have required the Company to repurchase the <ix:nonFraction unitRef="shares" contextRef="i090e4c427ee048bc8e9fcdb0974c1506_D20210318-20210318" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1NzM_fb0754ce-2887-46c7-9b94-947fc0e9cdcd">229,885</ix:nonFraction> common shares it purchased in the private placement at the original purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i997f64043d3c48f79904457d31ed425b_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1ODE_26302f55-00ce-41f5-9a55-3dd1c75ae92d">8.70</ix:nonFraction> per share. The Company classified these shares as redeemable common stock on the consolidated balance sheet, net of offering costs, as of March 31, 2021 and June 30, 2021. In August 2021, as a result of the termination of the letter of intent between the Company and Abingworth related to the contemplated co-development arrangement, Abingworth Bioventures 8 exercised it option to sell the <ix:nonFraction unitRef="shares" contextRef="i090e4c427ee048bc8e9fcdb0974c1506_D20210318-20210318" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1OTE_fb0754ce-2887-46c7-9b94-947fc0e9cdcd">229,885</ix:nonFraction> share of common stock it purchased in the Private Placement back to the Company at the original purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i997f64043d3c48f79904457d31ed425b_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM2MDA_26302f55-00ce-41f5-9a55-3dd1c75ae92d">8.70</ix:nonFraction> per share for an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ic20f813c6ba64ecd9f76496c37a6e54f_D20210318-20210318" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM2MTY_79d359b5-a2ac-407c-b1f6-948c555c79ea">2.0</ix:nonFraction> million. The Company adjusted the carrying amount of the redeemable common stock to its redemption value and subsequently retired these shares of common stock.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="ia44b3574dcbb400eab4fc130f52fbc48" continuedAt="i124c6a9bacd94bac92e7c62342afa97d">Convertible Preferred Stock (converted to Common Stock)&#8212;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i124c6a9bacd94bac92e7c62342afa97d"> Prior to the Merger, the Company had issued Series Seed convertible preferred stock (the &#8220;Series Seed preferred stock&#8221;), Series&#160;A convertible preferred stock (the &#8220;Series&#160;A preferred stock&#8221;) and Series&#160;B convertible preferred stock (the &#8220;Series&#160;B preferred stock&#8221;). As of December&#160;31, 2021, the Company&#8217;s Certificate of Incorporation, as amended and restated, authorized the Company to issue a total of <ix:nonFraction unitRef="shares" contextRef="i66be0cd2cf4d4a42b63843821d7cd60e_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzcxMTc_b90b20b2-7a92-4917-8941-ab4e4646faea">10,000,000</ix:nonFraction> shares of preferred stock, with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i66be0cd2cf4d4a42b63843821d7cd60e_I20211231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzcxNjc_4c3ac692-09c6-478d-bee3-194b57ba7b26"><ix:nonFraction unitRef="usdPerShare" contextRef="iba06b4b4e67a4951be1cc5d6e6014f25_I20201231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzcxNjc_fef242b7-10b1-4e56-bba8-fe68437e4400">0.001</ix:nonFraction></ix:nonFraction> per share. As of December&#160;31, 2021 and 2020, there was <ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzcyMTA_773da39b-c926-4bf5-a8bf-adc83341fd38">no</ix:nonFraction> preferred stock outstanding.</ix:continuation> </span></div><div id="i71bd745117f84268bb875bce92ea6db3_181"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0Mjc_e2e1b0c6-4d3b-4cc0-b660-cc7af848e5a7" continuedAt="i5d9654c0c63b4d3d916246b4bbc8d02d" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i5d9654c0c63b4d3d916246b4bbc8d02d" continuedAt="i4520af6bc4f14b3b82db5ff6ce29e3de"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Plans&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Merger on March&#160;13, 2019, X4&#8217;s 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;), Arsanis&#8217; 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) and Arsanis&#8217; 2017 Employee Stock Purchase Plan (the &#8220;2017 ESPP&#8221;) were assumed by the Company. In June 2019, the Company adopted the 2019 Inducement Equity Incentive Plan (the &#8220;2019 Plan&#8221;). These plans are administered by the Board of Directors or by a committee thereof. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than <ix:nonFraction unitRef="number" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0OA_6e09de7d-660d-4f33-bdff-13a8fcd71c11">100</ix:nonFraction>% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than <ix:nonNumeric contextRef="ibb68bbb183674891a54f752fa22ab0ec_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzg4Mw_77a22ab9-48b1-41d1-8aec-e1e35f250f53">ten years</ix:nonNumeric>. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over <ix:nonNumeric contextRef="i2dca859173e44d0ab9e6a946325f25cf_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzEwODg_7cc0acc2-b95a-444f-bedc-a435a078f999">four years</ix:nonNumeric>. Non-statutory options granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzEyNDI_d21e8b58-0c5c-4b61-b8a2-5336b084744c">three</span> or <ix:nonNumeric contextRef="i0cdc5828b647427eac8834bfe5c3918d_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzEyNDg_5442b17e-2b7a-4714-968c-77715a072f66">four years</ix:nonNumeric>. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee, Director and Consultant Equity Incentive Plan&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Board of Directors and shareholders of X4 adopted the 2015 Plan, which provided for the Company to grant incentive stock options or nonqualified stock options, restricted stock awards and other stock-based awards to employees, directors and consultants of the Company. The total number of shares of common stock that may be issued under the 2015 Plan is <ix:nonFraction unitRef="shares" contextRef="i24ce1b0b961a4ecf8f39191f8d76e3f5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzIwMjM_999d9e8b-2f25-4154-8684-107b785ef1ce">1.0</ix:nonFraction> million shares. As of December&#160;31, 2021, there were approximately 144 thousand shares available for issuance under the 2015 Plan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Plan, the Company may grant incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. On June 10, 2020, the Company's stockholders approved an amendment and restatement of the 2017 Plan. The amendments increased the number of shares of common stock reserved for issuance under the 2017 Plan by an additional <ix:nonFraction unitRef="shares" contextRef="i9744171d8b784611a88ca1bbe96d8305_I20200610" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzI1NzM_d758eb74-0981-43d4-8d6b-b4b084c705f8">474</ix:nonFraction> thousand shares and amended the &#8220;evergreen&#8221; provision of the 2017 Plan to provide for an automatic increase in the share reserve on the first day of each year, beginning on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1, 2021 and ending on January&#160;1, 2027, in an amount equal to  the lower of <ix:nonFraction unitRef="number" contextRef="ibcb5c3f88dc04b4394011f548ecf9639_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzI4MjM_66b4f295-5860-4aec-b310-e019c5f0b0a5">4.0</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on January&#160;1 of each year or an amount determined by the Company&#8217;s Board of Directors. As of December&#160;31, 2021, approximately <ix:nonFraction unitRef="shares" contextRef="i0cda38b2da094f1989f1b4c220bb9a44_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzMwMTg_23bf8127-6fee-4128-89e9-7331a45eca41">139</ix:nonFraction> thousand shares were available for future issuance under the 2017 Plan. Pursuant to the evergreen provision of the 2017 Plan, as of January 1, 2022, an additional <ix:nonFraction unitRef="shares" contextRef="ic32c961b47444fdbb27d84656b34b323_I20210101" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzMxNzU_1db05586-1569-4167-8ebb-2cfa1c891356">1.1</ix:nonFraction> million shares became available for future issuance under the 2017 Plan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Employee Stock Purchase Plan&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2017 ESPP provides participating employees with the opportunity to purchase shares of the Company&#8217;s common stock at defined purchase prices over six-month offering periods. For the twelve months ended December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="ic41788cc835c403ebdb1e9b363ffce18_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzM0ODQ_5bc184a8-b783-44d2-8d8a-6a4b75b53ad6">45,816</ix:nonFraction> shares of common stock were issued under the 2017 ESPP. As of December&#160;31, 2021, approximately <ix:nonFraction unitRef="shares" contextRef="ib547fe50b2a14b3280afdd293833e80c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzM1ODI_cb5984b6-e992-40e8-90ab-969b6fcbb4f8">183</ix:nonFraction> thousand shares were available for future issuance under the 2017 ESPP. Pursuant to the evergreen provision of the 2017 ESPP, on January 1, 2022, an additional <ix:nonFraction unitRef="shares" contextRef="i6bc5c13e743746e4a019f4cf7a0c9b49_D20210101-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzM3MzY_3919dedd-d035-4c79-89b5-b3a575ed5425">85</ix:nonFraction> thousand shares became available for future issuance under the 2017 ESPP. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i4520af6bc4f14b3b82db5ff6ce29e3de" continuedAt="i061cb2a9b2c04863b596f8c651ebfb0f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Inducement Equity Incentive Plan&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2019, the Board of Directors approved the adoption of the 2019 Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or following a bona fide period of non-employment), as an inducement material to such individual&#8217;s entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4). The total number of shares of common stock that may be issued under the 2019 Plan, as amended, is <ix:nonFraction unitRef="shares" contextRef="id65e88b8d02845c0a717fe27c8e5d78e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzQzMzE_e7967f79-4375-40e0-9ce3-23ab7804ef7c">1.3</ix:nonFraction> million shares. Shares that are expired, forfeited, canceled or otherwise terminated without having been fully exercised will be available for future grant under the 2019 Plan. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for future grants. As of December&#160;31, 2021, approximately <ix:nonFraction unitRef="shares" contextRef="id65e88b8d02845c0a717fe27c8e5d78e_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzQ3MTM_8752be12-e4f7-4729-b874-3fa78fe39b6e">483</ix:nonFraction> thousand shares were available for future issuance under the 2019 Plan. </span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Valuation&#8212; </span><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0Mjg_dca269fa-225b-4a43-b179-292988d0da46" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"><tr><td style="width:1.0%"></td><td style="width:60.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzItMy0xLTEtMjA5NDA_06f1d51c-5c99-4c7f-9ffc-a3e01190044e">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzItNS0xLTEtMjA5NDA_6abd1842-9e55-46dc-944b-f54e81b439f3">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzItNy0xLTEtMjA5NDA_3f8d22e5-cf41-4cf9-80fd-1431b44d3956">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzMtMy0xLTEtMjA5NDA_278bbfda-8d24-4f8f-8296-38bdf20fa741">5.96</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzMtNS0xLTEtMjA5NDA_70fa1e89-c998-41cb-8309-5ebf85d97e12">6.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzMtNy0xLTEtMjA5NDA_8aedafb1-2d8d-402b-9199-886cd96d99aa">5.99</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzQtMy0xLTEtMjA5NDA_63ca0f6c-b9b4-415e-8744-dc1fd39ef00d">97.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzQtNS0xLTEtMjA5NDA_682f4251-6dd2-41f2-ac4c-f71c82682480">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzQtNy0xLTEtMjA5NDA_d59d552e-7fae-4eb8-a914-961e0f1ea47d">88.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzUtMy0xLTEtMjA5NDA_d4df20df-04d9-477e-9da1-39f7a27441ff">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzUtNS0xLTEtMjA5NDA_9d909832-71a4-4b99-a1a7-e9284c93c062">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzUtNy0xLTEtMjA5NDA_37679f81-374f-44b3-a9b7-712d6bd57878">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0Mjk_e7668b96-33dc-48b5-98d0-07ace41d80b9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity for the twelve months ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.679%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(in Thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzEtMS0xLTEtMjA5NDA_fe2863bc-8558-4364-869e-ea02a65bfa33">1,874,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzEtMy0xLTEtMjA5NDA_1c026b26-aed5-4929-bc2d-874791d3a5f4">12.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzEtNS0xLTEtMjA5NDA_d4ed2ba9-6536-4ff4-b611-68e3a4d1e87f">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzEtNy0xLTEtMjA5NDA_c1085496-46ec-4d22-960c-ab326f0d2ed6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzItMS0xLTEtMjA5NDA_637a02e5-3819-41f4-b579-f6e192a49bd7">388,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzItMy0xLTEtMjA5NDA_c489b143-c071-409c-b2de-b3f870c917f0">6.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzMtMS0xLTEtMjA5NDA_90da361f-e3cf-4819-a46a-2cd472f197fa">5,860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzMtMy0xLTEtMjA5NDA_22339b5c-f5f8-4585-8854-1dbb0a32784b">7.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzQtMS0xLTEtMjA5NDA_051c9e87-9887-4358-a652-4fa6d817d1a5">340,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzQtMy0xLTEtMjA5NDA_6026838e-2246-4e68-84d3-2f6020a3d5c6">22.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzUtMS0xLTEtMjA5NDA_788a081b-9686-4764-b899-8657afd742b9">1,916,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzUtMy0xLTEtMjA5NDA_9f6c2e64-8bf2-4867-aa0b-58b2e62b9206">10.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzUtNS0xLTEtMjA5NDA_bc8e5c5c-3013-4b55-82d1-b4acb72b3e6e">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzUtNy0xLTEtMjA5NDA_e4fea3db-e808-4a05-80c4-189ed7343fa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzYtMS0xLTEtMjA5NDA_81852ffa-a156-45cb-8a7b-fe2a7d595b94">1,007,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzYtMy0xLTEtMjA5NDA_8d1d7ab4-0439-4eb5-aeac-e474d7bf37b3">11.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzYtNS0xLTEtMjA5NDA_ced22156-ec27-473c-b927-0cc406fd22c0">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzYtNy0xLTEtMjA5NDA_c87108bc-4278-4995-a24b-00cc62f4c8e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzctMS0xLTEtMjA5NDA_24273b6a-e429-4c30-bcf7-2412f0446594">1,689,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzctMy0xLTEtMjA5NDA_a16dac41-b2c6-4878-8856-b78e19093533">10.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzctNS0xLTEtMjA5NDA_8ab2f373-5996-4e4c-9784-418b1cbdec45">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzctNy0xLTEtMjA5NDA_9b06f068-6041-47a2-895a-67b67eabd015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock to the extent the stock option had a lower exercise price. The aggregate intrinsic value of stock options exercised during the twelve months ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU0MzQ_d79025c0-420d-499d-b4fb-a20ee55c2df2">13</ix:nonFraction> thousand and  $<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU0NDE_c33a7a2b-89b9-4b40-b818-62710d39e881">42</ix:nonFraction>&#160;thousand, respectively. The weighted average grant-date fair value per share of stock options granted during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="2" name="xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU2ODU_f65636c4-5302-4e6c-8bfb-d508c4159d92">5.17</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="2" name="xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU2ODk_e4a8f1d7-9699-46be-8173-edc8871e8769">6.12</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="2" name="xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU2OTc_dc00ce10-582e-4409-8015-daaafb530ffe">10.78</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; During the twelve months ended December&#160;31, 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU3OTA_b7954eb9-71d7-4bb9-9646-37794d164c2c">674,478</ix:nonFraction> restricted stock units to employees at a weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU4NzY_65d45f93-705d-4940-bbb4-0e4f39ba268b">8.25</ix:nonFraction> per share. The restricted stock units granted were primarily performance-based restricted stock units, which vest in part upon on the Company&#8217;s achievement of operational milestones and over time thereafter for the subsequent two years as the employee continues to provide services to the Company. As of December 31, 2021, all performance criteria had been achieved. The Company recognizes stock-based compensation expense using the accelerated attribution model based on the fair value of the awards as of the date of grant and management&#8217;s best estimate of the date each operational milestone will be achieved. These restricted stock units had a grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzY4Njc_ff262edd-ae79-4b53-8676-bc910ef413a7">5.6</ix:nonFraction> million, which is being recognized as stock-based compensation expense, net of estimated forfeitures, over the estimated vesting period. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i061cb2a9b2c04863b596f8c651ebfb0f"><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0MjU_f744e072-61f5-4d7f-b238-3dcfa272fbf3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock activity for the twelve months ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.275%"><tr><td style="width:1.0%"></td><td style="width:71.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c91a1db75564f1a9f51565f80cc6989_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZToxMWUzZGZmNmU3YTQ0ODgxOTYzZjJiMWYwN2QxMzVmMC90YWJsZXJhbmdlOjExZTNkZmY2ZTdhNDQ4ODE5NjNmMmIxZjA3ZDEzNWYwXzEtMS0xLTEtMjA5NDA_8342c959-082b-47b6-a6cd-a22b9e2aec51">572,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZToxMWUzZGZmNmU3YTQ0ODgxOTYzZjJiMWYwN2QxMzVmMC90YWJsZXJhbmdlOjExZTNkZmY2ZTdhNDQ4ODE5NjNmMmIxZjA3ZDEzNWYwXzItMS0xLTEtMjA5NDA_14942e1d-b1d8-451e-84a7-05d15cf30a54">674,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZToxMWUzZGZmNmU3YTQ0ODgxOTYzZjJiMWYwN2QxMzVmMC90YWJsZXJhbmdlOjExZTNkZmY2ZTdhNDQ4ODE5NjNmMmIxZjA3ZDEzNWYwXzMtMS0xLTEtMjA5NDA_83d27bda-9d37-4a76-bfee-f54250cfbc42">205,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZToxMWUzZGZmNmU3YTQ0ODgxOTYzZjJiMWYwN2QxMzVmMC90YWJsZXJhbmdlOjExZTNkZmY2ZTdhNDQ4ODE5NjNmMmIxZjA3ZDEzNWYwXzQtMS0xLTEtMjA5NDA_f523635b-2a9e-47bd-8c8b-29dd414da1da">116,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd6c8456214d407ab97760fec4594b56_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZToxMWUzZGZmNmU3YTQ0ODgxOTYzZjJiMWYwN2QxMzVmMC90YWJsZXJhbmdlOjExZTNkZmY2ZTdhNDQ4ODE5NjNmMmIxZjA3ZDEzNWYwXzUtMS0xLTEtMjA5NDA_f9feb78e-af33-42e8-b811-7581ccde8871">925,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, total unrecognized compensation expense related to unvested stock options and restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="ifd6c8456214d407ab97760fec4594b56_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzcyNDI_cce608e9-b36a-4ebe-8e9c-7bdf25313c9b">7.7</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzczMTU_8cf89364-7c24-402a-87c5-7d3057231dec">2.1</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0MjY_7a1770ee-445d-4add-8ddd-763c431b9925" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the consolidated statements of operations as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"><tr><td style="width:1.0%"></td><td style="width:50.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b422ab3eb7e4a40aa972b2f8fff304f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzItMS0xLTEtMjA5NDA_3cdaff68-202e-4e7f-8c1b-044af6b67a3e">2,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia31a8d360da2400681748e55aab5c168_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzItMy0xLTEtMjA5NDA_7c29ac68-65c8-404b-874a-d6439c6d5a80">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04d43b561c5475e947351e2ef934ba6_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzItNS0xLTEtMjA5NDA_5384eed8-cfe9-4600-9646-85cf5058130e">909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c01b2e36084c58b99dee21b846e65d_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzMtMS0xLTEtMjA5NDA_e1c85955-6178-4a28-805d-930da23b4000">3,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb0418b0f1a84b1485cef1e8244c3bbe_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzMtMy0xLTEtMjA5NDA_77549a7d-7dea-4e32-a309-f9566c0ff481">3,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if641bd9c2d33474caad13fd26380c7bd_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzMtNS0xLTEtMjA5NDA_0eedf0c4-1801-4bf3-ba14-61b28c839e9a">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzQtMS0xLTEtMjA5NDA_ff0cd16a-b416-4d49-bea8-fe2a8226d8ac">6,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzQtMy0xLTEtMjA5NDA_1b97db39-98ea-44d1-b048-a0196e904bf1">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzQtNS0xLTEtMjA5NDA_31f03653-a969-4039-aa85-592543ece4ef">2,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i71bd745117f84268bb875bce92ea6db3_184"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNzM_b6a39e32-73a0-4d02-8cac-02445cbb5197" continuedAt="i933c89db339e435c8111bcbc45c8030d" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i933c89db339e435c8111bcbc45c8030d" continuedAt="ie032e31723ae4e9aa2a0ed6d81a16fbf"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, the Company recorded no income tax benefits for the net operating losses incurred and research and development credits generated due to the uncertainty of realizing a benefit from those items. Additionally during the year ended December 31, 2021, the Company recorded a tax provision of $<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzM1MQ_e98dd81c-7e36-4538-a738-37945f50cb97">17</ix:nonFraction>&#160;thousand related to its Austrian subsidiary. During the year ended December 31, 2020, the Company recorded a tax provision of $<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzEwOTk1MTE2MzM2MzE_c50708b0-203e-4bcd-be0c-7bd1a43df374">148</ix:nonFraction> thousand related to local withholdings associated with a milestone payment received from a customer in a foreign jurisdiction.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNzQ_f2938c45-68de-44f0-ae09-916f84be3122" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before the provision for income taxes for the years ended December 31, 2021, 2020 and 2019 consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzItMS0xLTEtMjA5NDA_5528330a-01a0-4b91-a1d5-713f743621c8">89,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzItMy0xLTEtMjA5NDA_09c33011-77d9-4e44-98ce-350c9b2dd7af">62,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzItNS0xLTEtMjA5NDA_9052aef0-a521-4c10-92ac-da7ea3794903">52,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (Austria)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzMtMS0xLTEtMjA5NDA_8f227084-8a58-4e17-b784-897c80406380">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzMtMy0xLTEtMjA5NDA_3dc97329-cc8b-4ae4-8cdc-3e05c0c834ac">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzMtNS0xLTEtMjA5NDA_45da0c15-6399-455b-bb29-664eb9e8fbff">493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzQtMS0xLTEtMjA5NDA_0ab9ccce-6cce-444c-a433-fa67d9dfc26d">88,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzQtMy0xLTEtMjA5NDA_7e47c50b-fc5d-4126-845c-fc35ae898861">61,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzQtNS0xLTEtMjA5NDA_dec0aa8b-d34d-4fca-a71a-2800fe775027">52,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ie032e31723ae4e9aa2a0ed6d81a16fbf" continuedAt="i6e68c7f3b36d4d29abe6e435156e7c65"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNjk_39db70df-99d5-46fc-b711-d4a418844732" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzItMS0xLTEtMjA5NDA_bf54e030-0840-4ee0-affc-d4634715ccea">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzItMy0xLTEtMjA5NDA_9da81d0c-e98a-4147-b71e-286d405baeda">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzItNS0xLTEtMjA5NDA_c605fd72-d449-4c6e-a057-c47e0ed8bb9f">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzMtMS0xLTEtMjA5NDA_396524a5-4d3a-4612-a5b4-541cbb367df8">5.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzMtMy0xLTEtMjA5NDA_e193229d-6c17-47b6-a90a-e55ff6c44920">5.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzMtNS0xLTEtMjA5NDA_edec54fc-b3da-4c94-bb3c-c1c5b8165f7b">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzQtMS0xLTEtMjA5NDA_3210ff2f-6258-40fb-9d86-9806ab7b41b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzQtMy0xLTEtMjA5NDA_83d7979a-5ef4-4a22-83ff-e520af874d48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzQtNS0xLTEtMjA5NDA_b2448d62-2b9b-40bd-b8b5-60424d494441">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzUtMS0xLTEtMjA5NDA_35f75ba0-10c2-4b59-9bfd-68b6d1b01d51">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzUtMy0xLTEtMjA5NDA_4df2fda9-c31a-40b7-af88-b5ad479fb20a">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzUtNS0xLTEtMjA5NDA_f7c8286f-8c0f-4019-8b8f-efe9f2750b22">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of preferred stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="3" name="xfor:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzYtMS0xLTEtMjA5NDA_1f0c750a-946b-44a3-9f99-0d6dc0e33dd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="3" name="xfor:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzYtMy0xLTEtMjA5NDA_38c7f421-9b58-49fd-a7d1-aed4e9c0d816">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="3" name="xfor:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzYtNS0xLTEtMjA5NDA_15a56aed-cabe-4810-ae94-2330f4652af9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="3" name="xfor:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzctMS0xLTEtMjA5NDA_c7ffb736-2046-4d8a-a8c0-ed9182cb5de6">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="3" name="xfor:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzctMy0xLTEtMjA5NDA_ff2e626a-4761-452a-acf7-f5a25cf614bb">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="3" name="xfor:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzctNS0xLTEtMjA5NDA_f7ed6718-4b3c-49f2-967c-80b24be2804f">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax asset valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzgtMS0xLTEtMjA5NDA_e3c2471a-0a21-4edb-bf28-ab77be4118fe">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzgtMy0xLTEtMjA5NDA_57dd1c20-1ec8-4d29-a7cb-0fc7bc947752">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzgtNS0xLTEtMjA5NDA_9fd536cf-f58a-44ab-a62f-88e254783568">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzktMS0xLTEtMjA5NDA_350f9cf9-5e6f-45b9-ba49-38751808a7ba">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzktMy0xLTEtMjA5NDA_52e13927-9b42-4a47-8af6-55cf3e1f658a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzktNS0xLTEtMjA5NDA_ec8a64c0-cf27-4352-8ec6-2887d2ec4961">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzEwLTEtMS0xLTIwOTQw_2a441ecf-a226-49ed-9207-ac9e0d4f5cb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzEwLTMtMS0xLTIwOTQw_04d71e0e-3b00-4c25-9c47-b76437b72161">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzEwLTUtMS0xLTIwOTQw_a803b98b-6115-4bcd-9699-2e80e2f9df8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNzA_755f62f8-5f92-4799-9b43-f49264ed6ced" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzItMS0xLTEtMjA5NDA_18eba6b5-2f38-4044-9919-52d79a641601">101,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzItMy0xLTEtMjA5NDA_c3cc30ec-c574-4cd1-a18e-4f0c58f0c4cc">83,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzMtMS0xLTEtMjA5NDA_1c858389-ecfa-45f8-82ed-21a65445a65b">5,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzMtMy0xLTEtMjA5NDA_80a04307-e844-4fc1-b6ea-cdab8247250e">4,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="xfor:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzQtMS0xLTEtMjA5NDA_5006b66e-bd17-45b5-93f6-73bed6698f9b">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="xfor:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzQtMy0xLTEtMjA5NDA_a5514d88-7776-4ff6-a15d-097edbec2b9f">2,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="xfor:DeferredTaxAssetLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzctMS0xLTEtMjA5NDA_98f8de1c-2c00-499d-8461-f0ec4bd23356">1,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="xfor:DeferredTaxAssetLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzctMy0xLTEtMjA5NDA_ca621052-0555-4225-902c-a7dc3d41261b">1,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzgtMS0xLTEtMjA5NDA_fa934acb-5c9a-45b8-bd8e-0f70bff1abc9">3,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzgtMy0xLTEtMjA5NDA_64ac2afe-31a8-46f8-afce-2ca97ca8165b">2,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzktMS0xLTEtMjA5NDA_59f42e81-dce6-4598-b0f9-685f6379045c">113,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzktMy0xLTEtMjA5NDA_096e3163-d2f2-4f87-af7f-4d0fb58ed807">94,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEwLTEtMS0xLTIwOTQw_e846ab0a-2a4e-4477-9663-a78d553094df">111,835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEwLTMtMS0xLTIwOTQw_52f4456c-756d-4eb6-911b-f247dc4a7573">92,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzExLTEtMS0xLTIwOTQw_b67f6247-1686-4e50-afa8-55c205d35b81">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzExLTMtMS0xLTIwOTQw_9eb4119c-f4a5-4a11-8555-1a7992274c39">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="xfor:DeferredTaxLiabilityRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEyLTEtMS0xLTIwOTQw_6e990f00-f5b5-41e0-8dad-cd3b3c6135ce">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="xfor:DeferredTaxLiabilityRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEyLTMtMS0xLTIwOTQw_dcc95d29-886a-49e1-99ea-02c4e4b81197">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEzLTEtMS0xLTIwOTQw_f9661482-4deb-4a2f-9aac-d9a7c83be4ff">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEzLTMtMS0xLTIwOTQw_a4cbf002-0b64-490e-8177-ec30b9944657">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzE0LTEtMS0xLTIwOTQw_ae0360c9-7124-4b60-900f-ca4a289dbe8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzE0LTMtMS0xLTIwOTQw_070229bc-0ae7-45e7-a844-be64bc623c41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had U.S. federal and state net operating loss carryforwards of  $<ix:nonFraction unitRef="usd" contextRef="i097aafa6f7b841a1a0aa11212d0ac628_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3Xzk5MQ_db2f15e9-10b9-4603-9b03-8ccb31f26506">315.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id2f7ea03d3dc4a2db15e7efdf72553a9_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3Xzk5OA_2f7c97b8-d7a3-4f3b-b91c-eab1a3cf2301">308.2</ix:nonFraction> million, respectively, which may be available to offset future taxable income and begin to expire in 2031 and 2035, respectively. The Company has federal net operating losses $<ix:nonFraction unitRef="usd" contextRef="i097aafa6f7b841a1a0aa11212d0ac628_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzExNjg_106a85cd-844d-4a7a-ba23-0a21206edc8b">260.9</ix:nonFraction> million, which do not expire, and $<ix:nonFraction unitRef="usd" contextRef="i097aafa6f7b841a1a0aa11212d0ac628_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzExOTc_af70f9c1-e5cf-4f52-a274-a44fd5f8ec40">54.1</ix:nonFraction> million of federal net operating losses generated prior to 2018 that will expire at various dates through 2037. In addition, as of December 31, 2021, the Company had foreign net operating loss carryforward of $<ix:nonFraction unitRef="usd" contextRef="i32f34441bf9943299037a918d5a88ca2_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzE0MDE_90fedcbc-76ff-4717-9908-03a8903b017c">65.2</ix:nonFraction> million, which do not expire but are generally limited in their usage to an annual deduction equal to 75% of taxable income. As of December 31, 2021, the Company also had U.S. federal and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i5afd505d65084ae68ba1922355482038_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzE2NDM_8117bda8-af31-4b14-ad68-472dfadc1d4b">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i19aaafe0d3d04513a526d073e5d54606_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzE2NTA_a5a38d6d-5734-42e8-acf3-b2ad139f48b7">1.4</ix:nonFraction> million, respectively, which may be available to offset future tax liabilities and each begin to expire in 2032 and 2030, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, uncertain tax position reserves recorded were $<ix:nonFraction unitRef="usd" contextRef="i097aafa6f7b841a1a0aa11212d0ac628_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzE4NTQ_5b88fe9f-c028-47a1-abf9-df6542701379">0.2</ix:nonFraction> million for U.S. federal and state research and development tax credits. Additionally, during the year ended December 31, 2021, the Company released an uncertain tax position of $<ix:nonFraction unitRef="usd" contextRef="i32f34441bf9943299037a918d5a88ca2_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzIwMjc_eff70abc-e056-45ce-9250-b1010d504230">0.1</ix:nonFraction> million related to withholding taxes paid in 2021 on a milestone payment received from a non-U.S. customer in 2020.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i6e68c7f3b36d4d29abe6e435156e7c65"><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNzE_f62e2943-0f28-49c5-a59e-9907af0dc8aa" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s reserve for uncertain tax positions for the three years ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:82.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reserve for Uncertain Tax Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo0MGExMjNkNTY3YjY0NmNmODM4OWU0ZjkxOGI4ZjE3NC90YWJsZXJhbmdlOjQwYTEyM2Q1NjdiNjQ2Y2Y4Mzg5ZTRmOTE4YjhmMTc0XzEtMS0xLTEtMjA5NDA_13100f97-94f1-4d6a-97c0-ab8a8087454c">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in unrecognized tax benefit for tax positions taken during year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo0MGExMjNkNTY3YjY0NmNmODM4OWU0ZjkxOGI4ZjE3NC90YWJsZXJhbmdlOjQwYTEyM2Q1NjdiNjQ2Y2Y4Mzg5ZTRmOTE4YjhmMTc0XzItMS0xLTEtMjA5NDA_4e9e8466-3e6e-4205-a658-ed08287cdb95">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo0MGExMjNkNTY3YjY0NmNmODM4OWU0ZjkxOGI4ZjE3NC90YWJsZXJhbmdlOjQwYTEyM2Q1NjdiNjQ2Y2Y4Mzg5ZTRmOTE4YjhmMTc0XzMtMS0xLTEtMjA5NDA_efc0eaf0-79d3-450f-b2ff-25f568f74406">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of unrecognized tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo0MGExMjNkNTY3YjY0NmNmODM4OWU0ZjkxOGI4ZjE3NC90YWJsZXJhbmdlOjQwYTEyM2Q1NjdiNjQ2Y2Y4Mzg5ZTRmOTE4YjhmMTc0XzQtMS0xLTEtMjA5NDA_1a14f904-3c6b-4dfa-8926-9cc02715a660">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo0MGExMjNkNTY3YjY0NmNmODM4OWU0ZjkxOGI4ZjE3NC90YWJsZXJhbmdlOjQwYTEyM2Q1NjdiNjQ2Y2Y4Mzg5ZTRmOTE4YjhmMTc0XzUtMS0xLTEtMjA5NDA_e5544cdd-fc26-4386-86c6-3b129aea0428">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the U.S. net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each period, the Company evaluates the positive and negative evidence bearing upon its ability to realize its federal, state and foreign deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2021, 2020 and 2019. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNzI_defcf0c4-12c6-454c-8f96-bd4c7770675e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021, 2020 and 2019 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"></td><td style="width:41.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0e74a770feb4868bd1ab0a23e223cd7_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzItMS0xLTEtMjA5NDA_577f0e9a-9bf8-4676-8013-0e0a4340fcc4">92,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4203c993d0e41018d52d1c410bc3e56_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzItMy0xLTEtMjA5NDA_13525a3e-e619-434f-ae50-60f2ff861d86">73,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i610800df2fc44c33b927d13481ffc06a_I20181231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzItNS0xLTEtMjA5NDA_9b76db64-982f-4fa9-a470-51c8c2baf077">22,797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icea0d3791b8d40149f121f9b367a9acd_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzMtMS0xLTEtMjA5NDA_42422c64-86b1-46af-b9bb-4813be208e5f">19,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c50656da4cf4784852c501bf1c61d57_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzMtMy0xLTEtMjA5NDA_28609dc6-aae4-4cd7-86d6-2f808772b4ea">18,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78bed59ffcf84935afe7d39665a6ed77_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzMtNS0xLTEtMjA5NDA_2a48b2a2-58cf-4332-b4b9-261fa042c8df">14,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea0d3791b8d40149f121f9b367a9acd_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzQtMS0xLTEtMjA5NDA_229bab03-94dd-40bf-9841-2586425d6e1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c50656da4cf4784852c501bf1c61d57_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzQtMy0xLTEtMjA5NDA_25077b3f-f16a-4915-b36e-3bb7d8313cc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78bed59ffcf84935afe7d39665a6ed77_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzQtNS0xLTEtMjA5NDA_b3038292-5e35-4234-9b04-3afdf3ba1311">36,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance, end of year </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ac33b1c38294eb99c02be51a19dfc6d_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzUtMS0xLTEtMjA5NDA_12f7dbb9-df8c-4f8e-8408-fc859a87a6af">111,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0e74a770feb4868bd1ab0a23e223cd7_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzUtMy0xLTEtMjA5NDA_aa202993-0c97-46a8-9f97-a867c77e7938">92,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4203c993d0e41018d52d1c410bc3e56_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzUtNS0xLTEtMjA5NDA_82dafcfe-575f-4ba0-a16c-bd745a763be1">73,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. federal and state income tax returns are generally subject to tax examinations for the tax years ended December 31, 2018 through December 31, 2020. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90ZXh0cmVnaW9uOmIxMjk3ZjQ5MWRiYzRiYjJiOTQ2NDZhZGVmYWVhNTQ3XzE4NTE_ffa9858b-53af-43fb-a61b-99b16d7755b7" continuedAt="i8e1a722d8cba4504ba5bf8e3fc543c31" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i8e1a722d8cba4504ba5bf8e3fc543c31"><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90ZXh0cmVnaW9uOmIxMjk3ZjQ5MWRiYzRiYjJiOTQ2NDZhZGVmYWVhNTQ3XzE4NTI_a4984c97-bed0-4b20-bf7f-ab134b1a8a57" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.126%"><tr><td style="width:1.0%"></td><td style="width:58.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzMtMS0xLTEtMjA5NDA_d7079a49-cda2-45f9-9600-4a56f3e872b8">88,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzMtMy0xLTEtMjA5NDA_d1c0f64d-2a56-4949-9a42-1637fdacfcec">62,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzMtNS0xLTEtMjA5NDA_3e8b9df4-1a4f-4af6-8146-eb29bcac1e28">52,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruing dividends on Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzQtMS0xLTEtMjA5NDA_52deac61-4d4b-41b5-9460-1b91a27bb1f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzQtMy0xLTEtMjA5NDA_7ce946aa-498e-4d9d-9c5f-f9a6975da4f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:TemporaryEquityDividendsAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzQtNS0xLTEtMjA5NDA_e19251f8-0a3d-44f3-a61b-b50fb48100b1">592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend as a result of Class B Warrant price reset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzUtMS0xLTEtMjA5NDA_514a271b-bc02-4e1f-937e-e91c94755aa2">13,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzUtMy0xLTEtMjA5NDA_eba7bd74-de28-489f-98d7-0ec18ef50b6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzUtNS0xLTEtMjA5NDA_2a081f4b-516e-446d-a205-22db4cfd35a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzYtMS0xLTEtMjA5NDA_7926dcd8-8fb0-4aff-b2e1-0c584685f154">102,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzYtMy0xLTEtMjA5NDA_36ee0983-2625-458d-bc29-33d508fb766a">62,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzYtNS0xLTEtMjA5NDA_03dcdc84-e44f-4ef2-be83-72f9e954ca23">53,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock&#8212;basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzgtMS0xLTEtMjA5NDA_5ac82165-a324-4b45-87f6-a23201a3530c">25,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzgtMy0xLTEtMjA5NDA_0baf1c73-445e-4e6a-bab8-f8940251529e">20,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzgtNS0xLTEtMjA5NDA_7065e09e-e841-48c1-8b2e-f33383f155ea">11,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212; basic and diluted</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzktMS0xLTEtMjA5NDA_374e652f-7169-497c-9508-9e1f0c55fca5">3.99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzktMy0xLTEtMjA5NDA_6cb00948-9dca-4ce3-90e7-02625e3e7679">3.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzktNS0xLTEtMjA5NDA_a26d1ca7-3f54-44e8-aeb6-a11f323a46ed">4.63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted weighted average shares of common stock outstanding for the years ended December&#160;31, 2021 includes the weighted average effect of <ix:nonFraction unitRef="shares" contextRef="ib495f27eee5643c1aa40007ea1e395be_D20190416-20190416" decimals="INF" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90ZXh0cmVnaW9uOmIxMjk3ZjQ5MWRiYzRiYjJiOTQ2NDZhZGVmYWVhNTQ3XzU2Mw_0ae5b3fd-b405-422f-ba42-3ae603a6af73">3,808,032</ix:nonFraction> prefunded warrants for the purchase of shares of common stock, for which the remaining unfunded exercise price is less than or equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i834346b84a2147ecbd3cf27e5b2b7a1f_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90ZXh0cmVnaW9uOmIxMjk3ZjQ5MWRiYzRiYjJiOTQ2NDZhZGVmYWVhNTQ3Xzc2Ng_39e4b0ec-00da-4981-beb0-bef02a66468c">0.01</ix:nonFraction> per share. During the year ended December 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of subsequent sales of common stock. Such adjustment is accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#8217;s common stock and the estimated remaining life of the outstanding Class B Warrants. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities included outstanding stock options, unvested restricted stock units and warrants to purchase shares of common stock for the years ended December 31, 2021 and 2020. Potentially dilutive securities also included warrants to purchase preferred stock for the year ended 2019. These potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#8220;anti-dilutive.&#8221; Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. <ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90ZXh0cmVnaW9uOmIxMjk3ZjQ5MWRiYzRiYjJiOTQ2NDZhZGVmYWVhNTQ3XzE4NTA_0a7aed11-0178-472b-ad82-b4059d99eec6" continuedAt="i4bd6f8024aaf428f986b60f2d24d4b17" escape="true">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</ix:nonNumeric></span><ix:continuation id="i4bd6f8024aaf428f986b60f2d24d4b17"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia358f6661177462caadde0fb55c0679c_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzItMS0xLTEtMjA5NDA_aa9bc9b4-3e50-4130-8ee5-5e4ba51c0a2f">1,916,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7f118f44cef4d8da8cb50ea3570142e_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzItMy0xLTEtMjA5NDA_04efbf47-843f-4d2e-9920-1082cca58a1d">1,874,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i574f61ac83b744e4bac8486593ef48b8_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzItNS0xLTEtMjA5NDA_a1a0555e-2afc-4f88-960f-c4e17b8994e3">1,297,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ebe6af4f44d4c56a5d0c7916e1a7f3e_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzQtMS0xLTEtMjA5NDA_967ead67-f17d-4ba0-ac21-0821acb655c6">925,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifce6e198f34e4961a5cb7083bbca2927_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzQtMy0xLTEtMjA5NDA_0abfda09-1339-4acf-b5b9-34608d6b8c08">572,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1b7de7a2f0e407ba0289ebb81300e0e_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzQtNS0xLTEtMjA5NDA_4a8718f4-00af-4980-bfbc-7dfad6ac73cb">101,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock (excluding prefunded warrants, which are included in basic shares outstanding)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7ed78f3d9464a2eb083a1251fd15435_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzUtMS0xLTEtMjA5NDA_9b6cae7a-34c4-404c-b1cd-6c668b1507a2">9,449,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9372c9ab8f97446b99dcb15a6e0b1733_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzUtMy0xLTEtMjA5NDA_8a85d936-d006-40d2-87db-3aeba305b470">9,474,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15c8d1f64e434ebbac09001eadf96f1d_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzUtNS0xLTEtMjA5NDA_3ebb3e5b-bfde-4012-b97a-41596d869d1e">9,776,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzYtMS0xLTEtMjA5NDA_e71091a7-88e5-4b74-af99-ae6cf9729cc4">12,290,280</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzYtMy0xLTEtMjA5NDA_ec0ba778-fe3c-4bc7-b25d-fcf09b15afb4">11,921,377</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzYtNS0xLTEtMjA5NDA_ba6a3ce3-d4cf-45f4-8b74-01bd5d561bf3">11,175,673</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><div id="i71bd745117f84268bb875bce92ea6db3_190"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTAvZnJhZzpjNDQ5YWRlODY0ODE0MGU0ODUyMjk1NTllOWJhOTY4ZS90ZXh0cmVnaW9uOmM0NDlhZGU4NjQ4MTQwZTQ4NTIyOTU1OWU5YmE5NjhlXzEzNzg_6aae0086-6d1a-48ff-8be6-e6b1bb83f882" continuedAt="i6206d197211b4e4881325c6fb67779fc" escape="true">LOSS ON TRANSFER OF NONFINANCIAL ASSETS</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i6206d197211b4e4881325c6fb67779fc"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company entered into contractual arrangements with two third parties that transferred the rights to develop and commercialize the programs underlying IPR&amp;D intangible assets acquired in the Merger. As of December 31, 2019, all programs underlying IPR&amp;D intangible assets acquired in the Merger were transferred to these third parties and the Company had no continuing involvement in any ongoing research and development activities associated with the programs. The Company concluded that these third parties are &#8220;non-customers&#8221; as the underlying development programs transferred to these third parties are focused on potential drug candidates that were not aligned with the Company's strategic focus and, therefore, are not an output of the Company's ordinary activities. Accordingly, the Company accounted for these transactions under ASC Topic 610-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gains and Losses from the Derecognition of Nonfinancial Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 610-20&#8221;). As a result of the transfer of control of the IPR&amp;D projects to third parties, the Company derecognized the IPR&amp;D intangible assets through a charge to &#8220;loss on transfer of nonfinancial assets&#8221; in 2019 of $<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTAvZnJhZzpjNDQ5YWRlODY0ODE0MGU0ODUyMjk1NTllOWJhOTY4ZS90ZXh0cmVnaW9uOmM0NDlhZGU4NjQ4MTQwZTQ4NTIyOTU1OWU5YmE5NjhlXzEyMzI_d322c428-eb77-4c15-af3e-2ec81aa0cb21">3.9</ix:nonFraction> million, which included the carrying value of the IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="ibc0f8bba43d64d859d8549ce3f940062_I20191231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTAvZnJhZzpjNDQ5YWRlODY0ODE0MGU0ODUyMjk1NTllOWJhOTY4ZS90ZXh0cmVnaW9uOmM0NDlhZGU4NjQ4MTQwZTQ4NTIyOTU1OWU5YmE5NjhlXzEyODY_d0f9aab2-605f-4d5b-bad4-ff8c86fee9dc">4.9</ix:nonFraction> million, partially offset by $<ix:nonFraction unitRef="usd" contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTAvZnJhZzpjNDQ5YWRlODY0ODE0MGU0ODUyMjk1NTllOWJhOTY4ZS90ZXh0cmVnaW9uOmM0NDlhZGU4NjQ4MTQwZTQ4NTIyOTU1OWU5YmE5NjhlXzEzMTA_74c104af-2773-45b3-a1e0-4f891211fc81">1.0</ix:nonFraction> million of non-refundable, upfront fees received from the third parties.</span></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i71bd745117f84268bb875bce92ea6db3_193"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzUyNTk_46734591-b78a-4a58-8290-5492b9366397" continuedAt="i05aef101c41b4bcdb007b4ef8d47a50a" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i05aef101c41b4bcdb007b4ef8d47a50a"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Termination of Aspire Purchase Agreement</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2022, the Company terminated the Aspire Purchase Agreement, under which Aspire was committed to purchasing up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia2a4f9e0d29b44b3a8c743db5ab19895_D20220114-20220114" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwNzI_84fcfe6b-f959-4f97-bd1c-4591245f5a01">50.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company&#8217;s common stock, subject to certain restrictions. No shares of common stock were sold under the Aspire Purchase Agreement. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lincoln Park Capital Fund Purchase Agreement</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2022, the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a securities purchase agreement (the &#8220;LPC Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell shares of common stock to Lincoln Park, having an aggregate value of up to $<ix:nonFraction unitRef="usd" contextRef="i2d9b7bf5f3ef40dbb4d96393c1905d90_D20220114-20220114" decimals="-3" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzE2NDkyNjc0OTU2Njg_8f2b1a27-da7b-4037-b309-3d0118019219">50.0</ix:nonFraction> million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement, at the Company&#8217;s request from time to time during the <ix:nonNumeric contextRef="ie34513bfd4ce4c4298a4866e8aa61aad_D20201014-20201014" name="xfor:SaleOfStockPurchaseAgreementTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2NzI4NjM_e5e76214-e7c0-4f78-bc1a-32454257ca44">36</ix:nonNumeric>-month term of the LPC Purchase Agreement. In consideration for entering into the LPC Purchase Agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="ic6a4a6cada334ffd9ee919af14b029f6_I20220114" decimals="INF" name="xfor:SaleOfStockPurchaseAgreementSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzE2NDkyNjc0OTU2ODI_110e3843-cfd1-42c6-8a9f-20855da51b20">230,414</ix:nonFraction> shares of common stock to Lincoln Park as an initial commitment fee. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the LPC Purchase Agreement and the Registration Rights Agreement on January 14, 2022, the Company sold to Lincoln Park, as an initial purchase under the LPC Purchase Agreement, a total of <ix:nonFraction unitRef="shares" contextRef="ic6a4a6cada334ffd9ee919af14b029f6_I20220114" decimals="INF" name="xfor:PurchaseAgreementSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzE2NDkyNjc0OTU2OTc_b845a792-6649-4b36-8a34-d5805a0d8b8c">1,382,488</ix:nonFraction> shares of common stock, at a per share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ief44e634dee347efb955cc9c643e8ca1_D20220114-20220114" decimals="INF" name="us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzE2NDkyNjc0OTU3MDU_aa3c94a9-855d-4a87-b8d4-218e8f30633c">2.17</ix:nonFraction> per share, for aggregate consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="ief44e634dee347efb955cc9c643e8ca1_D20220114-20220114" decimals="-5" name="us-gaap:PaymentsForSecuritiesPurchasedUnderAgreementsToResell" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzE2NDkyNjc0OTU3MjI_885f3cce-7206-499c-a0cc-5a35ff4bc237">3.0</ix:nonFraction> million.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Hercules Loan Agreement</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2022, the Company entered into Amendment No. 3 the Hercules Loan Agreement. The amendment:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminated the Company&#8217;s ability to request additional term loan advances in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i5720729ba9eb468d8f2396ce7f061f2a_I20211231" decimals="-5" name="xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwNTg_3b208e3c-fe2e-48ad-be82-733a7076856a">7.5</ix:nonFraction>&#160;million through June 30, 2022;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the aggregate amount of term loan advances the Company may request from $<ix:nonFraction unitRef="usd" contextRef="i5720729ba9eb468d8f2396ce7f061f2a_I20211231" decimals="-5" name="xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTA5NzA_9f5cda4a-d05c-4f48-ac21-368edba68225">10.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i6e984764b25842acb5cf371ed696787e_I20220314" decimals="-5" name="xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTA5ODU_e9fbf8bf-fc5e-4a2e-ae79-e8d3a3411655">17.5</ix:nonFraction>&#160;million, subject to Hercules&#8217; investment committee&#8217;s sole discretion, through December 31, 2022; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modified the minimum cash covenant contingent upon the Company raising &#8220;cash proceeds&#8221; (as defined in the Hercules Loan Agreement, as amended by Amendment No. 3) of $<ix:nonFraction unitRef="usd" contextRef="ie9413c149a6a46d882b610a2ff34f1ff_D20220101-20220630" decimals="-6" name="xfor:DebtInstrumentDebtCovenantMinimumCashRequired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwMDA_6376935b-afad-430a-b968-c7e6ab348f63">33.0</ix:nonFraction>&#160;million between January 1, 2022 and June 30, 2022. The current minimum cash covenant requires that, following the initial test date for the covenant, the Company maintain a minimum level of cash equal to six times a cash flow metric based on the preceding three months cash flow, subject to reduction, upon achievement of certain performance milestones, to the greater of $<ix:nonFraction unitRef="usd" contextRef="i6a4e1b15e8914a5da92a4b13a532378d_I20220209" decimals="-5" name="xfor:DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwMTM_15ffdd94-6e86-4362-be69-da18c47ef30c">20.0</ix:nonFraction>&#160;million or three times the then-current cash flow metric, and further subject to extinguishment of the minimum cash covenant based upon achievement of additional milestones. If the Company raises the specified &#8220;cash proceeds&#8221; in the specified period, the Company would, at all times thereafter during which the minimum cash covenant is in effect, be required to maintain a minimum of $<ix:nonFraction unitRef="usd" contextRef="i3c992b94297b4f968244daa96427847c_D20220209-20220209" decimals="-5" name="xfor:DebtInstrumentDebtCovenantMinimumCashRequired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwMjg_4ab99676-66d9-4e9f-a22e-c93c0a76c07c">30.0</ix:nonFraction>&#160;million of cash, which would be further reduced to $<ix:nonFraction unitRef="usd" contextRef="i6a4e1b15e8914a5da92a4b13a532378d_I20220209" decimals="-5" name="xfor:DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwNDM_8eb89cc5-c6e7-490f-9f90-765fc21bcc7b">20.0</ix:nonFraction>&#160;million upon achievement of certain performance milestones and extinguished upon achievement of additional milestones.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 7 to these notes to the consolidated financial statements for further discussion of the Hercules Loan Agreement.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Q1 2022 Private Placement </span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the Company entered into a securities purchase agreement pursuant (the &#8220;Q1 2022 Private Placement&#8221;) to which it agreed to issue and sell to an investor (the &#8220;Investor&#8221;), in a private placement, <ix:nonFraction unitRef="shares" contextRef="i75e45f429fc6401584184ad501a62f94_D20220303-20220303" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3NDc_ec48edd6-0a8b-4363-88ce-b5b7937f2405">900,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i520c1054445641ac8c06d14b69d2bea3_I20220303" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3NzI_c5b66399-408f-422d-a161-51abd5759535">1.80</ix:nonFraction> per share and pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8f62b2544f6c4e2398c83ef365be248c_I20220303" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3NjE_51763385-e6a1-4a7d-a55c-7017b0736093">766,666</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i520c1054445641ac8c06d14b69d2bea3_I20220303" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3ODE_317050d1-0c23-4b27-8551-6ba30cdb276b">1.79</ix:nonFraction> per pre-funded warrant (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">representing the price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i520c1054445641ac8c06d14b69d2bea3_I20220303" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3OTA_c5b66399-408f-422d-a161-51abd5759535">1.80</ix:nonFraction> per share minus the $<ix:nonFraction unitRef="usdPerShare" contextRef="i520c1054445641ac8c06d14b69d2bea3_I20220303" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3OTg_dae0b6c0-b1ce-4735-b76f-a5cddd996601">0.01</ix:nonFraction> per share exercise price of each such pre-funded warrant)</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The pre-funded warrants are exercisable at any time after their original issuance date and will have no expiration date. The Q1 2022 Private Placement closed on March 7, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Company received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i75e45f429fc6401584184ad501a62f94_D20220303-20220303" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg4MTQ_180c249b-4326-4923-aeab-72a85ad0ed20">3.0</ix:nonFraction>&#160;million, before deducting offering expenses payable by the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on March 3, 2022, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investor, pursuant to which the Company agreed to register for resale the shares and the shares of common stock underlying the pre-funded warrants held by the Investor (the &#8220;Registrable Securities&#8221;). Under the Registration Rights Agreement, the Company has agreed to file a registration statement covering the resale of the Registrable Securities by no later than April 30, 2022 (the &#8220;Filing Deadline&#8221;). The Company has agreed to use commercially reasonable efforts to cause such registration statement to become effective as soon as practicable and to keep such registration statement effective until the date the Shares and the shares of Common Stock underlying the Pre-Funded Warrants covered by such registration statement have been sold or may be resold pursuant to Rule 144 without restriction. The Company has agreed to be responsible for all fees and expenses incurred in connection with the registration of the Registrable Securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event (i) the registration statement has not been filed by the Filing Deadline, (ii) the registration statement has not been declared effective prior to the earlier of (A) five business days after the date which the Company is notified by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) that the registration statement will not be reviewed by the SEC staff or is not subject to further comment by the SEC staff, or (B) 60 days following the Filing Deadline (or, in the event the SEC reviews and has written comments to the registration statement, 120 days following the Filing Deadline) or (iii) after the registration statement has been declared effective by the SEC, sales cannot be made pursuant to the registration statement for any reason including by reason of a stop order or the Company&#8217;s failure to update such registration statement, subject to certain limited exceptions, then the Company has agreed to make pro rata payments to the Investor as liquidated damages in an amount equal to 1% of the aggregate amount invested by the Investor in the Registrable Securities per 30-day period or pro rata for any portion thereof for each such month during which such event continues, subject to certain caps set forth in the Registration Rights Agreement. The Company has granted the Investor customary indemnification rights in connection with the registration statement. The Investor has also granted the Company customary indemnification rights in connection with the registration statement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class B Warrant Price Adjustments</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Purchase Agreement, the exercise price of the Company&#8217;s Class B warrants, which are currently exercisable, was adjusted from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTc5ODE_db32f683-b169-4131-82e0-5d5c8badd82f">3.65</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b4b699affe54fdf8181d6649b333e5f_I20220114" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTc5ODg_db1f9668-1b9e-465e-a630-3e17d61e3252">2.17</ix:nonFraction> per Class B warrant. In addition, as a result of the Q1 2022 Private Placement, the exercise price of the Class B warrants was further adjusted to $<ix:nonFraction unitRef="usdPerShare" contextRef="ie187101e5927453095022efb8232686c_I20220209" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg1NjM_97249a20-383f-473e-b4cd-f38726a3940d">1.80</ix:nonFraction> per Class B warrant.  No Class B warrant has been exercised to date.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>2
<FILENAME>ex1019.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1f7be45caf5e43b8ac268cf978b4fb03_38"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.19</font></div><div><font><br></font></div></div><div style="margin-bottom:26.5pt;margin-top:0.3pt;padding-left:36pt;padding-right:221.35pt;text-align:right;text-indent:36pt"><font><br></font></div><div style="margin-bottom:26.5pt;margin-top:0.3pt;padding-left:219.85pt;padding-right:221.35pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:134px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT </font></div><div style="margin-top:26.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">THIS SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) is entered into as of March 7, 2022, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) by and between X4 Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;), and Adam Mostafa (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) (collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; or individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;).</font></div><div style="margin-top:11.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">R E C I T A L S</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">WHEREAS, Executive has been employed by the Company as its Chief Financial Officer, pursuant to the Amended and Restated Executive Employment Agreement with the Company dated March 13, 2019, as amended on February 13, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;)&#59;</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">WHEREAS, the Company wishes to continue employing Executive as its Chief Financial Officer and to enter into a further amended and restated agreement embodying the terms of such employment&#59;</font></div><div style="margin-top:11.9pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">WHEREAS, Executive desires to continue in such employment and enter into such an agreement.</font></div><div style="margin-top:12.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">A G R E E M E N T</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">NOW, THEREFORE, in consideration of the premises and mutual covenants herein and for other good and valuable consideration, the Parties agree as follows&#58;</font></div><div style="margin-top:12.25pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Duties and Scope of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264808076 v1</font></div><div><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264808076 v2</font></div><div><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264808375 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Positions and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Executive&#8217;s position with Company shall be Chief Financial Officer (&#8220;CFO&#8221;), reporting to Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) or the CEO&#8217;s designee. Executive will render such business and professional services in the performance of Executive&#8217;s duties, consistent with Executive&#8217;s position within the Company, as shall reasonably be assigned to Executive by the Company&#8217;s Chief Executive Officer. The period of Executive&#8217;s at-will employment under the terms of this Agreement is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.&#8221;</font></div><div style="margin-top:11.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, Executive will perform Executive&#8217;s duties faithfully and to the best of Executive&#8217;s ability and will devote Executive&#8217;s full business efforts and time to the Company. For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity, for any direct or indirect remuneration, that may create a conflict of interest or interfere with Executive&#8217;s duties to the Company, without the prior approval of the Company&#8217;s Chief Executive Officer. Notwithstanding the foregoing, it is agreed and understood that provided that nothing contained in this Section 1(b) shall prevent or limit&#58; (x) Executive&#8217;s right to manage Executive&#8217;s personal investments on Executive&#8217;s own personal time, including, without limitation the right to make passive investments in the securities of (i) any entity which Executive does not control, directly or indirectly, and which does not compete with Company, or (ii) any publicly held entity, so long as Executive&#8217;s aggregate direct and indirect interest does not exceed two percent (2%) of the issued and outstanding securities of any class of securities of such publicly held entity&#59; (y) Executive&#8217;s participation in civic and charitable activities, including as a member of a board of a civic or charitable organization, so long as such activities do not interfere with Executive&#8217;s performance of Executive&#8217;s duties hereunder&#59; and (z) Executive&#8217;s performance of consulting services for the entities listed on Exhibit A hereto, provided that such services are limited to 2 hours per month for each listed entity via phone or email (i.e., not in person), and are performed outside of business hours and otherwise in a manner that does not interfere with Executive&#8217;s performance of Executive&#8217;s duties hereunder.</font></div><div style="margin-top:11.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. As a condition of Executive&#8217;s employment, Executive certifies to the Company that&#58; (a) Executive is free to enter into and fully perform the duties of Executive&#8217;s position&#59; (b) Executive is not subject to any employment, confidentiality, non-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">competition or other agreement that would restrict Executive&#8217;s performance for the Company&#59; (c) Executive&#8217;s signing this Agreement does not violate any order, judgment or injunction applicable to Executive, or conflict with or breach any agreement to which Executive is a party or by which Executive is bound&#59; and (d) all facts Executive has presented to the Company are accurate and true, including, but not limited to, all oral and written statements Executive has made (including those pertaining to Executive&#8217;s education, training, qualifications, licensing and prior work experience) in any job application, resume, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-style:italic;font-weight:400;line-height:174%">c.v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, interview or discussion with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">2. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Subject to Sections 6, 7, and 8 below, the parties agree that Executive's employment with the Company will be &#8220;at-will&#8221; employment and may be terminated at any time with or without cause or notice, for any reason or no reason. Executive understands and agrees that neither Executive&#8217;s job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of Executive&#8217;s employment with the Company.</font></div><div style="margin-top:12.2pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="margin-top:11.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, the Company will initially pay Executive as compensation for Executive&#8217;s services a base salary at a rate of $415,000.00 per year, as modified from time to time at the discretion of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). The Base Salary will be paid in regular installments in accordance with the Company&#8217;s normal payroll practices (subject to required withholding). Any increase or decrease in Base Salary (together with the then existing Base Salary) shall serve as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; for future employment under this Agreement. The first and last payment will be adjusted, if necessary, to reflect a commencement or termination date other than the first or last working day of a pay period.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Executive will also be eligible to earn an annual discretionary bonus with a target amount equal to 40% of the Base Salary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). The amount of this bonus, if any, will be determined in the sole discretion of the Company and based, in part, on Executive&#8217;s performance and the performance of the Company during the calendar </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">year. The Company will pay Executive this bonus, if any, by no later than March 15th of the following calendar year. The bonus is not earned until paid and, except as set forth in Section 8(a) of this Agreement, no pro-rated amount will be paid if Executive&#8217;s employment terminates for any reason prior to the payment date.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Executive will be eligible to receive awards of stock options, restricted stock or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board of Directors or a committee of the Board shall determine in its discretion whether Executive shall be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">4. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, Executive may take advantage of various benefits offered by the Company, such as group medical insurance, dental insurance, short-term disability, long term disability and the Company&#8217;s 401(k) plan. Executive will also be entitled to fifteen (15) days of paid time off per year, as well as two (2) personal days and eleven (11) paid holidays, exclusive of any sick days Executive may need. These benefits may be modified or changed from time to time at the sole discretion of the Company. The details of the Company&#8217;s full benefit offerings can be found in its Employee Handbook.</font></div><div style="margin-top:11.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">5. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Business Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, the Company will reimburse Executive for reasonable business travel, entertainment or other business expenses incurred by Executive in the furtherance of or in connection with the performance of Executive&#8217;s duties hereunder, in accordance with the Company&#8217;s expense reimbursement policy as in effect from time to time. All reimbursements provided under this Agreement will be made or provided in accordance with the requirements of Section 409A of the Internal Revenue Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) and the rules and regulations thereunder, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement)&#59; (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year&#59; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:11.9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Termination on Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Executive&#8217;s employment will terminate automatically upon Executive&#8217;s Death or, upon fourteen (14) days prior written notice from the Company, in the event of Disability.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Upon any termination for death or Disability, Executive shall be entitled to&#58; (i) Executive&#8217;s Base Salary through the effective date of termination&#59; (ii) the right to continue health care benefits under Title X of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;), at Executive&#8217;s cost, to the extent required and available by law&#59; (iii) reimbursement of expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company plans or policies, as then in effect.</font></div><div style="margin-top:12.45pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">7. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Involuntary Termination for Cause&#59; Resignation without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="margin-top:13.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Notwithstanding any other provision of this Agreement, the Company may terminate Executive&#8217;s employment at any time for Cause, which shall be effective on the date the Company gives notice to Employee of such termination in accordance with this Agreement unless otherwise agreed by the Parties. Executive may resign from Executive&#8217;s employment with the Company without Good Reason, provided that Executive provide at least four (4) weeks prior written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). Such resignation shall be effective upon the expiration of the Notice Period. In the event that the Company accelerates the effective date of a resignation, such acceleration shall not be construed as a termination of Executives employment by the Company or deemed Good Reason for such resignation.</font></div><div style="margin-top:13.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In the case of the Company&#8217;s termination of Executive&#8217;s employment for Cause, or Executive&#8217;s resignation without Good Reason, Executive shall be entitled to receive&#58; (i) Base Salary through the effective date of the termination or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">resignation, as applicable&#59; (ii) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (iii) the right to continue health care benefits under COBRA, at Executive&#8217;s cost, to the extent required and available by law&#59; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company plans or policies, as then in effect.</font></div><div style="margin-top:12.75pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">8.&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Involuntary Termination Without Cause&#59; Resignation for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="margin-top:11.4pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. The Company shall be entitled to terminate Executive without Cause and Executive may resign for Good Reason, subject to the following&#58;</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:115.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(i)&#160;&#160;&#160;&#160; If Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 23 below, Executive shall be entitled to receive&#58; (A) Executive&#8217;s Base Salary through the effective date of the termination or resignation&#59; (B) continuing severance pay at a rate equal to one hundred percent (100%) of Executive&#8217;s Base Salary, as then in effect (less applicable withholding), for a period of twelve (12) months from the date of such termination, to be paid periodically in accordance with the Company&#8217;s normal payroll practices&#59; (C) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (D) pro-rata portion of the Target Bonus for the calendar year in which the termination occurs based on the period worked by Executive during such calendar year prior to termination&#59; (E) provided that Executive elects COBRA coverage, the Company shall reimburse Executive for a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date Executive&#8217;s employment terminates, until the earlier of six months from the date of termination or the date upon which Executive becomes eligible to receive health benefits through another employer&#59; (F) accelerated vesting of any then-outstanding equity awards equal to the number of shares subject to such then-outstanding equity awards that would have vested had Executive otherwise remained employed for an additional six months after the date Executive&#8217;s employment with the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Company terminated&#59; and (G) no other severance or benefits of any kind, unless required by law or pursuant to any written Company plans or policies, as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(ii)&#160;&#160;&#160;&#160; If, within twelve (12) months after a Change of Control as defined below, Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 23 below, Executive shall be entitled to receive, in lieu of the benefits set forth in Section 8(a)(i)&#58; (A) Executive&#8217;s Base Salary through the effective date of the termination or resignation&#59; (B) continuing severance pay at a rate equal to one hundred percent (100%) of Executive&#8217;s Base Salary, as then in effect (less applicable withholding), for a period of twelve (12) months from the date of such termination, to be paid periodically in accordance with the Company&#8217;s normal payroll practices&#59; (C) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (D) an amount equal to Executive&#8217;s full Target Bonus for the calendar year in which the termination occurs in advance of such Target Bonus being earned&#59; (E) provided that Executive elects COBRA coverage, the Company shall reimburse Executive for a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date Executive&#8217;s employment terminates, until the earlier of six months from the date of termination or the date upon which Executive becomes eligible to receive health benefits through another employer&#59; (F) the full acceleration of vesting of any then-outstanding unvested equity awards as of the date Executive&#8217;s employment with the Company terminated&#59; and (G) no other severance or benefits of any kind, unless required by law or pursuant to any written Company plans or policies, as then in effect. For purposes of this Agreement, a &#8220;Change of Control&#8221; is defined as a Reorganization Event, as defined in the X4 Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), as it may be further amended from time to time, or any successor plan thereto.</font></div><div style="margin-bottom:26.7pt;margin-top:11.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Any severance payments contemplated by Sections 8(a)(i) and 8(a)(ii) above are conditional on Executive&#58; (i) continuing to comply with the terms of this Agreement and the Confidential Information Agreement&#59; and (ii) signing and not revoking a separation agreement and release of known and unknown claims in the form provided by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:26.7pt;margin-top:11.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Company (including non-disparagement and no cooperation provisions) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) and provided that such Release becomes effective and irrevocable no later than sixty (60) days following the termination date or such earlier date required by the release (such deadline, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). If the Release does not become effective by the Release Deadline, Executive will forfeit any rights to severance or benefits under Sections 8(a)i) or 8(a)(ii) or elsewhere in this Agreement. Any severance payments or other benefits under this Agreement will be paid on, or, in the case of installments, will not commence until, the sixtieth (60th) day following Executive&#8217;s separation from service, or, if later, such time as required by Section 23(b). Except as required by Section 23(b), any installment payments that would have been made to Employee during the sixty (60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive&#8217;s separation from service and the remaining payments will be made as provided in this Agreement, unless subject to the 6-month payment delay described herein. Notwithstanding the foregoing, this Section 8(b) shall not limit Executive&#8217;s ability to obtain expense reimbursements under Section 5 or any other compensation or benefits otherwise required by law or in accordance with written Company plans or policies, as then in effect.</font></div><div style="margin-bottom:26.7pt;margin-top:11.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">9. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="margin-top:11.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; shall mean&#58; (i) Executive&#8217;s continued failure to substantially perform the material duties and obligations under this Agreement (for reasons other than death or Disability), which failure, if curable within the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice from the Company of such failure&#59; (ii) Executive&#8217;s failure or refusal to comply with the policies, standards and regulations established by the Company from time to time which failure, if curable in the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice of such failure from the Company&#59; (iii) any act of willful misconduct, fraud, embezzlement, misrepresentation, or other unlawful act committed by Executive that benefits Executive at the expense of the Company&#59; (iv) the Executive&#8217;s violation of a federal or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">state law or regulation applicable to the Company&#8217;s business&#59; (v) the Executive&#8217;s violation of, or a plea of nolo contendere or guilty to, a felony under the laws of the United States or any state&#59; (vi) the Executive&#8217;s material breach of the terms of this Agreement or the Confidential Information Agreement (defined below) if not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice from the Company describing the breach in reasonable detail&#59; or (vii) the Company&#8217;s severe financial distress, whereby the Company is in the process of winding down its business and Executive&#8217;s employment is terminated in connection with such winding down&#59; provided that prior to such termination, a determination is made by the Company&#8217;s Board of Directors that none of the Company&#8217;s Officers (as that term is defined in Section 16 of the Securities Exchange Act of 1934) will receive severance payments in connection with the winding down of the Company&#8217;s business.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; means that Executive, at the time notice is given, has been unable to substantially perform Executive&#8217;s duties under this Agreement for not less than one-hundred and twenty (120) work days within a twelve (12) consecutive month period as a result of Executive&#8217;s incapacity due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; means Executive&#8217;s written notice of Executive&#8217;s intent to resign for Good Reason with a reasonable description of the grounds therefor within 10 days after the occurrence of one or more of the following without Executive&#8217;s consent, and subsequent resignation within 30 days following the expiration of any Company cure period (discussed below)&#58; (i) a material reduction of Executive&#8217;s duties, position or responsibilities, (ii) a material reduction in Executive&#8217;s Base Salary, which the parties agree is a reduction of at least 10% of Executive&#8217;s base salary (unless pursuant to a salary reduction program applicable generally to the Company&#8217;s similarly situated employees)&#59; (iii) relocation of Executive&#8217;s principal place of employment to a place that increases Executive&#8217;s one-way commute by more than sixty (60) miles as compared to Executive&#8217;s then-current principal place of employment immediately prior to such relocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(iv) a material breach of this Agreement by the Company&#59; or (v) any directive given to Executive by the Company that the Company knows is in violation of a law, regulation, or material Company policy and the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Company requires Executive to implement as a condition of his continued employment. Executive will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#8220;Good Reason&#8221; within 30 days of the initial existence of the grounds for &#8220;Good Reason&#8221; and a reasonable cure period of not less than 30 days following the date of such notice if such act or omission is capable of cure.</font></div><div style="margin-top:12.2pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">10. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Company Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Proprietary Information and Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In connection with Executive&#8217;s employment with the Company, Executive will receive and have access to Company confidential information and trade secrets. Executive agrees to continue to abide by the Confidentiality, Non-Solicitation, and Intellectual Property Agreement (the &#8220;Confidential Information Agreement&#8221;) Executive signed on April 17, 2018, which contains restrictive covenants and prohibits unauthorized use or disclosure of the Company&#8217;s confidential information and trade secrets, among other obligations. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Resignation on Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. On termination of Executive&#8217;s employment, regardless of the reason for such termination, Executive shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Executive may hold in the Company or any affiliate, unless otherwise agreed in writing by the Parties.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Notification of New Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In the event that Executive leaves the employ of the Company, Executive grants consent to notification by the Company to Executive&#8217;s new employer about Executive&#8217;s rights and obligations under this Agreement and the Confidential Information Agreement. Company agrees not to notify Executive&#8217;s new employer unless it has a reasonable belief that Executive has violated or intends to violate a provision of the Confidential Information Agreement.</font></div><div style="margin-top:0.2pt;padding-left:36pt"><font><br></font></div><div style="margin-top:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">11. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. To ensure the timely and economical resolution of disputes that may arise in connection with Executive&#8217;s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, Confidential Information Agreement, or Executive&#8217;s employment, or the termination </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">of Executive&#8217;s employment, including but not limited to all statutory claims, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration by a single arbitrator conducted in Boston, Massachusetts by Judicial Arbitration and Mediation Services Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) under the then applicable JAMS rules (at the following web address&#58; https&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;)&#59; provided, however, this arbitration provision shall not apply to sexual harassment claims to the extent prohibited by applicable law. A hard copy of the rules will be provided to Executive upon request. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In addition, all claims, disputes, or causes of action under this section, whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. The Company acknowledges that Executive will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this Agreement) shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award&#59; and (c) be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. Executive and the Company shall equally share all JAMS&#8217; arbitration fees. Except as modified in the Confidential Information Agreement, each party is responsible for its own attorneys&#8217; fees. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">judgments in the federal and state courts of any competent jurisdiction. To the extent applicable law prohibits mandatory arbitration of sexual harassment claims, in the event you intend to bring multiple claims, including a sexual harassment claim, the sexual harassment may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.</font></div><div><font><br></font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives of Executive upon Executive's death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer, conveyance or other disposition of Executive&#8217;s right to compensation or other benefits will be null and void.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. All notices, requests, demands and other communications called for under this Agreement shall be in writing and shall be delivered via e-mail, personally by hand or by courier, mailed by United States first-class mail, postage prepaid, or sent by facsimile directed to the Party to be notified at the address or facsimile number indicated for such Party on the signature page to this Agreement, or at such other address or facsimile number as such Party may designate by ten (10) days&#8217; advance written notice to the other Parties hereto. All such notices and other communications shall be deemed given upon personal delivery, three (3) days after the date of mailing, or upon confirmation of facsimile transfer or e-mail. Notices sent via e-mail under this Section shall be sent to either the e-mail address in this Agreement, or for e-mails sent by the Company to Executive, to the last e-mail address on file with the Company.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.9pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement, together with the 2017 Plan and related agreements, and the Confidential Information Agreement represent the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements whether written or oral. No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless in writing and signed by duly authorized representatives of the parties hereto.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. No Party shall be deemed to have waived any right, power or privilege under this Agreement or any provisions hereof unless such waiver shall have been duly executed in writing and acknowledged by the Party to be charged with such waiver. The failure of any Party at any time to insist on performance of any of the provisions of this Agreement shall in no way be construed to be a waiver of such provisions, nor in any way to affect the validity of this Agreement or any part hereof. No waiver of any breach of this Agreement shall be held to be a waiver of any other subsequent breach.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement will be governed by the laws of the Commonwealth of Massachusetts (with the exception of its conflict of laws provisions).</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Executive acknowledges that Executive has had the opportunity to discuss this matter with and obtain advice from Executive&#8217;s legal counsel, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily entering into this Agreement.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original, and all such counterparts shall constitute but one instrument.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. The section and subsection headings contained herein are for convenience only and shall not affect the construction hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Construction of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement has been negotiated by the respective Parties, and the language shall not be construed for or against either Party.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section 409A (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Deferred Compensation Separation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) will be paid or otherwise provided until Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A.</font></div><div style="margin-top:12.55pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of Executive&#8217;s termination (other than due to death), then the Deferred Compensation Separation Benefits that are payable within the first six (6) months following Executive&#8217;s separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive&#8217;s separation from service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive&#8217;s separation from service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&#8217;s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Agreement is intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;Any amount paid under this Agreement that satisfies the requirements of the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Compensation Separation Benefits for purposes of clause (a) above.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(d)&#160;&#160;&#160;&#160;Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Compensation Separation Benefits for purposes of clause (a) above. For purposes of this Agreement, &#8220;Section 409A Limit&#8221; will mean the lesser of two (2) times&#58; (i) Executive&#8217;s annualized compensation based upon the annual rate of pay paid to Executive during the Executive&#8217;s taxable year preceding Executive&#8217;s taxable year of Executive&#8217;s termination of employment as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto&#59; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Internal Revenue Code for the year in which Executive&#8217;s employment is terminated.</font></div><div style="margin-bottom:462.75pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(e) &#160;&#160;&#160;&#160;The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><div id="i1f7be45caf5e43b8ac268cf978b4fb03_41"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> each of the Parties has executed this Agreement as of the day and year first above written.</font></div><div style="margin-top:12pt;padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;COMPANY&#8221;</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</font></div><div style="margin-top:12pt;padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Paula Ragan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">___________ </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Paula Ragan</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">X4 Pharmaceuticals, Inc </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61 North Beacon Street, 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Floor </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Boston, MA 02134 </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ronny Mosston </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; </font></div><div style="padding-left:252pt"><font><br></font></div><div style="margin-top:35pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;EXECUTIVE&#8221;</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADAM MOSTAFA</font></div><div style="padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Adam Mostafa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_____________</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Adam Mostafa</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">___________________________</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:88.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SIGNATURE PAGE</font></div><div><font><br></font></div></div></div><div id="i1f7be45caf5e43b8ac268cf978b4fb03_44"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PERMITTED CONSULTING ENGAGEMENTS</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Abmed</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264808375 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>ex1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i880236acf9984a70a7326a606777f1d7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.20</font></div></div><div style="margin-top:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:10.85pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of March 7, 2022, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between X4 Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Derek M. Meisner (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:152.02pt;padding-right:152.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">R E C I T A L S</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive has been employed by the Company as its General Counsel and, subsequently, Chief Legal Officer, pursuant to the Executive Employment Agreement with the Company dated September 25, 2019, which was amended February 24, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company wishes to continue employing Executive to serve as its Chief Legal Officer and to enter into an agreement embodying the terms of such employment&#59;</font></div><div style="margin-top:0.5pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive desires to continue in such employment and enter into such an agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:152.12pt;padding-right:152.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">A G R E E M E N T</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and mutual covenants herein and for other good and valuable consideration, the Parties agree as follows&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Duties and Scope of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Positions and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As of November 4, 2019, Executive served as General Counsel of the Company.  As of October 6, 2021, Executive began serving and will continue to serve as Chief Legal Officer of the Company.  Executive will render such business and professional services in the performance of Executive&#8217;s duties, consistent with Executive&#8217;s position within the Company, as shall reasonably be assigned to Executive by the Company&#8217;s Chief Executive Officer. The period of Executive&#8217;s at-will employment under the terms of this Agreement is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:5.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the Employment Term, Executive will perform Executive&#8217;s duties faithfully and to the best of Executive&#8217;s ability and will devote Executive&#8217;s full business efforts and time to the Company. For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity, for any direct or indirect remuneration, that may create a conflict of interest or interfere with Executive&#8217;s duties to the Company, without the prior approval of the Company&#8217;s Chief Executive Officer.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#160;&#160;&#160;&#160;As a condition of Executive&#8217;s continued employment, Executive certifies to the Company that&#58; (a) Executive is free to enter into and fully perform the duties of Executive&#8217;s position&#59; (b) Executive is not subject to any employment, confidentiality, non-competition or other agreement that would restrict Executive&#8217;s performance for the Company&#59; (c) Executive&#8217;s signing this Agreement does not violate any order, judgment or injunction applicable to Executive, or conflict with or breach any agreement to which Executive is a party or by which Executive is bound&#59; and (d) all facts Executive has presented to the Company are accurate and true, including, but not limited to, all oral and written statements Executive has made (including those pertaining to Executive&#8217;s education, training, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">258415693 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">qualifications, licensing and prior work experience) in any job application, resume, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, interview or discussion with the Company.</font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to Sections 6, 7, and 8 below, the parties agree that Executive's employment with the Company will be &#8220;at-will&#8221; employment and may be terminated at any time with or without cause or notice, for any reason or no reason. Executive understands and agrees that neither Executive&#8217;s job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of Executive&#8217;s employment with the Company.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the Employment Term, the Company will pay Executive as compensation for Executive&#8217;s services a base salary, which was originally set at a rate of $400,000.00 per year and was increased to $418,000 effective in February 2020 and to $438,900 effective in July 2021, as may be further modified from time to time at the discretion of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Base Salary will be paid in regular installments in accordance with the Company&#8217;s normal payroll practices (subject to required withholding). Any increase or decrease in Base Salary (together with the then existing Base Salary) shall serve as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for future employment under this Agreement. The first and last payment will be adjusted, if necessary, to reflect a commencement or termination date other than the first or last working day of a pay period.</font></div><div style="padding-left:41pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Start Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive was eligible to earn a one-time bonus of $135,000.00, less applicable withholdings (&#8220;Start Bonus&#8221;). The Company paid Executive 50% of the Start Bonus, in advance of being earned, within thirty (30) days after November 4, 2019, and the other 50% of the Start Bonus on or about the same date that the Company paid annual bonuses to employees in approximately March 2020. Executive earned each portion of the Start Bonus as Executive remained continuously employed with the Company through the one-year anniversary of the applicable payment date of such portion. If Executive&#8217;s employment with the Company had terminated for any reason (except by the Executive for Good Reason, as defined below) prior to the one-year anniversary of the applicable payment date of such portion, Executive agreed to repay such unearned portion(s) with thirty (30) days after the date Executive&#8217;s employment terminated.</font></div><div style="padding-left:41pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive will also be eligible to earn an annual discretionary bonus with a target amount equal to 40% of the Base Salary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The amount of this bonus, if any, will be determined in the sole discretion of the Company and based, in part, on Executive&#8217;s performance and the performance of the Company during the calendar year. The Company will pay Executive this bonus, if any, by no later than March 15th of the following calendar year. The bonus is not earned until paid and, except as set forth in Section 8(a) of this Agreement, no pro-rated amount will be paid if Executive&#8217;s employment terminates for any reason prior to the payment date.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In connection with the commencement of Executive&#8217;s employment and as approved by the Board of Directors of the Company or the Compensation Committee thereof, the Company granted Executive a non-qualified stock option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the purchase of an aggregate of 55,000 shares of Common Stock of the Company at a price per share equal to the fair market value on the date of grant, as an inducement material to Executive joining the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listed Company Manual, under the Company&#8217;s 2019 Inducement Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Option is subject to all terms, vesting, and other provisions set forth in a separate option agreement under the Plan. The Option has a term of 10 years, except as set forth in the option agreement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the Plan, and is subject to a vesting schedule of four years, with 25% of the shares vesting on the first anniversary of Executive&#8217;s employment start date and the remainder vesting in equal installments over the following 36 months, provided, that Executive remains continuously employed by the Company on such vesting dates.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Executive will be eligible to receive awards of stock options, restricted stock or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board or a committee of the Board shall determine in its discretion whether Executive shall be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the Employment Term, Executive may take advantage of various benefits offered by the Company, such as group medical insurance, dental insurance, short-term disability, long- term disability and the Company&#8217;s 401(k) plan. Executive will also be entitled to fifteen (15) days of paid time off per year, as well as two (2) personal days and eleven (11) paid holidays, exclusive of any sick days Executive may need. These benefits may be modified or changed from time to time at the sole discretion of the Company. The details of the Company&#8217;s full benefit offerings can be found in its Employee Handbook.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the Employment Term, the Company will reimburse Executive for reasonable business travel, entertainment or other business expenses incurred by Executive in the furtherance of or in connection with the performance of Executive&#8217;s duties hereunder, in accordance with the Company&#8217;s expense reimbursement policy as in effect from time to time. All reimbursements provided under this Agreement will be made or provided in accordance with the requirements of Section 409A of the Internal Revenue Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the rules and regulations thereunder, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement)&#59; (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year&#59; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and (iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="padding-left:40.5pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination on Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive&#8217;s employment will terminate automatically upon Executive&#8217;s death or, upon fourteen (14) days prior written notice from the Company, in the event of Disability.</font></div><div style="padding-left:76.5pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon any termination for death or Disability, Executive shall be entitled to&#58; (i) Executive&#8217;s Base Salary through the effective date of termination&#59; (ii) the right to continue health care benefits under Title X of the Consolidated Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), at Executive&#8217;s cost, to the extent required and available by law&#59; (iii) reimbursement of expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company plans or policies, as then in effect.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Involuntary Termination for Cause&#59; Resignation without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any other provision of this Agreement, the Company may terminate Executive&#8217;s employment at any time for Cause, which shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effective on the date the Company gives notice to Employee of such termination in accordance with this Agreement unless otherwise agreed by the Parties. Executive may resign from Executive&#8217;s employment with the Company without Good Reason, provided that Executive provide at least four (4) weeks prior written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Such resignation shall be effective upon the expiration of the Notice Period. In the event that the Company accelerates the effective date of a resignation, such acceleration shall not be construed as a termination of Executive&#8217;s employment by the Company or deemed Good Reason for such resignation.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the case of the Company&#8217;s termination of Executive&#8217;s employment for Cause, or Executive&#8217;s resignation without Good Reason, Executive shall be entitled to receive&#58; (i) Base Salary through the effective date of the termination or resignation, as applicable&#59; (ii) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (iii) the right to continue health care benefits under COBRA, at Executive&#8217;s cost, to the extent required and available by law&#59; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company plans or policies, as then in effect.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Involuntary Termination Without Cause&#59; Resignation for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="margin-top:2.1pt;padding-right:5.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall be entitled to terminate Executive without Cause and Executive may resign for Good Reason, subject to the following&#58;</font></div><div style="margin-top:0.45pt;padding-left:36pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) &#160;&#160;&#160;&#160;If Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 23 below, Executive shall be entitled to receive&#58; (A) Executive&#8217;s Base Salary through the effective date of the termination or resignation&#59; (B) continuing severance pay at a rate equal to one hundred percent (100%) of Executive&#8217;s Base Salary, as then in effect (less applicable withholding), for a period of twelve (12) months from the date of such termination, to be paid periodically in accordance with the Company&#8217;s normal payroll practices&#59; (C) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (D) pro-rata portion of the Target Bonus for the calendar year in which the termination occurs based on the period worked by Executive during such calendar year prior to termination&#59; (E) provided that Executive elects COBRA coverage, the Company shall reimburse Executive for a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date Executive&#8217;s employment terminates, until the earlier of six (6) months from the date of termination or the date upon which Executive becomes eligible to receive health benefits through another employer&#59; (F) accelerated vesting of any then-outstanding unvested equity awards equal to the number of shares subject to such then-outstanding unvested equity awards that would have vested had Executive otherwise remained employed for an additional six (6) months after the date Executive&#8217;s employment with the Company terminated&#59; and (G) no other severance or benefits of any kind, unless required by law or pursuant to any written Company plans or policies, as then in effect.</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) &#160;&#160;&#160;&#160;If, within twelve (12) months after a Change of Control as defined below, Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 23 below, Executive shall be entitled to receive, in lieu of the benefits set forth in Section 8(a)(i)&#58; (A) Executive&#8217;s Base Salary through the effective date of the termination or resignation&#59; (B) continuing severance pay at a rate equal to one hundred percent (100%) of Executive&#8217;s Base Salary, as then in effect (less applicable withholding), for a period of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">twelve (12) months from the date of such termination, to be paid periodically in accordance with the Company&#8217;s normal payroll practices&#59; (C) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (D) an amount equal to Executive&#8217;s full Target Bonus for the calendar year in which the termination occurs in advance of such Target Bonus being earned&#59; (E) provided that Executive elects COBRA coverage, the Company shall reimburse Executive for a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date Executive&#8217;s employment terminates, until the earlier of six months from the date of termination or the date upon which Executive becomes eligible to receive health benefits through another employer&#59; (F) the full acceleration of vesting of any then-outstanding unvested equity awards as of the date Executive&#8217;s employment with the Company terminated&#59; and (G) no other severance or benefits of any kind, unless required by law or pursuant to any written Company plans or policies, as then in effect. For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined as a Reorganization Event, as defined in the the X4 Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2017 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as it may be further amended from time to time, or any successor plan&#160;thereto.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any severance payments contemplated by Section 8(a)(i)or 8(a)(ii) above are conditional on Executive&#58; (i) continuing to comply with the terms of this Agreement and the Confidential Information Agreement (as defined below)&#59; and (ii) signing and not revoking a separation agreement and release of known and unknown claims in the form provided by the Company (including nondisparagement and no cooperation provisions) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and provided that such Release becomes effective and irrevocable no later than sixty (60) days following the termination date or such earlier date required by the release (such deadline, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If the Release does not become effective by the Release Deadline, Executive will forfeit any rights to severance or benefits under Sections 8(a)(i) or 8(a)(ii) or elsewhere in this Agreement. Any severance payments or other benefits under this Agreement will be paid on, or, in the case of installments, will not commence until, the sixtieth (60th) day following Executive&#8217;s separation from service, or, if later, such time as required by Section 23(b). Except as required by Section 23(b), any installment payments that would have been made to Employee during the sixty (60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive&#8217;s separation from service and the remaining payments will be made as provided in this Agreement, unless subject to the 6- month payment delay described herein. Notwithstanding the foregoing, this Section 8(b) shall not limit Executive&#8217;s ability to obtain expense reimbursements under Section 5 or any other compensation or benefits otherwise required by law or in accordance with written Company plans or policies, as then in effect.</font></div><div style="padding-left:99pt;text-indent:-27pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean&#58; (i) Executive&#8217;s continued failure to substantially perform the material duties and obligations under this Agreement (for reasons other than death or Disability), which failure, if curable within the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice from the Company of such failure&#59; (ii) Executive&#8217;s failure or refusal to comply with the policies, standards and regulations established by the Company from time to time which failure, if curable in the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice of such failure from the Company&#59; (iii) any act of willful misconduct, fraud, embezzlement, misrepresentation, or other unlawful act committed by Executive that benefits Executive at the expense of the Company&#59; (iv) the Executive&#8217;s violation of a federal or state law or regulation applicable to the Company&#8217;s business&#59; (v) the Executive&#8217;s violation of, or a plea of nolo contendere or guilty to, a felony under the laws of the United States or any state&#59; (vi) the Executive&#8217;s material breach of the terms of this Agreement or the Confidential </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Information Agreement (defined below)&#59; or (vii) the Company&#8217;s severe financial distress, whereby the Company is in the process of winding down its business and Executive&#8217;s employment is terminated in connection with such winding down&#59; provided that prior to such termination, a determination is made by the Company&#8217;s Board of Directors that none of the Company&#8217;s Officers (as that term is defined in Section 16 of the Securities Exchange Act of 1934) will receive severance payments in connection with the winding down of the Company&#8217;s business.</font></div><div style="padding-left:41pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that Executive, at the time notice is given, has been unable to substantially perform Executive&#8217;s duties under this Agreement for not less than one-hundred and twenty (120) work days within a twelve (12) consecutive month period as a result of Executive&#8217;s incapacity due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation.</font></div><div style="padding-left:41pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s written notice of Executive&#8217;s intent to resign for Good Reason with a reasonable description of the grounds therefor within 10 days after the occurrence of one or more of the following without Executive&#8217;s consent, and subsequent resignation within 30 days following the expiration of any Company cure period (discussed below)&#58; (i) a material reduction of Executive&#8217;s duties, position or responsibilities&#59; (ii) </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a material reduction in Executive&#8217;s Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, which the parties agree is a reduction of at least 10% of Executive&#8217;s base salary (unless pursuant to a salary reduction program applicable generally to the Company&#8217;s similarly situated employees)&#59; (iii) relocation of Executive&#8217;s principal place of employment to a place that increases Executive&#8217;s one-way commute by more than sixty (60) miles as compared to Executive&#8217;s then-current principal place of employment immediately prior to such relocation&#59; (iv) a material breach of this Agreement by the Company&#59; or (v) any directive given to Executive by the Company that the Company knows is in violation of a law, regulation, or material Company policy and the Company requires Executive to implement as a condition of his continued employment.  Executive will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#8220;Good Reason&#8221; within 30 days of the initial existence of the grounds for &#8220;Good Reason&#8221; and a reasonable cure period of not less than 30 days following the date of such notice if such act or omission is capable of cure.</font></div><div style="padding-left:41pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Proprietary Information and Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive agrees to continue to abide by the Confidentiality, Non-Solicitation, Intellectual Property and Change of Control Agreement Executive signed on September 29, 2019, as amended on February 20, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:41pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation on Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. On termination of Executive&#8217;s employment, regardless of the reason for such termination, Executive shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Executive may hold in the Company or any affiliate, unless otherwise agreed in writing by the Parties.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notification of New Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that Executive leaves the employ of the Company, Executive grants consent to notification by the Company to Executive&#8217;s new employer about Executive&#8217;s rights and obligations under this Agreement and the Confidential Information Agreement. Company agrees not to notify Executive&#8217;s new employer unless it has a reasonable belief that Executive has violated or intends to violate a provision of the Confidential Information Agreement.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To ensure the timely and economical resolution of disputes that may arise in connection with Executive&#8217;s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, Confidential Information Agreement, or Executive&#8217;s employment, or the termination of Executive&#8217;s employment, including but not limited to all statutory claims, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration by a single arbitrator conducted in Boston, Massachusetts by Judicial Arbitration and Mediation Services Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) under the then applicable JAMS rules (at the following web address&#58; https&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;)&#59; provided, however, this arbitration provision shall not apply to sexual harassment claims to the extent prohibited by applicable law. A hard copy of the rules will be provided to you upon request. A hard copy of the rules will be provided to Executive upon request. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition, all claims, disputes, or causes of action under this section, whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. The Company acknowledges that Executive will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this Agreement) shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award&#59; and (c) be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. Executive and the Company shall equally share all JAMS&#8217; arbitration fees. Except as modified in the Confidential Information Agreement, each party is responsible for its own attorneys&#8217; fees. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. To the extent applicable law prohibits mandatory arbitration of sexual harassment claims, in the event you intend to bring multiple claims, including a sexual harassment claim, the sexual harassment may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.</font></div><div style="text-indent:90pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives of Executive upon Executive's death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer, conveyance or other disposition of Executive&#8217;s right to compensation or other benefits will be null and void.</font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:49.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices, requests, demands and other communications called for under this Agreement shall be in writing and shall be delivered via e-mail, personally by hand or by courier, mailed by United States first-class mail, postage prepaid, or sent by facsimile directed to the Party to be notified at the address or facsimile number indicated for such Party on the signature page to this Agreement, or at such other address or facsimile number as such Party may designate by ten (10) days&#8217; advance written notice to the other Parties hereto. All such notices and other communications shall be deemed given upon personal delivery, three (3) days after the date of mailing, or upon confirmation of facsimile transfer or e-mail. Notices sent via e-mail under this Section shall be sent to either the e-mail address in this Agreement, or for e-mails sent by the Company to Executive, to the last e-mail address on file with the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement, together with the Plan and related agreements, the 2017 Plan and related agreements, and the Confidential Information Agreement represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements whether written or oral, including, but not limited to, the Prior Agreement. No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless in writing and signed by duly authorized representatives of the parties hereto.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No Party shall be deemed to have waived any right, power or privilege under this Agreement or any provisions hereof unless such waiver shall have been duly executed in writing and acknowledged by the Party to be charged with such waiver. The failure of any Party at any time to insist on performance of any of the provisions of this Agreement shall in no way be construed to be a waiver of such provisions, nor in any way to affect the validity of this Agreement or any part hereof. No waiver of any breach of this Agreement shall be held to be a waiver of any other subsequent breach.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement will be governed by the laws of the Commonwealth of Massachusetts (with the exception of its conflict of laws provisions).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive acknowledges that Executive has had the opportunity to discuss this matter with and obtain advice from Executive&#8217;s legal counsel, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily entering into this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original, and all such counterparts shall constitute but one instrument.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effect of Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The section and subsection headings contained herein are for convenience only and shall not affect the construction hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Construction of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement has been negotiated by the respective Parties, and the language shall not be construed for or against either Party.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section 409A (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Deferred Compensation Separation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be paid or otherwise provided until Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of Executive&#8217;s termination (other than due to death), then the Deferred Compensation Separation Benefits that are payable within the first six (6) months following Executive&#8217;s separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive&#8217;s separation from service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive&#8217;s separation from service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&#8217;s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Agreement is intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Any amount paid under this Agreement that satisfies the requirements of the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Compensation Separation Benefits for purposes of clause (a) above.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Compensation Separation Benefits for purposes of clause (a) above. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A Limit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; will mean the lesser of two (2) times&#58; (i) Executive&#8217;s annualized compensation based upon the annual rate of pay paid to Executive during the Executive&#8217;s taxable year preceding Executive&#8217;s taxable year of Executive&#8217;s termination of employment as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto&#59; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Internal Revenue Code for the year in which Executive&#8217;s employment is terminated.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each of the Parties has executed this Agreement as of the day and year first above written.</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;COMPANY&#8221;</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Paula Ragan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">___________</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">      &#160;&#160;&#160;&#160;Paula Ragan, Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;</font></div><div style="padding-left:252pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X4 Pharmaceuticals, Inc.</font></div><div style="padding-left:252pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61 N. Beacon Street</font></div><div style="padding-left:252pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston, MA 02134</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58;   Ronny Mosston</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; </font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;EXECUTIVE&#8221;</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEREK M. MEISNER</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Derek M. Meisner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________</font></div><div><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:270pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>4
<FILENAME>ex1021.htm
<DESCRIPTION>EX-10.21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic97730044a03413295bc5825bab414e2_38"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.21</font></div></div><div style="margin-top:12pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:126px;margin-bottom:5pt;vertical-align:text-bottom;width:126px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) is entered into as of March 7, 2022, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) by and between X4 Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;), and Dr. Arthur Taveras (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) (collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; or individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;).</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">R E C I T A L S</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">WHEREAS, Executive has been employed by the Company as its Chief Scientific Officer, pursuant to the Executive Employment Agreement with the Company dated October 21, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">WHEREAS, the Company wishes to continue employing Executive as its Chief Scientific Officer and to enter into an amended and restated agreement embodying the terms of such employment&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">WHEREAS, Executive desires to continue such employment and enter into such an agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">A G R E E M E N T</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">NOW, THEREFORE, in consideration of the premises and mutual covenants herein and for other good and valuable consideration, the Parties agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Duties and Scope of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Positions and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. As of November 2, 2020, Executive will serve as Chief Scientific Officer of the Company. Executive will render such business and professional </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264807891 v1</font></div><div><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264807891 v2</font></div><div><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264807891 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">services in the performance of Executive&#8217;s duties, consistent with Executive&#8217;s position within the Company, as shall reasonably be assigned to Executive by the Company&#8217;s Chief Executive Officer. The period of Executive&#8217;s at-will employment under the terms of this Agreement is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.&#8221;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, Executive will perform Executive&#8217;s duties faithfully and to the best of Executive&#8217;s ability and will devote Executive&#8217;s full business efforts and time to the Company. For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity, for any direct or indirect remuneration, that may create a conflict of interest or interfere with Executive&#8217;s duties to the Company, without the prior approval of the Company&#8217;s Chief Executive Officer</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. As a condition of Executive&#8217;s employment, Executive certifies to the Company that&#58; (a) Executive is free to enter into and fully perform the duties of Executive&#8217;s position&#59; (b) Executive is not subject to any employment, confidentiality, non-competition or other agreement that would restrict Executive&#8217;s performance for the Company&#59; (c) Executive&#8217;s signing this Agreement does not violate any order, judgment or injunction applicable to Executive, or conflict with or breach any agreement to which Executive is a party or by which Executive is bound&#59; and (d) all facts Executive has presented to the Company are accurate and true, including, but not limited to, all oral and written statements Executive has made (including those pertaining to Executive&#8217;s education, training, qualifications, licensing and prior work experience) in any job application, resume, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">c.v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, interview or discussion with the Company.</font></div><div style="margin-top:0.1pt;text-indent:0.35pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Subject to Sections 6, 7, and 8 below, the parties agree that Executive's employment with the Company will be &#8220;at-will&#8221; employment and may be terminated at any time with or without cause or notice, for any reason or no reason. Executive understands and agrees that neither Executive&#8217;s job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">amendment, or extension, by implication or otherwise, of Executive&#8217;s employment with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, the Company will initially pay Executive as compensation for Executive&#8217;s services a base salary at a rate of $390,000.00 per year, as modified from time to time at the discretion of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). The Base Salary will be paid in regular installments in accordance with the Company&#8217;s normal payroll practices (subject to required withholding). Any increase or decrease in Base Salary (together with the then existing Base Salary) shall serve as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; for future employment under this Agreement. The first and last payment will be adjusted, if necessary, to reflect a commencement or termination date other than the first or last working day of a pay period.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Beginning for the calendar year 2021, Executive will also be eligible to earn an annual discretionary bonus with a target amount equal to 40% of the Base Salary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). The amount of this bonus, if any, will be determined in the sole discretion of the Company and based, in part, on Executive&#8217;s performance and the performance of the Company during the calendar year. The Company will pay Executive this bonus, if any, by no later than March 15th of the following calendar year. The bonus is not earned until paid and, except as set forth in Section 8(a) of this Agreement, no pro-rated amount will be paid if Executive&#8217;s employment terminates for any reason prior to the payment date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In connection with the commencement of Executive&#8217;s employment, and  as approved by the Board of Directors of the Company or the Compensation Committee thereof, the Company granted Executive a non-qualified stock option (the &#8220;Option&#8221;) for the purchase of an aggregate of 121,150 shares of Common Stock of the Company at a price per share equal to the fair market value on the date of grant, as an inducement material to Executive joining the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listed Company Manual, under the Company&#8217;s 2019 Inducement Equity Incentive Plan (the &#8220;Plan&#8221;). The Option is subject to all terms, vesting, and other provisions set forth in a separate option agreement under the Plan. The Option has a term of 10 years, except as set forth in the option agreement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">and the Plan, and is subject to a vesting schedule of four years, with 25% of the shares vesting on the first anniversary of Executive&#8217;s employment start date and the remainder vesting in equal installments over the following 36 months, provided, that Executive remains continuously employed by the Company on such vesting dates.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:114.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(i)&#160;&#160;&#160;&#160;Executive will be eligible to receive awards of stock options, restricted stock or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board or a committee of the Board shall determine in its discretion whether Executive shall be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, Executive may take advantage of various benefits offered by the Company, such as group medical insurance, dental insurance, short-term disability, long-term disability and the Company&#8217;s 401(k) plan. Executive will also be entitled to fifteen (15) days of paid time off per year, as well as two (2) personal days and eleven (11) paid holidays, exclusive of any sick days Executive may need. These benefits may be modified or changed from time to time at the sole discretion of the Company. The details of the Company&#8217;s full benefit offerings can be found in its Employee Handbook. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Business Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, the Company will reimburse Executive for reasonable business travel, entertainment or other business expenses incurred by Executive in the furtherance of or in connection with the performance of Executive&#8217;s duties hereunder, in accordance with the Company&#8217;s expense reimbursement policy as in effect from time to time. All reimbursements provided under this Agreement will be made or provided in accordance with the requirements of Section 409A of the Internal Revenue Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) and the rules and regulations thereunder, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement)&#59; (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year&#59; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Termination on Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Executive&#8217;s employment will terminate automatically upon Executive&#8217;s Death or, upon fourteen (14) days prior written notice from the Company, in the event of Disability.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Upon any termination for death or Disability, Executive shall be entitled to&#58; (i) Executive&#8217;s Base Salary through the effective date of termination&#59; (ii) the right to continue health care benefits under Title X of the Consolidated Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;), at Executive&#8217;s cost, to the extent required and available by law&#59; (iii) reimbursement of expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company plans or policies, as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Involuntary Termination for Cause&#59; Resignation without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:65.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Notwithstanding any other provision of this Agreement, the Company may terminate Executive&#8217;s employment at any time for Cause, which shall be effective on the date the Company gives notice to Employee of such termination in accordance with this Agreement unless otherwise agreed by the Parties. Executive may resign from Executive&#8217;s employment with the Company without Good Reason, provided that Executive provide at least four (4) weeks prior written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). Such resignation shall be effective upon the expiration of the Notice Period. In the event that the Company accelerates the effective date of a resignation, such acceleration shall not be construed as a termination of Executives employment by the Company or deemed Good Reason for such resignation.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:62.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In the case of the Company&#8217;s termination of Executive&#8217;s employment for Cause, or Executive&#8217;s resignation without Good Reason, Executive shall be entitled to receive&#58; (i) Base Salary through the effective date of the termination or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">resignation, as applicable&#59; (ii) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (iii) the right to continue health care benefits under COBRA, at Executive&#8217;s cost, to the extent required and available by law&#59; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company plans or policies, as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Involuntary Termination Without Cause&#59; Resignation for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:59pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. The Company shall be entitled to terminate Executive without Cause and Executive may resign for Good Reason, subject to the following&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">i.&#160;&#160;&#160;&#160;If Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 23 below, Executive shall be entitled to receive&#58; (A) Executive&#8217;s Base Salary through the effective date of the termination or resignation&#59; (B) continuing severance pay at a rate equal to one hundred percent (100%) of Executive&#8217;s Base Salary, as then in effect (less applicable withholding), for a period of twelve (12) months from the date of such termination, to be paid periodically in accordance with the Company&#8217;s normal payroll practices&#59; (C) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (D) pro-rata portion of the Target Bonus for the calendar year in which the termination occurs based on the period worked by Executive during such calendar year prior to termination&#59; (E) provided that Executive elects COBRA coverage, the Company shall reimburse Executive for a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date Executive&#8217;s employment terminates, until the earlier of six months from the date of termination or the date upon which Executive becomes eligible to receive health benefits through another employer&#59; (F) accelerated vesting of any then-outstanding unvested equity awards equal to the number of shares subject to such then-outstanding equity awards that would have vested had Executive otherwise remained employed for an additional six months after the date Executive&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">employment with the Company terminated&#59; and (G)  no other severance or benefits of any kind, unless required by law or pursuant to any written Company plans or policies, as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">ii.&#160;&#160;&#160;&#160;If, within twelve (12) months after a Change of Control as defined below, Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 23 below, Executive shall be entitled to receive, in lieu of the benefits set forth in Section 8(a)(i)&#58; (A) Executive&#8217;s Base Salary through the effective date of the termination or resignation&#59; (B) continuing severance pay at a rate equal to one hundred percent (100%) of Executive&#8217;s Base Salary, as then in effect (less applicable withholding), for a period of twelve (12) months from the date of such termination, to be paid periodically in accordance with the Company&#8217;s normal payroll practices&#59; (C) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (D) an amount equal to Executive&#8217;s full Target Bonus for the calendar year in which the termination occurs in advance of such Target Bonus being earned&#59; (E) provided that Executive elects COBRA coverage, the Company shall reimburse Executive for a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date Executive&#8217;s employment terminates, until the earlier of six months from the date of termination or the date upon which Executive becomes eligible to receive health benefits through another employer&#59; (F) the full acceleration of vesting of any then-outstanding unvested equity awards as of the date Executive&#8217;s employment with the Company terminated&#59; and (G) no other severance or benefits of any kind, unless required by law or pursuant to any written Company plans or policies, as then in effect. For purposes of this Agreement, a &#8220;Change of Control&#8221; is defined as a Reorganization Event, as defined in the X4 Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), as it may be further amended from time to time, or any successor plan thereto.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Any severance payments contemplated by Sections 8(a)(i) and 8(a)(ii) above are conditional on Executive&#58; (i) continuing to comply with the terms of this Agreement and the Confidential Information Agreement (as defined below)&#59; and (ii) signing and not revoking a separation agreement and release of known and unknown claims in the form </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">provided by the Company (including nondisparagement and no cooperation provisions) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) and provided that such Release becomes effective and irrevocable no later than sixty (60) days following the termination date or such earlier date required by the release (such deadline, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Release Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). If the Release does not become effective by the Release Deadline, Executive will forfeit any rights to severance or benefits under Sections 8(a)(i) or 8(a)(ii) or elsewhere in this Agreement. Any severance payments or other benefits under this Agreement will be paid on, or, in the case of installments, will not commence until, the sixtieth (60th) day following Executive&#8217;s separation from service, or, if later, such time as required by Section 23(b). Except as required by Section 23(b), any installment payments that would have been made to Employee during the sixty (60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive&#8217;s separation from service and the remaining payments will be made as provided in this Agreement, unless subject to the 6-month payment delay described herein. Notwithstanding the foregoing, this Section 8(b) shall not limit Executive&#8217;s ability to obtain expense reimbursements under Section 5 or any other compensation or benefits otherwise required by law or in accordance with written Company plans or policies, as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; shall mean&#58; (i) Executive&#8217;s continued failure to substantially perform the material duties and obligations under this Agreement (for reasons other than death or Disability), which failure, if curable within the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice from the Company of such failure&#59; (ii) Executive&#8217;s failure or refusal to comply with the policies, standards and regulations established by the Company from time to time which failure, if curable in the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice of such failure from the Company&#59; (iii) any act of willful misconduct, fraud, embezzlement, misrepresentation, or other unlawful act committed by Executive that benefits Executive at the expense of the Company&#59; (iv) the Executive&#8217;s violation of a federal or state law or regulation applicable to the Company&#8217;s business&#59; (v) the Executive&#8217;s violation of, or a plea of nolo contendere or guilty to, a felony under the laws of the United States or any state&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(vi) the Executive&#8217;s material breach of the terms of this Agreement or the Confidential Information Agreement (defined below)&#59; or (vii) the Company&#8217;s severe financial distress, whereby the Company is in the process of winding down its business and Executive&#8217;s employment is terminated in connection with such winding down&#59; provided that prior to such termination, a determination is made by the Company&#8217;s Board of Directors that none of the Company&#8217;s Officers (as that term is defined in Section 16 of the Securities Exchange Act of 1934) will receive severance payments in connection with the winding down of the Company&#8217;s business. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:59.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; means that Executive, at the time notice is given, has been unable to substantially perform Executive&#8217;s duties under this Agreement for not less than one-hundred and twenty (120) work days within a twelve (12) consecutive month period as a result of Executive&#8217;s incapacity due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; means Executive&#8217;s written notice of Executive&#8217;s intent to resign for Good Reason with a reasonable description of the grounds therefor within 10 days after the occurrence of one or more of the following without Executive&#8217;s consent, and subsequent resignation within 30 days following the expiration of any Company cure period (discussed below)&#58; (i) a material reduction of Executive&#8217;s duties, position or responsibilities&#59; (ii) </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">a material reduction in Executive&#8217;s Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, which the parties agree is a reduction of at least 10% of Executive&#8217;s base salary (unless pursuant to a salary reduction program applicable generally to the Company&#8217;s similarly situated employees)&#59; (iii) relocation of Executive&#8217;s principal place of employment to a place that increases Executive&#8217;s one-way commute by more than sixty (60) miles as compared to Executive&#8217;s then-current principal place of employment immediately prior to such relocation&#59; (iv) a material breach of this Agreement by the Company&#59; or (v) any directive given to Executive by the Company that the Company knows is in violation of a law, regulation, or material Company policy and the Company requires Executive to implement as a condition of his continued employment.  Executive will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#8220;Good Reason&#8221; within 30 days of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">initial existence of the grounds for &#8220;Good Reason&#8221; and a reasonable cure period of not less than 30 days following the date of such notice if such act or omission is capable of cure.</font></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Company Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:53pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Proprietary Information and Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In connection with Executive&#8217;s employment with the Company, Executive will receive and have access to Company confidential information and trade secrets. Executive agrees to continue to abide by the Confidentiality, Non-Solicitation, Intellectual Property and Change of Control Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Confidential Information Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) Executive signed October 23, 2020, which contains restrictive covenants and prohibits unauthorized use or disclosure of the Company&#8217;s confidential information and trade secrets, among other obligations.  However, Executive and the Company agree that this Agreement shall have the effect of amending the Confidential Information Agreement by deleting Section 8 thereof in its entirety.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:59.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Resignation on Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. On termination of Executive&#8217;s employment, regardless of the reason for such termination, Executive shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Executive may hold in the Company or any affiliate, unless otherwise agreed in writing by the Parties.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Notification of New Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In the event that Executive leaves the employ of the Company, Executive grants consent to notification by the Company to Executive&#8217;s new employer about Executive&#8217;s rights and obligations under this Agreement and the Confidential Information Agreement. Company agrees not to notify Executive&#8217;s new employer unless it has a reasonable belief that Executive has violated or intends to violate a provision of the Confidential Information Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. To ensure the timely and economical resolution of disputes that may arise in connection with Executive&#8217;s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, Confidential Information Agreement, or Executive&#8217;s employment, or the termination of Executive&#8217;s employment, including but not limited to all statutory claims, will be resolved </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration by a single arbitrator conducted in Boston, Massachusetts by Judicial Arbitration and Mediation Services Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) under the then applicable JAMS rules (at the following web address&#58; https&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;)&#59; provided, however, this arbitration provision shall not apply to sexual harassment claims to the extent prohibited by applicable law. A hard copy of the rules will be provided to Executive upon request. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In addition, all claims, disputes, or causes of action under this section, whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. The Company acknowledges that Executive will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this Agreement) shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award&#59; and (c) be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. Executive and the Company shall equally share all JAMS&#8217; arbitration fees. Except as modified in the Confidential Information Agreement, each party is responsible for its own attorneys&#8217; fees. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. To the extent applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">law prohibits mandatory arbitration of sexual harassment claims, in the event you intend to bring multiple claims, including a sexual harassment claim, the sexual harassment may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives of Executive upon Executive's death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer, conveyance or other disposition of Executive&#8217;s right to compensation or other benefits will be null and void.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. All notices, requests, demands and other communications called for under this Agreement shall be in writing and shall be delivered via e-mail, personally by hand or by courier, mailed by United States first-class mail, postage prepaid, or sent by facsimile directed to the Party to be notified at the address or facsimile number indicated for such Party on the signature page to this Agreement, or at such other address or facsimile number as such Party may designate by ten (10) days&#8217; advance written notice to the other Parties hereto. All such notices and other communications shall be deemed given upon personal delivery, three (3) days after the date of mailing, or upon confirmation of facsimile transfer or e-mail. Notices sent via e-mail under this Section shall be sent to either the e-mail address in this Agreement, or for e-mails sent by the Company to Executive, to the last e-mail address on file with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement, together with the Plan and related agreements, and the Confidential Information Agreement as amended by this Agreement represent the entire agreement and understanding between the parties as to the subject matter herein and supersedes </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">all prior or contemporaneous agreements whether written or oral. No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless in writing and signed by duly authorized representatives of the parties hereto.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. No Party shall be deemed to have waived any right, power or privilege under this Agreement or any provisions hereof unless such waiver shall have been duly executed in writing and acknowledged by the Party to be charged with such waiver. The failure of any Party at any time to insist on performance of any of the provisions of this Agreement shall in no way be construed to be a waiver of such provisions, nor in any way to affect the validity of this Agreement or any part hereof. No waiver of any breach of this Agreement shall be held to be a waiver of any other subsequent breach.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement will be governed by the laws of the Commonwealth of Massachusetts (with the exception of its conflict of laws provisions).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Executive acknowledges that Executive has had the opportunity to discuss this matter with and obtain advice from Executive&#8217;s legal counsel, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily entering into this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original, and all such counterparts shall constitute but one instrument.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. The section and subsection headings contained herein are for convenience only and shall not affect the construction hereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Construction of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement has been negotiated by the respective Parties, and the language shall not be construed for or against either Party.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:59.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section 409A (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Deferred Compensation Separation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) will be paid or otherwise provided until Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:56.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of Executive&#8217;s termination (other than due to death), then the Deferred Compensation Separation Benefits that are payable within the first six (6) months following Executive&#8217;s separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive&#8217;s separation from service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive&#8217;s separation from service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&#8217;s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Agreement is intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:53pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;Any amount paid under this Agreement that satisfies the requirements of the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Compensation Separation Benefits for purposes of clause (a) above.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:53.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(d)&#160;&#160;&#160;&#160;Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Compensation Separation Benefits for purposes of clause (a) above. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Section 409A Limit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; will mean the lesser of two (2) times&#58; (i) Executive&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">annualized compensation based upon the annual rate of pay paid to Executive during the Executive&#8217;s taxable year preceding Executive&#8217;s taxable year of Executive&#8217;s termination of employment as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto&#59; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Internal Revenue Code for the year in which Executive&#8217;s employment is terminated.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:57pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(e)&#160;&#160;&#160;&#160;The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><div id="ic97730044a03413295bc5825bab414e2_41"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> each of the Parties has executed this Agreement as of the day and year first above written.</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;COMPANY&#8221;</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</font></div><div style="margin-top:12pt;padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Paula Ragan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">______________</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Paula Ragan</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X4 Pharmaceuticals, Inc </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61 N. Beacon Street, 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Floor </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston, MA 02134 </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Ronny Mosston </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; </font></div><div style="padding-left:252pt"><font><br></font></div><div style="margin-top:35pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;EXECUTIVE&#8221;</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DR. ARTHUR TAVERAS</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Dr. Arthur Taveras</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Name</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; </font></div><div><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Enclosure</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidentiality, Non-Solicitation, Intellectual Property and Change of Control Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SIGNATURE PAGE</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>5
<FILENAME>ex1022.htm
<DESCRIPTION>EX-10.22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i123528e761634f61ac05640366cc50f0_38"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.22</font></div></div><div style="margin-bottom:26.5pt;margin-top:0.3pt;padding-left:36pt;padding-right:221.35pt;text-align:right;text-indent:36pt"><font><br></font></div><div style="margin-bottom:26.5pt;margin-top:0.3pt;padding-left:219.85pt;padding-right:221.35pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:134px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT </font></div><div style="margin-top:26.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) is entered into as of March 7, 2022, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) by and between X4 Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;), and Dr. Diego Cadavid (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) (collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; or individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;).</font></div><div style="margin-top:11.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">R E C I T A L S</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">WHEREAS, Executive has been employed by the Company as its Chief Medical Officer, pursuant to the Executive Employment Agreement with the Company dated November 23, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;)&#59;</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">WHEREAS, the Company wishes to continue employing Executive as its Chief Medical Officer and to enter into an amended and restated agreement embodying the terms of such employment&#59;</font></div><div style="margin-top:11.9pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">WHEREAS, Executive desires to continue in such employment and enter into such an agreement.</font></div><div style="margin-top:12.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">A G R E E M E N T</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">NOW, THEREFORE, in consideration of the premises and mutual covenants herein and for other good and valuable consideration, the Parties agree as follows&#58;</font></div><div style="margin-top:12.25pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Duties and Scope of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264808076 v1</font></div><div><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264808076 v2</font></div><div><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">264808076 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Positions and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. As of December 14, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;), Executive will serve as Chief Medical Officer of the Company. Executive will render such business and professional services in the performance of Executive&#8217;s duties, consistent with Executive&#8217;s position within the Company, as shall reasonably be assigned to Executive by the Company&#8217;s Chief Executive Officer. The period of Executive&#8217;s at-will employment under the terms of this Agreement is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.&#8221;</font></div><div style="margin-top:11.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, Executive will perform Executive&#8217;s duties faithfully and to the best of Executive&#8217;s ability and will devote Executive&#8217;s full business efforts and time to the Company. For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity, for any direct or indirect remuneration, that may create a conflict of interest or interfere with Executive&#8217;s duties to the Company, without the prior approval of the Company&#8217;s Chief Executive Officer. Notwithstanding the foregoing, it is agreed and understood that the Executive may continue his current teaching clinical care activities at the University of Massachusetts Medical School for which he may receive nominal compensation for so long as such activities do not create a conflict of interest or otherwise interfere with the performance of the Executive&#8217;s duties hereunder.</font></div><div style="margin-top:11.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. As a condition of Executive&#8217;s employment, Executive certifies to the Company that&#58; (a) Executive is free to enter into and fully perform the duties of Executive&#8217;s position&#59; (b) Executive is not subject to any employment, confidentiality, non-competition or other agreement that would restrict Executive&#8217;s performance for the Company&#59; (c) Executive&#8217;s signing this Agreement does not violate any order, judgment or injunction applicable to Executive, or conflict with or breach any agreement to which Executive is a party or by which Executive is bound&#59; and (d) all facts Executive has presented to the Company are accurate and true, including, but not limited to, all oral and written statements Executive has made (including those pertaining to Executive&#8217;s education, training, qualifications, licensing and prior work experience) in any job application, resume, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-style:italic;font-weight:400;line-height:174%">c.v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, interview or discussion with the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">2. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Subject to Sections 6, 7, and 8 below, the parties agree that Executive's employment with the Company will be &#8220;at-will&#8221; employment and may be terminated at any time with or without cause or notice, for any reason or no reason. Executive understands and agrees that neither Executive&#8217;s job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of Executive&#8217;s employment with the Company.</font></div><div style="margin-top:12.2pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="margin-top:11.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, the Company will initially pay Executive as compensation for Executive&#8217;s services a base salary at a rate of $415,000.00 per year, as modified from time to time at the discretion of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). The Base Salary will be paid in regular installments in accordance with the Company&#8217;s normal payroll practices (subject to required withholding). Any increase or decrease in Base Salary (together with the then existing Base Salary) shall serve as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; for future employment under this Agreement. The first and last payment will be adjusted, if necessary, to reflect a commencement or termination date other than the first or last working day of a pay period.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Beginning for the calendar year 2021, Executive will also be eligible to earn an annual discretionary bonus with a target amount equal to 40% of the Base Salary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). The amount of this bonus, if any, will be determined in the sole discretion of the Company and based, in part, on Executive&#8217;s performance and the performance of the Company during the calendar year. The Company will pay Executive this bonus, if any, by no later than March 15th of the following calendar year. The bonus is not earned until paid and, except as set forth in Section 8(a) of this Agreement, no pro-rated amount will be paid if Executive&#8217;s employment terminates for any reason prior to the payment date.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In connection with the commencement of Executive&#8217;s employment and as approved by of the Board of Directors of the Company or the Compensation Committee thereof, the Company granted Executive a non-qualified stock option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) for the purchase of an aggregate of 121,500 shares of Common Stock of the Company at a price </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">per share equal to the fair market value on the date of grant, as an inducement material to Executive joining the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listed Company Manual, under the Company&#8217;s 2019 Inducement Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). The Option is subject to all terms, vesting, and other provisions set forth in a separate option agreement under the Plan. The Option has a term of 10 years, except as set forth in the option agreement and the Plan, and is subject to a vesting schedule of four years, with 25% of the shares vesting on the first anniversary of Executive&#8217;s employment start date and the remainder vesting in equal installments over the following 36 months, provided, that Executive remains continuously employed by the Company on such vesting dates.</font></div><div style="margin-top:11.9pt;text-align:justify;text-indent:115.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(i) &#160;&#160;&#160;&#160;Executive will be eligible to receive awards of stock options, restricted stock or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board or a committee of the Board shall determine in its discretion whether Executive shall be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">4. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, Executive may take advantage of various benefits offered by the Company, such as group medical insurance, dental insurance, short-term disability, long term disability and the Company&#8217;s 401(k) plan. Executive will also be entitled to fifteen (15) days of paid time off per year, as well as two (2) personal days and eleven (11) paid holidays, and holiday shutdowns exclusive of any sick days Executive may need. These benefits may be modified or changed from time to time at the sole discretion of the Company. The details of the Company&#8217;s full benefit offerings can be found in its Employee Handbook.</font></div><div style="margin-top:11.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">5. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Business Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. During the Employment Term, the Company will reimburse Executive for reasonable business travel, entertainment or other business expenses incurred by Executive in the furtherance of or in connection with the performance of Executive&#8217;s duties hereunder, in accordance with the Company&#8217;s expense reimbursement policy as in effect from time to time. All reimbursements provided under this Agreement will be made or provided in accordance with the requirements of Section 409A of the Internal Revenue Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) and the rules and regulations thereunder, including, where applicable, the requirement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">that (i) any reimbursement is for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement)&#59; (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year&#59; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and (iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:11.9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Termination on Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Executive&#8217;s employment will terminate automatically upon Executive&#8217;s Death or, upon fourteen (14) days prior written notice from the Company, in the event of Disability.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Upon any termination for death or Disability, Executive shall be entitled to&#58; (i) Executive&#8217;s Base Salary through the effective date of termination&#59; (ii) the right to continue health care benefits under Title X of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;), at Executive&#8217;s cost, to the extent required and available by law&#59; (iii) reimbursement of expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company plans or policies, as then in effect.</font></div><div style="margin-top:12.45pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">7. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Involuntary Termination for Cause&#59; Resignation without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="margin-top:13.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Notwithstanding any other provision of this Agreement, the Company may terminate Executive&#8217;s employment at any time for Cause, which shall be effective on the date the Company gives notice to Employee of such termination in accordance with this Agreement unless otherwise agreed by the Parties. Executive may resign from Executive&#8217;s employment with the Company without Good Reason, provided that Executive provide at least four (4) weeks prior written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). Such resignation shall be effective upon the expiration of the Notice Period. In the event that the Company accelerates the effective date of a resignation, such acceleration shall not be construed as a termination of Executives </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">employment by the Company or deemed Good Reason for such resignation, provided however that the Company will pay the Executive for the full Notice Period.</font></div><div style="margin-top:13.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In the case of the Company&#8217;s termination of Executive&#8217;s employment for Cause, or Executive&#8217;s resignation without Good Reason, Executive shall be entitled to receive&#58; (i) Base Salary through the effective date of the termination or resignation, as applicable&#59; (ii) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (iii) the right to continue health care benefits under COBRA, at Executive&#8217;s cost, to the extent required and available by law&#59; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company plans or policies, as then in effect.</font></div><div style="margin-top:12.75pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">8.&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Involuntary Termination Without Cause&#59; Resignation for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="margin-top:11.4pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. The Company shall be entitled to terminate Executive without Cause and Executive may resign for Good Reason, subject to the following&#58;</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:115.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(i)&#160;&#160;&#160;&#160; If Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 23 below, Executive shall be entitled to receive&#58; (A) Executive&#8217;s Base Salary through the effective date of the termination or resignation&#59; (B) continuing severance pay at a rate equal to one hundred percent (100%) of Executive&#8217;s Base Salary, as then in effect (less applicable withholding), for a period of twelve (12) months from the date of such termination, to be paid periodically in accordance with the Company&#8217;s normal payroll practices&#59; (C) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (D) pro-rata portion of the Target Bonus for the calendar year in which the termination occurs based on the period worked by Executive during such calendar year prior to termination&#59; (E) provided that Executive elects COBRA coverage, the Company shall reimburse Executive for a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date Executive&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">employment terminates, until the earlier of twelve months from the date of termination or the date upon which Executive becomes eligible to receive health benefits through another employer&#59; (F) accelerated vesting of any then-outstanding equity awards equal to the number of shares subject to such then-outstanding equity awards that would have vested had Executive otherwise remained employed for an additional six months after the date Executive&#8217;s employment with the Company terminated&#59; and (G) no other severance or benefits of any kind, unless required by law or pursuant to any written Company plans or policies, as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(ii)&#160;&#160;&#160;&#160; If, within twelve (12) months after a Change of Control as defined below, Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 23 below, Executive shall be entitled to receive, in lieu of the benefits set forth in Section 8(a)(i)&#58; (A) Executive&#8217;s Base Salary through the effective date of the termination or resignation&#59; (B) continuing severance pay at a rate equal to one hundred percent (100%) of Executive&#8217;s Base Salary, as then in effect (less applicable withholding), for a period of twelve (12) months from the date of such termination, to be paid periodically in accordance with the Company&#8217;s normal payroll practices&#59; (C) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed&#59; (D) an amount equal to Executive&#8217;s full Target Bonus for the calendar year in which the termination occurs in advance of such Target Bonus being earned&#59; (E) provided that Executive elects COBRA coverage, the Company shall reimburse Executive for a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date Executive&#8217;s employment terminates, until the earlier of six months from the date of termination or the date upon which Executive becomes eligible to receive health benefits through another employer&#59; (F) the full acceleration of vesting of any then-outstanding unvested equity awards as of the date Executive&#8217;s employment with the Company terminated&#59; and (G) no other severance or benefits of any kind, unless required by law or pursuant to any written Company plans or policies, as then in effect. For purposes of this Agreement, a &#8220;Change of Control&#8221; is defined as a Reorganization Event, as defined in the X4 Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Plan (the &#8220;2017 Plan&#8221;), as it may be further amended from time to time, or any successor plan thereto.</font></div><div style="margin-bottom:26.7pt;margin-top:11.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Any severance payments contemplated by Sections 8(a)(i) and 8(a)(ii) above are conditional on Executive&#58; (i) continuing to comply with the terms of this Agreement and the Confidential Information Agreement (as defined below)&#59; and (ii) signing and not revoking a separation agreement and release of known and unknown claims in the form provided by the Company (including non-disparagement and no cooperation provisions) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) and provided that such Release becomes effective and irrevocable no later than sixty (60) days following the termination date or such earlier date required by the release (such deadline, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;). If the Release does not become effective by the Release Deadline, Executive will forfeit any rights to severance or benefits under Sections 8(a)i) or 8(a)(ii) or elsewhere in this Agreement. Any severance payments or other benefits under this Agreement will be paid on, or, in the case of installments, will not commence until, the sixtieth (60th) day following Executive&#8217;s separation from service, or, if later, such time as required by Section 23(b). Except as required by Section 23(b), any installment payments that would have been made to Employee during the sixty (60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive&#8217;s separation from service and the remaining payments will be made as provided in this Agreement, unless subject to the 6-month payment delay described herein. Notwithstanding the foregoing, this Section 8(b) shall not limit Executive&#8217;s ability to obtain expense reimbursements under Section 5 or any other compensation or benefits otherwise required by law or in accordance with written Company plans or policies, as then in effect.</font></div><div style="margin-bottom:26.7pt;margin-top:11.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">9. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="margin-top:11.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; shall mean&#58; (i) Executive&#8217;s continued failure to substantially perform the material duties and obligations under this Agreement (for reasons other than death or Disability), which failure, if curable within the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice from the Company of such failure&#59; (ii) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Executive&#8217;s failure or refusal to comply with the policies, standards and regulations established by the Company from time to time which failure, if curable in the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice of such failure from the Company&#59; (iii) any act of willful misconduct, fraud, embezzlement, misrepresentation, or other unlawful act committed by Executive that benefits Executive at the expense of the Company&#59; (iv) the Executive&#8217;s violation of a federal or state law or regulation applicable to the Company&#8217;s business&#59; (v) the Executive&#8217;s violation of, or a plea of nolo contendere or guilty to, a felony under the laws of the United States or any state&#59; (vi) the Executive&#8217;s material breach of the terms of this Agreement or the Confidential Information Agreement (defined below) if not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice from the Company describing the breach in reasonable detail&#59; or (vii) the Company&#8217;s severe financial distress, whereby the Company is in the process of winding down its business and Executive&#8217;s employment is terminated in connection with such winding down&#59; provided that prior to such termination, a determination is made by the Company&#8217;s Board of Directors that none of the Company&#8217;s Officers (as that term is defined in Section 16 of the Securities Exchange Act of 1934) will receive severance payments in connection with the winding down of the Company&#8217;s business.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; means that Executive, at the time notice is given, has been unable to substantially perform Executive&#8217;s duties under this Agreement for not less than one-hundred and twenty (120) work days within a twelve (12) consecutive month period as a result of Executive&#8217;s incapacity due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221; means Executive&#8217;s written notice of Executive&#8217;s intent to resign for Good Reason with a reasonable description of the grounds therefor within 10 days after the occurrence of one or more of the following without Executive&#8217;s consent, and subsequent resignation within 30 days following the expiration of any Company cure period (discussed below)&#58; (i) a material reduction of Executive&#8217;s duties, position or responsibilities&#59; (ii) </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">a material reduction in Executive&#8217;s Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, which the parties agree is a reduction of at least 10% of Executive&#8217;s base salary (unless pursuant to a salary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">reduction program applicable generally to the Company&#8217;s similarly situated employees)&#59; (iii) relocation of Executive&#8217;s principal place of employment to a place that increases Executive&#8217;s one-way commute by more than sixty (60) miles as compared to Executive&#8217;s then-current principal place of employment immediately prior to such relocation&#59; (iv) a material breach of this Agreement by the Company&#59; or (v) any directive given to Executive by the Company that the Company knows is in violation of a law, regulation, or material Company policy and the Company requires Executive to implement as a condition of his continued employment.  Executive will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#8220;Good Reason&#8221; within 30 days of the initial existence of the grounds for &#8220;Good Reason&#8221; and a reasonable cure period of not less than 30 days following the date of such notice if such act or omission is capable of cure.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">10. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Company Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Proprietary Information and Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In connection with Executive&#8217;s employment with the Company, Executive will receive and have access to Company confidential information and trade secrets. Executive agrees to continue to abide by the Confidentiality, Non-Solicitation, Intellectual Property and Change of Control Agreement (the &#8220;Confidential Information Agreement&#8221;) Executive signed on November 23, 2020, which contains restrictive covenants and prohibits unauthorized use or disclosure of the Company&#8217;s confidential information and trade secrets, among other obligations. However, Executive and the Company agree that this Agreement shall have the effect of amending the Confidential Information Agreement by deleting Section 8 thereof in its entirety. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Resignation on Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. On termination of Executive&#8217;s employment, regardless of the reason for such termination, Executive shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Executive may hold in the Company or any affiliate, unless otherwise agreed in writing by the Parties.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Notification of New Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In the event that Executive leaves the employ of the Company, Executive grants consent to notification by the Company to Executive&#8217;s new employer about Executive&#8217;s rights and obligations under this Agreement and the Confidential Information Agreement. Company agrees not to notify Executive&#8217;s new employer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">unless it has a reasonable belief that Executive has violated or intends to violate a provision of the Confidential Information Agreement.</font></div><div style="margin-top:0.2pt;padding-left:36pt"><font><br></font></div><div style="margin-top:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">11. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. To ensure the timely and economical resolution of disputes that may arise in connection with Executive&#8217;s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, Confidential Information Agreement, or Executive&#8217;s employment, or the termination of Executive&#8217;s employment, including but not limited to all statutory claims, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration by a single arbitrator conducted in Boston, Massachusetts by Judicial Arbitration and Mediation Services Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) under the then applicable JAMS rules (at the following web address&#58; https&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;)&#59; provided, however, this arbitration provision shall not apply to sexual harassment claims to the extent prohibited by applicable law. A hard copy of the rules will be provided to Executive upon request. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In addition, all claims, disputes, or causes of action under this section, whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. The Company acknowledges that Executive will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this Agreement) shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">otherwise be permitted by law&#59; (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award&#59; and (c) be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. Executive and the Company shall equally share all JAMS&#8217; arbitration fees. Except as modified in the Confidential Information Agreement, each party is responsible for its own attorneys&#8217; fees. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. To the extent applicable law prohibits mandatory arbitration of sexual harassment claims, in the event you intend to bring multiple claims, including a sexual harassment claim, the sexual harassment may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.</font></div><div><font><br></font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives of Executive upon Executive's death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer, conveyance or other disposition of Executive&#8217;s right to compensation or other benefits will be null and void.</font></div><div style="margin-top:12.15pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. All notices, requests, demands and other communications called for under this Agreement shall be in writing and shall be delivered via e-mail, personally by hand or by courier, mailed by United States first-class mail, postage prepaid, or sent by facsimile directed to the Party to be notified at the address or facsimile number indicated for such Party on the signature page to this Agreement, or at such other address or facsimile number as such Party may designate by ten (10) days&#8217; advance written notice to the other Parties hereto. All such notices and other communications shall be deemed given upon personal delivery, three (3) days after the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">date of mailing, or upon confirmation of facsimile transfer or e-mail. Notices sent via e-mail under this Section shall be sent to either the e-mail address in this Agreement, or for e-mails sent by the Company to Executive, to the last e-mail address on file with the Company.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision.</font></div><div style="margin-top:11.9pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement, together with the Plan and related agreements, and the Confidential Information Agreement, as amended by this Agreement, represent the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements whether written or oral. No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless in writing and signed by duly authorized representatives of the parties hereto.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. No Party shall be deemed to have waived any right, power or privilege under this Agreement or any provisions hereof unless such waiver shall have been duly executed in writing and acknowledged by the Party to be charged with such waiver. The failure of any Party at any time to insist on performance of any of the provisions of this Agreement shall in no way be construed to be a waiver of such provisions, nor in any way to affect the validity of this Agreement or any part hereof. No waiver of any breach of this Agreement shall be held to be a waiver of any other subsequent breach.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement will be governed by the laws of the Commonwealth of Massachusetts (with the exception of its conflict of laws provisions).</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. Executive acknowledges that Executive has had the opportunity to discuss this matter with and obtain advice from Executive&#8217;s legal counsel, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily entering into this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original, and all such counterparts shall constitute but one instrument.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Effect of Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. The section and subsection headings contained herein are for convenience only and shall not affect the construction hereof.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Construction of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This Agreement has been negotiated by the respective Parties, and the language shall not be construed for or against either Party.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline"> </font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(a)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section 409A (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Deferred Compensation Separation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8221;) will be paid or otherwise provided until Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A.</font></div><div style="margin-top:12.55pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(b)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of Executive&#8217;s termination (other than due to death), then the Deferred Compensation Separation Benefits that are payable within the first six (6) months following Executive&#8217;s separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive&#8217;s separation from service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive&#8217;s separation from service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&#8217;s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">benefit payable under this Agreement is intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(c)&#160;&#160;&#160;&#160;Any amount paid under this Agreement that satisfies the requirements of the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Compensation Separation Benefits for purposes of clause (a) above.</font></div><div style="margin-top:11.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(d)&#160;&#160;&#160;&#160;Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Compensation Separation Benefits for purposes of clause (a) above. For purposes of this Agreement, &#8220;Section 409A Limit&#8221; will mean the lesser of two (2) times&#58; (i) Executive&#8217;s annualized compensation based upon the annual rate of pay paid to Executive during the Executive&#8217;s taxable year preceding Executive&#8217;s taxable year of Executive&#8217;s termination of employment as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto&#59; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Internal Revenue Code for the year in which Executive&#8217;s employment is terminated.</font></div><div style="margin-bottom:462.75pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(e) &#160;&#160;&#160;&#160;The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><div id="i123528e761634f61ac05640366cc50f0_41"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> each of the Parties has executed this Agreement as of the day and year first above written.</font></div><div style="margin-top:12pt;padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;COMPANY&#8221;</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</font></div><div style="margin-top:12pt;padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Paula Ragan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">___________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Paula Ragan</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">X4 Pharmaceuticals, Inc </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61 North Beacon Street, 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Floor </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Boston, MA 02134 </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ronny Mosston </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; </font></div><div style="padding-left:252pt"><font><br></font></div><div style="margin-top:35pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;EXECUTIVE&#8221;</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DR. DIEGO CADAVID</font></div><div style="padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Diego Cadavid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">______________</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Diego Cadavid</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Enclosure</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidentiality, Non-Solicitation, Intellectual Property and Change of Control Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:88.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SIGNATURE PAGE</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>6
<FILENAME>ex1023.htm
<DESCRIPTION>EX-10.23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0461790e852a43938dac7e15605cbe01_38"></div><div style="min-height:75.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.23</font></div></div><div style="margin-top:12pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:126px;margin-bottom:5pt;vertical-align:text-bottom;width:126px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of March 7, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between X4 Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Mary DiBiase, Ph.D. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">R E C I T A L S</font></div><div style="margin-top:11.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive has been employed by the Company as its Chief Operating Officer, pursuant to the Executive Employment Agreement with the Company dated September 8, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company wishes to continue employing Executive as its Chief Operating Officer and to enter into an amended and restated agreement embodying the terms of such employment&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive desires to continue in such employment and enter into such an agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">A G R E E M E N T</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and mutual covenants herein and for other good and valuable consideration, the Parties agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Duties and Scope of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Positions and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of September 8, 2021, Executive will serve as Chief Operating Officer of the Company.  Executive will render such business and professional services in the performance of Executive&#8217;s duties, consistent with Executive&#8217;s position within the Company, as shall reasonably be assigned to Executive by the Company&#8217;s Chief Executive Officer.  The period of Executive&#8217;s at-will employment under the terms of this Agreement is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term, Executive will perform Executive&#8217;s duties faithfully and to the best of Executive&#8217;s ability and will devote Executive&#8217;s full business efforts and time to the Company.  For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity, for any direct or indirect remuneration, that may create a conflict of interest or interfere with Executive&#8217;s duties to the Company, without the prior approval of the Company&#8217;s Chief Executive Officer</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition of Executive&#8217;s employment, Executive certifies to the Company that&#58; (a) Executive is free to enter into and fully perform the duties of Executive&#8217;s position&#59; (b) Executive is not subject to any employment, confidentiality, non-competition or other agreement that would restrict Executive&#8217;s performance for the Company&#59; (c) Executive&#8217;s signing this Agreement does not violate any order, judgment or injunction applicable to Executive, or conflict with or breach any agreement to which Executive is a party or by which Executive is bound&#59; and (d) all facts Executive has presented to the Company </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265450719 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are accurate and true, including, but not limited to, all oral and written statements Executive has made (including those pertaining to Executive&#8217;s education, training, qualifications, licensing and prior work experience) in any job application, resume, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, interview or discussion with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Sections 6, 7, and 8 below, the parties agree that Executive's employment with the Company will be &#8220;at-will&#8221; employment and may be terminated at any time with or without cause or notice, for any reason or no reason.  Executive understands and agrees that neither Executive&#8217;s job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of Executive&#8217;s employment with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term, the Company will initially pay Executive as compensation for Executive&#8217;s services a base salary at a rate of $409,500.00 per year, as modified from time to time at the discretion of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Base Salary will be paid in regular installments in accordance with the Company&#8217;s normal payroll practices (subject to required withholding).  Any increase or decrease in Base Salary (together with the then existing Base Salary) shall serve as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for future employment under this Agreement.  The first and last payment will be adjusted, if necessary, to reflect a commencement or termination date other than the first or last working day of a pay period.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will also be eligible to earn an annual discretionary bonus with a target amount equal to 40% of the Base Salary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The amount of this bonus, if any, will be determined in the sole discretion of the Company and based, in part, on Executive&#8217;s performance and the performance of the Company during the calendar year.  The Company will pay Executive this bonus, if any, by no later than March 15th of the following calendar year.  The bonus is not earned until paid and, except as set forth in Section 8(a) of this Agreement, no pro-rated amount will be paid if Executive&#8217;s employment terminates for any reason prior to the payment date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Restricted Stock Unit Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In connection with the commencement of Executive&#8217;s employment as Chief Operating Officer of the Company and as approved bythe Board of Directors of the Company or the Compensation Committee thereof, the Company granted Executive a restricted stock unit award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of 27,000 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The shares of Common Stock underlying the Award will vest in equal annual installments over a three-year period on each anniversary of the Effective Date, subject to Executive&#8217;s continued employment through each such vesting date.  The Award is subject to all terms, vesting and other provisions set forth in a separate restricted stock unit agreement under the X4 Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Equity Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive will be eligible to receive awards of stock options, restricted stock or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time.  The Board or a committee of the Board shall determine in its discretion whether Executive shall be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time, including, but not limited to the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term, Executive may take advantage of various benefits offered by the Company, such as group medical insurance, dental insurance, short-term disability, long-term disability and the Company&#8217;s 401(k) plan.  Executive will also be entitled to twenty (20) days of paid time off per year, as well as two (2) personal days and eleven (11) paid holidays, exclusive of any sick days Executive may need.  These benefits may be modified or changed from time to time at the sole discretion of the Company.  The details of the Company&#8217;s full benefit offerings can be found in its Employee Handbook. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Business Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term, the Company will reimburse Executive for reasonable business travel, entertainment or other business expenses incurred by Executive in the furtherance of </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-2-</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265450719 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or in connection with the performance of Executive&#8217;s duties hereunder, in accordance with the Company&#8217;s expense reimbursement policy as in effect from time to time.  All reimbursements provided under this Agreement will be made or provided in accordance with the requirements of Section 409A of the Internal Revenue Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the rules and regulations thereunder, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement)&#59; (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year&#59; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and (iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination on Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment will terminate automatically upon Executive&#8217;s Death or, upon fourteen (14) days prior written notice from the Company, in the event of Disability.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon any termination for death or Disability, Executive shall be entitled to&#58; (i) Executive&#8217;s Base Salary through the effective date of termination&#59; (ii) the right to continue health care benefits under Title&#160;X of the Consolidated Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), at Executive&#8217;s cost, to the extent required and available by law&#59; (iii) reimbursement of expenses for which Executive is entitled to be reimbursed pursuant to Section&#160;6 above, but for which Executive has not yet been reimbursed&#59; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company plans or policies, as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Involuntary Termination for Cause&#59; Resignation without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement, the Company may terminate Executive&#8217;s employment at any time for Cause, which shall be effective on the date the Company gives notice to Employee of such termination in accordance with this Agreement unless otherwise agreed by the Parties. Executive may resign from Executive&#8217;s employment with the Company without Good Reason, provided that Executive provide at least four (4) weeks prior written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Such resignation shall be effective upon the expiration of the Notice Period. In the event that the Company accelerates the effective date of a resignation, such acceleration shall not be construed as a termination of Executives employment by the Company or deemed Good Reason for such resignation.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the case of the Company&#8217;s termination of Executive&#8217;s employment for Cause, or Executive&#8217;s resignation without Good Reason, Executive shall be entitled to receive&#58; (i) Base Salary through the effective date of the termination or resignation, as applicable&#59; (ii) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 6 above, but for which Executive has not yet been reimbursed&#59; (iii) the right to continue health care benefits under COBRA, at Executive&#8217;s cost, to the extent required and available by law&#59; and (iv) no other severance or benefits of any kind, unless required by law or pursuant to any other written Company plans or policies, as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Involuntary Termination Without Cause&#59; Resignation for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall be entitled to terminate Executive without Cause and Executive may resign for Good Reason, subject to the following&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">If Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 23 below, Executive shall be entitled to receive&#58; (A) Executive&#8217;s Base Salary through the effective date of the termination or resignation&#59; (B) continuing severance pay at a rate equal to one hundred percent (100%) of Executive&#8217;s Base Salary, as then in effect (less applicable withholding), for a period of twelve (12) months from the date of such termination, to be paid periodically in accordance with the </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-3-</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265450719 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company&#8217;s normal payroll practices&#59; (C) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 6 above, but for which Executive has not yet been reimbursed&#59; (D) pro-rata portion of the Target Bonus for the calendar year in which the termination occurs based on the period worked by Executive during such calendar year prior to termination&#59; (E) provided that Executive elects COBRA coverage, the Company shall reimburse Executive for a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date Executive&#8217;s employment terminates, until the earlier of six (6) months from the date of termination or the date upon which Executive becomes eligible to receive health benefits through another employer&#59; (F) accelerated vesting of any then-outstanding unvested equity awards equal to the number of shares subject to such then-outstanding unvested equity awards that would have vested had Executive otherwise remained employed for an additional six (6) months after the date Executive&#8217;s employment with the Company terminated&#59; (G) no other severance or benefits of any kind, unless required by law or pursuant to any written Company plans or policies, as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">If, within twelve (12) months after a Change of Control as defined below, Executive is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for Good Reason, then, subject to the limitations of Sections 8(b) and 23 below, Executive shall be entitled to receive, in lieu of the benefits set forth in Section 8(a)(i)&#58; (A) Executive&#8217;s Base Salary through the effective date of the termination or resignation&#59; (B) continuing severance pay at a rate equal to one hundred percent (100%) of Executive&#8217;s Base Salary, as then in effect (less applicable withholding), for a period of twelve (12) months from the date of such termination, to be paid periodically in accordance with the Company&#8217;s normal payroll practices&#59; (C) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 6 above, but for which Executive has not yet been reimbursed&#59; (D) an amount equal to Executive&#8217;s full Target Bonus for the calendar year in which the termination occurs in advance of such Target Bonus being earned&#59; (E) provided that Executive elects COBRA coverage, the Company shall reimburse Executive for a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date Executive&#8217;s employment terminates, until the earlier of six months from the date of termination or the date upon which Executive becomes eligible to receive health benefits through another employer&#59; (F) the full acceleration of vesting of any then-outstanding unvested equity awards as of the date Executive&#8217;s employment with the Company terminated&#59; and (G) no other severance or benefits of any kind, unless required by law or pursuant to any written Company plans or policies, as then in effect. For purposes of this Agreement, a &#8220;Change of Control&#8221; is defined as a Reorganization Event, as defined in the Plan, as it may be further amended from time to time, or any successor plan thereto.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any severance payments contemplated by Section&#160;8(a)(i) above are conditional on Executive&#58; (i) continuing to comply with the terms of this Agreement and the Confidential Information Agreement (as defined below)&#59; and (ii) signing and not revoking a separation agreement and release of known and unknown claims in the form provided by the Company (including nondisparagement and no cooperation provisions) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and provided that such Release becomes effective and irrevocable no later than sixty (60) days following the termination date or such earlier date required by the release (such deadline, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If the Release does not become effective by the Release Deadline, Executive will forfeit any rights to severance or benefits under Sections 8(a)(i) or 8(a)(ii) or elsewhere in this Agreement.  Any severance payments or other benefits under this Agreement will be paid on, or, in the case of installments, will not commence until, the sixtieth (60th) day following Executive&#8217;s separation from service, or, if later, such time as required by Section 23(b).  Except as required by Section 23(b), any installment payments that would have been made to Employee during the sixty (60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive&#8217;s separation from service and the remaining payments will be made as provided in this Agreement, unless subject to the 6-month payment delay described herein.  Notwithstanding the foregoing, this Section 8(b) shall not limit Executive&#8217;s ability to obtain expense reimbursements under Section 6 or any other compensation or benefits otherwise required by law or in accordance with written Company plans or policies, as then in effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-4-</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265450719 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean&#58; (i) Executive&#8217;s continued failure to substantially perform the material duties and obligations under this Agreement (for reasons other than death or Disability), which failure, if curable within the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice from the Company of such failure&#59; (ii) Executive&#8217;s failure or refusal to comply with the policies, standards and regulations established by the Company from time to time which failure, if curable in the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice of such failure from the Company&#59; (iii) any act of willful misconduct, fraud, embezzlement, misrepresentation, or other unlawful act committed by Executive that benefits Executive at the expense of the Company&#59; (iv) the Executive&#8217;s violation of a federal or state law or regulation applicable to the Company&#8217;s business&#59; (v) the Executive&#8217;s violation of, or a plea of nolo contendere or guilty to, a felony under the laws of the United States or any state&#59; (vi) the Executive&#8217;s material breach of the terms of this Agreement or the Confidential Information Agreement (defined below)&#59; or (vii) the Company&#8217;s severe financial distress, whereby the Company is in the process of winding down its business and Executive&#8217;s employment is terminated in connection with such winding down&#59; provided that prior to such termination, a determination is made by the Company&#8217;s Board of Directors that none of the Company&#8217;s Officers (as that term is defined in Section 16 of the Securities Exchange Act of 1934) will receive severance payments in connection with the winding down of the Company&#8217;s business.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that Executive, at the time notice is given, has been unable to substantially perform Executive&#8217;s duties under this Agreement for not less than one-hundred and twenty (120) work days within a twelve (12) consecutive month period as a result of Executive&#8217;s incapacity due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s written notice of Executive&#8217;s intent to resign for Good Reason with a reasonable description of the grounds therefor within 10 days after the occurrence of one or more of the following without Executive&#8217;s consent, and subsequent resignation within 30 days following the expiration of any Company cure period (discussed below)&#58; (i) a material reduction of Executive&#8217;s duties, position or responsibilities&#59; (ii) </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a material reduction in Executive&#8217;s Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, which the parties agree is a reduction of at least 10% of Executive&#8217;s base salary (unless pursuant to a salary reduction program applicable generally to the Company&#8217;s similarly situated employees)&#59; (iii) relocation of Executive&#8217;s principal place of employment to a place that increases Executive&#8217;s one-way commute by more than sixty (60) miles as compared to Executive&#8217;s then-current principal place of employment immediately prior to such relocation&#59; (iv) a material breach of this Agreement by the Company&#59; or (v) any directive given to Executive by the Company that the Company knows is in violation of a law, regulation, or material Company policy and the Company requires Executive to implement as a condition of his continued employment.  Executive will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for &#8220;Good Reason&#8221; within 30 days of the initial existence of the grounds for &#8220;Good Reason&#8221; and a reasonable cure period of not less than 30 days following the date of such notice if such act or omission is capable of cure.</font></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt;text-decoration:underline">Company Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Proprietary Information and Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive agrees to continue to abide by the Confidentiality, Non-Competition, Non-Solicitation and Intellectual Property Agreement Executive signed on May 23, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Resignation on Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On termination of Executive&#8217;s employment, regardless of the reason for such termination, Executive shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Executive may hold in the Company or any affiliate, unless otherwise agreed in writing by the Parties.</font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-5-</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265450719 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Notification of New Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that Executive leaves the employ of the Company, Executive grants consent to notification by the Company to Executive&#8217;s new employer about Executive&#8217;s rights and obligations under this Agreement and the Confidential Information Agreement.  Company agrees not to notify Executive&#8217;s new employer unless it has a reasonable belief that Executive has violated or intends to violate a provision of the Confidential Information Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To ensure the timely and economical resolution of disputes that may arise in connection with Executive&#8217;s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, Confidential Information Agreement, or Executive&#8217;s employment, or the termination of Executive&#8217;s employment, including but not limited to all statutory claims, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration by a single arbitrator conducted in Boston, Massachusetts by Judicial Arbitration and Mediation Services Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) under the then applicable JAMS rules (at the following web address&#58; </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#59; provided, however, this arbitration provision shall not apply to sexual harassment claims to the extent prohibited by applicable law. A hard copy of the rules will be provided to you upon request. A hard copy of the rules will be provided to Executive upon request.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; In addition, all claims, disputes, or causes of action under this section, whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.&#160; The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding.&#160; To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.&#160; The Company acknowledges that Executive will have the right to be represented by legal counsel at any arbitration proceeding.&#160; Questions of whether a claim is subject to arbitration under this Agreement) shall be decided by the arbitrator.&#160; Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator.&#160; The arbitrator shall&#58;&#160; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award&#59; and (c) be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law.&#160; Executive and the Company shall equally share all JAMS&#8217; arbitration fees.&#160; Except as modified in the Confidential Information Agreement, each party is responsible for its own attorneys&#8217; fees.&#160; Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.&#160; Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. To the extent applicable law prohibits mandatory arbitration of sexual harassment claims, in the event you intend to bring multiple claims, including a sexual harassment claim, the sexual harassment may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement will be binding upon and inure to the benefit of (a)&#160;the heirs, executors and legal representatives of Executive upon Executive's death and (b)&#160;any successor of the Company.  Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes.  For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company.  None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution.  Any other attempted assignment, transfer, conveyance or other disposition of Executive&#8217;s right to compensation or other benefits will be null and void.</font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-6-</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265450719 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All notices, requests, demands and other communications called for under this Agreement shall be in writing and shall be delivered via e-mail, personally by hand or by courier, mailed by United States first-class mail, postage prepaid, or sent by facsimile directed to the Party to be notified at the address or facsimile number indicated for such Party on the signature page to this Agreement, or at such other address or facsimile number as such Party may designate by ten (10) days&#8217; advance written notice to the other Parties hereto.  All such notices and other communications shall be deemed given upon personal delivery, three (3) days after the date of mailing, or upon confirmation of facsimile transfer or e-mail. Notices sent via e-mail under this Section shall be sent to either the e-mail address in this Agreement, or for e-mails sent by the Company to Executive, to the last e-mail address on file with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, together with the Plan and related agreements, and the Confidential Information Agreement represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements whether written or oral, including, but not limited to, the Executive&#8217;s Offer Letter of Employment, signed by Executive on May 23, 2017 and the Addendum to Employment Agreement, provided to Executive on November 1, 2019.  No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless in writing and signed by duly authorized representatives of the parties hereto.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Party shall be deemed to have waived any right, power or privilege under this Agreement or any provisions hereof unless such waiver shall have been duly executed in writing and acknowledged by the Party to be charged with such waiver.  The failure of any Party at any time to insist on performance of any of the provisions of this Agreement shall in no way be construed to be a waiver of such provisions, nor in any way to affect the validity of this Agreement or any part hereof.  No waiver of any breach of this Agreement shall be held to be a waiver of any other subsequent breach</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement will be governed by the laws of the Commonwealth of Massachusetts (with the exception of its conflict of laws provisions).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges that Executive has had the opportunity to discuss this matter with and obtain advice from Executive&#8217;s legal counsel, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily entering into this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original, and all such counterparts shall constitute but one instrument.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Effect of Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The section and subsection headings contained herein are for convenience only and shall not affect the construction hereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Construction of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement has been negotiated by the respective Parties, and the language shall not be construed for or against either Party.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section 409A </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-7-</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265450719 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Deferred Compensation Separation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be paid or otherwise provided until Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of Executive&#8217;s termination (other than due to death), then the Deferred Compensation Separation Benefits that are payable within the first six (6) months following Executive&#8217;s separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive&#8217;s separation from service.  All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.  Notwithstanding anything herein to the contrary, if Executive dies following Executive&#8217;s separation from service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&#8217;s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit.  Each payment and benefit payable under this Agreement is intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Any amount paid under this Agreement that satisfies the requirements of the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Compensation Separation Benefits for purposes of clause (a) above.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Compensation Separation Benefits for purposes of clause (a) above.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A Limit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; will mean the lesser of two (2) times&#58; (i) Executive&#8217;s annualized compensation based upon the annual rate of pay paid to Executive during the Executive&#8217;s taxable year preceding Executive&#8217;s taxable year of Executive&#8217;s termination of employment as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto&#59; or&#160;(ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section&#160;401(a)(17) of the Internal Revenue Code for the year in which Executive&#8217;s employment is terminated.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply.  The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-8-</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265450719 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> each of the Parties has executed this Agreement as of the day and year first above written.</font></div><div style="margin-top:12pt;padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;COMPANY&#8221;</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</font></div><div style="margin-top:12pt;padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Paula Ragan, PhD, CEO</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;X4 Pharmaceuticals, Inc&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;61 N. Beacon Street&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Boston, MA 02134&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58;   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ronny Mosston&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font><br></font></div><div style="margin-top:35pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;EXECUTIVE&#8221;</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MARY DIBIASE, PH.D.</font></div><div style="margin-top:12pt;padding-left:252pt"><font><br></font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mary DiBiase&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Name</font></div><div style="margin-top:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; ________________________________</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Enclosure</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidentiality, Non-Competition, Non-Solicitation, and Intellectual Property Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SIGNATURE PAGE</font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-9-</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265450719 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>ex_211xlistofsubsidiaries2.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie274b41aee144ccc870efc468778f64f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 21.1</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Subsidiaries</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The following is the name, jurisdiction of organization and percentage ownership by the Company of its subsidiaries.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:49.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company Owned by Percentage</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X4 Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X4 Pharmaceuticals (Austria) GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Austria</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X4 Pharmaceuticals Securities Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Massachusetts</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X4 Therapeutics Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>ex-231pricewaterhousecoope.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iec576300c1b24e2e891d966442d8a8d1_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EX 23.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (333-233161, 333-242372, 333-249544, 333-257422 and 333-261871) and Form S-8 (Nos. 333-221622, 333-223539, 333-230181, 333-230499, 333-233162, 333-237164, 333-239082, 333-254618 and 333-263430) of X4 Pharmaceuticals, Inc. of our report dated March 17, 2022 relating to the financial statements, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 17, 2022</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>ex-311q42021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib7f114793ab649be902076dcc0bce2ef_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paula Ragan, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of X4 Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 17, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paula Ragan, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paula Ragan, Ph.D.<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>ex-312q42021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib62dda376f5343929bc911df05d16d61_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Adam S. Mostafa, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of X4 Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 17, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Adam S. Mostafa</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam S. Mostafa<br>Chief Financial Officer and Treasurer<br>(Principal Financial Officer)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>ex-321q42021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic54d12368c7c4afc91ddb1379e59d73b_71"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paula Ragan, Ph.D., Chief Executive Officer of X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221;), and Adam S. Mostafa, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the undersigned have set their hands hereto as of the 17th day of March, 2022.</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Paula Ragan, Ph.D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Adam S. Mostafa&#160;&#160;&#160;&#160;</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paula Ragan, Ph.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Adam S. Mostafa</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Financial Officer</font></div><div style="margin-top:3pt;padding-left:288pt;text-align:justify;text-indent:-288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>xfor-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:97cd003e-9c40-40fd-8096-f110f9c5294b,g:4b68d2f2-b861-47a0-89c8-6e5f887cc91d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.x4pharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.x4pharma.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.x4pharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.x4pharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit" roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit">
        <link:definition>1004006 - Statement - Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical" roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical">
        <link:definition>1005007 - Statement - Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessandBasisofPresentation" roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessandBasisofPresentationDetails" roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Nature of the Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantPoliciesAdditionalInformationDetails" roleURI="http://www.x4pharma.com/role/SummaryofSignificantPoliciesAdditionalInformationDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandFundingAgreements" roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements">
        <link:definition>2110103 - Disclosure - License, Collaboration, and Funding Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails" roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails">
        <link:definition>2411406 - Disclosure - License, Collaboration, and Funding Agreements - Genzyme Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails" roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails">
        <link:definition>2412407 - Disclosure - License, Collaboration, and Funding Agreements - Georgetown Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails" roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails">
        <link:definition>2413408 - Disclosure - License, Collaboration, and Funding Agreements - Beth Israel Deaconess Medical Center Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails" roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails">
        <link:definition>2414409 - Disclosure - License, Collaboration, and Funding Agreements - Research and Development Incentive Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandFundingAgreementsDetails" roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails">
        <link:definition>2415410 - Disclosure - License, Collaboration, and Funding Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilities" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities">
        <link:definition>2116104 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesTables" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables">
        <link:definition>2317302 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2418411 - Disclosure - Fair Value of Financial Assets and Liabilities - Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails">
        <link:definition>2419412 - Disclosure - Fair Value of Financial Assets and Liabilities -Aggregate Fair Value of Warrant and Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails">
        <link:definition>2420413 - Disclosure - Fair Value of Financial Assets and Liabilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillRollforwardDetails" roleURI="http://www.x4pharma.com/role/GoodwillRollforwardDetails">
        <link:definition>2421414 - Disclosure - Goodwill Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNet">
        <link:definition>2122105 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetTables">
        <link:definition>2323303 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetDetails">
        <link:definition>2424415 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.x4pharma.com/role/AccruedExpenses">
        <link:definition>2125106 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.x4pharma.com/role/AccruedExpensesTables">
        <link:definition>2326304 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.x4pharma.com/role/AccruedExpensesDetails">
        <link:definition>2427416 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.x4pharma.com/role/LongTermDebt">
        <link:definition>2128107 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.x4pharma.com/role/LongTermDebtTables">
        <link:definition>2329305 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofLongTermDebtDetails" roleURI="http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails">
        <link:definition>2430417 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSVBLoanAgreementDetails" roleURI="http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails">
        <link:definition>2431418 - Disclosure - Long-Term Debt - SVB Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtFFGLoanAgreementsDetails" roleURI="http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails">
        <link:definition>2432419 - Disclosure - Long-Term Debt - FFG Loan Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtHerculesLoanAgreementsDetails" roleURI="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails">
        <link:definition>2433420 - Disclosure - Long-Term Debt - Hercules Loan Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtFuturePrincipalPaymentsDetails" roleURI="http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails">
        <link:definition>2434421 - Disclosure - Long-Term Debt - Future Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.x4pharma.com/role/Leases">
        <link:definition>2135108 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.x4pharma.com/role/LeasesTables">
        <link:definition>2336306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.x4pharma.com/role/LeasesDetails">
        <link:definition>2437422 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofLeaseExpenseDetails" roleURI="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails">
        <link:definition>2438423 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail">
        <link:definition>2439424 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1">
        <link:definition>2439424 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.x4pharma.com/role/CommitmentandContingencies">
        <link:definition>2140109 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockWarrants" roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrants">
        <link:definition>2141110 - Disclosure - Preferred and Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockWarrantsTables" roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsTables">
        <link:definition>2342307 - Disclosure - Preferred and Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockWarrantsAdditionalInformationDetails" roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails">
        <link:definition>2443425 - Disclosure - Preferred and Common Stock Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail" roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail">
        <link:definition>2444426 - Disclosure - Preferred and Common Stock Warrants - Schedule of Outstanding Warrants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails" roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails">
        <link:definition>2445427 - Disclosure - Preferred and Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock" roleURI="http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock">
        <link:definition>2146111 - Disclosure - Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails" roleURI="http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails">
        <link:definition>2447428 - Disclosure - Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock) - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.x4pharma.com/role/StockBasedCompensation">
        <link:definition>2148112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.x4pharma.com/role/StockBasedCompensationTables">
        <link:definition>2349308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2450429 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionValuationDetails" roleURI="http://www.x4pharma.com/role/StockBasedCompensationStockOptionValuationDetails">
        <link:definition>2451430 - Disclosure - Stock-Based Compensation - Stock Option Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetail" roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail">
        <link:definition>2452431 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>2453432 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails">
        <link:definition>2454433 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.x4pharma.com/role/IncomeTaxes">
        <link:definition>2155113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.x4pharma.com/role/IncomeTaxesTables">
        <link:definition>2356309 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" roleURI="http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>2457434 - Disclosure - Income Taxes - Schedule of Income Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" roleURI="http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails">
        <link:definition>2458435 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredIncomeTaxAssetDetails" roleURI="http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails">
        <link:definition>2459436 - Disclosure - Income Taxes - Deferred Income Tax Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2460437 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxValuationAllowanceDetails" roleURI="http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails">
        <link:definition>2461438 - Disclosure - Income Taxes - Deferred Tax Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.x4pharma.com/role/IncomeTaxesDetails">
        <link:definition>2462439 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.x4pharma.com/role/NetLossperShare">
        <link:definition>2163114 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.x4pharma.com/role/NetLossperShareTables">
        <link:definition>2364310 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails" roleURI="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails">
        <link:definition>2465440 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareAdditionalInformationDetails" roleURI="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails">
        <link:definition>2466441 - Disclosure - Net Loss per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails" roleURI="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails">
        <link:definition>2467442 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossonTransferofNonfinancialAssets" roleURI="http://www.x4pharma.com/role/LossonTransferofNonfinancialAssets">
        <link:definition>2168115 - Disclosure - Loss on Transfer of Nonfinancial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossonTransferofNonfinancialAssetsAdditionalInformationDetails" roleURI="http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails">
        <link:definition>2469443 - Disclosure - Loss on Transfer of Nonfinancial Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.x4pharma.com/role/SubsequentEvents">
        <link:definition>2170116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.x4pharma.com/role/SubsequentEventsDetails">
        <link:definition>2471444 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="xfor_SoftwareMember" abstract="true" name="SoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LineOfCreditCovenantMinimumCash" abstract="false" name="LineOfCreditCovenantMinimumCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_BusinessCombinationShareExchangeRatio" abstract="false" name="BusinessCombinationShareExchangeRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="xfor_A2015EquityIncentivePlanMember" abstract="true" name="A2015EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_HerculesLoanAgreementMember" abstract="true" name="HerculesLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_OneTimeUpfrontPayment" abstract="false" name="OneTimeUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" abstract="false" name="ClassOfWarrantOrRightWeightedAverageContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xfor_WarrantsRollForward" abstract="true" name="WarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix" abstract="false" name="CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_LongTermDebtIncludingAccretion" abstract="false" name="LongTermDebtIncludingAccretion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_Q12022PIPEMember" abstract="true" name="Q12022PIPEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ConversionOfRedeemableCommonStockToCommonStockValue" abstract="false" name="ConversionOfRedeemableCommonStockToCommonStockValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_LongTermDebtNonCurrentIncludingAccrection" abstract="false" name="LongTermDebtNonCurrentIncludingAccrection" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightIssued" abstract="false" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" abstract="false" name="ClassOfWarrantOrRightWarrantsExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" abstract="false" name="LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_WalthamLeaseMember" abstract="true" name="WalthamLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_DeferredTaxAssetLeaseLiability" abstract="false" name="DeferredTaxAssetLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_FundedMember" abstract="true" name="FundedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" abstract="false" name="StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_AspireCapitalFundLLCMember" abstract="true" name="AspireCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" abstract="true" name="IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ArsanisMember" abstract="true" name="ArsanisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_StockIssuedDuringPeriodValueLicenseAgreement" abstract="false" name="StockIssuedDuringPeriodValueLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock" abstract="false" name="RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" abstract="false" name="EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_DiscretionaryBorrowingsMember" abstract="true" name="DiscretionaryBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" abstract="false" name="ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_CollaborativeArrangementObligationPercentage" abstract="false" name="CollaborativeArrangementObligationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xfor_ResearchAndDevelopmentIncentiveProgramMember" abstract="true" name="ResearchAndDevelopmentIncentiveProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_NonStatutoryOptionsMember" abstract="true" name="NonStatutoryOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" abstract="false" name="ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_PrefundedWarrantsDomain" abstract="true" name="PrefundedWarrantsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_RedeemableCommonStockMember" abstract="true" name="RedeemableCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_PurchaseAgreementSharesPurchased" abstract="false" name="PurchaseAgreementSharesPurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_GenzymeAgreementMember" abstract="true" name="GenzymeAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" abstract="true" name="IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_MilestonePaymentObligation" abstract="false" name="MilestonePaymentObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ViennaLeaseArrangementMember" abstract="true" name="ViennaLeaseArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock" abstract="false" name="ScheduleOfOutstandingWarrantsTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" abstract="false" name="CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_MTSAustriaMember" abstract="true" name="MTSAustriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_HerculesAmendedAndRestatedLoanAgreementMember" abstract="true" name="HerculesAmendedAndRestatedLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_DebtInstrumentPrePaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrePaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="xfor_CommonStockRepurchasePricePerShare" abstract="false" name="CommonStockRepurchasePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="xfor_AccretionOnLongTermDebt" abstract="false" name="AccretionOnLongTermDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_AccruedExternalResearchAndDevelopmentExpenses" abstract="false" name="AccruedExternalResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_AbbiskoAgreementMember" abstract="true" name="AbbiskoAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_BidmcAgreementMember" abstract="true" name="BidmcAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" abstract="true" name="IssuanceOnAprilSixteenTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_NewViennaLeaseMember" abstract="true" name="NewViennaLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario" abstract="false" name="DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_SeriesSeedConvertiblePreferredStockMember" abstract="true" name="SeriesSeedConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LesseeOperatingLeaseRentFreePeriod" abstract="false" name="LesseeOperatingLeaseRentFreePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xfor_PrefundedWarrantsAxis" abstract="true" name="PrefundedWarrantsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" abstract="true" name="IssuanceOnNovemberNineTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" abstract="true" name="IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_DebtInstrumentDebtCovenantMinimumCashRequired" abstract="false" name="DebtInstrumentDebtCovenantMinimumCashRequired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_TwoThousandNineteenEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" abstract="true" name="IssuanceOnOctoberNineteenTwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ConversionOfConvertiblePreferredStockToCommonStockValues" abstract="false" name="ConversionOfConvertiblePreferredStockToCommonStockValues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_OperatingLeaseRightOfUseAssetAmortizationTerm" abstract="false" name="OperatingLeaseRightOfUseAssetAmortizationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid" abstract="false" name="StockAndWarrantIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" abstract="false" name="StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_CurrentOfficeSpaceUnderLeaseAgreement" abstract="false" name="CurrentOfficeSpaceUnderLeaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="xfor_AggregateBaseRent" abstract="false" name="AggregateBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ConversionOfRedeemableCommonStockToCommonStockShares" abstract="false" name="ConversionOfRedeemableCommonStockToCommonStockShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_CollaborativeAgreementExpenseReimbursement" abstract="false" name="CollaborativeAgreementExpenseReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ClassAWarrantMember" abstract="true" name="ClassAWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" abstract="false" name="ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_CambridgeMAOperatingLeaseArrangementMember" abstract="true" name="CambridgeMAOperatingLeaseArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_GeorgetownMember" abstract="true" name="GeorgetownMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_SaleOfStockPurchaseAgreementTerm" abstract="false" name="SaleOfStockPurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xfor_AllstonLeaseMember" abstract="true" name="AllstonLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount" abstract="false" name="SaleOfStockNumberOfSharesAuthorizedInTransactionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_MilestoneContractTerminationPeriod" abstract="false" name="MilestoneContractTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xfor_IntangibleAssetsPolicyPolicyTextBlock" abstract="false" name="IntangibleAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" abstract="true" name="IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" abstract="false" name="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_SaleOfStockPurchaseAgreementSharesIssued" abstract="false" name="SaleOfStockPurchaseAgreementSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity" abstract="false" name="AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_DFCIMember" abstract="true" name="DFCIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" abstract="true" name="IssuanceOnMarchThirteenTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_MinCashTestDate1Member" abstract="true" name="MinCashTestDate1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xfor_PaymentOnObligationUnderLicenseAgreement" abstract="false" name="PaymentOnObligationUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock" abstract="false" name="ResearchAndDevelopmentProgramsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_TwoThousandSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LincolnParkCapitalFundLLCMember" abstract="true" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter" abstract="false" name="CollaborativeAgreementFutureExpectedAnnualFeesThereafter" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_LeaseCostAdditionalInformationAbstract" abstract="true" name="LeaseCostAdditionalInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" abstract="true" name="IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightExpired" abstract="false" name="ClassOfWarrantOrRightExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_MilestonePaymentsPaid" abstract="false" name="MilestonePaymentsPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_HerculesFirstAmendedLoanAgreementMember" abstract="true" name="HerculesFirstAmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_MinCashTestDate2Member" abstract="true" name="MinCashTestDate2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_StockIssuedDuringPeriodSharesLicenseAgreement" abstract="false" name="StockIssuedDuringPeriodSharesLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_GrantAndIncentiveReceivables" abstract="false" name="GrantAndIncentiveReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_EmployeeStockPurchasePlansMember" abstract="true" name="EmployeeStockPurchasePlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember" abstract="true" name="IncentiveStockOptionsAndRestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnMarch232021Member" abstract="true" name="IssuanceOnMarch232021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_AccruedExpensesTextBlock" abstract="false" name="AccruedExpensesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_DeferredTaxLiabilityRightOfUseAsset" abstract="false" name="DeferredTaxLiabilityRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree" abstract="false" name="CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ClassBWarrantsMember" abstract="true" name="ClassBWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ReimbursementRateForResearchAndDevelopment" abstract="false" name="ReimbursementRateForResearchAndDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="xfor_HerculesSecondAmendedLoanAgreementMember" abstract="true" name="HerculesSecondAmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="xfor_FairValueOfNetAssetsAcquiredInReverseMerger" abstract="false" name="FairValueOfNetAssetsAcquiredInReverseMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_CambridgeLeaseMember" abstract="true" name="CambridgeLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo" abstract="false" name="LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" abstract="false" name="ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightExercised" abstract="false" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_PotentialMilestonePaymentsReceivable" abstract="false" name="PotentialMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" abstract="false" name="TemporaryEquityRepurchaseOfConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="xfor_ResearchAndDevelopmentIncentiveReceivable" abstract="false" name="ResearchAndDevelopmentIncentiveReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_SalesAgentsMember" abstract="true" name="SalesAgentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>xfor-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:97cd003e-9c40-40fd-8096-f110f9c5294b,g:4b68d2f2-b861-47a0-89c8-6e5f887cc91d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a67d49b9-bc51-47f9-9cb9-c775bbe20534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b067d861-5daa-4d6a-b040-1c7e5c567329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a67d49b9-bc51-47f9-9cb9-c775bbe20534" xlink:to="loc_us-gaap_Liabilities_b067d861-5daa-4d6a-b040-1c7e5c567329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2eff5265-9614-4e23-b6bb-4111fcf185cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a67d49b9-bc51-47f9-9cb9-c775bbe20534" xlink:to="loc_us-gaap_StockholdersEquity_2eff5265-9614-4e23-b6bb-4111fcf185cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3d4327c0-1466-455f-a875-e9da6d8427b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a67d49b9-bc51-47f9-9cb9-c775bbe20534" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3d4327c0-1466-455f-a875-e9da6d8427b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_51b94e85-7ca7-4d50-997f-f4ab8ea7c527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_45b9c603-3494-4fbb-b533-aa429b8e2c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51b94e85-7ca7-4d50-997f-f4ab8ea7c527" xlink:to="loc_us-gaap_CommonStockValue_45b9c603-3494-4fbb-b533-aa429b8e2c32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_92f5e48c-7e75-42ac-b222-18ad8cfc62c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51b94e85-7ca7-4d50-997f-f4ab8ea7c527" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_92f5e48c-7e75-42ac-b222-18ad8cfc62c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f5c4b99b-01b8-42ea-8b4f-1cc8ffef7e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51b94e85-7ca7-4d50-997f-f4ab8ea7c527" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f5c4b99b-01b8-42ea-8b4f-1cc8ffef7e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef937e03-d21c-4d34-9b25-cbca3c0332e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51b94e85-7ca7-4d50-997f-f4ab8ea7c527" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef937e03-d21c-4d34-9b25-cbca3c0332e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a6942c89-0989-41f6-83af-6da5acdc2568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2184a74e-34b4-4a2d-ba9c-035ed1389ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a6942c89-0989-41f6-83af-6da5acdc2568" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2184a74e-34b4-4a2d-ba9c-035ed1389ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9d0fe725-2da2-435e-a2ae-9acc431ada67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a6942c89-0989-41f6-83af-6da5acdc2568" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9d0fe725-2da2-435e-a2ae-9acc431ada67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eb6a5c7e-a7c0-4cf7-885b-2497446fb6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a6942c89-0989-41f6-83af-6da5acdc2568" xlink:to="loc_us-gaap_AccountsPayableCurrent_eb6a5c7e-a7c0-4cf7-885b-2497446fb6c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0c9d9b81-8b3f-441b-bd92-85ce67bc1007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a6942c89-0989-41f6-83af-6da5acdc2568" xlink:to="loc_us-gaap_LongTermDebtCurrent_0c9d9b81-8b3f-441b-bd92-85ce67bc1007" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3d60e70b-fa7d-4f21-9332-dae1ee067bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d55a8306-4cff-4162-97e1-d1077e0b087f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3d60e70b-fa7d-4f21-9332-dae1ee067bd3" xlink:to="loc_us-gaap_AssetsCurrent_d55a8306-4cff-4162-97e1-d1077e0b087f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1f80fa8b-4113-4015-8f97-ed665fed79c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3d60e70b-fa7d-4f21-9332-dae1ee067bd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1f80fa8b-4113-4015-8f97-ed665fed79c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_20ec71bd-2629-439e-8155-eb67ead905ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3d60e70b-fa7d-4f21-9332-dae1ee067bd3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_20ec71bd-2629-439e-8155-eb67ead905ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bb9fddb5-f1a2-49bd-bf8e-75192548379d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3d60e70b-fa7d-4f21-9332-dae1ee067bd3" xlink:to="loc_us-gaap_Goodwill_bb9fddb5-f1a2-49bd-bf8e-75192548379d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_57e63147-ff76-47ad-ab97-067d39853d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3d60e70b-fa7d-4f21-9332-dae1ee067bd3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_57e63147-ff76-47ad-ab97-067d39853d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4df2584c-4f1f-44a2-9c82-b6f24dcbda0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_9a545bf3-84a7-47d9-b7a7-7d389039e8a5" xlink:href="xfor-20211231.xsd#xfor_ResearchAndDevelopmentIncentiveReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4df2584c-4f1f-44a2-9c82-b6f24dcbda0a" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_9a545bf3-84a7-47d9-b7a7-7d389039e8a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2b23311d-7c85-4c9a-a39e-d7e214607e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4df2584c-4f1f-44a2-9c82-b6f24dcbda0a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2b23311d-7c85-4c9a-a39e-d7e214607e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86679eff-4f85-47f4-a59d-ce3b683f779a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4df2584c-4f1f-44a2-9c82-b6f24dcbda0a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86679eff-4f85-47f4-a59d-ce3b683f779a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_994aff9b-7b76-4eb6-97a6-da8a6552c818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtNonCurrentIncludingAccrection_37cdb931-51a0-465e-ad16-4db7d8fc968d" xlink:href="xfor-20211231.xsd#xfor_LongTermDebtNonCurrentIncludingAccrection"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_994aff9b-7b76-4eb6-97a6-da8a6552c818" xlink:to="loc_xfor_LongTermDebtNonCurrentIncludingAccrection_37cdb931-51a0-465e-ad16-4db7d8fc968d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e039686a-0197-4142-93fa-6a3c81de2bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_994aff9b-7b76-4eb6-97a6-da8a6552c818" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e039686a-0197-4142-93fa-6a3c81de2bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7f1fee68-44f4-4557-b10f-e3ed5060ce13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_994aff9b-7b76-4eb6-97a6-da8a6552c818" xlink:to="loc_us-gaap_LiabilitiesCurrent_7f1fee68-44f4-4557-b10f-e3ed5060ce13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e6415252-b2c2-46cd-9ec9-028dff515b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_994aff9b-7b76-4eb6-97a6-da8a6552c818" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e6415252-b2c2-46cd-9ec9-028dff515b1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d6e83f63-0b8a-4618-b5c4-bf32e7b7b1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_f0302cb9-05f1-46c8-aa63-3d636dc8e367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d6e83f63-0b8a-4618-b5c4-bf32e7b7b1e9" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_f0302cb9-05f1-46c8-aa63-3d636dc8e367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a05262b4-8ffc-450f-b77d-70e75325ea58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d6e83f63-0b8a-4618-b5c4-bf32e7b7b1e9" xlink:to="loc_us-gaap_NetIncomeLoss_a05262b4-8ffc-450f-b77d-70e75325ea58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_e301a507-5016-4547-a459-e4d3b4382f7a" xlink:href="xfor-20211231.xsd#xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d6e83f63-0b8a-4618-b5c4-bf32e7b7b1e9" xlink:to="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_e301a507-5016-4547-a459-e4d3b4382f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2a7d4d81-93fa-493e-a074-f633c4b5b54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b170e6bd-9543-4571-b573-96718c1f9174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2a7d4d81-93fa-493e-a074-f633c4b5b54d" xlink:to="loc_us-gaap_OperatingExpenses_b170e6bd-9543-4571-b573-96718c1f9174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_444f176a-03e5-47a7-8b99-c403b3bc82f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2a7d4d81-93fa-493e-a074-f633c4b5b54d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_444f176a-03e5-47a7-8b99-c403b3bc82f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3c215eba-7728-491b-b937-f021a267a64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c69c3169-d842-49c3-87e8-7acfdb014e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3c215eba-7728-491b-b937-f021a267a64a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c69c3169-d842-49c3-87e8-7acfdb014e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e4e78e4d-c28c-461d-b197-f546373b8b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3c215eba-7728-491b-b937-f021a267a64a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e4e78e4d-c28c-461d-b197-f546373b8b58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_a0745ffc-9cc6-4bef-9c3d-97f82021cca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3c215eba-7728-491b-b937-f021a267a64a" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_a0745ffc-9cc6-4bef-9c3d-97f82021cca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_aeb4277d-5b32-4400-994b-310158e1dc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3c215eba-7728-491b-b937-f021a267a64a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_aeb4277d-5b32-4400-994b-310158e1dc2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f6247b47-dc66-4c90-b69e-29e92869cacd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_53b12733-0d93-4159-a88a-8e73fd612df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f6247b47-dc66-4c90-b69e-29e92869cacd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_53b12733-0d93-4159-a88a-8e73fd612df8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_68625c37-358e-446c-9e17-7f9653cd628d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f6247b47-dc66-4c90-b69e-29e92869cacd" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_68625c37-358e-446c-9e17-7f9653cd628d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c00385b7-6040-4407-b037-0e000b03870d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f6247b47-dc66-4c90-b69e-29e92869cacd" xlink:to="loc_us-gaap_InterestExpense_c00385b7-6040-4407-b037-0e000b03870d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2abe76f4-e152-4c8e-a71f-f305300a9aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f6247b47-dc66-4c90-b69e-29e92869cacd" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2abe76f4-e152-4c8e-a71f-f305300a9aa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_4a3bb9fa-0978-4c14-a1f4-3bc73f435f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f6247b47-dc66-4c90-b69e-29e92869cacd" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_4a3bb9fa-0978-4c14-a1f4-3bc73f435f1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_131e4968-1dfb-47ec-9b1c-669a0693a052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f6247b47-dc66-4c90-b69e-29e92869cacd" xlink:to="loc_us-gaap_InvestmentIncomeInterest_131e4968-1dfb-47ec-9b1c-669a0693a052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_87810eeb-f3f1-455e-9da1-b1ce2d9d95dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e5673c15-cb36-4494-b24a-c932f57a9fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_87810eeb-f3f1-455e-9da1-b1ce2d9d95dd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e5673c15-cb36-4494-b24a-c932f57a9fee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc5f721b-e8cf-4372-a475-8a5546cc11e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_87810eeb-f3f1-455e-9da1-b1ce2d9d95dd" xlink:to="loc_us-gaap_NetIncomeLoss_fc5f721b-e8cf-4372-a475-8a5546cc11e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_77c1ab87-7dd4-4111-be41-22e477949bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a8b688db-cad2-4a85-baa8-dd0e6f8ea302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_77c1ab87-7dd4-4111-be41-22e477949bf9" xlink:to="loc_us-gaap_OperatingIncomeLoss_a8b688db-cad2-4a85-baa8-dd0e6f8ea302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_25ffdcb6-4bd4-4859-af4d-1adaa5667010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_77c1ab87-7dd4-4111-be41-22e477949bf9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_25ffdcb6-4bd4-4859-af4d-1adaa5667010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0850d67b-00e0-4335-9af7-e14efc1f4acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a9eedf33-44c3-4fcd-bab8-0f4cded1f133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0850d67b-00e0-4335-9af7-e14efc1f4acc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a9eedf33-44c3-4fcd-bab8-0f4cded1f133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_61f40ce0-b861-42de-bd2a-002c47448311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0850d67b-00e0-4335-9af7-e14efc1f4acc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_61f40ce0-b861-42de-bd2a-002c47448311" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75af7eec-34af-4a52-9ee4-4f57e7e1b2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b687613-80d2-4945-b343-86a6794ad8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75af7eec-34af-4a52-9ee4-4f57e7e1b2ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b687613-80d2-4945-b343-86a6794ad8c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e82c5fac-8c62-4b18-a4a4-e5a27fb4ce02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75af7eec-34af-4a52-9ee4-4f57e7e1b2ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e82c5fac-8c62-4b18-a4a4-e5a27fb4ce02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17142136-8492-422e-87f1-e4e7f7afb7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75af7eec-34af-4a52-9ee4-4f57e7e1b2ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17142136-8492-422e-87f1-e4e7f7afb7a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_901807a6-8b78-4614-8b6d-e18b7b5edfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75af7eec-34af-4a52-9ee4-4f57e7e1b2ea" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_901807a6-8b78-4614-8b6d-e18b7b5edfa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bea05ab-b744-4f07-9833-2be34dcdceb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_92f144a6-d658-4aa7-a961-f008f41e04af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bea05ab-b744-4f07-9833-2be34dcdceb6" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_92f144a6-d658-4aa7-a961-f008f41e04af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_77d5da3f-ce49-4a7e-a0f4-0d7d0c74e4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bea05ab-b744-4f07-9833-2be34dcdceb6" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_77d5da3f-ce49-4a7e-a0f4-0d7d0c74e4ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_35bba770-0aa0-409d-9f08-8d280d819293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bea05ab-b744-4f07-9833-2be34dcdceb6" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_35bba770-0aa0-409d-9f08-8d280d819293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a15d5ecf-ec95-42cd-8f94-66c10167b075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_91ae2d67-22d4-41f8-aba1-eab16a5c3372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a15d5ecf-ec95-42cd-8f94-66c10167b075" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_91ae2d67-22d4-41f8-aba1-eab16a5c3372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_2d82e119-4f9c-4982-a830-22974c34b039" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a15d5ecf-ec95-42cd-8f94-66c10167b075" xlink:to="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_2d82e119-4f9c-4982-a830-22974c34b039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_b8eaa2ec-18b2-4f4f-ba6d-d37803dd2ad4" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a15d5ecf-ec95-42cd-8f94-66c10167b075" xlink:to="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_b8eaa2ec-18b2-4f4f-ba6d-d37803dd2ad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_64112176-ded4-47ed-a2fe-89722cdd4dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a15d5ecf-ec95-42cd-8f94-66c10167b075" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_64112176-ded4-47ed-a2fe-89722cdd4dca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f59b8327-deb6-4511-97f9-ac6b314fabf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a15d5ecf-ec95-42cd-8f94-66c10167b075" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f59b8327-deb6-4511-97f9-ac6b314fabf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_51b5ee0b-c234-4e80-97cd-e3a61a3ecc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a15d5ecf-ec95-42cd-8f94-66c10167b075" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_51b5ee0b-c234-4e80-97cd-e3a61a3ecc0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bf2eb73b-b2e2-408f-8bcc-e7c8941376c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bf2eb73b-b2e2-408f-8bcc-e7c8941376c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e2094048-8ef4-4675-8019-33388af36346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_us-gaap_ProfitLoss_e2094048-8ef4-4675-8019-33388af36346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInLeaseLiabilities_004be6d2-f57c-48ec-a523-5d8421b85b8e" xlink:href="xfor-20211231.xsd#xfor_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_xfor_IncreaseDecreaseInLeaseLiabilities_004be6d2-f57c-48ec-a523-5d8421b85b8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability_cd324841-5574-4ee4-8be0-17a33a20607d" xlink:href="xfor-20211231.xsd#xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability_cd324841-5574-4ee4-8be0-17a33a20607d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e116e6ed-b4ad-4b09-925a-7ea0ff9899fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e116e6ed-b4ad-4b09-925a-7ea0ff9899fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashLeaseExpense_b95310f9-4365-4c21-8fb5-991c726fd351" xlink:href="xfor-20211231.xsd#xfor_NonCashLeaseExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_xfor_NonCashLeaseExpense_b95310f9-4365-4c21-8fb5-991c726fd351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashInterestExpense_239afb71-3bdd-418d-afaf-aa97a87613a2" xlink:href="xfor-20211231.xsd#xfor_NonCashInterestExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_xfor_NonCashInterestExpense_239afb71-3bdd-418d-afaf-aa97a87613a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_7e7e7d72-d192-4699-877f-29270846fa45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_7e7e7d72-d192-4699-877f-29270846fa45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c70b7151-5906-4873-8872-ef976442e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c70b7151-5906-4873-8872-ef976442e07c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_df7ee0c0-03a1-48d2-baac-7b12df1ec1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_df7ee0c0-03a1-48d2-baac-7b12df1ec1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_77bd0d61-47d8-49ac-b761-436f9d0574a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_us-gaap_ShareBasedCompensation_77bd0d61-47d8-49ac-b761-436f9d0574a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d81a5e21-8e5e-4a52-8413-d63de12b73b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d81a5e21-8e5e-4a52-8413-d63de12b73b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_347da65e-3f70-498a-8f66-ac9e98e02628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_347da65e-3f70-498a-8f66-ac9e98e02628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_c49fdeef-ae59-4c7e-b73f-e3e712e9dc0a" xlink:href="xfor-20211231.xsd#xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_c49fdeef-ae59-4c7e-b73f-e3e712e9dc0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_28ebd5ad-a75b-4726-a2e6-cc94b312008d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9b9e811-0ec7-468d-b3e0-35659edbe682" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_28ebd5ad-a75b-4726-a2e6-cc94b312008d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a326c094-a6e2-48c1-92d1-d53b62418c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_584d0513-fc5a-4343-8310-049058d2ea50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a326c094-a6e2-48c1-92d1-d53b62418c01" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_584d0513-fc5a-4343-8310-049058d2ea50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fc8565e1-75aa-4e3e-ad58-bd072f0c2bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a326c094-a6e2-48c1-92d1-d53b62418c01" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fc8565e1-75aa-4e3e-ad58-bd072f0c2bd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_593ad082-37a9-43fa-bfc9-fb4391ffd760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a326c094-a6e2-48c1-92d1-d53b62418c01" xlink:to="loc_us-gaap_RestrictedCashCurrent_593ad082-37a9-43fa-bfc9-fb4391ffd760" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_aa333bdb-c3be-4bd7-a229-0b1694ad3cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7db80132-d869-4317-aa07-64b5fca973c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_aa333bdb-c3be-4bd7-a229-0b1694ad3cda" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7db80132-d869-4317-aa07-64b5fca973c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ecbed4a3-2021-4048-8a19-fdd4a91bce67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_aa333bdb-c3be-4bd7-a229-0b1694ad3cda" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ecbed4a3-2021-4048-8a19-fdd4a91bce67" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_29ded594-857a-4279-a890-7d5b3773d69f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_563a8269-c86a-4951-97b8-90e935e90e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_29ded594-857a-4279-a890-7d5b3773d69f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_563a8269-c86a-4951-97b8-90e935e90e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_e38de4d5-460d-4f78-a15a-fd4ab95ebfa9" xlink:href="xfor-20211231.xsd#xfor_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_29ded594-857a-4279-a890-7d5b3773d69f" xlink:to="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_e38de4d5-460d-4f78-a15a-fd4ab95ebfa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_efa00d05-d310-45e5-9c82-8d18e18238be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_29ded594-857a-4279-a890-7d5b3773d69f" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_efa00d05-d310-45e5-9c82-8d18e18238be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_95ff6ff2-3d9d-4448-9d20-a67593d0afca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_29ded594-857a-4279-a890-7d5b3773d69f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_95ff6ff2-3d9d-4448-9d20-a67593d0afca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtIncludingAccretion_5315adba-99dc-47ed-adf0-0dbde05b5430" xlink:href="xfor-20211231.xsd#xfor_LongTermDebtIncludingAccretion"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_08444868-57a3-4e3b-8335-6855c30fa58f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_5315adba-99dc-47ed-adf0-0dbde05b5430" xlink:to="loc_us-gaap_LongTermDebt_08444868-57a3-4e3b-8335-6855c30fa58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccretionOnLongTermDebt_3fcd8496-4998-42a2-85f5-b31a6d8ad5b2" xlink:href="xfor-20211231.xsd#xfor_AccretionOnLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_5315adba-99dc-47ed-adf0-0dbde05b5430" xlink:to="loc_xfor_AccretionOnLongTermDebt_3fcd8496-4998-42a2-85f5-b31a6d8ad5b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_f42fbff6-ee6d-4b2e-ba5c-01bc68fc382e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_5315adba-99dc-47ed-adf0-0dbde05b5430" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_f42fbff6-ee6d-4b2e-ba5c-01bc68fc382e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LeasesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_bf20eedf-65b7-4ae3-b110-3343ea08e994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_28ef22e8-2689-419f-b26d-37de9b328a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bf20eedf-65b7-4ae3-b110-3343ea08e994" xlink:to="loc_us-gaap_OperatingLeaseCost_28ef22e8-2689-419f-b26d-37de9b328a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c8e41109-2ad8-493b-9fe6-6e1153e5cdda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bf20eedf-65b7-4ae3-b110-3343ea08e994" xlink:to="loc_us-gaap_ShortTermLeaseCost_c8e41109-2ad8-493b-9fe6-6e1153e5cdda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="xfor-20211231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_889b58d1-d878-469e-b932-c9a1e3992c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1d112507-7e98-4d94-8207-b81bf7bea44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_889b58d1-d878-469e-b932-c9a1e3992c91" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1d112507-7e98-4d94-8207-b81bf7bea44c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_80c85a62-f1af-4a65-b698-6dc20dc2e9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_889b58d1-d878-469e-b932-c9a1e3992c91" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_80c85a62-f1af-4a65-b698-6dc20dc2e9e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e2d432c1-2fd0-497b-94d5-0917bfdf2acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_889b58d1-d878-469e-b932-c9a1e3992c91" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e2d432c1-2fd0-497b-94d5-0917bfdf2acf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ed9ae258-1694-48e1-9974-8f4355fca2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_889b58d1-d878-469e-b932-c9a1e3992c91" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ed9ae258-1694-48e1-9974-8f4355fca2ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a1257940-7e5e-4f2b-b162-751a2915f065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_889b58d1-d878-469e-b932-c9a1e3992c91" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a1257940-7e5e-4f2b-b162-751a2915f065" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="xfor-20211231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fd721a8-096d-4a00-ad15-33e821ee5965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f413c6fd-4f89-426a-93f9-0261af33dc95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fd721a8-096d-4a00-ad15-33e821ee5965" xlink:to="loc_us-gaap_OperatingLeaseLiability_f413c6fd-4f89-426a-93f9-0261af33dc95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8379ec59-3701-485d-bd08-edb4273f9aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fd721a8-096d-4a00-ad15-33e821ee5965" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8379ec59-3701-485d-bd08-edb4273f9aa3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a9f1f2f7-42f1-4abb-acac-4fe76f16e0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f05b42f1-9c0f-47e1-8109-e076aa743e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a9f1f2f7-42f1-4abb-acac-4fe76f16e0b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f05b42f1-9c0f-47e1-8109-e076aa743e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_498fa8f6-b4fa-4431-bfee-b86f9efeb1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a9f1f2f7-42f1-4abb-acac-4fe76f16e0b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_498fa8f6-b4fa-4431-bfee-b86f9efeb1f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd46ad79-861a-41bb-8056-ea9c371b02ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_4224b79d-5970-4fc2-8ee4-d244e532395f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd46ad79-861a-41bb-8056-ea9c371b02ce" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_4224b79d-5970-4fc2-8ee4-d244e532395f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dc9021c0-3771-4701-bab1-72142359a76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd46ad79-861a-41bb-8056-ea9c371b02ce" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dc9021c0-3771-4701-bab1-72142359a76a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_67cb5eac-c774-464c-b661-be01c98c2d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd46ad79-861a-41bb-8056-ea9c371b02ce" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_67cb5eac-c774-464c-b661-be01c98c2d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e6dca0d4-48f5-4d87-a698-a313599f6738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd46ad79-861a-41bb-8056-ea9c371b02ce" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e6dca0d4-48f5-4d87-a698-a313599f6738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_4e4716cd-e3e7-4390-9227-0a505da53686" xlink:href="xfor-20211231.xsd#xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd46ad79-861a-41bb-8056-ea9c371b02ce" xlink:to="loc_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_4e4716cd-e3e7-4390-9227-0a505da53686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability_cb170af4-0818-497c-b75e-f5bab77c85e7" xlink:href="xfor-20211231.xsd#xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd46ad79-861a-41bb-8056-ea9c371b02ce" xlink:to="loc_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability_cb170af4-0818-497c-b75e-f5bab77c85e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_802a635a-32d1-496d-b63a-6e7f3d48a843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd46ad79-861a-41bb-8056-ea9c371b02ce" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_802a635a-32d1-496d-b63a-6e7f3d48a843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_33894e00-5e10-4bcd-95e8-89fa83dc9271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd46ad79-861a-41bb-8056-ea9c371b02ce" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_33894e00-5e10-4bcd-95e8-89fa83dc9271" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesDeferredIncomeTaxAssetDetails"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9cba0c3e-b12c-4a1d-a539-9cb0271bd09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxLiabilityRightOfUseAsset_99355aaa-d57b-4e79-b107-1a7fdfd4f295" xlink:href="xfor-20211231.xsd#xfor_DeferredTaxLiabilityRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9cba0c3e-b12c-4a1d-a539-9cb0271bd09b" xlink:to="loc_xfor_DeferredTaxLiabilityRightOfUseAsset_99355aaa-d57b-4e79-b107-1a7fdfd4f295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b4d30413-9f5d-445a-8a31-d0ce42380e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f8e638c8-00a8-498f-aa7c-ff04df64d0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b4d30413-9f5d-445a-8a31-d0ce42380e7d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_f8e638c8-00a8-498f-aa7c-ff04df64d0f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_810936c7-a4b4-4206-b80a-e94fdb353c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b4d30413-9f5d-445a-8a31-d0ce42380e7d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_810936c7-a4b4-4206-b80a-e94fdb353c96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_aff7e3cd-24b7-4ad1-a454-90176395628e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_441ebb21-cdad-4827-97d9-5ffc0feb1df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_aff7e3cd-24b7-4ad1-a454-90176395628e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_441ebb21-cdad-4827-97d9-5ffc0feb1df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_af5a6d9f-869f-4247-aaa7-a144dd47437c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_aff7e3cd-24b7-4ad1-a454-90176395628e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_af5a6d9f-869f-4247-aaa7-a144dd47437c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f1ff3014-d95f-4aff-aa4a-46315fe9f7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_2bf6fc53-cf12-48a2-9782-239d377aa380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f1ff3014-d95f-4aff-aa4a-46315fe9f7cb" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_2bf6fc53-cf12-48a2-9782-239d377aa380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bf5bcf14-3dba-4b29-97d2-bd60d041e36d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f1ff3014-d95f-4aff-aa4a-46315fe9f7cb" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bf5bcf14-3dba-4b29-97d2-bd60d041e36d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxAssetLeaseLiability_2b2ac22f-732c-4640-81ae-5d7c62f4b48d" xlink:href="xfor-20211231.xsd#xfor_DeferredTaxAssetLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f1ff3014-d95f-4aff-aa4a-46315fe9f7cb" xlink:to="loc_xfor_DeferredTaxAssetLeaseLiability_2b2ac22f-732c-4640-81ae-5d7c62f4b48d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_1a3aa792-a2fe-4cd7-92df-285d16af4c84" xlink:href="xfor-20211231.xsd#xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f1ff3014-d95f-4aff-aa4a-46315fe9f7cb" xlink:to="loc_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_1a3aa792-a2fe-4cd7-92df-285d16af4c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ba641930-abdb-4184-b08c-c87a40b0f175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f1ff3014-d95f-4aff-aa4a-46315fe9f7cb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ba641930-abdb-4184-b08c-c87a40b0f175" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>xfor-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:97cd003e-9c40-40fd-8096-f110f9c5294b,g:4b68d2f2-b861-47a0-89c8-6e5f887cc91d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit" xlink:type="extended" id="i933f9dee8d06438f83ee97c65984846f_ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_103a87bb-a17a-4f9b-b740-25779321d975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_103a87bb-a17a-4f9b-b740-25779321d975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_dd300538-b054-4333-ae87-6fe753101699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_dd300538-b054-4333-ae87-6fe753101699" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_b0155c37-4605-4e34-9e3f-a7cb5ccc5ead" xlink:href="xfor-20211231.xsd#xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_b0155c37-4605-4e34-9e3f-a7cb5ccc5ead" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aaf0214d-8e09-4d02-8469-fdce137395a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aaf0214d-8e09-4d02-8469-fdce137395a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fbabcb82-4a07-41df-9a7c-eca643b94182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fbabcb82-4a07-41df-9a7c-eca643b94182" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockShares_f8688899-c51b-41cf-ab5a-92b50d612d2b" xlink:href="xfor-20211231.xsd#xfor_ConversionOfRedeemableCommonStockToCommonStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockShares_f8688899-c51b-41cf-ab5a-92b50d612d2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockValue_90c7f95f-5e70-48a9-9b53-edf65f28c2c2" xlink:href="xfor-20211231.xsd#xfor_ConversionOfRedeemableCommonStockToCommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockValue_90c7f95f-5e70-48a9-9b53-edf65f28c2c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c9286bb6-40fa-4c68-bfa6-6de3118c878d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c9286bb6-40fa-4c68-bfa6-6de3118c878d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_45807ba8-8eda-4df2-b883-d1b7b6c5a911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_45807ba8-8eda-4df2-b883-d1b7b6c5a911" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_b335ea38-2b98-4512-9a33-dbc793601abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c6bd78c9-cf40-4872-9bd1-5d4869cdce59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_82192c18-e487-4ba9-bc3f-f6f4292e5888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_SharesOutstanding_82192c18-e487-4ba9-bc3f-f6f4292e5888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b1e757ad-0eca-4236-93f2-97ac2c58c59f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockholdersEquity_b1e757ad-0eca-4236-93f2-97ac2c58c59f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b48811b9-a8f5-40e6-b3f0-ee40ccdac5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b48811b9-a8f5-40e6-b3f0-ee40ccdac5a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_9ca61d57-f010-4639-bbdb-0d02b4b26d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_9ca61d57-f010-4639-bbdb-0d02b4b26d8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_5ac0b168-7856-4a00-908e-9a4430901d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_5ac0b168-7856-4a00-908e-9a4430901d14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity_0ac16475-2e50-4723-9b4d-e1d5832132b6" xlink:href="xfor-20211231.xsd#xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity_0ac16475-2e50-4723-9b4d-e1d5832132b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_9cbdb8f0-a90c-4bf9-8e86-6862ead3eae9" xlink:href="xfor-20211231.xsd#xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_9cbdb8f0-a90c-4bf9-8e86-6862ead3eae9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_37bd3c7d-5e62-4c5f-8acf-9362bd841e45" xlink:href="xfor-20211231.xsd#xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_37bd3c7d-5e62-4c5f-8acf-9362bd841e45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27a445c4-9fbc-47de-a078-079e1c14c518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27a445c4-9fbc-47de-a078-079e1c14c518" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4e104f83-79d9-4790-a41c-1b508b33be08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4e104f83-79d9-4790-a41c-1b508b33be08" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_405c5b77-889d-40b2-81d6-3547958512c8" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_405c5b77-889d-40b2-81d6-3547958512c8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised_078da3a4-1e50-48dc-8d63-2caa3d26572f" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised_078da3a4-1e50-48dc-8d63-2caa3d26572f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_78af97f7-e3f5-4d10-b5ac-2943b7e00ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_78af97f7-e3f5-4d10-b5ac-2943b7e00ddf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_36703c15-29ae-4f10-bf16-d30a91f3eed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_36703c15-29ae-4f10-bf16-d30a91f3eed7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_aea249cf-51f8-46f0-a1be-85024c9c24ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_aea249cf-51f8-46f0-a1be-85024c9c24ae" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b29cc5db-87a3-4a0d-8879-5f05a75bbd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b29cc5db-87a3-4a0d-8879-5f05a75bbd98" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_af811de6-ad85-4d41-b2f2-58c054557b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_af811de6-ad85-4d41-b2f2-58c054557b59" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_b529fcaf-f8e0-45b0-9acd-0d234a352eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_b529fcaf-f8e0-45b0-9acd-0d234a352eea" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_527ff798-8503-429c-81c1-ea42580c394b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_NetIncomeLoss_527ff798-8503-429c-81c1-ea42580c394b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_54f180d6-1888-47f5-8f63-dc4c52a3b2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e7581838-0d8f-47e6-9e04-0bf494655c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_384147f1-403a-44a6-afe1-815717715f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_384147f1-403a-44a6-afe1-815717715f80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3fb1b093-79d6-47d2-ac9e-3af302eb7bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3fb1b093-79d6-47d2-ac9e-3af302eb7bea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1e81df13-70de-4c6a-8b52-f669018a210a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:to="loc_us-gaap_StatementTable_1e81df13-70de-4c6a-8b52-f669018a210a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9b8ec97d-60fd-4ead-9ae1-602e712cea3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1e81df13-70de-4c6a-8b52-f669018a210a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9b8ec97d-60fd-4ead-9ae1-602e712cea3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9b8ec97d-60fd-4ead-9ae1-602e712cea3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9b8ec97d-60fd-4ead-9ae1-602e712cea3d" xlink:to="loc_us-gaap_ClassOfStockDomain_9b8ec97d-60fd-4ead-9ae1-602e712cea3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e91c552-86f6-4adc-a114-e435290a756a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9b8ec97d-60fd-4ead-9ae1-602e712cea3d" xlink:to="loc_us-gaap_ClassOfStockDomain_4e91c552-86f6-4adc-a114-e435290a756a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_aecd0225-a476-4f9f-a565-0a1569ba003b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4e91c552-86f6-4adc-a114-e435290a756a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_aecd0225-a476-4f9f-a565-0a1569ba003b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_eb488be8-7c93-484e-870c-51f64588d3b1" xlink:href="xfor-20211231.xsd#xfor_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4e91c552-86f6-4adc-a114-e435290a756a" xlink:to="loc_xfor_RedeemableCommonStockMember_eb488be8-7c93-484e-870c-51f64588d3b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_708c2021-2ed1-447d-8e5a-d9b5c4e6e4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1e81df13-70de-4c6a-8b52-f669018a210a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_708c2021-2ed1-447d-8e5a-d9b5c4e6e4dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_708c2021-2ed1-447d-8e5a-d9b5c4e6e4dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_708c2021-2ed1-447d-8e5a-d9b5c4e6e4dd" xlink:to="loc_us-gaap_EquityComponentDomain_708c2021-2ed1-447d-8e5a-d9b5c4e6e4dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_708c2021-2ed1-447d-8e5a-d9b5c4e6e4dd" xlink:to="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_36a2d976-4841-438b-9f17-ec2fbc3b621d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:to="loc_us-gaap_CommonStockMember_36a2d976-4841-438b-9f17-ec2fbc3b621d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eb54b389-ea37-488e-bdd1-9e2e2002a16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eb54b389-ea37-488e-bdd1-9e2e2002a16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_18d96903-c19e-4def-aa1c-155514daf54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_18d96903-c19e-4def-aa1c-155514daf54d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2bd6ddc8-cc58-4ac3-a5e1-739825766fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:to="loc_us-gaap_RetainedEarningsMember_2bd6ddc8-cc58-4ac3-a5e1-739825766fca" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical" xlink:type="extended" id="ibc455453297e4d199e34f3be9f6c8ad6_ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5181c5f8-33e0-40cf-8e97-52d9ef1b589b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c5e19ec9-0fb5-49d1-ac01-4f6f27f0efbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5181c5f8-33e0-40cf-8e97-52d9ef1b589b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c5e19ec9-0fb5-49d1-ac01-4f6f27f0efbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f6a791a0-be8a-4139-9426-ca94c3eb2baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5181c5f8-33e0-40cf-8e97-52d9ef1b589b" xlink:to="loc_us-gaap_StatementTable_f6a791a0-be8a-4139-9426-ca94c3eb2baa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d01fcf2c-fc70-4132-9d11-0c30542301d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f6a791a0-be8a-4139-9426-ca94c3eb2baa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d01fcf2c-fc70-4132-9d11-0c30542301d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d01fcf2c-fc70-4132-9d11-0c30542301d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d01fcf2c-fc70-4132-9d11-0c30542301d2" xlink:to="loc_us-gaap_EquityComponentDomain_d01fcf2c-fc70-4132-9d11-0c30542301d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e2c6f9a1-5a21-4c9d-bc6e-5371df24d0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d01fcf2c-fc70-4132-9d11-0c30542301d2" xlink:to="loc_us-gaap_EquityComponentDomain_e2c6f9a1-5a21-4c9d-bc6e-5371df24d0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_846b08ad-65d6-4889-ad6a-5ca3b1320ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e2c6f9a1-5a21-4c9d-bc6e-5371df24d0a5" xlink:to="loc_us-gaap_CommonStockMember_846b08ad-65d6-4889-ad6a-5ca3b1320ede" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#NatureoftheBusinessandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="extended" id="i18d4ea96af73403f89af2a2e2a7fc7b2_NatureoftheBusinessandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_01f7d6fd-0afc-4313-a9b7-29498b9d967c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_01f7d6fd-0afc-4313-a9b7-29498b9d967c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1e91d60f-5182-4b0c-ab69-6186cf9e8805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1e91d60f-5182-4b0c-ab69-6186cf9e8805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_BusinessCombinationShareExchangeRatio_75163a78-1068-4664-9348-979a6aafac82" xlink:href="xfor-20211231.xsd#xfor_BusinessCombinationShareExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_xfor_BusinessCombinationShareExchangeRatio_75163a78-1068-4664-9348-979a6aafac82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_78b54951-e465-479c-85bc-aa551d1aef10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_78b54951-e465-479c-85bc-aa551d1aef10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7dce121d-963b-4dba-b8c6-82c81a5c1fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7dce121d-963b-4dba-b8c6-82c81a5c1fdc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a7f4ff3c-834e-4e2a-8286-1686a9d757a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a7f4ff3c-834e-4e2a-8286-1686a9d757a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_401d62cd-5dc4-4842-a199-be448e9c96f0" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_401d62cd-5dc4-4842-a199-be448e9c96f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_045e1e70-1120-4f41-a2f4-866b4b41ceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_045e1e70-1120-4f41-a2f4-866b4b41ceb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_045e1e70-1120-4f41-a2f4-866b4b41ceb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_045e1e70-1120-4f41-a2f4-866b4b41ceb3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_045e1e70-1120-4f41-a2f4-866b4b41ceb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf44e192-07ae-496e-a971-1a100ea0bcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_045e1e70-1120-4f41-a2f4-866b4b41ceb3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf44e192-07ae-496e-a971-1a100ea0bcb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ArsanisMember_0877f301-c77e-4f1d-b5d1-bfa15b969957" xlink:href="xfor-20211231.xsd#xfor_ArsanisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf44e192-07ae-496e-a971-1a100ea0bcb7" xlink:to="loc_xfor_ArsanisMember_0877f301-c77e-4f1d-b5d1-bfa15b969957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_942bfe18-b93d-47c5-b741-813e1c3c87c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_942bfe18-b93d-47c5-b741-813e1c3c87c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_942bfe18-b93d-47c5-b741-813e1c3c87c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_942bfe18-b93d-47c5-b741-813e1c3c87c2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_942bfe18-b93d-47c5-b741-813e1c3c87c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e252d8fe-a900-4da4-8181-016ff2ed8448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_942bfe18-b93d-47c5-b741-813e1c3c87c2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e252d8fe-a900-4da4-8181-016ff2ed8448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5c8c8033-3029-40b9-ba42-4e3fd17cf728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e252d8fe-a900-4da4-8181-016ff2ed8448" xlink:to="loc_us-gaap_SubsequentEventMember_5c8c8033-3029-40b9-ba42-4e3fd17cf728" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d8bc3b04-a5fb-47fc-9eb2-7c4242da8c48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:to="loc_srt_StatementScenarioAxis_d8bc3b04-a5fb-47fc-9eb2-7c4242da8c48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d8bc3b04-a5fb-47fc-9eb2-7c4242da8c48_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_d8bc3b04-a5fb-47fc-9eb2-7c4242da8c48" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d8bc3b04-a5fb-47fc-9eb2-7c4242da8c48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e3fbc7cd-50bf-49b5-ba3c-c00c0a60c419" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_d8bc3b04-a5fb-47fc-9eb2-7c4242da8c48" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e3fbc7cd-50bf-49b5-ba3c-c00c0a60c419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_08c78e57-d2fe-4552-9855-c4d2110b46fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e3fbc7cd-50bf-49b5-ba3c-c00c0a60c419" xlink:to="loc_srt_ScenarioForecastMember_08c78e57-d2fe-4552-9855-c4d2110b46fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" xlink:type="extended" id="i82d14a9d07c2412f8950e3dc955c3d70_SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0d58dd46-9f90-45ac-a1c2-90361312b290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8052eaaf-8d99-4b7c-829a-ffd00962e21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0d58dd46-9f90-45ac-a1c2-90361312b290" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8052eaaf-8d99-4b7c-829a-ffd00962e21a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_59d705c1-aa24-4ea8-b71f-b127ce02f186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0d58dd46-9f90-45ac-a1c2-90361312b290" xlink:to="loc_us-gaap_RestrictedCash_59d705c1-aa24-4ea8-b71f-b127ce02f186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ae1c6fc2-2c92-45b7-920f-4a89c84e996d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0d58dd46-9f90-45ac-a1c2-90361312b290" xlink:to="loc_us-gaap_RestrictedCashCurrent_ae1c6fc2-2c92-45b7-920f-4a89c84e996d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0d58dd46-9f90-45ac-a1c2-90361312b290" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_500c6dad-90d6-4b36-bee6-409eab79727e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_500c6dad-90d6-4b36-bee6-409eab79727e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_500c6dad-90d6-4b36-bee6-409eab79727e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_500c6dad-90d6-4b36-bee6-409eab79727e" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_500c6dad-90d6-4b36-bee6-409eab79727e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_500c6dad-90d6-4b36-bee6-409eab79727e" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CambridgeMAOperatingLeaseArrangementMember_ab5b3c6d-9050-4266-a28b-2b53524988f7" xlink:href="xfor-20211231.xsd#xfor_CambridgeMAOperatingLeaseArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:to="loc_xfor_CambridgeMAOperatingLeaseArrangementMember_ab5b3c6d-9050-4266-a28b-2b53524988f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_8a7d444f-f97e-4e6b-854d-dd613d5df92a" xlink:href="xfor-20211231.xsd#xfor_WalthamLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:to="loc_xfor_WalthamLeaseMember_8a7d444f-f97e-4e6b-854d-dd613d5df92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseArrangementMember_c0da83c4-0364-4b40-bb7b-ce67a34c8736" xlink:href="xfor-20211231.xsd#xfor_ViennaLeaseArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:to="loc_xfor_ViennaLeaseArrangementMember_c0da83c4-0364-4b40-bb7b-ce67a34c8736" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember_d177f830-3d9f-4a4c-ac4d-04f062e6b8bd" xlink:href="xfor-20211231.xsd#xfor_AllstonLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:to="loc_xfor_AllstonLeaseMember_d177f830-3d9f-4a4c-ac4d-04f062e6b8bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2fdd053f-d3d0-4bd3-88d6-fa55c7813cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:to="loc_us-gaap_CreditFacilityAxis_2fdd053f-d3d0-4bd3-88d6-fa55c7813cff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2fdd053f-d3d0-4bd3-88d6-fa55c7813cff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2fdd053f-d3d0-4bd3-88d6-fa55c7813cff" xlink:to="loc_us-gaap_CreditFacilityDomain_2fdd053f-d3d0-4bd3-88d6-fa55c7813cff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_308b340e-e799-43bb-bd67-c9d74d1eabb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2fdd053f-d3d0-4bd3-88d6-fa55c7813cff" xlink:to="loc_us-gaap_CreditFacilityDomain_308b340e-e799-43bb-bd67-c9d74d1eabb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_6e42cd72-b311-4057-a393-e969cf097ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_308b340e-e799-43bb-bd67-c9d74d1eabb4" xlink:to="loc_us-gaap_LetterOfCreditMember_6e42cd72-b311-4057-a393-e969cf097ca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d80114c5-9595-4bfa-9efe-d45aef55eb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d80114c5-9595-4bfa-9efe-d45aef55eb55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d80114c5-9595-4bfa-9efe-d45aef55eb55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d80114c5-9595-4bfa-9efe-d45aef55eb55" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d80114c5-9595-4bfa-9efe-d45aef55eb55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_115531ce-4695-489a-a5ad-7f0bb8d61a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d80114c5-9595-4bfa-9efe-d45aef55eb55" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_115531ce-4695-489a-a5ad-7f0bb8d61a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_88287774-b76e-4ecc-8c07-c92f36f80ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_115531ce-4695-489a-a5ad-7f0bb8d61a83" xlink:to="loc_us-gaap_OtherAssetsMember_88287774-b76e-4ecc-8c07-c92f36f80ccd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i10e7792901a84076ac062a5bb9d93e8c_SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03b46deb-6582-44f8-a399-044d672d56a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4efc9565-7e03-4595-8671-a554b7cc49ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03b46deb-6582-44f8-a399-044d672d56a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4efc9565-7e03-4595-8671-a554b7cc49ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_59a5fc23-d537-47c0-a7e3-c480a3250162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03b46deb-6582-44f8-a399-044d672d56a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_59a5fc23-d537-47c0-a7e3-c480a3250162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a62cf655-dddd-4266-887d-23e4f27891e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03b46deb-6582-44f8-a399-044d672d56a6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a62cf655-dddd-4266-887d-23e4f27891e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3426a689-3926-4cff-9a99-bede41b3eaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a62cf655-dddd-4266-887d-23e4f27891e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3426a689-3926-4cff-9a99-bede41b3eaf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3426a689-3926-4cff-9a99-bede41b3eaf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3426a689-3926-4cff-9a99-bede41b3eaf0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3426a689-3926-4cff-9a99-bede41b3eaf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3426a689-3926-4cff-9a99-bede41b3eaf0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_fa67839b-25c0-4521-ad8a-c92e39f7c509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_fa67839b-25c0-4521-ad8a-c92e39f7c509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_4db8072b-1b27-4bac-ad31-87a90cea8523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:to="loc_us-gaap_ComputerEquipmentMember_4db8072b-1b27-4bac-ad31-87a90cea8523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ac99c6ba-ed29-40c4-991a-8ccf435f4c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:to="loc_us-gaap_EquipmentMember_ac99c6ba-ed29-40c4-991a-8ccf435f4c81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_dc82aad3-7054-4859-8b20-7ac11940b948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_dc82aad3-7054-4859-8b20-7ac11940b948" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3b70856e-5879-4bc1-a684-a81cff695e99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a62cf655-dddd-4266-887d-23e4f27891e4" xlink:to="loc_srt_RangeAxis_3b70856e-5879-4bc1-a684-a81cff695e99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b70856e-5879-4bc1-a684-a81cff695e99_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3b70856e-5879-4bc1-a684-a81cff695e99" xlink:to="loc_srt_RangeMember_3b70856e-5879-4bc1-a684-a81cff695e99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b763a80-e34e-442b-a70d-d7b6da6f8a26" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3b70856e-5879-4bc1-a684-a81cff695e99" xlink:to="loc_srt_RangeMember_3b763a80-e34e-442b-a70d-d7b6da6f8a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07916bfb-8228-4ba9-bc3c-67e6c7b9bfd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b763a80-e34e-442b-a70d-d7b6da6f8a26" xlink:to="loc_srt_MinimumMember_07916bfb-8228-4ba9-bc3c-67e6c7b9bfd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b8409694-ae75-4b53-b618-04bce38e5f10" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b763a80-e34e-442b-a70d-d7b6da6f8a26" xlink:to="loc_srt_MaximumMember_b8409694-ae75-4b53-b618-04bce38e5f10" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails" xlink:type="extended" id="iad9cfff39d0f4fb5aa647c9a3fb54b30_LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636c84f2-62f3-40c9-a3f7-db4316063c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestonePayments_4e5b3b12-cdac-4d2b-b7d8-3fc1f68196e9" xlink:href="xfor-20211231.xsd#xfor_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636c84f2-62f3-40c9-a3f7-db4316063c38" xlink:to="loc_xfor_MilestonePayments_4e5b3b12-cdac-4d2b-b7d8-3fc1f68196e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PaymentOnObligationUnderLicenseAgreement_ddc69302-3233-438c-abe5-168e9211756b" xlink:href="xfor-20211231.xsd#xfor_PaymentOnObligationUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636c84f2-62f3-40c9-a3f7-db4316063c38" xlink:to="loc_xfor_PaymentOnObligationUnderLicenseAgreement_ddc69302-3233-438c-abe5-168e9211756b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a82fe365-eefa-4df1-bf9f-33ee279f4f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636c84f2-62f3-40c9-a3f7-db4316063c38" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a82fe365-eefa-4df1-bf9f-33ee279f4f89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0e546dfa-fd99-4f80-b864-878709dc11d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a82fe365-eefa-4df1-bf9f-33ee279f4f89" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0e546dfa-fd99-4f80-b864-878709dc11d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e546dfa-fd99-4f80-b864-878709dc11d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0e546dfa-fd99-4f80-b864-878709dc11d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e546dfa-fd99-4f80-b864-878709dc11d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a40f9f3-a3d9-4820-9ba1-b9f2e2a75c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0e546dfa-fd99-4f80-b864-878709dc11d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a40f9f3-a3d9-4820-9ba1-b9f2e2a75c33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GenzymeAgreementMember_df51cffb-41c8-49f5-b4db-019d42d1daf6" xlink:href="xfor-20211231.xsd#xfor_GenzymeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a40f9f3-a3d9-4820-9ba1-b9f2e2a75c33" xlink:to="loc_xfor_GenzymeAgreementMember_df51cffb-41c8-49f5-b4db-019d42d1daf6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails" xlink:type="extended" id="i172388c6f28c4a22ab1ee83e94c5d44d_LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OneTimeUpfrontPayment_5579fb9a-afe7-4eae-ae4b-bea4bdf2d7cc" xlink:href="xfor-20211231.xsd#xfor_OneTimeUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_xfor_OneTimeUpfrontPayment_5579fb9a-afe7-4eae-ae4b-bea4bdf2d7cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestonePaymentsPaid_c1b5d653-d475-4d30-86d3-d3549eacfeb0" xlink:href="xfor-20211231.xsd#xfor_MilestonePaymentsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_xfor_MilestonePaymentsPaid_c1b5d653-d475-4d30-86d3-d3549eacfeb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestoneContractTerminationPeriod_0cf9c00f-1d44-47e1-9444-3918e133a1d7" xlink:href="xfor-20211231.xsd#xfor_MilestoneContractTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_xfor_MilestoneContractTerminationPeriod_0cf9c00f-1d44-47e1-9444-3918e133a1d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PaymentOnObligationUnderLicenseAgreement_65486f6d-482a-4c3f-a6d4-9a6d83007ff3" xlink:href="xfor-20211231.xsd#xfor_PaymentOnObligationUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_xfor_PaymentOnObligationUnderLicenseAgreement_65486f6d-482a-4c3f-a6d4-9a6d83007ff3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestonePaymentObligation_5c158da2-b6e5-44ff-a66d-d871f98b5f75" xlink:href="xfor-20211231.xsd#xfor_MilestonePaymentObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_xfor_MilestonePaymentObligation_5c158da2-b6e5-44ff-a66d-d871f98b5f75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_261d4aff-b361-4aca-b8d9-3f81bdcfb736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_261d4aff-b361-4aca-b8d9-3f81bdcfb736" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_89808cb8-1e30-4b22-a28a-601b3b774876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_261d4aff-b361-4aca-b8d9-3f81bdcfb736" xlink:to="loc_us-gaap_TypeOfArrangementAxis_89808cb8-1e30-4b22-a28a-601b3b774876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89808cb8-1e30-4b22-a28a-601b3b774876_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89808cb8-1e30-4b22-a28a-601b3b774876" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89808cb8-1e30-4b22-a28a-601b3b774876_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37d5a6cf-b17e-4256-8832-82e4fed26a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89808cb8-1e30-4b22-a28a-601b3b774876" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37d5a6cf-b17e-4256-8832-82e4fed26a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GeorgetownMember_c4fd650f-255c-43d1-bc81-e4a690dbb36f" xlink:href="xfor-20211231.xsd#xfor_GeorgetownMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37d5a6cf-b17e-4256-8832-82e4fed26a14" xlink:to="loc_xfor_GeorgetownMember_c4fd650f-255c-43d1-bc81-e4a690dbb36f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails" xlink:type="extended" id="idbf7b691580d490496c3d9a24338e21a_LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OneTimeUpfrontPayment_98435e8e-2034-438e-9937-47a5105f19d5" xlink:href="xfor-20211231.xsd#xfor_OneTimeUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_OneTimeUpfrontPayment_98435e8e-2034-438e-9937-47a5105f19d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PaymentOnObligationUnderLicenseAgreement_4952e2cb-b1bc-4d53-9d9f-661ac90e4dd3" xlink:href="xfor-20211231.xsd#xfor_PaymentOnObligationUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_PaymentOnObligationUnderLicenseAgreement_4952e2cb-b1bc-4d53-9d9f-661ac90e4dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementExpenseReimbursement_257870b1-b832-444a-a741-942267dec71d" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementExpenseReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_CollaborativeAgreementExpenseReimbursement_257870b1-b832-444a-a741-942267dec71d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeArrangementObligationPercentage_e84175db-34f1-4098-97be-3d812169f81d" xlink:href="xfor-20211231.xsd#xfor_CollaborativeArrangementObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_CollaborativeArrangementObligationPercentage_e84175db-34f1-4098-97be-3d812169f81d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree_12ceb433-4234-4878-90bb-f9feeecd184a" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree_12ceb433-4234-4878-90bb-f9feeecd184a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix_8a60f3a1-f04f-4735-b831-b7896350617d" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix_8a60f3a1-f04f-4735-b831-b7896350617d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter_d7e4f659-67e2-4b31-b6ce-18158c55189a" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter_d7e4f659-67e2-4b31-b6ce-18158c55189a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b0f04744-20ba-44db-93a9-e074cb23be81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b0f04744-20ba-44db-93a9-e074cb23be81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cc1dbd7f-512d-4082-b0e2-3d6a63570ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b0f04744-20ba-44db-93a9-e074cb23be81" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cc1dbd7f-512d-4082-b0e2-3d6a63570ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc1dbd7f-512d-4082-b0e2-3d6a63570ead_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cc1dbd7f-512d-4082-b0e2-3d6a63570ead" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc1dbd7f-512d-4082-b0e2-3d6a63570ead_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc97419c-b2b7-49a5-96b8-1ba585237490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cc1dbd7f-512d-4082-b0e2-3d6a63570ead" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc97419c-b2b7-49a5-96b8-1ba585237490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_BidmcAgreementMember_6b6fc62a-dc2a-4d25-88b6-b97a8533ee98" xlink:href="xfor-20211231.xsd#xfor_BidmcAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc97419c-b2b7-49a5-96b8-1ba585237490" xlink:to="loc_xfor_BidmcAgreementMember_6b6fc62a-dc2a-4d25-88b6-b97a8533ee98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DFCIMember_708dca46-da3f-40c0-bd26-68f14f0954a1" xlink:href="xfor-20211231.xsd#xfor_DFCIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc97419c-b2b7-49a5-96b8-1ba585237490" xlink:to="loc_xfor_DFCIMember_708dca46-da3f-40c0-bd26-68f14f0954a1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails" xlink:type="extended" id="i48e727d2427d442186a99a6704b5329d_LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ReimbursementRateForResearchAndDevelopment_7fbded35-d22e-43d6-b487-cb2d38970d1a" xlink:href="xfor-20211231.xsd#xfor_ReimbursementRateForResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:to="loc_xfor_ReimbursementRateForResearchAndDevelopment_7fbded35-d22e-43d6-b487-cb2d38970d1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GrantAndIncentiveReceivables_0727b392-cdae-473a-823f-3d84ac6e819c" xlink:href="xfor-20211231.xsd#xfor_GrantAndIncentiveReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:to="loc_xfor_GrantAndIncentiveReceivables_0727b392-cdae-473a-823f-3d84ac6e819c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c7103efc-c91c-4518-8e37-eb9e5a250857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c7103efc-c91c-4518-8e37-eb9e5a250857" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PotentialMilestonePaymentsReceivable_75416546-4ed6-49c3-9a58-14e99ef66eb5" xlink:href="xfor-20211231.xsd#xfor_PotentialMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:to="loc_xfor_PotentialMilestonePaymentsReceivable_75416546-4ed6-49c3-9a58-14e99ef66eb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cdbf029c-1594-4376-a28d-51f4741baaac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cdbf029c-1594-4376-a28d-51f4741baaac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d1477f87-57e8-4c53-8735-9802804d1f00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cdbf029c-1594-4376-a28d-51f4741baaac" xlink:to="loc_srt_StatementGeographicalAxis_d1477f87-57e8-4c53-8735-9802804d1f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d1477f87-57e8-4c53-8735-9802804d1f00_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d1477f87-57e8-4c53-8735-9802804d1f00" xlink:to="loc_srt_SegmentGeographicalDomain_d1477f87-57e8-4c53-8735-9802804d1f00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_42ab98be-d7fb-411b-97cd-d8bbe1b5fcfc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d1477f87-57e8-4c53-8735-9802804d1f00" xlink:to="loc_srt_SegmentGeographicalDomain_42ab98be-d7fb-411b-97cd-d8bbe1b5fcfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MTSAustriaMember_f32a0dcd-444c-4b27-89d4-eeb67e4fa9bd" xlink:href="xfor-20211231.xsd#xfor_MTSAustriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_42ab98be-d7fb-411b-97cd-d8bbe1b5fcfc" xlink:to="loc_xfor_MTSAustriaMember_f32a0dcd-444c-4b27-89d4-eeb67e4fa9bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5e7bbe2b-4e88-472f-9cdf-e15177827c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cdbf029c-1594-4376-a28d-51f4741baaac" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5e7bbe2b-4e88-472f-9cdf-e15177827c2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e7bbe2b-4e88-472f-9cdf-e15177827c2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e7bbe2b-4e88-472f-9cdf-e15177827c2e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e7bbe2b-4e88-472f-9cdf-e15177827c2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da7fb883-abe4-4c27-b819-5c891a7a65d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e7bbe2b-4e88-472f-9cdf-e15177827c2e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da7fb883-abe4-4c27-b819-5c891a7a65d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_5f999378-af9e-4059-b5ed-0bc69878ed9b" xlink:href="xfor-20211231.xsd#xfor_ResearchAndDevelopmentIncentiveProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da7fb883-abe4-4c27-b819-5c891a7a65d6" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_5f999378-af9e-4059-b5ed-0bc69878ed9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AbbiskoAgreementMember_92775ba4-5d3a-4f4c-a29a-3cea5ec547da" xlink:href="xfor-20211231.xsd#xfor_AbbiskoAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da7fb883-abe4-4c27-b819-5c891a7a65d6" xlink:to="loc_xfor_AbbiskoAgreementMember_92775ba4-5d3a-4f4c-a29a-3cea5ec547da" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails" xlink:type="extended" id="i647a946464084dbcb2b9f605c986d3ce_LicenseCollaborationandFundingAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23c06d5f-648e-4461-909d-d566324da2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PotentialMilestonePaymentsReceivable_dc3774e1-e2bd-4af1-9b90-b620efaad981" xlink:href="xfor-20211231.xsd#xfor_PotentialMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23c06d5f-648e-4461-909d-d566324da2cc" xlink:to="loc_xfor_PotentialMilestonePaymentsReceivable_dc3774e1-e2bd-4af1-9b90-b620efaad981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ad40e709-257b-4107-8bc1-eab57329db56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23c06d5f-648e-4461-909d-d566324da2cc" xlink:to="loc_us-gaap_Revenues_ad40e709-257b-4107-8bc1-eab57329db56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9e5f266-9407-43a0-a703-1a820cfab15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23c06d5f-648e-4461-909d-d566324da2cc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9e5f266-9407-43a0-a703-1a820cfab15c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ae208880-ea42-4640-b2f0-919ebcb33144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9e5f266-9407-43a0-a703-1a820cfab15c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ae208880-ea42-4640-b2f0-919ebcb33144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ae208880-ea42-4640-b2f0-919ebcb33144_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ae208880-ea42-4640-b2f0-919ebcb33144" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ae208880-ea42-4640-b2f0-919ebcb33144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c739bc8d-8620-4f1e-93d6-f9d00460c64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ae208880-ea42-4640-b2f0-919ebcb33144" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c739bc8d-8620-4f1e-93d6-f9d00460c64b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AbbiskoAgreementMember_ee7cd8a7-c389-46d5-9d15-82abf04b3ceb" xlink:href="xfor-20211231.xsd#xfor_AbbiskoAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c739bc8d-8620-4f1e-93d6-f9d00460c64b" xlink:to="loc_xfor_AbbiskoAgreementMember_ee7cd8a7-c389-46d5-9d15-82abf04b3ceb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i565f74db40fb4c07b2e3653b901f2c22_FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a3f3e95-86dc-4f34-a7e9-0dae3210ac10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_30a35c06-ceac-4531-8519-2c0654751b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a3f3e95-86dc-4f34-a7e9-0dae3210ac10" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_30a35c06-ceac-4531-8519-2c0654751b73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ca85fd75-a0cc-4d7f-af11-d4d650c4e7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a3f3e95-86dc-4f34-a7e9-0dae3210ac10" xlink:to="loc_us-gaap_DerivativeLiabilities_ca85fd75-a0cc-4d7f-af11-d4d650c4e7ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d0ccb42b-6329-42e7-b602-92bc7fed2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a3f3e95-86dc-4f34-a7e9-0dae3210ac10" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d0ccb42b-6329-42e7-b602-92bc7fed2d18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a3f3e95-86dc-4f34-a7e9-0dae3210ac10" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ea22823-67f1-465b-a77a-4a666c13d48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ea22823-67f1-465b-a77a-4a666c13d48a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ea22823-67f1-465b-a77a-4a666c13d48a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ea22823-67f1-465b-a77a-4a666c13d48a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ea22823-67f1-465b-a77a-4a666c13d48a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3e463d-892c-498d-86b4-f3e1e0a47780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ea22823-67f1-465b-a77a-4a666c13d48a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3e463d-892c-498d-86b4-f3e1e0a47780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cb6d7cd9-396d-4f48-9517-82b989625327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3e463d-892c-498d-86b4-f3e1e0a47780" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cb6d7cd9-396d-4f48-9517-82b989625327" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_93e0b32c-2a55-45de-a326-4517554abc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3e463d-892c-498d-86b4-f3e1e0a47780" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_93e0b32c-2a55-45de-a326-4517554abc0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_73674737-f4fd-4ac6-bb3d-b90f9a784022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3e463d-892c-498d-86b4-f3e1e0a47780" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_73674737-f4fd-4ac6-bb3d-b90f9a784022" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_447d094e-0469-4627-bb0e-1607e5ffd1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_447d094e-0469-4627-bb0e-1607e5ffd1ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_447d094e-0469-4627-bb0e-1607e5ffd1ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_447d094e-0469-4627-bb0e-1607e5ffd1ea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_447d094e-0469-4627-bb0e-1607e5ffd1ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_efe7888b-b83f-4f78-a3e1-78f8fb693af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_447d094e-0469-4627-bb0e-1607e5ffd1ea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_efe7888b-b83f-4f78-a3e1-78f8fb693af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2495fbf5-bc37-4dbb-9ef5-062d83c88370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_efe7888b-b83f-4f78-a3e1-78f8fb693af5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2495fbf5-bc37-4dbb-9ef5-062d83c88370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_f7c88a27-d3f6-4f57-949c-426b2de1a7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_f7c88a27-d3f6-4f57-949c-426b2de1a7f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f7c88a27-d3f6-4f57-949c-426b2de1a7f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_f7c88a27-d3f6-4f57-949c-426b2de1a7f0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f7c88a27-d3f6-4f57-949c-426b2de1a7f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_17be7268-ae7b-4d4e-8c1b-eeca760214e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_f7c88a27-d3f6-4f57-949c-426b2de1a7f0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_17be7268-ae7b-4d4e-8c1b-eeca760214e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_3d5f73cd-4a77-4696-9d1d-839dda2ec8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_17be7268-ae7b-4d4e-8c1b-eeca760214e3" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_3d5f73cd-4a77-4696-9d1d-839dda2ec8d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails" xlink:type="extended" id="ie3b42702645442ecb9333af26eb49cf5_FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f3dde4b7-7e9d-4faa-854c-3b3340f7c917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_556f362e-3950-4c47-975e-4737807eb90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f3dde4b7-7e9d-4faa-854c-3b3340f7c917" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_556f362e-3950-4c47-975e-4737807eb90e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_227565a0-a196-4adc-a405-08cbb980f716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_556f362e-3950-4c47-975e-4737807eb90e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_227565a0-a196-4adc-a405-08cbb980f716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f0fe3a59-3591-4c3d-9330-ab223baa3da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_556f362e-3950-4c47-975e-4737807eb90e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f0fe3a59-3591-4c3d-9330-ab223baa3da9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ebaf8f9-62c3-4f0e-a233-12353f6aaf22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_490d94c2-11e3-40cd-851a-5228893d5e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f3dde4b7-7e9d-4faa-854c-3b3340f7c917" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_490d94c2-11e3-40cd-851a-5228893d5e93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29e37316-d85c-4b11-a03e-c3146b7ada08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_490d94c2-11e3-40cd-851a-5228893d5e93" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29e37316-d85c-4b11-a03e-c3146b7ada08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_29e37316-d85c-4b11-a03e-c3146b7ada08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29e37316-d85c-4b11-a03e-c3146b7ada08" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_29e37316-d85c-4b11-a03e-c3146b7ada08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3fd25af4-d54f-4364-b9ed-ec75246e7bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29e37316-d85c-4b11-a03e-c3146b7ada08" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3fd25af4-d54f-4364-b9ed-ec75246e7bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_648fc1df-db99-431f-84d2-425b4ae47cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3fd25af4-d54f-4364-b9ed-ec75246e7bad" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_648fc1df-db99-431f-84d2-425b4ae47cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b44080e1-953d-4e8e-875e-a3de783131fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_490d94c2-11e3-40cd-851a-5228893d5e93" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b44080e1-953d-4e8e-875e-a3de783131fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b44080e1-953d-4e8e-875e-a3de783131fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b44080e1-953d-4e8e-875e-a3de783131fa" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b44080e1-953d-4e8e-875e-a3de783131fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6e33802c-12b8-47a6-8a20-34407cacca79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b44080e1-953d-4e8e-875e-a3de783131fa" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6e33802c-12b8-47a6-8a20-34407cacca79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_6a139b4c-fae3-42d9-abf3-ef0ef4537af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6e33802c-12b8-47a6-8a20-34407cacca79" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_6a139b4c-fae3-42d9-abf3-ef0ef4537af0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" xlink:type="extended" id="ifbe6e543c61a493c9f2744ac845d9a60_FairValueofFinancialAssetsandLiabilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28a0d255-6378-4612-af05-c6553e457207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0caada76-100b-4f6f-acbd-95c7db6bf4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28a0d255-6378-4612-af05-c6553e457207" xlink:to="loc_us-gaap_DerivativeLiabilities_0caada76-100b-4f6f-acbd-95c7db6bf4dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b215c698-7ce3-4a6c-84a9-92a302459e04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28a0d255-6378-4612-af05-c6553e457207" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b215c698-7ce3-4a6c-84a9-92a302459e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28a0d255-6378-4612-af05-c6553e457207" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_187dba2a-2c49-4a52-9799-00e03cdac58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_187dba2a-2c49-4a52-9799-00e03cdac58d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_187dba2a-2c49-4a52-9799-00e03cdac58d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_187dba2a-2c49-4a52-9799-00e03cdac58d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_187dba2a-2c49-4a52-9799-00e03cdac58d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4889f0ac-bd0c-4459-a282-ee8d6ce4cb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_187dba2a-2c49-4a52-9799-00e03cdac58d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4889f0ac-bd0c-4459-a282-ee8d6ce4cb8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GenzymeAgreementMember_e707b5c6-5029-4232-8966-6a9c3f4d9ce4" xlink:href="xfor-20211231.xsd#xfor_GenzymeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4889f0ac-bd0c-4459-a282-ee8d6ce4cb8e" xlink:to="loc_xfor_GenzymeAgreementMember_e707b5c6-5029-4232-8966-6a9c3f4d9ce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_833c124c-4b52-444d-854c-9486faaface2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_833c124c-4b52-444d-854c-9486faaface2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_833c124c-4b52-444d-854c-9486faaface2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_833c124c-4b52-444d-854c-9486faaface2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_833c124c-4b52-444d-854c-9486faaface2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a06ec8b6-1a69-4142-a302-3e00819869a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_833c124c-4b52-444d-854c-9486faaface2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a06ec8b6-1a69-4142-a302-3e00819869a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ArsanisMember_5e871581-1833-4552-9e68-8f8c4d3ec80d" xlink:href="xfor-20211231.xsd#xfor_ArsanisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a06ec8b6-1a69-4142-a302-3e00819869a6" xlink:to="loc_xfor_ArsanisMember_5e871581-1833-4552-9e68-8f8c4d3ec80d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddfcec38-2e76-4627-a798-dd5ccf32004b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddfcec38-2e76-4627-a798-dd5ccf32004b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddfcec38-2e76-4627-a798-dd5ccf32004b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddfcec38-2e76-4627-a798-dd5ccf32004b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ddfcec38-2e76-4627-a798-dd5ccf32004b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4686c4c-5669-430f-9cc4-51d902258a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddfcec38-2e76-4627-a798-dd5ccf32004b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4686c4c-5669-430f-9cc4-51d902258a95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_770fa1a9-eef2-4a70-9e3d-9f5cbfb0ea3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4686c4c-5669-430f-9cc4-51d902258a95" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_770fa1a9-eef2-4a70-9e3d-9f5cbfb0ea3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b65f0c2c-e658-470c-96b6-d5014bb1d6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b65f0c2c-e658-470c-96b6-d5014bb1d6a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b65f0c2c-e658-470c-96b6-d5014bb1d6a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b65f0c2c-e658-470c-96b6-d5014bb1d6a9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b65f0c2c-e658-470c-96b6-d5014bb1d6a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_29a48553-9cc1-4644-b09b-36ab6eb0815e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b65f0c2c-e658-470c-96b6-d5014bb1d6a9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_29a48553-9cc1-4644-b09b-36ab6eb0815e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_79bf11f8-11bd-4fba-a0d7-cb525f20575e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_29a48553-9cc1-4644-b09b-36ab6eb0815e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_79bf11f8-11bd-4fba-a0d7-cb525f20575e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_7609f851-1aa1-4b8c-a746-30205578ff06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_7609f851-1aa1-4b8c-a746-30205578ff06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7609f851-1aa1-4b8c-a746-30205578ff06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_7609f851-1aa1-4b8c-a746-30205578ff06" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7609f851-1aa1-4b8c-a746-30205578ff06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fdf1aa84-fae7-4884-add6-c9c5c0d2b7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_7609f851-1aa1-4b8c-a746-30205578ff06" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fdf1aa84-fae7-4884-add6-c9c5c0d2b7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_27c77db9-8a2b-407e-82fe-7e58d0799c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fdf1aa84-fae7-4884-add6-c9c5c0d2b7dc" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_27c77db9-8a2b-407e-82fe-7e58d0799c87" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="ibd283496e67e47559a90a6d6710c0dcd_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_601dc1c6-12d7-4be2-b30f-edbbadde5232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_601dc1c6-12d7-4be2-b30f-edbbadde5232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ecc34a04-9605-473e-aee4-b3fb93bd7e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ecc34a04-9605-473e-aee4-b3fb93bd7e7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f35737d1-e96b-436d-8b5d-66ff91b1aec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f35737d1-e96b-436d-8b5d-66ff91b1aec6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1a6140c9-7d20-4ccc-abb5-7720d8715ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1a6140c9-7d20-4ccc-abb5-7720d8715ace" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f14cb998-3a59-43d7-9ee8-5ebb372bd37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f14cb998-3a59-43d7-9ee8-5ebb372bd37b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8990a0d-461d-4696-8dc3-2f322614fbce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f14cb998-3a59-43d7-9ee8-5ebb372bd37b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8990a0d-461d-4696-8dc3-2f322614fbce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8990a0d-461d-4696-8dc3-2f322614fbce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8990a0d-461d-4696-8dc3-2f322614fbce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8990a0d-461d-4696-8dc3-2f322614fbce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8990a0d-461d-4696-8dc3-2f322614fbce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7a1b3611-5845-4c97-9996-0cfbe9e2f111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7a1b3611-5845-4c97-9996-0cfbe9e2f111" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1589883e-37fa-4cd8-b173-ccf97fa2d57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1589883e-37fa-4cd8-b173-ccf97fa2d57a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3a8adf40-d11a-46f9-ab94-25960334f1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:to="loc_us-gaap_ComputerEquipmentMember_3a8adf40-d11a-46f9-ab94-25960334f1c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SoftwareMember_af17b303-da48-464b-a3a3-534a4ceceebb" xlink:href="xfor-20211231.xsd#xfor_SoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:to="loc_xfor_SoftwareMember_af17b303-da48-464b-a3a3-534a4ceceebb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LabEquipmentMember_acf0393f-f5f4-46db-a174-71cf7b6ae628" xlink:href="xfor-20211231.xsd#xfor_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:to="loc_xfor_LabEquipmentMember_acf0393f-f5f4-46db-a174-71cf7b6ae628" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebtSVBLoanAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails" xlink:type="extended" id="i0c109b811f8c4d76a92841e7a74a4cc8_LongTermDebtSVBLoanAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_133d9846-07d9-4f68-87d3-1d1be4a3619d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_133d9846-07d9-4f68-87d3-1d1be4a3619d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8d515a48-2784-4b62-83ed-17b66f5119cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8d515a48-2784-4b62-83ed-17b66f5119cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_90d8444c-3fa6-4c94-a9c9-4a8a59f257ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:to="loc_us-gaap_InterestExpenseDebt_90d8444c-3fa6-4c94-a9c9-4a8a59f257ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0a0f142c-de6b-48e4-bbb0-c1169ab62fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0a0f142c-de6b-48e4-bbb0-c1169ab62fb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_6628a9f4-e040-4446-94ae-5ac37154a763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_6628a9f4-e040-4446-94ae-5ac37154a763" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_220fa1dc-ac78-4abc-8b6c-2a423e05aa5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6628a9f4-e040-4446-94ae-5ac37154a763" xlink:to="loc_srt_RangeAxis_220fa1dc-ac78-4abc-8b6c-2a423e05aa5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_220fa1dc-ac78-4abc-8b6c-2a423e05aa5a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_220fa1dc-ac78-4abc-8b6c-2a423e05aa5a" xlink:to="loc_srt_RangeMember_220fa1dc-ac78-4abc-8b6c-2a423e05aa5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_119be255-5419-4427-987e-a9349a4aca99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_220fa1dc-ac78-4abc-8b6c-2a423e05aa5a" xlink:to="loc_srt_RangeMember_119be255-5419-4427-987e-a9349a4aca99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c57e24d4-0c03-41d1-a399-222e5b6399d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_119be255-5419-4427-987e-a9349a4aca99" xlink:to="loc_srt_MinimumMember_c57e24d4-0c03-41d1-a399-222e5b6399d2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebtFFGLoanAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails" xlink:type="extended" id="id413d6c5c67742cb991f26f1b6982f4b_LongTermDebtFFGLoanAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_dc2af557-2488-4af0-99d2-17b9081e8649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_081dc3b7-1416-4216-a087-f91976a2925a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_dc2af557-2488-4af0-99d2-17b9081e8649" xlink:to="loc_us-gaap_InterestExpenseDebt_081dc3b7-1416-4216-a087-f91976a2925a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2ab3aef0-536b-4a3a-9290-4f626c07734f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_dc2af557-2488-4af0-99d2-17b9081e8649" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2ab3aef0-536b-4a3a-9290-4f626c07734f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_9e84818d-5ccc-459f-8bbc-bb559707ba5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_dc2af557-2488-4af0-99d2-17b9081e8649" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_9e84818d-5ccc-459f-8bbc-bb559707ba5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb34a8cb-d015-4b0d-81f2-3b189a43c4b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e84818d-5ccc-459f-8bbc-bb559707ba5f" xlink:to="loc_srt_RangeAxis_eb34a8cb-d015-4b0d-81f2-3b189a43c4b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb34a8cb-d015-4b0d-81f2-3b189a43c4b7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eb34a8cb-d015-4b0d-81f2-3b189a43c4b7" xlink:to="loc_srt_RangeMember_eb34a8cb-d015-4b0d-81f2-3b189a43c4b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_72411256-da84-4b9f-ac5e-8023d101bb4d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eb34a8cb-d015-4b0d-81f2-3b189a43c4b7" xlink:to="loc_srt_RangeMember_72411256-da84-4b9f-ac5e-8023d101bb4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_99645e6c-d84c-40e3-b8bb-94e9b2866a59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_72411256-da84-4b9f-ac5e-8023d101bb4d" xlink:to="loc_srt_MinimumMember_99645e6c-d84c-40e3-b8bb-94e9b2866a59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_047040b8-c1fa-4c43-82e2-dc5a403aa866" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_72411256-da84-4b9f-ac5e-8023d101bb4d" xlink:to="loc_srt_MaximumMember_047040b8-c1fa-4c43-82e2-dc5a403aa866" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebtHerculesLoanAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails" xlink:type="extended" id="if3de5dab83e24b2285852d319bb389e1_LongTermDebtHerculesLoanAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_8f7f1e3e-72e0-4410-9eb4-483ef24763c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_8f7f1e3e-72e0-4410-9eb4-483ef24763c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a3a91515-efed-4fc3-962d-5de1f40e2c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a3a91515-efed-4fc3-962d-5de1f40e2c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_e1f07b0d-4196-410d-8f57-6f6445fe2298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_e1f07b0d-4196-410d-8f57-6f6445fe2298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_effaf629-0cc2-4852-9141-c2da2cd51150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_effaf629-0cc2-4852-9141-c2da2cd51150" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_61d90ffa-a03c-4be1-9d8d-d9846beddb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_61d90ffa-a03c-4be1-9d8d-d9846beddb3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_13228b41-46c3-4090-988f-256c70b11f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_13228b41-46c3-4090-988f-256c70b11f94" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6de1ed92-039a-4520-8ecb-0bec93ee861f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6de1ed92-039a-4520-8ecb-0bec93ee861f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_6b9b24a7-0ebf-4e04-8344-e21561442e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_6b9b24a7-0ebf-4e04-8344-e21561442e6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_0c6e98c9-52e8-416b-9888-d0eb0f5b00bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_0c6e98c9-52e8-416b-9888-d0eb0f5b00bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6069d1fc-8149-456d-a092-7cc091235e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6069d1fc-8149-456d-a092-7cc091235e5c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentPrePaymentPremiumPercentage_a503fd91-f4b2-4b9e-bff2-859322e69f55" xlink:href="xfor-20211231.xsd#xfor_DebtInstrumentPrePaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_xfor_DebtInstrumentPrePaymentPremiumPercentage_a503fd91-f4b2-4b9e-bff2-859322e69f55" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_09a52b46-829b-4035-88cd-b270bbbac388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_09a52b46-829b-4035-88cd-b270bbbac388" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_99089fac-3efe-4a93-b42b-5c50498e7499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_InterestExpenseDebt_99089fac-3efe-4a93-b42b-5c50498e7499" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash_394c4327-e31a-497f-b7ae-e0d139de35c2" xlink:href="xfor-20211231.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_xfor_LineOfCreditCovenantMinimumCash_394c4327-e31a-497f-b7ae-e0d139de35c2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_83c12156-63d6-4652-b51f-14e63955550c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_us-gaap_DebtInstrumentAxis_83c12156-63d6-4652-b51f-14e63955550c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_83c12156-63d6-4652-b51f-14e63955550c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_83c12156-63d6-4652-b51f-14e63955550c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_83c12156-63d6-4652-b51f-14e63955550c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_83c12156-63d6-4652-b51f-14e63955550c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesAmendedAndRestatedLoanAgreementMember_432126c3-2663-4bb5-98bd-1d4e7e8c1b4d" xlink:href="xfor-20211231.xsd#xfor_HerculesAmendedAndRestatedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:to="loc_xfor_HerculesAmendedAndRestatedLoanAgreementMember_432126c3-2663-4bb5-98bd-1d4e7e8c1b4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesFirstAmendedLoanAgreementMember_59893045-fdd1-42b5-af0d-708f917d72e6" xlink:href="xfor-20211231.xsd#xfor_HerculesFirstAmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:to="loc_xfor_HerculesFirstAmendedLoanAgreementMember_59893045-fdd1-42b5-af0d-708f917d72e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesSecondAmendedLoanAgreementMember_739cbde8-5eec-4b42-8722-241d20b53db9" xlink:href="xfor-20211231.xsd#xfor_HerculesSecondAmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:to="loc_xfor_HerculesSecondAmendedLoanAgreementMember_739cbde8-5eec-4b42-8722-241d20b53db9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember_891ebaba-8961-4b53-995f-80d1598ec269" xlink:href="xfor-20211231.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:to="loc_xfor_HerculesLoanAgreementMember_891ebaba-8961-4b53-995f-80d1598ec269" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_bff58660-fad0-4b97-9821-2085d3be513d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_us-gaap_CreditFacilityAxis_bff58660-fad0-4b97-9821-2085d3be513d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bff58660-fad0-4b97-9821-2085d3be513d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_bff58660-fad0-4b97-9821-2085d3be513d" xlink:to="loc_us-gaap_CreditFacilityDomain_bff58660-fad0-4b97-9821-2085d3be513d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1a7401a3-ff65-457b-8a3c-7cc0b8754027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_bff58660-fad0-4b97-9821-2085d3be513d" xlink:to="loc_us-gaap_CreditFacilityDomain_1a7401a3-ff65-457b-8a3c-7cc0b8754027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DiscretionaryBorrowingsMember_174dc353-1c71-41f8-b031-1b508877ccb2" xlink:href="xfor-20211231.xsd#xfor_DiscretionaryBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1a7401a3-ff65-457b-8a3c-7cc0b8754027" xlink:to="loc_xfor_DiscretionaryBorrowingsMember_174dc353-1c71-41f8-b031-1b508877ccb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate1Member_e3d90a58-42fe-4426-95ab-61be9af1b805" xlink:href="xfor-20211231.xsd#xfor_MinCashTestDate1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1a7401a3-ff65-457b-8a3c-7cc0b8754027" xlink:to="loc_xfor_MinCashTestDate1Member_e3d90a58-42fe-4426-95ab-61be9af1b805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate2Member_f668ad72-2e6d-482a-b11b-7a704febaef7" xlink:href="xfor-20211231.xsd#xfor_MinCashTestDate2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1a7401a3-ff65-457b-8a3c-7cc0b8754027" xlink:to="loc_xfor_MinCashTestDate2Member_f668ad72-2e6d-482a-b11b-7a704febaef7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fb7833b7-d664-4629-b2c7-bf47ce7206a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_srt_RangeAxis_fb7833b7-d664-4629-b2c7-bf47ce7206a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb7833b7-d664-4629-b2c7-bf47ce7206a0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fb7833b7-d664-4629-b2c7-bf47ce7206a0" xlink:to="loc_srt_RangeMember_fb7833b7-d664-4629-b2c7-bf47ce7206a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca6f70e1-eda2-4b2f-a35a-0482d5fad29e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fb7833b7-d664-4629-b2c7-bf47ce7206a0" xlink:to="loc_srt_RangeMember_ca6f70e1-eda2-4b2f-a35a-0482d5fad29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_317a38e2-ec8f-4a10-805d-8a382617f8c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ca6f70e1-eda2-4b2f-a35a-0482d5fad29e" xlink:to="loc_srt_MinimumMember_317a38e2-ec8f-4a10-805d-8a382617f8c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_980eb6be-c922-458a-a60c-e5a2df446d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_us-gaap_VariableRateAxis_980eb6be-c922-458a-a60c-e5a2df446d03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_980eb6be-c922-458a-a60c-e5a2df446d03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_980eb6be-c922-458a-a60c-e5a2df446d03" xlink:to="loc_us-gaap_VariableRateDomain_980eb6be-c922-458a-a60c-e5a2df446d03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6d02c144-c862-4c68-8e34-c6b246a7fb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_980eb6be-c922-458a-a60c-e5a2df446d03" xlink:to="loc_us-gaap_VariableRateDomain_6d02c144-c862-4c68-8e34-c6b246a7fb2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_9a22ab5c-f91b-4530-b42d-15a9c2010930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6d02c144-c862-4c68-8e34-c6b246a7fb2b" xlink:to="loc_us-gaap_PrimeRateMember_9a22ab5c-f91b-4530-b42d-15a9c2010930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ad5402f4-47f2-451c-a3d2-7964c268ee2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_srt_StatementScenarioAxis_ad5402f4-47f2-451c-a3d2-7964c268ee2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ad5402f4-47f2-451c-a3d2-7964c268ee2d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_ad5402f4-47f2-451c-a3d2-7964c268ee2d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ad5402f4-47f2-451c-a3d2-7964c268ee2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_17b01b4d-58ee-47c3-a62e-87b08ccb7898" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_ad5402f4-47f2-451c-a3d2-7964c268ee2d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_17b01b4d-58ee-47c3-a62e-87b08ccb7898" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d95a7273-5959-4485-8429-2dfcc8271fc4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_17b01b4d-58ee-47c3-a62e-87b08ccb7898" xlink:to="loc_srt_ScenarioForecastMember_d95a7273-5959-4485-8429-2dfcc8271fc4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LeasesDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LeasesDetails" xlink:type="extended" id="i097da08992e74ceeab69775430611bb5_LeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_5bfba07e-7db8-4c08-9029-8a212ee39b1c" xlink:href="xfor-20211231.xsd#xfor_CurrentOfficeSpaceUnderLeaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_5bfba07e-7db8-4c08-9029-8a212ee39b1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e82fcfd9-086e-40c1-9c7d-46672dab565b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e82fcfd9-086e-40c1-9c7d-46672dab565b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3f5bf995-a19f-4143-b537-be2a4efad775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseLiability_3f5bf995-a19f-4143-b537-be2a4efad775" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df9168d0-f268-4ff8-8b3e-9d660af9bd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df9168d0-f268-4ff8-8b3e-9d660af9bd2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3685b040-d9f1-4339-ad92-6b726d440d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3685b040-d9f1-4339-ad92-6b726d440d0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_1f9ea566-89dd-4591-bd7e-177272c2c106" xlink:href="xfor-20211231.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_1f9ea566-89dd-4591-bd7e-177272c2c106" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AggregateBaseRent_fed223de-8b83-455d-ab9a-0e8aa6d956ed" xlink:href="xfor-20211231.xsd#xfor_AggregateBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_AggregateBaseRent_fed223de-8b83-455d-ab9a-0e8aa6d956ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bff7d722-74ac-42bf-8621-487a15780616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bff7d722-74ac-42bf-8621-487a15780616" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9569557f-9194-4941-b650-b71368c706e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9569557f-9194-4941-b650-b71368c706e5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm_37b591d9-97fd-4119-9b9c-86201a0277f8" xlink:href="xfor-20211231.xsd#xfor_OperatingLeaseRightOfUseAssetAmortizationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm_37b591d9-97fd-4119-9b9c-86201a0277f8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseRentFreePeriod_4238dbb6-231a-4ebe-854e-e8f3361637bc" xlink:href="xfor-20211231.xsd#xfor_LesseeOperatingLeaseRentFreePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_LesseeOperatingLeaseRentFreePeriod_4238dbb6-231a-4ebe-854e-e8f3361637bc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_d1476a25-3455-4651-900a-a26aea2b66a8" xlink:href="xfor-20211231.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_d1476a25-3455-4651-900a-a26aea2b66a8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0f4dc432-cc9d-4b5b-8346-2b195906c47c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseCost_0f4dc432-cc9d-4b5b-8346-2b195906c47c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3588d07e-9d5a-4ec8-b751-5b66d55a55cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_ShortTermLeaseCost_3588d07e-9d5a-4ec8-b751-5b66d55a55cb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_127996f8-b360-43aa-b6d0-355f39b536bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_LeaseCost_127996f8-b360-43aa-b6d0-355f39b536bf" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1063c8f2-0e58-4845-8a05-60fd0d79fc91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeasePayments_1063c8f2-0e58-4845-8a05-60fd0d79fc91" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_51fc8350-e808-4bdb-a4d2-f2f741af43b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_51fc8350-e808-4bdb-a4d2-f2f741af43b1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7a629c1d-3f1b-479d-8d10-7dd12023ccaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7a629c1d-3f1b-479d-8d10-7dd12023ccaa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_32832aaf-7809-4021-be23-8ea82f0a181d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_32832aaf-7809-4021-be23-8ea82f0a181d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_764beef2-00a4-43df-80e0-72bbf725e2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_SubleaseIncome_764beef2-00a4-43df-80e0-72bbf725e2fa" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_e8db4e9e-f3bd-4492-8c45-509ce1c95b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_e8db4e9e-f3bd-4492-8c45-509ce1c95b61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c12c5626-4ea6-414e-bcbc-61b0789b7b2c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e8db4e9e-f3bd-4492-8c45-509ce1c95b61" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c12c5626-4ea6-414e-bcbc-61b0789b7b2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c12c5626-4ea6-414e-bcbc-61b0789b7b2c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c12c5626-4ea6-414e-bcbc-61b0789b7b2c" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c12c5626-4ea6-414e-bcbc-61b0789b7b2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c12c5626-4ea6-414e-bcbc-61b0789b7b2c" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_db7a6584-cc1e-47ef-9a7e-189083be03e7" xlink:href="xfor-20211231.xsd#xfor_WalthamLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:to="loc_xfor_WalthamLeaseMember_db7a6584-cc1e-47ef-9a7e-189083be03e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseArrangementMember_628ae0f8-1558-4a62-9fc4-b66de1052e37" xlink:href="xfor-20211231.xsd#xfor_ViennaLeaseArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:to="loc_xfor_ViennaLeaseArrangementMember_628ae0f8-1558-4a62-9fc4-b66de1052e37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember_d759bec1-e82a-44f9-9192-f10782aaf2a9" xlink:href="xfor-20211231.xsd#xfor_AllstonLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:to="loc_xfor_AllstonLeaseMember_d759bec1-e82a-44f9-9192-f10782aaf2a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NewViennaLeaseMember_0db882bb-8391-453e-beaf-8cda83ba760c" xlink:href="xfor-20211231.xsd#xfor_NewViennaLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:to="loc_xfor_NewViennaLeaseMember_0db882bb-8391-453e-beaf-8cda83ba760c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CambridgeLeaseMember_061fedd5-d1e2-4d50-a25a-b359d640e0e1" xlink:href="xfor-20211231.xsd#xfor_CambridgeLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:to="loc_xfor_CambridgeLeaseMember_061fedd5-d1e2-4d50-a25a-b359d640e0e1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#PreferredandCommonStockWarrantsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails" xlink:type="extended" id="i1f95d873a41741e493921b7ea92babe7_PreferredandCommonStockWarrantsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_87ac13dc-f439-4107-b30f-8ee4c471638c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_87ac13dc-f439-4107-b30f-8ee4c471638c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightIssued_bbc1e5f7-8b69-4485-8506-580ae1b76713" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_xfor_ClassOfWarrantOrRightIssued_bbc1e5f7-8b69-4485-8506-580ae1b76713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_46e5ce3c-79dd-4ea1-a9ce-3d5f7c6fb8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_46e5ce3c-79dd-4ea1-a9ce-3d5f7c6fb8fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_6ebcf616-e69b-4db8-9a53-7ce9b52c4188" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_6ebcf616-e69b-4db8-9a53-7ce9b52c4188" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8f2afb58-b9c7-460a-8934-1ca9f0fc25ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8f2afb58-b9c7-460a-8934-1ca9f0fc25ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_18239d19-53d9-4b35-b615-bfb30fcebed5" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_18239d19-53d9-4b35-b615-bfb30fcebed5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_2951cd98-7983-4011-a655-f2872a0dabc4" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_2951cd98-7983-4011-a655-f2872a0dabc4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6951b698-2e6a-41f7-93e1-5583d83b5940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6951b698-2e6a-41f7-93e1-5583d83b5940" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e627b3b-6c65-4de5-aac1-60d753af4781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e627b3b-6c65-4de5-aac1-60d753af4781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e627b3b-6c65-4de5-aac1-60d753af4781_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e627b3b-6c65-4de5-aac1-60d753af4781" xlink:to="loc_us-gaap_EquityComponentDomain_1e627b3b-6c65-4de5-aac1-60d753af4781_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e017fe2c-4e4a-4624-a0ef-40284d6af6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e627b3b-6c65-4de5-aac1-60d753af4781" xlink:to="loc_us-gaap_EquityComponentDomain_e017fe2c-4e4a-4624-a0ef-40284d6af6ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember_521847a6-82da-4aea-a55d-2146df363212" xlink:href="xfor-20211231.xsd#xfor_ClassAWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e017fe2c-4e4a-4624-a0ef-40284d6af6ff" xlink:to="loc_xfor_ClassAWarrantMember_521847a6-82da-4aea-a55d-2146df363212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassBWarrantsMember_f4a86c82-54e6-4f19-83a2-2de80d24e88c" xlink:href="xfor-20211231.xsd#xfor_ClassBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e017fe2c-4e4a-4624-a0ef-40284d6af6ff" xlink:to="loc_xfor_ClassBWarrantsMember_f4a86c82-54e6-4f19-83a2-2de80d24e88c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_4b444e88-ce82-455c-aa92-9e13d5c489a3" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e017fe2c-4e4a-4624-a0ef-40284d6af6ff" xlink:to="loc_xfor_PreFundedWarrantMember_4b444e88-ce82-455c-aa92-9e13d5c489a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_83a79147-93bb-4e28-8545-022516f1fa84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_83a79147-93bb-4e28-8545-022516f1fa84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_83a79147-93bb-4e28-8545-022516f1fa84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_83a79147-93bb-4e28-8545-022516f1fa84" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_83a79147-93bb-4e28-8545-022516f1fa84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_83a79147-93bb-4e28-8545-022516f1fa84" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_69adc484-fd37-4841-87fa-a45fcc44afa0" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:to="loc_xfor_PreFundedWarrantMember_69adc484-fd37-4841-87fa-a45fcc44afa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_a55fac80-ccd1-49ad-8c57-baec9fd582f0" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_a55fac80-ccd1-49ad-8c57-baec9fd582f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member_6cf25f09-5abb-43d5-8c4f-31c39e6fd0da" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:to="loc_xfor_IssuanceOnMarch232021Member_6cf25f09-5abb-43d5-8c4f-31c39e6fd0da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_9715d505-bc2e-4356-a7a6-ad5f0e910e37" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:to="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_9715d505-bc2e-4356-a7a6-ad5f0e910e37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis_eb1df6da-221a-459a-a648-3f69f36d0257" xlink:href="xfor-20211231.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:to="loc_xfor_PrefundedWarrantsAxis_eb1df6da-221a-459a-a648-3f69f36d0257" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_eb1df6da-221a-459a-a648-3f69f36d0257_default" xlink:href="xfor-20211231.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xfor_PrefundedWarrantsAxis_eb1df6da-221a-459a-a648-3f69f36d0257" xlink:to="loc_xfor_PrefundedWarrantsDomain_eb1df6da-221a-459a-a648-3f69f36d0257_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_e13bf9fa-b37f-4b63-9951-d5aed01a1373" xlink:href="xfor-20211231.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xfor_PrefundedWarrantsAxis_eb1df6da-221a-459a-a648-3f69f36d0257" xlink:to="loc_xfor_PrefundedWarrantsDomain_e13bf9fa-b37f-4b63-9951-d5aed01a1373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember_3839b4b7-416f-4259-a255-184f616c6a9e" xlink:href="xfor-20211231.xsd#xfor_FundedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_PrefundedWarrantsDomain_e13bf9fa-b37f-4b63-9951-d5aed01a1373" xlink:to="loc_xfor_FundedMember_3839b4b7-416f-4259-a255-184f616c6a9e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail" xlink:type="simple" xlink:href="xfor-20211231.xsd#PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail" xlink:type="extended" id="i7921066bfff44283bf3fd5eaeaf1f202_PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_68e47ab3-07b9-45a8-9316-631518b2590b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a2c77758-67f3-4c7d-912d-d03e7676b055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_68e47ab3-07b9-45a8-9316-631518b2590b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a2c77758-67f3-4c7d-912d-d03e7676b055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0f8e6bc6-e184-45a4-9153-1579e006eb70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_68e47ab3-07b9-45a8-9316-631518b2590b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0f8e6bc6-e184-45a4-9153-1579e006eb70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_15203d76-e998-45d3-be0f-6fc885b67a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_68e47ab3-07b9-45a8-9316-631518b2590b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_15203d76-e998-45d3-be0f-6fc885b67a6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f9b22e03-851b-45a2-b26a-27d9ac06fbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_15203d76-e998-45d3-be0f-6fc885b67a6c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f9b22e03-851b-45a2-b26a-27d9ac06fbc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f9b22e03-851b-45a2-b26a-27d9ac06fbc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f9b22e03-851b-45a2-b26a-27d9ac06fbc3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f9b22e03-851b-45a2-b26a-27d9ac06fbc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_34a427b4-1ce8-486a-8d58-0ece2c318261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f9b22e03-851b-45a2-b26a-27d9ac06fbc3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_34a427b4-1ce8-486a-8d58-0ece2c318261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_03a16018-9ff0-4980-b209-40926429fe56" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_34a427b4-1ce8-486a-8d58-0ece2c318261" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_03a16018-9ff0-4980-b209-40926429fe56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails" xlink:type="extended" id="ib18a10cded3648a99261e9360f4dc991_PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_717d87de-0ee8-46b6-a6e7-f81ba7faeb24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d9990c0a-49d5-4e26-aad6-2d9904750990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_717d87de-0ee8-46b6-a6e7-f81ba7faeb24" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d9990c0a-49d5-4e26-aad6-2d9904750990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dbcffcc2-4b08-4b4f-8b80-69db954bfed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_717d87de-0ee8-46b6-a6e7-f81ba7faeb24" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dbcffcc2-4b08-4b4f-8b80-69db954bfed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_c6289e6d-0801-476d-a360-9cab588ea265" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_717d87de-0ee8-46b6-a6e7-f81ba7faeb24" xlink:to="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_c6289e6d-0801-476d-a360-9cab588ea265" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_48b5fc40-c944-44de-9bbf-bbb47be6ee57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_717d87de-0ee8-46b6-a6e7-f81ba7faeb24" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_48b5fc40-c944-44de-9bbf-bbb47be6ee57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1166844e-ee69-4ff3-b761-14b89c2d9c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_48b5fc40-c944-44de-9bbf-bbb47be6ee57" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1166844e-ee69-4ff3-b761-14b89c2d9c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1166844e-ee69-4ff3-b761-14b89c2d9c4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1166844e-ee69-4ff3-b761-14b89c2d9c4c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1166844e-ee69-4ff3-b761-14b89c2d9c4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1166844e-ee69-4ff3-b761-14b89c2d9c4c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_3dab39fd-7160-49ca-abbe-25e5dbf9dc8b" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_3dab39fd-7160-49ca-abbe-25e5dbf9dc8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_c660dc4e-ee48-4956-86ad-0786433a1532" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_c660dc4e-ee48-4956-86ad-0786433a1532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_cea37d50-9c7b-4eb4-9267-7eb8328472ec" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_cea37d50-9c7b-4eb4-9267-7eb8328472ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_5f071fbb-e6dd-488f-bb3e-69e172436bc9" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_5f071fbb-e6dd-488f-bb3e-69e172436bc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_acd48f0d-02d5-4966-9690-1d77ef6e9565" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_acd48f0d-02d5-4966-9690-1d77ef6e9565" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_47b37258-afdb-4ef0-a62c-4d9dade2a16a" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_47b37258-afdb-4ef0-a62c-4d9dade2a16a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_05877a87-6f0a-44eb-a9cd-af4636605341" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_05877a87-6f0a-44eb-a9cd-af4636605341" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_b96a63a1-04f4-4d6d-a6f0-03fed287622b" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_b96a63a1-04f4-4d6d-a6f0-03fed287622b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member_8bef556a-3e23-4b38-ae29-75aae89aad73" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnMarch232021Member_8bef556a-3e23-4b38-ae29-75aae89aad73" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_b5df93fa-39c8-4dd1-acac-fb67a6c841ac" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_b5df93fa-39c8-4dd1-acac-fb67a6c841ac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cf2b4f65-277f-4527-812a-46abcd76eb48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_48b5fc40-c944-44de-9bbf-bbb47be6ee57" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cf2b4f65-277f-4527-812a-46abcd76eb48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cf2b4f65-277f-4527-812a-46abcd76eb48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf2b4f65-277f-4527-812a-46abcd76eb48" xlink:to="loc_us-gaap_EquityComponentDomain_cf2b4f65-277f-4527-812a-46abcd76eb48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_91c497f1-61f8-4446-8051-931f904b028b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf2b4f65-277f-4527-812a-46abcd76eb48" xlink:to="loc_us-gaap_EquityComponentDomain_91c497f1-61f8-4446-8051-931f904b028b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_039a00b2-c611-4f6a-ba41-720f94d23bd2" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_91c497f1-61f8-4446-8051-931f904b028b" xlink:to="loc_xfor_PreFundedWarrantMember_039a00b2-c611-4f6a-ba41-720f94d23bd2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails" xlink:type="extended" id="i1898686d7c884d59a491ede1dcedd845_CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f327e6cd-2d67-4867-be5e-2bce1fb4a358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f327e6cd-2d67-4867-be5e-2bce1fb4a358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7ca1966e-f32e-449f-a9ff-4c34364da010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7ca1966e-f32e-449f-a9ff-4c34364da010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_38ecc796-857b-4986-a53e-abd111d867e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_DividendsCommonStock_38ecc796-857b-4986-a53e-abd111d867e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount_f0f57b21-164e-404d-b443-fe638368eea7" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount_f0f57b21-164e-404d-b443-fe638368eea7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockPurchaseAgreementTerm_e6eb0ae4-d23d-437a-aac5-c4f5b64e9f7b" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockPurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_SaleOfStockPurchaseAgreementTerm_e6eb0ae4-d23d-437a-aac5-c4f5b64e9f7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bfb9a99f-649d-44f4-ba8a-f4917f38386e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bfb9a99f-649d-44f4-ba8a-f4917f38386e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c16e121f-0f79-45bb-8986-03d57acf557f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c16e121f-0f79-45bb-8986-03d57acf557f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_99f9a1bb-9606-46a4-b09f-3e7c64538a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_99f9a1bb-9606-46a4-b09f-3e7c64538a56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_efcc2c34-3270-4f72-b43e-9694f43af0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_efcc2c34-3270-4f72-b43e-9694f43af0f8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_656cd707-804b-4bdf-95a8-218c961e6aff" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_656cd707-804b-4bdf-95a8-218c961e6aff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_c6af4175-7a5a-45e4-b341-72c6c7993f02" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_c6af4175-7a5a-45e4-b341-72c6c7993f02" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesLicenseAgreement_dc0ea641-ae39-4389-8eee-ac86f1708f35" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_StockIssuedDuringPeriodSharesLicenseAgreement_dc0ea641-ae39-4389-8eee-ac86f1708f35" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodValueLicenseAgreement_f91aace9-df4a-4a4c-9fd0-b46c36d30b82" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_StockIssuedDuringPeriodValueLicenseAgreement_f91aace9-df4a-4a4c-9fd0-b46c36d30b82" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CommonStockRepurchasePricePerShare_8beed2e7-8b28-4fa9-a2dc-289923f2fb32" xlink:href="xfor-20211231.xsd#xfor_CommonStockRepurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_CommonStockRepurchasePricePerShare_8beed2e7-8b28-4fa9-a2dc-289923f2fb32" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_bf6a8dff-f9d1-4588-8c30-f42ab4f37b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_bf6a8dff-f9d1-4588-8c30-f42ab4f37b94" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_b663490d-bffb-4b65-97bb-6e2ad8ce299e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_b663490d-bffb-4b65-97bb-6e2ad8ce299e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_6451ec68-b03f-4275-bde7-b05c22e8f4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_6451ec68-b03f-4275-bde7-b05c22e8f4b3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_415ca429-8c7c-4bd2-9462-e6dfc3cd3eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_415ca429-8c7c-4bd2-9462-e6dfc3cd3eaa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_403499d0-307e-4715-9a13-a6561c2eac6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_403499d0-307e-4715-9a13-a6561c2eac6a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_095d5ccb-0385-40ef-9ade-cda7e660eb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_095d5ccb-0385-40ef-9ade-cda7e660eb01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_095d5ccb-0385-40ef-9ade-cda7e660eb01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_095d5ccb-0385-40ef-9ade-cda7e660eb01" xlink:to="loc_us-gaap_EquityComponentDomain_095d5ccb-0385-40ef-9ade-cda7e660eb01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e79d13aa-6180-4fcd-86d4-0c08884f0986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_095d5ccb-0385-40ef-9ade-cda7e660eb01" xlink:to="loc_us-gaap_EquityComponentDomain_e79d13aa-6180-4fcd-86d4-0c08884f0986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_65c2fec6-f5cf-4dc1-8fa9-220ca7461dbf" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e79d13aa-6180-4fcd-86d4-0c08884f0986" xlink:to="loc_xfor_PreFundedWarrantMember_65c2fec6-f5cf-4dc1-8fa9-220ca7461dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember_16d83cfd-808d-4973-a6ef-60dfebcecb71" xlink:href="xfor-20211231.xsd#xfor_ClassAWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e79d13aa-6180-4fcd-86d4-0c08884f0986" xlink:to="loc_xfor_ClassAWarrantMember_16d83cfd-808d-4973-a6ef-60dfebcecb71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassBWarrantsMember_8d9aaefa-8bd4-4ce0-8284-d185a2eeddd4" xlink:href="xfor-20211231.xsd#xfor_ClassBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e79d13aa-6180-4fcd-86d4-0c08884f0986" xlink:to="loc_xfor_ClassBWarrantsMember_8d9aaefa-8bd4-4ce0-8284-d185a2eeddd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cf2ae1d9-1702-48f5-a615-8437d48e0315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cf2ae1d9-1702-48f5-a615-8437d48e0315" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf2ae1d9-1702-48f5-a615-8437d48e0315_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cf2ae1d9-1702-48f5-a615-8437d48e0315" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf2ae1d9-1702-48f5-a615-8437d48e0315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9575a99e-d5c7-4d99-9914-a324af6cf4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cf2ae1d9-1702-48f5-a615-8437d48e0315" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9575a99e-d5c7-4d99-9914-a324af6cf4ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GenzymeAgreementMember_35b1f571-170b-4234-a9d9-74a97cbc7ffe" xlink:href="xfor-20211231.xsd#xfor_GenzymeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9575a99e-d5c7-4d99-9914-a324af6cf4ea" xlink:to="loc_xfor_GenzymeAgreementMember_35b1f571-170b-4234-a9d9-74a97cbc7ffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ae5f975b-e771-4ecc-8762-1d1e5ce0b9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ae5f975b-e771-4ecc-8762-1d1e5ce0b9b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae5f975b-e771-4ecc-8762-1d1e5ce0b9b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae5f975b-e771-4ecc-8762-1d1e5ce0b9b2" xlink:to="loc_us-gaap_ClassOfStockDomain_ae5f975b-e771-4ecc-8762-1d1e5ce0b9b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_00c96274-1521-4ca1-82bb-8c7ff526ca7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae5f975b-e771-4ecc-8762-1d1e5ce0b9b2" xlink:to="loc_us-gaap_ClassOfStockDomain_00c96274-1521-4ca1-82bb-8c7ff526ca7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SeriesSeedConvertiblePreferredStockMember_9e3a5f52-aa06-4add-9ace-08f1e316cb0d" xlink:href="xfor-20211231.xsd#xfor_SeriesSeedConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_00c96274-1521-4ca1-82bb-8c7ff526ca7c" xlink:to="loc_xfor_SeriesSeedConvertiblePreferredStockMember_9e3a5f52-aa06-4add-9ace-08f1e316cb0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_40b549b0-8312-408b-b5d5-b82e70649c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_00c96274-1521-4ca1-82bb-8c7ff526ca7c" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_40b549b0-8312-408b-b5d5-b82e70649c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_cfb6948e-80a3-494f-93d5-a63f051b4191" xlink:href="xfor-20211231.xsd#xfor_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_00c96274-1521-4ca1-82bb-8c7ff526ca7c" xlink:to="loc_xfor_RedeemableCommonStockMember_cfb6948e-80a3-494f-93d5-a63f051b4191" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f8347e5f-bafc-48fc-96d1-1446db31f5fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_srt_RangeAxis_f8347e5f-bafc-48fc-96d1-1446db31f5fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8347e5f-bafc-48fc-96d1-1446db31f5fb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f8347e5f-bafc-48fc-96d1-1446db31f5fb" xlink:to="loc_srt_RangeMember_f8347e5f-bafc-48fc-96d1-1446db31f5fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a7f378ac-e16f-4433-9506-f7daf37ca7db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f8347e5f-bafc-48fc-96d1-1446db31f5fb" xlink:to="loc_srt_RangeMember_a7f378ac-e16f-4433-9506-f7daf37ca7db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12144f4a-98e4-41c1-85bd-1f65a7478dd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a7f378ac-e16f-4433-9506-f7daf37ca7db" xlink:to="loc_srt_MaximumMember_12144f4a-98e4-41c1-85bd-1f65a7478dd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fb9c32f9-41ec-41a0-a7a5-ae81e2aa21ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a7f378ac-e16f-4433-9506-f7daf37ca7db" xlink:to="loc_srt_MinimumMember_fb9c32f9-41ec-41a0-a7a5-ae81e2aa21ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_553138e6-9950-47c4-a259-5f5c9559506f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_srt_TitleOfIndividualAxis_553138e6-9950-47c4-a259-5f5c9559506f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_553138e6-9950-47c4-a259-5f5c9559506f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_553138e6-9950-47c4-a259-5f5c9559506f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_553138e6-9950-47c4-a259-5f5c9559506f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_883015d3-12e1-4462-b717-82159dc65bcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_553138e6-9950-47c4-a259-5f5c9559506f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_883015d3-12e1-4462-b717-82159dc65bcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SalesAgentsMember_0e08beb1-3205-4aa5-9dd0-ce091321595a" xlink:href="xfor-20211231.xsd#xfor_SalesAgentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_883015d3-12e1-4462-b717-82159dc65bcb" xlink:to="loc_xfor_SalesAgentsMember_0e08beb1-3205-4aa5-9dd0-ce091321595a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_afc635fc-4595-4a10-9023-f2e24690a6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_afc635fc-4595-4a10-9023-f2e24690a6b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_afc635fc-4595-4a10-9023-f2e24690a6b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_afc635fc-4595-4a10-9023-f2e24690a6b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_afc635fc-4595-4a10-9023-f2e24690a6b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_360a001b-0318-4c21-a551-097eb3323672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_afc635fc-4595-4a10-9023-f2e24690a6b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_360a001b-0318-4c21-a551-097eb3323672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6b11c99d-bf6e-4152-8f8c-cd54d69f9f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_360a001b-0318-4c21-a551-097eb3323672" xlink:to="loc_us-gaap_CommonStockMember_6b11c99d-bf6e-4152-8f8c-cd54d69f9f0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dc6349e9-312d-4900-9b06-131be9dd512a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dc6349e9-312d-4900-9b06-131be9dd512a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dc6349e9-312d-4900-9b06-131be9dd512a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dc6349e9-312d-4900-9b06-131be9dd512a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dc6349e9-312d-4900-9b06-131be9dd512a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_558dfe72-6d66-4fd5-9fcd-9910f15f17d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dc6349e9-312d-4900-9b06-131be9dd512a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_558dfe72-6d66-4fd5-9fcd-9910f15f17d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember_5c14c4cd-5574-498c-b523-6589dbdb282f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_558dfe72-6d66-4fd5-9fcd-9910f15f17d8" xlink:to="loc_us-gaap_EquityUnitPurchaseAgreementsMember_5c14c4cd-5574-498c-b523-6589dbdb282f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e75b1981-c2ed-4ef4-b5e4-ced9c736d26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e75b1981-c2ed-4ef4-b5e4-ced9c736d26e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e75b1981-c2ed-4ef4-b5e4-ced9c736d26e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e75b1981-c2ed-4ef4-b5e4-ced9c736d26e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e75b1981-c2ed-4ef4-b5e4-ced9c736d26e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_58c388f6-f105-48a2-bce7-6311eb8c8c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e75b1981-c2ed-4ef4-b5e4-ced9c736d26e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_58c388f6-f105-48a2-bce7-6311eb8c8c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_5b46f1ae-4806-4ff2-a85c-1597a464ca10" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58c388f6-f105-48a2-bce7-6311eb8c8c61" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_5b46f1ae-4806-4ff2-a85c-1597a464ca10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="ie5cd30d17bc449c0aa7c18fd99cf732a_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock_2af3cfd1-adfa-4897-898a-76f4192b65ed" xlink:href="xfor-20211231.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock_2af3cfd1-adfa-4897-898a-76f4192b65ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f11fbc8-8a25-4651-b5cc-01fe7965df43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f11fbc8-8a25-4651-b5cc-01fe7965df43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a82c2fd6-838e-42f3-92ad-d6b367d775bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a82c2fd6-838e-42f3-92ad-d6b367d775bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_15331e66-87a1-49d5-8873-aef3f242c399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_15331e66-87a1-49d5-8873-aef3f242c399" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2383e6c5-c890-47c7-b9a2-16c81e978a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2383e6c5-c890-47c7-b9a2-16c81e978a73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_62685a25-b587-406b-8144-e6ca4ed3ca58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_62685a25-b587-406b-8144-e6ca4ed3ca58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5688e8ef-7707-4879-8e6c-d151fc1a444d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5688e8ef-7707-4879-8e6c-d151fc1a444d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fe806a8a-706d-4694-a2d7-335959b899b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fe806a8a-706d-4694-a2d7-335959b899b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c199e973-9f31-44e6-8c8c-922c9180b62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c199e973-9f31-44e6-8c8c-922c9180b62f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ddf1613-4c8c-4efa-b657-6faf14ebb4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ddf1613-4c8c-4efa-b657-6faf14ebb4c6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_adfeb50b-c1d2-45d4-9bf6-395bbec20c2a" xlink:href="xfor-20211231.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_adfeb50b-c1d2-45d4-9bf6-395bbec20c2a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3c88dd6d-5d40-4872-a583-203e6e4886e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3c88dd6d-5d40-4872-a583-203e6e4886e6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52051375-3bc5-4c56-b7fa-ea6762463b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52051375-3bc5-4c56-b7fa-ea6762463b98" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d1e56646-9da8-4707-b74f-c4d7e0b5f2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d1e56646-9da8-4707-b74f-c4d7e0b5f2e0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7dc912a3-1448-4508-92bd-148bf5563598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7dc912a3-1448-4508-92bd-148bf5563598" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3fcc94c0-133c-46a2-a875-57b83024f7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3fcc94c0-133c-46a2-a875-57b83024f7bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df54b713-27f4-4642-aea7-de68ad843c2c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:to="loc_srt_RangeAxis_df54b713-27f4-4642-aea7-de68ad843c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df54b713-27f4-4642-aea7-de68ad843c2c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_df54b713-27f4-4642-aea7-de68ad843c2c" xlink:to="loc_srt_RangeMember_df54b713-27f4-4642-aea7-de68ad843c2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78d0ce4f-1cae-42bd-aaed-ae4f4d414f01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_df54b713-27f4-4642-aea7-de68ad843c2c" xlink:to="loc_srt_RangeMember_78d0ce4f-1cae-42bd-aaed-ae4f4d414f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b7f0370d-c768-40f5-bcac-923524533348" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_78d0ce4f-1cae-42bd-aaed-ae4f4d414f01" xlink:to="loc_srt_MinimumMember_b7f0370d-c768-40f5-bcac-923524533348" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b3a58f8b-e68c-484f-ae1f-64886522f216" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_78d0ce4f-1cae-42bd-aaed-ae4f4d414f01" xlink:to="loc_srt_MaximumMember_b3a58f8b-e68c-484f-ae1f-64886522f216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e48f3c6f-9088-400f-8e54-9e515621948a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:to="loc_us-gaap_PlanNameAxis_e48f3c6f-9088-400f-8e54-9e515621948a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e48f3c6f-9088-400f-8e54-9e515621948a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e48f3c6f-9088-400f-8e54-9e515621948a" xlink:to="loc_us-gaap_PlanNameDomain_e48f3c6f-9088-400f-8e54-9e515621948a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_453ac122-6249-4b8b-9633-700c9e675f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e48f3c6f-9088-400f-8e54-9e515621948a" xlink:to="loc_us-gaap_PlanNameDomain_453ac122-6249-4b8b-9633-700c9e675f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_A2015EquityIncentivePlanMember_1a9c2132-629e-4a9e-ab96-7471a300a6ee" xlink:href="xfor-20211231.xsd#xfor_A2015EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_453ac122-6249-4b8b-9633-700c9e675f7e" xlink:to="loc_xfor_A2015EquityIncentivePlanMember_1a9c2132-629e-4a9e-ab96-7471a300a6ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_36b8710b-36a5-4777-864c-294e0ffca257" xlink:href="xfor-20211231.xsd#xfor_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_453ac122-6249-4b8b-9633-700c9e675f7e" xlink:to="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_36b8710b-36a5-4777-864c-294e0ffca257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_729a64f0-3681-4ee5-b80f-1117b08309c7" xlink:href="xfor-20211231.xsd#xfor_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_453ac122-6249-4b8b-9633-700c9e675f7e" xlink:to="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_729a64f0-3681-4ee5-b80f-1117b08309c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e29e290-9b08-4dc5-a319-2eae4751e93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:to="loc_us-gaap_AwardTypeAxis_6e29e290-9b08-4dc5-a319-2eae4751e93c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e29e290-9b08-4dc5-a319-2eae4751e93c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6e29e290-9b08-4dc5-a319-2eae4751e93c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e29e290-9b08-4dc5-a319-2eae4751e93c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6e29e290-9b08-4dc5-a319-2eae4751e93c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b8f310a5-6e4e-414e-ae5f-3663e7c41e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b8f310a5-6e4e-414e-ae5f-3663e7c41e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember_0dee96c4-fe18-4c03-9cee-7e26a531346a" xlink:href="xfor-20211231.xsd#xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:to="loc_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember_0dee96c4-fe18-4c03-9cee-7e26a531346a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonStatutoryOptionsMember_5668712f-3f83-4658-8732-d2e30616bdad" xlink:href="xfor-20211231.xsd#xfor_NonStatutoryOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:to="loc_xfor_NonStatutoryOptionsMember_5668712f-3f83-4658-8732-d2e30616bdad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1447daea-4d58-4fc5-afa1-f90a906eb482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1447daea-4d58-4fc5-afa1-f90a906eb482" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f0bca29d-030d-4b2b-83fa-f4fa700b2776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f0bca29d-030d-4b2b-83fa-f4fa700b2776" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_f0bca29d-030d-4b2b-83fa-f4fa700b2776_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f0bca29d-030d-4b2b-83fa-f4fa700b2776" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_f0bca29d-030d-4b2b-83fa-f4fa700b2776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_f3da450d-2105-4e80-ac36-feda41fb1bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f0bca29d-030d-4b2b-83fa-f4fa700b2776" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_f3da450d-2105-4e80-ac36-feda41fb1bd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_EmployeeStockPurchasePlansMember_4ff7798e-c973-45cd-92a9-9e710968d9ee" xlink:href="xfor-20211231.xsd#xfor_EmployeeStockPurchasePlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_f3da450d-2105-4e80-ac36-feda41fb1bd5" xlink:to="loc_xfor_EmployeeStockPurchasePlansMember_4ff7798e-c973-45cd-92a9-9e710968d9ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#StockBasedCompensationRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" id="i9e3761c8f94f402390e7a6f527606ef0_StockBasedCompensationRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0d4664a-5843-413f-9c46-15a7d2b3619a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0d4664a-5843-413f-9c46-15a7d2b3619a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c28fc943-3181-443d-9c91-05c8cf09a3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c28fc943-3181-443d-9c91-05c8cf09a3f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f39f78bf-d7b4-4cb5-b34a-1700caec713a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f39f78bf-d7b4-4cb5-b34a-1700caec713a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d2f50a7f-3199-427b-b619-c95eca8d3caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d2f50a7f-3199-427b-b619-c95eca8d3caa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2a7f2b0e-3ae8-48c7-bbc6-2a7b838d64c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2a7f2b0e-3ae8-48c7-bbc6-2a7b838d64c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b5c6fe2-b9a3-466c-96a5-fde965b249ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_798eef09-7ef7-48c1-89f4-7e39648b1843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0d4664a-5843-413f-9c46-15a7d2b3619a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_798eef09-7ef7-48c1-89f4-7e39648b1843" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7dd323c1-0b77-4397-8126-3affde496b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_798eef09-7ef7-48c1-89f4-7e39648b1843" xlink:to="loc_us-gaap_AwardTypeAxis_7dd323c1-0b77-4397-8126-3affde496b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7dd323c1-0b77-4397-8126-3affde496b83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7dd323c1-0b77-4397-8126-3affde496b83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7dd323c1-0b77-4397-8126-3affde496b83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21158786-3ac5-4435-bf28-0172b62a0b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7dd323c1-0b77-4397-8126-3affde496b83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21158786-3ac5-4435-bf28-0172b62a0b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9bb5bff0-99c9-4b1e-b401-300a12c2d094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21158786-3ac5-4435-bf28-0172b62a0b8e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9bb5bff0-99c9-4b1e-b401-300a12c2d094" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="extended" id="i292d2a7d5f41406fb3ccd823fb4c4e43_StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6bfb0c7-389e-4d39-b22d-25c1a3a79272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d0d43b31-76c1-472a-8090-e27da474b0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6bfb0c7-389e-4d39-b22d-25c1a3a79272" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d0d43b31-76c1-472a-8090-e27da474b0bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ca53e14-180d-4b6c-9b22-e68731b1c572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6bfb0c7-389e-4d39-b22d-25c1a3a79272" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ca53e14-180d-4b6c-9b22-e68731b1c572" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ec9b65c0-7c53-4513-882a-fe4ff5d3147f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ca53e14-180d-4b6c-9b22-e68731b1c572" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ec9b65c0-7c53-4513-882a-fe4ff5d3147f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ec9b65c0-7c53-4513-882a-fe4ff5d3147f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ec9b65c0-7c53-4513-882a-fe4ff5d3147f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ec9b65c0-7c53-4513-882a-fe4ff5d3147f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f149af90-133a-4fda-8f8a-3c925e864e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ec9b65c0-7c53-4513-882a-fe4ff5d3147f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f149af90-133a-4fda-8f8a-3c925e864e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_db77bfe3-c481-4699-b749-0b7b15f0333a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f149af90-133a-4fda-8f8a-3c925e864e99" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_db77bfe3-c481-4699-b749-0b7b15f0333a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3e66e963-3b40-4485-8e07-9fa53882bb68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f149af90-133a-4fda-8f8a-3c925e864e99" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3e66e963-3b40-4485-8e07-9fa53882bb68" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i88819272fc2549378e9af038872d4d61_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_949768c6-e756-4058-997d-df22a143caa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_OperatingLossCarryforwards_949768c6-e756-4058-997d-df22a143caa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_bd9d565e-9581-46e8-8d29-09d25fb7a7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_bd9d565e-9581-46e8-8d29-09d25fb7a7d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_3d0497e8-da1c-4b4d-8e63-ccec87a3bb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_3d0497e8-da1c-4b4d-8e63-ccec87a3bb3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_15759f16-285b-49a4-bc05-11288db342ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_15759f16-285b-49a4-bc05-11288db342ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e6f4603b-2534-410a-bbfc-00e2a983658b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e6f4603b-2534-410a-bbfc-00e2a983658b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_e9b22376-8b19-4df3-b94f-7074aedfecb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_e9b22376-8b19-4df3-b94f-7074aedfecb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_aac31625-d642-4773-94ff-50fe2add4e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_e9b22376-8b19-4df3-b94f-7074aedfecb5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_aac31625-d642-4773-94ff-50fe2add4e70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_aac31625-d642-4773-94ff-50fe2add4e70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_aac31625-d642-4773-94ff-50fe2add4e70" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_aac31625-d642-4773-94ff-50fe2add4e70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_dcff0ce9-070d-4d6e-a950-8bdc4492b553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_aac31625-d642-4773-94ff-50fe2add4e70" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_dcff0ce9-070d-4d6e-a950-8bdc4492b553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_730ee783-1daf-4dbc-a7e6-2cc5f4d6b4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_dcff0ce9-070d-4d6e-a950-8bdc4492b553" xlink:to="loc_us-gaap_ResearchMember_730ee783-1daf-4dbc-a7e6-2cc5f4d6b4e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_39dac313-2cb7-480c-b41e-4ddff9cf3245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_e9b22376-8b19-4df3-b94f-7074aedfecb5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_39dac313-2cb7-480c-b41e-4ddff9cf3245" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_39dac313-2cb7-480c-b41e-4ddff9cf3245_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_39dac313-2cb7-480c-b41e-4ddff9cf3245" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_39dac313-2cb7-480c-b41e-4ddff9cf3245_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b2b5b84a-b14c-4b00-b668-c3fd1fc6c5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_39dac313-2cb7-480c-b41e-4ddff9cf3245" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b2b5b84a-b14c-4b00-b668-c3fd1fc6c5ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_1ff07ba2-b20a-44de-aa8b-2d35428ab3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b2b5b84a-b14c-4b00-b668-c3fd1fc6c5ed" xlink:to="loc_us-gaap_DomesticCountryMember_1ff07ba2-b20a-44de-aa8b-2d35428ab3d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2ddbe65c-4468-4554-9329-2d9b5c572450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b2b5b84a-b14c-4b00-b668-c3fd1fc6c5ed" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2ddbe65c-4468-4554-9329-2d9b5c572450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_55148714-cecd-45fa-a4f4-168dc1ccd730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b2b5b84a-b14c-4b00-b668-c3fd1fc6c5ed" xlink:to="loc_us-gaap_ForeignCountryMember_55148714-cecd-45fa-a4f4-168dc1ccd730" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesDeferredTaxValuationAllowanceDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails" xlink:type="extended" id="ice5db3d95a1c4a46b7e33f1a0cfc2b80_IncomeTaxesDeferredTaxValuationAllowanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_29286917-e151-4248-a7de-d17055cb3943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_29286917-e151-4248-a7de-d17055cb3943" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8e70078b-71b6-49b1-86e3-120593d4632c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8e70078b-71b6-49b1-86e3-120593d4632c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_7370c7e1-a2f5-4ccc-bd74-17b77be6d68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_7370c7e1-a2f5-4ccc-bd74-17b77be6d68c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_6a73ad22-c865-4db0-a158-915f34ea55d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_6a73ad22-c865-4db0-a158-915f34ea55d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_812b3997-92d0-479f-8b72-512a981b2975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_5fdbddf3-7793-4d35-a834-ce5c0f0df7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_29286917-e151-4248-a7de-d17055cb3943" xlink:to="loc_us-gaap_ValuationAllowanceTable_5fdbddf3-7793-4d35-a834-ce5c0f0df7ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_56635558-3897-485d-8304-965e3b0d0603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_5fdbddf3-7793-4d35-a834-ce5c0f0df7ce" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_56635558-3897-485d-8304-965e3b0d0603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_56635558-3897-485d-8304-965e3b0d0603_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_56635558-3897-485d-8304-965e3b0d0603" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_56635558-3897-485d-8304-965e3b0d0603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e6361984-789f-44e8-a7b0-8e80f4ac4a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_56635558-3897-485d-8304-965e3b0d0603" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e6361984-789f-44e8-a7b0-8e80f4ac4a4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9fab0583-7838-4d6a-a183-20619cfb79e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e6361984-789f-44e8-a7b0-8e80f4ac4a4b" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9fab0583-7838-4d6a-a183-20619cfb79e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#NetLossperShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails" xlink:type="extended" id="i8cc10a3cfc654a779b7ae99144562117_NetLossperShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_cdd68b20-6da3-4f37-9cd4-044236a0d670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0771a885-422b-4326-89ca-942585cc9883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_cdd68b20-6da3-4f37-9cd4-044236a0d670" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0771a885-422b-4326-89ca-942585cc9883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9f63d428-3fae-4908-af09-369fa51b7c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_cdd68b20-6da3-4f37-9cd4-044236a0d670" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9f63d428-3fae-4908-af09-369fa51b7c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_cdd68b20-6da3-4f37-9cd4-044236a0d670" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75362592-d68a-436e-a6aa-76b8a45cdca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75362592-d68a-436e-a6aa-76b8a45cdca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_75362592-d68a-436e-a6aa-76b8a45cdca7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75362592-d68a-436e-a6aa-76b8a45cdca7" xlink:to="loc_us-gaap_ClassOfStockDomain_75362592-d68a-436e-a6aa-76b8a45cdca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6abe1d85-db1d-468d-b990-5bd67470c7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75362592-d68a-436e-a6aa-76b8a45cdca7" xlink:to="loc_us-gaap_ClassOfStockDomain_6abe1d85-db1d-468d-b990-5bd67470c7d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_7a87b4a8-b9fb-4d95-8ab0-0c16c3ba27bd" xlink:href="xfor-20211231.xsd#xfor_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6abe1d85-db1d-468d-b990-5bd67470c7d7" xlink:to="loc_xfor_RedeemableCommonStockMember_7a87b4a8-b9fb-4d95-8ab0-0c16c3ba27bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6597a27-b46e-4884-8948-62d2c9ba5feb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:to="loc_srt_RangeAxis_f6597a27-b46e-4884-8948-62d2c9ba5feb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6597a27-b46e-4884-8948-62d2c9ba5feb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f6597a27-b46e-4884-8948-62d2c9ba5feb" xlink:to="loc_srt_RangeMember_f6597a27-b46e-4884-8948-62d2c9ba5feb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1f04ab2-a478-4d79-9714-0eb6fab0b148" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f6597a27-b46e-4884-8948-62d2c9ba5feb" xlink:to="loc_srt_RangeMember_b1f04ab2-a478-4d79-9714-0eb6fab0b148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88ad9525-7221-438c-831d-a917096aff90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b1f04ab2-a478-4d79-9714-0eb6fab0b148" xlink:to="loc_srt_MinimumMember_88ad9525-7221-438c-831d-a917096aff90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1345f4af-579c-4023-b079-e3c841ee1ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1345f4af-579c-4023-b079-e3c841ee1ade" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1345f4af-579c-4023-b079-e3c841ee1ade_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1345f4af-579c-4023-b079-e3c841ee1ade" xlink:to="loc_us-gaap_EquityComponentDomain_1345f4af-579c-4023-b079-e3c841ee1ade_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62fc1c7a-305a-4f7b-8ce5-080b0c16943b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1345f4af-579c-4023-b079-e3c841ee1ade" xlink:to="loc_us-gaap_EquityComponentDomain_62fc1c7a-305a-4f7b-8ce5-080b0c16943b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_3a6e964d-55e9-4bfc-ba08-6cfe135323a0" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62fc1c7a-305a-4f7b-8ce5-080b0c16943b" xlink:to="loc_xfor_PreFundedWarrantMember_3a6e964d-55e9-4bfc-ba08-6cfe135323a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended" id="i92b5247eaced4d9ba9a3a16e61d07167_NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cb389a5-b4ab-4d55-8e2f-b7a09d51290e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cac0585f-470a-4dc6-83c4-8242863d8b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cb389a5-b4ab-4d55-8e2f-b7a09d51290e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cac0585f-470a-4dc6-83c4-8242863d8b75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e5bfcb3-dc3b-46f1-9af2-f9750c553d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cb389a5-b4ab-4d55-8e2f-b7a09d51290e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e5bfcb3-dc3b-46f1-9af2-f9750c553d79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_964ca125-ba25-4583-8b70-a4ae22293ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e5bfcb3-dc3b-46f1-9af2-f9750c553d79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_964ca125-ba25-4583-8b70-a4ae22293ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_964ca125-ba25-4583-8b70-a4ae22293ca1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_964ca125-ba25-4583-8b70-a4ae22293ca1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_964ca125-ba25-4583-8b70-a4ae22293ca1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_59e47ba2-d685-4fd3-8886-a458743fd356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_964ca125-ba25-4583-8b70-a4ae22293ca1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_59e47ba2-d685-4fd3-8886-a458743fd356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b33e65a4-7c74-4734-85f2-245e5cc5377a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_59e47ba2-d685-4fd3-8886-a458743fd356" xlink:to="loc_us-gaap_WarrantMember_b33e65a4-7c74-4734-85f2-245e5cc5377a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_26eff808-c137-49fe-9aab-060a61338525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_59e47ba2-d685-4fd3-8886-a458743fd356" xlink:to="loc_us-gaap_StockOptionMember_26eff808-c137-49fe-9aab-060a61338525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2a6a3e9a-c7d1-4b10-81b5-f2e9370b4c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_59e47ba2-d685-4fd3-8886-a458743fd356" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2a6a3e9a-c7d1-4b10-81b5-f2e9370b4c30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_877a66a6-b88f-4a1d-a2fa-ae18de678ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e5bfcb3-dc3b-46f1-9af2-f9750c553d79" xlink:to="loc_us-gaap_StatementClassOfStockAxis_877a66a6-b88f-4a1d-a2fa-ae18de678ba4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_877a66a6-b88f-4a1d-a2fa-ae18de678ba4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_877a66a6-b88f-4a1d-a2fa-ae18de678ba4" xlink:to="loc_us-gaap_ClassOfStockDomain_877a66a6-b88f-4a1d-a2fa-ae18de678ba4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_05da73db-62cd-403b-9af8-b484b183461d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_877a66a6-b88f-4a1d-a2fa-ae18de678ba4" xlink:to="loc_us-gaap_ClassOfStockDomain_05da73db-62cd-403b-9af8-b484b183461d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_e2e64202-2c9e-46f3-a4d0-bf9b058c7fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_05da73db-62cd-403b-9af8-b484b183461d" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_e2e64202-2c9e-46f3-a4d0-bf9b058c7fed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LossonTransferofNonfinancialAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails" xlink:type="extended" id="i486bae9b20eb458cb5b199420e5f748f_LossonTransferofNonfinancialAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_02745214-4fc2-4148-8ddd-bcec8ecd9e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_b39fb94e-e669-40a5-bcf6-72aa96b86899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_02745214-4fc2-4148-8ddd-bcec8ecd9e72" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_b39fb94e-e669-40a5-bcf6-72aa96b86899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8d376254-a88a-4e50-ab8a-e362249ec04c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_02745214-4fc2-4148-8ddd-bcec8ecd9e72" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8d376254-a88a-4e50-ab8a-e362249ec04c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_07e2cddb-4eb9-4b1c-b058-7229375fba4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_02745214-4fc2-4148-8ddd-bcec8ecd9e72" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_07e2cddb-4eb9-4b1c-b058-7229375fba4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9509f877-5869-4cb2-81ba-1be9f37b2e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_02745214-4fc2-4148-8ddd-bcec8ecd9e72" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9509f877-5869-4cb2-81ba-1be9f37b2e73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92a50dc2-a432-4419-992d-54ac5d98d772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9509f877-5869-4cb2-81ba-1be9f37b2e73" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92a50dc2-a432-4419-992d-54ac5d98d772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_92a50dc2-a432-4419-992d-54ac5d98d772_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92a50dc2-a432-4419-992d-54ac5d98d772" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_92a50dc2-a432-4419-992d-54ac5d98d772_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c329025f-447c-4f86-92be-b95487687d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92a50dc2-a432-4419-992d-54ac5d98d772" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c329025f-447c-4f86-92be-b95487687d15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_40f4eaaf-2e33-465e-aafa-3410cd850c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c329025f-447c-4f86-92be-b95487687d15" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_40f4eaaf-2e33-465e-aafa-3410cd850c82" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/SubsequentEventsDetails" xlink:type="extended" id="ie6e6fbcb557740ea8fe1ac42cf51ad0e_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_234cc4bc-e0f9-4345-87d8-41a9d89177a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_234cc4bc-e0f9-4345-87d8-41a9d89177a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockPurchaseAgreementTerm_a9910be5-8a8b-4e2f-8b41-51efe9147c94" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockPurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_SaleOfStockPurchaseAgreementTerm_a9910be5-8a8b-4e2f-8b41-51efe9147c94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockPurchaseAgreementSharesIssued_32e71cc8-6295-4546-9540-8dc4711ef6b9" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockPurchaseAgreementSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_SaleOfStockPurchaseAgreementSharesIssued_32e71cc8-6295-4546-9540-8dc4711ef6b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PurchaseAgreementSharesPurchased_4d123918-841e-4f16-bf38-472a02b15fef" xlink:href="xfor-20211231.xsd#xfor_PurchaseAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_PurchaseAgreementSharesPurchased_4d123918-841e-4f16-bf38-472a02b15fef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_5b4742e8-6e62-41ce-9e9b-dfaf31094449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_5b4742e8-6e62-41ce-9e9b-dfaf31094449" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell_912fd7d9-58fe-4e00-ae25-a629e4fa4b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell_912fd7d9-58fe-4e00-ae25-a629e4fa4b03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c068fd6a-e0e0-4e18-a1be-9e5441eaadb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c068fd6a-e0e0-4e18-a1be-9e5441eaadb0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo_8cb660c2-daa5-45d9-a517-cdd6c1befc19" xlink:href="xfor-20211231.xsd#xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo_8cb660c2-daa5-45d9-a517-cdd6c1befc19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_0f6e0115-e197-4a9f-95cb-9dbbc2f2f235" xlink:href="xfor-20211231.xsd#xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_0f6e0115-e197-4a9f-95cb-9dbbc2f2f235" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequired_78097679-3f59-48be-ae63-d1faa673fabf" xlink:href="xfor-20211231.xsd#xfor_DebtInstrumentDebtCovenantMinimumCashRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequired_78097679-3f59-48be-ae63-d1faa673fabf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario_ee333155-7ee7-4645-8901-27123a210661" xlink:href="xfor-20211231.xsd#xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario_ee333155-7ee7-4645-8901-27123a210661" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26bc83fa-1879-4df1-92c6-a07db2c2cf0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26bc83fa-1879-4df1-92c6-a07db2c2cf0a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f1d779a5-fddc-4ba2-b51b-73a0e1b35cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f1d779a5-fddc-4ba2-b51b-73a0e1b35cce" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85b1b338-05b5-4202-b915-1853684ac613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_85b1b338-05b5-4202-b915-1853684ac613" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_56c6c9d5-5d99-43b5-b75b-cb4e1ba220c8" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_56c6c9d5-5d99-43b5-b75b-cb4e1ba220c8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_be0adf43-e799-418e-b83e-59efce34c78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_be0adf43-e799-418e-b83e-59efce34c78e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ca4eb6d7-1101-4d95-83f2-d516de560f1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_srt_CounterpartyNameAxis_ca4eb6d7-1101-4d95-83f2-d516de560f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca4eb6d7-1101-4d95-83f2-d516de560f1a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ca4eb6d7-1101-4d95-83f2-d516de560f1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca4eb6d7-1101-4d95-83f2-d516de560f1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e6ce82d-b1ff-45b3-9c32-01990e98d88d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ca4eb6d7-1101-4d95-83f2-d516de560f1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e6ce82d-b1ff-45b3-9c32-01990e98d88d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AspireCapitalFundLLCMember_9997b5d0-1b69-47dd-a4d5-25211cb4da86" xlink:href="xfor-20211231.xsd#xfor_AspireCapitalFundLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e6ce82d-b1ff-45b3-9c32-01990e98d88d" xlink:to="loc_xfor_AspireCapitalFundLLCMember_9997b5d0-1b69-47dd-a4d5-25211cb4da86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LincolnParkCapitalFundLLCMember_b06c5be9-2d88-439a-9f21-716be19ed42f" xlink:href="xfor-20211231.xsd#xfor_LincolnParkCapitalFundLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e6ce82d-b1ff-45b3-9c32-01990e98d88d" xlink:to="loc_xfor_LincolnParkCapitalFundLLCMember_b06c5be9-2d88-439a-9f21-716be19ed42f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e07ebe9f-2189-4338-be10-5c1a6c7219f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e07ebe9f-2189-4338-be10-5c1a6c7219f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e07ebe9f-2189-4338-be10-5c1a6c7219f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e07ebe9f-2189-4338-be10-5c1a6c7219f3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e07ebe9f-2189-4338-be10-5c1a6c7219f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_85b7f5f2-40b9-4fa8-8c59-e1509468b883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e07ebe9f-2189-4338-be10-5c1a6c7219f3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_85b7f5f2-40b9-4fa8-8c59-e1509468b883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bf6dddc4-2b34-4b02-a7b6-12f26ad4ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_85b7f5f2-40b9-4fa8-8c59-e1509468b883" xlink:to="loc_us-gaap_SubsequentEventMember_bf6dddc4-2b34-4b02-a7b6-12f26ad4ccba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406e1d3d-32a1-429f-8336-14c84fd76594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406e1d3d-32a1-429f-8336-14c84fd76594" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_406e1d3d-32a1-429f-8336-14c84fd76594_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406e1d3d-32a1-429f-8336-14c84fd76594" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_406e1d3d-32a1-429f-8336-14c84fd76594_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_34a82731-510a-4ec8-845c-589b6e2340b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406e1d3d-32a1-429f-8336-14c84fd76594" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_34a82731-510a-4ec8-845c-589b6e2340b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember_66b82f72-b268-42dc-9c75-19abcbda1ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_34a82731-510a-4ec8-845c-589b6e2340b5" xlink:to="loc_us-gaap_EquityUnitPurchaseAgreementsMember_66b82f72-b268-42dc-9c75-19abcbda1ee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_eaab0e98-c6a9-4e6d-a05e-15937aa09be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_eaab0e98-c6a9-4e6d-a05e-15937aa09be9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_eaab0e98-c6a9-4e6d-a05e-15937aa09be9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_eaab0e98-c6a9-4e6d-a05e-15937aa09be9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_eaab0e98-c6a9-4e6d-a05e-15937aa09be9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2806d8b7-354a-478d-bf3e-ba6f9a24318e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_eaab0e98-c6a9-4e6d-a05e-15937aa09be9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2806d8b7-354a-478d-bf3e-ba6f9a24318e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_b0838d15-6e48-4d46-a202-0203f482dc6c" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2806d8b7-354a-478d-bf3e-ba6f9a24318e" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_b0838d15-6e48-4d46-a202-0203f482dc6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_Q12022PIPEMember_c825d7a6-8778-42b2-93da-7e6619c1bfea" xlink:href="xfor-20211231.xsd#xfor_Q12022PIPEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2806d8b7-354a-478d-bf3e-ba6f9a24318e" xlink:to="loc_xfor_Q12022PIPEMember_c825d7a6-8778-42b2-93da-7e6619c1bfea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dbc2c2af-5517-4216-892c-5cd3561ac1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_DebtInstrumentAxis_dbc2c2af-5517-4216-892c-5cd3561ac1e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dbc2c2af-5517-4216-892c-5cd3561ac1e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_dbc2c2af-5517-4216-892c-5cd3561ac1e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dbc2c2af-5517-4216-892c-5cd3561ac1e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9c914a5f-3e1f-47c6-b92a-67209fe9782c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_dbc2c2af-5517-4216-892c-5cd3561ac1e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9c914a5f-3e1f-47c6-b92a-67209fe9782c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember_3c099fff-8e71-45dc-9d81-6f277aa66228" xlink:href="xfor-20211231.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9c914a5f-3e1f-47c6-b92a-67209fe9782c" xlink:to="loc_xfor_HerculesLoanAgreementMember_3c099fff-8e71-45dc-9d81-6f277aa66228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1600a8c5-a0eb-45b5-82e0-e5854d269568" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_srt_StatementScenarioAxis_1600a8c5-a0eb-45b5-82e0-e5854d269568" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1600a8c5-a0eb-45b5-82e0-e5854d269568_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1600a8c5-a0eb-45b5-82e0-e5854d269568" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1600a8c5-a0eb-45b5-82e0-e5854d269568_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_eaf066c2-0bd9-48fb-9d32-a81a1c182b5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1600a8c5-a0eb-45b5-82e0-e5854d269568" xlink:to="loc_srt_ScenarioUnspecifiedDomain_eaf066c2-0bd9-48fb-9d32-a81a1c182b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4f8cd39b-05d2-48cc-a572-961c126cb522" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_eaf066c2-0bd9-48fb-9d32-a81a1c182b5c" xlink:to="loc_srt_ScenarioForecastMember_4f8cd39b-05d2-48cc-a572-961c126cb522" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a709e0b-d0b5-4a27-b412-f17234b0ef90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a709e0b-d0b5-4a27-b412-f17234b0ef90" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a709e0b-d0b5-4a27-b412-f17234b0ef90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a709e0b-d0b5-4a27-b412-f17234b0ef90" xlink:to="loc_us-gaap_EquityComponentDomain_6a709e0b-d0b5-4a27-b412-f17234b0ef90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2698ddc3-0036-4f21-8907-6f5d2514d488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a709e0b-d0b5-4a27-b412-f17234b0ef90" xlink:to="loc_us-gaap_EquityComponentDomain_2698ddc3-0036-4f21-8907-6f5d2514d488" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_c7f03b84-eb4e-4017-9620-282eeb5c4af0" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2698ddc3-0036-4f21-8907-6f5d2514d488" xlink:to="loc_xfor_PreFundedWarrantMember_c7f03b84-eb4e-4017-9620-282eeb5c4af0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>xfor-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:97cd003e-9c40-40fd-8096-f110f9c5294b,g:4b68d2f2-b861-47a0-89c8-6e5f887cc91d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_889f2f43-04ce-4709-868d-d7585fbe22e0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LongTermDebtIncludingAccretion_c44c87a2-504f-42a6-b87d-0f99206ad55d_totalLabel_en-US" xlink:label="lab_xfor_LongTermDebtIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Accretion</link:label>
    <link:label id="lab_xfor_LongTermDebtIncludingAccretion_label_en-US" xlink:label="lab_xfor_LongTermDebtIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Accretion</link:label>
    <link:label id="lab_xfor_LongTermDebtIncludingAccretion_documentation_en-US" xlink:label="lab_xfor_LongTermDebtIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Accretion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtIncludingAccretion" xlink:href="xfor-20211231.xsd#xfor_LongTermDebtIncludingAccretion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LongTermDebtIncludingAccretion" xlink:to="lab_xfor_LongTermDebtIncludingAccretion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_86394573-c0d0-44b1-920d-d34b0ccc4670_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_be1878a0-b3a1-4ec5-9aca-385dd8ce810b_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_d415838d-89d3-4261-ba4b-cf3a5458400a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e9e327e3-4fd1-485c-867e-bc2964f9a034_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e4353794-fc7b-4012-a06f-70556bfc8b78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_d3af0536-b704-4996-8e94-6a21ea03d05a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_490ccf3a-1064-481d-a336-a4d7dc4ee4c2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_59fe908a-8036-4e81-bd1f-1939b1ad05e3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b90a3d98-bf8a-461c-9682-7fef4870444d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IntangibleAssetsPolicyPolicyTextBlock_b3246e09-8a89-403b-af8f-3cb424d742c7_terseLabel_en-US" xlink:label="lab_xfor_IntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_xfor_IntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_xfor_IntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label id="lab_xfor_IntangibleAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_xfor_IntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IntangibleAssetsPolicyPolicyTextBlock" xlink:href="xfor-20211231.xsd#xfor_IntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_xfor_IntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d4567356-3df9-4bb9-9942-6467d12b4d0f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_667b36f5-12ac-4580-9985-d984d98e665b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9187e162-e4fb-43cc-8772-1a999bc15698_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f2118527-ab9e-47c6-9191-0cd4a8f7bfe3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1bad8af0-304e-4750-98c8-6bceeea3488d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AccruedExpensesTextBlock_1fe2408d-a817-469a-a0d9-77aae9a7556b_terseLabel_en-US" xlink:label="lab_xfor_AccruedExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_xfor_AccruedExpensesTextBlock_label_en-US" xlink:label="lab_xfor_AccruedExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses [Text Block]</link:label>
    <link:label id="lab_xfor_AccruedExpensesTextBlock_documentation_en-US" xlink:label="lab_xfor_AccruedExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExpensesTextBlock" xlink:href="xfor-20211231.xsd#xfor_AccruedExpensesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AccruedExpensesTextBlock" xlink:to="lab_xfor_AccruedExpensesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CommonStockRepurchasePricePerShare_196ecd00-fcb0-4547-9543-b209c22add8e_terseLabel_en-US" xlink:label="lab_xfor_CommonStockRepurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_xfor_CommonStockRepurchasePricePerShare_label_en-US" xlink:label="lab_xfor_CommonStockRepurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Repurchase Price Per Share</link:label>
    <link:label id="lab_xfor_CommonStockRepurchasePricePerShare_documentation_en-US" xlink:label="lab_xfor_CommonStockRepurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Repurchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CommonStockRepurchasePricePerShare" xlink:href="xfor-20211231.xsd#xfor_CommonStockRepurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CommonStockRepurchasePricePerShare" xlink:to="lab_xfor_CommonStockRepurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_5bb601e1-0108-4bda-9c50-8ecc614678f3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_d449e59f-5609-47a3-994e-06bafa07d004_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MilestoneContractTerminationPeriod_d68d50d4-73bb-476e-a8cf-e0a3034aa679_terseLabel_en-US" xlink:label="lab_xfor_MilestoneContractTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_xfor_MilestoneContractTerminationPeriod_label_en-US" xlink:label="lab_xfor_MilestoneContractTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Contract, Termination Period</link:label>
    <link:label id="lab_xfor_MilestoneContractTerminationPeriod_documentation_en-US" xlink:label="lab_xfor_MilestoneContractTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Contract, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestoneContractTerminationPeriod" xlink:href="xfor-20211231.xsd#xfor_MilestoneContractTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MilestoneContractTerminationPeriod" xlink:to="lab_xfor_MilestoneContractTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_89d81dca-de22-440a-9aa8-91cfc8095c73_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fa992aae-b618-44a7-a730-a035079421d4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_838b8700-8cc0-40ed-9100-42f16e177dd6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_f48f8fae-066d-4040-823b-02522940a6b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0ca0be2-e409-4fea-9170-8073e79b77b6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b11ad713-5ef5-4725-b179-d6abe3acdff1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term&#8212;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e209b296-deaa-4e5b-b840-e2912a99f00c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency and Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_605b7f36-d892-40f2-a08e-6eb3bdd0ebd3_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, convertible preferred stock (in share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_acc394bf-5bf1-4247-8f48-959cde74821b_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_801d8315-4990-4ba5-af99-822cde31204c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8456d6f-4921-4102-b2f2-7244b78a3471_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_6ec78a95-e1e8-4b8c-8af4-40ed50133467_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_BusinessCombinationShareExchangeRatio_271dc589-d0cc-4939-b992-44954a605bea_terseLabel_en-US" xlink:label="lab_xfor_BusinessCombinationShareExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange ratio</link:label>
    <link:label id="lab_xfor_BusinessCombinationShareExchangeRatio_label_en-US" xlink:label="lab_xfor_BusinessCombinationShareExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Share Exchange Ratio</link:label>
    <link:label id="lab_xfor_BusinessCombinationShareExchangeRatio_documentation_en-US" xlink:label="lab_xfor_BusinessCombinationShareExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Share Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_BusinessCombinationShareExchangeRatio" xlink:href="xfor-20211231.xsd#xfor_BusinessCombinationShareExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_BusinessCombinationShareExchangeRatio" xlink:to="lab_xfor_BusinessCombinationShareExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_d797697a-2d0f-453e-b535-90d7693dfcc7_terseLabel_en-US" xlink:label="lab_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment Useful Life</link:label>
    <link:label id="lab_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_label_en-US" xlink:label="lab_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Useful Life [Table Text Block]</link:label>
    <link:label id="lab_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_documentation_en-US" xlink:label="lab_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:href="xfor-20211231.xsd#xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="lab_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_dbb39296-d921-431d-961d-090cfe5c9fd0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under loan and security agreements, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_db430393-d010-4613-9519-85fc135debf0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_933c7a3d-bc35-436b-aa63-e06dea1f81e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_992da525-44de-4afb-b02b-0f47ad19bcfe_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c6e60089-ba7f-4050-9056-712183f113fe_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_FairValueOfNetAssetsAcquiredInReverseMerger_34038d02-b265-476d-a9b8-5a9ca51774f0_terseLabel_en-US" xlink:label="lab_xfor_FairValueOfNetAssetsAcquiredInReverseMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of net assets acquired in the Merger in exchange for common shares, excluding cash acquired</link:label>
    <link:label id="lab_xfor_FairValueOfNetAssetsAcquiredInReverseMerger_label_en-US" xlink:label="lab_xfor_FairValueOfNetAssetsAcquiredInReverseMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Net Assets Acquired In Reverse Merger</link:label>
    <link:label id="lab_xfor_FairValueOfNetAssetsAcquiredInReverseMerger_documentation_en-US" xlink:label="lab_xfor_FairValueOfNetAssetsAcquiredInReverseMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Net Assets Acquired In Reverse Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueOfNetAssetsAcquiredInReverseMerger" xlink:href="xfor-20211231.xsd#xfor_FairValueOfNetAssetsAcquiredInReverseMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_FairValueOfNetAssetsAcquiredInReverseMerger" xlink:to="lab_xfor_FairValueOfNetAssetsAcquiredInReverseMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_18be3b30-076f-4598-af9f-e7aa7bd5aa53_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e33e337d-5751-4efe-8983-90e82eaefac8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_065c47f5-f83c-426f-b260-6b1648d7a65d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_fd5467e3-a155-4105-91c1-8258c6f5b493_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f67d9de9-e4d0-4d32-b6ea-cfd07ac25d5c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9dce937c-85e8-4f51-8a02-d29d4ffe8cff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_a0f12cd7-d16d-4eff-a035-1c9015493bfc_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Cost</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_84cd77fa-f978-4225-bd7f-8159c3437f64_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases recorded to income tax provision</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_9ae442bc-4251-454d-90c7-5fbd0fe3ddc4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_487ae802-9824-4dad-ab55-7cada46ef5a6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_cb6356c4-036e-40cb-9a2a-077992535893_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_e987b2e0-8f38-468d-9b63-8957c9dd535e_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October 25, 2016</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October Twenty Five Two Thousand Sixteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October Twenty Five Two Thousand Sixteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:to="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm_c8d11bc5-607a-4059-80d4-396f7a552f7f_terseLabel_en-US" xlink:label="lab_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, amortization term</link:label>
    <link:label id="lab_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm_label_en-US" xlink:label="lab_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Amortization Term</link:label>
    <link:label id="lab_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm_documentation_en-US" xlink:label="lab_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Amortization Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm" xlink:href="xfor-20211231.xsd#xfor_OperatingLeaseRightOfUseAssetAmortizationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm" xlink:to="lab_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LabEquipmentMember_c1f84302-b238-46e4-a7f3-7fd901345560_terseLabel_en-US" xlink:label="lab_xfor_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_xfor_LabEquipmentMember_label_en-US" xlink:label="lab_xfor_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_xfor_LabEquipmentMember_documentation_en-US" xlink:label="lab_xfor_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LabEquipmentMember" xlink:href="xfor-20211231.xsd#xfor_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LabEquipmentMember" xlink:to="lab_xfor_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues_744a58b4-be25-4ffe-9417-3fb325c4aa1a_terseLabel_en-US" xlink:label="lab_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred stock into common stock</link:label>
    <link:label id="lab_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues_label_en-US" xlink:label="lab_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Convertible Preferred Stock To Common Stock Values</link:label>
    <link:label id="lab_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues_documentation_en-US" xlink:label="lab_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Convertible Preferred Stock To Common Stock Values</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues" xlink:href="xfor-20211231.xsd#xfor_ConversionOfConvertiblePreferredStockToCommonStockValues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues" xlink:to="lab_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PurchaseAgreementSharesPurchased_b23ac3ac-4117-4780-9f04-779d7a2c05a8_terseLabel_en-US" xlink:label="lab_xfor_PurchaseAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Shares Purchased</link:label>
    <link:label id="lab_xfor_PurchaseAgreementSharesPurchased_label_en-US" xlink:label="lab_xfor_PurchaseAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Shares Purchased</link:label>
    <link:label id="lab_xfor_PurchaseAgreementSharesPurchased_documentation_en-US" xlink:label="lab_xfor_PurchaseAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PurchaseAgreementSharesPurchased" xlink:href="xfor-20211231.xsd#xfor_PurchaseAgreementSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PurchaseAgreementSharesPurchased" xlink:to="lab_xfor_PurchaseAgreementSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_f7e92087-7b69-4f46-a5f1-ceb306033a3f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c7b52f98-a1a5-4a08-a23d-e82f91c618db_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded form computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5c33c324-f0f4-4b69-a5c3-0ebf0014e1e1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8212;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DebtInstrumentPrePaymentPremiumPercentage_dab7b7f9-8e26-49a8-b774-923fcc9e96b2_terseLabel_en-US" xlink:label="lab_xfor_DebtInstrumentPrePaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment premium percentage</link:label>
    <link:label id="lab_xfor_DebtInstrumentPrePaymentPremiumPercentage_label_en-US" xlink:label="lab_xfor_DebtInstrumentPrePaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Pre Payment Premium Percentage</link:label>
    <link:label id="lab_xfor_DebtInstrumentPrePaymentPremiumPercentage_documentation_en-US" xlink:label="lab_xfor_DebtInstrumentPrePaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Pre Payment Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentPrePaymentPremiumPercentage" xlink:href="xfor-20211231.xsd#xfor_DebtInstrumentPrePaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DebtInstrumentPrePaymentPremiumPercentage" xlink:to="lab_xfor_DebtInstrumentPrePaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5d8f417e-cd9b-4a0f-8b4a-3f93ae1759a2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CambridgeMAOperatingLeaseArrangementMember_a5e65b5e-a90c-4d76-91b4-ad6dcda39bea_terseLabel_en-US" xlink:label="lab_xfor_CambridgeMAOperatingLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit security: Cambridge lease</link:label>
    <link:label id="lab_xfor_CambridgeMAOperatingLeaseArrangementMember_label_en-US" xlink:label="lab_xfor_CambridgeMAOperatingLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge M A Operating Lease Arrangement [Member]</link:label>
    <link:label id="lab_xfor_CambridgeMAOperatingLeaseArrangementMember_documentation_en-US" xlink:label="lab_xfor_CambridgeMAOperatingLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge M A Operating Lease Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CambridgeMAOperatingLeaseArrangementMember" xlink:href="xfor-20211231.xsd#xfor_CambridgeMAOperatingLeaseArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CambridgeMAOperatingLeaseArrangementMember" xlink:to="lab_xfor_CambridgeMAOperatingLeaseArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_ee08c2d7-118e-424b-8acf-f51ae913fe8f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_abc76883-17f4-4fee-a843-a952d1a2f40a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_07764ab5-bad3-4b83-a3ba-b6306359c401_terseLabel_en-US" xlink:label="lab_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash to Cash Flows</link:label>
    <link:label id="lab_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_label_en-US" xlink:label="lab_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash to Cash Flows [Table Text Block]</link:label>
    <link:label id="lab_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_documentation_en-US" xlink:label="lab_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash to Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:href="xfor-20211231.xsd#xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:to="lab_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember_0077522c-320c-411b-b3df-30c58870fcf2_terseLabel_en-US" xlink:label="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan</link:label>
    <link:label id="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:href="xfor-20211231.xsd#xfor_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_af61c264-ed25-4e8c-bbb2-c79e82f95a20_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_881362e0-3a7b-49bc-a577-0928bfaa157d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e42b3d79-89fa-4ae4-a532-5dac78743c5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, restricted stock units granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_766f4fc3-a091-4387-a4ec-4c235527aadd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_e9ab8d17-e8e2-4713-a32d-4bbef6be39bc_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MilestonePayments_e7273fde-d362-4412-86ee-c74bc1b97ee8_terseLabel_en-US" xlink:label="lab_xfor_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_xfor_MilestonePayments_label_en-US" xlink:label="lab_xfor_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_xfor_MilestonePayments_documentation_en-US" xlink:label="lab_xfor_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestonePayments" xlink:href="xfor-20211231.xsd#xfor_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MilestonePayments" xlink:to="lab_xfor_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_49fab154-7977-4b66-8aae-053cf2c9889e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceLineItems" xlink:to="lab_us-gaap_ValuationAllowanceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3b2f67f7-cc73-4c7a-829c-67eaa73503dd_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_420866e2-fbec-43bb-a0ef-d5b600836b81_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04a750ab-c50a-4067-b081-0979c4b3aa62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_34167d41-4af9-4536-9952-bccc9b95c5ca_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_b824dba6-beb9-4eec-a233-5f409acb3d15_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_76343b3d-11f0-40d1-b4a4-debf29987dc3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_c3bcf3f4-2288-47ce-8b0d-75bd829649f8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_af4225b9-47c1-4379-87e3-e042b58616d3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock_8b1ffb0e-5803-47ed-a383-b23339a0eae0_terseLabel_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Programs</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Programs, Policy [Policy Text Block]</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Programs, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock" xlink:href="xfor-20211231.xsd#xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock" xlink:to="lab_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5f2e3696-bca9-410d-82ed-9ca771648c05_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_55591cd4-80c3-494a-8156-9088ac2afa4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1a79ad2f-e1b6-4163-88aa-3de908413944_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4933c9b6-16ed-4dfb-b313-22a913b5e897_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred and Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f4072e3c-6c88-4d01-b402-376940e673be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_53563562-88cc-4d49-8024-a299474883de_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_24383ae0-9bc5-4786-a738-bd2d0f3cec32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CollaborativeArrangementObligationPercentage_b9040126-4996-482a-8455-b0753c0ead10_terseLabel_en-US" xlink:label="lab_xfor_CollaborativeArrangementObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Obligation, Percentage</link:label>
    <link:label id="lab_xfor_CollaborativeArrangementObligationPercentage_label_en-US" xlink:label="lab_xfor_CollaborativeArrangementObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Obligation, Percentage</link:label>
    <link:label id="lab_xfor_CollaborativeArrangementObligationPercentage_documentation_en-US" xlink:label="lab_xfor_CollaborativeArrangementObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeArrangementObligationPercentage" xlink:href="xfor-20211231.xsd#xfor_CollaborativeArrangementObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CollaborativeArrangementObligationPercentage" xlink:to="lab_xfor_CollaborativeArrangementObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9616558c-c079-46c2-b654-ecc3e945e6be_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability_20c7dd22-3d0b-465c-adb1-0699a9b94b57_terseLabel_en-US" xlink:label="lab_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of preferred stock warrant liability</link:label>
    <link:label id="lab_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability_label_en-US" xlink:label="lab_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Fair Value Of Preferred Stock Warrant Liability</link:label>
    <link:label id="lab_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability_documentation_en-US" xlink:label="lab_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Fair Value Of Preferred Stock Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" xlink:href="xfor-20211231.xsd#xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" xlink:to="lab_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12b04cc2-275c-4b51-bc22-d12bce30eea0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f7284614-2f27-4a11-929e-0abdfcd28155_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_de8f6730-a06a-4980-b332-98e641e20d9c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_25d25161-7c18-4f88-a980-280c20b6f17f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5242e308-3628-4437-94d7-990cd0c2eee6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses, other current assets and research and development incentive receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability_d4472b15-a046-46fe-82f8-21aa94cdd0a5_terseLabel_en-US" xlink:label="lab_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of preferred stock warrant and derivative liability</link:label>
    <link:label id="lab_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability_label_en-US" xlink:label="lab_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Convertible Preferred Stock Warrant Liability</link:label>
    <link:label id="lab_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability_documentation_en-US" xlink:label="lab_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Convertible Preferred Stock Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" xlink:href="xfor-20211231.xsd#xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" xlink:to="lab_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LongTermDebtNonCurrentIncludingAccrection_87efed14-e3fa-4230-939b-d3f9bc821ba3_terseLabel_en-US" xlink:label="lab_xfor_LongTermDebtNonCurrentIncludingAccrection" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including accretion, net of discount</link:label>
    <link:label id="lab_xfor_LongTermDebtNonCurrentIncludingAccrection_label_en-US" xlink:label="lab_xfor_LongTermDebtNonCurrentIncludingAccrection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Non Current Including Accrection</link:label>
    <link:label id="lab_xfor_LongTermDebtNonCurrentIncludingAccrection_documentation_en-US" xlink:label="lab_xfor_LongTermDebtNonCurrentIncludingAccrection" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Non Current Including Accrection</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtNonCurrentIncludingAccrection" xlink:href="xfor-20211231.xsd#xfor_LongTermDebtNonCurrentIncludingAccrection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LongTermDebtNonCurrentIncludingAccrection" xlink:to="lab_xfor_LongTermDebtNonCurrentIncludingAccrection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_c530e608-f616-42c1-944c-9feb2e832db8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceTable" xlink:to="lab_us-gaap_ValuationAllowanceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8a74f2ba-5c42-45ed-b237-6b43918c5490_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_28062611-5585-4110-8e06-81b91d844347_negatedLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruing dividends on Series A convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_cefce167-f472-4144-833e-a65e12b81d3b_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruing dividends on Series A convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividends, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDividendsAdjustment" xlink:to="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_74502184-e025-403d-858e-202d5c0edbd8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred shares into common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a298e627-e714-4064-a847-60608f702626_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MilestonePaymentObligation_b9e8e27e-4eb4-4db2-9b1b-bbdd5b441244_terseLabel_en-US" xlink:label="lab_xfor_MilestonePaymentObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment obligation</link:label>
    <link:label id="lab_xfor_MilestonePaymentObligation_label_en-US" xlink:label="lab_xfor_MilestonePaymentObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Obligation</link:label>
    <link:label id="lab_xfor_MilestonePaymentObligation_documentation_en-US" xlink:label="lab_xfor_MilestonePaymentObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestonePaymentObligation" xlink:href="xfor-20211231.xsd#xfor_MilestonePaymentObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MilestonePaymentObligation" xlink:to="lab_xfor_MilestonePaymentObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_0c1a57eb-d6e1-4661-8952-a82e98ab6c19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_6a5a08eb-48c1-41d3-b07a-b3da9d4405e6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_536cbd2a-b751-4fa1-847b-a3c8fb32d470_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:to="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_661139ea-a119-400a-af39-fa4c1702775c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e83be5c4-ca01-4a9c-901e-0511182d53d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_c22d3353-0dd1-490b-be04-7caad422c779_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_03ca2218-9870-4902-9027-e03f5bf0707a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_Q12022PIPEMember_7da2b8d2-103f-44b8-b4e1-c43bcc145aa5_terseLabel_en-US" xlink:label="lab_xfor_Q12022PIPEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Q1 2022 PIPE</link:label>
    <link:label id="lab_xfor_Q12022PIPEMember_label_en-US" xlink:label="lab_xfor_Q12022PIPEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Q1 2022 PIPE [Member]</link:label>
    <link:label id="lab_xfor_Q12022PIPEMember_documentation_en-US" xlink:label="lab_xfor_Q12022PIPEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Q1 2022 PIPE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_Q12022PIPEMember" xlink:href="xfor-20211231.xsd#xfor_Q12022PIPEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_Q12022PIPEMember" xlink:to="lab_xfor_Q12022PIPEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_98fb635a-4a26-4933-8d77-938e1240363a_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_288bab8a-8831-4f47-8b65-181ccc6fcfbf_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0618155c-ad41-4e9e-9431-1cffaee322b7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1a7ff5ed-8b87-45d9-a93c-2f5458c43f92_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MinCashTestDate1Member_a7a03c08-e33e-45a0-b157-a5e865acc619_terseLabel_en-US" xlink:label="lab_xfor_MinCashTestDate1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 1 [Member]</link:label>
    <link:label id="lab_xfor_MinCashTestDate1Member_label_en-US" xlink:label="lab_xfor_MinCashTestDate1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 1 [Member]</link:label>
    <link:label id="lab_xfor_MinCashTestDate1Member_documentation_en-US" xlink:label="lab_xfor_MinCashTestDate1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate1Member" xlink:href="xfor-20211231.xsd#xfor_MinCashTestDate1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MinCashTestDate1Member" xlink:to="lab_xfor_MinCashTestDate1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9aef59dc-8832-48cd-902f-fda351d14ad6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_ba13c92d-1855-4ef0-9dec-cacac5f883df_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_93d3bc40-db0c-4ba7-84a0-c182d93e0587_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash acquired in connection with the Merger</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d571a164-5b33-44a6-981a-0a5b2024011c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cb664183-ad1b-4f33-a103-1a7f30b91a02_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d622751b-038b-45f5-89ce-4eff84fef873_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_320eeef1-4efc-472b-81c5-1ebca1efbdff_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_a7c13c3f-cb0a-40e7-afd9-3b7354eb371c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid_0ac1fa72-fe65-484a-b677-e535262b32f8_terseLabel_en-US" xlink:label="lab_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property, equipment and right-of-use assets included in accounts payable</link:label>
    <link:label id="lab_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid_label_en-US" xlink:label="lab_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures And Intangible Assets Incurred But Not Yet Paid</link:label>
    <link:label id="lab_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures And Intangible Assets Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" xlink:href="xfor-20211231.xsd#xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" xlink:to="lab_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_422ba03c-8892-4fb8-874d-50bb072d6154_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AllstonLeaseMember_58619722-73b1-47ab-8c63-abb2d3f1f7e5_terseLabel_en-US" xlink:label="lab_xfor_AllstonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit security: Boston lease</link:label>
    <link:label id="lab_xfor_AllstonLeaseMember_3352bbcb-0d60-49ff-9b64-6c0fb8d971ce_verboseLabel_en-US" xlink:label="lab_xfor_AllstonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston Lease</link:label>
    <link:label id="lab_xfor_AllstonLeaseMember_label_en-US" xlink:label="lab_xfor_AllstonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease [Member]</link:label>
    <link:label id="lab_xfor_AllstonLeaseMember_documentation_en-US" xlink:label="lab_xfor_AllstonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember" xlink:href="xfor-20211231.xsd#xfor_AllstonLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AllstonLeaseMember" xlink:to="lab_xfor_AllstonLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c4efae45-fa2e-498c-8aca-2e5cc73920bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_eba3ec07-3335-417c-b9a9-9b541eed8461_terseLabel_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space area</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_label_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Office Space</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_documentation_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:href="xfor-20211231.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:to="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0be42157-6ff1-4872-8847-b1b7c7c32fc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_6bc5757a-08dc-4e70-b1b5-cb8934938cf9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ReimbursementRateForResearchAndDevelopment_8e50220b-8f74-4d01-b777-ac1a390fc176_terseLabel_en-US" xlink:label="lab_xfor_ReimbursementRateForResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement rate for research and development</link:label>
    <link:label id="lab_xfor_ReimbursementRateForResearchAndDevelopment_label_en-US" xlink:label="lab_xfor_ReimbursementRateForResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Rate For Research And Development</link:label>
    <link:label id="lab_xfor_ReimbursementRateForResearchAndDevelopment_documentation_en-US" xlink:label="lab_xfor_ReimbursementRateForResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Rate For Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ReimbursementRateForResearchAndDevelopment" xlink:href="xfor-20211231.xsd#xfor_ReimbursementRateForResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ReimbursementRateForResearchAndDevelopment" xlink:to="lab_xfor_ReimbursementRateForResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_aaaab121-36ab-4755-84e6-33f5fa43a37c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DiscretionaryBorrowingsMember_0e630835-c8fe-4318-83d4-07488d1ed5bd_terseLabel_en-US" xlink:label="lab_xfor_DiscretionaryBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary Borrowings [Member]</link:label>
    <link:label id="lab_xfor_DiscretionaryBorrowingsMember_label_en-US" xlink:label="lab_xfor_DiscretionaryBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary Borrowings [Member]</link:label>
    <link:label id="lab_xfor_DiscretionaryBorrowingsMember_documentation_en-US" xlink:label="lab_xfor_DiscretionaryBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DiscretionaryBorrowingsMember" xlink:href="xfor-20211231.xsd#xfor_DiscretionaryBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DiscretionaryBorrowingsMember" xlink:to="lab_xfor_DiscretionaryBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_ade8049c-e54d-46d4-819b-dc383a5d39b5_terseLabel_en-US" xlink:label="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options, warrants and pre-funded warrants an issuance of shares of common stock under employee stock purchase plans</link:label>
    <link:label id="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_label_en-US" xlink:label="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Exercise of Stock Options And Warrants</link:label>
    <link:label id="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_documentation_en-US" xlink:label="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Exercise of Stock Options And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:to="lab_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_HerculesFirstAmendedLoanAgreementMember_1e79c3e8-abdc-460b-aed4-ce3ca296b5df_terseLabel_en-US" xlink:label="lab_xfor_HerculesFirstAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules First Amended Loan Agreement</link:label>
    <link:label id="lab_xfor_HerculesFirstAmendedLoanAgreementMember_label_en-US" xlink:label="lab_xfor_HerculesFirstAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules First Amended Loan Agreement [Member]</link:label>
    <link:label id="lab_xfor_HerculesFirstAmendedLoanAgreementMember_documentation_en-US" xlink:label="lab_xfor_HerculesFirstAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules First Amended Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesFirstAmendedLoanAgreementMember" xlink:href="xfor-20211231.xsd#xfor_HerculesFirstAmendedLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_HerculesFirstAmendedLoanAgreementMember" xlink:to="lab_xfor_HerculesFirstAmendedLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_f8103577-6788-4cd2-b1fd-d90c260d92d5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Cost</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement_681b2ad3-9170-4898-846f-57fdda1be204_terseLabel_en-US" xlink:label="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Office Space Under Lease Agreement</link:label>
    <link:label id="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement_label_en-US" xlink:label="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Office Space Under Lease Agreement</link:label>
    <link:label id="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement_documentation_en-US" xlink:label="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current office space under lease agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:href="xfor-20211231.xsd#xfor_CurrentOfficeSpaceUnderLeaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:to="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_5bc8b498-1009-4223-a91a-e014503c4a7d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ArsanisMember_aafe3836-844b-4116-b498-6b49113a54f7_terseLabel_en-US" xlink:label="lab_xfor_ArsanisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arsanis</link:label>
    <link:label id="lab_xfor_ArsanisMember_label_en-US" xlink:label="lab_xfor_ArsanisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arsanis [Member]</link:label>
    <link:label id="lab_xfor_ArsanisMember_documentation_en-US" xlink:label="lab_xfor_ArsanisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arsanis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ArsanisMember" xlink:href="xfor-20211231.xsd#xfor_ArsanisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ArsanisMember" xlink:to="lab_xfor_ArsanisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_5460ad45-7ca6-4661-94d1-451ee90167fe_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_0d1a4229-cad6-40ef-9a0b-0fab4a3622a3_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_1b80f853-e463-4253-a5a6-268ba84989fd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d7c8e732-188b-425b-ae96-1fad516d90a3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d4b4bcec-667e-4569-9eed-cd44e481c68a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0af3bc7-58a4-483a-9dfd-a7a3c3f926d0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_9148fed1-5bbd-436a-9606-b25fa4bd05da_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_1b813f26-f6c6-43af-8be6-15f70394b75a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7d93ba90-3554-4edd-b25e-b267da33d31b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_78e9064f-6fa9-4d81-8e7d-4b23cec79cd5_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_HerculesSecondAmendedLoanAgreementMember_e3f7f0d4-1693-41ee-bec3-bcfc78f0aadb_terseLabel_en-US" xlink:label="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Second Amended Loan Agreement</link:label>
    <link:label id="lab_xfor_HerculesSecondAmendedLoanAgreementMember_label_en-US" xlink:label="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Second Amended Loan Agreement [Member]</link:label>
    <link:label id="lab_xfor_HerculesSecondAmendedLoanAgreementMember_documentation_en-US" xlink:label="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Second Amended Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:href="xfor-20211231.xsd#xfor_HerculesSecondAmendedLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:to="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_07be9d4b-6701-477d-8a5d-fd7a2be6d9ff_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LincolnParkCapitalFundLLCMember_d78cedc7-0b75-4465-9750-5688becbc169_terseLabel_en-US" xlink:label="lab_xfor_LincolnParkCapitalFundLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Capital Fund, LLC</link:label>
    <link:label id="lab_xfor_LincolnParkCapitalFundLLCMember_label_en-US" xlink:label="lab_xfor_LincolnParkCapitalFundLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
    <link:label id="lab_xfor_LincolnParkCapitalFundLLCMember_documentation_en-US" xlink:label="lab_xfor_LincolnParkCapitalFundLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Capital Fund, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LincolnParkCapitalFundLLCMember" xlink:href="xfor-20211231.xsd#xfor_LincolnParkCapitalFundLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LincolnParkCapitalFundLLCMember" xlink:to="lab_xfor_LincolnParkCapitalFundLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3961c454-48d6-48bf-a821-e836aa32f688_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_74743708-b971-47a5-a59e-b331c65a610a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockValue_733dd0e2-e586-491c-84ed-95dbba85e74a_verboseLabel_en-US" xlink:label="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable common stock into common stock</link:label>
    <link:label id="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockValue_d2204250-8b0d-43ee-94c4-86859fcf2178_terseLabel_en-US" xlink:label="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable common stock into common stock</link:label>
    <link:label id="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockValue_label_en-US" xlink:label="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Redeemable Common Stock To Common Stock Value</link:label>
    <link:label id="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockValue_documentation_en-US" xlink:label="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Redeemable Common Stock To Common Stock Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockValue" xlink:href="xfor-20211231.xsd#xfor_ConversionOfRedeemableCommonStockToCommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockValue" xlink:to="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d8fef952-c0e8-4885-98ca-bc94b9082b69_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_3a047373-c349-4b7a-9eef-a80681aa1469_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_58234c55-dae0-46f7-868c-ee79c3671d81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_2c5ce7f2-2d7e-4bbd-b35f-e98a1b1cab73_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PotentialMilestonePaymentsReceivable_d42911e9-0219-490f-9074-78a523062f28_terseLabel_en-US" xlink:label="lab_xfor_PotentialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments receivable</link:label>
    <link:label id="lab_xfor_PotentialMilestonePaymentsReceivable_label_en-US" xlink:label="lab_xfor_PotentialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments Receivable</link:label>
    <link:label id="lab_xfor_PotentialMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_xfor_PotentialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PotentialMilestonePaymentsReceivable" xlink:href="xfor-20211231.xsd#xfor_PotentialMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PotentialMilestonePaymentsReceivable" xlink:to="lab_xfor_PotentialMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_071a7dee-b68f-4830-b57e-2b35c517f56f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario_52f4b2f6-d1e3-4051-970c-769c1302c443_terseLabel_en-US" xlink:label="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Covenant, Minimum Cash Required, Conditional Scenario</link:label>
    <link:label id="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario_label_en-US" xlink:label="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Covenant, Minimum Cash Required, Conditional Scenario</link:label>
    <link:label id="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario_documentation_en-US" xlink:label="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Covenant, Minimum Cash Required, Conditional Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario" xlink:href="xfor-20211231.xsd#xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario" xlink:to="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_GeorgetownMember_cb4fd040-6d5c-4f73-8361-2b152f6a0a06_terseLabel_en-US" xlink:label="lab_xfor_GeorgetownMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Georgetown</link:label>
    <link:label id="lab_xfor_GeorgetownMember_label_en-US" xlink:label="lab_xfor_GeorgetownMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Georgetown [Member]</link:label>
    <link:label id="lab_xfor_GeorgetownMember_documentation_en-US" xlink:label="lab_xfor_GeorgetownMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Georgetown</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GeorgetownMember" xlink:href="xfor-20211231.xsd#xfor_GeorgetownMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_GeorgetownMember" xlink:to="lab_xfor_GeorgetownMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f7b3fdc6-3c11-409c-b1cf-895d1ca97e20_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d829bd8b-e120-4c2d-bd6b-7128aad9c571_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9f891096-8c0d-44e8-bf83-c46f9ebc37c1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of the Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_3e2497c9-78df-4317-bb3c-1ab6f7f6ce78_terseLabel_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in Thousands)</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:href="xfor-20211231.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_WarrantsRollForward_7e882a13-f4d9-49ab-aca4-1b97ff90043c_terseLabel_en-US" xlink:label="lab_xfor_WarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants</link:label>
    <link:label id="lab_xfor_WarrantsRollForward_label_en-US" xlink:label="lab_xfor_WarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Roll Forward]</link:label>
    <link:label id="lab_xfor_WarrantsRollForward_documentation_en-US" xlink:label="lab_xfor_WarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WarrantsRollForward" xlink:href="xfor-20211231.xsd#xfor_WarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_WarrantsRollForward" xlink:to="lab_xfor_WarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_672e6fe0-0ce9-4ed7-8753-1a7a46b5d2dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9ff2252e-1d12-4abc-9dd7-f634645fbfcc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4b6a95f8-ff9f-4cce-accd-42d36739b3bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_de23ccbd-3199-448b-8641-e425b7fd9694_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightExercised_4a679132-e9d4-4d79-85c1-a05c55433bff_negatedLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightExercised_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightExercised_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightExercised" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightExercised" xlink:to="lab_xfor_ClassOfWarrantOrRightExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_HerculesLoanAgreementMember_37f65e91-3f92-41ea-961c-c29b7a282468_terseLabel_en-US" xlink:label="lab_xfor_HerculesLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Loan Agreement</link:label>
    <link:label id="lab_xfor_HerculesLoanAgreementMember_label_en-US" xlink:label="lab_xfor_HerculesLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Loan Agreement [Member]</link:label>
    <link:label id="lab_xfor_HerculesLoanAgreementMember_documentation_en-US" xlink:label="lab_xfor_HerculesLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember" xlink:href="xfor-20211231.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_HerculesLoanAgreementMember" xlink:to="lab_xfor_HerculesLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_a72879b6-e0bb-4d44-b314-e97448b6526a_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_842d3899-e14c-4832-afe7-9142fafd7b67_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ef2376f7-5a43-43ac-8d73-ad01a8fdafa9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_ac731209-5d24-4110-a3e0-5633cf717b98_terseLabel_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Awards Grant In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Awards Grant In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:href="xfor-20211231.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5b380455-8224-423b-920f-612610c109e9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_661cd910-1c87-41ee-b07c-9c02ebd921f4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_ff31feca-a480-4e9e-842e-68f0de66fe7f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_a204cf98-2385-46c7-b53c-d623c84b5a03_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_40ef85d1-194f-41b8-ab33-0644455fcb53_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_542026ee-e178-4281-99ec-5fb908a17d21_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d15640f9-2ce3-43fd-805d-7c0932171b22_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_fb23a506-aa6b-4302-8e60-dd5fde58d233_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_af35a05d-6951-4169-972f-652bf2646a1c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_488a66fc-b3ef-4c86-92b1-cd61e019a19a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e7cc7b79-3959-4944-b3b2-7a5243bbfbba_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses_3aa9a209-a7cd-4cac-9cef-66715e019859_terseLabel_en-US" xlink:label="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued external research and development expenses</link:label>
    <link:label id="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued External Research And Development Expenses</link:label>
    <link:label id="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued External Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:href="xfor-20211231.xsd#xfor_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:to="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_05afe236-1295-4904-adee-1490739d8439_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveReceivable_4a6c7509-f38d-4e85-b939-d3098a6e696f_terseLabel_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development incentive receivable</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveReceivable_label_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Incentive Receivable</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveReceivable_documentation_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Incentive Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:href="xfor-20211231.xsd#xfor_ResearchAndDevelopmentIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:to="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_caf49df2-4f9b-4e1d-b14b-ebfd462d8407_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3a9a6ac8-e9f1-4154-b97d-01173b49c04a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interest</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_def2abbd-2ba5-4ead-908b-d390c58dc2e7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of common stock in connection with Merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e18ac764-057f-4c81-a1cc-6c1cf81d3141_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_1a3a7158-a476-4481-a6d0-04512db0e85d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_79e356d2-6938-453c-bbe5-879e1f31d2a7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs of convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_bd775386-078a-4a51-b65e-93a869286f3e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock_60128f8a-146e-4f4d-af75-f8d6bda7c85d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Compensating Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensatingBalancesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_df7a444b-b108-4691-92aa-bb9931f5f832_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_91283edb-4acf-4770-ab57-e060e00e7b2d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3fe974d0-ccc4-4bae-af7c-78a7ed51ffe4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_c74c7ad2-cfd3-44ae-8a76-45eeeb9263e1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5285f96d-c8c6-4855-80bd-c27844cc712c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ViennaLeaseArrangementMember_6d772fca-fa43-46f7-a52d-ce580765f165_terseLabel_en-US" xlink:label="lab_xfor_ViennaLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit security: Vienna Austria lease</link:label>
    <link:label id="lab_xfor_ViennaLeaseArrangementMember_5ff314de-91b4-4a7e-862c-b4ca4fd81162_verboseLabel_en-US" xlink:label="lab_xfor_ViennaLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Vienna Lease</link:label>
    <link:label id="lab_xfor_ViennaLeaseArrangementMember_label_en-US" xlink:label="lab_xfor_ViennaLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Lease Arrangement [Member]</link:label>
    <link:label id="lab_xfor_ViennaLeaseArrangementMember_documentation_en-US" xlink:label="lab_xfor_ViennaLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Lease Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseArrangementMember" xlink:href="xfor-20211231.xsd#xfor_ViennaLeaseArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ViennaLeaseArrangementMember" xlink:to="lab_xfor_ViennaLeaseArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8bf53d8a-8beb-405e-a2c4-0cd7f0dc129f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AggregateBaseRent_e877b4ad-daad-4bd8-8460-7bba766f3e15_terseLabel_en-US" xlink:label="lab_xfor_AggregateBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent</link:label>
    <link:label id="lab_xfor_AggregateBaseRent_label_en-US" xlink:label="lab_xfor_AggregateBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Base Rent</link:label>
    <link:label id="lab_xfor_AggregateBaseRent_documentation_en-US" xlink:label="lab_xfor_AggregateBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AggregateBaseRent" xlink:href="xfor-20211231.xsd#xfor_AggregateBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AggregateBaseRent" xlink:to="lab_xfor_AggregateBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_07028826-087e-44bb-81ef-e1c18b6b6a1e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_be3a6d86-bdfb-4ac8-869a-4be8c9178db0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance cost of convertible preferred stock, net of issuance cost (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c91d8e68-8f3c-4eaf-b8d3-6fa120a80c35_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_4e972894-afb6-472e-9570-b37974d7be09_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2b349e54-f4c8-4b58-9614-09563b4b4d23_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2d5260b5-0cdc-4bd6-8092-742a4f297db6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_679f580c-03b8-4557-9992-5dae35e0bb5f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_cd7a41a3-293c-45bb-834f-1b7921a6b18d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_25934dd5-0b8c-48dc-bb75-98fc701147f9_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_00bfa030-06e0-4302-98a1-6a76859df2c9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Amount</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6ff3b804-2549-47d3-9666-5d59c3632b77_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost of stock based awards, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_0fb14886-76f9-4559-bb7e-c3f469ec26f2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8b7448c2-0b56-4e43-9cf3-60c595a3fd60_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_ac1df5fa-4b29-4f39-9854-ec61897e1421_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_b83ed3e2-f61c-48f3-9303-9c80156b1622_terseLabel_en-US" xlink:label="lab_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_label_en-US" xlink:label="lab_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Permanent Differences</link:label>
    <link:label id="lab_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_documentation_en-US" xlink:label="lab_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Permanent Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:href="xfor-20211231.xsd#xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:to="lab_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_03cbd66a-0a2f-46fb-870c-50917fc8fba9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3d0707cc-d5ef-4411-96b4-92a4d1c99e22_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MTSAustriaMember_0f15d580-3712-45b9-a51a-e85db9c4ed3a_terseLabel_en-US" xlink:label="lab_xfor_MTSAustriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">X4 Austria</link:label>
    <link:label id="lab_xfor_MTSAustriaMember_label_en-US" xlink:label="lab_xfor_MTSAustriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTS Austria [Member]</link:label>
    <link:label id="lab_xfor_MTSAustriaMember_documentation_en-US" xlink:label="lab_xfor_MTSAustriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTS Austria</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MTSAustriaMember" xlink:href="xfor-20211231.xsd#xfor_MTSAustriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MTSAustriaMember" xlink:to="lab_xfor_MTSAustriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_3ef367a4-c09a-4cf3-96c1-d34c775cc48b_terseLabel_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced, amount</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_label_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_documentation_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:href="xfor-20211231.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:to="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock_a57daa25-79f7-41e0-95b8-1e1abf948317_terseLabel_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of fair value of common stock</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock_label_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Exercise Price, Maximum Percentage Of Fair Market Value Of Common Stock</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock_documentation_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Exercise Price, Maximum Percentage Of Fair Market Value Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock" xlink:href="xfor-20211231.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock" xlink:to="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember_fd640d09-c38d-4c76-8da5-6c890583cdfd_terseLabel_en-US" xlink:label="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan</link:label>
    <link:label id="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:href="xfor-20211231.xsd#xfor_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_204239f3-7645-4862-9f41-32e7a764f8bb_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On December 28, 2017</link:label>
    <link:label id="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On December Twenty Eight Two Thousand Seventeen One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On December Twenty Eight Two Thousand Seventeen One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:to="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_2760d596-4b43-4749-a7da-f73f212ba231_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 13, 2019</link:label>
    <link:label id="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March Thirteen Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March Thirteen Two Thousand Nineteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:to="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_3cbea06c-7e8a-4631-bdfa-9d382e7c3368_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember_1ff57b17-c6e4-469e-bfed-42f0f9881cd2_terseLabel_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Incentive Program</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember_label_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Incentive Program [Member]</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember_documentation_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Incentive Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:href="xfor-20211231.xsd#xfor_ResearchAndDevelopmentIncentiveProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:to="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_97ecea34-3aec-4db5-90c7-ef6e5a2a53f6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_32900e5e-f459-46af-b8ac-1bd6c1966efc_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_fe919400-c0f6-4ab9-a6cf-42a7e2eae05a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ef7c190e-ebc9-40b9-ae08-ffe59bf9989f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b0762dba-3a36-4dca-88b5-c0f2a358e335_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_47fe9f33-728c-46cd-b5ee-e3e486de8023_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_df68b8d6-b0e4-4cc9-8b76-fc56b7b0081a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_59c4c9ae-7036-48ec-b94a-8e532206e17c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and exercisable warrants to purchase shares preferred stock as of 12/31/2019</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7a6f8dab-5fb2-448d-ad25-739c757839ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and exerciseable, Number of warrants, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid_9e4b00d4-943c-4208-a1b5-e188bbd49f80_terseLabel_en-US" xlink:label="lab_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs not yet paid</link:label>
    <link:label id="lab_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock And Warrant Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock And Warrant Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid" xlink:href="xfor-20211231.xsd#xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c739e4b5-58d8-4a47-9de1-580a42936df9_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_d3aab804-14b8-4d8c-8bf1-f5e76817bf5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_fb17e0c1-7cc3-4071-b4b5-76c638e1741b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_b2bb9847-7838-454a-924f-7dcb5e71d2ff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_NonStatutoryOptionsMember_e9ff9193-996d-483e-8387-94d58b8d93cf_terseLabel_en-US" xlink:label="lab_xfor_NonStatutoryOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Options</link:label>
    <link:label id="lab_xfor_NonStatutoryOptionsMember_label_en-US" xlink:label="lab_xfor_NonStatutoryOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Options [Member]</link:label>
    <link:label id="lab_xfor_NonStatutoryOptionsMember_documentation_en-US" xlink:label="lab_xfor_NonStatutoryOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonStatutoryOptionsMember" xlink:href="xfor-20211231.xsd#xfor_NonStatutoryOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_NonStatutoryOptionsMember" xlink:to="lab_xfor_NonStatutoryOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LesseeOperatingLeaseRentFreePeriod_5c56c58f-b0f8-4685-9f9f-c539ea68b0a3_terseLabel_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseRentFreePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent-free period</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseRentFreePeriod_label_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseRentFreePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent-Free Period</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseRentFreePeriod_documentation_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseRentFreePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent-Free Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseRentFreePeriod" xlink:href="xfor-20211231.xsd#xfor_LesseeOperatingLeaseRentFreePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LesseeOperatingLeaseRentFreePeriod" xlink:to="lab_xfor_LesseeOperatingLeaseRentFreePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_SalesAgentsMember_612d3b7a-3feb-4978-8c6d-4b0026bfabeb_terseLabel_en-US" xlink:label="lab_xfor_SalesAgentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agents [Member]</link:label>
    <link:label id="lab_xfor_SalesAgentsMember_label_en-US" xlink:label="lab_xfor_SalesAgentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agents [Member]</link:label>
    <link:label id="lab_xfor_SalesAgentsMember_documentation_en-US" xlink:label="lab_xfor_SalesAgentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SalesAgentsMember" xlink:href="xfor-20211231.xsd#xfor_SalesAgentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_SalesAgentsMember" xlink:to="lab_xfor_SalesAgentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_15a6eb0f-b134-46e8-b04f-eb5ec886b82f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, equipment and intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72adfb8e-7c15-4320-a93c-53f42c7d97dc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_393c3bb4-7640-4997-89d8-52f88863f53d_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3fef9a09-97ca-4415-bbc8-b5ff3cac55a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3922022c-be6a-441f-a681-828266dd5e9c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_eddd3dba-332a-4290-9e39-9c81e81d34e9_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f4b7f637-6063-4f77-94fb-a01abcdee7da_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_3a2874c0-9b03-4609-bc92-71dc5cfb8e66_terseLabel_en-US" xlink:label="lab_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $11.4 million</link:label>
    <link:label id="lab_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_label_en-US" xlink:label="lab_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock And Warrants Issued During Period Value Common Stock And Warrants</link:label>
    <link:label id="lab_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_documentation_en-US" xlink:label="lab_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock and warrants issued during period value common stock and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:href="xfor-20211231.xsd#xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:to="lab_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_ca8b6edd-1e82-41ff-bf69-69ff8d040b07_terseLabel_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7a02c334-a49a-48c7-a7b7-8473cd1b94f4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPayment_7e9541f1-f659-45d8-a0c2-c41168a56053_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periodic payment</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_0aa7e674-c3a0-45b9-ba37-40db644d1acd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockShares_518df1ff-22f8-4030-b0f4-d21a7f2042ab_terseLabel_en-US" xlink:label="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable common stock into common stock (in shares)</link:label>
    <link:label id="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockShares_label_en-US" xlink:label="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Redeemable Common Stock To Common Stock Shares</link:label>
    <link:label id="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockShares_documentation_en-US" xlink:label="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Redeemable Common Stock To Common Stock Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockShares" xlink:href="xfor-20211231.xsd#xfor_ConversionOfRedeemableCommonStockToCommonStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockShares" xlink:to="lab_xfor_ConversionOfRedeemableCommonStockToCommonStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_bffc2b0a-ec01-4188-9e35-92392a040c11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_b72c5d20-9a19-40ba-9fb3-c51c45627c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_db839e7a-27e8-4cf1-99b2-07b7daf16cba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_13770bea-2014-49e6-b0d7-57ad2d531aa3_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of preferred stock warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_269986ce-6b7d-4573-9a14-40f5a2b3389a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_2aa123d4-3ac8-40b0-8b61-e6a01420b260_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_dca09609-6ce8-4295-a59e-6ac60eaf605c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c3bcc0ee-ebf2-4618-9da5-5de9b02bf55f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign (Austria)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_2ae51d38-129d-48e7-b07c-75cd95f10153_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On April 16, 2019</link:label>
    <link:label id="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On April Sixteen Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On April Sixteen Two Thousand Nineteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:to="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_070bb502-52dd-4732-9bf2-13e8a56ab25c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_97b1ddad-999b-4865-88f7-0c1f51fa061f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b8862dfd-f020-46f4-839a-e9e4cc70e5ae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_c12bf1ee-18a0-40a9-9d27-083ac9eb3952_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration, and Funding Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6149a83f-71f2-498b-81ae-0ab723e74c2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8e4e36b8-458d-47e2-8a8e-95bfedab5ba3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_69fe0a68-47b4-4909-8b85-849bd424d381_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_d97af961-fcd6-457b-af28-b8d55e2550c7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f66ff8c4-4716-406c-a31e-6bf1a0a39f50_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1110e7ef-f218-462f-bdea-d623f35d2aa9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_b2010add-e31a-4943-bce1-096620587126_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2ffc550c-d442-4d81-b087-122b1ceadb93_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5e834a24-72c0-44bf-895a-209f5065a4c8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_a36bac0c-035e-459b-880a-1bcda17b3d5d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_9fbbcb67-8ca8-4c9e-81b1-faf1228ed5b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3bc6b43e-518d-4945-acc3-2278ea01ad3a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_GrantAndIncentiveReceivables_73900635-1901-4576-9cc8-fdac4dfd4c41_terseLabel_en-US" xlink:label="lab_xfor_GrantAndIncentiveReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due under incentive receivable plan</link:label>
    <link:label id="lab_xfor_GrantAndIncentiveReceivables_label_en-US" xlink:label="lab_xfor_GrantAndIncentiveReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant and Incentive Receivables</link:label>
    <link:label id="lab_xfor_GrantAndIncentiveReceivables_documentation_en-US" xlink:label="lab_xfor_GrantAndIncentiveReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant and Incentive Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GrantAndIncentiveReceivables" xlink:href="xfor-20211231.xsd#xfor_GrantAndIncentiveReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_GrantAndIncentiveReceivables" xlink:to="lab_xfor_GrantAndIncentiveReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_80077a43-ae7c-47b1-80bc-80dc4096495b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6dccaeba-e52e-4086-92f4-5913f9ef8a24_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_99c4847e-547f-4d26-9512-9a83b9c6710a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7ba312cf-211d-4123-9e8d-688abca9d80a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_79a55448-02ad-4ccc-9bc0-5e6781d71e09_terseLabel_en-US" xlink:label="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three</link:label>
    <link:label id="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_label_en-US" xlink:label="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three</link:label>
    <link:label id="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_documentation_en-US" xlink:label="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:href="xfor-20211231.xsd#xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:to="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f27a3151-b9f0-481a-9b2d-a68fe1b85566_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1b4fcb2d-7cdf-4817-8696-06fda2648633_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0bd5490c-9dc1-4e2c-b7f7-138f9bb57426_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_84eb6663-0a7d-4b66-82be-92bb82e16c6c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_93b84694-5ebf-44b5-83ed-e24e10ca07ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityUnitPurchaseAgreementsMember_2b568cf5-537c-434e-a8e3-56394d4304d8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Unit Purchase Agreements</link:label>
    <link:label id="lab_us-gaap_EquityUnitPurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Unit Purchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:to="lab_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8b4d117c-b450-47a0-8958-28c97efc396f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2a5bd4e7-87d3-4dfc-b6db-9985e0bb197e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_95605419-d5c5-4ae4-ab70-024b83b32ffa_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9f258c97-bfb8-4a85-809a-fa8f2cfa5a68_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_b55dbaec-6805-4969-8292-de5a57b049d6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_NewViennaLeaseMember_611dcbbf-7c49-44e2-9cde-f62689ed4b74_terseLabel_en-US" xlink:label="lab_xfor_NewViennaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Vienna Lease</link:label>
    <link:label id="lab_xfor_NewViennaLeaseMember_label_en-US" xlink:label="lab_xfor_NewViennaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Vienna Lease [Member]</link:label>
    <link:label id="lab_xfor_NewViennaLeaseMember_documentation_en-US" xlink:label="lab_xfor_NewViennaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Vienna Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NewViennaLeaseMember" xlink:href="xfor-20211231.xsd#xfor_NewViennaLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_NewViennaLeaseMember" xlink:to="lab_xfor_NewViennaLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f0dcfa04-3832-47c8-9abe-ebb579fcdc50_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_68a2f87a-0713-4bb4-87ef-dc622eb2d5b0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e1129dc8-30ea-4635-bd49-a4c99087bfdf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemablePreferredStockMember_e0c47421-ed70-4ded-94fc-895d5cfe9703_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Preferred Stock</link:label>
    <link:label id="lab_us-gaap_RedeemablePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockMember" xlink:to="lab_us-gaap_RedeemablePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnMarch232021Member_106829bf-9d47-4dc8-8a91-079a961f1c3b_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnMarch232021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 23, 2021</link:label>
    <link:label id="lab_xfor_IssuanceOnMarch232021Member_label_en-US" xlink:label="lab_xfor_IssuanceOnMarch232021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 23, 2021 [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnMarch232021Member_documentation_en-US" xlink:label="lab_xfor_IssuanceOnMarch232021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 23, 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnMarch232021Member" xlink:to="lab_xfor_IssuanceOnMarch232021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2c88b0bf-d97e-4fd2-8ed5-e3c67f758dba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c275ea5-6f91-406c-9618-96a8ecc8d997_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_478847cd-40bd-46ed-867c-d81f5bc02be7_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_d0b6a988-6e5c-4e22-80ed-068039cc96d7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from transfer of non-financial assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_86432389-6973-4166-84f0-fea52f790fc9_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Transfer of Nonfinancial Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_0e8adc33-6bff-4400-807b-39506a516822_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_18ccd1db-1f74-48c7-bdbc-b4cd87a5d15d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b28a3485-ea31-40f5-b402-9cc98b1cf94b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_08a93693-fdad-4c73-9704-22e0964f5870_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6086487f-0ca5-4ac0-aac8-5245207473a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_56f4f854-b599-47ac-8358-b46246ef90df_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October 19, 2018</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October Nineteen Two Thousand Eighteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October Nineteen Two Thousand Eighteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:to="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_da7733ab-5fe4-4d2d-afa9-f6a3ce0d1231_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Significant Suppliers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_36690d0a-19ac-47e7-acbe-28dc83bcee04_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5e014fab-dacf-42a2-b150-b6d401fcd50e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_7204f88c-c15b-4ae9-8164-ece612366b7e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b1955d59-2dde-4541-8a90-863fddd409cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7d05cab0-6a71-4054-8867-12fd1e1c35a1_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_ef686d84-c75c-4e97-b0da-4b36e392c252_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_35ec6082-d903-4033-a33b-7939c59f0eb4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_87259f6d-666d-48db-beed-3c929a3b79fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_00824dbc-3787-47b8-acfc-bf2ca4bc1ee9_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:to="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants_2957a308-10bc-4af4-b88e-389870595316_terseLabel_en-US" xlink:label="lab_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred stock warrants into common stock warrants</link:label>
    <link:label id="lab_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants_label_en-US" xlink:label="lab_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrants</link:label>
    <link:label id="lab_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants_documentation_en-US" xlink:label="lab_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" xlink:href="xfor-20211231.xsd#xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" xlink:to="lab_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IncreaseDecreaseInLeaseLiabilities_2ea18317-61a1-410b-949c-ae24478352b1_terseLabel_en-US" xlink:label="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_xfor_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Lease Liabilities</link:label>
    <link:label id="lab_xfor_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:href="xfor-20211231.xsd#xfor_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6498d370-83fe-473e-91a0-1b2947ee7041_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b9477a90-21dd-460b-819e-19d235506127_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6ae24488-a69b-4623-aae0-bc736d2e2a21_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a3fe408d-61d1-4c2d-928d-9dfaaf334122_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2351bb10-f013-4cd1-bff3-aad12b43e788_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised_72bba42d-da64-4d93-9b74-b9af63313b6a_terseLabel_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_xfor_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5a93190e-cf29-4849-9294-225ed317c59e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3ec1f518-1afd-41f1-81b0-c4dbeeaf1c16_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3c2611fc-63cb-404f-a641-f9c599fb0939_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_1b3101cb-49db-4bfa-8167-048dcb285833_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cc65fec0-9774-4ddd-a627-8bd49b4017f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DeferredTaxLiabilityRightOfUseAsset_d180e353-451e-43db-8e97-60af1564cc4d_terseLabel_en-US" xlink:label="lab_xfor_DeferredTaxLiabilityRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_xfor_DeferredTaxLiabilityRightOfUseAsset_label_en-US" xlink:label="lab_xfor_DeferredTaxLiabilityRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Right Of Use Asset</link:label>
    <link:label id="lab_xfor_DeferredTaxLiabilityRightOfUseAsset_documentation_en-US" xlink:label="lab_xfor_DeferredTaxLiabilityRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxLiabilityRightOfUseAsset" xlink:href="xfor-20211231.xsd#xfor_DeferredTaxLiabilityRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DeferredTaxLiabilityRightOfUseAsset" xlink:to="lab_xfor_DeferredTaxLiabilityRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_39cc4956-2cb5-4301-b295-13c9f20a906f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_cc530447-e74f-4f60-a5aa-7813dd19a85c_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c8cfd6e8-ddaa-4b53-bc57-c9613f83fc64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a99a6aed-f165-434c-b29d-f6d5cd1c5605_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DFCIMember_312f8f58-98ed-435b-9b49-8136bd7c50b2_terseLabel_en-US" xlink:label="lab_xfor_DFCIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DFCI</link:label>
    <link:label id="lab_xfor_DFCIMember_label_en-US" xlink:label="lab_xfor_DFCIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DFCI [Member]</link:label>
    <link:label id="lab_xfor_DFCIMember_documentation_en-US" xlink:label="lab_xfor_DFCIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DFCI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DFCIMember" xlink:href="xfor-20211231.xsd#xfor_DFCIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DFCIMember" xlink:to="lab_xfor_DFCIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_52cbdc78-203a-4017-bce7-d74002088f2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d2948389-0353-4a16-9ce7-9bde51fea7f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_bcd6c495-6619-423f-9990-3f693c9a0f34_terseLabel_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of shares of common stock, redeemable common stock, warrants and pre-funded warrants, net of issuance costs</link:label>
    <link:label id="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_label_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Net of Issuance Costs</link:label>
    <link:label id="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:to="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_54dc571b-f279-4e96-997e-18c40ce2890e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6541e370-ecac-4dc0-8e65-e80a06779017_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d4de5654-6945-46e3-a7c7-dd31ceb90799_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_d88fecd0-b22a-4981-b599-7ce3e0a216e4_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c8e8b42e-d4e1-417b-bd5f-34156e2ac5b0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9219404a-52c3-45f3-b881-bb60eb906083_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_31a57c01-99af-41c2-b9d7-7789fd32718c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_465f6524-c177-45bb-ab83-e7ac5a94f063_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_243517f3-7aa3-41fc-a2e7-fdf43bf245a2_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_008ce89c-9f85-47c6-b895-2451d0479c31_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_884c8179-cc1b-4f27-a09c-782a6873ed33_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of replacement equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_2d25ef73-c221-486b-b521-f9e4bcc56196_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November 29, 2019</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Twenty Nine Two Thousand Nineteen One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Twenty Nine Two Thousand Nineteen One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:to="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e13874d1-921a-4cba-a8e7-7c425766d7dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_11154280-6884-428b-9a31-50eb6f5e170b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_e7ce79ef-0989-44cd-a9c9-b0569b0722c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_c520c2c9-051a-45b4-8f9e-505214815cb5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7692d7f5-deb3-41fd-81f1-c288eed71e03_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_a46466af-fa43-49c2-8d56-fa68b2401917_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_f6e9c19a-9baa-41e0-83b3-4a15f77e0b64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_850de51d-8fd8-4618-9602-127660ff4ff9_periodStartLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and exercisable warrants to purchase preferred shares, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_d6493d51-2d24-4bfe-8082-ea72f2381a53_periodEndLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and exercisable, ending balance (in dollars per share)</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Exercise Price</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:to="lab_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_badead99-37fa-435c-9f6f-fe9135479fab_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree_2de88e0c-6cce-47f1-82e6-cbc9d434c798_terseLabel_en-US" xlink:label="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, future expected annual fees, year one through three</link:label>
    <link:label id="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree_label_en-US" xlink:label="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Future Expected Annual Fees, Year One Through Three</link:label>
    <link:label id="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree_documentation_en-US" xlink:label="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Future Expected Annual Fees, Year One Through Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree" xlink:to="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_76e1b616-0872-4e09-a75e-51abaf7985c8_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_9e2e91ce-c997-47af-ab68-37123d1c676c_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_671902dc-463d-4de5-9bea-06a6b5cdfed7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_5db7b8be-9bf1-4dfe-b736-9482ee5644d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2ef8f8d8-529d-4262-9241-76840cb9c299_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e9388513-3fb4-403c-937a-14608131f84d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_eaa1a86a-94d8-4646-81d7-9131f04b1a44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, shares issued in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AuditInformationAbstract_label_en-US" xlink:label="lab_xfor_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_xfor_AuditInformationAbstract_documentation_en-US" xlink:label="lab_xfor_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AuditInformationAbstract" xlink:href="xfor-20211231.xsd#xfor_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AuditInformationAbstract" xlink:to="lab_xfor_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ba1505ae-ee90-427e-bbb6-c35d088a1953_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_0adb7e5f-3e0e-4e19-b5c3-b4a7b72e0511_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_aa1976cb-9063-43ab-b562-fe9b2d00ef38_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_702448d6-ced9-4c20-9bf0-2fd8ff6cdf22_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PrefundedWarrantsAxis_a2bfd9cb-a52e-4840-a025-c5a4b9946fe7_terseLabel_en-US" xlink:label="lab_xfor_PrefundedWarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Axis]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsAxis_label_en-US" xlink:label="lab_xfor_PrefundedWarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Axis]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsAxis_documentation_en-US" xlink:label="lab_xfor_PrefundedWarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis" xlink:href="xfor-20211231.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PrefundedWarrantsAxis" xlink:to="lab_xfor_PrefundedWarrantsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_21bd4481-5190-46c4-935d-38314384a34b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of common stock in connection with Merger (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_96c78b7b-cdb4-4776-8679-c90a479f177c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_adc5b9d9-489a-4438-be33-11a01eae86bc_negatedTerseLabel_en-US" xlink:label="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset, net of non-cash portion</link:label>
    <link:label id="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_label_en-US" xlink:label="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset, Non-cash Potion</link:label>
    <link:label id="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_documentation_en-US" xlink:label="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset, Non-cash Potion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:href="xfor-20211231.xsd#xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:to="lab_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6bce2849-f404-4f80-87d0-d4584d19ccdd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_baf2f373-9e0a-4d65-91ed-830fb03f72b5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_7b69e9e0-b46f-4b05-ade8-5407f03f6394_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_0b80fe93-dd5c-4c91-bed2-9d8218048a83_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_54bd9b8a-2cb3-4627-928e-f0283330263b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense Classification</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_7177d98a-7736-4667-9a93-687399a366d3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f44ca2de-8b86-44b0-90af-ee130d4f6578_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_23dcdf36-424a-4d1f-ae9c-203430881b70_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_BidmcAgreementMember_65a1878d-f645-42b0-91d4-d8c26e54a5a1_terseLabel_en-US" xlink:label="lab_xfor_BidmcAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bidmc Agreement</link:label>
    <link:label id="lab_xfor_BidmcAgreementMember_label_en-US" xlink:label="lab_xfor_BidmcAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bidmc Agreement [Member]</link:label>
    <link:label id="lab_xfor_BidmcAgreementMember_documentation_en-US" xlink:label="lab_xfor_BidmcAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bidmc Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_BidmcAgreementMember" xlink:href="xfor-20211231.xsd#xfor_BidmcAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_BidmcAgreementMember" xlink:to="lab_xfor_BidmcAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity_ad915b11-f251-4a22-ba7c-66e97c6349d8_terseLabel_en-US" xlink:label="lab_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of warrant liability to permanent equity</link:label>
    <link:label id="lab_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity_label_en-US" xlink:label="lab_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Additional Paid In Capital Reclassification Of Warranty Liability To Permanent Equity</link:label>
    <link:label id="lab_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity_documentation_en-US" xlink:label="lab_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Additional Paid In Capital Reclassification Of Warranty Liability To Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity" xlink:href="xfor-20211231.xsd#xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity" xlink:to="lab_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_acc85c96-0904-4a0d-8dd7-74e3fce24add_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_be99f4b0-ae64-475a-bf88-e63f62825954_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fe46b43b-5047-4ff3-bb04-9aa7799ae3bb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_fe6667d2-3f4f-410c-ad23-7e5931ed9fa5_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_fb2078db-3d95-4823-b0a6-cbf90af8a2b0_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_e5f450fb-7002-48b5-a6a0-163bf4703c4b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_0413d555-ad7f-44b5-86f6-4e423864abc8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_ebf0152d-30dc-4755-9e19-d1d9743a91ea_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_181f2a29-7318-4238-baf1-4fd8d8900199_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a43ca1cf-d9d2-4cf5-be12-dee7bfda36c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d10aa26c-be4d-4cd2-a9b3-ab60c8459eec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_bb4d39fa-7e4c-4ec9-933b-58ba5836ff33_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Nine Two Thousand Twenty One</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Nine Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Nine Two Thousand Twenty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:to="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f2b85088-35d6-4ed4-af7b-40ed49365a50_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_649b7470-2e1e-48fb-80f7-1cd900ca5c8f_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_1d4cdf56-be1a-416c-a666-504668f2d600_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9898b0b9-3576-459d-9afe-5c7deedf05a0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bcf5faad-9bea-4e3d-bbfc-33e6871431bc_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Total</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b0224d77-4456-473e-9bea-ee3792a603c4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8467ede0-ca5b-4261-a405-c7467f9ee9a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MilestonePaymentsPaid_1fa671cc-2702-4b54-94f0-634036c38f40_terseLabel_en-US" xlink:label="lab_xfor_MilestonePaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_xfor_MilestonePaymentsPaid_label_en-US" xlink:label="lab_xfor_MilestonePaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Paid</link:label>
    <link:label id="lab_xfor_MilestonePaymentsPaid_documentation_en-US" xlink:label="lab_xfor_MilestonePaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestonePaymentsPaid" xlink:href="xfor-20211231.xsd#xfor_MilestonePaymentsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MilestonePaymentsPaid" xlink:to="lab_xfor_MilestonePaymentsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_1119e56f-e3d3-4c67-bad5-3183d00e6ae1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_5e012e51-b958-4086-aa29-3916e400560a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_91719b9c-6292-4357-8960-f575e4f205d7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_eb3ed418-7e0d-40e9-a2ab-b44706b155b6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f926bb3a-e98a-49a5-a81c-7f277653a073_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_EmployeeStockPurchasePlansMember_b263ea11-cfbd-4162-a89a-192d10b74017_terseLabel_en-US" xlink:label="lab_xfor_EmployeeStockPurchasePlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plans</link:label>
    <link:label id="lab_xfor_EmployeeStockPurchasePlansMember_label_en-US" xlink:label="lab_xfor_EmployeeStockPurchasePlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plans [Member]</link:label>
    <link:label id="lab_xfor_EmployeeStockPurchasePlansMember_documentation_en-US" xlink:label="lab_xfor_EmployeeStockPurchasePlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_EmployeeStockPurchasePlansMember" xlink:href="xfor-20211231.xsd#xfor_EmployeeStockPurchasePlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_EmployeeStockPurchasePlansMember" xlink:to="lab_xfor_EmployeeStockPurchasePlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_58b5cf04-6861-4d8a-988c-63608caae5f5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_e99533a7-1792-440e-a92e-e4287afe66e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_3e6bb853-59ea-4a4e-8dc4-b5f25a40b0ae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_1eb61cd5-6f60-4096-a26e-a3ad1a820824_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93329c49-1101-48e4-a6e3-c5fe2e10344f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0595deb4-bd2c-4ea1-921d-db36df73ca39_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_bb736882-b5e2-4a05-be48-5d4a238e007c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_486a1c7d-d690-446e-adcf-c76d7dd266cf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_0375d4fe-a0b2-4db2-8b01-adb2e041435a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_5618d9ae-163b-402f-95cd-f17d71569fdd_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On September 12, 2018</link:label>
    <link:label id="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On September Twelve Two Thousand Eighteen One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On September Twelve Two Thousand Eighteen One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:to="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_90dd0a73-a0da-4168-8899-5a4b222bd67b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_0b0274cf-1bed-424a-8801-397729720fab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_26a58d89-5889-4367-af6f-302d42dc0bc8_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_73211ac7-0634-4757-aa84-624ff1d9d729_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b7c756eb-abdf-46ad-91c0-9f849019a987_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_dde88d61-df03-4329-b3bc-3624226277ff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_fe432df5-7d4e-4aee-833a-ca4300e25cd7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a99cba97-72bf-4530-a9cb-ad268e28aafe_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MinCashTestDate2Member_f347a180-6a42-4431-a3e2-55e25a57e477_terseLabel_en-US" xlink:label="lab_xfor_MinCashTestDate2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 2 [Member]</link:label>
    <link:label id="lab_xfor_MinCashTestDate2Member_label_en-US" xlink:label="lab_xfor_MinCashTestDate2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 2 [Member]</link:label>
    <link:label id="lab_xfor_MinCashTestDate2Member_documentation_en-US" xlink:label="lab_xfor_MinCashTestDate2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate2Member" xlink:href="xfor-20211231.xsd#xfor_MinCashTestDate2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MinCashTestDate2Member" xlink:to="lab_xfor_MinCashTestDate2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6de2ad41-357d-4946-8576-f31eb15843ea_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_GenzymeAgreementMember_28bf05b1-888b-4995-9b83-622a635df4ae_terseLabel_en-US" xlink:label="lab_xfor_GenzymeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Agreement</link:label>
    <link:label id="lab_xfor_GenzymeAgreementMember_label_en-US" xlink:label="lab_xfor_GenzymeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Agreement [Member]</link:label>
    <link:label id="lab_xfor_GenzymeAgreementMember_documentation_en-US" xlink:label="lab_xfor_GenzymeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GenzymeAgreementMember" xlink:href="xfor-20211231.xsd#xfor_GenzymeAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_GenzymeAgreementMember" xlink:to="lab_xfor_GenzymeAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock_30ee4f5a-43bd-4226-b9dd-a02e7b6da783_terseLabel_en-US" xlink:label="lab_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Assets and Leases</link:label>
    <link:label id="lab_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock_label_en-US" xlink:label="lab_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right Of Use Asset and Lease Liability, Policy [Policy Text Block]</link:label>
    <link:label id="lab_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right Of Use Asset and Lease Liability, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock" xlink:href="xfor-20211231.xsd#xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock" xlink:to="lab_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_90cb7d50-a60c-4170-803d-9c5216bcaa09_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_4a032a98-ab42-484c-bfcd-cdcd9d012a66_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_a65f20fb-2d92-4524-89aa-989753d3a56f_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_1acf1024-2575-41ed-a718-b8606d621f62_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4002db44-0d2c-4372-b2b8-5f321921b2fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d3b6c58b-93f0-402d-8bb4-13480b2ebd5c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_17cb75d6-59dc-48f1-a322-817f2e434a74_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_0adda8ab-2df3-4a9d-99fd-5b463c725b15_terseLabel_en-US" xlink:label="lab_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $11.5 million (in shares)</link:label>
    <link:label id="lab_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_label_en-US" xlink:label="lab_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock And Warrants Issued During Period Shares Common Stock And Warrants</link:label>
    <link:label id="lab_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_documentation_en-US" xlink:label="lab_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock and warrants issued during period shares common stock and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:href="xfor-20211231.xsd#xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:to="lab_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_NonCashInterestExpense_93086a7f-8f8e-4545-8321-6ae42100316b_terseLabel_en-US" xlink:label="lab_xfor_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount</link:label>
    <link:label id="lab_xfor_NonCashInterestExpense_label_en-US" xlink:label="lab_xfor_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense</link:label>
    <link:label id="lab_xfor_NonCashInterestExpense_documentation_en-US" xlink:label="lab_xfor_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashInterestExpense" xlink:href="xfor-20211231.xsd#xfor_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_NonCashInterestExpense" xlink:to="lab_xfor_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_c2d9a86c-4626-4ab3-8459-dd30114ba852_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ea23699c-b46f-454c-90b3-59c98ecf90ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares based compensation, vested period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fdc5bd9d-65f3-4601-acde-dc3fec707189_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred shares into common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d4181dba-a7e2-4421-b05c-3be748028ea0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_15f577fb-9122-42f9-83ca-3476e4b7315c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesLicenseAgreement_42ccd212-849e-4ac1-8ea4-a40b2f93f232_terseLabel_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for additional consideration (in shares)</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesLicenseAgreement_label_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares License Agreement</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesLicenseAgreement_documentation_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:to="lab_xfor_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f010853d-e615-418e-aac6-e5e04ffc308e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_084c2c23-ae5a-4442-8624-cf2d2811bcef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_3d171c29-4823-4037-bdd5-b6b6bcb7943e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_HerculesAmendedAndRestatedLoanAgreementMember_720aa899-675c-4009-9f17-4bbb72c00084_terseLabel_en-US" xlink:label="lab_xfor_HerculesAmendedAndRestatedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Amended and Restated Loan Agreement</link:label>
    <link:label id="lab_xfor_HerculesAmendedAndRestatedLoanAgreementMember_label_en-US" xlink:label="lab_xfor_HerculesAmendedAndRestatedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Amended And Restated Loan Agreement [Member]</link:label>
    <link:label id="lab_xfor_HerculesAmendedAndRestatedLoanAgreementMember_documentation_en-US" xlink:label="lab_xfor_HerculesAmendedAndRestatedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Amended And Restated Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesAmendedAndRestatedLoanAgreementMember" xlink:href="xfor-20211231.xsd#xfor_HerculesAmendedAndRestatedLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_HerculesAmendedAndRestatedLoanAgreementMember" xlink:to="lab_xfor_HerculesAmendedAndRestatedLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CambridgeLeaseMember_df245c35-dac5-4ff2-af13-351e61490709_terseLabel_en-US" xlink:label="lab_xfor_CambridgeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge Lease</link:label>
    <link:label id="lab_xfor_CambridgeLeaseMember_label_en-US" xlink:label="lab_xfor_CambridgeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge Lease [Member]</link:label>
    <link:label id="lab_xfor_CambridgeLeaseMember_documentation_en-US" xlink:label="lab_xfor_CambridgeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CambridgeLeaseMember" xlink:href="xfor-20211231.xsd#xfor_CambridgeLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CambridgeLeaseMember" xlink:to="lab_xfor_CambridgeLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_52523b58-1302-4be3-bf73-ba033879d3a0_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_d68a8b39-9747-4304-a63c-f455fd3a26a9_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Initial Price Paid Per Share</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Initial Price Paid Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock_393d5ade-84a3-438e-9a77-26ef82c7f391_terseLabel_en-US" xlink:label="lab_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants Table</link:label>
    <link:label id="lab_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock_label_en-US" xlink:label="lab_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Outstanding Warrants Table [Table Text Block]</link:label>
    <link:label id="lab_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock_documentation_en-US" xlink:label="lab_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Outstanding Warrants Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock" xlink:href="xfor-20211231.xsd#xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock" xlink:to="lab_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_7dc5ef96-fa54-4423-836e-998040ea1e51_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_cffb96f7-7fb5-4f8c-aeef-f13493e05375_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_4f22d291-eb99-483e-9210-9035849cc6e7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8a96af7-7426-41ff-ae11-b0b1e118d1ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_027d4c88-2c51-4ed8-a622-b440cef162e1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c808f705-63ff-458c-adcc-0b781b7859d2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5944bada-3625-4ae0-9271-436209e6d239_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_NonCashLeaseExpense_d547b42e-3c19-4cf0-9365-961751a57dd1_terseLabel_en-US" xlink:label="lab_xfor_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_xfor_NonCashLeaseExpense_label_en-US" xlink:label="lab_xfor_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Lease Expense</link:label>
    <link:label id="lab_xfor_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_xfor_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashLeaseExpense" xlink:href="xfor-20211231.xsd#xfor_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_NonCashLeaseExpense" xlink:to="lab_xfor_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0da78401-577e-472b-804f-44d226aa4a70_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward_339583f8-a7d0-4b8d-961e-b0fe99662ac1_terseLabel_en-US" xlink:label="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="xfor-20211231.xsd#xfor_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_xfor_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_892cb19e-fd66-424a-94eb-ed448840e762_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_032f82a4-3187-422d-bafe-f49c30979b42_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_30ddefba-2523-41bb-a554-50ace3611c6a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4cc38744-5cdf-4af7-80ae-cb2d4097d183_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_479acc1b-854c-4a3b-8989-de5e50bf2363_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightIssued_f8e83470-f0e4-4aa1-b9fc-72580d2cae7f_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightIssued_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightIssued_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightIssued" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightIssued" xlink:to="lab_xfor_ClassOfWarrantOrRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e1c9bf84-acdf-44a6-b08c-990bc5982ccf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_22dd7a7d-992b-45fe-8bbd-9e812f4fa65b_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_1a7a0fce-27f4-4ebd-bfbb-429ebf5d7cf2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_6bd3678e-3530-489a-979b-dfe2c48bd8b0_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_99c8aab5-ffc3-49cf-812f-bc7d99034e93_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d1da5aa1-c01b-4d2e-a101-0d09dc47dcf2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_62eca03e-9f9c-4c46-809d-892bc221f69a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassAWarrantMember_c0fb3465-ef7e-4f58-886c-e06359f5a577_terseLabel_en-US" xlink:label="lab_xfor_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant</link:label>
    <link:label id="lab_xfor_ClassAWarrantMember_label_en-US" xlink:label="lab_xfor_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant [Member]</link:label>
    <link:label id="lab_xfor_ClassAWarrantMember_documentation_en-US" xlink:label="lab_xfor_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember" xlink:href="xfor-20211231.xsd#xfor_ClassAWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassAWarrantMember" xlink:to="lab_xfor_ClassAWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2326738e-6253-43bd-8d33-6cdcc4a94a15_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_37758e28-e4a1-4f32-ae86-bffaa5472fec_negatedLabel_en-US" xlink:label="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Repurchase Of Convertible Preferred Stock</link:label>
    <link:label id="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_3f5c0809-73f8-4963-9b3a-7f188c5650ac_negatedTerseLabel_en-US" xlink:label="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Repurchase Of Convertible Preferred Stock</link:label>
    <link:label id="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_91f17ebe-3240-4db8-949e-fef0ed547315_terseLabel_en-US" xlink:label="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend as a result of Class B Warrant price reset</link:label>
    <link:label id="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_label_en-US" xlink:label="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Repurchase Of Convertible Preferred Stock</link:label>
    <link:label id="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_documentation_en-US" xlink:label="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Repurchase Of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:href="xfor-20211231.xsd#xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:to="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_16931c34-219f-4c0f-b9ea-f348d65b0325_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7fe4c0f0-4f35-47d7-bc0c-a818871df671_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e8ddb146-a6d3-47fc-b9f3-0ba524e2f230_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0f645e18-f285-45be-95bd-efbfb988cc37_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_ec024880-3572-4df4-ad34-e5632bf74e74_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_e158cd39-624b-4988-8859-2d4f0911799c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_SaleOfStockPurchaseAgreementTerm_f27b390b-33de-44e8-8f6a-a23457dba889_terseLabel_en-US" xlink:label="lab_xfor_SaleOfStockPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase agreement, term</link:label>
    <link:label id="lab_xfor_SaleOfStockPurchaseAgreementTerm_label_en-US" xlink:label="lab_xfor_SaleOfStockPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Purchase Agreement, Term</link:label>
    <link:label id="lab_xfor_SaleOfStockPurchaseAgreementTerm_documentation_en-US" xlink:label="lab_xfor_SaleOfStockPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockPurchaseAgreementTerm" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockPurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_SaleOfStockPurchaseAgreementTerm" xlink:to="lab_xfor_SaleOfStockPurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_eed9d5f4-5c42-45c5-b7b0-b0ca2bb78dae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_SoftwareMember_0e5a67fa-d6db-459f-8546-7d101f98a580_terseLabel_en-US" xlink:label="lab_xfor_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_xfor_SoftwareMember_label_en-US" xlink:label="lab_xfor_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software [Member]</link:label>
    <link:label id="lab_xfor_SoftwareMember_documentation_en-US" xlink:label="lab_xfor_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SoftwareMember" xlink:href="xfor-20211231.xsd#xfor_SoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_SoftwareMember" xlink:to="lab_xfor_SoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_RedeemableCommonStockMember_bba83906-a410-4d2d-858b-6cfa594575c9_terseLabel_en-US" xlink:label="lab_xfor_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock</link:label>
    <link:label id="lab_xfor_RedeemableCommonStockMember_label_en-US" xlink:label="lab_xfor_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock [Member]</link:label>
    <link:label id="lab_xfor_RedeemableCommonStockMember_documentation_en-US" xlink:label="lab_xfor_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember" xlink:href="xfor-20211231.xsd#xfor_RedeemableCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_RedeemableCommonStockMember" xlink:to="lab_xfor_RedeemableCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_55875889-e2fb-4d45-a409-e27631dae446_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings under loan and security agreement</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d7fbf3c3-c6dd-4d9d-a8b6-a1d959f8dfac_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8c0ea93f-ec11-42eb-be27-a2c48d4f7bd5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DeferredTaxAssetLeaseLiability_045b2dbc-805a-484a-bbcd-c8dccd4fde17_terseLabel_en-US" xlink:label="lab_xfor_DeferredTaxAssetLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_xfor_DeferredTaxAssetLeaseLiability_label_en-US" xlink:label="lab_xfor_DeferredTaxAssetLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Lease Liability</link:label>
    <link:label id="lab_xfor_DeferredTaxAssetLeaseLiability_documentation_en-US" xlink:label="lab_xfor_DeferredTaxAssetLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxAssetLeaseLiability" xlink:href="xfor-20211231.xsd#xfor_DeferredTaxAssetLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DeferredTaxAssetLeaseLiability" xlink:to="lab_xfor_DeferredTaxAssetLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_6518c60e-ab8e-453b-ad3f-5d75a2e87691_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a6fea553-703e-4fce-8c89-3f2a84b6f1ed_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_83d16783-e04f-4f0c-9275-abeb3ef7416b_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_7b534027-a01b-43a3-b79d-0edd43ee0684_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter_e74261a1-42fd-4c0d-a001-8a4baba378a9_terseLabel_en-US" xlink:label="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, future expected annual fees, thereafter</link:label>
    <link:label id="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter_label_en-US" xlink:label="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Future Expected Annual Fees, Thereafter</link:label>
    <link:label id="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter_documentation_en-US" xlink:label="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Future Expected Annual Fees, Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter" xlink:to="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_90c33cb3-3a2e-4166-8fe5-d05b41676270_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_6171b54b-c7e9-476c-b8be-2ef97a20cc10_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_43684246-8d74-4568-8ab2-730434ee91ec_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b40631e-7f60-4190-9c8f-bd2ac4bc25e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b4742bae-3e86-4198-8fee-ede7246c655b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_c96b583a-0156-4567-825c-4431fcab0e3b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_d3abb49d-87a2-48d7-b211-eb48f9ba6234_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5761a553-b8e1-46bf-9011-bf56064075a5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_49923229-7ceb-4201-b396-4fc8f07ae25e_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on transfer of nonfinancial assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_97603373-da25-4b87-b149-522e9a9f72f1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassBWarrantsMember_75bc6099-5bfb-42cd-b07c-90a3dfee423a_terseLabel_en-US" xlink:label="lab_xfor_ClassBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrants</link:label>
    <link:label id="lab_xfor_ClassBWarrantsMember_label_en-US" xlink:label="lab_xfor_ClassBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrants [Member]</link:label>
    <link:label id="lab_xfor_ClassBWarrantsMember_documentation_en-US" xlink:label="lab_xfor_ClassBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassBWarrantsMember" xlink:href="xfor-20211231.xsd#xfor_ClassBWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassBWarrantsMember" xlink:to="lab_xfor_ClassBWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_7cc78716-2d5e-4664-ae03-c3c3f2ea21c5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fd62a29a-5223-4561-bff6-e40358dc3cd3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_ced50bc4-68d0-4f58-ac55-3ddf7096f904_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PrefundedWarrantsDomain_b1da1867-1f81-4db5-a2d0-7ef4ed83ce47_terseLabel_en-US" xlink:label="lab_xfor_PrefundedWarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Domain]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsDomain_label_en-US" xlink:label="lab_xfor_PrefundedWarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Domain]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsDomain_documentation_en-US" xlink:label="lab_xfor_PrefundedWarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain" xlink:href="xfor-20211231.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PrefundedWarrantsDomain" xlink:to="lab_xfor_PrefundedWarrantsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8ec53d26-24f5-48e6-80b7-dfeb743c33dc_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_cd1782d9-de69-41d5-b61f-7533cc05b037_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_4e4296e9-54b9-4b0f-8080-6735f341f5e9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, current (included within prepaid expenses and other current assets)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_ce2a455c-2ade-4efa-8623-b9585e83d9c0_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_21692e50-8e07-4157-969e-5be1b7629d28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_e4015257-2e83-4aae-9fcb-a8f3bec279d2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_a4f7afbf-93f0-41ef-82c4-6b38a78de2af_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0704f36d-55fd-4439-ac4c-425505d39c9a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30ad7ff4-abed-4c45-a9ec-1d1e0f886906_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_598b785b-5aa4-487c-8839-48089be6f0b8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_20c4a82b-d607-45e7-8402-c4907b5969af_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PaymentOnObligationUnderLicenseAgreement_4adedf8b-7800-46b2-8be5-1fdf4a9075a2_terseLabel_en-US" xlink:label="lab_xfor_PaymentOnObligationUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment on obligation under license agreement</link:label>
    <link:label id="lab_xfor_PaymentOnObligationUnderLicenseAgreement_label_en-US" xlink:label="lab_xfor_PaymentOnObligationUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment On Obligation Under License Agreement</link:label>
    <link:label id="lab_xfor_PaymentOnObligationUnderLicenseAgreement_documentation_en-US" xlink:label="lab_xfor_PaymentOnObligationUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment On Obligation Under License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PaymentOnObligationUnderLicenseAgreement" xlink:href="xfor-20211231.xsd#xfor_PaymentOnObligationUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PaymentOnObligationUnderLicenseAgreement" xlink:to="lab_xfor_PaymentOnObligationUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_cd8054e2-a2e9-4e28-a347-d6de4f454771_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CollaborativeAgreementExpenseReimbursement_59f0b967-719e-456b-9710-0ab4fd7c64d2_terseLabel_en-US" xlink:label="lab_xfor_CollaborativeAgreementExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement , Expense Reimbursement</link:label>
    <link:label id="lab_xfor_CollaborativeAgreementExpenseReimbursement_label_en-US" xlink:label="lab_xfor_CollaborativeAgreementExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expense Reimbursement</link:label>
    <link:label id="lab_xfor_CollaborativeAgreementExpenseReimbursement_documentation_en-US" xlink:label="lab_xfor_CollaborativeAgreementExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expense Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementExpenseReimbursement" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementExpenseReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CollaborativeAgreementExpenseReimbursement" xlink:to="lab_xfor_CollaborativeAgreementExpenseReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_90cf5882-3f9d-422b-b352-9d1809b5551c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_31e9919d-b856-43ed-9495-190881c392e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2fc43842-11d4-444e-8dd3-747c21480c0c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ea92ec44-e786-4425-ac42-7158cc166c19_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_a2398a3b-8e97-4a75-a5fb-9bc15cf84dd1_terseLabel_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issuance</link:label>
    <link:label id="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_label_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses</link:label>
    <link:label id="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_documentation_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:to="lab_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fe8d75e9-aa74-4e9e-bbca-1f1b367f4202_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents&#8212;money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_aa989b0f-3c02-4e2d-86c8-321afbbda32e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_db7c84bf-2f10-430f-9f73-563f26858878_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1ba939f3-6680-4a4d-8090-09d793315307_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fd4cc09a-72b5-4165-8aeb-481e751919d3_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_c074fdb1-f94d-4370-92f4-ff648a0d9fbc_terseLabel_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Contractual Term (in Years)</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_label_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Abstract]</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_documentation_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:href="xfor-20211231.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:to="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ea2df04c-50a2-4c94-8109-71450ca3cc65_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequired_448e2f86-c24d-4759-ac5c-6be78e4e2623_terseLabel_en-US" xlink:label="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Covenant, Minimum Cash Required</link:label>
    <link:label id="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequired_label_en-US" xlink:label="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Covenant, Minimum Cash Required</link:label>
    <link:label id="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequired_documentation_en-US" xlink:label="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Covenant, Minimum Cash Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequired" xlink:href="xfor-20211231.xsd#xfor_DebtInstrumentDebtCovenantMinimumCashRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequired" xlink:to="lab_xfor_DebtInstrumentDebtCovenantMinimumCashRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7db795a2-13db-4d8f-91cf-8468468bc51c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_SeriesSeedConvertiblePreferredStockMember_608ccd12-1c79-4e8c-9744-84e531b31f93_terseLabel_en-US" xlink:label="lab_xfor_SeriesSeedConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed Convertible Preferred Stock</link:label>
    <link:label id="lab_xfor_SeriesSeedConvertiblePreferredStockMember_label_en-US" xlink:label="lab_xfor_SeriesSeedConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_xfor_SeriesSeedConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_xfor_SeriesSeedConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SeriesSeedConvertiblePreferredStockMember" xlink:href="xfor-20211231.xsd#xfor_SeriesSeedConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_SeriesSeedConvertiblePreferredStockMember" xlink:to="lab_xfor_SeriesSeedConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f3c02e38-f447-4598-8e8d-5365d3c6c1d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember_6d95a53b-e759-4768-830b-a328ea9cc0de_terseLabel_en-US" xlink:label="lab_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options and Restricted Stock Awards</link:label>
    <link:label id="lab_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember_label_en-US" xlink:label="lab_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options And Restricted Stock Awards [Member]</link:label>
    <link:label id="lab_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember_documentation_en-US" xlink:label="lab_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options And Restricted Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember" xlink:href="xfor-20211231.xsd#xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember" xlink:to="lab_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_87329aea-ba22-405a-b12f-26b2f1e9e58d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1051cc61-5814-4274-8456-067683a43efc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_734ab14d-ee87-4216-b92f-ecca046f0d0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMON STOCK, REDEEMABLE COMMON STOCK AND PREFERRED STOCK</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_FundedMember_ca0b78f6-6b6d-46be-ae19-90a9fcfd7be1_terseLabel_en-US" xlink:label="lab_xfor_FundedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded</link:label>
    <link:label id="lab_xfor_FundedMember_label_en-US" xlink:label="lab_xfor_FundedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded [Member]</link:label>
    <link:label id="lab_xfor_FundedMember_documentation_en-US" xlink:label="lab_xfor_FundedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember" xlink:href="xfor-20211231.xsd#xfor_FundedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_FundedMember" xlink:to="lab_xfor_FundedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AbbiskoAgreementMember_9a8dc087-7173-41c5-be54-45beaec64871_terseLabel_en-US" xlink:label="lab_xfor_AbbiskoAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abbisko Agreement</link:label>
    <link:label id="lab_xfor_AbbiskoAgreementMember_label_en-US" xlink:label="lab_xfor_AbbiskoAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abbisko Agreement [Member]</link:label>
    <link:label id="lab_xfor_AbbiskoAgreementMember_documentation_en-US" xlink:label="lab_xfor_AbbiskoAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abbisko Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AbbiskoAgreementMember" xlink:href="xfor-20211231.xsd#xfor_AbbiskoAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AbbiskoAgreementMember" xlink:to="lab_xfor_AbbiskoAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5760b107-7ace-4bac-957e-cdd8675b8489_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1bbc0875-f6fc-4af3-a312-4235c87c503d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_02f6437f-2013-489c-a90b-64a1cff33f7a_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_84cb4721-52e4-4442-9a33-cfbde17bc13a_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a8f59b7d-8ec5-43c0-be33-302400023dd2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_305847d2-64ca-4c5a-9314-3a834bce3c67_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_f5312609-3624-4c0a-b29b-d3cfcd92f0e1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_e4ce152d-dafa-4bac-b24b-28a9f3d35fa4_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e1f20386-9e88-414d-bddf-4eb715b4e227_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_74b35f1d-bffc-4036-b55e-f017b2641322_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0269bd7e-412a-4eef-be32-8aa3879c766a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f611f87-8e38-4a56-aa30-4fbcf4bb002e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AccretionOnLongTermDebt_16836220-f410-4bd0-a52d-3623283fe042_negatedLabel_en-US" xlink:label="lab_xfor_AccretionOnLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative accrual of end of term payments</link:label>
    <link:label id="lab_xfor_AccretionOnLongTermDebt_label_en-US" xlink:label="lab_xfor_AccretionOnLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion On Long Term Debt</link:label>
    <link:label id="lab_xfor_AccretionOnLongTermDebt_documentation_en-US" xlink:label="lab_xfor_AccretionOnLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion On Long Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccretionOnLongTermDebt" xlink:href="xfor-20211231.xsd#xfor_AccretionOnLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AccretionOnLongTermDebt" xlink:to="lab_xfor_AccretionOnLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31cc045c-58b4-441e-a53a-6031e9ca7ce2_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e207efcc-cbc0-4537-8b4b-6678027cd825_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_b26b3c6a-ce01-4db6-b25f-ce8ac1e4b31d_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of business</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e76eb199-d642-4299-aa75-c4c877fe5cf1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_a405484c-048c-431b-ace9-b592de0372fc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4455e8b2-df4e-4c7e-86b5-e2f31d34e733_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e596230-9074-4673-8e39-c2a60728a16c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d3e4389d-3e8d-4acf-8dde-60e951030b2f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current, Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ca5f6e3f-5e69-4e20-8a11-51597e54e151_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee taxes paid related to net share settlement of vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_8de0f606-cc83-4ad1-b0e5-83d1dca5ce68_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_645f4a34-1425-4d94-93c7-06fccd220793_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligation Incurred</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligation Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_028363c0-38e3-4091-b8c4-836a48d9d177_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9d3b72a5-a72f-43ae-b78e-f4aba6801020_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_OneTimeUpfrontPayment_9a4c8132-c67b-4536-a78b-bf076f89da94_terseLabel_en-US" xlink:label="lab_xfor_OneTimeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One time upfront payment</link:label>
    <link:label id="lab_xfor_OneTimeUpfrontPayment_label_en-US" xlink:label="lab_xfor_OneTimeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Upfront Payment</link:label>
    <link:label id="lab_xfor_OneTimeUpfrontPayment_documentation_en-US" xlink:label="lab_xfor_OneTimeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OneTimeUpfrontPayment" xlink:href="xfor-20211231.xsd#xfor_OneTimeUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_OneTimeUpfrontPayment" xlink:to="lab_xfor_OneTimeUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_f934bd52-3007-4e13-88fa-07f5c93bc7bc_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration period</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Warrants Expiration Period</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Warrants Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:to="lab_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4a5dc4e8-e2eb-49a7-8b0d-92abf36c2d4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_995fe4bb-d6b2-4b59-b4a1-d3a715f48391_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PreFundedWarrantMember_52becb73-b07b-4eb7-98c5-938a04fac962_terseLabel_en-US" xlink:label="lab_xfor_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant</link:label>
    <link:label id="lab_xfor_PreFundedWarrantMember_label_en-US" xlink:label="lab_xfor_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
    <link:label id="lab_xfor_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_xfor_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PreFundedWarrantMember" xlink:to="lab_xfor_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9bd69039-dd4e-4248-bed6-05ca787f7142_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AspireCapitalFundLLCMember_953d4102-69c7-4f2b-a007-50539b5f8fc1_terseLabel_en-US" xlink:label="lab_xfor_AspireCapitalFundLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aspire Capital Fund, LLC</link:label>
    <link:label id="lab_xfor_AspireCapitalFundLLCMember_label_en-US" xlink:label="lab_xfor_AspireCapitalFundLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aspire Capital Fund, LLC [Member]</link:label>
    <link:label id="lab_xfor_AspireCapitalFundLLCMember_documentation_en-US" xlink:label="lab_xfor_AspireCapitalFundLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aspire Capital Fund, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AspireCapitalFundLLCMember" xlink:href="xfor-20211231.xsd#xfor_AspireCapitalFundLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AspireCapitalFundLLCMember" xlink:to="lab_xfor_AspireCapitalFundLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_1ef0dbdd-8d3a-458b-8bcc-661aa37e0f37_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_A2015EquityIncentivePlanMember_64e9204d-2336-4ba7-8cad-6329c5728f9b_terseLabel_en-US" xlink:label="lab_xfor_A2015EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan</link:label>
    <link:label id="lab_xfor_A2015EquityIncentivePlanMember_label_en-US" xlink:label="lab_xfor_A2015EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xfor_A2015EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_xfor_A2015EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_A2015EquityIncentivePlanMember" xlink:href="xfor-20211231.xsd#xfor_A2015EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_A2015EquityIncentivePlanMember" xlink:to="lab_xfor_A2015EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7c428ca6-676b-4834-b64a-1d22a222f851_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_090f1fff-e0d8-4931-b1d8-d891d571953a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LeaseCostAdditionalInformationAbstract_f8a4d3b3-9b42-42cc-bacf-15889f7673f6_terseLabel_en-US" xlink:label="lab_xfor_LeaseCostAdditionalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other information</link:label>
    <link:label id="lab_xfor_LeaseCostAdditionalInformationAbstract_label_en-US" xlink:label="lab_xfor_LeaseCostAdditionalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost, Additional Information [Abstract]</link:label>
    <link:label id="lab_xfor_LeaseCostAdditionalInformationAbstract_documentation_en-US" xlink:label="lab_xfor_LeaseCostAdditionalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost, Additional Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LeaseCostAdditionalInformationAbstract" xlink:href="xfor-20211231.xsd#xfor_LeaseCostAdditionalInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LeaseCostAdditionalInformationAbstract" xlink:to="lab_xfor_LeaseCostAdditionalInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_35f6d673-2de0-4598-9f3a-1353dd8848a3_terseLabel_en-US" xlink:label="lab_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development expenses</link:label>
    <link:label id="lab_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Capitalized Research And Development Costs</link:label>
    <link:label id="lab_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Capitalized Research And Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="xfor-20211231.xsd#xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm_26447046-4e75-472a-a43f-860f3bbb64c0_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Contractual Term (Years)</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Contractual Term</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:to="lab_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_278be325-2867-49ea-9e36-a3feeecfcaa7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightExpired_61d9e8b1-a2e6-4f43-9d4f-8a55a7f2b99b_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightExpired_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Expired</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightExpired_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightExpired" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightExpired" xlink:to="lab_xfor_ClassOfWarrantOrRightExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_df2f7d07-abf2-48e7-a501-e01373927abb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_bf6f7d53-7c34-4675-ba16-4d0b435ab2b8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_23da0833-2afe-4440-a8c7-afbb17d2ce03_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November 29, 2019</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Twenty Nine Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Twenty Nine Two Thousand Nineteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:to="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ea1c02f4-fc76-4dc7-b365-3f34f14ebe8a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost of stock based awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_36716ab8-0058-41e0-822a-89eeb576ccc2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_989439d5-2907-4e32-90b0-4252ccb3b041_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_59960393-6708-4020-a293-dc5716765f62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_45ab963d-ab01-4065-b4ec-16880a881359_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_dc98282e-e7f7-459f-92d8-08af790a7168_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_2b6132d7-6371-455a-9e7a-4ead86b3a361_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_141467ac-c287-41d9-b032-d24e5ded5e57_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo_6951f97c-a48f-47c3-b28a-4ec910a552c9_terseLabel_en-US" xlink:label="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Two</link:label>
    <link:label id="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo_label_en-US" xlink:label="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Two</link:label>
    <link:label id="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo_documentation_en-US" xlink:label="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo" xlink:href="xfor-20211231.xsd#xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo" xlink:to="lab_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_WalthamLeaseMember_652dd2b3-6605-4555-8924-de0c4c109f5a_terseLabel_en-US" xlink:label="lab_xfor_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit security: Waltham lease</link:label>
    <link:label id="lab_xfor_WalthamLeaseMember_c227cb2c-2e12-497d-89fd-3c0440f2705b_verboseLabel_en-US" xlink:label="lab_xfor_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham Lease</link:label>
    <link:label id="lab_xfor_WalthamLeaseMember_label_en-US" xlink:label="lab_xfor_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham Lease [Member]</link:label>
    <link:label id="lab_xfor_WalthamLeaseMember_documentation_en-US" xlink:label="lab_xfor_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember" xlink:href="xfor-20211231.xsd#xfor_WalthamLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_WalthamLeaseMember" xlink:to="lab_xfor_WalthamLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_cc522c57-ba86-4724-b9da-96b98a0904e7_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, beginning of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_7d0bcdd2-6d62-4a5e-bcf9-833a4209afbf_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, end of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_9ceec9c3-35eb-494c-b87f-ce88b9d47b22_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_StockIssuedDuringPeriodValueLicenseAgreement_3b63b3f3-1f1c-43bd-8386-908a70d59c23_terseLabel_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodValueLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of additional common stock issued</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodValueLicenseAgreement_label_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodValueLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value License Agreement</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodValueLicenseAgreement_documentation_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodValueLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodValueLicenseAgreement" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_StockIssuedDuringPeriodValueLicenseAgreement" xlink:to="lab_xfor_StockIssuedDuringPeriodValueLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_a5fa5388-52cb-44f1-8e4e-44baa04db44a_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix_0109bb2c-0ff2-4fd5-afe0-1695e6f6ade5_terseLabel_en-US" xlink:label="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, future expected annual fees, year four through six</link:label>
    <link:label id="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix_label_en-US" xlink:label="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Future Expected Annual Fees, Year Four Through Six</link:label>
    <link:label id="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix_documentation_en-US" xlink:label="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Future Expected Annual Fees, Year Four Through Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix" xlink:to="lab_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_e64aa738-dbb4-4de9-a012-6eaa9656f1c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_f41ea6ed-6f6b-4c2b-8d6e-e9fd3fd1e6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_a772f87b-161e-46f7-bac6-067866536362_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0ce9b97d-3aed-4a35-a250-44777691a6ed_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount_6c045966-8f5e-4c24-b949-212a12255d4d_terseLabel_en-US" xlink:label="lab_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized in transaction, amount</link:label>
    <link:label id="lab_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount_label_en-US" xlink:label="lab_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number Of Shares Authorized in Transaction, Amount</link:label>
    <link:label id="lab_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount_documentation_en-US" xlink:label="lab_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number Of Shares Authorized in Transaction, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount" xlink:to="lab_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_SaleOfStockPurchaseAgreementSharesIssued_70c51dd1-2bd1-410f-87e6-96eed97e1721_terseLabel_en-US" xlink:label="lab_xfor_SaleOfStockPurchaseAgreementSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Purchase Agreement, Shares Issued</link:label>
    <link:label id="lab_xfor_SaleOfStockPurchaseAgreementSharesIssued_label_en-US" xlink:label="lab_xfor_SaleOfStockPurchaseAgreementSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Purchase Agreement, Shares Issued</link:label>
    <link:label id="lab_xfor_SaleOfStockPurchaseAgreementSharesIssued_documentation_en-US" xlink:label="lab_xfor_SaleOfStockPurchaseAgreementSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Purchase Agreement, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockPurchaseAgreementSharesIssued" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockPurchaseAgreementSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_SaleOfStockPurchaseAgreementSharesIssued" xlink:to="lab_xfor_SaleOfStockPurchaseAgreementSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_60288e49-9187-42c7-8b21-cc7297726bbf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6d43a0c5-e738-444d-b425-635a0613a17a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_da54ab82-b8e1-44aa-a985-bf6cf06f4aab_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_8b470f86-4e80-4a18-8ddc-283b556c042b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_b0535a35-9b80-45b8-8df2-3ecb771b1378_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Valuation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_3747e5ed-24a6-4c2b-b14e-956dd0c1bcca_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_de80f647-0ff3-4725-a1c5-4ddb28c40f61_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LineOfCreditCovenantMinimumCash_248c7a37-859e-44bb-8152-27c37f05ce32_terseLabel_en-US" xlink:label="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant, Minimum Cash</link:label>
    <link:label id="lab_xfor_LineOfCreditCovenantMinimumCash_label_en-US" xlink:label="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant, Minimum Cash</link:label>
    <link:label id="lab_xfor_LineOfCreditCovenantMinimumCash_documentation_en-US" xlink:label="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant, Minimum Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash" xlink:href="xfor-20211231.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LineOfCreditCovenantMinimumCash" xlink:to="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell_7b3f0fb0-3788-4634-930e-4fb1ca70ed38_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Securities Purchased under Agreements to Resell</link:label>
    <link:label id="lab_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell_label_en-US" xlink:label="lab_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Securities Purchased under Agreements to Resell</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell" xlink:to="lab_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_67529137-26d6-4788-b210-84ead3dc2a41_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>xfor-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:97cd003e-9c40-40fd-8096-f110f9c5294b,g:4b68d2f2-b861-47a0-89c8-6e5f887cc91d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_16a164b0-f4ba-4b95-bd5c-6bf969930bb6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_DocumentType_16a164b0-f4ba-4b95-bd5c-6bf969930bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_cfffc764-5233-4449-903a-6b074797f78d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_DocumentAnnualReport_cfffc764-5233-4449-903a-6b074797f78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7a156242-4699-4662-97e2-d4806de33ae9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_DocumentPeriodEndDate_7a156242-4699-4662-97e2-d4806de33ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4423c4c2-fbc4-4d29-80c5-8d24b6f59189" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_CurrentFiscalYearEndDate_4423c4c2-fbc4-4d29-80c5-8d24b6f59189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_080708c1-74b0-49df-9e22-7c74c8ad9cad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_DocumentTransitionReport_080708c1-74b0-49df-9e22-7c74c8ad9cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ed55abf5-945d-41df-8a2e-fb131a32ef88" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityFileNumber_ed55abf5-945d-41df-8a2e-fb131a32ef88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e6c0c73f-48bb-4f36-a014-a696588a443c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityRegistrantName_e6c0c73f-48bb-4f36-a014-a696588a443c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6f88b994-3bee-42be-8df6-67d5f17e732c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6f88b994-3bee-42be-8df6-67d5f17e732c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_990f9747-b0ec-46be-abdb-05a821c2cd57" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityTaxIdentificationNumber_990f9747-b0ec-46be-abdb-05a821c2cd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b3d4143a-3e06-4ea7-b26b-91c7847b6deb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityAddressAddressLine1_b3d4143a-3e06-4ea7-b26b-91c7847b6deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_1b159425-5f29-448e-8e10-4ac7bf9b021a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityAddressAddressLine2_1b159425-5f29-448e-8e10-4ac7bf9b021a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6cbfbff1-1c30-4e8b-b4a3-9b5dcedd7201" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityAddressCityOrTown_6cbfbff1-1c30-4e8b-b4a3-9b5dcedd7201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6a4eb8fe-7f74-4c76-80ee-4548ca541731" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityAddressStateOrProvince_6a4eb8fe-7f74-4c76-80ee-4548ca541731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_51f53a7c-9fcb-4876-8a56-e8073b55ce1d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityAddressPostalZipCode_51f53a7c-9fcb-4876-8a56-e8073b55ce1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_052145a2-9609-4165-952f-ea00999dae83" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_CityAreaCode_052145a2-9609-4165-952f-ea00999dae83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_68f0969c-2e74-4146-acaf-c9c4f11016bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_LocalPhoneNumber_68f0969c-2e74-4146-acaf-c9c4f11016bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d54d1ffc-35a6-47a4-980e-dcdd05c83586" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_Security12bTitle_d54d1ffc-35a6-47a4-980e-dcdd05c83586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f5dd5c2b-f964-4027-b425-44aa341bbce4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_TradingSymbol_f5dd5c2b-f964-4027-b425-44aa341bbce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_21df3b54-61e7-4da3-a7e7-1198f34bc79f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_SecurityExchangeName_21df3b54-61e7-4da3-a7e7-1198f34bc79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0b41e29a-9f98-40e6-829d-0af80e23c0a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0b41e29a-9f98-40e6-829d-0af80e23c0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_7da50f5b-38d0-4f2e-915c-4da05e1d84ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityVoluntaryFilers_7da50f5b-38d0-4f2e-915c-4da05e1d84ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7d432bf7-f013-42da-9b6b-c9e8c200cc5e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityCurrentReportingStatus_7d432bf7-f013-42da-9b6b-c9e8c200cc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_01f67b5a-d842-4aaa-b271-511a3a4ddf5c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityInteractiveDataCurrent_01f67b5a-d842-4aaa-b271-511a3a4ddf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_acbab4f1-9488-47f2-ab8f-95bef4811db4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_acbab4f1-9488-47f2-ab8f-95bef4811db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e927f926-0ca1-4ccd-bc1d-8f21c05449f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityFilerCategory_e927f926-0ca1-4ccd-bc1d-8f21c05449f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a9ba5ed8-f03a-42f6-a6ac-afc6970a29b4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntitySmallBusiness_a9ba5ed8-f03a-42f6-a6ac-afc6970a29b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_00db345f-a2c2-4335-b094-0bcdf3825cda" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityEmergingGrowthCompany_00db345f-a2c2-4335-b094-0bcdf3825cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f40fdecf-e6bc-4b8b-8157-2cceb7ec73a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityExTransitionPeriod_f40fdecf-e6bc-4b8b-8157-2cceb7ec73a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_59a1067c-24bc-4c8b-8364-0f240fb8606b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityShellCompany_59a1067c-24bc-4c8b-8364-0f240fb8606b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_523e4d0d-f4c5-4120-9124-6231eb0886ca" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityPublicFloat_523e4d0d-f4c5-4120-9124-6231eb0886ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_856b3330-7ca8-44ff-94b1-4c2515ed51a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_856b3330-7ca8-44ff-94b1-4c2515ed51a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d99dcec5-662b-4dd9-bcbc-cb6e6b819914" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d99dcec5-662b-4dd9-bcbc-cb6e6b819914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_592a8c94-09e3-4f4d-b040-9e33ea048b3e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_EntityCentralIndexKey_592a8c94-09e3-4f4d-b040-9e33ea048b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_733c78d9-f65a-4080-a591-d37cd04e7e42" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_AmendmentFlag_733c78d9-f65a-4080-a591-d37cd04e7e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5d044ad7-fa84-4faa-b607-b55d8baa46f9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_DocumentFiscalYearFocus_5d044ad7-fa84-4faa-b607-b55d8baa46f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c159ae20-d402-49bf-96f2-1782099e30d7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b348080a-308a-4a3e-b63b-dbe9e567b48e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c159ae20-d402-49bf-96f2-1782099e30d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AuditInformation" xlink:type="simple" xlink:href="xfor-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AuditInformationAbstract_d6b111c1-df4d-4476-881d-eefd23892a41" xlink:href="xfor-20211231.xsd#xfor_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_bea2bb46-dda0-4fdf-a60f-d1418cc17fa0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_AuditInformationAbstract_d6b111c1-df4d-4476-881d-eefd23892a41" xlink:to="loc_dei_AuditorName_bea2bb46-dda0-4fdf-a60f-d1418cc17fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_7edbaa66-68b8-4f87-a9c5-ce82fc30c8eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_AuditInformationAbstract_d6b111c1-df4d-4476-881d-eefd23892a41" xlink:to="loc_dei_AuditorLocation_7edbaa66-68b8-4f87-a9c5-ce82fc30c8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_df92e7a5-8931-48a3-aabd-591c3fb1185f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_AuditInformationAbstract_d6b111c1-df4d-4476-881d-eefd23892a41" xlink:to="loc_dei_AuditorFirmId_df92e7a5-8931-48a3-aabd-591c3fb1185f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_401e6198-cef4-4357-b306-39aa027f8167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_84e3dbaa-6859-483a-8dbc-81c648d4f2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_401e6198-cef4-4357-b306-39aa027f8167" xlink:to="loc_us-gaap_AssetsAbstract_84e3dbaa-6859-483a-8dbc-81c648d4f2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9722e964-4598-418c-aee8-d902e7f40514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_84e3dbaa-6859-483a-8dbc-81c648d4f2dd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9722e964-4598-418c-aee8-d902e7f40514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e14488e-5cee-48e0-abb1-002ac59c61c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9722e964-4598-418c-aee8-d902e7f40514" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e14488e-5cee-48e0-abb1-002ac59c61c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_773ac95b-06a6-41e1-9936-11693e27738a" xlink:href="xfor-20211231.xsd#xfor_ResearchAndDevelopmentIncentiveReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9722e964-4598-418c-aee8-d902e7f40514" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_773ac95b-06a6-41e1-9936-11693e27738a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf21f06f-1545-4d47-8644-27cf62d0dbce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9722e964-4598-418c-aee8-d902e7f40514" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf21f06f-1545-4d47-8644-27cf62d0dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e523ab40-3fda-463d-9d24-c924fe2d7cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9722e964-4598-418c-aee8-d902e7f40514" xlink:to="loc_us-gaap_AssetsCurrent_e523ab40-3fda-463d-9d24-c924fe2d7cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5b6affe5-0cb5-4020-9d47-34a48e2734fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_84e3dbaa-6859-483a-8dbc-81c648d4f2dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5b6affe5-0cb5-4020-9d47-34a48e2734fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_07710844-c822-412d-93fc-8aa197683118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_84e3dbaa-6859-483a-8dbc-81c648d4f2dd" xlink:to="loc_us-gaap_Goodwill_07710844-c822-412d-93fc-8aa197683118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4f663977-4a45-4a3d-b53f-1969e20234d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_84e3dbaa-6859-483a-8dbc-81c648d4f2dd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4f663977-4a45-4a3d-b53f-1969e20234d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b2f1311e-5cf6-462f-96dc-877399ab60f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_84e3dbaa-6859-483a-8dbc-81c648d4f2dd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b2f1311e-5cf6-462f-96dc-877399ab60f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0a8c10de-8c1c-4ad3-bd2a-ad9e400a7cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_84e3dbaa-6859-483a-8dbc-81c648d4f2dd" xlink:to="loc_us-gaap_Assets_0a8c10de-8c1c-4ad3-bd2a-ad9e400a7cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_4a6920db-1a6f-4a21-b306-aba081081c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_401e6198-cef4-4357-b306-39aa027f8167" xlink:to="loc_us-gaap_LiabilitiesAbstract_4a6920db-1a6f-4a21-b306-aba081081c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_29cf0cfc-415a-4632-b06f-4607ae99cad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a6920db-1a6f-4a21-b306-aba081081c29" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_29cf0cfc-415a-4632-b06f-4607ae99cad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_46f68770-16b2-42d8-b350-019c75dd96b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_29cf0cfc-415a-4632-b06f-4607ae99cad2" xlink:to="loc_us-gaap_AccountsPayableCurrent_46f68770-16b2-42d8-b350-019c75dd96b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b4056c8d-8945-4741-9fc4-adabb092126b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_29cf0cfc-415a-4632-b06f-4607ae99cad2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b4056c8d-8945-4741-9fc4-adabb092126b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7b594e93-e48b-443b-b4b2-6cca2e38438e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_29cf0cfc-415a-4632-b06f-4607ae99cad2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7b594e93-e48b-443b-b4b2-6cca2e38438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_71d1e857-e9b5-48d2-9433-180e147c5810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_29cf0cfc-415a-4632-b06f-4607ae99cad2" xlink:to="loc_us-gaap_LongTermDebtCurrent_71d1e857-e9b5-48d2-9433-180e147c5810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7369c62d-53e2-42db-868a-3dff9960c0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_29cf0cfc-415a-4632-b06f-4607ae99cad2" xlink:to="loc_us-gaap_LiabilitiesCurrent_7369c62d-53e2-42db-868a-3dff9960c0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtNonCurrentIncludingAccrection_8bf0e55a-0eae-4275-952e-e3cd962f65e3" xlink:href="xfor-20211231.xsd#xfor_LongTermDebtNonCurrentIncludingAccrection"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a6920db-1a6f-4a21-b306-aba081081c29" xlink:to="loc_xfor_LongTermDebtNonCurrentIncludingAccrection_8bf0e55a-0eae-4275-952e-e3cd962f65e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db245051-11c2-4a04-9f7f-f64d5239b4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a6920db-1a6f-4a21-b306-aba081081c29" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db245051-11c2-4a04-9f7f-f64d5239b4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d95cf903-98c7-4bce-a765-fc2c984ce1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a6920db-1a6f-4a21-b306-aba081081c29" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d95cf903-98c7-4bce-a765-fc2c984ce1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cf31415a-cc23-4a19-822e-0bf44ef54349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a6920db-1a6f-4a21-b306-aba081081c29" xlink:to="loc_us-gaap_Liabilities_cf31415a-cc23-4a19-822e-0bf44ef54349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7716c9a9-a5fc-486c-9b0f-a46299b356b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4a6920db-1a6f-4a21-b306-aba081081c29" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7716c9a9-a5fc-486c-9b0f-a46299b356b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_97273e6f-f5a5-46f4-8c77-febbea73c683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_401e6198-cef4-4357-b306-39aa027f8167" xlink:to="loc_us-gaap_StockholdersEquityAbstract_97273e6f-f5a5-46f4-8c77-febbea73c683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_26474164-0aa4-4715-85d9-4105f58d8f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97273e6f-f5a5-46f4-8c77-febbea73c683" xlink:to="loc_us-gaap_CommonStockValue_26474164-0aa4-4715-85d9-4105f58d8f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8c2276bd-aa31-490a-a307-aa0ad2ffaee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97273e6f-f5a5-46f4-8c77-febbea73c683" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8c2276bd-aa31-490a-a307-aa0ad2ffaee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_819bdef2-ee6c-4f89-b648-817c93f8ba02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97273e6f-f5a5-46f4-8c77-febbea73c683" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_819bdef2-ee6c-4f89-b648-817c93f8ba02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c32a1fe1-ce37-4ed5-b936-0b1e6b29d9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97273e6f-f5a5-46f4-8c77-febbea73c683" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c32a1fe1-ce37-4ed5-b936-0b1e6b29d9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_10422fbd-aa32-43e8-b554-58e64c0a9364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97273e6f-f5a5-46f4-8c77-febbea73c683" xlink:to="loc_us-gaap_StockholdersEquity_10422fbd-aa32-43e8-b554-58e64c0a9364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a624e5f4-18c9-4e03-afaa-20c46c2f4d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_401e6198-cef4-4357-b306-39aa027f8167" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a624e5f4-18c9-4e03-afaa-20c46c2f4d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b56ee417-079a-436a-90b9-6e98fdc0a17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_401e6198-cef4-4357-b306-39aa027f8167" xlink:to="loc_us-gaap_CommonStockSharesIssued_b56ee417-079a-436a-90b9-6e98fdc0a17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c67fc5d0-d1ac-4f7a-8efe-9cec672df2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_401e6198-cef4-4357-b306-39aa027f8167" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c67fc5d0-d1ac-4f7a-8efe-9cec672df2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4e605c15-5d76-432a-9fcb-61aa15b475a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_401e6198-cef4-4357-b306-39aa027f8167" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4e605c15-5d76-432a-9fcb-61aa15b475a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_34664da8-f543-4dd5-b0e9-dd7ac5504252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6158e652-dcbe-485f-a779-ac8cc0cf2643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34664da8-f543-4dd5-b0e9-dd7ac5504252" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6158e652-dcbe-485f-a779-ac8cc0cf2643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e6af36aa-2f9f-40ed-b8b0-e46d0c24926a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34664da8-f543-4dd5-b0e9-dd7ac5504252" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e6af36aa-2f9f-40ed-b8b0-e46d0c24926a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a932560a-ec61-40d4-b03f-c47ffe032c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34664da8-f543-4dd5-b0e9-dd7ac5504252" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a932560a-ec61-40d4-b03f-c47ffe032c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e0c3176b-c235-4505-91da-4135f993fff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34664da8-f543-4dd5-b0e9-dd7ac5504252" xlink:to="loc_us-gaap_CommonStockSharesIssued_e0c3176b-c235-4505-91da-4135f993fff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b49ef986-f61a-4992-8026-88c98e286066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b49ef986-f61a-4992-8026-88c98e286066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c2443cda-ddcb-4d8d-929a-e77b6f62fed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c2443cda-ddcb-4d8d-929a-e77b6f62fed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8b26ed62-4601-4d95-ad51-3c55ab34b06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c2443cda-ddcb-4d8d-929a-e77b6f62fed4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8b26ed62-4601-4d95-ad51-3c55ab34b06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ce49be36-f092-4d91-b1ed-cdf38f07f697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c2443cda-ddcb-4d8d-929a-e77b6f62fed4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ce49be36-f092-4d91-b1ed-cdf38f07f697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9aeca706-475f-482e-aae2-3ffa2c475115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c2443cda-ddcb-4d8d-929a-e77b6f62fed4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9aeca706-475f-482e-aae2-3ffa2c475115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_6ba7a350-18d5-4320-b696-cf7641c80a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c2443cda-ddcb-4d8d-929a-e77b6f62fed4" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_6ba7a350-18d5-4320-b696-cf7641c80a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_41fb95fc-3535-4232-8bac-7a9a12b1b164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c2443cda-ddcb-4d8d-929a-e77b6f62fed4" xlink:to="loc_us-gaap_OperatingExpenses_41fb95fc-3535-4232-8bac-7a9a12b1b164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4bc94a7d-3115-40e9-be82-008bfb41c2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_OperatingIncomeLoss_4bc94a7d-3115-40e9-be82-008bfb41c2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1153a7a5-f9fa-4a70-9ac9-60df423a29e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1153a7a5-f9fa-4a70-9ac9-60df423a29e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7bb40c30-ace2-409c-91a9-6ee6509bd28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:to="loc_us-gaap_InterestExpense_7bb40c30-ace2-409c-91a9-6ee6509bd28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_b7846b09-2bcd-42d8-8d82-7c13c83234f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_b7846b09-2bcd-42d8-8d82-7c13c83234f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_36533eaa-6c58-4864-9fe0-1fe605404baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_36533eaa-6c58-4864-9fe0-1fe605404baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dc1c37d3-b5e9-49d5-8d4a-cc16cb40d65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dc1c37d3-b5e9-49d5-8d4a-cc16cb40d65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_867f97b2-f7dd-4dd5-aebc-af579b181350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_867f97b2-f7dd-4dd5-aebc-af579b181350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_196aae9a-3e53-4537-bb22-c104a7e5b2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_196aae9a-3e53-4537-bb22-c104a7e5b2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c1a39e7-f836-4cff-bb08-443615a5924a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c1a39e7-f836-4cff-bb08-443615a5924a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_585265c3-0473-4b3c-9023-68e49727f337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13744b71-71e3-40c2-93d6-730a43b2a19b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_585265c3-0473-4b3c-9023-68e49727f337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5cff9b8f-2d48-4494-b9c9-d701d9875be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_NetIncomeLoss_5cff9b8f-2d48-4494-b9c9-d701d9875be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_cadf44da-ac76-43c9-b6e0-ed86925f3ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_cadf44da-ac76-43c9-b6e0-ed86925f3ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_0db0ffcf-73ea-4936-920c-c8b7ec2d16f8" xlink:href="xfor-20211231.xsd#xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_0db0ffcf-73ea-4936-920c-c8b7ec2d16f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_91d4f891-a95c-4c13-952c-452e77f42d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_91d4f891-a95c-4c13-952c-452e77f42d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_8b8e9adc-a2eb-4c1a-bad5-31fe7039fff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_8b8e9adc-a2eb-4c1a-bad5-31fe7039fff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e72ccedc-aa90-4e39-b85c-0c15e0ca2af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e72ccedc-aa90-4e39-b85c-0c15e0ca2af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c908bbf6-c390-47ca-8e91-92071b33279f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8817bb5d-ddcc-4daa-86ed-83a59abb9da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8817bb5d-ddcc-4daa-86ed-83a59abb9da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1dd8e53f-75c6-47e2-859a-979be339bf87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_770cf7e8-b891-4fda-93f1-d40121afb14e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1dd8e53f-75c6-47e2-859a-979be339bf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_92ac1d54-cfae-4687-83c0-000b050e7478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1e81df13-70de-4c6a-8b52-f669018a210a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_92ac1d54-cfae-4687-83c0-000b050e7478" xlink:to="loc_us-gaap_StatementTable_1e81df13-70de-4c6a-8b52-f669018a210a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9b8ec97d-60fd-4ead-9ae1-602e712cea3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1e81df13-70de-4c6a-8b52-f669018a210a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9b8ec97d-60fd-4ead-9ae1-602e712cea3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e91c552-86f6-4adc-a114-e435290a756a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9b8ec97d-60fd-4ead-9ae1-602e712cea3d" xlink:to="loc_us-gaap_ClassOfStockDomain_4e91c552-86f6-4adc-a114-e435290a756a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_aecd0225-a476-4f9f-a565-0a1569ba003b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4e91c552-86f6-4adc-a114-e435290a756a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_aecd0225-a476-4f9f-a565-0a1569ba003b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_eb488be8-7c93-484e-870c-51f64588d3b1" xlink:href="xfor-20211231.xsd#xfor_RedeemableCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4e91c552-86f6-4adc-a114-e435290a756a" xlink:to="loc_xfor_RedeemableCommonStockMember_eb488be8-7c93-484e-870c-51f64588d3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_708c2021-2ed1-447d-8e5a-d9b5c4e6e4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1e81df13-70de-4c6a-8b52-f669018a210a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_708c2021-2ed1-447d-8e5a-d9b5c4e6e4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_708c2021-2ed1-447d-8e5a-d9b5c4e6e4dd" xlink:to="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_36a2d976-4841-438b-9f17-ec2fbc3b621d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:to="loc_us-gaap_CommonStockMember_36a2d976-4841-438b-9f17-ec2fbc3b621d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eb54b389-ea37-488e-bdd1-9e2e2002a16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eb54b389-ea37-488e-bdd1-9e2e2002a16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_18d96903-c19e-4def-aa1c-155514daf54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_18d96903-c19e-4def-aa1c-155514daf54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2bd6ddc8-cc58-4ac3-a5e1-739825766fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e512847e-9de0-40fe-bb2b-92a941794cd4" xlink:to="loc_us-gaap_RetainedEarningsMember_2bd6ddc8-cc58-4ac3-a5e1-739825766fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1e81df13-70de-4c6a-8b52-f669018a210a" xlink:to="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_103a87bb-a17a-4f9b-b740-25779321d975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_103a87bb-a17a-4f9b-b740-25779321d975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_dd300538-b054-4333-ae87-6fe753101699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_dd300538-b054-4333-ae87-6fe753101699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_b0155c37-4605-4e34-9e3f-a7cb5ccc5ead" xlink:href="xfor-20211231.xsd#xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_b0155c37-4605-4e34-9e3f-a7cb5ccc5ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aaf0214d-8e09-4d02-8469-fdce137395a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aaf0214d-8e09-4d02-8469-fdce137395a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fbabcb82-4a07-41df-9a7c-eca643b94182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fbabcb82-4a07-41df-9a7c-eca643b94182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockShares_f8688899-c51b-41cf-ab5a-92b50d612d2b" xlink:href="xfor-20211231.xsd#xfor_ConversionOfRedeemableCommonStockToCommonStockShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockShares_f8688899-c51b-41cf-ab5a-92b50d612d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockValue_90c7f95f-5e70-48a9-9b53-edf65f28c2c2" xlink:href="xfor-20211231.xsd#xfor_ConversionOfRedeemableCommonStockToCommonStockValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockValue_90c7f95f-5e70-48a9-9b53-edf65f28c2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c9286bb6-40fa-4c68-bfa6-6de3118c878d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c9286bb6-40fa-4c68-bfa6-6de3118c878d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_45807ba8-8eda-4df2-b883-d1b7b6c5a911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_45807ba8-8eda-4df2-b883-d1b7b6c5a911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_b335ea38-2b98-4512-9a33-dbc793601abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_b335ea38-2b98-4512-9a33-dbc793601abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c6bd78c9-cf40-4872-9bd1-5d4869cdce59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4a062d7d-8e8d-4283-8d88-31e8bd13e902" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c6bd78c9-cf40-4872-9bd1-5d4869cdce59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_82192c18-e487-4ba9-bc3f-f6f4292e5888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_SharesOutstanding_82192c18-e487-4ba9-bc3f-f6f4292e5888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b1e757ad-0eca-4236-93f2-97ac2c58c59f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockholdersEquity_b1e757ad-0eca-4236-93f2-97ac2c58c59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b48811b9-a8f5-40e6-b3f0-ee40ccdac5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b48811b9-a8f5-40e6-b3f0-ee40ccdac5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_9ca61d57-f010-4639-bbdb-0d02b4b26d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_9ca61d57-f010-4639-bbdb-0d02b4b26d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_5ac0b168-7856-4a00-908e-9a4430901d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_5ac0b168-7856-4a00-908e-9a4430901d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity_0ac16475-2e50-4723-9b4d-e1d5832132b6" xlink:href="xfor-20211231.xsd#xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity_0ac16475-2e50-4723-9b4d-e1d5832132b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_9cbdb8f0-a90c-4bf9-8e86-6862ead3eae9" xlink:href="xfor-20211231.xsd#xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_9cbdb8f0-a90c-4bf9-8e86-6862ead3eae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_37bd3c7d-5e62-4c5f-8acf-9362bd841e45" xlink:href="xfor-20211231.xsd#xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_37bd3c7d-5e62-4c5f-8acf-9362bd841e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27a445c4-9fbc-47de-a078-079e1c14c518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27a445c4-9fbc-47de-a078-079e1c14c518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4e104f83-79d9-4790-a41c-1b508b33be08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4e104f83-79d9-4790-a41c-1b508b33be08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_405c5b77-889d-40b2-81d6-3547958512c8" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_405c5b77-889d-40b2-81d6-3547958512c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised_078da3a4-1e50-48dc-8d63-2caa3d26572f" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_xfor_StockIssuedDuringPeriodValueWarrantsExercised_078da3a4-1e50-48dc-8d63-2caa3d26572f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_78af97f7-e3f5-4d10-b5ac-2943b7e00ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_78af97f7-e3f5-4d10-b5ac-2943b7e00ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_36703c15-29ae-4f10-bf16-d30a91f3eed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_36703c15-29ae-4f10-bf16-d30a91f3eed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_aea249cf-51f8-46f0-a1be-85024c9c24ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_aea249cf-51f8-46f0-a1be-85024c9c24ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b29cc5db-87a3-4a0d-8879-5f05a75bbd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b29cc5db-87a3-4a0d-8879-5f05a75bbd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_af811de6-ad85-4d41-b2f2-58c054557b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_af811de6-ad85-4d41-b2f2-58c054557b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_b529fcaf-f8e0-45b0-9acd-0d234a352eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_b529fcaf-f8e0-45b0-9acd-0d234a352eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_527ff798-8503-429c-81c1-ea42580c394b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_NetIncomeLoss_527ff798-8503-429c-81c1-ea42580c394b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_54f180d6-1888-47f5-8f63-dc4c52a3b2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_SharesOutstanding_54f180d6-1888-47f5-8f63-dc4c52a3b2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e7581838-0d8f-47e6-9e04-0bf494655c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c5ed527-cd11-475b-9ea5-aedcd9b351ac" xlink:to="loc_us-gaap_StockholdersEquity_e7581838-0d8f-47e6-9e04-0bf494655c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_384147f1-403a-44a6-afe1-815717715f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_384147f1-403a-44a6-afe1-815717715f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3fb1b093-79d6-47d2-ac9e-3af302eb7bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16c6ca67-06da-406c-9b95-31e0b67dd0fa" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3fb1b093-79d6-47d2-ac9e-3af302eb7bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ef0388b4-2dff-47b3-b81c-057a09faf5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f6a791a0-be8a-4139-9426-ca94c3eb2baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ef0388b4-2dff-47b3-b81c-057a09faf5e4" xlink:to="loc_us-gaap_StatementTable_f6a791a0-be8a-4139-9426-ca94c3eb2baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d01fcf2c-fc70-4132-9d11-0c30542301d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f6a791a0-be8a-4139-9426-ca94c3eb2baa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d01fcf2c-fc70-4132-9d11-0c30542301d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e2c6f9a1-5a21-4c9d-bc6e-5371df24d0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d01fcf2c-fc70-4132-9d11-0c30542301d2" xlink:to="loc_us-gaap_EquityComponentDomain_e2c6f9a1-5a21-4c9d-bc6e-5371df24d0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_846b08ad-65d6-4889-ad6a-5ca3b1320ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e2c6f9a1-5a21-4c9d-bc6e-5371df24d0a5" xlink:to="loc_us-gaap_CommonStockMember_846b08ad-65d6-4889-ad6a-5ca3b1320ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5181c5f8-33e0-40cf-8e97-52d9ef1b589b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f6a791a0-be8a-4139-9426-ca94c3eb2baa" xlink:to="loc_us-gaap_StatementLineItems_5181c5f8-33e0-40cf-8e97-52d9ef1b589b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c5e19ec9-0fb5-49d1-ac01-4f6f27f0efbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5181c5f8-33e0-40cf-8e97-52d9ef1b589b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c5e19ec9-0fb5-49d1-ac01-4f6f27f0efbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="xfor-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6ee0cfc0-a884-4bb0-80ef-4c0ac02c3a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_95035984-470c-4ff7-a586-094b820e4594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ee0cfc0-a884-4bb0-80ef-4c0ac02c3a9b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_95035984-470c-4ff7-a586-094b820e4594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4070d8d8-6581-4312-ac63-09eca991952b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_95035984-470c-4ff7-a586-094b820e4594" xlink:to="loc_us-gaap_ProfitLoss_4070d8d8-6581-4312-ac63-09eca991952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_95035984-470c-4ff7-a586-094b820e4594" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d0e0d8c8-67ce-4d96-90ad-15e7f2f0e1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:to="loc_us-gaap_ShareBasedCompensation_d0e0d8c8-67ce-4d96-90ad-15e7f2f0e1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ecdf757c-d554-45d0-b64d-ad9ca3330222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ecdf757c-d554-45d0-b64d-ad9ca3330222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f3512af4-c630-44c7-9e9f-b490b35244c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f3512af4-c630-44c7-9e9f-b490b35244c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_af76c7da-c0ef-4a9d-bb4b-27293051f1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_af76c7da-c0ef-4a9d-bb4b-27293051f1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashLeaseExpense_0beaf3dd-3935-4ae1-be90-9dc12952ac5d" xlink:href="xfor-20211231.xsd#xfor_NonCashLeaseExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:to="loc_xfor_NonCashLeaseExpense_0beaf3dd-3935-4ae1-be90-9dc12952ac5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashInterestExpense_0a09a41f-994e-47e3-bb79-43863265925f" xlink:href="xfor-20211231.xsd#xfor_NonCashInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:to="loc_xfor_NonCashInterestExpense_0a09a41f-994e-47e3-bb79-43863265925f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a170fa8d-2fd0-4141-9217-375b531480dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a170fa8d-2fd0-4141-9217-375b531480dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability_e1318b08-fc4f-452d-a95a-42269ab8421c" xlink:href="xfor-20211231.xsd#xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:to="loc_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability_e1318b08-fc4f-452d-a95a-42269ab8421c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_bfb53d63-938f-4182-9857-7d58dfdbb47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_bfb53d63-938f-4182-9857-7d58dfdbb47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ef1a4c73-1e5c-4785-a353-a86df5f6a510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa050e4c-63b5-4894-afca-883d238274b0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ef1a4c73-1e5c-4785-a353-a86df5f6a510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dcc6ca85-38aa-48ed-b813-0264d2d3990d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ef1a4c73-1e5c-4785-a353-a86df5f6a510" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dcc6ca85-38aa-48ed-b813-0264d2d3990d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1626b927-6459-444c-8cdd-4559d45111ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ef1a4c73-1e5c-4785-a353-a86df5f6a510" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1626b927-6459-444c-8cdd-4559d45111ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_406cf17f-8dc6-4419-937a-13dab80f88cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ef1a4c73-1e5c-4785-a353-a86df5f6a510" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_406cf17f-8dc6-4419-937a-13dab80f88cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInLeaseLiabilities_dea9fe38-210b-47ce-ae19-9c9ac9a2fca4" xlink:href="xfor-20211231.xsd#xfor_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ef1a4c73-1e5c-4785-a353-a86df5f6a510" xlink:to="loc_xfor_IncreaseDecreaseInLeaseLiabilities_dea9fe38-210b-47ce-ae19-9c9ac9a2fca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_9494aa9a-9422-4e58-b4ef-19caf989b7e6" xlink:href="xfor-20211231.xsd#xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ef1a4c73-1e5c-4785-a353-a86df5f6a510" xlink:to="loc_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion_9494aa9a-9422-4e58-b4ef-19caf989b7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1f3d22b-f7c1-4a2d-a23c-ac41cfd742ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_95035984-470c-4ff7-a586-094b820e4594" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1f3d22b-f7c1-4a2d-a23c-ac41cfd742ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f7059a9e-240e-4038-a705-025eebe26ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ee0cfc0-a884-4bb0-80ef-4c0ac02c3a9b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f7059a9e-240e-4038-a705-025eebe26ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_bd527d81-846f-46ef-9197-bb2577c63c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f7059a9e-240e-4038-a705-025eebe26ce0" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_bd527d81-846f-46ef-9197-bb2577c63c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_8654315e-31f9-4800-bac4-d6a369773abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f7059a9e-240e-4038-a705-025eebe26ce0" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_8654315e-31f9-4800-bac4-d6a369773abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_24f367c0-8490-4eeb-8e0d-cbbf8cf29030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f7059a9e-240e-4038-a705-025eebe26ce0" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_24f367c0-8490-4eeb-8e0d-cbbf8cf29030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d8b208f-80d7-456c-bdb0-b057e2768a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f7059a9e-240e-4038-a705-025eebe26ce0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d8b208f-80d7-456c-bdb0-b057e2768a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09549986-ea29-4421-ae70-80807fdfe910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ee0cfc0-a884-4bb0-80ef-4c0ac02c3a9b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09549986-ea29-4421-ae70-80807fdfe910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_fb1b023b-bcea-470a-b87c-0b0bdafcc0bb" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09549986-ea29-4421-ae70-80807fdfe910" xlink:to="loc_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants_fb1b023b-bcea-470a-b87c-0b0bdafcc0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7fe1b018-fd15-468b-943c-837ae7f52770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09549986-ea29-4421-ae70-80807fdfe910" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7fe1b018-fd15-468b-943c-837ae7f52770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_a4bf3e79-e419-4e20-93bc-c855383fe1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09549986-ea29-4421-ae70-80807fdfe910" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_a4bf3e79-e419-4e20-93bc-c855383fe1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b9fd30bc-c44f-4279-a4e1-71a7aa88e6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09549986-ea29-4421-ae70-80807fdfe910" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b9fd30bc-c44f-4279-a4e1-71a7aa88e6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_7dc7824e-d4ba-403c-8e46-e6a00fc339f3" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09549986-ea29-4421-ae70-80807fdfe910" xlink:to="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_7dc7824e-d4ba-403c-8e46-e6a00fc339f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f1480293-0fcc-46e2-b1ef-69011f3f02c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09549986-ea29-4421-ae70-80807fdfe910" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f1480293-0fcc-46e2-b1ef-69011f3f02c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b47e96dd-c082-42c2-bfcd-725b6ae1f94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09549986-ea29-4421-ae70-80807fdfe910" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b47e96dd-c082-42c2-bfcd-725b6ae1f94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1ee6d92-e314-40d7-8207-88cba135a6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ee0cfc0-a884-4bb0-80ef-4c0ac02c3a9b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1ee6d92-e314-40d7-8207-88cba135a6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_535da9a5-ae9f-439d-984f-1dc5008f9fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ee0cfc0-a884-4bb0-80ef-4c0ac02c3a9b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_535da9a5-ae9f-439d-984f-1dc5008f9fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a98bd64-4118-4833-80ed-11211ccd2fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ee0cfc0-a884-4bb0-80ef-4c0ac02c3a9b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a98bd64-4118-4833-80ed-11211ccd2fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b92aa5b-0e85-4607-8a8a-873681f2ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ee0cfc0-a884-4bb0-80ef-4c0ac02c3a9b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b92aa5b-0e85-4607-8a8a-873681f2ed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0d06dda2-f6ba-4278-9b0d-46b952a70b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ee0cfc0-a884-4bb0-80ef-4c0ac02c3a9b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0d06dda2-f6ba-4278-9b0d-46b952a70b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_acb2e9ed-716f-4394-982e-020df48f3913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0d06dda2-f6ba-4278-9b0d-46b952a70b2c" xlink:to="loc_us-gaap_InterestPaidNet_acb2e9ed-716f-4394-982e-020df48f3913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9b7e4eb2-c45b-48c1-9a31-bd02e5955a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ee0cfc0-a884-4bb0-80ef-4c0ac02c3a9b" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9b7e4eb2-c45b-48c1-9a31-bd02e5955a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid_42f0425a-d6ed-4aa5-b76e-14a51800e13a" xlink:href="xfor-20211231.xsd#xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9b7e4eb2-c45b-48c1-9a31-bd02e5955a1a" xlink:to="loc_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid_42f0425a-d6ed-4aa5-b76e-14a51800e13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_ad044573-ecf6-4d47-9d56-394c188ef5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9b7e4eb2-c45b-48c1-9a31-bd02e5955a1a" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_ad044573-ecf6-4d47-9d56-394c188ef5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid_9d16b170-ffd6-4b55-81a3-8605c283ceaf" xlink:href="xfor-20211231.xsd#xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9b7e4eb2-c45b-48c1-9a31-bd02e5955a1a" xlink:to="loc_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid_9d16b170-ffd6-4b55-81a3-8605c283ceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues_c1146362-c2a8-45f8-ad3a-dbae44a36b73" xlink:href="xfor-20211231.xsd#xfor_ConversionOfConvertiblePreferredStockToCommonStockValues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9b7e4eb2-c45b-48c1-9a31-bd02e5955a1a" xlink:to="loc_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues_c1146362-c2a8-45f8-ad3a-dbae44a36b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockValue_21916c99-4034-42ca-92a2-018d89db74c8" xlink:href="xfor-20211231.xsd#xfor_ConversionOfRedeemableCommonStockToCommonStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9b7e4eb2-c45b-48c1-9a31-bd02e5955a1a" xlink:to="loc_xfor_ConversionOfRedeemableCommonStockToCommonStockValue_21916c99-4034-42ca-92a2-018d89db74c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants_dfb8c1cf-9beb-4ef9-9762-0e4ab4ceb9c2" xlink:href="xfor-20211231.xsd#xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9b7e4eb2-c45b-48c1-9a31-bd02e5955a1a" xlink:to="loc_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants_dfb8c1cf-9beb-4ef9-9762-0e4ab4ceb9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueOfNetAssetsAcquiredInReverseMerger_8150d71a-f057-449a-8391-d17d9835f108" xlink:href="xfor-20211231.xsd#xfor_FairValueOfNetAssetsAcquiredInReverseMerger"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9b7e4eb2-c45b-48c1-9a31-bd02e5955a1a" xlink:to="loc_xfor_FairValueOfNetAssetsAcquiredInReverseMerger_8150d71a-f057-449a-8391-d17d9835f108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="simple" xlink:href="xfor-20211231.xsd#NatureoftheBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_faef607b-a454-45e3-822c-8144baabe46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_24643d7c-c4ad-450a-99d8-dae605809377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_faef607b-a454-45e3-822c-8144baabe46a" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_24643d7c-c4ad-450a-99d8-dae605809377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#NatureoftheBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_361c9052-d761-4f47-8f90-01920ac301fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_361c9052-d761-4f47-8f90-01920ac301fe" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_045e1e70-1120-4f41-a2f4-866b4b41ceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_045e1e70-1120-4f41-a2f4-866b4b41ceb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf44e192-07ae-496e-a971-1a100ea0bcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_045e1e70-1120-4f41-a2f4-866b4b41ceb3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf44e192-07ae-496e-a971-1a100ea0bcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ArsanisMember_0877f301-c77e-4f1d-b5d1-bfa15b969957" xlink:href="xfor-20211231.xsd#xfor_ArsanisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf44e192-07ae-496e-a971-1a100ea0bcb7" xlink:to="loc_xfor_ArsanisMember_0877f301-c77e-4f1d-b5d1-bfa15b969957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_942bfe18-b93d-47c5-b741-813e1c3c87c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_942bfe18-b93d-47c5-b741-813e1c3c87c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e252d8fe-a900-4da4-8181-016ff2ed8448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_942bfe18-b93d-47c5-b741-813e1c3c87c2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e252d8fe-a900-4da4-8181-016ff2ed8448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5c8c8033-3029-40b9-ba42-4e3fd17cf728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e252d8fe-a900-4da4-8181-016ff2ed8448" xlink:to="loc_us-gaap_SubsequentEventMember_5c8c8033-3029-40b9-ba42-4e3fd17cf728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d8bc3b04-a5fb-47fc-9eb2-7c4242da8c48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:to="loc_srt_StatementScenarioAxis_d8bc3b04-a5fb-47fc-9eb2-7c4242da8c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e3fbc7cd-50bf-49b5-ba3c-c00c0a60c419" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_d8bc3b04-a5fb-47fc-9eb2-7c4242da8c48" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e3fbc7cd-50bf-49b5-ba3c-c00c0a60c419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_08c78e57-d2fe-4552-9855-c4d2110b46fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e3fbc7cd-50bf-49b5-ba3c-c00c0a60c419" xlink:to="loc_srt_ScenarioForecastMember_08c78e57-d2fe-4552-9855-c4d2110b46fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ebb42c45-c8eb-4248-ba39-c388932f10c2" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_01f7d6fd-0afc-4313-a9b7-29498b9d967c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_01f7d6fd-0afc-4313-a9b7-29498b9d967c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1e91d60f-5182-4b0c-ab69-6186cf9e8805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1e91d60f-5182-4b0c-ab69-6186cf9e8805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_BusinessCombinationShareExchangeRatio_75163a78-1068-4664-9348-979a6aafac82" xlink:href="xfor-20211231.xsd#xfor_BusinessCombinationShareExchangeRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_xfor_BusinessCombinationShareExchangeRatio_75163a78-1068-4664-9348-979a6aafac82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_78b54951-e465-479c-85bc-aa551d1aef10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_78b54951-e465-479c-85bc-aa551d1aef10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7dce121d-963b-4dba-b8c6-82c81a5c1fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7dce121d-963b-4dba-b8c6-82c81a5c1fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a7f4ff3c-834e-4e2a-8286-1686a9d757a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a7f4ff3c-834e-4e2a-8286-1686a9d757a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_401d62cd-5dc4-4842-a199-be448e9c96f0" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f19f9663-1f66-40ae-b119-57c6edf447dd" xlink:to="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_401d62cd-5dc4-4842-a199-be448e9c96f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="xfor-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_29b16e5d-946d-4547-b4dd-e92daa242090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_02571215-2211-4b66-a931-628965b057e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_29b16e5d-946d-4547-b4dd-e92daa242090" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_02571215-2211-4b66-a931-628965b057e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="xfor-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a027177a-9361-442c-a8b2-26b3ec268620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_UseOfEstimates_a027177a-9361-442c-a8b2-26b3ec268620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2b980b1d-a244-4299-8d31-44220666786b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2b980b1d-a244-4299-8d31-44220666786b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c2011b2c-ccae-490e-9424-065e8c509223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c2011b2c-ccae-490e-9424-065e8c509223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2b09e42d-2fd8-4524-bbb8-886dc482dfce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2b09e42d-2fd8-4524-bbb8-886dc482dfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ce77c9d0-3c05-4a92-9cc5-5d9b7d239126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ce77c9d0-3c05-4a92-9cc5-5d9b7d239126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock_e9b22840-2478-4d39-bf63-550b1ba73e65" xlink:href="xfor-20211231.xsd#xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock_e9b22840-2478-4d39-bf63-550b1ba73e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_848e286a-0dbe-4394-bf43-f37d6f4acf23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_848e286a-0dbe-4394-bf43-f37d6f4acf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_d65cbb11-0636-4d01-95c4-364cd59f9880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_d65cbb11-0636-4d01-95c4-364cd59f9880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IntangibleAssetsPolicyPolicyTextBlock_3c710aef-185b-4e73-9478-7454f0bb5786" xlink:href="xfor-20211231.xsd#xfor_IntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_xfor_IntangibleAssetsPolicyPolicyTextBlock_3c710aef-185b-4e73-9478-7454f0bb5786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a9bbefee-3266-4129-a4b3-0e207e7e5434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a9bbefee-3266-4129-a4b3-0e207e7e5434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2daae511-7a62-459e-b365-2602d9d87f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2daae511-7a62-459e-b365-2602d9d87f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_972ec42d-f481-4f24-9338-6222004eab2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_972ec42d-f481-4f24-9338-6222004eab2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock_cbf98409-ff8d-4db8-aac6-1d44ce0078a1" xlink:href="xfor-20211231.xsd#xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock_cbf98409-ff8d-4db8-aac6-1d44ce0078a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4c93f6fd-d20d-4b0c-86b3-9654ca7bcc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4c93f6fd-d20d-4b0c-86b3-9654ca7bcc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_31e79316-2c37-48f8-87af-5b6a0062f6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_31e79316-2c37-48f8-87af-5b6a0062f6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_0a59e4a0-c096-4714-b672-97c0fec4677e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_DebtPolicyTextBlock_0a59e4a0-c096-4714-b672-97c0fec4677e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f307249e-5e5f-4226-bec8-902c8f7647ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f307249e-5e5f-4226-bec8-902c8f7647ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_5d47a9be-5fac-4fbc-8a62-1e511b4bfd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_5d47a9be-5fac-4fbc-8a62-1e511b4bfd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7b16d276-860a-4ede-b851-a41ce7e17010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7b16d276-860a-4ede-b851-a41ce7e17010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_45906998-9d59-466e-9c08-dafd8e82aae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_45906998-9d59-466e-9c08-dafd8e82aae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_c493825a-5dcf-46b0-82c7-752979b1ab72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_c493825a-5dcf-46b0-82c7-752979b1ab72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e1799fd-59ac-43d9-a223-93a14dfeaf09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3dc0e7e-798c-4153-bc9c-ce27b524b065" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e1799fd-59ac-43d9-a223-93a14dfeaf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="xfor-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2aae03cd-274e-4d57-808f-7d37c3ed13d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock_26a7cf2b-9c32-4104-af9c-5012c8a1e492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensatingBalancesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2aae03cd-274e-4d57-808f-7d37c3ed13d0" xlink:to="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock_26a7cf2b-9c32-4104-af9c-5012c8a1e492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_eaad4c54-9bd2-42cf-ae28-8a44689eb4c9" xlink:href="xfor-20211231.xsd#xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2aae03cd-274e-4d57-808f-7d37c3ed13d0" xlink:to="loc_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_eaad4c54-9bd2-42cf-ae28-8a44689eb4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_b2255dee-8be5-4ede-9b63-3ebef60e25ee" xlink:href="xfor-20211231.xsd#xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2aae03cd-274e-4d57-808f-7d37c3ed13d0" xlink:to="loc_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_b2255dee-8be5-4ede-9b63-3ebef60e25ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3652422c-0115-4f7b-ab0e-b02d91d47644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3652422c-0115-4f7b-ab0e-b02d91d47644" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_500c6dad-90d6-4b36-bee6-409eab79727e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_500c6dad-90d6-4b36-bee6-409eab79727e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_500c6dad-90d6-4b36-bee6-409eab79727e" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CambridgeMAOperatingLeaseArrangementMember_ab5b3c6d-9050-4266-a28b-2b53524988f7" xlink:href="xfor-20211231.xsd#xfor_CambridgeMAOperatingLeaseArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:to="loc_xfor_CambridgeMAOperatingLeaseArrangementMember_ab5b3c6d-9050-4266-a28b-2b53524988f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_8a7d444f-f97e-4e6b-854d-dd613d5df92a" xlink:href="xfor-20211231.xsd#xfor_WalthamLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:to="loc_xfor_WalthamLeaseMember_8a7d444f-f97e-4e6b-854d-dd613d5df92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseArrangementMember_c0da83c4-0364-4b40-bb7b-ce67a34c8736" xlink:href="xfor-20211231.xsd#xfor_ViennaLeaseArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:to="loc_xfor_ViennaLeaseArrangementMember_c0da83c4-0364-4b40-bb7b-ce67a34c8736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember_d177f830-3d9f-4a4c-ac4d-04f062e6b8bd" xlink:href="xfor-20211231.xsd#xfor_AllstonLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3eec1a1c-ae10-4925-bdad-6575d6363af6" xlink:to="loc_xfor_AllstonLeaseMember_d177f830-3d9f-4a4c-ac4d-04f062e6b8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2fdd053f-d3d0-4bd3-88d6-fa55c7813cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:to="loc_us-gaap_CreditFacilityAxis_2fdd053f-d3d0-4bd3-88d6-fa55c7813cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_308b340e-e799-43bb-bd67-c9d74d1eabb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2fdd053f-d3d0-4bd3-88d6-fa55c7813cff" xlink:to="loc_us-gaap_CreditFacilityDomain_308b340e-e799-43bb-bd67-c9d74d1eabb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_6e42cd72-b311-4057-a393-e969cf097ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_308b340e-e799-43bb-bd67-c9d74d1eabb4" xlink:to="loc_us-gaap_LetterOfCreditMember_6e42cd72-b311-4057-a393-e969cf097ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d80114c5-9595-4bfa-9efe-d45aef55eb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d80114c5-9595-4bfa-9efe-d45aef55eb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_115531ce-4695-489a-a5ad-7f0bb8d61a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d80114c5-9595-4bfa-9efe-d45aef55eb55" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_115531ce-4695-489a-a5ad-7f0bb8d61a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_88287774-b76e-4ecc-8c07-c92f36f80ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_115531ce-4695-489a-a5ad-7f0bb8d61a83" xlink:to="loc_us-gaap_OtherAssetsMember_88287774-b76e-4ecc-8c07-c92f36f80ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0d58dd46-9f90-45ac-a1c2-90361312b290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_ece09ccf-08c5-4c34-8000-1692d74624d7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0d58dd46-9f90-45ac-a1c2-90361312b290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8052eaaf-8d99-4b7c-829a-ffd00962e21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0d58dd46-9f90-45ac-a1c2-90361312b290" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8052eaaf-8d99-4b7c-829a-ffd00962e21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_59d705c1-aa24-4ea8-b71f-b127ce02f186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0d58dd46-9f90-45ac-a1c2-90361312b290" xlink:to="loc_us-gaap_RestrictedCash_59d705c1-aa24-4ea8-b71f-b127ce02f186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ae1c6fc2-2c92-45b7-920f-4a89c84e996d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_0d58dd46-9f90-45ac-a1c2-90361312b290" xlink:to="loc_us-gaap_RestrictedCashCurrent_ae1c6fc2-2c92-45b7-920f-4a89c84e996d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_18de8697-e3ba-4ce2-a554-27209482e68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23f8138d-595c-4d77-9cc2-226f58609980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18de8697-e3ba-4ce2-a554-27209482e68a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23f8138d-595c-4d77-9cc2-226f58609980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f19f7171-ce30-4e23-b05d-ca9e67f739d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18de8697-e3ba-4ce2-a554-27209482e68a" xlink:to="loc_us-gaap_RestrictedCashCurrent_f19f7171-ce30-4e23-b05d-ca9e67f739d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2a7027e0-400b-465f-a949-db2d70c2c9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18de8697-e3ba-4ce2-a554-27209482e68a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2a7027e0-400b-465f-a949-db2d70c2c9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a0083686-41f0-447f-8546-dcd140d31efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18de8697-e3ba-4ce2-a554-27209482e68a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a0083686-41f0-447f-8546-dcd140d31efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0fff8de2-9977-4638-a42a-636512bdb3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a62cf655-dddd-4266-887d-23e4f27891e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0fff8de2-9977-4638-a42a-636512bdb3af" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a62cf655-dddd-4266-887d-23e4f27891e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3426a689-3926-4cff-9a99-bede41b3eaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a62cf655-dddd-4266-887d-23e4f27891e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3426a689-3926-4cff-9a99-bede41b3eaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3426a689-3926-4cff-9a99-bede41b3eaf0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_fa67839b-25c0-4521-ad8a-c92e39f7c509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_fa67839b-25c0-4521-ad8a-c92e39f7c509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_4db8072b-1b27-4bac-ad31-87a90cea8523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:to="loc_us-gaap_ComputerEquipmentMember_4db8072b-1b27-4bac-ad31-87a90cea8523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ac99c6ba-ed29-40c4-991a-8ccf435f4c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:to="loc_us-gaap_EquipmentMember_ac99c6ba-ed29-40c4-991a-8ccf435f4c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_dc82aad3-7054-4859-8b20-7ac11940b948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df021530-2f88-4374-9b9b-332e35083cc0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_dc82aad3-7054-4859-8b20-7ac11940b948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3b70856e-5879-4bc1-a684-a81cff695e99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a62cf655-dddd-4266-887d-23e4f27891e4" xlink:to="loc_srt_RangeAxis_3b70856e-5879-4bc1-a684-a81cff695e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b763a80-e34e-442b-a70d-d7b6da6f8a26" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3b70856e-5879-4bc1-a684-a81cff695e99" xlink:to="loc_srt_RangeMember_3b763a80-e34e-442b-a70d-d7b6da6f8a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07916bfb-8228-4ba9-bc3c-67e6c7b9bfd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b763a80-e34e-442b-a70d-d7b6da6f8a26" xlink:to="loc_srt_MinimumMember_07916bfb-8228-4ba9-bc3c-67e6c7b9bfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b8409694-ae75-4b53-b618-04bce38e5f10" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b763a80-e34e-442b-a70d-d7b6da6f8a26" xlink:to="loc_srt_MaximumMember_b8409694-ae75-4b53-b618-04bce38e5f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03b46deb-6582-44f8-a399-044d672d56a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a62cf655-dddd-4266-887d-23e4f27891e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03b46deb-6582-44f8-a399-044d672d56a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4efc9565-7e03-4595-8671-a554b7cc49ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03b46deb-6582-44f8-a399-044d672d56a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4efc9565-7e03-4595-8671-a554b7cc49ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_59a5fc23-d537-47c0-a7e3-c480a3250162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_03b46deb-6582-44f8-a399-044d672d56a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_59a5fc23-d537-47c0-a7e3-c480a3250162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#SummaryofSignificantPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0cbbf3b9-f256-41b8-bcd4-c5b38f39a95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_93ff7f98-89a9-4bd0-b50d-013b70c29200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0cbbf3b9-f256-41b8-bcd4-c5b38f39a95b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_93ff7f98-89a9-4bd0-b50d-013b70c29200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_caae7eb5-bfce-4a2e-974f-88ea27c1f3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0cbbf3b9-f256-41b8-bcd4-c5b38f39a95b" xlink:to="loc_us-gaap_NumberOfReportingUnits_caae7eb5-bfce-4a2e-974f-88ea27c1f3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70f2fd94-60f1-4219-847a-1d5e626144b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0cbbf3b9-f256-41b8-bcd4-c5b38f39a95b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70f2fd94-60f1-4219-847a-1d5e626144b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreements"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7e4a6549-63a9-4acf-a24f-f8fab8f844d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ba3aa953-5a5c-4324-b052-7cd6e7ea6d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7e4a6549-63a9-4acf-a24f-f8fab8f844d8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ba3aa953-5a5c-4324-b052-7cd6e7ea6d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d2743ac8-c99b-4a83-afdf-d231b406db68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a82fe365-eefa-4df1-bf9f-33ee279f4f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d2743ac8-c99b-4a83-afdf-d231b406db68" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a82fe365-eefa-4df1-bf9f-33ee279f4f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0e546dfa-fd99-4f80-b864-878709dc11d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a82fe365-eefa-4df1-bf9f-33ee279f4f89" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0e546dfa-fd99-4f80-b864-878709dc11d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a40f9f3-a3d9-4820-9ba1-b9f2e2a75c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0e546dfa-fd99-4f80-b864-878709dc11d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a40f9f3-a3d9-4820-9ba1-b9f2e2a75c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GenzymeAgreementMember_df51cffb-41c8-49f5-b4db-019d42d1daf6" xlink:href="xfor-20211231.xsd#xfor_GenzymeAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a40f9f3-a3d9-4820-9ba1-b9f2e2a75c33" xlink:to="loc_xfor_GenzymeAgreementMember_df51cffb-41c8-49f5-b4db-019d42d1daf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636c84f2-62f3-40c9-a3f7-db4316063c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a82fe365-eefa-4df1-bf9f-33ee279f4f89" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636c84f2-62f3-40c9-a3f7-db4316063c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestonePayments_4e5b3b12-cdac-4d2b-b7d8-3fc1f68196e9" xlink:href="xfor-20211231.xsd#xfor_MilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636c84f2-62f3-40c9-a3f7-db4316063c38" xlink:to="loc_xfor_MilestonePayments_4e5b3b12-cdac-4d2b-b7d8-3fc1f68196e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PaymentOnObligationUnderLicenseAgreement_ddc69302-3233-438c-abe5-168e9211756b" xlink:href="xfor-20211231.xsd#xfor_PaymentOnObligationUnderLicenseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636c84f2-62f3-40c9-a3f7-db4316063c38" xlink:to="loc_xfor_PaymentOnObligationUnderLicenseAgreement_ddc69302-3233-438c-abe5-168e9211756b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_51e19f61-7cf9-4da6-895e-8ba456848a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_261d4aff-b361-4aca-b8d9-3f81bdcfb736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_51e19f61-7cf9-4da6-895e-8ba456848a7b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_261d4aff-b361-4aca-b8d9-3f81bdcfb736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_89808cb8-1e30-4b22-a28a-601b3b774876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_261d4aff-b361-4aca-b8d9-3f81bdcfb736" xlink:to="loc_us-gaap_TypeOfArrangementAxis_89808cb8-1e30-4b22-a28a-601b3b774876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37d5a6cf-b17e-4256-8832-82e4fed26a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89808cb8-1e30-4b22-a28a-601b3b774876" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37d5a6cf-b17e-4256-8832-82e4fed26a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GeorgetownMember_c4fd650f-255c-43d1-bc81-e4a690dbb36f" xlink:href="xfor-20211231.xsd#xfor_GeorgetownMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37d5a6cf-b17e-4256-8832-82e4fed26a14" xlink:to="loc_xfor_GeorgetownMember_c4fd650f-255c-43d1-bc81-e4a690dbb36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_261d4aff-b361-4aca-b8d9-3f81bdcfb736" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OneTimeUpfrontPayment_5579fb9a-afe7-4eae-ae4b-bea4bdf2d7cc" xlink:href="xfor-20211231.xsd#xfor_OneTimeUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_xfor_OneTimeUpfrontPayment_5579fb9a-afe7-4eae-ae4b-bea4bdf2d7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestonePaymentsPaid_c1b5d653-d475-4d30-86d3-d3549eacfeb0" xlink:href="xfor-20211231.xsd#xfor_MilestonePaymentsPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_xfor_MilestonePaymentsPaid_c1b5d653-d475-4d30-86d3-d3549eacfeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestoneContractTerminationPeriod_0cf9c00f-1d44-47e1-9444-3918e133a1d7" xlink:href="xfor-20211231.xsd#xfor_MilestoneContractTerminationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_xfor_MilestoneContractTerminationPeriod_0cf9c00f-1d44-47e1-9444-3918e133a1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PaymentOnObligationUnderLicenseAgreement_65486f6d-482a-4c3f-a6d4-9a6d83007ff3" xlink:href="xfor-20211231.xsd#xfor_PaymentOnObligationUnderLicenseAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_xfor_PaymentOnObligationUnderLicenseAgreement_65486f6d-482a-4c3f-a6d4-9a6d83007ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MilestonePaymentObligation_5c158da2-b6e5-44ff-a66d-d871f98b5f75" xlink:href="xfor-20211231.xsd#xfor_MilestonePaymentObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a283f773-e688-4784-b70c-56c94d0e5fcd" xlink:to="loc_xfor_MilestonePaymentObligation_5c158da2-b6e5-44ff-a66d-d871f98b5f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cfbd53ae-c165-4a2f-bf92-3ecee7851021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b0f04744-20ba-44db-93a9-e074cb23be81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cfbd53ae-c165-4a2f-bf92-3ecee7851021" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b0f04744-20ba-44db-93a9-e074cb23be81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cc1dbd7f-512d-4082-b0e2-3d6a63570ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b0f04744-20ba-44db-93a9-e074cb23be81" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cc1dbd7f-512d-4082-b0e2-3d6a63570ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc97419c-b2b7-49a5-96b8-1ba585237490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cc1dbd7f-512d-4082-b0e2-3d6a63570ead" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc97419c-b2b7-49a5-96b8-1ba585237490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_BidmcAgreementMember_6b6fc62a-dc2a-4d25-88b6-b97a8533ee98" xlink:href="xfor-20211231.xsd#xfor_BidmcAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc97419c-b2b7-49a5-96b8-1ba585237490" xlink:to="loc_xfor_BidmcAgreementMember_6b6fc62a-dc2a-4d25-88b6-b97a8533ee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DFCIMember_708dca46-da3f-40c0-bd26-68f14f0954a1" xlink:href="xfor-20211231.xsd#xfor_DFCIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc97419c-b2b7-49a5-96b8-1ba585237490" xlink:to="loc_xfor_DFCIMember_708dca46-da3f-40c0-bd26-68f14f0954a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b0f04744-20ba-44db-93a9-e074cb23be81" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OneTimeUpfrontPayment_98435e8e-2034-438e-9937-47a5105f19d5" xlink:href="xfor-20211231.xsd#xfor_OneTimeUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_OneTimeUpfrontPayment_98435e8e-2034-438e-9937-47a5105f19d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PaymentOnObligationUnderLicenseAgreement_4952e2cb-b1bc-4d53-9d9f-661ac90e4dd3" xlink:href="xfor-20211231.xsd#xfor_PaymentOnObligationUnderLicenseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_PaymentOnObligationUnderLicenseAgreement_4952e2cb-b1bc-4d53-9d9f-661ac90e4dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementExpenseReimbursement_257870b1-b832-444a-a741-942267dec71d" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementExpenseReimbursement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_CollaborativeAgreementExpenseReimbursement_257870b1-b832-444a-a741-942267dec71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeArrangementObligationPercentage_e84175db-34f1-4098-97be-3d812169f81d" xlink:href="xfor-20211231.xsd#xfor_CollaborativeArrangementObligationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_CollaborativeArrangementObligationPercentage_e84175db-34f1-4098-97be-3d812169f81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree_12ceb433-4234-4878-90bb-f9feeecd184a" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree_12ceb433-4234-4878-90bb-f9feeecd184a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix_8a60f3a1-f04f-4735-b831-b7896350617d" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix_8a60f3a1-f04f-4735-b831-b7896350617d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter_d7e4f659-67e2-4b31-b6ce-18158c55189a" xlink:href="xfor-20211231.xsd#xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e06c1967-72af-4c7c-8350-94df3930850f" xlink:to="loc_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter_d7e4f659-67e2-4b31-b6ce-18158c55189a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1081d160-db9d-473c-b172-a03f21784b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cdbf029c-1594-4376-a28d-51f4741baaac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1081d160-db9d-473c-b172-a03f21784b0d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cdbf029c-1594-4376-a28d-51f4741baaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d1477f87-57e8-4c53-8735-9802804d1f00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cdbf029c-1594-4376-a28d-51f4741baaac" xlink:to="loc_srt_StatementGeographicalAxis_d1477f87-57e8-4c53-8735-9802804d1f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_42ab98be-d7fb-411b-97cd-d8bbe1b5fcfc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d1477f87-57e8-4c53-8735-9802804d1f00" xlink:to="loc_srt_SegmentGeographicalDomain_42ab98be-d7fb-411b-97cd-d8bbe1b5fcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MTSAustriaMember_f32a0dcd-444c-4b27-89d4-eeb67e4fa9bd" xlink:href="xfor-20211231.xsd#xfor_MTSAustriaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_42ab98be-d7fb-411b-97cd-d8bbe1b5fcfc" xlink:to="loc_xfor_MTSAustriaMember_f32a0dcd-444c-4b27-89d4-eeb67e4fa9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5e7bbe2b-4e88-472f-9cdf-e15177827c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cdbf029c-1594-4376-a28d-51f4741baaac" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5e7bbe2b-4e88-472f-9cdf-e15177827c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da7fb883-abe4-4c27-b819-5c891a7a65d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e7bbe2b-4e88-472f-9cdf-e15177827c2e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da7fb883-abe4-4c27-b819-5c891a7a65d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_5f999378-af9e-4059-b5ed-0bc69878ed9b" xlink:href="xfor-20211231.xsd#xfor_ResearchAndDevelopmentIncentiveProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da7fb883-abe4-4c27-b819-5c891a7a65d6" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_5f999378-af9e-4059-b5ed-0bc69878ed9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AbbiskoAgreementMember_92775ba4-5d3a-4f4c-a29a-3cea5ec547da" xlink:href="xfor-20211231.xsd#xfor_AbbiskoAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da7fb883-abe4-4c27-b819-5c891a7a65d6" xlink:to="loc_xfor_AbbiskoAgreementMember_92775ba4-5d3a-4f4c-a29a-3cea5ec547da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cdbf029c-1594-4376-a28d-51f4741baaac" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ReimbursementRateForResearchAndDevelopment_7fbded35-d22e-43d6-b487-cb2d38970d1a" xlink:href="xfor-20211231.xsd#xfor_ReimbursementRateForResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:to="loc_xfor_ReimbursementRateForResearchAndDevelopment_7fbded35-d22e-43d6-b487-cb2d38970d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GrantAndIncentiveReceivables_0727b392-cdae-473a-823f-3d84ac6e819c" xlink:href="xfor-20211231.xsd#xfor_GrantAndIncentiveReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:to="loc_xfor_GrantAndIncentiveReceivables_0727b392-cdae-473a-823f-3d84ac6e819c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c7103efc-c91c-4518-8e37-eb9e5a250857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c7103efc-c91c-4518-8e37-eb9e5a250857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PotentialMilestonePaymentsReceivable_75416546-4ed6-49c3-9a58-14e99ef66eb5" xlink:href="xfor-20211231.xsd#xfor_PotentialMilestonePaymentsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_737b2bb5-2306-43c1-8279-41ff765d9b75" xlink:to="loc_xfor_PotentialMilestonePaymentsReceivable_75416546-4ed6-49c3-9a58-14e99ef66eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LicenseCollaborationandFundingAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12561297-6c76-4d64-96cd-9c0ca43b524b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9e5f266-9407-43a0-a703-1a820cfab15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12561297-6c76-4d64-96cd-9c0ca43b524b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9e5f266-9407-43a0-a703-1a820cfab15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ae208880-ea42-4640-b2f0-919ebcb33144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9e5f266-9407-43a0-a703-1a820cfab15c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ae208880-ea42-4640-b2f0-919ebcb33144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c739bc8d-8620-4f1e-93d6-f9d00460c64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ae208880-ea42-4640-b2f0-919ebcb33144" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c739bc8d-8620-4f1e-93d6-f9d00460c64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AbbiskoAgreementMember_ee7cd8a7-c389-46d5-9d15-82abf04b3ceb" xlink:href="xfor-20211231.xsd#xfor_AbbiskoAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c739bc8d-8620-4f1e-93d6-f9d00460c64b" xlink:to="loc_xfor_AbbiskoAgreementMember_ee7cd8a7-c389-46d5-9d15-82abf04b3ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23c06d5f-648e-4461-909d-d566324da2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9e5f266-9407-43a0-a703-1a820cfab15c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23c06d5f-648e-4461-909d-d566324da2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PotentialMilestonePaymentsReceivable_dc3774e1-e2bd-4af1-9b90-b620efaad981" xlink:href="xfor-20211231.xsd#xfor_PotentialMilestonePaymentsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23c06d5f-648e-4461-909d-d566324da2cc" xlink:to="loc_xfor_PotentialMilestonePaymentsReceivable_dc3774e1-e2bd-4af1-9b90-b620efaad981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ad40e709-257b-4107-8bc1-eab57329db56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23c06d5f-648e-4461-909d-d566324da2cc" xlink:to="loc_us-gaap_Revenues_ad40e709-257b-4107-8bc1-eab57329db56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities" xlink:type="simple" xlink:href="xfor-20211231.xsd#FairValueofFinancialAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1258256b-eeec-4160-b267-2588d460f725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d9a90031-707a-43e5-9859-fd23c28067f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1258256b-eeec-4160-b267-2588d460f725" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d9a90031-707a-43e5-9859-fd23c28067f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="xfor-20211231.xsd#FairValueofFinancialAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d99155c4-3678-4226-8b2c-d7473530eefe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_52e85fe0-9ecf-4efa-bd57-b2684a7fea27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d99155c4-3678-4226-8b2c-d7473530eefe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_52e85fe0-9ecf-4efa-bd57-b2684a7fea27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_eb559744-af60-4023-9219-c98072a4e01b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d99155c4-3678-4226-8b2c-d7473530eefe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_eb559744-af60-4023-9219-c98072a4e01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_b5f15547-de48-41df-950c-55790d6fe912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d99155c4-3678-4226-8b2c-d7473530eefe" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_b5f15547-de48-41df-950c-55790d6fe912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_47240385-4344-4ece-a5fb-bff84e74247b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_47240385-4344-4ece-a5fb-bff84e74247b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ea22823-67f1-465b-a77a-4a666c13d48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ea22823-67f1-465b-a77a-4a666c13d48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3e463d-892c-498d-86b4-f3e1e0a47780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ea22823-67f1-465b-a77a-4a666c13d48a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3e463d-892c-498d-86b4-f3e1e0a47780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cb6d7cd9-396d-4f48-9517-82b989625327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3e463d-892c-498d-86b4-f3e1e0a47780" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cb6d7cd9-396d-4f48-9517-82b989625327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_93e0b32c-2a55-45de-a326-4517554abc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3e463d-892c-498d-86b4-f3e1e0a47780" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_93e0b32c-2a55-45de-a326-4517554abc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_73674737-f4fd-4ac6-bb3d-b90f9a784022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3e463d-892c-498d-86b4-f3e1e0a47780" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_73674737-f4fd-4ac6-bb3d-b90f9a784022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_447d094e-0469-4627-bb0e-1607e5ffd1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_447d094e-0469-4627-bb0e-1607e5ffd1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_efe7888b-b83f-4f78-a3e1-78f8fb693af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_447d094e-0469-4627-bb0e-1607e5ffd1ea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_efe7888b-b83f-4f78-a3e1-78f8fb693af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2495fbf5-bc37-4dbb-9ef5-062d83c88370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_efe7888b-b83f-4f78-a3e1-78f8fb693af5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2495fbf5-bc37-4dbb-9ef5-062d83c88370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_f7c88a27-d3f6-4f57-949c-426b2de1a7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_f7c88a27-d3f6-4f57-949c-426b2de1a7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_17be7268-ae7b-4d4e-8c1b-eeca760214e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_f7c88a27-d3f6-4f57-949c-426b2de1a7f0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_17be7268-ae7b-4d4e-8c1b-eeca760214e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_3d5f73cd-4a77-4696-9d1d-839dda2ec8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_17be7268-ae7b-4d4e-8c1b-eeca760214e3" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_3d5f73cd-4a77-4696-9d1d-839dda2ec8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a3f3e95-86dc-4f34-a7e9-0dae3210ac10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f6d89191-b432-48e6-bee9-1db926467382" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a3f3e95-86dc-4f34-a7e9-0dae3210ac10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_30a35c06-ceac-4531-8519-2c0654751b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a3f3e95-86dc-4f34-a7e9-0dae3210ac10" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_30a35c06-ceac-4531-8519-2c0654751b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ca85fd75-a0cc-4d7f-af11-d4d650c4e7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a3f3e95-86dc-4f34-a7e9-0dae3210ac10" xlink:to="loc_us-gaap_DerivativeLiabilities_ca85fd75-a0cc-4d7f-af11-d4d650c4e7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d0ccb42b-6329-42e7-b602-92bc7fed2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a3f3e95-86dc-4f34-a7e9-0dae3210ac10" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d0ccb42b-6329-42e7-b602-92bc7fed2d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_56e776a1-43bc-460c-a5a3-e13844a1a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_490d94c2-11e3-40cd-851a-5228893d5e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_56e776a1-43bc-460c-a5a3-e13844a1a6e3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_490d94c2-11e3-40cd-851a-5228893d5e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29e37316-d85c-4b11-a03e-c3146b7ada08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_490d94c2-11e3-40cd-851a-5228893d5e93" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29e37316-d85c-4b11-a03e-c3146b7ada08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3fd25af4-d54f-4364-b9ed-ec75246e7bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29e37316-d85c-4b11-a03e-c3146b7ada08" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3fd25af4-d54f-4364-b9ed-ec75246e7bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_648fc1df-db99-431f-84d2-425b4ae47cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3fd25af4-d54f-4364-b9ed-ec75246e7bad" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_648fc1df-db99-431f-84d2-425b4ae47cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b44080e1-953d-4e8e-875e-a3de783131fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_490d94c2-11e3-40cd-851a-5228893d5e93" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b44080e1-953d-4e8e-875e-a3de783131fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6e33802c-12b8-47a6-8a20-34407cacca79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b44080e1-953d-4e8e-875e-a3de783131fa" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6e33802c-12b8-47a6-8a20-34407cacca79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_6a139b4c-fae3-42d9-abf3-ef0ef4537af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6e33802c-12b8-47a6-8a20-34407cacca79" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_6a139b4c-fae3-42d9-abf3-ef0ef4537af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f3dde4b7-7e9d-4faa-854c-3b3340f7c917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_490d94c2-11e3-40cd-851a-5228893d5e93" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f3dde4b7-7e9d-4faa-854c-3b3340f7c917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_556f362e-3950-4c47-975e-4737807eb90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f3dde4b7-7e9d-4faa-854c-3b3340f7c917" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_556f362e-3950-4c47-975e-4737807eb90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_227565a0-a196-4adc-a405-08cbb980f716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_556f362e-3950-4c47-975e-4737807eb90e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_227565a0-a196-4adc-a405-08cbb980f716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f0fe3a59-3591-4c3d-9330-ab223baa3da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_556f362e-3950-4c47-975e-4737807eb90e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f0fe3a59-3591-4c3d-9330-ab223baa3da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ebaf8f9-62c3-4f0e-a233-12353f6aaf22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_556f362e-3950-4c47-975e-4737807eb90e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ebaf8f9-62c3-4f0e-a233-12353f6aaf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3a7b91de-0fe3-4710-8a6f-7d170b0f5e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3a7b91de-0fe3-4710-8a6f-7d170b0f5e2e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_187dba2a-2c49-4a52-9799-00e03cdac58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_187dba2a-2c49-4a52-9799-00e03cdac58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4889f0ac-bd0c-4459-a282-ee8d6ce4cb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_187dba2a-2c49-4a52-9799-00e03cdac58d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4889f0ac-bd0c-4459-a282-ee8d6ce4cb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GenzymeAgreementMember_e707b5c6-5029-4232-8966-6a9c3f4d9ce4" xlink:href="xfor-20211231.xsd#xfor_GenzymeAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4889f0ac-bd0c-4459-a282-ee8d6ce4cb8e" xlink:to="loc_xfor_GenzymeAgreementMember_e707b5c6-5029-4232-8966-6a9c3f4d9ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_833c124c-4b52-444d-854c-9486faaface2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_833c124c-4b52-444d-854c-9486faaface2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a06ec8b6-1a69-4142-a302-3e00819869a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_833c124c-4b52-444d-854c-9486faaface2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a06ec8b6-1a69-4142-a302-3e00819869a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ArsanisMember_5e871581-1833-4552-9e68-8f8c4d3ec80d" xlink:href="xfor-20211231.xsd#xfor_ArsanisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a06ec8b6-1a69-4142-a302-3e00819869a6" xlink:to="loc_xfor_ArsanisMember_5e871581-1833-4552-9e68-8f8c4d3ec80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddfcec38-2e76-4627-a798-dd5ccf32004b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddfcec38-2e76-4627-a798-dd5ccf32004b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4686c4c-5669-430f-9cc4-51d902258a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddfcec38-2e76-4627-a798-dd5ccf32004b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4686c4c-5669-430f-9cc4-51d902258a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_770fa1a9-eef2-4a70-9e3d-9f5cbfb0ea3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4686c4c-5669-430f-9cc4-51d902258a95" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_770fa1a9-eef2-4a70-9e3d-9f5cbfb0ea3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b65f0c2c-e658-470c-96b6-d5014bb1d6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b65f0c2c-e658-470c-96b6-d5014bb1d6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_29a48553-9cc1-4644-b09b-36ab6eb0815e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b65f0c2c-e658-470c-96b6-d5014bb1d6a9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_29a48553-9cc1-4644-b09b-36ab6eb0815e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_79bf11f8-11bd-4fba-a0d7-cb525f20575e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_29a48553-9cc1-4644-b09b-36ab6eb0815e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_79bf11f8-11bd-4fba-a0d7-cb525f20575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_7609f851-1aa1-4b8c-a746-30205578ff06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_7609f851-1aa1-4b8c-a746-30205578ff06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fdf1aa84-fae7-4884-add6-c9c5c0d2b7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_7609f851-1aa1-4b8c-a746-30205578ff06" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fdf1aa84-fae7-4884-add6-c9c5c0d2b7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_27c77db9-8a2b-407e-82fe-7e58d0799c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fdf1aa84-fae7-4884-add6-c9c5c0d2b7dc" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_27c77db9-8a2b-407e-82fe-7e58d0799c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28a0d255-6378-4612-af05-c6553e457207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_92ba9ddd-2a61-4b1e-b85f-96698efef22a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28a0d255-6378-4612-af05-c6553e457207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0caada76-100b-4f6f-acbd-95c7db6bf4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28a0d255-6378-4612-af05-c6553e457207" xlink:to="loc_us-gaap_DerivativeLiabilities_0caada76-100b-4f6f-acbd-95c7db6bf4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b215c698-7ce3-4a6c-84a9-92a302459e04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28a0d255-6378-4612-af05-c6553e457207" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b215c698-7ce3-4a6c-84a9-92a302459e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/GoodwillRollforwardDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#GoodwillRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/GoodwillRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d293ba77-7df4-4499-af7d-bb35132e356a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_84009b9c-b853-4759-93e6-8c1ad67a39ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d293ba77-7df4-4499-af7d-bb35132e356a" xlink:to="loc_us-gaap_GoodwillGross_84009b9c-b853-4759-93e6-8c1ad67a39ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6c129ac6-b208-485b-ae96-fec595fd4564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d293ba77-7df4-4499-af7d-bb35132e356a" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6c129ac6-b208-485b-ae96-fec595fd4564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_3e2ab0e1-e0eb-4d29-8a2f-7636bf70d052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d293ba77-7df4-4499-af7d-bb35132e356a" xlink:to="loc_us-gaap_GoodwillRollForward_3e2ab0e1-e0eb-4d29-8a2f-7636bf70d052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e8453628-031b-4cca-9769-30bbe1e13931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3e2ab0e1-e0eb-4d29-8a2f-7636bf70d052" xlink:to="loc_us-gaap_Goodwill_e8453628-031b-4cca-9769-30bbe1e13931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3f3ff6bc-31e1-43ec-a1a7-b3cc32ddb34c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3e2ab0e1-e0eb-4d29-8a2f-7636bf70d052" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3f3ff6bc-31e1-43ec-a1a7-b3cc32ddb34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ce0e7105-c138-476d-b3e0-70224ad3f694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3e2ab0e1-e0eb-4d29-8a2f-7636bf70d052" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ce0e7105-c138-476d-b3e0-70224ad3f694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ec9fa049-763a-493e-961b-8a26cbd721f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3e2ab0e1-e0eb-4d29-8a2f-7636bf70d052" xlink:to="loc_us-gaap_Goodwill_ec9fa049-763a-493e-961b-8a26cbd721f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="xfor-20211231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_95206663-df21-4aaa-8947-40afe7891468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a2865a7f-ea28-4201-96d0-8dfba7bae66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_95206663-df21-4aaa-8947-40afe7891468" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a2865a7f-ea28-4201-96d0-8dfba7bae66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="xfor-20211231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_89cdb433-ce84-4d1c-8532-19f794f9f01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e14c312e-a710-4921-91de-d688140afca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_89cdb433-ce84-4d1c-8532-19f794f9f01c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e14c312e-a710-4921-91de-d688140afca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_50431632-8378-47f9-8e11-0d2e6d95a3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f14cb998-3a59-43d7-9ee8-5ebb372bd37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_50431632-8378-47f9-8e11-0d2e6d95a3bc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f14cb998-3a59-43d7-9ee8-5ebb372bd37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8990a0d-461d-4696-8dc3-2f322614fbce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f14cb998-3a59-43d7-9ee8-5ebb372bd37b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8990a0d-461d-4696-8dc3-2f322614fbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8990a0d-461d-4696-8dc3-2f322614fbce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7a1b3611-5845-4c97-9996-0cfbe9e2f111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7a1b3611-5845-4c97-9996-0cfbe9e2f111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1589883e-37fa-4cd8-b173-ccf97fa2d57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1589883e-37fa-4cd8-b173-ccf97fa2d57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3a8adf40-d11a-46f9-ab94-25960334f1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:to="loc_us-gaap_ComputerEquipmentMember_3a8adf40-d11a-46f9-ab94-25960334f1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SoftwareMember_af17b303-da48-464b-a3a3-534a4ceceebb" xlink:href="xfor-20211231.xsd#xfor_SoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:to="loc_xfor_SoftwareMember_af17b303-da48-464b-a3a3-534a4ceceebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LabEquipmentMember_acf0393f-f5f4-46db-a174-71cf7b6ae628" xlink:href="xfor-20211231.xsd#xfor_LabEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4764130a-42d9-4faf-9c2d-4beca4ad3673" xlink:to="loc_xfor_LabEquipmentMember_acf0393f-f5f4-46db-a174-71cf7b6ae628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f14cb998-3a59-43d7-9ee8-5ebb372bd37b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_601dc1c6-12d7-4be2-b30f-edbbadde5232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_601dc1c6-12d7-4be2-b30f-edbbadde5232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ecc34a04-9605-473e-aee4-b3fb93bd7e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ecc34a04-9605-473e-aee4-b3fb93bd7e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f35737d1-e96b-436d-8b5d-66ff91b1aec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f35737d1-e96b-436d-8b5d-66ff91b1aec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1a6140c9-7d20-4ccc-abb5-7720d8715ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b50f5519-36a3-436b-bb30-c3ea8d67e833" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1a6140c9-7d20-4ccc-abb5-7720d8715ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpenses" xlink:type="simple" xlink:href="xfor-20211231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1facd41b-cf95-4c72-9571-6f53dccab88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExpensesTextBlock_704f5b67-ca3c-4d85-b905-9323f31c196d" xlink:href="xfor-20211231.xsd#xfor_AccruedExpensesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1facd41b-cf95-4c72-9571-6f53dccab88c" xlink:to="loc_xfor_AccruedExpensesTextBlock_704f5b67-ca3c-4d85-b905-9323f31c196d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="xfor-20211231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_eaa91a4c-07c9-40b1-a55c-392bc9cddcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9dd9befe-5005-4edb-b1e7-25a16f8b4963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_eaa91a4c-07c9-40b1-a55c-392bc9cddcf3" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9dd9befe-5005-4edb-b1e7-25a16f8b4963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_dd7d2f0e-e82d-4006-804d-130c614d99f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ec1ca639-5cd5-4748-9c58-d68ecc5cd939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dd7d2f0e-e82d-4006-804d-130c614d99f5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ec1ca639-5cd5-4748-9c58-d68ecc5cd939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_a2f8a56b-1cae-4bde-96f2-df6d7e37656d" xlink:href="xfor-20211231.xsd#xfor_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dd7d2f0e-e82d-4006-804d-130c614d99f5" xlink:to="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_a2f8a56b-1cae-4bde-96f2-df6d7e37656d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_fb8998c6-6f93-4430-b010-40ab628cf16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dd7d2f0e-e82d-4006-804d-130c614d99f5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_fb8998c6-6f93-4430-b010-40ab628cf16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_daf6f52d-68a8-4c83-97ba-31deeaeb8965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dd7d2f0e-e82d-4006-804d-130c614d99f5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_daf6f52d-68a8-4c83-97ba-31deeaeb8965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f7fd7cba-c1d3-456a-a067-9d4fc172d87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dd7d2f0e-e82d-4006-804d-130c614d99f5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f7fd7cba-c1d3-456a-a067-9d4fc172d87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebt" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0ef706e1-1898-4f65-b46f-e0fce1bed86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_57539fa9-690e-4971-8060-5662da514c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0ef706e1-1898-4f65-b46f-e0fce1bed86c" xlink:to="loc_us-gaap_LongTermDebtTextBlock_57539fa9-690e-4971-8060-5662da514c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6fbde6ce-1521-4dcf-b3ed-e2d096fe3063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_7c8bb914-ffa6-4f7a-beb1-81d75f63368d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6fbde6ce-1521-4dcf-b3ed-e2d096fe3063" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_7c8bb914-ffa6-4f7a-beb1-81d75f63368d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_97cc3d4f-1249-410f-9e0b-93d7ffbb301f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6fbde6ce-1521-4dcf-b3ed-e2d096fe3063" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_97cc3d4f-1249-410f-9e0b-93d7ffbb301f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a31f5b2f-0e3e-4a6a-abf0-0e7e35cf77fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_60012b85-1637-4410-8318-87bb30eaf427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a31f5b2f-0e3e-4a6a-abf0-0e7e35cf77fb" xlink:to="loc_us-gaap_LongTermDebt_60012b85-1637-4410-8318-87bb30eaf427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccretionOnLongTermDebt_75bd4209-df53-4bd7-903e-187d19e33299" xlink:href="xfor-20211231.xsd#xfor_AccretionOnLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a31f5b2f-0e3e-4a6a-abf0-0e7e35cf77fb" xlink:to="loc_xfor_AccretionOnLongTermDebt_75bd4209-df53-4bd7-903e-187d19e33299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtIncludingAccretion_f36101b3-acdc-4ba7-b336-ec7849fb8eff" xlink:href="xfor-20211231.xsd#xfor_LongTermDebtIncludingAccretion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a31f5b2f-0e3e-4a6a-abf0-0e7e35cf77fb" xlink:to="loc_xfor_LongTermDebtIncludingAccretion_f36101b3-acdc-4ba7-b336-ec7849fb8eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_76085150-19c8-47f2-81c0-0d9202a04110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a31f5b2f-0e3e-4a6a-abf0-0e7e35cf77fb" xlink:to="loc_us-gaap_LongTermDebtCurrent_76085150-19c8-47f2-81c0-0d9202a04110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3da838e1-c816-4f45-8c2c-68c33ca8cf54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a31f5b2f-0e3e-4a6a-abf0-0e7e35cf77fb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3da838e1-c816-4f45-8c2c-68c33ca8cf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_de5681c4-fb22-4535-8c70-8fdb5740f55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a31f5b2f-0e3e-4a6a-abf0-0e7e35cf77fb" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_de5681c4-fb22-4535-8c70-8fdb5740f55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebtSVBLoanAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0d98aaef-6df4-4d5f-9600-9b9d198a48ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_6628a9f4-e040-4446-94ae-5ac37154a763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d98aaef-6df4-4d5f-9600-9b9d198a48ed" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_6628a9f4-e040-4446-94ae-5ac37154a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_220fa1dc-ac78-4abc-8b6c-2a423e05aa5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6628a9f4-e040-4446-94ae-5ac37154a763" xlink:to="loc_srt_RangeAxis_220fa1dc-ac78-4abc-8b6c-2a423e05aa5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_119be255-5419-4427-987e-a9349a4aca99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_220fa1dc-ac78-4abc-8b6c-2a423e05aa5a" xlink:to="loc_srt_RangeMember_119be255-5419-4427-987e-a9349a4aca99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c57e24d4-0c03-41d1-a399-222e5b6399d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_119be255-5419-4427-987e-a9349a4aca99" xlink:to="loc_srt_MinimumMember_c57e24d4-0c03-41d1-a399-222e5b6399d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6628a9f4-e040-4446-94ae-5ac37154a763" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_133d9846-07d9-4f68-87d3-1d1be4a3619d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_133d9846-07d9-4f68-87d3-1d1be4a3619d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8d515a48-2784-4b62-83ed-17b66f5119cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8d515a48-2784-4b62-83ed-17b66f5119cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_90d8444c-3fa6-4c94-a9c9-4a8a59f257ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:to="loc_us-gaap_InterestExpenseDebt_90d8444c-3fa6-4c94-a9c9-4a8a59f257ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0a0f142c-de6b-48e4-bbb0-c1169ab62fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_74be73fa-3542-48d3-970d-91c53ebd1f09" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0a0f142c-de6b-48e4-bbb0-c1169ab62fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebtFFGLoanAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8baa855d-02c0-440c-b234-f9277dc93c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_9e84818d-5ccc-459f-8bbc-bb559707ba5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8baa855d-02c0-440c-b234-f9277dc93c81" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_9e84818d-5ccc-459f-8bbc-bb559707ba5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb34a8cb-d015-4b0d-81f2-3b189a43c4b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e84818d-5ccc-459f-8bbc-bb559707ba5f" xlink:to="loc_srt_RangeAxis_eb34a8cb-d015-4b0d-81f2-3b189a43c4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_72411256-da84-4b9f-ac5e-8023d101bb4d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eb34a8cb-d015-4b0d-81f2-3b189a43c4b7" xlink:to="loc_srt_RangeMember_72411256-da84-4b9f-ac5e-8023d101bb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_99645e6c-d84c-40e3-b8bb-94e9b2866a59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_72411256-da84-4b9f-ac5e-8023d101bb4d" xlink:to="loc_srt_MinimumMember_99645e6c-d84c-40e3-b8bb-94e9b2866a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_047040b8-c1fa-4c43-82e2-dc5a403aa866" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_72411256-da84-4b9f-ac5e-8023d101bb4d" xlink:to="loc_srt_MaximumMember_047040b8-c1fa-4c43-82e2-dc5a403aa866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_dc2af557-2488-4af0-99d2-17b9081e8649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e84818d-5ccc-459f-8bbc-bb559707ba5f" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_dc2af557-2488-4af0-99d2-17b9081e8649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_081dc3b7-1416-4216-a087-f91976a2925a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_dc2af557-2488-4af0-99d2-17b9081e8649" xlink:to="loc_us-gaap_InterestExpenseDebt_081dc3b7-1416-4216-a087-f91976a2925a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2ab3aef0-536b-4a3a-9290-4f626c07734f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_dc2af557-2488-4af0-99d2-17b9081e8649" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2ab3aef0-536b-4a3a-9290-4f626c07734f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebtHerculesLoanAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5f34e95c-e810-43a1-8c41-025a82bffc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f34e95c-e810-43a1-8c41-025a82bffc7a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_83c12156-63d6-4652-b51f-14e63955550c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_us-gaap_DebtInstrumentAxis_83c12156-63d6-4652-b51f-14e63955550c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_83c12156-63d6-4652-b51f-14e63955550c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesAmendedAndRestatedLoanAgreementMember_432126c3-2663-4bb5-98bd-1d4e7e8c1b4d" xlink:href="xfor-20211231.xsd#xfor_HerculesAmendedAndRestatedLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:to="loc_xfor_HerculesAmendedAndRestatedLoanAgreementMember_432126c3-2663-4bb5-98bd-1d4e7e8c1b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesFirstAmendedLoanAgreementMember_59893045-fdd1-42b5-af0d-708f917d72e6" xlink:href="xfor-20211231.xsd#xfor_HerculesFirstAmendedLoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:to="loc_xfor_HerculesFirstAmendedLoanAgreementMember_59893045-fdd1-42b5-af0d-708f917d72e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesSecondAmendedLoanAgreementMember_739cbde8-5eec-4b42-8722-241d20b53db9" xlink:href="xfor-20211231.xsd#xfor_HerculesSecondAmendedLoanAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:to="loc_xfor_HerculesSecondAmendedLoanAgreementMember_739cbde8-5eec-4b42-8722-241d20b53db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember_891ebaba-8961-4b53-995f-80d1598ec269" xlink:href="xfor-20211231.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e6b5c1-5c3e-4fdd-8e2f-492caf1eb354" xlink:to="loc_xfor_HerculesLoanAgreementMember_891ebaba-8961-4b53-995f-80d1598ec269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_bff58660-fad0-4b97-9821-2085d3be513d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_us-gaap_CreditFacilityAxis_bff58660-fad0-4b97-9821-2085d3be513d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1a7401a3-ff65-457b-8a3c-7cc0b8754027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_bff58660-fad0-4b97-9821-2085d3be513d" xlink:to="loc_us-gaap_CreditFacilityDomain_1a7401a3-ff65-457b-8a3c-7cc0b8754027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DiscretionaryBorrowingsMember_174dc353-1c71-41f8-b031-1b508877ccb2" xlink:href="xfor-20211231.xsd#xfor_DiscretionaryBorrowingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1a7401a3-ff65-457b-8a3c-7cc0b8754027" xlink:to="loc_xfor_DiscretionaryBorrowingsMember_174dc353-1c71-41f8-b031-1b508877ccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate1Member_e3d90a58-42fe-4426-95ab-61be9af1b805" xlink:href="xfor-20211231.xsd#xfor_MinCashTestDate1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1a7401a3-ff65-457b-8a3c-7cc0b8754027" xlink:to="loc_xfor_MinCashTestDate1Member_e3d90a58-42fe-4426-95ab-61be9af1b805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate2Member_f668ad72-2e6d-482a-b11b-7a704febaef7" xlink:href="xfor-20211231.xsd#xfor_MinCashTestDate2Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1a7401a3-ff65-457b-8a3c-7cc0b8754027" xlink:to="loc_xfor_MinCashTestDate2Member_f668ad72-2e6d-482a-b11b-7a704febaef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fb7833b7-d664-4629-b2c7-bf47ce7206a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_srt_RangeAxis_fb7833b7-d664-4629-b2c7-bf47ce7206a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca6f70e1-eda2-4b2f-a35a-0482d5fad29e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fb7833b7-d664-4629-b2c7-bf47ce7206a0" xlink:to="loc_srt_RangeMember_ca6f70e1-eda2-4b2f-a35a-0482d5fad29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_317a38e2-ec8f-4a10-805d-8a382617f8c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ca6f70e1-eda2-4b2f-a35a-0482d5fad29e" xlink:to="loc_srt_MinimumMember_317a38e2-ec8f-4a10-805d-8a382617f8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_980eb6be-c922-458a-a60c-e5a2df446d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_us-gaap_VariableRateAxis_980eb6be-c922-458a-a60c-e5a2df446d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6d02c144-c862-4c68-8e34-c6b246a7fb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_980eb6be-c922-458a-a60c-e5a2df446d03" xlink:to="loc_us-gaap_VariableRateDomain_6d02c144-c862-4c68-8e34-c6b246a7fb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_9a22ab5c-f91b-4530-b42d-15a9c2010930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6d02c144-c862-4c68-8e34-c6b246a7fb2b" xlink:to="loc_us-gaap_PrimeRateMember_9a22ab5c-f91b-4530-b42d-15a9c2010930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ad5402f4-47f2-451c-a3d2-7964c268ee2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_srt_StatementScenarioAxis_ad5402f4-47f2-451c-a3d2-7964c268ee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_17b01b4d-58ee-47c3-a62e-87b08ccb7898" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_ad5402f4-47f2-451c-a3d2-7964c268ee2d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_17b01b4d-58ee-47c3-a62e-87b08ccb7898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d95a7273-5959-4485-8429-2dfcc8271fc4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_17b01b4d-58ee-47c3-a62e-87b08ccb7898" xlink:to="loc_srt_ScenarioForecastMember_d95a7273-5959-4485-8429-2dfcc8271fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_8f9486c2-cfa4-4fda-8343-21e2bf38f184" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_8f7f1e3e-72e0-4410-9eb4-483ef24763c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_8f7f1e3e-72e0-4410-9eb4-483ef24763c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a3a91515-efed-4fc3-962d-5de1f40e2c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a3a91515-efed-4fc3-962d-5de1f40e2c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_e1f07b0d-4196-410d-8f57-6f6445fe2298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_e1f07b0d-4196-410d-8f57-6f6445fe2298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_effaf629-0cc2-4852-9141-c2da2cd51150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_effaf629-0cc2-4852-9141-c2da2cd51150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_61d90ffa-a03c-4be1-9d8d-d9846beddb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_61d90ffa-a03c-4be1-9d8d-d9846beddb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_13228b41-46c3-4090-988f-256c70b11f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_13228b41-46c3-4090-988f-256c70b11f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6de1ed92-039a-4520-8ecb-0bec93ee861f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6de1ed92-039a-4520-8ecb-0bec93ee861f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_6b9b24a7-0ebf-4e04-8344-e21561442e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_6b9b24a7-0ebf-4e04-8344-e21561442e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_0c6e98c9-52e8-416b-9888-d0eb0f5b00bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_0c6e98c9-52e8-416b-9888-d0eb0f5b00bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6069d1fc-8149-456d-a092-7cc091235e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6069d1fc-8149-456d-a092-7cc091235e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentPrePaymentPremiumPercentage_a503fd91-f4b2-4b9e-bff2-859322e69f55" xlink:href="xfor-20211231.xsd#xfor_DebtInstrumentPrePaymentPremiumPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_xfor_DebtInstrumentPrePaymentPremiumPercentage_a503fd91-f4b2-4b9e-bff2-859322e69f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_09a52b46-829b-4035-88cd-b270bbbac388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_09a52b46-829b-4035-88cd-b270bbbac388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_99089fac-3efe-4a93-b42b-5c50498e7499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_us-gaap_InterestExpenseDebt_99089fac-3efe-4a93-b42b-5c50498e7499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash_394c4327-e31a-497f-b7ae-e0d139de35c2" xlink:href="xfor-20211231.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7a450dec-0a54-4fe5-a6ca-beb7dba762f3" xlink:to="loc_xfor_LineOfCreditCovenantMinimumCash_394c4327-e31a-497f-b7ae-e0d139de35c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LongTermDebtFuturePrincipalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_35d10fa4-a9fa-4bd9-83ee-d4128201d54f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4567ad46-0f50-442f-a426-39b260cfe617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_35d10fa4-a9fa-4bd9-83ee-d4128201d54f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4567ad46-0f50-442f-a426-39b260cfe617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c497bd2-7278-41d6-94e9-4e513d72c472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_35d10fa4-a9fa-4bd9-83ee-d4128201d54f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c497bd2-7278-41d6-94e9-4e513d72c472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ed052c02-e0bc-427e-9a05-5ba3be3b61f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_35d10fa4-a9fa-4bd9-83ee-d4128201d54f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ed052c02-e0bc-427e-9a05-5ba3be3b61f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_65bbb410-924a-4afe-b160-5e55dde424ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_35d10fa4-a9fa-4bd9-83ee-d4128201d54f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_65bbb410-924a-4afe-b160-5e55dde424ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/Leases" xlink:type="simple" xlink:href="xfor-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_23e29941-b355-4aae-afca-0e5817fe098e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_e6fc47a2-b745-4b5f-97f6-44dd3a50c1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_23e29941-b355-4aae-afca-0e5817fe098e" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_e6fc47a2-b745-4b5f-97f6-44dd3a50c1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesTables" xlink:type="simple" xlink:href="xfor-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_56499319-7dfc-44c6-9113-9168116d6a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_db05aa8a-bafa-431f-aaec-ca951c2e9af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56499319-7dfc-44c6-9113-9168116d6a4b" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_db05aa8a-bafa-431f-aaec-ca951c2e9af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5e8dee9a-4b04-4752-bc99-b2f283f99277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56499319-7dfc-44c6-9113-9168116d6a4b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5e8dee9a-4b04-4752-bc99-b2f283f99277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3dcfd74a-a953-4de8-8ae4-51c83a4aa1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_e8db4e9e-f3bd-4492-8c45-509ce1c95b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dcfd74a-a953-4de8-8ae4-51c83a4aa1c2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_e8db4e9e-f3bd-4492-8c45-509ce1c95b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c12c5626-4ea6-414e-bcbc-61b0789b7b2c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e8db4e9e-f3bd-4492-8c45-509ce1c95b61" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c12c5626-4ea6-414e-bcbc-61b0789b7b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c12c5626-4ea6-414e-bcbc-61b0789b7b2c" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_db7a6584-cc1e-47ef-9a7e-189083be03e7" xlink:href="xfor-20211231.xsd#xfor_WalthamLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:to="loc_xfor_WalthamLeaseMember_db7a6584-cc1e-47ef-9a7e-189083be03e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseArrangementMember_628ae0f8-1558-4a62-9fc4-b66de1052e37" xlink:href="xfor-20211231.xsd#xfor_ViennaLeaseArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:to="loc_xfor_ViennaLeaseArrangementMember_628ae0f8-1558-4a62-9fc4-b66de1052e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember_d759bec1-e82a-44f9-9192-f10782aaf2a9" xlink:href="xfor-20211231.xsd#xfor_AllstonLeaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:to="loc_xfor_AllstonLeaseMember_d759bec1-e82a-44f9-9192-f10782aaf2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NewViennaLeaseMember_0db882bb-8391-453e-beaf-8cda83ba760c" xlink:href="xfor-20211231.xsd#xfor_NewViennaLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:to="loc_xfor_NewViennaLeaseMember_0db882bb-8391-453e-beaf-8cda83ba760c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CambridgeLeaseMember_061fedd5-d1e2-4d50-a25a-b359d640e0e1" xlink:href="xfor-20211231.xsd#xfor_CambridgeLeaseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ea41761e-0784-4a40-87e0-bda322d76e11" xlink:to="loc_xfor_CambridgeLeaseMember_061fedd5-d1e2-4d50-a25a-b359d640e0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e8db4e9e-f3bd-4492-8c45-509ce1c95b61" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_5bfba07e-7db8-4c08-9029-8a212ee39b1c" xlink:href="xfor-20211231.xsd#xfor_CurrentOfficeSpaceUnderLeaseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_5bfba07e-7db8-4c08-9029-8a212ee39b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e82fcfd9-086e-40c1-9c7d-46672dab565b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e82fcfd9-086e-40c1-9c7d-46672dab565b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3f5bf995-a19f-4143-b537-be2a4efad775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseLiability_3f5bf995-a19f-4143-b537-be2a4efad775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df9168d0-f268-4ff8-8b3e-9d660af9bd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df9168d0-f268-4ff8-8b3e-9d660af9bd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3685b040-d9f1-4339-ad92-6b726d440d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3685b040-d9f1-4339-ad92-6b726d440d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_1f9ea566-89dd-4591-bd7e-177272c2c106" xlink:href="xfor-20211231.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_1f9ea566-89dd-4591-bd7e-177272c2c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AggregateBaseRent_fed223de-8b83-455d-ab9a-0e8aa6d956ed" xlink:href="xfor-20211231.xsd#xfor_AggregateBaseRent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_AggregateBaseRent_fed223de-8b83-455d-ab9a-0e8aa6d956ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bff7d722-74ac-42bf-8621-487a15780616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bff7d722-74ac-42bf-8621-487a15780616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9569557f-9194-4941-b650-b71368c706e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9569557f-9194-4941-b650-b71368c706e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm_37b591d9-97fd-4119-9b9c-86201a0277f8" xlink:href="xfor-20211231.xsd#xfor_OperatingLeaseRightOfUseAssetAmortizationTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm_37b591d9-97fd-4119-9b9c-86201a0277f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseRentFreePeriod_4238dbb6-231a-4ebe-854e-e8f3361637bc" xlink:href="xfor-20211231.xsd#xfor_LesseeOperatingLeaseRentFreePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_LesseeOperatingLeaseRentFreePeriod_4238dbb6-231a-4ebe-854e-e8f3361637bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_d1476a25-3455-4651-900a-a26aea2b66a8" xlink:href="xfor-20211231.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_d1476a25-3455-4651-900a-a26aea2b66a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0f4dc432-cc9d-4b5b-8346-2b195906c47c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseCost_0f4dc432-cc9d-4b5b-8346-2b195906c47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3588d07e-9d5a-4ec8-b751-5b66d55a55cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_ShortTermLeaseCost_3588d07e-9d5a-4ec8-b751-5b66d55a55cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_127996f8-b360-43aa-b6d0-355f39b536bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_LeaseCost_127996f8-b360-43aa-b6d0-355f39b536bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1063c8f2-0e58-4845-8a05-60fd0d79fc91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeasePayments_1063c8f2-0e58-4845-8a05-60fd0d79fc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_51fc8350-e808-4bdb-a4d2-f2f741af43b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_51fc8350-e808-4bdb-a4d2-f2f741af43b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7a629c1d-3f1b-479d-8d10-7dd12023ccaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7a629c1d-3f1b-479d-8d10-7dd12023ccaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_32832aaf-7809-4021-be23-8ea82f0a181d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_32832aaf-7809-4021-be23-8ea82f0a181d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_764beef2-00a4-43df-80e0-72bbf725e2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c3d003ae-feb7-4f96-9fc7-f269843be5a4" xlink:to="loc_us-gaap_SubleaseIncome_764beef2-00a4-43df-80e0-72bbf725e2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LeasesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8ca220b8-700e-40d3-a4a3-50eff84b9b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_b2f80ce3-817a-4c9f-97dc-d09ba6cf5dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8ca220b8-700e-40d3-a4a3-50eff84b9b40" xlink:to="loc_us-gaap_LeaseCostAbstract_b2f80ce3-817a-4c9f-97dc-d09ba6cf5dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_39437ea0-70f1-461c-a213-6143ffa32498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_b2f80ce3-817a-4c9f-97dc-d09ba6cf5dc2" xlink:to="loc_us-gaap_OperatingLeaseCost_39437ea0-70f1-461c-a213-6143ffa32498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_a625516c-5631-4255-b48f-3da742a37680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_b2f80ce3-817a-4c9f-97dc-d09ba6cf5dc2" xlink:to="loc_us-gaap_ShortTermLeaseCost_a625516c-5631-4255-b48f-3da742a37680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_2583866a-b858-4711-826b-331a55e1b9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_b2f80ce3-817a-4c9f-97dc-d09ba6cf5dc2" xlink:to="loc_us-gaap_LeaseCost_2583866a-b858-4711-826b-331a55e1b9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LeaseCostAdditionalInformationAbstract_e44dabc8-cafd-4bcc-a9ff-e1c4f7f53e06" xlink:href="xfor-20211231.xsd#xfor_LeaseCostAdditionalInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8ca220b8-700e-40d3-a4a3-50eff84b9b40" xlink:to="loc_xfor_LeaseCostAdditionalInformationAbstract_e44dabc8-cafd-4bcc-a9ff-e1c4f7f53e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_7b1a8915-66cc-435e-9c7b-3d2ac2675dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_LeaseCostAdditionalInformationAbstract_e44dabc8-cafd-4bcc-a9ff-e1c4f7f53e06" xlink:to="loc_us-gaap_OperatingLeasePayments_7b1a8915-66cc-435e-9c7b-3d2ac2675dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7ad22d7e-b3b6-4a1a-b359-3476cc7677c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_LeaseCostAdditionalInformationAbstract_e44dabc8-cafd-4bcc-a9ff-e1c4f7f53e06" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7ad22d7e-b3b6-4a1a-b359-3476cc7677c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f4591adc-35c9-4732-926f-359e820c28f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_LeaseCostAdditionalInformationAbstract_e44dabc8-cafd-4bcc-a9ff-e1c4f7f53e06" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f4591adc-35c9-4732-926f-359e820c28f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_421aaff6-36d5-417c-8b6c-ea02c1727bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_LeaseCostAdditionalInformationAbstract_e44dabc8-cafd-4bcc-a9ff-e1c4f7f53e06" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_421aaff6-36d5-417c-8b6c-ea02c1727bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_94a6f8bc-fed4-4da0-b013-7c1b15ef132b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_LeaseCostAdditionalInformationAbstract_e44dabc8-cafd-4bcc-a9ff-e1c4f7f53e06" xlink:to="loc_us-gaap_SubleaseIncome_94a6f8bc-fed4-4da0-b013-7c1b15ef132b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="xfor-20211231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_38311eea-06d9-4246-90a9-940990b80871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7ae0794c-90b0-4779-8319-0b0be2062c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38311eea-06d9-4246-90a9-940990b80871" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7ae0794c-90b0-4779-8319-0b0be2062c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_702aa3eb-2680-4c3e-8ae2-b8fc71106225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38311eea-06d9-4246-90a9-940990b80871" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_702aa3eb-2680-4c3e-8ae2-b8fc71106225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2535de82-6965-4c9e-975c-1300a6d62e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38311eea-06d9-4246-90a9-940990b80871" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2535de82-6965-4c9e-975c-1300a6d62e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ae34b7eb-9eae-4283-8cc6-d19ef0495658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38311eea-06d9-4246-90a9-940990b80871" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ae34b7eb-9eae-4283-8cc6-d19ef0495658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4ccac9f2-8159-4422-a7e1-58af7e3ec75e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38311eea-06d9-4246-90a9-940990b80871" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4ccac9f2-8159-4422-a7e1-58af7e3ec75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f88956a-f048-4f5b-9e63-68f93eb865d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38311eea-06d9-4246-90a9-940990b80871" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f88956a-f048-4f5b-9e63-68f93eb865d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a31d9442-ec8a-40f1-bba9-e44ba308dc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38311eea-06d9-4246-90a9-940990b80871" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a31d9442-ec8a-40f1-bba9-e44ba308dc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bfde18fd-1166-438d-a084-b83ea61a4c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38311eea-06d9-4246-90a9-940990b80871" xlink:to="loc_us-gaap_OperatingLeaseLiability_bfde18fd-1166-438d-a084-b83ea61a4c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="xfor-20211231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="xfor-20211231.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f810398e-5291-4178-be7e-7389ab260882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e0e59150-065a-43fd-b547-7d971b7b8681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f810398e-5291-4178-be7e-7389ab260882" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e0e59150-065a-43fd-b547-7d971b7b8681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrants" xlink:type="simple" xlink:href="xfor-20211231.xsd#PreferredandCommonStockWarrants"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PreferredandCommonStockWarrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0fa53ab7-15b2-4f80-9b1b-632c9ce883e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_263db362-d960-4447-bd84-9648cc5eaf32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0fa53ab7-15b2-4f80-9b1b-632c9ce883e5" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_263db362-d960-4447-bd84-9648cc5eaf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsTables" xlink:type="simple" xlink:href="xfor-20211231.xsd#PreferredandCommonStockWarrantsTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_72a6d1dd-0a95-4bb1-aec3-a124a971082a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock_a66063cd-74d9-47c4-8bb2-50c4c45fc20d" xlink:href="xfor-20211231.xsd#xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_72a6d1dd-0a95-4bb1-aec3-a124a971082a" xlink:to="loc_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock_a66063cd-74d9-47c4-8bb2-50c4c45fc20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#PreferredandCommonStockWarrantsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f4d16312-f996-417f-804e-d7b31c73b31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f4d16312-f996-417f-804e-d7b31c73b31c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e627b3b-6c65-4de5-aac1-60d753af4781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e627b3b-6c65-4de5-aac1-60d753af4781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e017fe2c-4e4a-4624-a0ef-40284d6af6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e627b3b-6c65-4de5-aac1-60d753af4781" xlink:to="loc_us-gaap_EquityComponentDomain_e017fe2c-4e4a-4624-a0ef-40284d6af6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember_521847a6-82da-4aea-a55d-2146df363212" xlink:href="xfor-20211231.xsd#xfor_ClassAWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e017fe2c-4e4a-4624-a0ef-40284d6af6ff" xlink:to="loc_xfor_ClassAWarrantMember_521847a6-82da-4aea-a55d-2146df363212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassBWarrantsMember_f4a86c82-54e6-4f19-83a2-2de80d24e88c" xlink:href="xfor-20211231.xsd#xfor_ClassBWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e017fe2c-4e4a-4624-a0ef-40284d6af6ff" xlink:to="loc_xfor_ClassBWarrantsMember_f4a86c82-54e6-4f19-83a2-2de80d24e88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_4b444e88-ce82-455c-aa92-9e13d5c489a3" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e017fe2c-4e4a-4624-a0ef-40284d6af6ff" xlink:to="loc_xfor_PreFundedWarrantMember_4b444e88-ce82-455c-aa92-9e13d5c489a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_83a79147-93bb-4e28-8545-022516f1fa84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_83a79147-93bb-4e28-8545-022516f1fa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_83a79147-93bb-4e28-8545-022516f1fa84" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_69adc484-fd37-4841-87fa-a45fcc44afa0" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:to="loc_xfor_PreFundedWarrantMember_69adc484-fd37-4841-87fa-a45fcc44afa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_a55fac80-ccd1-49ad-8c57-baec9fd582f0" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_a55fac80-ccd1-49ad-8c57-baec9fd582f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member_6cf25f09-5abb-43d5-8c4f-31c39e6fd0da" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:to="loc_xfor_IssuanceOnMarch232021Member_6cf25f09-5abb-43d5-8c4f-31c39e6fd0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_9715d505-bc2e-4356-a7a6-ad5f0e910e37" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_532ff7a8-501d-44b2-99d9-ac2673a535fa" xlink:to="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_9715d505-bc2e-4356-a7a6-ad5f0e910e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis_eb1df6da-221a-459a-a648-3f69f36d0257" xlink:href="xfor-20211231.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:to="loc_xfor_PrefundedWarrantsAxis_eb1df6da-221a-459a-a648-3f69f36d0257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_e13bf9fa-b37f-4b63-9951-d5aed01a1373" xlink:href="xfor-20211231.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_PrefundedWarrantsAxis_eb1df6da-221a-459a-a648-3f69f36d0257" xlink:to="loc_xfor_PrefundedWarrantsDomain_e13bf9fa-b37f-4b63-9951-d5aed01a1373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember_3839b4b7-416f-4259-a255-184f616c6a9e" xlink:href="xfor-20211231.xsd#xfor_FundedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_PrefundedWarrantsDomain_e13bf9fa-b37f-4b63-9951-d5aed01a1373" xlink:to="loc_xfor_FundedMember_3839b4b7-416f-4259-a255-184f616c6a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8d08cce9-9dc4-4ea2-9373-87de6d347af3" xlink:to="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_87ac13dc-f439-4107-b30f-8ee4c471638c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_87ac13dc-f439-4107-b30f-8ee4c471638c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightIssued_bbc1e5f7-8b69-4485-8506-580ae1b76713" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_xfor_ClassOfWarrantOrRightIssued_bbc1e5f7-8b69-4485-8506-580ae1b76713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_46e5ce3c-79dd-4ea1-a9ce-3d5f7c6fb8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_46e5ce3c-79dd-4ea1-a9ce-3d5f7c6fb8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_6ebcf616-e69b-4db8-9a53-7ce9b52c4188" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_6ebcf616-e69b-4db8-9a53-7ce9b52c4188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8f2afb58-b9c7-460a-8934-1ca9f0fc25ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8f2afb58-b9c7-460a-8934-1ca9f0fc25ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_18239d19-53d9-4b35-b615-bfb30fcebed5" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_18239d19-53d9-4b35-b615-bfb30fcebed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_2951cd98-7983-4011-a655-f2872a0dabc4" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_2951cd98-7983-4011-a655-f2872a0dabc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6951b698-2e6a-41f7-93e1-5583d83b5940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ca024475-aea4-46d4-908b-31ccf0c51875" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6951b698-2e6a-41f7-93e1-5583d83b5940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail" xlink:type="simple" xlink:href="xfor-20211231.xsd#PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e6aa3e16-fb71-4409-a333-7350e51f173b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WarrantsRollForward_e6a3d652-b1be-49ca-abbb-93ba177580d0" xlink:href="xfor-20211231.xsd#xfor_WarrantsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6aa3e16-fb71-4409-a333-7350e51f173b" xlink:to="loc_xfor_WarrantsRollForward_e6a3d652-b1be-49ca-abbb-93ba177580d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1fbf9aeb-4977-4472-b7dd-c5ee1ea8ac47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsRollForward_e6a3d652-b1be-49ca-abbb-93ba177580d0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1fbf9aeb-4977-4472-b7dd-c5ee1ea8ac47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightIssued_dacdcdbd-59d2-45b6-b5bf-3323e8d51e36" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsRollForward_e6a3d652-b1be-49ca-abbb-93ba177580d0" xlink:to="loc_xfor_ClassOfWarrantOrRightIssued_dacdcdbd-59d2-45b6-b5bf-3323e8d51e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightExercised_fc3d1ee3-2bdd-4904-bca0-9b3071142f78" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsRollForward_e6a3d652-b1be-49ca-abbb-93ba177580d0" xlink:to="loc_xfor_ClassOfWarrantOrRightExercised_fc3d1ee3-2bdd-4904-bca0-9b3071142f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c0885619-62de-4bad-b584-3ae59e4d67d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsRollForward_e6a3d652-b1be-49ca-abbb-93ba177580d0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c0885619-62de-4bad-b584-3ae59e4d67d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightExpired_5ffded7a-b3eb-4ff2-a23b-106efd03df47" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsRollForward_e6a3d652-b1be-49ca-abbb-93ba177580d0" xlink:to="loc_xfor_ClassOfWarrantOrRightExpired_5ffded7a-b3eb-4ff2-a23b-106efd03df47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward_2ffe3d83-bfad-4074-8d0d-ca897b42a52d" xlink:href="xfor-20211231.xsd#xfor_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6aa3e16-fb71-4409-a333-7350e51f173b" xlink:to="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward_2ffe3d83-bfad-4074-8d0d-ca897b42a52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_529c3f1b-ff16-4aa4-9158-bc6754343ff0" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward_2ffe3d83-bfad-4074-8d0d-ca897b42a52d" xlink:to="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_529c3f1b-ff16-4aa4-9158-bc6754343ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_8d884a13-266f-4a10-99e3-b0c1d747ee32" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_WarrantsWeightedAverageExercisePriceRollForward_2ffe3d83-bfad-4074-8d0d-ca897b42a52d" xlink:to="loc_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice_8d884a13-266f-4a10-99e3-b0c1d747ee32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm_d56935b0-2cfe-4932-b514-70ab0765e811" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6aa3e16-fb71-4409-a333-7350e51f173b" xlink:to="loc_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm_d56935b0-2cfe-4932-b514-70ab0765e811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_15203d76-e998-45d3-be0f-6fc885b67a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6aa3e16-fb71-4409-a333-7350e51f173b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_15203d76-e998-45d3-be0f-6fc885b67a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f9b22e03-851b-45a2-b26a-27d9ac06fbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_15203d76-e998-45d3-be0f-6fc885b67a6c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f9b22e03-851b-45a2-b26a-27d9ac06fbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_34a427b4-1ce8-486a-8d58-0ece2c318261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f9b22e03-851b-45a2-b26a-27d9ac06fbc3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_34a427b4-1ce8-486a-8d58-0ece2c318261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_03a16018-9ff0-4980-b209-40926429fe56" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_34a427b4-1ce8-486a-8d58-0ece2c318261" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_03a16018-9ff0-4980-b209-40926429fe56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_68e47ab3-07b9-45a8-9316-631518b2590b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_15203d76-e998-45d3-be0f-6fc885b67a6c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_68e47ab3-07b9-45a8-9316-631518b2590b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a2c77758-67f3-4c7d-912d-d03e7676b055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_68e47ab3-07b9-45a8-9316-631518b2590b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a2c77758-67f3-4c7d-912d-d03e7676b055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0f8e6bc6-e184-45a4-9153-1579e006eb70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_68e47ab3-07b9-45a8-9316-631518b2590b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0f8e6bc6-e184-45a4-9153-1579e006eb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_55ee1fd1-d63f-4069-85f2-eea682977643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_48b5fc40-c944-44de-9bbf-bbb47be6ee57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_55ee1fd1-d63f-4069-85f2-eea682977643" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_48b5fc40-c944-44de-9bbf-bbb47be6ee57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1166844e-ee69-4ff3-b761-14b89c2d9c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_48b5fc40-c944-44de-9bbf-bbb47be6ee57" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1166844e-ee69-4ff3-b761-14b89c2d9c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1166844e-ee69-4ff3-b761-14b89c2d9c4c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_3dab39fd-7160-49ca-abbe-25e5dbf9dc8b" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_3dab39fd-7160-49ca-abbe-25e5dbf9dc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_c660dc4e-ee48-4956-86ad-0786433a1532" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_c660dc4e-ee48-4956-86ad-0786433a1532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_cea37d50-9c7b-4eb4-9267-7eb8328472ec" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_cea37d50-9c7b-4eb4-9267-7eb8328472ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_5f071fbb-e6dd-488f-bb3e-69e172436bc9" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_5f071fbb-e6dd-488f-bb3e-69e172436bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_acd48f0d-02d5-4966-9690-1d77ef6e9565" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_acd48f0d-02d5-4966-9690-1d77ef6e9565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_47b37258-afdb-4ef0-a62c-4d9dade2a16a" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_47b37258-afdb-4ef0-a62c-4d9dade2a16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_05877a87-6f0a-44eb-a9cd-af4636605341" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_05877a87-6f0a-44eb-a9cd-af4636605341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_b96a63a1-04f4-4d6d-a6f0-03fed287622b" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_b96a63a1-04f4-4d6d-a6f0-03fed287622b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member_8bef556a-3e23-4b38-ae29-75aae89aad73" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnMarch232021Member_8bef556a-3e23-4b38-ae29-75aae89aad73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_b5df93fa-39c8-4dd1-acac-fb67a6c841ac" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5e93a407-3e4b-440a-9ba8-0a9cb687f327" xlink:to="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_b5df93fa-39c8-4dd1-acac-fb67a6c841ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cf2b4f65-277f-4527-812a-46abcd76eb48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_48b5fc40-c944-44de-9bbf-bbb47be6ee57" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cf2b4f65-277f-4527-812a-46abcd76eb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_91c497f1-61f8-4446-8051-931f904b028b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf2b4f65-277f-4527-812a-46abcd76eb48" xlink:to="loc_us-gaap_EquityComponentDomain_91c497f1-61f8-4446-8051-931f904b028b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_039a00b2-c611-4f6a-ba41-720f94d23bd2" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_91c497f1-61f8-4446-8051-931f904b028b" xlink:to="loc_xfor_PreFundedWarrantMember_039a00b2-c611-4f6a-ba41-720f94d23bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_717d87de-0ee8-46b6-a6e7-f81ba7faeb24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_48b5fc40-c944-44de-9bbf-bbb47be6ee57" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_717d87de-0ee8-46b6-a6e7-f81ba7faeb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d9990c0a-49d5-4e26-aad6-2d9904750990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_717d87de-0ee8-46b6-a6e7-f81ba7faeb24" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d9990c0a-49d5-4e26-aad6-2d9904750990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dbcffcc2-4b08-4b4f-8b80-69db954bfed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_717d87de-0ee8-46b6-a6e7-f81ba7faeb24" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dbcffcc2-4b08-4b4f-8b80-69db954bfed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_c6289e6d-0801-476d-a360-9cab588ea265" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_717d87de-0ee8-46b6-a6e7-f81ba7faeb24" xlink:to="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_c6289e6d-0801-476d-a360-9cab588ea265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock" xlink:type="simple" xlink:href="xfor-20211231.xsd#CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3a451d7c-e72b-432d-b2db-49f4108ade5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_70fa9b3b-d88a-4b6d-8093-3f7b089b93bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3a451d7c-e72b-432d-b2db-49f4108ade5c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_70fa9b3b-d88a-4b6d-8093-3f7b089b93bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_765086dd-a30a-4295-a654-9071d00e4610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_765086dd-a30a-4295-a654-9071d00e4610" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_095d5ccb-0385-40ef-9ade-cda7e660eb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_095d5ccb-0385-40ef-9ade-cda7e660eb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e79d13aa-6180-4fcd-86d4-0c08884f0986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_095d5ccb-0385-40ef-9ade-cda7e660eb01" xlink:to="loc_us-gaap_EquityComponentDomain_e79d13aa-6180-4fcd-86d4-0c08884f0986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_65c2fec6-f5cf-4dc1-8fa9-220ca7461dbf" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e79d13aa-6180-4fcd-86d4-0c08884f0986" xlink:to="loc_xfor_PreFundedWarrantMember_65c2fec6-f5cf-4dc1-8fa9-220ca7461dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember_16d83cfd-808d-4973-a6ef-60dfebcecb71" xlink:href="xfor-20211231.xsd#xfor_ClassAWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e79d13aa-6180-4fcd-86d4-0c08884f0986" xlink:to="loc_xfor_ClassAWarrantMember_16d83cfd-808d-4973-a6ef-60dfebcecb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassBWarrantsMember_8d9aaefa-8bd4-4ce0-8284-d185a2eeddd4" xlink:href="xfor-20211231.xsd#xfor_ClassBWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e79d13aa-6180-4fcd-86d4-0c08884f0986" xlink:to="loc_xfor_ClassBWarrantsMember_8d9aaefa-8bd4-4ce0-8284-d185a2eeddd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cf2ae1d9-1702-48f5-a615-8437d48e0315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cf2ae1d9-1702-48f5-a615-8437d48e0315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9575a99e-d5c7-4d99-9914-a324af6cf4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cf2ae1d9-1702-48f5-a615-8437d48e0315" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9575a99e-d5c7-4d99-9914-a324af6cf4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GenzymeAgreementMember_35b1f571-170b-4234-a9d9-74a97cbc7ffe" xlink:href="xfor-20211231.xsd#xfor_GenzymeAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9575a99e-d5c7-4d99-9914-a324af6cf4ea" xlink:to="loc_xfor_GenzymeAgreementMember_35b1f571-170b-4234-a9d9-74a97cbc7ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ae5f975b-e771-4ecc-8762-1d1e5ce0b9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ae5f975b-e771-4ecc-8762-1d1e5ce0b9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_00c96274-1521-4ca1-82bb-8c7ff526ca7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae5f975b-e771-4ecc-8762-1d1e5ce0b9b2" xlink:to="loc_us-gaap_ClassOfStockDomain_00c96274-1521-4ca1-82bb-8c7ff526ca7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SeriesSeedConvertiblePreferredStockMember_9e3a5f52-aa06-4add-9ace-08f1e316cb0d" xlink:href="xfor-20211231.xsd#xfor_SeriesSeedConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_00c96274-1521-4ca1-82bb-8c7ff526ca7c" xlink:to="loc_xfor_SeriesSeedConvertiblePreferredStockMember_9e3a5f52-aa06-4add-9ace-08f1e316cb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_40b549b0-8312-408b-b5d5-b82e70649c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_00c96274-1521-4ca1-82bb-8c7ff526ca7c" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_40b549b0-8312-408b-b5d5-b82e70649c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_cfb6948e-80a3-494f-93d5-a63f051b4191" xlink:href="xfor-20211231.xsd#xfor_RedeemableCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_00c96274-1521-4ca1-82bb-8c7ff526ca7c" xlink:to="loc_xfor_RedeemableCommonStockMember_cfb6948e-80a3-494f-93d5-a63f051b4191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f8347e5f-bafc-48fc-96d1-1446db31f5fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_srt_RangeAxis_f8347e5f-bafc-48fc-96d1-1446db31f5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a7f378ac-e16f-4433-9506-f7daf37ca7db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f8347e5f-bafc-48fc-96d1-1446db31f5fb" xlink:to="loc_srt_RangeMember_a7f378ac-e16f-4433-9506-f7daf37ca7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12144f4a-98e4-41c1-85bd-1f65a7478dd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a7f378ac-e16f-4433-9506-f7daf37ca7db" xlink:to="loc_srt_MaximumMember_12144f4a-98e4-41c1-85bd-1f65a7478dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fb9c32f9-41ec-41a0-a7a5-ae81e2aa21ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a7f378ac-e16f-4433-9506-f7daf37ca7db" xlink:to="loc_srt_MinimumMember_fb9c32f9-41ec-41a0-a7a5-ae81e2aa21ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_553138e6-9950-47c4-a259-5f5c9559506f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_srt_TitleOfIndividualAxis_553138e6-9950-47c4-a259-5f5c9559506f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_883015d3-12e1-4462-b717-82159dc65bcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_553138e6-9950-47c4-a259-5f5c9559506f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_883015d3-12e1-4462-b717-82159dc65bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SalesAgentsMember_0e08beb1-3205-4aa5-9dd0-ce091321595a" xlink:href="xfor-20211231.xsd#xfor_SalesAgentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_883015d3-12e1-4462-b717-82159dc65bcb" xlink:to="loc_xfor_SalesAgentsMember_0e08beb1-3205-4aa5-9dd0-ce091321595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_afc635fc-4595-4a10-9023-f2e24690a6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_afc635fc-4595-4a10-9023-f2e24690a6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_360a001b-0318-4c21-a551-097eb3323672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_afc635fc-4595-4a10-9023-f2e24690a6b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_360a001b-0318-4c21-a551-097eb3323672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6b11c99d-bf6e-4152-8f8c-cd54d69f9f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_360a001b-0318-4c21-a551-097eb3323672" xlink:to="loc_us-gaap_CommonStockMember_6b11c99d-bf6e-4152-8f8c-cd54d69f9f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dc6349e9-312d-4900-9b06-131be9dd512a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dc6349e9-312d-4900-9b06-131be9dd512a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_558dfe72-6d66-4fd5-9fcd-9910f15f17d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dc6349e9-312d-4900-9b06-131be9dd512a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_558dfe72-6d66-4fd5-9fcd-9910f15f17d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember_5c14c4cd-5574-498c-b523-6589dbdb282f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_558dfe72-6d66-4fd5-9fcd-9910f15f17d8" xlink:to="loc_us-gaap_EquityUnitPurchaseAgreementsMember_5c14c4cd-5574-498c-b523-6589dbdb282f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e75b1981-c2ed-4ef4-b5e4-ced9c736d26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e75b1981-c2ed-4ef4-b5e4-ced9c736d26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_58c388f6-f105-48a2-bce7-6311eb8c8c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e75b1981-c2ed-4ef4-b5e4-ced9c736d26e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_58c388f6-f105-48a2-bce7-6311eb8c8c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_5b46f1ae-4806-4ff2-a85c-1597a464ca10" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58c388f6-f105-48a2-bce7-6311eb8c8c61" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_5b46f1ae-4806-4ff2-a85c-1597a464ca10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4da67207-4845-48e7-ac96-3105c7b6506c" xlink:to="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f327e6cd-2d67-4867-be5e-2bce1fb4a358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f327e6cd-2d67-4867-be5e-2bce1fb4a358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7ca1966e-f32e-449f-a9ff-4c34364da010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7ca1966e-f32e-449f-a9ff-4c34364da010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_38ecc796-857b-4986-a53e-abd111d867e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_DividendsCommonStock_38ecc796-857b-4986-a53e-abd111d867e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount_f0f57b21-164e-404d-b443-fe638368eea7" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount_f0f57b21-164e-404d-b443-fe638368eea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockPurchaseAgreementTerm_e6eb0ae4-d23d-437a-aac5-c4f5b64e9f7b" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockPurchaseAgreementTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_SaleOfStockPurchaseAgreementTerm_e6eb0ae4-d23d-437a-aac5-c4f5b64e9f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bfb9a99f-649d-44f4-ba8a-f4917f38386e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bfb9a99f-649d-44f4-ba8a-f4917f38386e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c16e121f-0f79-45bb-8986-03d57acf557f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c16e121f-0f79-45bb-8986-03d57acf557f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_99f9a1bb-9606-46a4-b09f-3e7c64538a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_99f9a1bb-9606-46a4-b09f-3e7c64538a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_efcc2c34-3270-4f72-b43e-9694f43af0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_efcc2c34-3270-4f72-b43e-9694f43af0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_656cd707-804b-4bdf-95a8-218c961e6aff" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod_656cd707-804b-4bdf-95a8-218c961e6aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_c6af4175-7a5a-45e4-b341-72c6c7993f02" xlink:href="xfor-20211231.xsd#xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses_c6af4175-7a5a-45e4-b341-72c6c7993f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesLicenseAgreement_dc0ea641-ae39-4389-8eee-ac86f1708f35" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_StockIssuedDuringPeriodSharesLicenseAgreement_dc0ea641-ae39-4389-8eee-ac86f1708f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodValueLicenseAgreement_f91aace9-df4a-4a4c-9fd0-b46c36d30b82" xlink:href="xfor-20211231.xsd#xfor_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_StockIssuedDuringPeriodValueLicenseAgreement_f91aace9-df4a-4a4c-9fd0-b46c36d30b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CommonStockRepurchasePricePerShare_8beed2e7-8b28-4fa9-a2dc-289923f2fb32" xlink:href="xfor-20211231.xsd#xfor_CommonStockRepurchasePricePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_xfor_CommonStockRepurchasePricePerShare_8beed2e7-8b28-4fa9-a2dc-289923f2fb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_bf6a8dff-f9d1-4588-8c30-f42ab4f37b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_bf6a8dff-f9d1-4588-8c30-f42ab4f37b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_b663490d-bffb-4b65-97bb-6e2ad8ce299e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_b663490d-bffb-4b65-97bb-6e2ad8ce299e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_6451ec68-b03f-4275-bde7-b05c22e8f4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_6451ec68-b03f-4275-bde7-b05c22e8f4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_415ca429-8c7c-4bd2-9462-e6dfc3cd3eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_415ca429-8c7c-4bd2-9462-e6dfc3cd3eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_403499d0-307e-4715-9a13-a6561c2eac6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ed6a766-0bf3-41fd-90b8-ad8992f5df86" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_403499d0-307e-4715-9a13-a6561c2eac6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="xfor-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ac129d0-4219-448f-bae8-eaac0bb4c558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0a345c70-030b-4a74-b1b2-f6cb80897723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ac129d0-4219-448f-bae8-eaac0bb4c558" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0a345c70-030b-4a74-b1b2-f6cb80897723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="xfor-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e53956bb-c63f-4b8d-92ab-3bcc358ab0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_de64f047-d6cd-4ddf-bd86-70314c3ec61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e53956bb-c63f-4b8d-92ab-3bcc358ab0f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_de64f047-d6cd-4ddf-bd86-70314c3ec61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9b2e76f1-ec25-4cb1-b9d3-8ccf4e3fa6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e53956bb-c63f-4b8d-92ab-3bcc358ab0f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9b2e76f1-ec25-4cb1-b9d3-8ccf4e3fa6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_299ccb69-ce4d-45b2-b963-5e33d876d792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e53956bb-c63f-4b8d-92ab-3bcc358ab0f2" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_299ccb69-ce4d-45b2-b963-5e33d876d792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_09a2e775-bf68-4655-b94c-14422873800a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e53956bb-c63f-4b8d-92ab-3bcc358ab0f2" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_09a2e775-bf68-4655-b94c-14422873800a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24d1d108-e781-41cf-b25a-8ae9cfb1344c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24d1d108-e781-41cf-b25a-8ae9cfb1344c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df54b713-27f4-4642-aea7-de68ad843c2c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:to="loc_srt_RangeAxis_df54b713-27f4-4642-aea7-de68ad843c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78d0ce4f-1cae-42bd-aaed-ae4f4d414f01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_df54b713-27f4-4642-aea7-de68ad843c2c" xlink:to="loc_srt_RangeMember_78d0ce4f-1cae-42bd-aaed-ae4f4d414f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b7f0370d-c768-40f5-bcac-923524533348" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_78d0ce4f-1cae-42bd-aaed-ae4f4d414f01" xlink:to="loc_srt_MinimumMember_b7f0370d-c768-40f5-bcac-923524533348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b3a58f8b-e68c-484f-ae1f-64886522f216" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_78d0ce4f-1cae-42bd-aaed-ae4f4d414f01" xlink:to="loc_srt_MaximumMember_b3a58f8b-e68c-484f-ae1f-64886522f216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e48f3c6f-9088-400f-8e54-9e515621948a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:to="loc_us-gaap_PlanNameAxis_e48f3c6f-9088-400f-8e54-9e515621948a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_453ac122-6249-4b8b-9633-700c9e675f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e48f3c6f-9088-400f-8e54-9e515621948a" xlink:to="loc_us-gaap_PlanNameDomain_453ac122-6249-4b8b-9633-700c9e675f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_A2015EquityIncentivePlanMember_1a9c2132-629e-4a9e-ab96-7471a300a6ee" xlink:href="xfor-20211231.xsd#xfor_A2015EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_453ac122-6249-4b8b-9633-700c9e675f7e" xlink:to="loc_xfor_A2015EquityIncentivePlanMember_1a9c2132-629e-4a9e-ab96-7471a300a6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_36b8710b-36a5-4777-864c-294e0ffca257" xlink:href="xfor-20211231.xsd#xfor_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_453ac122-6249-4b8b-9633-700c9e675f7e" xlink:to="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_36b8710b-36a5-4777-864c-294e0ffca257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_729a64f0-3681-4ee5-b80f-1117b08309c7" xlink:href="xfor-20211231.xsd#xfor_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_453ac122-6249-4b8b-9633-700c9e675f7e" xlink:to="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_729a64f0-3681-4ee5-b80f-1117b08309c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e29e290-9b08-4dc5-a319-2eae4751e93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:to="loc_us-gaap_AwardTypeAxis_6e29e290-9b08-4dc5-a319-2eae4751e93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6e29e290-9b08-4dc5-a319-2eae4751e93c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b8f310a5-6e4e-414e-ae5f-3663e7c41e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b8f310a5-6e4e-414e-ae5f-3663e7c41e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember_0dee96c4-fe18-4c03-9cee-7e26a531346a" xlink:href="xfor-20211231.xsd#xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:to="loc_xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember_0dee96c4-fe18-4c03-9cee-7e26a531346a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonStatutoryOptionsMember_5668712f-3f83-4658-8732-d2e30616bdad" xlink:href="xfor-20211231.xsd#xfor_NonStatutoryOptionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:to="loc_xfor_NonStatutoryOptionsMember_5668712f-3f83-4658-8732-d2e30616bdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1447daea-4d58-4fc5-afa1-f90a906eb482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35b4710b-eb9a-4444-83b7-950fd2218b39" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1447daea-4d58-4fc5-afa1-f90a906eb482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f0bca29d-030d-4b2b-83fa-f4fa700b2776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f0bca29d-030d-4b2b-83fa-f4fa700b2776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_f3da450d-2105-4e80-ac36-feda41fb1bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_f0bca29d-030d-4b2b-83fa-f4fa700b2776" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_f3da450d-2105-4e80-ac36-feda41fb1bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_EmployeeStockPurchasePlansMember_4ff7798e-c973-45cd-92a9-9e710968d9ee" xlink:href="xfor-20211231.xsd#xfor_EmployeeStockPurchasePlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_f3da450d-2105-4e80-ac36-feda41fb1bd5" xlink:to="loc_xfor_EmployeeStockPurchasePlansMember_4ff7798e-c973-45cd-92a9-9e710968d9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_582e938f-506a-4290-ae8c-f839b1493130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock_2af3cfd1-adfa-4897-898a-76f4192b65ed" xlink:href="xfor-20211231.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock_2af3cfd1-adfa-4897-898a-76f4192b65ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f11fbc8-8a25-4651-b5cc-01fe7965df43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f11fbc8-8a25-4651-b5cc-01fe7965df43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a82c2fd6-838e-42f3-92ad-d6b367d775bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a82c2fd6-838e-42f3-92ad-d6b367d775bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_15331e66-87a1-49d5-8873-aef3f242c399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_15331e66-87a1-49d5-8873-aef3f242c399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2383e6c5-c890-47c7-b9a2-16c81e978a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2383e6c5-c890-47c7-b9a2-16c81e978a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_62685a25-b587-406b-8144-e6ca4ed3ca58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_62685a25-b587-406b-8144-e6ca4ed3ca58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5688e8ef-7707-4879-8e6c-d151fc1a444d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5688e8ef-7707-4879-8e6c-d151fc1a444d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fe806a8a-706d-4694-a2d7-335959b899b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fe806a8a-706d-4694-a2d7-335959b899b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c199e973-9f31-44e6-8c8c-922c9180b62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c199e973-9f31-44e6-8c8c-922c9180b62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ddf1613-4c8c-4efa-b657-6faf14ebb4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ddf1613-4c8c-4efa-b657-6faf14ebb4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_adfeb50b-c1d2-45d4-9bf6-395bbec20c2a" xlink:href="xfor-20211231.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_adfeb50b-c1d2-45d4-9bf6-395bbec20c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3c88dd6d-5d40-4872-a583-203e6e4886e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3c88dd6d-5d40-4872-a583-203e6e4886e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52051375-3bc5-4c56-b7fa-ea6762463b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52051375-3bc5-4c56-b7fa-ea6762463b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d1e56646-9da8-4707-b74f-c4d7e0b5f2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d1e56646-9da8-4707-b74f-c4d7e0b5f2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7dc912a3-1448-4508-92bd-148bf5563598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7dc912a3-1448-4508-92bd-148bf5563598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3fcc94c0-133c-46a2-a875-57b83024f7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49d8fb63-3f76-4ec2-89ee-b816008ddbfc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3fcc94c0-133c-46a2-a875-57b83024f7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationStockOptionValuationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#StockBasedCompensationStockOptionValuationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationStockOptionValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45c7b81e-d385-4c6f-bb20-de41bf3dfacf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_18100c71-1904-4913-bc52-77f39f3d6605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45c7b81e-d385-4c6f-bb20-de41bf3dfacf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_18100c71-1904-4913-bc52-77f39f3d6605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_02dc6977-1703-405b-8d88-f488e4b1e967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45c7b81e-d385-4c6f-bb20-de41bf3dfacf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_02dc6977-1703-405b-8d88-f488e4b1e967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_04751233-fbe4-416b-a5df-ace37de2204a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45c7b81e-d385-4c6f-bb20-de41bf3dfacf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_04751233-fbe4-416b-a5df-ace37de2204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c7bd58f-a7c0-4b77-9963-c2ec555babc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45c7b81e-d385-4c6f-bb20-de41bf3dfacf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c7bd58f-a7c0-4b77-9963-c2ec555babc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="xfor-20211231.xsd#StockBasedCompensationSummaryofStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38ec24d-4c47-4a76-94fd-b6be89b4592c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_44e401e9-09db-499c-ba98-5c9d2f552bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38ec24d-4c47-4a76-94fd-b6be89b4592c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_44e401e9-09db-499c-ba98-5c9d2f552bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2c053026-ae30-42f9-8541-4dfefcd40a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_44e401e9-09db-499c-ba98-5c9d2f552bfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2c053026-ae30-42f9-8541-4dfefcd40a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e168b930-d2a1-4d62-b7c7-bd96666fd486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_44e401e9-09db-499c-ba98-5c9d2f552bfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e168b930-d2a1-4d62-b7c7-bd96666fd486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1a809d7b-828a-4ddd-b7d2-6ad39946941f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_44e401e9-09db-499c-ba98-5c9d2f552bfa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1a809d7b-828a-4ddd-b7d2-6ad39946941f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_48658e02-2f4b-45f9-a968-e36550980923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_44e401e9-09db-499c-ba98-5c9d2f552bfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_48658e02-2f4b-45f9-a968-e36550980923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20fdea30-9d01-42c3-aad0-0365ec79e4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_44e401e9-09db-499c-ba98-5c9d2f552bfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20fdea30-9d01-42c3-aad0-0365ec79e4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7ab4ef90-8d61-48a1-8cc4-f9f662180977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38ec24d-4c47-4a76-94fd-b6be89b4592c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7ab4ef90-8d61-48a1-8cc4-f9f662180977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_50c1392d-ce9b-47ac-a094-98c1bbed4fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38ec24d-4c47-4a76-94fd-b6be89b4592c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_50c1392d-ce9b-47ac-a094-98c1bbed4fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4cb966c9-b045-47a1-bf60-67b9ba87f84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38ec24d-4c47-4a76-94fd-b6be89b4592c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4cb966c9-b045-47a1-bf60-67b9ba87f84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fa31238-334a-436e-a49f-afcb7439b9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4cb966c9-b045-47a1-bf60-67b9ba87f84a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fa31238-334a-436e-a49f-afcb7439b9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bb098453-0f78-4f3c-b532-b0ee9dfbe0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4cb966c9-b045-47a1-bf60-67b9ba87f84a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bb098453-0f78-4f3c-b532-b0ee9dfbe0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_99edc370-fda1-441e-b051-6e902f0ddb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4cb966c9-b045-47a1-bf60-67b9ba87f84a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_99edc370-fda1-441e-b051-6e902f0ddb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_79262470-187f-4e69-ba16-dd44ea39cdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4cb966c9-b045-47a1-bf60-67b9ba87f84a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_79262470-187f-4e69-ba16-dd44ea39cdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9cd160bc-1d20-4841-a4d9-ffff42a533b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4cb966c9-b045-47a1-bf60-67b9ba87f84a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9cd160bc-1d20-4841-a4d9-ffff42a533b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03668f08-c587-4833-9cbd-f0f076625263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38ec24d-4c47-4a76-94fd-b6be89b4592c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03668f08-c587-4833-9cbd-f0f076625263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_fcbeb033-dc7f-4911-bb54-06e5617c0754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38ec24d-4c47-4a76-94fd-b6be89b4592c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_fcbeb033-dc7f-4911-bb54-06e5617c0754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_1e43cbd9-c65a-420b-8735-41e0e04544e8" xlink:href="xfor-20211231.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38ec24d-4c47-4a76-94fd-b6be89b4592c" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_1e43cbd9-c65a-420b-8735-41e0e04544e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5e42fb32-daa0-4512-a343-ce874421ae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_1e43cbd9-c65a-420b-8735-41e0e04544e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5e42fb32-daa0-4512-a343-ce874421ae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3307da2c-e5ea-40aa-b10f-e73791821a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_1e43cbd9-c65a-420b-8735-41e0e04544e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3307da2c-e5ea-40aa-b10f-e73791821a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7529c31c-2661-4604-9e31-204cc53f023e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_1e43cbd9-c65a-420b-8735-41e0e04544e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7529c31c-2661-4604-9e31-204cc53f023e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_36e23f3a-17dd-4111-9b9c-11e355034162" xlink:href="xfor-20211231.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d38ec24d-4c47-4a76-94fd-b6be89b4592c" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_36e23f3a-17dd-4111-9b9c-11e355034162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_86b9f682-b11e-4b40-9f45-15543593db64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_36e23f3a-17dd-4111-9b9c-11e355034162" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_86b9f682-b11e-4b40-9f45-15543593db64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_86411b13-e57c-461f-ad19-fb87e896ddb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_36e23f3a-17dd-4111-9b9c-11e355034162" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_86411b13-e57c-461f-ad19-fb87e896ddb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2a95865f-6f9b-40f8-8b16-33c73afab526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_36e23f3a-17dd-4111-9b9c-11e355034162" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2a95865f-6f9b-40f8-8b16-33c73afab526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f1af59e6-0497-4c0d-a24f-4cbe5d3e567f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_36e23f3a-17dd-4111-9b9c-11e355034162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f1af59e6-0497-4c0d-a24f-4cbe5d3e567f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#StockBasedCompensationRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0386b114-40f2-495b-9f96-276dc92d22a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_798eef09-7ef7-48c1-89f4-7e39648b1843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0386b114-40f2-495b-9f96-276dc92d22a4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_798eef09-7ef7-48c1-89f4-7e39648b1843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7dd323c1-0b77-4397-8126-3affde496b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_798eef09-7ef7-48c1-89f4-7e39648b1843" xlink:to="loc_us-gaap_AwardTypeAxis_7dd323c1-0b77-4397-8126-3affde496b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21158786-3ac5-4435-bf28-0172b62a0b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7dd323c1-0b77-4397-8126-3affde496b83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21158786-3ac5-4435-bf28-0172b62a0b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9bb5bff0-99c9-4b1e-b401-300a12c2d094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21158786-3ac5-4435-bf28-0172b62a0b8e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9bb5bff0-99c9-4b1e-b401-300a12c2d094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0d4664a-5843-413f-9c46-15a7d2b3619a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_798eef09-7ef7-48c1-89f4-7e39648b1843" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0d4664a-5843-413f-9c46-15a7d2b3619a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0d4664a-5843-413f-9c46-15a7d2b3619a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c28fc943-3181-443d-9c91-05c8cf09a3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c28fc943-3181-443d-9c91-05c8cf09a3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f39f78bf-d7b4-4cb5-b34a-1700caec713a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f39f78bf-d7b4-4cb5-b34a-1700caec713a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d2f50a7f-3199-427b-b619-c95eca8d3caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d2f50a7f-3199-427b-b619-c95eca8d3caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2a7f2b0e-3ae8-48c7-bbc6-2a7b838d64c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2a7f2b0e-3ae8-48c7-bbc6-2a7b838d64c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b5c6fe2-b9a3-466c-96a5-fde965b249ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1f7faef-e188-4cc7-a738-6d5fe45cc4be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b5c6fe2-b9a3-466c-96a5-fde965b249ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11266511-b303-4502-95c0-2d211bb128f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ca53e14-180d-4b6c-9b22-e68731b1c572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11266511-b303-4502-95c0-2d211bb128f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ca53e14-180d-4b6c-9b22-e68731b1c572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ec9b65c0-7c53-4513-882a-fe4ff5d3147f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ca53e14-180d-4b6c-9b22-e68731b1c572" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ec9b65c0-7c53-4513-882a-fe4ff5d3147f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f149af90-133a-4fda-8f8a-3c925e864e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ec9b65c0-7c53-4513-882a-fe4ff5d3147f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f149af90-133a-4fda-8f8a-3c925e864e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_db77bfe3-c481-4699-b749-0b7b15f0333a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f149af90-133a-4fda-8f8a-3c925e864e99" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_db77bfe3-c481-4699-b749-0b7b15f0333a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3e66e963-3b40-4485-8e07-9fa53882bb68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f149af90-133a-4fda-8f8a-3c925e864e99" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3e66e963-3b40-4485-8e07-9fa53882bb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6bfb0c7-389e-4d39-b22d-25c1a3a79272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ca53e14-180d-4b6c-9b22-e68731b1c572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6bfb0c7-389e-4d39-b22d-25c1a3a79272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d0d43b31-76c1-472a-8090-e27da474b0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6bfb0c7-389e-4d39-b22d-25c1a3a79272" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d0d43b31-76c1-472a-8090-e27da474b0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d599bf97-1aca-4753-ba2d-b3f4f9392a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b34318dc-9a34-4b3c-91f2-14be1f88e172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d599bf97-1aca-4753-ba2d-b3f4f9392a95" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b34318dc-9a34-4b3c-91f2-14be1f88e172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4f4ad2fb-5c3c-4f81-8df8-6086b89d185a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_606cb3b1-e4cf-43ab-9a8a-6651bc909127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4f4ad2fb-5c3c-4f81-8df8-6086b89d185a" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_606cb3b1-e4cf-43ab-9a8a-6651bc909127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ecdeb368-9274-4dbb-bdf8-8aca781cf026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4f4ad2fb-5c3c-4f81-8df8-6086b89d185a" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ecdeb368-9274-4dbb-bdf8-8aca781cf026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6f0faa1a-1b14-4146-81ea-aa4182a7fe87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4f4ad2fb-5c3c-4f81-8df8-6086b89d185a" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6f0faa1a-1b14-4146-81ea-aa4182a7fe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_f54ef14f-edf1-44d9-b7cf-7b9b4564f8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4f4ad2fb-5c3c-4f81-8df8-6086b89d185a" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_f54ef14f-edf1-44d9-b7cf-7b9b4564f8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_91bb9ca8-4fe9-47fd-92ba-dd0764a89005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4f4ad2fb-5c3c-4f81-8df8-6086b89d185a" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_91bb9ca8-4fe9-47fd-92ba-dd0764a89005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_74f42e97-cd9b-4598-8f50-63c1161bcb19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_74872147-111f-443b-83e9-45f3da879479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74f42e97-cd9b-4598-8f50-63c1161bcb19" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_74872147-111f-443b-83e9-45f3da879479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e0fcd0c4-cbb7-4765-9812-cedbdaf15295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74f42e97-cd9b-4598-8f50-63c1161bcb19" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e0fcd0c4-cbb7-4765-9812-cedbdaf15295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1d5928d9-a19d-413b-a3cb-6dd724c93bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74f42e97-cd9b-4598-8f50-63c1161bcb19" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1d5928d9-a19d-413b-a3cb-6dd724c93bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a936b34a-85e7-41f6-a4ed-8a836095c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fb518a1e-7271-4711-8ab9-c80056bc7890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a936b34a-85e7-41f6-a4ed-8a836095c59c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fb518a1e-7271-4711-8ab9-c80056bc7890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4448affd-071e-4ef6-a4e8-2d56cb858046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a936b34a-85e7-41f6-a4ed-8a836095c59c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4448affd-071e-4ef6-a4e8-2d56cb858046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_20a90471-90a9-48b7-b06b-90840ae53c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a936b34a-85e7-41f6-a4ed-8a836095c59c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_20a90471-90a9-48b7-b06b-90840ae53c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3b5ead30-4619-44ed-8ab3-fc754dc76b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a936b34a-85e7-41f6-a4ed-8a836095c59c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3b5ead30-4619-44ed-8ab3-fc754dc76b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability_bde91148-d69e-4fea-a0ea-95515077878e" xlink:href="xfor-20211231.xsd#xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a936b34a-85e7-41f6-a4ed-8a836095c59c" xlink:to="loc_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability_bde91148-d69e-4fea-a0ea-95515077878e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_e4a4393e-664c-40d9-a8d5-0b359daeac8b" xlink:href="xfor-20211231.xsd#xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a936b34a-85e7-41f6-a4ed-8a836095c59c" xlink:to="loc_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_e4a4393e-664c-40d9-a8d5-0b359daeac8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d1b2d8a0-0811-41a7-9eb1-eaeebefed09d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a936b34a-85e7-41f6-a4ed-8a836095c59c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d1b2d8a0-0811-41a7-9eb1-eaeebefed09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f5b3dc7a-f8b2-4eb6-a0ba-9a21e3e92a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a936b34a-85e7-41f6-a4ed-8a836095c59c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f5b3dc7a-f8b2-4eb6-a0ba-9a21e3e92a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0726b854-47dd-4c9f-a565-68c4cbf9b457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a936b34a-85e7-41f6-a4ed-8a836095c59c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0726b854-47dd-4c9f-a565-68c4cbf9b457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesDeferredIncomeTaxAssetDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3334a229-7a63-455f-8ca9-d0d063ce97aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7dc16516-ee5d-44d4-8072-c0933c75268b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3334a229-7a63-455f-8ca9-d0d063ce97aa" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7dc16516-ee5d-44d4-8072-c0933c75268b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_7dc16516-ee5d-44d4-8072-c0933c75268b" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b8e6fc5b-4876-4b66-8083-cda2d11fe43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b8e6fc5b-4876-4b66-8083-cda2d11fe43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d24683bc-a1c7-48c6-af98-fef58654679d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d24683bc-a1c7-48c6-af98-fef58654679d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b0c57d66-bade-40ee-ac03-1b1c519201e0" xlink:href="xfor-20211231.xsd#xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b0c57d66-bade-40ee-ac03-1b1c519201e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxAssetLeaseLiability_bf27bcd5-237e-40f6-b6f2-6c2a7ea30f86" xlink:href="xfor-20211231.xsd#xfor_DeferredTaxAssetLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_xfor_DeferredTaxAssetLeaseLiability_bf27bcd5-237e-40f6-b6f2-6c2a7ea30f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e64a74c8-4ce5-4ac2-890f-b2de440f425a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e64a74c8-4ce5-4ac2-890f-b2de440f425a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_df5859ea-1575-4849-9493-6ea517083dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_df5859ea-1575-4849-9493-6ea517083dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cc687473-e7d5-407d-a8e0-4cc69bf3ce1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cc687473-e7d5-407d-a8e0-4cc69bf3ce1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_75f60f0a-5772-47bf-a920-5c00ab8fa5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_75f60f0a-5772-47bf-a920-5c00ab8fa5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DeferredTaxLiabilityRightOfUseAsset_0f9b89a1-afac-42d0-a8da-ae781fcb1c23" xlink:href="xfor-20211231.xsd#xfor_DeferredTaxLiabilityRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_xfor_DeferredTaxLiabilityRightOfUseAsset_0f9b89a1-afac-42d0-a8da-ae781fcb1c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ce70228c-1a99-43e1-88d3-f837135df846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ce70228c-1a99-43e1-88d3-f837135df846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2987231c-5774-47e9-823b-7d8a5a117e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_54f2f037-13af-4907-a867-f0d546943e93" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2987231c-5774-47e9-823b-7d8a5a117e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_896cfed5-a7b5-41ba-804f-0ab198eddc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_e9b22376-8b19-4df3-b94f-7074aedfecb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_896cfed5-a7b5-41ba-804f-0ab198eddc2a" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_e9b22376-8b19-4df3-b94f-7074aedfecb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_aac31625-d642-4773-94ff-50fe2add4e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_e9b22376-8b19-4df3-b94f-7074aedfecb5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_aac31625-d642-4773-94ff-50fe2add4e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_dcff0ce9-070d-4d6e-a950-8bdc4492b553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_aac31625-d642-4773-94ff-50fe2add4e70" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_dcff0ce9-070d-4d6e-a950-8bdc4492b553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_730ee783-1daf-4dbc-a7e6-2cc5f4d6b4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_dcff0ce9-070d-4d6e-a950-8bdc4492b553" xlink:to="loc_us-gaap_ResearchMember_730ee783-1daf-4dbc-a7e6-2cc5f4d6b4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_39dac313-2cb7-480c-b41e-4ddff9cf3245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_e9b22376-8b19-4df3-b94f-7074aedfecb5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_39dac313-2cb7-480c-b41e-4ddff9cf3245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b2b5b84a-b14c-4b00-b668-c3fd1fc6c5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_39dac313-2cb7-480c-b41e-4ddff9cf3245" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b2b5b84a-b14c-4b00-b668-c3fd1fc6c5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_1ff07ba2-b20a-44de-aa8b-2d35428ab3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b2b5b84a-b14c-4b00-b668-c3fd1fc6c5ed" xlink:to="loc_us-gaap_DomesticCountryMember_1ff07ba2-b20a-44de-aa8b-2d35428ab3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2ddbe65c-4468-4554-9329-2d9b5c572450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b2b5b84a-b14c-4b00-b668-c3fd1fc6c5ed" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2ddbe65c-4468-4554-9329-2d9b5c572450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_55148714-cecd-45fa-a4f4-168dc1ccd730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b2b5b84a-b14c-4b00-b668-c3fd1fc6c5ed" xlink:to="loc_us-gaap_ForeignCountryMember_55148714-cecd-45fa-a4f4-168dc1ccd730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_e9b22376-8b19-4df3-b94f-7074aedfecb5" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_949768c6-e756-4058-997d-df22a143caa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_OperatingLossCarryforwards_949768c6-e756-4058-997d-df22a143caa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_bd9d565e-9581-46e8-8d29-09d25fb7a7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_bd9d565e-9581-46e8-8d29-09d25fb7a7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_3d0497e8-da1c-4b4d-8e63-ccec87a3bb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_3d0497e8-da1c-4b4d-8e63-ccec87a3bb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_15759f16-285b-49a4-bc05-11288db342ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_15759f16-285b-49a4-bc05-11288db342ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e6f4603b-2534-410a-bbfc-00e2a983658b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3ac0a672-0b6a-42de-af78-80eec616e045" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e6f4603b-2534-410a-bbfc-00e2a983658b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fbd8ea79-f44f-4268-b985-eee647dbac52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_896cfed5-a7b5-41ba-804f-0ab198eddc2a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fbd8ea79-f44f-4268-b985-eee647dbac52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesDeferredTaxValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_55d48d9d-de13-432e-a92c-1372a2c5ab5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_5fdbddf3-7793-4d35-a834-ce5c0f0df7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_55d48d9d-de13-432e-a92c-1372a2c5ab5e" xlink:to="loc_us-gaap_ValuationAllowanceTable_5fdbddf3-7793-4d35-a834-ce5c0f0df7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_56635558-3897-485d-8304-965e3b0d0603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_5fdbddf3-7793-4d35-a834-ce5c0f0df7ce" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_56635558-3897-485d-8304-965e3b0d0603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e6361984-789f-44e8-a7b0-8e80f4ac4a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_56635558-3897-485d-8304-965e3b0d0603" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e6361984-789f-44e8-a7b0-8e80f4ac4a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9fab0583-7838-4d6a-a183-20619cfb79e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e6361984-789f-44e8-a7b0-8e80f4ac4a4b" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9fab0583-7838-4d6a-a183-20619cfb79e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_29286917-e151-4248-a7de-d17055cb3943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_5fdbddf3-7793-4d35-a834-ce5c0f0df7ce" xlink:to="loc_us-gaap_ValuationAllowanceLineItems_29286917-e151-4248-a7de-d17055cb3943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_29286917-e151-4248-a7de-d17055cb3943" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8e70078b-71b6-49b1-86e3-120593d4632c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8e70078b-71b6-49b1-86e3-120593d4632c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_7370c7e1-a2f5-4ccc-bd74-17b77be6d68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_7370c7e1-a2f5-4ccc-bd74-17b77be6d68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_6a73ad22-c865-4db0-a158-915f34ea55d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_6a73ad22-c865-4db0-a158-915f34ea55d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_812b3997-92d0-479f-8b72-512a981b2975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_64a0e7e2-c0a5-4d2d-9be4-b87bc8c79148" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_812b3997-92d0-479f-8b72-512a981b2975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e0de6bf8-9427-4f87-af61-9120be053cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e1c78d4e-e77c-4934-820a-7097c6954bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0de6bf8-9427-4f87-af61-9120be053cbd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e1c78d4e-e77c-4934-820a-7097c6954bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_518fc538-3562-47af-9e94-4dc8f636616b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0de6bf8-9427-4f87-af61-9120be053cbd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_518fc538-3562-47af-9e94-4dc8f636616b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_48e7df13-52b5-45bb-95b6-e6b6d76adf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0de6bf8-9427-4f87-af61-9120be053cbd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_48e7df13-52b5-45bb-95b6-e6b6d76adf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShare" xlink:type="simple" xlink:href="xfor-20211231.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_af5319ed-b748-4c9b-af12-8c5a766ff50a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e4e441df-9d20-4f6c-a3c6-7f3f26760858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_af5319ed-b748-4c9b-af12-8c5a766ff50a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e4e441df-9d20-4f6c-a3c6-7f3f26760858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="xfor-20211231.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d7f20d0a-094d-421a-865c-42743a6ca3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fe4d9b18-f400-43c4-976b-f35a3f45511f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d7f20d0a-094d-421a-865c-42743a6ca3db" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fe4d9b18-f400-43c4-976b-f35a3f45511f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ac672bdc-6749-4af7-883c-884cd7993e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d7f20d0a-094d-421a-865c-42743a6ca3db" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ac672bdc-6749-4af7-883c-884cd7993e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_37e5d81c-f548-466b-996d-234ec51e6957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_43d5d0c9-b87f-4963-8323-22cb614a1c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37e5d81c-f548-466b-996d-234ec51e6957" xlink:to="loc_us-gaap_NetIncomeLoss_43d5d0c9-b87f-4963-8323-22cb614a1c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_7e17670b-35a5-464b-862c-07c23cfccf93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37e5d81c-f548-466b-996d-234ec51e6957" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_7e17670b-35a5-464b-862c-07c23cfccf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_64170d7e-cd2d-4181-8162-7683ba093383" xlink:href="xfor-20211231.xsd#xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37e5d81c-f548-466b-996d-234ec51e6957" xlink:to="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_64170d7e-cd2d-4181-8162-7683ba093383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f7f32b5b-e017-4946-8e56-d0d6365913cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37e5d81c-f548-466b-996d-234ec51e6957" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f7f32b5b-e017-4946-8e56-d0d6365913cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3715c64e-e814-4434-85aa-c4e04a52b7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37e5d81c-f548-466b-996d-234ec51e6957" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3715c64e-e814-4434-85aa-c4e04a52b7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_d6c1e8ed-e498-4bb5-9a2b-dda38837b6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37e5d81c-f548-466b-996d-234ec51e6957" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_d6c1e8ed-e498-4bb5-9a2b-dda38837b6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#NetLossperShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0ac64d73-90cf-4690-b138-b7082e07f3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ac64d73-90cf-4690-b138-b7082e07f3a6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75362592-d68a-436e-a6aa-76b8a45cdca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75362592-d68a-436e-a6aa-76b8a45cdca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6abe1d85-db1d-468d-b990-5bd67470c7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75362592-d68a-436e-a6aa-76b8a45cdca7" xlink:to="loc_us-gaap_ClassOfStockDomain_6abe1d85-db1d-468d-b990-5bd67470c7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_RedeemableCommonStockMember_7a87b4a8-b9fb-4d95-8ab0-0c16c3ba27bd" xlink:href="xfor-20211231.xsd#xfor_RedeemableCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6abe1d85-db1d-468d-b990-5bd67470c7d7" xlink:to="loc_xfor_RedeemableCommonStockMember_7a87b4a8-b9fb-4d95-8ab0-0c16c3ba27bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6597a27-b46e-4884-8948-62d2c9ba5feb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:to="loc_srt_RangeAxis_f6597a27-b46e-4884-8948-62d2c9ba5feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1f04ab2-a478-4d79-9714-0eb6fab0b148" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f6597a27-b46e-4884-8948-62d2c9ba5feb" xlink:to="loc_srt_RangeMember_b1f04ab2-a478-4d79-9714-0eb6fab0b148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88ad9525-7221-438c-831d-a917096aff90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b1f04ab2-a478-4d79-9714-0eb6fab0b148" xlink:to="loc_srt_MinimumMember_88ad9525-7221-438c-831d-a917096aff90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1345f4af-579c-4023-b079-e3c841ee1ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1345f4af-579c-4023-b079-e3c841ee1ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62fc1c7a-305a-4f7b-8ce5-080b0c16943b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1345f4af-579c-4023-b079-e3c841ee1ade" xlink:to="loc_us-gaap_EquityComponentDomain_62fc1c7a-305a-4f7b-8ce5-080b0c16943b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_3a6e964d-55e9-4bfc-ba08-6cfe135323a0" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62fc1c7a-305a-4f7b-8ce5-080b0c16943b" xlink:to="loc_xfor_PreFundedWarrantMember_3a6e964d-55e9-4bfc-ba08-6cfe135323a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_cdd68b20-6da3-4f37-9cd4-044236a0d670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_31dc06b2-0c0c-4ddd-85b0-17585d2d7ca3" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_cdd68b20-6da3-4f37-9cd4-044236a0d670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0771a885-422b-4326-89ca-942585cc9883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_cdd68b20-6da3-4f37-9cd4-044236a0d670" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0771a885-422b-4326-89ca-942585cc9883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9f63d428-3fae-4908-af09-369fa51b7c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_cdd68b20-6da3-4f37-9cd4-044236a0d670" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9f63d428-3fae-4908-af09-369fa51b7c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7a9d3003-8e04-4b2c-97c8-e1043a836c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e5bfcb3-dc3b-46f1-9af2-f9750c553d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7a9d3003-8e04-4b2c-97c8-e1043a836c80" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e5bfcb3-dc3b-46f1-9af2-f9750c553d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_964ca125-ba25-4583-8b70-a4ae22293ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e5bfcb3-dc3b-46f1-9af2-f9750c553d79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_964ca125-ba25-4583-8b70-a4ae22293ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_59e47ba2-d685-4fd3-8886-a458743fd356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_964ca125-ba25-4583-8b70-a4ae22293ca1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_59e47ba2-d685-4fd3-8886-a458743fd356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b33e65a4-7c74-4734-85f2-245e5cc5377a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_59e47ba2-d685-4fd3-8886-a458743fd356" xlink:to="loc_us-gaap_WarrantMember_b33e65a4-7c74-4734-85f2-245e5cc5377a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_26eff808-c137-49fe-9aab-060a61338525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_59e47ba2-d685-4fd3-8886-a458743fd356" xlink:to="loc_us-gaap_StockOptionMember_26eff808-c137-49fe-9aab-060a61338525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2a6a3e9a-c7d1-4b10-81b5-f2e9370b4c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_59e47ba2-d685-4fd3-8886-a458743fd356" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2a6a3e9a-c7d1-4b10-81b5-f2e9370b4c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_877a66a6-b88f-4a1d-a2fa-ae18de678ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e5bfcb3-dc3b-46f1-9af2-f9750c553d79" xlink:to="loc_us-gaap_StatementClassOfStockAxis_877a66a6-b88f-4a1d-a2fa-ae18de678ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_05da73db-62cd-403b-9af8-b484b183461d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_877a66a6-b88f-4a1d-a2fa-ae18de678ba4" xlink:to="loc_us-gaap_ClassOfStockDomain_05da73db-62cd-403b-9af8-b484b183461d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_e2e64202-2c9e-46f3-a4d0-bf9b058c7fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_05da73db-62cd-403b-9af8-b484b183461d" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_e2e64202-2c9e-46f3-a4d0-bf9b058c7fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cb389a5-b4ab-4d55-8e2f-b7a09d51290e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e5bfcb3-dc3b-46f1-9af2-f9750c553d79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cb389a5-b4ab-4d55-8e2f-b7a09d51290e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cac0585f-470a-4dc6-83c4-8242863d8b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5cb389a5-b4ab-4d55-8e2f-b7a09d51290e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cac0585f-470a-4dc6-83c4-8242863d8b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LossonTransferofNonfinancialAssets" xlink:type="simple" xlink:href="xfor-20211231.xsd#LossonTransferofNonfinancialAssets"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LossonTransferofNonfinancialAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3b8b731-0bd5-4070-a002-2d0f30abcdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_ed8ec570-0f26-4743-a6df-e5c69183ee1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3b8b731-0bd5-4070-a002-2d0f30abcdb7" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_ed8ec570-0f26-4743-a6df-e5c69183ee1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#LossonTransferofNonfinancialAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0c6b517-3e3b-41fc-8e1f-474cb79070d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9509f877-5869-4cb2-81ba-1be9f37b2e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0c6b517-3e3b-41fc-8e1f-474cb79070d5" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9509f877-5869-4cb2-81ba-1be9f37b2e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92a50dc2-a432-4419-992d-54ac5d98d772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9509f877-5869-4cb2-81ba-1be9f37b2e73" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92a50dc2-a432-4419-992d-54ac5d98d772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c329025f-447c-4f86-92be-b95487687d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_92a50dc2-a432-4419-992d-54ac5d98d772" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c329025f-447c-4f86-92be-b95487687d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_40f4eaaf-2e33-465e-aafa-3410cd850c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c329025f-447c-4f86-92be-b95487687d15" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_40f4eaaf-2e33-465e-aafa-3410cd850c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_02745214-4fc2-4148-8ddd-bcec8ecd9e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9509f877-5869-4cb2-81ba-1be9f37b2e73" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_02745214-4fc2-4148-8ddd-bcec8ecd9e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_b39fb94e-e669-40a5-bcf6-72aa96b86899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_02745214-4fc2-4148-8ddd-bcec8ecd9e72" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_b39fb94e-e669-40a5-bcf6-72aa96b86899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8d376254-a88a-4e50-ab8a-e362249ec04c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_02745214-4fc2-4148-8ddd-bcec8ecd9e72" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8d376254-a88a-4e50-ab8a-e362249ec04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_07e2cddb-4eb9-4b1c-b058-7229375fba4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_02745214-4fc2-4148-8ddd-bcec8ecd9e72" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_07e2cddb-4eb9-4b1c-b058-7229375fba4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="xfor-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_a0ee5ee6-050b-4698-b2c6-c14bda9d4060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_d63aae75-7e11-4a9f-af8b-aeaf37c4f773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_a0ee5ee6-050b-4698-b2c6-c14bda9d4060" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_d63aae75-7e11-4a9f-af8b-aeaf37c4f773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="xfor-20211231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_94f9a151-cf0d-44e1-ba34-fc3b0380e822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_94f9a151-cf0d-44e1-ba34-fc3b0380e822" xlink:to="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ca4eb6d7-1101-4d95-83f2-d516de560f1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_srt_CounterpartyNameAxis_ca4eb6d7-1101-4d95-83f2-d516de560f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e6ce82d-b1ff-45b3-9c32-01990e98d88d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ca4eb6d7-1101-4d95-83f2-d516de560f1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e6ce82d-b1ff-45b3-9c32-01990e98d88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AspireCapitalFundLLCMember_9997b5d0-1b69-47dd-a4d5-25211cb4da86" xlink:href="xfor-20211231.xsd#xfor_AspireCapitalFundLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e6ce82d-b1ff-45b3-9c32-01990e98d88d" xlink:to="loc_xfor_AspireCapitalFundLLCMember_9997b5d0-1b69-47dd-a4d5-25211cb4da86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LincolnParkCapitalFundLLCMember_b06c5be9-2d88-439a-9f21-716be19ed42f" xlink:href="xfor-20211231.xsd#xfor_LincolnParkCapitalFundLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e6ce82d-b1ff-45b3-9c32-01990e98d88d" xlink:to="loc_xfor_LincolnParkCapitalFundLLCMember_b06c5be9-2d88-439a-9f21-716be19ed42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e07ebe9f-2189-4338-be10-5c1a6c7219f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e07ebe9f-2189-4338-be10-5c1a6c7219f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_85b7f5f2-40b9-4fa8-8c59-e1509468b883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e07ebe9f-2189-4338-be10-5c1a6c7219f3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_85b7f5f2-40b9-4fa8-8c59-e1509468b883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bf6dddc4-2b34-4b02-a7b6-12f26ad4ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_85b7f5f2-40b9-4fa8-8c59-e1509468b883" xlink:to="loc_us-gaap_SubsequentEventMember_bf6dddc4-2b34-4b02-a7b6-12f26ad4ccba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406e1d3d-32a1-429f-8336-14c84fd76594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406e1d3d-32a1-429f-8336-14c84fd76594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_34a82731-510a-4ec8-845c-589b6e2340b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406e1d3d-32a1-429f-8336-14c84fd76594" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_34a82731-510a-4ec8-845c-589b6e2340b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember_66b82f72-b268-42dc-9c75-19abcbda1ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_34a82731-510a-4ec8-845c-589b6e2340b5" xlink:to="loc_us-gaap_EquityUnitPurchaseAgreementsMember_66b82f72-b268-42dc-9c75-19abcbda1ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_eaab0e98-c6a9-4e6d-a05e-15937aa09be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_eaab0e98-c6a9-4e6d-a05e-15937aa09be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2806d8b7-354a-478d-bf3e-ba6f9a24318e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_eaab0e98-c6a9-4e6d-a05e-15937aa09be9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2806d8b7-354a-478d-bf3e-ba6f9a24318e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_b0838d15-6e48-4d46-a202-0203f482dc6c" xlink:href="xfor-20211231.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2806d8b7-354a-478d-bf3e-ba6f9a24318e" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember_b0838d15-6e48-4d46-a202-0203f482dc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_Q12022PIPEMember_c825d7a6-8778-42b2-93da-7e6619c1bfea" xlink:href="xfor-20211231.xsd#xfor_Q12022PIPEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2806d8b7-354a-478d-bf3e-ba6f9a24318e" xlink:to="loc_xfor_Q12022PIPEMember_c825d7a6-8778-42b2-93da-7e6619c1bfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dbc2c2af-5517-4216-892c-5cd3561ac1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_DebtInstrumentAxis_dbc2c2af-5517-4216-892c-5cd3561ac1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9c914a5f-3e1f-47c6-b92a-67209fe9782c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_dbc2c2af-5517-4216-892c-5cd3561ac1e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9c914a5f-3e1f-47c6-b92a-67209fe9782c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember_3c099fff-8e71-45dc-9d81-6f277aa66228" xlink:href="xfor-20211231.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9c914a5f-3e1f-47c6-b92a-67209fe9782c" xlink:to="loc_xfor_HerculesLoanAgreementMember_3c099fff-8e71-45dc-9d81-6f277aa66228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1600a8c5-a0eb-45b5-82e0-e5854d269568" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_srt_StatementScenarioAxis_1600a8c5-a0eb-45b5-82e0-e5854d269568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_eaf066c2-0bd9-48fb-9d32-a81a1c182b5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1600a8c5-a0eb-45b5-82e0-e5854d269568" xlink:to="loc_srt_ScenarioUnspecifiedDomain_eaf066c2-0bd9-48fb-9d32-a81a1c182b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4f8cd39b-05d2-48cc-a572-961c126cb522" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_eaf066c2-0bd9-48fb-9d32-a81a1c182b5c" xlink:to="loc_srt_ScenarioForecastMember_4f8cd39b-05d2-48cc-a572-961c126cb522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a709e0b-d0b5-4a27-b412-f17234b0ef90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a709e0b-d0b5-4a27-b412-f17234b0ef90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2698ddc3-0036-4f21-8907-6f5d2514d488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a709e0b-d0b5-4a27-b412-f17234b0ef90" xlink:to="loc_us-gaap_EquityComponentDomain_2698ddc3-0036-4f21-8907-6f5d2514d488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_c7f03b84-eb4e-4017-9620-282eeb5c4af0" xlink:href="xfor-20211231.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2698ddc3-0036-4f21-8907-6f5d2514d488" xlink:to="loc_xfor_PreFundedWarrantMember_c7f03b84-eb4e-4017-9620-282eeb5c4af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5eb09c9f-7586-4ee6-ba14-9133029ca437" xlink:to="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_234cc4bc-e0f9-4345-87d8-41a9d89177a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_234cc4bc-e0f9-4345-87d8-41a9d89177a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockPurchaseAgreementTerm_a9910be5-8a8b-4e2f-8b41-51efe9147c94" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockPurchaseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_SaleOfStockPurchaseAgreementTerm_a9910be5-8a8b-4e2f-8b41-51efe9147c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SaleOfStockPurchaseAgreementSharesIssued_32e71cc8-6295-4546-9540-8dc4711ef6b9" xlink:href="xfor-20211231.xsd#xfor_SaleOfStockPurchaseAgreementSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_SaleOfStockPurchaseAgreementSharesIssued_32e71cc8-6295-4546-9540-8dc4711ef6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PurchaseAgreementSharesPurchased_4d123918-841e-4f16-bf38-472a02b15fef" xlink:href="xfor-20211231.xsd#xfor_PurchaseAgreementSharesPurchased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_PurchaseAgreementSharesPurchased_4d123918-841e-4f16-bf38-472a02b15fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_5b4742e8-6e62-41ce-9e9b-dfaf31094449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_5b4742e8-6e62-41ce-9e9b-dfaf31094449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell_912fd7d9-58fe-4e00-ae25-a629e4fa4b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell_912fd7d9-58fe-4e00-ae25-a629e4fa4b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c068fd6a-e0e0-4e18-a1be-9e5441eaadb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c068fd6a-e0e0-4e18-a1be-9e5441eaadb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo_8cb660c2-daa5-45d9-a517-cdd6c1befc19" xlink:href="xfor-20211231.xsd#xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo_8cb660c2-daa5-45d9-a517-cdd6c1befc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_0f6e0115-e197-4a9f-95cb-9dbbc2f2f235" xlink:href="xfor-20211231.xsd#xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree_0f6e0115-e197-4a9f-95cb-9dbbc2f2f235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequired_78097679-3f59-48be-ae63-d1faa673fabf" xlink:href="xfor-20211231.xsd#xfor_DebtInstrumentDebtCovenantMinimumCashRequired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequired_78097679-3f59-48be-ae63-d1faa673fabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario_ee333155-7ee7-4645-8901-27123a210661" xlink:href="xfor-20211231.xsd#xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario_ee333155-7ee7-4645-8901-27123a210661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26bc83fa-1879-4df1-92c6-a07db2c2cf0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26bc83fa-1879-4df1-92c6-a07db2c2cf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f1d779a5-fddc-4ba2-b51b-73a0e1b35cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f1d779a5-fddc-4ba2-b51b-73a0e1b35cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85b1b338-05b5-4202-b915-1853684ac613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_85b1b338-05b5-4202-b915-1853684ac613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_56c6c9d5-5d99-43b5-b75b-cb4e1ba220c8" xlink:href="xfor-20211231.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_56c6c9d5-5d99-43b5-b75b-cb4e1ba220c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_be0adf43-e799-418e-b83e-59efce34c78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d3ee7c2f-c085-417b-839f-d10bf02b6eb2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_be0adf43-e799-418e-b83e-59efce34c78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" #( ,@# 2(  A$! Q$!_\0
M'  !  (# 0$!              8' P0%" (!_\0 &P$!  (# 0$
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M8 KK8GHB>.8,9@.],#%7]:=,XX%>7$VBHW>N1-S!R60
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MW!M+D3-IFTS:9F9&9&9F)4*&\.I8^W^W_\0 /!   @$" @4)!@0& P$
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MC6?,,OG?90!(!.ZLMQF\JREU#>5Z"EAF.X5ES#-Y5EN+^5#E)%CONS&U6:1
M>)JP()K;(H\-];)%/]:'*2+'?^8VH7(%]U 7%SN%9I'5%\V-J#*0P/B*Q/YC
M?75A?S5^O1T=RL33Q<_BS1(+EQMV 5_$,T6#FT?HZ5H.0PT^QKAQF-O"M ";
M1V(P.626QFMUNI7/^<IEBQ P'(YMN2QS-\LU:<Y]@9<6[)"D#QC8C%/$WV>'
MI7\/S3DMBL#A>5EVW) 9<P]+T,:#>%N5@B^2 "_J37/N<H5Q<[X/D<VT( ,C
M6XD5IC%Z1B&*:+%-A8T?<BKY#C6F%ET-)I4*( O)_P#SZG^^E:11191A(0!Z
MU_$$F(@65X,7C&C)^$_Z*T1/! L4N(DPC2L/B/\ IK3&)TC&,28,0<+%&^Y%
M \!QK"8*/$)AN9PG%KF;>XV(OSWU_">*3W9HYW']8Q6C<1S%M)X* ORV%4[3
M<;#;QI#HZ(X?#AF'(L+%&OM%8G\QOKJPOYJ_7HX.\G)\WQ*8C=>^7PJ;!-(8
MA)EZX%[68'_RL!BN5Y-L(78"U[W6U-HYK/*P-\64&?->]ZTGSF4S\_BCC?JV
ML4%LW_M8=L3BFQ!CPKX5KK;.&\:P*P8ID;"P2PJV7>7^*H<#'EBFBRE<4(QG
MS WO4V+T=I.31SXC;,@C#JQ\['=6)QF%TQ)A&Q 02 0JU\JV\:AQF%TG)@\<
ML(ADF$882CBM3:.21FY57#S-M9F;>U8'1_+$#"F(A\OO9*FQFC=)2:-DGMRR
MB,2*Q\['<:Q>*Q67'2XC+MEC'5"BVRL F&TF^';!-+R3B,,0'\-M1*FGI4F6
M^:0P(<X^5<W21IF+&1Y7WNQWFL0RX=RI<D&OPS^E8=FP[A1(I)_K_P H_\0
M*1   @ $!0,% 0$!         1$ (3%!$%%A@9$@P? P<:&QT>%@\?_:  @!
M 0 !/R'_ !I2QB)^<:OSTC5^>D/=FH"YZ5(^C)-HU?GI&K\](<0F1"&XZ0IW
MD)381J_/2-7YZ0W<A0(FYZD4LH1R[8L&N,SV_8!88Q=(PFD2]7^@& #,+4OQ
M70)S-D7+,LA88"^:336!:((.H1  @1!O!P8UK3+;&OZ\V3VXQ8:0E_'=QC<M
M2GQETVV%.=AWX@XDM5!,$KO*![F\#(5$DDGY] (PYIEO!R@)"(-L&[DB!N"
MTA %Q$T@@N($/"9F#@$F=7)<Q++$-=>B<XOT AX;,P8,7'LW#O 6:'UC4PUW
MO\('\PO\@GQ%K>@AFE"+9]\=5RKW#:*S"4;I[<XTMC<ZVQWXZ4#1*-SBG.""
MB7K3^T%ZE2ZD+)P/^3.JD-PX$QUSP3($S.3R6.!QVO0QKD*&;'2"26;[;00A
M)9,R3A/,$(O.1B'U&#,DH1I8%Z%2PZ-WBO/1)_<1-A3[ ]-0&XY[OS$FNXW
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M.G6)4UW6(4ZK_/0Q&S&>E*JEL.O[+I=S6.6DST@ &#AYP.L"2K2MNM^1VT@
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C(5 7NS34($+ 8L2P!P$JRLJ3]XS1/)IZQ^NVP5Z _P"H_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>xfor-20211231_g1.jpg
<TEXT>
begin 644 xfor-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI=&-H($)U
M8VML97D   60 P "    %   $*:0!  "    %   $+J2D0 "     S W  "2
MD@ "     S W  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
M   ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,082
M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3
ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C
MY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ X7_A./%G_0T:S_X,)?\
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M<\-QG&%S7FWPM\.:UXH_M?3;*ZEMM%ECC;4_)2,R3A262)&;[K-\W.0O][/
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MUOL_VC'F>7D[=V.-V,9QQFH***T("BBBF 4444 %%%% !1110 4444 %%%%
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M--;EPKLT;C*2+R=JA@.0<\8DU3P[X42ZT;5_#OAVQO-$_M&*.>XMM9DF^5R
MJSPR+E"=P. 3C!#=17G^L_$;Q;K]O;PZIK<\B6T@EB\M5B*N/NME "2.H)Z&
MEUWXC>+/$EK%;ZQK$DT4,@E18XTBPXZ'Y%&<=L]*:ISLKO\ $3E'L>E>*=*\
M,W'BSQCKVI:#+=QZ%';0M8P7;H+F23/[UB.8P%VC X^4FJMMX$\)MXF%W-IE
MPNE7?AE]773VN'\RV<%>%;()X)QNSSG\.%/Q0\9'7?[8_MN07WD"W+B&,*T8
M)8 H%VG!9B"1GFJ4GCGQ)-K%[JLVJ/)>WUJUI/(\:'="V,H%QA1Q_"!^M"IS
M2M?\0YX]CTFT^'WA7Q%KWA6\LK*32].U*PFO+FQ-TSAC$R_+YC?, =_)'9>
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MRQ&XGCIG%5[.=]Q<T>QZ3!X7\":1X]\2Z+JZ6[R0RQ_V;!J5_):P!&7>X,R
MD$9P-W7@<DDUYYXRTAM"\77]@VGMIPCDREL;CSPBL 1B3 W+@Y&1G'!Y!J_:
M?$WQ?8:M?:G:ZR\=U?E3<MY$960J H.PKM!P ,@"N?U35+W6M4N-1U2X>YN[
MA]\LK]6/\@ . !P  !Q50C).[9,G%K0J4445L0?7W_"%>%O^A:T?_P  (O\
MXFC_ (0KPM_T+6C_ /@!%_\ $UMT5XG-+N>C9&)_PA7A;_H6M'_\ (O_ (FC
M_A"O"W_0M:/_ . $7_Q-;=%'-+N%D8G_  A7A;_H6M'_ / "+_XFC_A"O"W_
M $+6C_\ @!%_\36W11S2[A9&)_PA7A;_ *%K1_\ P B_^)H_X0KPM_T+6C_^
M $7_ ,36W11S2[A9&)_PA7A;_H6M'_\  "+_ .)H_P"$*\+?]"UH_P#X 1?_
M !-;=%'-+N%D8G_"%>%O^A:T?_P B_\ B:/^$*\+?]"UH_\ X 1?_$UMT4<T
MNX61B?\ "%>%O^A:T?\ \ (O_B:/^$*\+?\ 0M:/_P" $7_Q-;=%'-+N%D8G
M_"%>%O\ H6M'_P# "+_XFC_A"O"W_0M:/_X 1?\ Q-;=%'-+N%D8G_"%>%O^
MA:T?_P  (O\ XFC_ (0KPM_T+6C_ /@!%_\ $UMT4<TNX61B?\(5X6_Z%K1_
M_ "+_P")H_X0KPM_T+6C_P#@!%_\36W11S2[A9&)_P (5X6_Z%K1_P#P B_^
M)H_X0KPM_P!"UH__ ( 1?_$UMT4<TNX61B?\(5X6_P"A:T?_ , (O_B:/^$*
M\+?]"UH__@!%_P#$UMT4<TNX61B?\(5X6_Z%K1__   B_P#B:/\ A"O"W_0M
M:/\ ^ $7_P 36W11S2[A9&)_PA7A;_H6M'_\ (O_ (FC_A"O"W_0M:/_ . $
M7_Q-;=%'-+N%D8G_  A7A;_H6M'_ / "+_XFC_A"O"W_ $+6C_\ @!%_\36W
M11S2[A9&)_PA7A;_ *%K1_\ P B_^)H_X0KPM_T+6C_^ $7_ ,36W11S2[A9
M&)_PA7A;_H6M'_\  "+_ .)H_P"$*\+?]"UH_P#X 1?_ !-;=%'-+N%D8G_"
M%>%O^A:T?_P B_\ B:/^$*\+?]"UH_\ X 1?_$UMT4<TNX61B?\ "%>%O^A:
MT?\ \ (O_B:/^$*\+?\ 0M:/_P" $7_Q-;=%'-+N%D8G_"%>%O\ H6M'_P#
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M_ "+_P")H_X0KPM_T+6C_P#@!%_\36W11S2[A9&&?!7A;:?^*:T?I_SX1?\
MQ-"^"_"VT?\ %-:/T_Y\(O\ XFMP_=./2D7[H^E'-+N%D8O_  A7A;_H6M'_
M / "+_XFC_A"O"W_ $+6C_\ @!%_\36W11S2[A9&)_PA7A;_ *%K1_\ P B_
M^)H_X0KPM_T+6C_^ $7_ ,36W11S2[A9&)_PA7A;_H6M'_\  "+_ .)H_P"$
M*\+?]"UH_P#X 1?_ !-;=%'-+N%D8G_"%>%O^A:T?_P B_\ B:/^$*\+?]"U
MH_\ X 1?_$UMT4<TNX61B?\ "%>%O^A:T?\ \ (O_B:/^$*\+?\ 0M:/_P"
M$7_Q-;=%'-+N%D8;>"O"VTX\-:/T_P"?"+_XFA?!7A;:/^*:TCI_SX1?_$UM
MMRIQUQ2C[HHYI=PLC$_X0KPM_P!"UH__ ( 1?_$T?\(5X6_Z%K1__ "+_P")
MK;HHYI=PLC$_X0KPM_T+6C_^ $7_ ,31_P (5X6_Z%K1_P#P B_^)K;HHYI=
MPLC$_P"$*\+?]"UH_P#X 1?_ !-'_"%>%O\ H6M'_P# "+_XFMNBCFEW"R,3
M_A"O"W_0M:/_ . $7_Q-'_"%>%O^A:T?_P  (O\ XFMNBCFEW"R,3_A"O"W_
M $+6C_\ @!%_\31_PA7A;_H6M'_\ (O_ (FMNBCFEW"R,-O!7A;:?^*:T?I_
MSX1?_$TH\%>%MH_XIK2/_ "+_P")K:894@>E*.@HYI=PLC$_X0KPM_T+6C_^
M $7_ ,31_P (5X6_Z%K1_P#P B_^)K;HHYI=PLC$_P"$*\+?]"UH_P#X 1?_
M !-'_"%>%O\ H6M'_P# "+_XFMNBCFEW"R,3_A"O"W_0M:/_ . $7_Q-'_"%
M>%O^A:T?_P  (O\ XFMNBCFEW"R,3_A"O"W_ $+6C_\ @!%_\31_PA7A;_H6
MM'_\ (O_ (FMNBCFEW"R,-_!7A;;_P BUI'X6$?_ ,32_P#"%>%O^A:T?_P
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M_P# "+_XFC_A"O"W_0M:/_X 1?\ Q-;=%'-+N%D8G_"%>%O^A:T?_P  (O\
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MFO./$.I3H]SJ&ERWT2VVJ16WVB?4S&A<2JC0Q6R91U !SO"GDGYL4:[:&_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN2ZGTFQDN)0!),]LA=\8QEB,GH/R%6&L+-H;B%K2!HKHDSH8QME)&"6'\60
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M_?V/_P"-T?\ "D_#G_/[JG_?V/\ ^-T6#^V\'W?W'A=%>Z?\*3\.?\_NJ?\
M?V/_ .-T?\*3\.?\_NJ?]_8__C=%@_MO!]W]QX717NG_  I/PY_S^ZI_W]C_
M /C='_"D_#G_ #^ZI_W]C_\ C=%@_MO!]W]QX717N9^"?AP*3]MU3_O['_\
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M4_[^Q_\ QNBP?VW@^[^X\+HKW,_!/PX%.+W5.G_/6/\ ^-T#X)^',<WNJ?\
M?V/_ .-T6#^V\'W?W'AE%>Z?\*3\.?\ /[JG_?V/_P"-T?\ "D_#G_/[JG_?
MV/\ ^-T6#^V\'W?W'A=%>Z?\*3\.?\_NJ?\ ?V/_ .-T?\*3\.?\_NJ?]_8_
M_C=%@_MO!]W]QX717NG_  I/PY_S^ZI_W]C_ /C='_"D_#G_ #^ZI_W]C_\
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M_P#</_?1_P :- U+%%5_L-O_ '#_ -]'_&C[#;_W#_WT?\:- U+%%5_L-O\
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MP_\ ?1_QHT#4L457^PV_]P_]]'_&C[#;_P!P_P#?1_QHT#4L457^PV_]P_\
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M !H^PV_]P_\ ?1_QHT'J6**K_8;?^X?^^C_C1]AM_P"X?^^C_C1H&I8HJO\
M8;?^X?\ OH_XT?8;?^X?^^C_ (T:!J6**K_8;?\ N'_OH_XT?8;?^X?^^C_C
M1H&I8HJO]AM_[A_[Z/\ C1]AM_[A_P"^C_C1H&I._P!QOI2C[HJLUE;A20AZ
M?WS2BQM\#Y#_ -]FC06I8HJO]AM_[A_[Z/\ C1]AM_[A_P"^C_C1H/4L457^
MPV_]P_\ ?1_QH^PV_P#</_?1_P :- U+%%5_L-O_ '#_ -]'_&C[#;_W#_WT
M?\:- U+%%5_L-O\ W#_WT?\ &C[#;_W#_P!]'_&C0-2:3[G/J/YTZJSV, 7A
M"/\ @9I?L-O_ '#_ -]'_&C06I@^'_AYX<\+3"30(+VS'FF9HEU2Z:)W(P6:
M-I"C' ')!Z#T%3Q>!O#L/AFR\/QZ=C2[&99[>W\^3Y'5RX.[=N/S$G!)%:_V
M&W_N'_OH_P"-'V&W_N'_ +Z/^-&@]3-\3>$-$\86EO;>(K1KJ*VF$\*K<21;
M) " V48'.":9+X-T:XTV.RN5OITAG^T12S:E<O/%)C&4F,AD3C(PK <GU-:O
MV&W_ +A_[Z/^-'V&W_N'_OH_XT:!J<]=_#7PI>+I(?39(O[&B\K3VM;R>!K=
M>^#&ZG)QRQY/K4NH?#_P[JBP?VA:W,[PV[VOFMJ%QYDL+L&:*60/NE0D9VN6
M'YUN?8;?^X?^^C_C1]AM_P"X?^^C_C1H&I!J6AZ=J^A3:-?VJOITT7DO;H3&
M-G]T;2"!QVQ5:3PGHDOB#3M<>P4ZEIL#6]K<;V!CC((*XSAA@G[P.,G%:'V&
MW_N'_OH_XT?8;?\ N'_OH_XT:!J<]IOPW\+Z2UF+*RN?)L9OM%M;3:A<300R
M9)WK"\A0,"Q(.W()R.>:U;+PUI.G1:G':6FU=6GDN+T/([^<[@!CEB<#  VC
M '8"KGV&W_N'_OH_XT?8;?\ N'_OH_XT:!J1Z1I%EH.CVVEZ5"8+.U3RX8R[
M/L7TRQ)/XFKE5_L-O_</_?1_QH^PV_\ </\ WT?\:- U+%-BQY28QC:,8Q_2
MH?L-O_</_?1_QIL=E;F-3LSP.0YHT%J6J*K_ &&W_N'_ +Z/^-'V&W_N'_OH
M_P"-&@]2Q15?[#;_ -P_]]'_ !H^PV_]P_\ ?1_QHT#4L457^PV_]P_]]'_&
MC[#;_P!P_P#?1_QHT#4L457^PV_]P_\ ?1_QH^PV_P#</_?1_P :- U+%%5_
ML-O_ '#_ -]'_&C[#;_W#_WT?\:- U+%%5_L-O\ W#_WT?\ &C[#;_W#_P!]
M'_&C0-2Q15?[#;_W#_WT?\:/L-O_ '#_ -]'_&C0-2Q15?[#;_W#_P!]'_&C
M[#;_ -P_]]'_ !HT#4L4444AA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_/"[_P"^%_\ BJ/^$]TO_GA=_P#?"_\ Q5>?44?5X!]=JGH/_">Z7_SPN_\
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MST@_,T?Z9Z0?F:+R[ARQ[$1T;2]I_P");:=/^>"_X4BZ-IFT9TVTSC_G@O\
MA4Q^V;3Q!^9I%^V;1Q!T]6IW?<.6/8C_ +&TO_H&VG_?A?\ "C^QM+_Z!MI_
MWX7_  J7_3/2#\S1_IGI!^9I7EW#ECV(O[&TO_H&VG_?A?\ "C^QM+_Z!MI_
MWX7_  J7_3/2#\S1_IGI!^9HO+N'+'L1?V-I?_0-M/\ OPO^%']C:7_T#;3_
M +\+_A4O^F>D'YFC_3/2#\S1>7<.6/8B_L;2_P#H&VG_ 'X7_"K4,,5O$(K>
M-(HUZ(BA0/P%1?Z9Z0?F:/\ 3/2#\S1J]V-<JV18HJO_ *9Z0?F:/],](/S-
M*Q5R=ONGZ4+]T?2J[?;-IX@Z>K4H^V;1Q!^;46%<L457_P!,](/S-'^F>D'Y
MFBP[EBBJ_P#IGI!^9H_TST@_,T6"Y8HJO_IGI!^9H_TST@_,T6"Y8HJO_IGI
M!^9H_P!,](/S-%@N6**K_P"F>D'YFC_3/2#\S18+D[?=/TI1]T56;[9M/RP'
MCU-*#>8'$'YM185RQ15?_3/2#\S1_IGI!^9HL.Y8HJO_ *9Z0?F:/],](/S-
M%@N6**K_ .F>D'YFC_3/2#\S18+EBBJ_^F>D'YFC_3/2#\S18+D[_=_PI:K/
M]LV_=@/XM2_Z9Z0?F:+"N<IHOP^_L>2!O[3\[R=,N;#'V?;GSI_-W_>/3ICO
MUR.E7+CPG>?\*OA\)Z9K36-S%IT5@NI+!D@(JHS!-PP64$?>XSG)Q6__ *9Z
M0?F:/],](/S-%AW.'T;X6QV7P^D\':A>VKZ?M1HIM/LWMIUF5@WG,[2R!GW*
MIZ #&,8P!4G^'7BJZ\6:=K6I>+H-12SE:1;-K)X8XY&@,7G+^]?Y@=K;!M4G
M=C:6)KT/_3/2#\S1_IGI!^9HL%SF#X.U>Q\+:9HGAWQ%'8P6>G_891/IZSI-
M\@7S0 ZLK\$_>*\\@U5;X:1Z?;Z0WA;59-,O-,TYM,,TT9F6YMV&2'"LC!@_
MSJR,N"3P1P.Q_P!,](/S-'^F>D'YFBP7.3\ >"]4\)WNM7&MZNFN76IO#(VH
MM$8I9-B; C)R % &"&).XY QDT]"^'.J:-X^U+Q3+KMCJ%SJ,W[QKK3',L,&
M?]3$XG 48 &=IZ#CM7<?Z9Z0?F:/],](/S-%@N<5IGPS;2]3LI(-8!LM)>\F
MTJV-K\UO+<YRSOOQ(J[GVJ%7[W).*J^$OAEK'A'3=7M[3Q)9RWFK"5Y]4;2G
M^UM,X.V0N9RIVEB0NWDY[DFN_P#],](/S-'^F>D'YFBP7.2^'/@*Z\ Z>]@=
M1L;ZWD+22RII[Q7$\I(^>20S.&XR,!1VYZY[6J_^F>D'YFC_ $ST@_,T6"Y8
MIL?^K7KT'6H?],](/S-(GVP1K\L(X'4M185RS15?_3/2#\S1_IGI!^9HL.Y8
MHJO_ *9Z0?F:/],](/S-%@N6**K_ .F>D'YFC_3/2#\S18+EBBJ_^F>D'YFC
M_3/2#\S18+EBBJ_^F>D'YFC_ $ST@_,T6"Y8HJO_ *9Z0?F:/],](/S-%@N6
M**K_ .F>D'YFC_3/2#\S18+EBBJ_^F>D'YFC_3/2#\S18+EBBBBD,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILG^
MJ;_=-.ILF?+;'7!Q0!4&K:;& CW]JC+PRM,H(/H>:/[9TO\ Z"5I_P!_U_QK
MR_5?^0S>YZ_:)/\ T(U4KM6&35[GE/'23M8];_MG2_\ H)6G_?\ 7_&C^V=+
M_P"@E:?]_P!?\:\DHI_5EW%]?EV/6_[9TO\ Z"5I_P!_U_QH_MG2_P#H)6G_
M '_7_&O)**/JR[A]?EV/6_[9TO\ Z"5I_P!_U_QH_MG2_P#H)6G_ '_7_&O)
M**/JR[A]?EV/6_[9TO\ Z"5I_P!_U_QH_MG2_P#H)6G_ '_7_&O)**/JR[A]
M?EV/6_[9TO\ Z"5I_P!_U_QH_MG2_P#H)6G_ '_7_&O)**/JR[A]?EV/6_[9
MTO\ Z"5I_P!_U_QH_MG2_P#H)6G_ '_7_&O)**/JR[A]?EV/6SK.E[3_ ,3&
MTZ?\]T_QI%UG2PH_XF-H./\ GNG^->2T4?5EW#Z_+L>M_P!LZ7_T$K3_ +_K
M_C1_;.E_]!*T_P"_Z_XUY)11]67</K\NQZW_ &SI?_02M/\ O^O^-']LZ7_T
M$K3_ +_K_C7DE%'U9=P^OR['K?\ ;.E_]!*T_P"_Z_XT?VSI?_02M/\ O^O^
M->244?5EW#Z_+L>M_P!LZ7_T$K3_ +_K_C5J&:*XB$MO(DL;='1@P/XBO&J]
M.\(?\BK9_P# _P#T-JQJT5"-TSHP^)=:?*T;5%%%<YW"-]T_2A?NC'I0V=IQ
MUQ2C[HH **** "BBB@ HHHH **** "BBB@!'^XV?2E'W1]*1ONG'I2CH* "B
MBB@ HHHH **** "BBB@!LGW.?;T_K3J1_NT.ZQQL\C!4499F. !ZT 4/[=TW
M_A(O["^U+_:?V;[5]GVG/E;MN[.,=2.,YY!Q@U)J>JV6CVT<^HS>3%)/';HV
MQFS)(X1!P#U9@,]!WKRQ[K7(K0>/QIUD;$Z@-3-R+V3SSIY00[?)\G;CR<28
MW]1NZ\54\27\%WJ$RZKJUR-93Q59K;Z?]K<1FS^T0^6X@SL*$8;S<9WDKN_A
MH ]?O]5L],>T2^F\IKVX%M -I.^0J6"\#CA3R>.*K:;XDTO5KI;:PN&>=K2.
M]$;PNA$+LRJQW 8.48;3R,<@5Y7]MBO?$.@G4]5NG\1IXIE6\TU[IREO$#.(
MB("=J+L\O:X W;LY.37;:?!#:_&*]M[:)(88O#EFD<<:A511<7   '  '&*
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MW7/89_B5NBY2+2<3X[%ILQY_!9,?C70T %%%% !1110 4444 %%%% !1110
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MKRUO999WCR\MN?DX5  ", @ # &,').GKOAN/6[FPNTO[S3;W3Y'>"ZLS&6
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M6W_/4?D:?M*G</84.R,#_A M+_Y[W?\ WVO_ ,31_P (%I?_ #WN_P#OM?\
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MB@ HHHH *;)_JVXSP:=39,^6V.3@XH (_P#5)C^Z*=38\^6N>N!FG4 %%%%
M!1110 4444 %%%% !1110 4444 !^Z?I2+]T?2AONGOQ0O"C/7% "T444 %%
M%% !1110 4444 %%%% "-PI^E*/NCZ4C?=/TH7[HSZ4 +1110 4444 %%%%
M!1110 4444 (WW3]*4=!2-]P]^*4?=% !1110 4444 %%%% !1110 C_ '?_
M -?]*6FO]WIFG4 %%%% !1110 4444 %%%% !1110 4444 %-C_U:_0=<_UY
MIU-C&(E&,?*./2@!U%%<_P",M2O-/T>V339_LUQ?7]M9+<[58P"2159P&!!;
M;G&01DC(/0@'045Q&JV#>#)='OM)U'4IEFU&WL;JWO\ 4)KI;A)G$>X>:S;'
M4L&RFT$!@01C'.KJ'BI;(!=7BFN7\7O:0L8Y41$_> AQYA+QC@B,%?NXSSD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?0U83Q=*S0WATT#1Y[W[%'=_:/WFXL8PYCVX"%QMSNS@@D#LK>$9KF62ZO\
M45EOIKRUN))([?9&$MWW+&J%B0#\W)8\L3[4)X1E5H;-M1!T>"]^VQ6GD8D#
M!_,"&3=@H'.<;<\ $GG(!$GC&[DDLITT=3IE]??8X+G[5\_WBN]H]O"G:V/F
M)Z9QFKNF^)CJ'V",V7E75Q//%/"9<_9_))#G./F^;8!P/O@UR\%A?R:EI>FV
M?VY;*RU1K@VUSIK1>0@9CS<9,<BY/RA><,,]#70:!I2+XKUO5XTGCBGD6.%)
MHFCPVU?-90P!PQ5>>A*DCU(!9U_6WTC4;-561U>WNIF1755;RT# '*D]^,$8
M[YJA;^-GB1)M;TU;&";39-2A:.Y\UC&FTLK+M7#88$ $CKS6GKGA_P#MFZMY
MOM/D^3;W$./+W9\U N>HZ8SCO[54N?!L%[]A2[N2\%MIDNG2((\&59%12P.?
ME(V>_7VH S+KQ+KL6M6ZWEFMA;2:5<W8CAG64NRA"H+-&-KKGD#<OS#K5^V\
M3:A>*L>D:3]O>WM89KDS7:Q,6D4,%3Y,,V.3G8O(_!C>$=1N;J*74M;2X$&G
MS6,2I9[.) H,C'><M\HSC /8"IX?#%]I[EM'U>.V,UM%!<&2T\TDQIL$D?S@
M*V/[P<<#CKD @\0^,I_#S&6ZL+5+;<@C$^H+'<3@E0S1Q;3NV[NA93P>!QFI
M/XCU>VU/6TN@HMK75+2VM_(F7<JR>5P=T1R"'W'N"2H/ :I-1\!SWG]JI!JL
M,*:FXDFF>Q#W!("X4R;@"F5!V[1C) (J[?>$I+R^U"47ZI#>W=K=F,P$LCP^
M7QNW8((C';@G//2@!I\7RC-[_9H_L47ILS>>?^\#;_+W^5MQL\SY<[L]\4R/
MQC=-=EI-*CCL!JITLS_:LR%]^Q7";,%2<#[P(YX.,F0^$)2#8G41_8QO?MAM
M/(_>;M_F;/,W8V>9\V-N>V:>WA/=9^1]MQ_Q.1JF[RO2;S/+Z_AN_'% #=)\
M5RZOK4MI;V5N889I(9<7J_:(=A*[Y(2H*JQ'&&)Y''7'2US<GA>YN]<L[[4M
M0@N5L;@S0.+%4N /FQ&TH;!0;N@09P,GKGI* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *;)_JVQP<&G4V3_5-GIM- 'DFJ_\AF]SS_I$G_H1
MJI5O5<?VQ>XZ?:'Q_P!]&JE>O'8^:E\3"BBNET'2]/GTE+J^196EO!;E3YI*
MKLS\@C!RW.>>.*4I**N.$'-V1S5%=G9Z%I<MO9PFVWM<1W1,[,ZN#&Y"';G
MXZ@BFP:#9#0V>6%5NX[6.Y5T=F.&.02>%YY&T*< ?>-1[6)K]7E_7WG/6&L7
M&G6LD$*1LLDL<I+@DY0Y'?I4\GB6^EM+^V<1&*^D\QUVGY&SD[>>,X'7/2NH
MU&SM[CQ!?W#VWE3VEY:E)@S9E#, 003CZ8 Z5)+IEK?ZA&EVLDD<NJ7"NGFN
M%(",1P#@'(ZBHYX[M&WL:B]U2\OT.5NO$MQ<R74PM;6&XNX_*EFC#[BN ".6
M(&0 .!6;<7MU=A!=W,TX083S9"VWZ9Z5T\.CZ=<06E\+/ >PGG:V21]LCH<
M9SN[]CVK)\16EM:2V#6EO]G%Q91S/&&8X9BV?O$GL*N,HWLD8U(3MS29CUT_
M@+_D/3?]>S?^A+7,5T_@+_D/3?\ 7LW_ *$M%7X&+#_Q8GH-%%%>8?0 ?NG'
MI2+]T?2AONG/I0F-BXZ8XH 6BBB@ HHHH **** "BBB@ HHHH 1N5..N*4?=
M%(WW#GIBA<;1CIB@!:*** "BBB@ HHHH **** "BBB@!&&5('I2CH*1_N-]*
M4?=&/2@ HHHH **** "BBB@ HHHH 1QE?6EILF-G/3(]/ZTZ@#QJ/5O$TD>A
M7&DW]U<W4&H:S,]H\S,+V.&X($!R?[F53/"G;V%6M;\1R:S8ZW=:7JEXME<W
MFBB!H+EXF2.:2,.JE2"A()#8(/6NZTSP7IVE75E/;S73-937<T8D=2";E]\F
M<*. >G3CKFJ$WPST9X=9CM+B]LAJU[!?2?9V3]S+$X<&,,A !<;B"""2>E !
M#;OX:\>:7I]A>7T]AJEI<&6"]O9;HQR1%"LB-*S,,ARI&<?=.,YS2\1>+G\-
M^*-:FCMKN^>WL=.VVIO0D+&>Z>'*H5.UN<ELG< HXQFNBTOPPEAJ[:K?:G?:
MO?\ D?9XY[WR@88RVYE58D11D@$G!)VCG  JOK'@C3=;U"\O+N>Z22\CM(Y!
M$Z@ 6TYG3&5/5C@^W3!YH F\.>(+K5KW5M/U.PALK[2YTBE6WN3/&X>)9%97
M*(>C8(*CD=ZX;7;]]*^*^A:+X=UG5M2UJ]U W>IPSW;26]K8[3NC,0Q&G8J=
MN[CD_,,^BV&B6VGZQJFI0O*TVJ21R3*Y!52D8C&WC(X49R3S7.Z)\-K7P_XF
MO]<T[7M7%SJ5SY]XLHMI!-\V?+W-"7"=L*PX[T >9ZGXP\10_!/Q3)%'KAFA
MU2=(M:2\C"P*+I0%!,HE  ^7 7'/I7M7B6UM[K0+@7VJW6DVD8$T]U:SB!UC
M0[F'F8RJD#DC!QT(K%G^&NCW'@;4_"KW-\+'4KE[F:02)YJLTHD(4[< ;AW!
MX_.M'QGX1M/''AN70]2N[VUM9G5Y#9R*C.%.0I+*PQG!QCL* /*M(\4ZIJ^C
MV<=C>:G%X>UCQ8EE87$US)]I>S"LTBB8GS,,\9&[=N +#/&!MZ;JEM)X)UFY
M\6^(-7M--\,Z]>VHDAOGBENXXV*QH\JXD<_. ,,"Q SFNN/@&UD\/VNE7.K:
MA,EA<0W&GS^7;1O8O%PGEB.)4QC(PRL""167JWP?T/6-#L-+N+_4TAL[V34'
M96A8W5PYR9)E>-D8Y)XV@88C&.* .9MM7,/P7T[Q1X^UC6K*.!)C:VT%^\$U
MXKL?LX=D(>1]F,?-@CYFSR:]"^'\VLW/P]T6;Q-N_M22U5I]ZX8YZ;AV;;C(
M]<UF:[\,[?Q)<Z3<ZOXBUF>YTF1I;>0BUP7)!W-'Y&PD8 'R_KS776-O+:64
M<$]Y->R(,-<7 0._/4A%5?;@"@">FQ_ZM>,<#C%.IL?^J3'3:/3^G% #JIZQ
M<&TT*_N1!-<F&VDD\BW8B23"D[4(Y#'H,<YJY10!X/H\FF_\)+:3Z+_PC\$5
MUH6H+-!H2LX7"QE$GN,@3RX!;E59><YR&K2ATIM$L_#G_"(6JVVJ:GX1OBTD
M(Q)=7"Q6[1,Y_B8.QP3TW&O9J* /)/#7_")'XC^%CX3^SB<Z1=?;5@^\'Q!_
MKN_G9SNW?/\ WNU;7C#13XA\8W6F1MLFG\.2F!\_ZN9;B-HW_!U4_A7H-0W<
M,ES:2PPW,MH[J0L\(0O&?4!U9<_4$4 >4ZG/_P )9\-;_P 17EO);_VSJ.F0
M)&=T<D<$=W"FS/4?O6G8'C[P^IHZ_P"&]&T]/B#+8Z9:V[:4EM<:<(HPJV4I
MA5C)"HXC8E%)*@$[1G.*]ATZPATO3+:PM=WDV\:QH7.6( QDGN3U)[FK- 'B
MOB9?#IU[XA?:3$?%/G0?V*I_X^!/]C@\HVPZ[_,QNV<X"[N,5)XETNU,/Q$U
MRZM(9-7T^ZLY+6Y9<O;2):VS;HSU0[NI7&<#/05ZM8:-;Z=J>J7T#RM+JDZ3
MS!R"JLL21 +@<#;&#SGG/TK0H \?\5#3#<^+_P"UPA\7><I\.[O^/K;Y4?V?
M[+WV^=OW;.^_=Q5;Q1HUI<+X\U6\MU.J6NI:<(+I21);-Y-H28G',9.>2I!(
M ST%>TT4 >4:G#I/ABY\7V%MHUO_ &.4TPO81RFTME,LCH\DC(#MCVJI<[2"
MJD,"":Y_28=+D7Q=:-K&C6.F21Z7.9M(TYQII/FRB3,8<B2(E!')(&52 0Q7
M!%>[T4 <1\,+FWDTS4K>RL],A@M[O N-%F9["Y8HI+0J>(\<!D4D!MW))-=O
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4V3_ %;?0TZFR?ZML],&@#R35O\ D-7N?^?B3_T(U4KN;GP+
M]LNI;G^T=OG.9-OD9QDYQG=47_"O?^HG_P"2_P#]E7HJM32W/#EA:S;=OR.+
MJ>WO;JT#BTN9H!(,.(I"N[ZXZ]:ZW_A7O_43_P#)?_[*C_A7O_43_P#)?_[*
MG[:GW$L+76R_%')QWUW$L8BNID$88(%D(V ]0/3/>G#5+\6X@%]<B$+M$?G-
MM ],9QBNJ_X5[_U$_P#R7_\ LJ/^%>_]1/\ \E__ +*E[:EW']6Q';\3E9=4
MOYP@GOKF0(^]0\S':WJ,G@^] U._#!A>W 8.7!\ULAB,$]>ISUKJO^%>_P#4
M3_\ )?\ ^RH_X5[_ -1/_P E_P#[*CVU+N'U;$=OQ.:L-9N]/N8I4?S?)1DC
M24DJ@8<[<$%3[@@TW5-4GU:Z6:Y"@I&(U"Y. /<DDGDG))ZUT_\ PKW_ *B?
M_DO_ /94?\*]_P"HG_Y+_P#V5'M:5[W']7Q%N6VGJCBZZ?P%_P AZ;_KV;_T
M):N_\*]_ZB?_ )+_ /V5:F@^%O[#OWN?MGG[HC'M\K;C)!SG)]*FI6@X-)ET
M<-5C44FCH****X#V /0TB_='TI3]T_2D7[H^E "T444 %%%% !1110 4444
M%%%% "-]T_2E'W1]*1ONGZ4H^Z,^E !1110 4444 %%%% !1110 4444 (WW
M3]*4?=%(WW3]*4=!0 4444 %%%% !1110 4444 (_P!W_"EI'^[Q2T %%%%
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MQ#N>">% (YKI_!FKW6M^%+:[U HUVLDUM.\:[5=X9GB9@.< E"<=LT ;M%<
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MP?\ ?!_QHL%_(L457Q>?WX/^^#_C1B\_OP?]\'_&BP7\BQ15?%Y_?@_[X/\
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M:+!?R+%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !39/\ 5-_NFG4V3_5MCG@T $?^J7']T4ZO%Z*[/JWF>7]?
M_N_C_P  ]HHKQ>BCZKYC^O\ ]W\?^ >T45XO11]5\P^O_P!W\?\ @'M%%>+T
M4?5?,/K_ /=_'_@'M%%>+T4?5?,/K_\ =_'_ (![117GW@+_ )#TW_7LW_H2
MUZ#7/4AR2L=M&K[6'-:P4445F; ?NGZ4B_='TH;[I^E"_='TH 6BBB@ HHHH
M **** "BBB@ HHHH 1ONGZ=J4?='TI&^Z?I0OW1]* %HHHH **** "BBB@ H
MHHH **** $;[I^E*.@S2/]QOI2C[HH **** "BBB@ HHHH **** $?[O%+39
M/N<^H_G3J "BBB@ HHHH **** "BBB@ HHHH **** "FQ_ZM?H.N?ZTZFQ8\
MI,8QM&,8_I0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\P
MG\0^+(_&)\%IJ$7VN:Z$\6J%(MR6FTL5V8P7&,=/7M@T >GT5Y[X\\:ZAIEY
M!I_AUQNMYX1J%T55A'O8!8P""-S#)/'  ]:R?%GC'4-/\>:GITGB_P#L&TMX
MHFMT_LQ;GS&9 2,[<CGU]: /6**Y?PQXI6;PKI,_BJ[M=/U*\CSY,\JQ-+\Q
M"L%)'WA@\?WJY;3_ !=XBEU73=7GOHFTC5-7?3DT[[.H,*Y*J_F#YB<KSGC\
M^ #U&BO+M/\ %WB*75=-U>>^B;2-4U=].33OLZ@PKDJK^8/F)RO.>/SXU/M_
MBW3O'MC!JFJ6;V=]+)_H:P!(HHOX-LS!2\A/\ R>^,= #O:*** "BBB@ HHH
MH **Y#7=8%MXR6PO/$O]AV?V 3*=UNGF2>8P/,J-V'05%8^*]12WMH88%U=[
MO4IK2SNI)! L\2(7$I*H01PPRJX.W('- ':45R \67T=Z;.&P^UW4VJ262))
M=!4CVP"0D,(\[1SU!/4\\"GV/C*\N)+=KK1TM[=]0;3976[WNDREAD+L 9,K
MC.0?]GU .LHKE;OQC/I^O6=A?6-I"+RZ%O'%_:*M=!6)"RF$+C82.SD@'UR*
M2#QA>2PB\DTB./3_ .TC8--]K)=?WIB\PKLQMW;?XNY].0#JZ*I:;J']H_:W
M6+9%#<O!&^[/F;,*Q]L.'7'/W<]\#GH?%=ZUU#9V5A]LN+F_O8$-Q="-8Q!)
MC)*Q_=QTX)Z D\F@#KJ*Y32?&5SJ,FEO<Z2MK:ZE+);QR?:M[K*BL6!4*!MS
M&X#9SP"0,U7L_&VJ7PTPQ:!"HU;S%M-U_@[DY;?^[^5<!B"-QX' SP =G17.
MZ;XL^WR:7$UEY4E]+<PRCS=PA> D, <?,"1P>./RJK'XSNKJ2TAL-)26XNKR
MZM562ZV(OD,069MA."!G !QTYH ZRBN7MO%\U];V$5CIR-J-W+<1M;R7.V.'
MR&VR$R!22,[<87G<,XYK7T/5_P"V-/:9X#;7$,KP7$!;=Y4B'# -_$.X/<$=
M.E &C17$ZSXLU5[6*ZTBT6+3SJT5E]K,H,C@3".0^64("$AE#;MW0X'6I)?B
M-81ZD\9:Q^R1WGV1S_:"_:=V[87$&.4W=]V=H+ 'C(!V5%<'8Z_K;:Y</J,I
M6V_MM=.B@MY8RJ#9N.<P[B/?<"<\8QSL6/B34-2M1?0Z3MTN99#%=+= R@*#
MM9HRN &(XP6(R,@#. #I**X8?$2&&PL@#9-.=-AO+C^T-12W8ET#!$PF'<C)
M/"+RO3.!;E\;3SM*VC:4EW;Q:9'J9EFNO)S&X8[,!&^;Y>G3KDC'(!UU%<ZW
MB>ZO9S'X>TQ;_P NTCNIO.N1!@2 E$7Y6#.0">2JCCYN>*=]XTCTNZU!;H;&
M6Z@MH$N[A(8U:2$2'<VWY% R227.>G4"@#KJ*XS_ (6);?V;)*J6+3Q7B6CN
MFH!K1=ZE@YG"\+@$<KG=QCO73Z5>3W^GI<75LEN[$X$<XF1USPZ.,95A@C(!
MYY H N45Q&I^(;QM#;58]3_L^SN-7CM(I=L>(;=9?+=\NI&6(9LG@#;QU)%U
MZ>.XO8]'\0'7K9--FGDN,0O]CE7_ %?S1(JG=EOE()^3/3- ';T5Q]M=ZIJV
ML:=:#6+FRCDT:.[D-M%"2\A8 D[XVP.>@Q22>*[K0H]1M=4:*\FL[R&"*ZF<
M0(R2C<K3,%(3;R"0N"0.!F@#L:*YJ^UV^A\,)KKQQVZ6T@DFBBF6>*YMR<%T
MD !QM.]3A3D8(P:Z6@ HHHH **** "FR9\ML<'!Q3J;)_JFS_=- 'C-%%%>P
M?,!1110 4444 %%%% !1110!T_@+_D/3?]>S?^A+7H->?> O^0]-_P!>S?\
MH2UZ#7G8CXSV\'_""BBBL#L _=./2D7[@[\4I^Z?I2+]T?2@!:*** "BBB@
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M"HKSSQ7XVUQ-)U"Y\/:>D=E9:C%8OJ#3@R[Q.B2%82A!3DIN+ YR0N #7H=
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M&_O8[ZQT_7DL]*O[Y;^6W:R\V19/,61U63S  C,N<;206/..*[>BB@ HHHH
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M /$4>SGV#FCW.PHKC_\ A:?A;_GXO/\ P7S_ /Q%'_"T_"W_ #\7G_@OG_\
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M8T.R+/\ P@6E_P#/>[_[[7_XFC_A M+_ .>]W_WVO_Q-5O\ A:?A;_GXO/\
MP7S_ /Q%'_"T_"W_ #\7G_@OG_\ B*+UO,/8T.R+/_"!:7_SWN_^^U_^)H_X
M0+2_^>]W_P!]K_\ $U6_X6GX6_Y^+S_P7S__ !%'_"T_"W_/Q>?^"^?_ .(H
MO6\P]C0[(L_\(%I?_/>[_P"^U_\ B:/^$"TO_GO=_P#?:_\ Q-5O^%I^%O\
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MCF^*7A8J1]HO#Q_T#Y__ (B@?%+PM@?Z1>?^"^?_ .(H]G/L'-'N=C17'_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>xfor-20211231_g2.jpg
<TEXT>
begin 644 xfor-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )# \@# 2(  A$! Q$!_\0
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MGHRG(H =13?,0N4W+OQG;GFAI$1@&95+= 3UH =1110 4444 %%%% !1110
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M#XU?!#Q1X*TJ[MK&_P!6BA2*XO-WE(4GCD.[:">B$<#J:^=/!O[//[5WP_\
M"NE^'-"^+WA6ST?3(%MK6W.FK)Y<:]!N:V+'ZDFO3HRA['E;5[];]O(\VM&?
MMN9)VMTMW\SZ7L(+OQ'\$WB^+5AIME/=:7*/$%K&X:TC7:WF8;)^4+SG)QZU
M^3_[-8\)>)OVD?"7ACQ-K>I7/POL=8NY/#=OJ2[8)IF<&)7!X7>5CW8ZM@'&
MXU][?%'X$_';XJ?L_P!GX"U7QWH$NMWEY(VN:PL3PB>U# Q01K'$HQ_>R!G:
M!R":D^+?["7A[Q?^SQX=^'_AJ6'2-;\,[9M*UB92"TQ(,[2E><2'+''0A<?=
MQ5T:E.BI*4OB?3IY_P!=#.M3J5G&2C\*Z]?+^NIP'_!5*>6S\'_#*:W@-Q-%
MXAWQPKP781Y"CZGBN3^/U[\>_P!KSP[I/@-_@G+X.LFOX[N;5M2GW+#M##(9
M@NT88DXRQQ@"O7?C)^R[\2OC9\*?AGHFN^(="?Q/X8U$7%_J.Z;R[R-1M5Q\
MF?,( W9 &<G-?68RJ@=2!4*O&C""BDY*_?0MT)5IS<FU%V[:GYO_ +4GBKPM
M-\>/@S\'/$FO6UGX)\$6MK<:Y>7A/ERR)$NV-@ 22T<:K_VW.:U/V#_B5X=\
M$?M)_$?X8>'M9M]5\'ZW<2:IH$]N3Y6Y1N,:@X.?*;!X_P"6%>N_"+]B2&'X
MA>/_ !I\7;?0/'&K>([SS[6'R&FAM$+,Q $BCG!11CH$Z\TGQ8_8CA;XG?#_
M ,<?"2#0/!6H^';OSKRU\EH8;M RL!B-3SC>IR.0_M6SK47'V-^F_2^]_O,5
M1K*7MK==NMMK?<?%=A\.?$3>)_C)\7?!<\R>)_A]XTDO# G(EM&GN#*<=]NT
M;AW0O7N'P1^+6D_&[_@H-HGC/2&"V^H>$0TT!/-M,L&V6)O=6!&>XP>]?2O[
M-/[.6K?!GQ%\5[[7+S3=2L_&.L-J$%O:AV\N)GF8I('4 G$H&!D<&O.?@?\
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M444 %%%% !1110 4444 %%%% !1110 4444 ?CU\"?%&J_#S]K*T\9S7LO\
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MNI^L3&LS]H#3?%7[5'[76A^ O!>J6^E)X TU+QM1NHS+!#=_NY&8K@ACN,*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9HH J:GI%CK5J;;4;*WO[<G)ANHED3\F!%&FZ59:+:BVT^SM[&V4Y$-M$L:
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MH **** "BBB@ HHI* "EI!2T %%%% !24M% "44M% "44M% "44M% "44M%
M"44M% "44M% "44M% "44M% "44M% "44M% "4M%% !4<C;:DJ"Z;:I/M_6@
M!P:G U4CES5A6H FHIJFG4 %%)2T %)2T4 )12T4 )12T4 )12T4 )12T4 )
M12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )
M12T4 )12T4 )12T4 )12T4 )12T4 )36XI],DZ4 *K4ZH5:I%- #J*** "BB
MB@ HHHH ***3- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %-/44ZF?Q?C0 ZEI*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *K7W^IR!SG'Y\?UJS4%\I>SF Z[21^'- &3;S;JT8FXK MYOWC
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ML=6U72=(\576N>&5UZWLI-6DU&.)K:(V1E\L7>P@!I<#>>?X00: /H>'X?\
MARWCLXTT>U\NS-P8$9-RIY^?.X/!WY.<]<UDZ;\-_ VDQSV%KIEBA:>!I(FE
M+N)(SOA7YF+ +C<J=!V%>*V_BKQ7X@TXK/XIO+=+/PUJFHP3:;,I^T/!<[;>
M1Y#&/,PHP2HVOUY!JEKGB+5/$GC'P_?W^IW*-9:I83V\4,@@B\Z727DV'CG?
M+@8)_B('6@#Z#T_X6^%=*\2#7[318(-6#R2)<*6^1I!^\*+G:I;^+:!GO755
M\HW7Q*U^V\'O=:5XOOM2U.]\,SZCJQ=5;^R;U7B"!5V_N3N>1/*;KLSC@FO?
MM2T75-.^%^JV6D:A>WNM-IT_V6ZO)?,F,[1L4.[ _B(QV% &]:^)=(OM4GTV
MVU6RN-1@SYMG%<(TT>.NY <CJ.HJ[=74%C TUQ-';PKC=)*P51DX&2?<UX/X
M2UKP':^#? 4&GZ=#J?BZVA46EE:)F]MKP0,)GN "&0!MP<OP21U)%>9S>.O$
M?B;P5.NI:F+S[?IJ76J6,U\MP]O<+=0;=L2QC[, Q9#&YYP,9()H ^Q+6[@O
MH1-;S1W$1) DB8,I(.",CT((_"I:\Y_9_ 7X76  P/M=[V_Z>Y:]&H ^=_VL
MOC$/!NBOH=M=&UW6YN=1N(SAHX.R#W;^7UK\R]>\2:C\2M6-Q=%HM.1O]&L@
M?DC7L2.['N:^DOV[M1NKC7/$ZR;@IU""W//_ "R"@C\,U\Z^&?)AC4\5^LY/
MA(4Z$(]TF_5GU>$I*%.*+]OX9C2W^YV]*YO7=!-O()8BT4J'<KH<,I]0:[QM
M8MXUQD5BZQ=PW$38(KZJK2IN%D>E**L?6'[!O[2&H7URO@[7KEIUWB&-G.2K
MG[C#T#8P1ZX-?8_Q(\)WGBR/PVMF8<:?K=M?SB9B T,>[>!P<GGI7Y4_LLVM
MQ>?'"RAL2WF.8A\O_752/Y&OU>^(GB]_!GAT7-O"MQJ-W<PV%C _W9+B5PB!
MO]D9+'V4U^29_0A2KQG'>6_RZGRV/IQC--=3R"_^!OB_3=5U^32;VWETMKVP
M?3H8[DV]W]CB67? )BC>4RM+\KKSM&W(ZU2TW]G_ ,5PZ;>VC#3K9-0CUJW9
M5O99OLRW?E/"Q9P6E(,6ULG.3D>E='=?'#7-)O/B-97MG8[]#BD;2+E5<)=2
M16Z231R#=PP+A@ >5SZ4VW_: O;SQ1JGA*!=,/BF:[@MM)MY69(PCV<<\DTQ
MSR%+/A5PS8 '<CY<\L:OPK\6:YK#ZGJ5KIECNN]#E6U2Z:8JEF[F4EM@!)W
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M&)./W0&*]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M2HV^\OUJ2HV^\OUH D7I7G_BWQI<2236^G3BUM(LK-=]69NF$_QKJ/%FI-I?
MAV]N$.)-FQ?JQP/YUX7XTU=M-TZ<QIY@LXLB/. SX[FO'S?,UE&$]O%7G)VB
MGM?JWZ'3@L$\RQ7U>[4$KR:WMLDGTOK]Q+?:I;J[2NBRGO<7KEV/YFLVW\9:
M6FI16R36BWC,=BP/Y;Y&"0"#UZ5X??>+KGQ/JD5T%W6]LKM=R2$FW10G#( ,
ML-V01U-&FWT_VZ=[JSMUBN'CFBFM,[FCV?+GC<"5QDCIWK\FEG&;2J>UEB97
M]7^6WR/T.&2Y9"'LU0C;T7Y[GVGX%\9G5 +2YE,K]$D88;Z-Z^Q[UV]?+/PT
M\020VMI-+=%YU=MQVE3M#>G<#CFOI+1_$5GK%NCQ2J'8?<)[^WK7Z)D.<O,:
M;IXAKVD?E==['R&:9:L#-.DGR/\ #R-2O*/BW<G^T(4R=J+G\AG^M>K$X&3P
M*\=^+5ZC:B7@Q<2*A(1<#/ XS[FGQ1+ERV2ONU^89+&^,CZ,^?M-\9RQZQJ4
MEM"T<$,JRR+]\2QOGG_9.1G/I7T%\+_B-!<$6[7 EA.,Y.63CC(['^=?)FJL
MEUXAOK.^MV%U%EHAY<GDR1R)\X?'!QMP.0!74_"2\_L34C9):-9LD<(925^4
MG<R '/S!>1GWK\OP>*J9=5CB*+VW7='WN*PT,93=*:]#[K5@RAE.01D&EK$\
M'ZD-3T"VE!RP7:WUK;K]UH5HXBE&K#:2N?E-2FZ4W"6Z"BBBMS,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#.UZ,2:5/D [</S['-<GIS;6QW!
MQ7<W$?G021G^)2OYBN"M6VW# D$YR<4 =/:MP*T4^[639MP*U(V^6@"9?OBI
M*B7[ZU+0 GEIY@DVKOQMW8YQZ9H\M?,W[1OQC=CG'IFG44 9.L>&;+6=+O;%
MA)9+><RS6,A@FW9R&WK@YX_QKGM.T?PA\-M.O+:ZOK=/MDGG7<NJW"O+<-@
M%MW4    #  KS#XY?M 7&E7T_AOPM,%NX_DN]07GRF[HG^T.Y[5\H^,/B5H7
MAFZ:3Q!JSW6I2'<T*DSSGW([?C7TN#R6=>"J5I<J>RZGIT<%*HN:;L?H-9_$
MCP5>,(K;7])<JGEA5G087^[]/:MVVNM)U-0+>6SNP2K 1LC\CH>/3M7Y86?[
M17A.:X,=SI^I6</\,[1*X/U .16[;_&KP6-DUKXC^QR+R/EDC93^5=\L@A]F
MHUZHW>7QZ2/T[2PM8S,5MH5,QW2[4 \P^K>OXU8KX@^#_P"US-9WRVSZW'XJ
MTI?];"TF;B%?[RD\D#T-?:>CZO::]I=KJ-A,MQ9W,8DBD7H5-?.XW+ZN!:Y]
M4]FCSJV'G0?O;$D6GVL%S)<1VT,=Q)]^58P';ZGJ:$T^UC:9EMH5:8[I66,
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M.N9;*^M9%EAN(6*O&P.001T-?J#^QQ^VI:?&.WM_"7BZ6*R\:1)MAN#A8]2
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M +BW'K(G('XC(_&NYHK6E4E1J1J1W3N7&3A)270_&_XZ>%KG2]:B\211.(6
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M4&-J>9@D$Y(.!UKZ]^+&FK'-#=@#+'T_ _TKY?\ B$D6A^*%FE"M;3)YTF^
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M^!GP=U#XS^+AIL#M::7; 2ZA?;<B*//W1ZNW0?G7ED<FU<GMS7Z3_LK^ 8?
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M6K1<+<6S&&5<]U9<'->FZ%X)'B+X<:EXC\((WB?4-+F\N\TJV_U@3&1(@_B
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MMY2X(3R\8P,#CVJOXH^%O@_QMI-EI>O^&=*UC3[(*MM;WMHDJ0@# " CY1@
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M#^ZP'/;-?7?P?T6V^Q[HXX_L5HJI%&"74RDEGD!8D]2<5@>'?@9NF6]6RM=
MCG(66WA3$IAR"4..!GN*]JM+."PMT@MH4@A485(U  KFQ>(EC:[Q%1+FV^1Z
MF39=4R_#JC.?,KW^=OR)J***YCZ,**** "JUXN5SWQ_+G_&K-1S#]V3C..:
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M2#S;E+@DKD%WW=U/J:YZ[M9(V!(EMY%;*28*LK Y!!]0:^UM2TO3/V<? _\
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MG16/D\;-3JZ=#E_"'@&U\)ZAJ>I-?7FKZOJ7EK<ZA?LID9(P1&@"*JJJ[FX
MZDDUC^'?AG<^ ;*1-&UO4M2M(5G:WT6_EA%NS2,S[2XBW@;F/.3^->@45X)P
M'EW@'X'Z?X9\'Z)IMVSBZL=6;7&^SRDH+@E]L8+#)C16" <<(.E0^,?@/8ZE
MX+N],TB>:/4$M]36S>YF.P27N3(7(&< GC'3WKU>B@#SK3?@IIL:P7&I:GJ>
MKZJMQ9W+7UU,ID/V8EHHAA0 @9F)&,DL233[WX*Z5->2WUCJ>J:1JDEW=7?V
MZSG42 7!4S1?,I&PE%(!&00"#7H5% 'G,/P)\/Z?+9C3+C4=)LXK>WM;BSL[
MDK'>QP$M$)3@MD$G)4@L"0<BDT[X7B]^*'B/Q=JMM# ;RQ&DV\-O.S^9$"=T
M[\ +(R[4P,X5.M>CT4 >76O[/NC65O;06^LZS!$MM#977EW"*UY!"3Y*2,$R
M-JG;N3:Q7@DUN1_"NR;QE:>(KS4]2U&6PDEEL+2ZD1HK1I%*ML(4.1M) 5F(
M&>G2NUHH *\T\*WT2^/_ (E:W/A8+(V]KYF>-D4&]_R+FO2Z\ FOY&^#?C.[
MMV_TGQ+KUQ:VY/?S9UMP/IA30!Z#\#[&6'X>VFH7((O-8FEU6?=UW3.6&?HN
MT?A7?56TVQCTO3[6SA&V&WB6%!Z*H 'Z"K- !1110 5'-<16R;Y9%B7IEC@5
M'?7]OIEJ]S=3+! @RSL>*^>_'WQ7GU?Q TL2366BV6V)&V%Y7DD;:LAC'(&>
MF?0U2BY;&-2IR:+5L]QU+QGH^E0F2>\3H<*H)+$#ITK(TCXF6-U"CZC$^FA^
M5DDY0^V1T-?/UM9^*M-U3Q/=^-O%::3H=C);VMC<:BD960 @O/@8QO!VX[=:
M[GX>>'=/T?0M5T#P[=WM]IL.KO#?2^(9&0+',NYFM93]X*&&WMFKY4E<MTZM
MV[K2W]7\CVC2/$>F:\K'3[V*YV]54_,/?!YK2KY\;6O"_AWQ--X=L=3NM(\1
M^'[8NLVI'FX@7 ,A<\.N6 .>M>M^$?','B:&!#$8KEH]Q*G=&V.I5NX/45#5
MA<SB^6HK/\SJ****DT"BBB@ HHHH KW:[D_3^H_45! VX"KDH)C..HY%4(\+
M(RCIGCZ4 75J2HHZE6@!:*** "BBB@ HHHH \G_:>^#,/QS^#^L>'@B_VG&O
MVO3I".4N$!*C/HPRI_WJ_'/PGKEW\-_B!I.JO$T5WHVH)+)%("""CX=3Z'&1
M7[R5^6/_  49^"*^ ?BA'XNT^'9I'B;=)*%Z)=+CS![;@0WUW5X^84;I55\S
M]7X'S1*<\KK/W9W<?6VJ^:U^7F>D_MW>$X_'/P)L_$]@JRMH]Q%J"/U/V>50
MK8/IRI_"OAGPEJSW-N^FO,J3,=]M)+R"W382>Q[5^@G[->I6_P :/V8(M"U+
M9,R6T^A70;GH,1L1ZX*G\*_.#4M#N?#NLW^DWBXNK"XDM9<\?,C%<_I7C>RA
MB*3I3/H\IQ%3+,5.FMX-KU1V.F>-]3\,7<EOJ%JLD></&R8!KKK'Q)X=UY?E
MG:PE/\$G*UY[I^M37$<5G>0#48L[4!_UHSV#=_H:WKGX>V;;&COA9W##+03#
M)0_W2R\9KYW%8-4/XEK/K_6I^LX#'UZROAVVENG_ )[/\SLH[6VM26CO89D8
M8VISN'H16?9^%[F^\0G2+#:TC*+N%L86-6Y*GV%9NA^#+R&5<WR2QY_@R3Q7
MM7PZT]H;?6;XPK'/%;%83C+85"1D]^>:]#AO!4LPQZP-5MTYIWM_=U_2WS.G
M/\SJ9?E<\:H6G':_=M+IVW/'/&7AW3-+OGLI-?MI-20A9(UA?8A]&<<"J'AK
M0[BT\7:7:RK'N:XC(+./+92?O;NFW'>M30]%CO=):[F/F3SEI9';J6)))/XF
MJBV;GP7J@#,%T^^C2-O]B13N3/89&?QK]9SO@?"X7#+$X'W'&S:;;377?6_S
ML?D>7<1XO'5OJN/:DJJ<4TDFFU9;:-'UOXR\)7?V?PO<V=]%&MFK6]Y;RMYD
M9/WD(P/3'/H17E>B?M"6MQ\2],\-0V2Q7*WHLI-DOE2MO!PP[M@\^@ YKF?A
M3\:=;\)V=VFHK_:NEM@++=2E7C(&-JL.6&.,5GZM\0M,U+Q5>ZY#X5M&N;J)
M8))9,[RBC"$,.58>HQGOFO&J9Y@,/3]GB'>7:U[7_(_&Y>%N?U,TEBL)+EC[
MJ;4N52Y=NMVK:--=]6CWWQI\0]!^'\;'5M0C2Y,1EAM8SODF'0;0/4\5Y/\
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MM^@KWRBNJMG&*K1Y4U'T-IXRK-6V]!J(L:JJJ%51@*HP /2G445XAPA1110
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MK3$[X]$MG9-/M?0;1@RL/[S_ ("H]/\ V=_!T7B";6M1TZ+5;YV_=QS1*EM
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MTW]'^AT.GV::;8VUI$6,<$:Q*6.3A1@9_*K%%%<ISA1110 4444 %0W4?F(
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MCW *H#V^:O2JYKX<^%6\&^#]/TV9_.O0IFNYO^>MPY+R-^+$_ABNEH ****
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MKM]FG $D2F1BB, 2 0I48S6]J&IV>E0K->W<%G$SB,27$BHI8\!<D]3Z59H
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M2!N*D#.PG;NYQ7+^'?@;%?:3X[_ME'TN?Q9=^<;:UN!+]AC4AE5&*XR9-TI
M&,OCFO8:* /.-.^"MEIOB)=3BU:]$+7O]ISV:)$BS71 #.7";PC$;C&&VY[8
MXKT>BB@#XS\(PI\-_P!I_P")O@;/EV>L>7XFT^/;A<R<3!?^!9_*O*OVR_"H
ML_%6C>(44[+^W-M*V./,CZ<_[I_2O9OVR\_#_P"+WPC^(ROY-LMX^A7[[>##
M+R-WMRWTJI^U-X;&O?"/4)T^:73)4O$/7*@[6_0U\IB(>SKM'[#EN)YI87%_
MSQY7ZKW7^2?S/D/X:ZA?Z;XNM)=.CMY).DJ7+JD;1<;LL>G'?K7:?'S6M6\+
MZDUE=+]M\-:@1+87MO'NCV@<J[+GD=L]17BYFPV".#79>#?B1K_@FXDGTJ_:
M,3;1+'*HE5@IR.&SC'M6\:O+3<._];'TF(RZ5?&0QE+EYHJUFOQYM;6Z:?\
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M]3EJ-6NK_>?RCQ%1^I3J8:][2:^YLZ>BBBO:/A HHHH **** "BBB@ HHHH
M2HV^\OUJ2HV^\OUH D7I2TB]*6@ HHHH **** "BBB@ HHHH *\)\=:?_8/C
MR1T&V*YQ(OX]:]VKS/XV:49--L]21?FMWVL?]DU\SQ!A_;8-U%O!W_S/<R>K
M[/$J#VEH2Z7<":T!SGBJVO6XNM.E4C/%9_A.]$UDG?BMB7YDD0^E?+TY*MA[
M/JCV91=*L8OP7U,V>L7^F.<"0;U'N*]BKYYL[IO#OC:TN1POF8;Z&OH1'$B*
MRG*L,BOH>'*_/AI4'O!_@_Z9Y>=4N6M&JMI+\4.HHHKZT^>/C7X1_"7PO^U+
MXT^)_BSXEV#>)I['Q!/HNG:9=SN(-/MX<!=B*PPS9R6KTW6OV6/!&C?L^^)?
M -WJ5\WAMO.U"&[UBZ,YTIP"R/$QY18R,X';/K4/C;]EK5I/'&L>*?AQ\1M4
M^'%[KK+)JUK:VT=S;7,@&/-"/]QSW(ZU!K'[)=[>?!F7X>VWQ#UIH=4O_MFN
MZMJ!-S<WJ%@TD,>6 A1B.V?UH \0_8AU&7XZ_$:]\:^-=:AU_7_!.F1:5HEF
MR$'R2"#>[6ZL^,;O4_2NF_9Y^!?@[]I_PKXB^(7Q+L)/%/B#5=9O+>,W5S(%
MTV&)RD<4*JP"8'/Y5[-J'[,ECIGQ0\$>-/!FICPI<>'[$:3=645L)(M1L0 %
MB?D88=GY/3TKF]>_9+US3/$FMW_PU^*.L?#S3-<N6O-0TBVM8[F#SF^_)#NP
M8BW.<=Z /-/VP/A?I7PJ_9S\!>%(1JOBO2+3Q99_Z+J%P;BYN8V,A,"L<=02
MJCMFN ^&OAOP]XW_ &B_!]G\+?AE??"35?"][]M\2?VC=B&:2T*X$7D;R7SG
MZ<\U].ZY^R=;W_PQ\&^#K7Q7JCKX?UVWUQ]2U5C=SW3QN69"2PVAB>,<#TK9
M^*W[.L?CKXG>$OB'H&MMX5\7:#)LDO(K<2I?6I^]!*N1D<D YX!/M0!\M?M>
M?$6?XO:Y%<66J6]OX(\'^)K'3HH/.3?J>H&8>=-MSGRH1\H8\;BQK]!;6YAO
M+>.>WE2>&10R21L&5AZ@C@BOFSXI?L!_#'QU:&31=&M?#&L3:@EY=:E$DDS3
MQ[RTT15GP!)D@D=,\5]"^&_#>F^#] L-$T>T2QTNPA6WMK:,DK'&HP%&>>*
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M"Q7T8,N,CWK@_@'\>K+XF3ZIHUQ<?\32TFDDMC)A6N;4L=C8_O*"%8>P-/\
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M HHHH **** "BBB@!*C;[R_6I*C;[R_6@"1>E+2+TI: "BBB@ HHHH ****
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M G\ZGKY:T/Q)>^'?%?Q2M$NYY9O$^NW.G:<LD[-Y5RBQ(5C!/R?NY=_''R4
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M-]R7,"H\))*,-LV5R<$?2O4Z "BBB@ HHHH JWK87'X#\?\ ZV:C@6DNCNE
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M8BIFO[Z$^=,PSN=NV\COBCQ5^T%XG\1-:M'/+I#6=PTELMC*T:1QD?*F!W7
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M%%%%(84444 %%%% !1110 E1M]Y?K4E1M]Y?K0!(O2EI%Z4M !1110 4444
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MT>QOK/2/+MB)B;B-HU:X.[#>6K$ *!NZFO7--T=+7P]:Z5<$7"1VJVTAQ@.
M@4_G0!P/A'QUXT\76.A^([70]-D\,ZM(KQVHG9+Z"U?[D[LWR-QAC&!D!L9)
M%,\0_'O1[/0]9NM+BGN+BVM+FXL);J!X[34#!_K!#+_'M/7'H2,@4W0OACXJ
MT73=)\,Q>)X8/">F2H8I+:%DU"6W0Y2W>3=M"]%+ 995QQDFN0M/V66L[&[T
MV*]TR.SCM;NWLKH6CM=$S @&4LY4; Q'[L*6XSZ$ ]4^&/C6X\=Z#=W]S;1V
MKPW]Q9A(F)!6-RH;GN:Z^N3^&O@F3P'H=UI\MVMXTU]<7@D5"@ D<L%QD]/6
MNLH *\Z^.C?\4II0_O:YIRC_ ,"4KT6O._C<N_0= 3^]X@TX?E.#_2@#T2BB
MB@!&42*58!E88((R"*\Z^&/P7TSX7^)/%&I:>P,.K3(\$.,?9HP"3&/;<21[
M8KT:B@ I,#TJCKFL0Z#ITE]<)(]O&1YAB3<54G!8CT'4^U>.^*OC1;3^+M,>
MU@?4-!L9BTTMK+GS&QPVT8SMSG!KIHX>I7^%&4ZD:>[/;S&I*DJ"5Z''2C8N
M[=M&[&-V.<>E<QX0^(6G^.;NZ&D+)-8VZ+ONG!4%S_  >>!WI?#?C/\ M[2+
MN]\F-)$N9K>&U64;W\LD8.>-QP3CT-1*E.-[K;]2U)/8Z9HU=2K*&7^Z1Q69
M'X9TV+Q)/KRVP_M2>W2U><L3F-&9E&.@P6;GKS3_  _KUMXDTN&_M"WER9!5
MAAD8'!4^X-276MV5C?Q6<\ZQ3R1-,BMP"JXW<^V>E9\LK\MM1W5KEW:/2J6K
M:+9ZYIEW87<9-M=*4E\MS&QSW#*00?<'-8^D^/M-\0Z\^FZ4WV]88A)/<Q.-
MD>>@YY)^G2NFIRC*#M)6!-2V,#POX(TKPA'=BQ2:6:[8-<7-Y.\\TV!A0SN2
M2 . .@K<,*,J@HI"_=&.GTI]%0,**** "JEX_P##]!^?_P"JK=4+AM\HYSW_
M *?TH ?"O JRM0QU.M #J*** "BBB@ HHKYU^+/B]='^*7B1-6O/%@T73_#U
MO=I'X<EE5+=VDF#2N(R,<*O)R,*>P- 'T517SI;_ !X\3>&--T[2+^UM=5UW
M3-'M+W5-L<TS7LDH)$<#0H4#;%SO;Y2Q '&36KJ'Q+\3>+-4\/:AI:P:9X7_
M .$KCTJ0>8ZWDRH'5]Z_=V%QC9UX!SVH ]VHKS'XG:IXHM?B'X$L?#-Q;QM=
MK?FYAOG86SJD2%2ZK\S$$\8Z9S7!:#\<-=USQDJ:? IO-;@L[2UL+R8FTLYU
M-U]HDRO+#$!QC!;Y>E 'T717BUC\9_$OB#4+C0M*TG2X_$&EQWDFIM=SO]E/
MV>41[82OS?.2#EONC@@FN>U[XU>(O'_A"[U;PM!#I.CV=QID=U--,PO"TSPO
M((]OR[560+S][+8Q0!]%45RWQ(\83>"?#/VZUM5O+Z>ZM[&UAD?9&9II5C0N
M>R@MDXYP.*XCQ9\7?$'@V'1=*U6QTVU\0ZC=7$2W*":XL_)A0/YNR(&0%@R@
M(>AR2<8R >P45\TV?Q6U_P 4?$KPO()[[1[6\DL$N-+8LJ!BUZLF P!*OY2$
M9 ) 7BO?M8U+5;.X5+'2!?Q%<F0W*QX//&"/I^= 'P#_ ,% O@;J>E^+9?&V
MG0/-I6I[?.=!GR9P,$'T!QD'ZU\56'BB\T>ZVR;AM/![BOVWUIM4\1:7<Z;J
M?A"&]L+E#'+!->H593VZ5\3_ !>_X)_7>HW5_J^@Q2:;8#]X+' NI5]0NT@M
MCZ9KXO'Y//VDJM%<REJUV?\ D?O/#?&E!X6GA<;4=.I32BG9M22T2=DVI+;:
MS]3YFTGXA:5K4*1ZFJQR=/.S@UM+HUMJ"E[&]AF4]%8@&N[^#?P7T+PI-JLM
MVG]L:I%,(3]OL6A-NN,[1&^>2?XOPK@OVE-.L_!OB32+C146SEO87>YM8/E3
MY2 K[>V>?RKRJV46PWUAM?UIOLS[7 \;J>:/*Y4Y)KJUIM?X6DTK=?P*TOAJ
M\C8'R3[%2#7N'[*WQ:U'X7_$2PTZ>Y9M$U21;>[M\EE0GA9 .S XZ=LU\IZ?
MXZNVPDCN?;->A?#26]\0>+-*MK**2:ZDG18TC^\6)XQ7@TO:86O"I3W37_#'
MW^+^IYQ@*V%KV<91=_+3?7:V]S]=O&6B2^(O"^IZ= (A/=0-"K39VC/<X].M
M4-%^&_A_1]"BTW^R[6=!&$EDDB#-(<<DGKS716,;PV=NDA)D6-5;<<G('/-3
MU^V1JS4.5.RW/X1E%<W<9%$D$21QJ$C0!54= !T%/HHK(84444 %%%% !111
M0 4444 )4;?>7ZU)4;?>7ZT 2+TI:1>E+0 4444 %%%% !1110 4444 %%%%
M !364.I4C((P:=10!\^:&O\ 9NOZC:=/)N'3![#=6KJR[;@GUYJKXDC-I\3M
M60  2%)!CW45>UD?ZI_5:_'7#V<JM+^5M?B?H_-S^SJ?S)/\ TV<8VGI6%K"
MSZ!JL.I6@_>0.)4]_4?B*O0R%&R#6CLBU*W:&0=:EOVD%9VDMAK]W*[5T]SU
MC0-:M_$6CVNHVK;H9TW#V/<'Z'(K0KP+0O$NH_#/4)46(WFDS-NDM\X*G^\A
M['VKV#PQXTTGQ=;[]/N0TH&7MW^61/J*_1<MS:EC8JG-VJ+=?JNY\=CLOJ8:
M3G!7AT?^9NT445[YY 4444 %%%% !1110 4444 %%%% !7$Z]+]HUB0<?*<9
M'M@?SS7:LP523T'-<"[FXOI')!R<Y'OS_6@#5TM<3Q?45U"?<7Z5SNFK^^C^
MM=$GW5^E #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KSWXS?-8>%DZ[O$-CQZX<G^E>A5Y[\7_F?P
M8G][Q%:\_0.: /0J2EKF?B)'(OA>XNXBV^R9;K"D@D*<GI[9_*@3=E<Z:BN<
M\-^*8]4TN&Z+^?"Z;O/09Q[,!W]ZQ+SXQ:4GB"/2;"&;4Y@I>8P\&-0?0]3[
M57*R7.*5VSL]6U"WTO3;BZNF58(T+-N[C'3'?/I7R05U'PA/=3WVAW%M:7CO
M<HQB(58V;(X[ 9 YKZ4UCQ%IVL:.L]O.K&)Q,D<RE&9E.=H5L9.,UOWVGVNN
M:7<0R(CQ7D!C9MH)*,/_ *]=V%Q7U:]XWN85::KK1GE'P(TCQ%86<]\L5K;:
M!J,HN$AG)\[&,%UQT!P.#Z5XQXYFMI?B9KD$-\HL!<F4?99R(]Y'./?J./>O
MK=?#L'_"-1Z*TD@MEMUMB\;;&*@ =1TR!7G?QB^%V@3>!;J>STZWT^[LMLD5
MQ;Q@%1D [L=1@_I7;A\9#ZPYR7Q:?\$BI1?LU%=#@?A3XEM](\80:%+KEU8Z
M/*OFPV\; (9R1\K-U /IT)K8_:-\6V6I#3]&M6;S;>YWSWD>0(N"/+#>I[UT
MFG^&_!>C?#6>TMKRWNRY1)+U<--)<;AMX/(.[&!Z5Z'JWA;3O$6C_P!GZA:A
M[5P#)"ORAC[X]Z53$4HUU6<7I\OF*-.7L^2Y\S:5JE]X0UFQU/P_/&;R\9;:
M19 /+D#$ ;A]<'-?46A6]_:Z9$FIW2W=\?FED1 J@GLH]!7DW@7]G[2UL))]
M=%U-*;AVMK<RL@@C#G9G'5L '->PV-K]ALXK?S99Q&-OF3MN=OJ>YK''UZ=5
MI0W6[L5AZ<J:]XL4445Y)V!1110 R1ML;'OCBJ*_-*W.1G /TXJW<R;5'KU_
M+_Z^*K6ZX44 68Q4JU&M24 +1110 4444 %8O_"'Z3_PD-_K;6H?4+ZT2QN'
M=BRR0H6*H5/'5V[<YK:HH \ZC^ ?@^"QM+.&UO(+2WA%J88[^95FMPY=()<-
M^\C4DA5;@ X''%7Y/@[X8D\21:W]EN$N(KQ=12WCNI%MA=!=OG>4#MW[>"<<
MUVU% ',^,/A[I'C:XTZYU 745YI_F?9;JRNI+>6+S%"OAD(ZJ,5E3?!/PA);
MK%%IC6ACCMXX);6=XY+?R-_E-&P.58>8_P PY.XYS7=T4 <%<?!#PE-IMI9I
M9W%K]G$R_:+6[EBGF69MTRRR!MT@D;EMQ.32:E\#?"&IW,,C:?+;0QK;JUI9
MW,D-O+Y!'D%XU8*Q3 P2.@ KOJ* ,OQ)X;T[Q=HMQI6JVXN;*?&Y,E2&!#*R
MD<JP8 @CD$"N=;X/^'#I5O9JEY%/;W+WD>I1WLJWHF==KR>>#N)9?E//( '8
M5VU% '%67P=\*:??Z;>V^FLEQIPA%N_G.<>7YA4G)^8YFD))R26YKM:** "B
MBB@#GO$G@#0/%C%]2TV*6X*[?M"?)*!Z;A@U\_\ CS]@'P7XRU">_CU;4K6Y
MD'69A,/S.#BOJ&BN:MAJ.(CRU8W1[.7YQC\KG[3"57%VMT>G;5/0^'E_X)EZ
M:DNX>*L+O!_X]#G;W_BZU[M\&?V3?!GP9O%U&S275=70DQ7EWC]T",?*HX!Z
M\]>:]KHKDI97A*,U4A#5>K_,]?&<79UCJ+P]:O[CW248W\GRI-KR"BBBO4/C
MPHHHH **** "BBB@ HHHH **** $J-OO+]:DJ-OO+]: )%Z4M(O2EH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH 2HV^\OUJ2HV^\OUH D7I2TB]*6@ HHHH **** "BBB@ HHHH ****
M"BBB@#QCX@>&[O0;J:>W4M9R,73:.%!Y*_@?T-<%_:\^_!-?3]Q;17D+PS1K
M+$XPRL,@US/_  K'P[]H\[[%DYSMW';^5=6'J1I04'TV]#@Q%"56HYQZ[GEW
MA72;WQ)<I'%&=F?FD/0"O=-/LTTZRAMH_N1J%%+9V-OI\(BMH4AC'\*#%3U%
M6K[3T-J-'V2\PHHHK Z0HHHH **** "BBB@ HHHH **** "L[7IA#I<N3MW8
M3/U-:-8/BZ8I:11@_>))'MC']: ,+35R0Q').:Z"U6L;34X%;UNOR_A0!;A'
MSK5I?NBJT7WUJROW10 M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 >>?#-CIOBSQ_HS<>5JJW\
M8_V9XE;CVW*U+^T#H][KWP=\2Z?I]E+J-Y/"BI:P+N>3]ZA( [\ U'>M_P (
M[\<K"<_+;^(M+>U)_P"F]NV]?S1W_*O1J /G'_A#?%-QXBTR-].NDB\,ZLNG
M:5<R)N5X&263[3_N@&&,GU4BN*TSP?XPL_#5V5CO=/U6+26AUT_8FLA>R&:(
MNK7$DI$\K 2['0#A\9&0*^PZJZEIEIK-A/8W]M%>6<ZE);>= Z.I[$'@T ?*
M-Q;P7VH>+8/"_AV]MO#AU?35N+>:PFF2V3[)(3)]B5@SKO*90\9(<@BJ.F^!
M/&\FGV[C2-5FTVPM;Y;G3;RV$$VHV(U%76T0H<1EXLLJ+U "\9-?6F@^&]+\
M+V(LM(T^WTVTW%_)MHPBECU)QU-:5 'RO>:+X@NOBII^I6>AZG8RP^)("GDZ
M:Y/]FE0/,DNG/RQ;2%\B,#:<Y!Y-6E\+W7PI^$OAGQO9:/+%XLTFZD>]M)6*
MW%_'/*\1C?)^8_/&RYZ;1BOIZJ&I:#IVL7%E<7UC!=S6,OG6SS(&,+XQN7/0
MX[T ?-WB+X;WWAN"ZL+_ $75O$5W+H")HMW9!Y%@U=WE>>3(/[EVD>-A(V!M
M7&>,5TOA3PW>6_CR7_A)="U;4O%;ZDLB:U S+;"P-LJ%3+]WRPV\&'J6(;'>
MO>Z3KQ0!\GZMX!U7Q=X9\:^%KC3Y-:L?!5I<6&D1D^;]L><K+&PY^9XH-L>#
MSEO6KVG>$_$+?$*&9+.\M9FUFVN=,N8=(D#0Z6$3$1G:0)%&%#HT)7=DG@D@
MU]*:+H6G>';+['I=E!86N]I/)MT"+N8Y9L#N3WJ_0 4444 1SG]V1G&>*IP_
M.Q8]2<U->/@8]OY\?XTR!>E %A*D%,6I* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $J-OO+]:DJ-OO+]: )%Z4M(O2EH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD_%LV^
M\CC#?=497ZDG^@KK*XC6IC<:Q)SD*Q _# _I0!:TY/E%;=NORUE6*?*.*V85
M^6@":/[RU.OW14*??6IE^Z* %HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#AOB_HMU?>%X]4TR
M/S=7T*X35+1!U<QYWQ_\"0NOXBNH\.Z]:>*-"L-6L)/-L[V%9XF_V6&<'W'3
M\*T*\LT^;_A37BF33KH^7X*UFY,EC<G[FG73G+0.?X8W.2IZ DCN* /5****
M "L3QIXRTCX?^&+_ ,0:[=K9:78Q^9+*W)]@!W). ![UMU\2_P#!2;Q)>I:>
M"?#J&2/3KN6:ZGVG"R,@4*I]<;B:X,=B?JF'E6M=H^BX?RI9UF=' MV4GJ_)
M*[MYZ:'G7Q*_;R\?>,-8F_X0X1>&=#C;$1>-99Y /XG9A@9] *U?AS_P4$\8
M>'M0@B\;Z?:Z]I+$+)=648BN(AGEL#Y6^G%?(FO7[VI$47R*..*I:9J;[BLC
M;D(P0:_-XYECN;VWM'Z=/NV/ZCJ<,</^R^HO#1LM+VU_\"^+\3]NO"/BW2O'
M7ANPUW1+Q+[3+V,2PS1]P>Q'8@\$=B*V*^&_^";?CZ7^S/&/AN[N-NFV;1WU
MNTS@)%O)5P">F2 :^W;2_MM0C+VMQ%<H#@M"X8?F*_2,#BEBZ$:NS9_+F?Y2
M\FS"KA$[QBU9^35U?SLR>BBBN\^="BBFLVU2QZ 9H IW+;I /?\ EQ_C4L(X
MJN.93GJ./\?UJU&* )5IU(M+0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 E1M]Y?K4E1M]Y?K0!(O2EI%Z4M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -9@BECT R:X&-_/O
M&D)W9.<_7G^M=IJTWDZ;<,.#L('U/']:XVQ&^0MZL30!O62_**U(U^6L^T7I
M6DG2@"1/OK4M1K]\5)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %5-6TFSUW3;G3]0MH[RR
MN$,<L$JY5U/8BK=% 'A?Q$TOQ-\*? ^J/IFNK=^'((]]O]ON/*O-/8'*".4@
MB9<X&QQDCC)K3^ 'QFUCXF:9Y&N>'[RQO84S_:26[+:7'T)^ZWMR/2O5-2T:
MPUCR?MUG#>"%_,C6= X5O[P![^]7%4(H50%4#  Z"@!D]Q%:Q-+-(D4:\EY&
M"@?B:^;/VQO >F?&SX<JOA_5M/O/$^ARF\M;6*[C+S+C$D8&>I R/<8[U\X?
MMH_&[6-4^+FJ>%;N\FL]#TMEACLT<JDIV@F1A_$3FO"19SS(+FQG\Z/J'A;Y
ME^N.17PN99U&3J854KQV;O;[M'U/Z'X6X!J4HX?-GB^2KI)14;I)K9OF6Z>M
MN^C.1UB,W!9)4:&YC.UXY!M((]C67:VLFXJHRS<#%=M=;[R4-J$(O&[O)G?^
M?6M72['0M/MS>2R_957@^8"2/H:^/A47PH_:ZV#DY>TFRGX;T&[CL1:QSR0(
M_P TVUB Y]"!UQ[UV.B>*-;^#5W9ZSHVN3V%ZD@9+993LE /(=,X*GWKB?$'
MQ@TK1(F@T> W-QT$T@X'T%6?@C\)?&/[2'CJ&UMXYOLQ<->7\BGR[6+/))Z9
MQT7O793HU').'Q/:WZ'F8O'X.G2E3JV]FE[U[-6\_P"K]#]=/ACXT3XB?#[0
M/$L<?DC4K1)S'_=8C# >V0:Z>LKPIX;L_!_AG2]#L%V6>GVZ6T0[[54#)]SU
M_&M6OUJGS*$5/>VOJ?Q5BI4I5ZDJ"M!M\J\KZ?@%0W+;8\>I_3J?Y5-52\DY
MVCTQ^?\ ^HUH<I% N>35M!4$*]*LKVH <*6BB@ HHHH **** "BBB@ HHHH
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M ZU^F-O\,?ACXIU&_,7AC0[R\T^X^S7.VR0&*4*&VG@<X8'\:/#?Q"^'6AW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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..BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855189416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 14, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,809,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement, the (&#8220;2022 Proxy Statement&#8221;) for its&#160;2022&#160;Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant's fiscal year ended&#160;December&#160;31, 2021,&#160;are incorporated by reference into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412853944168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts, US<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855259432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81,787<span></span>
</td>
<td class="nump">$ 78,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ResearchAndDevelopmentIncentiveReceivable', window );">Research and development incentive receivable</a></td>
<td class="nump">747<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,344<span></span>
</td>
<td class="nump">3,682<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">87,878<span></span>
</td>
<td class="nump">83,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">17,351<span></span>
</td>
<td class="nump">27,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">8,710<span></span>
</td>
<td class="nump">7,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">3,258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets, Total</a></td>
<td class="nump">117,176<span></span>
</td>
<td class="nump">122,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,283<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,870<span></span>
</td>
<td class="nump">8,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term Debt, Current Maturities</a></td>
<td class="nump">795<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Liabilities, Current, Total</a></td>
<td class="nump">14,023<span></span>
</td>
<td class="nump">11,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LongTermDebtNonCurrentIncludingAccrection', window );">Long-term debt, including accretion, net of discount</a></td>
<td class="nump">33,139<span></span>
</td>
<td class="nump">33,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">4,776<span></span>
</td>
<td class="nump">4,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">52,764<span></span>
</td>
<td class="nump">50,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">347,374<span></span>
</td>
<td class="nump">267,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(282,871)<span></span>
</td>
<td class="num">(194,175)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">64,412<span></span>
</td>
<td class="nump">72,799<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 117,176<span></span>
</td>
<td class="nump">$ 122,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">28,127,657<span></span>
</td>
<td class="nump">16,305,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">28,127,657<span></span>
</td>
<td class="nump">16,305,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LongTermDebtNonCurrentIncludingAccrection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt Non Current Including Accrection</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LongTermDebtNonCurrentIncludingAccrection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ResearchAndDevelopmentIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Incentive Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ResearchAndDevelopmentIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412854819000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">28,127,657<span></span>
</td>
<td class="nump">16,305,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">28,127,657<span></span>
</td>
<td class="nump">16,305,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855337544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">50,647<span></span>
</td>
<td class="nump">41,932<span></span>
</td>
<td class="nump">30,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">24,702<span></span>
</td>
<td class="nump">20,942<span></span>
</td>
<td class="nump">17,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">9,758<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Loss on transfer of nonfinancial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">85,107<span></span>
</td>
<td class="nump">62,874<span></span>
</td>
<td class="nump">51,703<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(85,107)<span></span>
</td>
<td class="num">(59,874)<span></span>
</td>
<td class="num">(51,703)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,642)<span></span>
</td>
<td class="num">(2,688)<span></span>
</td>
<td class="num">(2,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(366)<span></span>
</td>
<td class="num">(437)<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">905<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(3,572)<span></span>
</td>
<td class="num">(2,109)<span></span>
</td>
<td class="num">(1,104)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</a></td>
<td class="num">(88,679)<span></span>
</td>
<td class="num">(61,983)<span></span>
</td>
<td class="num">(52,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(88,696)<span></span>
</td>
<td class="num">(62,131)<span></span>
</td>
<td class="num">(52,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Accruing dividends on Series A convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock', window );">Temporary Equity Repurchase Of Convertible Preferred Stock</a></td>
<td class="num">(13,943)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (102,639)<span></span>
</td>
<td class="num">$ (62,131)<span></span>
</td>
<td class="num">$ (53,399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (3.99)<span></span>
</td>
<td class="num">$ (3.09)<span></span>
</td>
<td class="num">$ (4.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding - basic and diluted (in shares)</a></td>
<td class="nump">25,749<span></span>
</td>
<td class="nump">20,077<span></span>
</td>
<td class="nump">11,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (88,696)<span></span>
</td>
<td class="num">$ (62,131)<span></span>
</td>
<td class="num">$ (52,926)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Repurchase Of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846724344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Redeemable Common Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, convertible preferred stock (in share) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,079,567<span></span>
</td>
<td class="nump">107,371<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance, convertible preferred stock at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,675,000<span></span>
</td>
<td class="nump">$ 734,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock', window );">Temporary Equity Repurchase Of Convertible Preferred Stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ConversionOfRedeemableCommonStockToCommonStockShares', window );">Conversion of redeemable common stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ConversionOfRedeemableCommonStockToCommonStockValue', window );">Conversion of redeemable common stock into common stock</a></td>
<td class="nump">734,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 734,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (734,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred shares into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,808,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,079,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred shares into common stock</a></td>
<td class="nump">64,675,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">64,671,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64,675,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, convertible preferred stock (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance, convertible preferred stock at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(77,086,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,151,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (79,237,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Exchange of common stock in connection with Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,440,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Exchange of common stock in connection with Merger</a></td>
<td class="nump">45,541,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">45,539,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Fair value of replacement equity awards</a></td>
<td class="nump">817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity', window );">Reclassification of warrant liability to permanent equity</a></td>
<td class="nump">5,235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants', window );">Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $11.5 million (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,336,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants', window );">Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $11.4 million</a></td>
<td class="nump">139,388,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">139,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">345,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="nump">447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</a></td>
<td class="nump">2,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(119,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(52,807,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,807,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,128,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">129,220,000<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">261,367,000<span></span>
</td>
<td class="num">(119,000)<span></span>
</td>
<td class="num">(132,044,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock', window );">Temporary Equity Repurchase Of Convertible Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ConversionOfRedeemableCommonStockToCommonStockValue', window );">Conversion of redeemable common stock into common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, convertible preferred stock (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance, convertible preferred stock at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">127,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</a></td>
<td class="nump">$ 5,428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares under employee stock purchase plan (in shares)</a></td>
<td class="nump">26,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares under employee stock purchase plan</a></td>
<td class="nump">$ 169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations (in shares)</a></td>
<td class="nump">132,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations</a></td>
<td class="num">$ (14,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(62,131,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,131,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,305,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">72,799,000<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">267,077,000<span></span>
</td>
<td class="num">(119,000)<span></span>
</td>
<td class="num">(194,175,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock', window );">Temporary Equity Repurchase Of Convertible Preferred Stock</a></td>
<td class="num">(13,943,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance cost of convertible preferred stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,435,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance costs of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">73,868,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">73,858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ConversionOfRedeemableCommonStockToCommonStockValue', window );">Conversion of redeemable common stock into common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, convertible preferred stock (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance, convertible preferred stock at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">5,860<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,129,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</a></td>
<td class="nump">$ 6,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares under employee stock purchase plan (in shares)</a></td>
<td class="nump">45,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares under employee stock purchase plan</a></td>
<td class="nump">$ 219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(88,696,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,696,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,127,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 64,412,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="nump">$ 347,374,000<span></span>
</td>
<td class="num">$ (119,000)<span></span>
</td>
<td class="num">$ (282,871,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock Repurchased and Retired During Period, Shares</a></td>
<td class="num">(229,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock Repurchased and Retired During Period, Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,875)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Additional Paid In Capital Reclassification Of Warranty Liability To Permanent Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ConversionOfRedeemableCommonStockToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Redeemable Common Stock To Common Stock Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ConversionOfRedeemableCommonStockToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ConversionOfRedeemableCommonStockToCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Redeemable Common Stock To Common Stock Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ConversionOfRedeemableCommonStockToCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock and warrants issued during period shares common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock and warrants issued during period value common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Repurchase Of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852058584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 11.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846593736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (88,696)<span></span>
</td>
<td class="num">$ (62,131)<span></span>
</td>
<td class="num">$ (52,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,180<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
<td class="nump">2,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">9,758<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Loss on transfer of nonfinancial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,393<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_NonCashInterestExpense', window );">Accretion of debt discount</a></td>
<td class="nump">756<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability', window );">Change in fair value of preferred stock warrant and derivative liability</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">337<span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets and research and development incentive receivable</a></td>
<td class="num">(1,755)<span></span>
</td>
<td class="num">(1,655)<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
<td class="num">(2,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(152)<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(698)<span></span>
</td>
<td class="num">(1,067)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion', window );">Operating lease right-of-use asset, net of non-cash portion</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(3,889)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(70,905)<span></span>
</td>
<td class="num">(58,818)<span></span>
</td>
<td class="num">(48,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash, cash equivalents and restricted cash acquired in connection with the Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from transfer of non-financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchase of property, equipment and intangible assets</a></td>
<td class="num">(615)<span></span>
</td>
<td class="num">(1,362)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(615)<span></span>
</td>
<td class="num">(1,362)<span></span>
</td>
<td class="nump">27,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants', window );">Proceeds from exercise of stock options, warrants and pre-funded warrants an issuance of shares of common stock under employee stock purchase plans</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee taxes paid related to net share settlement of vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from borrowings under loan and security agreements, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,388<span></span>
</td>
<td class="nump">9,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of borrowings under loan and security agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts', window );">Proceeds from sale of shares of common stock, redeemable common stock, warrants and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">75,985<span></span>
</td>
<td class="num">(277)<span></span>
</td>
<td class="nump">139,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">74,245<span></span>
</td>
<td class="nump">12,394<span></span>
</td>
<td class="nump">140,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(319)<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,406<span></span>
</td>
<td class="num">(47,384)<span></span>
</td>
<td class="nump">119,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">80,702<span></span>
</td>
<td class="nump">128,086<span></span>
</td>
<td class="nump">8,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">83,108<span></span>
</td>
<td class="nump">80,702<span></span>
</td>
<td class="nump">128,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,906<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid', window );">Acquisition of property, equipment and right-of-use assets included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Lease Obligation Incurred</a></td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid', window );">Issuance costs not yet paid</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ConversionOfRedeemableCommonStockToCommonStockValue', window );">Conversion of redeemable common stock into common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants', window );">Conversion of convertible preferred stock warrants into common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_FairValueOfNetAssetsAcquiredInReverseMerger', window );">Fair value of net assets acquired in the Merger in exchange for common shares, excluding cash acquired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Expenditures And Intangible Assets Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Convertible Preferred Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ConversionOfConvertiblePreferredStockToCommonStockValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Convertible Preferred Stock To Common Stock Values</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ConversionOfConvertiblePreferredStockToCommonStockValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ConversionOfRedeemableCommonStockToCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Redeemable Common Stock To Common Stock Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ConversionOfRedeemableCommonStockToCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_FairValueOfNetAssetsAcquiredInReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Net Assets Acquired In Reverse Merger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_FairValueOfNetAssetsAcquiredInReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset, Non-cash Potion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ProceedsFromExerciseOfStockOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Exercise of Stock Options And Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ProceedsFromExerciseOfStockOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance or Sale of Equity, Net of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock And Warrant Issuance Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852162696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text">NATURE OF THE BUSINESS AND BASIS OF PRESENTATION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X4 Pharmaceuticals, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a late-stage clinical biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases. The Company&#8217;s lead product candidate, mavorixafor, is a potential first-in-class, once-daily, oral inhibitor of CXCR4 and is currently in a Phase 3 clinical trial for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. The Company is also conducting a 14-day, proof-of-concept Phase 1b clinical trial of mavorixafor in patients with chronic neutropenia disorders, and a Phase 1b clinical trial of mavorixafor in combination with ibrutinib in Waldenstr&#246;m&#8217;s macroglobulinemia. The Company is headquartered in Boston, Massachusetts and has an additional facility in Vienna, Austria. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern Assessment&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-15,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2014-15&#8221;), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. As of December 31, 2021, the Company had $81.8 million of cash and cash equivalents and an accumulated deficit of $282.9 million. As further discussed in Note 2, the Company has a covenant under its Amended and Restated Loan Agreement  (the &#8220;Hercules Loan Agreement&#8221;) with Hercules Capital Inc. (&#8220;Hercules&#8221;), which will require that the Company maintain a minimum level of cash, as defined, beginning on </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 1, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is in violation of this covenant, Hercules could require the repayment of all outstanding debt. Based on its current cash expenditure forecast and considering this covenant, the Company expects that its existing cash and cash equivalents will fund its operations into the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fourth quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company believes that, in the aggregate, these conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Nevertheless, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In order to fund its operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> beyond 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company will need to raise additional funds, which could be through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If the Company is unable to obtain future funding when needed, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or pre-commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. There is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The impact of the ongoing COVID-19 pandemic continues to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Impacts to the Company&#8217;s business have included temporary closures or postponements of activation of its clinical trial sites or facilities, disruptions or restrictions on its employees&#8217; ability to travel, disruptions to or delays in ongoing clinical trials, including patient enrollment at a slower pace than initially projected and the diversion of healthcare resources away from the conduct of the Company&#8217;s clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as the Company&#8217;s clinical trial sites and hospital staff supporting the conduct of the Company&#8217;s clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Arsanis&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;26, 2018, Arsanis, Inc., a publicly held Delaware corporation (&#8220;Arsanis&#8221;), Artemis AC Corp., a Delaware corporation and a wholly-owned subsidiary of Arsanis (&#8220;Merger Sub&#8221;), and X4 Therapeutics, Inc. (&#8220;X4&#8221;) entered into an Agreement and Plan of Merger, as amended on December&#160;20, 2018 and March&#160;8, 2019 (the &#8220;Merger Agreement&#8221;), pursuant to which the Merger Sub merged with and into X4, with X4 surviving the merger as a wholly-owned subsidiary of Arsanis. The transactions described in the foregoing sentence may be referred to in these consolidated financial statements as &#8220;the Merger.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as a reverse merger in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Under this method of accounting, X4 was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i)&#160;the Company&#8217;s stockholders own a substantial majority of the voting rights in the combined organization, (ii)&#160;the Company designated a majority of the members of the initial board of directors of the combined organization and (iii)&#160;the Company&#8217;s senior management hold all key positions in the senior management of the combined organization. Accordingly, for accounting purposes, the business combination was treated as the equivalent of X4 issuing stock to acquire the net assets of Arsanis. As a result, as of the closing date of the Merger, the net assets of Arsanis were recorded at their acquisition-date fair values in the </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements of the Company and the reported operating results prior to the business combination are those of the Company. In addition, transaction costs incurred by the Company in connection with the business combination have been expensed as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;13, 2019, Arsanis, X4 and Merger Sub completed the Merger pursuant to the terms of the Merger Agreement. Pursuant to the terms of the Merger Agreement, each outstanding share of X4&#8217;s common stock and preferred stock was exchanged for 0.5702 shares of Arsanis&#8217; common stock (the &#8220;Exchange Ratio&#8221;). In addition, all outstanding options exercisable for common stock and warrants exercisable for convertible preferred stock of X4 became options and warrants exercisable for the same number of shares of common stock of Arsanis multiplied by the Exchange Ratio. In connection with the Merger, X4 changed its name to X4 Therapeutics, Inc. Following the closing of the Merger, X4 Therapeutics, Inc. became a wholly-owned subsidiary of the Company, which changed its name to X4 Pharmaceuticals, Inc. As used herein, the words &#8220;the Company&#8221; refers to, for periods following the Merger, X4 Pharmaceuticals, Inc. (formerly Arsanis, Inc.), together with is direct and indirect subsidiaries, and for periods prior to the Merger, X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.), and its direct and indirect subsidiaries, as applicable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the Merger, stockholders of X4 owned approximately 64% of the combined organization&#8217;s outstanding common stock. On March&#160;14, 2019, the combined organization&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;XFOR.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;13, 2019, immediately following the closing of the Merger, the Company effected a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1-for-6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Unless otherwise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">noted, all references to common stock share and per share amounts have also been adjusted to reflect the exchange ratio of 0.5702.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH (&#8220;X4 Austria&#8221;), which is incorporated in Vienna, Austria, and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852059416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and the constraint of variable consideration from contracts with customers. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The COVID-19 pandemic has impacted and is expected to continue to impact the clinical development timelines for certain of the Company's clinical programs. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency and Currency Translation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s foreign subsidiary, X4 Austria, is the U.S. dollar but X4 Austria maintains its books and records in Euro. Monetary assets and liabilities are translated at current exchange rates as of the balance sheet date, non-monetary assets such as property and equipment and equity accounts are translated at historic rates and income and expenses are translated at the average exchanges rates for the period. Adjustments resulting from the translation of the consolidated financial statements of the Company&#8217;s foreign operations into U.S. dollars are included in the determination of net loss and are recorded in other expense, net. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Significant Suppliers&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and research and development incentive receivables. The Company generally maintains cash balances in various operating accounts at financial institutions that management believes to be of high credit quality in amounts that may exceed federally insured limits. The Company has not experienced losses related to its cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of active pharmaceutical ingredients and formulated drugs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:97%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Letter of credit security: Cambridge lease</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Letter of credit security: Waltham lease </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Letter of credit security: Vienna Austria lease</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Boston lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s lease agreement for its facilities in Massachusetts and Austria, the Company maintains letters of credit, which are secured by restricted cash, for the benefit of the landlord. In accordance with the Company&#8217;s Loan and Security Agreement with Hercules, as most recently amended on February 9, 2022 and as further described in Note 7, effective as of the earlier of (a) certain specified events impacting the Company&#8217;s Phase III trial of mavorixafor for the treatment of WHIM syndrome and (b) September 1, 2022, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest as further described in Note 7.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets to the sum to the total of amounts shown in the Company&#8217;s consolidated statements of cash flows as of December&#160;31, 2021, 2020, 2019 and 2018:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:46.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current (included within prepaid expenses and other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current (included within other assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,702&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.636%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or 10 years</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right-of-Use Assets and Leases&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;), Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 842&#8221;). Under ASC 842, at the inception of an arrangement, the Company determines whether the arrangement contains a lease based on the unique facts and circumstances present. Leases with a non-cancellable term greater than one year are recognized on the balance sheet as right-of-use assets with associated current and non-current lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Options to renew a lease are not included in the Company&#8217;s initial lease term assessment unless there is reasonable certainty that the Company will renew the lease. If a lease is cancellable without penalty, the Company excludes from the lease term periods following the cancellation notice period unless it is reasonably certain that the Company will not cancel the lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use operating asset may be required for items such as incentives received or accrued rent. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates it incurs to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company has referenced the effective rate of its Hercules borrowings, as adjusted for differences terms, to determine calculate its incremental borrowing rate for each of its operating leases. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 842, components of a lease are split into lease components and non-lease components. A policy election is available pursuant to which an entity may elect to not separate lease and non-lease components. Rather, each lease component and the related non-lease components are accounted for together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components as a combined lease component for its office and laboratory building leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value. To date, the Company has not recorded any material impairment losses on long-lived assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested quantitatively for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action, a significant decline in the price of the Company&#8217;s common stock, or unanticipated competition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it operates in a single operating segment and has a single reporting unit. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. See Note 4 for more information on the Company&#8217;s goodwill impairment test as of December 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the Merger, the Company acquired certain in-process research and development (&#8220;IPR&amp;D&#8221;) assets, which were classified as indefinite-lived intangible assets. Acquired IPR&amp;D represents the fair value assigned to research and development assets that the Company acquires and have not been completed at the acquisition date. The fair value of IPR&amp;D acquired in a business combination is recorded on the Company&#8217;s consolidated balance sheets at the acquisition-date fair value and is determined by estimating the costs to develop the technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the projected net cash flows to present value. IPR&amp;D is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned or transferred to a third party.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected discounted cash flow models used to estimate the Company&#8217;s IPR&amp;D reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Probability of successfully completing clinical trials and obtaining regulatory approval;</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market size, market growth projections, and market share;</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Estimates of future cash flows from potential milestone payments and royalties related to out-licensed product sales; and</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A discount rate reflecting the Company's weighted average cost of capital and specific risk inherent in the underlying assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company entered into an out-licensing arrangement with a third party that transferred the rights to develop and commercialize one of the programs underlying an IPR&amp;D intangible asset. In addition, the Company entered into amended out-licensing option agreements with a third party who had previously entered into an option agreement with Arsanis to license the rights to develop and commercialize two other programs underlying the IPR&amp;D intangible assets. Following the amendment to these option agreements, the options were exercised by the third party and the in-process research and development programs were out-licensed to the third party. As of December 31, 2019, all programs underlying IPR&amp;D intangible assets acquired in the Merger were transferred to these third parties. As a result of the transfer of the IPR&amp;D projects to third parties, the Company derecognized the IPR&amp;D intangibles asset through a charge to &#8220;loss on transfer of nonfinancial assets&#8221; during 2019. (See Note 15) </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, the Company&#8217;s preferred stock warrant liability and preferred stock repurchase liability were carried at fair value, determined according to Level&#160;3 inputs in the fair value hierarchy described above. The embedded derivative liability related to the redemption features of the Company&#8217;s debt with Hercules as described further below is carried at fair value and is a Level 3 measurement. The Company&#8217;s cash equivalents, consisting of money market funds invested in U.S. Treasury securities, are carried at fair value, determined based on Level 1 and Level&#160;2 inputs in the fair value hierarchy described above. The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company&#8217;s outstanding loan and security agreement with Hercules approximates its fair value at December&#160;31, 2021 because the debt bears interest at a variable market rate and the Company&#8217;s credit risk has not materially changed since the inception of the agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2018, the Company adopted ASC Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;), as amended, using the modified retrospective transition method. The modified retrospective method requires that the cumulative effect of initially applying ASC 606 be recognized as an adjustment to the opening balance of retained earnings or accumulated deficit of the annual period that includes the date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of initial application. The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had no</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements that were in the scope of ASC 606 on January&#160;1, 2018 and thus there was no impact to the consolidated financial statements as a result of the adoption. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaboration arrangements and leases. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are generated primarily through research, development and commercialization agreements. The terms of these agreements may contain multiple promised goods and services, which may include (i) licenses, or options to obtain licenses, to the Company&#8217;s technology, and (ii) in certain cases, services in connection with the manufacturing of preclinical and clinical materials. Payments to the Company under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; milestone payments; payments for clinical and commercial product supply, and royalties on future product sales. To date, the Company&#8217;s license agreement with Abbisko Therapeutics Co., Ltd. (&#8220;Abbisko&#8221;) represents its only revenue-generating agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and are therefore within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are deemed to be within the scope of ASC 808, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of ASC 606. The Company&#8217;s policy is generally to recognize amounts received from collaborators in connection with joint operating activities that are within the scope of ASC 808 as a reduction in research and development expense. To date, there have been no transactions within the scope of ASC 808.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company determines it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligation(s) in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligation(s) in the contract; and (5) recognize revenue when (or as) the Company satisfies its performance obligation(s). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and; allocating the transaction price to each performance obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: </span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and </span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time based on the use of an output or input method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes non-refundable payments for contingent milestones, including preclinical research and development, clinical development and regulatory, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most-likely-amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of the achievement of contingent milestones and the likelihood of a significant reversal of such milestone revenue, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect licensing revenue in the period of adjustment. This quarterly assessment may result in the recognition of revenue related to a contingent milestone payment before the milestone event has been achieved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Programs&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds under the research and development incentive program from the Austrian government are recognized as other income in an amount equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. Incentive income recognized upon incurring qualifying expenses in advance of receipt of proceeds from research and development incentives is recorded in the consolidated balance sheet as research and development incentive receivable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with internal research and development and external research and development services, including drug development and preclinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the related services have been performed, or when it is no longer expected that the goods will be delivered or the services rendered. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs consist of payments made to secure commitments under certain debt financing arrangements. These amounts are recognized as interest expense over the period of the financing arrangement using the effective interest method. If the financing arrangement is canceled or forfeited, or if the utility of the arrangement to the Company is otherwise compromised, these costs are recognized as interest expense immediately. The Company&#8217;s consolidated financial statements present debt issuance costs related to a recognized debt liability as a direct reduction from the carrying amount of that debt liability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures all stock-based awards granted to employees, nonemployees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has also issued stock-based awards with performance-based vesting conditions that vest in part upon the Company&#8217;s achievement of operational milestones and over time thereafter for the subsequent two years as the employee continues to provide services. The Company assesses the probability of achievement of these operational milestones and recognizes stock-based compensation for these awards using the accelerated attribution model based on the fair value of the awards as of the date of grant and its best estimate of the date each operational milestone will be achieved. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for only the portion of awards that are expected to vest. In developing a forfeiture rate estimate, the Company has considered its historical experience to estimate pre-vesting forfeitures for service-based awards. The impact of a forfeiture rate adjustment is recognized in full in the period of adjustment, and if the actual forfeiture rate is materially different from the Company&#8217;s estimate, the Company may be required to record adjustments to stock-based compensation expense in future periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Prior to March&#160;13, 2019, the Company was a private company and lacked company-specific historical and implied volatility information for its common stock. Therefore, the Company estimates its expected common stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities: Hercules Loan Redemption Feature&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan agreement with Hercules (see Note&#160;7) contains a redemption feature that, upon an event of default, provides Hercules the option to accelerate and demand repayment of the debt, including a prepayment premium, or, at its election, charge additional contingent interest fees on any overdue interest or principal payments. The redemption feature meets the definition of a derivative instrument as the repayment of the debt contains a substantial premium, resulting in the redemption feature not being clearly and closely related to its host instrument. Accordingly, the Company classifies this derivative as a liability within other liabilities (non-current) on its consolidated balance sheets. The derivative liability was initially recorded at fair value on the date of the Hercules Loan Agreement and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of this derivative liability, which is included in other liabilities, are recognized as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss. Changes in the fair value of this derivative liability will continue to be recognized until all amounts outstanding under the Hercules Loan Agreement are repaid or until the Hercules Loan Agreement is terminated. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021 and 2020, all foreign currency remeasurement gains and losses were included in net loss as the Company has deemed the functional currency of its foreign subsidiary to be the U.S. Dollar. Comprehensive loss includes net loss as well as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">translation adjustments of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$119 thousand for the year ended December 31, 2019. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to the Merger with Arsanis on March 13, 2019, the Company followed the two-class method when computing net loss per share as the Company had issued shares that met the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. In addition, during the year ended December 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of subsequent sales of common stock. Such adjustment is accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#8217;s common stock and the estimated remaining life of the outstanding Class B Warrants. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Basic shares outstanding includes the weighted average effect of the Company&#8217;s outstanding prefunded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive shares of common stock. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of convertible preferred stock or common stock are considered potential dilutive shares of common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In accordance with ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Derivative and Hedging (Topic 815), and Leases (Topic 842)- Effective Dates, </span>as the Company meets the definition of a &#8220;smaller reporting company&#8221;, the Company has elected to defer the adoption of ASU 2016-13 until January 1, 2023. The Company expects that the adoption of ASU 2016-13 may accelerate the timing and could increase the level of credit loss expense in the consolidated statement of operations and will likely require an increased level of disclosure in the notes to the consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412853124040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Funding Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration, and Funding Agreements</a></td>
<td class="text">LICENSE, COLLABORATION AND FUNDING ARRANGEMENTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genzyme Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2014, the Company entered into a license agreement with Genzyme  (the &#8220;Genzyme Agreement&#8221;) pursuant to which the Company was granted an exclusive license to certain patents and intellectual property owned or controlled by Genzyme related to the CXCR4 receptor to develop and commercialize products containing licensed compounds (including but not limited to mavorixafor) for all therapeutic, prophylactic and diagnostic uses, with the exception of autologous and allogenic human stem cell therapy. Under the terms of the Genzyme Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize licensed products for use in the field in the United States and at least one other major market country. The Company has the right to grant sublicenses of the licensed rights that cover mavorixafor to third parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Genzyme Agreement, the Company is obligated to pay Genzyme milestone payments in the aggregate amount of up to $25.0 million, contingent upon the achievement by the Company of certain clinical-stage regulatory and sales milestones with respect to licensed products. The Company is also obligated to pay Genzyme tiered royalties based on net sales of licensed products that the Company commercializes under the agreement. The obligation to pay royalties for each licensed product expires on a country-by-country basis on the latest of (i)&#160;the expiration of&#160;licensed patent rights that cover that licensed product in that country, (ii)&#160;the expiration of regulatory exclusivity in that country and (iii)&#160;ten years after the first commercial sale of such licensed product in that country. Royalty rates are subject to reduction under the agreement in specified circumstances, including in any country if the Company is required to obtain a license from any third party to the extent the Company&#8217;s patent rights might infringe the third party&#8217;s patent rights, if a licensed product is not covered by a valid claim in that country or if sales of generic products reach certain thresholds in that country. If the Company enters into a sublicense under the Genzyme Agreement, the Company will be obligated to pay Genzyme a percentage of certain upfront fees, maintenance fees, milestone payments and royalty payments paid to the Company by the sublicensee. Under the Genzyme Agreement, the Company will itself manufacture and supply, or enter into manufacturing or supply agreements with Genzyme or third parties to manufacture and supply, clinical and commercial supplies of licensed compounds and each licensed product. The Company is also responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Genzyme Agreement will remain in effect until the expiration of the royalty term in all countries for all licensed products.&#160;The Genzyme Agreement may be terminated by either party with at least 90 days&#8217; notice in the event of material breach by the other party that remains uncured for 90 days, by either party for insolvency or bankruptcy of the other party, immediately by Genzyme if the Company challenges the licensed patents, or immediately by the Company if a material safety issue arises. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company incurred $0.9&#160;million of payment obligations to Genzyme. For the years ended December 31, 2021 and 2019, the Company did not incur any payment obligations to Genzyme under the Genzyme Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Georgetown Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company entered into a license agreement (the &#8220;Georgetown Agreement&#8221;) with Georgetown University (&#8220;Georgetown&#8221;) pursuant to which the Company obtained an exclusive, worldwide license to make, have made, use, sell, offer for sale and import of products covered by patent rights co-owned by Georgetown. The rights licensed to the Company are for all therapeutic, prophylactic and diagnostic uses in all disease indications in humans and animals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Georgetown Agreement, the Company paid a one-time, upfront fee of $50 thousand and the Company may be required to make milestone payments of up to an aggregate of $800 thousand related to commercial sales of a product. The Company recorded the upfront payment as research and development expense in the consolidated statement of operations and comprehensive loss because the acquired technology represented in-process research and development and had no alternative future use. Under the Georgetown Agreement, the Company is solely responsible for all development and commercialization activities and costs in its respective territories. The Company is also responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights. The term of the Georgetown Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event (i)&#160;the Company fails to pay any amount and fails to cure such failure within 30 days after receipt of notice, (ii)&#160;the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within 45 days after receipt of notice, or (iii)&#160;the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown Agreement at any time upon at least 60 days&#8217; written notice.  During the years ended December&#160;31, 2021, 2020 and 2019, the Company did not incur any payment obligations to Georgetown under the Georgetown Agreement and no milestone payments were made or due under the Georgetown Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beth Israel Deaconess Medical Center Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company entered into a license agreement (the &#8220;BIDMC Agreement&#8221;) with Beth Israel Deaconess Medical Center (&#8220;BIDMC&#8221;), pursuant to which the Company obtained an exclusive, worldwide license to make, have made, use, sell, offer for sale and import products covered by patent rights co-owned by BIDMC. The rights licensed to the Company are for all fields of use. Under the terms of the BIDMC Agreement, the Company paid a one-time, upfront fee of $20 thousand and the Company is responsible for all future patent prosecution costs. The Company recorded the upfront payment as research and development expense in the consolidated statement of operations because the acquired technology represented in-process research and development and had no alternative future use. The term of the BIDMC Agreement will continue until the expiration of the last valid claim within the patent rights covering the licensed products. BIDMC may terminate the agreement in the event (i)&#160;the Company fails to pay any amount and fails to cure such failure within 15 days after receipt of notice, (ii)&#160;the Company is in material breach of any material provision of the BIDMC Agreement and fails to remedy such breach within 60 days after receipt of notice, or (iii)&#160;the Company declares insolvency or bankruptcy. The Company may terminate the BIDMC Agreement at any time upon at least 90 days&#8217; written notice.  The Company did not incur any payment obligations under the BIDMC Agreement during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dana Farber Cancer Institute Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a license agreement (the &#8220;DFCI Agreement&#8221;) with the Dana Farber Cancer Institute (&#8220;DFCI&#8221;) pursuant to which the Company obtained a non-exclusive, royalty-bearing license to use, make, have made, develop, market, import, distribute, sell and have sold products covered by patent rights owned by DFCI. Under the terms of the DFCI Agreement, the Company paid a one-time, upfront fee of $25 thousand and approximately $35&#160;thousand for reimbursement of DFCI&#8217;s past patent expenses relating to the patent rights. The Company will pay 25% of DFCI&#8217;s ongoing patent prosecution expenses and an annual license maintenance fee of $10&#160;thousand in each of the first three years, $40&#160;thousand in each of the subsequent three years and $50&#160;thousand every year after that until commercialization. The Company may be required to make milestone payments of up to an aggregate of approximately $32.0 million related to development, regulatory and commercial sales events. No such milestone payments have been incurred to date. The Company recorded the upfront payment as research and development expense in the consolidated statement of operations and comprehensive loss because the acquired technology represented in-process research and development and had no alternative future use. The term of the DCFI Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. DFCI may terminate the agreement if certain events occur. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Incentive Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's wholly-owned subsidiary X4 Austria participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses incurred by X4 Austria. Under the program, the reimbursement rate for qualifying research and development expenses incurred by the Company through X4 Austria is 14% for the current year. X4 Austria also participated in a COVID-19 incentive program, which provides reimbursement for qualified capital spending during a defined time period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes incentive income from Austrian research and development incentives when qualifying expenses have been incurred, there is reasonable assurance that the payment will be received, and the consideration can be reliably measured. Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each reporting date, management estimates the reimbursable incentive income available to the Company based on available information at the time.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the years ended December&#160;31, 2021 and 2020, the amounts due under these programs were $0.7 million and $0.9 million, respectively, which is included in research and development incentive receivable on the consolidated balance sheet. During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded $0.8 million, $0.5 million and $0.4 million, respectively, of income related to the program on the consolidated statement of operations and comprehensive loss within &#8220;other income&#8221;.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Abbisko Agreement </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into a license agreement with Abbisko (the &#8220;Abbisko Agreement&#8221;). Under the terms of the Abbisko Agreement, the Company granted Abbisko the exclusive right to develop, manufacture and commercialize mavorixafor in mainland China, Taiwan, Hong Kong and Macau, the (&#8220;Abbisko Territory&#8221;). The agreement provides Abbisko with the exclusive rights in the Abbisko Territory to develop and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in multiple oncology indications. The Company retains the full rest-of-world rights to develop and commercialize mavorixafor outside of Greater China for all indications and the ability to utilize data generated pursuant to the Abbisko collaboration for rest-of-world development. Assuming mavorixafor is developed by Abbisko in six indications, the Company would be entitled to milestone payments of up to $208.0&#160;million, which will vary based on the ultimate sales, if any, of the approved licensed products. In addition, upon commercialization of mavorixafor in the Abbisko Territory, the Company is eligible to receive a tiered royalty, with a percentage range in the low double-digits, on net sales of approved licensed products. Abbisko is obligated to use commercially reasonable efforts to develop and commercialize mavorixafor in the Abbisko Territory. Abbisko has responsibility for all activities and costs associated with the further development, manufacture and commercialization of mavorixafor in the Abbisko Territory.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of a qualified financing (as such term is defined in the Abbisko Agreement), Abbisko was required to pay the Company a one-time, non-refundable, non-creditable financial milestone payment of $3.0 million. Abbisko achieved such qualified financing in March 2020 and, as a result, the Company was eligible to receive the milestone payment, which was received by the Company in April 2020. The Company is also eligible to receive potential development and regulatory milestone payments, which vary based on the number of indications developed, and potential commercial milestone payments based on annual net sales of mavorixafor-based licensed products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into the Abbisko Agreement, the Company evaluated the Abbisko Agreement under ASC 606 and determined the Abbisko Agreement contained a single performance obligation related to the exclusive license to develop and commercialize mavorixafor and the transfer of know-how that was satisfied at the inception of the arrangement. The transaction price related to the transfer of the license and know-how was fully constrained and the Company ascribed no transaction price to the development, regulatory and commercial milestones under the &#8220;most-likely amount&#8221; method. The Company concluded that any consideration related to the initial transfer of the license and know-how will be recognized when it is probable that Abbisko will achieve the related financial milestone and other operational milestones. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Abbisko and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur. As a result of Abbisko&#8217;s achievement of the qualified financing, the Company reversed the constraint related to this milestone and recognized $3.0 million of license revenue during the year ended December 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the future sale of clinical and commercial supply are optional goods that will be subject to the customer's future purchasing decisions and do not represent performance obligations in the Abbisko Agreement. The Company concluded that the amount to be charged for the clinical supply will be reflective of market value and, therefore, the Abbisko Agreement does not provide a discount on such supply that would be accounted for as material right at the outset of the contract. In arriving at these conclusions, the Company considered the complexity of the manufacturing process for the licensed compound and the potential ability for Abbisko to obtain the compound directly from other manufactures in the future. The Company expects that it will recognize revenue at a point in time when such clinical supply (and commercial supply, if applicable) is delivered to Abbisko in the future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the transaction price, including its estimated variable consideration for milestones included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852161576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text">FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2020 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents consisted of money market funds invested in U.S. Treasury securities. The money market funds were valued based on reported market pricing for the identical asset or by using inputs observable in active markets for similar securities, which represents a Level&#160;2 measurement in the fair value hierarchy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s warrant liability and derivative liability, for which fair values are determined using Level&#160;3 inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"><tr><td style="width:1.0%"/><td style="width:76.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.751%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Embedded Derivative Liability</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Embedded Derivative Liability&#8212;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative liability recognized in connection with the Company&#8217;s loan agreement with Hercules (see Note&#160;7), which is associated with additional fees due to Hercules upon events of default, was determined based on significant inputs not observable in the market, which represents a Level&#160;3 measurement within the fair value hierarchy. The fair value of this embedded derivative liability, which is reported within other non-current liabilities on the consolidated balance sheets, is estimated by the Company at each reporting date based, in part, on the results of third-party valuations, which were prepared based on a discounted cash flow model that considered the timing and probability of occurrence of a redemption upon an event of default, the potential amount of prepayment fees or contingent interest upon an event of default and the Company&#8217;s risk-adjusted discount rate of 14%. As of December&#160;31, 2021 and December&#160;31, 2020, the fair value of this derivative liability was $821&#160;thousand and $455 thousand, respectively.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested quantitatively for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. During the fourth quarter of 2021, the Company&#8217;s market capitalization, measured as the price of the Company&#8217;s common stock multiplied by common shares outstanding, was below the value of the Company&#8217;s net assets, including goodwill. As a result of the sustained decline in the market price of the Company&#8217;s common stock, the fair value of the Company&#8217;s single reporting unit, determined based on Company&#8217;s market capitalization on December 31, 2021, was lower than its carrying value and the Company concluded that goodwill was impaired. Accordingly, the Company recorded an impairment charge of $9.8 million to reduce the carrying amount of goodwill to $17.4&#160;million as of December 31, 2021. Should the market value of the Company&#8217;s common stock continue to decline, additional impairment charges may be recorded in the future. </span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward of the Company&#8217;s goodwill and accumulated impairment losses.  </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"><tr><td style="width:1.0%"/><td style="width:80.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, gross amount, at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment loss, at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852166104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">PROPERTY AND EQUIPMENT<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.896%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>Depreciation and amortization expense related to property and equipment was approximately $499 thousand, $351 thousand, and $103&#160;thousand for the years ended December 31, 2021, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852068232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AccruedExpensesTextBlock', window );">Accrued Expenses</a></td>
<td class="text">ACCRUED EXPENSES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AccruedExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AccruedExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412853134824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text">LONG-TERM DEBT<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt premium, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative accrual of end of term payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(795)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hercules Loan Agreements-&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into the Hercules Loan Agreement, as amended in June 2019, December 2019, March 2020, December 2020, and February 2022, with Hercules, under which the Company has borrowed an aggregate of $32.5&#160;million of term loans to date. The Hercules Loan Agreement provides for maximum borrowings of up to $50.0 million, which include, subject to Hercules investment committee&#8217;s sole discretion, a right of the Company to request that Hercules make additional term loan advances in an aggregate amount of up to $17.5 million through December 31, 2022. Borrowings under the Hercules Loan Agreement accrue interest at a variable rate equal to the greater of (i)&#160;8.75%, or (ii)&#160;8.75% plus&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;prime rate minus 6.0%.&#160;&#160;In an event of default, and until such event is no longer continuing, the interest rate applicable to borrowings under the Amended and Restated Loan Agreement would be increased by 4.0%.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Hercules Loan Agreement are repayable in monthly interest-only payments through January 1, 2023, and in equal monthly payments of principal and accrued interest from February 1, 2023 until the maturity date of the loan, which is July 1, 2024. The Company may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium of up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the principal amount outstanding as of the date of repayment.&#160;In addition, the Hercules Loan Agreement provides for payments of $0.8 million, which was settled on January 1, 2022, $1.3&#160;million and $0.8&#160;million payable on July 1, 2023 and July 1, 2024, respectively, which payments are accelerated upon the prepayment of the borrowings upon the Company&#8217;s election on upon default of the loan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the Company&#8217;s personal property and other assets except for their intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Hercules Loan Agreement, effective as of the earlier of (a) certain specified events impacting the Company&#8217;s Phase 3 trial of mavorixafor for the treatment of WHIM and (b) September 1, 2022, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount greater than or equal to the greater of $30.0 million or six multiplied by a metric based on prior months&#8217; cash expenditures; provided, however, that from and after the Company&#8217;s achievement of certain financing milestones through June 30, 2022, the Company must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount of $30.0 million. Following the achievement of certain operational performance milestones, the required level shall be reduced to the greater of $20.0 million, or, if the Company had not met the financing milestones noted above, three multiplied by the current cash expenditures metric; and provided further, that subject to the achievement of additional operational milestones, this covenant will be extinguished. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hercules Loan Agreement restricts the Company&#8217;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized interest expense under the Hercules Loan Agreement as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.693%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the years ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual effective interest rate on the Hercules Loan Agreement as of December&#160;31, 2021 is 10.7%. There were no principal payments due or paid under the Hercules Loan Agreement during the year ended December&#160;31, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, future principal payments and accrued end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"/><td style="width:76.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.026%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,471&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including end-of-term payments</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,657&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852145784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements for its facilities in Boston, Massachusetts, which is the Company&#8217;s principal executive offices; Vienna, Austria, which is the Company&#8217;s research and development center; and Waltham, Massachusetts, which the Company has sublet to a third party. The Company previously had a lease agreement for a facility in Cambridge, Massachusetts, which served as its prior corporate headquarters. There are no restrictions or financial covenants associated with any of the lease agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Boston Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company leases approximately 28,000 square feet of office space in Boston, Massachusetts (&#8220;Boston Lease&#8221;), which leased was entered into in November 2019 and serves as the Company&#8217;s headquarters. Base rental payments are approximately $1.0 million annually, plus certain operating expenses.  The term of the Boston Lease will continue until November 2026, unless earlier terminated. The Company has the right to sublease the premises, subject to landlord consent and also has the right to renew the Boston Lease for an additional five years at the then prevailing effective market rental rate. The Company is required to maintain a security deposit in the form of a letter of credit for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the benefit of the landlord.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Boston lease, the Company participated in the construction of the office space and incurred construction costs to prepare the office space for its use, which have been partially reimbursed by the landlord. The Company concluded that these construction costs generate and enhance the landlord&#8217;s assets, and, as such, unreimbursed construction costs incurred to prepare the office space for its use have been classified a part of the right-of-use asset. The commencement date for the Boston Lease was September 1, 2020 upon substantial completion of the landlord's asset. On the commencement date, the Company recognized a lease liability of $4.6&#160;million reflecting the future rent payments for the term of the Boston Lease discounted at the Company&#8217;s collateralized borrowing rate, and a right-of-use asset of $8.0&#160;million measured as the lease liability plus rent payments made and unreimbursed construction costs incurred prior to the commencement date. The Company began recognizing rent expense &#160;&#160;&#160;&#160;following the commencement date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Waltham Lease&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 6,000 square feet of office space in Waltham, Massachusetts (&#8220;Waltham Lease&#8221;). The Waltham Lease, as amended, commenced on January 1, 2019, and expires approximately 5 years from the commencement date. The base rent is approximately $263&#160;thousand annually. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#8217; right-of-use assets or lease liabilities. The Company is subleasing the space to a third party for the duration of the lease. The right-of-use asset is being amortized to rent expense over the 5 year term of the lease.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vienna Austria Leases&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has an operating lease, as amended, for approximately 400 square meters of laboratory and office space in Vienna, Austria, which commenced on March 1, 2019, as amended, for a term of 2 years terminating in April 2021. The annual base rent for the previous lease was approximately $154&#160;thousand. In September 2020, the Company entered into a new operating lease for approximately 1,200 square meters of laboratory and office space in Vienna, Austria (&#8220;Vienna Lease&#8221;), which commenced in February 2021 following construction of laboratory and office space for a term of 7 years. The Company contributed $709 thousand to building improvements, which are classified as part of the right-of-use asset. The Company recorded a right-of-use asset and associated lease liabilities upon the commencement of the Vienna Lease in the first quarter of 2021. The annual base rent for the Vienna Lease, following a 6-month rent free period, will be approximately $300 thousand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cambridge Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; In August 2017, the Company entered into a non-cancellable operating lease agreement for office space of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 13,000 square feet in Cambridge, Massachusetts (&#8220;Cambridge Lease&#8221;), which had an original expiration date of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 31, 2022. Base rent was approximately $832&#160;thousand annually and the monthly rent expense was recognized on a straight-line basis over the term of the lease as the Company amortizes the associated operating lease right-of-use asset. The Company reached an agreement with the landlord on July 17, 2020 to terminate the lease effective September 30, 2020 in exchange for a fee. The Company accounted for the lease modification prospectively from the date of the termination through the new lease termination date of September 30, 2020, at which time the right-of-use asset and associated lease liabilities were retired from the consolidated balance sheet. The Company was required to maintain a letter of credit of $264&#160;thousand, secured by restricted cash, for the benefit of the landlord through December 31, 2020.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three years ended December&#160;31, 2021, 2020, and 2019 were as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:40.891%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Leased assets obtained in exchange for new operating lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:97%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities due under lease agreements that have commenced as of December&#160;31, 2021 are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"><tr><td style="width:1.0%"/><td style="width:78.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,851&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852166104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with clinical research organizations (&#8220;CROs&#8221;) pursuant to which the Company and the CROs are conducting clinical trials of mavorixafor&#160;for the treatment of WHIM syndrome, Waldenstr&#246;m&#8217;s and CN. The Company may terminate these agreements by providing notice pursuant to the contractual provisions of such agreements and would incur early termination fees. The Company also has agreements with contract manufacturing organizations (&#8220;CMOs&#8221;) for the production of mavorixafor for use in clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 3 for a summary of the Company&#8217;s license agreements, which commit the Company to contingent milestone and royalty fees based on future operational events. In March 2021, the Company terminated its license agreement with Adimab LLC and has no further obligations on the agreement. &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31, 2021 or December&#160;31, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852145784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Preferred and Common Stock Warrants</a></td>
<td class="text">PREFERRED AND COMMON STOCK WARRANTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, the Company issued warrants for the purchase of its preferred stock and had classified these preferred stock warrants as a liability on its consolidated balance sheet as the warrants were deemed to be freestanding financial instruments that may have required the Company to transfer assets upon exercise. The liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and was subsequently remeasured to fair value as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss. Upon the closing of the Merger, pursuant to the Merger Agreement, all of the outstanding X4 preferred stock was converted to common stock and the X4 preferred stock warrants converted to warrants for the purchase of common stock. The Company assessed the features of the warrants and determined that they qualified for classification as permanent equity upon the closing of the Merger. Accordingly, the Company remeasured the warrants to fair value upon the closing of the Merger, which was $5.2&#160;million at March&#160;13, 2019, with $288&#160;thousand of expense recorded during the three months ended March&#160;31, 2019. Upon the closing of the Merger, the warrant liability was reclassified to additional paid-in capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its issuance of common stock in public offerings that closed on April 16, 2019 and November 29, 2019, the Company issued 3,900,000 Class A warrants, which are exercisable for shares of the Company's common stock, and 5,416,667 Class B warrants, which are exercisable for shares of the Company's common stock or prefunded warrants to purchase shares of the Company's common stock. The Class A warrants have an exercise price of $13.20 per warrant, expire on April 15, 2024 and were immediately exercisable upon issuance. The Class B warrants were immediately exercisable upon issuance, had an initial exercise price of $15.00 per share and expire on a date that is the earlier of (a) the date that is 30 calendar days from the date on which the Company issues a press release announcing top-line data from its Phase 3 clinical trial of mavorixafor for the treatment of patients with WHIM syndrome (or, if such date is not a business day, the next business day) and (b) November 28, 2024. The Class B warrants have a contingent price adjustment feature pursuant to which the exercise price of the Class B warrants is adjusted to the lowest weighted average offering price at which the Company sells its common stock or certain securities convertible into or exercisable for the Company&#8217;s common stock in one or more subsequent offerings, if the weighted average offering price for such offering is below $15.00. As a result of the sales of the Company&#8217;s stock at below $15.00 during the year ended December 31, 2021, the exercise price of the Class B Warrants was ultimately adjusted to $3.65. On March 23, 2021, the Company completed a private placement sale of its common stock priced at $8.70 and in the fourth quarter of 2021, the Company sold shares of its common stock at various price points, the lowest of which was $3.65. Accordingly, the exercise price of the Class B warrants was ultimately adjusted to $3.65 as of December 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, in connection with the sale of its common stock in a private placement, the Company issued pre-funded warrants to purchase an aggregate of 50,000 shares of common stock at a price of $8.70 per share of common stock (or $8.69 per pre-funded warrant). The price per pre-funded warrant represents the price of $8.70 per share sold in the private placement, minus the $0.01 per share exercise price of each such pre-funded warrant. The pre-funded warrants are exercisable, subject to certain beneficial ownership restrictions, at any time after their original issuance and will not expire. </span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company entered into a securities purchase agreement pursuant to which it agreed to issue and sell to an investor, in a private placement, pre-funded warrants to purchase an aggregate of 2,008,032 shares of the Company&#8217;s common stock at a purchase price of $4.97 per pre-funded warrant (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">representing the price of $4.98 per share in the private placement, minus the $0.01 per share exercise price of each such pre-funded warrant)</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The pre-funded warrants are exercisable at any time after their original issuance and will not expire.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of outstanding warrants for the period ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Number of warrants</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term (Years)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable as of  December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,354,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058,032&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,130,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,257,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company&#8217;s outstanding warrants to purchase shares of common stock consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.735%"><tr><td style="width:1.0%"/><td style="width:33.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.425%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Issuable</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 25, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 24, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 28, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 28, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 12, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 12, 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 19, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 19, 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 13, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 12, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 16, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,866,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,416,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 28, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 23, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 9, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,008,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,257,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) In November 2019, the Company received $11.999 per pre-funded warrant, or $21.0 million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.001 per pre-funded warrant. </span></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) In March 2021, the Company received $8.69 per pre-funded warrant, or $435 thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.</span></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) In November 2021, the Company received $4.97 per pre-funded warrant, or $10.0 million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852121208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">COMMON STOCK, REDEEMABLE COMMON STOCK AND PREFERRED STOCK</a></td>
<td class="text">COMMON STOCK, REDEEMABLE COMMON STOCK AND PREFERRED STOCK<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s Certificate of Incorporation, as amended and restated, authorizes the Company to issue 125,000,000 shares of $0.001 par value common stock. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No cash dividends </span><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been declared or paid to date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;12, 2019, the Company sold 5,670,000 shares of common stock and, in lieu of common stock, prefunded warrants to purchase 2,130,000 shares of common stock, and accompanying Class&#160;A warrants to purchase 3,900,000 shares of its common stock. The common stock was issued at a price to the public of $11.00 per share and accompanying Class&#160;A warrant and the prefunded warrants were issued at a price of $10.999 per prefunded warrant and accompanying Class&#160;A warrant. The Class&#160;A warrants have an exercise price of $13.20, will expire 5 years from the date of issuance, and are immediately exercisable with certain restrictions. The gross proceeds from the offering, which closed on April 16, 2019, were $85.8 million before deducting underwriting discounts and offering expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 26, 2019, the Company sold 3,666,667 shares of common stock and, in lieu of common stock, prefunded warrants to purchase 1,750,000 shares of common stock, and accompanying Class&#160;B warrants to purchase 5,416,667 shares of its common stock or prefunded warrants to purchase shares of common stock. The common stock was issued at a price to the public of $12.00 per share and accompanying Class&#160;B warrant and the prefunded warrants were issued at a price of $11.999 per prefunded warrant and accompanying Class&#160;B warrant. The Class B warrants have an exercise price of  $3.65 per warrant, as adjusted based on a down-round contingent price adjustment feature; expire on a date that is the earlier of (a) the date that is 30 calendar days from the date on which the Company issues a press release announcing top-line data from its Phase 3 clinical trial of mavorixafor for the treatment of patients with WHIM syndrome (or, if such date is not a business day, the next business day) and (b) November 28, 2024; and were immediately exercisable upon issuance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald &amp; Co., and Stifel, Nicolaus &amp; Company, Incorporated (collectively the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell, at the Company&#8217;s sole discretion through one or more of the Sales Agents, shares of its common stock having an aggregate offering price of up to $50.0&#160;million. To date, the Company has sold approximately $14.3 million, net of offering costs, of common stock under the ATM Sales Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2021, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with several institutional and accredited investors (the &#8220;Investors&#8221;) pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the &#8220;Private Placement&#8221;) an aggregate of 6,271,836 shares of common stock and, to certain Investors, in lieu of common stock, pre-funded warrants to purchase an aggregate of 50,000 shares of common stock at a price of $8.70 per share of common stock (or $8.69 per pre-funded warrant). The Private Placement closed on March 23, 2021 and the Company received gross proceeds of $55.0 million, before deducting offering expenses payable by the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the common stock offerings, the Company evaluated the Class A, Class B and prefunded warrants for liability or equity classification in accordance with the provisions of ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and determined that equity treatment was appropriate because neither the Class A, Class B or prefunded warrants meet the definition of a liability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2020, the Company entered into a common stock purchase agreement (the &#8220;Aspire Purchase Agreement&#8221;) with Aspire Capital Fund, LLC, (&#8220;Aspire Capital&#8221;), which provided that, upon the terms and subject to the conditions and limitations set forth in the Aspire Purchase Agreement, Aspire Capital was committed to purchase up to an aggregate of $50.0 million of shares of the Company&#8217;s common stock at the Company&#8217;s request from time to time during the 36-month term of the Purchase Agreement. Concurrently with entry into the Aspire Purchase Agreement, the Company also entered into a registration rights agreement with Aspire Capital (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company filed with the SEC a prospectus supplement to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-242372), registering the issuance and sale of common stock that the Company may offer to Aspire Capital from time to time under the Aspire Purchase Agreement. No shares of common stock were sold pursuant to the Aspire Purchase Agreement. As further discussed in Note 16, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in January 2022 the Company elected to terminate the Aspire Purchase Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Common Stock&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the July 2014 license agreement with Genzyme (see Note&#160;3), in August 2015, the Company issued to Genzyme for no additional consideration 107,371 shares of common stock, which had an aggregate fair value of $734 on the date of issuance. Genzyme had the right to require the Company to repurchase all, but not less than all, of these shares of common stock at any time during the term of the license agreement for a price of $0.001 per share. Because of this redemption feature, the shares of common stock issued to Genzyme were classified outside of stockholders&#8217; deficit on the consolidated balance sheets. As a result of the Merger, these shares were exchanged for common stock.</span></div>On March 18, 2021, the Company entered into an Option Agreement, as amended (the &#8220;Option Agreement&#8221;) with Abingworth Bioventures 8 LP (&#8220;Abingworth Bioventures 8&#8221;), which was one of the Investors party to the Securities Purchase Agreement. Pursuant to the Option Agreement, if the Company and a syndicate, of which Abingworth Bioventures 8 was a part, did not execute a definitive co-development agreement, as defined in the Option Agreement, by August 2, 2021, Abingworth Bioventures 8 could have required the Company to repurchase the 229,885 common shares it purchased in the private placement at the original purchase price of $8.70 per share. The Company classified these shares as redeemable common stock on the consolidated balance sheet, net of offering costs, as of March 31, 2021 and June 30, 2021. In August 2021, as a result of the termination of the letter of intent between the Company and Abingworth related to the contemplated co-development arrangement, Abingworth Bioventures 8 exercised it option to sell the 229,885 share of common stock it purchased in the Private Placement back to the Company at the original purchase price of $8.70 per share for an aggregate of $2.0 million. The Company adjusted the carrying amount of the redeemable common stock to its redemption value and subsequently retired these shares of common stock.Convertible Preferred Stock (converted to Common Stock)&#8212; Prior to the Merger, the Company had issued Series Seed convertible preferred stock (the &#8220;Series Seed preferred stock&#8221;), Series&#160;A convertible preferred stock (the &#8220;Series&#160;A preferred stock&#8221;) and Series&#160;B convertible preferred stock (the &#8220;Series&#160;B preferred stock&#8221;). As of December&#160;31, 2021, the Company&#8217;s Certificate of Incorporation, as amended and restated, authorized the Company to issue a total of 10,000,000 shares of preferred stock, with a par value of $0.001 per share. As of December&#160;31, 2021 and 2020, there was no preferred stock outstanding.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852144952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Plans&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Merger on March&#160;13, 2019, X4&#8217;s 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;), Arsanis&#8217; 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) and Arsanis&#8217; 2017 Employee Stock Purchase Plan (the &#8220;2017 ESPP&#8221;) were assumed by the Company. In June 2019, the Company adopted the 2019 Inducement Equity Incentive Plan (the &#8220;2019 Plan&#8221;). These plans are administered by the Board of Directors or by a committee thereof. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzEyNDI_d21e8b58-0c5c-4b61-b8a2-5336b084744c">three</span> or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee, Director and Consultant Equity Incentive Plan&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Board of Directors and shareholders of X4 adopted the 2015 Plan, which provided for the Company to grant incentive stock options or nonqualified stock options, restricted stock awards and other stock-based awards to employees, directors and consultants of the Company. The total number of shares of common stock that may be issued under the 2015 Plan is 1.0 million shares. As of December&#160;31, 2021, there were approximately 144 thousand shares available for issuance under the 2015 Plan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Plan, the Company may grant incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. On June 10, 2020, the Company's stockholders approved an amendment and restatement of the 2017 Plan. The amendments increased the number of shares of common stock reserved for issuance under the 2017 Plan by an additional 474 thousand shares and amended the &#8220;evergreen&#8221; provision of the 2017 Plan to provide for an automatic increase in the share reserve on the first day of each year, beginning on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1, 2021 and ending on January&#160;1, 2027, in an amount equal to  the lower of 4.0% of the number of shares of the Company&#8217;s common stock outstanding on January&#160;1 of each year or an amount determined by the Company&#8217;s Board of Directors. As of December&#160;31, 2021, approximately 139 thousand shares were available for future issuance under the 2017 Plan. Pursuant to the evergreen provision of the 2017 Plan, as of January 1, 2022, an additional 1.1 million shares became available for future issuance under the 2017 Plan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Employee Stock Purchase Plan&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2017 ESPP provides participating employees with the opportunity to purchase shares of the Company&#8217;s common stock at defined purchase prices over six-month offering periods. For the twelve months ended December&#160;31, 2021, 45,816 shares of common stock were issued under the 2017 ESPP. As of December&#160;31, 2021, approximately 183 thousand shares were available for future issuance under the 2017 ESPP. Pursuant to the evergreen provision of the 2017 ESPP, on January 1, 2022, an additional 85 thousand shares became available for future issuance under the 2017 ESPP. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Inducement Equity Incentive Plan&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2019, the Board of Directors approved the adoption of the 2019 Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or following a bona fide period of non-employment), as an inducement material to such individual&#8217;s entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4). The total number of shares of common stock that may be issued under the 2019 Plan, as amended, is 1.3 million shares. Shares that are expired, forfeited, canceled or otherwise terminated without having been fully exercised will be available for future grant under the 2019 Plan. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for future grants. As of December&#160;31, 2021, approximately 483 thousand shares were available for future issuance under the 2019 Plan. </span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Valuation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"><tr><td style="width:1.0%"/><td style="width:60.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity for the twelve months ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.078%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.679%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(in Thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(340,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,236&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,689,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock to the extent the stock option had a lower exercise price. The aggregate intrinsic value of stock options exercised during the twelve months ended December&#160;31, 2021 and 2020 was $13 thousand and  $42&#160;thousand, respectively. The weighted average grant-date fair value per share of stock options granted during the years ended December&#160;31, 2021, 2020 and 2019 was $5.17, $6.12, and $10.78, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; During the twelve months ended December&#160;31, 2021, the Company granted 674,478 restricted stock units to employees at a weighted average grant date fair value of $8.25 per share. The restricted stock units granted were primarily performance-based restricted stock units, which vest in part upon on the Company&#8217;s achievement of operational milestones and over time thereafter for the subsequent two years as the employee continues to provide services to the Company. As of December 31, 2021, all performance criteria had been achieved. The Company recognizes stock-based compensation expense using the accelerated attribution model based on the fair value of the awards as of the date of grant and management&#8217;s best estimate of the date each operational milestone will be achieved. These restricted stock units had a grant date fair value of $5.6 million, which is being recognized as stock-based compensation expense, net of estimated forfeitures, over the estimated vesting period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock activity for the twelve months ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.275%"><tr><td style="width:1.0%"/><td style="width:71.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.155%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, total unrecognized compensation expense related to unvested stock options and restricted stock units was $7.7 million, which is expected to be recognized over a weighted average period of 2.1 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the consolidated statements of operations as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"><tr><td style="width:1.0%"/><td style="width:50.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852247416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, the Company recorded no income tax benefits for the net operating losses incurred and research and development credits generated due to the uncertainty of realizing a benefit from those items. Additionally during the year ended December 31, 2021, the Company recorded a tax provision of $17&#160;thousand related to its Austrian subsidiary. During the year ended December 31, 2020, the Company recorded a tax provision of $148 thousand related to local withholdings associated with a milestone payment received from a customer in a foreign jurisdiction.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before the provision for income taxes for the years ended December 31, 2021, 2020 and 2019 consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,314)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (Austria)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,679)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,983)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,807)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of preferred stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax asset valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had U.S. federal and state net operating loss carryforwards of  $315.0 million and $308.2 million, respectively, which may be available to offset future taxable income and begin to expire in 2031 and 2035, respectively. The Company has federal net operating losses $260.9 million, which do not expire, and $54.1 million of federal net operating losses generated prior to 2018 that will expire at various dates through 2037. In addition, as of December 31, 2021, the Company had foreign net operating loss carryforward of $65.2 million, which do not expire but are generally limited in their usage to an annual deduction equal to 75% of taxable income. As of December 31, 2021, the Company also had U.S. federal and state research and development tax credit carryforwards of $4.3 million and $1.4 million, respectively, which may be available to offset future tax liabilities and each begin to expire in 2032 and 2030, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, uncertain tax position reserves recorded were $0.2 million for U.S. federal and state research and development tax credits. Additionally, during the year ended December 31, 2021, the Company released an uncertain tax position of $0.1 million related to withholding taxes paid in 2021 on a milestone payment received from a non-U.S. customer in 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s reserve for uncertain tax positions for the three years ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"/><td style="width:82.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reserve for Uncertain Tax Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in unrecognized tax benefit for tax positions taken during year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of unrecognized tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the U.S. net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each period, the Company evaluates the positive and negative evidence bearing upon its ability to realize its federal, state and foreign deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2021, 2020 and 2019. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021, 2020 and 2019 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"/><td style="width:41.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,797)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance, end of year </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,835)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,197)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,410)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. federal and state income tax returns are generally subject to tax examinations for the tax years ended December 31, 2018 through December 31, 2020. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856524520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.126%"><tr><td style="width:1.0%"/><td style="width:58.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruing dividends on Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend as a result of Class B Warrant price reset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,639)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,131)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,399)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock&#8212;basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212; basic and diluted</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.99)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.09)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.63)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted weighted average shares of common stock outstanding for the years ended December&#160;31, 2021 includes the weighted average effect of 3,808,032 prefunded warrants for the purchase of shares of common stock, for which the remaining unfunded exercise price is less than or equal to $0.01 per share. During the year ended December 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of subsequent sales of common stock. Such adjustment is accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#8217;s common stock and the estimated remaining life of the outstanding Class B Warrants. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities included outstanding stock options, unvested restricted stock units and warrants to purchase shares of common stock for the years ended December 31, 2021 and 2020. Potentially dilutive securities also included warrants to purchase preferred stock for the year ended 2019. These potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#8220;anti-dilutive.&#8221; Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock (excluding prefunded warrants, which are included in basic shares outstanding)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,449,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,474,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,776,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,290,280&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,921,377&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,673&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852260216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss on Transfer of Nonfinancial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Loss on Transfer of Nonfinancial Assets</a></td>
<td class="text">LOSS ON TRANSFER OF NONFINANCIAL ASSETS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company entered into contractual arrangements with two third parties that transferred the rights to develop and commercialize the programs underlying IPR&amp;D intangible assets acquired in the Merger. As of December 31, 2019, all programs underlying IPR&amp;D intangible assets acquired in the Merger were transferred to these third parties and the Company had no continuing involvement in any ongoing research and development activities associated with the programs. The Company concluded that these third parties are &#8220;non-customers&#8221; as the underlying development programs transferred to these third parties are focused on potential drug candidates that were not aligned with the Company's strategic focus and, therefore, are not an output of the Company's ordinary activities. Accordingly, the Company accounted for these transactions under ASC Topic 610-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gains and Losses from the Derecognition of Nonfinancial Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 610-20&#8221;). As a result of the transfer of control of the IPR&amp;D projects to third parties, the Company derecognized the IPR&amp;D intangible assets through a charge to &#8220;loss on transfer of nonfinancial assets&#8221; in 2019 of $3.9 million, which included the carrying value of the IPR&amp;D of $4.9 million, partially offset by $1.0 million of non-refundable, upfront fees received from the third parties.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852099832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Termination of Aspire Purchase Agreement</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2022, the Company terminated the Aspire Purchase Agreement, under which Aspire was committed to purchasing up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$50.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company&#8217;s common stock, subject to certain restrictions. No shares of common stock were sold under the Aspire Purchase Agreement. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lincoln Park Capital Fund Purchase Agreement</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2022, the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a securities purchase agreement (the &#8220;LPC Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell shares of common stock to Lincoln Park, having an aggregate value of up to $50.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement, at the Company&#8217;s request from time to time during the 36-month term of the LPC Purchase Agreement. In consideration for entering into the LPC Purchase Agreement, the Company issued 230,414 shares of common stock to Lincoln Park as an initial commitment fee. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the LPC Purchase Agreement and the Registration Rights Agreement on January 14, 2022, the Company sold to Lincoln Park, as an initial purchase under the LPC Purchase Agreement, a total of 1,382,488 shares of common stock, at a per share price of $2.17 per share, for aggregate consideration of approximately $3.0 million.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Hercules Loan Agreement</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2022, the Company entered into Amendment No. 3 the Hercules Loan Agreement. The amendment:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminated the Company&#8217;s ability to request additional term loan advances in an aggregate amount of $7.5&#160;million through June 30, 2022;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the aggregate amount of term loan advances the Company may request from $10.0&#160;million to $17.5&#160;million, subject to Hercules&#8217; investment committee&#8217;s sole discretion, through December 31, 2022; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modified the minimum cash covenant contingent upon the Company raising &#8220;cash proceeds&#8221; (as defined in the Hercules Loan Agreement, as amended by Amendment No. 3) of $33.0&#160;million between January 1, 2022 and June 30, 2022. The current minimum cash covenant requires that, following the initial test date for the covenant, the Company maintain a minimum level of cash equal to six times a cash flow metric based on the preceding three months cash flow, subject to reduction, upon achievement of certain performance milestones, to the greater of $20.0&#160;million or three times the then-current cash flow metric, and further subject to extinguishment of the minimum cash covenant based upon achievement of additional milestones. If the Company raises the specified &#8220;cash proceeds&#8221; in the specified period, the Company would, at all times thereafter during which the minimum cash covenant is in effect, be required to maintain a minimum of $30.0&#160;million of cash, which would be further reduced to $20.0&#160;million upon achievement of certain performance milestones and extinguished upon achievement of additional milestones.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 7 to these notes to the consolidated financial statements for further discussion of the Hercules Loan Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855116696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and the constraint of variable consideration from contracts with customers. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The COVID-19 pandemic has impacted and is expected to continue to impact the clinical development timelines for certain of the Company's clinical programs. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s consolidated financial statements.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency and Currency Translation</a></td>
<td class="text">Foreign Currency and Currency Translation&#8212; The functional currency of the Company&#8217;s foreign subsidiary, X4 Austria, is the U.S. dollar but X4 Austria maintains its books and records in Euro. Monetary assets and liabilities are translated at current exchange rates as of the balance sheet date, non-monetary assets such as property and equipment and equity accounts are translated at historic rates and income and expenses are translated at the average exchanges rates for the period. Adjustments resulting from the translation of the consolidated financial statements of the Company&#8217;s foreign operations into U.S. dollars are included in the determination of net loss and are recorded in other expense, net.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Significant Suppliers</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Significant Suppliers&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and research and development incentive receivables. The Company generally maintains cash balances in various operating accounts at financial institutions that management believes to be of high credit quality in amounts that may exceed federally insured limits. The Company has not experienced losses related to its cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of active pharmaceutical ingredients and formulated drugs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December&#160;31, 2021 and 2020.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:</span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.636%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or 10 years</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock', window );">Right-of-Use Assets and Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right-of-Use Assets and Leases&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for leases in accordance with Accounting Standards Codification (&#8220;ASC&#8221;), Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 842&#8221;). Under ASC 842, at the inception of an arrangement, the Company determines whether the arrangement contains a lease based on the unique facts and circumstances present. Leases with a non-cancellable term greater than one year are recognized on the balance sheet as right-of-use assets with associated current and non-current lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Options to renew a lease are not included in the Company&#8217;s initial lease term assessment unless there is reasonable certainty that the Company will renew the lease. If a lease is cancellable without penalty, the Company excludes from the lease term periods following the cancellation notice period unless it is reasonably certain that the Company will not cancel the lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use operating asset may be required for items such as incentives received or accrued rent. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates it incurs to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company has referenced the effective rate of its Hercules borrowings, as adjusted for differences terms, to determine calculate its incremental borrowing rate for each of its operating leases. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 842, components of a lease are split into lease components and non-lease components. A policy election is available pursuant to which an entity may elect to not separate lease and non-lease components. Rather, each lease component and the related non-lease components are accounted for together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components as a combined lease component for its office and laboratory building leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value. To date, the Company has not recorded any material impairment losses on long-lived assets.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span>Goodwill is tested quantitatively for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action, a significant decline in the price of the Company&#8217;s common stock, or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. See Note 4 for more information on the Company&#8217;s goodwill impairment test as of December 31, 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_IntangibleAssetsPolicyPolicyTextBlock', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the Merger, the Company acquired certain in-process research and development (&#8220;IPR&amp;D&#8221;) assets, which were classified as indefinite-lived intangible assets. Acquired IPR&amp;D represents the fair value assigned to research and development assets that the Company acquires and have not been completed at the acquisition date. The fair value of IPR&amp;D acquired in a business combination is recorded on the Company&#8217;s consolidated balance sheets at the acquisition-date fair value and is determined by estimating the costs to develop the technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the projected net cash flows to present value. IPR&amp;D is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned or transferred to a third party.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected discounted cash flow models used to estimate the Company&#8217;s IPR&amp;D reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Probability of successfully completing clinical trials and obtaining regulatory approval;</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market size, market growth projections, and market share;</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Estimates of future cash flows from potential milestone payments and royalties related to out-licensed product sales; and</span></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A discount rate reflecting the Company's weighted average cost of capital and specific risk inherent in the underlying assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div>During the year ended December 31, 2019, the Company entered into an out-licensing arrangement with a third party that transferred the rights to develop and commercialize one of the programs underlying an IPR&amp;D intangible asset. In addition, the Company entered into amended out-licensing option agreements with a third party who had previously entered into an option agreement with Arsanis to license the rights to develop and commercialize two other programs underlying the IPR&amp;D intangible assets. Following the amendment to these option agreements, the options were exercised by the third party and the in-process research and development programs were out-licensed to the third party. As of December 31, 2019, all programs underlying IPR&amp;D intangible assets acquired in the Merger were transferred to these third parties. As a result of the transfer of the IPR&amp;D projects to third parties, the Company derecognized the IPR&amp;D intangibles asset through a charge to &#8220;loss on transfer of nonfinancial assets&#8221; during 2019. (See Note 15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div>Prior to the Merger, the Company&#8217;s preferred stock warrant liability and preferred stock repurchase liability were carried at fair value, determined according to Level&#160;3 inputs in the fair value hierarchy described above. The embedded derivative liability related to the redemption features of the Company&#8217;s debt with Hercules as described further below is carried at fair value and is a Level 3 measurement. The Company&#8217;s cash equivalents, consisting of money market funds invested in U.S. Treasury securities, are carried at fair value, determined based on Level 1 and Level&#160;2 inputs in the fair value hierarchy described above. The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company&#8217;s outstanding loan and security agreement with Hercules approximates its fair value at December&#160;31, 2021 because the debt bears interest at a variable market rate and the Company&#8217;s credit risk has not materially changed since the inception of the agreement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2018, the Company adopted ASC Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;), as amended, using the modified retrospective transition method. The modified retrospective method requires that the cumulative effect of initially applying ASC 606 be recognized as an adjustment to the opening balance of retained earnings or accumulated deficit of the annual period that includes the date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of initial application. The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had no</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements that were in the scope of ASC 606 on January&#160;1, 2018 and thus there was no impact to the consolidated financial statements as a result of the adoption. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaboration arrangements and leases. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are generated primarily through research, development and commercialization agreements. The terms of these agreements may contain multiple promised goods and services, which may include (i) licenses, or options to obtain licenses, to the Company&#8217;s technology, and (ii) in certain cases, services in connection with the manufacturing of preclinical and clinical materials. Payments to the Company under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; milestone payments; payments for clinical and commercial product supply, and royalties on future product sales. To date, the Company&#8217;s license agreement with Abbisko Therapeutics Co., Ltd. (&#8220;Abbisko&#8221;) represents its only revenue-generating agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and are therefore within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are deemed to be within the scope of ASC 808, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of ASC 606. The Company&#8217;s policy is generally to recognize amounts received from collaborators in connection with joint operating activities that are within the scope of ASC 808 as a reduction in research and development expense. To date, there have been no transactions within the scope of ASC 808.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company determines it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligation(s) in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligation(s) in the contract; and (5) recognize revenue when (or as) the Company satisfies its performance obligation(s). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and; allocating the transaction price to each performance obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: </span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and </span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time based on the use of an output or input method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes non-refundable payments for contingent milestones, including preclinical research and development, clinical development and regulatory, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most-likely-amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of the achievement of contingent milestones and the likelihood of a significant reversal of such milestone revenue, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect licensing revenue in the period of adjustment. This quarterly assessment may result in the recognition of revenue related to a contingent milestone payment before the milestone event has been achieved.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock', window );">Research and Development Programs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Programs&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds under the research and development incentive program from the Austrian government are recognized as other income in an amount equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. Incentive income recognized upon incurring qualifying expenses in advance of receipt of proceeds from research and development incentives is recorded in the consolidated balance sheet as research and development incentive receivable.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Cost</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with internal research and development and external research and development services, including drug development and preclinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers.</span>Nonrefundable advance payments for services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the related services have been performed, or when it is no longer expected that the goods will be delivered or the services rendered.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend', window );">Patent Cost</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs consist of payments made to secure commitments under certain debt financing arrangements. These amounts are recognized as interest expense over the period of the financing arrangement using the effective interest method. If the financing arrangement is canceled or forfeited, or if the utility of the arrangement to the Company is otherwise compromised, these costs are recognized as interest expense immediately. The Company&#8217;s consolidated financial statements present debt issuance costs related to a recognized debt liability as a direct reduction from the carrying amount of that debt liability.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures all stock-based awards granted to employees, nonemployees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has also issued stock-based awards with performance-based vesting conditions that vest in part upon the Company&#8217;s achievement of operational milestones and over time thereafter for the subsequent two years as the employee continues to provide services. The Company assesses the probability of achievement of these operational milestones and recognizes stock-based compensation for these awards using the accelerated attribution model based on the fair value of the awards as of the date of grant and its best estimate of the date each operational milestone will be achieved. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for only the portion of awards that are expected to vest. In developing a forfeiture rate estimate, the Company has considered its historical experience to estimate pre-vesting forfeitures for service-based awards. The impact of a forfeiture rate adjustment is recognized in full in the period of adjustment, and if the actual forfeiture rate is materially different from the Company&#8217;s estimate, the Company may be required to record adjustments to stock-based compensation expense in future periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Prior to March&#160;13, 2019, the Company was a private company and lacked company-specific historical and implied volatility information for its common stock. Therefore, the Company estimates its expected common stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to </span></div>the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text">Derivative Liabilities: Hercules Loan Redemption Feature&#8212; The Company&#8217;s loan agreement with Hercules (see Note&#160;7) contains a redemption feature that, upon an event of default, provides Hercules the option to accelerate and demand repayment of the debt, including a prepayment premium, or, at its election, charge additional contingent interest fees on any overdue interest or principal payments. The redemption feature meets the definition of a derivative instrument as the repayment of the debt contains a substantial premium, resulting in the redemption feature not being clearly and closely related to its host instrument. Accordingly, the Company classifies this derivative as a liability within other liabilities (non-current) on its consolidated balance sheets. The derivative liability was initially recorded at fair value on the date of the Hercules Loan Agreement and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of this derivative liability, which is included in other liabilities, are recognized as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss. Changes in the fair value of this derivative liability will continue to be recognized until all amounts outstanding under the Hercules Loan Agreement are repaid or until the Hercules Loan Agreement is terminated.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021 and 2020, all foreign currency remeasurement gains and losses were included in net loss as the Company has deemed the functional currency of its foreign subsidiary to be the U.S. Dollar. Comprehensive loss includes net loss as well as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">translation adjustments of</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to the Merger with Arsanis on March 13, 2019, the Company followed the two-class method when computing net loss per share as the Company had issued shares that met the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. In addition, during the year ended December 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of subsequent sales of common stock. Such adjustment is accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#8217;s common stock and the estimated remaining life of the outstanding Class B Warrants. </span>Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Basic shares outstanding includes the weighted average effect of the Company&#8217;s outstanding prefunded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive shares of common stock. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of convertible preferred stock or common stock are considered potential dilutive shares of common stock.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text">Recently Issued Accounting Pronouncements<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In accordance with ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Derivative and Hedging (Topic 815), and Leases (Topic 842)- Effective Dates, </span>as the Company meets the definition of a &#8220;smaller reporting company&#8221;, the Company has elected to defer the adoption of ASU 2016-13 until January 1, 2023. The Company expects that the adoption of ASU 2016-13 may accelerate the timing and could increase the level of credit loss expense in the consolidated statement of operations and will likely require an increased level of disclosure in the notes to the consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_IntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_IntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Programs, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right Of Use Asset and Lease Liability, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856578888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensatingBalancesTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:97%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Letter of credit security: Cambridge lease</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Letter of credit security: Waltham lease </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Letter of credit security: Vienna Austria lease</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Boston lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash to Cash Flows</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets to the sum to the total of amounts shown in the Company&#8217;s consolidated statements of cash flows as of December&#160;31, 2021, 2020, 2019 and 2018:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:46.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current (included within prepaid expenses and other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current (included within other assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,702&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Property and Equipment Useful Life</a></td>
<td class="text">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.636%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or 10 years</span></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensatingBalancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes disclosure of  these arrangements and the amount involved, if determinable, for the most recent audited balance sheet required and for any subsequent unaudited balance sheet required in the notes to the financial statements. Compensating balances that are maintained under an agreement to assure future credit availability are generally disclosed in the notes to the financial statements along with the amount and terms of such agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 6.H.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13728-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensatingBalancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment Useful Life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash to Cash Flows</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412853998872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2020 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s warrant liability and derivative liability, for which fair values are determined using Level&#160;3 inputs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"><tr><td style="width:1.0%"/><td style="width:76.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.751%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Embedded Derivative Liability</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a rollforward of the Company&#8217;s goodwill and accumulated impairment losses.  </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"><tr><td style="width:1.0%"/><td style="width:80.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, gross amount, at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment loss, at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412853153064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.896%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852043816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846559928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt premium, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative accrual of end of term payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(795)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, future principal payments and accrued end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"/><td style="width:76.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.026%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,471&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including end-of-term payments</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,657&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852154696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three years ended December&#160;31, 2021, 2020, and 2019 were as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:40.891%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%">Leased assets obtained in exchange for new operating lease liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:97%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities due under lease agreements that have commenced as of December&#160;31, 2021 are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"><tr><td style="width:1.0%"/><td style="width:78.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,851&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852153848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock', window );">Schedule of Outstanding Warrants Table</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of outstanding warrants for the period ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Number of warrants</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term (Years)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable as of  December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,354,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058,032&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,130,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,257,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Outstanding Warrants Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412848529624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Stock Option Valuation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"><tr><td style="width:1.0%"/><td style="width:60.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity for the twelve months ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.078%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.679%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(in Thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(340,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,236&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,689,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock activity for the twelve months ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.275%"><tr><td style="width:1.0%"/><td style="width:71.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.155%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expense Classification</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the consolidated statements of operations as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"><tr><td style="width:1.0%"/><td style="width:50.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412848504376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before the provision for income taxes for the years ended December 31, 2021, 2020 and 2019 consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,314)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign (Austria)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,679)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,983)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,807)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of preferred stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax asset valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021, 2020 and 2019 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"/><td style="width:41.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,797)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance, end of year </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,835)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,197)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,410)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s reserve for uncertain tax positions for the three years ended December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"/><td style="width:82.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reserve for Uncertain Tax Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in unrecognized tax benefit for tax positions taken during year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of unrecognized tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852154696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.126%"><tr><td style="width:1.0%"/><td style="width:58.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruing dividends on Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend as a result of Class B Warrant price reset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,639)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,131)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,399)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock&#8212;basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212; basic and diluted</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.99)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.09)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.63)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock (excluding prefunded warrants, which are included in basic shares outstanding)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,449,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,474,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,776,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,290,280&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,921,377&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,673&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856126280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 12, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Mar. 13, 2019</div></th>
<th class="th">
<div>Mar. 03, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 26, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,787<span></span>
</td>
<td class="nump">$ 78,708<span></span>
</td>
<td class="nump">$ 126,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 282,871<span></span>
</td>
<td class="nump">$ 194,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses', window );">Proceeds from common stock issuance</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 85,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=xfor_ArsanisMember', window );">Arsanis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_BusinessCombinationShareExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_BusinessCombinationShareExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Share Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_BusinessCombinationShareExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=xfor_ArsanisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=xfor_ArsanisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855997416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 1,321<span></span>
</td>
<td class="nump">$ 1,730<span></span>
</td>
<td class="nump">$ 1,902<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current (included within prepaid expenses and other current assets)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Other assets</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_CambridgeMAOperatingLeaseArrangementMember', window );">Letter of credit security: Cambridge lease | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember', window );">Letter of credit security: Waltham lease | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Other assets</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaLeaseArrangementMember', window );">Letter of credit security: Vienna Austria lease | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Other assets</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember', window );">Letter of credit security: Boston lease | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">$ 1,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_CambridgeMAOperatingLeaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_CambridgeMAOperatingLeaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaLeaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaLeaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846540344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81,787<span></span>
</td>
<td class="nump">$ 78,708<span></span>
</td>
<td class="nump">$ 126,184<span></span>
</td>
<td class="nump">$ 8,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current (included within prepaid expenses and other current assets)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Other assets</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
<td class="nump">1,902<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 83,108<span></span>
</td>
<td class="nump">$ 80,702<span></span>
</td>
<td class="nump">$ 128,086<span></span>
</td>
<td class="nump">$ 8,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856165752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852516392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 1,321<span></span>
</td>
<td class="nump">$ 1,730<span></span>
</td>
<td class="nump">$ 1,902<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412853752328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Funding Agreements - Genzyme Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PaymentOnObligationUnderLicenseAgreement', window );">Payment on obligation under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_GenzymeAgreementMember', window );">Genzyme Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PaymentOnObligationUnderLicenseAgreement', window );">Payment on obligation under license agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PaymentOnObligationUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment On Obligation Under License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PaymentOnObligationUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_GenzymeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_GenzymeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856108536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Funding Agreements - Georgetown Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PaymentOnObligationUnderLicenseAgreement', window );">Payment on obligation under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_GeorgetownMember', window );">Georgetown</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_OneTimeUpfrontPayment', window );">One time upfront payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_MilestonePaymentsPaid', window );">Payments made</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_MilestoneContractTerminationPeriod', window );">Termination period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PaymentOnObligationUnderLicenseAgreement', window );">Payment on obligation under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_MilestonePaymentObligation', window );">Payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_MilestoneContractTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Contract, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_MilestoneContractTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_MilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_MilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_MilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_MilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_OneTimeUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One Time Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_OneTimeUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PaymentOnObligationUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment On Obligation Under License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PaymentOnObligationUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_GeorgetownMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_GeorgetownMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856029944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Funding Agreements - Beth Israel Deaconess Medical Center Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PaymentOnObligationUnderLicenseAgreement', window );">Payment on obligation under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_BidmcAgreementMember', window );">Bidmc Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_OneTimeUpfrontPayment', window );">One time upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PaymentOnObligationUnderLicenseAgreement', window );">Payment on obligation under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_DFCIMember', window );">DFCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_OneTimeUpfrontPayment', window );">One time upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PaymentOnObligationUnderLicenseAgreement', window );">Payment on obligation under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CollaborativeAgreementExpenseReimbursement', window );">Collaborative Agreement , Expense Reimbursement</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CollaborativeArrangementObligationPercentage', window );">Collaborative Arrangement, Obligation, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree', window );">Collaborative agreement, future expected annual fees, year one through three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix', window );">Collaborative agreement, future expected annual fees, year four through six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter', window );">Collaborative agreement, future expected annual fees, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CollaborativeAgreementExpenseReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expense Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CollaborativeAgreementExpenseReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Future Expected Annual Fees, Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Future Expected Annual Fees, Year Four Through Six</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Future Expected Annual Fees, Year One Through Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CollaborativeArrangementObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Obligation, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CollaborativeArrangementObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_OneTimeUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One Time Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_OneTimeUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PaymentOnObligationUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment On Obligation Under License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PaymentOnObligationUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_BidmcAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_BidmcAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_DFCIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_DFCIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856041256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Funding Agreements - Research and Development Incentive Program (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">$ 426<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
<td class="nump">$ 517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_ResearchAndDevelopmentIncentiveProgramMember', window );">Research and Development Incentive Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_GrantAndIncentiveReceivables', window );">Amount due under incentive receivable plan</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_AbbiskoAgreementMember', window );">Abbisko Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PotentialMilestonePaymentsReceivable', window );">Potential milestone payments receivable</a></td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=xfor_MTSAustriaMember', window );">X4 Austria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ReimbursementRateForResearchAndDevelopment', window );">Reimbursement rate for research and development</a></td>
<td class="nump">0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_GrantAndIncentiveReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant and Incentive Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_GrantAndIncentiveReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ReimbursementRateForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Rate For Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ReimbursementRateForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_ResearchAndDevelopmentIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_ResearchAndDevelopmentIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_AbbiskoAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_AbbiskoAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=xfor_MTSAustriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=xfor_MTSAustriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852158456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Funding Agreements (Details) - Abbisko Agreement<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PotentialMilestonePaymentsReceivable', window );">Potential milestone payments receivable</a></td>
<td class="nump">$ 208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_AbbiskoAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_AbbiskoAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846372440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Measured on a Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents&#8212;money market funds</a></td>
<td class="nump">$ 47,793<span></span>
</td>
<td class="nump">$ 44,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents&#8212;money market funds</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">16,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents&#8212;money market funds</a></td>
<td class="nump">27,793<span></span>
</td>
<td class="nump">28,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents&#8212;money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412848506024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities -Aggregate Fair Value of Warrant and Derivative Liabilities (Details) - Level 3 - Embedded derivative liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 455<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 821<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855121288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Narrative (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855280872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill Rollforward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 27,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">(9,758)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 17,351<span></span>
</td>
<td class="nump">$ 27,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846684840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,238<span></span>
</td>
<td class="nump">$ 1,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(724)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_SoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 576<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855227864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">$ 5,417<span></span>
</td>
<td class="nump">$ 3,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AccruedExternalResearchAndDevelopmentExpenses', window );">Accrued external research and development expenses</a></td>
<td class="nump">1,507<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 7,870<span></span>
</td>
<td class="nump">$ 8,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AccruedExternalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued External Research And Development Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AccruedExternalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855116792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount of long-term debt</a></td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AccretionOnLongTermDebt', window );">Cumulative accrual of end of term payments</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LongTermDebtIncludingAccretion', window );">Long-Term Debt, Including Accretion</a></td>
<td class="nump">33,934<span></span>
</td>
<td class="nump">33,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term Debt, Current Maturities</a></td>
<td class="num">(795)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Principal amount of long-term debt</a></td>
<td class="nump">33,139<span></span>
</td>
<td class="nump">33,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt Instrument, Unamortized Discount (Premium), Net</a></td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AccretionOnLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion On Long Term Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AccretionOnLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LongTermDebtIncludingAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Including Accretion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LongTermDebtIncludingAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412946060104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - SVB Loan Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (162)<span></span>
</td>
<td class="num">$ (566)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855188232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - FFG Loan Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (162)<span></span>
</td>
<td class="num">$ (566)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412847212616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Hercules Loan Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 21, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 13, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesAmendedAndRestatedLoanAgreementMember', window );">Hercules Amended and Restated Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase in interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesAmendedAndRestatedLoanAgreementMember', window );">Hercules Amended and Restated Loan Agreement | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesAmendedAndRestatedLoanAgreementMember', window );">Hercules Amended and Restated Loan Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesFirstAmendedLoanAgreementMember', window );">Hercules First Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesFirstAmendedLoanAgreementMember', window );">Hercules First Amended Loan Agreement | Discretionary Borrowings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember', window );">Hercules Second Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_DebtInstrumentPrePaymentPremiumPercentage', window );">Payment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember', window );">Hercules Second Amended Loan Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPayment', window );">Periodic payment</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember', window );">Hercules Second Amended Loan Agreement | Min Cash Test Date 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LineOfCreditCovenantMinimumCash', window );">Line of Credit, Covenant, Minimum Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember', window );">Hercules Second Amended Loan Agreement | Min Cash Test Date 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LineOfCreditCovenantMinimumCash', window );">Line of Credit, Covenant, Minimum Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,000<span></span>
</td>
<td class="nump">$ 531,000<span></span>
</td>
<td class="nump">$ 414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,642,000<span></span>
</td>
<td class="nump">$ 2,686,000<span></span>
</td>
<td class="nump">$ 1,807,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments of both interest and principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_DebtInstrumentPrePaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Pre Payment Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_DebtInstrumentPrePaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LineOfCreditCovenantMinimumCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit, Covenant, Minimum Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LineOfCreditCovenantMinimumCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xfor_HerculesAmendedAndRestatedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xfor_HerculesAmendedAndRestatedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xfor_HerculesFirstAmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xfor_HerculesFirstAmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=xfor_DiscretionaryBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=xfor_DiscretionaryBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=xfor_MinCashTestDate1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=xfor_MinCashTestDate1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=xfor_MinCashTestDate2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=xfor_MinCashTestDate2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412848502344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Future Principal Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">21,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">11,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance Lease, Liability, Payment, Due</a></td>
<td class="nump">$ 33,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412848152792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 01, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 11, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 13, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,710<span></span>
</td>
<td class="nump">$ 7,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
<td class="nump">4,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm', window );">Right-of-use asset, amortization term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">$ 827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">3,820<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
<td class="nump">$ 5,090<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8212;operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8212;operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember', window );">Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace', window );">Office space area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AggregateBaseRent', window );">Base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaLeaseArrangementMember', window );">2019 Vienna Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace', window );">Office space area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AggregateBaseRent', window );">Base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember', window );">Boston Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CurrentOfficeSpaceUnderLeaseAgreement', window );">Current Office Space Under Lease Agreement | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Lease not yet commenced, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_NewViennaLeaseMember', window );">New Vienna Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace', window );">Office space area | ft&#178;</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AggregateBaseRent', window );">Base rent</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseRentFreePeriod', window );">Rent-free period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_CambridgeLeaseMember', window );">Cambridge Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace', window );">Office space area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_AggregateBaseRent', window );">Base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AggregateBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AggregateBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CurrentOfficeSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current office space under lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CurrentOfficeSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Office Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LesseeOperatingLeaseRentFreePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent-Free Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LesseeOperatingLeaseRentFreePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_OperatingLeaseRightOfUseAssetAmortizationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Amortization Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_OperatingLeaseRightOfUseAssetAmortizationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaLeaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaLeaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_NewViennaLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_NewViennaLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_CambridgeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_CambridgeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846676504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease cost</a></td>
<td class="nump">$ 2,087<span></span>
</td>
<td class="nump">$ 1,290<span></span>
</td>
<td class="nump">$ 827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LeaseCostAdditionalInformationAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">3,820<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 1,343<span></span>
</td>
<td class="nump">$ 5,090<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8212;operating leases</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8212;operating leases</a></td>
<td class="nump">11.30%<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LeaseCostAdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Cost, Additional Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LeaseCostAdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855135240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026 and thereafter</a></td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">7,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(1,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 5,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412847224856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock Warrants - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 29, 2019</div></th>
<th class="th"><div>Nov. 26, 2019</div></th>
<th class="th"><div>Apr. 16, 2019</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 03, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightIssued', window );">Class Of Warrant Or Right Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,058,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod', window );">Warrant expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued', window );">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights', window );">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,257,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,354,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PrefundedWarrantsAxis=xfor_FundedMember', window );">Funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember', window );">Issuance on November 29, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,416,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member', window );">Issuance On March 23, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember', window );">Issuance on November Nine Two Thousand Twenty One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,008,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassAWarrantMember', window );">Class A Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightIssued', window );">Class Of Warrant Or Right Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember', window );">Class B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightIssued', window );">Class Of Warrant Or Right Issued</a></td>
<td class="nump">5,416,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant | Issuance On March 23, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Warrants Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PrefundedWarrantsAxis=xfor_FundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PrefundedWarrantsAxis=xfor_FundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_ClassAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412848144184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock Warrants - Schedule of Outstanding Warrants (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_WarrantsRollForward', window );"><strong>Number of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding and exercisable warrants to purchase shares preferred stock as of 12/31/2019</a></td>
<td class="nump">13,354,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightIssued', window );">Class Of Warrant Or Right Issued</a></td>
<td class="nump">2,058,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="num">(2,130,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding and exerciseable, Number of warrants, ending balance (in shares)</a></td>
<td class="nump">13,257,160<span></span>
</td>
<td class="nump">13,354,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightExpired', window );">Issued</a></td>
<td class="nump">25,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice', window );">Outstanding and exercisable warrants to purchase preferred shares, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 13.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice', window );">Outstanding and exercisable, ending balance (in dollars per share)</a></td>
<td class="nump">$ 7.96<span></span>
</td>
<td class="nump">$ 13.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm', window );">Weighted Average Contractual Term (Years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">13,257,160<span></span>
</td>
<td class="nump">13,354,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember', window );">Issuance on November 29, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_WarrantsRollForward', window );"><strong>Number of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding and exerciseable, Number of warrants, ending balance (in shares)</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Weighted Average Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_WarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_WarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412847616328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred and Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 03, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
<th class="th"><div>Nov. 26, 2019</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,257,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,354,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued', window );">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.999<span></span>
</td>
<td class="nump">$ 10.999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember', window );">Issuance On October 25, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember', window );">Issuance On December 28, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember', window );">Issuance On September 12, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember', window );">Issuance On October 19, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember', window );">Issuance On March 13, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember', window );">Issuance On April 16, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,866,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember', window );">Issuance on November 29, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,416,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember', window );">Issuance on November 29, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member', window );">Issuance On March 23, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member', window );">Issuance On March 23, 2021 | Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember', window );">Issuance on November Nine Two Thousand Twenty One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,008,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412845345560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock) - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Oct. 14, 2020</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Nov. 26, 2019</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
<th class="th"><div>Apr. 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Cash dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="nump">6,271,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,666,667<span></span>
</td>
<td class="nump">5,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod', window );">Warrant expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses', window );">Proceeds from common stock issuance</a></td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockIssuedDuringPeriodValueLicenseAgreement', window );">Fair value of additional common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 734,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock Repurchased and Retired During Period, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember', window );">Issuance on November 29, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember', window );">Equity Unit Purchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_SaleOfStockPurchaseAgreementTerm', window );">Purchase agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=xfor_SalesAgentsMember', window );">Sales Agents [Member] | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount', window );">Number of shares authorized in transaction, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Common Stocks, Including Additional Paid in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xfor_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="nump">229,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xfor_RedeemableCommonStockMember', window );">Redeemable Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock Repurchased and Retired During Period, Value</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_GenzymeAgreementMember', window );">Genzyme Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_StockIssuedDuringPeriodSharesLicenseAgreement', window );">Shares issued for additional consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_CommonStockRepurchasePricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="nump">2,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.999<span></span>
</td>
<td class="nump">$ 10.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassAWarrantMember', window );">Class A Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember', window );">Class B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,416,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Warrants Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CommonStockRepurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Repurchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CommonStockRepurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Number Of Shares Authorized in Transaction, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_SaleOfStockPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_SaleOfStockPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_StockIssuedDuringPeriodSharesLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_StockIssuedDuringPeriodSharesLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_StockIssuedDuringPeriodValueLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_StockIssuedDuringPeriodValueLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xfor_SalesAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xfor_SalesAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xfor_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xfor_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xfor_RedeemableCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xfor_RedeemableCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_GenzymeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_GenzymeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_ClassAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412848208296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock', window );">Maximum percentage of fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercises in period, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue', window );">Options granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.17<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 10.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember', window );">Incentive Stock Options and Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Shares based compensation, vested period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share based compensation, restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share based compensation, restricted stock units granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share based compensation, grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost of stock based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost of stock based awards, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xfor_A2015EquityIncentivePlanMember', window );">Two Thousand Fifteen Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xfor_TwoThousandSeventeenEquityIncentivePlanMember', window );">Two Thousand Seventeen Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance (in shares)</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Aggregate intrinsic value, options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xfor_TwoThousandSeventeenEquityIncentivePlanMember', window );">Two Thousand Seventeen Equity Incentive Plan | Employee Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based compensation arrangement by share-based payment award, shares issued in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares)</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xfor_TwoThousandNineteenEquityIncentivePlanMember', window );">Two Thousand Nineteen Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Non-Statutory Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Shares based compensation, vested period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Non-Statutory Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Shares based compensation, vested period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Awards Grant In Period Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-Based Payment Award, Exercise Price, Maximum Percentage Of Fair Market Value Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xfor_A2015EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xfor_A2015EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xfor_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xfor_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=xfor_EmployeeStockPurchasePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=xfor_EmployeeStockPurchasePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xfor_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xfor_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xfor_NonStatutoryOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xfor_NonStatutoryOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846515576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Valuation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 15 days<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">97.30%<span></span>
</td>
<td class="nump">94.90%<span></span>
</td>
<td class="nump">88.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856081832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,874,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, (in shares)</a></td>
<td class="nump">388,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(5,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(340,653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">1,916,051<span></span>
</td>
<td class="nump">1,874,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, ending balance (in shares)</a></td>
<td class="nump">1,007,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, ending balance (in shares)</a></td>
<td class="nump">1,689,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 12.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">6.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">7.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">22.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">10.01<span></span>
</td>
<td class="nump">$ 12.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">11.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 10.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract', window );"><strong>Weighted Average Contractual Term (in Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in Thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding beginning balance</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846554312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested beginning balance (in shares)</a></td>
<td class="nump">572,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">674,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(205,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(116,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending balance (in shares)</a></td>
<td class="nump">925,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846372280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 6,180<span></span>
</td>
<td class="nump">$ 5,428<span></span>
</td>
<td class="nump">$ 2,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">2,723<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 3,457<span></span>
</td>
<td class="nump">$ 3,112<span></span>
</td>
<td class="nump">$ 1,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855235368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (89,865)<span></span>
</td>
<td class="num">$ (62,539)<span></span>
</td>
<td class="num">$ (52,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign (Austria)</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="num">(493)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</a></td>
<td class="num">$ (88,679)<span></span>
</td>
<td class="num">$ (61,983)<span></span>
</td>
<td class="num">$ (52,807)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856000296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(5.40%)<span></span>
</td>
<td class="num">(5.90%)<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences', window );">Other permanent differences</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="nump">23.70%<span></span>
</td>
<td class="nump">27.20%<span></span>
</td>
<td class="nump">26.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change In Fair Value Of Preferred Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412855250936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Income Tax Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Components of Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 101,863<span></span>
</td>
<td class="nump">$ 83,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">5,444<span></span>
</td>
<td class="nump">4,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development expenses</a></td>
<td class="nump">1,760<span></span>
</td>
<td class="nump">2,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_DeferredTaxAssetLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">1,243<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">3,372<span></span>
</td>
<td class="nump">2,452<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">113,682<span></span>
</td>
<td class="nump">94,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(111,835)<span></span>
</td>
<td class="num">(92,197)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_DeferredTaxLiabilityRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_DeferredTaxAssetLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_DeferredTaxAssetLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Capitalized Research And Development Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_DeferredTaxLiabilityRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability, Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_DeferredTaxLiabilityRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412845997704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">260,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="nump">54,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">308,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">65,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412846015992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Valuation Allowance (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance, beginning of year</a></td>
<td class="num">$ (92,197)<span></span>
</td>
<td class="num">$ (73,410)<span></span>
</td>
<td class="num">$ (22,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Increases recorded to income tax provision</a></td>
<td class="num">(19,638)<span></span>
</td>
<td class="num">(18,787)<span></span>
</td>
<td class="num">(14,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired', window );">Acquisition of business</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(36,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance, end of year</a></td>
<td class="num">$ (111,835)<span></span>
</td>
<td class="num">$ (92,197)<span></span>
</td>
<td class="num">$ (73,410)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412852405288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecognized Tax Benefits, Period Increase (Decrease)</a></td>
<td class="num">$ (100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Unrecognized Tax Benefits, Increase Resulting from Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856106456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (88,696)<span></span>
</td>
<td class="num">$ (62,131)<span></span>
</td>
<td class="num">$ (52,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Accruing dividends on Series A convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock', window );">Deemed dividend as a result of Class B Warrant price reset</a></td>
<td class="nump">13,943<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (102,639)<span></span>
</td>
<td class="num">$ (62,131)<span></span>
</td>
<td class="num">$ (53,399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding - basic and diluted (in shares)</a></td>
<td class="nump">25,749<span></span>
</td>
<td class="nump">20,077<span></span>
</td>
<td class="nump">11,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (3.99)<span></span>
</td>
<td class="num">$ (3.09)<span></span>
</td>
<td class="num">$ (4.63)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Repurchase Of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412848135672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 26, 2019</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding - basic and diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,749,000<span></span>
</td>
<td class="nump">20,077,000<span></span>
</td>
<td class="nump">11,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding - basic and diluted (in shares)</a></td>
<td class="nump">3,808,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.999<span></span>
</td>
<td class="nump">$ 10.999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412856005864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded form computation of diluted net loss per share (in shares)</a></td>
<td class="nump">12,290,280<span></span>
</td>
<td class="nump">11,921,377<span></span>
</td>
<td class="nump">11,175,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded form computation of diluted net loss per share (in shares)</a></td>
<td class="nump">9,449,128<span></span>
</td>
<td class="nump">9,474,403<span></span>
</td>
<td class="nump">9,776,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded form computation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,916,051<span></span>
</td>
<td class="nump">1,874,514<span></span>
</td>
<td class="nump">1,297,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded form computation of diluted net loss per share (in shares)</a></td>
<td class="nump">925,101<span></span>
</td>
<td class="nump">572,460<span></span>
</td>
<td class="nump">101,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412845924296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss on Transfer of Nonfinancial Assets - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Loss on transfer of nonfinancial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from transfer of non-financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Carrying value of IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140412844402616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 03, 2022</div></th>
<th class="th"><div>Feb. 09, 2022</div></th>
<th class="th"><div>Jan. 14, 2022</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Oct. 14, 2020</div></th>
<th class="th"><div>Nov. 26, 2019</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,271,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,666,667<span></span>
</td>
<td class="nump">5,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,257,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,354,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights', window );">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.999<span></span>
</td>
<td class="nump">$ 10.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo', window );">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree', window );">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_DebtInstrumentDebtCovenantMinimumCashRequired', window );">Debt Instrument, Debt Covenant, Minimum Cash Required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember', window );">Issuance on November 29, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,416,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember', window );">Equity Unit Purchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_SaleOfStockPurchaseAgreementTerm', window );">Purchase agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_SaleOfStockPurchaseAgreementSharesIssued', window );">Sale of Stock, Purchase Agreement, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_PurchaseAgreementSharesPurchased', window );">Purchase Agreement, Shares Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,382,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare', window );">Accelerated Share Repurchases, Initial Price Paid Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell', window );">Payments for Securities Purchased under Agreements to Resell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in dollars per share)</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights', window );">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Hercules Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree', window );">Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_DebtInstrumentDebtCovenantMinimumCashRequired', window );">Debt Instrument, Debt Covenant, Minimum Cash Required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario', window );">Debt Instrument, Debt Covenant, Minimum Cash Required, Conditional Scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Issuance on November 29, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Q1 2022 PIPE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Convertible preferred stock exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xfor_AspireCapitalFundLLCMember', window );">Aspire Capital Fund, LLC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term Purchase Commitment, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xfor_LincolnParkCapitalFundLLCMember', window );">Lincoln Park Capital Fund, LLC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term Purchase Commitment, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with agreements to purchase and then resell securities to counterparties (reverse repurchase agreements).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_DebtInstrumentDebtCovenantMinimumCashRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Covenant, Minimum Cash Required</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_DebtInstrumentDebtCovenantMinimumCashRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Covenant, Minimum Cash Required, Conditional Scenario</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PurchaseAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PurchaseAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_SaleOfStockPurchaseAgreementSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Purchase Agreement, Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_SaleOfStockPurchaseAgreementSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_SaleOfStockPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_SaleOfStockPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_Q12022PIPEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_Q12022PIPEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xfor_AspireCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xfor_AspireCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xfor_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xfor_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>xfor-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xfor="http://www.x4pharma.com/20211231"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="xfor-20211231.xsd" xlink:type="simple"/>
    <context id="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica45cd390e2849f4b2b75e21159c3a2f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i124b0568b1914873ac60885d7abe74b5_I20220314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2022-03-14</instant>
        </period>
    </context>
    <context id="ib7fea33dfd0f43f88c85204776483478_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedee6e787d804eec9aef3377417aa32d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id03c381eb978491b8ef9300074bfc781_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i572b67d5b62c4080a9192cbe762029fb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8462e5cfa36e4e91b441a3ad10cfb348_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9ecf8ce3e9b74e56acb8ff0af3fb7c60_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i51b86b7cc383415ab9c2160568c774c4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i176b3693f32c4dc59cff0f728a8aa927_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9399ce4d3f59464796fe4fa19123abea_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i13bac80900904f72b4b9131b22a45f6a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia15232c68ac3485b97f216f1936f809b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib34264e2c11b4c15b0b5b0a7b86698e8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9c7918b22f9243ddaf0f3d3d10ab77d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd5d9882306b44ada5d3504a50879658_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4db0920d51934739ab1e898d8dd9ec84_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e6ba7741627488daf0ea92b674d371a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ea504a912184f6781687f27b056d117_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a487a492bc94ba59c6f135aa8c86c42_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i373cd781460447af8b7b7a8138e80603_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac2e90cc41804bbb8dbab70f418649b8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9cef3e8a10ac450289a7a934bddd328c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3a7b1480c3841f595013f06c59a2f9a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf1406e0d5074a2d82a899bd3bb3214a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i820d81ce3a29475a8c344011da28e038_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ed4bb840e6c490cb44e0c1b2416b76b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id095d9ce2828470d851a6cbfc3424820_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11e0524bed0045f9a3d87f7528ddd21a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i764dfda255314eb5b4c9af8e6f5029a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9a7b73207d14b36af0c17c6d6540372_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i153dbfb5749f4329b178c4b7931cafdc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d20d773aefb40a2ab1e4fd2d6abeacc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie38b2bc6981e4baeac34e666d1e848eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4851434b4d774d8bab2622f9881c9440_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58f79127b745453d84e4c71a65761e38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if884965b97674d2897920860dc9dd9de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64ff3d38d9274c5cb80f3c6ad6dc0169_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50217e3e4bd4418faec03cc4d6e2b168_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b8eb923c43342b496d1759d3a72b849_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54176cdc44bb45e8811df78b7fe967ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1dacdd07b5414e26a65fa9a53ef63e97_D20190313-20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xfor:ArsanisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="ib146624f4ddd4ad1ad0d121c7a5b8e07_I20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">xfor:ArsanisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-13</instant>
        </period>
    </context>
    <context id="if607c1606fbc49f59e2bf4de1d5b33a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:CambridgeMAOperatingLeaseArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38b2d39313774d1fa99f7f76bc2c53de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:CambridgeMAOperatingLeaseArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i420c5ba492444c13b294e4e2a546f0a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44c4ebf0462b4732860b5713ee5382d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica794810f5b2410aa3cb05ea67f5c7f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ce2db152304447e9853c0b52d13069e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5d8948ba512458fa854441df3e3e3bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4963d68c5d634e58ab61d1a2cddf748b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e897132b145489baf3f95f1211bbfe1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id55dcfd048fd4851ae346aa2bda82ea8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c76fdda3bb7478080cca4e3d51fa3d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98a725b19ab442bbb8edee0d639f20dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6cc17360a88043f9b6abb29bb3af7296_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i77964c20016f452c85f7147fb9ecc320_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic33f057257bb48b2afd09c10a0ad9385_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icda50709fc3f40a7ab505de422bb1006_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9784cfb07e534c2e87bde589e4247ab1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GenzymeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad3dd65af95a4a2aba2fdcc47b856359_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GenzymeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i225e901df8314c699611cba3ac017ff1_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i88010e5c3d6844f290c1e8ba4fb22318_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ceee2c8aded43179b9372ebcdc986a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad92d608e2c943b5a764b11f90964ae8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f97f5094be74d7ba79c0c8d4e004d44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1ce81a516a94a338811f3c4a44d3f09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8606b5dae8b041ddbf2eda066e840243_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GeorgetownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1954fbe47872474aa699d20fef1a95c1_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:BidmcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i380c26c2cda946c08040104fb3a0b055_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:BidmcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8829b46536ce4ec9827623894b9f4010_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:BidmcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62733706ba0e4d2db3cb0b4113c64983_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:BidmcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id39cf2b1c7eb411c8bf1eb3d7c157ca3_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:DFCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:DFCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf4a376dcdfb4942aaeaac1e7d14026a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xfor:MTSAustriaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i07dd80c3754e46e787921f0939875ae9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac899978347d423a8c974cde8043327f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie326aa2ac0af4123b2815995684d76f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16c580853b2d45d38376f5d122ceae9e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1ac70d6741a4930924fed60eceb574a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iccd109dd37804ba9bfecda161164e492_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:AbbiskoAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ce09a35448e44b7923a92354c5363c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:AbbiskoAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1f0240e57043459f99d9c4df35fbe4a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad1d2efd6bc94ac6831e430b69a1aaae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0c66368b5a4481390647875c1cd56b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41915bc16d8a42a0b9187f4f75b87df1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id29e21fcd99849af88c7d951ec6f37ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52444c1398e14dcba086b4397b35d5a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe6cb9ee46884d369d83ce82d8bf1038_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i280356e3a07941a2bcd0573cdc71bda1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8b2e9b7ab3a498986022689b55633be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6aa3b74a39643e7b24682ca039984a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42028c40df934c66818f46c7b7a459d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92061fb2c1cd4c7cbb46ced4db254c28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8b315bcebad4db0a5801ae168cf944a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12294001c3724c64a759185c687b58e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7406aa31e3374111bed602d9d3287a73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia84c45f7f16b4da88327ddbf122756a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb0a1ce7184c4d82850f7e0ca90dd59a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if504bda89d6b40c4857f885c3a5dd5be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05e4745ffaea4f638a14e69eb5e2e780_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee282cd049d2469f96e0d412a363884a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife90678c9c334675bb4fb9c5a64484fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad13cbd0ab104e089c980b940e3d7116_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie79fc5b3e5da4f21bc81f95a0112b9b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc702a2739324d80b4ef222aca509be2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie38293cc2bff405a9e1e6bc59761a28b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06df3f074d7447b6806efcb5f9c98d10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddc7cf15c96346e19207edcffa291f0c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e2a6d6e83924b2daa8ee08212fd793d_D20181001-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6605f338210c4eb6af0923abf8445fec_I20201221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesFirstAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-21</instant>
        </period>
    </context>
    <context id="ia221aaf88dc34cd18ee78f500786ae65_I20201221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:DiscretionaryBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesFirstAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-21</instant>
        </period>
    </context>
    <context id="i441b3dd525cf4ccba63a00aba76d1e05_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesAmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iedf2b97d940c42ffbf9fc1761bc75923_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesAmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4cd6cf3938894c7ebded737f6ab8df03_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesAmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i03e6b6f8a9c740948d0f053e9e9b88c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58af1e2574894b2ea2b9227befb6de70_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i044152b2a50d4484a5e19b0c3e40e9a3_D20230701-20230701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="i1e9fe3e1ad55446c8ece9e5d397f6127_D20240701-20240701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="i815e2b3d5b21461cb22c4cf956eab5d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8783c36c8464089a5c02a0e660c689e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82a84700b1c1468b831735d87f46a242_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie11078f4d8a0419ea19c205259a627ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i21716a46c2a345a29fc88ac84ad6249e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7f823743b9a246098193cea2dbb84829_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70dd855dda9a41448556d07389f6ef62_D20191111-20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-11</startDate>
            <endDate>2019-11-11</endDate>
        </period>
    </context>
    <context id="iec7ca8d65d8941a693c86e1d5e2e006d_I20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-11</instant>
        </period>
    </context>
    <context id="i96305963db034551a189b94796a2792a_D20190313-20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="i649b92ccef0a45d48c9c43fe57d79944_I20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-13</instant>
        </period>
    </context>
    <context id="ie206b7a7c0f04cad9646717d502a7f9d_D20190313-20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="ib03c7b0ffaa94e54a5fcb3da8d3bffcd_D20190313-20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="ibdb04900d7d94d69b89541fbd440e0f4_I20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-13</instant>
        </period>
    </context>
    <context id="i30884f0e4d634f7b8bc5bacaa38c8f3e_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:NewViennaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="ief7e7ceedd0a4127b22dedc2456e45ed_I20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:NewViennaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="i5dfd25fd846b472ba0ec52e244589a8e_D20210201-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:NewViennaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i7af38d4d2ff7443faf6ac2b41a13a62e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:CambridgeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f4a3cbd5679460ab78ce920e0af42b2_I20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2019-03-13</instant>
        </period>
    </context>
    <context id="i8b1ee4ca82b14441a5df67868c7c2fee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8f4b97ac998545cd8301f39db19e7d4d_D20190416-20190416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-16</startDate>
            <endDate>2019-04-16</endDate>
        </period>
    </context>
    <context id="i5a1dd2dc5c7e49e4a433ec1811b9e03c_D20191129-20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-29</startDate>
            <endDate>2019-11-29</endDate>
        </period>
    </context>
    <context id="i9f1955aa1b534854878550a58ccbf898_I20190416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-16</instant>
        </period>
    </context>
    <context id="i30903cfad3dd426ab86057983e126f26_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="i5faaf777d178421b83561c0fd16627c8_D20191126-20191126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2019-11-26</startDate>
            <endDate>2019-11-26</endDate>
        </period>
    </context>
    <context id="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie12ba0825f69455cbb72564897ee2268_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i997f64043d3c48f79904457d31ed425b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i358bda413e094c3b8732326b0da80424_I20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="ib4dbd5cea64e45acb7901cd8377332fd_I20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="iffc0e7e2a65446eaaa63bbb1c1af5689_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberNineTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i445218cd5fbd4b9cb04297a8f4e11d1d_I20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="i4b714c637a6647028b196f7cbd99f053_I20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="i1a2348e83e324b7b82456649b542f965_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1eea12429adf41968b80ecfea410785d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33bf01c5e0304c2189fa034c75eb5241_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5e02cabb20347e4812e2c13fe49c590_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberNineteenTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09e8bb1f0686446a9a8a7b9564378965_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarchThirteenTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22fa089c31854eeeaeeac178d4940454_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnAprilSixteenTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69c23f7b906f436f93692639aef06e09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddf524fe86fd469f8009f330de097712_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="i0bd64677f69e44d5ba2d48dae0391b34_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="ice9673b6146f4de3b3a39b86599af702_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="ic04f75350f324bb38f14095eadb12430_D20190412-20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2019-04-12</startDate>
            <endDate>2019-04-12</endDate>
        </period>
    </context>
    <context id="ibc57ac90fb9b4a139e8cb4ea7c012b1c_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="ic5d3611fd3c8401fb735dc5668ae2bdd_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="i7f7afe3aab394972900909f3eb5f8d6e_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="i8c32e3e005c345c99931e9ec6e8fd87d_I20191126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-26</instant>
        </period>
    </context>
    <context id="ie95bdf26dc21489e97c2cbbf4958cf38_I20191126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-26</instant>
        </period>
    </context>
    <context id="ic2e5e675d68a4f6fb4aacb2424a63a15_I20191126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2019-11-26</instant>
        </period>
    </context>
    <context id="i0367f472bfd0499fb8ee3740bd659aef_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xfor:SalesAgentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i9356b89607b64810becde53ca7553153_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xfor:SalesAgentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id058b9443dcc41a5ab90c45eaf52eb0f_D20210318-20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="i7e2c3583b72c4f10ba6fe68a4c9b2efc_D20150801-20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:GenzymeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-01</startDate>
            <endDate>2015-08-31</endDate>
        </period>
    </context>
    <context id="idaea2c14fe1c4ed986fa022e040501e2_D20150801-20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2015-08-01</startDate>
            <endDate>2015-08-31</endDate>
        </period>
    </context>
    <context id="i090e4c427ee048bc8e9fcdb0974c1506_D20210318-20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="ic20f813c6ba64ecd9f76496c37a6e54f_D20210318-20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="i66be0cd2cf4d4a42b63843821d7cd60e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba06b4b4e67a4951be1cc5d6e6014f25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xfor:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb68bbb183674891a54f752fa22ab0ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2dca859173e44d0ab9e6a946325f25cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xfor:IncentiveStockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i45311149808649259f5690565adeef41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xfor:NonStatutoryOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0cdc5828b647427eac8834bfe5c3918d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xfor:NonStatutoryOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i24ce1b0b961a4ecf8f39191f8d76e3f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:A2015EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9744171d8b784611a88ca1bbe96d8305_I20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="ibcb5c3f88dc04b4394011f548ecf9639_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0cda38b2da094f1989f1b4c220bb9a44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic32c961b47444fdbb27d84656b34b323_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic41788cc835c403ebdb1e9b363ffce18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">xfor:EmployeeStockPurchasePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib547fe50b2a14b3280afdd293833e80c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">xfor:EmployeeStockPurchasePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bc5c13e743746e4a019f4cf7a0c9b49_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">xfor:EmployeeStockPurchasePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="id65e88b8d02845c0a717fe27c8e5d78e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c91a1db75564f1a9f51565f80cc6989_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd6c8456214d407ab97760fec4594b56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b422ab3eb7e4a40aa972b2f8fff304f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia31a8d360da2400681748e55aab5c168_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if04d43b561c5475e947351e2ef934ba6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48c01b2e36084c58b99dee21b846e65d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb0418b0f1a84b1485cef1e8244c3bbe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if641bd9c2d33474caad13fd26380c7bd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i097aafa6f7b841a1a0aa11212d0ac628_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2f7ea03d3dc4a2db15e7efdf72553a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32f34441bf9943299037a918d5a88ca2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5afd505d65084ae68ba1922355482038_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19aaafe0d3d04513a526d073e5d54606_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0e74a770feb4868bd1ab0a23e223cd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4203c993d0e41018d52d1c410bc3e56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i610800df2fc44c33b927d13481ffc06a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icea0d3791b8d40149f121f9b367a9acd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c50656da4cf4784852c501bf1c61d57_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78bed59ffcf84935afe7d39665a6ed77_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ac33b1c38294eb99c02be51a19dfc6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib495f27eee5643c1aa40007ea1e395be_D20190416-20190416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-16</startDate>
            <endDate>2019-04-16</endDate>
        </period>
    </context>
    <context id="i834346b84a2147ecbd3cf27e5b2b7a1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia358f6661177462caadde0fb55c0679c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib7f118f44cef4d8da8cb50ea3570142e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i574f61ac83b744e4bac8486593ef48b8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2ebe6af4f44d4c56a5d0c7916e1a7f3e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifce6e198f34e4961a5cb7083bbca2927_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1b7de7a2f0e407ba0289ebb81300e0e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic7ed78f3d9464a2eb083a1251fd15435_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9372c9ab8f97446b99dcb15a6e0b1733_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15c8d1f64e434ebbac09001eadf96f1d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc0f8bba43d64d859d8549ce3f940062_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2a4f9e0d29b44b3a8c743db5ab19895_D20220114-20220114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xfor:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-14</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="i2d9b7bf5f3ef40dbb4d96393c1905d90_D20220114-20220114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xfor:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-14</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="ie34513bfd4ce4c4298a4866e8aa61aad_D20201014-20201014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-14</startDate>
            <endDate>2020-10-14</endDate>
        </period>
    </context>
    <context id="ic6a4a6cada334ffd9ee919af14b029f6_I20220114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-14</instant>
        </period>
    </context>
    <context id="ief44e634dee347efb955cc9c643e8ca1_D20220114-20220114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-14</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="i5720729ba9eb468d8f2396ce7f061f2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e984764b25842acb5cf371ed696787e_I20220314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-14</instant>
        </period>
    </context>
    <context id="ie9413c149a6a46d882b610a2ff34f1ff_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6a4e1b15e8914a5da92a4b13a532378d_I20220209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-09</instant>
        </period>
    </context>
    <context id="i3c992b94297b4f968244daa96427847c_D20220209-20220209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="i75e45f429fc6401584184ad501a62f94_D20220303-20220303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-03</startDate>
            <endDate>2022-03-03</endDate>
        </period>
    </context>
    <context id="i520c1054445641ac8c06d14b69d2bea3_I20220303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="i8f62b2544f6c4e2398c83ef365be248c_I20220303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="i7b4b699affe54fdf8181d6649b333e5f_I20220114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-14</instant>
        </period>
    </context>
    <context id="ie187101e5927453095022efb8232686c_I20220209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:Q12022PIPEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-09</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>xfor:reporting_unit</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMS0xLTEtMS0yMDk0MA_e1a96f6c-b105-4af2-a47c-0d188566f10c">0001501697</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMi0xLTEtMS0yMDk0MA_351beaa2-2baf-4cdd-a29b-5524dce3fb13">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfNC0xLTEtMS0yMDk0MA_b227d98c-872d-43a2-a34a-6c6938d69cee">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfNS0xLTEtMS0yMDk0MA_eb0346f1-13cd-45b4-bf26-490f39cfa39a">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfNy0xLTEtMS0yMDk0MA_27e4cc91-53ad-4c95-aeb8-c832a7c47c7f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfOS0xLTEtMS0yMDk0MA_7904e6a5-890f-4109-a5d7-8070be49f95b">61 North Beacon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMTAtMS0xLTEtMjA5NDA_4b0737b9-6325-42ca-a1ed-3c188491520c">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressStateOrProvince
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMTEtMS0xLTEtMjA5NDA_bae15610-582b-44d7-be1f-e9a1ca8693c1">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCityOrTown
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMTItMS0xLTEtMjA5NDA_2614ee0a-d4cf-4a10-8247-b77f4290fe1b">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMTMtMS0xLTEtMjA5NDA_ea7399ef-7d82-46b3-81db-6a33266dca43">02134</dei:EntityAddressPostalZipCode>
    <dei:DocumentType
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMC9mcmFnOjE1OTBiMTExNDJjZTRiNjY5YzI1MzczZTMyMTliMDg3L3RhYmxlOjkyNDViYmRmMjU5OTRlZjU4N2YxNTUyMjJhMGY1Y2JiL3RhYmxlcmFuZ2U6OTI0NWJiZGYyNTk5NGVmNTg3ZjE1NTIyMmEwZjVjYmJfMTQtMS0xLTEtMzI5MDg_5640202b-406a-46d2-a705-63865014a927">10-K</dei:DocumentType>
    <us-gaap:NumberOfReportingUnits
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTEvZnJhZzozZTJlNDYyODAwNjc0ZDNjYmZkZmIxOWY4M2JiOTNkMi90ZXh0cmVnaW9uOjNlMmU0NjI4MDA2NzRkM2NiZmRmYjE5ZjgzYmI5M2QyXzIy_c5f1c124-34cb-48e0-964c-7358b6da33b4"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i45311149808649259f5690565adeef41_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzEyNDI_d21e8b58-0c5c-4b61-b8a2-5336b084744c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6NDZjMGJhZWRkN2E5NDc0Y2EzZWM3Y2RjOTcxNGYwMjQvdGFibGVyYW5nZTo0NmMwYmFlZGQ3YTk0NzRjYTNlYzdjZGM5NzE0ZjAyNF8wLTAtMS0xLTMyNjUzL3RleHRyZWdpb246MzhiNDk1YzNkZGJiNDU1ODkxYTE2ODUzODI1MDZiNWRfNDk0NzgwMjMyNTAzOQ_5640202b-406a-46d2-a705-63865014a927">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6NGNmZWI3NDE1ZjQwNDRmYTg4NDA2Y2QwMWZiYzM3ODUvdGFibGVyYW5nZTo0Y2ZlYjc0MTVmNDA0NGZhODg0MDZjZDAxZmJjMzc4NV8wLTAtMS0xLTIwOTQw_4d441a8c-a7a3-4eaf-9cde-65c8bcbd6d67">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18yOTk_e563dbad-76c2-4597-813c-51fb466db35e">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18yOTk_baa31d10-b28e-4919-a307-f8be78572e01">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6NzcyMGU4Yjk4YjMxNDk2Y2EyNjJmMmM5ODAwOGIxMGEvdGFibGVyYW5nZTo3NzIwZThiOThiMzE0OTZjYTI2MmYyYzk4MDA4YjEwYV8wLTAtMS0xLTMyOTA0_3c05c02c-6200-4e24-985f-5a63d1e3fc95">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNzA_42c6e4de-6935-4bbb-a7d0-5fd212f20605">001-38295</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y180Nzk_48912097-4e31-4cd7-a582-8cb823e4a653">X4 PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8wLTAtMS0xLTIwOTQwL3RleHRyZWdpb246NWVkYWMzODFlMGE3NDRhNDg1YjFlZDU4NzVjNTZmYTNfNQ_27e4cc91-53ad-4c95-aeb8-c832a7c47c7f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8wLTEtMS0xLTIwOTQwL3RleHRyZWdpb246MjI0ZWQ1YWQ1ODI3NGM3N2I4Y2NiNzRiZDJlYzFiMGFfMTA5OTUxMTYyNzgyMA_197a1343-c7ca-4c09-837c-29eda66fe1c6">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8yLTAtMS0xLTIwOTQwL3RleHRyZWdpb246MWU1OWM2ZWNiN2M2NDk0M2FhNDBmZjdjZGE3OWZiNTlfNQ_7904e6a5-890f-4109-a5d7-8070be49f95b">61 North Beacon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8yLTAtMS0xLTIwOTQwL3RleHRyZWdpb246MWU1OWM2ZWNiN2M2NDk0M2FhNDBmZjdjZGE3OWZiNTlfOQ_4b0737b9-6325-42ca-a1ed-3c188491520c">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8yLTAtMS0xLTIwOTQwL3RleHRyZWdpb246MWU1OWM2ZWNiN2M2NDk0M2FhNDBmZjdjZGE3OWZiNTlfMTI_2614ee0a-d4cf-4a10-8247-b77f4290fe1b">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8yLTAtMS0xLTIwOTQwL3RleHRyZWdpb246MWU1OWM2ZWNiN2M2NDk0M2FhNDBmZjdjZGE3OWZiNTlfMTY_bae15610-582b-44d7-be1f-e9a1ca8693c1">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6ODNjNWFkOTQ5MTE0NGQzMTgwZWQwOGE1NmJmZTI4YzIvdGFibGVyYW5nZTo4M2M1YWQ5NDkxMTQ0ZDMxODBlZDA4YTU2YmZlMjhjMl8yLTEtMS0xLTIwOTQwL3RleHRyZWdpb246NDgxNTJlZjI1NGNiNGZjYTg3YzRiYTA4NGQ2M2E1MzlfNQ_ea7399ef-7d82-46b3-81db-6a33266dca43">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y182NDU_c025ee48-3306-4909-ab84-baf46428696f">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y182NDk_4f888a77-3272-4ca4-a6e4-86223831abef">529-8300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6OGI1OGYxNDEyNTMxNGYyYThmOTJmMzY1YzJkNjI5Y2IvdGFibGVyYW5nZTo4YjU4ZjE0MTI1MzE0ZjJhOGY5MmYzNjVjMmQ2MjljYl8xLTAtMS0xLTIwOTQw_910a5344-73b5-4dad-8e60-b78e077e460c">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6OGI1OGYxNDEyNTMxNGYyYThmOTJmMzY1YzJkNjI5Y2IvdGFibGVyYW5nZTo4YjU4ZjE0MTI1MzE0ZjJhOGY5MmYzNjVjMmQ2MjljYl8xLTItMS0xLTIwOTQw_ed7810a8-e42c-465e-ba30-13d95df13068">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6OGI1OGYxNDEyNTMxNGYyYThmOTJmMzY1YzJkNjI5Y2IvdGFibGVyYW5nZTo4YjU4ZjE0MTI1MzE0ZjJhOGY5MmYzNjVjMmQ2MjljYl8xLTQtMS0xLTIwOTQw_00ce34d6-37a5-4f4c-8c7d-a082a4e34c3a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjc4_84d7b1b6-ea88-4aec-b7d7-42c062043c4b">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjcx_d9706a96-a287-40a3-a4cd-fb5c16a7df39">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjcy_88a175d7-c41e-42b6-8c19-4d9f5e0a8f77">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjcz_e361f7d2-5bc1-4751-9e18-ff6d7ac8d8bc">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MzQ2ZTQyMGEzOTk3NGFiNGIyYTZiZGMyNDRjMzk0MzkvdGFibGVyYW5nZTozNDZlNDIwYTM5OTc0YWI0YjJhNmJkYzI0NGMzOTQzOV8xLTAtMS0xLTIwOTQw_18246dbd-8dfd-49db-a48b-b7d00db4c0b8">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MzQ2ZTQyMGEzOTk3NGFiNGIyYTZiZGMyNDRjMzk0MzkvdGFibGVyYW5nZTozNDZlNDIwYTM5OTc0YWI0YjJhNmJkYzI0NGMzOTQzOV8xLTQtMS0xLTIwOTQw_96b056e1-c441-4d7b-a28b-542fe6a643b8">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MzQ2ZTQyMGEzOTk3NGFiNGIyYTZiZGMyNDRjMzk0MzkvdGFibGVyYW5nZTozNDZlNDIwYTM5OTc0YWI0YjJhNmJkYzI0NGMzOTQzOV8yLTQtMS0xLTIwOTQw_f224d76e-d77b-4b8b-8902-d097acac4556">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18yNDEy_17343d9f-c998-4d15-925b-8798729ecadf">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjc1_14246325-df15-4343-8171-bb4538c604c8">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjc2_d5a4df9c-50e9-4997-9ac9-77729ec38f4e">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ica45cd390e2849f4b2b75e21159c3a2f_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zMDMy_4b9fc1c1-c569-4f55-bf67-531249d541f9"
      unitRef="usd">158000000</dei:EntityPublicFloat>
    <dei:AuditorName
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MTFkYjJkOWE3OWViNDY5NmJlNDI0N2ZiZGQ5ZjEyNGYvdGFibGVyYW5nZToxMWRiMmQ5YTc5ZWI0Njk2YmU0MjQ3ZmJkZDlmMTI0Zl8wLTEtMS0xLTMyMDIz_9caf83f2-5223-4fe3-9472-2a3f82126f67">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MTFkYjJkOWE3OWViNDY5NmJlNDI0N2ZiZGQ5ZjEyNGYvdGFibGVyYW5nZToxMWRiMmQ5YTc5ZWI0Njk2YmU0MjQ3ZmJkZDlmMTI0Zl8wLTItMS0xLTMyMDI5_f982cfad-a132-4624-843e-56be904acfc0">Boston, Massachusetts, US</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGFibGU6MTFkYjJkOWE3OWViNDY5NmJlNDI0N2ZiZGQ5ZjEyNGYvdGFibGVyYW5nZToxMWRiMmQ5YTc5ZWI0Njk2YmU0MjQ3ZmJkZDlmMTI0Zl8wLTMtMS0xLTMyMDI1_99c85bef-de89-4e66-9321-040bebbe8ae0">238</dei:AuditorFirmId>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i124b0568b1914873ac60885d7abe74b5_I20220314"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zMTQ2_b78b2617-1263-4b17-a764-7438e5478966"
      unitRef="shares">30809376</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM183L2ZyYWc6MWNjM2MzYWYzZmI2NDdlNWJiYzM1YmNlMjQzMjBmNGMvdGV4dHJlZ2lvbjoxY2MzYzNhZjNmYjY0N2U1YmJjMzViY2UyNDMyMGY0Y18zNjc3_c0454bc9-aa2f-48cb-a2df-4ad49742fcbd">Portions of the registrant&#x2019;s definitive proxy statement, the (&#x201c;2022 Proxy Statement&#x201d;) for its&#160;2022&#160;Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant's fiscal year ended&#160;December&#160;31, 2021,&#160;are incorporated by reference into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzMtMS0xLTEtMjA5NDA_4841dc6f-838b-4805-85a9-ea428a2587ab"
      unitRef="usd">81787000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzMtMy0xLTEtMjA5NDA_a0287f36-6bce-41ef-9dd3-eeb15e811b73"
      unitRef="usd">78708000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <xfor:ResearchAndDevelopmentIncentiveReceivable
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzQtMS0xLTEtMjA5NDA_0cecbac6-571c-4bf6-9c20-747e34773655"
      unitRef="usd">747000</xfor:ResearchAndDevelopmentIncentiveReceivable>
    <xfor:ResearchAndDevelopmentIncentiveReceivable
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzQtMy0xLTEtMjA5NDA_9a18ae40-5d79-4dca-a984-5fabe87c585d"
      unitRef="usd">917000</xfor:ResearchAndDevelopmentIncentiveReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzUtMS0xLTEtMjA5NDA_9ce6bded-587a-46b0-8d71-dc4c65381f39"
      unitRef="usd">5344000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzUtMy0xLTEtMjA5NDA_cc1190e5-c9c0-4dd9-ab17-f552a7f711a3"
      unitRef="usd">3682000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzYtMS0xLTEtMjA5NDA_35d2764d-a4e8-4f8b-bea0-b1653d581e64"
      unitRef="usd">87878000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzYtMy0xLTEtMjA5NDA_f1780210-e950-4352-b102-5b59d19f2134"
      unitRef="usd">83307000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzctMS0xLTEtMjA5NDA_07354f83-931c-4b48-b0e3-731f091ababb"
      unitRef="usd">1514000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzctMy0xLTEtMjA5NDA_2b98a0be-1e2e-4b4e-85fe-457ee822e6c1"
      unitRef="usd">1237000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzgtMS0xLTEtMjA5NDA_e6d708e3-ad1a-439c-8184-d6f4d33b5857"
      unitRef="usd">17351000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzgtMy0xLTEtMjA5NDA_3873fd7d-524c-40f2-a83a-c80b58582e82"
      unitRef="usd">27109000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzktMS0xLTEtMjA5NDA_c03a58f9-f021-4538-a920-ddf50f9d09a4"
      unitRef="usd">8710000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzktMy0xLTEtMjA5NDA_5abad821-81d1-4f48-9c80-2f380cb7b475"
      unitRef="usd">7960000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzEwLTEtMS0xLTIwOTQw_421c8eb2-853c-463e-b56c-a0b2fbb99601"
      unitRef="usd">1723000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzEwLTMtMS0xLTIwOTQw_21253a7a-b724-45eb-85c9-b222a791e1d3"
      unitRef="usd">3258000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzExLTEtMS0xLTIwOTQw_6977bd6c-74a4-44a4-9826-35838025f201"
      unitRef="usd">117176000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzExLTMtMS0xLTIwOTQw_250a0ab4-37fb-48d9-857c-70eb78b5c06c"
      unitRef="usd">122871000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE0LTEtMS0xLTIwOTQw_aa10247e-b21e-4bf8-bc41-e7d26e6b43f2"
      unitRef="usd">4283000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE0LTMtMS0xLTIwOTQw_5778456c-6927-404f-8b1a-c6e35ea4c360"
      unitRef="usd">3144000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE1LTEtMS0xLTIwOTQw_effbafdc-fb47-4f42-b1df-702b3e36b7a0"
      unitRef="usd">7870000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE1LTMtMS0xLTIwOTQw_11584f53-d5c0-4eee-a140-78c97676f829"
      unitRef="usd">8018000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE2LTEtMS0xLTIwOTQw_d02de8eb-c7cb-43d0-85b8-c52b207034aa"
      unitRef="usd">1075000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE2LTMtMS0xLTIwOTQw_efee1350-26b6-44b8-993b-bbc40c3bb599"
      unitRef="usd">786000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE3LTEtMS0xLTIyOTA2_9461fd5f-329e-4d0f-ba88-9f70cb211b39"
      unitRef="usd">795000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE3LTMtMS0xLTIyOTE3_bd3432ef-dc7d-4132-96b5-462bd0d9614a"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE3LTEtMS0xLTIwOTQw_7f3f412c-5e19-46f8-835e-b093fb03eb4a"
      unitRef="usd">14023000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE3LTMtMS0xLTIwOTQw_d3abe624-cc10-4436-8732-fb2773cca0b0"
      unitRef="usd">11948000</us-gaap:LiabilitiesCurrent>
    <xfor:LongTermDebtNonCurrentIncludingAccrection
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE4LTEtMS0xLTIwOTQw_adf0cb05-a824-4c30-84a8-e8a5f505d839"
      unitRef="usd">33139000</xfor:LongTermDebtNonCurrentIncludingAccrection>
    <xfor:LongTermDebtNonCurrentIncludingAccrection
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE4LTMtMS0xLTIwOTQw_bcada0e7-8c17-413f-8966-a22dcdb89f89"
      unitRef="usd">33178000</xfor:LongTermDebtNonCurrentIncludingAccrection>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE5LTEtMS0xLTIwOTQw_b2db3ab9-7780-4858-9239-eb5d3ee8d5f4"
      unitRef="usd">4776000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzE5LTMtMS0xLTIwOTQw_9831c511-4d54-4ec5-8ae1-1dc66e48a1a8"
      unitRef="usd">4484000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIwLTEtMS0xLTIwOTQw_41b495ad-b6ed-408e-b368-8296d0e6549c"
      unitRef="usd">826000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIwLTMtMS0xLTIwOTQw_ee642691-4741-481a-8256-8d844aecce7a"
      unitRef="usd">462000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIxLTEtMS0xLTIwOTQw_40f271dc-4857-4b46-9f33-f14b410c3048"
      unitRef="usd">52764000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIxLTMtMS0xLTIwOTQw_8951dadf-0af6-41f3-9b9a-ab5ea3571dab"
      unitRef="usd">50072000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIyLTEtMS0xLTIwOTQw_45905920-cc0f-482b-a1d8-3bd9b1fac91b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzIyLTMtMS0xLTIwOTQw_63ea7083-259f-443c-ab69-842515dd1be4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTg_353be018-cfe3-4607-b99d-0908e6ca1a52"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTg_8f584324-c4ee-449a-97d1-b48a21641c38"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMzI_9da05b84-b52c-4c0b-b26d-33501d3f440d"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMzI_e18a517f-1fed-4594-a06d-f812edbda00a"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTIx_8a493780-a82f-49be-9e6f-98f1df151f38"
      unitRef="shares">28127657</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTIx_a1b11bf1-1296-498e-aecd-3024972e65a7"
      unitRef="shares">28127657</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTA5OTUxMTYyODAxNg_3f2e4547-57a4-422d-9455-cc7df03e7945"
      unitRef="shares">16305731</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246MGUyZGQ0MDFjZWQzNDUwNzkxZDlhMGRlZmFlNGU3MmRfMTA5OTUxMTYyODAxNg_60e9ad08-000e-40db-a75b-f79f206008e2"
      unitRef="shares">16305731</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTEtMS0xLTIwOTQw_d4fb8fb7-851e-4bbc-af66-d14d95cf8788"
      unitRef="usd">28000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI0LTMtMS0xLTIwOTQw_a3457f01-5137-43da-8795-45c80c2c0d0d"
      unitRef="usd">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI1LTEtMS0xLTIwOTQw_de3a429c-0921-4726-918a-93319120d463"
      unitRef="usd">347374000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI1LTMtMS0xLTIwOTQw_378fde8b-711c-482d-beb6-25478a056f22"
      unitRef="usd">267077000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI2LTEtMS0xLTIwOTQw_9729950e-cbae-4be9-b51f-3a1b622f1420"
      unitRef="usd">-119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI2LTMtMS0xLTIwOTQw_22b46b0a-8910-4bb6-83fc-e4bfeaccfa0a"
      unitRef="usd">-119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI3LTEtMS0xLTIwOTQw_22a66740-e097-4e40-8819-d47b232958d3"
      unitRef="usd">-282871000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI3LTMtMS0xLTIwOTQw_902ec729-f4e1-40d3-bbb2-9d0b21a237a1"
      unitRef="usd">-194175000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI4LTEtMS0xLTIwOTQw_3ce4dbd7-9bd2-4bd7-a2e0-4aa5199ecd67"
      unitRef="usd">64412000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI4LTMtMS0xLTIwOTQw_cdced4eb-fa09-4e06-912a-97a5825d4aa1"
      unitRef="usd">72799000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI5LTEtMS0xLTIwOTQw_2b762dc4-70c3-48b6-9aa3-096b686b634a"
      unitRef="usd">117176000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzAvZnJhZzozYWI2OTg5ODFhZGM0MGUxYWE1ZjhlZjBhOThhNmUxNy90YWJsZTpmNmNkODE1NDJlNTU0ZDE2OWVkYTFhNDQ3MjlhOWIxYS90YWJsZXJhbmdlOmY2Y2Q4MTU0MmU1NTRkMTY5ZWRhMWE0NDcyOWE5YjFhXzI5LTMtMS0xLTIwOTQw_5317bd7b-777d-4943-8218-602e26f7cd2a"
      unitRef="usd">122871000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzItMS0xLTEtMjA5NDA_64c37d92-4972-4a27-abe3-1954a14bba5c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzItMy0xLTEtMjA5NDA_72fb5fe5-5976-4074-9a1e-a1a32d73ac1f"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzItNS0xLTEtMjA5NDA_38bfbc44-a968-478f-ae5f-58e9273979cb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzQtMS0xLTEtMjA5NDA_1169d4be-31b2-46c2-9b5a-e4a9c73174cb"
      unitRef="usd">50647000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzQtMy0xLTEtMjA5NDA_2f2999bf-f5ea-4680-804f-ad0c4900adb1"
      unitRef="usd">41932000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzQtNS0xLTEtMjA5NDA_92aa94aa-045a-4c2a-9bea-801280d657c4"
      unitRef="usd">30163000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzUtMS0xLTEtMjA5NDA_f5579993-d235-4d0b-ad9b-116002568b82"
      unitRef="usd">24702000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzUtMy0xLTEtMjA5NDA_f473bcc9-a219-44f5-87ae-f7c632742d31"
      unitRef="usd">20942000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzUtNS0xLTEtMjA5NDA_1dfcdb13-a89b-4f89-9e6f-93b82e4ea6d0"
      unitRef="usd">17640000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtMS0xLTEtMjQ2ODQ_a33cd8f7-3034-4a58-b67a-3348b73c0088"
      unitRef="usd">9758000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtMy0xLTEtMjQ2OTM_67240a0e-2907-40f8-83ec-585e2e51c5a7"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtNS0xLTEtMjQ3MDA_05e1841b-f985-4be2-9dda-8aa5bc73cdf7"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtMS0xLTEtMjA5NDA_734d722c-e56c-47e2-9dbd-28deda23f54b"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtMy0xLTEtMjA5NDA_e21d9815-b8e5-45c6-8427-e5d72eb6c929"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzYtNS0xLTEtMjA5NDA_5476a137-99a3-416a-889d-8770d719dd8a"
      unitRef="usd">-3900000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:OperatingExpenses
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzctMS0xLTEtMjA5NDA_57295849-8c88-4e94-bc14-a4f41ca469d4"
      unitRef="usd">85107000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzctMy0xLTEtMjA5NDA_9f76a6e7-de19-48b8-a100-0dd98e6f8307"
      unitRef="usd">62874000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzctNS0xLTEtMjA5NDA_8713251f-18e3-44bd-8d93-52e6a9978e7a"
      unitRef="usd">51703000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzgtMS0xLTEtMjA5NDA_a5b3b8a3-1dce-4804-a767-51c7b41f44b9"
      unitRef="usd">-85107000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzgtMy0xLTEtMjA5NDA_5ba321a7-746f-4e8f-bc04-2c122ad608f4"
      unitRef="usd">-59874000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzgtNS0xLTEtMjA5NDA_946ade17-6b7c-42e0-b942-f86e11f37de0"
      unitRef="usd">-51703000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEwLTEtMS0xLTIwOTQw_d631cbef-5ab1-4438-b311-c2dac11e9005"
      unitRef="usd">10000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEwLTMtMS0xLTIwOTQw_004516b5-be89-451b-a180-ce07c5404119"
      unitRef="usd">273000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEwLTUtMS0xLTIwOTQw_8b7df6fc-a58a-44f8-bdcf-09bd52366ee7"
      unitRef="usd">1197000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzExLTEtMS0xLTIwOTQw_890aa1da-7e58-4fca-a874-ff89a586d12e"
      unitRef="usd">3642000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzExLTMtMS0xLTIwOTQw_482491d5-6c14-4871-a0d3-470c242a2d64"
      unitRef="usd">2688000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzExLTUtMS0xLTIwOTQw_59a11b8a-f64d-4d93-90ce-231a56a789fb"
      unitRef="usd">2147000</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEyLTEtMS0xLTIwOTQw_ae551835-4bc6-4c85-b250-827abf3da085"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEyLTMtMS0xLTIwOTQw_949bf2bf-09a3-47b5-9341-922da6f84bfa"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEyLTUtMS0xLTIwOTQw_270a89c1-5d0e-439c-8585-e67565ac8508"
      unitRef="usd">288000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEzLTEtMS0xLTIwOTQw_6968aa11-e228-4eb1-ab33-d1a94fca9322"
      unitRef="usd">-366000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEzLTMtMS0xLTIwOTQw_1eb011f2-b23b-46a0-b76b-6951f3cf2c02"
      unitRef="usd">-437000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzEzLTUtMS0xLTIwOTQw_8e8e2be5-aa35-427c-bcfd-7e035262cec4"
      unitRef="usd">183000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE0LTEtMS0xLTIwOTQw_8c6fb076-01f4-4c17-b722-83727e0a95b7"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE0LTMtMS0xLTIwOTQw_e8cfa013-5595-45dc-bb07-ff3274708222"
      unitRef="usd">-162000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE0LTUtMS0xLTIwOTQw_1943cb61-b80d-4e20-9b82-0f02f4f6e808"
      unitRef="usd">-566000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE1LTEtMS0xLTIwOTQw_b98a3021-8ddd-4131-a0d5-9eaf0d6d18b6"
      unitRef="usd">426000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE1LTMtMS0xLTIwOTQw_2b671815-602f-43ce-93e5-da547ec661fd"
      unitRef="usd">905000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE1LTUtMS0xLTIwOTQw_13c492ed-0f50-40ad-a5ce-9e5db2679164"
      unitRef="usd">517000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE2LTEtMS0xLTIwOTQw_43fa6532-1df7-4b50-9f45-01feade2df02"
      unitRef="usd">-3572000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE2LTMtMS0xLTIwOTQw_66717fe3-cacd-4650-a5a3-a4226cf878a5"
      unitRef="usd">-2109000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE2LTUtMS0xLTIwOTQw_1a50974a-4a09-4024-83d6-271b8e7758e7"
      unitRef="usd">-1104000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE3LTEtMS0xLTIwOTQw_7834e1ee-8d17-49cf-80d0-d4e6776fcf4e"
      unitRef="usd">-88679000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE3LTMtMS0xLTIwOTQw_81e70eab-d483-4273-b5f4-4ca2f8299c78"
      unitRef="usd">-61983000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE3LTUtMS0xLTIwOTQw_d3d2f98d-57e0-44d4-b9e6-bc1d4f1fac33"
      unitRef="usd">-52807000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE4LTEtMS0xLTIwOTQw_7506a8f9-ea8f-498a-bc06-59a40cd45861"
      unitRef="usd">17000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE4LTMtMS0xLTIwOTQw_e0cc0092-954c-4e92-9ac2-8040f7a07b41"
      unitRef="usd">148000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE4LTUtMS0xLTIwOTQw_79d196b5-20f0-4579-8b50-e4fd28386ced"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE5LTEtMS0xLTIwOTQw_7022ec17-9143-4e18-9ebd-a6be1db9605f"
      unitRef="usd">-88696000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE5LTMtMS0xLTIwOTQw_f0defb84-800c-4d18-a679-570d41f7bcfb"
      unitRef="usd">-62131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzE5LTUtMS0xLTIwOTQw_3e8b9df4-1a4f-4af6-8146-eb29bcac1e28"
      unitRef="usd">-52807000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIwLTEtMS0xLTIwOTQw_91061fa7-6579-457b-ba9e-a3ddf0ca6147"
      unitRef="usd">0</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIwLTMtMS0xLTIwOTQw_cec9f4c6-e60b-44d3-a208-a7acda79aca0"
      unitRef="usd">0</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIwLTUtMS0xLTIwOTQw_e19251f8-0a3d-44f3-a61b-b50fb48100b1"
      unitRef="usd">592000</us-gaap:TemporaryEquityDividendsAdjustment>
    <xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIxLTEtMS0xLTIyMTA4_826d96b3-00e3-449b-bf2f-131ecfaf410e"
      unitRef="usd">13943000</xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock>
    <xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIxLTMtMS0xLTIyMTA4_c416d35e-c8d0-4a90-a0cc-626fffe28791"
      unitRef="usd">0</xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock>
    <xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIxLTUtMS0xLTIyMTA4_85097665-9454-40ff-9eed-bfbb00961c0d"
      unitRef="usd">0</xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIyLTEtMS0xLTIwOTQw_4a916e5c-0e58-4db7-ad27-72ddd14a6882"
      unitRef="usd">-102639000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIyLTMtMS0xLTIwOTQw_7921055e-95d9-42d8-8e5e-8135e10c5dcd"
      unitRef="usd">-62131000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIyLTUtMS0xLTIwOTQw_03dcdc84-e44f-4ef2-be83-72f9e954ca23"
      unitRef="usd">-53399000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIzLTEtMS0xLTIwOTQw_95efe689-2c28-4f71-9bb2-b46f9dc468f2"
      unitRef="usdPerShare">-3.99</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIzLTMtMS0xLTIwOTQw_ff0e219e-d888-4d62-820d-520551baef81"
      unitRef="usdPerShare">-3.09</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzIzLTUtMS0xLTIwOTQw_a26d1ca7-3f54-44e8-aeb6-a11f323a46ed"
      unitRef="usdPerShare">-4.63</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI0LTEtMS0xLTIwOTQw_c8911434-14fa-4c0f-996b-0d4b4cd5be97"
      unitRef="shares">25749000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI0LTMtMS0xLTIwOTQw_20459814-9c8f-45a7-a5cf-a9b81ec7be86"
      unitRef="shares">20077000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI0LTUtMS0xLTIwOTQw_7065e09e-e841-48c1-8b2e-f33383f155ea"
      unitRef="shares">11530000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI2LTEtMS0xLTIwOTQw_5a21fb3b-0476-44f1-bef8-7ef52005622a"
      unitRef="usd">-88696000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI2LTMtMS0xLTIwOTQw_10d7559f-1cde-4004-ad3b-05cff5352937"
      unitRef="usd">-62131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI2LTUtMS0xLTIwOTQw_8edcdbf5-cb87-4461-b23c-9c6d385c69f4"
      unitRef="usd">-52807000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI3LTEtMS0xLTIwOTQw_32c186a4-2d16-4b3f-8621-397a3d1893c3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI3LTMtMS0xLTIwOTQw_ea083ede-ccba-42dc-b720-1a87568a286e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI3LTUtMS0xLTIwOTQw_4609de80-6b04-49f9-8577-25fdceb2da90"
      unitRef="usd">-119000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI4LTEtMS0xLTIwOTQw_0c41decd-2397-4513-82c8-34503cbf580d"
      unitRef="usd">-88696000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI4LTMtMS0xLTIwOTQw_5befb7db-6697-4b48-b911-c48cb45161d2"
      unitRef="usd">-62131000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzMvZnJhZzpiODNmMzhkY2U3Zjc0ZjVhYTdhNDlhNzJlNjAwMzE4OS90YWJsZTpjMTllOGI3M2EzNTA0MzUzYWM2NjVhNWE0MDI1OTRhNy90YWJsZXJhbmdlOmMxOWU4YjczYTM1MDQzNTNhYzY2NWE1YTQwMjU5NGE3XzI4LTUtMS0xLTIwOTQw_3fa83e8f-909d-46fe-bc23-6564d726f3bc"
      unitRef="usd">-52926000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i572b67d5b62c4080a9192cbe762029fb_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMS0xLTEtMjA5NDA_df67ba12-0a32-4ab4-b54c-3f4b0569bb39"
      unitRef="shares">40079567</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i572b67d5b62c4080a9192cbe762029fb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMy0xLTEtMjA5NDA_308c72a4-7da1-4381-9a96-fc910e87edf4"
      unitRef="usd">64675000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i8462e5cfa36e4e91b441a3ad10cfb348_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtNS0xLTEtMjA5NDA_05461faf-2252-40af-90ae-87b951869ec1"
      unitRef="shares">107371</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i8462e5cfa36e4e91b441a3ad10cfb348_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtNy0xLTEtMjA5NDA_89c64764-0b0c-4da5-a574-7f41b9c69dce"
      unitRef="usd">734000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i9ecf8ce3e9b74e56acb8ff0af3fb7c60_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMTAtMS0xLTIwOTQw_5319f095-b7dc-4813-8cde-df72e0968938"
      unitRef="shares">351652</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9ecf8ce3e9b74e56acb8ff0af3fb7c60_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMTItMS0xLTIwOTQw_1e0e63dc-848c-4451-bf1a-258e2b2eca41"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i51b86b7cc383415ab9c2160568c774c4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMTQtMS0xLTIwOTQw_79fa2ba7-7949-4232-847c-3c70cb7e2547"
      unitRef="usd">2151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i176b3693f32c4dc59cff0f728a8aa927_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMTYtMS0xLTIwOTQw_c1bb9023-3875-4ca3-ac02-2bd28234d79a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9399ce4d3f59464796fe4fa19123abea_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMTgtMS0xLTIwOTQw_0423767c-b699-43a0-8f47-b6f41f51fc7c"
      unitRef="usd">-79237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzgtMjAtMS0xLTIwOTQw_d6ec5b03-dc29-425a-9adf-3b2fcff11e4a"
      unitRef="usd">-77086000</us-gaap:StockholdersEquity>
    <xfor:ConversionOfRedeemableCommonStockToCommonStockShares
      contextRef="ia15232c68ac3485b97f216f1936f809b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzktNS0xLTEtMjA5NDA_9719fe8c-8d59-4efb-9d64-fc5ad1d00f46"
      unitRef="shares">-107371</xfor:ConversionOfRedeemableCommonStockToCommonStockShares>
    <xfor:ConversionOfRedeemableCommonStockToCommonStockValue
      contextRef="ia15232c68ac3485b97f216f1936f809b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzktNy0xLTEtMjA5NDA_655fe9da-8360-41b8-9a2d-277badbecbaf"
      unitRef="usd">-734000</xfor:ConversionOfRedeemableCommonStockToCommonStockValue>
    <xfor:ConversionOfRedeemableCommonStockToCommonStockShares
      contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzktMTAtMS0xLTIwOTQw_baefd410-cad9-4879-a779-66d4c22d1854"
      unitRef="shares">107364</xfor:ConversionOfRedeemableCommonStockToCommonStockShares>
    <xfor:ConversionOfRedeemableCommonStockToCommonStockValue
      contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzktMTQtMS0xLTIwOTQw_4017de09-e628-4434-b460-bf3f5ca929d3"
      unitRef="usd">734000</xfor:ConversionOfRedeemableCommonStockToCommonStockValue>
    <xfor:ConversionOfRedeemableCommonStockToCommonStockValue
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzktMjAtMS0xLTIwOTQw_bce6f307-10cd-48d9-866e-80ad0a3bec6d"
      unitRef="usd">734000</xfor:ConversionOfRedeemableCommonStockToCommonStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib34264e2c11b4c15b0b5b0a7b86698e8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTEtMS0xLTIwOTQw_a2ee6bd2-6701-4ce9-bdcc-2ab294a41961"
      unitRef="shares">-40079567</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ib34264e2c11b4c15b0b5b0a7b86698e8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTMtMS0xLTIwOTQw_239bfb41-75dd-4d52-b4be-cff9dcf16dfd"
      unitRef="usd">-64675000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTEwLTEtMS0yMDk0MA_03f7e8d7-a474-43e4-b159-9cca166fbf45"
      unitRef="shares">3808430</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTEyLTEtMS0yMDk0MA_256a6696-f736-4a67-8be9-2a39941c53da"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTE0LTEtMS0yMDk0MA_300a1be3-3e09-4eae-9bcf-194508b5b1b2"
      unitRef="usd">64671000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEwLTIwLTEtMS0yMDk0MA_6b2b61e9-96d2-43ee-8671-f70636dd012b"
      unitRef="usd">64675000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzExLTEwLTEtMS0yMDk0MA_bd20eb06-0878-414e-97d0-e2e969a18b9d"
      unitRef="shares">2440582</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzExLTEyLTEtMS0yMDk0MA_d41a090c-ed74-4a7a-bcd4-e0a91f23585b"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzExLTE0LTEtMS0yMDk0MA_cea25c7b-52c4-4cf9-923e-5013c55a4d5a"
      unitRef="usd">45539000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzExLTIwLTEtMS0yMDk0MA_5c7153f7-5c09-432e-bcad-c468ac24e3e5"
      unitRef="usd">45541000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEyLTE0LTEtMS0yMDk0MA_7ab7c097-75b3-4606-8691-20f6400956e3"
      unitRef="usd">817000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEyLTIwLTEtMS0yMDk0MA_d911f495-a38a-4a85-b0cc-035f7ebbde60"
      unitRef="usd">817000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <xfor:AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity
      contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEzLTE0LTEtMS0yMDk0MA_e52788cc-e353-4ac2-b348-50b9ac2931ef"
      unitRef="usd">5235000</xfor:AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity>
    <xfor:AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzEzLTIwLTEtMS0yMDk0MA_4b8fef13-3db5-4292-9ad1-38c29a993a82"
      unitRef="usd">5235000</xfor:AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i9c7918b22f9243ddaf0f3d3d10ab77d4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE0LTAtMS0xLTIwOTQwL3RleHRyZWdpb246Yzg2NWNjZjZlMjc5NDYyOGJhNTk2ZGVmNjBmNjkxZjBfMTEx_fd3cb8cd-ca15-4929-bb6e-f03dbd342fff"
      unitRef="usd">11400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <xfor:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants
      contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE0LTEwLTEtMS0yMDk0MA_ba9ebeb3-63f9-497e-8729-f1ffaf81b12b"
      unitRef="shares">9336667</xfor:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants>
    <xfor:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE0LTEyLTEtMS0yMDk0MA_ec5d274d-a655-4f69-ba0c-bbaeeef6ea25"
      unitRef="usd">9000</xfor:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
    <xfor:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE0LTE0LTEtMS0yMDk0MA_2619920c-8971-4ef6-9d73-9f7a17acbc92"
      unitRef="usd">139379000</xfor:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
    <xfor:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE0LTIwLTEtMS0yMDk0MA_a4738aa3-6357-459b-8499-94d90779b54f"
      unitRef="usd">139388000</xfor:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE1LTEwLTEtMS0yMDk0MA_258c2e9d-a9af-4b5d-a1bf-c3501139dd6b"
      unitRef="shares">50321</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE1LTEyLTEtMS0yMDk0MA_d752c4cf-64bd-45ed-9d7a-6353e5a4dfba"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE1LTE0LTEtMS0yMDk0MA_b12a3d66-cf0a-4527-a259-d4f912978517"
      unitRef="usd">344000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE1LTIwLTEtMS0yMDk0MA_d31df909-bccd-4d61-b82c-4026ef8f9275"
      unitRef="usd">345000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <xfor:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ia7e00e53288f4ae0b2a910654ede4186_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE2LTEwLTEtMS0yMDk0MA_4cb32bd7-fc1e-438b-9c97-2f6b61fb9ff4"
      unitRef="shares">33846</xfor:StockIssuedDuringPeriodSharesWarrantsExercised>
    <xfor:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE2LTE0LTEtMS0yMDk0MA_98dc2893-2e53-4070-8888-b184b938c66c"
      unitRef="usd">447000</xfor:StockIssuedDuringPeriodValueWarrantsExercised>
    <xfor:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE2LTIwLTEtMS0yMDk0MA_fa3ffbdc-e97f-4704-bcb2-70fddacc6f02"
      unitRef="usd">447000</xfor:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifaf324ef8c0849ddb4d41585c33fe160_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE3LTE0LTEtMS0yMDk0MA_6d135327-1965-4855-8111-0aac63770d80"
      unitRef="usd">2050000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE3LTIwLTEtMS0yMDk0MA_1299424c-92eb-4bc8-a431-a331e8ef0c11"
      unitRef="usd">2050000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="icd5d9882306b44ada5d3504a50879658_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE4LTE2LTEtMS0yMDk0MA_665cff66-e1f8-407f-bb40-a86818402cc4"
      unitRef="usd">-119000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE4LTIwLTEtMS0yMDk0MA_dfd27cf4-2482-42ca-bb8c-75f255312f90"
      unitRef="usd">-119000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i4db0920d51934739ab1e898d8dd9ec84_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE5LTE4LTEtMS0yMDk0MA_36b922ba-f3eb-4db9-8f1c-8fc3b62e034d"
      unitRef="usd">-52807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzE5LTIwLTEtMS0yMDk0MA_1551cd39-d5a8-43d1-b5a4-b60f77e01ab4"
      unitRef="usd">-52807000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i8e6ba7741627488daf0ea92b674d371a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTEtMS0xLTIwOTQw_e5a12d66-e13e-45f3-ae0d-ad4055dc98fe"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i8e6ba7741627488daf0ea92b674d371a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTMtMS0xLTIwOTQw_de7c974d-685c-42d6-9425-7ea8a34b2178"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5ea504a912184f6781687f27b056d117_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTUtMS0xLTIwOTQw_ecc93510-dc6c-411d-827d-d0aab1b4a1d0"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5ea504a912184f6781687f27b056d117_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTctMS0xLTIwOTQw_54ca94ce-8c3a-4594-835f-e40ba1190bdc"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i5a487a492bc94ba59c6f135aa8c86c42_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTEwLTEtMS0yMDk0MA_1d90293a-9ddc-4eb8-b0d3-8e639a0c4a2d"
      unitRef="shares">16128862</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5a487a492bc94ba59c6f135aa8c86c42_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTEyLTEtMS0yMDk0MA_ec9f9fa0-985b-4320-b79b-2f580e3f82ce"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i373cd781460447af8b7b7a8138e80603_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTE0LTEtMS0yMDk0MA_e8874ebe-407e-45ae-89ca-6aadaca7f8a8"
      unitRef="usd">261367000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac2e90cc41804bbb8dbab70f418649b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTE2LTEtMS0yMDk0MA_4db4b12e-0c72-469b-9340-5c07098feb1b"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cef3e8a10ac450289a7a934bddd328c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTE4LTEtMS0yMDk0MA_095ce1d6-10a2-4dfa-9d9d-bdf6af4e0bac"
      unitRef="usd">-132044000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIwLTIwLTEtMS0yMDk0MA_d19f4f35-019c-4064-b35c-f2f78b7b0889"
      unitRef="usd">129220000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9c7918b22f9243ddaf0f3d3d10ab77d4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTEwLTEtMS0yMDk0MA_e94b5780-2970-4052-b696-889f3d2ab5d4"
      unitRef="shares">17689</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9c7918b22f9243ddaf0f3d3d10ab77d4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTEyLTEtMS0yMDk0MA_261f65f3-c4f7-4c4f-b423-9cb6054e25c0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icf1406e0d5074a2d82a899bd3bb3214a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTE0LTEtMS0yMDk0MA_58c418bc-bcd0-4449-8069-ca183e5538ab"
      unitRef="usd">127000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTIwLTEtMS0yMDk0MA_343a9642-c7f1-44b3-a2e5-d06b5ce64861"
      unitRef="usd">127000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icf1406e0d5074a2d82a899bd3bb3214a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIyLTE0LTEtMS0yMDk0MA_1b7c9e0e-6ea1-4a61-97e3-570031dc65b0"
      unitRef="usd">5428000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIyLTIwLTEtMS0yMDk0MA_ff5bdf88-5143-47c6-9cc9-d1648abc4464"
      unitRef="usd">5428000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTEwLTEtMS0yMDk0MA_225c869e-6332-495b-9e3d-a769c19eaa50"
      unitRef="shares">26643</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icf1406e0d5074a2d82a899bd3bb3214a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTE0LTEtMS0yMDk0MA_777530c5-7fb1-4d0b-bce1-011aa56a58dc"
      unitRef="usd">169000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTIwLTEtMS0yMDk0MA_d4f0c51c-648c-4712-ad61-be1906e11413"
      unitRef="usd">169000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTEwLTEtMS0yMDk0MA_d9bee1e9-ed8a-4bde-9d4a-c44e298a2736"
      unitRef="shares">132537</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="icf1406e0d5074a2d82a899bd3bb3214a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTE0LTEtMS0yMDk0MA_72f4fa8d-2be5-4095-abdf-3b0da60f4991"
      unitRef="usd">-14000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTIwLTEtMS0yMDk0MA_6e6deda1-292a-4b4e-8205-d547ee408525"
      unitRef="usd">-14000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:NetIncomeLoss
      contextRef="i820d81ce3a29475a8c344011da28e038_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI1LTE4LTEtMS0yMDk0MA_ec15160f-630f-4859-9b56-8e76f6518289"
      unitRef="usd">-62131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI1LTIwLTEtMS0yMDk0MA_7edc0120-694a-4758-83c1-acb1b6faf143"
      unitRef="usd">-62131000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5ed4bb840e6c490cb44e0c1b2416b76b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTEtMS0xLTIwOTQw_8c2f8121-9dc9-4e46-967d-7f0857403f18"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5ed4bb840e6c490cb44e0c1b2416b76b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTMtMS0xLTIwOTQw_46c9a19b-7da7-4c40-8caf-eeffd456b42b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="id095d9ce2828470d851a6cbfc3424820_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTUtMS0xLTIwOTQw_3d8ff65c-68f7-4519-ae82-d719dd63e801"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="id095d9ce2828470d851a6cbfc3424820_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTctMS0xLTIwOTQw_ea19e808-494f-4f55-aa53-cc5796d1bd13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="i11e0524bed0045f9a3d87f7528ddd21a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTEwLTEtMS0yMDk0MA_18d0fcd4-7304-4395-992c-2899eb50d48d"
      unitRef="shares">16305731</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i11e0524bed0045f9a3d87f7528ddd21a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTEyLTEtMS0yMDk0MA_e667e3d7-09bd-4199-b3e3-4061e5960026"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i764dfda255314eb5b4c9af8e6f5029a7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTE0LTEtMS0yMDk0MA_b814f9a4-aade-49d9-b8aa-ce5dfbbaa2b3"
      unitRef="usd">267077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if9a7b73207d14b36af0c17c6d6540372_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTE2LTEtMS0yMDk0MA_7bfea6ca-254d-4f95-bef1-e71249c10a87"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i153dbfb5749f4329b178c4b7931cafdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTE4LTEtMS0yMDk0MA_497fbb18-ef15-4315-aaf7-e7cf164062e8"
      unitRef="usd">-194175000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTIwLTEtMS0yMDk0MA_1ca44b47-f5de-4a34-8c31-60d7382bb766"
      unitRef="usd">72799000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2d20d773aefb40a2ab1e4fd2d6abeacc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTUtMS0xLTIxNDIw_fe35c42f-afcf-41aa-9ded-8fdab671fbdb"
      unitRef="shares">229885</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2d20d773aefb40a2ab1e4fd2d6abeacc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTctMS0xLTIxNDIw_e00ad86a-02a7-4391-9eee-f9b7d22a77f0"
      unitRef="usd">1875</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTEwLTEtMS0yMTQyMA_1d96cdcf-37ac-4165-8671-78a0c484205e"
      unitRef="shares">9435951</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTEyLTEtMS0yMTQyMA_b20c2c8a-d2bd-440e-856a-86b958123da5"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie38b2bc6981e4baeac34e666d1e848eb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTE0LTEtMS0yMTQyMA_52d8794d-a24d-4b89-b8ec-287753881f88"
      unitRef="usd">73858000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIxLTIwLTEtMS0yMTQyMA_cf6a4d88-c653-4c99-964d-48e730b82279"
      unitRef="usd">73868000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTEwLTEtMS0yMTQyOQ_b25d2674-3db9-4f76-9e32-fea28ce13010"
      unitRef="shares">45816</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie38b2bc6981e4baeac34e666d1e848eb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTE0LTEtMS0yMTQyOQ_0001a728-ad5b-4d9d-be17-4fc2c4077987"
      unitRef="usd">219000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzIzLTIwLTEtMS0yMTQyOQ_0cdfb6f0-2cc7-4b13-a324-f673bb39f7c7"
      unitRef="usd">219000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTEwLTEtMS0yMTQyOQ_ced4932f-696a-4c7e-ae2e-d8de25ab05f0"
      unitRef="shares">5860</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie38b2bc6981e4baeac34e666d1e848eb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTE0LTEtMS0yMTQyOQ_9c14345b-cae8-4797-b852-eaec62516f8d"
      unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI0LTIwLTEtMS0yMTQyOQ_4e1384e3-71a0-4ba0-860d-b7bbcf7a0d4a"
      unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <xfor:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI1LTEwLTEtMS0yMTQyOQ_72a42782-1c41-455e-8c35-9fae75fa58b2"
      unitRef="shares">2129768</xfor:StockIssuedDuringPeriodSharesWarrantsExercised>
    <xfor:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI1LTEyLTEtMS0yMTQyOQ_b7134618-61b3-4fbb-83c1-40f05a72f4c5"
      unitRef="usd">2000</xfor:StockIssuedDuringPeriodValueWarrantsExercised>
    <xfor:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI1LTIwLTEtMS0yMTQyOQ_6bb5f06c-b2d9-4941-88a8-100baf709389"
      unitRef="usd">2000</xfor:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iff31e12df6ce481db0f0422577ce703e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTEwLTEtMS0yMTQyOQ_9004e88b-ef28-4d75-a7d2-2b9c4d85088f"
      unitRef="shares">204531</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI2LTIwLTEtMS0yMTQyOQ_475eace6-240a-4a8e-9042-262e851f2441"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI3LTUtMS0xLTIxNDI5_67cf086b-fcd9-48ce-a2b3-69e029d8ddb5"
      unitRef="shares">229885</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i2d20d773aefb40a2ab1e4fd2d6abeacc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI3LTctMS0xLTIxNDI5_dd193a7b-2c80-4180-8cc8-7e7d63ba3877"
      unitRef="usd">1875</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI3LTIwLTEtMS0yMTQyOQ_003bb8f4-255d-44be-9845-1d2697789670"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie38b2bc6981e4baeac34e666d1e848eb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI4LTE0LTEtMS0yMTQyOQ_d0eed81d-1dbe-4eb9-80df-b3daae931eec"
      unitRef="usd">6180000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI4LTIwLTEtMS0yMTQyOQ_1c2cd843-f296-406c-98b7-d8ca911086e8"
      unitRef="usd">6180000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i4851434b4d774d8bab2622f9881c9440_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI5LTE4LTEtMS0yMTQyOQ_32e27d24-f54a-4481-9194-0d519bfdbe22"
      unitRef="usd">-88696000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI5LTIwLTEtMS0yMTQyOQ_697e3f89-7008-480a-a0bb-36756809e004"
      unitRef="usd">-88696000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i58f79127b745453d84e4c71a65761e38_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI5LTEtMS0xLTI4NDI2_fc146611-4291-4e40-be62-8caf0b8245b4"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i58f79127b745453d84e4c71a65761e38_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzI5LTMtMS0xLTI4NDI2_b021e53f-a894-4eca-992d-cdb75a90ba14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="if884965b97674d2897920860dc9dd9de_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTUtMS0xLTIxNDI5_60a0d684-acf0-46a9-add6-e28b16cfdff4"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="if884965b97674d2897920860dc9dd9de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTctMS0xLTIxNDI5_d6306a62-4f7a-4266-ab7a-1fba0799d536"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i64ff3d38d9274c5cb80f3c6ad6dc0169_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTEwLTEtMS0yMTQyOQ_b1fb7c95-dddc-4769-bd82-2960fe2ed1c5"
      unitRef="shares">28127657</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i64ff3d38d9274c5cb80f3c6ad6dc0169_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTEyLTEtMS0yMTQyOQ_5f9f5fb0-103c-4cda-8f66-3d5c24723ff0"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50217e3e4bd4418faec03cc4d6e2b168_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTE0LTEtMS0yMTQyOQ_0206898a-5f3f-4412-9237-91f4f44ff233"
      unitRef="usd">347374000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b8eb923c43342b496d1759d3a72b849_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTE2LTEtMS0yMTQyOQ_e2d00d7f-c352-48b6-a329-b3dffdc252bc"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54176cdc44bb45e8811df78b7fe967ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTE4LTEtMS0yMTQyOQ_c8378bff-615c-478d-8f9e-dd322bb448ba"
      unitRef="usd">-282871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzYvZnJhZzo3Yjk3NDIxMDRhOTE0NTIwOTkyMGIyOWQ4ZWQyNjI2Ny90YWJsZTo1Y2NmMDg4ZWQxZTQ0ZjNmOTAwMWRiMWI0MWQ4MzRmNC90YWJsZXJhbmdlOjVjY2YwODhlZDFlNDRmM2Y5MDAxZGIxYjQxZDgzNGY0XzMwLTIwLTEtMS0yMTQyOQ_6bdc80b3-9942-4163-bd55-f55592f380e0"
      unitRef="usd">64412000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMtMS0xLTEtMjA5NDA_fddff930-c91f-4e0b-bc50-98666c1919ba"
      unitRef="usd">-88696000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMtMy0xLTEtMjA5NDA_a818a1b8-adf7-4ea4-9bb3-91e21ed2c435"
      unitRef="usd">-62131000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMtNS0xLTEtMjA5NDA_63772221-89ec-4d89-a418-8bfcdf775f11"
      unitRef="usd">-52807000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzUtMS0xLTEtMjA5NDA_5188c55f-7b88-411d-878b-9441ef941b33"
      unitRef="usd">6180000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzUtMy0xLTEtMjA5NDA_b45000f4-937c-44f3-b3c5-74facb9ca60e"
      unitRef="usd">5428000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzUtNS0xLTEtMjA5NDA_cffcaf3f-39b2-4cf9-9660-e70db80ec272"
      unitRef="usd">2050000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzYtMS0xLTEtMjA5NDA_f70ffcf0-1643-4593-aeee-011ec21d4bed"
      unitRef="usd">499000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzYtMy0xLTEtMjA5NDA_f656bb85-85de-4a90-a4a6-c095a37cf56e"
      unitRef="usd">351000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzYtNS0xLTEtMjA5NDA_92be13e6-acb9-4902-8e6e-1f628c882b8a"
      unitRef="usd">103000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctMS0xLTEtMjQ5MDk_c4596918-bca9-4b28-ad21-90ee6fc90049"
      unitRef="usd">9758000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctMy0xLTEtMjQ5MTY_93c7caf7-5ebb-4c80-ba4a-2690922d5d0e"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctNS0xLTEtMjQ5MjM_46ce44e8-70ec-44f1-bca2-140cc2d09aa0"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctMS0xLTEtMjA5NDA_786f0bcb-edb7-4582-91af-855016db2ee7"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctMy0xLTEtMjA5NDA_24d51a8e-076f-48c9-993d-d6161e181bc1"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzctNS0xLTEtMjA5NDA_04536759-2bcd-42df-99c6-c09d48f1a111"
      unitRef="usd">-3900000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <xfor:NonCashLeaseExpense
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzgtMS0xLTEtMjA5NDA_1d715745-a315-4bdc-bf14-4127dee544d1"
      unitRef="usd">1393000</xfor:NonCashLeaseExpense>
    <xfor:NonCashLeaseExpense
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzgtMy0xLTEtMjA5NDA_9dd43480-9ace-4b9a-b6a1-0c4d9ad7a536"
      unitRef="usd">879000</xfor:NonCashLeaseExpense>
    <xfor:NonCashLeaseExpense
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzgtNS0xLTEtMjA5NDA_efb127a5-1345-44c3-bca5-026ecdcf682d"
      unitRef="usd">569000</xfor:NonCashLeaseExpense>
    <xfor:NonCashInterestExpense
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzktMS0xLTEtMjA5NDA_f6adfe8f-ac42-48b0-ba2e-b6306e9394c7"
      unitRef="usd">756000</xfor:NonCashInterestExpense>
    <xfor:NonCashInterestExpense
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzktMy0xLTEtMjA5NDA_1e445b8b-6e89-4c1d-b393-7014fb7d681a"
      unitRef="usd">532000</xfor:NonCashInterestExpense>
    <xfor:NonCashInterestExpense
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzktNS0xLTEtMjA5NDA_43b1cb2d-ab9e-4e4b-b891-d96bed1a44fe"
      unitRef="usd">695000</xfor:NonCashInterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEwLTEtMS0xLTIwOTQw_d9a2c005-24d3-4cf8-99e0-184c06de4709"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEwLTMtMS0xLTIwOTQw_2c002828-c225-42b1-b6d3-f67c8d1b43a5"
      unitRef="usd">-162000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEwLTUtMS0xLTIwOTQw_c1d10148-6512-475a-bd39-2ddfc94b4675"
      unitRef="usd">-566000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <xfor:ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzExLTEtMS0xLTIwOTQw_7dadd906-4752-4d32-bdb9-df38f0d01635"
      unitRef="usd">366000</xfor:ChangeInFairValueOfConvertiblePreferredStockWarrantLiability>
    <xfor:ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzExLTMtMS0xLTIwOTQw_eb7e2e1e-033a-4e8d-94ff-8327285fe9cf"
      unitRef="usd">437000</xfor:ChangeInFairValueOfConvertiblePreferredStockWarrantLiability>
    <xfor:ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzExLTUtMS0xLTIwOTQw_16084cb0-24f5-4206-8787-2d2c551d2b11"
      unitRef="usd">105000</xfor:ChangeInFairValueOfConvertiblePreferredStockWarrantLiability>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEyLTEtMS0xLTIwOTQw_2f059066-3724-4d59-b345-fdfbc9960948"
      unitRef="usd">-337000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEyLTMtMS0xLTIwOTQw_e8be4d51-0f27-4cf1-ae23-1adbd9509161"
      unitRef="usd">413000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzEyLTUtMS0xLTIwOTQw_0056c27b-da13-48d1-a6df-88022ab16d34"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE0LTEtMS0xLTIwOTQw_0ad8764d-e406-4227-8f01-25407afe0cf0"
      unitRef="usd">1755000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE0LTMtMS0xLTIwOTQw_081b2d6e-c13a-4f38-8e2c-3a5fa9a913d3"
      unitRef="usd">1655000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE0LTUtMS0xLTIwOTQw_de512b99-1443-471c-ac8e-2b184140e6dd"
      unitRef="usd">-109000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE1LTEtMS0xLTIwOTQw_1081c65b-ff02-411f-b84a-ae4ea6e40f10"
      unitRef="usd">1166000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE1LTMtMS0xLTIwOTQw_03267c97-6787-4110-8df4-9779e3aae56c"
      unitRef="usd">1031000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE1LTUtMS0xLTIwOTQw_8d7de448-5798-4385-8b2c-6424a23676ab"
      unitRef="usd">-2752000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE2LTEtMS0xLTIwOTQw_4a44ba75-00be-469c-907d-5845b849f240"
      unitRef="usd">-152000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE2LTMtMS0xLTIwOTQw_8358003a-85e4-40f5-9e5d-8a23135f2e1a"
      unitRef="usd">1517000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE2LTUtMS0xLTIwOTQw_b0adebba-981f-4291-9466-36dec4c8cf32"
      unitRef="usd">160000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <xfor:IncreaseDecreaseInLeaseLiabilities
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE3LTEtMS0xLTIwOTQw_0f44895d-d4ba-4844-8692-a542a1f1de2a"
      unitRef="usd">-698000</xfor:IncreaseDecreaseInLeaseLiabilities>
    <xfor:IncreaseDecreaseInLeaseLiabilities
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE3LTMtMS0xLTIwOTQw_6001753b-565d-4db0-bac6-0dbd1d2c1dc7"
      unitRef="usd">-1067000</xfor:IncreaseDecreaseInLeaseLiabilities>
    <xfor:IncreaseDecreaseInLeaseLiabilities
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE3LTUtMS0xLTIwOTQw_cf608bcd-6e92-4b80-a4be-abde36a79b77"
      unitRef="usd">-753000</xfor:IncreaseDecreaseInLeaseLiabilities>
    <xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE4LTEtMS0xLTIwOTQw_4a4e37c0-2116-4450-b516-5a7fe4a81b2f"
      unitRef="usd">59000</xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion>
    <xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE4LTMtMS0xLTIwOTQw_bee56822-561b-46ed-9314-562109133f1e"
      unitRef="usd">3889000</xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion>
    <xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE4LTUtMS0xLTIwOTQw_79107f82-7033-47ca-aa21-4add4651f4d3"
      unitRef="usd">0</xfor:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE5LTEtMS0xLTIwOTQw_f804a9f0-eee0-4d9c-ae06-c4301bc7fef9"
      unitRef="usd">-70905000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE5LTMtMS0xLTIwOTQw_918b77ff-b371-4e62-9c9f-8bba1eb86c90"
      unitRef="usd">-58818000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzE5LTUtMS0xLTIwOTQw_8342940f-c974-4953-98de-7d461fc1ae9a"
      unitRef="usd">-48055000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIxLTEtMS0xLTIwOTQw_70f40c67-2e2d-43fe-a638-9ad1b6f279c1"
      unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIxLTMtMS0xLTIwOTQw_79bdb56d-73b8-4210-8e4c-f95cec29cc42"
      unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIxLTUtMS0xLTIwOTQw_b04ccbab-1796-4d10-bd91-a3b57b3b93d0"
      unitRef="usd">26406000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIyLTEtMS0xLTIwOTQw_202f1d80-14aa-41ed-be71-eff83c368397"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIyLTMtMS0xLTIwOTQw_ca2fa08d-6224-4400-9e08-418c216f82b9"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIyLTUtMS0xLTIwOTQw_f4ec505c-911e-4636-b140-0124a73b04cc"
      unitRef="usd">1000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIzLTEtMS0xLTIwOTQw_555bd57c-10ab-4b6f-ab01-b3b844ee3307"
      unitRef="usd">615000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIzLTMtMS0xLTIwOTQw_8dadd94d-4713-435a-b1d4-8f27f8abd200"
      unitRef="usd">1362000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzIzLTUtMS0xLTIwOTQw_16cb1138-851b-4110-b972-9ffb3eea8a4b"
      unitRef="usd">174000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI0LTEtMS0xLTIwOTQw_0b6d1609-d64d-4266-b804-15ac4ff42af3"
      unitRef="usd">-615000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI0LTMtMS0xLTIwOTQw_4bffefc9-e711-4ad4-a707-3cd9c4d72eb6"
      unitRef="usd">-1362000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI0LTUtMS0xLTIwOTQw_ea453984-4b93-442f-b837-4c4894390c21"
      unitRef="usd">27232000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <xfor:ProceedsFromExerciseOfStockOptionsAndWarrants
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI2LTEtMS0xLTIwOTQw_860329a0-a3e8-4884-ab47-c8e9e109d316"
      unitRef="usd">260000</xfor:ProceedsFromExerciseOfStockOptionsAndWarrants>
    <xfor:ProceedsFromExerciseOfStockOptionsAndWarrants
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI2LTMtMS0xLTIwOTQw_3924602b-c5a8-42e4-b50c-334b6a3a488f"
      unitRef="usd">561000</xfor:ProceedsFromExerciseOfStockOptionsAndWarrants>
    <xfor:ProceedsFromExerciseOfStockOptionsAndWarrants
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI2LTUtMS0xLTIwOTQw_f86fa0ae-c537-4fea-a733-3121ba7bb739"
      unitRef="usd">792000</xfor:ProceedsFromExerciseOfStockOptionsAndWarrants>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI3LTEtMS0xLTIwOTQw_85df5fd7-810b-473d-8354-bfecd0478721"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI3LTMtMS0xLTIwOTQw_a5e6b9a1-145a-4274-8f1f-a20a3804cb21"
      unitRef="usd">278000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI3LTUtMS0xLTIwOTQw_0362abfd-abb1-41ff-9a78-510c3166c9cb"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI4LTEtMS0xLTIwOTQw_bd54a16a-d572-4113-8b5b-594d37fba590"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI4LTMtMS0xLTIwOTQw_52f695df-16e7-4c70-9c8d-5621dad1a926"
      unitRef="usd">12388000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzI4LTUtMS0xLTIwOTQw_16d8e259-bf4d-4d09-8e15-eba3159fcc6f"
      unitRef="usd">9849000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTEtMS0xLTIwOTQw_2d2392f3-3dc6-4f23-ab8f-c9cb9b55ac5d"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTMtMS0xLTIwOTQw_6061f7c3-77da-49aa-a7cc-9fdba9dbb0a1"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTUtMS0xLTIwOTQw_6bd4f808-dd6b-43eb-9009-9d45c6b27ed1"
      unitRef="usd">9368000</us-gaap:RepaymentsOfLongTermDebt>
    <xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMyLTEtMS0xLTIwOTQw_0e86a8a2-81cc-49fc-ab69-2481977753c2"
      unitRef="usd">75985000</xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts>
    <xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMyLTMtMS0xLTIwOTQw_d3b74589-e79b-4b73-bcaf-f2681b69fdb3"
      unitRef="usd">-277000</xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts>
    <xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMyLTUtMS0xLTIwOTQw_66a05378-ca3d-485c-b7cc-e7458e2faedf"
      unitRef="usd">139388000</xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTEtMS0xLTIxNjg5_3b4e54ec-1e71-415a-ad24-4bec3f2702aa"
      unitRef="usd">2000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTMtMS0xLTIxNjg5_11d32fab-dc97-4c8b-9a44-d78049b6d931"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMxLTUtMS0xLTIxNjg5_8a88a74e-2a1a-4973-8098-e40df8feb184"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMzLTEtMS0xLTIwOTQw_3c6f7cdd-4b1d-4b3c-904d-df9c0af41f6a"
      unitRef="usd">74245000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMzLTMtMS0xLTIwOTQw_93d84f4e-4745-4ecc-beb0-c8ac8e30b778"
      unitRef="usd">12394000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzMzLTUtMS0xLTIwOTQw_f386cfe8-b181-438c-80b5-a52e1cb031b2"
      unitRef="usd">140661000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM0LTEtMS0xLTIwOTQw_75ede47d-b54b-4ed4-a208-48280ada82d4"
      unitRef="usd">-319000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM0LTMtMS0xLTIwOTQw_0b64f5e2-abf0-46a2-82b3-814e6bdf18d9"
      unitRef="usd">402000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM0LTUtMS0xLTIwOTQw_9de4c16d-9a06-451b-83e0-001aca24d785"
      unitRef="usd">-250000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM1LTEtMS0xLTIwOTQw_6d58520e-d5d6-485f-a075-1931d3999220"
      unitRef="usd">2406000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM1LTMtMS0xLTIwOTQw_ca4cfc67-b885-4cc5-b83f-aea837397838"
      unitRef="usd">-47384000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM1LTUtMS0xLTIwOTQw_0c869328-b136-450b-869c-9e6c4855a39a"
      unitRef="usd">119588000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM2LTEtMS0xLTIwOTQw_2cabfdf5-0938-4b29-81a6-3e968ee1aaca"
      unitRef="usd">80702000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM2LTMtMS0xLTIwOTQw_fe93ae28-ee78-424c-ae20-d1ed906d8c40"
      unitRef="usd">128086000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM2LTUtMS0xLTIwOTQw_be03a281-68d4-47bf-8f4a-94e26ba3fc65"
      unitRef="usd">8498000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM3LTEtMS0xLTIwOTQw_4e0a8e42-f26a-4a5d-aec6-e6cd42b5f9ef"
      unitRef="usd">83108000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM3LTMtMS0xLTIwOTQw_c57e9e4a-f548-4a6c-bc02-a346ac84ebe9"
      unitRef="usd">80702000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzM3LTUtMS0xLTIwOTQw_f1ad6674-ca51-4cd8-91cc-2f67629e0c3a"
      unitRef="usd">128086000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQwLTEtMS0xLTIwOTQw_3eb3a79c-9b6d-4453-a1f5-950cd88b6466"
      unitRef="usd">2906000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQwLTMtMS0xLTIwOTQw_3821f426-dc98-488a-b1dd-0ced9f6df4ce"
      unitRef="usd">2099000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQwLTUtMS0xLTIwOTQw_a88d5908-6475-4687-81a1-8cc63e21fb96"
      unitRef="usd">1284000</us-gaap:InterestPaidNet>
    <xfor:CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTEtMS0xLTIwOTQw_bc883f7b-b93c-4386-b6f9-0b9b4faa8d07"
      unitRef="usd">0</xfor:CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid>
    <xfor:CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTMtMS0xLTIwOTQw_afb03b58-066d-49f2-a2ea-3cc24f13eee1"
      unitRef="usd">54000</xfor:CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid>
    <xfor:CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTUtMS0xLTIwOTQw_6d523f97-e662-4aaf-8ff8-94ad02ccaae3"
      unitRef="usd">40000</xfor:CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTEtMS0xLTIxNzIy_11f1ccc4-808d-4e18-8fb4-8e63e1d3c917"
      unitRef="usd">1343000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTMtMS0xLTIxNzIy_40c575cc-143e-4caf-8a99-27e2ed829440"
      unitRef="usd">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQyLTUtMS0xLTIxNzIy_14cf9156-9cbc-4619-899f-baff59db47ca"
      unitRef="usd">0</us-gaap:CapitalLeaseObligationsIncurred>
    <xfor:StockAndWarrantIssuanceCostsIncurredButNotYetPaid
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQzLTEtMS0xLTIwOTQw_6257aa5d-264c-42d1-98e3-ec1a8f9ca9a7"
      unitRef="usd">24000</xfor:StockAndWarrantIssuanceCostsIncurredButNotYetPaid>
    <xfor:StockAndWarrantIssuanceCostsIncurredButNotYetPaid
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQzLTMtMS0xLTIwOTQw_8edf76a7-9099-48dd-bf79-b8a533399c9e"
      unitRef="usd">0</xfor:StockAndWarrantIssuanceCostsIncurredButNotYetPaid>
    <xfor:StockAndWarrantIssuanceCostsIncurredButNotYetPaid
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQzLTUtMS0xLTIwOTQw_62146c3d-d022-4e32-9922-b9c45673ddaa"
      unitRef="usd">775000</xfor:StockAndWarrantIssuanceCostsIncurredButNotYetPaid>
    <xfor:ConversionOfConvertiblePreferredStockToCommonStockValues
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ0LTEtMS0xLTIwOTQw_d0b98bf8-a15b-461b-8dbc-a57e69ad0124"
      unitRef="usd">0</xfor:ConversionOfConvertiblePreferredStockToCommonStockValues>
    <xfor:ConversionOfConvertiblePreferredStockToCommonStockValues
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ0LTMtMS0xLTIwOTQw_2a1ed8a8-3f3c-4367-a4b1-6165e40f938c"
      unitRef="usd">0</xfor:ConversionOfConvertiblePreferredStockToCommonStockValues>
    <xfor:ConversionOfConvertiblePreferredStockToCommonStockValues
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ0LTUtMS0xLTIwOTQw_6c63333d-c0fa-4d1c-9c98-12eb26e3a3e8"
      unitRef="usd">64675000</xfor:ConversionOfConvertiblePreferredStockToCommonStockValues>
    <xfor:ConversionOfRedeemableCommonStockToCommonStockValue
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ1LTEtMS0xLTIwOTQw_3b9f332a-3725-4249-9f60-59e457835193"
      unitRef="usd">0</xfor:ConversionOfRedeemableCommonStockToCommonStockValue>
    <xfor:ConversionOfRedeemableCommonStockToCommonStockValue
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ1LTMtMS0xLTIwOTQw_c7b0c84c-ce2f-4969-a1fa-01f3ad2674dc"
      unitRef="usd">0</xfor:ConversionOfRedeemableCommonStockToCommonStockValue>
    <xfor:ConversionOfRedeemableCommonStockToCommonStockValue
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ1LTUtMS0xLTIwOTQw_78d16797-0abc-4881-b691-be26dbe5b3e6"
      unitRef="usd">734000</xfor:ConversionOfRedeemableCommonStockToCommonStockValue>
    <xfor:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ2LTEtMS0xLTIwOTQw_77757ef6-5e4a-4249-96f0-871dccccf547"
      unitRef="usd">0</xfor:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants>
    <xfor:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ2LTMtMS0xLTIwOTQw_def483b6-fb05-47d1-8aca-2daed652b896"
      unitRef="usd">0</xfor:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants>
    <xfor:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ2LTUtMS0xLTIwOTQw_a3a9e350-bbc5-4699-8f8b-0f636c091e0a"
      unitRef="usd">5235000</xfor:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants>
    <xfor:FairValueOfNetAssetsAcquiredInReverseMerger
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ3LTEtMS0xLTIwOTQw_5869c871-f57c-4c8c-844f-7c5c4342cda5"
      unitRef="usd">0</xfor:FairValueOfNetAssetsAcquiredInReverseMerger>
    <xfor:FairValueOfNetAssetsAcquiredInReverseMerger
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ3LTMtMS0xLTIwOTQw_f103033a-0f35-4da8-8968-561859e034e2"
      unitRef="usd">0</xfor:FairValueOfNetAssetsAcquiredInReverseMerger>
    <xfor:FairValueOfNetAssetsAcquiredInReverseMerger
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xMzkvZnJhZzpiNTM2M2Q4NzYyZGI0YmUyYWE1YTA5M2U2YTNhNzIyMy90YWJsZTo0N2ExYjE3MWY1NzE0YjdjOTNlOWE0OGI4NGYxZGM3My90YWJsZXJhbmdlOjQ3YTFiMTcxZjU3MTRiN2M5M2U5YTQ4Yjg0ZjFkYzczXzQ3LTUtMS0xLTIwOTQw_ab1d4050-2803-49cf-838e-9d6b6c2bd3aa"
      unitRef="usd">19952000</xfor:FairValueOfNetAssetsAcquiredInReverseMerger>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzEwMzMy_882d0ff2-a729-49d7-9e53-977f551ec75a">NATURE OF THE BUSINESS AND BASIS OF PRESENTATION&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;X4 Pharmaceuticals, Inc. (together with its subsidiaries, the &#x201c;Company&#x201d;) is a late-stage clinical biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases. The Company&#x2019;s lead product candidate, mavorixafor, is a potential first-in-class, once-daily, oral inhibitor of CXCR4 and is currently in a Phase 3 clinical trial for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#x201c;WHIM&#x201d;) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. The Company is also conducting a 14-day, proof-of-concept Phase 1b clinical trial of mavorixafor in patients with chronic neutropenia disorders, and a Phase 1b clinical trial of mavorixafor in combination with ibrutinib in Waldenstr&#xf6;m&#x2019;s macroglobulinemia. The Company is headquartered in Boston, Massachusetts and has an additional facility in Vienna, Austria. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern Assessment&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#160;2014-15,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic 205-40) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2014-15&#x201d;), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. As of December 31, 2021, the Company had $81.8 million of cash and cash equivalents and an accumulated deficit of $282.9 million. As further discussed in Note 2, the Company has a covenant under its Amended and Restated Loan Agreement  (the &#x201c;Hercules Loan Agreement&#x201d;) with Hercules Capital Inc. (&#x201c;Hercules&#x201d;), which will require that the Company maintain a minimum level of cash, as defined, beginning on &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 1, 2022. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company is in violation of this covenant, Hercules could require the repayment of all outstanding debt. Based on its current cash expenditure forecast and considering this covenant, the Company expects that its existing cash and cash equivalents will fund its operations into the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fourth quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, the Company believes that, in the aggregate, these conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Nevertheless, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In order to fund its operations&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; beyond 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company will need to raise additional funds, which could be through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If the Company is unable to obtain future funding when needed, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or pre-commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. There is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impact of the COVID-19 Pandemic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The impact of the ongoing COVID-19 pandemic continues to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Impacts to the Company&#x2019;s business have included temporary closures or postponements of activation of its clinical trial sites or facilities, disruptions or restrictions on its employees&#x2019; ability to travel, disruptions to or delays in ongoing clinical trials, including patient enrollment at a slower pace than initially projected and the diversion of healthcare resources away from the conduct of the Company&#x2019;s clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as the Company&#x2019;s clinical trial sites and hospital staff supporting the conduct of the Company&#x2019;s clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merger with Arsanis&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;26, 2018, Arsanis, Inc., a publicly held Delaware corporation (&#x201c;Arsanis&#x201d;), Artemis AC Corp., a Delaware corporation and a wholly-owned subsidiary of Arsanis (&#x201c;Merger Sub&#x201d;), and X4 Therapeutics, Inc. (&#x201c;X4&#x201d;) entered into an Agreement and Plan of Merger, as amended on December&#160;20, 2018 and March&#160;8, 2019 (the &#x201c;Merger Agreement&#x201d;), pursuant to which the Merger Sub merged with and into X4, with X4 surviving the merger as a wholly-owned subsidiary of Arsanis. The transactions described in the foregoing sentence may be referred to in these consolidated financial statements as &#x201c;the Merger.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction was accounted for as a reverse merger in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Under this method of accounting, X4 was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i)&#160;the Company&#x2019;s stockholders own a substantial majority of the voting rights in the combined organization, (ii)&#160;the Company designated a majority of the members of the initial board of directors of the combined organization and (iii)&#160;the Company&#x2019;s senior management hold all key positions in the senior management of the combined organization. Accordingly, for accounting purposes, the business combination was treated as the equivalent of X4 issuing stock to acquire the net assets of Arsanis. As a result, as of the closing date of the Merger, the net assets of Arsanis were recorded at their acquisition-date fair values in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated financial statements of the Company and the reported operating results prior to the business combination are those of the Company. In addition, transaction costs incurred by the Company in connection with the business combination have been expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;13, 2019, Arsanis, X4 and Merger Sub completed the Merger pursuant to the terms of the Merger Agreement. Pursuant to the terms of the Merger Agreement, each outstanding share of X4&#x2019;s common stock and preferred stock was exchanged for 0.5702 shares of Arsanis&#x2019; common stock (the &#x201c;Exchange Ratio&#x201d;). In addition, all outstanding options exercisable for common stock and warrants exercisable for convertible preferred stock of X4 became options and warrants exercisable for the same number of shares of common stock of Arsanis multiplied by the Exchange Ratio. In connection with the Merger, X4 changed its name to X4 Therapeutics, Inc. Following the closing of the Merger, X4 Therapeutics, Inc. became a wholly-owned subsidiary of the Company, which changed its name to X4 Pharmaceuticals, Inc. As used herein, the words &#x201c;the Company&#x201d; refers to, for periods following the Merger, X4 Pharmaceuticals, Inc. (formerly Arsanis, Inc.), together with is direct and indirect subsidiaries, and for periods prior to the Merger, X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.), and its direct and indirect subsidiaries, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately following the Merger, stockholders of X4 owned approximately 64% of the combined organization&#x2019;s outstanding common stock. On March&#160;14, 2019, the combined organization&#x2019;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#x201c;XFOR.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;13, 2019, immediately following the closing of the Merger, the Company effected a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1-for-6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reverse stock split of its common stock (the &#x201c;Reverse Stock Split&#x201d;). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Unless otherwise&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;noted, all references to common stock share and per share amounts have also been adjusted to reflect the exchange ratio of 0.5702.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH (&#x201c;X4 Austria&#x201d;), which is incorporated in Vienna, Austria, and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzE0NzY_815909d9-328f-4281-aed9-18ae1a892460"
      unitRef="usd">81800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzE1Mzg_ee7682f5-4996-4f49-96d6-4f3db6e4d771"
      unitRef="usd">-282900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <xfor:BusinessCombinationShareExchangeRatio
      contextRef="i1dacdd07b5414e26a65fa9a53ef63e97_D20190313-20190313"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzgxODY_6512ab49-6cb6-4b51-a1c7-dbe8fe7671be"
      unitRef="number">0.5702</xfor:BusinessCombinationShareExchangeRatio>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ib146624f4ddd4ad1ad0d121c7a5b8e07_I20190313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzkxNTM_49d6903d-cd41-492e-b512-01764197ba64"
      unitRef="number">0.64</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <xfor:BusinessCombinationShareExchangeRatio
      contextRef="i1dacdd07b5414e26a65fa9a53ef63e97_D20190313-20190313"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDUvZnJhZzoyNzdlNjRhMWRlMmQ0ODczOWQ5ZDkzMWE1NTVkNjFkMy90ZXh0cmVnaW9uOjI3N2U2NGExZGUyZDQ4NzM5ZDlkOTMxYTU1NWQ2MWQzXzk5ODU_c96c7a39-c7fe-416d-a469-172da1697f69"
      unitRef="number">0.5702</xfor:BusinessCombinationShareExchangeRatio>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDkw_79721b5c-223c-4d82-ab8a-9e567cb4e6e2">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and the constraint of variable consideration from contracts with customers. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The COVID-19 pandemic has impacted and is expected to continue to impact the clinical development timelines for certain of the Company's clinical programs. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency and Currency Translation&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s foreign subsidiary, X4 Austria, is the U.S. dollar but X4 Austria maintains its books and records in Euro. Monetary assets and liabilities are translated at current exchange rates as of the balance sheet date, non-monetary assets such as property and equipment and equity accounts are translated at historic rates and income and expenses are translated at the average exchanges rates for the period. Adjustments resulting from the translation of the consolidated financial statements of the Company&#x2019;s foreign operations into U.S. dollars are included in the determination of net loss and are recorded in other expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Significant Suppliers&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and research and development incentive receivables. The Company generally maintains cash balances in various operating accounts at financial institutions that management believes to be of high credit quality in amounts that may exceed federally insured limits. The Company has not experienced losses related to its cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of active pharmaceutical ingredients and formulated drugs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:97%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%"&gt;Letter of credit security: Cambridge lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%"&gt;Letter of credit security: Waltham lease &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%"&gt;Letter of credit security: Vienna Austria lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Boston lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s lease agreement for its facilities in Massachusetts and Austria, the Company maintains letters of credit, which are secured by restricted cash, for the benefit of the landlord. In accordance with the Company&#x2019;s Loan and Security Agreement with Hercules, as most recently amended on February 9, 2022 and as further described in Note 7, effective as of the earlier of (a) certain specified events impacting the Company&#x2019;s Phase III trial of mavorixafor for the treatment of WHIM syndrome and (b) September 1, 2022, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest as further described in Note 7.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets to the sum to the total of amounts shown in the Company&#x2019;s consolidated statements of cash flows as of December&#160;31, 2021, 2020, 2019 and 2018:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, current (included within prepaid expenses and other current assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current (included within other assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Right-of-Use Assets and Leases&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for leases in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 842&#x201d;). Under ASC 842, at the inception of an arrangement, the Company determines whether the arrangement contains a lease based on the unique facts and circumstances present. Leases with a non-cancellable term greater than one year are recognized on the balance sheet as right-of-use assets with associated current and non-current lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Options to renew a lease are not included in the Company&#x2019;s initial lease term assessment unless there is reasonable certainty that the Company will renew the lease. If a lease is cancellable without penalty, the Company excludes from the lease term periods following the cancellation notice period unless it is reasonably certain that the Company will not cancel the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use operating asset may be required for items such as incentives received or accrued rent. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates it incurs to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company has referenced the effective rate of its Hercules borrowings, as adjusted for differences terms, to determine calculate its incremental borrowing rate for each of its operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance in ASC 842, components of a lease are split into lease components and non-lease components. A policy election is available pursuant to which an entity may elect to not separate lease and non-lease components. Rather, each lease component and the related non-lease components are accounted for together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components as a combined lease component for its office and laboratory building leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value. To date, the Company has not recorded any material impairment losses on long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested quantitatively for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action, a significant decline in the price of the Company&#x2019;s common stock, or unanticipated competition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that it operates in a single operating segment and has a single reporting unit. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. See Note 4 for more information on the Company&#x2019;s goodwill impairment test as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with the Merger, the Company acquired certain in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) assets, which were classified as indefinite-lived intangible assets. Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that the Company acquires and have not been completed at the acquisition date. The fair value of IPR&amp;amp;D acquired in a business combination is recorded on the Company&#x2019;s consolidated balance sheets at the acquisition-date fair value and is determined by estimating the costs to develop the technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the projected net cash flows to present value. IPR&amp;amp;D is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned or transferred to a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The projected discounted cash flow models used to estimate the Company&#x2019;s IPR&amp;amp;D reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Probability of successfully completing clinical trials and obtaining regulatory approval;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Market size, market growth projections, and market share;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Estimates of future cash flows from potential milestone payments and royalties related to out-licensed product sales; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A discount rate reflecting the Company's weighted average cost of capital and specific risk inherent in the underlying assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company entered into an out-licensing arrangement with a third party that transferred the rights to develop and commercialize one of the programs underlying an IPR&amp;amp;D intangible asset. In addition, the Company entered into amended out-licensing option agreements with a third party who had previously entered into an option agreement with Arsanis to license the rights to develop and commercialize two other programs underlying the IPR&amp;amp;D intangible assets. Following the amendment to these option agreements, the options were exercised by the third party and the in-process research and development programs were out-licensed to the third party. As of December 31, 2019, all programs underlying IPR&amp;amp;D intangible assets acquired in the Merger were transferred to these third parties. As a result of the transfer of the IPR&amp;amp;D projects to third parties, the Company derecognized the IPR&amp;amp;D intangibles asset through a charge to &#x201c;loss on transfer of nonfinancial assets&#x201d; during 2019. (See Note 15) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Merger, the Company&#x2019;s preferred stock warrant liability and preferred stock repurchase liability were carried at fair value, determined according to Level&#160;3 inputs in the fair value hierarchy described above. The embedded derivative liability related to the redemption features of the Company&#x2019;s debt with Hercules as described further below is carried at fair value and is a Level 3 measurement. The Company&#x2019;s cash equivalents, consisting of money market funds invested in U.S. Treasury securities, are carried at fair value, determined based on Level 1 and Level&#160;2 inputs in the fair value hierarchy described above. The carrying values of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company&#x2019;s outstanding loan and security agreement with Hercules approximates its fair value at December&#160;31, 2021 because the debt bears interest at a variable market rate and the Company&#x2019;s credit risk has not materially changed since the inception of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1, 2018, the Company adopted ASC Topic 606,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;), as amended, using the modified retrospective transition method. The modified retrospective method requires that the cumulative effect of initially applying ASC 606 be recognized as an adjustment to the opening balance of retained earnings or accumulated deficit of the annual period that includes the date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of initial application. The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;had no&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;arrangements that were in the scope of ASC 606 on January&#160;1, 2018 and thus there was no impact to the consolidated financial statements as a result of the adoption. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaboration arrangements and leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are generated primarily through research, development and commercialization agreements. The terms of these agreements may contain multiple promised goods and services, which may include (i) licenses, or options to obtain licenses, to the Company&#x2019;s technology, and (ii) in certain cases, services in connection with the manufacturing of preclinical and clinical materials. Payments to the Company under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; milestone payments; payments for clinical and commercial product supply, and royalties on future product sales. To date, the Company&#x2019;s license agreement with Abbisko Therapeutics Co., Ltd. (&#x201c;Abbisko&#x201d;) represents its only revenue-generating agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and are therefore within the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are deemed to be within the scope of ASC 808, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of ASC 606. The Company&#x2019;s policy is generally to recognize amounts received from collaborators in connection with joint operating activities that are within the scope of ASC 808 as a reduction in research and development expense. To date, there have been no transactions within the scope of ASC 808.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company determines it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligation(s) in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligation(s) in the contract; and (5) recognize revenue when (or as) the Company satisfies its performance obligation(s). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and; allocating the transaction price to each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:49.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:49.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time based on the use of an output or input method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes non-refundable payments for contingent milestones, including preclinical research and development, clinical development and regulatory, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most-likely-amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of the achievement of contingent milestones and the likelihood of a significant reversal of such milestone revenue, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect licensing revenue in the period of adjustment. This quarterly assessment may result in the recognition of revenue related to a contingent milestone payment before the milestone event has been achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Programs&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds under the research and development incentive program from the Austrian government are recognized as other income in an amount equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. Incentive income recognized upon incurring qualifying expenses in advance of receipt of proceeds from research and development incentives is recorded in the consolidated balance sheet as research and development incentive receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with internal research and development and external research and development services, including drug development and preclinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonrefundable advance payments for services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the related services have been performed, or when it is no longer expected that the goods will be delivered or the services rendered. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs consist of payments made to secure commitments under certain debt financing arrangements. These amounts are recognized as interest expense over the period of the financing arrangement using the effective interest method. If the financing arrangement is canceled or forfeited, or if the utility of the arrangement to the Company is otherwise compromised, these costs are recognized as interest expense immediately. The Company&#x2019;s consolidated financial statements present debt issuance costs related to a recognized debt liability as a direct reduction from the carrying amount of that debt liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures all stock-based awards granted to employees, nonemployees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has also issued stock-based awards with performance-based vesting conditions that vest in part upon the Company&#x2019;s achievement of operational milestones and over time thereafter for the subsequent two years as the employee continues to provide services. The Company assesses the probability of achievement of these operational milestones and recognizes stock-based compensation for these awards using the accelerated attribution model based on the fair value of the awards as of the date of grant and its best estimate of the date each operational milestone will be achieved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for only the portion of awards that are expected to vest. In developing a forfeiture rate estimate, the Company has considered its historical experience to estimate pre-vesting forfeitures for service-based awards. The impact of a forfeiture rate adjustment is recognized in full in the period of adjustment, and if the actual forfeiture rate is materially different from the Company&#x2019;s estimate, the Company may be required to record adjustments to stock-based compensation expense in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Prior to March&#160;13, 2019, the Company was a private company and lacked company-specific historical and implied volatility information for its common stock. Therefore, the Company estimates its expected common stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Liabilities: Hercules Loan Redemption Feature&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan agreement with Hercules (see Note&#160;7) contains a redemption feature that, upon an event of default, provides Hercules the option to accelerate and demand repayment of the debt, including a prepayment premium, or, at its election, charge additional contingent interest fees on any overdue interest or principal payments. The redemption feature meets the definition of a derivative instrument as the repayment of the debt contains a substantial premium, resulting in the redemption feature not being clearly and closely related to its host instrument. Accordingly, the Company classifies this derivative as a liability within other liabilities (non-current) on its consolidated balance sheets. The derivative liability was initially recorded at fair value on the date of the Hercules Loan Agreement and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of this derivative liability, which is included in other liabilities, are recognized as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss. Changes in the fair value of this derivative liability will continue to be recognized until all amounts outstanding under the Hercules Loan Agreement are repaid or until the Hercules Loan Agreement is terminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2021 and 2020, all foreign currency remeasurement gains and losses were included in net loss as the Company has deemed the functional currency of its foreign subsidiary to be the U.S. Dollar. Comprehensive loss includes net loss as well as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;foreign currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;translation adjustments of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$119 thousand for the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods prior to the Merger with Arsanis on March 13, 2019, the Company followed the two-class method when computing net loss per share as the Company had issued shares that met the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. In addition, during the year ended December 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of subsequent sales of common stock. Such adjustment is accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#x2019;s common stock and the estimated remaining life of the outstanding Class B Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Basic shares outstanding includes the weighted average effect of the Company&#x2019;s outstanding prefunded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive shares of common stock. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of convertible preferred stock or common stock are considered potential dilutive shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13&#x201d;), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In accordance with ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326), Derivative and Hedging (Topic 815), and Leases (Topic 842)- Effective Dates, &lt;/span&gt;as the Company meets the definition of a &#x201c;smaller reporting company&#x201d;, the Company has elected to defer the adoption of ASU 2016-13 until January 1, 2023. The Company expects that the adoption of ASU 2016-13 may accelerate the timing and could increase the level of credit loss expense in the consolidated statement of operations and will likely require an increased level of disclosure in the notes to the consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc4_38afc8f5-47c5-4df2-949a-d13a76e7c347">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and the constraint of variable consideration from contracts with customers. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The COVID-19 pandemic has impacted and is expected to continue to impact the clinical development timelines for certain of the Company's clinical programs. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDcw_2227df33-07c0-4cc0-82ea-a43d5353eaca">Foreign Currency and Currency Translation&#x2014; The functional currency of the Company&#x2019;s foreign subsidiary, X4 Austria, is the U.S. dollar but X4 Austria maintains its books and records in Euro. Monetary assets and liabilities are translated at current exchange rates as of the balance sheet date, non-monetary assets such as property and equipment and equity accounts are translated at historic rates and income and expenses are translated at the average exchanges rates for the period. Adjustments resulting from the translation of the consolidated financial statements of the Company&#x2019;s foreign operations into U.S. dollars are included in the determination of net loss and are recorded in other expense, net.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDY3_28cc0137-58a6-4ca4-a115-13cb9cf512b0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Significant Suppliers&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and research and development incentive receivables. The Company generally maintains cash balances in various operating accounts at financial institutions that management believes to be of high credit quality in amounts that may exceed federally insured limits. The Company has not experienced losses related to its cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of active pharmaceutical ingredients and formulated drugs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDcz_da0d82b4-f5a0-429a-b2a5-fca350e35898">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December&#160;31, 2021 and 2020.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCompensatingBalancesTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg2_7df0113b-0b9f-4ae3-b8e5-c11ab6d6cd9e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:97%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%"&gt;Letter of credit security: Cambridge lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%"&gt;Letter of credit security: Waltham lease &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%"&gt;Letter of credit security: Vienna Austria lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Boston lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensatingBalancesTextBlock>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if607c1606fbc49f59e2bf4de1d5b33a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzEtMS0xLTEtMjA5NDA_03d10196-306f-4859-a66c-d121c117b7a7"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i38b2d39313774d1fa99f7f76bc2c53de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzEtMy0xLTEtMjA5NDA_e89f421e-ed31-4f7c-8088-a44f6f1d591e"
      unitRef="usd">264000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i420c5ba492444c13b294e4e2a546f0a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzItMS0xLTEtMjA5NDA_7e908f8c-b57d-4d34-8a49-76fb3b188873"
      unitRef="usd">250000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i44c4ebf0462b4732860b5713ee5382d7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzItMy0xLTEtMjA5NDA_08a8deeb-4d23-4e4b-b940-f1ac4484ce5e"
      unitRef="usd">250000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ica794810f5b2410aa3cb05ea67f5c7f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzMtMS0xLTEtMjA5NDA_c9549536-2c10-4ae6-bb60-c71729070323"
      unitRef="usd">216000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2ce2db152304447e9853c0b52d13069e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzMtMy0xLTEtMjA5NDA_b8f942fc-f37c-46f6-9b7d-91caf8f085f4"
      unitRef="usd">336000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ic5d8948ba512458fa854441df3e3e3bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzQtMS0xLTEtMjA5NDA_a9d3c969-0282-4dcc-ba5f-9627876d7b74"
      unitRef="usd">855000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i4963d68c5d634e58ab61d1a2cddf748b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzQtMy0xLTEtMjA5NDA_32504454-fc53-46f3-9641-904e04c161f0"
      unitRef="usd">1144000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzYtMS0xLTEtMjA5NDA_032a0a8e-00c1-4721-be46-b9282a69dbb8"
      unitRef="usd">1321000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCash
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzYtMy0xLTEtMjA5NDA_e3d71efe-00b6-443e-a134-62f169e3fb51"
      unitRef="usd">1994000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzctMS0xLTEtMjA5NDA_d3959ead-f218-4849-a61b-c749976e9049"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzctMy0xLTEtMjA5NDA_e5a8a330-d2fa-4cb1-9432-c9bbd21d3fa7"
      unitRef="usd">264000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7e897132b145489baf3f95f1211bbfe1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzgtMS0xLTEtMjA5NDA_1e59d8d0-675c-4ea5-9861-5e17a1cd0dcf"
      unitRef="usd">1321000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id55dcfd048fd4851ae346aa2bda82ea8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpkZGU5ZjAwOTM4MTA0NDlhOWM2MmMyZGJiMzZiYzljZC90YWJsZXJhbmdlOmRkZTlmMDA5MzgxMDQ0OWE5YzYyYzJkYmIzNmJjOWNkXzgtMy0xLTEtMjA5NDA_209fe493-ff02-40e3-b9c7-c5c282f479a0"
      unitRef="usd">1730000</us-gaap:RestrictedCashNoncurrent>
    <xfor:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDcx_f36d8cc0-4ef8-4dbf-a4f2-7225d5a0e802">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets to the sum to the total of amounts shown in the Company&#x2019;s consolidated statements of cash flows as of December&#160;31, 2021, 2020, 2019 and 2018:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, current (included within prepaid expenses and other current assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current (included within other assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</xfor:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzEtMS0xLTEtMjA5NDA_deec8f4c-0e5c-4652-9872-a663c3a7ca24"
      unitRef="usd">81787000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzEtMy0xLTEtMjA5NDA_429901b6-7441-4cf7-bc76-1b0b6ff9aa6a"
      unitRef="usd">78708000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzEtNS0xLTEtMjA5NDA_af8ae244-e74d-4ce5-b777-5de38f0147fb"
      unitRef="usd">126184000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzEtNy0xLTEtMjA5NDA_0fe71895-6195-487a-ba55-5c54ba1124de"
      unitRef="usd">8134000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzItMS0xLTEtMjA5NDA_d3959ead-f218-4849-a61b-c749976e9049"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzItMy0xLTEtMjA5NDA_861d4e9d-595a-46ae-ba5d-23f7dffcc254"
      unitRef="usd">264000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzItNS0xLTEtMjA5NDA_cb15feab-9104-4ea7-a252-ab03abaf3ca0"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzItNy0xLTEtMjA5NDA_bc90582b-1940-406e-9c54-0e69d96c652b"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7e897132b145489baf3f95f1211bbfe1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzMtMS0xLTEtMjA5NDA_1e59d8d0-675c-4ea5-9861-5e17a1cd0dcf"
      unitRef="usd">1321000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzMtMy0xLTEtMjA5NDA_825d2574-6ae0-4156-993b-11fca39b830e"
      unitRef="usd">1730000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzMtNS0xLTEtMjA5NDA_31c2b347-7776-47b7-b22c-23c718f05bae"
      unitRef="usd">1902000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzMtNy0xLTEtMjA5NDA_1ad8d7dc-71aa-4788-be31-8eb2fd32cd34"
      unitRef="usd">364000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzQtMS0xLTEtMjA5NDA_2a0d3cc7-0817-477f-aef3-b089bbaae976"
      unitRef="usd">83108000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzQtMy0xLTEtMjA5NDA_75a9c2a1-0eda-4b32-98eb-021fdec81841"
      unitRef="usd">80702000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzQtNS0xLTEtMjA5NDA_3902cb70-a890-4a73-877d-c9830089cb41"
      unitRef="usd">128086000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i13bac80900904f72b4b9131b22a45f6a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTo1NzkxOGZkYzA1Y2E0NzYzYTA3ZjM1ODQzZGIwZTRkOS90YWJsZXJhbmdlOjU3OTE4ZmRjMDVjYTQ3NjNhMDdmMzU4NDNkYjBlNGQ5XzQtNy0xLTEtMjA5NDA_f0fd0f5a-bbaf-4121-8010-9585488f7e85"
      unitRef="usd">8498000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDY0_0483ef62-6cd1-4de6-92f0-0fae4c1ccfb6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:&lt;/span&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <xfor:PropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg1_2398ec26-ad68-4520-9406-45c1f1a7789a">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xfor:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3c76fdda3bb7478080cca4e3d51fa3d7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzEtMS0xLTEtMjA5NDAvdGV4dHJlZ2lvbjpjZWVlOGRkODJiMGE0Yjk0OWE1NGNkMjJkNDM2YzAyMl80_060e9437-9a3a-4110-8173-cb9a8898401c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i98a725b19ab442bbb8edee0d639f20dd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzEtMS0xLTEtMjA5NDAvdGV4dHJlZ2lvbjpjZWVlOGRkODJiMGE0Yjk0OWE1NGNkMjJkNDM2YzAyMl8xMA_18233494-7457-4168-a48a-a4b7e9b45f78">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6cc17360a88043f9b6abb29bb3af7296_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzItMS0xLTEtMjA5NDA_65c8ad6c-b434-43b3-8602-ea5c6348eeb7">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i77964c20016f452c85f7147fb9ecc320_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzMtMS0xLTEtMjA5NDAvdGV4dHJlZ2lvbjo4YzViNGJlZmE5MjQ0ZTdkYTc5NTI4ZTQ4NWQ0YjRlOF80_dab89219-15fa-4640-a2d9-633b537913f0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic33f057257bb48b2afd09c10a0ad9385_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzMtMS0xLTEtMjA5NDAvdGV4dHJlZ2lvbjo4YzViNGJlZmE5MjQ0ZTdkYTc5NTI4ZTQ4NWQ0YjRlOF8xMA_c9d2bb8f-1a6b-4d5e-9836-45861bfdf0dc">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="icda50709fc3f40a7ab505de422bb1006_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90YWJsZTpjZjk3N2VjODI5MTc0ZmQ1YWIzOTU2MGZkN2U1ODQxOC90YWJsZXJhbmdlOmNmOTc3ZWM4MjkxNzRmZDVhYjM5NTYwZmQ3ZTU4NDE4XzQtMS0xLTEtMjA5NDAvdGV4dHJlZ2lvbjo0NDk2YTgxOTU5MWQ0MTQ4YjM4NzMzYWExMjdiMWQyY18yOQ_251e63c7-36fa-411b-9b7d-59b39e702340">10 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <xfor:RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg3_b471481a-4109-4550-99a1-c6ddaac89512">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Right-of-Use Assets and Leases&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for leases in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 842&#x201d;). Under ASC 842, at the inception of an arrangement, the Company determines whether the arrangement contains a lease based on the unique facts and circumstances present. Leases with a non-cancellable term greater than one year are recognized on the balance sheet as right-of-use assets with associated current and non-current lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Options to renew a lease are not included in the Company&#x2019;s initial lease term assessment unless there is reasonable certainty that the Company will renew the lease. If a lease is cancellable without penalty, the Company excludes from the lease term periods following the cancellation notice period unless it is reasonably certain that the Company will not cancel the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use operating asset may be required for items such as incentives received or accrued rent. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates it incurs to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company has referenced the effective rate of its Hercules borrowings, as adjusted for differences terms, to determine calculate its incremental borrowing rate for each of its operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance in ASC 842, components of a lease are split into lease components and non-lease components. A policy election is available pursuant to which an entity may elect to not separate lease and non-lease components. Rather, each lease component and the related non-lease components are accounted for together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components as a combined lease component for its office and laboratory building leases.&lt;/span&gt;&lt;/div&gt;</xfor:RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc5_33aa04e9-8339-44ed-abdd-5da68200f2b0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value. To date, the Company has not recorded any material impairment losses on long-lived assets.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg4_2ea8ac87-834b-4ba8-8dad-bf32bd479f0b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;Goodwill is tested quantitatively for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action, a significant decline in the price of the Company&#x2019;s common stock, or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit. To perform its quantitative test, the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. See Note 4 for more information on the Company&#x2019;s goodwill impairment test as of December 31, 2021.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <xfor:IntangibleAssetsPolicyPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDgw_0279c8a4-5b4d-43c3-8eb9-2d6ba0bd3bfe">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with the Merger, the Company acquired certain in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) assets, which were classified as indefinite-lived intangible assets. Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that the Company acquires and have not been completed at the acquisition date. The fair value of IPR&amp;amp;D acquired in a business combination is recorded on the Company&#x2019;s consolidated balance sheets at the acquisition-date fair value and is determined by estimating the costs to develop the technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the projected net cash flows to present value. IPR&amp;amp;D is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned or transferred to a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The projected discounted cash flow models used to estimate the Company&#x2019;s IPR&amp;amp;D reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Probability of successfully completing clinical trials and obtaining regulatory approval;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Market size, market growth projections, and market share;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Estimates of future cash flows from potential milestone payments and royalties related to out-licensed product sales; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A discount rate reflecting the Company's weighted average cost of capital and specific risk inherent in the underlying assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;During the year ended December 31, 2019, the Company entered into an out-licensing arrangement with a third party that transferred the rights to develop and commercialize one of the programs underlying an IPR&amp;amp;D intangible asset. In addition, the Company entered into amended out-licensing option agreements with a third party who had previously entered into an option agreement with Arsanis to license the rights to develop and commercialize two other programs underlying the IPR&amp;amp;D intangible assets. Following the amendment to these option agreements, the options were exercised by the third party and the in-process research and development programs were out-licensed to the third party. As of December 31, 2019, all programs underlying IPR&amp;amp;D intangible assets acquired in the Merger were transferred to these third parties. As a result of the transfer of the IPR&amp;amp;D projects to third parties, the Company derecognized the IPR&amp;amp;D intangibles asset through a charge to &#x201c;loss on transfer of nonfinancial assets&#x201d; during 2019. (See Note 15)</xfor:IntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDY1_32c73d10-c361-4143-bea9-62159c1a7184">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;Prior to the Merger, the Company&#x2019;s preferred stock warrant liability and preferred stock repurchase liability were carried at fair value, determined according to Level&#160;3 inputs in the fair value hierarchy described above. The embedded derivative liability related to the redemption features of the Company&#x2019;s debt with Hercules as described further below is carried at fair value and is a Level 3 measurement. The Company&#x2019;s cash equivalents, consisting of money market funds invested in U.S. Treasury securities, are carried at fair value, determined based on Level 1 and Level&#160;2 inputs in the fair value hierarchy described above. The carrying values of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company&#x2019;s outstanding loan and security agreement with Hercules approximates its fair value at December&#160;31, 2021 because the debt bears interest at a variable market rate and the Company&#x2019;s credit risk has not materially changed since the inception of the agreement.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc0_262c37c6-89b7-4a59-9095-b381e242cb5e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDgx_d8b13678-a8d1-4b2a-81a9-08ebb8725750">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1, 2018, the Company adopted ASC Topic 606,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;), as amended, using the modified retrospective transition method. The modified retrospective method requires that the cumulative effect of initially applying ASC 606 be recognized as an adjustment to the opening balance of retained earnings or accumulated deficit of the annual period that includes the date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of initial application. The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;had no&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;arrangements that were in the scope of ASC 606 on January&#160;1, 2018 and thus there was no impact to the consolidated financial statements as a result of the adoption. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaboration arrangements and leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are generated primarily through research, development and commercialization agreements. The terms of these agreements may contain multiple promised goods and services, which may include (i) licenses, or options to obtain licenses, to the Company&#x2019;s technology, and (ii) in certain cases, services in connection with the manufacturing of preclinical and clinical materials. Payments to the Company under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; milestone payments; payments for clinical and commercial product supply, and royalties on future product sales. To date, the Company&#x2019;s license agreement with Abbisko Therapeutics Co., Ltd. (&#x201c;Abbisko&#x201d;) represents its only revenue-generating agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and are therefore within the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are deemed to be within the scope of ASC 808, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of ASC 606. The Company&#x2019;s policy is generally to recognize amounts received from collaborators in connection with joint operating activities that are within the scope of ASC 808 as a reduction in research and development expense. To date, there have been no transactions within the scope of ASC 808.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company determines it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligation(s) in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligation(s) in the contract; and (5) recognize revenue when (or as) the Company satisfies its performance obligation(s). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and; allocating the transaction price to each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:49.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:49.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time based on the use of an output or input method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes non-refundable payments for contingent milestones, including preclinical research and development, clinical development and regulatory, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most-likely-amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of the achievement of contingent milestones and the likelihood of a significant reversal of such milestone revenue, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect licensing revenue in the period of adjustment. This quarterly assessment may result in the recognition of revenue related to a contingent milestone payment before the milestone event has been achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <xfor:ResearchAndDevelopmentProgramsPolicyPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDgy_09c74b36-50c6-4d32-8e38-e2d50536d2d6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Programs&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds under the research and development incentive program from the Austrian government are recognized as other income in an amount equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. Incentive income recognized upon incurring qualifying expenses in advance of receipt of proceeds from research and development incentives is recorded in the consolidated balance sheet as research and development incentive receivable.&lt;/span&gt;</xfor:ResearchAndDevelopmentProgramsPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDgz_4134a6de-7480-42ea-80fd-2d9701e1d0a8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with internal research and development and external research and development services, including drug development and preclinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers.&lt;/span&gt;Nonrefundable advance payments for services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the related services have been performed, or when it is no longer expected that the goods will be delivered or the services rendered.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDY2_9a133d9f-e82c-4f36-a314-afe3d0fa768e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend>
    <us-gaap:DebtPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg5_fddeae18-ea57-4210-9c96-b6d22faf7a15">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs consist of payments made to secure commitments under certain debt financing arrangements. These amounts are recognized as interest expense over the period of the financing arrangement using the effective interest method. If the financing arrangement is canceled or forfeited, or if the utility of the arrangement to the Company is otherwise compromised, these costs are recognized as interest expense immediately. The Company&#x2019;s consolidated financial statements present debt issuance costs related to a recognized debt liability as a direct reduction from the carrying amount of that debt liability.&lt;/span&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDg0_5f8a1218-7c46-479a-b3fc-188fa57bd5de">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures all stock-based awards granted to employees, nonemployees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with service-based vesting conditions and records the expense for these awards using the straight-line method. The Company has also issued stock-based awards with performance-based vesting conditions that vest in part upon the Company&#x2019;s achievement of operational milestones and over time thereafter for the subsequent two years as the employee continues to provide services. The Company assesses the probability of achievement of these operational milestones and recognizes stock-based compensation for these awards using the accelerated attribution model based on the fair value of the awards as of the date of grant and its best estimate of the date each operational milestone will be achieved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for only the portion of awards that are expected to vest. In developing a forfeiture rate estimate, the Company has considered its historical experience to estimate pre-vesting forfeitures for service-based awards. The impact of a forfeiture rate adjustment is recognized in full in the period of adjustment, and if the actual forfeiture rate is materially different from the Company&#x2019;s estimate, the Company may be required to record adjustments to stock-based compensation expense in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Prior to March&#160;13, 2019, the Company was a private company and lacked company-specific historical and implied volatility information for its common stock. Therefore, the Company estimates its expected common stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to &lt;/span&gt;&lt;/div&gt;the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc1_53c911ba-35b9-408f-a5b5-012759ab5cd4">Derivative Liabilities: Hercules Loan Redemption Feature&#x2014; The Company&#x2019;s loan agreement with Hercules (see Note&#160;7) contains a redemption feature that, upon an event of default, provides Hercules the option to accelerate and demand repayment of the debt, including a prepayment premium, or, at its election, charge additional contingent interest fees on any overdue interest or principal payments. The redemption feature meets the definition of a derivative instrument as the repayment of the debt contains a substantial premium, resulting in the redemption feature not being clearly and closely related to its host instrument. Accordingly, the Company classifies this derivative as a liability within other liabilities (non-current) on its consolidated balance sheets. The derivative liability was initially recorded at fair value on the date of the Hercules Loan Agreement and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of this derivative liability, which is included in other liabilities, are recognized as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss. Changes in the fair value of this derivative liability will continue to be recognized until all amounts outstanding under the Hercules Loan Agreement are repaid or until the Hercules Loan Agreement is terminated.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc2_21a0a9c1-2e7f-4a54-aa9f-272861e66c06">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2021 and 2020, all foreign currency remeasurement gains and losses were included in net loss as the Company has deemed the functional currency of its foreign subsidiary to be the U.S. Dollar. Comprehensive loss includes net loss as well as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;foreign currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;translation adjustments of&lt;/span&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzM0NDc2_e1b32c87-f8e6-4a2f-9762-ddf6afb4e316"
      unitRef="usd">-119000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDc3_5e799dfb-c372-4d17-a206-0dde7c14099d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDcy_309e7ab1-234d-482b-aebd-023155537dd7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods prior to the Merger with Arsanis on March 13, 2019, the Company followed the two-class method when computing net loss per share as the Company had issued shares that met the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. In addition, during the year ended December 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of subsequent sales of common stock. Such adjustment is accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#x2019;s common stock and the estimated remaining life of the outstanding Class B Warrants. &lt;/span&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Basic shares outstanding includes the weighted average effect of the Company&#x2019;s outstanding prefunded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive shares of common stock. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of convertible preferred stock or common stock are considered potential dilutive shares of common stock.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNDgvZnJhZzo5YjAyNmIwYzIwODY0YjJmYWFjMWEyN2E1NmNmMGU0OC90ZXh0cmVnaW9uOjliMDI2YjBjMjA4NjRiMmZhYWMxYTI3YTU2Y2YwZTQ4XzQxNDY5_67cfab32-2d6b-4cc5-a9d6-1fb5038dc12d">Recently Issued Accounting Pronouncements&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13&#x201d;), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In accordance with ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326), Derivative and Hedging (Topic 815), and Leases (Topic 842)- Effective Dates, &lt;/span&gt;as the Company meets the definition of a &#x201c;smaller reporting company&#x201d;, the Company has elected to defer the adoption of ASU 2016-13 until January 1, 2023. The Company expects that the adoption of ASU 2016-13 may accelerate the timing and could increase the level of credit loss expense in the consolidated statement of operations and will likely require an increased level of disclosure in the notes to the consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzE0OTUy_f54652a4-473e-4e81-9d1d-248e5fcdbe82">LICENSE, COLLABORATION AND FUNDING ARRANGEMENTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genzyme Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July&#160;2014, the Company entered into a license agreement with Genzyme  (the &#x201c;Genzyme Agreement&#x201d;) pursuant to which the Company was granted an exclusive license to certain patents and intellectual property owned or controlled by Genzyme related to the CXCR4 receptor to develop and commercialize products containing licensed compounds (including but not limited to mavorixafor) for all therapeutic, prophylactic and diagnostic uses, with the exception of autologous and allogenic human stem cell therapy. Under the terms of the Genzyme Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize licensed products for use in the field in the United States and at least one other major market country. The Company has the right to grant sublicenses of the licensed rights that cover mavorixafor to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Genzyme Agreement, the Company is obligated to pay Genzyme milestone payments in the aggregate amount of up to $25.0 million, contingent upon the achievement by the Company of certain clinical-stage regulatory and sales milestones with respect to licensed products. The Company is also obligated to pay Genzyme tiered royalties based on net sales of licensed products that the Company commercializes under the agreement. The obligation to pay royalties for each licensed product expires on a country-by-country basis on the latest of (i)&#160;the expiration of&#160;licensed patent rights that cover that licensed product in that country, (ii)&#160;the expiration of regulatory exclusivity in that country and (iii)&#160;ten years after the first commercial sale of such licensed product in that country. Royalty rates are subject to reduction under the agreement in specified circumstances, including in any country if the Company is required to obtain a license from any third party to the extent the Company&#x2019;s patent rights might infringe the third party&#x2019;s patent rights, if a licensed product is not covered by a valid claim in that country or if sales of generic products reach certain thresholds in that country. If the Company enters into a sublicense under the Genzyme Agreement, the Company will be obligated to pay Genzyme a percentage of certain upfront fees, maintenance fees, milestone payments and royalty payments paid to the Company by the sublicensee. Under the Genzyme Agreement, the Company will itself manufacture and supply, or enter into manufacturing or supply agreements with Genzyme or third parties to manufacture and supply, clinical and commercial supplies of licensed compounds and each licensed product. The Company is also responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Genzyme Agreement will remain in effect until the expiration of the royalty term in all countries for all licensed products.&#160;The Genzyme Agreement may be terminated by either party with at least 90 days&#x2019; notice in the event of material breach by the other party that remains uncured for 90 days, by either party for insolvency or bankruptcy of the other party, immediately by Genzyme if the Company challenges the licensed patents, or immediately by the Company if a material safety issue arises. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company incurred $0.9&#160;million of payment obligations to Genzyme. For the years ended December 31, 2021 and 2019, the Company did not incur any payment obligations to Genzyme under the Genzyme Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Georgetown Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company entered into a license agreement (the &#x201c;Georgetown Agreement&#x201d;) with Georgetown University (&#x201c;Georgetown&#x201d;) pursuant to which the Company obtained an exclusive, worldwide license to make, have made, use, sell, offer for sale and import of products covered by patent rights co-owned by Georgetown. The rights licensed to the Company are for all therapeutic, prophylactic and diagnostic uses in all disease indications in humans and animals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Georgetown Agreement, the Company paid a one-time, upfront fee of $50 thousand and the Company may be required to make milestone payments of up to an aggregate of $800 thousand related to commercial sales of a product. The Company recorded the upfront payment as research and development expense in the consolidated statement of operations and comprehensive loss because the acquired technology represented in-process research and development and had no alternative future use. Under the Georgetown Agreement, the Company is solely responsible for all development and commercialization activities and costs in its respective territories. The Company is also responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights. The term of the Georgetown Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event (i)&#160;the Company fails to pay any amount and fails to cure such failure within 30 days after receipt of notice, (ii)&#160;the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within 45 days after receipt of notice, or (iii)&#160;the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown Agreement at any time upon at least 60 days&#x2019; written notice.  During the years ended December&#160;31, 2021, 2020 and 2019, the Company did not incur any payment obligations to Georgetown under the Georgetown Agreement and no milestone payments were made or due under the Georgetown Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Beth Israel Deaconess Medical Center Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company entered into a license agreement (the &#x201c;BIDMC Agreement&#x201d;) with Beth Israel Deaconess Medical Center (&#x201c;BIDMC&#x201d;), pursuant to which the Company obtained an exclusive, worldwide license to make, have made, use, sell, offer for sale and import products covered by patent rights co-owned by BIDMC. The rights licensed to the Company are for all fields of use. Under the terms of the BIDMC Agreement, the Company paid a one-time, upfront fee of $20 thousand and the Company is responsible for all future patent prosecution costs. The Company recorded the upfront payment as research and development expense in the consolidated statement of operations because the acquired technology represented in-process research and development and had no alternative future use. The term of the BIDMC Agreement will continue until the expiration of the last valid claim within the patent rights covering the licensed products. BIDMC may terminate the agreement in the event (i)&#160;the Company fails to pay any amount and fails to cure such failure within 15 days after receipt of notice, (ii)&#160;the Company is in material breach of any material provision of the BIDMC Agreement and fails to remedy such breach within 60 days after receipt of notice, or (iii)&#160;the Company declares insolvency or bankruptcy. The Company may terminate the BIDMC Agreement at any time upon at least 90 days&#x2019; written notice.  The Company did not incur any payment obligations under the BIDMC Agreement during the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dana Farber Cancer Institute Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company entered into a license agreement (the &#x201c;DFCI Agreement&#x201d;) with the Dana Farber Cancer Institute (&#x201c;DFCI&#x201d;) pursuant to which the Company obtained a non-exclusive, royalty-bearing license to use, make, have made, develop, market, import, distribute, sell and have sold products covered by patent rights owned by DFCI. Under the terms of the DFCI Agreement, the Company paid a one-time, upfront fee of $25 thousand and approximately $35&#160;thousand for reimbursement of DFCI&#x2019;s past patent expenses relating to the patent rights. The Company will pay 25% of DFCI&#x2019;s ongoing patent prosecution expenses and an annual license maintenance fee of $10&#160;thousand in each of the first three years, $40&#160;thousand in each of the subsequent three years and $50&#160;thousand every year after that until commercialization. The Company may be required to make milestone payments of up to an aggregate of approximately $32.0 million related to development, regulatory and commercial sales events. No such milestone payments have been incurred to date. The Company recorded the upfront payment as research and development expense in the consolidated statement of operations and comprehensive loss because the acquired technology represented in-process research and development and had no alternative future use. The term of the DCFI Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. DFCI may terminate the agreement if certain events occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Incentive Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's wholly-owned subsidiary X4 Austria participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses incurred by X4 Austria. Under the program, the reimbursement rate for qualifying research and development expenses incurred by the Company through X4 Austria is 14% for the current year. X4 Austria also participated in a COVID-19 incentive program, which provides reimbursement for qualified capital spending during a defined time period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes incentive income from Austrian research and development incentives when qualifying expenses have been incurred, there is reasonable assurance that the payment will be received, and the consideration can be reliably measured. Management has assessed the Company&#x2019;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each reporting date, management estimates the reimbursable incentive income available to the Company based on available information at the time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the years ended December&#160;31, 2021 and 2020, the amounts due under these programs were $0.7 million and $0.9 million, respectively, which is included in research and development incentive receivable on the consolidated balance sheet. During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded $0.8 million, $0.5 million and $0.4 million, respectively, of income related to the program on the consolidated statement of operations and comprehensive loss within &#x201c;other income&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Abbisko Agreement &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company entered into a license agreement with Abbisko (the &#x201c;Abbisko Agreement&#x201d;). Under the terms of the Abbisko Agreement, the Company granted Abbisko the exclusive right to develop, manufacture and commercialize mavorixafor in mainland China, Taiwan, Hong Kong and Macau, the (&#x201c;Abbisko Territory&#x201d;). The agreement provides Abbisko with the exclusive rights in the Abbisko Territory to develop and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in multiple oncology indications. The Company retains the full rest-of-world rights to develop and commercialize mavorixafor outside of Greater China for all indications and the ability to utilize data generated pursuant to the Abbisko collaboration for rest-of-world development. Assuming mavorixafor is developed by Abbisko in six indications, the Company would be entitled to milestone payments of up to $208.0&#160;million, which will vary based on the ultimate sales, if any, of the approved licensed products. In addition, upon commercialization of mavorixafor in the Abbisko Territory, the Company is eligible to receive a tiered royalty, with a percentage range in the low double-digits, on net sales of approved licensed products. Abbisko is obligated to use commercially reasonable efforts to develop and commercialize mavorixafor in the Abbisko Territory. Abbisko has responsibility for all activities and costs associated with the further development, manufacture and commercialization of mavorixafor in the Abbisko Territory.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the closing of a qualified financing (as such term is defined in the Abbisko Agreement), Abbisko was required to pay the Company a one-time, non-refundable, non-creditable financial milestone payment of $3.0 million. Abbisko achieved such qualified financing in March 2020 and, as a result, the Company was eligible to receive the milestone payment, which was received by the Company in April 2020. The Company is also eligible to receive potential development and regulatory milestone payments, which vary based on the number of indications developed, and potential commercial milestone payments based on annual net sales of mavorixafor-based licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon entering into the Abbisko Agreement, the Company evaluated the Abbisko Agreement under ASC 606 and determined the Abbisko Agreement contained a single performance obligation related to the exclusive license to develop and commercialize mavorixafor and the transfer of know-how that was satisfied at the inception of the arrangement. The transaction price related to the transfer of the license and know-how was fully constrained and the Company ascribed no transaction price to the development, regulatory and commercial milestones under the &#x201c;most-likely amount&#x201d; method. The Company concluded that any consideration related to the initial transfer of the license and know-how will be recognized when it is probable that Abbisko will achieve the related financial milestone and other operational milestones. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Abbisko and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur. As a result of Abbisko&#x2019;s achievement of the qualified financing, the Company reversed the constraint related to this milestone and recognized $3.0 million of license revenue during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the future sale of clinical and commercial supply are optional goods that will be subject to the customer's future purchasing decisions and do not represent performance obligations in the Abbisko Agreement. The Company concluded that the amount to be charged for the clinical supply will be reflective of market value and, therefore, the Abbisko Agreement does not provide a discount on such supply that would be accounted for as material right at the outset of the contract. In arriving at these conclusions, the Company considered the complexity of the manufacturing process for the licensed compound and the potential ability for Abbisko to obtain the compound directly from other manufactures in the future. The Company expects that it will recognize revenue at a point in time when such clinical supply (and commercial supply, if applicable) is delivered to Abbisko in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-evaluates the transaction price, including its estimated variable consideration for milestones included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <xfor:MilestonePayments
      contextRef="i9784cfb07e534c2e87bde589e4247ab1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzEwNTI_fc59ccc1-e825-40eb-8833-ca83d063cef3"
      unitRef="usd">25000000</xfor:MilestonePayments>
    <xfor:PaymentOnObligationUnderLicenseAgreement
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzMzMjY_786fbb90-c277-4635-830f-57fd5d5e831c"
      unitRef="usd">900000</xfor:PaymentOnObligationUnderLicenseAgreement>
    <xfor:PaymentOnObligationUnderLicenseAgreement
      contextRef="iad3dd65af95a4a2aba2fdcc47b856359_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzM0MjY_39633822-ae17-4b08-8c72-8a7f973c3fed"
      unitRef="usd">0</xfor:PaymentOnObligationUnderLicenseAgreement>
    <xfor:PaymentOnObligationUnderLicenseAgreement
      contextRef="i9784cfb07e534c2e87bde589e4247ab1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzM0MjY_41c7f22b-c59c-47b0-b551-f63bd6c8df07"
      unitRef="usd">0</xfor:PaymentOnObligationUnderLicenseAgreement>
    <xfor:OneTimeUpfrontPayment
      contextRef="i225e901df8314c699611cba3ac017ff1_D20161201-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzQwODE_b4d9613d-bc2d-4806-83be-c085f5608145"
      unitRef="usd">50000</xfor:OneTimeUpfrontPayment>
    <xfor:MilestonePaymentsPaid
      contextRef="i225e901df8314c699611cba3ac017ff1_D20161201-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzQxNjg_a912035e-1b63-417f-aa9e-162492eea938"
      unitRef="usd">800000</xfor:MilestonePaymentsPaid>
    <xfor:MilestoneContractTerminationPeriod
      contextRef="i225e901df8314c699611cba3ac017ff1_D20161201-20161231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzUzNDg_9c2bdce8-41e2-43b7-9e9c-13cf176a13df">P60D</xfor:MilestoneContractTerminationPeriod>
    <xfor:PaymentOnObligationUnderLicenseAgreement
      contextRef="i88010e5c3d6844f290c1e8ba4fb22318_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU0MzY_9712e907-c4db-48ee-9f9a-a03c95973ea9"
      unitRef="usd">0</xfor:PaymentOnObligationUnderLicenseAgreement>
    <xfor:PaymentOnObligationUnderLicenseAgreement
      contextRef="i0ceee2c8aded43179b9372ebcdc986a8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU0MzY_ddf1da52-3692-457b-bd6a-4348d26ef73a"
      unitRef="usd">0</xfor:PaymentOnObligationUnderLicenseAgreement>
    <xfor:PaymentOnObligationUnderLicenseAgreement
      contextRef="iad92d608e2c943b5a764b11f90964ae8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU0MzY_fd5bf045-0f8e-4d6e-9e72-826528e9092f"
      unitRef="usd">0</xfor:PaymentOnObligationUnderLicenseAgreement>
    <xfor:MilestonePaymentObligation
      contextRef="i9f97f5094be74d7ba79c0c8d4e004d44_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU1MTk_4813a8cc-d490-464d-847c-3925f07bbd31"
      unitRef="usd">0</xfor:MilestonePaymentObligation>
    <xfor:MilestonePaymentObligation
      contextRef="if1ce81a516a94a338811f3c4a44d3f09_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU1MTk_8fb23a5a-de0b-4a43-bd65-f723ae3d9b2d"
      unitRef="usd">0</xfor:MilestonePaymentObligation>
    <xfor:MilestonePaymentObligation
      contextRef="i8606b5dae8b041ddbf2eda066e840243_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzU1MTk_b2d04d22-bb36-4bd8-b660-d4ab7e0a858b"
      unitRef="usd">0</xfor:MilestonePaymentObligation>
    <xfor:OneTimeUpfrontPayment
      contextRef="i1954fbe47872474aa699d20fef1a95c1_D20161201-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzYxMDQ_e859041c-4f97-4b32-96a4-7501a9e0cc00"
      unitRef="usd">20000</xfor:OneTimeUpfrontPayment>
    <xfor:PaymentOnObligationUnderLicenseAgreement
      contextRef="i380c26c2cda946c08040104fb3a0b055_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzcwNTE_4e20afcb-e3b3-4286-983d-c8ec5d416355"
      unitRef="usd">0</xfor:PaymentOnObligationUnderLicenseAgreement>
    <xfor:PaymentOnObligationUnderLicenseAgreement
      contextRef="i8829b46536ce4ec9827623894b9f4010_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzcwNTE_e843c3d1-6265-4f66-b39c-49c471e6aeb7"
      unitRef="usd">0</xfor:PaymentOnObligationUnderLicenseAgreement>
    <xfor:PaymentOnObligationUnderLicenseAgreement
      contextRef="i62733706ba0e4d2db3cb0b4113c64983_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzcwNTE_e8816431-d415-4fe1-9ffb-5d327eee43e7"
      unitRef="usd">0</xfor:PaymentOnObligationUnderLicenseAgreement>
    <xfor:OneTimeUpfrontPayment
      contextRef="id39cf2b1c7eb411c8bf1eb3d7c157ca3_D20201101-20201130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc2MjM_fcbb5497-43d4-46d0-a4e9-65dad121afd9"
      unitRef="usd">25000</xfor:OneTimeUpfrontPayment>
    <xfor:CollaborativeAgreementExpenseReimbursement
      contextRef="id39cf2b1c7eb411c8bf1eb3d7c157ca3_D20201101-20201130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc2NDQ_1621f971-9637-43aa-91f8-b6dfdf6c0035"
      unitRef="usd">35000</xfor:CollaborativeAgreementExpenseReimbursement>
    <xfor:CollaborativeArrangementObligationPercentage
      contextRef="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc3NDg_bc182657-53cc-4f6e-85b5-d4b30190425c"
      unitRef="number">0.25</xfor:CollaborativeArrangementObligationPercentage>
    <xfor:CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree
      contextRef="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc4Mzg_b9f1c18a-0f76-4d07-920c-3f308a50a4d5"
      unitRef="usd">10000</xfor:CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree>
    <xfor:CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix
      contextRef="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc4NzU_ecea90b2-e557-470c-9686-22d6c62b9f2c"
      unitRef="usd">40000</xfor:CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix>
    <xfor:CollaborativeAgreementFutureExpectedAnnualFeesThereafter
      contextRef="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzc5MjA_54f7a853-ac5b-4978-91fe-363394d0b3d1"
      unitRef="usd">50000</xfor:CollaborativeAgreementFutureExpectedAnnualFeesThereafter>
    <xfor:PaymentOnObligationUnderLicenseAgreement
      contextRef="id6fcbaf938dd46049822d03e66c6a6bf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzgwNjQ_c79ce50e-bf04-4460-99b1-99a7f700cd57"
      unitRef="usd">32000000</xfor:PaymentOnObligationUnderLicenseAgreement>
    <xfor:ReimbursementRateForResearchAndDevelopment
      contextRef="ibf4a376dcdfb4942aaeaac1e7d14026a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzkwNzc_b241f78c-ad6e-41a0-bb99-42e0e3b995da"
      unitRef="number">0.14</xfor:ReimbursementRateForResearchAndDevelopment>
    <xfor:GrantAndIncentiveReceivables
      contextRef="i07dd80c3754e46e787921f0939875ae9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzI3NDg3NzkwODQ1MDg_f69e5e94-7b33-409f-9f23-2ce6ea829a54"
      unitRef="usd">700000</xfor:GrantAndIncentiveReceivables>
    <xfor:GrantAndIncentiveReceivables
      contextRef="iac899978347d423a8c974cde8043327f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzMyOTg1MzQ4OTkzMzA_2e7d7684-16f9-44ec-a3e0-4735dd2730c3"
      unitRef="usd">900000</xfor:GrantAndIncentiveReceivables>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie326aa2ac0af4123b2815995684d76f6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzI3NDg3NzkwODQ1MTU_6c3be5e5-7a71-4885-8980-436546ce025f"
      unitRef="usd">800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i16c580853b2d45d38376f5d122ceae9e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzEwOTk1MTE2NDM4NjI_5336c4c8-4357-4f04-8f93-5fa0158dd03b"
      unitRef="usd">500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if1ac70d6741a4930924fed60eceb574a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzEwOTk1MTE2NDM4NjU_5a51e459-0b82-44d2-902b-5e05da97f9f2"
      unitRef="usd">400000</us-gaap:OtherNonoperatingIncomeExpense>
    <xfor:PotentialMilestonePaymentsReceivable
      contextRef="iccd109dd37804ba9bfecda161164e492_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzExMTMx_265cbc3f-f92a-4bca-8d14-b87653e00cba"
      unitRef="usd">208000000</xfor:PotentialMilestonePaymentsReceivable>
    <us-gaap:Revenues
      contextRef="i3ce09a35448e44b7923a92354c5363c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzExOTYw_a6779858-91b7-4dbe-8131-6586fbcaa007"
      unitRef="usd">3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ce09a35448e44b7923a92354c5363c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTQvZnJhZzo3YzAwY2VmYjcwNDQ0MTkxOTU3ZDg5MmFlZTU2ODI0YS90ZXh0cmVnaW9uOjdjMDBjZWZiNzA0NDQxOTE5NTdkODkyYWVlNTY4MjRhXzEwOTk1MTE2NDI4MzU_a6779858-91b7-4dbe-8131-6586fbcaa007"
      unitRef="usd">3000000</us-gaap:Revenues>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzQ5NDc4MDIzMzc3NDU_1e18d19a-1372-4d86-b69e-ad2a57ebe7ad">FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2021 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2020 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash equivalents consisted of money market funds invested in U.S. Treasury securities. The money market funds were valued based on reported market pricing for the identical asset or by using inputs observable in active markets for similar securities, which represents a Level&#160;2 measurement in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll-forward of the aggregate fair values of the Company&#x2019;s warrant liability and derivative liability, for which fair values are determined using Level&#160;3 inputs:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Embedded Derivative Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Embedded Derivative Liability&#x2014;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the embedded derivative liability recognized in connection with the Company&#x2019;s loan agreement with Hercules (see Note&#160;7), which is associated with additional fees due to Hercules upon events of default, was determined based on significant inputs not observable in the market, which represents a Level&#160;3 measurement within the fair value hierarchy. The fair value of this embedded derivative liability, which is reported within other non-current liabilities on the consolidated balance sheets, is estimated by the Company at each reporting date based, in part, on the results of third-party valuations, which were prepared based on a discounted cash flow model that considered the timing and probability of occurrence of a redemption upon an event of default, the potential amount of prepayment fees or contingent interest upon an event of default and the Company&#x2019;s risk-adjusted discount rate of 14%. As of December&#160;31, 2021 and December&#160;31, 2020, the fair value of this derivative liability was $821&#160;thousand and $455 thousand, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested quantitatively for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. During the fourth quarter of 2021, the Company&#x2019;s market capitalization, measured as the price of the Company&#x2019;s common stock multiplied by common shares outstanding, was below the value of the Company&#x2019;s net assets, including goodwill. As a result of the sustained decline in the market price of the Company&#x2019;s common stock, the fair value of the Company&#x2019;s single reporting unit, determined based on Company&#x2019;s market capitalization on December 31, 2021, was lower than its carrying value and the Company concluded that goodwill was impaired. Accordingly, the Company recorded an impairment charge of $9.8 million to reduce the carrying amount of goodwill to $17.4&#160;million as of December 31, 2021. Should the market value of the Company&#x2019;s common stock continue to decline, additional impairment charges may be recorded in the future. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a rollforward of the Company&#x2019;s goodwill and accumulated impairment losses.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, gross amount, at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment loss, at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzQxMjg_b750b653-8a0f-405d-85ef-1798e4afe419">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2021 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2020 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1f0240e57043459f99d9c4df35fbe4a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzMtMS0xLTEtMjA5NDA_d8e0449c-b939-499c-bb09-61ad981a8470"
      unitRef="usd">20000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iad1d2efd6bc94ac6831e430b69a1aaae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzMtMy0xLTEtMjA5NDA_89661581-5d0d-4c65-8ca8-4f7e77992b09"
      unitRef="usd">27793000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic0c66368b5a4481390647875c1cd56b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzMtNS0xLTEtMjA5NDA_a97109d0-2b10-4cc9-be23-5f2b9fb7cbe6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i41915bc16d8a42a0b9187f4f75b87df1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzMtNy0xLTEtMjA5NDA_6196ca80-e2f7-4dc7-8244-2e7bd4ca6a1e"
      unitRef="usd">47793000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1f0240e57043459f99d9c4df35fbe4a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzQtMS0xLTEtMjA5NDA_e3cc5517-d62c-467f-82c0-2fe7787ad997"
      unitRef="usd">20000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iad1d2efd6bc94ac6831e430b69a1aaae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzQtMy0xLTEtMjA5NDA_4580c453-2f5e-4634-8c92-1ebde7a30924"
      unitRef="usd">27793000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic0c66368b5a4481390647875c1cd56b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzQtNS0xLTEtMjA5NDA_b96eb2a9-739f-47da-8a27-c3b2a4bfa996"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i41915bc16d8a42a0b9187f4f75b87df1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzQtNy0xLTEtMjA5NDA_36ab0494-89e2-4bc1-ad0f-5d9971f4bd17"
      unitRef="usd">47793000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i1f0240e57043459f99d9c4df35fbe4a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzYtMS0xLTEtMjA5NDA_08202086-2fe5-4485-be51-6008dced5b7d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iad1d2efd6bc94ac6831e430b69a1aaae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzYtMy0xLTEtMjA5NDA_fb8014e7-42e5-4513-a9b4-55c95c67e04e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic0c66368b5a4481390647875c1cd56b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzYtNS0xLTEtMjA5NDA_f1e70f05-92fe-4833-93c5-b01e88ff748d"
      unitRef="usd">821000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i41915bc16d8a42a0b9187f4f75b87df1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzYtNy0xLTEtMjA5NDA_1c20acf7-ec7c-4e1f-bb2e-8b684563501d"
      unitRef="usd">821000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1f0240e57043459f99d9c4df35fbe4a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzctMS0xLTEtMjA5NDA_9cb3d801-dd1c-44ed-9cde-9949827669b9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iad1d2efd6bc94ac6831e430b69a1aaae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzctMy0xLTEtMjA5NDA_9f331b77-d608-4e76-8d75-61388d7f03d7"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic0c66368b5a4481390647875c1cd56b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzctNS0xLTEtMjA5NDA_d095593f-6ea1-4bfb-ba13-b38608fb56e2"
      unitRef="usd">821000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i41915bc16d8a42a0b9187f4f75b87df1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTpiOWRjY2QxMmVjZDY0ZDcyODlkNTQ5NWU0OWNhNjYyMS90YWJsZXJhbmdlOmI5ZGNjZDEyZWNkNjRkNzI4OWQ1NDk1ZTQ5Y2E2NjIxXzctNy0xLTEtMjA5NDA_b4597964-b569-42ce-b6c6-1a12d7ef94e4"
      unitRef="usd">821000</us-gaap:DerivativeLiabilities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id29e21fcd99849af88c7d951ec6f37ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzMtMS0xLTEtMjA5NDA_fd465a07-ca8c-4ce4-a4ab-43e1d84644cb"
      unitRef="usd">16816000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i52444c1398e14dcba086b4397b35d5a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzMtMy0xLTEtMjA5NDA_5e11dda6-e0db-4d74-b04d-2e1661354f61"
      unitRef="usd">28018000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibe6cb9ee46884d369d83ce82d8bf1038_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzMtNS0xLTEtMjA5NDA_0b8b15f9-df7f-4141-a74c-ac2f37a1980c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i280356e3a07941a2bcd0573cdc71bda1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzMtNy0xLTEtMjA5NDA_4ea26e70-a891-4fc7-8538-751704b3c685"
      unitRef="usd">44834000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id29e21fcd99849af88c7d951ec6f37ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzQtMS0xLTEtMjA5NDA_c3378028-7eff-44f6-82a8-f723d6b9fad5"
      unitRef="usd">16816000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i52444c1398e14dcba086b4397b35d5a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzQtMy0xLTEtMjA5NDA_80eafca5-4968-4591-ad29-25b552b09970"
      unitRef="usd">28018000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibe6cb9ee46884d369d83ce82d8bf1038_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzQtNS0xLTEtMjA5NDA_698dcde6-a7d3-4f13-b02e-81e326e23809"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i280356e3a07941a2bcd0573cdc71bda1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzQtNy0xLTEtMjA5NDA_820815f5-0c19-4d80-bff9-e3c4867c9683"
      unitRef="usd">44834000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia8b2e9b7ab3a498986022689b55633be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzYtMS0xLTEtMjA5NDA_ac5fca5f-05ac-44fb-8c46-5fd0ea8b4391"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic6aa3b74a39643e7b24682ca039984a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzYtMy0xLTEtMjA5NDA_8227dd92-eb0e-4662-ae08-455aad133b61"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i42028c40df934c66818f46c7b7a459d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzYtNS0xLTEtMjA5NDA_f09f45a6-cd9f-4a21-a3ee-3e3e8d25db12"
      unitRef="usd">455000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i92061fb2c1cd4c7cbb46ced4db254c28_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzYtNy0xLTEtMjA5NDA_1d1f84b6-a35a-4649-b3e4-ffbc448eb6a9"
      unitRef="usd">455000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id29e21fcd99849af88c7d951ec6f37ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzctMS0xLTEtMjA5NDA_8300ccb7-098c-4363-ace3-923ec17d1071"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i52444c1398e14dcba086b4397b35d5a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzctMy0xLTEtMjA5NDA_37486488-4c5c-4535-bd98-450a37c64604"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibe6cb9ee46884d369d83ce82d8bf1038_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzctNS0xLTEtMjA5NDA_50f19b1e-dbfc-43b8-8e66-072335827c38"
      unitRef="usd">455000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i280356e3a07941a2bcd0573cdc71bda1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTplNjY5ZWRlOGU3N2E0OWU4YmMzMGQ3MzI3MmRkOTkxNi90YWJsZXJhbmdlOmU2NjllZGU4ZTc3YTQ5ZThiYzMwZDczMjcyZGQ5OTE2XzctNy0xLTEtMjA5NDA_b012635c-1b60-43fc-89f4-a6bcf1f665f6"
      unitRef="usd">455000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzQxMjk_680099db-71ad-44c1-96ae-94ecbe72551a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll-forward of the aggregate fair values of the Company&#x2019;s warrant liability and derivative liability, for which fair values are determined using Level&#160;3 inputs:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Embedded Derivative Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id8b315bcebad4db0a5801ae168cf944a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTowMmMxNGQ5ZjA5ODY0NTYyYmYwN2RhMDhlZmIxNDA1Yi90YWJsZXJhbmdlOjAyYzE0ZDlmMDk4NjQ1NjJiZjA3ZGEwOGVmYjE0MDViXzQtMy0xLTEtMjA5NDA_82a521d0-6466-400f-9a03-e13b6a34cac1"
      unitRef="usd">18000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i12294001c3724c64a759185c687b58e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTowMmMxNGQ5ZjA5ODY0NTYyYmYwN2RhMDhlZmIxNDA1Yi90YWJsZXJhbmdlOjAyYzE0ZDlmMDk4NjQ1NjJiZjA3ZGEwOGVmYjE0MDViXzUtMy0xLTEtMjA5NDA_4a517bb8-0a0d-4fd4-8388-96150f3f0399"
      unitRef="usd">437000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7406aa31e3374111bed602d9d3287a73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTowMmMxNGQ5ZjA5ODY0NTYyYmYwN2RhMDhlZmIxNDA1Yi90YWJsZXJhbmdlOjAyYzE0ZDlmMDk4NjQ1NjJiZjA3ZGEwOGVmYjE0MDViXzYtMy0xLTEtMjA5NDA_dc9a4773-2d0a-4882-9753-2e0af3137902"
      unitRef="usd">455000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="ia84c45f7f16b4da88327ddbf122756a5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTowMmMxNGQ5ZjA5ODY0NTYyYmYwN2RhMDhlZmIxNDA1Yi90YWJsZXJhbmdlOjAyYzE0ZDlmMDk4NjQ1NjJiZjA3ZGEwOGVmYjE0MDViXzctMy0xLTEtMjE5NDA_18356007-e856-4fe4-9584-266432213a8b"
      unitRef="usd">366000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibb0a1ce7184c4d82850f7e0ca90dd59a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTowMmMxNGQ5ZjA5ODY0NTYyYmYwN2RhMDhlZmIxNDA1Yi90YWJsZXJhbmdlOjAyYzE0ZDlmMDk4NjQ1NjJiZjA3ZGEwOGVmYjE0MDViXzgtMy0xLTEtMjE5NDA_91a9acab-f5ee-4a72-84e7-0586cd5917b2"
      unitRef="usd">821000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilities
      contextRef="ic0c66368b5a4481390647875c1cd56b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzQxMDE_f1e70f05-92fe-4833-93c5-b01e88ff748d"
      unitRef="usd">821000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i42028c40df934c66818f46c7b7a459d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzQxMDg_f09f45a6-cd9f-4a21-a3ee-3e3e8d25db12"
      unitRef="usd">455000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzEwOTk1MTE2Mzk2NTM_2d6ec310-bf7c-4c02-917c-22d88444a931"
      unitRef="usd">9800000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzEwOTk1MTE2NDA1NjI_383680f8-0c49-4530-9419-ed03f8f9b20f"
      unitRef="usd">17400000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90ZXh0cmVnaW9uOmVlMTVhZWVkYmIyZTRkYjc4ODMxNGQzY2M3YTE1NTYyXzEwOTk1MTE2NDAzNjc_eb282c08-c3c8-4750-9754-91f2c0b1715c">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a rollforward of the Company&#x2019;s goodwill and accumulated impairment losses.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, gross amount, at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment loss, at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:GoodwillGross
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzEtMi0xLTEtMzAzNzU_59ba0a50-14f9-433d-ada6-66594768c9bb"
      unitRef="usd">27109000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzItMi0xLTEtMzAzODA_92a73d24-b457-45e5-922d-d672bd8e1236"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzQtNi0xLTEtMjkxOTY_b54002c4-2a0c-43bb-9500-a2f6508c1efa"
      unitRef="usd">27109000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzUtNi0xLTEtMjkxOTY_68106217-2ddc-447c-806d-262e623460fd"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzYtNi0xLTEtMjkxOTY_efabfb5b-9b00-4e3d-9d34-8a3d6ea80187"
      unitRef="usd">9758000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNTcvZnJhZzplZTE1YWVlZGJiMmU0ZGI3ODgzMTRkM2NjN2ExNTU2Mi90YWJsZTo5MDFjNGIxNjk1OGE0NjlmOTU4NjdlNzkwZmEzYmY1MC90YWJsZXJhbmdlOjkwMWM0YjE2OTU4YTQ2OWY5NTg2N2U3OTBmYTNiZjUwXzctNi0xLTEtMjkxOTY_126289a9-54c2-4a56-9daa-8bb64aba7126"
      unitRef="usd">17351000</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90ZXh0cmVnaW9uOmJmZjcwNTk0NGY4NTQ3ZjZhZTcxNDAyNTMyYTgxNDU4XzI2NA_9dcb5b45-99be-44d4-a1d2-e101a698085e">PROPERTY AND EQUIPMENT&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;Depreciation and amortization expense related to property and equipment was approximately $499 thousand, $351 thousand, and $103&#160;thousand for the years ended December 31, 2021, 2020 and 2019, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90ZXh0cmVnaW9uOmJmZjcwNTk0NGY4NTQ3ZjZhZTcxNDAyNTMyYTgxNDU4XzI2Mw_d1473b4e-5a63-4b5b-9413-303fcb385867">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if504bda89d6b40c4857f885c3a5dd5be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzEtMS0xLTEtMjA5NDA_9bc6edc9-e3a6-4df4-8fb4-e4f36d87034d"
      unitRef="usd">228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i05e4745ffaea4f638a14e69eb5e2e780_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzEtMy0xLTEtMjA5NDA_47db4429-3915-4700-bad4-65f6863c050b"
      unitRef="usd">228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iee282cd049d2469f96e0d412a363884a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzItMS0xLTEtMjA5NDA_46b58041-1061-4b10-a16d-0a145e9592a4"
      unitRef="usd">1251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ife90678c9c334675bb4fb9c5a64484fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzItMy0xLTEtMjA5NDA_c7a84bab-5a77-4e78-86f6-c0cc7fe8a516"
      unitRef="usd">910000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iad13cbd0ab104e089c980b940e3d7116_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzMtMS0xLTEtMjA5NDA_c3bc71f5-c908-4f65-9825-b0be7cf31ed1"
      unitRef="usd">150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie79fc5b3e5da4f21bc81f95a0112b9b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzMtMy0xLTEtMjA5NDA_cddfff24-88f8-4761-b524-ae0bae093021"
      unitRef="usd">47000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idc702a2739324d80b4ef222aca509be2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzQtMS0xLTEtMjA5NDA_13a5d065-4fee-4ced-943f-ffb48292338a"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie38293cc2bff405a9e1e6bc59761a28b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzQtMy0xLTEtMjA5NDA_a684f624-2c31-417f-a71a-3c7ed7283521"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i06df3f074d7447b6806efcb5f9c98d10_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzUtMS0xLTEtMjA5NDA_51c9b0fc-782b-4354-be0e-7f7d4a38f502"
      unitRef="usd">576000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iddc7cf15c96346e19207edcffa291f0c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzUtMy0xLTEtMjA5NDA_581c4b17-0ae4-46a9-b3fd-bdf9ce0267be"
      unitRef="usd">293000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzYtMS0xLTEtMjA5NDA_e43e16ec-cfac-4804-84e3-2dc010f61478"
      unitRef="usd">2238000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzYtMy0xLTEtMjA5NDA_ced03ebf-4715-402e-af49-be705a44329f"
      unitRef="usd">1511000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzctMS0xLTEtMjA5NDA_5ca6c871-24e3-4e80-934f-0eee84d49890"
      unitRef="usd">724000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzctMy0xLTEtMjA5NDA_71072401-aaeb-4158-98a4-ac3108f95c92"
      unitRef="usd">274000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzgtMS0xLTEtMjA5NDA_cbbf7999-7d24-43ef-bbac-edf721186d11"
      unitRef="usd">1514000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90YWJsZTphNTUwYjI5ODc0MGI0YzM4YmIxYzE1NWU1YjFjMmMyZi90YWJsZXJhbmdlOmE1NTBiMjk4NzQwYjRjMzhiYjFjMTU1ZTViMWMyYzJmXzgtMy0xLTEtMjA5NDA_58be4b24-464a-4bea-bd4e-1624ec290110"
      unitRef="usd">1237000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90ZXh0cmVnaW9uOmJmZjcwNTk0NGY4NTQ3ZjZhZTcxNDAyNTMyYTgxNDU4XzE3OQ_12750ced-9a54-44a5-97c1-1b1446a8af4e"
      unitRef="usd">499000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90ZXh0cmVnaW9uOmJmZjcwNTk0NGY4NTQ3ZjZhZTcxNDAyNTMyYTgxNDU4XzE4Mw_c61c0936-15f3-44d8-96b5-b663d6141eca"
      unitRef="usd">351000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjAvZnJhZzpiZmY3MDU5NDRmODU0N2Y2YWU3MTQwMjUzMmE4MTQ1OC90ZXh0cmVnaW9uOmJmZjcwNTk0NGY4NTQ3ZjZhZTcxNDAyNTMyYTgxNDU4XzE5MQ_24c57391-80fd-4c37-a4d7-f6653943422a"
      unitRef="usd">103000</us-gaap:DepreciationDepletionAndAmortization>
    <xfor:AccruedExpensesTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90ZXh0cmVnaW9uOjcyODY4ZGM5MjU4NTRiOTZiMWRkNWM5ZDkwOGM1MDJmXzY5_8d9de8d4-ad6b-4af3-80a2-9f916a3e4a08">ACCRUED EXPENSES&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</xfor:AccruedExpensesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90ZXh0cmVnaW9uOjcyODY4ZGM5MjU4NTRiOTZiMWRkNWM5ZDkwOGM1MDJmXzcw_f8a9f141-7a45-434e-bb05-9deb083506bb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzEtMS0xLTEtMjA5NDA_999fd609-33ca-4880-932d-2956e81b1683"
      unitRef="usd">5417000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzEtMy0xLTEtMjA5NDA_a0e08511-789e-4c58-8335-f6e7bead7098"
      unitRef="usd">3756000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <xfor:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzItMS0xLTEtMjA5NDA_e415eea4-42f9-47e1-b338-88cabdd42b46"
      unitRef="usd">1507000</xfor:AccruedExternalResearchAndDevelopmentExpenses>
    <xfor:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzItMy0xLTEtMjA5NDA_31537070-6c1e-4eac-a891-6f92e230e282"
      unitRef="usd">3150000</xfor:AccruedExternalResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzMtMS0xLTEtMjA5NDA_177ec833-825d-4c12-b26d-847da1f4da89"
      unitRef="usd">632000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzMtMy0xLTEtMjA5NDA_15b7d11b-b49a-42b1-bf57-ef257da7736e"
      unitRef="usd">627000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzQtMS0xLTEtMjA5NDA_f3a98ae8-79ab-4aa1-8f4c-ef21cc7262c4"
      unitRef="usd">314000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzQtMy0xLTEtMjA5NDA_8db89237-04d3-42d2-86d2-21f862b57486"
      unitRef="usd">485000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzUtMS0xLTEtMjA5NDA_6d83eaa5-4885-408d-9238-081daac35ebd"
      unitRef="usd">7870000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjMvZnJhZzo3Mjg2OGRjOTI1ODU0Yjk2YjFkZDVjOWQ5MDhjNTAyZi90YWJsZTowMzQ1N2UzOGJiNGM0NjZkYWUwMTM2NGM4NmEwMDg5ZS90YWJsZXJhbmdlOjAzNDU3ZTM4YmI0YzQ2NmRhZTAxMzY0Yzg2YTAwODllXzUtMy0xLTEtMjA5NDA_afa0a44e-a0af-4d1e-b5cc-b031370c6d6d"
      unitRef="usd">8018000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzkzNjA_261cd5be-cc87-4577-9a48-ffdbc4aa05bc">LONG-TERM DEBT&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt premium, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative accrual of end of term payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hercules Loan Agreements-&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into the Hercules Loan Agreement, as amended in June 2019, December 2019, March 2020, December 2020, and February 2022, with Hercules, under which the Company has borrowed an aggregate of $32.5&#160;million of term loans to date. The Hercules Loan Agreement provides for maximum borrowings of up to $50.0 million, which include, subject to Hercules investment committee&#x2019;s sole discretion, a right of the Company to request that Hercules make additional term loan advances in an aggregate amount of up to $17.5 million through December 31, 2022. Borrowings under the Hercules Loan Agreement accrue interest at a variable rate equal to the greater of (i)&#160;8.75%, or (ii)&#160;8.75% plus&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;prime rate minus 6.0%.&#160;&#160;In an event of default, and until such event is no longer continuing, the interest rate applicable to borrowings under the Amended and Restated Loan Agreement would be increased by 4.0%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Hercules Loan Agreement are repayable in monthly interest-only payments through January 1, 2023, and in equal monthly payments of principal and accrued interest from February 1, 2023 until the maturity date of the loan, which is July 1, 2024. The Company may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium of up to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0% &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the principal amount outstanding as of the date of repayment.&#160;In addition, the Hercules Loan Agreement provides for payments of $0.8 million, which was settled on January 1, 2022, $1.3&#160;million and $0.8&#160;million payable on July 1, 2023 and July 1, 2024, respectively, which payments are accelerated upon the prepayment of the borrowings upon the Company&#x2019;s election on upon default of the loan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the Company&#x2019;s personal property and other assets except for their intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Hercules Loan Agreement, effective as of the earlier of (a) certain specified events impacting the Company&#x2019;s Phase 3 trial of mavorixafor for the treatment of WHIM and (b) September 1, 2022, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount greater than or equal to the greater of $30.0 million or six multiplied by a metric based on prior months&#x2019; cash expenditures; provided, however, that from and after the Company&#x2019;s achievement of certain financing milestones through June 30, 2022, the Company must maintain cash in an account or accounts in which Hercules has a first priority security interest in an aggregate amount of $30.0 million. Following the achievement of certain operational performance milestones, the required level shall be reduced to the greater of $20.0 million, or, if the Company had not met the financing milestones noted above, three multiplied by the current cash expenditures metric; and provided further, that subject to the achievement of additional operational milestones, this covenant will be extinguished. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Hercules Loan Agreement restricts the Company&#x2019;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized interest expense under the Hercules Loan Agreement as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the years ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual effective interest rate on the Hercules Loan Agreement as of December&#160;31, 2021 is 10.7%. There were no principal payments due or paid under the Hercules Loan Agreement during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, future principal payments and accrued end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including end-of-term payments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzkzNjE_e596ee13-0375-4e13-873b-d213f30d1dbd">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt premium, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative accrual of end of term payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzEtMS0xLTEtMjA5NDA_c213fbd0-0d35-401b-acc4-50e4ba2c3bdb"
      unitRef="usd">32500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzEtMy0xLTEtMjA5NDA_0007bfc6-a1a6-450e-9a12-de82575a3766"
      unitRef="usd">32500000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzItMS0xLTEtMjA5NDA_1d9ccc8f-d117-4440-9ed7-47943d3f53be"
      unitRef="usd">-277000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzItMy0xLTEtMjA5NDA_4f0d568d-7eaa-4802-bdb8-e186e849c5f3"
      unitRef="usd">-223000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <xfor:AccretionOnLongTermDebt
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzMtMS0xLTEtMjA5NDA_2391077b-43aa-4ad2-9be5-92d38d54f795"
      unitRef="usd">-1157000</xfor:AccretionOnLongTermDebt>
    <xfor:AccretionOnLongTermDebt
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzMtMy0xLTEtMjA5NDA_b15a4ad2-73f9-4f58-be72-b793ca0bdec5"
      unitRef="usd">-455000</xfor:AccretionOnLongTermDebt>
    <xfor:LongTermDebtIncludingAccretion
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzQtMS0xLTEtMjA5NDA_50762749-50d4-42c5-bdae-21bedfd18adc"
      unitRef="usd">33934000</xfor:LongTermDebtIncludingAccretion>
    <xfor:LongTermDebtIncludingAccretion
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzQtMy0xLTEtMjA5NDA_ca25c375-f4ab-42dc-84ee-d4b50d95f3f5"
      unitRef="usd">33178000</xfor:LongTermDebtIncludingAccretion>
    <us-gaap:LongTermDebtCurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzUtMS0xLTEtMjIwNDE_887f25d6-214d-4dab-aecd-afa0379ba15b"
      unitRef="usd">795000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzUtMy0xLTEtMjIwNTk_0495613f-3b4a-4f0d-9ffb-2f90eb658b22"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzYtMS0xLTEtMjIwNDE_e9b5f40c-e713-43f4-8314-5538b75abb01"
      unitRef="usd">33139000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZToxNTJmMjQyMmMwOGY0ZDNiOTU2NzdhYzE1MjEzM2FmMS90YWJsZXJhbmdlOjE1MmYyNDIyYzA4ZjRkM2I5NTY3N2FjMTUyMTMzYWYxXzYtMy0xLTEtMjIwNTk_09e15300-2830-4cca-b6ce-ab01341fdb43"
      unitRef="usd">33178000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i0e2a6d6e83924b2daa8ee08212fd793d_D20181001-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NTE2Nzk_8ff4a9db-0feb-48c5-ba11-b393139c0922"
      unitRef="usd">32500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6605f338210c4eb6af0923abf8445fec_I20201221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2Mzk3MzM_53691066-140a-4195-bc8c-85627242e547"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="ia221aaf88dc34cd18ee78f500786ae65_I20201221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDAxOTM_81ef8c44-8456-4af1-9262-7581b3235ff6"
      unitRef="usd">17500000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="i441b3dd525cf4ccba63a00aba76d1e05_D20190601-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2MzkzNDU_0204841f-e472-4931-a479-2078cf7c3c25"
      unitRef="number">0.0875</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iedf2b97d940c42ffbf9fc1761bc75923_D20190601-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2MzkzNTc_b1fcf7bc-7281-4eb3-a72f-b95e588a9d66"
      unitRef="number">0.0875</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="i4cd6cf3938894c7ebded737f6ab8df03_D20190601-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2Mzk0MDc_4a4d92e0-50d6-4220-a9b2-657741eac762"
      unitRef="number">0.060</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="i441b3dd525cf4ccba63a00aba76d1e05_D20190601-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2Mzk2NDk_d2ba2ba8-105a-410e-9df3-18e90011f9e1"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <xfor:DebtInstrumentPrePaymentPremiumPercentage
      contextRef="i03e6b6f8a9c740948d0f053e9e9b88c3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzI3NDg3NzkwOTM0MjY_b5b1cfe6-2b46-44bb-b020-2cf7c64d1d04"
      unitRef="number">0.010</xfor:DebtInstrumentPrePaymentPremiumPercentage>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="i58af1e2574894b2ea2b9227befb6de70_D20220101-20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDA4ODk_41538761-77f4-4ddd-9821-b75f3a89a37c"
      unitRef="usd">800000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="i044152b2a50d4484a5e19b0c3e40e9a3_D20230701-20230701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDA4OTQ_4bf0b420-3fbe-4efd-b578-72c1a8d1061c"
      unitRef="usd">1300000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="i1e9fe3e1ad55446c8ece9e5d397f6127_D20240701-20240701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDA5MDI_23e5a9e3-9149-474d-906f-a7e47c7074f3"
      unitRef="usd">800000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <xfor:LineOfCreditCovenantMinimumCash
      contextRef="i815e2b3d5b21461cb22c4cf956eab5d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDM0NjA_b2c75f00-635f-4a8b-9ec1-f10288bd60df"
      unitRef="usd">30000000</xfor:LineOfCreditCovenantMinimumCash>
    <xfor:LineOfCreditCovenantMinimumCash
      contextRef="i815e2b3d5b21461cb22c4cf956eab5d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NTI0NDM_b2c75f00-635f-4a8b-9ec1-f10288bd60df"
      unitRef="usd">30000000</xfor:LineOfCreditCovenantMinimumCash>
    <xfor:LineOfCreditCovenantMinimumCash
      contextRef="ie8783c36c8464089a5c02a0e660c689e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzEwOTk1MTE2NDM2OTk_99cc5c5f-c655-4e70-bd74-61c09b738fa7"
      unitRef="usd">20000000</xfor:LineOfCreditCovenantMinimumCash>
    <us-gaap:InterestExpenseDebt
      contextRef="i82a84700b1c1468b831735d87f46a242_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzItMS0xLTEtMjIzNTE_867f551d-a0d3-4064-ac5e-527514b3f5d2"
      unitRef="usd">3642000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ie11078f4d8a0419ea19c205259a627ba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzItMy0xLTEtMjIzNTE_993c58b1-5a1d-4391-b1b6-469aeb9b5199"
      unitRef="usd">2686000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i21716a46c2a345a29fc88ac84ad6249e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzItNS0xLTEtMjIzNTE_9e42fed2-06d9-4356-8ddd-0862fbd48a40"
      unitRef="usd">1807000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i82a84700b1c1468b831735d87f46a242_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzMtMS0xLTEtMjIzNTE_54f4967e-ce0d-4682-95e2-98e3baecc968"
      unitRef="usd">756000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ie11078f4d8a0419ea19c205259a627ba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzMtMy0xLTEtMjIzNTE_e8869c39-191c-40be-bba0-93db97fd50c4"
      unitRef="usd">531000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i21716a46c2a345a29fc88ac84ad6249e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTpmMzdmYTBmMzRjMDc0NDA1OGQ0MjE1Y2Q2OWI2M2MwMC90YWJsZXJhbmdlOmYzN2ZhMGYzNGMwNzQ0MDU4ZDQyMTVjZDY5YjYzYzAwXzMtNS0xLTEtMjIzNTE_e9cbfa57-cbf0-4ffb-a232-43e7fec932a3"
      unitRef="usd">414000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i03e6b6f8a9c740948d0f053e9e9b88c3_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzkxMjM_0ac3c7bc-e0c0-449e-976b-8749f4fab583"
      unitRef="number">0.107</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="i7f823743b9a246098193cea2dbb84829_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzkxNDM_a06edf4b-ff78-4932-9bf5-a20c0a91ab0a"
      unitRef="usd">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90ZXh0cmVnaW9uOmY3NzczOTA4NjhiNjRlOTJhZWY3MGFiZGJlYWMxZjJlXzkzNjI_b5b4570b-4e9e-40ac-9c40-619d8a91674d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, future principal payments and accrued end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including end-of-term payments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTo4ZGY3NGZlNDdhNzQ0MGFjODQwODZlNGM1NDQwMzY1Zi90YWJsZXJhbmdlOjhkZjc0ZmU0N2E3NDQwYWM4NDA4NmU0YzU0NDAzNjVmXzEtMS0xLTEtMjA5NDA_794261e6-8ec9-48c0-8888-305f9334e7b7"
      unitRef="usd">795000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTo4ZGY3NGZlNDdhNzQ0MGFjODQwODZlNGM1NDQwMzY1Zi90YWJsZXJhbmdlOjhkZjc0ZmU0N2E3NDQwYWM4NDA4NmU0YzU0NDAzNjVmXzItMS0xLTEtMjA5NDA_1eabb795-b0f9-4cb7-825f-567d75306d5b"
      unitRef="usd">21471000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTo4ZGY3NGZlNDdhNzQ0MGFjODQwODZlNGM1NDQwMzY1Zi90YWJsZXJhbmdlOjhkZjc0ZmU0N2E3NDQwYWM4NDA4NmU0YzU0NDAzNjVmXzMtMS0xLTEtMjA5NDA_bc2514e7-4d76-41be-8959-81385364a411"
      unitRef="usd">11391000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjYvZnJhZzpmNzc3MzkwODY4YjY0ZTkyYWVmNzBhYmRiZWFjMWYyZS90YWJsZTo4ZGY3NGZlNDdhNzQ0MGFjODQwODZlNGM1NDQwMzY1Zi90YWJsZXJhbmdlOjhkZjc0ZmU0N2E3NDQwYWM4NDA4NmU0YzU0NDAzNjVmXzUtMS0xLTEtMjA5NDA_594a3ebd-5e40-48c8-9a27-8878c5c5fa13"
      unitRef="usd">33657000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzY1MTc_cc37db75-7569-4691-82ea-47693575f256">LEASES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements for its facilities in Boston, Massachusetts, which is the Company&#x2019;s principal executive offices; Vienna, Austria, which is the Company&#x2019;s research and development center; and Waltham, Massachusetts, which the Company has sublet to a third party. The Company previously had a lease agreement for a facility in Cambridge, Massachusetts, which served as its prior corporate headquarters. There are no restrictions or financial covenants associated with any of the lease agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Boston Lease&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company leases approximately 28,000 square feet of office space in Boston, Massachusetts (&#x201c;Boston Lease&#x201d;), which leased was entered into in November 2019 and serves as the Company&#x2019;s headquarters. Base rental payments are approximately $1.0 million annually, plus certain operating expenses.  The term of the Boston Lease will continue until November 2026, unless earlier terminated. The Company has the right to sublease the premises, subject to landlord consent and also has the right to renew the Boston Lease for an additional five years at the then prevailing effective market rental rate. The Company is required to maintain a security deposit in the form of a letter of credit for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.9&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the benefit of the landlord.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Boston lease, the Company participated in the construction of the office space and incurred construction costs to prepare the office space for its use, which have been partially reimbursed by the landlord. The Company concluded that these construction costs generate and enhance the landlord&#x2019;s assets, and, as such, unreimbursed construction costs incurred to prepare the office space for its use have been classified a part of the right-of-use asset. The commencement date for the Boston Lease was September 1, 2020 upon substantial completion of the landlord's asset. On the commencement date, the Company recognized a lease liability of $4.6&#160;million reflecting the future rent payments for the term of the Boston Lease discounted at the Company&#x2019;s collateralized borrowing rate, and a right-of-use asset of $8.0&#160;million measured as the lease liability plus rent payments made and unreimbursed construction costs incurred prior to the commencement date. The Company began recognizing rent expense &#160;&#160;&#160;&#160;following the commencement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Waltham Lease&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 6,000 square feet of office space in Waltham, Massachusetts (&#x201c;Waltham Lease&#x201d;). The Waltham Lease, as amended, commenced on January 1, 2019, and expires approximately 5 years from the commencement date. The base rent is approximately $263&#160;thousand annually. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#x2019; right-of-use assets or lease liabilities. The Company is subleasing the space to a third party for the duration of the lease. The right-of-use asset is being amortized to rent expense over the 5 year term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Vienna Austria Leases&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has an operating lease, as amended, for approximately 400 square meters of laboratory and office space in Vienna, Austria, which commenced on March 1, 2019, as amended, for a term of 2 years terminating in April 2021. The annual base rent for the previous lease was approximately $154&#160;thousand. In September 2020, the Company entered into a new operating lease for approximately 1,200 square meters of laboratory and office space in Vienna, Austria (&#x201c;Vienna Lease&#x201d;), which commenced in February 2021 following construction of laboratory and office space for a term of 7 years. The Company contributed $709 thousand to building improvements, which are classified as part of the right-of-use asset. The Company recorded a right-of-use asset and associated lease liabilities upon the commencement of the Vienna Lease in the first quarter of 2021. The annual base rent for the Vienna Lease, following a 6-month rent free period, will be approximately $300 thousand. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cambridge Lease&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; In August 2017, the Company entered into a non-cancellable operating lease agreement for office space of&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately 13,000 square feet in Cambridge, Massachusetts (&#x201c;Cambridge Lease&#x201d;), which had an original expiration date of&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;July 31, 2022. Base rent was approximately $832&#160;thousand annually and the monthly rent expense was recognized on a straight-line basis over the term of the lease as the Company amortizes the associated operating lease right-of-use asset. The Company reached an agreement with the landlord on July 17, 2020 to terminate the lease effective September 30, 2020 in exchange for a fee. The Company accounted for the lease modification prospectively from the date of the termination through the new lease termination date of September 30, 2020, at which time the right-of-use asset and associated lease liabilities were retired from the consolidated balance sheet. The Company was required to maintain a letter of credit of $264&#160;thousand, secured by restricted cash, for the benefit of the landlord through December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the three years ended December&#160;31, 2021, 2020, and 2019 were as follows (dollars in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt; For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%"&gt;Leased assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:97%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities due under lease agreements that have commenced as of December&#160;31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <xfor:CurrentOfficeSpaceUnderLeaseAgreement
      contextRef="i70dd855dda9a41448556d07389f6ef62_D20191111-20191111"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzQ5NDc4MDIzNTU4NTc_36e6d722-b394-4ec1-9b87-8eb01e9b95e1"
      unitRef="sqft">28000</xfor:CurrentOfficeSpaceUnderLeaseAgreement>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="i70dd855dda9a41448556d07389f6ef62_D20191111-20191111"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzQ5NDc4MDIzNTU4NTg_65f2f88c-2cd5-4c97-a639-7c29091bc3c5"
      unitRef="usd">1000000</xfor:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="iec7ca8d65d8941a693c86e1d5e2e006d_I20191111"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzQ5NDc4MDIzNTU4NTk_152146b9-7455-4ae2-be39-1449185f8e43">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace
      contextRef="i96305963db034551a189b94796a2792a_D20190313-20190313"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzIxODU_e611d172-452c-425d-8001-cd55fc3ceeef"
      unitRef="sqft">6000</xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i649b92ccef0a45d48c9c43fe57d79944_I20190313"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzIzMzU_a5c5ec97-557c-4c9c-b20d-268643f23924">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <xfor:AggregateBaseRent
      contextRef="i96305963db034551a189b94796a2792a_D20190313-20190313"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzIzOTc_1c8ddee7-37a7-4c4c-8c15-0f9ba480bdfb"
      unitRef="usd">263000</xfor:AggregateBaseRent>
    <xfor:OperatingLeaseRightOfUseAssetAmortizationTerm
      contextRef="ie206b7a7c0f04cad9646717d502a7f9d_D20190313-20190313"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzI4MDI_85e6819d-6933-487f-826d-fefc07e7f000">P5Y</xfor:OperatingLeaseRightOfUseAssetAmortizationTerm>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace
      contextRef="ib03c7b0ffaa94e54a5fcb3da8d3bffcd_D20190313-20190313"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzI5MTg_228dbe01-c1a4-4ab6-8c0a-c6471892f024"
      unitRef="sqft">400</xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ibdb04900d7d94d69b89541fbd440e0f4_I20190313"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzMwNDg_f6c64689-fae7-426c-986a-22802c1408c6">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <xfor:AggregateBaseRent
      contextRef="ib03c7b0ffaa94e54a5fcb3da8d3bffcd_D20190313-20190313"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzMxMzE_e0de4d08-2024-4209-9dc6-b83b7227ee4c"
      unitRef="usd">154000</xfor:AggregateBaseRent>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace
      contextRef="i30884f0e4d634f7b8bc5bacaa38c8f3e_D20200901-20200901"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzM0NDE_663d1477-f839-4b2f-9abb-5bae40d25917"
      unitRef="sqft">1200</xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ief7e7ceedd0a4127b22dedc2456e45ed_I20200901"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzM1NzM_27d1f1b4-769d-4768-b4e0-1f3e1a5b7fb4">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <xfor:LesseeOperatingLeaseRentFreePeriod
      contextRef="i5dfd25fd846b472ba0ec52e244589a8e_D20210201-20210731"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzM3Njg_3e1d7690-af18-443c-be46-1e4aa4055dd6">P6M</xfor:LesseeOperatingLeaseRentFreePeriod>
    <xfor:AggregateBaseRent
      contextRef="i30884f0e4d634f7b8bc5bacaa38c8f3e_D20200901-20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzM4MTc_5cf039aa-0b24-42f8-9543-82fb68407879"
      unitRef="usd">300000</xfor:AggregateBaseRent>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace
      contextRef="i7af38d4d2ff7443faf6ac2b41a13a62e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzQ5NDc4MDIzNTU4NzM_a625449c-f45b-4be1-b5bf-11d47f5666cc"
      unitRef="sqft">13000</xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace>
    <xfor:AggregateBaseRent
      contextRef="i7af38d4d2ff7443faf6ac2b41a13a62e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzQ5NDc4MDIzNTU4ODE_84652321-65f7-4e5a-9413-75530bbb49b6"
      unitRef="usd">832000</xfor:AggregateBaseRent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzY1MTg_b5d05669-3916-40d6-a99a-a1a6122479e2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the three years ended December&#160;31, 2021, 2020, and 2019 were as follows (dollars in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt; For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:97%"&gt;Leased assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:97%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzItMi0xLTEtMjA5NDA_df811954-249d-471c-b0da-0204c4fb8ca2"
      unitRef="usd">2087000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzItNC0xLTEtMjA5NDA_3290b3f1-76bb-441e-a8b6-1c9fc40683f1"
      unitRef="usd">1290000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzItNi0xLTEtMjY2MDY_e49edd92-91ef-4a1b-a63e-ca2bf55fca01"
      unitRef="usd">827000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzMtMi0xLTEtMjA5NDA_d7a13d3a-ab8e-414b-a571-b31af66766bc"
      unitRef="usd">42000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzMtNC0xLTEtMjA5NDA_a4068e34-6c95-461d-8e5d-0ccfee5b7532"
      unitRef="usd">157000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzMtNi0xLTEtMjY2MjU_9c10ff56-38cc-4218-825b-03d9fd382276"
      unitRef="usd">122000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzQtMi0xLTEtMjA5NDA_9cf5c70a-b530-401f-94ce-c7c8c97bade4"
      unitRef="usd">2129000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzQtNC0xLTEtMjA5NDA_3c894205-de91-48f6-a844-7f751bdb1e31"
      unitRef="usd">1447000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzQtNi0xLTEtMjY2MzI_0cd89f93-47bf-4975-80e0-a186eb9f27f1"
      unitRef="usd">949000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzctMi0xLTEtMjA5NDA_a76f78af-384f-4a92-b6e7-dacd35448ac6"
      unitRef="usd">1257000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzctNC0xLTEtMjA5NDA_c38e92d1-6fd8-4f08-b652-f2e0edb0f0d4"
      unitRef="usd">3820000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzctNi0xLTEtMjY2Mzk_ed3a49a7-dccf-4fac-a68c-6cb137c6e050"
      unitRef="usd">1007000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzgtMi0xLTEtMjA5NDA_aca0ffbf-42c9-4a8b-be0a-52c2810514eb"
      unitRef="usd">1343000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzgtNC0xLTEtMjA5NDA_f5ed7876-ef0d-4bff-9214-6a8409752ebe"
      unitRef="usd">5090000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzgtNi0xLTEtMjY2NDY_74735c6d-ddf1-4b49-88fd-4f4ca2361dff"
      unitRef="usd">484000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzktMi0xLTEtMjA5NDA_8f46ec62-7f11-4249-a14c-5b1241564d85">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzktNC0xLTEtMjA5NDA_888e780a-5637-4ab5-ae25-0bd014534e21">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzktNi0xLTEtMjY2NTM_0f9d9568-75f0-46db-9016-c5899d5eb401">P3Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzEwLTItMS0xLTIwOTQw_148293db-d11f-4b16-9542-c2af17930089"
      unitRef="number">0.113</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzEwLTQtMS0xLTIwOTQw_b8bff499-ece9-4379-b96a-7b1e04d670cf"
      unitRef="number">0.112</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzEwLTYtMS0xLTI2NjYw_e76acbee-377e-4854-b0a3-7cf91cfa0dd7"
      unitRef="number">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:SubleaseIncome
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzExLTItMS0xLTIwOTQw_c959da6a-af4b-4fcd-af4a-4eff2f912fda"
      unitRef="usd">196000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzExLTQtMS0xLTIwOTQw_0d4ff793-4099-468c-b2da-ea604938fb95"
      unitRef="usd">194000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTo4MTU4YmFmOTk5MTY0OTgzYTNjZmFjYmM2ZjQ3NWQwZS90YWJsZXJhbmdlOjgxNThiYWY5OTkxNjQ5ODNhM2NmYWNiYzZmNDc1ZDBlXzExLTYtMS0xLTI2NjY3_7e282d5c-2122-48b5-92a7-63db425fd3bb"
      unitRef="usd">14000</us-gaap:SubleaseIncome>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90ZXh0cmVnaW9uOjExN2IxNGU4N2VkYzQxMTZhYWQ2MGM1ZDdjMzAwODE1XzY1MTQ_515786ed-2bdc-4b07-b5f0-f150f606ecb8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities due under lease agreements that have commenced as of December&#160;31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.264%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzEtMS0xLTEtMjA5NDA_9b20420e-6fed-46cf-9a85-50d1f97c9e54"
      unitRef="usd">1596000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzItMS0xLTEtMjA5NDA_836f8d70-4229-44ea-9b5a-f3ad979442d2"
      unitRef="usd">1625000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzMtMS0xLTEtMjA5NDA_d88c0eec-024f-4fba-808c-4d70c10700c9"
      unitRef="usd">1390000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzQtMS0xLTEtMjA5NDA_54847360-329b-48dd-906e-0bfe9dcf4ab2"
      unitRef="usd">1418000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzUtMS0xLTEtMjA5NDA_79a1de07-34de-4b41-beee-ffdd579c9b35"
      unitRef="usd">1693000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzYtMS0xLTEtMjA5NDA_daca3dca-8c1b-4a82-b4e9-73280e66f487"
      unitRef="usd">7722000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzctMS0xLTEtMjA5NDA_e64b7c92-160e-44e6-b477-817b14a88dfc"
      unitRef="usd">1871000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNjkvZnJhZzoxMTdiMTRlODdlZGM0MTE2YWFkNjBjNWQ3YzMwMDgxNS90YWJsZTpkMWNmOTQxYThkNzU0MjFjYmZkMzBkM2M4OTliYmQ3OS90YWJsZXJhbmdlOmQxY2Y5NDFhOGQ3NTQyMWNiZmQzMGQzYzg5OWJiZDc5XzgtMS0xLTEtMjA5NDA_cb673c2c-6b2f-487a-8c9b-82a1e375870d"
      unitRef="usd">5851000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzIvZnJhZzpiOGQ4NGM4MzU3Yzk0ZmIxYjViMTgyNmZmODFjMjU1YS90ZXh0cmVnaW9uOmI4ZDg0YzgzNTdjOTRmYjFiNWIxODI2ZmY4MWMyNTVhXzMwNzE_59183d0d-6681-466d-9ddb-56a2eaa2d816">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with clinical research organizations (&#x201c;CROs&#x201d;) pursuant to which the Company and the CROs are conducting clinical trials of mavorixafor&#160;for the treatment of WHIM syndrome, Waldenstr&#xf6;m&#x2019;s and CN. The Company may terminate these agreements by providing notice pursuant to the contractual provisions of such agreements and would incur early termination fees. The Company also has agreements with contract manufacturing organizations (&#x201c;CMOs&#x201d;) for the production of mavorixafor for use in clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreements. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See Note 3 for a summary of the Company&#x2019;s license agreements, which commit the Company to contingent milestone and royalty fees based on future operational events. In March 2021, the Company terminated its license agreement with Adimab LLC and has no further obligations on the agreement. &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Agreements&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzQ5NDc4MDIzMzYxMDI_4e8f10b1-9a35-42ab-8142-7d19eb7c3b7d">PREFERRED AND COMMON STOCK WARRANTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Merger, the Company issued warrants for the purchase of its preferred stock and had classified these preferred stock warrants as a liability on its consolidated balance sheet as the warrants were deemed to be freestanding financial instruments that may have required the Company to transfer assets upon exercise. The liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and was subsequently remeasured to fair value as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss. Upon the closing of the Merger, pursuant to the Merger Agreement, all of the outstanding X4 preferred stock was converted to common stock and the X4 preferred stock warrants converted to warrants for the purchase of common stock. The Company assessed the features of the warrants and determined that they qualified for classification as permanent equity upon the closing of the Merger. Accordingly, the Company remeasured the warrants to fair value upon the closing of the Merger, which was $5.2&#160;million at March&#160;13, 2019, with $288&#160;thousand of expense recorded during the three months ended March&#160;31, 2019. Upon the closing of the Merger, the warrant liability was reclassified to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its issuance of common stock in public offerings that closed on April 16, 2019 and November 29, 2019, the Company issued 3,900,000 Class A warrants, which are exercisable for shares of the Company's common stock, and 5,416,667 Class B warrants, which are exercisable for shares of the Company's common stock or prefunded warrants to purchase shares of the Company's common stock. The Class A warrants have an exercise price of $13.20 per warrant, expire on April 15, 2024 and were immediately exercisable upon issuance. The Class B warrants were immediately exercisable upon issuance, had an initial exercise price of $15.00 per share and expire on a date that is the earlier of (a) the date that is 30 calendar days from the date on which the Company issues a press release announcing top-line data from its Phase 3 clinical trial of mavorixafor for the treatment of patients with WHIM syndrome (or, if such date is not a business day, the next business day) and (b) November 28, 2024. The Class B warrants have a contingent price adjustment feature pursuant to which the exercise price of the Class B warrants is adjusted to the lowest weighted average offering price at which the Company sells its common stock or certain securities convertible into or exercisable for the Company&#x2019;s common stock in one or more subsequent offerings, if the weighted average offering price for such offering is below $15.00. As a result of the sales of the Company&#x2019;s stock at below $15.00 during the year ended December 31, 2021, the exercise price of the Class B Warrants was ultimately adjusted to $3.65. On March 23, 2021, the Company completed a private placement sale of its common stock priced at $8.70 and in the fourth quarter of 2021, the Company sold shares of its common stock at various price points, the lowest of which was $3.65. Accordingly, the exercise price of the Class B warrants was ultimately adjusted to $3.65 as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, in connection with the sale of its common stock in a private placement, the Company issued pre-funded warrants to purchase an aggregate of 50,000 shares of common stock at a price of $8.70 per share of common stock (or $8.69 per pre-funded warrant). The price per pre-funded warrant represents the price of $8.70 per share sold in the private placement, minus the $0.01 per share exercise price of each such pre-funded warrant. The pre-funded warrants are exercisable, subject to certain beneficial ownership restrictions, at any time after their original issuance and will not expire. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company entered into a securities purchase agreement pursuant to which it agreed to issue and sell to an investor, in a private placement, pre-funded warrants to purchase an aggregate of 2,008,032 shares of the Company&#x2019;s common stock at a purchase price of $4.97 per pre-funded warrant (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;representing the price of $4.98 per share in the private placement, minus the $0.01 per share exercise price of each such pre-funded warrant)&lt;/span&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The pre-funded warrants are exercisable at any time after their original issuance and will not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of outstanding warrants for the period ended December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Number of warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable as of  December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,354,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,058,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,130,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,257,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company&#x2019;s outstanding warrants to purchase shares of common stock consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.735%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Common&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Stock Issuable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 25, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 24, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 28, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 28, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 12, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 19, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 19, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 13, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 12, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 16, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,866,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,416,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 28, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 23, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 9, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,008,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,257,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a) In November 2019, the Company received $11.999 per pre-funded warrant, or $21.0 million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.001 per pre-funded warrant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(b) In March 2021, the Company received $8.69 per pre-funded warrant, or $435 thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(c) In November 2021, the Company received $4.97 per pre-funded warrant, or $10.0 million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i8f4a3cbd5679460ab78ce920e0af42b2_I20190313"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzExNTE_1a0cc4ea-6a05-48bc-ae4a-a36b4aa5cc36"
      unitRef="usd">5200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i8b1ee4ca82b14441a5df67868c7c2fee_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzExNzg_3111a7db-668d-4d45-a4fd-020882980af1"
      unitRef="usd">288000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <xfor:ClassOfWarrantOrRightIssued
      contextRef="i8f4b97ac998545cd8301f39db19e7d4d_D20190416-20190416"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzE0ODk_663070fc-b0a0-494c-9a53-1bdc624c60a2"
      unitRef="shares">3900000</xfor:ClassOfWarrantOrRightIssued>
    <xfor:ClassOfWarrantOrRightIssued
      contextRef="i5a1dd2dc5c7e49e4a433ec1811b9e03c_D20191129-20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzE1Nzg_994aa8d8-e8b9-4b94-9756-3310d1acd091"
      unitRef="shares">5416667</xfor:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9f1955aa1b534854878550a58ccbf898_I20190416"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzE3ODE_053dfafe-e329-4d6b-bae7-3df867a7b366"
      unitRef="usdPerShare">13.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i30903cfad3dd426ab86057983e126f26_I20191129"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzE5NTc_3e89c92b-0fb4-43cd-ac6e-abd0e1d3b7fa"
      unitRef="usdPerShare">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod
      contextRef="i5faaf777d178421b83561c0fd16627c8_D20191126-20191126"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzIxMDM_6966d187-5ef8-4e12-94a1-c5e33879845f">P30D</xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i30903cfad3dd426ab86057983e126f26_I20191129"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODgwMzA_3e89c92b-0fb4-43cd-ac6e-abd0e1d3b7fa"
      unitRef="usdPerShare">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i30903cfad3dd426ab86057983e126f26_I20191129"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzE2NDkyNjc0NDgxODk_3e89c92b-0fb4-43cd-ac6e-abd0e1d3b7fa"
      unitRef="usdPerShare">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2MzUwMzk_db32f683-b169-4131-82e0-5d5c8badd82f"
      unitRef="usdPerShare">3.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg3OTc_fac2fc83-c8a3-48ec-8eb8-277aec0b64df"
      unitRef="usdPerShare">3.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg3OTg_3b94a08a-18bf-4200-9aab-6de31f67eaad"
      unitRef="usdPerShare">3.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie12ba0825f69455cbb72564897ee2268_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4MDY_cf396b2e-378a-40cf-8601-d75884205ed1"
      unitRef="shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i997f64043d3c48f79904457d31ed425b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4MTU_26302f55-00ce-41f5-9a55-3dd1c75ae92d"
      unitRef="usdPerShare">8.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i358bda413e094c3b8732326b0da80424_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4MzM_46834671-68c5-4726-8b58-dda58e7fa4c6"
      unitRef="usdPerShare">8.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i997f64043d3c48f79904457d31ed425b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4MjQ_26302f55-00ce-41f5-9a55-3dd1c75ae92d"
      unitRef="usdPerShare">8.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="ib4dbd5cea64e45acb7901cd8377332fd_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4NDQ_4107738c-4107-4343-80c8-4d90323904ee"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iffc0e7e2a65446eaaa63bbb1c1af5689_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4NTg_c4c737a7-4a7a-4a8c-8abe-a91cd7c5de97"
      unitRef="shares">2008032</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i445218cd5fbd4b9cb04297a8f4e11d1d_I20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4NjY_7e2f45db-09da-422f-9a3b-659087cfaed0"
      unitRef="usdPerShare">4.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iffc0e7e2a65446eaaa63bbb1c1af5689_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4ODM_fc07253f-75ab-4e15-8eea-bc248bec20d7"
      unitRef="usdPerShare">4.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i4b714c637a6647028b196f7cbd99f053_I20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzEwOTk1MTE2Mzg4NzU_be201be2-234b-402d-91d5-d767faa29a6d"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <xfor:ScheduleOfOutstandingWarrantsTableTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMzNjE_80003a11-8f03-43f4-b9ab-9dff0cbbc5c9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of outstanding warrants for the period ended December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Number of warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable as of  December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,354,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,058,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,130,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,257,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xfor:ScheduleOfOutstandingWarrantsTableTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzUtMS0xLTEtMjA5NDA_d8b91f98-956e-44ba-8f28-d5ed3ace036c"
      unitRef="shares">13354403</us-gaap:ClassOfWarrantOrRightOutstanding>
    <xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzUtMy0xLTEtMjA5NDA_b28b884a-e75f-454e-af1e-cc0f742e02bd"
      unitRef="usdPerShare">13.52</xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzUtNS0xLTEtMjA5NDA_b09cf4c4-ae6a-4fef-adc9-963903381e55">P3Y8M12D</xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm>
    <xfor:ClassOfWarrantOrRightIssued
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzYtMS0xLTEtMjA5NDA_61fdb862-e5e8-4269-8799-89b275d6cadf"
      unitRef="shares">2058032</xfor:ClassOfWarrantOrRightIssued>
    <xfor:ClassOfWarrantOrRightExercised
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzUtMS0xLTEtMjM5Njk_7e840ed9-c900-4b85-8e09-3f4b9098579d"
      unitRef="shares">2130000</xfor:ClassOfWarrantOrRightExercised>
    <xfor:ClassOfWarrantOrRightExpired
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzYtMS0xLTEtMjM5OTM_4050bda9-b5c2-4aa0-b70f-6a8f93a3b5c3"
      unitRef="shares">25275</xfor:ClassOfWarrantOrRightExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzctMS0xLTEtMjA5NDA_0c3e0594-8d20-42b4-820a-0aa39e4359f6"
      unitRef="shares">13257160</us-gaap:ClassOfWarrantOrRightOutstanding>
    <xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzctMy0xLTEtMjA5NDA_57bcc236-1e3e-4aff-be9d-b9781c266871"
      unitRef="usdPerShare">7.96</xfor:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTo0MTg3MjYzNmIwMmM0ZjVjYTNlODRjODNkNTNhMmQyMS90YWJsZXJhbmdlOjQxODcyNjM2YjAyYzRmNWNhM2U4NGM4M2Q1M2EyZDIxXzctNS0xLTEtMjA5NDA_9b69d004-5471-47e6-b3c1-aacf8a887d17">P2Y8M12D</xfor:ClassOfWarrantOrRightWeightedAverageContractualTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1a2348e83e324b7b82456649b542f965_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEtMi0xLTEtMjA5NDA_ebf8f055-4f51-4980-9110-0dcd6aea39f1"
      unitRef="shares">5155</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1a2348e83e324b7b82456649b542f965_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEtNC0xLTEtMjA5NDA_e78fd035-478c-4c27-b959-75e73e2432cc"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1eea12429adf41968b80ecfea410785d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzItMi0xLTEtMjA5NDA_d30aabaf-51b6-4761-a6b5-5e9f44d210c5"
      unitRef="shares">115916</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1eea12429adf41968b80ecfea410785d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzItNC0xLTEtMjA5NDA_da635238-9f5a-4e1c-b996-eef955c5ec2a"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i33bf01c5e0304c2189fa034c75eb5241_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzQtMi0xLTEtMjA5NDA_9c07dee9-201a-4ab0-9333-0d1a197061f6"
      unitRef="shares">20220</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i33bf01c5e0304c2189fa034c75eb5241_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzQtNC0xLTEtMjA5NDA_71816b89-b723-4d30-94be-9947894398a8"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id5e02cabb20347e4812e2c13fe49c590_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzUtMi0xLTEtMjA5NDA_a92501bb-a21d-49f7-b061-325c33857491"
      unitRef="shares">20016</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id5e02cabb20347e4812e2c13fe49c590_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzUtNC0xLTEtMjA5NDA_5090f534-023f-401b-83af-8beeab3671d0"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i09e8bb1f0686446a9a8a7b9564378965_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzYtMi0xLTEtMjA5NDA_ac76abcb-3cd4-4d4d-92a4-46c9354fbf00"
      unitRef="shares">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i09e8bb1f0686446a9a8a7b9564378965_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzYtNC0xLTEtMjA5NDA_a2caf6da-db49-4c47-b949-b7795c48f4f5"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i22fa089c31854eeeaeeac178d4940454_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzctMi0xLTEtMjA5NDA_8b084ca4-5621-428d-9a5c-a1f7db92ee2a"
      unitRef="shares">3866154</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i22fa089c31854eeeaeeac178d4940454_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzctNC0xLTEtMjA5NDA_c8bae902-c812-48dd-b952-fff18c820407"
      unitRef="usdPerShare">13.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzktMi0xLTEtMjA5NDA_59b4a8c7-9879-4115-a9c3-ee0762feedc7"
      unitRef="shares">5416667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzktNC0xLTEtMjA5NDA_db32f683-b169-4131-82e0-5d5c8badd82f"
      unitRef="usdPerShare">3.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i69c23f7b906f436f93692639aef06e09_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEwLTItMS0xLTIwOTQw_74ebe51c-daa9-43b6-971d-820d3506c611"
      unitRef="shares">1750000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i69c23f7b906f436f93692639aef06e09_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEwLTQtMS0xLTIwOTQw_9da3b7c5-12c1-4c0d-ab2a-a831338f0bdb"
      unitRef="usdPerShare">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie12ba0825f69455cbb72564897ee2268_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzExLTItMS0xLTIzMzMw_388d4a58-7729-4059-a959-c6d25530326a"
      unitRef="shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i997f64043d3c48f79904457d31ed425b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzExLTQtMS0xLTIzMzQ0_6bc97754-1a33-465b-8791-ef8e7609625c"
      unitRef="usdPerShare">8.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iffc0e7e2a65446eaaa63bbb1c1af5689_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEyLTItMS0xLTIzMzM3_cc8166a2-ee0a-49ff-9179-f490753806ca"
      unitRef="shares">2008032</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iffc0e7e2a65446eaaa63bbb1c1af5689_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzEyLTQtMS0xLTIzMzUx_45716721-3436-4069-a2c4-82db56a2f122"
      unitRef="usdPerShare">4.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90YWJsZTozMWZiZjE3Njc0YTI0ZDgxYWM2M2ZlYjQ5YjI5NzAwNi90YWJsZXJhbmdlOjMxZmJmMTc2NzRhMjRkODFhYzYzZmViNDliMjk3MDA2XzExLTItMS0xLTIwOTQw_590ddb40-ce2a-4c07-8446-34a913663c5a"
      unitRef="shares">13257160</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iddf524fe86fd469f8009f330de097712_I20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyMTU_a56bd920-133b-40e8-8611-3f28f12ca214"
      unitRef="usdPerShare">11.999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="i0bd64677f69e44d5ba2d48dae0391b34_I20191129"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyNDU_6eeeb928-01e0-476e-95f4-461a60572897"
      unitRef="usd">21000000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i0bd64677f69e44d5ba2d48dae0391b34_I20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODk4MjE_bc8adfa9-f067-4f5a-b336-f1e1a734ea9c"
      unitRef="usdPerShare">0.001</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i358bda413e094c3b8732326b0da80424_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzI3NDg3NzkwNzM0MzY_46834671-68c5-4726-8b58-dda58e7fa4c6"
      unitRef="usdPerShare">8.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="ib4dbd5cea64e45acb7901cd8377332fd_I20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzI3NDg3NzkwNzM1Mzk_1160c256-6874-4c39-b5f9-c075cdd53ae2"
      unitRef="usd">435000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="ib4dbd5cea64e45acb7901cd8377332fd_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODk4MjY_4107738c-4107-4343-80c8-4d90323904ee"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i445218cd5fbd4b9cb04297a8f4e11d1d_I20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODk4NDE_7e2f45db-09da-422f-9a3b-659087cfaed0"
      unitRef="usdPerShare">4.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="ice9673b6146f4de3b3a39b86599af702_I20211130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODc0NTA_625099b9-b4a8-4a6b-a259-ba63b7c67aa7"
      unitRef="usd">10000000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i4b714c637a6647028b196f7cbd99f053_I20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzUvZnJhZzo2MDMyNDI2OWFkZGM0MWUwODM2OTU3ZjVkOTMwNjNhNS90ZXh0cmVnaW9uOjYwMzI0MjY5YWRkYzQxZTA4MzY5NTdmNWQ5MzA2M2E1XzMyOTg1MzQ4ODk4NDY_be201be2-234b-402d-91d5-d767faa29a6d"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzcyNDI_eb03b82b-90cc-4dd2-8ed0-92b69ed20506">COMMON STOCK, REDEEMABLE COMMON STOCK AND PREFERRED STOCK&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s Certificate of Incorporation, as amended and restated, authorizes the Company to issue 125,000,000 shares of $0.001 par value common stock. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No cash dividends &lt;/span&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have been declared or paid to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;12, 2019, the Company sold 5,670,000 shares of common stock and, in lieu of common stock, prefunded warrants to purchase 2,130,000 shares of common stock, and accompanying Class&#160;A warrants to purchase 3,900,000 shares of its common stock. The common stock was issued at a price to the public of $11.00 per share and accompanying Class&#160;A warrant and the prefunded warrants were issued at a price of $10.999 per prefunded warrant and accompanying Class&#160;A warrant. The Class&#160;A warrants have an exercise price of $13.20, will expire 5 years from the date of issuance, and are immediately exercisable with certain restrictions. The gross proceeds from the offering, which closed on April 16, 2019, were $85.8 million before deducting underwriting discounts and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 26, 2019, the Company sold 3,666,667 shares of common stock and, in lieu of common stock, prefunded warrants to purchase 1,750,000 shares of common stock, and accompanying Class&#160;B warrants to purchase 5,416,667 shares of its common stock or prefunded warrants to purchase shares of common stock. The common stock was issued at a price to the public of $12.00 per share and accompanying Class&#160;B warrant and the prefunded warrants were issued at a price of $11.999 per prefunded warrant and accompanying Class&#160;B warrant. The Class B warrants have an exercise price of  $3.65 per warrant, as adjusted based on a down-round contingent price adjustment feature; expire on a date that is the earlier of (a) the date that is 30 calendar days from the date on which the Company issues a press release announcing top-line data from its Phase 3 clinical trial of mavorixafor for the treatment of patients with WHIM syndrome (or, if such date is not a business day, the next business day) and (b) November 28, 2024; and were immediately exercisable upon issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2020, the Company entered into a Controlled Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales Agreement (the &#x201c;ATM Sales Agreement&#x201d;) with B. Riley Securities, Inc., Cantor Fitzgerald &amp;amp; Co., and Stifel, Nicolaus &amp;amp; Company, Incorporated (collectively the &#x201c;Sales Agents&#x201d;), pursuant to which the Company may offer and sell, at the Company&#x2019;s sole discretion through one or more of the Sales Agents, shares of its common stock having an aggregate offering price of up to $50.0&#160;million. To date, the Company has sold approximately $14.3 million, net of offering costs, of common stock under the ATM Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 18, 2021, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with several institutional and accredited investors (the &#x201c;Investors&#x201d;) pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the &#x201c;Private Placement&#x201d;) an aggregate of 6,271,836 shares of common stock and, to certain Investors, in lieu of common stock, pre-funded warrants to purchase an aggregate of 50,000 shares of common stock at a price of $8.70 per share of common stock (or $8.69 per pre-funded warrant). The Private Placement closed on March 23, 2021 and the Company received gross proceeds of $55.0 million, before deducting offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each of the common stock offerings, the Company evaluated the Class A, Class B and prefunded warrants for liability or equity classification in accordance with the provisions of ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and determined that equity treatment was appropriate because neither the Class A, Class B or prefunded warrants meet the definition of a liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 14, 2020, the Company entered into a common stock purchase agreement (the &#x201c;Aspire Purchase Agreement&#x201d;) with Aspire Capital Fund, LLC, (&#x201c;Aspire Capital&#x201d;), which provided that, upon the terms and subject to the conditions and limitations set forth in the Aspire Purchase Agreement, Aspire Capital was committed to purchase up to an aggregate of $50.0 million of shares of the Company&#x2019;s common stock at the Company&#x2019;s request from time to time during the 36-month term of the Purchase Agreement. Concurrently with entry into the Aspire Purchase Agreement, the Company also entered into a registration rights agreement with Aspire Capital (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company filed with the SEC a prospectus supplement to the Company&#x2019;s shelf registration statement on Form S-3 (File No. 333-242372), registering the issuance and sale of common stock that the Company may offer to Aspire Capital from time to time under the Aspire Purchase Agreement. No shares of common stock were sold pursuant to the Aspire Purchase Agreement. As further discussed in Note 16, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in January 2022 the Company elected to terminate the Aspire Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Common Stock&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the requirements of the July 2014 license agreement with Genzyme (see Note&#160;3), in August 2015, the Company issued to Genzyme for no additional consideration 107,371 shares of common stock, which had an aggregate fair value of $734 on the date of issuance. Genzyme had the right to require the Company to repurchase all, but not less than all, of these shares of common stock at any time during the term of the license agreement for a price of $0.001 per share. Because of this redemption feature, the shares of common stock issued to Genzyme were classified outside of stockholders&#x2019; deficit on the consolidated balance sheets. As a result of the Merger, these shares were exchanged for common stock.&lt;/span&gt;&lt;/div&gt;On March 18, 2021, the Company entered into an Option Agreement, as amended (the &#x201c;Option Agreement&#x201d;) with Abingworth Bioventures 8 LP (&#x201c;Abingworth Bioventures 8&#x201d;), which was one of the Investors party to the Securities Purchase Agreement. Pursuant to the Option Agreement, if the Company and a syndicate, of which Abingworth Bioventures 8 was a part, did not execute a definitive co-development agreement, as defined in the Option Agreement, by August 2, 2021, Abingworth Bioventures 8 could have required the Company to repurchase the 229,885 common shares it purchased in the private placement at the original purchase price of $8.70 per share. The Company classified these shares as redeemable common stock on the consolidated balance sheet, net of offering costs, as of March 31, 2021 and June 30, 2021. In August 2021, as a result of the termination of the letter of intent between the Company and Abingworth related to the contemplated co-development arrangement, Abingworth Bioventures 8 exercised it option to sell the 229,885 share of common stock it purchased in the Private Placement back to the Company at the original purchase price of $8.70 per share for an aggregate of $2.0 million. The Company adjusted the carrying amount of the redeemable common stock to its redemption value and subsequently retired these shares of common stock.Convertible Preferred Stock (converted to Common Stock)&#x2014; Prior to the Merger, the Company had issued Series Seed convertible preferred stock (the &#x201c;Series Seed preferred stock&#x201d;), Series&#160;A convertible preferred stock (the &#x201c;Series&#160;A preferred stock&#x201d;) and Series&#160;B convertible preferred stock (the &#x201c;Series&#160;B preferred stock&#x201d;). As of December&#160;31, 2021, the Company&#x2019;s Certificate of Incorporation, as amended and restated, authorized the Company to issue a total of 10,000,000 shares of preferred stock, with a par value of $0.001 per share. As of December&#160;31, 2021 and 2020, there was no preferred stock outstanding.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzQ2Mw_4235cdd0-099b-4a64-9873-1e6ca1021ec7"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzUwNg_431e6f99-17e4-4cb3-980c-aa5b8629f7aa"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzUwNg_4e215f32-0a8c-4fe2-9f60-3609b24e1bfa"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DividendsCommonStock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4Xzk2Mg_dd2a421a-fe4d-4959-b799-02a4c9ccbe79"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic04f75350f324bb38f14095eadb12430_D20190412-20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEyNDc_07f44a8a-1316-4b4e-b1fe-b724024b80a5"
      unitRef="shares">5670000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibc57ac90fb9b4a139e8cb4ea7c012b1c_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEzMzQ_6bbe01e8-66a3-45e9-bb5a-8a67214f01d6"
      unitRef="shares">2130000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic5d3611fd3c8401fb735dc5668ae2bdd_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE0MDc_cec05837-4c72-4333-9c6e-a39f250154ce"
      unitRef="shares">3900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7f7afe3aab394972900909f3eb5f8d6e_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE0OTQ_978709dc-54d0-4876-8571-fb425e421eb0"
      unitRef="usdPerShare">11.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibc57ac90fb9b4a139e8cb4ea7c012b1c_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE1OTM_4f8ab273-d735-4e2d-9ac9-289956368958"
      unitRef="usdPerShare">10.999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic5d3611fd3c8401fb735dc5668ae2bdd_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE2OTk_f6b95a7b-a9e2-4728-bb80-58d389d42018"
      unitRef="usdPerShare">13.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod
      contextRef="ic04f75350f324bb38f14095eadb12430_D20190412-20190412"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE3MTU_12b4a340-944f-4fa8-b966-20d9d3c00954">P5Y</xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod>
    <xfor:ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses
      contextRef="ic04f75350f324bb38f14095eadb12430_D20190412-20190412"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE4Nzk_3762b6a5-f924-4dc2-89e7-95ca667fccc1"
      unitRef="usd">85800000</xfor:ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5faaf777d178421b83561c0fd16627c8_D20191126-20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzIxNzk_20278519-23ed-4569-b2d7-9a3f423712f3"
      unitRef="shares">3666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i8c32e3e005c345c99931e9ec6e8fd87d_I20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzIyNjY_fc897d08-4970-4006-a5ed-ad5ed062d0da"
      unitRef="shares">1750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie95bdf26dc21489e97c2cbbf4958cf38_I20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzIzMzk_17fcef91-639e-415d-be2e-b493dec8ce4a"
      unitRef="shares">5416667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic2e5e675d68a4f6fb4aacb2424a63a15_I20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzI0ODM_c207cd6f-0efa-464e-aa7c-61e8d6111964"
      unitRef="usdPerShare">12.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8c32e3e005c345c99931e9ec6e8fd87d_I20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzI1ODI_42c99f77-9721-43c2-93cd-9478791371ef"
      unitRef="usdPerShare">11.999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE2NDkyNjc0NTA3Mzk_741c2478-783a-4af5-a636-44636952d69a"
      unitRef="usdPerShare">3.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod
      contextRef="i5faaf777d178421b83561c0fd16627c8_D20191126-20191126"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzI4MzA_76bad7ae-5b4b-4375-afb2-85a9e7bf5e3d">P30D</xfor:ClassOfWarrantOrRightWarrantsExpirationPeriod>
    <xfor:SaleOfStockNumberOfSharesAuthorizedInTransactionAmount
      contextRef="i0367f472bfd0499fb8ee3740bd659aef_D20200807-20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzM3NjA_287567b0-1de4-4faa-ba5f-18621eb02ae3"
      unitRef="usd">50000000</xfor:SaleOfStockNumberOfSharesAuthorizedInTransactionAmount>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="i9356b89607b64810becde53ca7553153_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzE2NDkyNjc0NTE4MzQ_540c8bf4-548c-491d-bbdd-d151ab41f1ab"
      unitRef="usd">14300000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id058b9443dcc41a5ab90c45eaf52eb0f_D20210318-20210318"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1MjA_d68c3ff9-71da-483a-83a1-551cf97f0c28"
      unitRef="shares">6271836</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie12ba0825f69455cbb72564897ee2268_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1MzA_cf396b2e-378a-40cf-8601-d75884205ed1"
      unitRef="shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i358bda413e094c3b8732326b0da80424_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1NDQ_46834671-68c5-4726-8b58-dda58e7fa4c6"
      unitRef="usdPerShare">8.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses
      contextRef="id058b9443dcc41a5ab90c45eaf52eb0f_D20210318-20210318"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1NjI_15921d50-e410-464e-b4e1-23a36c7159c6"
      unitRef="usd">55000000</xfor:ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses>
    <xfor:StockIssuedDuringPeriodSharesLicenseAgreement
      contextRef="i7e2c3583b72c4f10ba6fe68a4c9b2efc_D20150801-20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzYxNDA_90e006f5-ed45-4674-9389-33ccd41fb5dc"
      unitRef="shares">107371</xfor:StockIssuedDuringPeriodSharesLicenseAgreement>
    <xfor:StockIssuedDuringPeriodValueLicenseAgreement
      contextRef="idaea2c14fe1c4ed986fa022e040501e2_D20150801-20150831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzYyMDQ_f6473887-07c7-4068-bf3a-308ca899f3c4"
      unitRef="usd">734000</xfor:StockIssuedDuringPeriodValueLicenseAgreement>
    <xfor:CommonStockRepurchasePricePerShare
      contextRef="i7e2c3583b72c4f10ba6fe68a4c9b2efc_D20150801-20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzY0MTk_bafc024e-cca9-4d42-ba8e-cd6735f39137"
      unitRef="usdPerShare">0.001</xfor:CommonStockRepurchasePricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i090e4c427ee048bc8e9fcdb0974c1506_D20210318-20210318"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1NzM_fb0754ce-2887-46c7-9b94-947fc0e9cdcd"
      unitRef="shares">229885</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i997f64043d3c48f79904457d31ed425b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1ODE_26302f55-00ce-41f5-9a55-3dd1c75ae92d"
      unitRef="usdPerShare">8.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i090e4c427ee048bc8e9fcdb0974c1506_D20210318-20210318"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM1OTE_fb0754ce-2887-46c7-9b94-947fc0e9cdcd"
      unitRef="shares">229885</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i997f64043d3c48f79904457d31ed425b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM2MDA_26302f55-00ce-41f5-9a55-3dd1c75ae92d"
      unitRef="usdPerShare">8.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ic20f813c6ba64ecd9f76496c37a6e54f_D20210318-20210318"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzEwOTk1MTE2NDM2MTY_79d359b5-a2ac-407c-b1f6-948c555c79ea"
      unitRef="usd">2000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i66be0cd2cf4d4a42b63843821d7cd60e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzcxMTc_b90b20b2-7a92-4917-8941-ab4e4646faea"
      unitRef="shares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i66be0cd2cf4d4a42b63843821d7cd60e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzcxNjc_4c3ac692-09c6-478d-bee3-194b57ba7b26"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="iba06b4b4e67a4951be1cc5d6e6014f25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzcxNjc_fef242b7-10b1-4e56-bba8-fe68437e4400"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xNzgvZnJhZzozMWE5MzMyNmNlYWE0MTlmOTA5ODEzNTcwNDQwZGY5OC90ZXh0cmVnaW9uOjMxYTkzMzI2Y2VhYTQxOWY5MDk4MTM1NzA0NDBkZjk4XzcyMTA_773da39b-c926-4bf5-a8bf-adc83341fd38"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0Mjc_e2e1b0c6-4d3b-4cc0-b660-cc7af848e5a7">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Plans&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon completion of the Merger on March&#160;13, 2019, X4&#x2019;s 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#x201c;2015 Plan&#x201d;), Arsanis&#x2019; 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;) and Arsanis&#x2019; 2017 Employee Stock Purchase Plan (the &#x201c;2017 ESPP&#x201d;) were assumed by the Company. In June 2019, the Company adopted the 2019 Inducement Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;). These plans are administered by the Board of Directors or by a committee thereof. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzEyNDI_d21e8b58-0c5c-4b61-b8a2-5336b084744c"&gt;three&lt;/span&gt; or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Employee, Director and Consultant Equity Incentive Plan&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, the Board of Directors and shareholders of X4 adopted the 2015 Plan, which provided for the Company to grant incentive stock options or nonqualified stock options, restricted stock awards and other stock-based awards to employees, directors and consultants of the Company. The total number of shares of common stock that may be issued under the 2015 Plan is 1.0 million shares. As of December&#160;31, 2021, there were approximately 144 thousand shares available for issuance under the 2015 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2017 Plan, the Company may grant incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. On June 10, 2020, the Company's stockholders approved an amendment and restatement of the 2017 Plan. The amendments increased the number of shares of common stock reserved for issuance under the 2017 Plan by an additional 474 thousand shares and amended the &#x201c;evergreen&#x201d; provision of the 2017 Plan to provide for an automatic increase in the share reserve on the first day of each year, beginning on&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January&#160;1, 2021 and ending on January&#160;1, 2027, in an amount equal to  the lower of 4.0% of the number of shares of the Company&#x2019;s common stock outstanding on January&#160;1 of each year or an amount determined by the Company&#x2019;s Board of Directors. As of December&#160;31, 2021, approximately 139 thousand shares were available for future issuance under the 2017 Plan. Pursuant to the evergreen provision of the 2017 Plan, as of January 1, 2022, an additional 1.1 million shares became available for future issuance under the 2017 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Employee Stock Purchase Plan&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2017 ESPP provides participating employees with the opportunity to purchase shares of the Company&#x2019;s common stock at defined purchase prices over six-month offering periods. For the twelve months ended December&#160;31, 2021, 45,816 shares of common stock were issued under the 2017 ESPP. As of December&#160;31, 2021, approximately 183 thousand shares were available for future issuance under the 2017 ESPP. Pursuant to the evergreen provision of the 2017 ESPP, on January 1, 2022, an additional 85 thousand shares became available for future issuance under the 2017 ESPP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Inducement Equity Incentive Plan&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 17, 2019, the Board of Directors approved the adoption of the 2019 Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or following a bona fide period of non-employment), as an inducement material to such individual&#x2019;s entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4). The total number of shares of common stock that may be issued under the 2019 Plan, as amended, is 1.3 million shares. Shares that are expired, forfeited, canceled or otherwise terminated without having been fully exercised will be available for future grant under the 2019 Plan. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for future grants. As of December&#160;31, 2021, approximately 483 thousand shares were available for future issuance under the 2019 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Valuation&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity for the twelve months ended December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(in Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,874,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(340,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,689,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock to the extent the stock option had a lower exercise price. The aggregate intrinsic value of stock options exercised during the twelve months ended December&#160;31, 2021 and 2020 was $13 thousand and  $42&#160;thousand, respectively. The weighted average grant-date fair value per share of stock options granted during the years ended December&#160;31, 2021, 2020 and 2019 was $5.17, $6.12, and $10.78, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; During the twelve months ended December&#160;31, 2021, the Company granted 674,478 restricted stock units to employees at a weighted average grant date fair value of $8.25 per share. The restricted stock units granted were primarily performance-based restricted stock units, which vest in part upon on the Company&#x2019;s achievement of operational milestones and over time thereafter for the subsequent two years as the employee continues to provide services to the Company. As of December 31, 2021, all performance criteria had been achieved. The Company recognizes stock-based compensation expense using the accelerated attribution model based on the fair value of the awards as of the date of grant and management&#x2019;s best estimate of the date each operational milestone will be achieved. These restricted stock units had a grant date fair value of $5.6 million, which is being recognized as stock-based compensation expense, net of estimated forfeitures, over the estimated vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted stock activity for the twelve months ended December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, total unrecognized compensation expense related to unvested stock options and restricted stock units was $7.7 million, which is expected to be recognized over a weighted average period of 2.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was classified in the consolidated statements of operations as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0OA_6e09de7d-660d-4f33-bdff-13a8fcd71c11"
      unitRef="number">1</xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ibb68bbb183674891a54f752fa22ab0ec_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzg4Mw_77a22ab9-48b1-41d1-8aec-e1e35f250f53">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2dca859173e44d0ab9e6a946325f25cf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzEwODg_7cc0acc2-b95a-444f-bedc-a435a078f999">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0cdc5828b647427eac8834bfe5c3918d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzEyNDg_5442b17e-2b7a-4714-968c-77715a072f66">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i24ce1b0b961a4ecf8f39191f8d76e3f5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzIwMjM_999d9e8b-2f25-4154-8684-107b785ef1ce"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i9744171d8b784611a88ca1bbe96d8305_I20200610"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzI1NzM_d758eb74-0981-43d4-8d6b-b4b084c705f8"
      unitRef="shares">474000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="ibcb5c3f88dc04b4394011f548ecf9639_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzI4MjM_66b4f295-5860-4aec-b310-e019c5f0b0a5"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0cda38b2da094f1989f1b4c220bb9a44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzMwMTg_23bf8127-6fee-4128-89e9-7331a45eca41"
      unitRef="shares">139000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic32c961b47444fdbb27d84656b34b323_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzMxNzU_1db05586-1569-4167-8ebb-2cfa1c891356"
      unitRef="shares">1100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ic41788cc835c403ebdb1e9b363ffce18_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzM0ODQ_5bc184a8-b783-44d2-8d8a-6a4b75b53ad6"
      unitRef="shares">45816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib547fe50b2a14b3280afdd293833e80c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzM1ODI_cb5984b6-e992-40e8-90ab-969b6fcbb4f8"
      unitRef="shares">183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i6bc5c13e743746e4a019f4cf7a0c9b49_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzM3MzY_3919dedd-d035-4c79-89b5-b3a575ed5425"
      unitRef="shares">85000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="id65e88b8d02845c0a717fe27c8e5d78e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzQzMzE_e7967f79-4375-40e0-9ce3-23ab7804ef7c"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id65e88b8d02845c0a717fe27c8e5d78e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzQ3MTM_8752be12-e4f7-4729-b874-3fa78fe39b6e"
      unitRef="shares">483000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0Mjg_dca269fa-225b-4a43-b179-292988d0da46">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.517%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzItMy0xLTEtMjA5NDA_06f1d51c-5c99-4c7f-9ffc-a3e01190044e"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzItNS0xLTEtMjA5NDA_6abd1842-9e55-46dc-944b-f54e81b439f3"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzItNy0xLTEtMjA5NDA_3f8d22e5-cf41-4cf9-80fd-1431b44d3956"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzMtMy0xLTEtMjA5NDA_278bbfda-8d24-4f8f-8296-38bdf20fa741">P5Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzMtNS0xLTEtMjA5NDA_70fa1e89-c998-41cb-8309-5ebf85d97e12">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzMtNy0xLTEtMjA5NDA_8aedafb1-2d8d-402b-9199-886cd96d99aa">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzQtMy0xLTEtMjA5NDA_63ca0f6c-b9b4-415e-8744-dc1fd39ef00d"
      unitRef="number">0.973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzQtNS0xLTEtMjA5NDA_682f4251-6dd2-41f2-ac4c-f71c82682480"
      unitRef="number">0.949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzQtNy0xLTEtMjA5NDA_d59d552e-7fae-4eb8-a914-961e0f1ea47d"
      unitRef="number">0.885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzUtMy0xLTEtMjA5NDA_d4df20df-04d9-477e-9da1-39f7a27441ff"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzUtNS0xLTEtMjA5NDA_9d909832-71a4-4b99-a1a7-e9284c93c062"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplZDUwNDk2YmQ5YjM0NGQxYWUwNDIzYzBjYjQ4YWM5ZC90YWJsZXJhbmdlOmVkNTA0OTZiZDliMzQ0ZDFhZTA0MjNjMGNiNDhhYzlkXzUtNy0xLTEtMjA5NDA_37679f81-374f-44b3-a9b7-712d6bd57878"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0Mjk_e7668b96-33dc-48b5-98d0-07ace41d80b9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity for the twelve months ended December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(in Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,874,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(340,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,689,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzEtMS0xLTEtMjA5NDA_fe2863bc-8558-4364-869e-ea02a65bfa33"
      unitRef="shares">1874514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzEtMy0xLTEtMjA5NDA_1c026b26-aed5-4929-bc2d-874791d3a5f4"
      unitRef="usdPerShare">12.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzEtNS0xLTEtMjA5NDA_d4ed2ba9-6536-4ff4-b611-68e3a4d1e87f">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzEtNy0xLTEtMjA5NDA_c1085496-46ec-4d22-960c-ab326f0d2ed6"
      unitRef="usd">7</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzItMS0xLTEtMjA5NDA_637a02e5-3819-41f4-b579-f6e192a49bd7"
      unitRef="shares">388050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzItMy0xLTEtMjA5NDA_c489b143-c071-409c-b2de-b3f870c917f0"
      unitRef="usdPerShare">6.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzMtMS0xLTEtMjA5NDA_90da361f-e3cf-4819-a46a-2cd472f197fa"
      unitRef="shares">5860</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzMtMy0xLTEtMjA5NDA_22339b5c-f5f8-4585-8854-1dbb0a32784b"
      unitRef="usdPerShare">7.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzQtMS0xLTEtMjA5NDA_051c9e87-9887-4358-a652-4fa6d817d1a5"
      unitRef="shares">340653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzQtMy0xLTEtMjA5NDA_6026838e-2246-4e68-84d3-2f6020a3d5c6"
      unitRef="usdPerShare">22.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzUtMS0xLTEtMjA5NDA_788a081b-9686-4764-b899-8657afd742b9"
      unitRef="shares">1916051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzUtMy0xLTEtMjA5NDA_9f6c2e64-8bf2-4867-aa0b-58b2e62b9206"
      unitRef="usdPerShare">10.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzUtNS0xLTEtMjA5NDA_bc8e5c5c-3013-4b55-82d1-b4acb72b3e6e">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzUtNy0xLTEtMjA5NDA_e4fea3db-e808-4a05-80c4-189ed7343fa4"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzYtMS0xLTEtMjA5NDA_81852ffa-a156-45cb-8a7b-fe2a7d595b94"
      unitRef="shares">1007236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzYtMy0xLTEtMjA5NDA_8d1d7ab4-0439-4eb5-aeac-e474d7bf37b3"
      unitRef="usdPerShare">11.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzYtNS0xLTEtMjA5NDA_ced22156-ec27-473c-b927-0cc406fd22c0">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzYtNy0xLTEtMjA5NDA_c87108bc-4278-4995-a24b-00cc62f4c8e7"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzctMS0xLTEtMjA5NDA_24273b6a-e429-4c30-bcf7-2412f0446594"
      unitRef="shares">1689992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzctMy0xLTEtMjA5NDA_a16dac41-b2c6-4878-8856-b78e19093533"
      unitRef="usdPerShare">10.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzctNS0xLTEtMjA5NDA_8ab2f373-5996-4e4c-9784-418b1cbdec45">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNmU5MTc5ZTk0YjU0ZmMxYjZjNjQwODlhMDdkYmNhNC90YWJsZXJhbmdlOmU2ZTkxNzllOTRiNTRmYzFiNmM2NDA4OWEwN2RiY2E0XzctNy0xLTEtMjA5NDA_9b06f068-6041-47a2-895a-67b67eabd015"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU0MzQ_d79025c0-420d-499d-b4fb-a20ee55c2df2"
      unitRef="usd">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU0NDE_c33a7a2b-89b9-4b40-b818-62710d39e881"
      unitRef="usd">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU2ODU_f65636c4-5302-4e6c-8bfb-d508c4159d92"
      unitRef="usdPerShare">5.17</xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue>
    <xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU2ODk_e4a8f1d7-9699-46be-8173-edc8871e8769"
      unitRef="usdPerShare">6.12</xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue>
    <xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU2OTc_dc00ce10-582e-4409-8015-daaafb530ffe"
      unitRef="usdPerShare">10.78</xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU3OTA_b7954eb9-71d7-4bb9-9646-37794d164c2c"
      unitRef="shares">674478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzU4NzY_65d45f93-705d-4940-bbb4-0e4f39ba268b"
      unitRef="usdPerShare">8.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzY4Njc_ff262edd-ae79-4b53-8676-bc910ef413a7"
      unitRef="usd">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0MjU_f744e072-61f5-4d7f-b238-3dcfa272fbf3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted stock activity for the twelve months ended December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3c91a1db75564f1a9f51565f80cc6989_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZToxMWUzZGZmNmU3YTQ0ODgxOTYzZjJiMWYwN2QxMzVmMC90YWJsZXJhbmdlOjExZTNkZmY2ZTdhNDQ4ODE5NjNmMmIxZjA3ZDEzNWYwXzEtMS0xLTEtMjA5NDA_8342c959-082b-47b6-a6cd-a22b9e2aec51"
      unitRef="shares">572460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZToxMWUzZGZmNmU3YTQ0ODgxOTYzZjJiMWYwN2QxMzVmMC90YWJsZXJhbmdlOjExZTNkZmY2ZTdhNDQ4ODE5NjNmMmIxZjA3ZDEzNWYwXzItMS0xLTEtMjA5NDA_14942e1d-b1d8-451e-84a7-05d15cf30a54"
      unitRef="shares">674478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZToxMWUzZGZmNmU3YTQ0ODgxOTYzZjJiMWYwN2QxMzVmMC90YWJsZXJhbmdlOjExZTNkZmY2ZTdhNDQ4ODE5NjNmMmIxZjA3ZDEzNWYwXzMtMS0xLTEtMjA5NDA_83d27bda-9d37-4a76-bfee-f54250cfbc42"
      unitRef="shares">205185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZToxMWUzZGZmNmU3YTQ0ODgxOTYzZjJiMWYwN2QxMzVmMC90YWJsZXJhbmdlOjExZTNkZmY2ZTdhNDQ4ODE5NjNmMmIxZjA3ZDEzNWYwXzQtMS0xLTEtMjA5NDA_f523635b-2a9e-47bd-8c8b-29dd414da1da"
      unitRef="shares">116652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifd6c8456214d407ab97760fec4594b56_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZToxMWUzZGZmNmU3YTQ0ODgxOTYzZjJiMWYwN2QxMzVmMC90YWJsZXJhbmdlOjExZTNkZmY2ZTdhNDQ4ODE5NjNmMmIxZjA3ZDEzNWYwXzUtMS0xLTEtMjA5NDA_f9feb78e-af33-42e8-b811-7581ccde8871"
      unitRef="shares">925101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ifd6c8456214d407ab97760fec4594b56_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzcyNDI_cce608e9-b36a-4ebe-8e9c-7bdf25313c9b"
      unitRef="usd">7700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iee628eec0cbd46928d7d4fd42f1ea74c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzczMTU_8cf89364-7c24-402a-87c5-7d3057231dec">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90ZXh0cmVnaW9uOjBiY2Q3OGFlMjdmYTQ3MGJiOWU3NjljNjYwNTdhZmNmXzc0MjY_7a1770ee-445d-4add-8ddd-763c431b9925">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was classified in the consolidated statements of operations as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b422ab3eb7e4a40aa972b2f8fff304f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzItMS0xLTEtMjA5NDA_3cdaff68-202e-4e7f-8c1b-044af6b67a3e"
      unitRef="usd">2723000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia31a8d360da2400681748e55aab5c168_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzItMy0xLTEtMjA5NDA_7c29ac68-65c8-404b-874a-d6439c6d5a80"
      unitRef="usd">2316000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if04d43b561c5475e947351e2ef934ba6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzItNS0xLTEtMjA5NDA_5384eed8-cfe9-4600-9646-85cf5058130e"
      unitRef="usd">909000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48c01b2e36084c58b99dee21b846e65d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzMtMS0xLTEtMjA5NDA_e1c85955-6178-4a28-805d-930da23b4000"
      unitRef="usd">3457000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb0418b0f1a84b1485cef1e8244c3bbe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzMtMy0xLTEtMjA5NDA_77549a7d-7dea-4e32-a309-f9566c0ff481"
      unitRef="usd">3112000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if641bd9c2d33474caad13fd26380c7bd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzMtNS0xLTEtMjA5NDA_0eedf0c4-1801-4bf3-ba14-61b28c839e9a"
      unitRef="usd">1141000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzQtMS0xLTEtMjA5NDA_ff0cd16a-b416-4d49-bea8-fe2a8226d8ac"
      unitRef="usd">6180000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzQtMy0xLTEtMjA5NDA_1b97db39-98ea-44d1-b048-a0196e904bf1"
      unitRef="usd">5428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODEvZnJhZzowYmNkNzhhZTI3ZmE0NzBiYjllNzY5YzY2MDU3YWZjZi90YWJsZTplNGFjODAyMjkxMGI0ZWQzYWEzMjFmNGFhNjNkOWNhMC90YWJsZXJhbmdlOmU0YWM4MDIyOTEwYjRlZDNhYTMyMWY0YWE2M2Q5Y2EwXzQtNS0xLTEtMjA5NDA_31f03653-a969-4039-aa85-592543ece4ef"
      unitRef="usd">2050000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNzM_b6a39e32-73a0-4d02-8cac-02445cbb5197">INCOME TAXES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, the Company recorded no income tax benefits for the net operating losses incurred and research and development credits generated due to the uncertainty of realizing a benefit from those items. Additionally during the year ended December 31, 2021, the Company recorded a tax provision of $17&#160;thousand related to its Austrian subsidiary. During the year ended December 31, 2020, the Company recorded a tax provision of $148 thousand related to local withholdings associated with a milestone payment received from a customer in a foreign jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before the provision for income taxes for the years ended December 31, 2021, 2020 and 2019 consisted of the following: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign (Austria)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of preferred stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company had U.S. federal and state net operating loss carryforwards of  $315.0 million and $308.2 million, respectively, which may be available to offset future taxable income and begin to expire in 2031 and 2035, respectively. The Company has federal net operating losses $260.9 million, which do not expire, and $54.1 million of federal net operating losses generated prior to 2018 that will expire at various dates through 2037. In addition, as of December 31, 2021, the Company had foreign net operating loss carryforward of $65.2 million, which do not expire but are generally limited in their usage to an annual deduction equal to 75% of taxable income. As of December 31, 2021, the Company also had U.S. federal and state research and development tax credit carryforwards of $4.3 million and $1.4 million, respectively, which may be available to offset future tax liabilities and each begin to expire in 2032 and 2030, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, uncertain tax position reserves recorded were $0.2 million for U.S. federal and state research and development tax credits. Additionally, during the year ended December 31, 2021, the Company released an uncertain tax position of $0.1 million related to withholding taxes paid in 2021 on a milestone payment received from a non-U.S. customer in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s reserve for uncertain tax positions for the three years ended December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reserve for Uncertain Tax Position&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in unrecognized tax benefit for tax positions taken during year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of unrecognized tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the U.S. net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each period, the Company evaluates the positive and negative evidence bearing upon its ability to realize its federal, state and foreign deferred tax assets. Management has considered the Company&#x2019;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2021, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021, 2020 and 2019 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance, end of year &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. federal and state income tax returns are generally subject to tax examinations for the tax years ended December 31, 2018 through December 31, 2020. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period. The Company&#x2019;s policy is to record interest and penalties related to income taxes as part of its income tax provision.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzM1MQ_e98dd81c-7e36-4538-a738-37945f50cb97"
      unitRef="usd">17000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzEwOTk1MTE2MzM2MzE_c50708b0-203e-4bcd-be0c-7bd1a43df374"
      unitRef="usd">148000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNzQ_f2938c45-68de-44f0-ae09-916f84be3122">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before the provision for income taxes for the years ended December 31, 2021, 2020 and 2019 consisted of the following: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign (Austria)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzItMS0xLTEtMjA5NDA_5528330a-01a0-4b91-a1d5-713f743621c8"
      unitRef="usd">-89865000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzItMy0xLTEtMjA5NDA_09c33011-77d9-4e44-98ce-350c9b2dd7af"
      unitRef="usd">-62539000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzItNS0xLTEtMjA5NDA_9052aef0-a521-4c10-92ac-da7ea3794903"
      unitRef="usd">-52314000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzMtMS0xLTEtMjA5NDA_8f227084-8a58-4e17-b784-897c80406380"
      unitRef="usd">1186000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzMtMy0xLTEtMjA5NDA_3dc97329-cc8b-4ae4-8cdc-3e05c0c834ac"
      unitRef="usd">556000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzMtNS0xLTEtMjA5NDA_45da0c15-6399-455b-bb29-664eb9e8fbff"
      unitRef="usd">-493000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzQtMS0xLTEtMjA5NDA_0ab9ccce-6cce-444c-a433-fa67d9dfc26d"
      unitRef="usd">-88679000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzQtMy0xLTEtMjA5NDA_7e47c50b-fc5d-4126-845c-fc35ae898861"
      unitRef="usd">-61983000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTpkMGMyMDRhZWZlYTQ0MDNhYjQ1Y2YwZTEwOWYyNzU1Yi90YWJsZXJhbmdlOmQwYzIwNGFlZmVhNDQwM2FiNDVjZjBlMTA5ZjI3NTViXzQtNS0xLTEtMjA5NDA_dec0aa8b-d34d-4fca-a71a-2800fe775027"
      unitRef="usd">-52807000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNjk_39db70df-99d5-46fc-b711-d4a418844732">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of preferred stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzItMS0xLTEtMjA5NDA_bf54e030-0840-4ee0-affc-d4634715ccea"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzItMy0xLTEtMjA5NDA_9da81d0c-e98a-4147-b71e-286d405baeda"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzItNS0xLTEtMjA5NDA_c605fd72-d449-4c6e-a057-c47e0ed8bb9f"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzMtMS0xLTEtMjA5NDA_396524a5-4d3a-4612-a5b4-541cbb367df8"
      unitRef="number">0.054</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzMtMy0xLTEtMjA5NDA_e193229d-6c17-47b6-a90a-e55ff6c44920"
      unitRef="number">0.059</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzMtNS0xLTEtMjA5NDA_edec54fc-b3da-4c94-bb3c-c1c5b8165f7b"
      unitRef="number">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzQtMS0xLTEtMjA5NDA_3210ff2f-6258-40fb-9d86-9806ab7b41b0"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzQtMy0xLTEtMjA5NDA_83d7979a-5ef4-4a22-83ff-e520af874d48"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzQtNS0xLTEtMjA5NDA_b2448d62-2b9b-40bd-b8b5-60424d494441"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzUtMS0xLTEtMjA5NDA_35f75ba0-10c2-4b59-9bfd-68b6d1b01d51"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzUtMy0xLTEtMjA5NDA_4df2fda9-c31a-40b7-af88-b5ad479fb20a"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzUtNS0xLTEtMjA5NDA_f7c8286f-8c0f-4019-8b8f-efe9f2750b22"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <xfor:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzYtMS0xLTEtMjA5NDA_1f0c750a-946b-44a3-9f99-0d6dc0e33dd0"
      unitRef="number">0</xfor:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability>
    <xfor:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzYtMy0xLTEtMjA5NDA_38c7f421-9b58-49fd-a7d1-aed4e9c0d816"
      unitRef="number">0</xfor:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability>
    <xfor:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzYtNS0xLTEtMjA5NDA_15a56aed-cabe-4810-ae94-2330f4652af9"
      unitRef="number">0.001</xfor:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability>
    <xfor:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzctMS0xLTEtMjA5NDA_c7ffb736-2046-4d8a-a8c0-ed9182cb5de6"
      unitRef="number">0.037</xfor:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <xfor:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzctMy0xLTEtMjA5NDA_ff2e626a-4761-452a-acf7-f5a25cf614bb"
      unitRef="number">0.009</xfor:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <xfor:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzctNS0xLTEtMjA5NDA_f7ed6718-4b3c-49f2-967c-80b24be2804f"
      unitRef="number">0.014</xfor:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzgtMS0xLTEtMjA5NDA_e3c2471a-0a21-4edb-bf28-ab77be4118fe"
      unitRef="number">0.237</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzgtMy0xLTEtMjA5NDA_57dd1c20-1ec8-4d29-a7cb-0fc7bc947752"
      unitRef="number">0.272</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzgtNS0xLTEtMjA5NDA_9fd536cf-f58a-44ab-a62f-88e254783568"
      unitRef="number">0.268</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzktMS0xLTEtMjA5NDA_350f9cf9-5e6f-45b9-ba49-38751808a7ba"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzktMy0xLTEtMjA5NDA_52e13927-9b42-4a47-8af6-55cf3e1f658a"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzktNS0xLTEtMjA5NDA_ec8a64c0-cf27-4352-8ec6-2887d2ec4961"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzEwLTEtMS0xLTIwOTQw_2a441ecf-a226-49ed-9207-ac9e0d4f5cb8"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzEwLTMtMS0xLTIwOTQw_04d71e0e-3b00-4c25-9c47-b76437b72161"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZToyZmQwYTM0ODQyOTU0NDlhOGUwMzcyODcxYTQ5MTlmMS90YWJsZXJhbmdlOjJmZDBhMzQ4NDI5NTQ0OWE4ZTAzNzI4NzFhNDkxOWYxXzEwLTUtMS0xLTIwOTQw_a803b98b-6115-4bcd-9699-2e80e2f9df8c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNzA_755f62f8-5f92-4799-9b43-f49264ed6ced">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzItMS0xLTEtMjA5NDA_18eba6b5-2f38-4044-9919-52d79a641601"
      unitRef="usd">101863000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzItMy0xLTEtMjA5NDA_c3cc30ec-c574-4cd1-a18e-4f0c58f0c4cc"
      unitRef="usd">83671000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzMtMS0xLTEtMjA5NDA_1c858389-ecfa-45f8-82ed-21a65445a65b"
      unitRef="usd">5444000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzMtMy0xLTEtMjA5NDA_80a04307-e844-4fc1-b6ea-cdab8247250e"
      unitRef="usd">4616000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <xfor:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzQtMS0xLTEtMjA5NDA_5006b66e-bd17-45b5-93f6-73bed6698f9b"
      unitRef="usd">1760000</xfor:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <xfor:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzQtMy0xLTEtMjA5NDA_a5514d88-7776-4ff6-a15d-097edbec2b9f"
      unitRef="usd">2193000</xfor:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <xfor:DeferredTaxAssetLeaseLiability
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzctMS0xLTEtMjA5NDA_98f8de1c-2c00-499d-8461-f0ec4bd23356"
      unitRef="usd">1243000</xfor:DeferredTaxAssetLeaseLiability>
    <xfor:DeferredTaxAssetLeaseLiability
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzctMy0xLTEtMjA5NDA_ca621052-0555-4225-902c-a7dc3d41261b"
      unitRef="usd">1440000</xfor:DeferredTaxAssetLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzgtMS0xLTEtMjA5NDA_fa934acb-5c9a-45b8-bd8e-0f70bff1abc9"
      unitRef="usd">3372000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzgtMy0xLTEtMjA5NDA_64ac2afe-31a8-46f8-afce-2ca97ca8165b"
      unitRef="usd">2452000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzktMS0xLTEtMjA5NDA_59f42e81-dce6-4598-b0f9-685f6379045c"
      unitRef="usd">113682000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzktMy0xLTEtMjA5NDA_096e3163-d2f2-4f87-af7f-4d0fb58ed807"
      unitRef="usd">94372000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEwLTEtMS0xLTIwOTQw_e846ab0a-2a4e-4477-9663-a78d553094df"
      unitRef="usd">111835000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEwLTMtMS0xLTIwOTQw_52f4456c-756d-4eb6-911b-f247dc4a7573"
      unitRef="usd">92197000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzExLTEtMS0xLTIwOTQw_b67f6247-1686-4e50-afa8-55c205d35b81"
      unitRef="usd">1847000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzExLTMtMS0xLTIwOTQw_9eb4119c-f4a5-4a11-8555-1a7992274c39"
      unitRef="usd">2175000</us-gaap:DeferredTaxAssetsNet>
    <xfor:DeferredTaxLiabilityRightOfUseAsset
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEyLTEtMS0xLTIwOTQw_6e990f00-f5b5-41e0-8dad-cd3b3c6135ce"
      unitRef="usd">1847000</xfor:DeferredTaxLiabilityRightOfUseAsset>
    <xfor:DeferredTaxLiabilityRightOfUseAsset
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEyLTMtMS0xLTIwOTQw_dcc95d29-886a-49e1-99ea-02c4e4b81197"
      unitRef="usd">2175000</xfor:DeferredTaxLiabilityRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEzLTEtMS0xLTIwOTQw_f9661482-4deb-4a2f-9aac-d9a7c83be4ff"
      unitRef="usd">1847000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzEzLTMtMS0xLTIwOTQw_a4cbf002-0b64-490e-8177-ec30b9944657"
      unitRef="usd">2175000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzE0LTEtMS0xLTIwOTQw_ae0360c9-7124-4b60-900f-ca4a289dbe8b"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTplNWE1MDUxNDNkNzg0NTJlYmY1OGNmZjllZDM3OWRiMS90YWJsZXJhbmdlOmU1YTUwNTE0M2Q3ODQ1MmViZjU4Y2ZmOWVkMzc5ZGIxXzE0LTMtMS0xLTIwOTQw_070229bc-0ae7-45e7-a844-be64bc623c41"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i097aafa6f7b841a1a0aa11212d0ac628_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3Xzk5MQ_db2f15e9-10b9-4603-9b03-8ccb31f26506"
      unitRef="usd">315000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id2f7ea03d3dc4a2db15e7efdf72553a9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3Xzk5OA_2f7c97b8-d7a3-4f3b-b91c-eab1a3cf2301"
      unitRef="usd">308200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i097aafa6f7b841a1a0aa11212d0ac628_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzExNjg_106a85cd-844d-4a7a-ba23-0a21206edc8b"
      unitRef="usd">260900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i097aafa6f7b841a1a0aa11212d0ac628_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzExOTc_af70f9c1-e5cf-4f52-a274-a44fd5f8ec40"
      unitRef="usd">54100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i32f34441bf9943299037a918d5a88ca2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzE0MDE_90fedcbc-76ff-4717-9908-03a8903b017c"
      unitRef="usd">65200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i5afd505d65084ae68ba1922355482038_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzE2NDM_8117bda8-af31-4b14-ad68-472dfadc1d4b"
      unitRef="usd">4300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i19aaafe0d3d04513a526d073e5d54606_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzE2NTA_a5a38d6d-5734-42e8-acf3-b2ad139f48b7"
      unitRef="usd">1400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i097aafa6f7b841a1a0aa11212d0ac628_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzE4NTQ_5b88fe9f-c028-47a1-abf9-df6542701379"
      unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i32f34441bf9943299037a918d5a88ca2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzIwMjc_eff70abc-e056-45ce-9250-b1010d504230"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNzE_f62e2943-0f28-49c5-a59e-9907af0dc8aa">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s reserve for uncertain tax positions for the three years ended December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reserve for Uncertain Tax Position&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in unrecognized tax benefit for tax positions taken during year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of unrecognized tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie3a7b1480c3841f595013f06c59a2f9a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo0MGExMjNkNTY3YjY0NmNmODM4OWU0ZjkxOGI4ZjE3NC90YWJsZXJhbmdlOjQwYTEyM2Q1NjdiNjQ2Y2Y4Mzg5ZTRmOTE4YjhmMTc0XzEtMS0xLTEtMjA5NDA_13100f97-94f1-4d6a-97c0-ab8a8087454c"
      unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo0MGExMjNkNTY3YjY0NmNmODM4OWU0ZjkxOGI4ZjE3NC90YWJsZXJhbmdlOjQwYTEyM2Q1NjdiNjQ2Y2Y4Mzg5ZTRmOTE4YjhmMTc0XzItMS0xLTEtMjA5NDA_4e9e8466-3e6e-4205-a658-ed08287cdb95"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iedee6e787d804eec9aef3377417aa32d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo0MGExMjNkNTY3YjY0NmNmODM4OWU0ZjkxOGI4ZjE3NC90YWJsZXJhbmdlOjQwYTEyM2Q1NjdiNjQ2Y2Y4Mzg5ZTRmOTE4YjhmMTc0XzMtMS0xLTEtMjA5NDA_efc0eaf0-79d3-450f-b2ff-25f568f74406"
      unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo0MGExMjNkNTY3YjY0NmNmODM4OWU0ZjkxOGI4ZjE3NC90YWJsZXJhbmdlOjQwYTEyM2Q1NjdiNjQ2Y2Y4Mzg5ZTRmOTE4YjhmMTc0XzQtMS0xLTEtMjA5NDA_1a14f904-3c6b-4dfa-8926-9cc02715a660"
      unitRef="usd">-100000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib7fea33dfd0f43f88c85204776483478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo0MGExMjNkNTY3YjY0NmNmODM4OWU0ZjkxOGI4ZjE3NC90YWJsZXJhbmdlOjQwYTEyM2Q1NjdiNjQ2Y2Y4Mzg5ZTRmOTE4YjhmMTc0XzUtMS0xLTEtMjA5NDA_e5544cdd-fc26-4386-86c6-3b129aea0428"
      unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90ZXh0cmVnaW9uOjg4YjYxNGNiMzQ0NjQ5MTNhZTYzMjZiYTM5YjYzN2E3XzUyNzI_defcf0c4-12c6-454c-8f96-bd4c7770675e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021, 2020 and 2019 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance, end of year &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia0e74a770feb4868bd1ab0a23e223cd7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzItMS0xLTEtMjA5NDA_577f0e9a-9bf8-4676-8013-0e0a4340fcc4"
      unitRef="usd">92197000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib4203c993d0e41018d52d1c410bc3e56_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzItMy0xLTEtMjA5NDA_13525a3e-e619-434f-ae50-60f2ff861d86"
      unitRef="usd">73410000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i610800df2fc44c33b927d13481ffc06a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzItNS0xLTEtMjA5NDA_9b76db64-982f-4fa9-a470-51c8c2baf077"
      unitRef="usd">22797000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="icea0d3791b8d40149f121f9b367a9acd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzMtMS0xLTEtMjA5NDA_42422c64-86b1-46af-b9bb-4813be208e5f"
      unitRef="usd">19638000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i1c50656da4cf4784852c501bf1c61d57_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzMtMy0xLTEtMjA5NDA_28609dc6-aae4-4cd7-86d6-2f808772b4ea"
      unitRef="usd">18787000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i78bed59ffcf84935afe7d39665a6ed77_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzMtNS0xLTEtMjA5NDA_2a48b2a2-58cf-4332-b4b9-261fa042c8df"
      unitRef="usd">14485000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="icea0d3791b8d40149f121f9b367a9acd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzQtMS0xLTEtMjA5NDA_229bab03-94dd-40bf-9841-2586425d6e1c"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i1c50656da4cf4784852c501bf1c61d57_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzQtMy0xLTEtMjA5NDA_25077b3f-f16a-4915-b36e-3bb7d8313cc7"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i78bed59ffcf84935afe7d39665a6ed77_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzQtNS0xLTEtMjA5NDA_b3038292-5e35-4234-9b04-3afdf3ba1311"
      unitRef="usd">36128000</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8ac33b1c38294eb99c02be51a19dfc6d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzUtMS0xLTEtMjA5NDA_12f7dbb9-df8c-4f8e-8408-fc859a87a6af"
      unitRef="usd">111835000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia0e74a770feb4868bd1ab0a23e223cd7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzUtMy0xLTEtMjA5NDA_aa202993-0c97-46a8-9f97-a867c77e7938"
      unitRef="usd">92197000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib4203c993d0e41018d52d1c410bc3e56_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODQvZnJhZzo4OGI2MTRjYjM0NDY0OTEzYWU2MzI2YmEzOWI2MzdhNy90YWJsZTo3YmVhZmZjODZjOGM0ZDRlYTllNjcxM2RiMzE3ZTlkMy90YWJsZXJhbmdlOjdiZWFmZmM4NmM4YzRkNGVhOWU2NzEzZGIzMTdlOWQzXzUtNS0xLTEtMjA5NDA_82dafcfe-575f-4ba0-a16c-bd745a763be1"
      unitRef="usd">73410000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90ZXh0cmVnaW9uOmIxMjk3ZjQ5MWRiYzRiYjJiOTQ2NDZhZGVmYWVhNTQ3XzE4NTE_ffa9858b-53af-43fb-a61b-99b16d7755b7">NET LOSS PER SHARE&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follow:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.126%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruing dividends on Series A convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividend as a result of Class B Warrant price reset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders&#x2014; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted weighted average shares of common stock outstanding for the years ended December&#160;31, 2021 includes the weighted average effect of 3,808,032 prefunded warrants for the purchase of shares of common stock, for which the remaining unfunded exercise price is less than or equal to $0.01 per share. During the year ended December 31, 2021, in accordance with the Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of subsequent sales of common stock. Such adjustment is accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend is calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#x2019;s common stock and the estimated remaining life of the outstanding Class B Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities included outstanding stock options, unvested restricted stock units and warrants to purchase shares of common stock for the years ended December 31, 2021 and 2020. Potentially dilutive securities also included warrants to purchase preferred stock for the year ended 2019. These potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#x201c;anti-dilutive.&#x201d; Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,874,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock (excluding prefunded warrants, which are included in basic shares outstanding)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,449,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,474,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,776,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,290,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,921,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,175,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90ZXh0cmVnaW9uOmIxMjk3ZjQ5MWRiYzRiYjJiOTQ2NDZhZGVmYWVhNTQ3XzE4NTI_a4984c97-bed0-4b20-bf7f-ab134b1a8a57">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follow:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.126%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruing dividends on Series A convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividend as a result of Class B Warrant price reset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders&#x2014; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzMtMS0xLTEtMjA5NDA_d7079a49-cda2-45f9-9600-4a56f3e872b8"
      unitRef="usd">-88696000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzMtMy0xLTEtMjA5NDA_d1c0f64d-2a56-4949-9a42-1637fdacfcec"
      unitRef="usd">-62131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzMtNS0xLTEtMjA5NDA_3e8b9df4-1a4f-4af6-8146-eb29bcac1e28"
      unitRef="usd">-52807000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzQtMS0xLTEtMjA5NDA_52deac61-4d4b-41b5-9460-1b91a27bb1f7"
      unitRef="usd">0</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzQtMy0xLTEtMjA5NDA_7ce946aa-498e-4d9d-9c5f-f9a6975da4f9"
      unitRef="usd">0</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzQtNS0xLTEtMjA5NDA_e19251f8-0a3d-44f3-a61b-b50fb48100b1"
      unitRef="usd">592000</us-gaap:TemporaryEquityDividendsAdjustment>
    <xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzUtMS0xLTEtMjA5NDA_514a271b-bc02-4e1f-937e-e91c94755aa2"
      unitRef="usd">13943000</xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock>
    <xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzUtMy0xLTEtMjA5NDA_eba7bd74-de28-489f-98d7-0ec18ef50b6a"
      unitRef="usd">0</xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock>
    <xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzUtNS0xLTEtMjA5NDA_2a081f4b-516e-446d-a205-22db4cfd35a1"
      unitRef="usd">0</xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzYtMS0xLTEtMjA5NDA_7926dcd8-8fb0-4aff-b2e1-0c584685f154"
      unitRef="usd">-102639000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzYtMy0xLTEtMjA5NDA_36ee0983-2625-458d-bc29-33d508fb766a"
      unitRef="usd">-62131000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzYtNS0xLTEtMjA5NDA_03dcdc84-e44f-4ef2-be83-72f9e954ca23"
      unitRef="usd">-53399000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzgtMS0xLTEtMjA5NDA_5ac82165-a324-4b45-87f6-a23201a3530c"
      unitRef="shares">25749000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzgtMy0xLTEtMjA5NDA_0baf1c73-445e-4e6a-bab8-f8940251529e"
      unitRef="shares">20077000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzgtNS0xLTEtMjA5NDA_7065e09e-e841-48c1-8b2e-f33383f155ea"
      unitRef="shares">11530000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzktMS0xLTEtMjA5NDA_374e652f-7169-497c-9508-9e1f0c55fca5"
      unitRef="usdPerShare">-3.99</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzktMy0xLTEtMjA5NDA_6cb00948-9dca-4ce3-90e7-02625e3e7679"
      unitRef="usdPerShare">-3.09</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZToxYTY5ZTE0NGFjYTI0ODgwOTU4MTZmMjI0NDBkMTMyMS90YWJsZXJhbmdlOjFhNjllMTQ0YWNhMjQ4ODA5NTgxNmYyMjQ0MGQxMzIxXzktNS0xLTEtMjA5NDA_a26d1ca7-3f54-44e8-aeb6-a11f323a46ed"
      unitRef="usdPerShare">-4.63</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib495f27eee5643c1aa40007ea1e395be_D20190416-20190416"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90ZXh0cmVnaW9uOmIxMjk3ZjQ5MWRiYzRiYjJiOTQ2NDZhZGVmYWVhNTQ3XzU2Mw_0ae5b3fd-b405-422f-ba42-3ae603a6af73"
      unitRef="shares">3808032</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i834346b84a2147ecbd3cf27e5b2b7a1f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90ZXh0cmVnaW9uOmIxMjk3ZjQ5MWRiYzRiYjJiOTQ2NDZhZGVmYWVhNTQ3Xzc2Ng_39e4b0ec-00da-4981-beb0-bef02a66468c"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90ZXh0cmVnaW9uOmIxMjk3ZjQ5MWRiYzRiYjJiOTQ2NDZhZGVmYWVhNTQ3XzE4NTA_0a7aed11-0178-472b-ad82-b4059d99eec6">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:97%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,874,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock (excluding prefunded warrants, which are included in basic shares outstanding)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,449,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,474,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,776,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,290,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,921,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,175,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia358f6661177462caadde0fb55c0679c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzItMS0xLTEtMjA5NDA_aa9bc9b4-3e50-4130-8ee5-5e4ba51c0a2f"
      unitRef="shares">1916051</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib7f118f44cef4d8da8cb50ea3570142e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzItMy0xLTEtMjA5NDA_04efbf47-843f-4d2e-9920-1082cca58a1d"
      unitRef="shares">1874514</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i574f61ac83b744e4bac8486593ef48b8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzItNS0xLTEtMjA5NDA_a1a0555e-2afc-4f88-960f-c4e17b8994e3"
      unitRef="shares">1297029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2ebe6af4f44d4c56a5d0c7916e1a7f3e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzQtMS0xLTEtMjA5NDA_967ead67-f17d-4ba0-ac21-0821acb655c6"
      unitRef="shares">925101</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifce6e198f34e4961a5cb7083bbca2927_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzQtMy0xLTEtMjA5NDA_0abfda09-1339-4acf-b5b9-34608d6b8c08"
      unitRef="shares">572460</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic1b7de7a2f0e407ba0289ebb81300e0e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzQtNS0xLTEtMjA5NDA_4a8718f4-00af-4980-bfbc-7dfad6ac73cb"
      unitRef="shares">101773</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic7ed78f3d9464a2eb083a1251fd15435_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzUtMS0xLTEtMjA5NDA_9b6cae7a-34c4-404c-b1cd-6c668b1507a2"
      unitRef="shares">9449128</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9372c9ab8f97446b99dcb15a6e0b1733_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzUtMy0xLTEtMjA5NDA_8a85d936-d006-40d2-87db-3aeba305b470"
      unitRef="shares">9474403</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i15c8d1f64e434ebbac09001eadf96f1d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzUtNS0xLTEtMjA5NDA_3ebb3e5b-bfde-4012-b97a-41596d869d1e"
      unitRef="shares">9776871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzYtMS0xLTEtMjA5NDA_e71091a7-88e5-4b74-af99-ae6cf9729cc4"
      unitRef="shares">12290280</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzYtMy0xLTEtMjA5NDA_ec0ba778-fe3c-4bc7-b25d-fcf09b15afb4"
      unitRef="shares">11921377</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xODcvZnJhZzpiMTI5N2Y0OTFkYmM0YmIyYjk0NjQ2YWRlZmFlYTU0Ny90YWJsZTpmODIxNDU3NmEyNGU0MGQ1YTQ0ZDRiMWFhYWQ5NTYwNi90YWJsZXJhbmdlOmY4MjE0NTc2YTI0ZTQwZDVhNDRkNGIxYWFhZDk1NjA2XzYtNS0xLTEtMjA5NDA_ba6a3ce3-d4cf-45f4-8b74-01bd5d561bf3"
      unitRef="shares">11175673</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTAvZnJhZzpjNDQ5YWRlODY0ODE0MGU0ODUyMjk1NTllOWJhOTY4ZS90ZXh0cmVnaW9uOmM0NDlhZGU4NjQ4MTQwZTQ4NTIyOTU1OWU5YmE5NjhlXzEzNzg_6aae0086-6d1a-48ff-8be6-e6b1bb83f882">LOSS ON TRANSFER OF NONFINANCIAL ASSETS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company entered into contractual arrangements with two third parties that transferred the rights to develop and commercialize the programs underlying IPR&amp;amp;D intangible assets acquired in the Merger. As of December 31, 2019, all programs underlying IPR&amp;amp;D intangible assets acquired in the Merger were transferred to these third parties and the Company had no continuing involvement in any ongoing research and development activities associated with the programs. The Company concluded that these third parties are &#x201c;non-customers&#x201d; as the underlying development programs transferred to these third parties are focused on potential drug candidates that were not aligned with the Company's strategic focus and, therefore, are not an output of the Company's ordinary activities. Accordingly, the Company accounted for these transactions under ASC Topic 610-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gains and Losses from the Derecognition of Nonfinancial Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 610-20&#x201d;). As a result of the transfer of control of the IPR&amp;amp;D projects to third parties, the Company derecognized the IPR&amp;amp;D intangible assets through a charge to &#x201c;loss on transfer of nonfinancial assets&#x201d; in 2019 of $3.9 million, which included the carrying value of the IPR&amp;amp;D of $4.9 million, partially offset by $1.0 million of non-refundable, upfront fees received from the third parties.&lt;/span&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTAvZnJhZzpjNDQ5YWRlODY0ODE0MGU0ODUyMjk1NTllOWJhOTY4ZS90ZXh0cmVnaW9uOmM0NDlhZGU4NjQ4MTQwZTQ4NTIyOTU1OWU5YmE5NjhlXzEyMzI_d322c428-eb77-4c15-af3e-2ec81aa0cb21"
      unitRef="usd">-3900000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ibc0f8bba43d64d859d8549ce3f940062_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTAvZnJhZzpjNDQ5YWRlODY0ODE0MGU0ODUyMjk1NTllOWJhOTY4ZS90ZXh0cmVnaW9uOmM0NDlhZGU4NjQ4MTQwZTQ4NTIyOTU1OWU5YmE5NjhlXzEyODY_d0f9aab2-605f-4d5b-bad4-ff8c86fee9dc"
      unitRef="usd">4900000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="id03c381eb978491b8ef9300074bfc781_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTAvZnJhZzpjNDQ5YWRlODY0ODE0MGU0ODUyMjk1NTllOWJhOTY4ZS90ZXh0cmVnaW9uOmM0NDlhZGU4NjQ4MTQwZTQ4NTIyOTU1OWU5YmE5NjhlXzEzMTA_74c104af-2773-45b3-a1e0-4f891211fc81"
      unitRef="usd">1000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzUyNTk_46734591-b78a-4a58-8290-5492b9366397">SUBSEQUENT EVENTS&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Termination of Aspire Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2022, the Company terminated the Aspire Purchase Agreement, under which Aspire was committed to purchasing up to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$50.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the Company&#x2019;s common stock, subject to certain restrictions. No shares of common stock were sold under the Aspire Purchase Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lincoln Park Capital Fund Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2022, the Company and Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) entered into a securities purchase agreement (the &#x201c;LPC Purchase Agreement&#x201d;) and a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company has the right to sell shares of common stock to Lincoln Park, having an aggregate value of up to $50.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement, at the Company&#x2019;s request from time to time during the 36-month term of the LPC Purchase Agreement. In consideration for entering into the LPC Purchase Agreement, the Company issued 230,414 shares of common stock to Lincoln Park as an initial commitment fee. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon execution of the LPC Purchase Agreement and the Registration Rights Agreement on January 14, 2022, the Company sold to Lincoln Park, as an initial purchase under the LPC Purchase Agreement, a total of 1,382,488 shares of common stock, at a per share price of $2.17 per share, for aggregate consideration of approximately $3.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amendment to Hercules Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 9, 2022, the Company entered into Amendment No. 3 the Hercules Loan Agreement. The amendment:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;terminated the Company&#x2019;s ability to request additional term loan advances in an aggregate amount of $7.5&#160;million through June 30, 2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;increased the aggregate amount of term loan advances the Company may request from $10.0&#160;million to $17.5&#160;million, subject to Hercules&#x2019; investment committee&#x2019;s sole discretion, through December 31, 2022; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;modified the minimum cash covenant contingent upon the Company raising &#x201c;cash proceeds&#x201d; (as defined in the Hercules Loan Agreement, as amended by Amendment No. 3) of $33.0&#160;million between January 1, 2022 and June 30, 2022. The current minimum cash covenant requires that, following the initial test date for the covenant, the Company maintain a minimum level of cash equal to six times a cash flow metric based on the preceding three months cash flow, subject to reduction, upon achievement of certain performance milestones, to the greater of $20.0&#160;million or three times the then-current cash flow metric, and further subject to extinguishment of the minimum cash covenant based upon achievement of additional milestones. If the Company raises the specified &#x201c;cash proceeds&#x201d; in the specified period, the Company would, at all times thereafter during which the minimum cash covenant is in effect, be required to maintain a minimum of $30.0&#160;million of cash, which would be further reduced to $20.0&#160;million upon achievement of certain performance milestones and extinguished upon achievement of additional milestones.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 7 to these notes to the consolidated financial statements for further discussion of the Hercules Loan Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="ia2a4f9e0d29b44b3a8c743db5ab19895_D20220114-20220114"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwNzI_84fcfe6b-f959-4f97-bd1c-4591245f5a01"
      unitRef="usd">50000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="i2d9b7bf5f3ef40dbb4d96393c1905d90_D20220114-20220114"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzE2NDkyNjc0OTU2Njg_8f2b1a27-da7b-4037-b309-3d0118019219"
      unitRef="usd">50000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <xfor:SaleOfStockPurchaseAgreementTerm
      contextRef="ie34513bfd4ce4c4298a4866e8aa61aad_D20201014-20201014"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2NzI4NjM_e5e76214-e7c0-4f78-bc1a-32454257ca44">P36M</xfor:SaleOfStockPurchaseAgreementTerm>
    <xfor:SaleOfStockPurchaseAgreementSharesIssued
      contextRef="ic6a4a6cada334ffd9ee919af14b029f6_I20220114"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzE2NDkyNjc0OTU2ODI_110e3843-cfd1-42c6-8a9f-20855da51b20"
      unitRef="shares">230414</xfor:SaleOfStockPurchaseAgreementSharesIssued>
    <xfor:PurchaseAgreementSharesPurchased
      contextRef="ic6a4a6cada334ffd9ee919af14b029f6_I20220114"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzE2NDkyNjc0OTU2OTc_b845a792-6649-4b36-8a34-d5805a0d8b8c"
      unitRef="shares">1382488</xfor:PurchaseAgreementSharesPurchased>
    <us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare
      contextRef="ief44e634dee347efb955cc9c643e8ca1_D20220114-20220114"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzE2NDkyNjc0OTU3MDU_aa3c94a9-855d-4a87-b8d4-218e8f30633c"
      unitRef="usdPerShare">2.17</us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare>
    <us-gaap:PaymentsForSecuritiesPurchasedUnderAgreementsToResell
      contextRef="ief44e634dee347efb955cc9c643e8ca1_D20220114-20220114"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzE2NDkyNjc0OTU3MjI_885f3cce-7206-499c-a0cc-5a35ff4bc237"
      unitRef="usd">3000000</us-gaap:PaymentsForSecuritiesPurchasedUnderAgreementsToResell>
    <xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo
      contextRef="i5720729ba9eb468d8f2396ce7f061f2a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwNTg_3b208e3c-fe2e-48ad-be82-733a7076856a"
      unitRef="usd">7500000</xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo>
    <xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree
      contextRef="i5720729ba9eb468d8f2396ce7f061f2a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTA5NzA_9f5cda4a-d05c-4f48-ac21-368edba68225"
      unitRef="usd">10000000</xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree>
    <xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree
      contextRef="i6e984764b25842acb5cf371ed696787e_I20220314"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTA5ODU_e9fbf8bf-fc5e-4a2e-ae79-e8d3a3411655"
      unitRef="usd">17500000</xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree>
    <xfor:DebtInstrumentDebtCovenantMinimumCashRequired
      contextRef="ie9413c149a6a46d882b610a2ff34f1ff_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwMDA_6376935b-afad-430a-b968-c7e6ab348f63"
      unitRef="usd">33000000</xfor:DebtInstrumentDebtCovenantMinimumCashRequired>
    <xfor:DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario
      contextRef="i6a4e1b15e8914a5da92a4b13a532378d_I20220209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwMTM_15ffdd94-6e86-4362-be69-da18c47ef30c"
      unitRef="usd">20000000</xfor:DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario>
    <xfor:DebtInstrumentDebtCovenantMinimumCashRequired
      contextRef="i3c992b94297b4f968244daa96427847c_D20220209-20220209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwMjg_4ab99676-66d9-4e9f-a22e-c93c0a76c07c"
      unitRef="usd">30000000</xfor:DebtInstrumentDebtCovenantMinimumCashRequired>
    <xfor:DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario
      contextRef="i6a4e1b15e8914a5da92a4b13a532378d_I20220209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzQ5NDc4MDIzOTEwNDM_8eb89cc5-c6e7-490f-9f90-765fc21bcc7b"
      unitRef="usd">20000000</xfor:DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i75e45f429fc6401584184ad501a62f94_D20220303-20220303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3NDc_ec48edd6-0a8b-4363-88ce-b5b7937f2405"
      unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i520c1054445641ac8c06d14b69d2bea3_I20220303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3NzI_c5b66399-408f-422d-a161-51abd5759535"
      unitRef="usdPerShare">1.80</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8f62b2544f6c4e2398c83ef365be248c_I20220303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3NjE_51763385-e6a1-4a7d-a55c-7017b0736093"
      unitRef="shares">766666</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i520c1054445641ac8c06d14b69d2bea3_I20220303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3ODE_317050d1-0c23-4b27-8551-6ba30cdb276b"
      unitRef="usdPerShare">1.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i520c1054445641ac8c06d14b69d2bea3_I20220303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3OTA_c5b66399-408f-422d-a161-51abd5759535"
      unitRef="usdPerShare">1.80</us-gaap:SaleOfStockPricePerShare>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i520c1054445641ac8c06d14b69d2bea3_I20220303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg3OTg_dae0b6c0-b1ce-4735-b76f-a5cddd996601"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="i75e45f429fc6401584184ad501a62f94_D20220303-20220303"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg4MTQ_180c249b-4326-4923-aeab-72a85ad0ed20"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6b3f8b3ba54d40b8b4c0116541e93c5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTc5ODE_db32f683-b169-4131-82e0-5d5c8badd82f"
      unitRef="usdPerShare">3.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7b4b699affe54fdf8181d6649b333e5f_I20220114"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTc5ODg_db1f9668-1b9e-465e-a630-3e17d61e3252"
      unitRef="usdPerShare">2.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie187101e5927453095022efb8232686c_I20220209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxYmQ3NDUxMTdmODQyNjhiYjg3NWJjZTkyZWE2ZGIzL3NlYzo3MWJkNzQ1MTE3Zjg0MjY4YmI4NzViY2U5MmVhNmRiM18xOTMvZnJhZzo3ZGQzM2M3ODFkYWM0MGViOTUyZWM1NzczMmFjMWE0ZC90ZXh0cmVnaW9uOjdkZDMzYzc4MWRhYzQwZWI5NTJlYzU3NzMyYWMxYTRkXzEwOTk1MTE2OTg1NjM_97249a20-383f-473e-b4cd-f38726a3940d"
      unitRef="usdPerShare">1.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@?2$;.(DC%\0(PD$$1XIH@59FD+$.I<J-R_@P8RM\K30;[<;D$VB"_-M9I.
M"\%[97YCG)PH6R?G0A,P!:W5\ [R1(=$]!G:+XMGAQQ^5_!I6RYZ-N4B9HJK
M18]&+&0FWRWN=H72D^(6IA"P_]E[<N<]TR]!IE1J,IE,"H<DZN<"'C%Q2<B,
MF#(A5IKPR\CL-XK,0_"6A.],H"M/Y".K5@$<"M:>VW/<_CFVB?#+R.SCD32
M&139"MBQ4%P#4*M*92CV&];B#HN$8WA8&>UJP.IJUV7X]?&P^9+5MKAZG!<.
M-_Y1Q:IS<'QAPJH]!E(D-"6KXB1C_W1_U!38 Y9.V;PXI[JE)BHKDK(EF#JG
M9Z!-LCCZ*6ZT6-O#D(706F3V,F84I, T@/=+(?3NQGQ@?P!W]3]02P,$%
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M-D$%7[.VU)_E[C=^""@Q_G)9*OL?[?:V"9V@O%5:5H?!0%")>O_)?AP2<30
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M&(;7+!T+HQ<4'%:4CR=3>&Q*N%H1IVY1]%C%V4AA(+VBD',4Y05"X@I&1H:
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MG,&4-P;P^UJ"9A]NS,%L=Q"_^A=02P,$%     @ T(%Q5/%:PBQ[ @  N 8
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ML>8'8N(DB_SU3/8ID4^D9X/T[!W2J8<9RV3%Y>8M[=D+1<EEG$SR;/),^LO
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MJ?*PH(K>7DNQ1U*CP9O^4B6SL@;Z/-=U?U(2_LO!3MW.15Z(E"=4L00]*?B
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M ]/\KV'6W&;6 D=0+MC@O"_8=<V@,_\+F#6WD93Q"#N>L@D#D.*5F+6PX9$
M'?*%L)DU\3SM$09+Q=^864^%#9(D8-S%E(1!2O%W8]9B\&Q=& @4SR?+ F#
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M;<,/"5H?P/[:&#H:_H+A:2K^ E!+ P04    " #0@7%4Z.=YS\@)  !!*P
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M1+W(P^V;#(P2)Z,U@S12\(X%''62[X1L^']F:2768L(L,UC9F" RW<;&^%Z
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M(CC3-$IL@9-"ECYP+M@>?#A=$8O(9 4+6,))&P). 7:\JCD@2$[M7*>*.?R
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M:P%E:0&>EP:^&"_H@/[COE?_!5!+ P04    " #0@7%4I1SV-_$H  "3A@
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M_3C[/%"F<#S[?2*,\SB=/$13E<P#Z+%P)118476EU)IP()?&9<EKHWB4F+J
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M J[VM]/LK"7D%.Z()%=K/EGD4[VMRE9QM[7?C2N*P@$HR>*)UMF2-% [!:^
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M3K0 ]^<:X[?X00ZJ]Z:7_P-02P,$%     @ T(%Q5-CPR%J^ @  R 4  !D
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M4,<[B4.2S=GA27K42?6ZX1S.%+&H+%50G2B=)KD'J,[,V<5J&Q^T\@0&%D1
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M,>T+7]B0PYH,5IEU-/<DVL4&*8=V] ?S)+JZ%(I:F;)>*V/1J-"FEM7G='$
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MC_U5_WA??5U78F\/L%[DSCMG[5*Z/AO427-.FS*XILE1J',;'FHU7P%U_4%
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M@X"1^L&;@K^_C8WW)N.?,R7A%9J \8E!;E0/M$'S0?;=?P%02P,$%     @
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M04T+\'YAC&]NB$'[GQ9>_ ]02P,$%     @ T(%Q5%>UUY\B!@  B0\  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULG5=K;]LV%/TK%UXQ)(!JZ^&7
M\@*2-D,'M&D0MRN&81]HZ3KB0HDN2<7)O]^]E*PX=E[;%YN2R,-S[I,\6FES
M8PM$!W>EJNQQKW!N>3 8V*S 4MB^7F)%7Q;:E,+1H[D>V*5!D?M%I1K$83@>
ME$)6O9,C_^[2G!SIVBE9X:4!6Y>E,/=GJ/3JN!?UUB^NY'7A^,7@Y&@IKG&&
M[OORTM#3H$/)98F5E;H"@XOCWFET<#;D^7["'Q)7=F,,K&2N]0T__)X?]T(F
MA HSQPB"_F[Q RK%0$3C9XO9Z[;DA9OC-?IO7CMIF0N+'[3Z(7-7'/>F/<AQ
M(6KEKO3J$[9Z1HR7:67]+ZR:N4G8@ZRV3I?M8F)0RJKY%W>M'3863)];$+<+
M8L^[V<BS_"B<.#DR>@6&9Q,:#[Q4OYK(R8J=,G.&ODI:YTXNR.^?M;6P1 .S
M0A@\&CC"Y:^#K,4X:S#B9S"B&+[HRA46SJL<\\<  R+4L8K7K,[B%Q$_8M:'
M) H@#N/H!;RD4YEXO.09O'-A*EE=6[A<JX2_3N?6&0J*OU_ 'W;X0X\_?,V*
MER]9\44,SKX#NQ09'O<HO2R:6^R=7)Q_@\]?9S.X/+^"V:?3JW,X$U9F(*H<
M<JEJASE4M+M:^]!Z=<(Y(^>U$W.%X#1DNBPI!RB<LIM"JQR-A96PD F5U4HP
M"CTMM*(D/8 _49C&E[ G*W"%KBUM: / NPR7;F.CG()NW[N)?T+ZB5*XJ$LT
MPFES !=K;N]@;SH-QNEXGX?C.(B2R ]'<3 -)_MPFF6F)B>1K%N9(VT'Q'B&
M1J*%4U)0W:)QD@61?19H#-'S@N#77Z9Q%!]V_WNC--Z'CX@EYAT<"Q141RSE
M*^@%?%"":)W!#V&,J$B3D1GR=V*\%R5!.DSV=Y [.6\Q,(F+PC@8)^F.YB1(
MTI0I5IJ2NC'5#U]!V!,DE IB8V'+7#?16RKSG3"(1\%DF)('@G R@2@*1DGX
M0/@_Q<9:[NXF1#[IIXV@I!\V@V%_3+;:#<S5VQ0!-0OK:"%[G_H,!1S"/<6@
M!?1!2.4 RSD)6)<$D%6FZIR@>.K.-KA84-'G;1**K6D0)K&/F=JCK1J'VVZK
M96VR@BH[+WB:8>#GK@J9%7Z%0>YW3+>N6E2\0Y-)BVT<20L*+?,3%=!:_%D+
MQ=9^%_;#Z,$;??A8&P9::WY.<D":J8=EVN2BH@U6TC5<MN-87!L._,H%_O,6
M+Q*&@E1LFGP;@0N#R/^AYD-$B+*WT7JUK>>6Q! ^6*%V3=6'64WXS7JFP:9@
MWG7%<&Q'GXCY5G:2H5R[RCY4-'$KI-H.5+;;.L<8C_RWU+:ATD0LKNO]AIV_
MD8KM3>6C"EC;M2/.E,ANWL\RVH5@63M_*76.BJPJ;OA)5D2I%0:%)/$TC7Q\
MJPE-*NGNF8_WD"Z7HKKW234YM(]C7WCMY"?K9.EI/ 27D@M<@[S@,-N(V]YF
MJ1V97PJE[IN,I.,/6,PHWAS7U#:'\D?0;4(N^<A$];ZFHFL;4M0M9>:ZFEM7
MDAS%[+M\(GMTJ?1,IK\MNQF5NTD?+E_1()35#T*>9++=+#8IM RX:7D;\O17
M=BRHR, <L>)>V&R[,+KTD"1U2775'S=)^4O]N:E<;:%:Z5KE!,J\B6A-F<9?
M=]<%;;C4?OD],!0U1DO1S +9]7%X2":0[]?<^_YE=,CRR!*:09XLFE7MG;#A
ML=:%&]%1VZ8B=$D#<TUE:+=-_,\CB6S,8D6)CV+ZP=;\N3FF,)_.6<_&V_]P
MS1MX=IV#3B<ZYU3**?<9<(Z9("NU,=G6D[+UL(^=0I#-J91O.JD-A$<GKZTS
MU=<F)1^%]B.I49!&XR <132:3H;!*!K2*$XG01BG\/V51$[I]!!18QI-XF X
M#H'&P622="7F^7WW&M]X=^STV*!MFFS8+DVID341LQMA^Y &PV$:1/&41R1C
M&"8TFDS&)(JDQ:0H#.)IR ><E-IBTIQUHLDH&!/?IP[S@XWK$1U,K_TED,LP
M5>[FIM2][>Z9I\WUZF%Z<TG](LRUK+BW+VAIV)^,>F":BU_SX/327[8H+^CJ
MYH<%W971\ 3ZOM 4LNT#;]#=OD_^!5!+ P04    " #0@7%4#7$48FD$   R
M"@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RM5DUSVS80_2L[;"9M
M9V1]VHD3RYJ1+3OQ3"Q[++<]='J R"6)!@08 #2C_/KN@I1,I;;;0RX2 2S>
M[GN["V!:&_O9Y8@>OA9*N],H][Y\/QBX.,="N+XI4=-*:FPA/ UM-G"E19&$
M384:C(?#-X-"2!W-IF'NULZFIO)*:KRUX*JB$'9SALK4I]$HVD[<R2SW/#&8
M34N1X0K];^6MI=%@AY+( K631H/%]#2:C]Z?';)],/A=8NTZW\!,UL9\YL%5
M<AH-.2!4&'M&$/3W@.>H% -1&%]:S&CGDC=VO[?HEX$[<5D+A^=&_2$3GY]&
MQQ$DF(I*^3M3?\26SQ'CQ4:Y\ MU8WLTB2"NG#=%NYDB**1N_L775H?.AN/A
M,QO&[89QB+MQ%*)<""]F4VMJL&Q-:/P1J(;=%)S4G)25M[0J:9^??3+. :ES
M;X5V*5HP*2R-3J46.I9"P=PY]&XZ\.2,MPSB%OBL 1X_ SP:P[71/G=PH1-,
M]@$&%.4NU/$VU+/QBX@+C/LP&?5@/!R]>P%OLJ,^"7B39_ ^&)/44BD0.H$K
M[87.Y%IARQ@6TL7*N,HB_#E?.V^I@/YZP>WASNUA<'OXXQ7_#^";U0INEG!_
M-U^N+B_NX.82EC?+RZOE?'E^-?\$\]7JXGX%B\I*G8'/$38H+"#G!TA=+-84
MSE;A7K X-T4I](:,/%HRD]H;B"FQ+$=%T0I+/#*D/B7-:NES\+6AK=(F4 KK
M)3H:"0^^Y<LHC&RY7VC-4!,]T.%0ACS$IBC0L@[R&P:[TIK,BL)!17%:M>'8
MKV[O7HNB/%EP/-N\B29O(OY2R2;4L/\:;8:V3[*RTD_0%%0"/\8)U*31/E&6
M AU^)P@S[:J;BP1THZO4%3N7^L&HAR K^V CHS/#2Y;PA(WS@-)J%^S""2<;
M!\X9$M%3"$U..D+VX;[CFGS&JDI"4CA+3T5+I%[_=#P>#T^TT0?-J836A;G1
M"3D+^!WINE'MI/T_NI"GU) #,J$6*8TG!.Z)Q%89Q$18)D2JK:B@MC9$7,E,
M=ZFVY'YVP'WK,9-Q@\N:A<*FL]]8[ 6/ 4(#75EEY;E(]B&,3:@W[::C+U53
M'(?Y3&WV&T700J59>'*P)<G,1;B&V@JC7CR'>U-27&]&PX/QL <?Z 9M*H-/
M".*86E,$Z 5%&YM,RW"//7U<P"]MAABX@6S3\VLH?<%E0S?5EI[OG#ZAG>GF
M:9<>ZYY2]S?=GJY)5R=1^Y23;7S?VM9^J7-\;DV54?%"G MJ&L9N0U?MR=B-
M37>I-A#;LJ.VX 9FJU>3_CNZ'94B@7I0YY*Z0S[6-5+I6!LJ\T&H"O_-E#$.
MNQB!*)T,U'9I2EYAO8%7H_YP:]'&=D!U1 D51+ '54DIHXI/D;)'DB"]-Y+'
M-.XIV'_J)AET[O&"3Q1^K3@(!=5<Z;O9W8-HWKP#'LV;U]0U:<OUI#"EK</^
MVZ.H.7&W V_*\"I8&T_='#YS>M2A90-:3PTU7SM@![MGXNP?4$L#!!0    (
M -"!<50GX2QU4 8   T1   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;*58VW+;-A#]%8SJZ20SC.Z.G?@R8[O.)!G'=>TX?>CT 2(A$35), !HV7_?
MLPN2HAS)2=H'2R*!/7L[NPOX<&GLG4N5\N(ASPIWU$N]+]\.!BY.52Y=WY2J
MP,K<V%QZ/-K%P)56R82%\FPP'@Y?#W*IB][Q(;^[LL>'IO*9+M25%:[*<VD?
M3U5FED>]4:]Y<:T7J:<7@^/#4B[4C?*WY97%TZ!%272N"J=-(:R:'_5.1F]/
MI[2?-WS1:NDZOP5Y,C/FCAX^)$>](1FD,A5[0I#XNE=G*LL("&9\K3%[K4H2
M[/YNT-^Q[_!E)ITZ,]F?.O'I46^_)Q(UEU7FK\WRO:K]V26\V&2./\4R[!V_
MZ8FX<M[DM3 LR'41ON5#'8>.P/YPB\"X%ABSW4$16_F;]/+XT)JEL+0;:/2#
M765I&*<+2LJ-MUC5D//'-]7,J:^5*KPXO\>G.QQXP-+B(*XA3@/$> O$:"P^
MF<*G3IP7B4K6 0:PIS5JW!AU.GX6\3<5]\5D%(GQ<#QZ!F_2.CEAO,F/.BG^
M.IDY;T&)OY^!G[;P4X:?_I\8?@?B]O3F_(_;\\O/XOP+/F_$9V61;LG4-7-Q
MXDIME;BJ;)R"A.)D897*2>7OA?@HBPH5)493#MDX$CY5XLSDI2P>A:^15,*O
MMR)%HD+^K%BF.DZ;;4OI1&SR7'N6-Z(,<KI8B*JD%SN[P_X0U,RRVM2.[E]_
MV1^/]@X"!%9!Y_@N0@>8_8.J).E868_6@?I&/C17JNN+2R-<*O&.\+JR8JE@
ME#-94AO[K$=]<:$+5$@AKJ2]$V>RU%YFXAU$_U,D)>2V(D;BXN),O""7Q\.#
M[C9^-3IX*: $YB="%_!<"J?BRFJOX6;96"-;:UZ0Y@;MZFR#P2TNV241PH4F
M4C-E+'4CMP7NNKOS.NS\!C4BHUPE"\Y3($4W&+"%GUD3;4&KS;:E#<O=B$20
MOB<*2?3E!30O0$]Q+[-*D>@&8FTD3:;!2_;"<0QB4R0Z/#K,,XPLGR+8;.;F
M$$9"^HV$M530#AC6Y,)C#)%>_DZ0,UA.0I/7KW+J?%QB#?4W*^J+#P79YS18
M&P(/\P(C"(XI\9R=W=!KYRK0:#P91M/1] =C+B0%"8H0(5 V%#538ZY47]R6
M$%0/H*3OU/%F:SC8M/PLD83Y7CUQ'7]#C74[V\I8U?O65 *+JA&VCZ+)_CB:
M[N]O"0[G78H2B+Q!E&@^S+V=<7^TMUJ(.$TKCJZG$/ME65KSH'$^4-FCV)FL
M*-L7)[ KX5# R??*QE4&4RX,W%OK.N_4S'*8WFR*TEK76$%>&LQ(WK@%N2\^
M8U$V F]#];\^>#H0GE)?SG2F_2/9W%2!3$)=(;A,]8P4R>1>%C'4HL+6ZECF
MIJ+T(YA[_=UV-/C4FFJ1BH]5@=(9!E</6JO  9PJ76W4)K0-JKMQRN7C>MGN
MC+J3B3K*J&//6D=I0E@' <;< X;CW$P_U08(M$4;T [V>@9J/,.Y1>4S4*<^
MNW2\RTVBY[IV#M'7>96+6+H4^#@S2%94>+0"TEF5IECSS4K-([=NX"P(WL5*
M):YNV.(%"@?G49PLDJ;I;6%&J#$B!K;.'I^2ZB6G;M*ALI@IOU2J4\_!/VX$
M:_D,I,-<LP2WV5%*DK:</>FIP#)<#9J>VM2]IS0F1  J0%IIY*,G64==T#"0
MK;9,W2ON JP6R@@.\TD_< >'ZV%E#K4B5W3NX)-](NJHXWH3JR18A)")/!QO
M6Z$UZJ TJSCP@-,FXU3#@- !Y^VL0D?A*Q1H2U&%=Z90+A)UVT=JX*L-'6CM
M0&5K(X+IM!=_Q:LFQ$\]B3@G\PJCCWK8RD[U0.RJM$L;T[93,41CDSN=3K#R
M L-M_@U=:V-=J>+ _.>X6_-UM1GATB993_725%D2.C=.&FT\$+DYA:X>S*N3
MRF;?-#<L-9\C+A&(W="1)]$&-G$M/#GB$F)4:V*K"*>).1,BP*VG\N?IP;E<
M)>[G<G(#TEP:%-!>33),RP+/KN$<S3*3Z80G ?H&E%/E.1RI&-MQZ35N4<.K
MG.L<#K;-G4U7JD'GBIHKN^"+.-T+T-O#;;5]V][U3\(5=[4]_*/@D[0+C2->
MIN80'?;W=GOA$-H\>%/RA7=F/*[/_#-5$D.;-F!];A"%^H$4M/\!.?X74$L#
M!!0    ( -"!<525R,+P]RH  *V4   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;,U]:V_<QK+@7R&\V+LV,)(M.0_'3@+(<G*/+YP;KYV<L\!B/W#(
M'@V/.>2$34J>\^NWGMW5?$E.[@(+!+%FANRNKJYW55=_?]=VG_S>N3[[?*@;
M_\.C?=\?7SY]ZHN].^3^O#VZ!G[9M=TA[^%C=_/4'SN7E_32H7YZ^>S9-T\/
M>=4\^O%[^NY]]^/W[=#75>/>=YD?#H>\.[UV=7OWPZ.+1_K%A^IFW^,73W_\
M_IC?N(^N__WXOH-/3\,H975PC:_:)NO<[H='5Q<O7U]^C2_0$W^OW)TW?V>X
ME&W;?L(/;\L?'CU#B%SMBAZ'R.&?6W?MZAI' CC^D$$?A3GQ1?NWCOXS+1X6
ML\V]NV[K?U1EO__AT8M'6>EV^5#W']J[OSE9$ %8M+6G_V=W_.S7WSS*BL'W
M[4%>!@@.5</_YI\%$>:%%\\67KB4%RX);IZ(H'R3]_F/WW?M7=;ATS :_D%+
MI;<!N*K!7?G8=_!K!>_U/W[DW<C:7?:QNFFJ757D39]=%44[-'W5W&3OV[HJ
M*N>SQ_K7D^^?]C U#O"TD&E>\S27"]-<7&:_M$V_]]E/3>G*=("G ', _%(!
M?WVY.N(;5YQGSR\VV>6SRXN5\9X'1#RG\9XOC#>WXO]]M?5]!X3S?U8F^"I,
M\!5-\-7"!+][AUC^R?<5$)/S<TC\LA'^[;^]N+RX?)7]MG<9L.0Q[W*B='BF
MAZ^NV\,Q;T[TU+>O?%:TC8>5E?!JF>VJ)F^**J\SW\,7P&>]SZH&'T)6K_H3
M$&*_S_[]ZNH]<-\?0]4!0@YY ZR*#V=]"Y\^N<PI-%G>E%GN@;V/"(4'&/(^
MRW<[X#^"!R!L.YP[/R"F/<()S[N>7ZVK?%O550^(W]#S9>6+NO5#1ZL&P'!S
M<.KYE[*<I\'U*0KN7?*&1EF"SGT&X>=AZ'+HD##B<_CIZ+JJ+<\3OEG&!@@;
ME$0P 6 9!O(/@ X>+>JA=)ML.\"R 1%-V\.:87O@C;YE/.5%T0WP'@ ,>^3R
MKMC3[*6[!:%[I-W2E? ;%1!&U=$/;9?5>?$)7[;?[K*Z;6[.:I"8I>*;@<&5
M@TY 4H._:@<2,>M0])VUN[,!/IC=N6G;\JZJZXAE7#)P5,5SW.8=[%_-7U>E
M$_K==>V!]AM9SS,=LBATG3\G<A?:)H$,D,%3$?,PPKZ"ISO8DII6WE6N*0"+
MGYKV#I#?N:9D %N J0,Z[CZY_LP?78'[B#CA'SI0'K>XK3L I.V$I*L^V[JZ
M NQZY((MTD3NVX96,H!XZWBI55<,!]A,F!J@_A4T$+!F<],BW@#N"C;#\!-,
M5 \$?[J:N[TC>H'-1P(H]CDP ;.JG6!#,/*JXI+/L^OXO*'-#F$NVJX,Y"C4
MC)_N]A50$'P'Z(6'#H[Q)HC_]>]OWYQ=?)<!^DMW &SM<T^D0[2-TU>>("B8
M1H5Q!X=_\W.,'I!NM$&63 % AU+/9R"$LL)U/9#*2)[]#Q_?/7;M39<? +U7
M7A]3_J^ ^1 U\OU#^&UCY\%U(+OE=SE+(/PNT @ S=QC=X'IXZX=ZE)E9C(B
M8& X$GS)'F\208$H_.=0WK $:)$*;RO/ Q5YUYV0?I!8>)6XY\QQR,I1' )*
MBA[% L@$L%!0_"-8904"N6,6Z_>M=PD8*+-PE0,0 #^)5(1R'VDAP\<Z1!DL
MY$]IF/,5/?IUT*-?KVI!,,; U&JRZZ%#Z$X$=?CP6Y<WOB8Y,J=@_XN&MIIW
M-S1D8,)""WUT00/O9'P_;$'<56!W;;+_]55V!;(-T+I!BL/7?C__>)Z5;5WG
M'0G^^$B&=C;R!$L)-':98)B;B<U_&KKV'*TMUZ-AMZ0LD31E0<BWO0"/JH)E
M3-:QK B,M<UK(G+V%G"3-\ @S=EA-!51#[P&S E"I6<L(C<PC^LG_(%MKCEH
M5((K%"A7&A)&*N%(,4]?)(UX"ZH$5J!+\3(*"I4HZX!#RG\"7IG1F$V0MX0W
MXL#&IKI?9=^S]:(ZD=%A)UN[U[P:4?E!+I<.> X,_P &(!N4LQ<+8R3)66\)
M>C;X[!K+?1-8[IM5OKAN8=]1'3/@ ,1UYTK0@Q\J_XG@L#;0Q^%X!/78S5JX
M_T\F4G;\.6Q(A6;&P#M"0OG8]O !?JI1O&W_J4:I$<W%9/*")^]P<C)1/ P$
MEF!1'6D@?"3W;&W1'TC7()II6F;+!7NLHJG NL+=<_ .V XCTP9,72 5G"8R
M/4TB?$C,CA94.WACD46>Z@V!(CZJ?C"&N3$]1M8,K&H/!IVN_@]0(LBL,)N:
MQC+ "1G,(2.X4D"%><!>+]E&'2T(#054J-$\*8F0D3T=\R^:"+U?1FHZ((C+
MT@&EEZ2*D5VJKCP#-ZA'G#4#6D0 34<+\T@L)Q1*Y8"&THXTZ\+V4*R !24L
M&T&*EH:%H$/,1:,+QQU9//#$"6'+,W\ #&7-<-@"AP*.ER $E)/%6Y%0(B."
MZ5BE%P<RLN,^[PYYX6!3"]KA&]RO0'KHQ0V,U;(;;A(<LSF4+,E\%DL!*"$O
M09!Z7 &[<?#V]H1+,4P(I.FZ;B#C);HV<7%(D]YUMQ52+*Q Q)HL%LVJ/[6<
M-;'V;1!KWZY+&R4S^N.G2&9S@NM/#F4M!:4:]79@94 1R&N B;J"EU"& R.*
M2B(R )L+D$BD2*JE<X!=#J6@P>?\Q/$]#D#2Z)8Q.T]YZ'HLJD2V 6Z1+D&=
MG\0G0N.F5!O@#4@J(EZ-NM""X8]G:YOQ(FS&BU4,OK?6PD]J+<SMQ)\91[?A
M_8)- FJ4=#A;0BW(><9L ;:]DIT[@JRN6 ^3[CU@(.!?],4Y8&?E9]7(*+)0
M70/[_ N&'+Q&%<@I1B<:EY,=')CFL!FWXDJJB8YON-U0 ['L:*M=3J86F%WH
M0P"3U'5[YU^&$%&9_<XOO,,7?MT!SZ+!VC45BIWL.9+(M]G)H?&!U#GT:#T$
MM#R7G][EVQ;42PLVGOT17KYXIH]@(&#?@MP 'Z\#R)F$/^XQJ$+RCD,%:,P@
MX887?YJN[58,.S;34!S4;%S"?R2_U"8"?.Z"1XQOY$<T.L%0[L'U_075IFO(
M9F5EC/$-KVYT=\.#Z=;D%.% (Q@LPW^@UZVF,]E8?85Z34,#=^B1E94_MIZX
M9B/6H>^CNVDL;Y6]B_0$XR;T@G,Z5*(-6YIJDB;V9VJ0J_,6#=D;LAE02K"6
MG3,ODP%3,]:8JJ2+@3XZM\> /(AKLD#3T &\PAC):Y Q@ KQXO-CU8-$%W2@
M!7 "<(]U7A 8J/E8/_#.\./$'[F7@-% 'M99U9R1DG)B_084XAX@)F8&79--
MWP79]-VJ3/F@\2V,P%[%;26BG]46?V6\.941K+H="7V.>C7T=5<2$9"R,$'L
MCSV,F*-/> T\A,J:".LQCG[Y[-75QVOZZ^+5DTWV6WL$3^O%5Y<; <$^AM_K
MH^?9[Q3?DJ\WJGK0G#VJ@Y(C^7;(E$A*:4PE<"X%MLA9(9,F/D_6$Q%N+B(#
M8WPEVW<87P,]Z4RP*XF"81C<PR#GN@["2DYN:H%/@)^%43J20D!'&,] :Q8#
M<XX$4O"H1$3+M"-6\[,A3Y[,^U9(4CUJ!),@D,^\K"16,[:3G<2*D5O(BA2
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M>I:6D%AY&''W(<LTS0?'\HX1[LCZP,EW\)MB[K=6\GACX<ZFE)B9^&5(_8[
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M.9YV+"5W(3I)E6BQ3=1])U'<A1LE;6[@LTPQ?1V@0U4WI7?KTA?=UH@7F)Q
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MZM/6KR0P&Z;3FN LRS1FCOM[]*TWWPH/.6I&,K4[$:<>AXXJI#HT;'+^6A>
M:=S)1DI*X@JMH<C=9,S?D-M@XF*7Z+JI8,$$B2$>9D-\ZC XAO.<R0PIP;Z@
M]7NCG;<]0"0'F8.>O>&PS;,F;@O<A@W<AJUPNZ=[7UH*?Q_XHE2ZX4(< DMK
ME'\-EC=8>0N'K"K(HX E25F4@I!$?T_(CFNG4D!_N V:D[=G6O?2+$+(-)D"
M*U0I;7CX0+P@Q]$IG+V?[!W76@Z:Q >MZO!IRATM3>-V];8C.#H-1X/Q<6M
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M^VU!XQ6U,Z#S7"G[*K@ W<">_P502P,$%     @ T(%Q5&Y1C;64 @  ?P4
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M[0+HO%+*'@R78'ASE_\ 4$L#!!0    ( -"!<52'3 :<0P,  (X'   9
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;(U5;6_30 S^*U:8T"9U2Y.TZU;:
M2MT& HE)$QL@A/AP39SVQ+V$>UGAW^.[=%DWUHHOB7UG/WY\MN\F:VU^VA6B
M@]]2*#M-5LXUXS2UY0HELR>Z044[M3:2.5+-,K6-059%)RG2O-\_327C*IE-
MXMJ-F4VT=X(KO#%@O93,_+E H=?3)$L>%C[QY<J%A70V:=@2;]%];FX,:6F'
M4G&)RG*MP& ]3>;9^&(8[*/!%XYKNR5#R&2A]<^@?*BF23\00H&E"PB,?O=X
MB4($(*+Q:X.9="&#X[;\@/XNYDZY+)C%2RV^\LJMILE9 A76S OW2:_?XR:?
M2+#4PL8OK%O; 44LO75:;IQ)EURU?_9[<PY;#F?]'0[YQB&/O-M D>45<VPV
M,7H-)E@36A!BJM&;R'$5BG+K#.UR\G.SCUHMC^_02+C"A8/#.[80:(\FJ2/P
M8)*6&Z"+%BC? 93E<*V56UEXJRJLG@*DQ*JCEC]0N\CW(EYA>0)%UH.\GV=[
M\(HNU2+B%3OQ*,$K;DNAK3<(W^<+ZPRUQ8\]X(,.?!#!!SO ;VE:*B\0=!U/
M\J4#W(L0IF]L&U;B-*'QLFCN,6G+XT)YJL"^U#0-UF$5PK@50JT%C157RS$<
M<D5+VENF*GM$)$J4"S3Q!)\H-X:KDC=, )/:*Q>PQ-,X!U#DO6&__RC$PR->
MDGO9 X71BY6EP3A<^6@$>5[ I9=>L#!H<=-3$+)#U1(.^ W[0S/M+&2];#B"
MP7 (SY(LBMYY,0B_;'0&']':,4V",>0%C38QWK^4#T?GPR-X_>HLS_(WSR [
MPL]A#F*4XGPC4+@]K3#L6F'XWZUPS9PWW'&T07MDM:M%]B*_W")SV_;<5H7#
MP/2@]BZT>=.5NSMZZI"V/-1(5)MC71\_K4WE$3R-L8E-]AY-2?E8XL\4S)<&
M,9C!&@F>V4T3VF<=.(9OR$RX#:@]M_G!G7;$ADCF=.Y4MB 60)0'HRS( \BR
M7G&>_5-%2D3X"/<BZUC$4VJJEXJ8;MV1$LTRO@26)HHFH+TNN]7NL9FW=^RC
M>?M273.SY,J"P)I<^R<CJIII;_]6<;J)-^Y".[J_H[BB!Q--,*#]6FOWH(0
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MVH3&@@O569-S1<U%N;.:=@NRLXO/2"$9^' OER6:LYEO"92W_+0#N&P!Q!L
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M)80KW;,YP/BT9WPZS/CAYNK!'0&D_L)PNY+@"/[S\F,K27:H3 9A_+ RT<_
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M(%"S 'V?*65W#^R@_T]R^0]02P,$%     @ T(%Q5&FT[#0I!@  #A$  !D
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MX)U*&!2$P:D$OR!DJ=MY[EGAED23^52*/9(&#=;,(*M^QH9Z,6X6REI+>,N
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M <#[C1#Z;6*N-.4E>?X?4$L#!!0    ( -"!<518PS4W! ,  /8(   9
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(U637/:,!#]*QI/#\E,&G^!<3+
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MH7<IH5\3K'2WTFX3EV"%QT/!MT@8M+9F!C;[EJWS19CID[D2>I=HGAK/J_Y
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M"\$>%_P W7&F<HDF+(5TF\#5>AI1P5K4*#C(&$-R@4+_$PJ\P'^<Q>CTY$S
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M8.MMO:[7^K"QG6+VLCY3,6>%1!G,=%9TTM?I8K,]M#E1?%GML$RX4CRO#A=
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M!69^*H1>=>P3H'[R#7X!4$L#!!0    ( -"!<50]3?6SWP(  *$(   9
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M\I$3^3!!GWFF=A)]R&*(#P/8&GQ3 7FJX(:,1EQ!=(E<?(&(0_  H.7Y[LZ
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M0Y-78+V59.R^,.ONP+WLG_/E@%6(G1.TMY*.QS5]R=.\4"!:H&,<M/J+)Z]
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M,F<2HUYTIV\W4;PU!]B2*SP.S;#$'Q8('8#O"\[5ZT2?B<,O,/T+4$L#!!0
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M[1+/:U N .?G4IK7@3L2ZG\ P[]02P,$%     @ T(%Q5 _@LKIB @  O 4
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M9SY7R0!XOI)2'VZ25\[%SSW3?P!02P,$%     @ T(%Q5!VAB[(_ @  . 4
M !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&ULA51;;YLP%/XK%NI#*Z4A
M0"!K19":HFB3,BEJVNUAVH.!DV#5V,PV2?/O9QN"LI6T+^#+^6Z8X_C Q:LL
M 11ZJRB3<Z=4JKYW79F74&$YYC4PO;/EHL)*3\7.E;4 7%A015U_,HG<"A/F
M)+%=6XLDYHVBA,%:(-E4%1;'!5!^F#N><UIX(KM2F04WB6N\@PVHEWHM],SM
M60I2 9.$,R1@.W<>O/M%9.IMP0\"!WDV1B9)QOFKF7PKYL[$& (*N3(,6+_V
M\ B4&B)MXT_'Z?22!G@^/K$O;7:=)<,2'CG]20I5SITO#BI@BQNJGOCA*W1Y
M0L.7<RKM$QW:VD@7YXU4O.K VD%%6/O&;]UW. /XW@6 WP%\Z[L5LBY3K' 2
M"WY PE1K-C.P42U:FR/,',I&";U+-$XE*\YVM\\@*I1"IM M6C:J$8#6@K"<
MU)BB-3[J0U 27:>@,*'R!ETAPM!SR1N)62%C5VDCAL[-.]%%*^I?$$TA'Z/
M&R%_XGLOFQ1=7]W\R^+J&'T6O\_B6]K@(JU.D!*94RY-AE\/F51"G_OO#\B#
MGCRPY-,+Y-JJ/Y2T184693I@G\SNPMC=#TA->ZGI9U+!D%2+BLZD?&\Z\X;%
MPEXL_$QL.B06OA/SO.#N@EC4BT4?BBT)PRP'M +=2".T(C@CE*CCZ/27C5#:
MP)"=Z-UG#H(HG/UGQSUK!'.G?,=B1YA$%+8:-QG/-(%H^[2=*%[;WLBXTIUF
MAZ6^VD"8 KV_Y5R=)J;=^LLR^0M02P,$%     @ T(%Q5%Z$S',"!@  +!P
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M.B]?394WDNV*%QTK)B5+B\LM):J3Y +J_S5C\OXF?W=2OR"<_0-02P,$%
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M]JK8JLP1>"G">)+D_HN#-1Y8XV.LD8O5JY)=5A+%;E8\L.)CK+&+%>^S1I/
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MK3,#\4%(EAFPBB!+\O(W^F8FH@: I > # "-!6 #P&,!Q #(6(!K .Y8@&<
MWEB ;P#^6$!@ ,%80&@ 8=$.9?V*XE]$,EJ><78$7%LK;_J@Z* "K6J>Y+K9
MUY*K?Q.%D\L;U5N4<[H!4;X!*Y9EJ@/7DL5?P9>(\RB7 OP!UN52 .P>7!^D
MD,HVR;?60C)P<^#Q3G4=6.\B3H4V;7A[?D%EE*3BA7)WN[X SY^] ,_  HC2
M/,G!;9Y(\5)=5,>?=^P@U"CB;"%5ECK616PR>E-FA'HR^C/B<^#@EP Y"'7
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MXIA)96+,E_.[NK!R_X,*YFX;]U\%MMVIU\9DL]/M=B<<M/N#^@GHE1/0\T[
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M41*G\]"=AM)/T$P#&8<]M8-K:<7.$,TYATD)B'&#BC?VPAXFM2)CLR0?Z\]
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M7 .-@1<+U/TE8_(P*!Q4QT6S/U!+ P04    " #0@7%4K/09:,0"   ;!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6R554MSVC 0_BL[/B4S(7Z
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MKQ<J&T#W,RG-=F,)ZN]A_S=02P,$%     @ T(%Q5&)1Z&$$ P  J@D  !D
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MOOD!54(MPQ?S7-HGVE2QGH/BE52\J,!:04%9^28O52$: -P^ O K@+\+"(\
M@@H0G L(*T!H*U.F8NLP(8I$?<$W2)AHS68:MI@6K=.GS/@^4T)_I1JGHIGB
M\?/52%<N06->Z.4DB37D"LW*I8!XBHY&W;Z8-J!Q3J2D*8W+X8L)*$)S>:EI
MGF83=/'E$GU!E*''C*\D88GLNTJK-QK<N%(Z*I7Z1Y1B']USIC*);ED"R7L"
M5Z==Y^YO<Q_Y)QDG$%^C ']%ON?C X+&Y\.] _#)V7#<.Y%-4#L96+[@F),9
M$7 UW_=H* 1A"] _JT+S5]2,FY)7.SS<$)&@/S\U);I34,B_)P2%M:#0"@J/
M"'KDBN1(VJ533A<W9!U: "5?R_*9#6L=M7%7EW;=-&4_J!7ZW?=!D_T@WVN]
M,;W+IU7GTSJ9SP-(("+.D%Z_>FM9ZSUS::L'Y4]PHF3M>HKVY_"P4POJ?+"'
M)5^[6?F.'^QX>" HP.T=#_>#>E[OL(7=.IWNR72^ P.A$S(.DD1OIU0J0<S)
M<X:)O7J2WN<P$7MOF[SWP396A,T_* A;G1T?#T5A[.\8>2 *XQ#O6.DV#K$"
MQ,)>!J06NF*JW-/KT?K",;3'[,[XR%Q$[.'X1E/>8NZ)6% F40ZIIO2N.UJ2
M*"\&94?QI3TJYUSI@]<V,WV9 F$"]/>4<[7MF GJZUGT'U!+ P04    " #0
M@7%4**OE+MT"  "6!P  &0   'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6R-
M56UOVC 0_BM6M \@M<U["A4@ =FT2NM6E7;[,.V#20YBU;&9[93NW\]V0@8T
ML'XA?GF>NWONN/-HR\6S+  4>BTIDV.G4&ISX[HR*Z#$\HIO@.F;%1<E5GHK
MUJ[<","Y)974#3PO<4M,F#,9V;-[,1GQ2E'"X%X@694E%G]F0/EV[/C.[N"!
MK ME#MS):(/7L #UM+D7>N>V5G)2 I.$,R1@-7:F_DV:&+P%?">PE7MK9)0L
M.7\VF]M\['@F(*"0*6,!Z\\+S(%28TB'\;NQZ;0N#7%_O;/^R6K76I98PIS3
M'R17Q=@9."B'%:ZH>N#;S]#HB8V]C%-I?]&VP7H.RBJI>-F0=00E8?47OS9Y
MV"/XR0E"T!""8T)T@A VA/"]A*@A1#8SM12;AQ0K/!D)OD7"H+4UL[#)M&PM
MGS!3]H42^I9HGIK<LHR7@![Q*TATB1;Z;Y57%!!?H>;J"Y<2S4#_PP =H'LI
M*$RH[&O>TR)%O0]]] $1AAX+7DG,<CERE0[1.'*S)IQ9'4YP(AP_0'><J4*B
MCRR'_-" J[6U H.=P%EPUF(*V14*_0L4>('?$=#\_72O@YZ^F^X/SZ@)VW*%
MUE[XWW*AE,B,<EGILOR<+J42NH5^G7$1M2XBZR(ZX>*)$04Y6BBLH+."-3VV
M=#-57B:7@^$@B4?NRWY>.V!)$(?#0UC: 8N#T(]:V(&(N!41GQ6A9X+N>(9Z
M4]U"@N!^EY#:1++GVO<'R9&,MZ X/L*D;S&7T3#L5I"T"I*S"II*]TS[]=%*
M\!+-=6<05A&V1M\V(+ 9G!(MW[;F!?K*]98IP2DU\%NF0(!475E(.LHY2*Z/
MZC3O@"7^<! >I:(#%@<#[_HH&>[>Q"I!K.WDERCC%5-U;[>G[>,RM3/UZ'RF
M'YWZC?AGIGZQ[K!8$YT?"BMMTKNZUD&)^A6H-XIO[%Q<<J6GK%T6^N$$80#Z
M?L6YVFV,@_8IGOP%4$L#!!0    ( -"!<52<06Z;M ,  &@.   9    >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;)U736_;.!#]*X2  BG0U9<=.RYL XG5
M8GLH-G"VNX=%#[0TLHA(I$O2<?+O.Z1DV>E*E)N++5)Z;SAOAL/A_"#DHRH
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M;F/]*'8_05Y0U^(%(E;I+]IE<_N^@X*MTB+)@PV#A/'LG^YS(2H!N-<00/(
M<AS0:0CP\P#_W(!.'I!*[6:EI#K,J::3D10[).UL@V8O4C'3:%,^XW;=%UJ:
MI\S$Z<D]#T0"Z"O=@T(_H%^HE-2N!/HX!TU9K*[,Z--BCCY^N$(?$./H:R2V
MBO)0C5QM"%@8-\B33;-DI"$9)NB+X#I2Z(Z'$!X"N(9Y09^\TI^25L0Y!#?(
MQ]>(> 2?(#0[/]P[$3X_.QP/6ZKQB\7P4SS_?Q<#S8Q.C*^!!R_HC\]F'KK7
MD*@_6[)TBBR=-$NG(<L3EQ"(-6?_0(BTR;4$#BNF3RYH!M5-H:R'/$^,HXS<
MYZK&]3G^\9QY.\Y!'=VBCFYK'16U[O;&!Y79M-.LE*M3I61HO0H%W#^JI%MC
MB3N#HTKJ<QKJZ!5U]%KKF)LJE&9!6LGM5D=",OW2LM#] KA_P>TT*+(,6NG_
MN@%K&7R-8J$4"HR#O)CWT8[*TQ8QJ"V#C[M>TV88%BR&[V9QC;C0YLVV_,N\
M;) 6"/8;9F<+?HK@L$:0]+QA$T'LE4[K?;]SEV/USCDPN&+VN'VKP0JD-.G3
MK:84:"-.*=UG*]WL4+I%*=M=JVQYZBKC;@<W<B8E9]+*>:&I!F1>.(9>0&/T
M\U8R%;*@SN,P06FZ^)*NBTO;Q>V^^]:#DL,=G!1OT+P+2M_$[<9I/IC,YQ _
MVV]PZ62X=TDI2V/#_>\K9;\F9:_;K&1I?;C=^]YVI.O.UWP\2M_#[<;W" JH
M#*),='.VF3XXPNA?].87#"D]C7@77'!2&A=I-RZ;(,B*JR[V-:*)V')]2FY2
M]Z..WZ0W*>V(M-O1&7J_T[%(Z5CDDHY%2L<B[8[U'M7K'WJX4U/=K30L"<AU
MVOB9<VQ1LX__8K1H+F_3ENIH?&J:SJQ%+&&RCO4+E6O&%8IA92"]F[ZA)+,F
M,+O18I.V14NA39.57D:F<09I)YCG*R'TZXU-4+3BD_\ 4$L#!!0    ( -"!
M<53D);.;) ,  ,X(   9    >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;)56
M6V_:,!3^*U;4ATUJFRL$)D"BI-/Z4*DJNSQ,>S#) :(Y-K4=Z/[]CITT!6I8
M]P*V<[XOYSL7GXQV0OY6:P!-GBO&U=A;:[WYY/LJ7T-%U;78 ,<G2R$KJG$K
M5[[:2*"%!57,CX*@[U>TY-YD9,\>Y&0D:LU*#@^2J+JJJ/QS TSLQE[HO1P\
MEJNU-@?^9+2A*YB#_K9YD+CS.Y:BK("K4G B83GVIN&G+#7VUN!["3NUMR9&
MR4*(WV9S5XR]P#@$#')M&"C^;6$&C!DB=..IY?2Z5QK@_OJ%_;/5CEH65,%,
ML!]EH==C;^"1 I:T9OI1[+Y JZ=G^'+!E/TEN]8V\$A>*RVJ%HP>5"5O_NES
M&X<]0-@_ 8A:0'0,2$X XA80OQ>0M(#$1J:18N.044TG(REV1!IK9#,+&TR+
M1ODE-VF?:XE/2\3IR1W/107D*WT&1:Y(!DN0$@IS0+Y35E.;G2G#\J \!_(A
M TU+ICZB\?QV1N98AT7-X)*$T54PO'2!+@]IITIA.?^\AVH!\A?R?)MGY,/%
M1W)!2DZ^KD6M*"_4R->HSWCIYZV6FT9+=$)+&)%[P?5:D5M>0'%(X&-@NNA$
M+]&YB<XR9I!?DSB\)%$0A0Z'9N^'!PYX]FYX.#RC)NYR'5N^^ 2?,U_W8@O8
MQMK$WI$[13 7Y!$4R"UN?CX*Q@AVW([*XM<9GY+.I\3ZE)SPZ?65]+5<%K J
M.2_YBH@E^0-4NFJAX>U97G.Y;2=7PR@<IB-_NY\AAUD:)V%P:)8YS*(HW6,[
M4-?KU/7.JL/NPKM88> DY$)B41(M,-*VYS3VPD:*;6FN4)?"AKN_[U,X[,>#
M(X4NLT$Z. I$YC)+DD'/K;#?*>R?53C-GVH48#.(R5K4"@V4LWG[;QPX2L+L
MGQ;96XNKN!]& [>(M!.1_G\1 M;]F?)+WQ9,&(:#N'>DR6'G*-/,8798IHTP
M?^^FKT"N[,14)!<UU\VUUIUV0WEJ9]'1^0T.ZV:VOM(TD_Z>2NP^11@LD3*X
M3M$IV4S/9J/%QLZ3A= XG>QRC1\<((T!/E\*H5\VY@7=)\SD+U!+ P04
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M;[+N^K %\,(# +\#^.\!PP. H ,$IP*&'6!H.].68ON0$$7B2/ 5"!.MV<S
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MR^#GC(4QBJWWAJPY!2/A118%YG1E9/J12YY1I>$QH88PKI_0_MLJ@<>')W@
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M /M\)J5Y'K@S0WW.'?T&4$L#!!0    ( -"!<51F15"J;0,  *L,   9
M>&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;,U776^;.AC^*Q97F[05; B$*8G4
M-CTZD[:=JE'/+J9=.. $JV SVS3=O]]KAY OBKJ[W 1_O,_CY_T@?IELI'K2
M!6,&O52ET%.O,*;^Y/LZ*UA%]96LF8"=E505-3!5:U_7BM'<@:K2)T$0^Q7E
MPIM-W-J]FDUD8THNV+U"NJDJJG[?L%)NIA[V=@L/?%T8N^#/)C5=LP4SC_6]
M@IG?L>2\8D)S*9!BJZEWC3_-<6@!SN)_SC;Z8(RL*TLIG^SD<S[U JN(E2PS
MEH+"XYG=LK*T3*#C5TOJ=6=:X.%XQ_Z/<QZ<65+-;F7YG>>FF'IC#^5L19O2
M/,C-OZQU:&3Y,EEJ]XLVK6W@H:S11E8M&!147&R?]*4-Q $ QZ\ 2 L@IX#H
M%4#8 L*W J(6$+G(;%UQ<9A30V<3)3=(66M@LP,73(<&][FP>5\8!;L<<&;V
M#4KKB]0:U4RA14$50Q_1 JHK;TJ&Y I="\,_YKQL;'[0@F6-XH8SC>Y>LK+)
M68Y62E;H5E9U8ZC+):#F%@![/?37QBB^!-LE'&"D158 6AB9/16RS)G2Z-V<
M&<I+_1[$:(O2$]^ MU:SG[6>W6P](Z]XA@GZ*H4I0*D F<<$/H2IBQ79Q>J&
M##+.67:%0OP!D8#@'D&W;X<'/?#YF^$X'? F[#(?.K[P%3Z;V+_.ZQU5@HNU
M1O==/G]\ 6+TV;!*_QR0%76R(B<K&I"UKS>]U\4Z7?"^H^Q85][6FX!Z*W?U
MYBH'O>.BK:'W?46T51,[-?9/\AD*AZ0!&4.*G@^3VV.(4X+#)#DVG/<9XF04
M)V%G>!2941>9T6!DOE.EJ# #,8X[IOB24I]TLI*+2GUREJ@TBE),QB>9[[-+
MHB@(3Q+?8Y<D\3C!_7D?=V$9#X;E[E?#S6_T7VT]'@ASVO&EEY1]'.ROHN"B
M\M_*.7I34QP'(WQ2 'V&XR0:X>BD OH,29H$).TO 7QP3>/!V#PP#==F9AUU
M-R5Z%-S 1?FP>#QU[O@$LC^!7%19[.\I'%Y6683G[S$9X>"L*L[M1@F)XN"T
M*,[M@"PYNP[\@RZN8FKMNF$-?C7";)N4;K7KN*]=GWFR?F,[<=<=[FFV;?Q7
MJM9<:%2R%5 &5PG<.&K;&6\G1M:N5UQ* YVG&Q;P-<&4-8#]E91F-[$'=-\G
MLS]02P,$%     @ T(%Q5'RLF7+> @  'P@  !D   !X;"]W;W)K<VAE971S
M+W-H965T-S@N>&ULO5;;;MLP#/T5P1B&%ECK2RY-NR1 $F]8@'8(TG5[&/:@
MV'0LU)8\24G:OQ\E.Z[;YO:TEUB2>0YY2)E,?R/DHTH!-'G*,ZX&3JIU<>.Z
M*DHAI^I2%,#Q32)D3C5NY=)5A00:6U">N8'G==V<,NX,^_9L)H=]L=(9XS"3
M1*WRG,KG,61B,W!\9WLP9\M4FP-WV"_H$NY!/Q0SB3NW9HE9#EPQP8F$9.",
M_)NP9^RMP4\&&]58$Z-D(<2CV4SC@>.9@""#2!L&BH\U3"#+#!&&\;?B=&J7
M!MA<;]F_6NVH94$53$3VB\4Z'3@]A\20T%6FYV+S#2H]'<,7B4S97[*I;#V'
M1"NE15Z!,8*<\?))GZH\- !^=P\@J #!6T![#Z!5 5JG MH5H&TS4TJQ>0BI
MIL.^%!LBC36RF85-ID6C?,9-V>^UQ+<,<7IX*Y0BF/\?DG*5@"0B(=\%3QBG
M/&(T(R.E0"MR049QS$RI\&S*R_MF"G<6@J8L4^=H\G ?DK,/Y^0#8<B8BI6B
M/%9]5V.@QIT;54&-RZ""/4'Y ;D37*>*?.$QQ*\)7%18RPRV,L?!0<80HDO2
M\C^1P O\'0%-3H=[.^#AR7#_^H":5EVTEN5K[>&;8E:P0DS#189?38P%T90O
MV2*#;;U^WR*&3#7DZL\!C^W:8]MZ;!^Y)KIQ37CSFE#K=E>I2^*.)39-:#W$
M#*Z;N3]J$;ZW:%U[+T:O)'5J29V#DF921 "Q(HD4^5MA%Z<HZQQ5=M0B+"VZ
M#0O?VZ>L6ROK'E0VY<2*PY+-00&544KP0R0AK+'-%]BT]8$K<55[N?I/E[!7
M>^P=U#6A4CXSOB1KFJW 5&HZFW^D>?$YW/5-]MXEO_W^TKB-UIF#7-H1I$@D
M5ER7[:4^K:?<R#;W-^=CG'[EL'JA*4?G'95+QA7)($%*[_(*0Y+E."HW6A2V
M02^$QG9OERE.<)#& -\G0NCMQCBH_Q,,_P%02P,$%     @ T(%Q5,%HB2%'
M!P  @20  !D   !X;"]W;W)K<VAE971S+W-H965T-SDN>&ULO5I;;]LV%/XK
MA+&'%O!L\2)?BB1 XB1KVJ3QFG9[&/; R'0L5!)=DDH:H#]^1[(LRK%$J]VT
M/"26S>_P7#^>P_CH2:HO>B6$0=_B*-''O94QZS?#H0Y6(N9Z(-<B@4^64L7<
MP*-Z&.JU$GR1@^)H2#QO-(QYF/1.CO+WYNKD2*8F"A,Q5TBG<<S5\YF(Y--Q
M#_>V;WP,'U8F>V-X<K3F#^).F,_KN8*G82EE$<8BT:%,D!++X]XI?G/KDPR0
MK_@C%$^Z\AIEIMQ+^25[N%H<][Q,(Q&)P&0B./QY%#,119DDT.-K(;17[ID!
MJZ^WTB]SX\&8>Z[%3$9_A@NS.NY->F@AECR-S$?Y]%84!OF9O$!&.O^-GHJU
M7@\%J38R+L"@01PFF[_\6^&("@"S!@ I *0M@!8 VA; "@!K"_ +@-\6,"H
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MX"N41E!$Y2BD<A13.0JJ'$55CL(J1W&5H\#*4605*+(*%%D%BJP"15:!(JM
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #0@7%4^@.\0>\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #0
M@7%4F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( -"!<536Y%VHTP8  (P;   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #0
M@7%4/L$H_R0"  !Z!0  &               @($7#P  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ T(%Q5-[GPI3.!0  E!<  !@
M         ("!<1$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( -"!<53Q6L(L>P(  +@&   8              " @747  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #0@7%4)S>QQJ<&  !8&@
M&               @($F&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ T(%Q5&>5%&\?"@  ZCD  !@              ("! R$  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( -"!<53X^28#.0(
M *8$   8              " @5@K  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " #0@7%4Z.=YS\@)  !!*P  &               @(''
M+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ T(%Q5)#?
M  KO#@  Z"<  !@              ("!Q3<  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( -"!<52E'/8W\2@  ).&   9
M  " @>I&  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
MT(%Q5*MOTUC"$@  5T$  !D              ("!$G   'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " #0@7%4<5&6MZT'  !#%0  &0
M            @($+@P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( -"!<538\,A:O@(  ,@%   9              " @>^*  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ T(%Q5#7>2122 @
M>P4  !D              ("!Y(T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " #0@7%41$3/I]0(  !X%@  &0              @(&M
MD   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( -"!<50I
M2F(AVPH  '(>   9              " @;B9  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ T(%Q5$6;')<G!@  8@X  !D
M     ("!RJ0  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -"!<517M=>?(@8  (D/   9              "
M@>W7  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ T(%Q
M5 UQ%&)I!   ,@H  !D              ("!1MX  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " #0@7%4)^$L=5 &   -$0  &0
M        @('FX@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( -"!<525R,+P]RH  *V4   9              " @6WI  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ T(%Q5',"8OO%!   *0P
M !D              ("!FQ0! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " #0@7%4+TW 1UH$  "4#   &0              @(&7&0$
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -"!<50<-4H&
ML0(  +P%   9              " @2@> 0!X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ T(%Q5&Y1C;64 @  ?P4  !D
M ("!$"$! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #0
M@7%4ATP&G$,#  ".!P  &0              @(';(P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -"!<52=(1^3_0,  &0)   9
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M970S-2YX;6Q02P$"% ,4    " #0@7%4)+8)Z-<#  !^#0  &0
M    @('D/@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M -"!<50XS+L5K0,  # /   9              " @?)" 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ T(%Q5%C#-3<$ P  ]@@  !D
M             ("!UD8! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " #0@7%48%/X=?X"  "^"P  &0              @($12@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -"!<50-HF>KSP(
M ,L'   9              " @49- 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ T(%Q5->Q#02O @  V0<  !D              ("!
M3% ! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #0@7%4
MEHZ=+!@#  !U"@  &0              @($R4P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( -"!<51;+Y WW@,  +,.   9
M      " @8%6 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ T(%Q5%-2X%]G P  @@L  !D              ("!EEH! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #0@7%4CD: RF$"   _!0
M&0              @($T7@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( -"!<51(Z[ZEY0,  + 3   9              " @<Q@ 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ T(%Q5(@1UI$
M P  = <  !D              ("!Z&0! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " #0@7%4S#<NYK8"  #^"0  &0
M@($?: $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( -"!
M<50]3?6SWP(  *$(   9              " @0QK 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ T(%Q5  =,AZN P  ! \  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( -"!<52RL']+304  /H9   9
M  " @1M] 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
MT(%Q5!VAB[(_ @  . 4  !D              ("!GX(! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " #0@7%47H3,<P(&   L'   &0
M            @($5A0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( -"!<51D5MHAM ,  'L,   9              " @4Z+ 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ T(%Q5-]1AM6/ @
M" <  !D              ("!.8\! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    " #0@7%4UYL*^\H%   !'@  &0              @('_
MD0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( -"!<53,
MF/)2&00  !,/   9              " @0"8 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ T(%Q5-SZ$ .-!0  ;Q\  !D
M     ("!4)P! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -"!<52L]!EHQ (  !L'   9              "
M@0"W 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ T(%Q
M5&)1Z&$$ P  J@D  !D              ("!^[D! 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    " #0@7%4**OE+MT"  "6!P  &0
M        @($VO0$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0
M   ( -"!<52<06Z;M ,  &@.   9              " @4K  0!X;"]W;W)K
M<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ T(%Q5(_?38EN P  2@L
M !D              ("!-<0! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"% ,4    " #0@7%41Y">UN@#  "6#P  &0              @(':QP$
M>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( -"!<53D);.;
M) ,  ,X(   9              " @?G+ 0!X;"]W;W)K<VAE971S+W-H965T
M-S,N>&UL4$L! A0#%     @ T(%Q5%G/*PB0 @  W@8  !D
M ("!5,\! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " #0
M@7%4SA/O2ZP#  #F"@  &0              @($;T@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( -"!<52(C]EN.P,  /,*   9
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M;',O+G)E;'-02P$"% ,4    " #0@7%4(62,;^,%   ?-   #P
M    @ 'SZP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ T(%Q5+M)TM]B
M @  M"X  !H              ( ! _(! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ T(%Q5-TG:PL8 @  A2T  !,
M ( !G?0! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %< 5P#8%P  YO8!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>243</ContextCount>
  <ElementCount>491</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - License, Collaboration, and Funding Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements</Role>
      <ShortName>License, Collaboration, and Funding Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122105 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135108 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2140109 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2141110 - Disclosure - Preferred and Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PreferredandCommonStockWarrants</Role>
      <ShortName>Preferred and Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2146111 - Disclosure - Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock</Role>
      <ShortName>Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2148112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2163114 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2168115 - Disclosure - Loss on Transfer of Nonfinancial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LossonTransferofNonfinancialAssets</Role>
      <ShortName>Loss on Transfer of Nonfinancial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2170116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2317302 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2323303 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2326304 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/AccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2329305 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/LongTermDebt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2342307 - Disclosure - Preferred and Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PreferredandCommonStockWarrantsTables</Role>
      <ShortName>Preferred and Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/PreferredandCommonStockWarrants</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2349308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/StockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2356309 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2364310 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/NetLossperShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of the Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - License, Collaboration, and Funding Agreements - Genzyme Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails</Role>
      <ShortName>License, Collaboration, and Funding Agreements - Genzyme Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - License, Collaboration, and Funding Agreements - Georgetown Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails</Role>
      <ShortName>License, Collaboration, and Funding Agreements - Georgetown Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - License, Collaboration, and Funding Agreements - Beth Israel Deaconess Medical Center Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails</Role>
      <ShortName>License, Collaboration, and Funding Agreements - Beth Israel Deaconess Medical Center Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2414409 - Disclosure - License, Collaboration, and Funding Agreements - Research and Development Incentive Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails</Role>
      <ShortName>License, Collaboration, and Funding Agreements - Research and Development Incentive Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2415410 - Disclosure - License, Collaboration, and Funding Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails</Role>
      <ShortName>License, Collaboration, and Funding Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Fair Value of Financial Assets and Liabilities - Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Fair Value of Financial Assets and Liabilities -Aggregate Fair Value of Warrant and Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities -Aggregate Fair Value of Warrant and Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2420413 - Disclosure - Fair Value of Financial Assets and Liabilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2421414 - Disclosure - Goodwill Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/GoodwillRollforwardDetails</Role>
      <ShortName>Goodwill Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2424415 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/AccruedExpensesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Long-Term Debt - SVB Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails</Role>
      <ShortName>Long-Term Debt - SVB Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Long-Term Debt - FFG Loan Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails</Role>
      <ShortName>Long-Term Debt - FFG Loan Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - Long-Term Debt - Hercules Loan Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails</Role>
      <ShortName>Long-Term Debt - Hercules Loan Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Long-Term Debt - Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails</Role>
      <ShortName>Long-Term Debt - Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2437422 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/LeasesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - Preferred and Common Stock Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails</Role>
      <ShortName>Preferred and Common Stock Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - Preferred and Common Stock Warrants - Schedule of Outstanding Warrants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail</Role>
      <ShortName>Preferred and Common Stock Warrants - Schedule of Outstanding Warrants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Preferred and Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails</Role>
      <ShortName>Preferred and Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Stock-Based Compensation - Stock Option Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationStockOptionValuationDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2452431 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2457434 - Disclosure - Income Taxes - Schedule of Income Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2458435 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2459436 - Disclosure - Income Taxes - Deferred Income Tax Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails</Role>
      <ShortName>Income Taxes - Deferred Income Tax Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2460437 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2461438 - Disclosure - Income Taxes - Deferred Tax Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2462439 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2465440 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2466441 - Disclosure - Net Loss per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2467442 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2469443 - Disclosure - Loss on Transfer of Nonfinancial Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails</Role>
      <ShortName>Loss on Transfer of Nonfinancial Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="xfor-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2471444 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/SubsequentEvents</ParentRole>
      <Position>79</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="xfor-20211231.htm">xfor-20211231.htm</File>
    <File>ex-231pricewaterhousecoope.htm</File>
    <File>ex-311q42021.htm</File>
    <File>ex-312q42021.htm</File>
    <File>ex-321q42021.htm</File>
    <File>ex1019.htm</File>
    <File>ex1020.htm</File>
    <File>ex1021.htm</File>
    <File>ex1022.htm</File>
    <File>ex1023.htm</File>
    <File>ex_211xlistofsubsidiaries2.htm</File>
    <File>xfor-20211231.xsd</File>
    <File>xfor-20211231_cal.xml</File>
    <File>xfor-20211231_def.xml</File>
    <File>xfor-20211231_lab.xml</File>
    <File>xfor-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>xfor-20211231_g1.jpg</File>
    <File>xfor-20211231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="802">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xfor-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 30,
   "contextCount": 243,
   "dts": {
    "calculationLink": {
     "local": [
      "xfor-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xfor-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "xfor-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xfor-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 639,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 11,
    "total": 13
   },
   "keyCustom": 82,
   "keyStandard": 409,
   "memberCustom": 49,
   "memberStandard": 35,
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.x4pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - License, Collaboration, and Funding Agreements",
     "role": "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements",
     "shortName": "License, Collaboration, and Funding Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122105 - Disclosure - Property and Equipment, Net",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xfor:AccruedExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - Accrued Expenses",
     "role": "http://www.x4pharma.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xfor:AccruedExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - Long-Term Debt",
     "role": "http://www.x4pharma.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135108 - Disclosure - Leases",
     "role": "http://www.x4pharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140109 - Disclosure - Commitment and Contingencies",
     "role": "http://www.x4pharma.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141110 - Disclosure - Preferred and Common Stock Warrants",
     "role": "http://www.x4pharma.com/role/PreferredandCommonStockWarrants",
     "shortName": "Preferred and Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146111 - Disclosure - Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock)",
     "role": "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock",
     "shortName": "Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.x4pharma.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148112 - Disclosure - Stock-Based Compensation",
     "role": "http://www.x4pharma.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155113 - Disclosure - Income Taxes",
     "role": "http://www.x4pharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163114 - Disclosure - Net Loss per Share",
     "role": "http://www.x4pharma.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "id03c381eb978491b8ef9300074bfc781_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168115 - Disclosure - Loss on Transfer of Nonfinancial Assets",
     "role": "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssets",
     "shortName": "Loss on Transfer of Nonfinancial Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "id03c381eb978491b8ef9300074bfc781_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170116 - Disclosure - Subsequent Events",
     "role": "http://www.x4pharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317302 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323303 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326304 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.x4pharma.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xfor:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "xfor:ResearchAndDevelopmentIncentiveReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329305 - Disclosure - Long-Term Debt (Tables)",
     "role": "http://www.x4pharma.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - Leases (Tables)",
     "role": "http://www.x4pharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xfor:ScheduleOfOutstandingWarrantsTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342307 - Disclosure - Preferred and Common Stock Warrants (Tables)",
     "role": "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsTables",
     "shortName": "Preferred and Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xfor:ScheduleOfOutstandingWarrantsTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356309 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.x4pharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364310 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.x4pharma.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xfor:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of the Business and Basis of Presentation (Details)",
     "role": "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails",
     "shortName": "Nature of the Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i1dacdd07b5414e26a65fa9a53ef63e97_D20190313-20190313",
      "decimals": "INF",
      "lang": "en-US",
      "name": "xfor:BusinessCombinationShareExchangeRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details)",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "iedee6e787d804eec9aef3377417aa32d_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xfor:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i3c76fdda3bb7478080cca4e3d51fa3d7_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details)",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i3c76fdda3bb7478080cca4e3d51fa3d7_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.x4pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Policies - Additional Information (Details)",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xfor:PaymentOnObligationUnderLicenseAgreement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - License, Collaboration, and Funding Agreements - Genzyme Agreement (Details)",
     "role": "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails",
     "shortName": "License, Collaboration, and Funding Agreements - Genzyme Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i9784cfb07e534c2e87bde589e4247ab1_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "xfor:MilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xfor:PaymentOnObligationUnderLicenseAgreement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - License, Collaboration, and Funding Agreements - Georgetown Agreement (Details)",
     "role": "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails",
     "shortName": "License, Collaboration, and Funding Agreements - Georgetown Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i225e901df8314c699611cba3ac017ff1_D20161201-20161231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "xfor:OneTimeUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i91a4a2f1793e40d196c3ea1427d1df0c_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xfor:PaymentOnObligationUnderLicenseAgreement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - License, Collaboration, and Funding Agreements - Beth Israel Deaconess Medical Center Agreements (Details)",
     "role": "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails",
     "shortName": "License, Collaboration, and Funding Agreements - Beth Israel Deaconess Medical Center Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i1954fbe47872474aa699d20fef1a95c1_D20161201-20161231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "xfor:OneTimeUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414409 - Disclosure - License, Collaboration, and Funding Agreements - Research and Development Incentive Program (Details)",
     "role": "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails",
     "shortName": "License, Collaboration, and Funding Agreements - Research and Development Incentive Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i07dd80c3754e46e787921f0939875ae9_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "xfor:GrantAndIncentiveReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "iccd109dd37804ba9bfecda161164e492_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "xfor:PotentialMilestonePaymentsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415410 - Disclosure - License, Collaboration, and Funding Agreements (Details)",
     "role": "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails",
     "shortName": "License, Collaboration, and Funding Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i3ce09a35448e44b7923a92354c5363c2_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i41915bc16d8a42a0b9187f4f75b87df1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - Fair Value of Financial Assets and Liabilities - Measured on a Recurring Basis (Details)",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i41915bc16d8a42a0b9187f4f75b87df1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i7406aa31e3374111bed602d9d3287a73_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - Fair Value of Financial Assets and Liabilities -Aggregate Fair Value of Warrant and Derivative Liabilities (Details)",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities -Aggregate Fair Value of Warrant and Derivative Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "id8b315bcebad4db0a5801ae168cf944a_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i41915bc16d8a42a0b9187f4f75b87df1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420413 - Disclosure - Fair Value of Financial Assets and Liabilities - Narrative (Details)",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "iedee6e787d804eec9aef3377417aa32d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421414 - Disclosure - Goodwill Rollforward (Details)",
     "role": "http://www.x4pharma.com/role/GoodwillRollforwardDetails",
     "shortName": "Goodwill Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "iedee6e787d804eec9aef3377417aa32d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424415 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.x4pharma.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)",
     "role": "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails",
     "shortName": "Long-Term Debt - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Long-Term Debt - SVB Loan Agreement (Details)",
     "role": "http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails",
     "shortName": "Long-Term Debt - SVB Loan Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Long-Term Debt - FFG Loan Agreements (Details)",
     "role": "http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails",
     "shortName": "Long-Term Debt - FFG Loan Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i8b1ee4ca82b14441a5df67868c7c2fee_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - Long-Term Debt - Hercules Loan Agreements (Details)",
     "role": "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
     "shortName": "Long-Term Debt - Hercules Loan Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i441b3dd525cf4ccba63a00aba76d1e05_D20190601-20190630",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityInterestRateDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Long-Term Debt - Future Principal Payments (Details)",
     "role": "http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails",
     "shortName": "Long-Term Debt - Future Principal Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437422 - Disclosure - Leases (Details)",
     "role": "http://www.x4pharma.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie206b7a7c0f04cad9646717d502a7f9d_D20190313-20190313",
      "decimals": null,
      "lang": "en-US",
      "name": "xfor:OperatingLeaseRightOfUseAssetAmortizationTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)",
     "role": "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Schedule of Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)",
     "role": "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i572b67d5b62c4080a9192cbe762029fb_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i572b67d5b62c4080a9192cbe762029fb_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i8b1ee4ca82b14441a5df67868c7c2fee_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - Preferred and Common Stock Warrants - Additional Information (Details)",
     "role": "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
     "shortName": "Preferred and Common Stock Warrants - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i445218cd5fbd4b9cb04297a8f4e11d1d_I20211109",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xfor:ScheduleOfOutstandingWarrantsTableTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "iedee6e787d804eec9aef3377417aa32d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - Preferred and Common Stock Warrants - Schedule of Outstanding Warrants (Detail)",
     "role": "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail",
     "shortName": "Preferred and Common Stock Warrants - Schedule of Outstanding Warrants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xfor:ScheduleOfOutstandingWarrantsTableTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "xfor:ClassOfWarrantOrRightExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Preferred and Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Details)",
     "role": "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails",
     "shortName": "Preferred and Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i1a2348e83e324b7b82456649b542f965_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock) - Additional Information (Details)",
     "role": "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock) - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Stock-Based Compensation - Stock Option Valuation (Details)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationStockOptionValuationDetails",
     "shortName": "Stock-Based Compensation - Stock Option Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "iedee6e787d804eec9aef3377417aa32d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452431 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i3c91a1db75564f1a9f51565f80cc6989_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i3c91a1db75564f1a9f51565f80cc6989_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details)",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457434 - Disclosure - Income Taxes - Schedule of Income Loss Before Income Taxes (Details)",
     "role": "http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Income Loss Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i9c7918b22f9243ddaf0f3d3d10ab77d4_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i9c7918b22f9243ddaf0f3d3d10ab77d4_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458435 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "role": "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459436 - Disclosure - Income Taxes - Deferred Income Tax Asset (Details)",
     "role": "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails",
     "shortName": "Income Taxes - Deferred Income Tax Asset (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460437 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i097aafa6f7b841a1a0aa11212d0ac628_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ia0e74a770feb4868bd1ab0a23e223cd7_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461438 - Disclosure - Income Taxes - Deferred Tax Valuation Allowance (Details)",
     "role": "http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails",
     "shortName": "Income Taxes - Deferred Tax Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i610800df2fc44c33b927d13481ffc06a_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib7fea33dfd0f43f88c85204776483478_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462439 - Disclosure - Income Taxes (Details)",
     "role": "http://www.x4pharma.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465440 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails",
     "shortName": "Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466441 - Disclosure - Net Loss per Share - Additional Information (Details)",
     "role": "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
     "shortName": "Net Loss per Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ib495f27eee5643c1aa40007ea1e395be_D20190416-20190416",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467442 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails",
     "shortName": "Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469443 - Disclosure - Loss on Transfer of Nonfinancial Assets - Additional Information (Details)",
     "role": "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails",
     "shortName": "Loss on Transfer of Nonfinancial Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ibc0f8bba43d64d859d8549ce3f940062_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "id058b9443dcc41a5ab90c45eaf52eb0f_D20210318-20210318",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471444 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.x4pharma.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "i5720729ba9eb468d8f2396ce7f061f2a_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "xfor:LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of the Business and Basis of Presentation",
     "role": "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20211231.htm",
      "contextRef": "ie294c9705a0c4d438e39f902deb96d3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 87,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r58",
      "r118",
      "r119",
      "r254",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r253",
      "r284",
      "r331",
      "r334",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r547",
      "r549",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r253",
      "r284",
      "r331",
      "r334",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r547",
      "r549",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r253",
      "r284",
      "r321",
      "r331",
      "r334",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r547",
      "r549",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r253",
      "r284",
      "r321",
      "r331",
      "r334",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r547",
      "r549",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r57",
      "r58",
      "r118",
      "r119",
      "r254",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r138",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r138",
      "r142",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r195",
      "r196",
      "r318",
      "r319",
      "r548",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r318",
      "r319",
      "r548",
      "r556",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r138",
      "r142",
      "r236",
      "r332",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r198",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.",
        "label": "Accelerated Share Repurchases, Initial Price Paid Per Share",
        "terseLabel": "Accelerated Share Repurchases, Initial Price Paid Per Share"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesInitialPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37",
      "r498"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesDetails",
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r41"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r220"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r63",
      "r64",
      "r65",
      "r538",
      "r554",
      "r555"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r62",
      "r65",
      "r72",
      "r73",
      "r74",
      "r130",
      "r131",
      "r132",
      "r430",
      "r550",
      "r551",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r368",
      "r369",
      "r370",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": {
     "auth_ref": [
      "r298",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.",
        "label": "Adjustments to Additional Paid in Capital, Fair Value",
        "terseLabel": "Fair value of replacement equity awards"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r335",
      "r337",
      "r374",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r298",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r337",
      "r365",
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r84",
      "r100",
      "r266",
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Debt discount amortization"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded form computation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r177",
      "r186",
      "r192",
      "r200",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r426",
      "r431",
      "r459",
      "r496",
      "r498",
      "r519",
      "r535"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Assets, Total"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r51",
      "r113",
      "r200",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r426",
      "r431",
      "r459",
      "r496",
      "r498"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r338",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r439",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r330",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r330",
      "r333",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interest"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r129",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Lease Obligation Incurred",
        "terseLabel": "Lease Obligation Incurred"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash, cash equivalents and restricted cash acquired in connection with the Merger"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r32",
      "r102"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents\u2014money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r96",
      "r102",
      "r107"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r96",
      "r462"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r110",
      "r113",
      "r145",
      "r146",
      "r147",
      "r150",
      "r152",
      "r159",
      "r160",
      "r161",
      "r200",
      "r239",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r282",
      "r283",
      "r287",
      "r291",
      "r459",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r307",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Convertible preferred stock exercise price (in dollars per share)",
        "verboseLabel": "Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding and exerciseable, Number of warrants, ending balance (in shares)",
        "periodStartLabel": "Outstanding and exercisable warrants to purchase shares preferred stock as of 12/31/2019",
        "terseLabel": "Class of warrant or right, outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r307",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r421",
      "r422",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Collaboration, and Funding Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r235",
      "r524",
      "r542"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r237",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r498"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r24",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.",
        "label": "Common Stocks, Including Additional Paid in Capital",
        "terseLabel": "Common Stocks, Including Additional Paid in Capital"
       }
      }
     },
     "localname": "CommonStocksIncludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r79",
      "r527",
      "r544"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r164",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Significant Suppliers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r282",
      "r283",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r112",
      "r121",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r272",
      "r273",
      "r477",
      "r520",
      "r522",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r43",
      "r268",
      "r474",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Increase in interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r112",
      "r121",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r272",
      "r273",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Principal payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r257",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "xfor_LongTermDebtIncludingAccretion",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedTerseLabel": "Debt Instrument, Unamortized Discount (Premium), Net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r18",
      "r19",
      "r392",
      "r521",
      "r533"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r393"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r398",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r100",
      "r175"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r53",
      "r58",
      "r59",
      "r441",
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Embedded derivative liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r440"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r445",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Preferred and Common Stock Warrants"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r54",
      "r55",
      "r58",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r435",
      "r436",
      "r437",
      "r438",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r305",
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Cash dividends"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r116",
      "r384",
      "r409"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r384",
      "r409"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r384",
      "r409"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r384",
      "r409"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r384",
      "r409"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r384",
      "r409"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost of stock based awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost of stock based awards, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP) Name [Axis]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entities identify multiple employee stock ownership plans by unique name.",
        "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP), Plan [Domain]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r72",
      "r73",
      "r74",
      "r130",
      "r131",
      "r132",
      "r134",
      "r139",
      "r141",
      "r158",
      "r201",
      "r298",
      "r305",
      "r368",
      "r369",
      "r370",
      "r404",
      "r405",
      "r446",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r550",
      "r551",
      "r552",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityUnitPurchaseAgreementsMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts and securities that allow the holder to buy equity units from the entity.",
        "label": "Equity Unit Purchase Agreements [Member]",
        "terseLabel": "Equity Unit Purchase Agreements"
       }
      }
     },
     "localname": "EquityUnitPurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r100",
      "r277"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of preferred stock warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r259",
      "r270",
      "r271",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r450",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r449",
      "r450",
      "r452",
      "r453",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r259",
      "r322",
      "r323",
      "r328",
      "r329",
      "r450",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r259",
      "r270",
      "r271",
      "r322",
      "r323",
      "r328",
      "r329",
      "r450",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r259",
      "r270",
      "r271",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r450",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r259",
      "r270",
      "r271",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r455",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "terseLabel": "Finance Lease, Liability, Payment, Due"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency and Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office furniture",
        "verboseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "negatedLabel": "Loss on transfer of nonfinancial assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r100",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r202",
      "r204",
      "r498",
      "r518"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/GoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/GoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r205",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill, Gross"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/GoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r205",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "negatedTerseLabel": "Goodwill, Impaired, Accumulated Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/GoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r100",
      "r203",
      "r207",
      "r210"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Goodwill impairment",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/GoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/GoodwillRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r217",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r115",
      "r408"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r77",
      "r177",
      "r185",
      "r188",
      "r191",
      "r193",
      "r516",
      "r525",
      "r529",
      "r545"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r115",
      "r408"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign (Austria)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r222",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r387",
      "r389",
      "r391",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r116",
      "r385",
      "r390",
      "r397",
      "r406",
      "r410",
      "r412",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r117",
      "r140",
      "r141",
      "r176",
      "r383",
      "r407",
      "r411",
      "r546"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r381",
      "r382",
      "r390",
      "r391",
      "r396",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets and research and development incentive receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Carrying value of IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Loss on Transfer of Nonfinancial Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset.",
        "label": "Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]",
        "terseLabel": "Patent Cost"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r75",
      "r174",
      "r472",
      "r475",
      "r528"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r84",
      "r264",
      "r269",
      "r272",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r94",
      "r97",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r82",
      "r173"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r492",
      "r494"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease expense",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r113",
      "r187",
      "r200",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r427",
      "r431",
      "r432",
      "r459",
      "r496",
      "r497"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r113",
      "r200",
      "r459",
      "r498",
      "r523",
      "r540"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r113",
      "r200",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r427",
      "r431",
      "r432",
      "r459",
      "r496",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Liabilities, Current, Total"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Embedded derivative liability"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPayment": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments of both interest and principal.",
        "label": "Line of Credit Facility, Periodic Payment",
        "terseLabel": "Periodic payment"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Credit outstanding"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r38",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtFFGLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/LongTermDebtSVBLoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r258",
      "r267",
      "r270",
      "r271",
      "r522",
      "r536"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "xfor_LongTermDebtIncludingAccretion",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Principal amount of long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Long-term Debt, Current Maturities",
        "terseLabel": "Long-term Debt, Current Maturities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r121",
      "r238",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r121",
      "r238",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Principal amount of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Amount",
        "terseLabel": "Long-term Purchase Commitment, Amount"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r96",
      "r98",
      "r101"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r66",
      "r68",
      "r74",
      "r78",
      "r101",
      "r113",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r148",
      "r177",
      "r185",
      "r188",
      "r191",
      "r193",
      "r200",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r447",
      "r459",
      "r526",
      "r543"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138",
      "r143",
      "r144",
      "r149",
      "r152",
      "r177",
      "r185",
      "r188",
      "r191",
      "r193"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses [Abstract]"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r177",
      "r185",
      "r188",
      "r191",
      "r193"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r485",
      "r494"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability",
        "verboseLabel": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r482",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r480"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r491",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2014operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r490",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term\u2014operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r41"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r439",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r61",
      "r63",
      "r460",
      "r461",
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/SummaryofSignificantPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Payments for Repurchase of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForSecuritiesPurchasedUnderAgreementsToResell": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with agreements to purchase and then resell securities to counterparties (reverse repurchase agreements).",
        "label": "Payments for Securities Purchased under Agreements to Resell",
        "terseLabel": "Payments for Securities Purchased under Agreements to Resell"
       }
      }
     },
     "localname": "PaymentsForSecuritiesPurchasedUnderAgreementsToResell",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Employee taxes paid related to net share settlement of vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r88",
      "r418",
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Purchase of property, equipment and intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r338",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Issuance of Other Long-term Debt",
        "terseLabel": "Proceeds from borrowings under loan and security agreements, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from Issuance of Warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r91",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from line of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Proceeds from transfer of non-financial assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r66",
      "r68",
      "r74",
      "r95",
      "r113",
      "r133",
      "r140",
      "r141",
      "r177",
      "r185",
      "r188",
      "r191",
      "r193",
      "r200",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r425",
      "r428",
      "r429",
      "r433",
      "r434",
      "r447",
      "r459",
      "r529"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r224",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r219"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r221",
      "r498",
      "r530",
      "r541"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r221",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemablePreferredStockMember": {
     "auth_ref": [
      "r10",
      "r113",
      "r200",
      "r239",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r279",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series.",
        "label": "Redeemable Preferred Stock [Member]",
        "terseLabel": "Redeemable Preferred Stock"
       }
      }
     },
     "localname": "RedeemablePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of borrowings under loan and security agreement"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r379",
      "r514",
      "r574"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Cost"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r107",
      "r517",
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r3",
      "r11",
      "r107"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash, current (included within prepaid expenses and other current assets)"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r107",
      "r557"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r305",
      "r371",
      "r498",
      "r539",
      "r553",
      "r555"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r130",
      "r131",
      "r132",
      "r134",
      "r139",
      "r141",
      "r201",
      "r368",
      "r369",
      "r370",
      "r404",
      "r405",
      "r446",
      "r550",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r171",
      "r172",
      "r184",
      "r189",
      "r190",
      "r194",
      "r195",
      "r197",
      "r317",
      "r318",
      "r515"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r76",
      "r113",
      "r171",
      "r172",
      "r184",
      "r189",
      "r190",
      "r194",
      "r195",
      "r197",
      "r200",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r459",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r489",
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensatingBalancesTextBlock": {
     "auth_ref": [
      "r11",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes disclosure of  these arrangements and the amount involved, if determinable, for the most recent audited balance sheet required and for any subsequent unaudited balance sheet required in the notes to the financial statements. Compensating balances that are maintained under an agreement to assure future credit availability are generally disclosed in the notes to the financial statements along with the amount and terms of such agreement.",
        "label": "Schedule of Compensating Balances [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCompensatingBalancesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Classification"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r145",
      "r146",
      "r150",
      "r152",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r209",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r213",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LossonTransferofNonfinancialAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r11",
      "r107",
      "r517",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r338",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r344",
      "r353",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Stock Option Valuation"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r47",
      "r110",
      "r159",
      "r160",
      "r278",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r291",
      "r296",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r389",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Shares based compensation, vested period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share based compensation, restricted stock units granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share based compensation, restricted stock units granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested ending balance (in shares)",
        "periodStartLabel": "Nonvested beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Share based compensation, grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable, ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercises in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted, (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r346",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Aggregate intrinsic value, options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, shares issued in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r336",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r338",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Outstanding ending balance",
        "periodStartLabel": "Outstanding beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r359",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r308",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r486",
      "r494"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r108",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r110",
      "r113",
      "r145",
      "r146",
      "r147",
      "r150",
      "r152",
      "r159",
      "r160",
      "r161",
      "r200",
      "r239",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r282",
      "r283",
      "r287",
      "r291",
      "r298",
      "r459",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r50",
      "r72",
      "r73",
      "r74",
      "r130",
      "r131",
      "r132",
      "r134",
      "r139",
      "r141",
      "r158",
      "r201",
      "r298",
      "r305",
      "r368",
      "r369",
      "r370",
      "r404",
      "r405",
      "r446",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r550",
      "r551",
      "r552",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r158",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r22",
      "r23",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Exchange of common stock in connection with Merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r49",
      "r261",
      "r298",
      "r299",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred shares into common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r22",
      "r23",
      "r298",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of shares under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r298",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued (in shares)",
        "verboseLabel": "Issuance cost of convertible preferred stock, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r22",
      "r23",
      "r298",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r298",
      "r305",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r50",
      "r298",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "verboseLabel": "Exchange of common stock in connection with Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r50",
      "r298",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred shares into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r22",
      "r23",
      "r298",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of shares under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r298",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance costs of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r22",
      "r23",
      "r298",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r50",
      "r298",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r22",
      "r23",
      "r298",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Stock Repurchased and Retired During Period, Shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r22",
      "r23",
      "r298",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Stock Repurchased and Retired During Period, Value",
        "terseLabel": "Stock Repurchased and Retired During Period, Value"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r113",
      "r199",
      "r200",
      "r459",
      "r498"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r305",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "COMMON STOCK, REDEEMABLE COMMON STOCK AND PREFERRED STOCK"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r487",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r470",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r470",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r470",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r470",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r499",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r239",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance, convertible preferred stock",
        "periodStartLabel": "Beginning balance, convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDividendsAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).",
        "label": "Temporary Equity, Dividends, Adjustment",
        "negatedLabel": "Accruing dividends on Series A convertible preferred stock",
        "terseLabel": "Accruing dividends on Series A convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityDividendsAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r10",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance, convertible preferred stock (in shares)",
        "periodStartLabel": "Beginning balance, convertible preferred stock (in share)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r380",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDetails",
      "http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Acquisition"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Unrecognized Tax Benefits, Period Increase (Decrease)"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Valuation Allowance [Line Items]",
        "terseLabel": "Valuation Allowance [Line Items]"
       }
      }
     },
     "localname": "ValuationAllowanceLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowanceTable": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.",
        "label": "Valuation Allowance [Table]",
        "terseLabel": "Valuation Allowance [Table]"
       }
      }
     },
     "localname": "ValuationAllowanceTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r122",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "negatedPeriodEndLabel": "Valuation allowance, end of year",
        "negatedPeriodStartLabel": "Valuation allowance, beginning of year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "negatedLabel": "Increases recorded to income tax provision"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from business combination.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired",
        "negatedLabel": "Acquisition of business"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average shares of common stock outstanding - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_A2015EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 Equity Incentive Plan",
        "label": "2015 Equity Incentive Plan [Member]",
        "terseLabel": "Two Thousand Fifteen Equity Incentive Plan"
       }
      }
     },
     "localname": "A2015EquityIncentivePlanMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_AbbiskoAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abbisko Agreement",
        "label": "Abbisko Agreement [Member]",
        "terseLabel": "Abbisko Agreement"
       }
      }
     },
     "localname": "AbbiskoAgreementMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_AccretionOnLongTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "xfor_LongTermDebtIncludingAccretion",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion On Long Term Debt",
        "label": "Accretion On Long Term Debt",
        "negatedLabel": "Cumulative accrual of end of term payments"
       }
      }
     },
     "localname": "AccretionOnLongTermDebt",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AccruedExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses",
        "label": "Accrued Expenses [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedExpensesTextBlock",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_AccruedExternalResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued External Research And Development Expenses",
        "label": "Accrued External Research And Development Expenses",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentExpenses",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment To Additional Paid In Capital Reclassification Of Warranty Liability To Permanent Equity",
        "label": "Adjustment To Additional Paid In Capital Reclassification Of Warranty Liability To Permanent Equity",
        "terseLabel": "Reclassification of warrant liability to permanent equity"
       }
      }
     },
     "localname": "AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantyLiabilityToPermanentEquity",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AggregateBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Base Rent",
        "label": "Aggregate Base Rent",
        "terseLabel": "Base rent"
       }
      }
     },
     "localname": "AggregateBaseRent",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AllstonLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allston Lease",
        "label": "Allston Lease [Member]",
        "terseLabel": "Letter of credit security: Boston lease",
        "verboseLabel": "Boston Lease"
       }
      }
     },
     "localname": "AllstonLeaseMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ArsanisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arsanis",
        "label": "Arsanis [Member]",
        "terseLabel": "Arsanis"
       }
      }
     },
     "localname": "ArsanisMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_AspireCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aspire Capital Fund, LLC",
        "label": "Aspire Capital Fund, LLC [Member]",
        "terseLabel": "Aspire Capital Fund, LLC"
       }
      }
     },
     "localname": "AspireCapitalFundLLCMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.x4pharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "xfor_BidmcAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bidmc Agreement",
        "label": "Bidmc Agreement [Member]",
        "terseLabel": "Bidmc Agreement"
       }
      }
     },
     "localname": "BidmcAgreementMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_BusinessCombinationShareExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Share Exchange Ratio",
        "label": "Business Combination Share Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "localname": "BusinessCombinationShareExchangeRatio",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "xfor_CambridgeLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge Lease",
        "label": "Cambridge Lease [Member]",
        "terseLabel": "Cambridge Lease"
       }
      }
     },
     "localname": "CambridgeLeaseMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_CambridgeMAOperatingLeaseArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge M A Operating Lease Arrangement",
        "label": "Cambridge M A Operating Lease Arrangement [Member]",
        "terseLabel": "Letter of credit security: Cambridge lease"
       }
      }
     },
     "localname": "CambridgeMAOperatingLeaseArrangementMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Expenditures And Intangible Assets Incurred But Not Yet Paid",
        "label": "Capital Expenditures And Intangible Assets Incurred But Not Yet Paid",
        "terseLabel": "Acquisition of property, equipment and right-of-use assets included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresAndIntangibleAssetsIncurredButNotYetPaid",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ChangeInFairValueOfConvertiblePreferredStockWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Fair Value Of Convertible Preferred Stock Warrant Liability",
        "label": "Change In Fair Value Of Convertible Preferred Stock Warrant Liability",
        "terseLabel": "Change in fair value of preferred stock warrant and derivative liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfConvertiblePreferredStockWarrantLiability",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ClassAWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Warrant",
        "label": "Class A Warrant [Member]",
        "terseLabel": "Class A Warrant"
       }
      }
     },
     "localname": "ClassAWarrantMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ClassBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B Warrants",
        "label": "Class B Warrants [Member]",
        "terseLabel": "Class B Warrants"
       }
      }
     },
     "localname": "ClassBWarrantsMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Additional Exercise Price of Warrants or Rights",
        "label": "Class of Warrant or Right, Additional Exercise Price of Warrants or Rights",
        "terseLabel": "Class of Warrant or Right, Additional Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued",
        "label": "Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued",
        "terseLabel": "Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Exercised",
        "label": "Class Of Warrant Or Right Exercised",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_ClassOfWarrantOrRightExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Expired",
        "label": "Class Of Warrant Or Right Expired",
        "terseLabel": "Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpired",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Issued",
        "label": "Class Of Warrant Or Right Issued",
        "terseLabel": "Class Of Warrant Or Right Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_ClassOfWarrantOrRightWarrantsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Warrants Expiration Period",
        "label": "Class Of Warrant Or Right Warrants Expiration Period",
        "terseLabel": "Warrant expiration period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsExpirationPeriod",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xfor_ClassOfWarrantOrRightWeightedAverageContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Weighted Average Contractual Term",
        "label": "Class Of Warrant Or Right Weighted Average Contractual Term",
        "terseLabel": "Weighted Average Contractual Term (Years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageContractualTerm",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "xfor_ClassOfWarrantOrRightWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Weighted Average Exercise Price",
        "label": "Class Of Warrant Or Right Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding and exercisable, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding and exercisable warrants to purchase preferred shares, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "xfor_CollaborativeAgreementExpenseReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Expense Reimbursement",
        "label": "Collaborative Agreement, Expense Reimbursement",
        "terseLabel": "Collaborative Agreement , Expense Reimbursement"
       }
      }
     },
     "localname": "CollaborativeAgreementExpenseReimbursement",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_CollaborativeAgreementFutureExpectedAnnualFeesThereafter": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Future Expected Annual Fees, Thereafter",
        "label": "Collaborative Agreement, Future Expected Annual Fees, Thereafter",
        "terseLabel": "Collaborative agreement, future expected annual fees, thereafter"
       }
      }
     },
     "localname": "CollaborativeAgreementFutureExpectedAnnualFeesThereafter",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Future Expected Annual Fees, Year Four Through Six",
        "label": "Collaborative Agreement, Future Expected Annual Fees, Year Four Through Six",
        "terseLabel": "Collaborative agreement, future expected annual fees, year four through six"
       }
      }
     },
     "localname": "CollaborativeAgreementFutureExpectedAnnualFeesYearFourThroughSix",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Future Expected Annual Fees, Year One Through Three",
        "label": "Collaborative Agreement, Future Expected Annual Fees, Year One Through Three",
        "terseLabel": "Collaborative agreement, future expected annual fees, year one through three"
       }
      }
     },
     "localname": "CollaborativeAgreementFutureExpectedAnnualFeesYearOneThroughThree",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_CollaborativeArrangementObligationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Obligation, Percentage",
        "label": "Collaborative Arrangement, Obligation, Percentage",
        "terseLabel": "Collaborative Arrangement, Obligation, Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementObligationPercentage",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xfor_CommonStockRepurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Repurchase Price Per Share",
        "label": "Common Stock Repurchase Price Per Share",
        "terseLabel": "Common stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockRepurchasePricePerShare",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "xfor_ConversionOfConvertiblePreferredStockToCommonStockValues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Convertible Preferred Stock To Common Stock Values",
        "label": "Conversion of Convertible Preferred Stock To Common Stock Values",
        "terseLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredStockToCommonStockValues",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrants",
        "label": "Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrants",
        "terseLabel": "Conversion of convertible preferred stock warrants into common stock warrants"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrants",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ConversionOfRedeemableCommonStockToCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Of Redeemable Common Stock To Common Stock Shares",
        "label": "Conversion Of Redeemable Common Stock To Common Stock Shares",
        "terseLabel": "Conversion of redeemable common stock into common stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfRedeemableCommonStockToCommonStockShares",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_ConversionOfRedeemableCommonStockToCommonStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Of Redeemable Common Stock To Common Stock Value",
        "label": "Conversion Of Redeemable Common Stock To Common Stock Value",
        "terseLabel": "Conversion of redeemable common stock into common stock",
        "verboseLabel": "Conversion of redeemable common stock into common stock"
       }
      }
     },
     "localname": "ConversionOfRedeemableCommonStockToCommonStockValue",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_CurrentOfficeSpaceUnderLeaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current office space under lease agreement.",
        "label": "Current Office Space Under Lease Agreement",
        "terseLabel": "Current Office Space Under Lease Agreement"
       }
      }
     },
     "localname": "CurrentOfficeSpaceUnderLeaseAgreement",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "xfor_DFCIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DFCI",
        "label": "DFCI [Member]",
        "terseLabel": "DFCI"
       }
      }
     },
     "localname": "DFCIMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_DebtInstrumentDebtCovenantMinimumCashRequired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Debt Covenant, Minimum Cash Required",
        "label": "Debt Instrument, Debt Covenant, Minimum Cash Required",
        "terseLabel": "Debt Instrument, Debt Covenant, Minimum Cash Required"
       }
      }
     },
     "localname": "DebtInstrumentDebtCovenantMinimumCashRequired",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Debt Covenant, Minimum Cash Required, Conditional Scenario",
        "label": "Debt Instrument, Debt Covenant, Minimum Cash Required, Conditional Scenario",
        "terseLabel": "Debt Instrument, Debt Covenant, Minimum Cash Required, Conditional Scenario"
       }
      }
     },
     "localname": "DebtInstrumentDebtCovenantMinimumCashRequiredConditionalScenario",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_DebtInstrumentPrePaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Pre Payment Premium Percentage",
        "label": "Debt Instrument Pre Payment Premium Percentage",
        "terseLabel": "Payment premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrePaymentPremiumPercentage",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "xfor_DeferredTaxAssetLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Lease Liability",
        "label": "Deferred Tax Asset, Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetLeaseLiability",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Capitalized Research And Development Costs",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Capitalized Research And Development Costs",
        "terseLabel": "Capitalized research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_DeferredTaxLiabilityRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liability, Right Of Use Asset",
        "label": "Deferred Tax Liability, Right Of Use Asset",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilityRightOfUseAsset",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_DiscretionaryBorrowingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discretionary Borrowings",
        "label": "Discretionary Borrowings [Member]",
        "terseLabel": "Discretionary Borrowings [Member]"
       }
      }
     },
     "localname": "DiscretionaryBorrowingsMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change In Fair Value Of Preferred Stock Warrant Liability",
        "label": "Effective Income Tax Rate Reconciliation, Change In Fair Value Of Preferred Stock Warrant Liability",
        "terseLabel": "Change in fair value of preferred stock warrant liability"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiability",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xfor_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Other Permanent Differences",
        "label": "Effective Income Tax Rate Reconciliation, Other Permanent Differences",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xfor_EmployeeStockPurchasePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plans",
        "label": "Employee Stock Purchase Plans [Member]",
        "terseLabel": "Employee Stock Purchase Plans"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlansMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_FairValueOfNetAssetsAcquiredInReverseMerger": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Net Assets Acquired In Reverse Merger",
        "label": "Fair Value Of Net Assets Acquired In Reverse Merger",
        "terseLabel": "Fair value of net assets acquired in the Merger in exchange for common shares, excluding cash acquired"
       }
      }
     },
     "localname": "FairValueOfNetAssetsAcquiredInReverseMerger",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_FundedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funded",
        "label": "Funded [Member]",
        "terseLabel": "Funded"
       }
      }
     },
     "localname": "FundedMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_GenzymeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genzyme Agreement",
        "label": "Genzyme Agreement [Member]",
        "terseLabel": "Genzyme Agreement"
       }
      }
     },
     "localname": "GenzymeAgreementMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_GeorgetownMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Georgetown",
        "label": "Georgetown [Member]",
        "terseLabel": "Georgetown"
       }
      }
     },
     "localname": "GeorgetownMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_GrantAndIncentiveReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant and Incentive Receivables",
        "label": "Grant and Incentive Receivables",
        "terseLabel": "Amount due under incentive receivable plan"
       }
      }
     },
     "localname": "GrantAndIncentiveReceivables",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_HerculesAmendedAndRestatedLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Amended And Restated Loan Agreement",
        "label": "Hercules Amended And Restated Loan Agreement [Member]",
        "terseLabel": "Hercules Amended and Restated Loan Agreement"
       }
      }
     },
     "localname": "HerculesAmendedAndRestatedLoanAgreementMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_HerculesFirstAmendedLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules First Amended Loan Agreement",
        "label": "Hercules First Amended Loan Agreement [Member]",
        "terseLabel": "Hercules First Amended Loan Agreement"
       }
      }
     },
     "localname": "HerculesFirstAmendedLoanAgreementMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_HerculesLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Loan Agreement [Member]",
        "label": "Hercules Loan Agreement [Member]",
        "terseLabel": "Hercules Loan Agreement"
       }
      }
     },
     "localname": "HerculesLoanAgreementMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_HerculesSecondAmendedLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Second Amended Loan Agreement",
        "label": "Hercules Second Amended Loan Agreement [Member]",
        "terseLabel": "Hercules Second Amended Loan Agreement"
       }
      }
     },
     "localname": "HerculesSecondAmendedLoanAgreementMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IncentiveStockOptionsAndRestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Options And Restricted Stock Awards",
        "label": "Incentive Stock Options And Restricted Stock Awards [Member]",
        "terseLabel": "Incentive Stock Options and Restricted Stock Awards"
       }
      }
     },
     "localname": "IncentiveStockOptionsAndRestrictedStockAwardsMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Lease Liabilities",
        "label": "Increase (Decrease) in Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset, Non-cash Potion",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset, Non-cash Potion",
        "negatedTerseLabel": "Operating lease right-of-use asset, net of non-cash portion"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetNonCashPotion",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_IntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets, Policy",
        "label": "Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance On April Sixteen Two Thousand Nineteen",
        "label": "Issuance On April Sixteen Two Thousand Nineteen [Member]",
        "terseLabel": "Issuance On April 16, 2019"
       }
      }
     },
     "localname": "IssuanceOnAprilSixteenTwoThousandNineteenMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance On December Twenty Eight Two Thousand Seventeen One",
        "label": "Issuance On December Twenty Eight Two Thousand Seventeen One [Member]",
        "terseLabel": "Issuance On December 28, 2017"
       }
      }
     },
     "localname": "IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnMarch232021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance On March 23, 2021",
        "label": "Issuance On March 23, 2021 [Member]",
        "terseLabel": "Issuance On March 23, 2021"
       }
      }
     },
     "localname": "IssuanceOnMarch232021Member",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance On March Thirteen Two Thousand Nineteen",
        "label": "Issuance On March Thirteen Two Thousand Nineteen [Member]",
        "terseLabel": "Issuance On March 13, 2019"
       }
      }
     },
     "localname": "IssuanceOnMarchThirteenTwoThousandNineteenMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on November Nine Two Thousand Twenty One",
        "label": "Issuance on November Nine Two Thousand Twenty One [Member]",
        "terseLabel": "Issuance on November Nine Two Thousand Twenty One"
       }
      }
     },
     "localname": "IssuanceOnNovemberNineTwoThousandTwentyOneMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on November Twenty Nine Two Thousand Nineteen",
        "label": "Issuance on November Twenty Nine Two Thousand Nineteen [Member]",
        "terseLabel": "Issuance on November 29, 2019"
       }
      }
     },
     "localname": "IssuanceOnNovemberTwentyNineTwoThousandNineteenMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on November Twenty Nine Two Thousand Nineteen One",
        "label": "Issuance on November Twenty Nine Two Thousand Nineteen One [Member]",
        "terseLabel": "Issuance on November 29, 2019"
       }
      }
     },
     "localname": "IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance On October Nineteen Two Thousand Eighteen",
        "label": "Issuance On October Nineteen Two Thousand Eighteen [Member]",
        "terseLabel": "Issuance On October 19, 2018"
       }
      }
     },
     "localname": "IssuanceOnOctoberNineteenTwoThousandEighteenMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance On October Twenty Five Two Thousand Sixteen",
        "label": "Issuance On October Twenty Five Two Thousand Sixteen [Member]",
        "terseLabel": "Issuance On October 25, 2016"
       }
      }
     },
     "localname": "IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance On September Twelve Two Thousand Eighteen One",
        "label": "Issuance On September Twelve Two Thousand Eighteen One [Member]",
        "terseLabel": "Issuance On September 12, 2018"
       }
      }
     },
     "localname": "IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_LeaseCostAdditionalInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Cost, Additional Information",
        "label": "Lease Cost, Additional Information [Abstract]",
        "terseLabel": "Other information"
       }
      }
     },
     "localname": "LeaseCostAdditionalInformationAbstract",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "terseLabel": "Lease not yet commenced, amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Office Space",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Office Space",
        "terseLabel": "Office space area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "xfor_LesseeOperatingLeaseRentFreePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rent-Free Period",
        "label": "Lessee, Operating Lease, Rent-Free Period",
        "terseLabel": "Rent-free period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentFreePeriod",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xfor_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park Capital Fund, LLC",
        "label": "Lincoln Park Capital Fund, LLC [Member]",
        "terseLabel": "Lincoln Park Capital Fund, LLC"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_LineOfCreditCovenantMinimumCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit, Covenant, Minimum Cash",
        "label": "Line of Credit, Covenant, Minimum Cash",
        "terseLabel": "Line of Credit, Covenant, Minimum Cash"
       }
      }
     },
     "localname": "LineOfCreditCovenantMinimumCash",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three",
        "label": "Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three",
        "terseLabel": "Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Three"
       }
      }
     },
     "localname": "LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheThree",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Two",
        "label": "Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Two",
        "terseLabel": "Line Of Credit Facility, Terms, Additional Term Loan Advances Receivable, Tranche Two"
       }
      }
     },
     "localname": "LineOfCreditFacilityTermsAdditionalTermLoanAdvancesReceivableTrancheTwo",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LongTermDebtIncludingAccretion": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Including Accretion",
        "label": "Long-Term Debt, Including Accretion",
        "totalLabel": "Long-Term Debt, Including Accretion"
       }
      }
     },
     "localname": "LongTermDebtIncludingAccretion",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LongTermDebtNonCurrentIncludingAccrection": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt Non Current Including Accrection",
        "label": "Long Term Debt Non Current Including Accrection",
        "terseLabel": "Long-term debt, including accretion, net of discount"
       }
      }
     },
     "localname": "LongTermDebtNonCurrentIncludingAccrection",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_MTSAustriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTS Austria",
        "label": "MTS Austria [Member]",
        "terseLabel": "X4 Austria"
       }
      }
     },
     "localname": "MTSAustriaMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_MilestoneContractTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Contract, Termination Period",
        "label": "Milestone Contract, Termination Period",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "MilestoneContractTerminationPeriod",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xfor_MilestonePaymentObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Obligation",
        "label": "Milestone Payment Obligation",
        "terseLabel": "Payment obligation"
       }
      }
     },
     "localname": "MilestonePaymentObligation",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_MilestonePaymentsPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Paid",
        "label": "Milestone Payments Paid",
        "terseLabel": "Payments made"
       }
      }
     },
     "localname": "MilestonePaymentsPaid",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_MinCashTestDate1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Min Cash Test Date 1",
        "label": "Min Cash Test Date 1 [Member]",
        "terseLabel": "Min Cash Test Date 1 [Member]"
       }
      }
     },
     "localname": "MinCashTestDate1Member",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_MinCashTestDate2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Min Cash Test Date 2",
        "label": "Min Cash Test Date 2 [Member]",
        "terseLabel": "Min Cash Test Date 2 [Member]"
       }
      }
     },
     "localname": "MinCashTestDate2Member",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_NewViennaLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Vienna Lease",
        "label": "New Vienna Lease [Member]",
        "terseLabel": "New Vienna Lease"
       }
      }
     },
     "localname": "NewViennaLeaseMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Interest Expense",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Accretion of debt discount"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Lease Expense",
        "label": "Non Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_NonStatutoryOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Statutory Options",
        "label": "Non-Statutory Options [Member]",
        "terseLabel": "Non-Statutory Options"
       }
      }
     },
     "localname": "NonStatutoryOptionsMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_OneTimeUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Upfront Payment",
        "label": "One Time Upfront Payment",
        "terseLabel": "One time upfront payment"
       }
      }
     },
     "localname": "OneTimeUpfrontPayment",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_OperatingLeaseRightOfUseAssetAmortizationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset, Amortization Term",
        "label": "Operating Lease, Right-Of-Use Asset, Amortization Term",
        "terseLabel": "Right-of-use asset, amortization term"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationTerm",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xfor_PaymentOnObligationUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment On Obligation Under License Agreement",
        "label": "Payment On Obligation Under License Agreement",
        "terseLabel": "Payment on obligation under license agreement"
       }
      }
     },
     "localname": "PaymentOnObligationUnderLicenseAgreement",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_PotentialMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payments Receivable",
        "label": "Potential Milestone Payments Receivable",
        "terseLabel": "Potential milestone payments receivable"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsReceivable",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_PreFundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrant",
        "label": "Pre Funded Warrant [Member]",
        "terseLabel": "Pre Funded Warrant"
       }
      }
     },
     "localname": "PreFundedWarrantMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails",
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_PrefundedWarrantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded Warrants",
        "label": "Prefunded Warrants [Axis]",
        "terseLabel": "Prefunded Warrants [Axis]"
       }
      }
     },
     "localname": "PrefundedWarrantsAxis",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_PrefundedWarrantsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded Warrants [Domain]",
        "label": "Prefunded Warrants [Domain]",
        "terseLabel": "Prefunded Warrants [Domain]"
       }
      }
     },
     "localname": "PrefundedWarrantsDomain",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ProceedsFromExerciseOfStockOptionsAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Exercise of Stock Options And Warrants",
        "label": "Proceeds From Exercise of Stock Options And Warrants",
        "terseLabel": "Proceeds from exercise of stock options, warrants and pre-funded warrants an issuance of shares of common stock under employee stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndWarrants",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses",
        "label": "Proceeds From Issuance Of Common Stock Before Underwriting Discounts Commissions And Other Expenses",
        "terseLabel": "Proceeds from common stock issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockBeforeUnderwritingDiscountsCommissionsAndOtherExpenses",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance or Sale of Equity, Net of Issuance Costs",
        "label": "Proceeds from Issuance or Sale of Equity, Net of Issuance Costs",
        "terseLabel": "Proceeds from sale of shares of common stock, redeemable common stock, warrants and pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant and Equipment Useful Life",
        "label": "Property, Plant and Equipment Useful Life [Table Text Block]",
        "terseLabel": "Property and Equipment Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_PurchaseAgreementSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Shares Purchased",
        "label": "Purchase Agreement, Shares Purchased",
        "terseLabel": "Purchase Agreement, Shares Purchased"
       }
      }
     },
     "localname": "PurchaseAgreementSharesPurchased",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_Q12022PIPEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Q1 2022 PIPE",
        "label": "Q1 2022 PIPE [Member]",
        "terseLabel": "Q1 2022 PIPE"
       }
      }
     },
     "localname": "Q12022PIPEMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_RedeemableCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Common Stock",
        "label": "Redeemable Common Stock [Member]",
        "terseLabel": "Redeemable Common Stock"
       }
      }
     },
     "localname": "RedeemableCommonStockMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ReimbursementRateForResearchAndDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Rate For Research And Development",
        "label": "Reimbursement Rate For Research And Development",
        "terseLabel": "Reimbursement rate for research and development"
       }
      }
     },
     "localname": "ReimbursementRateForResearchAndDevelopment",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "xfor_ResearchAndDevelopmentIncentiveProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Incentive Program",
        "label": "Research and Development Incentive Program [Member]",
        "terseLabel": "Research and Development Incentive Program"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveProgramMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ResearchAndDevelopmentIncentiveReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Incentive Receivable",
        "label": "Research And Development Incentive Receivable",
        "terseLabel": "Research and development incentive receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveReceivable",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ResearchAndDevelopmentProgramsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Programs, Policy",
        "label": "Research and Development Programs, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Programs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentProgramsPolicyPolicyTextBlock",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right Of Use Asset and Lease Liability, Policy",
        "label": "Right Of Use Asset and Lease Liability, Policy [Policy Text Block]",
        "terseLabel": "Right-of-Use Assets and Leases"
       }
      }
     },
     "localname": "RightOfUseAssetAndLeaseLiabilityPolicyPolicyTextBlock",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_SaleOfStockNumberOfSharesAuthorizedInTransactionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Number Of Shares Authorized in Transaction, Amount",
        "label": "Sale of Stock, Number Of Shares Authorized in Transaction, Amount",
        "terseLabel": "Number of shares authorized in transaction, amount"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesAuthorizedInTransactionAmount",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_SaleOfStockPurchaseAgreementSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Purchase Agreement, Shares Issued",
        "label": "Sale of Stock, Purchase Agreement, Shares Issued",
        "terseLabel": "Sale of Stock, Purchase Agreement, Shares Issued"
       }
      }
     },
     "localname": "SaleOfStockPurchaseAgreementSharesIssued",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_SaleOfStockPurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Purchase Agreement, Term",
        "label": "Sale Of Stock, Purchase Agreement, Term",
        "terseLabel": "Purchase agreement, term"
       }
      }
     },
     "localname": "SaleOfStockPurchaseAgreementTerm",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails",
      "http://www.x4pharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xfor_SalesAgentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agents",
        "label": "Sales Agents [Member]",
        "terseLabel": "Sales Agents [Member]"
       }
      }
     },
     "localname": "SalesAgentsMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ScheduleOfOutstandingWarrantsTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Outstanding Warrants Table",
        "label": "Schedule Of Outstanding Warrants Table [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants Table"
       }
      }
     },
     "localname": "ScheduleOfOutstandingWarrantsTableTableTextBlock",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash to Cash Flows",
        "label": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash to Cash Flows [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash to Cash Flows"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_SeriesSeedConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Seed Convertible Preferred Stock",
        "label": "Series Seed Convertible Preferred Stock [Member]",
        "terseLabel": "Series Seed Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesSeedConvertiblePreferredStockMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Awards Grant In Period Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Awards Grant In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Exercise Price, Maximum Percentage Of Fair Market Value Of Common Stock",
        "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Exercise Price, Maximum Percentage Of Fair Market Value Of Common Stock",
        "terseLabel": "Maximum percentage of fair value of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceMaximumPercentageOfFairMarketValueOfCommonStock",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in Thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Contractual Term (in Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_SoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software",
        "label": "Software [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_StockAndWarrantIssuanceCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock And Warrant Issuance Costs Incurred But Not Yet Paid",
        "label": "Stock And Warrant Issuance Costs Incurred But Not Yet Paid",
        "terseLabel": "Issuance costs not yet paid"
       }
      }
     },
     "localname": "StockAndWarrantIssuanceCostsIncurredButNotYetPaid",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and warrants issued during period shares common stock and warrants.",
        "label": "Stock And Warrants Issued During Period Shares Common Stock And Warrants",
        "terseLabel": "Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $11.5 million (in shares)"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and warrants issued during period value common stock and warrants.",
        "label": "Stock And Warrants Issued During Period Value Common Stock And Warrants",
        "terseLabel": "Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $11.4 million"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_StockIssuedDuringPeriodSharesLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares License Agreement",
        "label": "Stock Issued During Period Shares License Agreement",
        "terseLabel": "Shares issued for additional consideration (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesLicenseAgreement",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Warrants Exercised",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_StockIssuedDuringPeriodValueLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value License Agreement",
        "label": "Stock Issued During Period Value License Agreement",
        "terseLabel": "Fair value of additional common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueLicenseAgreement",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Warrants Exercised",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Repurchase Of Convertible Preferred Stock",
        "label": "Temporary Equity Repurchase Of Convertible Preferred Stock",
        "negatedLabel": "Temporary Equity Repurchase Of Convertible Preferred Stock",
        "negatedTerseLabel": "Temporary Equity Repurchase Of Convertible Preferred Stock",
        "terseLabel": "Deemed dividend as a result of Class B Warrant price reset"
       }
      }
     },
     "localname": "TemporaryEquityRepurchaseOfConvertiblePreferredStock",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Equity Incentive Plan",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "Two Thousand Nineteen Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Seventeen Equity Incentive Plan",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "Two Thousand Seventeen Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ViennaLeaseArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vienna Lease Arrangement",
        "label": "Vienna Lease Arrangement [Member]",
        "terseLabel": "Letter of credit security: Vienna Austria lease",
        "verboseLabel": "2019 Vienna Lease"
       }
      }
     },
     "localname": "ViennaLeaseArrangementMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_WalthamLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waltham Lease",
        "label": "Waltham Lease [Member]",
        "terseLabel": "Letter of credit security: Waltham lease",
        "verboseLabel": "Waltham Lease"
       }
      }
     },
     "localname": "WalthamLeaseMember",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesDetails",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_WarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants",
        "label": "Warrants [Roll Forward]",
        "terseLabel": "Number of warrants"
       }
      }
     },
     "localname": "WarrantsRollForward",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_WarrantsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Weighted Average Exercise Price",
        "label": "Warrants, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.x4pharma.com/20211231",
     "presentation": [
      "http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.H.3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13728-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r575": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r576": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r577": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r578": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r579": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r580": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r581": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r582": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r583": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r584": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r585": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r586": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001628280-22-006547-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-006547-xbrl.zip
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M' XZYV+CJY.5^YXN^BL5'F,,E=M4^<*'*O5O^&S&?\!S]F]02P,$%     @
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M:\LDBA:+1;CHA$K/H^EYY%1UHUPIPT-F66,\<B/XY(2-?QD]"P(X4K0JN+1
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M<3G-VK2UZIPWOR#AUL4+V0K;B-\;8@NMCQD$"6]M[)[*04PJ*N(2+KQ\7NM
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M8C#1*KK';6PANU5M9+8M>N+"]&U)O??(,?R-UTO'$J0E$,/YW\BJD4\8!.H
M.P)<7$V=?L9?4,)2[P;;F 8;QI728TRT@P.>R <++UG45,6I1,<5!4&*9C!P
MJ2A1GZ/^S:.NDQ5>9_IJX!]0RB?Z-OXDV<QZKH3;JM*+0 _7$DSR*<*>;MR>
MCG\>A2J8V9YLU/_&2EZ!ZD]:O]'Z3[93ZW\\1]RP)<#I9H+=D;#?ND*89TDZ
MPJL6SPVZL'&UZ=X6A&E>\7UL0H"F:<I<[5,G4RR@H54NJ<MA@FR'%;9RH0#
MI( .=H\/)#>P7!9@N0RPQ$$:5$M_=($65R_@N>S2HZ#Q^[@>1OQ/YWS_.3<T
M:.25'&(3KD ;G;E(2X;F;8\J)GZ']H4@S8.O+"E62G>!%!WK@./R*3R+6M35
MJQH<EU7"(P&9L"P:P;(#8:JY8LI219*5D*<H+%1^U8JR.F0>06M)G-A<71."
MZM:1EZ*]TE:5JGRS>LH7$AE H ']  _(IL0%'"90UW; @A92!*0-@4QCS+Q%
M(K6Y5%A9$S-FD>XA@&?,)C"%2U<^U/+8[&B75&Q9U>-"YA,JA^+F0S@U@LOL
MSABJ@AD6D(.)AU^T=FO9(;L#P6HVS0'P84.5<V*E7O5BG_A&9U 4]B'/$G[7
M[E2I&)-*2\68JOJKZ,\52^OQ/O<YM;5< 38NX-_I* F&Z.:B'O</METNM4P^
M+5HFVY9J]W3A1G/F$ MQU5>RJMQ-[\CHI5)QQ^VI43(>."ZY)9-!C<WQNS@B
MME<)/MNV;,M7:%1A+;@1-4F>>@7]H280]%1MUN;QD &QT2!YX_MGC*@L-V8:
M#9>K"T>8('O?&ZL@Q*8J9/D?HGPRW9><-L(SA"]HVY$BB]1H>P@73WR,M9!L
MMZ@@F;J=4NJ<G2;14V9#F G;C1I?FB YIQ[EROJJ+5/^"KY?=#)UOHFR+L7V
MIS4-&>R[ NRINGMH%$#V&),W84ZNL0?JQ%@/D2S(2="H<5#)$=!VC?.4W355
M&UPA1@E$V"+7;I5"M''#L:3390?U<K7:U3O>]-VN;.[2[KNY)9Q1R:, VAOG
M<#E@,7'DYR-@*N-$Y=@I8#;4O_\>"J>!!Q(MS7#%^6K5$("!Z@Y'P4%-7?-*
MI!T!< NDG!9FI:J(2UEQ/&DI][9,)MQK6+91>6,-=P[MN4_99H5E\W0[+9OW
M8IH-01AREQF\7S"92B/KND@#$S(@%+T60;.W#)0&K9"\(U@D>SM0LA!KG.1!
M2-I.BX@_C.%B&[E#\[0.UE\B:D%]G5$*M?'"X6]F1L&J*5E!)QVXG?"3.O^'
M;23^D/O#VRV%%>U1U[%-RRC14HTZ*DNFQGL%XZ<ZY;QOL%K8.MF[ZJ&3Z09;
MH$6@$@;<KRH#%II*D=QJO)3UU8#./:(2"\B@63GVT:.#K-,&GY22.NI<YN7@
MK)H:TB0PW!?PFLI&8QL(O1Q]HVR?"BD=(1W+R^LJ H:6.V%PSU^,/%J1#OUN
M/(9S@B=WE3Q-!?B#DL/;J/&=8S,,_"6'DT9<-C!U/6VUK4,L!L$EOCD2HL;$
MMJ+B=NDT5DS9'-!3[;L-*>W-J".ZW;I;,S;1*'"HNJ65:+&6@8X$W(6?PPYC
ML1O@31@K1T;>/#)RN5Z76UDUOU:!&W.[<X_LGJ2ZQ3AI"9LDL^H=/+? 0$80
M0IASPI)())0J!3IB&1*;E<<V4[8S4ZP/2(H\S.J#+X-HI.9JA+9.B9<%H#!=
MI-3<!/N4<U,3&^3 S;] PCIR#*V5LUGL6^9=,6JV3%"P[=6U_+6G'EV;N9_?
M/<'Z+\'E&K*+93:W?-F75?TZAD!5'2B^LRZUU_1%+>%8Q+IS%T]CDZ3(E]8.
M%(+,;*MSX.)I?)("@!-M>I1$I(_,XL0BN<(M92+_:TUN*0<P N-$]@P,B&M3
ME O7P P.#^K"#LIEI9!1V0A>-(((-]U%4TV>IE;5*,R JE!O@/'E5KE8)15:
MGC$ 2,S]')80D*2D3SG(K&[0H*X$<RF&OHBTGG,)-0[V0LZLRK.SQ<TZW,YV
M>6"WT?NNN.E*,:WFPV)<@/V31,U<97:B([2GA(M5:FT:P'5028@=I+*<] P)
M&];IWC]*=57#>'1/52/0,D!%FF,P?JB8IMR :1)O] &! -.)O.ZRH#R^4PNR
M0^49*2-$EM4@%IBXIA!D-"HJ43F7AZ-89B;U[(%9NL[ALM94K/[[L)G.FFP&
MSV.3C(XL>:K>HE""654-TJK:;+ST28%$U$1HK^PJKVC52[7D,#@R%66[8C\D
MT%/8=<@ 8R=KG;C2!4E<Z$^&1F-H/-MN0V,C$R<%DKL6<R#V )B.1$RFU$K4
MH'R@8KQ(A2NK8$]+70@YQG@E5D")/0Z2-!-[D!&YKLFM!IG@(VHD04JS(*70
M3:ZW"!(B,Z,8H(%O%HCH3,  HHKLE^'))0\74G\.TDP[K;[7&Y3J7;DXR(4*
M\;BBWM7CCE)&FM$]QZ;J9.8N'CD-ZFKXIIC\26LV-NZVNPVJ7M4YV+;@#4.H
M;Q60:-*, (YF[="Z-:::KKQO6V#)^R0&?*BIL)KK&D'.]";"E*Z-1QQAJ=*J
M ?Q1^7E+D;.V67<D(9B*4L!0G#E9EX7/**AL3):@:R'5Z',O%9<F)2DME4E$
M?6$8N)Z(8F!J+W(91_O7%#Q@G-F\]X#=,0<5LT/QD#1ZDQR'E1.7ODYZCP3B
M.^GD<'NX+DT?""#T.B<MS+T[-;H?+D %46H;E^.7,!$V4NB4D(C^*>B;%,*H
M<A#3"1RK[V%./58D!D4WC-,\6>E067^/6YA'C$F=Y.-W0EO:Z_&--6HE/+DU
M'I-R4-A$X'^-*4_W+GI,S6)2KU3BA^+>+'R\1>GLDH^Q6HO!5;)WD6:)\4@2
M(&Q;I+$K.(?2[AE\6^B,<9).@SG0=DR.12>6WNA;53\#);=BW0+CG'4*@%,@
M#0R$#7UT:V5A?,RB1V\D7*9*C?P_B8MPVZSG6'L>CM]2++Y0D@"2C8M=LFL6
M9? +0@RUNC7U[VFR2W%GQ;.31$ER;"H&M,A=<]5&4F?YBF!-I@8 YLW66G E
M!V:MX,?U,V/;1>%_%NZHDYDU+!Z:JUS#(",G8$G5&^HPT./JQN)C; GB;O9D
M2_<)4LB?T?Q8;O"QUC+6N=X']ZIY-7:,^X9I;N]Z4".V3'_L)P"SD@9(V)O8
MTQ%A.N/N#MG\B-WDXAFY?$'0H9%0R!.S:G/NE:&X.H-*4![51+5\,:@O;K-S
M4_F%]"M:6<+03J4EZ>AD4QUA9#C7XN"IX/10/%(\%CE6T$S*B??$[_!ZC<2E
MR%;CEO'@8^!."SC !)B#@ ;-LQ0++E[G9 Z0UND_4G92/GR55W18<(&-!+ZY
M8.C)-FQLPYV#[34.KV*M&^*D#R+L(L,>TPUMNAQ[N/!.8MQG#E!X8>^D2?HC
M-G);J4^%5/U:(JL=IH@!=2WOS/NE?=V^8.9^\KRSWSEF9=I4D,Y!HTXSTW5@
MCK?#1(>3NP7^BP&2(?P4F*9:?EE-5<Y+X7'E(:_ 2!3Y.W(4#EYGL/TR3C.\
M^V]5F@*G %Z38>#DPOM?V!8*Q'27@:][2SH%_G;-&9(I5\OY8SMQGCQ20OUO
M_^UU ^(6]IR88\IE=#S(.$4OR='5NBM^."<P0 ^QA&G"<=&GS[UIELWYQW_\
MK7?"_[J[NVM_5+-4^4E[%,_H;S3@?D'S^PZ%T -[Y4C6%BAP=QCD*5FE+D$5
MN*Y(+\4%+#BQ^S/:@J8J 5(BD2A%5<J]-(Q1ALG:63Y0>-OKX_>1I.<6L?..
MV'1?&W#K^C&IH!?Z?^#Z_%&]W.LH<.?%2Y'N5B O;^%(^Y0Q R)J>@](N%.<
M"^+T-A&68\I"30UB\&P],B]C9_'"^Y@GI'=_Q':ZI(#[P/$QJ%J9YF\C33G5
M&]?B3&G>%G%<PV<+-%2'@ARM*66,1H'BG.KO)M/8&'M!93,02$A(0]JQC%*1
M,>($Y%G@(P&;8$&)M'%;H9GOD*HTAWD"SQV/O5V<(,X:A  5*H!?0*F:::I\
M'+!-A0*_$B1[_I206Y$D5#J1%E9;]#[&%+3-'+OHDVR!IEPO">81RXQ.4HZW
MH7J*"VZ)T"^8/P)<KEI@AZP,5D2 8*12=4#>%3,*SA]MQUA_D&9!8:+QN+HT
MNR?%&@FK.WS!QAXLY_JG8@C#O_$P9K:),V!*I:K&Z-8L::,E#D,7(7$+1O,7
M\DA@,S[(M1'H';OI'A*EGO!!& ) X:J!,L8<"\&38E*1"=&QPR[G"46EXJOA
M &P2([*^@BN4&U>H$89=A!KN[9*!C=@@N01*C('@B.RXX 78,8QIS:-4AZ8[
MYA(CDI/X?\@W ZGV:FZ1XAU GZQ3M, =HLYRL5?4@05![-;/*A!(V_LY^*1Q
M]UN6'\)D_V-GP1;^21+#>>69+7PHS X)<(@5-Z70 T$B^M2$F^$)JS"-,2 %
M_9FVCH0[AYO2[SQM"793>\4>B^. "R50M0/83A^K8F:<UXBTO[!O*"N7U6GC
M!F(]1QOJA!86X"9<;:,@RJ%>0G\2(3;<@P-)<[2RF( "]TAPS]- RKTRN-65
ME1<X.$T%-(X93:8&3L+7.!:!_?^4^V2*NM)@N :G)-MH#V?LN%CL.HWQEYQ:
M:(U>)NDR@Y:MJ)013K7^M'RCVO=(3Z9"*EX:+KCT/,T"09;L0&GCQIK;L)K"
M*;/8#\:!=BS9#ZN]%*"%\8@+CA"7@,>0"ZY240PL.P>*:1+I16JFP:^^C#%^
M8[)<.H3#KS(N$PE[ =><+)XZH&NZ<B/9/D"5/7C<CWDTDF+01'=DX<#== ;%
MFE98!@4GC34Q@0R+@B,%91BAPT$<+B/#,CQ2LA3=!8FON?1M]<G4%,(D35OR
M 80'4TS_DSW V@,Z3_: ;P0W$0S;I#62':*K$]2CC%6Z$A95$<,G? )X.DC]
M8"3RNH1=*ABC\#O/,-.>K <NK\%@J!7*DBTZQ==Q$>=R]TG*4\6E61YFP3S4
MSC=L>?A5XTI5JJ4/Y0[.\R','^LT!:%!F,)JR=T>:K?B#V,O"53 FD@N/JA=
M\;)Q_Y$6^S4#:P[/VANTVG=7-BULJ-$^18?O;./%:F_J2[$9$Q?I]E1O,9)"
M(Y1MS.41\"XA7,,_P;!):@S:F#&+7V(<7%9'TI+GG5]@?_UG*A5&"-D,]RHU
MF,MN1"D[A[)MU2-V/=(!FS+K,+Q36M.XCSJVH149XV,!4R:-B).*Z"'YDTTC
MLA,JI\R0+DI*70MC5H$U &W,8\.:;+D\6[>?U#Z!Y*)'<'UJ1]V&=X^F"E\^
MT\D$0V"2 LVV))X@7+"'P?ZF1A*PBRNBB 8WZ9#^*'@3D"J'R=II5<_ATDF,
M%D=KZ9"=8NZNGEHJ7S97"^+A98-N:?^%8:K4A"<E& @4I6.=((C1C!^'<NIQ
MN;@ )A$9YRZEMV/5?(N:>-]189G-,\) YGJV[#OPL*);O3#U$_D[KNI3:_%V
MFN.6J[552B,:4HVH<#W,\C8._&\9>+%9!GVX90SZDH*E-QS<V&?S%TZD94RL
M:)W3*.DEFB&32H"S/)*H"8SC#D-A<;41#M9,X$3\% 8WXI=A<$NJP6V@/+T/
M2"-L">LB!@&W;$JO)Q:$:"7 &X+/L=9<+N1! ?K[8IKCL6)@-Q.R.&$523(T
MII)2,U8C2MC2PKR*,AOO2<%CHPL'BN!E9=N56.AQH&( Z8"&C&^D#-LGF<%#
MV7J5&+)&\?4XJ27>PR5.I#*Q,(M[7J=2]QTSKBI)K^!03QUAQQJN_6$58NE/
M4DE5D(7S.R4<RY,V!$0?3FC_/13AG"Q)0LY'(NEK3M4<^@(!*_K(=P_WJMF4
M)I\ SY!LI4AA. CYP8Q:#@\46V+8)YDQB9!(WZ;ITH$7%.82JZF582=NXH-$
M]2:<SM\R)U%3^!,/Q[XWM02V*J;(]AX/,6FQ,CP:*H)PN4O/MTPMWRR/[FT9
MC[ZF>BB;+_]0%PY'4,^Z[/#"PJTPM<P1BB'4!88H90P<XUJ]VBM,+P@)5+?*
M1G,<$.%"J\KH"538<'.X(-06A[['1A_N@67RJ%)J4&5FO9JP_WIFH.[VFH'6
M*[>[6<YSM&6<!S,P)HV(N:L(O"R>L&)HI91MAF0:L1 ,LNU9TM8CXET+75ZB
MW;(@T956+[1+ME;V4&=W6-VF5"W AB48VQ6[BJ3@MA190%BB?5%0.4V=O;&E
M /IB'58E-@"*OJ (;; _/T$?=R8-.SAGFAP-17RU5/^4TF;2SZ/&$K!D)I%(
MW@J:9C5UB*5O4*<N7#0U)A%W@];L,K5N]LIFK_;QEEWM&_79^U"T@-R\ FAK
MO5'-NGOL(X8J'8NPT\N2Z-NI_Z@^KYO7L0W0]63+J.P#,:3-$A?P1590J\HA
M$ ZYX(EK^D4/$=3:[UB3 X9\&V!H1KV!07*.'"8J"-AV8L"*CK0'\O:BVP4Q
M2S8DEW.2R"%>Q&?X;I*2,0J,IMC6TW?K1M);..3 5FMF5L]?=.RJ[+A/@Y2B
M3)RX[<<(!\G_0@W>NV.3)9452'+;8%69M9O4_&) #C^2N"7\.KKS&:7CFV_A
M OIH$ZXM:$I[#HN2W79$GUG RDHFE@:F.JR;9N&#<NH?\6A_'BYRNF5<Y$>,
M?Z$(@Y_579. J)5%$YIA<5?=6K\76)XONN/VKO"W<ACTKD6P;-@7B!9PMM@8
MY)@)14G=YFM_'F(\VS)B[%O6O'FWIA.;=$] '^;3314K/_$<(T3S2(+-I!(;
M<TE13]@U3QF$U+)'^;>V-O.RWZ<4!-BR[TIS3.@-2(5BB=.24@-HML<> FA>
M![[*43G\:Z%3L3KTD SB(>$ON';,05B(1ZEH<T_6%(Y-6D*2?YH[U#W8LCMT
M@0W1=8(R?,.NIYM:WZL+RXI8&&?2$HA'H:SHM*Z!E@@L4#L/)IQ.8S+P" BY
M8\F7;4TF;DN&ON: X-2?BU0[6T:J P:E<-(_ ;/""-9-$ZPVV0A%F4[^=2H3
M-'5+;&\WB5I/V+,?!5RD*Q)VZ>39% !<H+P9F&#VDYW<VLD/M]I.WGPNL6UQ
M;A?N=0%>827*IIE%2;K9(NPF.]MM_9O.I8:G>-\+@WFHHDF.\0*E1*5"V1^S
MS5I-L%:2#1HGJ\.?1VYM6V"/"2SH'9SUGVKM_05K[57;N:IHP=D?XI1"D)!@
MR;N:>)(H+C=A*75=96S+78R3^F19:FU J9"K[?@4W$D1-9C>QP6?7:>>8XFK
M;;GL]-(MID8A"8EV1_6U!$Z6 A/+#6?QDGB[YOU;T/#\E5G4A;NHZV)+7LJ6
M-"(?O=SYV@G;+:B'&EM7;!;*AAG7MTVNE*7%0\/X8W$"N6>[;GSI4<-O^^HB
M>5]SVP,WB#EP]QT@ <<>FBKRZV]YJ1U,;<2P6YEEUVV^R14C*4)^K\4E#'"D
MM6F^8 ,FVMJ9+M=03H//WN[Q'G=Y2;^L;[I0-76N-R^*W9? 'Y,8:^YP C3,
MB;HT4(@=XJ5RN&%E2F2 B[ Q3;6MN!N@N/9T31"E]6FLO9L%+R^N\<+TX*QV
MV&;W/E<K2D=3[>>AKK3CDPS&A7'F"/->[C]N25B4V HE5^B6TCZ_Z!S1VF+[
M W"4K',2,(T(G4,I7AZQZ*\<BLMMD'=*!!4U6Y=4[:6]PHP*&&B2J/FT=G>]
M,)_-X=1F%&H;H\J?5HHL4',#+%C &[P<PUK3.L/FGE#^ ]V\]2_7=Z:"@?L!
MIV%S%HYY7ZTCMI*_ZMC2Y*P<[#"NM,BQ[>K:R+?VN\!E=[M[YJQOL%P=UKFX
M*IK8_OF[+%&*[0R-E"RT:S>=6!JW@0RD$*+4QQ>0-G:!5#J-DVR?V@4R)%.A
MD298?@4.BE*/LFFIA2"?20?/I'?OF11%])W#7Y^JJT0Q"K$:".5]J6%\>T^-
M^+^>\:OWIS=^;?)2^M_@4F))@F L08C*LE.*K*KTLJ/"-,9CME@EVDIZ7-WE
M/-OCQD+WW5":FA]+_5!T=VLV,)5PX\]8'.U[W^9U^Z0MSZQ P-+#GDUD6.B"
MTS+O8@_%!^+>]+[^]H K\)1^KVJFV"K*YVP32O>AQ[Q$I#DJXW3XI=I4?IX8
M9%B#L]5G$IP+K&=25+YYX,$'(7NYV9)*;?-9;2BSA@CNHYW=_AZ"7<(ET8*J
MOR>8KW.%Z0:Y-J7@L,LR8PTJ4B(Q4&*_Q"W H-*B19%I!CQ3GX,9 BF^0+82
MYQ!C!#_IB!W$B&3P8UZ LA?)QU),4>TMZ!UT@*YV.R>6^)=F?A'[VB;BTNYB
MN!<Y#M?O&/P@Z!"1TCONMD^0QVU1\7>]M[(8+<6SQ8F>Q$BT3C0 ZG=ES#?#
M*G$6@%:A2.DJI[&WU.NXQLSDX$]K]S(6"R0T)I.:@%1)U"/)#H0 -PN;!,6I
MO1ON;%J6YM5L& !YV^AH))/ I#!*U52I5F,67*GKY#:A-C5@8^Y[:LUK,.H$
M^_",%>U5;*UE\'[83E[Z<MRMJ2()M\74%G*:D+I5E?!H(HV9X:2G ?*G#AO$
MPA+*$4R,'J PGX?WQB87TT+*FT>Q@J1I _^*)U$@]:5$:U/<(\+(N7+=OJ7]
M?L)R!98[^C(LATL)_'_M!)WQR5#WCD9J?*1[A\-3->H>GX[&9R>GP]YX>'#X
M6Z^SLW$ N+(V3'UQD._=#G"IJF,7E_3FTOOPYN9R<'WM??AI<#5X][JUH>Z$
M-!VO"*#514(NB'D;&U-E#U;A0W,5,@N2=&P*(]1E4E;6S_@HE6'O'G4?7X?]
M_F'^P,J=1+:F6<V[M^_[E_\6*+E]R_BUY[W_J7_UMG\Q^.7FS47_Y^N6]^;R
MXJ]PKO5L].6"D/Z&G"TPA7M=G52"-Z5_PTT&).Y=J8G:5$8?;=AOQ3^K/;&-
M.=Y+P$6LRM5L7W.G?8.U#7G>%U.LQE> HG?4;B?9MIMV;UPVUR_8)%67F$!3
MZ>*^/43&CB49U4CGZ%$(TQ867F_\%;UO3<<=[Y+,RB\!T: %(@/$DK6\WG>A
ME-.OG&TV;:@0>1W&H&MM,R'8-@1][Z#;.>PU?C' T[(L8@;>3*JXBB/LZ!JG
MN+-;L)\#K'13WM#U)[LV-CT\:A)8%YUC\.O@ L#Z_PVV5NOHO^J_]=Z^N[[I
MO^Y_Q]/;%KSCHOJ^KV9X#3,U5@V!];_]UGQV4+=M?P;2: H4_N9,=@OV_K?5
M_S1]6??+QX<MIO>?W2J3]U_K6U^[BW)<IZ?MH^/M=U(\:!G_,G-C4R9N,9<W
M>/O^YW?_?CNXO/'Z/UX-!OA3XZ=__>;'R_[-+U<#[WW_Q\%W=Q3U&N4HJMWY
MH1I]FB38S6=?#F%,_SS?O-P9_/K3FY=O@+R^F*P:O+CW@ZNW;VYN!J^\BW>7
MU[_\?//F\D=O</DCD"7>I.L5M-F0E2$:<A/%G%EFY >W+!I;F> 40S5/];GY
MX3D6WP[5XCR(:&CZTO-RU >JG+<Z(:.='#+M)W]<7(GV 5^+#.Y"YILWR\=M
M^NA9YB]_UFL?=#HK/SUH?]EGG?;IR?$W'_6@?=8Y_<+YK-Z!LX/VT=G16L,^
MH]WE'89#3.<J^M?.X<Z#Y"@X\+P[_^QURA$[" VK!SP+?#_4&X**%9*6+?F.
MJP4%;&-+/>UVC_\J:_W+'.L%%3$/,5*AXO0H+9\N\S/BN4\"YDG / F8)T[T
M)&">CG4=\_)PIOVU9<E:=I_O%YGZ1XN*7K=]UCO]$DEQ=MH^.UC]\0;X)"]L
MIP88W$-J?>RBO8+ 3AZBK]XAUB0Y[IT>G!Z>''FWCVG?N((02_\>QOX"_C/-
M9N&+_P]02P,$%     @ T(%Q5!"/]9MA,@  "3H!  H   !E>#$P,C N:'1M
M[7WK=]LVMN_W^U?@I',Z]EJR8OGMI-.U',=M,S=Q<FWWM//I+$B$)"84J1*D
M%?6OO_L!@ !)V7*:1%+CSDPGD2@0CXV]?_O]PW^]?'M^\Y]W%V)<3!+Q[M<7
MKU^=BR<[3Y_^MG_^].G+FY?BEYLWK\5!=[<G;G*9ZKB(LU0F3Y]>7#X13\9%
M,7WV].EL-NO.]KM9/GIZ<_44ASIXFF295MVHB)[\^ -^ O]6,OKQ__SP7SL[
MXF4V*"<J+<0@5[)0D2AUG([$;Y'2'\3.CGGJ/)O.\W@T+L3>[MZ>^"W+/\2W
MDK\OXB)1/]IQ?GC*?__A*;WDAWX6S7_\(8IO11S]ZTE\<K*[MW\D!\/3TY,#
M>;PKC_?WCN31[M'Q\?&P%QW_;P\F^10>Y]_H8IZH?SV9Q.G.6.'[GQWO38OG
MLS@JQL]ZN[O__21XKE ?BQV9Q*/T&<T6OAUFL#;S]2!+LOS9=[OTSW/\9F<H
M)W$R?_;/FWBBM+A4,W&5363ZSXZ&'=[1*H^'_*"._U3/>OAR^NO,S ;&2>)4
MV=GQE"X^CN-^7(C>;G=O]X>G^ .[J.;29#Z"U179]-E!]Q"&]]8P@/U4^8H6
M<?;FXO+EQ4MQ=OE27%U<WYS=P%\N?K\X__7FU?]<B(LW[UZ__0\\<R/.?KZZ
MN, _A4NE?_$'_?S'QG<M&P#[=8);,)51!$2X0V?X[+![$F[+^U(7\7#.'\5I
M!+OT;/]H^N5/^Z!UHVY^>74M/F&WQ%8QCK7X_KN3O;W=YW9_OOX*>!\C-<AR
MB2SE60E;FN-30 2C7"F^UJN:WI,?:8=ZS[<%[!;=".!2<5ID0FJ1#<4;F0_&
MXKA#K*F#NZK6>U,OAD,U*.);)5X"QUV+G>W/A4PCT5?%3*E4_'X@WHUE/I$#
M51;Q0":Z(UZE@^X&;.YY-IG*=+X.N]JA/7T)]/I!O.F*-RK6J<K%UEKOW\5'
M-2B1.-=A!\46O#'ARY+,1:Z&*L?;SW=_[6GQG<R+6.DUV$F1Y< R0>K&42F3
MYE;*]=_(M;C2W65@S&YW]]"AD:7!#Z,_"WT2-81W'^YU=_<:@,A]O"Y0\4I<
MB'/Q2@"X$:_%]7)[M.P6K0G*^^V7BZN+L^N.< Q2C.'B]%%<JLDTR>9PF4",
M(E,R,@@O5EQH\;,"MB\3^+A,M4I0*G2$+OM:_5'"JI)Y1YR/8S44K]4('GL[
M',8#E7?$M,QU*6&I<$=QV.K-%_1"4ML<0A.SN!@'KX](G[M6TT)-^B!X]@X1
M(_5..V(VC@$RS?#BPT\C>.HGU<]+F<_%W@$!J=T-$/7O\AC8VEI!U.^_.SQ]
M_E!2WBSZ]REL%NLQO +H<P #Q&FIS%U $T)%KO ]O!7^8"Y$"[435(+GB(T9
M=)\*Z8@;*#B+:%A\/SPS(>RO2Z!CY6[#W=M?9S^+%,C-.H]JFR.EX[QV''%:
MWR/::6^;Z6M_KY>4<<OR[X9$Z[5+M-XZ2;0S\;- J78AWL#_+D73M/%WD&F7
M;W_KB!LDI)_>7EUTD%B <'0,'):8+=XPO&[37$UB#>]%TIF4!4!(>/!6I2"<
MM!B#@@._Q.^&P(\S^$4N1ED6T4>W,BEE/U'AR,Q&##YFTD/F, 2TG\TT7..3
M9:_Q)Y'A\7'M]N_L'_F@[6L?1*_[_7>]H]WGS7^OI^1]6?*YP?E>#[*I0D*I
M,,DJ!?$78E[6$GE\OR42#=0K(J,MN;U9=/0N8R\&DQ)3U4JI1YP1K+@$YD:0
M^< BYDK*$I*)D%O5<;WAE@8<=849[.V@R'"L(P+6/7^L/D"@E$9$9(-[,(N3
MI)+>/G!J TV--U9#TT Y@ON<17P?'3M*\U9/\VP(?R8'$K]_ +L(7)S8O<J!
MD<-F#OABVS$1Y/:.GVL1T4%UF*7KPBD?S2>GYH#I>S.\F6T'%Z7'DJ8I-<RD
MG\QA1^!C#7>+31/>5@6JE7L![TKUF-F9KKCAA<0@AEK7(($4<(L\8$2$&>)+
MLM!7*A;\Q3><6,FW :8H3V.\@<6M])(99>G+<NJC]>;4_0WCU&_[L(WTZ8H9
M],LRMUI@C:8[=>YG^-A"!B:&$KC2L$1[J%$_<=B^TL4"GM&/D[B85XPZ4K=9
MH5J>Q$$KCJN&,(^".6\!VV'?Y/CV3QGSG:@,@?<=*R3,K$6:D7E(6A.Y2D=R
M1&H?ZN>,Q2L6UQ'98%!.S3MR8N!E4I#PP1%@<1T"\60^ F5R4%C+,?T9]( R
M]2"\+,1$SDWH@) XWC")![1],7GJM!D _@Q\4RV2$^9 PGWIT--961@E!*T]
M<@JB"W2*FNB[5QY\(6UB0W#A8,.XS64&!\NDM&)VLVC?SC23>Q3;^]HD:@OC
MHN &5K0)= E4TJ1[NEBD PM ]-X/ 'X,45.NV\DBP4S,,CQF)72C6B=F41F9
MRP3(HO =R%-TV7^/-Y[&GP<+P$L>(TG',B&&D6;IS@"FKHK8,A9F/)7YCEC%
M+"N32"!/R)%'M,S+ YY#PQ+=!:>I#K9;?H9PD65" -:BS/#'VSA+B#\A1\PC
M-*V_+Z,1/43,Z7V9#FCFP%V YLA<X8//CN&5S-N(A<$'?>!Z9#J;^PO-C'$]
MV%$IINC!HE_-VQ[H@PH1\1KQ.+>B;8' > A<6=<\#E/80#S]J$XU$MBK!/:>
M\UKA^[Q4:-09)"4RJPX(I((V)(DG,0_0H==DJ,604,OC N \7#,8 ]=3?_E$
M1DILN2'A_9DFG%W(F,\@:SD@%94#*S-R?K C%O)6/]#+4NJS7,$1PI@+0[_Z
M65%DDV>[U4]D7V=)631_\N,/!1VQ^R72Q YZFN54JV?V#\^C6$\3.7\6I\09
MZ$?/C;PPKT,K\BU>XX%,#.\GML9?FS<?['5/#T[PY06(E"*R+S;SZM*\GA91
M\[O3D^[I[N*O=[L]]]U3&IO'AQ5H((E_/=E_XA8I!Q]&.5+9CF&>0_K'&F*?
M[4T_BEXHQ=!45E\=+^R)%]VU!$\^RX%5+.#$Q_<QXH-]6./>X<E![_#H=%_<
M[B\?959MS%,ZO# (C_\]SBN9/E([>*D_[,@A<-=G,IG)N7[RH$C$Q7/Y- BQ
M(L3P1PFS .3$B+\#'&.@4FV-% S%9EG^0:B/J&0KX-C;%G2^S_J6D?*=!X95
M3E1UX[_0@FC$9W$!,Q\LL<1!][:[2FS1851\&\-PL)O ; 8E660:CMS%X#4P
M:K=%3CX,ER[AM%C+",R]#3.?GQ4[OZ'ZN"8F<W%=@;UK-6"#[%$'0RKQMI^
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M82)J&(9&BCD%I=*SC,J2N]1,2@]';9C$*9J!.RCF[G;B6V%9BR@-DM0J"\%
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M"!^2HH>6IYQCT/"\8*.9HNN2!2T>P,,&)"?X1Q4R()XMXUQ,9/X!&"[FDR%
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M32I=VU1LXQLDY-B( $_5(><WO&'>4J*E%C]659ZH&I0"FZ'<;DX3<(]N-0I
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MR>7.Y$+7?5P69:;:''"N<8D):QP!W">H'TOX 0A!@Q*F,1FB=%$AJ.%C4 "
M,G)8:(>I8HP)/&0Y1'@?*&.-,CH*7O^0F F=/B@1[*?D=\*#]$HTD" 5A,#&
M@%E(XF?L8'P0XG#;/%FG28*1M"]125NO/'RIX(S))&<LJ8&,48]D6811=OV&
M4TO&>8J4JX 8(FT%A8<3"O3FI572"=D3::/,FJ0H@*X4T/0L+3&H'@U\.,!!
M[W^-(/,XVT9SIBM>R]H/TI=D>FM-" #M/G$7[=!BOA,J9B*4$DS[#LKV3;B"
MTESA:$**%T>C#&A>R2T&>K(P-^,RO-R?"I-YQ,>+\1"9C\/:5@=Z8I(*-.1K
M;L@YSOU#--[P>SG6'%_9\CHF5>W>0*+&PA1)$<6,!6 Y'9"J@9H7% ("AX]^
MU2GNB#9CB6?HCFG$7Z #!"TV>QE;EOB,?*!QBQIK#5-YW=;$=G!MZ3<"!N7"
M@V#OV^9UO"S2X+-X/U^[JBO>4%Y'H@G38D,?3=SFBL0K3'FNY/>ND@-?IC*C
M *57Y)E/L[Q^LQWGG%66X)<9NH\(H68J'?N*UR23Y+5RM"WR'&H_D,*@0MS=
ME';7TW5XPVWZLQ%H\Q(8 .'G,6<BP8V<:/VK#]*M?]A#1)RQ&Q2G!^/R$=89
M("(QN&H!L3/^4B7 B+7(*!-PLSX#7\#\%X4,DK0U_4):'FEX,!6X6J4^A!DR
MK(@'JI;^*=7N,C<@P4VUO"B!8Q\>[1_"'=DYV#43/I=Y*/\MWF)\6VBG_TZB
M:.XXH6)U5670ZY\ S=A9#4$I*998OP#]N#"A#['T]QP_\(4/GP)R4-<Y#%R.
MXM(ZXEJ11L)DQ:@5R2K*R0/@,50)OX*8H:WC42L/:K4(G(+WZBGE9./KZ(A[
MQ-WSE6P;QV@,_VC:-J;M^T2P/IJV;S)M:R2$],K47[LCYFJ(/)BJ$&\VD.\X
M+3-#P,2_!X<6)VNN9;Z6NJH?X' @R Q5R5O-XSE <H8+%JYE:B8CNF)F=+@I
MS.H\&PC(@ZP&JO:/!'#08@H3IHL=(F#TG79Z^-RDD:9E'B]7)I_#NB@?Q\P$
M)YI_,V#3[Q]TC]>';:*5V*:F=-7T+9"XBJ3C H0PYR$[<C'OV ":2F*:>!O%
M7%U_TQ4GN-MS($_R&\H,9-5$QW>XYX%NTJF\)B.4HH(\32NE-JDQ0LBT 8/%
MOE'RZ&]LBK*J" Z)>=N.$K*8*M\EJK\#^V&P DZ*\Y"]E1E:M@'1]CEZ8)7]
MSGO<"?7!C:GM2Q5^.+IY-QZ O^E@R_Q-;-X'>GNI$C6.UAW_=[>8822E0GY&
MH^ UT#:&T0(A7DM0[THLT<$K@<_&5,K+9Y0=3=RYP-R9N9BI$'-AD&&7&=)X
M1R 1^9_D4\!!>P26X-+IZ.*.B--D4O_47J@Z;#SH]7<^[](%:2146EM10M49
M*1QM' $.4  D^X>[:).DVT8:,%T:6)WO#%DH' B8T"(5.X-=_&-.>9CT7:HX
M$*MK&K"_RP--TSC"OQ+JB\L<YV,X0 3,D+[I[WNB5$AL*U?53NN[;=TQ&.$W
MQ>M_@V?F9C,*<T;@>#**ZPI3+7:;)\&G#<0#XA(XT AE;9F$AE5:.G\-&S%*
MT\_=U>!U>[C-X99QFY<FSG[X!57==:=+W\O-F:EH-@(4X%;M0>799C:I*HV@
MR$#P@PY)&@E&<QJ'!$.+*MU ;P-ZK\I,\RHGEE5#U3+#KQFC((<@M1DL[IC5
M14E-="J=NWKG]$2K3: %S8%]!%SVZ":,<^KN'@,E WE;_4$6R5& ;)I53Z^8
MK78+:JP]MB;&@][)J>$=;_ HD!M>( \L<8D8?;O1=G-W'9M@-Z_T'E"[<ET
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M]J>MX'6(!2:X##A'031 ;"NJ<GNGL6+*YH"^G;IYNV6VM:36Z&[;;NW81&/
MH>F6UR+%.D;*DXZE^3GL,!;0 =Z$<7($\I:)D<O-MMS*ROJ-!AS:;P1 4FL
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M9* 18'4!85<R0X!^$Y;&WD<_ _RM4@>YRE+,Y%)[K87$\<9)'-+^Q>1A*?0
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M<S%KVX-,VNG(&I:TQ<I$<#3<4ZC!C=AR%:?LYBOI[I.N:M"44<5"60$?@C\
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M+I[#:R\:9C0R[O!D%,;CT:(D8@->MO+V\'2%]5VPKG^!-1&8A8!,YID#PC>
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M0T^]DE%RHL Q(Y-\3DG068I@=([02,%\! /%.<4L6&Z9TQ"2!A'!?P;W^<E
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MO&Q27F/TKAL& U-2[X6X0+Q-/5(0V!\9M.+4 ;40CRD2>N6]/ V!F2/#<*^
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M%$MM-94D6.>=5L*H)V,?'P?$15E&3;Q "H#4C%INI& 6XZ@1!/TFE*FGUE*
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M$S 7(#Y<I7)U!J;3!ARSH UV1HG427/M1<.,1L8=GHS">#RZ,Q\NKY__VU1
M4]+^. ?9[!Z;7B6<!5=T/82/(08(HP=+3:S\Z"_)X@V0E>GM=X\G.=<5$WR7
M";Z=K&AN'IPUVZ][^T=UW'P%;/ J5?P<T,[%3K?3KC*X+^"'&FY<%(YT,))J
M'6(FO2(9$Y9F"GN;"4,I$<([P^C:"P QU:V4GP! SBI)T+X:WR_/PM>[5</\
M]I#EP$E+\V!*JYD_/:<-Y]W[X!#A(3"548I$QG2*,:UBF361"4; 2(JX]D)Q
M>5,Q?G](3VM["/;DS>%P\$N6\23'Y@.+2BDC94:)!,X"BLJ,""Q3@A"J*#8V
M #"<I#PK0N6)XZ8:_;F8Y+__2Q$L_QQ5QJ$7CA/FE4$!^A\5<%YZ)\GWJ!C0
M4)"P+SAMJ0H,'JX^Z2ZU2.PQ"%M_KR9ZLO3_LK/VM&PDY,%7CD_RU&MFG$H7
MX8B4A?[O_\("_8G);_;WY*ZFBL>J&S]?4/&$7E?\I\KH*5Y73/]4\<2WOZ.2
MS[TDHW0WR\D#UX],^Z]\+8YY5 ]N4J74[HY[1=55@,BTXE)/GA\H.)_73$PY
MABHWA878/>_;8>^W*W'M:J"N#51S6LA7B%0X<X=I\^[*<% Y/>S")Y^)^LO2
M_3EJU0.L<KC;XS^@MSHU=^>8V$)Q2^FM3@/\5W7<>M4Y:V[6SIOM1NI'<=YI
M'_9;[==].!/N7,!]'-5YAWP9X'>.]MC^40TUVG7<*/I1O#Z$<\&]@=][].ZH
MT8>@_*AWU.FILR]6<6N,#*>,99):GC%O?*:"0)F5*B I Q-IWB*M*"BFN(;N
MXSU6Y#RZWC]%J9\2[X1W5R)_!Y&O7Q?YM $H2+W* B,N8X('B+HIRC#UFON(
M(2!7:R_^O=7:68GZ<A!\;6HU)^L?;D[X))M:_KF>1].&M]>U 2$7*/,BH]*
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M@6Q/-CFYI5?T,"^NU3M/%S_MPJ7ALI4!/-HP>26?NJ/"3QV8@>N:7DH4IM:
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MTW"6@DIK:$9%^30(65$J5LQ,QU1A!2<<S4YRHY3#'(,O>-8%00R]\\K_GJK
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MPO;VYHH$_#:GP+; O^T$F&=TCJCL:>I8+:\'G(A]78L$YK.\I&_..D'!O+9
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M Y@84,^X$BZV:#+K=E)SQQ$<^>&SAGNBN8H/]">S:HXZM/ZT@4EC@BV$>(O
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MCW<._A\+9:DMNK>O3"2(4DL!;I +H[_V=_:?V#WV=@Y'=*-'[B87Z&; I^P
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M-34[SQ>*VZ29FK96@GS7YP4N,9UZJ;*\*R'&X#$HG^,\(HO<$JK7TM!B_W/
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MC,G=3J;@AC$YJZ=P,;D[0O<6\/1\>X.8FK[.3K+!^PK.E@M_R-DD-,-L,$&
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M1B<3:3M1^>C'-3XK+^0OF5M. \0]>(6]NR#WQ*HM0@7FI$$7VK?VUIF]RR&
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M!+JG]Z#W?.+'(;IH,07("TLXUL(GP>=<:JS.9YOCW8X1D@CW3+F-7**>+IB
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MB"XN^0PF*.JDW;7!L]&D%U<?$\H;%.RFA;W'I$;#0A>(#7-M00KZ(.F57>'
M?QW>K+C-DE;/?!W5BP=+<8WE[[0K>5DH_*W;&,?1,^?]K9;1+X$D>-E>[0)#
MS6FBI'?,:@9GDY\W/:9(2=['ME'T>O_F*XVQ0!OIY F!3>J0F[J1F@V?G5H"
MX$2_1EJ,:2\JB=V,33/ZBI?8,31JDD3@R=$?;C!,&KT,L>QRBE/4]ZJ:6"@E
MHR"8WUU<DO0'FO8.AI%$CY(9]T58!#,CG3SPT7@<%_EUW8@ IK^4!QKE34,9
MW0A+HH?K5+C.@NM-PL7*?FWW6N;!B[P:E154 2,N-?,+<H[*YR(Z8/Z15F*
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MUY<T!;5JH0>.5J<S]P(FLY1YR:Y.="HH\>!<W+#T"1/A&':OX*&:;?@@Y\L
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M1$&&O7PJKX?3,BG;;3=7P:YW-0Z0>HT@)K'WI*,K39X'79&;D35W+VC"HH%
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M"S2V;XKQ\VJ\%_$V*R)9^8[AX 6=1 ?3@MHP/3EE-!&BWO3[]R=\CJ$3U4H
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M;_U<I;[/@NL4_93@@VXW=G#T.DZC0Z(FY!$OVVL4")3<Y;%9P15)WJR1H:?
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M4*Y><[JU8RXS;QP94M]L@ENV9F,Z;"Y/5;C[+8O,.37*OMI5D2\W5S,R8N$
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M7^WK("D%JK0WSXC62R M7*O46SN[HG,*? TJD3:R(,/$0W+J1U&+<XZZO@/
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MTA/*,(ZNT76J[H[G*6Z]],\MM-CE++Z>26\62FE"*O?2E.>^MZY#2>[)=3N
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ML*+(:214(_4O%[9/[FDX2CP!(_)R\31' #?&AQI<S9%Y.FY_ZL^DNECE*6[
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M'E8J+\=A1C_W"-*#$+"?G]GB+?W3;SP7!T:A/OB$GEHZK85RZCU^MD'[ S?
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M4T=:=].BL3VAV5N6XF%1;R>8,OJ&8<M<P53^3D:G1(-?M B5X3=G^MTP7)A
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MI&1#2,JSGA]YIITE-W$,9/#'1N*E54_ M<)DG8"'O-R&V7OY]K7T--Y=1_.
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MO],TP:Z&&=<S4._'CO^71N1.<-D[97QB#@DVK:B@;H4),T,T;@[XY441"=@
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MQ,/6;X:*!I,7:6AK @YNUM(O3%0\BKR;RUIR4H)C_B41K31 .997Z7"D#PY
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MSTX;J^#*#)#NY%*ZKC(N<NBC)EE"QD<+A"PMW9AJL].?D,H?BZQ3ZKN)+D1
M61Z_2)/3BPQ4-K=0QCE^&I.\^ZT9A?)O+H(TFFNNOD-DHIDI;)7PCPQ!Q"XP
MWFT?(QAH5>EJ;A70"#-6)>M:?^0>W$XSY=\V [G\CO8.>Q7C%BMJ7G 7EI(
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MK1 3#<X-.*M$H'4;W^D:[RAX$I7*3PQ^<-)P%-[7\/N]X6C'8K<__R(1'?
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MSI\)BF_P+H=[:;$ALJUQM RUI, 0,Z[D/$K&;?SA/.L1ZD_&\Z1]VD"NGT
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M(K1I[R)Q); A,S6#4L''2.VP>.P(KPJ*/R8TAQEROS#,*BME>#,\C?J5+Z2
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M,_N]['N4R5@<9/_K=JB,6@++G2UPD2+8PSP5&RE;,%I(GB)*R2RI9[QA=IM
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MU5M%7_*\/T1?E@ %?8LQ7RO2'*Q8"4?HP<?Z8H6CU--6/0,Y)_0MD<(J^H)
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M11>P?!=XL^8BH@Z6IYX3O,SAKH/9&P0=G0GC&S- T9<$#3!8@Y_W#CUDOEZ
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M[_)Y\%%[A\$3)RFA3Q!DEY<VHD,E<@T4:@<PN<6>$O0A*#OPX24OUB61,\5
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MK21F9%'D$=F4XF0+Q&$-@U%=T=DCH-QJBI8$_EG>T,\K'C;I+.8.;AG^<Y:
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M(WUA)0!'&9.%*&1DNW"J$D^X&:^I*D_QZEFF((<K*<CE%\VVEN-PTVLY'K(
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M)J.]+F7-VN(DRBS-W.*[Q)E4E@]I^?!68?G F"C3QV.FCS^?S!GQS)Q6/IH
M\1E"J>IW>>[5_?N92R"%"F,=QO"'^*<UWT#2^O=O[8_MJXD4U3+'7KL\_*UU
M].5XP=S'UQ.>H&C]R.]6<J":9S1>C17A#Y-@* N(I&4[:^$U!XK.M$\(?%]Y
MGZM/R+#!#4P#\+^"6T_X9_/RN7GM )KEO:,7S//^\*^!B. J>6T:LA2)SCS]
MC+TK?H"4RWZ'WK^+>V(^XJ'B^$L&#8R6BRX#Z+TD^8"@A_RRY#2NMV];H-[_
M:Y#R_X?%AR4?VA=\Z& 03E\SS'W'<^9>UO?QW&L/O9;KJYP/K/RU)MDWB+?R
MUUK[MK'88 _$^N9KS'<1MOU_]HR]"3_*.UW#@@Z*]SWO5GE\Y('@MVNB9H[V
MCTC\Y_T3ODKZ=W#S-+I,G;6DOWXN)"Q5YYQ.2\*:N_;>Y"H)WCEWB6;,&Y37
MV;-^2':-HA<STN6#"R$ 60B=[_(:[?PN/B8Z$SG9W4WLQX/WKSY [8:+S_^S
M]X\%! +B0,&M)U4E^=<!G12C'J6>B7,AC^]3ST7Q\LK]HL?#^K%/T,KBQ^(%
MAS%U+'K)\B?B$R)S=O<1UOM4\E\;V_,6VLGY]7;&>.%JUV#^47^%%2BK"C47
MF/&F3"I7$&:715I21G@$!A72U0[I#!UZ5E8*'7ZD'1%*?WG#&*A52Z"9 JP:
M 19L+%<>EP$L1:AU)E1C@E!'M@^04<]&I4USYT*WG[(;ULO H7V<9(J2-Y>2
M#:!D4U'RME"R_2 E\TMB4\!&=RX</JFX)PE^-+CZ">VQA?WN,*^Q+2[DKAOX
MZ2;IA#)""COO->FL?W,DO/R#M[O(!3XA2]'--M"-]S#=0(.[3]#1;A</^99
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MV4HB3+V;R#2XPZ(?8C,=L"[$J1^*'+A]<=^_36B@G=(^&_+CD#6T=B_8U]Z
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M%[4+<4'AH<+#I^+AUJB,LA2T L1M!T15'6O' 1$2A).H7SC@;F5XXYBU,P=
M #_EJ=L!(-LB3YW2ZW8#QG:T,A7&I-XX]L@ 5P-DA.BV=\#NL(YG&D"7,'V>
M)C_SIN&64O841NZ2\1/C PLZO:W/AU2S!=A^D%0%J6J)D>O0]4802=**R3,W
MA980N9 U5$&D@LB=LX<JB-P-B-S1*E-*CZR"I(D7,8J6.*CLHCL":-MF%U5X
MMO5XINJ9U!+.7KR[-U"UH5OX('0MV_5"KOG)#(9#/JPTZ70X4K7^,XRY"G86
M17S\O>LJ8JUTN^Q]:X'UF*[&-G>%WD-%,&3LSZC9Y=.,K6>37V56+WHT+D^T
M%SL#BF2?L2\4RI/.J6W:'%X/LX'F"&.,7AIC?#:X9:SWL#GFX[YV$4,GQY%O
M)+_:T ZY")NDVJ=X\.N:I;03:O]-N_WWVF&2/WHYB"/6:6BG,5]Z.LS*RZ)F
MN7A+DO9AH5BHC#L?+M'6]'J2QITML^VX!PZ(PNO+]ZS9_+=?%%:5DG8-5RN1
M;IRT#T*6!6G<AR\D42 :;F30/2,'V:/158#5W!7"1(N-4>"  C*L;Z%59[N@
M3(:[*;/.]F*9JJ.T]5@V \B(KIL>ML8]%&B1N&VB_!/*/[%)$Y) !OTMR/IR
M-FLV_ZW'L36JVPK'ZHAC*XC8SC'.$.9/LII8-*7F;1\V;EV\M@+';0='5<UI
MU\'QV;':"AP5."X&CMMF E7@N$IP?! @BN=?OYFA]%#LX_]=,X-2 %H# )W;
M,IAKF;+>/-&QI;6Z_4YRSUA#.XI3%D"8"T#>(<>Z86< /85E8!Q'0WZ.^2>U
M\P[M-2#@AG)T#55$RY:"(-XZ'5%U"-YE'"0*!W<9!SW+\0C'08QMV\MQ<**,
M_27$OVAG>=1+J3UJ8A1"!U2 J0#S0<#<+KW1/% -R'88+PV%ESN,E]BQ+0/P
MTK9,RQ%X:8_#Y07+!FD<@&4U1\XOO7CPHKBYT["9P\PVXN8R908V8$;V 784
M;NXN;IH*-W<0-Z7#DO_H$6P?W$5)^K=N8QW2J.XD?G&\2UD.HLW\-P(" 4B%
M@Y(S#6<V"BKD^W")ELE9VH )>=[V&%A+Y--W.F_0, Q$#$]WR6Y"GZ6@;T>@
M3Y^5M(\= UN6;AV$)N$_ZD)K=,>UQA&N+6)N57 X'PZW##PX^]@R@!=@")K@
M^NH.U6<)E":H[]L*#A4<3L"A-UDWL0?*WW"0I/<*$14B3B#B,C;$C9B10L2=
M1D1'(>*.(.(,.'0-PS1-YR"T;8,0;R&?HD)!Y2#<-@<AQ@=$> C75X2K/DN@
M4%#?=Q4*[BX*SHJLL9X16:.@<)>@<)FN51LP(ULU(]WJQ'TP8?SOVO96P5P-
M8&XR$,9$ %)]#DEWLDP;2^$'.HYYY_*W',301YJQ< X**ES;RDB8+5/Q5"3,
MCD?"8%WI>#L"?HO[_OBY*!+OG3(?0H);6=--*6];Z\W#R\#!1DQ)N?-VVI")
M56V974&Y!2V9LK3,C')J__T/;.OO14TU,/AH[5XX#')[IC)@[HX!<\M0727[
M;;T!$Q-EP53PEL-;I6),CF<+EHU1<+>C<+<U%6$4W.T*W!D*[A3<Y7!GS("[
M14,T%>3M*.1M66]?!7G;#WFF@CP%>3GDF8M WD/QF KW=A3WS.V:D<*]^;AW
M,*!^AQ746W'-R>=-BW^@GV2QX%@IZU @_O>W<3BXD<M;?<I/!H.D^TX?/4+]
M+.D,!_,?&6/(V;#;I>G]>_['==Q#?,7>86O6VJ[_*!$1WX4GV%WESYMT=#*N
M&?)31G\@&O'!OJ.=6WJ?[1V,3;S+)RA?[A#^]<D%RF?XX5]^>C#)9"<WJ[)<
M]IS5$OL\VJ:4\WG$5ZU#^QE[5_SP/HRS?H?>OXM[8N[BH6(SY-["=DP>;/A>
M?EG.PO/V7<N&B4C!2GY8SG%?S+&@K;%KSCXQK;E7N83SQ&L<(Y_TY$-CM8Q]
M79]_^>F#=75G]8/=]ZRGC?7AMQJ.N?*WNONV^[2W/GS-<)YVM!X:*V1!F?9"
MK]TJ3<-2FL;6:QKZG(! P["P.180:-B3Q;%"UNW%$=^Q"6_2FRA)M5 63LY$
MV4AVQX*A4"J2B#_!TDPH%KN]DF^5<@6ADP?-[5)&P*RX92D"&!_HM@J>W&[#
MHJW@?NOA?L&N>S)TI&Q^<)AT^ZR7Y4!_GG3BX%YAUU8:!K<L!D3UT=M^W'(4
M;BG<(M48D)D-"UJE"IIGLPE5=:KO.LU MQ7=UW.7&A8]V+%7]F#WV>"6L9YP
MH0$NTE[^^W,Z[%#M@EY#'Z#SF_VCW>Z<M[T0N64Q(PHBMQ\B70616P^1$_;'
M46D3V_/<@TJ^FT!'@7Z#1%L-5&HCE,RO?6)^.J3IO;Q ].714U5/ =I%?VP7
MVFQ?5IUQ8."=+I^R _CI_5/AY\;BIX ^V<K@DM_'T69%J.<(;"./85LSI%WM
M<E\[2?B7(OKRR+:QMVX3TR"Z8AJ;S32(ODISTJ+<XHBE[(=VPN*LQU+%*7:!
M4V#%*3:<4^#7X!3-=*!=4;Z9+%-\8A?X!%%\8L/Y!'D5B2)FUXEV2$/Z,PX5
MI]@%3F$H3K'AG&*EKNQ%.<4)F.R/XH\QS9AB%+O *%0V^08SBN=T/,"6XY$#
M/XW#:Y8&22\;=@9\XRAPD9SU'):_G.8MEZP_8%V?I1K.68O^:'S,9^ M'_/O
M*=?>=KKVMBQZ%-(>+.7;VVK?'K'^H1!PEQ"PK*=B6J9M'(2>:3K8KK:V.X[Y
M,<W8/(GZ]V'G7L:&ZB+JQ9S"OG^;VM4-2VE?5)3.&IHH)0UYD5T^_GMM1LEI
M[?CX\&T.E*SWBXOT'#S3_GY#H]HE[251S,^: %,55KJ=8:5+\:$-F)***]U^
M[+05=BKLM*O-T4?!I:?)OD1)B#-]!%//@D'"M<G\ 6*L$%;AEFE<E8NBT'4.
MNFYA3OY2O&H#IF0I?-UZ?'44OBI\S?'564@W/6*!,,N.Y2[:*P?2)+UF@^2V
M!\5%^9G)XH$"SJT%SJ68T 9,20'G]@.GJX!3 6<.G&X.G*V[H#/,(&9B*0@E
M+P.A']G@1FMG*64=_D$:)#V69=H)"^%.[5 0E$+4;474I;C3!DQ)(>KV(^KZ
M]E8!ZBL!JCZS@@ G<8OHY"",@G@A'?0T^2E#@XPYH4'3V)BC)]P#84-'M$>U
M3S2%EQS27L#_:O>R03P8#IBJ"Y '#VV? ]38OL(Z'@0/+5/O8%N.Z8Z@HK&^
MP#"%BC52,V>4GI,%!HX3O@^ 8Y<L&*;03VD1CR<4SN'RL[MB+?,WE@;##E_0
M0]J/![237U/XN97Q0\L(Z!LP(Q4^M/WHN3[)2*%GO=$3ZX^$#RT*JQ,.4*QP
M5>&J*E>G<'6G<'69-"R%JUN#J]BU=-<["&V#7W'#R9*ODUGD"V/J[\,>D]Y0
M9Z(8.NTFO6N.EOGEF9#9*"_/@-S&'"R=";/:)[Y:D(YZE0ZS@1P1'PW""GL5
M]F[ C.P#XBKLW6[L7<:)H;!WX[%W5&;=<(AQ0 O]M9?@ 9\4[7$@RV;HMMJB
M:FVUOOI"KM0' %1>4AY4A98;,".NJ3JJ^,)VHZ6IT'*7T#+75(EN$!L;Y""T
M;-?UIA35$B/)W XE2]N#-8(G$+1076?C9T-CE.,N?T,\R+0_AOS 1#$4/AKZ
M61S&-(WY.K^)>T%G*%32F0;EMPT1SG0,$T@;#T!R T;;O.:C5]"LH'D#9D0.
MB*&P>38V'PRHWV$%^?(_BJ')YTV+?Z"?9+%@JRGK4"CE^/XV#@<W<GVK3_G)
M8)!TW^FC1ZB?)9WA8/XC8ZB1#;M=FMZ_YW]<QSW$5^P=MF:M[?K/$H&!>V2"
MWU7^O$E')^.:(3]E] >B$1_L.]JYI??9WL'8Q+M\@O+E#N%?GUR@?(8?_N6G
M!Y-<=G*S*LMESUDML<^C;4HYDT=\U3JTG[%WQ0_OPSCK=^C]N[@GYBX>*C9#
M[BULQ^3!AN_EE^4L/&_?M6R8B!3^Y(?E'/?%' O:&KOF[!/3FGN5,Z<G7K.P
M]Z0G'QJK9>SK^OS+3Q^LJSNK'^R^9SUMK ^_U7#,E;_5W;?=I[WUX6N&\[2C
M]=!8(47&M!=Z[59I0Y;2AK9=&])GYE@0'?(L[+Q+8VE#-$861#9+/3*4>K13
M@J=2CS9D1N1 %YD?ZXO#J,\*[(KETE98O>U8O6CL*I;&RV-&,S81.D-[T :Y
MB%41T3/.JFL)I''P@R^9YEF6=D*SC"/S,&,##LS'QX<J-&9+(7/+,%/%I6X_
M9CH*,W<),RNQ,:9K"N76(!T 20&1-$NB7C(7.D=E!/!$T.DB900^BJ(Z_"7I
MX$;[,^YTZ#5K*#S<YO(!6]9\A ,B42ZV[09$5P'B+@%BF:BA&RZ$OSB&83A6
M-?[EDJMM'?9X/S]W3A[&G&#0D2K93/F2Q",#;#,=L&Z<:<W#HM_(DY711O%R
M[6.<9$',>@'?C,]=_S<QQ/_^!\'F^XR38,IBODY9<,.T3TG*_Q[VKK.(7S?M
M]^!$A7]>LXQU.OP:C0;B'0JWMU2/W:X9F0<8*S5VNU%;E<+;*=2>4F,-JTL!
MQ_@(?\8<XZ!G9@[?)^+WVJ6\\&#?S-P8;"VEU9[0^QZ3ER=Q^4</"K)3J"([
M2$<^5H6;VZKO+A,ML@%34OKNUB.GJ<KE[39R<L77+L.;\" !')V;'/DHF#:'
MU\-LH!%KOEMUE4BJ@'1+@7294(X-F)("TNT'4E4Y;^>!U"F!E,P'4K(0D'YB
M?@IA2AIQGU"Q?0I*%5!N*5 N$[^Q 5-20+G]0*E*X>T\4+J3UMH%;;4E*LKJ
M[#-[@,U%Q69_,(P'VINS.ZY7AF^UX[@;\[<J;-Q2;%PFE&,#IJ2P<?NQ496J
MVWEL]%9GC55PJ>!R<;C<OFXE"BZW'"Y5K;JMATO]P0Z85&#4R.RZ H-KCI50
M?.'Y6*GLKML%EB7CV3[54O7%W&*L)'@?_U-AY<9B);O[FV!\UXFS01)EE8(^
MI&C_G T@$Z5:Z^>EH6=C;]T>JC8456\V52-BX'[*!=);+H.F-\F0CS9)^C)T
M_3#I92#$<L(^'[_I$&Y*H9C(.43"A:P/!;OXK1?L.@9!EPNTYT._$P=:,PB2
M86\ %;\^Q6E7<85MYPJ&POI-YPH&QO\Q01R7? "6-^(+# \ -X 2?8<W,8NT
MUAT+AE"K6#N+^!VB9E^FI>P_PQAX -=@+UD@'C-T4CQZ25.?]EB&SNXZ[)YS
M",%BH."AX@X[P!V(X@X;SAW(@MSA4]RCO2"F'<4=%'=8B#L0+CLH]K#9[($\
M67@0!+ZA\Q1F^#EL;Y/G-9=E>[JM6+9BV5"GIGUZ60.>_0J3__?'BV.MW<L&
MG-Z9=I0$PZZH2/X2:[&QMV[54;\\_&V'C_H5O4MZ2?>>0_> ]3* @<O@AG6I
M.OL[</8/F\>[>?8O_SW[[!_23C#LY)+M<=S[X=-,H< N4,)1Z]-N4L(\%#AB
M4=R+%2'L&B$<-S\J0J@2PC'U64?1P"[1P/E%2]% E0;.4P9Q THNVC%2J$,T
M_"M,_##A(]'.Z373VK C-! V[2,ZH-JGN,/R,E)T( LVMT735PV(YZVBA6E:
MF-LK>:+]KGP#@K/PSB@;\L8B$.D=@M^L_#R0QZ*91?OBTH&UWL,('Y]8%1W6
M ,Y@J-VPE-W&@YMQ:_S<Y5U_('B^=/_,^V)-__EIF/;B[$:VM>PE RU:;%ZJ
MQ?;,%MO&A%NFEBVV7X/&%UN_?\P[I^#OI'&/\[Q>%,,PP0_83U(X0UGN,(LS
M+BP)MY]VRT^OEG1C 0[^O=9E-+^++\0/B)G,AL'-Z'$XZ)K/#]@/-LBT-__]
M#Y<0_?W_^\]__O/_$S_C]V\UGP5TR.4M<,SE Q!M6&>/YTW\5J-\"$!/70CO
MA*M 8&]B?N4V&78@_X@_W.VS00P4T[G7( DI&G:T.-+Z(LB3_RZ,LZ"39 R*
M^L]>F 493XWW_'_G3:W="\'!S;_$O\%)1J1^\047K$!+TGS]>AD=).F]UN_0
MWO1BQ.'_[,4.]D/'M#!V(M<DMNO[KF/Y ?,(HW;H&W]C[.X]O(387</Z.#/7
MIWW5.M&PO3_W"'PZN^ WZ.C_M,LO)R?-BV_U!J/3I,?V7Q]7:@LAYGP(6>)$
M$[Q7+^ !"GJ%19Y-4Y?MSZ?-JR\7K<MZT\KY,,V&E+.]02*01T:, "<4>%9$
MC6 #^"&VWH1OR^B1O"$YM =OW04WM,<5*1E"@CW#;,CW06)!"E^XX4I4..28
M(W NS $U98!I\'4.5QG?-GZ!?PY:D?OLAG8B0%=XD0AYR6\0;T[9L,>?$B^D
MP\%-DO)9A]-DSQ49T$M&= QM:1!?W@[M9^Q=\<-[#H2<P=^_BX6:A\1#A10H
MB1^(>%)YA>.67QZ=XGT]/\G2.B"_+"_OBTN%AC5VS8($T?F7]7T\]]I#K\7&
MOHGG/_K0:Q^^9CCFR@=KD'UB6 N]=D$+S%REUIMGL=#@;Z,FIHLI]H)A=2"G
M_+?FQ4GSL/7EJGW8/+YL:.W3P_TQPX1<H G@ V5XKP9&@[78VIX6*?I2'%=L
MW1$7.-_EO;]RZ0K*G8]UF%\TWJZ.QW7VG#_>O]LY&V,^\X/L0#NGPP[5+NAU
M17]8X%A+J!*B#=]E+FW&H?:/2/SG_1)KM1GOD3NQ,1M;V=2&=GZC'<WDO35@
MGAM.0."4$O:/2J#VC #TR:6?LD;/URGF:!.DMC+Y0L(W%[9%>9M<7!Y)VB"%
M^U"61@K;4KR.N!R<W(+E"A*$A<FK5TC@\I,7(U$>MB+NB=\&M$^#?"#PVR3_
M;2BL*K&TKVRV6$Z\?8+M#9&?37O?==T7&*QMD]5K)MX^%X!6*>S7RMTZ6W2_
MY)^G@V'*=J!FSNP5N(H'G=V=/<C_"ZAI[@-:VD(2U&KEA8WXY$OHB753&K:3
M5!Z1_1KS!#\A<QQQX2@8)&D-5,R*+%FY/X4YO=(:+F9H>)(JNN$JV_Z$RE8#
M[;D>-"G>^"X>\$\%"RSKF_,T[@5QGW:FZ7.12*G7LT_,1EYOX^RCKVQ*?2V(
M;(:TJUWN:R=)-J 1W5F8G).]+K#Q*F4TX\J& D<%C@\NQ?+$I)!Q"62<39VC
MZY5R>PHZZWGK-D'G21S<4-8!@O]Z_^MZE[&3QBE_2V'D_IC0-(1_%$IEIH!3
M >>#2[$\*6V&1U;!B(*11V#D:]SIQ%QN;';B[$>\LR"B#) **A99BH)<6ON+
M4\SF\WB%%0HK.%9\AB9)O^]K'],XO%ZC/4J!A0*+302+"7JIJ<>JUN]1B+'1
MB/$II;T@B:$&"=,.4\J"'PHW%&Z\'&[0X,=UF@Q[(9+CELQE.P#EJ>2T^3B@
M\$3A"<0+<)U;E'J['22[&U2G<$3I'PL%!.34\FE_<8+9? ZOD$(A!4>*(_J3
M[_!)\#E.E<*A@$(!Q<,)[4L1R^8S=P42"B0@AFJ8IO1>^[JO70[8+4U?J$*N
M0@J%%%N"%%,4T]!.EO)IR(SO:?ZZ8B:NOO,P:#VMNH*JO&>MIO*>N?=A[97W
MYE?)F+N\&UW KWUZU/JW=G6F'9Z=7IX=MX^:5ZTC[5/[M'EZV&X>:Y=7_!<G
MK=.KZ0)_'S:GMH6']XF[6+FU95YK[UMX/47<:BT[3IXL+\]"O9Z9_[]J,6C=
M+$Y,;M0M=2T?G&J,VDM&/5'_L0@K=?8^7.2%<9)(:_="UF>B8+&L=L.@>>JY
M*)9<3='Y%*?=I5JDKEY^>ZT=_H0V<8_G-;15M/=Z^V+HT(.C)V@!BD1I'VE'
M]&.]O&%LD#VI!?%&;-3FD1!LE:%(J'[[8DR0T.6 _U46BCOKL_S%@ICR GI)
MMY^R&^CX])-IQTF6*1JKSUZ:BL;JMR_V@S3&+XGE!87OG+^4I:FX)PE^-+@0
M&3+6%<H@)[PNM%V&"X(2Q4\W20?*FD,3$.R\UUK_&<:#>^T-M.4,XL%;A8'U
M.@>6HL_Z[8OW,'W2[$;[U$ENE4!9LTVS%3'5;E], NUSH';O(-'&J&I4P&1$
M7R]/4:]"3,ZJRDFOS>%1%P?')X17X^%P5N'A$.O^^AZ.&G@TA#'^HG5^=G&E
MG7W2P+=QWN)_G%YI%ZW/[<NKUD7K2#O_\O&X?:@U#P_/OIQ>M4\_:Y_:%R?U
M[E]TE<PIVS(E8\-5:)L"7?!HP(:"V60-K=T+YC<+6UN#-O'&696E9GNGSOIQ
M#]HRR7+KLYGSE%OJ-3;H*]-NZ$^FT6$8#T37)_YS (WU:.\>;.E!%65\:0+,
MA GPH2W+:]#S>[*AG\5A3%,H0?\&7B_;*Q[FWR@;+%+QOB,6L*[/4LW (A@#
MBQ?Q'_2&^"DON-\1HQD;6C8F5B:E:44\%8R953I)QD?)[PHJRF&_5 ZS7#E,
M1\IAD"N'6:D<9C.40R:5PU JAWF]??X1D' CD'"U*$DU1H.;HIK1@",_T^X9
M3;.B7C\?=YR$FN@,,+T8#7Y;T!D"4(^M1$_(!&_ =<D"V4ZRG \7%?C:5E9^
M;-VB\FR.5K#8DWV^E5HR3/ERBO.<]PQ[]'%82^A4KD4T3COW,&B-=CJC3IC\
M<I^/,\O?-WI%@:C%^L@CLM31R(:=_ C X9LX!O"K56Z')AN2)FD7MEZT$:4C
M-U0_+Q_7X5MSS7I\)!UHAA8$K \K)[_PI1>76I$8=[/+OQG063T9'H#&&M34
MRQOK<7(?T+P=ZE$R] <:]9/AH+J=DF RK>G''5BW7);E2S9DHB^&]CF!Y>._
M"U@ZW=/SE9#L0<8XDPP$8Q7-/#A!]&DJ&I5GPVY.O71L4?CAX102C"W#=2*_
M \NPKS4ST0YVF&7YZ0%%0,-%%Y)'A],8^QST&0E&/77#>$0E[&=^.[PQ#H6+
M59Y5>GV=LFO^PD8^_I1"NF)6V?*PLN5 ;72TQ0_.[:1L\%J>#NCG*N@0/IF&
M<I[\>Z+G.T@0*7]7)TNTD&5!&OO55=G7KA;B5&$B>O3F7)6_#IA-^'V8#?++
M8I9=. 62LVA1FG3%6O 9\L/ RM;#PYY<SL%][4EWMM#RD69QSA2E^%(?RLL6
MV4LX#Q(#^G!TY=$;QY+R>(U:"N]K9QSB)IZ*A8K-[@#*@"P*""Q$NLG7/3X\
MGV9Y\TP 5"%N9?L:%[_$,98=GZOH$<5I5_;G%#0HT 4^+>,="DJNEB;]*7IP
M\M.:"]QOQL#EK?;F_+!Y]C&73."SLG-1*/M[QI7X"O$UB=,%BRF^"'#./YJ&
M0A8LQ_5E_W)?B[C4E,+$1PV0.O0V*P&:]OM\\$*J2H<=V96(SW+8H956WF,-
ME.".LHD2V.GC+(.=*%XI)K60CO!Z>M!7<8##80#;,3H <K8+'>\YJPZL-^2;
M7:Y<OAR<_R59]:K<ZYREW3+!7L42<A$'!)A\=V!4L-V)+Y !JE,G/;%;@%RI
M^'3.W6]O&+1Y75 BA-,6@70E>K!+,1 VLKBE4;XPY! !I)>FG!/Q_T4I'U7.
MS\L#F FN73V^@+4-_MLT[_W.)\AZUYS Q44Y11 3Y12E?!B#OM^C.?"F24=+
M. 559I WY>*D)="70[AXLK)_MVR*D.32\4_E/7%A!X XX9.+?D[S^0K#%($;
M"SETF/9A/_E+)$^"NZ;9$HNB7 'H =L:9WW_SW+S%6>-_P@"/"RG9(6]A ,^
MR,SYAVM.=V>CK9(87Q[X7$)/ A8.T]R@RH\XS%!@2)S]R.8>UF)A%Y"Y'CS5
MC2H!3HY'"%@"E*3L _LOQK6O7<(.5&XNY\;N^"KV^*L:<"*HQMG^ ) GYD-A
M/Z%92\"D0%7HD+0+\)&S69 ON78LW[G8''/XE(LLY+'1:'[2SI .RB_-5(U$
MLVFA5,?7O9CKSM#!C@\[[@J-J$NY7.;?5_!:-,^[95Q<YG]/? +.,ZB:4@.E
M56UR@9E\!7F]$W,).%__"J7SU8;UXVM:88I^*3)5M.0E26)Q6^>CSZP[LMFT
M]W,R6SJPV=XWG*?U['LD7-HDBS7MF^G%LC?)&U+I197& ;L%1G63<&HZ3,#L
MD6G'Q^>/!S(_><KY05C_K(6GX&.2#< <=<)9-@UN^*0'@VR9R<ZM);1)JR!2
MU[2IK+7YN:LOVEM\6RBJL(CSQW\*B\U,?4^@ N?[7 [CB$IT;,]H,*S<D@NZ
M)2=3+I_FEH0PV*U)O)K.)Q:_B85Z_LY8AT@]VTP$'I_?FA<GS</6EZOV8?/X
M4FN?'LX7>FK@7Q7C'DL4^]@\;IX>MK3+WUJM&2EB=1O[FS8(XQS<N9P,DOP=
M^!"T[$;8CG(5HOA7+LV7W6G6*Q!Z[KYE&T\1"!VR[UDOT,(8[UONTU[[2'-H
MUWB9P2[VVB7S\A[D8*LL<O R\I#[&)$(/EUUSXEI@HONE8L^U&T]]&52&U<E
M)+]*,V>Q!,TL8X-%6@0]K[;H<\GLT85>I)3 FF:P])D) L;J>69F:U6'PS0%
M&Q\59^?=DP[/Q)Q7?S[F?& ]@UP1V]#@;Z?61P%B143\$/P -OZ?M#,6O#6.
MTPO-7-<VP;;P7\^:8G5JHKA/K>;VK_@.(J\_I300]N%A+QY<0 CV, OWA&N$
MCU[\(O:=B%'#"*-0CTPC<MW M8AN.HYMNH;IN'^W0<C Q,![6LB"N$L[V?_L
M(4X,/=IE\$9T36G_'9RD9B^$OUJC8]0<'-(TA6B2/VEGR/; DMRE _[=N\&[
MWK"+PD2$B\-K.7GQY6."T(0^'!I_WOM'R<]C<O'SFW$R#+^W?O[UV?M^]CVX
M^];]PS@]^G)W<A5VSX[^N#_]?A-_^WYMG'[]_?M?5S_N__K:(G]];O\Z-DX[
MWWXEQLG7WW^<_OH#GURUC+^^7^LGW[^9W[IM\_37G_$W\L4ZZ?YY<]J]B$^P
M>W?RJ_GSK][O-W_]2GY]^]HF9U?7UMG1IYN_/I_H)Y^_W'W[VL)_?;_I_/7]
MX\W9U0U_[LO=Z;VG?_OZ>_;75;][VCW]<7;4PJ='OW=.K[[H?QVUR-G7/W]\
MN_IT<WKTAW'RO7-S]K5]]^U2/O/OWV_\;M@YZWXCW\@?Y@E_YJ3[!9]>7?PX
MN?IF_?7UXN;D:TL_/0KNS[ZVK&_?/]W\^]?)X.12OSN^:@U.OC>MTZ/FWZ9K
MXC"P(^0:KH],5[>0:U$/,6H2EQ++=:B_]\'%#<=U_G4P?D0^Y 6BGD,3!<-;
M@C96*3$H#K6E' JB5&W&SVSHZB9C@4=99!B.8V*'4H.$@D/IBD/5D4/=CW,H
MJA/7B0P;V7[ D(E9A+PP-!!C/K:8B['O&'L?'+?AZ&Z-.-2*-(+ZBX,7+&/"
MY2)<Y>PGZR1]$0X /H >6.>UE.O<G';\#INK-Y#E5F8F,]YHCO5<F>J.\Z!W
MQ5YPEG4TVHEVL1$7Y3XHKK045_IC2F[2 Q;PDVHCR\$!,OW(1EY =.28#N/;
MY1BV97&N9#Y;:'J +;R4T+2H&KWS-/M<*4/1[,O2[(0DX5'L4F;JR H=#YEA
M0!'U7!-9$?69ZP26:X5['SQ<)YK=&:O2.22#Q!"KUV>]3 8X)R)*,!BS/3Y)
MA%A4G]MH=K0JLXS<BE:^$YPOG<$VY%X#:0=6*L_J&-67*>'""YCMARQ$8'Y!
MINWKR T=C,+ #&S+<'$$I2BLAF&:-=)X5NW%V7EZ7I410]'SNNEY0O ( HP]
MG5DH\ *="QZAAZB/'119%J%.Y&!,C;T/1L-V28WH>946#&S46?:X2@:0_?%\
M,4.NP,*%<[>/9ZU*!E'<Z86XT[<I:<.P0L*W)T349"XR(]='/J,Z\C&7-4++
MQ<PV]SZX3L-UGFU@799 -LC4L<-$ORI!11']RQ']A$@28<?EC%A'S+.X2&)8
MA-.[3I#E6UZ(O8A@ XC>:!CZJLPA+T[T6Q2X-\]& CE,@_N\(,5_AG$_S_SK
ML?EMO'9>BUJ=521?_/,.[0VX$M4JUO^4*5ZU0EX53/M:',/B8HF!/$/X6DP7
M^3HSD&/@2/<P]:GO[WW #0LK<\@6$_+JS"&*D-=$R!-"!_$]E^H^0Y@1!H3,
MD&M%_"?+8<PEA-D!!D(F1IUBS;8^MOMSDH10:$L%9[RT#%&LM&(SJV,SUU/R
M K-#1W>Y@$!#3+ENXP7(Q:Z)0CLR0\/P+==R.)MQ&H:%:^3J5>$9-148%-6^
M"-5." >&ZQA1Z(3((B:7\O6((.H:% 6N#A3K$BXA['T@3@/K7HVH=NN-#A?P
M,THB-,R8"L%8DZ @FV#UKH\9S9C8@K/H2\:$A53QH=7QH1]3TD.@&]1R(P]%
M?*>X:F*XB'I$1V$867KDA;I'P3+:<+!>(R5%61MJ*CPH2EX?)4](%!;U:>AR
M(G9QR"DY,EWD<6D"D<AP]<!W?-.!&.V&9]>)DK?>W""BCU809;'=_&=EDL0H
MUNLTZ07*M[IJOM.Z%3Q'2!'MV[.K/V[_-@D.7.83Y%H&5V5L@R'?L@-$=9]$
MON]QAB/LG XQ:J3)*/M#744(1<(O3\(GXR1,,+$,ZE#D.\3D6@#S.3$''O()
M(=3Q,,.A"-DDUJIBHFIDC-B8D,W90L2"M7]D"3<^3=&@H\/*8)3GA7)M?DV
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MR \X-R !)H2&MNY&)A=JO)EJC6($.\X(7LY)HQC!"S."J:QSTZ8APPZR?2=
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MF# (/;9GE#E:W-"E,I9K3,$OH ,H"GY!"I[0"TR7<$DPM) -,;BFZV!$]=!
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M]E\O-_]Z\_ :!JXU?]*X T?U*CD4!_6R<DX_TBP.E%*V0H8^W:>=RVG89E:
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M;TYE;5G7@DH2]T02\Q;DB@RQP)2\ T'\RQZ?Q6I++DL!,WF54H@43;"@N22
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MF;\9E+NLQ+4<<>&B $/DRA/(\R0!462K0^3OA%4IHBU)TFEK6\RG3-;XPB9
MN=F27JM!N:J+)G$^HRY<C$)JQK*ZH Y0Q@"&4\P_9J8VE/-$8^DFK'6%^OI
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M).1):U_",*B41,U1Z8E,N^]@7.7S!OE\OM$I1F)U1%8J:EE *T*VW;R$*'U
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MQ.Q(0.O#[D\'K]Y4I["H2(@EIC7P:1E5@_]9S;BZ >8-NT;L A%#)6I5<)C
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MBZ6Q;R::J,07Z4I5R'N33&&" OF;]%#I<BA]?O9_#-2^SO[2I43,^X_^((+
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ML;^E01Z(K'""R,N"V/>2R %R<'TA0C_Q>+Q7./[I6SI0.)R$)5R(#"ZHY]O
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M]-W7;MIG8NX^4ULM^/X8F9@[E&ZYO[[[3,.=O*8#W2.)7!Z(E-M@,3,[B)A
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MF*L]\@K>Z7_( K#3$A=9H9."OA4Z=IHRU\XCSAG+DS1T5QN2/P8[NR?,BHC
MK@H;R, Z['@"D4*CX5:/BK>RSKM6Y<BC9"-SO+RDM-!%QS_7G/@-5I>S#N77
MD,^\GL-Z6,T;&(.7!3!LXF%/<&V>\]/AZV?TD_O3TY%U7LW@EB6!-WK@!=_S
ME!YZ_S=.9_V)2.+XOK;HU@TQB FI1Q/4@?5FRD&_5G\>(5X,11*(.3&3DK6
MVP:2I48M 66;%-6:VEM5HK%N+@752\2/C>^32"!)RI0.GS$2^E+X+:;E?Q?"
M*EBN[G5>UB#D093"%!ILLM# ( ?JNLN[PV391OS&>$Q8#3(+0+"Q.4T 9ER!
M=H.:GU(_6I":>NU ]C=6K=G,HE,]Y,N:IE(RLFWK -,T"T?*98V56"I%<]#C
M")<PO!@+*CV!XAN$:SNA]?,9&XO%I4E]0J^(^$H#+SF;2?6"!IP"H>@=QC7C
MFX;:BIH1,<WX)^1+,%W0+0S;2NJ)='"+*:$&\5 5U(\UU93V.P?C"-7#)6[V
MO$<1-^5XK*:#?Z:A#ZSCHIT<C&0>'2ZR6H!" ZKF>+[LDY?X1 MH.@W.F*K4
MFS1.4&,/]=A$O; )J!@I#4LMJ)SW5K/4J]FP%MQ(.:BQH(U0JMVP"LZD[@E;
MLD*;1+VPD!)4RPKH%S3.*;H+UMX ?7EJ3OJR<6_5Q;2NL8=09Y_/V%(IP"W:
M$^P#(OU:3&"3NSGA&8*BJ_:>\8^+9BZ?!7K&)WL3JMH5T=2L"5M:&4X.+'.T
M+%#:EJ!]-U:S(!0I\;#IG*PA6(* '\C^ $$,N@].!]G*.3$[F(H TP->(- +
M _P<:62J)HH,K";^!&0S7\Z4185T 43$X?1:-H@4?0!:"A"[M"/ZY+R8EZB9
M(PG2_&KBD' !,S@)2<(XAV8$S+3$5<#VTT[@'XENT<*B#9)/X&DPBR!I, &E
M]L,YE>H F-6 $30&IB$O]Q3-)% [,"0"KU4;/3@Z/(WV.3C\:34!G4-,K\NZ
MFD[:;3/96RT*V,(I&@]TYD4!9XYV#FTI4 <N^#<!G!UN8+?:AG"^\NC5&8("
MI(9J).L;]2U6V/N<+, M>TB#$:!8O;WJ7PE@GSM^AX]7E4;<VXM%*?\"Q]2*
M;30N03XHR],4 PU0\UQ:=)J:VZ]J.3;\ "C8FI%5)>4682?AZ]>LE#Q[!D2X
M8%,298I2IQ9>-A (>#'I*?P0[T@C9HQ.1$UJXTM?,10U(WEJ@X\UUVI= >N&
MD#X,J5@K<II7%T)5<2:BGEZ,C2<.K!?P'9*<!'$74^1S2OIF HB ^!7L-.8O
MRR\A'+I_JTWY#FM6$Y"OO]RV;#DQ^#T# N KRY9L#4^5T'8XRK@+;&:+<LP-
MDEZUU4V7UR.F31U/T'>$%_6L/E).CK/B]VIZ@1Y4+LVZO2%_>I2''WR?,2<0
MJ9WX/ACR@> VRSBW0\ZBQ'.<PLN<'4V)ZHX9V1 >KTWGJ^SVG3#6:59CFI52
M<M!'5DK/XVQ#0@UV=ANH5&O4I0-K=7 4U<*Z%&-.HRQ0A2*Q+EJ1APH6"&OE
MU$([:BI0>,,_Q-#KUD<+C"C#+!O48OMV4CE%1^]<=#ILKIH\:HDO_:IZ6LBE
MD3EGB.!%;::=!"HP+T#;J5#/&"K$M%5@,-)4,,N7N _.&!<*.X3!6!0&94<)
MM;@NX>B4+0(\& P?='*0A0%CJ:=(IJE)MHN$M\CLG&JJ?<WY7#I51[V1IN*"
M<GAP(T"9 -Y8&;K+'!0*+N6=^9#>5OCJ#,POY+_&3I-UVHC^QDE+9NWZ&KU^
MY1='S1A/!*3Q@"HL#-O-UIS]:+#9\-]:D"=)Y*R1PAWVK&RTB*-*AP5F275Z
M-EF#J'MV1M-""2"B*%3\I*.YU!8^B:GUDX314/ZTU$3Z/B@(O2T@;_9-M0 B
MSWK6-NK0^!G-Q'"($\48>6#FFHH%PLGOLS3EHS!FC3=,&:]X6.8"Y'50FO^F
M)?1,'3!"<2BU3_V=T'^5(PWVCE1P?'D!G^F=.P=M%A:]JD)(>T+96OA'W)L:
MS?/!-)%BIROG94C_74N:_K6J.)K2AU-^#*KZ]*($+B-%@OY(RO[O4N1?!!\\
MP1*6)S&(_""S@XPE=L(9M[/"]S(>Q&GA9,/D*2_QBRQE>9'F1>!DC&49%II,
MPRSBGN^M^OIW0T70![X3NL OK3 E_5M'ZU:L"))34@KDH!0HQBGS6B4GF5/Y
M6;"+0("@+5V7><N7C$?0BAJ#<LL4-Y,>4!A\3"P%1"L<<5&2D345NH'LJ,>/
M2I0:S4P9V!T3[9@,&15:;!EOYQ37/5*VM':8=<_1A)7C)U=^%;(X3.]1TRPF
MY#ZA+Z F,672T]NZ%3\N^$6G-X'!! N?7E=C=,48/-L4Q7H94DC32V9*S$O%
M07E^])^E/:SV 7?2E!KE5,H->OUB3K^,4+?+NG7@^Q<Y,O:1I86/=KZH*: C
M%MU'(Y09\'K9#HB<3 =M)&K;/O4\:%*;@NU>>VJ2DOK29DA1JSG4YK&KASK*
MZ>:G4K7E-!KK0EW#+4)CGTQ]>S(U MGVV=3[;.J'R*;>FAT]4 A\-\).7&'B
M\S2(_)"%>>A%F9<$0<A])WJD</_62B6K*]^NV@SRR%F6^,P1/$Q$((J$17D1
M!MR-F!^ZH#]U6@=Y\*7E_5]T8)9S8E9@_Y*CK=.SE=U;BQFBBH#Y8R$N,"G@
MN\#J8;9H,RLCL:@6-0@C&+ FWR",- &+#6P4D)$PV'BI[)UU]OPV,UY%.W#/
MT##1=L:!]?P3F\S&K22[-(<?C$F&-R@1BWD;&41LE-1!1N07[20QXR!C&J'F
M**,@%Z#;P+B=[V%,PF=$ZHWZ?BTNT"^/;DE9@6HX,!<YE0/1J">M(JT+3((^
M!B(7J+'*KVA#%U,\K;R<R4 L?%W,2UFJ9!U6;Z<=^QNN^U8B'@9=VJ (E^0"
M!"I-;-'&<,C=W7FN&M'I99>F1[Q/YV2D:F<.VJ_F7:'[L\%1L:I.KKE$&SP*
MQ\7='D?]2/!F@RV.(YN*\X5Q\2DBKN[/2#GD,7]=HA90HT(5O&ECBG>?$SS4
M>1M6)];?K8E@S4+O5N><&QCY(\1FPM<I0K;="Z'UPFU3/;!>"V&=5L!B N)Y
MQ*E 8:8D"G('K8<*=!O9S1/W3)D:1R(7DPPFX;LC"_T !ZO7<A!P>T#@X-#+
ML <*MLZ&FP^.%Z=YP@([S )N!W[N8^>:U/9XE#$G@^W%K)J^A!5IEK X2[/<
M]X( = P6L8P[+!99[OI^_BT""SLB&80G'A5*>#S%K9^JJ&L;]3T1]<4P[MC:
M=AJ_(O&]Q"80G<%J"LPBSA?4EDJ&,C00[/CEJ_\-"L1/1QH*UK),&="]0=!/
M/H8_@OR6-B,H)Z) R)!0?L>RVT'M'3_4<VK'1P8DL2(K\@$'OYBV?MWU$]9Q
ME&$H0JV^4<+L6JAXAIB2/!J+>6MPKW&"G*_PRF["G<V,0C1;XR/J6=,;&.9F
MJ'FS9EHV)\R"L3=3LMD-&9\MM=7?0IT()$[P"-HO^N-<Y)=3H-:+I8SZHRHE
MZKPDC?5:NI: 2O@BQ\,>C-B!WVM4)Q&8IQWM\,Q'0<_0"2F7B7Y0?8J!>3$W
M??<8%C*A0@?&1BN9K)#[*)111:V9]+,T*K*BP3U&;'%*BB>IX1KMLJIS@_Q4
MZC2&LOH2EM(CY+1&%BYC;*Z"(&J:AF"]&:RXFDKXT+R&VUT(3'.@8#\\5];<
M OUGOMQU5-AY[Z#6A9%@$[D8-S),B4$LY69:2^'F%2\(\=&S(PQG'=@&K.::
M5@Q?GP4;<X79#*R6VCT\*(,P$W9%I@)5!AK$TWB]N%CE$::G4)IE"A;XXUV.
MQ4<GEDR<LS%+[L?4T9XFY'O3^8^VFSS:R1&3CGYZ/,G4WQLW. AQ+UZV+M6E
MX5"5 65U@? TT.Y#T!Q<'F!#RB^;S14:T#0<,?\(SOFG_8D]T(F=R/N&PXST
MY;NHJQM0,Q1GD$YW/"+U<7,)W')_(@]U(L];;@@W:#7V3?)W!O;:E)#:,"E@
MGP@%;^&:E"!7+=F8X@X:'P<<LUI@ =8<L_.X%OE6PV" G_"A_8D^T(D>]@-*
M6CIJN:3$Z/]I+#DRJJD( ;GH$B#;G#\$K,Q$CC+5JLOF"D0<HO&G\Q:@T@4/
MI:*\6WDX!__,V6Q)N/D"..3N^ 6WFMX_'RUJ35N4'R)1K ./C)L.,BL(]*YR
M/3%?IF461$M&_HY*N3'T7&6,F9JPANOWS!&5]JK,#YGMTOJE*!.539H>"4]-
MZV!@71Z@;8SW33J7-R]&P7C[*ZID.A.[J(5*T5VSKIO+"DQ)9)9@>52+9KQF
MGP;CJ&R^&@Z^I,4KCGOG+9G?5"JRO&Y'<)3-6](@@-E,?J&U2]]<I=*H5Q8N
MMZ[2<72T\\4GG$\CC4PR(HU-T<CKNW@7VB70L#T!I- .IKF$B1*KOD.D5#!6
MUV['+5O1,]L[EXF<R<!JDSO33852MHRL#4VC^C']>_=Z;0W+T8QQANEQ!AAN
MTUDV*L@SOZRKQ072I$ROQ[&5MX;0:>AH,"8$O*PH,3V_;+/#E2_'XI(CX%X>
M6$]:CZ\;/GTDKZQ&@KT  _Q/= .<2"=XUSEC[YP]/7KG?O"]//:YZ]BY'[EV
MX :^G0F6VI'GAFGNLMA-@C7.V2)VBH)YH1LD/&.>B)T@28+8$X%(5\'BWX!S
M%@G%(DJQ#%+9#01YF[+6):.;R)]^2%,59:CK4KHC#1>?1)7]>GCX$A'7[9_)
MZU>0RZ\+_<A@K(R9DO0UT;8RMPV=9"T,%B'-K)3,3O,,UDYS:3W!A)U/Y5P.
M^=0(RD[1#3.6#K6&PL$,.-6% '&H+4*=V=*^JANW)-<<.6U >-*K52>K3,QO
MT#F[ZO%IM MUTIVT<M/^23X?0G^C6Q-3A3OGE/JZN:6318.I@9_*"8G6#FM6
M95C/@IR?Y72V4,>&*+CA-Q?3E>_"\0P8[<JAKS]A OI3 H#I25?NTS'5/BFG
MIE)DIK*"O): @Y:DC)$O2[ 80 (O1_BA=-G35\H:=@!U"J([!==';:A;E!;H
M,"7EZFR_92[^3FZS:&\@WM] _)U@)*YB9G\LJCD9Z&6N2T50G%U>%%E'0@)#
M\X[^C$M7KB1^[8_J*Q^5IX[J;(6+/)&J.P7^Z;NR[9IK_=<\U:>C-BOYOW<X
M;9U[N_:L1ZM#Z&=),&B$CQJW3SW;!]<5FO0"VS$-!D)5B:;$UC#GEM(1I>U@
M?$GQ>>#C;$^>#TN>OB+/-ZNBJSN_9C%#((@\)SCMN3S(::5/B@BFU-8]/6*$
M<XPD[/7 <2.Y;$A375P&:1;_*\-,HPTQ*,+58PA3EROHDMBU$K EU76/6]Z"
M6W;WN.4];OEA<,M;<<A#\[5PF..FCB-X$H2ISYPBA/_P6,"7P]#[=G#+6PWQ
MGU_6)14EV(3I:6/K,ZJH45-1P2J_LF[((SLW+"WDB\-OU:+-%^F^*)$\Z^R3
MD0DOD;4FB+=7IBKC:TFBT<YKC! 8I\GK,L-ALNI:X6O0J<<YE6JLRVL)'NVF
M902J)/*$"PD7L K!Y@20W  .YB)3;M>VH@BA8?44-*0S$RA-RHW&F438,$L)
M4=/\[%4XZ2 ]**)$U_QXI%/'R<%<@%2;BF5K)"\PY;B<7DNX.>S>FX/7,&Y-
M;UE:C<@7M1*0&WT$O1-JD\"4_:#*X+4GY7WQ2?71I!LWOBUM-V/+UI+4]714
M'=!&!O$_M; 1F(.9HL070A]Y@\5];2I,,Z43[VI_KM326I]U.YQ@!:O'8GJ4
MI5\QV;E2;?1RZ+/OB*>;<#-(U\73T.YI=1T4OA6H*V<+Y><GBLRPSFQ73 AU
M*!BD+DUMF.*!VOY>(2^X ^5<QOET0K#. 49 !?F 4!F:YD)YY(TJ;:1_Z15N
M1]\^8CKP:XE"?Z6!R7L'<%O]P_G@15[NQWED)VD6VP$+4SMUTM#._,057N#E
M62AV-+57G:MUW*')=\)?:^9-R&S5QJP(12F_S6WI$MK?"<(5"Q8W.D^VH<BB
M6;]"PF:N9,!1#X-U,AI\S7JI4E3Y@DJ+*2^H#JZ-^A"W0>"0Z7L_K:YE9;H:
M*&(!9G[3SG>.!1%U-98:A0S86X-*06O3/A_V_K^2T-(7=35Y5LG2:F^!(3];
M@!(#;]PS GCGIP\\R5P_BA.;)=A)/?.8G;@LM9U$9%F";35"9ZA*9SG<S(CY
MV%\ZB*(@\5T!SV2@CWIN*+[-^K\*B/Q*!E)-KO*83.5Y6^+N/PQ$;+U4CC^*
M8"<#H#ZO9J@#8KDV6< W<J)] =_;MO>5"3_77$)A-C2CV-?W75_?%XBK*QB-
MDDT"8D9&@_8)%9JF,@[SNFJ+25"\;K6XQ89OJ[[N;26(KO24+-)/Y2GHFA#Z
M7M::'1/*5Z(YU&0'-8-PQF8]4&TN@$ EUZ/.I4"9)C 0B\8'J_&S1A7X-)H$
M%%3+4^O',F5 E8.529-356&6]'AX:$]4[<N[4Z,S4X7)>UK,?K?:ER-P;%KM
M-Z1]N0$B5,R!7%'*.]'D<*'Q8FHN $QGG2A5YO)"%Z*^(<N8DGGREC?TDJTZ
M5)31D(.MHKM(+"N"!O6[467X):T+@G8A#BWO2Y]<2Y\1I>3.I'G0?:F-GN"W
MAVN5H37]IJ8+"U()7PJDR?8EQLX1U.#;*%F[SKQ1B62RK-*%F H9+)S5)<P9
M:R=KV-M][)X.S:C*+^DBZ=)]9* \L="AJD!O33"W;2;SWR8$=\2L9A5BDNU.
MVOQ'?$Z7+'Q2/M6P3A4A[0JORSP6XV-%D<-MZ-+R9'+%D[(DU(W.W<P9/:VG
M01^MR0.%(UI@K7P)\*.*E:)-KZ&]TK]HSQ'LT$N=*M"?6U?6JA%]DNN*7.LM
M((R*RK$;8E5^I,*VM4"/)SJ[0-&8@=Y&WFJ)A2T$YAPH)*H&FZJ_KF8T_-3E
M-M#5ZBVO)84NHV&!^L1HD >!?F293-'+?%A??Z\])3WA(;PWR\KFJD)2ZZSL
M9]7!R/I]#CI2JWS)K[49M4;F*_D;IE1GDZZ#K6X"H9X-K]VW<KUAM]EXJ4N9
M]XFG4LZ1MB.$9'+F=U0Y,.MC54[G9FUW&8/& ^R*:69+#:[MF&M6(7A;ZJ$]
M*)GBN,9 5/CRD^PTA7V-C* VNEIUAZD;ZL#"Q4P0VD![8PR"4^EM;<&5P3M4
ML7:X!]4&[M_9?XD#)N)N65S/.@D$>WIHG-:CYL/W&I<X2=>XA&2VT:VB7W]5
MRA3L*T%(M[+H, I&:D,;41F4?95=$9K2Q'02)%V1H2:R;BA92?P6*=Y2+L>[
MSA4L<!.5$'V8K%KB^GK=5E!*B7'7;TQ2:W\"=W^=4K.J1G13)6ZOLY>N97E
M"]@7KVI;JT%M?=[FLJ3TAE%W"48;7PCZWGIGJ"H[#X<I&23*H%Z_%%DPQ6CI
M0!Z";MU5O59VWL)H;E78VMV1ZB-?J&KXT\TY$"H0UI<T,#S5**#Z!-/*1,8V
MM[UXUT5"USX(75H]DFW/K-4!91DL*OZCE6BM/Y'^7(U5#6Y3.4/(6JN;27BQ
M*II#!Z?(LVG- $2R2O+O4+%KNA65<U566+7/(6K"\5NPM?2BXX58F8@\V[8G
MA5Y>W;DH)1I[A0%LF,QMU+>RKXK+-0/ <('S;^9BUOQH/7&?ZEJB2[TQ9)X\
M:9[JO"=]!#]93[S!MWL5N;-Q>4'[B<]V70]I.'C6?VIL1)LSHS#?!%&$+P5/
MV[*GZ[^C-=-[O)F4Z/"IP1IZ5/8$]Q^>,W>N@=&:HE1*R\9W[;R9==B0).I*
MO+:E.%3D9Z#/#^I/28S\51_?IVNV]N!ZFBJ&8:YNNYKAP:R4%.DJ7+7!\/XU
MQ7I@RLI08ZV2!QSV3YJ$],!KB8AZAZR?ZJZSTC,*(+8;.:C^<KL 7V$2JMVK
M9!(K_*OCL<: [8NE0&N9TT IV$ '!SV5L>=;-=(@=?HF:-.KDVI?H2Q$"3&9
M&[RJ@P"538X]9962T^D*9L;#;+X2=.WVI=2^ FW+8^4)>))JDJBZZS3OUL6D
M%1["#8$)4-&.+X>)%AOW9X]8_5N(56^/6-TC5A\&L;H5@3H(LZ=16@2>DT4Q
M"P(OYHD3.U$4N;[/?5\(M@D?NC4\OX-2:2WSU(X=*6U-?=U@Z"3 "!R9KT!H
M*"!H*!>;=;\5!6.-Y:]KRS>+[*,R5=N&?%T#[C45ZRF+$#6A5OM!5.1"]T"%
MPRCY0KH:-Y@D-/+ SR54RS,47VWY-.GY9XTT.5IS7:X)WV':T0?6R\T>ZJ'
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M=K6\3B4Y=W5J\.;O8W$R5<;UCM##QX(7/3//X)B.=9\GUNH5W@?/90Y+<]A
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M1@EPMC*&WP8D>MRN!U_JIM.L8'1DC:F^8^(NY]=+-M0@&/3L-2T@P2"M6T"
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MI73LJE]W76:VK[FO#)>UF6;5-=#5C<J[36'4RY81")XF/9@3GKT$SG;[0.D
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M&:/$75"*, HEC,W=3&4L6_5E'4O'G9Z<J7OB'/YZ]BH@_7,VKU3':ZKGIG-
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M[V[SISUH<GZ;O-*XNL9SN]:6\ZOE@U_:I9;GIQ5V_6E#Y92/:6:*'\^]1(P
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M'[JR(%UQ*W\:_?EEIYG3SM.F2Y?LI:3#8F_9DU@VPKP8M/K-RYR(^L(=.U%
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M0,HB?[E3:^=J;_\\C8W6;\YI8[]^3(.,GI'4$45YQ#VFR!!X16G0FG-N#:S
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M.8M$1H]\9CWB&O/43ITA&CPF.),$UA&P8)VRGPY$6G;#O"(E_Q<&@565TZQ
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MAJAP7@^<#NN!YR_N]GPMTO4*S:[I2_&OS+</,-_R/>#2G BFE21(J8PC'D)
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M>7P?XY+FPC>"CNLN^JM4<+[_\_\TE9OO9"Y>5<)Y-JJ8%>'/'209%6UN'GR
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MP=O8\Z5K:>T,0'0-3#< IIWSOPYV!\WW&9QVS_</WIT?@3JAA@$>!4(2X@Y
MR0A.D:>V.*PQUN;%2T(VGTG Y2GVPO]Y2'!9X\<2_+B-;;#&CR?%CW>S^.&T
M2XD;@Z*/!G&F#')&6@1$-6(>I,(^%?RX=_VF-7ZL\6,E?MS",IK@!UWCQ_?'
MC\,1?M"]SX?G1U%)ZUV,"- ^(JX%1PY;AI1/AOAD<0CJQ4NS^4SBI4\/'S]]
M+.3]T%4QCU;'=T_O5FYNG23_:R;)/WP%[5H8=XLLKH//MX/[;POFIC?"! O\
MT";N$$\^Y%<6<<!F4-2$IF"!+AKYC-+?UZ"S!IWO6PY\#3KW YTY&Q4'GI+*
MA8PP&*H\'[AQ-%@4K<3<,)V<$1ET[IWRL@:=->C\J#EY:]"Y)^C,&+;L2$6J
M:1 >44(I&+9.($.M0I(%QZE(P$;S48;GA#G%M/SO@05!>#D?B*RC7XM'\_*)
M,#D^8;<L8C;UF^ES>43?]%=3=R*T_.BJ(/E=3(#Y$H+]?HPK$E";=C#LP?\>
MY&DZ@-N^:G?]EQ]TEWSZSPGVI__NV(]FN/]YY]L>W?VV]X\/?(_^^\OAY3NX
MUJ>3PX_O:/,?39#T\+EYN76^O[U#_G-Y".-Z=R2(4%K&@*@+'G&'%7(YPIV(
MP$EB&;W3+QH1L.0LKWYO&+\_LM*,K/6JM>"*R^IX-<(P MJ&V*L_L\>]6,I^
M]1N#$SMHG-BON3_6*;SERY'.?)GMZ&-V1E8[EI&-1I:HANW%_(74;9=J2K^5
M6F+=(0P_]'\?5PPKVVR\K:L:;3 ;;7O6CW^,7OP96OVSMKWXH]4ISU1^].?L
MH=@E9S'+-JL^_O.\%08G?QBY227/*J9V'=4WKCXEFT7[S&%-]9G2FTJL_AAO
MDI6?77598C;Q#2][C<?K>5:=6UZ@<00>2X7P!IZN!SA1/?63[,*.O8>>"GW=
M3-"9PF-7ZXJG'^A?L^DEDQR0V^?A+/5 /Q-Y74Y( <_H@Y5Q_:F-C=L]_$]C
MAMPM\6=9U>8K*->H-LGV,.[!G0_.8_MK;,(P3GZ)<B5G7YH?]\" >??M\. $
M[OD![I6-ET]?FI>OOC1ID^\?M%MY_/OS1LPI_(8>BKWM-R?[_X#G.WAW ==J
M?3I]=]G\Q[O+P\MCL?_Q7ZU/VUZ $5,;,%/M.ARL)<41R00<CTN?D+%:(($#
M249Y$P7/Q['%_?VUM]H_S_P<T5-#-EO))'[YCG#?&Z\.H^T=G'?7,/5P,+6[
M %.:R:2#PHA3:A#GT2+CA$6)V6"4X9R&W.MQ0U+QW+PM/S]_Y'<"HY\P<>F9
M@-%)+\8U'#T<'#47X"C 0N(8/0+AST7>G$4::X\X0)0G&,Q,;TH1FV=5!.(7
MX49BS8V>$QR]Z0Y[:S1Z.#1ZMX!&@FNNF,2(4>,0UR$@@V5$V*5H@D_<ND*.
M.-&_'CEZNBQ'V$JR83LAMQGI19L&L;<F2L\*F5I?USSI 9'IPP(R*6-)B%@A
MQD/,E6@(<C%&E%((0AEO'!/%;#//Y.S9KY%_/=WR^ZS>$_<A3?=KZKC&K5O@
MUAJO'@ZO#A?M.NLM"QZL.4]<+DY*D>/1(,6HQE'*Q+5Z\5)M*'KOLVZWW3IK
MFK5BL^:=\T>CE</'L3_XQ1C6;\\-JCYT1J4<8MCYYN&K6Z7QWAJW'@ZW_ )N
M1<F=\H8B@*"8W>,2<$LII$D^,VFU#LEGGJ456<"MW]<4Z]$HUA4U_^<2S!JC
MW+([*I Z4XS!>H1NSO,=*Y%?MN/VPT_0\]8%3Z *?N$*U-\+[(\7P-X[J9BG
M'DE'$P)&FNFJ<4A32R)30BL<<@5J+1;!_EXD]0&VT"/FK>=WLY"W.L/2&/N:
M_/*KDM*+6"KB@N*"$)4TIU([IY5P/AH:K0R.'1%%7UR3RJ[G.]=P,=^Z)K_S
M_5-52]ZCV:S$8?'O(V??O^Z>GK8&Q:3=ZH379=&.8\>#6LPE&-K=W)'YV23>
M7^[6,''6@NW*]_[1Y,W+#P )7_"GT]UOAY__#=!Q?+%W^@GN_>9S\_,'<CB?
M> _7_K1]C&%K7^X=A,_[!W^?'GY^T]K[N/MM?WN7?CH]Y,V/S8N]@W^?_ >@
M9N]RYT@8HEG  4FI">)2!F1"<$A("Q)H:=!$5K .$A_#5D9;S3!/B3 1M.+8
M@I1RX!?,>>>#"PG/)^J_WF\V=P^:.WL'[QM;>]N-U_M[![M[_]C9>[V[\WYQ
MGTWOD[G=5JW1]?>?':\!>SLX&5G@CB>5K.%.&@ Q3H0EN;WH]9OX>Y\S.#B)
M#1!@N/-%XP1(W-0Y@O/6X*3AX2<9QQI@CD;;\R>-;N_8=EJ799[ZC=]R>3N*
M_WS]]WZ_O"1__MXX&_;Z0]L9- ;=QOE)"WXTF+I-'41HY)^4LP<PBV'HJZ;.
MH]L->BW0TIE3GMJOW5[KFP4E7&WGW((J_W[0BW8PZG3^\9^[S4;_HA-ZW=.X
MT?AHVP!(_0'\A'+Y9U6*6OW9+S=_O;?9F'[N4WM1ZE6W.G80\Z5GSU.XB\99
MK_NUE7&OT>D"K,>9)\QCR8*0M=(0AEZ^W"^S P/K#^'QIZZ6!W#>';9S6RT_
M[#5@4MN3VV?92S'V9P<(,]%=OCKU;>$1.L.4[]_+@URQ1,VI)1I-(@RVS#W<
M=W:NRS>&I:K%_*ILWN+@TR/)=+GB'RVP2EK^)CGQL&8=>):M\?QMCIM^/<6N
M:[R/L;'7!6EC99XMB,DI3%XY9S&U5\9BVZX?8"( &_7.\D7[S&PPD$D_TD(@
M&JUV[ ^ZG5A$K]>]L.W!11&RABOMWK+(#4%RXLC ZW9@J>/7:IIV.XUFV?=9
M_6W,WF>T9T"6!TO&6,GH5@">[!I__?6Z#""+<:<+=^SE0&*CZX ?U8+:[93+
MCW^_V5BET5=^<"/)U,](,G>!.)UV6@FV5]F$$PFMZX;>4DRW\@Y=-4AZQT$^
MZ5[9K:0".#G(&NP0WP7LC7FCN&$?OMWOSTIE1O,*KS-VS<XN_.@K7"-C9-^#
MM%>Z",2XGS<-2'SH]N!RL&'ZY<7H#HTSVQMT8J^"[VZ1W/Q6]GP4(0?M>!9]
M40<>F+\%T 2+<9!_ 3#?'F;=D2\WR H$=@IL6=@U@R[<J]OO9_])#U1&ANYA
M46<.=%O6M8OZ(R,SZ+CB(FZWXUCEP-:%;=WJI*P!JNWGV[8%3W9J829 B0U.
M6KTP&G;9V'.'A*XR.>HE*8Q_L<MB?42N,MRG?E7;6'CR$^O G!H.5O]D>J.*
M6>_-XYRJNJ$8OD%3F:'5?$W]/>E-3KP=1Y27[PLJ21)_V/:YO>B_^._9IX1'
MK"^O\JZ<GXV;'T[^KE.S'![^PQMO_[GU=W/K]<Z'@]W76W^]WVCL[KU>31.>
MR\#W]@]VWC<.]K.E\'[_K]WMK8.=[<:;W;TM,!FV_FJ\/X WBCUQZT=96HEY
MM:EQ=]/A4979E3LB>P+R$\S";];O92)*XUC PWD,GN>PI\5C7+AR9A&N:P&E
MX!^AU0-TZ]:8FS^*WZ(?9KR!C^%R^4?EK/-YJYWMD_\=PB_FB-!&PYYV,ZP6
MR 8$[!P#K(^&E#$QGL*( *_[@S%R3_NURPVR2LD 76 4MG:_4B7PXU;>]W8P
M++@,\_@U&P<P Y/!P_NCT5:D_M1^:YT.3QMG0/] # "];8DIY2O6/&R4Q3#S
M,+X8#2Z.GC2K#[C8E]$Y\,INN6*V6^7)LZD %\MG1#?@E[4J@J%U&P&HW.)B
M9H553)5\RTK!PNKF<?MN?U \_S;KOV%[,-97"WIWPO)F+9M6=?UR]<X #"%[
MGBU"N$[Y=.XRM4*;T,A!PWH/MG\UL.EU*ZJIFJ,RHFF>"9.0Q0EV87'ME>\E
M(!<=GY\JK^?(5KOJU#PL[-)/\,W,H^=$0O^*Q_#@;WM='V-F*B/N^:2\;XF8
MV,)>BH%3K?>@7M,B$J$;JZ_5M0]&?KB+XKOH?85/P1"R( C]D[SBV>Z:O<J4
M &TVM@:-PL%Z\:S;*\Z)Q?T1O]HVP'AF@2>QLF=ZHY&.MW=F>.,]WIOYJ%=Z
M:N>S]?D[\)1 Y%RILU!LM8(T\,^+//!L1;6G-ON<GZ%83L/!"=CO@T+*&L=#
MD.V.CQ6& 5KW8D4U?8EHYR?*<S"9J-:\WR%^.\L67=D(8PBHW!UYY\_OL781
MH[.)&&W>@F NWQOW]6F+']NG3?!3.;6WX:I?BQSM9C?:<.3>_F<,,'?'6QX^
M*AOE.;JX/XPB8;2YW;S8V]ZE^Q_??"F1L(\?SO>WFW3_X -<Y]]?]@^:YWN?
M]TX6:\L<GC<O=_-]Q.''OTMMF4\'6[QY>2CV8,Q[']^)YN46;=)<6^:=V-OV
MO+F]>PF??X/_/>)1)X(=0<8R@3BU#FG"*5*!F.B49TZ%>?>Q,%8S"Z2/8\.I
M=X8**Y,Q@LD@#([S[NZW?^^\V?G[;V"LE;.[V=S? \JZ__I_&A^W_OY[J]#6
M6SN]KQ_%G-.;DKP'<TDZPSFFEA/&C0K&B4A)Q"N9JWPRXOJVU\K>S\ISVXR]
MX]B;A?56OY\Y!5 1 .A!?^(L'?;\B:V<#YE!G/5BB@44^P.0^YJ8A,Q3^GV@
M+15:YK34N2^.KUS(TTCM7&0/V (S<;9=4!R45ASD'^21C"]P#D2[$3+%*S@,
M]# !X0,UURGNZ@FM:4VV\834%DTYX9.S/L0!W*$/PX9[]B/\:G@&PP,.WO/
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MQ1M'&^(@/V;UYY>M'M*\W/N\<Z1!V3)+"-(),\19XL@9@$\34L+>.2^\F:\
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M2P-BWU'ULE];4@ SOQP1L"8]%1(D18'R]<P@)Y)!8)@*'X)@-F;/)EL\!@;
MT1T"%(5GHH;O)G!K-?Q(:AA B&"8^MQY&5X@SCA#&GN->#!Y%0SF,18U?',M
M_),H83]O^#ZH'N9<4*)]$,D%[HQWH'R-LCKQ2$@@HY.Y!*\-W\?< GO;.T<J
MTL1%< B;8!&G-"%CP1R6PF"M?+(Q%_CFFV;Q_/]#Z6$?C53,2<)EXB$RQRPS
M3L,(C$T*TY$T,/QD>OA7-($GDN+QWL'6D:0"&^- ^W(+$&EE[F8AX)\Y4JR\
M5-;FDD+X^9O#W"D"])(I*R4' =..&)F4=\&8A 6[%G[6>O@A0>CPR$6*"?Q!
ME/'LB:,!&1($"DJ")6"IL3+<2P_G7V41:'6&MOSLX33S,E]ZOGA95$5<4%P0
MHI+F5&H')J=P '@42&!P[(@H_>*V9($O#(@_ E%8B'.KI4R!D,TJWK/XM]Z9
M>\-3N+2?.UE"P0 W"@N+/0^<Z<A,,K#PT1D9F#O:+E08_A]-HH:SNO_]H.N_
MG'3;(?;Z._\[; TN]KJ#N-WJ^W:W/^S% [C9JS9\Y\DWV/%H@UTV/^[ 1H!-
M=@K7^;B#FP?MT_V#+;&_O7.Y=^#/][;?G7_ZQZ'8?SV_P9K?#@^^7,(FHX?T
MWR>'!^^^[7\\%,U,9 ^:9.]R"^]MO_KRZ?,7_I]+GS?Q4728.4T=,M@#PPV!
M(@W*'!GJI(F!8H%E!8RP*V+8&A1'(8_*6]#&SO*(K?,^<4<B2*X51-@7C0BP
M=0:K,.@-@1J_WF\V]_<:[P_V7__/1N/OG>V=G>;6J[]V&M,?-+;VMAMO_]YY
ML_,W?*-Z;[2/:^%8LG\6=X(L0CZWDZNUO7[<L\\9-8\L:<) I7$6M-.:>4&B
M-I%AV*V/MYG*%?]H#6R[Y6^PO8!NG\)#%EG_O_^?IH2. ZM/D=72.)B8 &4X
MZL]^XW6.JZ:6SSJ]F\!N\-W>6;=7EF>C8?L-V+8%F[,EWHO] 7PQP =#,,][
M<//^C&$QZ#9:F9DUGBK[H,QXF?#"'?I;HW'>D"L^O4+_WGCSCC;/CSAEV1V#
M42:)F1[R7%>,(=B$WA*8^YBKB1%:&D$L/6C6J!8VR]!=6%T,,<JHM HZV^T^
M'Y]G3"E.@)DR6AF5^'82\-;V]GOOB\#^V[:'<7+K7W:Q/YSO'1]Q!LN:C$%$
MQ>R3<PP6&WMDK0##C9H$4WZG--3'V,;K15RQB)$2D1A%V&876 +^;9+$B$EL
M'.61N&17!:&6\'#;:WS-TPL+6G16/\_]9M$87[N@>X\W&J#76\!8*TW0;@%I
M"Y42+PDZ9>=G55"3NM$_Y_7-]/4;L(Z-_M!]CGZ054>^\/\.0;DFP(.&NR@7
MJ*Z^T3CKGN?+YN^ Q9!B+W9\7'77ZAN]&$8/4HS4 E'Y*S.# !+>&K1K159=
M)P^FVRF/#M\'D[7=!G-V,,AW@/&>MN!E*".NO[+\6?M3)'>S\7KJIJ/AYO'4
M]R_7JQUSX[GN%Q5<6]*P9=JV-YD9U[6]D.\=6O"[0;<'WVXEF*&+S=7Z=]&#
M<R<V?^7VW1Z-?FH?SZK?U/H6 [J,O>XOO(^_T.;Q$3![RRFQ*$6>FXMFGXP"
M;,;PMC?>NZA,/OJUN&>][9],!&420%ZPEA=H><T*BREZUNT7G\<?O=B&[W^-
M?YZWPN!DE$0Z]:LZN0]/?F)=O]L>#E;_9-H2%K/YLA[$/O:>*+_[#:)RSL<P
M]?>D-QK/F3V.R/6B_8)L@N'^8=OG]J+_XK]GGQ(>L;Z\HG#_^=FXVM507^3[
M3\URF^4_O/'VGUM_-[=>[WPXV'V]]=?[C<;NWNO5H9'G,O"]_8.=]XV#?;!>
M]][O_[6[O74 ]NJ;W;VMO=>[6W^!Y0IO-'?V#M[?^E&69ER6OTOMV6OMTSE[
MUFLP?_,^A]W.;1!@! /8!JID4#1QN7)/R>_@.%J^@4XL*"D78V>BE+H]8!&M
MHL6 %\2;Q=+HDSW!?J=1JJY7WJZJK]!\?BB@6[BE)>LQ3TK R@,UX\XQG0C'
M1D0;'*&<X:Q,B<&<4#1Z<8TR+=JS"G=L#WO Q( !M[JA,F]A,LI'_;5UNUS'
M[ESL;?LCK!+G5EM$&)&(.PZH3A+\491C6">-K<C%LJ6ZUKB=Y:^=L)'#(NU6
M',Y_N%%(Z(Q?NY\WQ]FPYT]L_]8N$B^4]08GEPM_$V:B!K2(5GFPBAWQ51;@
M#>1I:>1C;Y@CQ?OI??0@8X-6[+\&SAO#JXO%T,=:T)8*6JZ&<22=BQB0'DEI
M&>(B IMSPB)M\_$^G@#693YJ3-BM!&VCF#W6^PJ8  0:91DK\-IZ"/GR(C!)
M2 K,:XY)<HJ)X(64VD;J0EC+UQ/+%VX"D/GHL=!,(>X519PQAHR7$5DPV:C
M1' ?<U<K<[V7KC7H+S'V9^#M'&S/XLX%V1N K7N6HZ%9QHJ)/73MEK^KOT\E
M95-DUCIFN%$4!FSR^8GH1-)!QAN+VWN0!Y"KXBK*PUO[AT!4]@_>'1FE%3;!
M(\$#1EPKB;10!"7'J8A@<D:'2P1PF9CDN&SE+;D1\)1OC?PN<RKO/,)5%J7H
MCG+SN&KP!TH^^NY"1?8/FD<\:>NH8BB >D \YE@_+ >BVA@AF=1&Z))&<M6I
MF[D\D1M)6(5.RY5>,4; @AAEFMQ/PAY7$:XE;+6$T?V#+T=).B.L<LB:2'-J
MN08&I3$2.C!M H?)UZMZGVTTSEOM-LC!6:LWYC]+,QCN9*9=ESXT6LR=?/_B
M#ZA,M1E* _:J_R,,>Q?1]GZ])6;YZ!X -;>,8V0X3X@G"TMLI(29#@9V'3 !
MP<$:F\\R:.0IZS=2KWM:=$VH0]99M]B.CS5)SMKF]#2&%GS<OAB!0C[0"M(Q
M.&GXV!M8L-ER+!LNFY>I7Z'+<:_;[X\3VR8WZJ84>R4$<G[2\G"%=C>GLW5K
M#\*X,^]&I>MNE3UY/W?!W$G"Z43)W7I6]M.4$_Y5A*_%#P"_O?-,PSO'.>.F
M.P2AS=^"F<RSL=4)^_#</9#CV.G?U+?P]%F6WUV:81Q?CIB2U$DK4#*4(QX\
M1=I$A8SP5DJ5O/?DQ4LM-A=KMXPS*UU9%UC8,/1Y51K#J25JA-$:%0$?26.&
MN;(\/X"G;9**+A_(SR:2M4DI%8C2P&6=9D(2CU,@4E+E=;5Q"*$2C5ZL_6R/
MN!=VO^6]0#%56A#@@RP&Q(4TR-&@<E)ZXI0I0A/+YJF4RYO2/0,_F_:,1A8Q
M%IYQX8'',A)-!"-;IZ!5&)^VO4Z>UGZ0QQ$T&/_A4?+:J( UXD:!<8NQ1%:
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MR^C:+;?<3#W\MK>]=61PQ%@F@6+@P,:EXL@P;1!CW@=.DA/!Y_/!:H.I)>7
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M*OY;'4]]^]=)+#@]"I[5?[6&W)K_\RC$'GOX^;OJSWV#5=H/%MI7X#&$M],
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M.;),SS9#K<=\7;,7J_6X[L6EUJ\8T$7L=2NK95: &K-:(L_2$1R*&FO$+0:
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MPV&\N'&G^6ZWL5W;V_QG^_.DIEQWYJ9V%[C_=C>'%S&CD1%%F07$,=92BV,
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ME^O8L--\_YP!U54%DL?W$_I"&V??L(W"L120XU@@3L&G=9G DMDH,;/2)L7
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MA-Q>^7#N456T9BG'92^VMP4?BI-]$F\O3OZ7&*D[^.MZ>C-X\_]02P,$%
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M'E@HBA@9QQ&^HFQ^B2<H]CE)'/P5(Y],"/:X'/@8D*X4*+V.$)OBZ [-<;A
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MK/FN<J/3!+DTG3C"<;\9:8)J?TH$J=0R8?3M!4U?T!Z2T]/W!Y\7Y(,(8[J
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M>]QNUW03:M@OVS@5^(:#O]_G6#&8I*VT"9.[<(\\X44D&O;\BOV*<^2K"!K
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M?[DZ[;\\/POS^?*E*98 !'I5LBQDYA=MP2M/MJ(P463DP9;&A-D$Z[N!M-U
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M8&+8_>M<2_<J$0UJ)9/A07F9?!%6J9"<TMD'PSJG>]UYZE%>O'P-[PL7&/F
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MD0U&^,0SR%+3P2U91RYS!C9G3D21*84PP/;T,-+3XEA3/6T@UL'!T7L!7W7
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ME6R"LVJTHRG282(8U55_%-5:ZJVZ&_@47I&\5 B5+P<T@,7W+PJ-5B'^G.7
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M>'#H7TJE<75F=,R#6@X_]K/)>/)Y_G[]J)=^/HYWUGY,2=O *=&I##;( CW
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M[^Z#QU[VN7ZZA#O,8+D%L69;$QC''-S-%=[]>WSXE&ZA@FTEMI!?AWOQ-IS
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MM:CA(UG]4[7;W;\SRE2(A>Q&=J_S:!-\5>-EAQ .$SH[&THTHFI+?0[!.^5
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M:L\-"9)QDIGA0@8*V=7I0O<DK&=_Y'<O_ [[?CV\MKS%M$F-;P"JJHN_$];
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MD:(C?'57OY-,C+CCI]X@S,>NG#T]/OP/ 37B(  JAWHS/?BB)R-G[A5%'';
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M*KAG#%"$IZ<&Q&M?AZV-8FITVQ1;8LI@L2+*&X:1=88';L@G.X^^L4C>+X4
M&#P2%3LZ+R>:V>S61G'WP'%^# ON6,YC-:'/K7VWI-AN9\B_?-7.@H[XG%AD
MM2*'6!?DOP V[MA1]<;STG:\K >QSK7K8%<BKB1;C_+<<2N>B/9(:#]\>YB/
MU'5[LE ?P%R"2^E#\]R\W80T*M7B<RK/"06X^["(,_]49UFC)ON4W\Q%Y-O
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M;'&=]R"!:BIT!@&$'D(M!@J$9#/N:&Y('T\)#B2:3)__[B;@LJ)ZUPLZ6(8
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M&W%/WBJP/AF/9GZ3.@=/Z%S<X*F9V>G%D1TO2^EK[&O L/'R62UG@&V3*E\
M(BE^;+-T#F,^^YGM@UU2W^*&U*9;_<@HE_7PMP>BN5$BLR=2CJC$'@V,>1/O
MC>H_0U&,OO=?QNU1"TWU.\76+Z8'$WS2F( +_A[#B]LS)X5+&7AB!/"<YUIH
MY.3&6,?H2@Y42I*'*7!&;3B,*V/A&/K( M\1#Y300\Z%#1B'IWS9G"X%<L'R
MU&FA/[QU%MLKQ@R30YVPH,R^X_-I:8Z 98(2IY5)(^>IOBM[?U<,S2>JF,BK
M+?>=.3W=(O6<[\>1DNI5%A.^8?(&H4!)NF9)\=K,MTZL,0GMWZ)@(KYMZ(W?
MM%IN:N7<)CS?2EH]>MJ]1C%%4>>?%3YR4B+\/L K/U1* 4HQKEVQC\R'@[PN
MX&5.'(VA%)7>1&,^G @ 5!S: MOEQ;>+F'S95;6!^Y>73Q>0@ZPF%DS$59::
M)$F91KB(T=SM8I3/Y9YU%^WBUR1]M4J32<FB'T'J\XEJ)F892 Y?<!@63K\>
M&=0((I8$CQX\M[&RJ,1<<GXJB4BJ+Z68DGUY] K'"1U%;;?QQ@(_F?,J,J?
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ML==0EI6Y!)YZ?++\KTD_HG/+?IB[LO7R=(;\OCND'P*=/'8BF'==ZM[^9#-
M(E<J5> F>+A?\-735'-N^'"VN3P)ZM?SA9ZQ+8G&$*U!F=+$/)XTU<K]+YDA
MTDR3)+7XAY+IU'G1M=VH,Y/5YVX.3SM+,N\>"Q4@'W66U H*K[;K,Y[X9%@M
MZ!Q(WR#4!W&5ZX./QR%77Y?I7R--.4\^7&R_EM((H:-+I^H&56MIR11HRSQE
M-4S=0>J59Z:7X/WTO'<S::+R<#(F7[2P!P@$VP/7ZIK1*%I3]@$&\=2P )1L
M@,.3LK_&'[5%(!KOFST+=%&F0N)5/EX.;13H.AW E%LQ6_^GHD/I8T]L8C='
MJ 'I6.;?89*)X^K#9 </N5$?^2.^X/]V<?4_?)6"Z$N__V0,-8?<F4SZ?I+]
MXZ]E>!T;S/# J@['F$FM$V/(VVY6%5Q\(IL3)<%E_K$'P*;?XMUAZZV*#4_M
MK7^Y[:,JBNGY0ZQ(+:- .+L[GK7(DL3W ?!\/^$!P,?X #CP^RV5Y(74 R -
MU_.B_6>6M\UQI>NFY]=[2M\]_X"3]#!MR_.D_>#^4N^>MNDZ6* <\'\KD%P$
M6R7",9/@KQ](P@=Y$C&G\SB62#_3YJ4KB$\LD6H7N:#=4C?HW1XV/O(C[J]Y
M)^>9[IW^!*?S'X<KW>.Y9U"2"S^>US&(X4(%\&'RNM/UTD&:7CX R$O3;]$>
M ")F[>#7[9SBJK@8/%5F.F%%K[/JY=Z)W>1OO1?X<:W(.2_X'G<_(A? \!?L
M@[!H=T<C+BRQ:/WX,T_Z'O Z*_@/1?RFR5-3T_RN8R%N &&Z&U9 0+X'D%[.
ME8$J[U3SXU;HOO_XY7W/G(7?,.J)"\4+BV%KM0'J&D<:_-V71W*=2#+DIB75
M/2\6/8'0Z4$2J*H?<B69W8G0\XVG[FV.AO84V*G4'9):[6UCYQ]6/KP>YSO8
MHTNO=*_U3)2+:S0>FM'>'8:D&(<</'/R$>'W2]X*D*V;^C"I"32.E*[[0AG-
MD(G 5VSIWA%*HW#A!1=?OGHC8;_']'Z,2%O&IA@)*3X:JD</"->FK$,8+LE
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M/;[A!LV'@H$@-SW4;%O'9UW--94)ATW0L(Z/Z"SK##6+M!SRLD2&M61[<S(
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M3/#(D87-2%;."S/!F6*&.8#<FG/=!_(X/#[DK[ ,4=MH[R.$FAIY%BKRM!?
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M8)KH_TXD /;6 OH#($IUY![^ 9 )=@YS<?PLN*92]0#P?@#\L-2>3O<Z^/8
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M-#MZK".TLJM+,<4GOL*/) 0>_S VV$!@=AVWD4:14F];8>"=PF.Y6!?_LA(
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M1(O;7CONR*5J5+\2T^YG*AP>U3&*3\C7 Q)@X6+T$5V >((RH6CP/C/X%M:
MU>9/8]T?OJQ:X(C1VD"";:)=7M!:T0CNU/7_T9VCJ?M/U@"+(,R4]SW%Z0.
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M]DRU\\4+\W0)P5+Q"V1]2V*M]LS,K!DOPB7Y)N.P8!)6&%A/U$<7^COD[T>
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MGD58G:3H&[B<\6V&G^8K5A.T;QGKG79[S2'4I!D@8]78A.<@F[#!X-1F:^U
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MV*;F"W$*)NQJ_5^=_%EUVSDZ.IWOL>65G0[(T@G*D^@4>[__-M9QX  /)3<
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MW"8[.FBNA?+@FG8=.6E_J;V>U6H3H FK&.(Y&4E1+DAV,;-TCN? !6$[^4H
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M05/T\GWWW'O/6?>N=;[OG)_WS3RS)FO>F;S[?6;O_>R9)'>S=ZN 1RJ*8$4
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M'&8ZL3M YR*R #K2!G>_5Q,KGP,>M1"LMXK)"O<B<.#?9^6IJ[L%SU$B\K6
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MQ%^=@#/V= $L2'%P8 G)IS.<?V:JE/WAG;NH302@I&2'1FJZI&[J0\7AP<#
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MP='XR8498 :^/<8TM&_PDP@) X*'RG_5P:OKC.KW43UWW&2Y"LW6Q4"B+^3
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M-;,G/#^G9 %(\D;,B9!7[C ]'NQ^",:1/,,.?+9QD^$'=N?X_,G44)Z(N7J
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MF6^RI/Y%>;OGJ>?)D.+9-_4TGL_#66-]J$5/&A81E7B5_CIS>2,581D$AQ_
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MO>QES)?613$>O8OW^;#M3+8UA\8WF6QDWEK7UAO7S:"VT87[D'!*%O0O_5'
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M8)MEV/H]6='QDF$VS4.O S=]4+>B@:Z83J-=,D3T"9R4S-0:W.EZJ79:N84
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M59EK8RDS6G:? !OM L(_BQ21>+C:\HX#NHY(5ZR/4/SQJ:ET\^UYK]JVT3#
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M/R"BM^?YA-X314;57=?+U(4R?M<$+]$*'PXZ/Z%Q#@,%YOKZ< \D$3L%N3=
M3!T_!NL5<JHYY;9C'F@]4>%@E;QK&$=@NCS[X&4K]S]K(:";06E?+TV[N3'A
MN=.#&0 IN7WG=^,(P,Y#O^WUUU)=:_9E>90W[G 9%S81+:#XQ86$.VP$!O(?
M-I9"7<:X*V<3Z-X!/F.4U>./W&[?_<4CRSNI2C+6#A1WC;* R)&T2$B)92H-
M_E5<'BR]58L<>3.;\9'\S26FB8>#64T9LU^.>=;3] ''(H\^"K:+MN&$6?"P
MO]^PR-EV)>D(/%MK-(DP%L]N;Y5"ZR26S'45+G%-*-6C>ZM*WZW[ZFJ,?N9
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ML0:U@G]5':0I+DF2!#W6)S6NDZ<X<*6]7/$B]]R]2US QN@#=%JJ7:VVJ0I
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MDBZJ>/?L*C+UN %S#[GF% 07^GO"'6=0[4[2U*Z='=D8?Y#]^N8E<Q!&MML
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MRI(;:.)"8<\UO*ZANN\]\GVK7JDZN;GVTMNV9OM,;!/2(?L"R]\!#<-Z?>N
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MPYV<[SY1D./6X/.N>\^7C2?T8>.VDVN3L2O64QXC\1!UUX%C"?+9+OFVU+M
M;DZZ58DA[3\2Q69NM=;]U2^RGQ(IS9!C?&A.2D0FV%('I3PH>50 C!8$,5+Q
MD\WV:.$1H3ZR!.-G'\M?,;9S+I5O!D%'=05>M'+;XUN1*8=4D3HNJ?H!F-D+
M;UJ(3F)3W=Y2C%1@7ZU*Z*!Q+'I2A*F[T--9^'2%_SB\5KE6IBV(_\>045;#
M=W62PMKH%.T$U3A&MC6Q,5T=D:[HL&9?<S8Q^ABI$) SVCFHPQ_V6O-I(J?$
MT*MPM\R 8([*5DAK />4?S_'ZP<:U'VS)CVW0\"R3W]X3.4@OL8NM,H'+,7*
M$M4AE+&@"#8A!2=7'Y9@'[8L<0RXY?[J#O?1;,>%)A++#2W'+"03I!_NZ*E,
M3W^5EQ2B\N$/*+L#7[A&PXE'6H!7#"/",E+V/>; >,&,)H.XKJ'+M3B*?*;H
M .F_PIA2/N^6 >>5'L,-X*=^:UKKPX6^#R<L\T;?]O ^[+YIC[2A YO5_Z)C
MZN05%;\]/DV/8);XO=\W ,FQHHO/9OY1V_@U4.]'\5(:\'&8Z]^8'(/NC&YQ
M?QIE=#@D#X(K>O[]M A\I@B0_>\*_!^7,\!5Z[@95/OB QX_$^-9?"4-D[Y*
M6*S*6>^D]O*>MOL H<889']^5EG\!O")TVE7!R9:[)^]:%S>.W [-O:/;L0:
M_*Z)S&0[/TE3AO_[)*$3'<B%%I'[_\U'^1\]6&E^NG]WKKS6)5-B\^"),OYG
M4(.]W[_ ^)-*1-#7<58L. P!FKGHW& _">&1S[@@A$BL'E#R9L0T:91\KS:C
MQ6!C^,$U<ZA>HA9JY2N29MKEH5!$L-^]3#L^ =Z:'!B?S_EGJZ,;P"WVCY*2
MZTVNJ[O0NPHPDMF^(ABDWZ)\I+1B8P[D>MU+GHL Z"$>XP8G?UX\7!QBG#=1
M6;FOSNF=M..QS"JW UX3]-57[K@!$,YM>](R/\7>1_NN#"@&!' =)L6>&'OY
M4_IFK$BP?Q3BN::9QS6/:N$^>>-+!:16AWG3XL$UQXQ*I"6@IAO QX+C&\#T
M8MNP5Z #3'LT:]PIK=7S\3"7\<OL_9P/!3, YGJ.U.,+3L*A%DZ<_<*N(HO=
M@4SR],R$@</L6X,+).'^1]^(\V]+0^'+.-_5(=IMR=H,!]%,D1_U%:/O%)-\
M/Z'.RG/0C*@[X"]G=UNFK4AS#2PI \G\]K!"2XGM-?-_]),\L;W;U^GOV'T-
M%/8_W#KZ-4@\)*,(N_?,J_FK?'Z%"W@YZ=HL8,,+M">#W1E9[3B%$V),([9D
MF0,?)5T3OXQ*,7 2[>0G- >)2:-&6CBQ1&%E>R(J[^+O.[$S^J3-0F0^@!+]
MI5:A@3,EHD)FO!'3=LD-\;DE+N5Q#MEL*NBTCX%> Y"_<6@I\OM*(6L'^@ .
M)6O:F52UX/^*L[XE/CB7\3WVNQOUB;B?(Y!"49[_:GI??:K(7JN@!6]\/)\*
MK00'-D'84S,>-(D)]LCD(<F"2[\GJP.:]4$MD!X@IT):LRJ3.#+GBG!IG@+=
M(HZU'A T%=,Q+BS-JPNQ3II>66SL1X"ZI]N.G]8;FQ)IQZP:8?80P<<'I+8T
M# F>J4)VE*$6'V( \;>_TYC=DQ'XB2R0OK]TANFJK@0+]GFZAB0H?=(&ZQ"M
MP#:P(NE/71(:TLVXJ4_"792=1@.4+YC(,ZQ3':)K<A2C/BA5/+>(#Z:CORKJ
M>@1Y/OCOM4LV!G\'D#R^N@%<X H+*_G66)L!6BC'.R9&.:T\_0(Q+B!F^SGK
MC^R/JL?S_^=:&0*BE-NZ<"@,AZZO+6G#X&=&G:H9P?Y'\!.B<2%< 5(<_]7/
MU G[9HD\EB:S=D/="ZC<&MT:^79V:)Q8Y-1DF TKK</I-:]66?Z+!:/H1X:Q
M4(A?<MI[CGVX_/E@?=LG1B2:R>"MI(TX-.MQP$\R+\-H7KU7\*#8%3,._N+
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M*V!ZF[9NL M^;%0K'05[<I2ZNUX)1\!M(JT\673KYUBS='G'FQ]C=+0QK>'
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MM3)YD^==>[9"<^^5)I:H5@H9P0*GGRP/'8.#BF+LH;_#+#A<TZP)]Q.'R *
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MLZ[X35/85\,3(C.;'7OBH5\29Q;?*8CVI2)/Y$D@A6K8@@APF8-I#*(T?T$
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MR+#'1XL/)O:ULVB<2/V7NU;J/VT>3("] >S8Y7YT%(C=4C@;/F:9RO^B>V=
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M>!F"4ZNKC)/A&&:!6A"GL:BQ#; 9P7O8\V'M0T#E+N_)L,:XR[&%\+A.C8[
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M*?\N&"Y7 W,P9]4T);A_W7>JZ:>7][&Y+L$K*OUCV/$^+Q*&>(B#6XRZ[-T
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MT>MGD&]BX&%J4AH=S$G+K"JZS_8-W"?^[5A]=+1[:5]O1V;;".'H&^!0T@V
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M'L90.X-&0>:)Y-:<&"8C$U5<TZZZ#ZLT#4&/&2\]\*E\7O,C7*TT-YU&-.:
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M-47NL\[M)CN5YP8]2\O(F+TJI/0"2]L#T]!+X1:3HG5.$>?H!J>C$1OF <)
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MOB:T"ZQU6*21IP1D7HK.V%4L((RWQ=%V>P2[XCC])*(%003^_7[YQ<^<IPB
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MG'#39*%$+&6OFQ]BI3WR-.'-*:8GNY---X#B8WD3T$/L*(@5"AJ156<,4)V
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MM_;#9:MZGK7)7'B,>>1Q!).04D5#L8 $,PF%1T(O1(3$26J\6[S<W]P(:$M
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M\6"C@'8P;@HVZQHIC^L3Z>;$XENC!UAVBEC8;^.,M8$M_>(C.#+]KO4#C8)
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MJ V 6R:\(<2;&V-WVNEIOZW?UKP'G89 OXQ@2T?]T#K<7*G9W,?IFU)OD+?
MD.%?;&S'IOP7&-8>J?N&1'^DS'Z#B/A"B?^&A/=T7L!!>W&(>/@U6PIE2:Y$
M>S-KDX%J05.!19 (B 15:P*G 4RI3R&EG$<4(3] R#C$X70_<R/W[DIDOI;0
MXEC]#)P&(0K#@#0R2ZZ%7%\>O1T8*8N(@V$0FRC$P DYNWB"RWB<#2 X\_AT
M$0.7==@)$3#X> ^7QR?QJ(;_J[Z[>KWBGT2EJR@=6/L+C_DD2@2%/!8^1''L
M0YQ&@3*B Y%B0F/FIP[EVBQ$<'"83U&PK=E&;ZE0GUJU2AS=5SNX- P'*281
M\; :)(29&B2?ASKA+8$TY"3E"'F1L-OD##PZ4^Y@9C0L%GZEX<&>Q(LT",YN
M#B,[Q(9W#QGV/[TSR Z8HZX?RR9<[N L25G>RC;$^;;XE-U_K:XYS_3R1I9M
M>5+QL<B86'^L;#]7+J(P9I0'BN&22!&>)&I50@F%)&18TC#@*+%(\]U+EKD1
M8*V-WK-W=P/R M22Z@.N3J>NU+"^4:"TVOIXN?Z\833+$,-IL(.8;I#&CG/Y
M"<?'YE+.9.,TU;6<\<?+\F[.( B?OYW3KXL)[^<,@L7N#9UAFG1,\:,;N96_
ME:*^YGI+FR0B-ZNWWUE]<^A=7MP^"IU>?77_7E^7W=R<4ULS/TP%@<3W4X@\
M3WTGPQ1*@IB?>$&21'9Y@-QEF=N:6$O'N\O^>:N)OJLJ6EV &GJP$M] WFD$
MEO6=].Y>JG5T9Y^A--LX3#1 (Z^'M18PEU#IT=SL![=; _1V>X#6VH!:G2&O
M/0X(ZK"9CWK(,VUZI/[ '>10&J#)OH?071:"._*]R3R@-D3O-YQ0'U-L8K0%
M#JF(&(*,J*%$)&4P]7P!O<CW?1SP*.2.I\U6<LR-?[?/'SM%Z@S.UYOT*^]=
MB=9UK&S/A$<;@0D/?PW ;P]VQZE<T1/-D0YS[61YH5-;)\!.'\^Z->>:MLZZ
MHO@U51\DS#0(N4</,YJI&RUVBN3J"=HJ C::[%R)Z909--E;;T@'S@KG+L_$
MZ>-Z W>89ZY_DP,7V7JO++&;2CR4"Q8$/ RC$'J<*YLG]2BDPD,P881P% 0L
M2=)!RFNMNYR;>7.V)!3XHN4&M>"607 &X)O1X["0CLR" Z Y7$6M X"FJ:6U
MZ78>5;0.8#"NGW7XI!T1<9$MWJXJM:7[72R7_^\J_[;ZK'9ZN=X'Z@#E8N&%
MC 2!CV&*$T_S3Z#V7#K@UPME1*67> DQX9^+/<V-=AIA@986_EV+"SIYF^C^
MTXGM+1$^3S*#XC8RM[A#9DPIQG <89)2L#_?Y\^_J#9J$OD'TM_"YMN:.2ZW
M/@EA&"O9\83Y PZ'R?_'5P@%'V\^OFV3N"><!!3S /J* R!"%$.*A \9"BEC
M/HJ(19+&_=;G1@/_QP=:0* EM#@2/ #-X!"V#Q0CS^QM%"[GNC> P^+,LP\L
M$YUB&KTD=N>0I[0^>[)X\-!T9X6GY-TY_3OYH1%3K5CZ.JS:G-$,-4_P,8(W
MPPFTZ;-[O(S'P@D<I]P>@WDEL@>A2_:U7)UB2>,P(A"1(%9;@#"$F"<)3$,L
M_ !Y81P:;0%.M#^W%;\6KZY^:>M/V(7-U'G@#,;HGH(.AQ&JVYQ0>^#]_VX?
M$V_VCRIXN+,__C&WF:O= ;?R=2%X5KTCK#ZK_20>2*8O?[W*BR+_IKYY3=2(
MU\6M,::$8@(Q#G6<)TH@IG$$?>PSQF+))+6J;F/7_=SF?2,WR#=UQ>SFOR7X
M9O0P'J0CLT?M2-3I#1I4.]FOP%IZL!8?=/(/QR]NN U*/Y8B3,I.;O#LDY=C
M*Z[%>[B0JN5*O,^>=9B*FJ3W.C="<\#Z*_E;7M31A1_46_DFUU(LO-C7]5D9
M)!PI@A.I@"E25.<S*8D081#0Q(;@'&28&\MM5(!+K0/8*-&&+%R!6@_0A.9J
M3<"71A?+ Q:7$3-CQ9''861J'&<('.KR.(,X<%$>>SDFKLCC#-1A.1[WIERC
M0_8B438A?7E9OB9%\4/FA:ZK6GY^HG\3K+K+WWY_S(K&,^>31$J=E!93G$ 4
M\122-&0PD!&*,$.A3 .[ HA]Q)D;F1X)^+K:#J-5*H$=G:Y JQ6H<K#1R[:\
M8J\A-:/8Z09J9+8=?8P<8G^&@';@\)]>(DT< 30$?(=!0(.TZI1*9?6:E%_O
M1%F](97P6_<128@7,@]#H5.THHAXD/I1 DDD<!P1M3_WC0)_SO0Q-SI54@(M
M)M!R BTH\%U.FTX@:G $UQ^GD=EL9(BL4JCTA6JR]"F'D V6-N4<!A=2IAQ]
M=,IT*>=DWTN5<O:CCKY*H6A6G+A@TN9D*=\\B?\2I+A34(I%2H2,4LZTNS+0
MR3BX#D624'(21C[W$;&[_F$MP=SX4KU5R-)':0VZH9MR3"C']E36LE_M7W^[
MVMQ_N]*6(-7IES)^!;0.H%9B0'>E*W[#>BRMI9C6:>D*TH'?TKDAQ_MN3W39
M%-]E^8-84.*'+ TX]'$4022D!U,N&&1$_7\D%;MQJV.7W>;G1E*==+K(GQ+/
M\O;9+G)F9.2.Q\A,LX;BYCP4]A>_CFH\['VNW2ZFO:9U5+V#VU?'/^486J3L
MG6OVCR>=FD=GTZR_+^LL!8LTY"%ER(.<>@PB2A*(D=J>,7T'-0V%%V&K4X4S
M?<UM,FM1KP#3UK100CZ3Y3K@2'53%1FK!&_^3EJ-]#5S-<ZKIMX>^)957T'U
M58!?17%O&D1M,BIFW# 0UB,31;U=Z<1L4@9O"3I@W-9E-(:-TCK3W[0Q69<5
M/XC ,GC$T3S0&7E?Z1P:.F>O6)5-43J=^N1>:%ODU8_-1UKSY%I[HIJB'5N7
MUF[5Q%(6"UG=/NHFR@\Z@WRIIN2'IV9['R4^\6,$(QJ&$"$2PQ3[!'HDHGHS
MX?D^6SS6.<@^5Z2H#.V/J>2WF:'[6HPW6=="JBW"?;:J0QLH6=8U'?^HR*^I
MP?$G2\-GLG>"T3A&/@XAX3Z%2*H7@_A>"/7)3^C1U"=>T+X3;U>&=;IF_$9T
M.DSQ/H@ZBNAG>AD,#>PY#N_8MKM6"-(ZT]&VUF!+;4!_@.W/=>F::]VOVJ)8
M.Y?/:_V5.416H$7@"JPQ4-_6* RX3YAZX(;=@DPF_;2[FZD'Y6#C-+D ;G;2
M.Y(5=6K47]4V[ZFH1?M=;2=^6^6T%,6S3JIQLWI\JLI/0F.?+;-:$_WC4Z'3
MJRH-LG+MZ6G2"/,X"))(+7U>B-7Z%\D(XI3IZ@528B2%Q$EH;Q.-(NL\[9]7
M^U:/W>(VSJB&@2>$D#KH3ZH]>A)0B'T605]01GPA*9?2UJJ9R9B.;\&\W;%;
MYC"<9G;)BP_0R#:(UJ\K(K>E8N-3V582-%J"735U['6K)Z@5W3KB&#J)^*A#
M,:A5,8ZDDUH0HX*];RV,VYF;9:#;:(R6Y3+_IDFKK#.K:WE$>:<:O?Z>E0N2
M,#]DH82,>@0B3R202)["D"9AA 0-$]\JAZM9MW/SX7Y^^QITF<JN@!] +VUJ
M"+3[F;4N;<V!1AN@U0%?M$*68>"&@V-&\<-#/O:^<3RTK4G9#KQ!6=:PZTEI
MTPZ.?1ZT?-JEB@-YS"J=$_M1.Y(JQ;6ZA_V8\9N5IE7!7SU5'_+JOT2EHQ06
M'F&^)$D I8@CB# BD,9) D441D$<T#"01I63^PHR-_+;\MKKVVF/ZVQ88IT#
MJS[,ZM(F/Y6B2VR=K=H2CMD*$,;R)^W >20_]()G4RR@QZB>Y\@IQVKT [!:
M"["M!E!Z'%Z5 9TJ0.D"E#) :5-'ZDPT)C;5&Z89FZE*-XPY1I9%&_H#>[YB
M0X_V)RS7T!^%W5H- [3G>M=3K06BK.JN2_%&T&J!@H#JB'B(<1I )"F&.$$<
M1AZE7A+PV(^,RHJ>Z6-NBU4G(A"-C+;7+P]!-#.R>T(S\MJP1J45[PIH 8>\
M%WE2^X'O/1[V,_&]QI.*'MY;//U1!\M6F<RZ]&8=>-G>/(AP[*=)$, DI#Y$
M":$0LSB$A-* A]*7B3!/*G?8_MRF]GM1J6ZT"<J:! EE4\3YQU_ JUS+WA1(
ML;!ACF :*EN?4D:AQV.=NU-*F-(8P9AYBCYYFOA,+)Y%0?,)4-WN9\3#B :\
M]_W!,["U^P$R,DVVPK6U7!RN"!W!Q,+6[8?-1";L#D8#V:*G%3]K8AYY;#K+
M\;3,.P;AF8_--O+M4[Y<OFLN;BX8$I((%$%) J'X$"MCDC " Q$QEH1IX-GE
M.YI6_+DM82\8$:/7S;K9$GS1"($6(DO/],2OGYGQ/=^7:FQ/^<_T/LTQ].K(
ML/YL\5?;*OQ/"\(Z,CPO$(EU3 J''=S1*W3Z2^,#TNE*A0*>WTJ9,?%93_F%
MH"04S$M@J#8F$/D)@S0EJ=J31,@7@F,4^\9;/ <!YK: -J*!^L] C2JQ,,Y=
M\#?8T8R,ZL@KR.F;O/4>J',\K[50GVR&H%9D9/0M]DXCC\)$FZN11L-N-]8#
MRK/;-9=VI]O/]=!Z9\/7IYV)=X2-(7<K&S/N^JGZFA?9?PN^\*A @4Z<$TL=
M#HJ3 &*,$DA]FK"$A8%DX22;OE,2SFU9TJ.JK&ZUTV=_OP)D+><+W%\Y.:@C
M;Z6&&*KY[Y8.]CX;16>P[[DT!O/8VIR4\N?8O5P">; -RL6.W):+W:6I2]VQ
MB"F+DB@AT,.<0202G3N-1I!1G(8H#3&35D43CW<S-^+>&%KU!7RYS+^5S>7Q
M?/V7^E3)L@3T"9#-.+@_=",3Z8%YVLDX' >>QV!0(CO1U:1L=%[=?4JY\&D'
MW\0GD3W0)S7?=$NZML*[O-!QF:J5K]<K_D8\BV5>Q_HML(B\(/ HQ#)!$'$%
M*$V2!!+FDS#U)/,3HY1BEOW.C3EV) >%3I&G%-(I/6KAZY!(OA'?8J=L,18&
M[HEQ$!Z98';!K>NI*+%!)W<=,O=F;' MO _C@#R1TV$HL.V\#/:0G74N6#0W
MG4_!7L<=5X+#XXXFH?9\?U **1NH2075!BTMB/H_ZJME,XP)A2B)(HB1B&$8
MRD@2%)(P88N5N%?"\3L+X_!4AT;3(VVFQT&W(QH\6EY+"_ DIH9&8"^()K(#
MZX/"5L@V0QOX8ROG:8>'O3%X"8MA[<&3O4UK$EY2^L JO/B @V&H*^450B]
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M=87!(-(12&D,?4EXY,<\]>RLB.W&9S=)BVS%LD>R!.1!5\C0\7E+)2]4G3\
M?BY1]V4@S::M*SPC3]OW:Q2&35=^3-U!)^U.!Y-.VF.J[4_:HY_I65^T*5_V
M7A\K^YVW"%%$F6 PCA.A-OAQ"E,A.&0<(8&PSV),;.;PF;[F-J5KV8#O6 ;R
M")9FTW@@A$:>U=LE&1M!=7ZS&K#++DKWJHJG,1FG-N*1_EZFPN%IQ4_6*3SS
MB!M/?!#5:U)^_5CDSQD7_-6/WTK!;U8W=8;-;'5_S:KL.:LR45[3LBH(4R:
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M#@C0(K$I6UMC,9P!^#)C.*CY.+$*DQJ?+S,\^Z;K"TGA7!.R4LVHQG42FT7
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MB+S(AVGB,9C$*?-#+V (&>WD!I%F;B2D-0 ;A:[J6@&@T^D*M%HU"7T[O:[
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M][6>MR),'G%-KODZ?WC(5_7MUCJ&?+O^R4(DC"4T26&81KHB29VMA 8P(5&
M0DHEI48<8M;=W&BDS1S9B-S<];YJ;H64VU6+;!-NGD7\/)T,C^/(C-(70H<D
MG";(]$S%>;:+B1-RFJA[F);3Z"F'B[77C!5/@K_]KN;GBBR[/"'7*_YFD]&G
M2Q"\" E)B;X82Q*=W9L1'?FLC)4X3OQ(VR@X,KK[8=_UW*BF%1Z(5GH=J'P\
M&Y)H-;"XB6@W*.<9:%RH1V:C_Y^[-^V1&\?21O\*@?=BWFH@V:.%DLB93^FM
MKP&7T["SN^^@/@2X9FHFK,B*Q7;.K[^DEE@R(A0D@U)J!BB4G6E)YYR'TL-#
M\BP=RIWBVVI&0*L.]G3?UA,?#&6'?,W!T!XIWS(@ZFXIDE[ ]:8XNCUQO!1%
M+TL/4@S]GN#K=-X*H=^PU;>UB;1>?EDN?I3:R%F44263-(=Q0C+M;D8(4B$E
MC/5?BY0(C%*K^>"2H*FQ?^LEM<J:LD)U^L,2= J[NIAG\+5U+J]';1RWT@,P
M#X>R'XTK7<DS#Q_9B>PW\=A]O'"]A^-XFG ^5J;$8/G#%**3Y8^Z"1JB.2\R
M[32J%&NG4>(,,I(2*-*(8)K+G.16"1!N8J=&&6>K99:=[MJ%[)1W\&+LQ\'"
M3QP$W8&IY:QSLE4;?!T66 ?7<!" 1W(+PP#MYA$ZX]7K#=H_;3Q/T-G" R_0
M_6[?(A%4NY%WJLG@W@6E[[K9<:H0$2J!2!&F63X6D,6(0<F40'FB7<'(J=#G
M18E3(_A&8==2$)=@M3NM" K6P'S=Z&H.+1IM]_)/!NH::(U.X((.EZ2.7,+!
M$H3CH@VV-WJFSFY69:6??<O_W)2KTLQA;:5J^B#OU#\6IE1$W95(KM;-54LI
M9BDE-*<<0TF4"9W(D/8J"Z$'(BY2A@B/D--IJ9\:4R.AG<KF _M1*ZT]S$9K
MQX1;OW&Q(ZSAT1Z8Q3H#P)X%VQ+K+?R-%6!K!NCL")C&>Q6.85-\_509-_WW
M*KB.4H.O>UKX$NQ[BJSTXE\EE#$!$T8S[9!1 4F$F5YVDXAG6/!$%K,?<LD6
M(6JO[XMV^4SW%1AP^ZDK4Z*_2MX<;3:UU\M*_UQ5II*^_MW/<OT(?I?+![D,
M5XW]8%#LV'$(H ?F0XO:Z_N:CU-P_116H]59/Q ^F?+JIR!QJ:I^\OZK"R"T
M72:W'8]EC"DO<@2CK*A#X6)(8\YASF.N<"S2&#GE!IX7-34'KE5O6^Q :_QO
MWO4.7L)JN9@, M;0J\C]8@8=:$/TDKZ,QE!5#%Z*>ZT*!F?,[JE><.Z.@#&S
M]_7.:TQ36L09AA05N>DHK7DB%Q&,4!8G@D429^+JD-G[*1XG]$1^UOJ&")B]
MMS@V"(O<P*3A#UJ8:-G[XYWJ(8-E[\?;RK8WVRI4]C[ EG6?%_-9_JS_934K
MB$RS7"0P)RF&R%188DQF$.M_B%4:BX0&7"5MY4YOB63TJDN/\879JJ@72I46
MO:Y3XY^673K*J@D)K61=_[$\N"O<HFDW0->OF+Q ?_WEDE:[N6"DQ=(13*.M
ME':2)[-,.@+#98UT?+,?@_U-5G))Y[>5N!7?RZHTWI0YU6NCNF9,%$66XAQ&
M!:80T2R&+,\D)"G%.4EPKE+IXOU<D#<U%ZA5MPZHH <*N_'0)9CM&"@@> -S
MSSYNA[IV\9SA",<2E:!4<TGFJ"1C"<!+>K&]S=,UXH]2;.;R3NW:4U0/;:7+
MU>[P.8_B!"O-+3'*)40*"4A5D4&%1<X$+;CC\LI2[M2(IE/;.#PO:E8[>CR6
MN%OZ/.'1'-KKV0-R7V?0*=VNP\ @80".>(5U?RQEC^L N0%RY (YWN[)54<9
M=T(5%"'$((LCO63+20Q)0JE>MQ&2QBI3.$UF3[4[]FU-EVM+;KHF*>^EM '/
MG>5#657FFV%MJ6C3*J]NC[>R[(]W'EFBZ3Z5@FE?DBN(BB*"E&4%E%$>R2B2
M!4M$B^S[RK+;?0!<.UD#G@_6F@T!J2653S@CM-'M)FSVYT7#P[+OZ^1\7C3R
MB%$#978>/,^G#=EAVV0S);_H0M8U5/ZB?2$Y2Y4D!1(1Y)PCB!B5QD_D4"]+
M"RFR6"GIU!5G)+VGYF?NJ7U5 ]2QA]^!XZ8UJ&,P)V3]?2M9V[>RO>Z@;^5-
MUZG^!NQ9?W/<M[)# -00!*;G\<8L/.F/H/OX4\EX W)R@AI1?/B3G]WZO;ZJ
M5JZI&\8+Q LJ$LB52"%">A+3TU<.42:E9"3)4^D4<^*EQ=2FI']H18UGK!?L
MR]W.1Q,[MZE*4Y-L;J)@&V^Y#J![E'/1MFY;EW5]MP4P[\E*/=>EWA9L7C[0
M_BBP@,-Z_?E1D,%Z_?.DO9VKYNIVB@E<4^XJ)$<[<CJOR62.H"Z"Y7(D=?EA
M?E2[[5/RL7K2RY9/)@<M_5U^9W(YRQ*<*9(+R#'7-(I-R^"(Z1^3 B/$>1$G
MW(50>V1-C39KW8!C7^ ^+.U8+!!" W/5KO70#6@4O0$M8."/1MN N[X6F 1E
MG3YYHW*+A>$O&<3F%H]2 ?\H9571.H]LSU5LW^Q<%$6B.(6*(NUVY:J -$LT
M2\@,1T6>J3C/K*L#]$F:'D>LM9@ZT$9[2>4:K"3?F(+#_P8:,\#MQI VU1X6
M[3F3=<0[,_THD9"0Q Q!1 OMYN8)APQQBI3 <9PG=@%/01$?)\@IB6+2H?LI
M)*K]_!P4J8'9>1^=@XV*B]3L")E#U810T(U4*.$<A(%J(MB@T5L&H?<!XU4^
ML+'CH-B!U0U7^K%-J>?;2NR%L_^N)6XT1]]57PU%&]=:7_!Y81I)-#^^H:MR
M9>ZOWZQ[R1^K\L^-7'W:MGO#3&6IP!1B)AE$428A33B"$1>%B@2/$^+4!7AH
MA:<V6^[UJVRM:TN/&$>EWF[86@-VYES1OF_P-\+1I9_ .(^V+@@_Q/[+AH%Q
M'V;M,932K[. &7@(SJZ"AI;K4Z[WX6$I'^BZWF'_JC^/F<1%P1 54%#]/\0$
MAACE$2P8HT5N0H!C^_73T>.G-@T8O<"RSY>RP<S"6[\*B8&)<JL;J.'X>BT<
M+J5MKX%EK/*U#O XUJ<]9WU_#=JCNT:L,WM.X\-:LF>O\O.F;SE?;"IS</1E
M,2^YIDW'%.3S#YC29[A5$G1:#I*!?!F,H$Y$C[A1I__+9K^<N"WNN"*.BET^
M]F9GCKWW(KI>''M_E:8GB/[]VT55:[JA\WNY_)[,HB)*,$YR&.%"0H08@SB6
M"LJ8QYCE+*>Q4W+/*]@P->?!N07(:XZ_Y;GUM$=UZ%/O@ %6>TB<"+#:H@'V
MX  &C\#!5J\SEN$#KT:V8_P@K-<9J),!6:^D2M#@K";T>9?VS61*<X%SR(2J
M\Q'TLC8G5"]P)>8D+K!@49"\_!>"IW=F=9"8[Y67?T4^@]U@Z0$16.9ZB%3*
M3:DY!1D6*<P5C9.(XHBG5GL0PPW5*&F"346Y)@9K:,@MW8/@0 X]H_?$L76)
M*",61C@#U!AA:B]%3R$N[0P<EH%HY^[VWF,P_6^^+!=*KE9Z+J/S#W);>FJ&
M)"D23!"DBN40%8F$)"LBR-+"I*H43$96G6GLQ$V-BKH.3D][Z@(E7<N37\#8
M>B\G$'+#[^?4H.UK"HRJVP)S0?=T+$ )O:_3)W+LO1T+\T_L[]C<Y<<G=T]R
M62<PU_$%W8G/\RQA*2(R0U A[8,BEF%(\AC!B&1YRA!#(DE=B.2,G*DQR%;-
M)OKL9EN0\MF-0L["*K(DCUAF B"X.;;*(8Y( @N44*024@B6N_GW 8 =QZ'?
M0?NI@?936&CM:#D 7 /SL0=.SCQ\ 86@!'Q.UJC,>\'@EY1[Z7+W?H+OVD/
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MO2]\8;/MG;48-Q/?%Z2C+'WO!WG6X>9\N=&+XS;JN91;5RXEB1Z+A$,F\YH
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M7;FZU(<SX-#U4^-H S(P1?[/& N'\/DQQF2D(/H!Q\8MJ/Y:3'M#Z[T?/EZ
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M[_6^U>Z(*.>;=?E#?C-A_W4J0!/D*H79F30KF4VSHWVGNH[07^2R.;A_/OV
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M5@*Q_4W@#7X,_)X\WK?B)LT//B6W/<ESITY-N&K;1F55<]E7[)Y5*6>ER%-
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M+9?BCWH^OU^(CWKF%]_,;K,]DNM_U3:4FJ6"E@3KCTI>EA+@$C) 4JPWAUA
M6%"*:>F4#F0]\M2XKY?.S0RS!]K.!HL"7V1^[ 5K,GYV4G>G_G=)__MQ&L@Y
M(QC4%K,??51#S!F48RO,_0$>)E@?)?E/67_[OI'B_H=<T6^:$N6*UVO91-KO
M;VL0JG*"% &T%"G C ACF4G 4B6KJB@@Y?;FF>/@4Z.O7NRDDSOI!6^34ARL
M%==9L+#O(F(;F=MZR>^2*P![;>:]\':P'"/B/I)5:8U_($/3$[%!(]3UF>,9
MJ)[:'ABOOL]P^SX(6<_>=:]<6_[W_4*\HQLY(Q7D+*LD4*(H (:8@@I+!J3
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M]QJZOWG97=+U>V\<= ]/C?-]+]%C/SQ 9KQBBF! FVTUI@5@*>&@JE+&\XI
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M/S_4"[K@YF?C\&\"']_5:SY?FG8S]VR]65&^F4$$B]+T1"U@;KJC,FTL"81
MP07GF%:89DX=L&X5:&KL^-OST].\^>K0>2*VXIJCS45?"K#NE6RVEJI7,Z%;
M/?_3L6KRK;-J9YR-.5>Q6=O,@]'E+NFT23X>S,I6H62G4;)3*?F]5RID^?=
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M$ITS8L/UZ>P?-V+5.F<=#VO9N=_NV4JD2:KI\A?NV;HI!#JK4JYR0B! JA(
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M@D7Y9)_7.6R_O\,AQNWS=U:]D_Y^YZ_R>_6V>2^?E_.:O^PE RJ.$<$09)G
M &,L 1$"@1*7'&:8I#QULL<O#32UC^PN9\PU7/PBE';K.01 D5?V?CY=*V7R
M>_=GE!2Z:Y $7?@7!QN5 JZI?$P&5Z_WI(7')UJOFK.I5=L$B\X?E.DL:N*_
M1;M!.'[/)=4F.<<8R))H@QW#W 1F0U!F.>$\*PJ>.=4;\1%B<G2RU<&$XC;=
M<AOAKS6!"S<KENP3&>O8S+0'\RKI%3@+^4C4=0.>86G-1Y!Q*>\&J$[H\)9G
M>17!77(IQ?J#UJK?##RHO?U#FUW<'.K_8;I@+[YIL;BI_; V5^D-NZGC=K\0
M#Z;P4.=M7<\H1!6AB $BJQ)@6FHJS14#%>-9SA7!0EB=QL<4<FI4VZN9F%?,
M=%S>'>;7US;DX\VLQ1':!.8K,EUOI\JHN'67) \JV?>U)*V>R;ZBR5;39$_5
M1.N:-,KVIT@N_:]B3;534>)7G_+1BAJ_WM2[%D>..B=7BBO'&7O,XLQ1T3LJ
M[AQW+/\L5_W(HZ20#]H^:<)HC 3SY?IY)6=*$E'FL@*4EAA@64G &*<@4QE#
M1:FP?D&<3CIL1Y[:)_SM43[<__5_$)C!_UM/HWQ)'NGJO^4F,66\'?=-]C-A
M>9@1 ]_8AQA])MMIOIL1O(O&VXD>-JO-":W@&6QVHX^>K>8$RKG,-+<'^'8L
MNQ="OXAZU[3>T/G_6S^]70HYH[0BE:DHBW@*3;BP *3@!""84<68H A*MWYE
MYX:9&C^UDB:=J,:38(1-M+2)$=>U6]E99(<I*!Q>D?G&%RJ/3F5#2-S8I^SL
MHT?N4C:DWFF/LL&K?:M+_Y"+9VFLJ[YO\S_KS?>WSWIS_2A7QPY'P4I.,%,
MJBP%&&F2J%2)0%X@!0N2$U(ZE9%T&WYJE-%)W[1C^+:HS>;*M9RT$_IV%DP\
M3"/32@]GX^/I16\J>B>]\'$=NW[(!2Y<[23"R!6M?> Y+77M]13/LKEFAVBV
MC5*\>U[IO>'GMD)/$_+1_/*PK[T4LXS1"E4*@:(@FN(HUM9/6J4@K419(93E
M*'7JEN$NPM1HKA?,'+FT/M=E*[%_*)K'O"B!.4\K"DK(<H"S(@>$2@8PR629
M9R::$,T6\IO)97G5F:G:F=D7)?[<B%'GPNY#%/?-C_PQ:J0$C!IHWRX?C=>H
M3:F]-X4@O[4).NPEV;^NS\&];PLM=-J9[(=6OW6BY^CS<,DF]UK$WBB'+3_L
M+L:X%8>]83HI,NS_)(]3R+ZSIQ3[;^'>2_CF97=)]P(V[U\GQ,/S1N\6%J8+
MT#^EJ5TJQ?T/N:+?9/_U?:;SKW+UN U1Y&F)E6 94)7^]F%4IJ"""@.E"DQH
M*BK%K*+#7D?\J7T\>ZF33NQD3^[$"-X0]W])NK+E[5=Z+2P.-R<]V7^B[\4>
M#G?)]1?((AIW"B^0PY'II%^DD0Y37^^%"G3&^FJ3.'CZ.KY4XYW+OAKB!R>V
MKR?%+6'RIE-?[Y,X;L5YU$9"KOM&$C-)H5 IYB!/*0285QB0+*U F>$\Y11Q
M7N3ND?1>LDS-\/G[HC8DTQ27\(JV]YL1NZWI2#A'MCD.VGWNW*:M*LE.E].>
M.7*]ZYH3.J;_)E0CA/W[R?,*F0$W 7<^>>"V1WIL5]])MOFXT+S<F$CF;V^7
M/^2"+C:_U(OZ\?G1'&I_,6$@*REF&!,)%2D AV:K6>:FW'O.0<%D2226L(!6
M:<#N0T^-+8VXR4YZO3K-/_0*W"6="FV$1Z^$@[GO-B\6>[UH:$?FS&D![; G
MB@;X2/N9L,"[;46\L!O<1K@]<;PM@)>F!^:[WQ/\3.]M2-,ODIIX)C/B^HLT
M+9KUI^H7^<CD:E8*5E:Y-J\S)!C @BA095P!@@OS_XP[5H^Q&71JGX==&)\I
M8=^)ZF946V%M9SV'1C RY9\%+_F]E3-@^( ++$'M7*N!1S5H7: XMER=[O4Y
M49&K6JY_D\8_L?@A5YN:S>5G/1]RI1FM.<#I5D.1$LY%IIF'EZ9N*N&@*K'>
MXF.9HXRA3%7VYJGUL%/CGE;PQ$B>[(F>;&5OTSI<?,_6,V!SZ! #U]B'!7:0
M7N>H6[!U\<?'P'@L/_J-KZ^CT]L5J6%GM?731G0RNVIXZ!QVOOO&VB>[8/E=
M'*4R@>T2$: P-MU5*@*() +DJ,@%X@7/A%LQ@X'!IL;F 6J@G(/4Q>UZ.U#C
M^%5-!Y6=H,GO<>N@#$ 2IQ;*N0%?IQ[*@.H7:Z(,W>-A%.KGZD]1_4/N!_ <
M-(!J?M&<4ZU[\U#H;6F.&)#&<8G+0M,(2AF@"!))*\Y3894GXRO !*FE5:&S
M7CHECGNLM;]L%7$P;'QFR,)\C(Q[?*8Z"_G]9<A]C$H?[!W,R\AS,)*AZ3$7
M@8S.&_ ;-#]]GCN>(7J#U@<FZ2W/\<Q*X-^E>)[+!W4^5N) $*Y%JS<O7ZDV
ME'?V%BD1K*BD@%$( 4YS_5,&%8 %@RJ3E<R)<,I2N%FDJ7V-?GM^?*2K%Y.T
ML+\>DUYZQR#YVZ?,SD0>=R)B^SG.Q:;M H'Z"+6[[:1H(]OH$B>]*QRT82/G
M;Q=KW$CZ8#">1-:'>[(?,1^>?>GQZ_5O3RM)Q</B'W15FZ&^T(W,9EF:9YP7
M&<A)A@&&I7$*YP5("[T+0!0CJ9S.I&P'GAK)]L(E]4(/IS^8R4J+Z4:MUJ#;
M$6@,*,>.26BD3EJQ33_*+<Q?AM!U)D17J(+2GO7@HY*;*R3'%.9\_PUYK=^7
M<WW'VI0(V;S\NMS(<XZY$F'*,BR E*343)45@%7:4)2<TQ07*A6IFZ%H._+4
MJ.KMPR^_//R:_/;UX>W_ODN^O'_W_OTO]V\^O4_V?Y'<__HN^?SE_8?W7_05
M[;]Y9%-:S8RE/1@#[]AFWY[,_R-II4Z,V/'=J<YPA4^"M!I]_-Q'%U#.ICPZ
M/<##!?O!M%H6G?=(DQ,KB2I P0IA.E)+0&56@2JEE>)*E$S:%TG=?_+4:*F5
MS<$7=P"3A8/35_G('-&*Y>.,/ # P<OH"\1([L,K+X*;1_"<KH.NOH,;QO/A
MG9/SP#EW]@(/<KEGK%[_]W+;^ZY[?2I*!$^):4!:(H SG@,F<[VCRYFDDA>8
MV'5&'AAC:H332>G5<_T"BA8L=#LVD?GH!!8?:KJ CP-)W8[32'1E_QJY,=<P
M (,<=N'6\=AL6/8#7KMRZ:WG"O>+32WJ^7-SK&%")^M-+=?O?_+YLZ;3-B/H
M\>FY?4D>U'NZ6M2+;^N^_?-NDY*71<JR5!.D?@T 9I2#*B\EX$*0HLP9P:2:
M_9 KMG0_:0@EI,OJV!<UX@:HT]$</A@M0:]FLM,SZ17M$_>VJIJ[WID;].]^
ME9O$)'$UW>D;M9/[S695,WVM<0AME@>UM3L;W?=L(]AKXWK6\1JO0NQ-\-$[
MX/P*]$J:BD'=U(]S.A)Z,B*=E@03\Y5.3T+#?/DT)?A(?I^GHVS^7Y_-)Z\[
MZ]E+^C=.4WZ_$!T%SC+&C(F> U4H#C!5"%"408 ARCDI>9XB)P^FGQA3,^.W
M53QH5\6CK?UFB..@/<IRIU$"$F:4:@*R1/>!\2X;YSF;=E^&^',4F?U/BJRT
M*C31".U$'=1D>;.=ETZ5<+Q^&Y1!N=M3E%'Y^3:XCCGXQJ?Y'@[13;.I>% F
M5_/#?/F':P/:H4=,:)5MQ33KJDD<;B2-TI_6!I+ APD# XY\?G!=]=,C XM[
M_-[O7Y>+95O%8O&MC0?ONKIL7_(4J@*C4FEH,P3T%I4#6J4,%)AF7"F$5$E=
M3(:K(T[-.M@7N"_[\I=.YK\Z%XRS!]Z.78+"&9EB;D;2F6BLT0G*-M=''95R
MK$$XYAW[&]U[IMP_BUK/W8=Z]?A1S CF#)<:S!S*IHLV!!5%"'#%A,Q*QC-D
M13(G3YX:F73")4:ZY.,[^TXHAW@-<\--*,0^&[ $P*F_R5EEO5N:'#YMM"XF
M9Y78;UQR_@+/IFMSNEYKX]GL:S_5"_E1&QCK&24JKU@I )$\!QCQ%#"IER%*
M(4[3%"(AW!JLG1ME:DNR$7(7VOZ[$31I)'7\I)_'U.XS?C-2D9>M#TCN'="&
M0 C;[>SL2.-V-AM2]J2+V>#%;A2P7FUF7R2=OU^;;87>*=]S_OSX/#<=%M[)
MIY7D=>.\?"?7?%4_M7[,SRMC"6Q>[G_6ZQE*<X)+ ?4>@%. >4Y!A3(,$"4(
M,RX1+ZS:>MPLR=2HY%?].[-(>AFU3:NEM*21V^=EF&I&13OV3L(1:&LJ"@;2
M$%WI0?:H2O_MF*9NEV(4*@L&5D]WX1[H6^E"2%6;8KN?ZA]2?%QL]$MGJFK<
MK]=RLW[S\@O]_Y:KAHQW'WB5HPP6:050 ?7>A:<4,%@Q(!!77%10I7;AE;<(
M,34BW.D YD:)9*=%TJIQ@YWE-4MV9EAL["/38BC8/2IO^.,6N"*'AR C5^KP
MA^JT@L<-S_+<.*ZDWH5^H+R>UYW9(3&760X%$%31-JZ)0<P )+122*!<4>RT
M:SP98FKTUDJ8]"(ZF7D#0%IN%6^")_8^T0T9]RWB1>7#[@]/AQEW<WA1S9.=
MX>4K;VQDW?UAB".;R4S!%)$"5)(0@$T2'!-" 2Q9F>4,2PBMMGR#HTQMF1_W
M9NY^2)I/Z,/"MX_U ;#7/;E!X(J\[+V1\F]C?0Z),%VL#Y[\.DVLSREWL8?U
MV8L]CX/EQIPPZRW5CUI(\>;E[VMC5GQ<_##=#!;?NDH!M5S/2LSTESW3/*!,
M*%F*"L#R7 *59B6#!<X0A+/-<D/GEN?"UD,[T<16@(C."+E)N F8>.ID-ZVD
M_O)L"G74B[_J_W4:)'2K@N-9L?VL6!X:1\$ZML]'P]S$I7S>A_GO/<Q;X9/[
MZS"['R0[(Q;V1-E^^'&/EIUA.3EC=G]".+L&SE)85$R44ILT4.]=I%3FQ L"
M0BDB9<7+HK ^>+XXRI_*KOGZQ_)VNP;>8-<XP?6:=LT04D'L&AC-KH&O;]=
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M.]*./@>1&;J-J6\52%H-DE:%N[[79J]&%W_?*]*0<^"*G[Y AJ_^Z2S)^)5
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M0GMH \_^T80LF%HG?03:TOS37I?Z^V_?5DWDQ<?%9E4OUC5O@M=FF.:"8TF
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MNQ%?/0SW1'F;N-O3FWQL+IAFN6F.LGGYN##NJOI'4^6_^^856%8PQ0) A J
MF8D,X%2  L&*YR4DJF+V=M?@6%,CE*]_+).OWY?/:W,(^Z%6&RD722M]LA5_
MN!6&,]PV%EDP$"-3BI'S/%Y>=MDP<"ZV63  1[+/+@,9RD*S0F382AM^Q(B6
MFI4NA]::W2U^%IMI+_AQL=ZLFC?E5SW-766$DF.HJ;0 15DP@ G"@!68@DQ
M2"&$BN1.)[^7!IH:K1HYDYV@=XD1U;/@Q$5P[8RS$)!%)E%/M)PMLFM0!#7&
M+@XVJAUV3>5C$^SJ];X-Y>BF.49LTGAG:96J3"D%9"H(P!7* ,OT3X)4F<C+
MK,H1=>L4M__XJ9'!5KHNB]EQ_1]A9[?J_1&)O-;MP?!HL79.Y\"]TPZ&&+DI
MVCGU3KN=G;W*8]/4U)5XNUQO[H5H&F[1^<>%_L5C&QK0MW%1A&*!& (5:]KK
M< Z8J=>9Y814JBQ*I KKS9/=F%-;X ^;[W*5U#M!'4Q^2Y0M]DSAL8OMCFE*
MRQB)[Y*=S,F>T#;-<+PA==A-A8=VI%W5=8@#[:[<$!K<95D^:KS=EIMN![LN
MQUL]6/J=5-)4^_E*?]ZOUW*SUC_T_]:U\>A<]/6_9=.A33__^_U"O),_Y'S9
M= LV JYG*%>%,&7Y32L@@/.*@$HAO5=#.1*"$$RH57VPL&)-C>OWI#9U4QNQ
MFPP&L1.\[R-D64(U\#Q:?"I>97:B;R);^9ORJJU6;:G5[2\ZS>Z2_3GLE4ON
M30#%WAPV^KW*!#I\F%YE(D?Z=HT[H6Z?N^"X#WX1PXTVWD<S.$('W]7P3P]6
MVD":_TIQ_T.NZ#?][5\TG_AG.C>M$F:PP+A,<0&P+'. 2T@!Q4@!4J0*,<8*
MS*V*4OD*,+7/:2]MTHF;[,G;-#I)_O)?#LUNO.?%XJ,9&>W(G\>!5/QK4Q 9
M^IOK(02;@M>OBN ]%2&*(UCAZ%$B8?BYKUTHP4IKBW()=L_Q=)]W;=@?U-OE
M7/]BV;9IW$O/,>VW?]487/CU5_W3VC1W7B[6K1L9EH1)!', 25$"7$D**FE*
MC2$EI>2*4^I6N36XB%/[5!WH=9"ZUW0_W?M[ZP_<?*>+Y/ F/_]_^,FW/$-X
MU2F-_3V,/YON!QC1  ]["!)>S'$/4J+!?'(8$V^D4/N5IKR/Z0Z0B4H2E@$*
MI=Z=*(Q );#>F- \IZ6"K'*(@1L::6JT_G&]?K9-G;\.H^\^P@.<5]LP=+*&
M@NQ6^]\#NE<W]*]!&,"</X+%W6[O'_#*!OJ1'M<M\>,;_$SN7^4?]YPOGQ>;
M>O'M\VJYT#_REK(_+^<U?VG_NZO*+Q14I4A+0)F" !.I?\KUQU.F&2I1!4O*
MK C45X"I\>H7::(,YR_)O5@^]66>6K)-=HHEAYJY6<;.<V1G]\9$/C)I:]$O
M@WN7M((GOW=_1NFFX(M>4!/568A1#5!?B([-2^_G^$;Y'CG=FYW1C*E"$U^.
M0,E1T]@]!XQFVH84*</_?W?7UMLVKH3?]U?PL0N8@$21E+0/"Z27+ KT)$6;
M[N)@'PS>E.B<1.Y:<MK\^T-*EBT[MB)*HB*<E^[&ELF9;\3A<#B7@#".N%4?
MN=/3S$V]E439!O*>Q*^;4AJ.RFO<O[:CU". MPV$D<-W3TXU<?!N&[O/0W=;
MG^YQ8#2[M6G?<IU=K1[+/(&;'UJY/%VEF;KYL:KSALR?)F]HFZ6" LF\* @@
M8HF"&&,/LDAH:RCAW \E$LKK'D?2BX2YZ8J:";#*0,T&0/$"(,^/+8Y1_>31
MX4CJ'&7'NN<DP!4+P! -#M+<:C;Z9&CU$X'%$=>Y*"8Z^_83R4@'XD$@MIZ4
M^XT\W1%Z$.<'9^MA(_6S,.LVYE_5^C$5ZG11NJM55O4M+^O/Y3>K@MTWOS=Q
M'5>KXM^JT$?0U6UF(D"6BOG"0PF&B0B-::KW(QY0 H,DP(F/%5>15<:),TKG
MMG=]R]8[VH!H%J\4FGJ335^UC*^J5K*243NSV)W0NUG6LQ"EXPWRA0[S"[#C
MKRXX:AC2GQ;@215@S],"7#R8 ^=X-KUS^$<]%KBC=M*3A7/0CP\G[B>TVW'R
M=;'\8E[_BY]IO@QHZ%/&(^AY)(+85QZ,$&(PBI7B)*1"B$Z%]@Y&G9LF-YEA
M:5ZDIF3<OQ3+-^MM'IXAMJ,-? A;NW[M#89K7=@/A\Z*[23?;4I(_Z"A@/1?
MQ\KG<,1)%,5))NI%??K+OD[%=?I87GM?LG1=EK*_3O8??DH9+^O +.,HQD$L
M"41QV1HL0##VN <Q(D@('G /6Y82Z#;QW):QH;:J &^,KQ_;+CVVGLB.H'?U
M38X/I7-O94T=V)&W "6V?U;5]?]8K_)\_^683DP[M$9V:W:<?&)'IQTDSUV?
MEK\?H\S)-_U^K=:%,4+>IWEY#?-9;R7IYN%*%4L2Q]0+X@#2T-,FA8<\R)#^
M4PJB;8V0DH2B959V=I W?0N@M)+0:;7%U6I[1HC+E7=4[*/!!*BY &^V?/RJ
MCR;*LHV4C9BZ*KAQ47^ELBI#D!Y8;*439@[KK[3/_XHE63H!TUZEI=L0/2//
M-SQ7_VST+!\>U:XL/B:,QS20D'$-//8H@1PK 7T:11Z+(C\@L57P^*E9YF9X
M[8D$)9664=PG@>RF?@;#X_I$=83,RQ<K]J'1;1",&]U\<J9I Y3;F'T68]SZ
M<+]5_\=J)7^D]_=+*>((14A!%2:AJ0F0P!C)"'H12\+88]J4L8KMJ >>V]JN
MZ;);TSN8$*=^@&0(:1!J?4B(2:8)F3ZE,AE1'K" ^LNJ??/7@JT+=V =3^(>
ML@7@ZC;-,A-OQMF]N3+JB:*/?4Q#)J! D7[9?!E#[NECOD18$:DD423<HO@A
MDZXQK*>8 D%5M?(:!E^WO:0/((ZWCQ<7G_5N<<SDJ!O$;O!)]X1CEHZW@6??
M]ZGX=:+^LLE>S/?5:\R?GU8LNY"/YE7-392O/F7S>V525<2=N1I>TICX21P*
MR'"40!R* '(4&74H8M]CA"#1R3P<DZBY[3B&+9,:<%2+?%&F^>8'U9K*-'C#
M'Z@9!'L.]0\J'DU A4V1K)%DW:YU7DN"CC76_XOP;$J@32_$J6JD32I,R[)J
MXZ+>7G=MI+DF+,PV+CJ'E=M&'KO'=OP7NR_NV$-90Z[N5$"0E(@'D%*/F(,&
M@5&,,)3*$UCX7IR03F%,9\:?W2:I"CV-N><2U>+,E=BLM21^ UOBP;VAWD)U
MG@!5(!0*C@1$RD<0QZ'4H"82!L+#V$M0Z!&^?%1KOIH UN8\[H"MT?LT'+T.
M!L P1!SOY0=0] D)/H&)Q;XZ#)N)MLANKXO=UG:>\=9=ZL3/IMMPSM-\L'>T
M/-;/'V=N-*N*H??WJQ_E9G.1E67-UH\J?UNY#99"$(0$"2%G$36UQ3#DL60P
MICR.F!=[6(7UE>-G6V=4)Q)Z7#D>$^+N)=YQ %C-0M-WI3>9)\4L4[JZ"2:4
M'A=ZWX944KW!,*(@%TD,HR!@&'DQ2WAR*)C._BVW8G'O SLI%)5)E^+HYB@;
M#]F)+F$^O -UO9$%T(:,%R_ 'MX]%V4B=LW'^/&\5KB-ZICK-O.D7CLK,(Y=
M>G8_[IEQD21*F!B9CYE8/:@;]O.+7OXFO#8S9YYR^LO56J6WV<$3[U/]0],;
M-V7WRU@H)6(1P( HK@UH+""/P@0*%45Z!\(A1[M8EVYJ;0RR>F@]Q\IN2S%8
MZ[F ;)!JF3 QALRZ*<')Y#"-CMRQ RIJRUQE0R\X9&D!:E$=/]=D; 'T+BG:
M(@'LDR%&Q'O<O(<Q")LVQ6%$*)]E,XPY=@_/T%>3<E754GF_69OB#Z6Y5@8^
M?DJ%*7]\<;M695S[,N TX$$20#_Q!<0!E]KPU >$V(M8Z$D2"]0]']MFYKEY
MDPXCI]G>K:LE]*!-I"J1+;6M!V8EC [>$E<0N[8_2_2V!7XJPD%%>151#;:T
M@QWQKC"V\+ZXPGHBO\R(F-LY;_K@UNK6L1IP.H=/'SX/7$&]!NB1RJ;8_8?<
MM/[2)X0+H5^^S;TQ:-^K[VLEJ@W)-/.[3CZO5]_5NGC:]I!D)&$DB")(D-"F
M.TY\&"ELRG9PQCPL.<:=+A2&$#&W?:+L/JEWB)I*R[Z=@^31OC],A;+CK<(>
M8+ODNX$(#<_5ZTO =*E] R$ZR 0<.E:?4K8']7)K!7JY*39K9?I_")-$G&4;
M=G^I5&XZ2%SJM_?F;KW:W-Y]37\N/=^+N;GS\Q)3K3&1!+)$>="G,5$TH4PJ
MTKW<[4!JYJ8 #\M<LYJA!4A*ELKV5J(JZ6B8 HDRCD3CK@6))@(4%6<@3W_:
M%(D=*M,.MO64DG*L1(\*F.^%5'$#:G9 Q0^X+(5D6 *&)[!E"GR=5D@VU7XG
M%-94%8$G$)IE[>"10&ZO+SQTD@EK$(^$QV&=XK$&[>?DWR7%-LH=_)46=]^R
M%3>7"29DZ6/V?5/DARZL+R;:QAQ:WK(\S7=9M-41YF,FUN:"^[VJ_KM4%#,6
M!A&4G&.(I8HA\WP$J6(LIH0FOK#J*#()U7/;>IL9Z,WB%#\TXZ#).:A8?^:X
MWG$/2O87S?3VK6N@Q@"\J5'HV%UKVO>IVPW%[-X2Q]O^W%X0ZRN.204VZAW(
M-)1/>DDRJ3".;U&FG7QHYZTZP69?33[!OF)42:C/BQQB@3B,)%50Q8D,$NDK
M:E?QOV6NN6U3-:G&B],O=[(-V&Z:?R2X7%^+G$!JVSG*3?W]#K XZ@;U?+Y7
M:NMTEO'S_9G._\3>&?]5J(QI7?0MR[5IGR:IDK6W/0Q1$H4<^M17$-/$Q&H*
M"CT:1I22@ :T<YVYL[/,3U=4A/9PHY]'\F4_^2CX.%<.7:&Q<H"_R/I@#_?Y
M&29S8;_(9--'_?+#_<R#"_F?35Z4'3=N5K65HJY4485]?%KE^O-W++_[O%X]
MIE+)MT_?<J6-E.OORG@#LML+$T>2%JG*+WA>M@Q=>D+%W&2A!$P;%Y@%!#)$
M/(AQ&(8T]HW-86-7N"!R;DJFP2,H5F!=<PDR58![4\E-?VK^7V@^P<;4P4TS
ML*H9!&S'X6]V=HR3-Z"; ?3:<G6L'(]$NF/0E*FJX_+>&"9_-5\;/D'-*.!/
MX,VW2LB_@AV[8,\O^+OF>$33RZ5 1K79G! ZJ;'G$NIC*]'I7'VB_YBQ6,O(
MDJN-R2[2?YAZROG%IKA;K4T=L(]9HW-H%>&_I,+#)*841@E1YKAJTH-P#)&/
MF(\0(1)WVE8&T#"W7:,BO2QB7Q(/V(YZLST4>_H7@+7G28PFI@ZWF.[!=VWW
MLNI 7+*P %LQ7.L/*C%<'(CAIBF&%])51A.#31"A<W%,%4[H3"R6T86# &V/
M,^PW](01AX-X/XP]'#;4L)WILWXI[U@CNK&:N@J%7(:>(+Z4/D1<_X-]+X%1
MJ"B,J5(R#I4?HD[%O*UFG=ON<[3<:MJ;80';A6?=H[JS(.QVF]'@G79_>15D
M^VT@HR'\.EM&?Z1[[Q"=$.NZ)[0/]BJ[0"?^SNG];C\>I33PC1ZE[ I"/11%
M2A\L8M^4<40BA!'7QU A0A2'(:*<)P.* ]?SS$Z;'Q?!-81:-5=Y"=B.UV+#
MX7*MG?L@-;1B\#$.+FL&[^9ZS:K!QPR_4#?XV>/]E,+.Y5$6/S$-FY94XH!I
M>P\J$QR&,9:08T0@#0CSJ!\P/[1JO?=\BKFI@LOTISXB[9W+98VJLE^>G2(X
M 68W'3 ,(L?+?^^.+:FK6LV-M^[/\S[JDC\QS:2K_3R;QPN]Y<E^:]RT9-OH
M=?3AGTWZ_6%?S%XR@AF/$.21TH<ZS!AD<40@3ZA(/)KH#ZSB8<[,,[?57I,)
M5$VGW2H_!V>WI3X"2([7^PZ?'8D.^@.\ ,.H2__<7).N_Q<8/E8"+SW>3Q-\
M.E$D\V.FIU%Y4=8[:*2\+B..0R\QE<E4Y$',_ A&4@J(HH 38FXGD)5ZL)E\
M;CJCIK,L!6.G+JPP[Z9#7"'I6+$8LHWOX5GAWAVZ5<F69E[\>!JG#VBCJB$K
M B;537V@.598O<88&N.[;TN[;9)<-J+=]:YM>E0^ZU=Q7Z KSS</W\W_Y65D
MYSZ4E7M$'W," F-NE![A1NDE" 9*\##TN1^$5@U4'-(Z-QU9%;>X+DG=%[+K
M&V4\OF@[NF/F(3#7+IU&E//)7N-54_&:V<I=O/<6&WX/BA7N69XH5MJ9<!S%
M6H]/[RO%:CL#_GRLM[LI>UK1J^S6U)(W7?WVZB4(<:B(DA!A1JOL$NYC!6-"
MI?2$SX6P<IN=G&5N.M\0"<LN"X9,2\/X)(P=+>"AX+@V=0TN18V+UHDNM&$K
M"..:KB=GFM9&;6/VF3':^G!?+UHS)]QT\;XM;^A,C=<KS<.9KQOQ&KFQD3\6
MZB%?2GVD3B@.33F3P)3^)I#Y@D L)4>1P/I+J^;H8Q(W-QUS5(-A3WU9&+GY
M]W5QITPU$Y:!PQ_]71X]2^XL[_9&E7I7#^'KR-*Y6W$:,?9P18Z/]\C^RQ$)
MG-CI.3ZTSSVE#N88V(SOW>I192PK_I5FZ</FP<2:+Q&.1,B"$$8D+NOU<1CY
M!$$4BB!,/")4T"F7L,MD<U/AAYX_<X-8D;P 6Z++=)">#=5.@=VN:<>&<%*_
MZ03H]6PS-Q#%*=O']4>S?S^X%G@Z]WD[-<;K]&]KX>9L7[:VW_0SRK<.@?QR
MM?Y:M1I+55X[ ^2W3(^T"Z4KDX%R=7^_#'F0> GW8!!&$<0TP# ./*V4$^X+
M%GI*!E9.WEY4S$U'UTP +36P9V/G])-@8QC91XINL_P,+W8V=3^A=3.>G8O"
ML:YW(@5KDW@0BJ/:OOTHF=3('036L34[;+">]VG&OUKZ_TW4@=)F<>D]W=O*
M;Y_VCS1=L-5=3_ZGRLMZ>+(NC7>S,A]=;XJ\8&6G]+]4>GMGGGE4:W:KOBB3
MRJ\_?[?*RNS*3=6<TU_2D*#8UT8RHM*T1-/JF2/?@Q%63 92((:M_"+S86UN
MZK[BK#Q[[\K#:DWRJ&R#'N<#<=<;OMD0/*-]IWD)V(3EP#'#G]HN"[?P+$#C
MU?K0>+7,Q_JI/4P+4 ,%MDB!'52@@579QGG$2\39R7_<.\?YL#?M%>5\^#YW
MHSD_"L\9#,W5ID]P__W]E_H3_8^A[_=?_@=02P,$%     @ T(%Q5/"GM]QR
MQ@  XC<) !4   !X9F]R+3(P,C$Q,C,Q7W!R92YX;6SLO5F36TF.)OK>OR)O
MS>M%I>]+67>/*;64R4:5DBE57=/WA>8+7.(4@U23#*74O_["#V/?=$B>$\=#
MD[5HB0C1L7P.!^!PX%__Y]>3Q4]?<+V9KY;_]B?^9_:GGW"95GF^_/AO?_K[
MAU?@_O0___U?_N5?_Q^ __W+^S<_O5BETQ-<;G]ZOL:PQ?S3[_/MIY_^D7'S
MSY_*>G7RTS]6ZW_.OP2 ?^_^T?/5YV_K^<=/VY\$$^+F=]=_\39EQB2"3XJ!
M8B6#8]Y X9P5G[3P*OZ_'_^BHG%9% '1&0[*!@;.)P<&=7'.IN1Y[CYT,5_^
M\R_UEQ@V^!,QM]QT?_VW/WW:;C__Y>>??__]]S]_C>O%GU?KCS\+6OKG\Y_^
MT]F/?[WU\[_+[J>Y]_[G[KL7/[J9W_6#]+'\Y__]MS>_I4]X$F"^W&S#,M4%
M-O._;+HOOEFEL.UD_EVZ?KKW)^K?X/S'H'X)N #)__QUD__T[__RTT\[<:Q7
M"WR/Y:?Z^]_?O[Z^I/K\*:Q/PI_3ZN3G^@,_/U\1'(C4[I]NOWW&?_O39G[R
M>8'G7_NTQO)O?_I:5FM:4G N=@O^C]T__/ERW<]KW!!4.C[?T!?._GU=97\:
M\.L6EQEW?)VOL%BE:S^TJ%)=7?S+18BXZ+XZRSB?=9_Z+&ZVZY"VLRB58XX%
MD,P%4($P&(V,D"-ZU,9&Y6ZP7$G>$,V=$C:8_OQQ]>5G^N"?JQC^2]4_PNZ/
MG3QN+;F3S6&TG^^[#_2S,VX"-RHR*"H2Z=%KB%DG,+%XX[UD,9JC2;^ZXG7*
MK^KUV3K]M%IG7)/Q.%\RK--M'5\#[ME/_/PYK.F#('V:+_+YOZY69 B=;5<#
M2&^G&B+W3S\1UP77:\QO=IJYE[F.LRV95.Q^<@BM/ULN3\/B/7Y>K;>S5$I)
MUBC00DI02GGP3 :BGUEEO2W6Y<&T?W7E7B@0[:/@8&DV@H9WN)ZO\LME?D$G
M\,P&KHU0 A2!EWXQ KQ% 9F$9#)*&= /!H=K2_?"@VP?#X?+<V) /#]=5TF]
MFF]26/PGAO4Y#TH)F5024&)2H++PY%4E#>1#D2=5M.?N>$S<MWHO6*AV83&(
M5!LQ%1_68;F95]F?F3L2B&4N<;#U!%0^%_ H!-AD57(A^Q2&.SQNKMX+&;I=
M9 PBU8F1\7*YG6^_O9HO\-?3DXCK&6:M0RP:O-(9%"?:71!((.>2!RF0 JRC
M$7%SU5Y(,.TBX2@I-H& ]_AQ7H6PW/X:3G"&)K%D90'E8@15I(' N()@O-'.
M!:5D&@@%UU?NA03;.A*.D&83:'B]3*LUF;).\+^1_/'YZG2Y77][OLHX,P3>
MZ+T"&1%!B8ATYA4#QF9=N$4KQ5#@>)"07EAQK6-E.%DW 9T/X>OK3.*;E_DN
MI75F$;UGQ5,(!9%A(C^:& DQ1V Z.,&32%G;@4!S#PF]X.);A\L0\FT"*,]R
M)A5LSGY[,U\B)]%DQ16%VQ*9 86!V!$F@N?).F4C!5QQ()#<L7R_M!9K'2''
M"K91=(@9CUQ[)33H0K&6(B& 0TX.=D@V%A])S6$T=(A^Z&@XZSF,8%M"QW/Z
MX]OUA]7ORYE)L<12./ DB7!T$2*)!GS4.6'.5C ^+#8N%^^'C(8SH4,(M25<
M=%[4V_6[]>K+?)G(B0H*HRL(ME@%*ED#CE5W2BN7@E;<RH'!<8."?@AI.#<Z
MF'A;@LF[U68;%O_?_'/G:6M>M PV@2^)@C17N0C: #IF9=0Z(3\^%7;_^OT@
MTG">="#13IU#KSRL,71T,RVXTD& -XS.16XT>"T*8&#,>Y\#.GDT)*ZNV \$
M#:=$#Q;?Q&JO]1>+=Y]6R_,$GG&%>>,3"*PVC2L#(84"R2=5BU&XB<=;@YNK
M]E-_PWG0H\0X,01^PW2Z)OAR$3_,MPN<9:TR+R6!U,'4(B,%GLXUR"EGII.3
MVAU?5G%SU7X0:#@!>I08)X; AW6HE6Z_?3N)J\6LZ)QU$A&*-X1=)BAFKD&2
M4B%(Q6-,J([6_[4E^RF_X8SFX0)L9/.__)H^A>5'[-+V@N="[HD"P]&"RA3Y
M!$M_XMR[(E5,UI?!#,#5E?OAH.%4Y='B;"),^ <N%O]K28'P;Q@V=*;EUYO-
M*1UJ+"J.P@=R9[TC7".YL\)G8*&081,RL7"\87B0A'ZE5\UG*H<0<!-(^8_5
MXI04L.ZN@->;F<U!LZ(C2)<9J"(0/->I@IYI"G:<"D/=D-U8NA\RFL]2'B/0
M)A!Q5C6T*PBI1R(IX;3RH:2(Q4)A7((2F3 >321_&%TB2E+2QU<9/T1!/WPT
MGZL<0+Q-P.3UDCZ-Q#'_@B_"-IRQ-6.\D 1T  *V(.&$ %%8#IKS((/*N>CA
M;MCOHJ ?3)I/6 X@WHEA\CJ5];/3/*>?>+;=XF:GA%>+\'$64@R1HFCPRM$I
M:8N $%T!KR,6Y3C/\7@WY/[U^T&DX83E0*)MPHYTQ^3SL,6/J_6W&7IABQ<&
M6 H<5$H98N(97!$\,:V4+T/==UQ;N!\D&DY?'BO,)K#PVTE8+'XYW<R7N-G,
M@H]!8W9T)$H2A2@&@@D)0DG&6Q:$'\!*W+%P/RPTG,L\5IA-8.'E":X_DG_T
MU_7J]^VGYZN3SV'Y;<98)JGH D$D.O^DU!"95\!BHA#="9WR4(44=Q+0#QL-
M)SF'$FX;&/EZ6<"^>_LR*_7E+:8":"(%6=%%<%Q;$"EAM)BL#$,5Z]U>O1\Z
M&LZ"#B+6)J#QVR=<+,Z!K7W@S-@$0E7J4Z5>&@)V$<17=(:9H8KSKJ[;#PX-
M)T./%&430'AW&A?S]&JQ"MN9%A)59AF*2AH4%PP\%PJ,D!PC<\ZDH4Z/*\OV
M>UW8?,KS4$$V@0*"[TFM45^E?_[VB<2V>7NZK;T,ZIW/S&D3I90,; H4,ZE"
MX9**U6,6FI/3I/E@6?&'Z.B'D^83H(.)NI&7AYO+9PZ8?_GVOE*"RX0?\.OV
M%_KA?\ZR]SDA;01C1 25LZ<XBZQCBH:.2\>]Y\?CIS<Y_6#4<)YT',&W88:(
MK758O%YF_/J_L)ZF(KA476R/$E11%*$S1<84I<3 E(MRL*3Z]:7[H:3Y-.DQ
M IT8$<\(X[GBO,O;62F3=03@8C2)@20"07L.6=:^0@HM*G$T$JXMV0\!#6=!
M#Q=@(R?+Y</\5_25S4P3G2ID"R4X1>"MR7W#+$2MLXLA*%.&:X!Q8_%^:&@X
M 3J$4)O"Q2[RWC&1.,5=2%YV5DR \I'<)E,$<.L$\V3<6#X^JW'O\OVPT7!"
M=!C!#H:.?_WYEB#?T!<.[7/6W02]7I85?;5^UG5Z^[4\N_49@W0_>YBR(QNA
M529F-U>X@$HVD7.>R/Y7'T"I6KCO> ;$DH5TY"8H_CVA/+C"44?_[NZNJRV+
M&$2,RD#.H=:'Y +!L *9*^Y2XK8$=OS!?[G@-!W0AE/6-0_@0#E.[?GMR'YS
MUCEQ9C'3060,&!<I*"[.0O 4U21THB3)DAO@[?"-1:=I@38J# Z29QM0>#5?
MG[S.LUR\0!LT."\Y*%?K3$/,0'YLDH6$X_3Q9;O7EIRF\]FH,#A EJV>[,]7
MR\UJ,<]= B0L:NO5WSXA;C>''/'W?]A G4Y[T7KDH7^Z@8\A?)YU#SFK2_>V
MO)HO:;$Y^76KW975!9 4XVBX=[3Q"[G^4I/7+YD!Z4-@PA;'S4-><PF;V.G[
M;-%N3_V,B^WF_"N=@('QLTZU_V,?Z@ZU&N=K/-ML2+@7O#J%LEH]LGG:$]QE
M )=C L>342ZK(O)#K[X.Y_4Z'=-X%Z.AXMR\#"#T"0^:Z]2?E1)>,.&M$-@]
M<]&U9)V<)0B(#K)G9$"+8OK![/6QR+E!SK0 .D:_=T+E&&$W@)CG8?/IV3+7
MWU[^U^G\2UC4O/RS[?.P7G^;+S_^1UB<XLPC5\HY!)WJVWF'#$*,I'(F0M(^
M&9[T* CJ15X+B#H*!JNQ=3(AT#I/\#VIA%:O7+W +[A8?:XV_#5Y$,M:__P>
M$Q*;<8$S:V5(7D=@IK[(Y,C!>VF <^,E"OJV"]_S@_9;<IHX:7CTC"CH!NS4
MNS5^#O/\\NMG7&Z0V'N[_83K:]*;I2)X8:8 UTJ#RLJ",TJ!L*D8D1D9]H?N
MV@ZW4CV(FR8,&\]&#:V/!B!VG7C40H:H&,B2 R@C,_@L%"0O5$&1;8KC''G[
MPV;P&[SQ8'.XC \'R&H;%@/9H-5G7&^_O:/8=TN0KX=S9U]_Q>U,1Q-*00V,
MB*X/RAGQ0HB7*M#9+*Q499SP["&J6CC;!O&U!Q-] W;FKZM5_GV^6,R8M9PY
M,HC)"5%K[ C^LI! 0N#>&B<Y?ZB=]>&0.:>@A4-I$'@<)-(&H/"60!WJ&]$W
M&#;XO@Z?>EO^3N=I%<U,%6.DMQ8(Q[I>AF:(6M)QZHU'4JU4>9PCZ$&R6CB2
M!@'-<,)O 4F7[M>OJV4Z.V"C*)P@7V/$0DZ^$?7R.Y-XR+WW/D3#RCCYT3O)
MF6:FPAC(.5K8#2!F1_^,!9<XRPCT6R*<9PDQBP A>U2,!?+!'GK.?:R?.\UT
MA=&R@7N)LP&7]LT\Q/EBOIWCI114,%Y0< 8\4.RF FFO2Y^'&)BCTY4G\5"1
MVN&(N(.8:1W8T6\;CA5_ V;D"@LW T7A4V&)O"_%=1?>"8@U': ,LP%]G33S
M4,7K($!JZO+A:'7?#Y]C9-\ BIZE5 =+;-Z%;S4[>9X@4*88.CX9<!-%[9GB
M2#B:D<I]LCIG3U\>YW"ZDYYFT'.4MF\>7,>+O@T K4]IU5LRFD7%M$DN@_/5
MD;>*UU:_BD[D$"/S@HL'GX8>A:&[29KV4!L/1@,HH $D70\+S_DY[^HTLU%[
MA5X"*A=!*5G[SM,.,2D%@=(I^> LWJ&"\IMT39O*&0E3 ZJB 6"]62T_?L#U
MR0N,VPL6>.;HR&5$7U.7+@OP2DK@CB%7-FG''ZH-/L)%NDW,M(F=D2!TK-!;
MP,UMDVJE\<F(#%IB=SA'<,8%D+D4[PU++#W4_GE(SWK:I,Y8J#E.Y!,&]ET5
MP%70_[I:GK'P>ID6I_6-=CVJ,76%U"X6AIKDPS#4$6ZV:X./@#*1AR>*T7AC
MBL ]Y1:]EVS&^3DJ AM1S U8G'O.W2NYSAR%TDQSX+PV$@I,D4]G"Q2CLA;2
M1Q4>ZK,QN!>T9Y+Y,1RA02+\8371 K1JZOR*E*YRXG4JGDGP+EE0,2$$:S24
M)))W*B%_L#'QD9<5=]+4C$LT#)B&D7T#*+K"Q"P5R;LC/B4A22+<@Q-D6UDL
M2F'12JK1T]7-.$%#IQ7WDFX#]QFU-<U\V_46J16TJV6UG;A,E15KN4D^> BZ
M>H7.)/"1%0C*".^CU":. Y0'B)KV^FMHX PE_08L3-?=Z--J00K8U&*C[;>K
M]6]6(@FGZ$#AHRD*R&A:*!@C!BN3>7#RUC&/CNZC:5JG9_1KLH&4T0"LKK3.
MVE7Q"U,3HK6]7@@D%LLU.)WK1#*FBW;9%3.>4;I*R=3ONH;1\!T&Z6!Q-P"7
M9SEWNXCV4YCGU\OGX?.<CLHK;,U<$L*:F"&$^@K6LP!!,DM_92&+4@+B2%=D
MWZ5MZLO[42 UL$I: %E*IR>GB_JLMXL0:B/0-7["Y6;^!6N'MA-\L]IL?D6R
M[Q_"UYGC/F8L A#I$%?%>8A&.7#<)B^+(T=AM$O9?0B=^E <!WXC*JL!++['
M;9@O,;\,ZR7YCILK[+[ ,D_S[2Q)$7A!3HZ$I% 5LX98'RZQ2 Y&%#[[!WMI
M' Z_[],V;;I@),0-K)(&0'9;4#/.E!!E9[)K8W1TM7V8 NW0J,0"<3/.$^G;
MM$R;2Q@)1$>*O(',PM58>9GOX"<8H5"34+A+Y% BDQ!J+SK!DC))%)4?H6SR
M+LJFMDJ/6$-YM&(: -JM[LK=X,$\B]H@*FZ!61](1B: 9]&#0>]*I@W#[4.M
M@P:)%*\2-+6=&AE60ZBA@;/NP5[=R=B2=&:0>:C.H0W@B$SP">E;(A<Q4GGE
MT4W21TN)/CZN#E5(B^!Z=KK]M%K/_YOVB4+#=.(:=+:&9"3JQ-04P? 0N([*
MZO#0G*\!L75)5"]H#3[:9SIH':B.)]<L[5TG_T^XG:>PN,[%D9W3KG_RN&W4
M'N#B,7NJ266,RL%!O=RK+??KC"CTD+,-26ORVO4XA\)C]%2[LD5(W&_7W9JY
MRPV_PW6W:V:&UQ!$"\@IUL8Z=5R6M1Y"<BFQ5(11X]SO]"!NZBS]P/AYP((-
MHI[&ST@TH9 #2:%(\:7.$L\0762 RF26A/+"C%-%=>P9.>V+NX$0=I0Z6D36
M54\R>"FT80'(<>3$2U8D(UD@*5L*A< BF7':D1P__^C'P=:A"FD17&?A+[(D
MN:UCRX744"L/P?/:O(=+7;R7I3PXP6*:+,2TR:U!(76 &IZ".W\AR,VJG-6\
MTG=#+2*Z<K]5;[:.=>_W6&EP=_]0+@=R_W?7@Q=$7 #46G*;;,V_.\]K8_U0
MF^;P.C&#"QY*Y&J<)VWW$'3\)>(77)[B*]JNM0:M?N0_YMM/ST\W6UIN_?+K
M>8'^9H/TOUSO2:/R6+PS4"@B!N6] ,=$[4N>O$-1IUZ.\Z+F &*G#0*&0-'M
M.\9Q-=; @7I1R7_6,O&RXI(\2R43B2M31$/G@\O@A2='P=IHBA$%\SAWC_>2
M-&T,, ; AI%^ S"ZN\'K&5<S%X7!;$1]Y$8BREY#R)H43WY&B%+%A\<@'V/%
M'B!K6GLUD.IO6:RA]-  J/Z*2Y+1@GAYED_FRWF53VT7?,Y.0N4C2C*UC*PL
ML<,A<HJ.NZ'QA=EB_#AMQ+Y#V+1V:AQ@#:F+%J!UUIGQ]<GG,%_7/5+=VYD/
MF()E!I35!903""&@  I<@J"06',^3FO#N^F9-C$Q$I".EWP+^ GS9:7[[?+%
M?//Y++1^6UZ3>I8?YW&!9WW73 PVU/XTW%%\K:1@$(TW0!Z#43PY%N0X2?N>
M!$Z;IQ@)82/H9G_(^1WDEOBQAMCC^.HSQ4OT]>&2U#7?(B0%&S$DL,$'+B*/
M?*3ZP%ND3%MV,PZ0CI-W S5;%PQ<5F#/5$Q>!9M)H[QVI48/$9T QEPLD7 O
M<)R,PAW$3'N^C1K0'2CQ!D#SZVJYNL[%^32%<P%Q:96*EH/E==8Y2X($E U8
MR8*2403NQPGGODO:M,?9&( :5AL->$ZOEU]PLST;_T+LT+&,I"?B@VL9ZMS$
MXDN=L6P9^) \&)8+6=H@_,V>+X.E>^^F:-K\P,"*7XV@A2;0M*/[/ RU,9(@
M)(.0:CLDYA-X'FH9+!K-?,S"C=.LXP8ATZ8 QL;.X3)OPH]^18%G5[SS+/^?
MT]TN>%O^$=;KL*2P(%JG3&0>1$QYUV'493JN;>(R.2FD&NDJ^4&RIG65Q@74
M</IH EXO<#W_TB7'KD2B%U^KDV&DT5)B;>B>M*M-)VIS)*1 M-1R6,54'*E-
MU7=)F]:!&A=FP^JE@<.OLK&I?"!Q\O)KE=KI?/-IMW]J][=93CQ)6YO]:XHZ
ME,^:]HZJ77.X262ULWEPKO=QZ:<'29LV7S NT(;52P- ZYYTWRNSF3.V>!L%
M%)OSKI(H8$P0BK8^<L>E'J=;[,-T3?MB9UR(#:B1!O!U/R/<FQ#0!Y"H249:
M6HA1"$B<46R".HH\C@$[#E6C/=89%U7#Z*&!'-9E]NV\=F>^/"6F+JO;?L&R
M6I]UIO@0ON*&[/0ZD/KFR[#^]GJ+)UT?PEKULUHL.GF<1<@R\2 ]6BA.&E"I
M%!(%<[71M^$Z:"_4.,[;B$SU K5[FJ!N!0O-; MB\4R^O^ 2RWP[TTX+HY,$
MIBR)-TJ*X)F08!RJVEZA2#E.(<4]!/6"HW_*<#Q.!RT<V;B]<L6A"?D^N@(B
MJXI^KR#ZY"%;QK-W5D<<QP.\1L:T,<4HV?^#I=R M?F )Y]7:[*@NX87+^9?
MYAF7>7.9Y9FED(M2))&0NN>_J;:!HH ;LS->Z")+&>?^^ONT31L]C &F@?4Q
M::ZM:W1_@Z'W^/ETG3Z%#;XM=,Q_P?6V5GN\.R=NUP6/Y<A*286,-=;Z;#JW
MO6 )DHL6D\C<E!O3C>\9+7#(ZM,&#T."ZG$4T$0^]YH1?O8ES!=U(-F'U95'
M4&>=?7X)FWF:>9YK0SL.P>M$3B&7=:H"_4D+M+8HD?5(U^/[$3JMTS_Z<3FP
MIAHX4,];W9V_.>^8J)7>\\4I@7WFHJ,0/2<( F-E)T ,61-,"EHF?1GK-/T.
M8=.Z\V, ;4A--.#,_P/KE'',S\ADAX_XZ^E)Q/7;TK%VY;'P32[1BI2P<AD\
M X62O 5'&XDEKI&E(,)(>#N,WG[U'.PIX? 1%-< /*]'0<DS%V,QD&0EWJ;:
MC(HD1TZ$Y5%*8?U(*>'[8\T#KU3NZ9+[:K4FO9X-;DK?/JS#<A.ZB4VDP^YO
MBQUL+QSWR[ZZCML8=:[EKG2.Y4#",9C!R:!]B-'G,$X1U3C\]-NR3^O)W_2*
M;V!+WR& "U9XS@ZUI !!I_H>! 4XX@&\K2^,I(_%C9.-?("H?D!\4J7*0ZE@
M,,?XD?HXW!N9OL>,>-(-F[Z,%\)=O5O/^VI?D\!Q/1\&I&K4_A!C26_X5G(/
MM8P6(?&L%:12YQX:9\E.)@:,L<@T0ZNL&\7"]"+O^#[B9XM\J-J8<70\%PIM
M+<O$;#)T,D0MH!CC&7=!<#;.?>5U.III$3<0+FZW$C]8Z@V<QQ?4/U^$S>9,
M2,^^SC<S3Z%L\C:#8253K! R^("<_BK0<I$PR'$Z=MU+4B-(.D#/]T'F**$W
M@)ZK]+]8G83Y<J8H)$N:!.$,A6JJRX5PK@"5U,*S8/58/01OT=((7HY3\DWG
M[3B)MX"9^QR)OV%-8LP"ILR$T!!4O8JJK0^#-AI8X-KX&(BD<;+HWR%L6C0=
MJ_=;,<!P2I@04]UEU)T.Z!D?&)5SD>*D.ET(E%,(CD(GT+P8I9W+,O+O>>[?
M6V3:)S\# 6-0239@92ZL[\[3JS'O:EDCF<X"6^929P4$9@J?%=EB"GL#9!]U
M4FA0Y9%]F[O(:J35[8#^S='";P!)-W@XVV.HN7#*(OB,#!0K6.MB(U DX16W
M7J61FJ3=24XCGL[QZKYYW7:T[!L T&U;*DT0V=>#U2D2B71$>^$6,(D2DXQ&
M\-&;(;?@U R@WOO[TQX@ZP; <L\XSXM#6*LHG0<*$2QQY$@TF7:51X%$C0A\
MI'YZ#Y(U[;DU/(B&TT$+@/K^@,XSQKC+GLYV"8E[.O$SDL\?> *NM>8JAZ+5
M.%:I-XG3OH4> 6BCZ*8!T-V<T7G&A8C9Y)P<I.Z9;4B2HDKD8*5W0EMC2AHG
M-W0W/=.^>1X>3@-(O0'L7'B3;XB7[@W.C)MD4C 6F*D]Y9E)X*.O557(HK$Y
MLS+R3<8%+8V,C!@P1CM,S T A0SD&L,&7^#N]]?+FV7)J\7BU6K]>UCGF0K,
MB-S%'JXVDW"R-I-PE3<7,Y?H1QH2O@^5C81Q!R+B]GNG<=33 /1N<')[N@IG
M,C@;(P1N0\V?1HA6,2![:[VDD,/;<?K)?H^RR7OUCX2)AY^\'*>@@P'W&=?S
M5:VB6&_'@-WSL%Y_JU,(3E:GR^VS[78]CZ?;7>7[;GC?+&?)F)8.(M-U?*.D
MLQ^=!5/0:LD9-WZ<GD9[DSIYC_])@#FP"B='ZN&O@R*C6";5B-HP74N3%474
MLL[22U$G<ETQW(@^'_MYUIA%?N."[W&T<NR;K0\#AA!$^VXRU8O3-6VO=SMX
M=Z? K_A[]ZW-+(1"Z%%5E,Q34,T$.&4\E)R02PJ/]$@UT_WHF[RGZ>-8Q!&4
M=; 9I%T05^."L.MW=\E6B2&FZ 3%Y8QV&85SX&ES 9+;K62DF-^--=VV!WF3
M/ZR?%()'J&I2!';F?F?3-UT'_#OO]:^]CMSMMEEQQCGG/23-([&8R-)''<"+
MJ%DV7&01>QW"AZP^^</[1SB$1]?*U,4X^S'8[;"99\D6KPMHM R4"QY\U!(P
M%Z.+<$DD,0+JNL4G?YC?'.CVUTG+Q^UN"UV5P!5G]S=,]*/;.=;'A<*9&$U-
MN8>:2J5XJP0#)J/DW"5GW5@50<?0/?E3_@9\Q&&5VT!V\2%WY/O,*NV8C<&1
MG&O.-A<!T9&P,X\VFJ2#Y_S1/<IA@#QFJX#I/<UA5=L CK^;A(U2:@S2@8C>
M@=)<D$<MB9^8K)>&\1#'*6<9)DL^9L> 1M+D^VCHR.3CR^4P77OVS[ F$[-U
MB?SKHJJO8XE)DASHK)SQ*2?43RE)SG^XZYN!==@(4&]+\_8+Q:L"94ECUL)"
MRIS7<8D1/(;:X#FG[*/4/(PUXF0O0ALI8Q_K%GLX)35P1-^V^$YP+Q)W@+2)
M0$4*_&*2!8HI2GB!VKF1GDBW?E4]H.)O>H5':6'R2[]KSNTU <TB1ZMMR, P
MA3HWT=0^%62;;4@B:9?T2#U[;M/2V@7SB' Z3@]MX>F^J/]9(LYV(UXWL_HV
MC?/H(;C235HT$&5A@*A82CE0:/2HMRBW26SMAGED] VNM1;.R@=B]VM\>7(V
M>-86"N/DBYK:92WF""PS$544)KNQRE7[4=C:S?*C@_$XG361[[YL!;;YL+KO
MQ4I8__/#JOZ*VYD.B45N'%BGZZM@QL SAQ3/*R699SSS<5XL[DMI:Y?.XZ%S
M5!U.?1-XR=R]O+W'5%^OS\L\A=VL]K/A?]_>S$.<+TC4%.#C^B0L+UZ7SEA(
MW)"<@;S@V@922(KF5 :D[>NDX%+$&W.L[[DM'(G UJZQAX=O,^J=&N*[EB[+
M?#ZR\OX;JHO;U2L_36<.G3".')[@6:(@K_B:*S-@G!$8LL2 OA>2CZ.CM2OP
MD0#[B,IJ'Y=G%TYW<BIMS#+9#!J- )5T 1=2H8#1B)B=XJCT0+!\@(S6;K8G
M0^50JFHW@MKMN^Z;;S]W[OC+K[A.\PWFF;#DVNA4Y[%&VG8V(P1F'3#KD2=.
M+/.Q.C;N2VMK5]@3A?C'Z[%=I'9[\6X&%7*FBI-@??;$H*>30M47VE$S%Z6,
MR!X5J/>3VMSE]C3A__%J;.*8OV\;GI\15UAC.NEH+3CG,R@6!3B>#4A-;&JG
MN4C]!B#MMVYS=]9CGN3C:*-1H'7;Z#9G9-9SD$$![R(XEQ.X;"2(%(+,PF@K
MRC$XNWO9Z2<&3 JS 731P+';)R'6;:A((LZU=P8N-YV2W^,NF8N_X?K+/.%.
M*N\QK3XNNT_9E35;%XJWQ0+*>N60.8.H0P+AE8P6&<LCC94>F[/IYQ0TE35]
M-) TL&D>/'A>GGQ>K+[ASMMY=_;B\]TB+"EX-);)Q#7Q59N>E\IFX0:R9,'S
M(A'S..,V#B2X'\1_Y&NK057:+G*[77@OE[. 02B?2FT]ZT"9FI/C$<%I)E3R
M2:B CQYIW4MN/]3^$-=9XZNS7<SNMN9[W&S7\[0]>S[_K(JTFZU#XBTXWY[6
MYWQ1^)1TCN!LD/42+U,,8#WHPG0@@<?L)TAI]2&]'Y:?]-W6-&IN%]?=YKV+
MW[^NZTR^4!SG&0V$[*JKI#A$401HEYA66MLX4NG\0>3VP^^3ONIZ/'4V@-G[
MFF;V':?WUS!?=A.#UQ05+#]>%=3%1+2HA2\I%"BN-F34D8$/*0/+0JH@M4 <
MIYCK$9CKMQ^>]"5;JU!I8/=<GZY*<BW%>E?]+CJNZ/ "QQ,'#$IHQY+TZA&&
ME_=#Y ]QB7:X^!O SNT7"YJB3<>R >X<N?&V:'#%2,A))2V"C"*-%)4=]&Y$
M_!CW6T>IH9%W<'<\5T"K'7?2D>ETI8XA-203IH#%HKPRM279B/7\!SP;>=+7
M5P,IHB4X77:WRW2.O\?M?'U7(#>33G':)"0I)@,H%<CU+<C)]FK+K>6Z.#8>
MT'I2V4C/Z3>#/*@<33V-M1_\+HN[NP99(H_,=_4&=>!R%A"21Y"A2"8PVCA2
M>+$'D=,^%YD$?_LK9VCX/;FAV+N'^)](EBDLKDNEE0G9UTE\(N.R'Y#KH\[.
MQL*D<U&!R*6Z E%"I! %F+:!^1**QG'>#TTQ.[N88#T/#"(ZLC!<>O!*&$C!
MJR0QBAC^F)V]/RZ^,SM['ZFW$ 0_./<N,UY2$0E*JAWTN!3@JT].L3S32DC&
M\U@QS+$S)A]KAO9>^MYKQN0^PF\ 2??, A+)%!\XZ$"*5LEGB,D@:&EY+D)E
M%L89(O'D9DSNI>Y^,R;WD'T# +H]]] I$YD+&8RNOJMS'D(V 70*,I* &/DA
MHX#G:<R8W$>]WYTQN8^L&P#+'1&5YG1D4S0-4G9CQU(!A]Z"%MECX5$[/T[V
M_\ )6X\U!7F0$^HP,3< E%Z5EI<7S?77L$P4V&RVFUG2R#TF#ZQ$#8KL,07/
M! !53!&V,"QQPE+;>ZANY) [$#&'%,H.H;[!H/I828^P^?1JL?I],VB:XN)#
MQTTLW$W[\*F BX4N(CV#2/A+#()S"E2,#!SA@(Y/1M 028:Q#XD[J!K@%KQ^
MYKOUZLN<Y/?+M[]O:"LLWW[&-6EM^?%9VLZ_=.UW+^3@-9/:5Q'8^A2\% M!
M.P/,J^CHL%?:CY,)V9_61NS9L6BZX^Y\3*4U</02:V6^[4H#%+,LN^S(NW1U
M@CFO66@CB7(D-\1SKV\.Y1@(;I<T3 NCL;6]&D3T#8#FVH%?G[4LTWR!UPI-
M/JSV%64)3)/ $AA9'0'G%822 C@GLY!.6!7'N2(=@YMI@XM'!O+D<&A@2W07
MR;_<? @VRPQI8R?:V#;5>>K>@&<4P'.-M@CR;CF.TTOY;GJFM:_3X^2NLJ;C
ME-8 ]%X@K9SF'>WTYP6>594^.UFMM_/_WO&$*1>K;8*LZW1/G1E$HS*$[%.0
M4C(AQKDEZ$/=M-:R.5@.KM &0/K7U2K_/E\L7I]\#O-UEWNHCD^1FHM0%)"W
MPT"I9,&C+Q"59U%J05\9)\2YFYYI*Z": ^( 2FL!>F<E]6^7+^:;SZM=)]:W
MY35I=OFQ%DX\VVQP6Q^E6)-L#I"Z\##47'U4$8057C+-"_UW'"SV(W#:\JCV
MP#F"6H\MKCJ^!<JOJV45XIM:@_OR:_5)<,8BAB)S!NDE22D@AXB>@<^)"PH-
M0]+]1E;?\>'3-L%M!E2#R'[J]CEG]-,.0-+C]H*%P'Q0O(#W"FMMM:0-8#TH
MZ8P41GNA^_7)N?OSI^U#VR2"CM% (P?FIDH.R;B^_%J%=#K??-HE6%]@W,X"
MMZP$ET&47.L@% <ON 5I==22*\?R.&'M=TF;MLEL,V@<1Y73'X_//]'ACJ^7
MK\@?[6JGW]Y? 7O6I>JB!_0,N>0N,@<E*?($M*!HR>LZID08'Z)3@J=>AO 8
M*J;M-]L,0!]7FPT8U>YA,)T/J3L?JK#/3X=8:*/59FE>UK=/W GP3ENP6;M<
M,CFK=IQ[EWM)FK;#;#,8'59U[;P;NOW6[T)R9]4:5XJN>:#X7M:^?K6=KM,0
MI)80G,E%%Q,T'^=2IC^-$[>9;0ZM(VFW 1-ZFS,Z(CZ'>7YQ1L_9MGRVS-V6
M/4L Y%1?<1%OT@4Z'ASF^G!  A-&99&E]VR<D>N'T=O:.,)AT/-=D ZNRDF=
MU?OY?)92'2Z[>1>^=96?W @3O;!@E*:(4-&F=REG<FBTSTISSLLXY8O?):VU
M08:/!,1C%-2DD22&UJ=$QYGGW UX9R85;@NXG SQQ#UY,#8 EYD\9U:<2X\(
MNAO4M3;"\/%P=XR:IDX^WF:HRZ->92=C\ 7KD'?.(LDK(02L/"4?Z'^"/)P;
MEWWWQ-_?7ZNUR8.#8F@,>;<'GPN1=7R]GW_\M'U;R'7N7(&S1.N[57<7[I57
M(?A0WTP(4*@=1(4%N$^A>.>CQ7ZCVHZAHK5Q@H\!N9%TU$ZHW+^2;I9XH>!,
M1"@V<5"AYJ.$3!"2XJEDJT0:YREW?QJG/5D?N2IQ)-4=;BA7M G'!.7KY1?<
MW)=0L$S[X!&$8EB[W#@(]"4*G#1B1&$2CI/'V9_61M[E/=)3@J&4UD#D4=GK
M9AW3TJ](L%?F'L]B[166'0>G#,G+D- \]Q9B%-K:9&1RXY0?/D!4DX\-!L/#
MS<?$ RFG 9R1R!)BWE0V?@L+O*/FQQFM)-=(:"@4LSO&()(QAVR"--Y:&49Z
M$_I]VII\&3 6Z@9650O@"]_.'[KN=A.QF$^KU,X9$JI(8^F0<,HS<G0Q@D.6
M(<58*%X7GLEQCMKODM:D^S<:] 955!/)Y/X2G/GLHF"ND'^2+2AM$L1,[DID
MVJ*PQ@4[SGG;G\9I4S2/C,:15-=N,/)JO@S+=+<@F=?*>PKC,(B:42<@!;35
MEW;,EES0CW2IO#^MC;1$?:1@9"BE39U,O.IVG,\H/.LM=S:(]>IPZZ[YII 1
M8L)0,PT!HK,)6&0QAY(2BS?J;^[)'NZU;)/1QV  6#V*-AKR!]_CHLL\KCZ$
MK_^8;S_5'H8DQU>K]3V/#&U!8I0[*)EK"KI<!*]D B<MB;501&;'=1/WI;C)
MP&5HP#ZJ6MM)<U_=HN?M>=Z6KO+BS6KYD18ZV14+JU@D6@]8[R(5"@9>Q@3)
M:2V=)-[#.&YE3P*;C'!&P^@(2FO HK['SV>;[VVYQD?T)4M6"5>UX%<01T$A
M!\N##>0$H<EF%/#=1U&3$<Q8:!M$+=,_(+ASTZQWN:E="\=NS-+U'F4V)^N$
M0L@JUC[PU9ZC(C&:P%A)4OHB]_80^ZX^[;WR5([B*+IIP+J=.Q;D05P.!ZC/
M'BYZ?<Y*?70CO 0B/]5TO(#(*; SGG%>9*'8;AP[]WW:IGWK-Y$/.)"JVO'V
M^LMQ%I5%;W*&Q)P@XYZ(P9(R6*&C"<B+5^-<I/2G<=H7?X^,R9%4UT >\64I
MF,BZO_R:NE=A[PGS;[L"HOK_:OZ_T$'0A63G4T6[.\TZ5N7J%Z[\Y"QP)._#
M"T#)%9T-V8(3C'YQ*08N=3!EG G((S#3R'"<H3.14ZN] 9?@*&9W8X1N5^:E
MQ6E-5%P5ZT[4,RUU#KX;U>9)1])G\(X\=YZ39LP57\(XSPT?E\]IW>;1]DO#
M8&G@$#G.;KC@7<R&5,*Y ^6DK'K)0$$<YRGE6C#=WLZ8UB=O$^A[J?+(>9(D
M@?6V ?2*Z$4(.@+#.E/=U ,ON #.2N-X$9C=.*W4QD?O:-Y[H^C=1Y6M3$,]
M_?QYT8DR+,Y%^7I95NN3G3(O@I_,*"8) HJIZ1IA'?C(,C$9:S<ERZ(8J2%J
M/P*G;<\Q&A['4$\#KO-YHZ4Z:H)"XUE(4: G.V^YZ=P51>Z*0&""Y:)<D9[+
M4=!U@Y")V^&/H>Q;[Q</EWP#P#D7RT57C_,ZK&6^(Y?R8KY)B]7F=(V7+U.B
M18510%)DIY5+''R0'&)F K77.O#Q?,5C*)^VM\NH!^ZC*73J^J:S%WU=CX0\
MWQ(;M83F9FDUQ76GE;)?3K>_KK;_B=U>G2E1F!(Z0#:T6Q6Y&1"M0> J:.X8
M0RYO />^)EB'$S&M>7Q<J*PFT%L3!K9CM7L7^C8NYA\[]5[P-@N9*:6M!$S%
M@,K*@L_: !T<B3N'1=]\"SZ8_7R0L&FKG":!YA@JF]I"=M=SEV6%UZZ,[]Y?
M/G,3N6502IVM&+4&QX,$9YA.PLF$H5^7U+V7GK9H:3IK.*Z.ID;@KI'AINM)
M?6]3PP^K*[?)70?$^AB9*R,-R5,$!ZK.Y M9DMV/ 94*TD3;K]CD4 JFO6F:
M\'1^#(VU!,OWF!%/:I.C*SS=9G FN.<F>5^K:U2]20[@!86-C+OL?(Y6);<W
M(GLN/NTU3AM@'$-/+>'P>SU?K[%Z\5 @ETCB3 5\1!(M%@_>TB9DJ$)4":-/
M8C@[^1 IT][ M('1\74X-6*O-"G^%;>[4.W\1?WKY7NLHL"_X?IC'=3--<N6
M!RA,6U#*!W#2<\C<9N^D+ISULYA[+#KM3<IT*!Q++ZT.&_XUU,3!JFP_X2^G
MF_D2-YNPS+^$S7RS*N^N+'*=D7Y#A_M_^"##AP_D9: AQ&>='@F9[U:+>;K>
M@!>+839"4-UT+:0@0XA$X892,=!'*3-.>O=^FH[-R)P+^ 5NTGK^^6RF6"?K
MM]=D_8'$^\NBEK<*993,MI;VA]KPDI%#X;.#') B+L>\M'84*>Q/Z\23#8=!
MTLV,S,@J>_(6[@5NPWQQT'3UO==X7'MW)V?CFSUI>/),"\C6<%!%67#%,]JA
M7K"0).,%GYC9^RU]PGQ:GY!T]1:GB32P\TO.WG9V^:8/7:M?C)&B)J4AN>J.
M"N4@!NDA2>>\%.0=W PIABI.Z$]DLX9N'^S<*D\824D-7(2<[_,K#;>>?9UO
M9HR. E[+_LDFL2HN#D$4!<Z8J*+B%/R,4ZIP#T$3ERR,!8![3M1CM-$HJ'8A
M#[Y8G83Y<I:*4D@[#Y@-",H;A. M!QXX8QA83'%<U^U>TJ8%VB  Z &JP[4Q
M=9[CV9I\DOGF;W@2*6)FSMI"MAN2M41YX1FBSA26E\!U],9[;;_G:]W^V/8P
M<(2^5H,(KP&K\MMIW.!_G9($7WZA7S[0/^OVAE<B%N1D9KW,M8]X+3V@#>*X
M1)YD<G8LM^AN@B;N$/M(1]40VF@35&>;#(46V96ZM1B9W!S(VG)7<6#*KL99
MC?,Z[UZ2IB[;'$#AWP?1 =)O#T9G!E8GEQR3$B2K3VE9]+2_5&TO+TOF-A4K
M'@5"+9QJ ZGZ80 =(/<)P;-9;R\K3G]+N SK^:K;4]G%)"-3$'2IHS%* E\O
M'VPB(RUR<*F?[:$5KH"&_G83,/>2,'%GP9$/L6$D/S5TSNC^^W+S&=.\S#&?
M[RA98K(I@V:QD'\8=15)@L188L&PI+@?#C[WD3&-O1E(M:NAY=P(6%ZMUIC"
M9GL1 B3K4%O(@@RPTKJ;$$I[266*D%A4IO2Z2-H+*==IF! FPRCV#J@<(>4&
MG)EK-K=:VMUK0%Q_P3<4F;ZFO;69%>Z+-T8"+\;0&4N!:.3<@[;)8*8 U>9Q
MQE;VH6[B;A2/%((-KJ<&L'?V^/3&D]-GV^=AO?Y&;.Y*R1@O-IN2@06RXDIR
M2<YCM""\\B[Z[(T=YYEF+_*F=;2'1\5=LSH&55$#N'M?;S27F%^&]9)XV#Q+
MZ?3DM-NM+[#,TWP[X^AY-JR KH.T560)0C0>#'<F%8_.,3V2Q?L>;=.FG$9'
MW,#*F;[569>,/<_S/E^=Q/FRTU;7M?=*GY/Y:F8U-S)8!YP9!\H8!5[2*>&M
M#R:$$FZ-)KHGP]UKN6G#OM& -)*\&[!;5\I6SQY(=3QMSL26R1-]=5JK.L[?
MK\RLBUIYS0&5T10&^01.1]HN06N>>< RTGB#O4F=UHL;_QP=574-8'/7&K5C
M\-UZGO =[MJ2UZ:HR 7/X(TDIS?'VD0_&7 B.1YTXB6/U&7C'HJF?<8Q.M(&
M440#@+KC9I182557'XG!_UC5RI_SU@\75=:S8(LJI>MRK[!V& _$H#/ C3/!
M9ZMM>+1:EA[T3OM>8W0P/H(2IZY1N+OU_15[_PO2C^'?EZ3*W]?SRG!]<E!+
MUZIW<C+?;,[FCG3M\KL'^9MNX#KYN**FI7)2H)P2$+CW$%$IASYY4U@O7W D
M J=]XS&N]]B"3ENMB/[M].0DK+^MRF_SC\LY!61AN;U=BGE('73/3QZD^OD0
M+L:O>18^<H.:CFAE:L6\LA!5SH!>Y!"$$LR/XZZ/6//\D'POWPHPH2TY)QH$
M 8)">MJOP4L.1CAO=#=O;AS.^]'7;*7S/HBYY2D.KYJG;;3&-UY3&+&IC%F6
M.3&T"-:[!(IK"3%1%)M0V*B%BLR,DT(=SYC]O0Y=>+G9SD_"EH[SP(3EU@;P
MLCXS4(*B<Q<%"!,E)D'.JAC':%VGHUGCM \";AJG(T3=0/!:[X1I3SZOC6.6
MZ=N'=5AN2")G3F'WU\6NI5$GM&]7'LU%[UBD*)V,=VV<0-ZAR[)C63!CC'5F
MG);H!Y,\[7W$2/![' 4V@-3GJV4-Q]<=,^_GFW\^)QKFV_JG61*,\TA;+:6N
M])PAN1E" <D-7=+,"S%.+N4!HJ:]M!@);4,IH04\W7EA?'N3,(]*9! EUS9%
MQ$^,T8%SAB)C)W))XSSN[$7>M'<18V%L<,4T@+9WZ]5G7&^_O5M4UW>9*V>?
M:S'@3;X26IM\9B 3TZ""%^!3TJ"SCS8+Z;D8:9!93PJGO948"7.CJ&?JA._[
M^<=/V[>%'-2NP0NQU;6I?#,/<;Z8$[,=;S<Y1!^%<(J!4)8V5I8>8C$2M"9G
M(08K\68T=$\Z]Z#EI[UF&!A=CZ2%!LS;ZY//8;[N>E2O7\PWGU>;L-B-/'TS
M_X)YUV#H)H]..13.!& YXJ[]>2Q*0I&U1DN%5$;RV@ZA=MI;A)',WNAJ:P":
M?UVM\N_SQ>*.IM'GW]IQ.,M&IQ@Y(<;(VJN7@.-U4B"-2EG[XIT;)TO2F\1I
M!VV,!,)Q%#3UX7N3E;O-O$R6LX %N*L-W-!*BIG(X%NE56$Q:@K">QVVO9:;
M=HS!&(?K\%)NP&)=-.?[&SD*IVN\]$-O,A9\C$0C@A3UWIB+.D8\2F HF"5Y
M:B7':0C?F\1^*5_V1# WKH8:@-YO^+'R\AX_K]874KO%5+VQ0TUVV 8C*/;V
M"%$:#<(PD7UVMKAQ!ASW(J\?Y)[:-</PFFD ;K71Z/(4:_7*\]6R$](_YMM/
MST\WV]4)KF]RYZW 5',^1;G:+4O4*FCIP A!U"D,48R#N_WH[ ? IW;1,**N
MIO;5:CT6K5ZSCB^(R\5JE_I9KSZNP\D]/D6*Y&XJYJ$4EVN1JH,0D@&>E4K(
MF'6!]_+<#EB\'\">RMW"HZB@"6-W%XMG)7=G$8Y*7I;Z/BV+.E.N/AARAMP%
M;[1*P<:4U%@6[KO$]4/=4[MM&%HK#0#M9E#T:KZ<;['+Z.P8NC8MYL/J/2[Q
M][?KEUVAS4QRM%YR R))"\H5!\Z& CJ:P)@1Y<H@^*''01Y.=C]P/K5KB<?3
M9 .P?8'QUG4+"^3"JL @,4_AD^4*HK$"O$VLD']AK!WG^O4.8OI![*G<30PE
M]0: T[T:^B5L:@N#DVJW.Z6\/6_]_;HK6: ]4R_WSER)69',"D7AD49=0 EA
M(&)RX)E(KEBC;!BG4<0!Q/8#WE.[>QA;:PT \P6NYU]"9>+6)8K.1*N/Q$D)
M)+D2R:6H(3NOT7M4L>31#-M]-/6#V5.[71A(!PV@J6Z3-7ZBG4+,T/:@J/ON
MN,A&;K*PIH[X"Z P(T2G.83:D=<BMVR\M]2]*.R'M*=R$3&J?AK W8Z5#^'K
M33Z4]LQX[^I$4U^;$B#XQ.K8C)(=.E%3D2-%"G=3U*_ ]ZE=-@PB_P9P=-XG
MY?R=]ZUTCO+2U6'-.B<ZW$V=9"Z2!:N%MS[R$.TX'9._0U@_5#VU^X0AM=$
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MTL==2.B,C3H.A%D1@4=!CD:L5T-UNKVSP;.$P>G11L+?2="T2;NQ\32$%AH
MTTWR0_(^&0K[,0L/BB42B><!7$I%25U4<GP4$!T"GM&R=6.#YQBI-P":[D75
MI]4BOS[YO%Y]V36Q/']AE6H;WBS!,JU .>W!1<' AL2Y5RQZ-<XPE0>(FC;3
M-C:8AM+&U+TFZAO.G1<9+7/:(&AG:X%4K78Q3D%PG#Q*XS7Z7KY1O^81Y\NV
M\IIMA)CN</&V@(DS*!/91@;' &7MPJ;HB V69<@VFAQ,<4$,V%+D<N$)6S8<
MIK*;2C] ?A.K_6_SY?SD].2,<&8]-[%$<$*XZE%1/)ED F/1)$M6LO3K:MM+
M\=>6GECUARAN-804IU9_^'J%\%@''AI/8$=;'ZS4GMN&.V"T#5 ZU*7?;(]^
MZK^Z](2]-X90_\%2;,##O/<0?'-9"2FC,ADC&.T$R:6X^C#2$T<J&RNR-F&<
M0N3OT];*T\(ITL.'*:AER%TV:YTI+,EKH\$BDW78M 9G+.^NQZ--2?DTS@RK
M'L0UFKX[$ ]]X7:@<EK&V\O-=GY2.Z.<\_8%-S/M@RY)2,BZ3K:TB=$I@!*2
M<BQ(H1DWX_2WWXO,1E-^(V/P:(4]I;+ZB_OMG.?U\\/B];*LZ)_M>A8.6K+2
M:ZW12E/VY_012E!2C$5&#T7H6B45'7GQ64'24;HB?? Z/K$2E'M+&+TLQ1;O
MP!%;M?\*@ZC)\66\AL-)>-H'[5603E)BL@<J>E>0[B/^!H[37T]KG%-?$G]>
MK:N4_KZ<;S>S%"C@P:@AEOIP/0@$;U4A1Q>#L(D7&<9I.W(W/<T6LA\#H0%$
MWP" N@X%=TRT?+/:;%ZMUD@'PZY&/WW[L [+#4EM-[>W^]MBI\3\?TXWV^H3
M_(K;M^5#^#JSK(B2*? VK' *LK@'IVP GC4:8;A2<9PP=1Q^FJVB/P; #:B^
M51?PS3R11/#Y:D%;9K7N/B\L\ZO3928M//NXQMU]TR$N7^_/'L3%.XR3@5RZ
MM^N/83G_[V[1YZOEAM";PQF(WEUAZ6UY-2>JTCPL?JNM,CN*+C!N406CE0<C
MZY$<ZN0A49OCNA*B*XZ"F''N5@<A__BZEPO-?;G:\_7%?),6J\WI^NH<G2 #
M[7@).M0W>%*H^HI*@$W9T*$43';C^,E[$#FM._GXB+Q=03../I^Z*?TK+O_[
MVPE>?.&(H/K8)1_5\/;BNRE[G(55,B0'R?M8&R9(""47R"3_J)C)T?S ]OCJ
M],>[=W*=JE<CRGN^?<67.FOP%)PH*(T&Q!) 97*;8O$%I$04UA=5W#A5L</S
M\B-8]WWP_=!LT G0T4! 6<N[WI8K''6E' RU,IGH+UWWI^(81&<4..LL\SEQ
MGL>)!^\DIY6'+--@9#6TPAI W6WAA;OE=588H(-B)"#:V77 N'*"@8^!I.:+
M0!&L3G*<JO$]"9T6J0- 8_5X>IIZI,5-3^Z\&+7H6JY&)PFG,T7YHB&J' D;
M/BN1>;XU%.R>L19W?_[$Z?DQ];D:5K@-F*D!#/[EK:Z1)CE5!!A! E4L>9)J
ML9"CDMPP(Y,<QP\?DHM6ZH^;.(HG@\?4IO-O\P76H37X+GSK&)XIU%%&+B#E
M4-M)B0C19@>R)%Z,X]Y@O\'QMSYZXO$)DZEX-9B\IT;+&=%OEV_C8OZQ4]W?
MEZ2VLY3+Q1DQRSD9+YD *23)1[H$H4X8Y\:A)Z!8;6(O$/5=<5IKU@:V1M'.
MT\]N$EFX7?V^?-P$Y[VK/G*.LQ_W3:4Y-4?NB^%@4R%7-0<#SFL$%X/2QBD7
M[#B7*3]JFE,8GE4H!:(DJ:J0 L6-% 74QI$QIQ)O#8/\(\TY8IIS'WP_0IIS
M'W0T$,G=G1IQWC&7H@/>M;&,0M2)O@$,X^1=6:N<_2/-^4@8Z97FW$=A#:!N
MWW2+M%D'DVJC_#I(N-8(.2<%.(&J8!8F\''ZE_T :<Z]H'%DFG,?/4T=?5TZ
M<^=CAU7)1K,"0G=5"IE#3(Y#+9+P+$?:K*57E'7SDY]6:G,O':Z&$F@#1FG0
ML).V&$695@*:VA+"NCHIBR70)GF5&>HRTD"R/Y*:(QV\D\%C:D/Y=HD?YB?X
M]\^DHN7V+"TRT]KZ$NL0N8*VCK)!"*@B1 PJYB*R3:F7M;SSXW^@Y.9>JEX-
M*O>ID7,K/?LNS/,L\:CI7)"057W,GLDK<2;37Z56'D,J&%DOY-SY\3]0ZO)@
MY!PO]V:0\YR@7\/\#[@^F2\[/;[#]7R59XS"_<3(NR"3KD@ZR,$K^I/TW"&7
M,O#+<8+]8'3O6M,^FV@,4\-H9&J ]<[N&ZV<*2;72_[:3E\6""8K\+5J63)F
M2Y&]8#;HW<MH[<[: -LHVID:<C>M\B5O,YVX=CD(B 9U?=A>V2"NLK.\>!=U
ML?J@(_%RC5ZPTC\VK ;2P%._Q/L%MY]>;]8!%R_HV"=Q;"CVS_,4%L_IV[B^
M_,E'N-O;GYA'O?([4E9-W012?)NUI( A<:/KD]Y22WH$2$R(UFE.^OOC)G"/
M=$)DA2E+'HY@==1.+=CS]245,JM2%#+B2.UV_[@)/!;?CW 3N \Z&DA_WGU[
MD!+/,=L"F@ORLIBC$Y(AR32;8*2V#,,X><S_.VX"]\)(KYO ?136 .KVO9TH
MR5O%?8(HH@7E@P9OZN56#+HV9[?*C]-6Y@>X"=P+&D?>!.ZCIZD#LU_F^23=
MK,@WT91D**C,J4:666AP+AJ(W@:G:Q6T=[U"LKL^_6G=".ZER]60@IT:&2]>
M/7]]1K9E+J=0IQD&66H=*8.8A0'C"E>%>:T"[X6'R\^<N)W08Z'@0"$V<#@-
MFK5 9A+WQH(5@7A/-H&3FH%7N4@OF=-LG/F#?]P(C^2 30:/J<WBW3>3WBFI
MT2&)4JI:!X_@?=<],U#HI0OWN5\2\T>_$=Y+U=^_$=Y'[E,CIW=B7WDM4*0(
MD<?ZCD=+\-D7,(:'Y!FJG">X=GD:]\8'XVL4[4P-N>NB/6?AY=?/E:7W.#^)
MI[1.QY;0]>EWY!!KP9M2*D @GX<$)X2Q&9/EN1?H^J_Y UTM'PR[D334%O N
MI7>YN=[A.E5U?\09.L6M)N]#JMIMD'D'WD:DV-QQP8TO[B#H/;SJ#W35/!#X
M!M126_ [WU6O3NOLS+JW:M/@9\OE:5B\0MS\)X9U=2\^K5>G'S_1;X@S+A)&
M5=\TBNI8.$O<LABA^(*(*7.GPA'F< ]2?J#+ZX&MY%CZ?'KH?;4Z79^Q^]O\
MZ\P%PXH,'"B^(SE;J>N900>'==Z0P VWQYSE_2GIA5WS!W8'T^;3@NZ'3[C&
M4+:U"8Q%58SV=:H7.3>Q\F<2 G=<NZ0U=WX,>WM)02^HVC^@>K3VGGH%T7M:
MCJC_1-][@5]PL>HFJ;Q>5C^)Q/9NO?JX#B>/4#VT'R&/6CETA(R:JAKBC)Q:
M;ACDZ',UO:F^#!,0F"R"6Z<B&Z<"X$>M&DHY%B9\ JY]S==94Q]D9M"\*(IE
M8P@AC2+0/ZJ&CL7W(U0-[8..B2=]7@CSKUAMV>=/M2RRJS3(7%E;G 5MT='I
MJR6XZK-YQX1C*O/2;_A/KZF?]Y+QPU4+[86-U="*FAIM^/$F"V?CUY4(T;N(
MD&W709%'\#;5VNT8D4==4NEE4/NA[3XRIALW/)!Z5T/+>NI [&\??GMV6N=C
MA?,2!BD"RT2M4BK55@@6G,\*$*.IWGOPL5].X.8G3ZC[832U&DIL#51MW%W\
MIM$2WX(D@=VC$5' IUP N>;6.F&3&&?XZ^&%K$^ICN*0HVDXA36 NGW+J7*@
M;>EJ3_Z()+!$FRHZ[D$GYWFPP>B1.LG_ (6L>T'CR$+6??0T]8%WGG)X]F#*
MX;R%=?&U3,1!*!Y!,>TA:LS 8C+>68?9]VLJNL^J3ZOP=2_=KQY#$5,C[%F,
M\\T_5S=K>KVP5L>@0&<90!5R$X+P 63"H#%I97._S/7=G_^T"F4/1LT PFW@
M(!PTC6^EC2)&#4(R0VY%XD#FW9,[6XHE0?IX\V'T4RV:':W&IS%G;S)X3&TZ
MKQ4RO:>(_=5J??<Y,2/[D3%3G)Z%P-HXS4!4%,6G*+)TWK+,^YG3_FO^0.6U
M>X%B-;Z&I@;>7TE*6Z+_POUXCPGG7^I.WLR8%39*W_7+QYK]#B0L66I%DPK)
M(!U<_=IX/;3*#U1;>S"X!M-" T=\-W&91+?ZC%5LRX^[@<MG%9NS9#F36!(D
MSQ,HS1TXE!8P>M1!:.:T'>70?IBN'ZC4]A 4CJ"\J2W;N]6V[J6PN-7P[')S
MS:Q6W&A%8D*RTLHG"3YH!URA]UB,P=CO64J?U7Z@BMJ#+=W@6GGJU3*/4 <S
M287+$ZA=$=IPX2V81#&*RD:!-RF#3RP%):,6ZH_9%WM-!:-#H ACP"MFR2@$
M!L$R"3PXP5()D>L_:E<>L79E#WP_QHC?/=#1@!M[]^5"0,&<<PPP* '** 91
M% :>>XPI2LG5.+,&_N_H>+,71GI=%.ZCL 90MV\Z.5GI8W(9G!$,5.$(ON8;
MBL^,*<.2&>D,^P$N"O>"QI$7A?OH:>K Z9Z;!D2;L@L6DG3DZ)NLP6>NR>\/
ML3 59<)^5X)'7.,T<_FWESY[7./L(]P&S-2@L:20B1'#!8QR"$H9#I[Y#%D;
M(X7*0=P<%O!4KW&>4LW.,4?Q9/"8VG3VRF[D)*U5R %%S*!"(8:BI\.'3 F6
M$+*_V1AT[)S3T[BZV0L(>^><]M%* Q;X/7[!Y2F2%Y,50\L\"&UK)2=M5A<3
ML1&BME+X'/4XI6+G%/Q ]S>'(.PHA;2:O'P5YNO_"(M37%UF&)YM-KC=A&5^
M,P]QOIAOYWA0UK+W9P^2KCR,DX'RE!>+OYAOTF*U.24VKJ9GG- F0GU>3S@Q
M-?PPEF#C7"87LE@Q3O7*0U0=:Y;N^NP/),U?Z(?^.<L^>((P!\ML()\"ZV,#
M[:%DVGG",6/+./U9'R1KVB-R,(S<-$C#J>*I6ZD/NSJ#$6W5ARN5#(]EL>[B
MZC'L5O:>:YT42&,=U-9*=+Z)!-G6S@N2(2'DZ=JMG:3_AJ%^?'Z[) _Q=+V>
M+S_^$C;S*_M'"W2Z( ./J8 B#Q%BUK9N3Z>"+1C$.&4,^U+:L'7;!TG_/WOO
MUMS&L:L-_R+4U^?#I9/8ZTU55NR*L]:J?:7J ]IF;9GTIB0GWK_^0U.BCI0T
M0TYSFLG.A2)1U@P.3Z,!-!IXUKJU4%@'_OTM?_=6_'-,_FNYBA>XWL0Q/R^_
M7EW2K\GUI;_:Z/E.!ABU]K6?:2BTDR@F)'C!/23OF!5!(>-MLL4MN)DW[F@/
M[+D4WP'X[])9_UBM\A^+\_,[5J(N)%ME(:,BV?)<P.LZWTE;S[(IZ+EH@N$7
MB)JW>*P9%*=2PZG[C]OEMUJ&A^OO@-J=R=Y]5)]SG"2.X8TJ*Q233E,(4\=*
M8D((ND2(I3B%5@EE&V]I[;W1-SMU<&\SN,YUK1]HI/[]S2Z0/B\7_W-U$S&<
M%9.=YYY#5+5+JD,#$=$#S]$+HXR5KHT!;<E5QU[N&(2^XN7.!X0.G();6?SP
M_?;;_[? =;V \?V7>OWBYOIO$,*1@V-L[<)J=(1@:XHC&&,2EUFYT!;>+]+7
M"5!GQ]-S0)].N3U!]D:TFX.)I_S=].3(0:(R,H/SY* IOZDNB J*1(XL*&M=
MX^SH$#([ ?"$.'D.BI,KK2=$;L+%BXW$^+:F)9IL4_8@?9V97,BO]YI;<")Z
MYXW0LG5*ZRE1G:!M>B@\![H#]=(IQ,3VMKI$%B5)1P1-#I'.Y M)"DD5\4/1
M9(B)M2GU>8&H3O)(LT!L'[UT"C&YG2(F34UM6"BJU#J.1%Y()(E%SXH/UBDF
M&H<W3XGJ)#\T"\3VT4M/$/OA^SVQO5LC^;O+]'WC92AE,_,*@2E3BS9K+X_(
M$+AA%G4IF6/S4.,YXCJQ:AW'&9.HM2>D[F+H9E$39=8Y%VM?_$(N1.TG1.L9
MK"NN1.-E*(UK39XGKA,7;RI #(@F#M%.IX"[N%W*-^9>**]++!IBJM/F<HS@
MD7YD1F0GDW/2'C&8?41=)Y";"A)# MA#]-,3YG[XOMU)OO]X'BXN-@NT6"(X
MT++,LI#36K0%KSQY+\)$D9&'YG5EN\CJQ.OK> L^4)4]X?+PT_K'XKBQ!-Q&
MM,+0^L=:3IQI&W*)UXK %*PA6"J4;;'=BK5.K/#A,&Q7P3$!)CI8)#_A>O%M
M4X%_>[C\\_+B<GVUV9D>2&FS-\FLBY6UI72PM#<9;^IE.(I#I<\Y"$PN^R:0
M'TEH)P#N V:KX^F\ T@WVEU_N;N*$F21Z#4XD\GL%*D@6-IA60XH!6<A\<8N
M32/.YFV"U+]7U .@.EA@/X:+VE:Q_N_M_UR1*3E_D+6\*[0XDRQ(G9B!A*'V
M)),<G.8>!'VFE=4\VC8.TF 2.]DGND#6XYO"3=3< 7[O]K][TCY+P>F2K8;
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MSNMY]7KU[?IBVO8^6N!1&MH'M%,:5/*T-CW)BZ42T:,HG+<YNGN!J$X!MB\
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MZ4&0V/W\>7>5:;$P@00[ X&X8:$8XP)%84!Q6 ;E1(#(>00;ZG!(\K&PV'U
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MWK/VY-*B\44/NRDR^)7#X'1")Q$-)=Z!17MS/6=WHZ#K!FR/!NZ>,1^TB,J
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M.+B6>\C[.K 8AWDAK63;@?UX)K-O(P_.<PW&$ -*:JQW^PCT680DC*6ETV:
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M5O\WM5P?Z*.*F$^DPW=AL?YG6/\W7EYW1+O?)OM,A")3R1Q"IGU*.6_KA),
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M^-5?T^6$SD0I))',ZG!\)>FP<5Q0>!A*R:B\B:X-@N^1,?+C\7&@,!]*+QV
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M(Q."Q'Q=BJV%>9C.#"2' XCMM]ZT#YH>^K;66NL@ 'R:Q6NFM"JB,&F!RU!
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M 9C^/O^.=7C2'[.G3?+#[5KYB5&!H<4ZAC%08IY%!A]1070V)I>LYZJ->SN
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M_[E=9;ZV!RZ5+BH4T-:3$V1"0F0D%Y3)*8[(0V[SO.))LL:MP8V4P1RMGP[
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M<FAO=7-E8V]O<&4N:'1M4$L! A0#%     @ T(%Q5"OZ"7S6!P  &R0  !
M             ( !,@,  &5X+3,Q,7$T,C R,2YH=&U02P$"% ,4    " #0
M@7%40WD^9-('   2)   $               @ $V"P  97@M,S$R<30R,#(Q
M+FAT;5!+ 0(4 Q0    ( -"!<50X(5F,Q00  $ 5   0              "
M 383  !E>"TS,C%Q-#(P,C$N:'1M4$L! A0#%     @ T(%Q5+G\>RI8-
MH5H!  H              ( !*1@  &5X,3 Q.2YH=&U02P$"% ,4    " #0
M@7%4$(_UFV$R   ).@$ "@              @ &I3   97@Q,#(P+FAT;5!+
M 0(4 Q0    ( -"!<53!R#B?(#(  #5% 0 *              "  3)_  !E
M>#$P,C$N:'1M4$L! A0#%     @ T(%Q5#J3I+KB,P  !U !  H
M     ( !>K$  &5X,3 R,BYH=&U02P$"% ,4    " #0@7%4-@YTW.\P  #2
M20$ "@              @ &$Y0  97@Q,#(S+FAT;5!+ 0(4 Q0    ( -"!
M<53*;05?/@,  '$3   >              "  9L6 0!E>%\R,3%X;&ES=&]F
M<W5B<VED:6%R:65S,BYH=&U02P$"% ,4    " #0@7%4[HR/0>A2!  /V"0
M$0              @ $5&@$ >&9O<BTR,#(Q,3(S,2YH=&U02P$"% ,4
M" #0@7%4".H;_YX9  #:)0$ $0              @ $L;04 >&9O<BTR,#(Q
M,3(S,2YX<V102P$"% ,4    " #0@7%4^Q/^#X$?   N,0$ %0
M    @ 'YA@4 >&9O<BTR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ T(%Q
M5/(Z*(WK>0  RG4% !4              ( !K:8% 'AF;W(M,C R,3$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( -"!<53-Z:PF2J8  $W]   4
M  "  <L@!@!X9F]R+3(P,C$Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( -"!<50I
MVHWYHS ! *M# 0 4              "  4?'!@!X9F]R+3(P,C$Q,C,Q7V<R
M+FIP9U!+ 0(4 Q0    ( -"!<51.:/0Z<2L! )JI#  5              "
M 1SX!P!X9F]R+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #0@7%4\*>W
MW'+&  #B-PD %0              @ ' (PD >&9O<BTR,#(Q,3(S,5]P<F4N
9>&UL4$L%!@     2 !( > 0  &7J"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
